PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lin, CY; Varma, MG; Joubel, A; Madabushi, S; Lichtarge, O; Barber, DL				Lin, CY; Varma, MG; Joubel, A; Madabushi, S; Lichtarge, O; Barber, DL			Conserved motifs in somatostatin, D-2-dopamine, and alpha(2B)-adrenergic receptors for inhibiting the Na-H exchanger, NHE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY; MUSCARINIC ACETYLCHOLINE-RECEPTOR; ACTIVATED CALCIUM CHANNELS; PROTEIN-COUPLED RECEPTORS; ARACHIDONIC-ACID RELEASE; HAMSTER OVARY CELLS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; NEUROTRANSMITTER RELEASE	Receptor subtypes within families of G protein-coupled receptors that are activated by similar ligands can regulate distinct intracellular effectors. We identified conserved motifs within intracellular domains 2 and 3 of selective subtypes of several G protein-coupled receptor families that confer coupling to the Na-H exchanger, NHE1 A T(s,p)V motif within intracellular domain 2 and a QQ(r) motif within intracellular domain 3 are shared by the somatostatin receptor subtypes SSTR1, -3, and -4, which couple to the inhibition of NHE1, but not by SSTR2 and -5, which do not signal to NHE1 Only the collective substitution of cognate SSTR2 residues with these two motifs conferred the ability of mutant SSTR2 to inhibit NHE1. Both motifs are present in D-2-dopamine receptors, which inhibit NHE1, and in alpha(2B)-adrenergic receptors, which couple to the inhibition of NHE1, but not in alpha(2A)-adrenergic receptors, which do not regulate NHE1. These findings indicate that motifs shared by different subfamilies of G protein-coupled receptors, but not necessarily by receptor subtypes within a subfamily, can confer coupling to a common effector.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Baylor Coll Med, Houston, TX 77030 USA	University of California System; University of California San Francisco; Baylor College of Medicine	Barber, DL (corresponding author), Univ Calif San Francisco, Box 0512,513 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040259, R01DK040259] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32DE07204] Funding Source: Medline; NIDDK NIH HHS [DK40259] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Audubert F, 1999, BBA-MOL CELL BIOL L, V1437, P265, DOI 10.1016/S1388-1981(99)00018-9; BARBER DL, 1989, J BIOL CHEM, V264, P21038; Beukers MW, 1999, TRENDS PHARMACOL SCI, V20, P475, DOI 10.1016/S0165-6147(99)01403-0; BITO H, 1994, J BIOL CHEM, V269, P12722; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P402; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Cai K, 1999, BIOCHEMISTRY-US, V38, P12893, DOI 10.1021/bi9912443; Chung DA, 2002, BIOCHEMISTRY-US, V41, P3596, DOI 10.1021/bi015811+; Cussac D, 2002, AM J PHYSIOL-RENAL, V282, pF943, DOI 10.1152/ajprenal.0108.2001; Cypess AM, 1999, J BIOL CHEM, V274, P19455, DOI 10.1074/jbc.274.27.19455; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; FLORIO T, 1992, J BIOL CHEM, V267, P24169; Florio T, 2000, J PHYSIOL-PARIS, V94, P239, DOI 10.1016/S0928-4257(00)00214-X; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; FUJII Y, 1994, FEBS LETT, V355, P117, DOI 10.1016/0014-5793(94)01159-1; GANZ MB, 1990, J BIOL CHEM, V265, P8989; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hofland LJ, 1999, ANN MED, V31, P23; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; HOU CF, 1994, J BIOL CHEM, V269, P10357; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KOCHHAR N, 1992, FEBS LETT, V299, P19, DOI 10.1016/0014-5793(92)80090-4; Kreienkamp HJ, 1997, FEBS LETT, V419, P92, DOI 10.1016/S0014-5793(97)01437-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; Miettinen HM, 1999, J BIOL CHEM, V274, P27934, DOI 10.1074/jbc.274.39.27934; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MORO O, 1993, J BIOL CHEM, V268, P22273; NEVE KA, 1994, METHODS NEUROSCI, V25, P225; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1994, ENDOCRINOLOGY, V135, P2814, DOI 10.1210/en.135.6.2814; Reardon DB, 1996, BIOCHEM J, V314, P401, DOI 10.1042/bj3140401; Roosterman D, 1998, FEBS LETT, V425, P137, DOI 10.1016/S0014-5793(98)00221-X; Rufini S, 1999, AM J PHYSIOL-CELL PH, V277, pC814, DOI 10.1152/ajpcell.1999.277.4.C814; Schwartz DD, 1997, J PHARMACOL EXP THER, V282, P248; SENOGLES SE, 1994, ENDOCRINOLOGY, V134, P783, DOI 10.1210/en.134.2.783; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Viana F, 1996, J NEUROSCI, V16, P6000; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wade SM, 1999, MOL PHARMACOL, V56, P1005, DOI 10.1124/mol.56.5.1005; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; Ye WZ, 1999, CELL MOL BIOL, V45, P1183	75	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15128	15135		10.1074/jbc.M212315200	http://dx.doi.org/10.1074/jbc.M212315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12566440	hybrid			2022-12-27	WOS:000182516100071
J	van Hemert, MJ; Deelder, AM; Molenaar, C; Steensma, HY; van Heusden, GPH				van Hemert, MJ; Deelder, AM; Molenaar, C; Steensma, HY; van Heusden, GPH			Self-association of the spindle pole body-related intermediate filament protein Fin1p and its phosphorylation-dependent interaction with 14-3-3 proteins in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE PHOSPHORYLATION; BINDING PROTEIN; 14-3-3-PROTEINS; CELLS; IDENTIFICATION; TRANSCRIPTION; HYDROXYLASE; KINASE; DOMAIN	The Fin1 protein of the yeast Saccharomyces cerevisiae forms filaments between the spindle pole bodies of dividing cells. In the two-hybrid system it binds to 14-3-3 proteins, which are highly conserved proteins involved in many cellular processes and which are capable of binding to more than 120 different proteins. Here, we describe the interaction of the Fin1 protein with the 14-3-3 proteins Bmh1p and Bmh2p in more detail. Purified Fin1p interacts with recombinant yeast 14-3-3 proteins. This interaction is strongly reduced after dephosphorylation of Fin1p. Surface plasmon resonance analysis showed that Fin1p has a higher affinity for Bmh2p than for Bmh1p (K-D 289 versus 585 nm). Sequences in both the central and C-terminal part of Fin1p are required for the interaction with Bmh2p in the two-hybrid system. In yeast strains lacking 14-3-3 proteins Fin1 filament formation was observed, indicating that the 14-3-3 proteins are not required for this process. Fin1 also interacts with itself in the two-hybrid system. For this interaction sequences at the C terminus, containing one of two putative coiled-coil regions, are sufficient. Fin1p-Fin1p interactions were demonstrated in vivo by fluorescent resonance energy transfer between cyan fluorescent protein-labeled Fin1p and yellow fluorescent protein-labeled Fin1p.	Leiden Univ, Inst Mol Plant Sci, Sect Yeast Genet, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 ZA Leiden, Netherlands; Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Delft University of Technology	van Heusden, GPH (corresponding author), Leiden Univ, Inst Mol Plant Sci, Sect Yeast Genet, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.	Heusden@RULBIM.Leidenuniv.nl	van Heusden, Paul/S-3495-2017	van Heusden, Paul/0000-0002-6422-8034; van Hemert, Martijn/0000-0002-2617-9243				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Banik U, 1997, J BIOL CHEM, V272, P26219, DOI 10.1074/jbc.272.42.26219; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Biggins S, 2001, GENETICS, V159, P453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callejo M, 2002, J BIOL CHEM, V277, P38416, DOI 10.1074/jbc.M202050200; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; HAILEY DW, 2003, IN PRESS METHODS ENZ; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; James P, 1996, GENETICS, V144, P1425; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; Knetsch MLW, 1997, BBA-MOL CELL RES, V1357, P243, DOI 10.1016/S0167-4889(97)00060-8; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Mayordomo I, 2002, BIOCHEM J, V365, P51, DOI 10.1042/BJ20020053; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; ROTH D, 1993, FEBS LETT, V320, P207, DOI 10.1016/0014-5793(93)80587-K; Russnak R, 1996, GENE EXPRESSION, V6, P241; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; Stomski FC, 1999, BLOOD, V94, P1933; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Hemert MJ, 2002, P NATL ACAD SCI USA, V99, P5390, DOI 10.1073/pnas.072556099; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; van Heusden GPH, 2001, YEAST, V18, P1479, DOI 10.1002/yea.765; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	45	15	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15049	15055		10.1074/jbc.M212495200	http://dx.doi.org/10.1074/jbc.M212495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12551942	hybrid, Green Published			2022-12-27	WOS:000182516100062
J	Atreya, CE; Johnson, EF; Irwin, JJ; Dow, A; Massimine, KM; Coppens, I; Stempliuk, V; Beverley, S; Joiner, KA; Shoichet, BK; Anderson, KS				Atreya, CE; Johnson, EF; Irwin, JJ; Dow, A; Massimine, KM; Coppens, I; Stempliuk, V; Beverley, S; Joiner, KA; Shoichet, BK; Anderson, KS			A molecular docking strategy identifies eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DISCOVERY; STRUCTURE-BASED DESIGN; TOXOPLASMA-GONDII; LEISHMANIA-TROPICA; AUTOMATED DOCKING; METHOTREXATE; MECHANISM; BINDING; CHARGES; SHAPE	Protozoal parasites are unusual in that their thymidylate synthase (TS) and dihydrofolate reductase (DHFR) enzymes exist on a single polypeptide. In an effort to probe the possibility of substrate channeling between the TS and DHFR active sites and to identify inhibitors specific for bifunctional TS-DHFR, we used molecular docking to screen for inhibitors targeting the shallow groove connecting the two active sites. Eosin B is a 100 muM non-active site inhibitor of Leishmania major TS-DHFR identified by molecular docking. Eosin B slows both the TS and DHFR reaction rates. When Arg-283, a key residue to which eosin B is predicted to bind, is mutated to glutamate, however, eosin B only minimally inhibits the TS-DHFR reaction. Additionally, eosin B was found to be a 180 muM inhibitor of Toxoplasma gondii in both biochemical and cell culture assays.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA; Northwestern Univ, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Yale University; Yale University; Northwestern University; Washington University (WUSTL)	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.		Joiner, Keith/AAH-1059-2021	Beverley, Stephen/0000-0001-5319-0811; Irwin, John/0000-0002-1195-6417; Joiner, Keith/0000-0003-3062-823X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059953] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44630] Funding Source: Medline; NIGMS NIH HHS [GM07205, GM59953] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON KS, 1990, CHEM REV, V90, P1131, DOI 10.1021/cr00105a004; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GILSON MK, 1987, NATURE, V330, P84, DOI 10.1038/330084a0; GILSON MK, 1991, J COMPUT AID MOL DES, V5, P5; Gradler U, 2001, J MOL BIOL, V306, P455, DOI 10.1006/jmbi.2000.4256; GRUMONT R, 1986, P NATL ACAD SCI USA, V83, P5387, DOI 10.1073/pnas.83.15.5387; GRUMONT R, 1988, BIOCHEMISTRY-US, V27, P3776, DOI 10.1021/bi00410a039; GUNER OF, 1991, J CHEM INF COMP SCI, V31, P408, DOI 10.1021/ci00003a007; Jones TR, 1997, J MED CHEM, V40, P677, DOI 10.1021/jm960613f; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; Li JB, 1998, J PHYS CHEM A, V102, P1820, DOI 10.1021/jp972682r; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; Lorber DM, 1998, PROTEIN SCI, V7, P938; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MENG EC, 1993, PROTEINS, V17, P266, DOI 10.1002/prot.340170305; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; Nakaar V, 1999, J BIOL CHEM, V274, P5083, DOI 10.1074/jbc.274.8.5083; RASHIN AA, 1990, J PHYS CHEM-US, V94, P1725, DOI 10.1021/j100368a005; REICH SH, 1992, J MED CHEM, V35, P847, DOI 10.1021/jm00083a007; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; Schneider G, 2002, DRUG DISCOV TODAY, V7, P64, DOI 10.1016/S1359-6446(02)00004-1; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SHOICHET BK, 1993, PROTEIN ENG, V6, P723, DOI 10.1093/protein/6.7.723; Shoichet BK, 1999, PROTEINS, V34, P4, DOI 10.1002/(SICI)1097-0134(19990101)34:1<4::AID-PROT2>3.0.CO;2-6; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; Su AI, 2001, PROTEINS, V42, P279, DOI 10.1002/1097-0134(20010201)42:2<279::AID-PROT150>3.0.CO;2-U; Tondi D, 2001, CHEM BIOL, V8, P593, DOI 10.1016/S1074-5521(01)00034-5; Tondi D, 1999, CHEM BIOL, V6, P319, DOI 10.1016/S1074-5521(99)80077-5; Waheed AA, 2000, ANAL BIOCHEM, V287, P73, DOI 10.1006/abio.2000.4793	37	20	21	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14092	14100		10.1074/jbc.M212690200	http://dx.doi.org/10.1074/jbc.M212690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556445	hybrid			2022-12-27	WOS:000182405000070
J	Li, JQ; Sheng, SH; Perry, CJ; Kleyman, TR				Li, JQ; Sheng, SH; Perry, CJ; Kleyman, TR			Asymmetric organization of the pore region of the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; CYSTEINE MUTAGENESIS; SELECTIVITY FILTER; ION PERMEATION; MEMBRANE TOPOLOGY; LINING SEGMENTS; MOLECULAR-BASIS; CA2+ CHANNEL; ENAC; RESIDUES	Epithelial sodium channels (ENaCs) are composed of three homologous subunits that have regions preceding the second transmembrane domain (also referred as pre-M2) that form part of the channel pore. To identify residues within this region of the beta-subunit that line the pore, we systematically mutated residues Gln(523)-Ile(536). to cysteine. Wild type and mutant mouse ENaCs were expressed in Xenopus oocytes, and a two-electrode voltage clamp was used to examine the properties of mutant channels. Cysteine substitutions of 9 of 13 residues significantly altered Li+ to Na+ current ratios, whereas only cysteine replacement of betaGly(529) resulted in K+-permeable channels. Besides betaG525C, large increases in the inhibitory constant of amiloride were observed with mutations at betaGly(529) and betaSer(531) within the previously identified 3-residue tract that restricts K+ permeation. Cysteine substitution preceding (betaPhe(524) and betaGly(525)), within (betaGly(530)) or following (betaLeu(533)) this 3-residue tract, resulted in enhanced current inhibition by external MTSEA. External MTSET partially blocked channels with cysteine substitutions at betaGln(523), betaPhe(524), and betaTrp(527). MTSET did not inhibit alphabetaG525Cgamma, although previous studies showed that channels with cysteine substitutions at the corresponding sites within the alpha- and gamma-subunits were blocked by MTSET. Our results, placed in context with previous observations, suggest that pore regions from the three ENaC subunits have an asymmetric organization.	Univ Pittsburgh, Div Renal & Electrolyte, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania	Kleyman, TR (corresponding author), Univ Pittsburgh, Div Renal & Electrolyte, Dept Med, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702; Solvi, Cwyn/0000-0003-2517-6179	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Koch SE, 2000, J BIOL CHEM, V275, P34493, DOI 10.1074/jbc.M005569200; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; Wu XS, 2000, J BIOL CHEM, V275, P31778, DOI 10.1074/jbc.M004829200	28	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13867	13874		10.1074/jbc.M300149200	http://dx.doi.org/10.1074/jbc.M300149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576470	hybrid			2022-12-27	WOS:000182405000040
J	Agorio, A; Chalar, C; Cardozo, S; Salinas, G				Agorio, A; Chalar, C; Cardozo, S; Salinas, G			Alternative mRNAs arising from trans-splicing code for mitochondrial and cytosolic variants of Echinococcus granulosus thioredoxin glutathione reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INCORPORATION; PROCESSING PEPTIDASE; MOLECULAR-CLONING; SEC INCORPORATION; SYSTEM; GLUTAREDOXIN; DROSOPHILA; SIGNAL; GENE; IDENTIFICATION	Thioredoxin and glutathione systems are the major thiol-dependent redox systems in animal cells. They transfer via the reversible oxidoreduction of thiols the reducing equivalents of NADPH to numerous substrates and substrate reductases and constitute major defenses against oxidative stress. In this study, we cloned from the helminth parasite Echinococcus granulosus two trans-spliced mRNA variants that encode thioredoxin glutathione reductases (TGR). These variants code for mitochondrial and cytosolic selenocysteine-containing isoforms that possess identical glutaredoxin (Grx) and thioredoxin reductase (TR) domains and differ exclusively in their N termini. Western blot analysis of subcellular fractions with specific anti-TGR antibodies showed that TGR is present in both compartments. The biochemical characterization of the native purified TGR suggests that the Grx and TR domains of the enzyme can function either coupled or independently of each other, because the Grx domain can accept electrons from either TR domains or the glutathione system and the TR domains can transfer electrons to either the fused Grx domain or to E. granulosus thioredoxin.	Univ Republica, Fac Ciencias Quim, Catedra Inmunol, Montevideo 11600, Uruguay; Univ Republica, Fac Ciencias, Secc Bioquim, Montevideo 11500, Uruguay	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay	Salinas, G (corresponding author), Univ Republica, Fac Ciencias Quim, Catedra Inmunol, Avenida Alfredo Navarro 3051,Piso 2, Montevideo 11600, Uruguay.		Agorio, Astrid/ABI-1407-2020	Salinas, Gustavo/0000-0003-3350-3002; Agorio, Astrid/0000-0001-9603-7710				Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Brehm K, 2000, J BIOL CHEM, V275, P38311, DOI 10.1074/jbc.M006091200; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Chalar C, 1999, BIOCHEM BIOPH RES CO, V262, P302, DOI 10.1006/bbrc.1999.1168; DARLEYUSMAR V, 1987, MITOCHONDRIA PRACTIC, P160; Fernandez C, 2002, MOL BIOCHEM PARASIT, V122, P171, DOI 10.1016/S0166-6851(02)00098-1; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Gonzalez G, 2000, MOL BIOCHEM PARASIT, V105, P177, DOI 10.1016/S0166-6851(99)00166-8; Goto C, 2001, BIOFACTORS, V14, P25, DOI 10.1002/biof.5520140105; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Grundner-Culemann E, 1999, RNA, V5, P625, DOI 10.1017/S1355838299981542; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P611, DOI 10.1006/bbrc.1999.1703; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; LUTHMAN M, 1979, P NATL ACAD SCI USA, V76, P2158, DOI 10.1073/pnas.76.5.2158; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; Missirlis F, 2001, CURR BIOL, V11, P1272, DOI 10.1016/S0960-9822(01)00393-1; Moriwaki K, 1999, J BIOCHEM, V126, P874, DOI 10.1093/oxfordjournals.jbchem.a022529; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Osborne S A, 2001, BMC Genomics, V2, P10, DOI 10.1186/1471-2164-2-10; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Salinas G, 1998, EXP PARASITOL, V90, P298, DOI 10.1006/expr.1998.4339; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Watabe S, 1999, EUR J BIOCHEM, V264, P74, DOI 10.1046/j.1432-1327.1999.00578.x; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	47	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12920	12928		10.1074/jbc.M209266200	http://dx.doi.org/10.1074/jbc.M209266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12538593	hybrid			2022-12-27	WOS:000182189500043
J	Parvathenani, LK; Tertyshnikova, S; Greco, CR; Roberts, SB; Robertson, B; Posmantur, R				Parvathenani, LK; Tertyshnikova, S; Greco, CR; Roberts, SB; Robertson, B; Posmantur, R			P2X(7) mediates superoxide production in primary microglia and is up-regulated in a Transgenic mouse model of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVATION; EXTRACELLULAR ATP; RAT MICROGLIA; NITRIC-OXIDE; IN-VIVO; PURINERGIC RECEPTORS; NUCLEOTIDE RECEPTOR; P2Z PURINORECEPTOR; HUMAN NEUTROPHILS; XENOPUS-OOCYTES	Primary rat microglia stimulated with either ATP or 2'- and 3'-O-(4-benzoylbenzoyl)-ATP (BzATP) release copious amounts of superoxide (O-2(.-)). ATP and BzATP stimulate O-2(.-) production through purinergic receptors, primarily the P2X(7) receptor. O is produced through the activation of the NADPH oxidase. Although both p42/44 MAPK and p38 MAPK were activated rapidly in cells stimulated with BzATP, only pharmacological inhibition of p38 MAPK attenuated O-2(.-) production. Further more, an inhibitor of phosphatidylinositol 3-kinase attenuated O-2(.-) production to a greater extent than an inhibitor of p38 MAPK. Both ATP and BzATP stimulated microglia-induced cortical cell death indicating this pathway may contribute to neurodegeneration. Consistent with this hypothesis, P2X(7) receptor was specifically up-regulated around beta-amyloid plaques in a mouse model of Alzheimer's disease (Tg2576).	Bristol Myers Squibb Co, Pharmaceut Res Inst, Neurosci Drug Discovery, Wallingford, CT 06492 USA	Bristol-Myers Squibb	Parvathenani, LK (corresponding author), CuraGen Corp, 322 E Main St, Branford, CT 06405 USA.							Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Combs CK, 2001, J NEUROSCI, V21, P1179; Cunha RA, 2000, LIFE SCI, V68, P119, DOI 10.1016/S0024-3205(00)00923-1; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Janabi N, 1996, J IMMUNOL, V157, P2129; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; KETTENMANN H, 1993, GLIA, V7, P93, DOI 10.1002/glia.440070115; Klegeris A, 2000, J LEUKOCYTE BIOL, V67, P127, DOI 10.1002/jlb.67.1.127; Klegeris A, 1999, NEUROPHARMACOLOGY, V38, P1017, DOI 10.1016/S0028-3908(99)00014-3; Lal AS, 1999, BIOCHEM BIOPH RES CO, V259, P465, DOI 10.1006/bbrc.1999.0759; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; McDonald DR, 1997, J NEUROSCI, V17, P2284; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Norenberg W, 1997, BRIT J PHARMACOL, V121, P1087, DOI 10.1038/sj.bjp.0701241; NORENBERG W, 1994, BRIT J PHARMACOL, V111, P942; NUTTLE LC, 1993, MOL PHARMACOL, V44, P93; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; Parvathenani LK, 2000, NEUROREPORT, V11, P2293, DOI 10.1097/00001756-200007140-00045; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rane MJ, 1997, J IMMUNOL, V159, P5070; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Toescu EC, 1998, NEUROSCIENCE, V86, P925, DOI 10.1016/S0306-4522(98)00123-7; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Visentin S, 1999, J PHYSIOL-LONDON, V519, P723, DOI 10.1111/j.1469-7793.1999.0723n.x; Wang X, 2000, CELL CALCIUM, V27, P205, DOI 10.1054/ceca.2000.0110; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	50	382	414	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13309	13317		10.1074/jbc.M209478200	http://dx.doi.org/10.1074/jbc.M209478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551918	hybrid			2022-12-27	WOS:000182189500091
J	Sharypova, LA; Niehaus, K; Scheidle, H; Holst, O; Becker, A				Sharypova, LA; Niehaus, K; Scheidle, H; Holst, O; Becker, A			Sinorhizobium meliloti acpXL mutant lacks the C28 hydroxylated fatty acid moiety of lipid A and does not express a slow migrating form of lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; RHIZOBIUM-ETLI; MENINGOCOCCAL POLYSACCHARIDES; GENETIC-CHARACTERIZATION; POLYACRYLAMIDE GELS; CHEMICAL PROPERTIES; MOLECULAR-WEIGHT; WHITE CLOVER; K-ANTIGENS; NODULES	Lipid A is the hydrophobic anchor of lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria. Lipid A of all Rhizobiaceae is acylated with a long fatty acid chain, 27-hydroxyoctacosanoic acid. Biosynthesis of this long acyl substitution requires a special acyl carrier protein, AcpXL, which serves as a donor of C28 (omega-1)-hydroxylated fatty acid for acylation of rhizobial lipid A (Brozek, K.A., Carlson, R.W., and Raetz, C. R. (1996) J. BioL Chem 271,32126-32136). To determine the biological function of the C28 acylation of lipid A, we constructed an acpXL mutant of Sinorhizobium meliloti strain 1021. Gas-liquid chromatography and mass spectrometry analysis of the fatty acid composition showed that the acpXL mutation indeed blocked C28 acylation of lipid A. SDS-PAGE analysis of acpXL mutant LPS revealed only a fast migrating band, rough LPS, whereas the parental strain 1021 manifested both rough and smooth LPS. Regardless of this, the LPS of parental and mutant strains had a similar sugar composition and exposed the same antigenic epitopes, implying that different electrophoretic profiles might account for different aggregation properties of LPS molecules with and without a long acyl chain. The acpXL mutant of strain 1021 displayed sensitivity to deoxycholate, delayed nodulation of Medicago sativa, and a reduced competitive ability. However, nodules elicited by this mutant on roots of M. sativa and Medicago truncatula had a normal morphology and fixed nitrogen. Thus, the C28 fatty acid moiety of lipid A is not crucial, but it is beneficial for establishing an effective symbiosis with host plants. acpXL lies upstream from a cluster of five genes, including msbB (lpxXL), which might be also involved in biosynthesis and transfer of the C28 fatty acid to the lipid A precursor.	Univ Bielefeld, Fak Biol, Lehrstuhl Genet, Inst Genet, D-33501 Bielefeld, Germany; Res Ctr Borstel, Ctr Med & Biosci, Div Struct Biochem, D-23845 Borstel, Germany	University of Bielefeld; Forschungszentrum Borstel	Sharypova, LA (corresponding author), Univ Bielefeld, Fak Biol, Lehrstuhl Genet, Inst Genet, Postfach 100131, D-33501 Bielefeld, Germany.		Niehaus, Karsten/A-3966-2010					Albus U, 2001, NEW PHYTOL, V151, P597, DOI 10.1046/j.0028-646x.2001.00214.x; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BREWIN NJ, 1991, ANNU REV CELL BIOL, V7, P191, DOI 10.1146/annurev.cb.07.110191.001203; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; Capela D, 2001, P NATL ACAD SCI USA, V98, P9877, DOI 10.1073/pnas.161294398; CASSE F, 1979, J GEN MICROBIOL, V113, P229, DOI 10.1099/00221287-113-2-229; Choma A, 2000, SYST APPL MICROBIOL, V23, P185, DOI 10.1016/S0723-2020(00)80003-X; Clementz T, 1997, J BIOL CHEM, V272, P10353; DAZZO FB, 1991, J BACTERIOL, V173, P5371, DOI 10.1128/jb.173.17.5371-5384.1991; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Geiger O, 2002, FEMS MICROBIOL LETT, V208, P153, DOI 10.1111/j.1574-6968.2002.tb11075.x; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; Lagares A, 2001, J BACTERIOL, V183, P1248, DOI 10.1128/JB.183.4.1248-1258.2001; LAGARES A, 1992, J BACTERIOL, V174, P5941, DOI 10.1128/jb.174.18.5941-5952.1992; LIU TY, 1971, J BIOL CHEM, V246, P2849; LIU TY, 1971, J BIOL CHEM, V246, P4703; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Niehaus K, 1998, MOL PLANT MICROBE IN, V11, P906, DOI 10.1094/MPMI.1998.11.9.906; Niehaus K, 1998, Subcell Biochem, V29, P73; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PETROVICS G, 1993, MOL MICROBIOL, V8, P1083, DOI 10.1111/j.1365-2958.1993.tb01653.x; PITTMAN MARGARET, 1931, JOUR EXP MED, V53, P471, DOI 10.1084/jem.53.4.471; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 1999, APPL ENVIRON MICROB, V65, P5186; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; Ridley BL, 2000, GLYCOBIOLOGY, V10, P1013, DOI 10.1093/glycob/10.10.1013; ROLFE BG, 1980, PLANT SCI LETT, V19, P277, DOI 10.1016/0304-4211(80)90082-6; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; Russa R, 1996, ARCH MICROBIOL, V165, P26, DOI 10.1007/s002030050292; Sambrook J., 1989, MOL CLONING, pA1; SHANDS JW, 1980, J BIOL CHEM, V255, P1221; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Tauch A, 1998, PLASMID, V40, P126, DOI 10.1006/plas.1998.1362; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Urbanik-Sypniewska T, 2000, IMMUNOBIOLOGY, V202, P408, DOI 10.1016/S0171-2985(00)80043-1; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; Valverde C, 1997, BIOTECHNIQUES, V22, P230, DOI 10.2144/97222bm07; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; York GM, 1997, MOL MICROBIOL, V25, P117, DOI 10.1046/j.1365-2958.1997.4481804.x; ZEVENHUIZEN LPTM, 1980, ARCH MICROBIOL, V125, P1, DOI 10.1007/BF00403191	56	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12946	12954		10.1074/jbc.M209389200	http://dx.doi.org/10.1074/jbc.M209389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566460	hybrid			2022-12-27	WOS:000182189500046
J	Chahdi, A; Choi, WS; Kim, YM; Beaven, MA				Chahdi, A; Choi, WS; Kim, YM; Beaven, MA			Mastoparan selectively activates phospholipase D2 in cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; RBL-2H3 CELLS; EXOCYTOSIS; RECEPTOR; D1; CALMODULIN; SECRETION	Both known isoforms of phospholipase (PL) D, PLD1 and PLD2, require phosphatidylinositol 4,5-bisphosphate for activity. However, PLD2 is fully active in the presence of this phospholipid, whereas PLD1 activation is dependent on additional factors such as ADP-ribosylation factor-1 (ARF-1) and protein kinase Calpha. We find that mastoparan, an activator of G(i) and mast cells, stimulates an intrinsic PLD activity, most likely PLD2, in fractions enriched in plasma membranes from rat basophilic leukemia 2H3 mast cells. Overexpression of PLD2, but not of PLD1, results in a large increase in the mastoparan-inducible PLD activity in membrane fractions, particularly those enriched in plasma membranes. As in previous studies, expressed PLD2 is localized primarily in the plasma membrane and PLD1 in granule membranes. Studies with pertussis toxin and other agents indicate that mastoparan stimulates PLD2 independently of G(i), ARF-1, protein kinase C, and calcium. Kinetic studies indicate that mastoparan interacts synergistically with phosphatidylinositol 4,5-bisphosphate and that oleate, itself a weak stimulant of PLD2 at low concentrations, is a competitive inhibitor of mastoparan stimulation of PLD2. Therefore, mastoparan may be useful for investigating the regulation of PLD2, particularly in view of the well studied molecular interactions of mastoparan with certain other strategic signaling proteins.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Med Coll Wisconsin, Dept Med Nephrol, Milwaukee, WI 53226 USA; Konkuk Univ, Coll Med, Dept Immunol, Chungcheongbuk Do 380701, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Medical College of Wisconsin; Konkuk University	Beaven, MA (corresponding author), NHLBI, Lab Mol Immunol, NIH, Rm 8N109,Bldg 10,9000 Rockville Pike, Bethesda, MD 20892 USA.	beavenm@nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000993, ZIAHL000993] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI H, 1990, J BIOL CHEM, V265, P745; Ali H, 1996, J PHARMACOL EXP THER, V276, P837; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Boyano-Adanez MD, 2002, NEUROCHEM INT, V40, P261, DOI 10.1016/S0197-0186(01)00067-5; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Chahdi A, 2000, J PHARMACOL EXP THER, V292, P122; Choi WS, 2002, J IMMUNOL, V168, P5682, DOI 10.4049/jimmunol.168.11.5682; Cissel DS, 1998, J PHARMACOL EXP THER, V285, P110; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Farquhar M, 2002, CHEM BIOL, V9, P63, DOI 10.1016/S1074-5521(01)00098-9; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Lee SY, 1998, FEBS LETT, V432, P50, DOI 10.1016/S0014-5793(98)00831-X; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Millar CA, 1999, BIOCHEM BIOPH RES CO, V254, P734, DOI 10.1006/bbrc.1998.0110; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Min DS, 2000, J NEUROCHEM, V75, P274, DOI 10.1046/j.1471-4159.2000.0750274.x; MIZUNO K, 1995, BRIT J PHARMACOL, V116, P2090, DOI 10.1111/j.1476-5381.1995.tb16416.x; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; Murase T, 2002, BIOCHEMISTRY-US, V41, P1618, DOI 10.1021/bi011782r; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Senyshyn J, 1998, J IMMUNOL, V160, P5136; SHAHDI A, 2002, MOL IMMUNOL, V38, P1269; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; Way G, 2000, BIOCHEM J, V346, P63, DOI 10.1042/0264-6021:3460063; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	52	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12039	12045		10.1074/jbc.M212084200	http://dx.doi.org/10.1074/jbc.M212084200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556526	hybrid			2022-12-27	WOS:000182015700043
J	Gordon, EHJ; Sjogren, T; Lofqvist, M; Richter, CD; Allen, JWA; Higham, CW; Hajdu, J; Fulop, V; Ferguson, SJ				Gordon, EHJ; Sjogren, T; Lofqvist, M; Richter, CD; Allen, JWA; Higham, CW; Hajdu, J; Fulop, V; Ferguson, SJ			Structure and kinetic properties of Paracoccus pantotrophus cytochrome cd(1) nitrite reductase with the d(1) heme active site ligand tyrosine 25 replaced by serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; THIOSPHAERA-PANTOTROPHA; PSEUDOMONAS-AERUGINOSA; C-DOMAIN; MUTAGENESIS; CATALYSIS; CLONING; PROTEIN; ENZYME; SYSTEM	The 1.4-Angstrom crystal structure of the oxidized state of a Y25S variant of cytochrome cd(1) nitrite reductase from Paracoccus pantotrophus is described. It shows that loss of Tyr(25), a ligand via its hydroxy group to the iron of the d(1) heme in the oxidized (as prepared) wild-type enzyme, does not result in a switch at the e heme of the unusual bishistidinyl coordination to the histidine/methionine coordination seen in other conformations of the enzyme. The Ser(25) side chain is seen in two positions in the d(1) heme pocket with relative occupancies of similar to7:3, but in neither case is the hydroxy group bound to the iron atom; instead, a sulfate ion from the crystallization solution is bound between the Ser(25) side chain and the heme iron. Unlike the wild-type enzyme, the Y25S mutant is active as a reductase toward nitrite, oxygen, and hydroxylamine without a reductive activation step. It is concluded that Tyr(25) is not essential for catalysis of reduction of any substrate, but that the requirement for activation by reduction of the wild-type enzyme is related to a requirement to drive the dissociation of this residue from the active site. The Y25S protein retains the d(1) heme less well than the wild-type protein, suggesting that the tyrosine residue has a role in stabilizing the binding of this cofactor.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Uppsala, Dept Biochem, S-75123 Uppsala, Sweden; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Oxford; Uppsala University; University of Warwick	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Pk Rd, Oxford OX1 3QU, England.		Hubbard, Ruth E/G-5414-2010; Fulop, Vilmos/AAZ-7720-2021	Hubbard, Ruth E/0000-0002-8688-5836; 				Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Allen JWA, 2000, BIOCHEM BIOPH RES CO, V279, P674, DOI 10.1006/bbrc.2000.4009; ALLEN JWA, 2001, HDB METALLOPROTEINS, P424; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cutruzzola F, 1997, FEBS LETT, V412, P365, DOI 10.1016/S0014-5793(97)00583-8; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; DRYDEN SC, 1990, NUCLEIC ACIDS RES, V18, P7267, DOI 10.1093/nar/18.24.7267; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Fulop V, 2001, ADV INORG CHEM, V51, P163; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; Gordon EHJ, 2001, BIOCHEM BIOPH RES CO, V281, P788, DOI 10.1006/bbrc.2001.4425; Jafferji A, 2000, J BIOL CHEM, V275, P25089, DOI 10.1074/jbc.M001377200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MICHEL LO, 1995, GENE, V152, P41, DOI 10.1016/0378-1119(94)00691-K; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nurizzo D, 1999, J BIOL CHEM, V274, P14997, DOI 10.1074/jbc.274.21.14997; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARALES RE, 1993, GENE, V133, P23, DOI 10.1016/0378-1119(93)90220-W; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; Ranghino G, 2000, BIOCHEMISTRY-US, V39, P10958, DOI 10.1021/bi000178y; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; ROBERTSON LA, 1983, J GEN MICROBIOL, V129, P2847; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Sjogren T, 2001, J BIOL CHEM, V276, P29450, DOI 10.1074/jbc.M103657200; Steensma E, 2001, J BIOL CHEM, V276, P5846, DOI 10.1074/jbc.M007345200; Van Spanning RJM, 1999, J BACTERIOL, V181, P4129, DOI 10.1128/JB.181.13.4129-4132.1999; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975	39	26	28	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11773	11781		10.1074/jbc.M211886200	http://dx.doi.org/10.1074/jbc.M211886200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556530	hybrid			2022-12-27	WOS:000182015700009
J	Nikiforov, MA; Popov, N; Kotenko, I; Henriksson, M; Cole, MD				Nikiforov, MA; Popov, N; Kotenko, I; Henriksson, M; Cole, MD			The Mad and Myc basic domains are functionally equivalent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; DNA-BINDING; MYC/MAX/MAD NETWORK; TRANSCRIPTIONAL REPRESSOR; ANTAGONIST MAD1; DIFFERENTIATION; GENE; PROTEIN; CELLS; TRANSFORMATION	The Myc/Max/Mad family of transcription factors plays a fundamental role in the regulation of cell proliferation, oncogenic transformation, and cell differentiation. However, it remains unclear whether different heterodimers, such as Myc/Max and Mad/Max, recognize the same or different target genes an vivo. We show by chromatin immunoprecipitation that Myc target genes are also recognized by Mad1 in differentiated HL60 cells. We also substituted the complete basic region of Myc for the corresponding region of Mad. Wild-type cMyc was then compared with c-Myc(Mad-BR) in oncogenic transformation, regulation of cell proliferation, induction of apoptosis, activation of chromosomal gene expression, and direct binding to chromosomal sites by chromatin immunoprecipitation. We find that the wildtype c-Myc and c-Myc/MadBR proteins have indistinguishable biological activity and target gene recognition in vivo. These data are consistent with a model in which Myc and Mad regulate a common set of target genes.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Karolinska Inst, Microbiol & Tumorbiol Ctr, SE-17177 Stockholm, Sweden	Princeton University; Karolinska Institutet	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Henriksson, Marie Arsenian/F-5010-2015	Arsenian Henriksson, Marie/0000-0001-6376-7792				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS LJ, 1993, ONCOGENE, V8, P125; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Winston RL, 2000, CHEM BIOL, V7, P245, DOI 10.1016/S1074-5521(00)00099-5; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	43	20	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11094	11099		10.1074/jbc.M212298200	http://dx.doi.org/10.1074/jbc.M212298200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538578	hybrid			2022-12-27	WOS:000181855400031
J	Raffai, RL; Hasty, AH; Wang, YW; Mettler, SE; Sanan, DA; Linton, MF; Fazio, S; Weisgraber, KH				Raffai, RL; Hasty, AH; Wang, YW; Mettler, SE; Sanan, DA; Linton, MF; Fazio, S; Weisgraber, KH			Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; BONE-MARROW TRANSPLANTATION; E-DEFICIENT MICE; APOLIPOPROTEIN-E; CHYLOMICRON REMNANTS; LDL RECEPTOR; CELL-SURFACE; IN-VIVO	The importance of hepatocyte-derived apolipoprotein (apo) E in the clearance of remnant lipoproteins in the liver is controversial. To address this controversy, we compared remnant clearance in two mouse models in which apoE is primarily derived either from hepatocytes or from an extrahepatic source. Hypomorphic apoE mice universally express reduced levels of apoE in all tissues, with the liver remaining the primary source of apoE. This mouse model of hepatocyte-derived apoE was compared with Apoe(-/-) mice transplanted with mouse bone marrow as a model of primarily non-hepatocyte-derived apoE. Immunohistochemical analysis of liver sections revealed that only the hepatocyte-derived apoE model had detectable levels of apoE on hepatic sinusoidal surfaces. The non-hepatocyte-derived apoE model with plasma apoE levels similar to those in the hepatocyte-derived model had 2-fold more total plasma cholesterol, 4-fold more total plasma triglycerides, and 8-fold higher levels of apoB48, similar to Apoe(-/-) mice. Both the hepatocyte-derived and the non-hepatocyte-derived apoE models had delayed clearance of an infused bolus of I-125-labeled remnants compared with wild-type mice. However, after 3 It, plasma remnants reached wild-type levels only in the hepatocyte-derived apoE model, which had accumulated 70 +/- 5% of wildtype levels of remnants in the liver while the non-hepatocyte-derived apoE model had accumulated only 38 +/- 4%. These results demonstrate the existence of a role for both hepatically derived and localized apoE in remnant clearance. This role likely represents the enrichment of remnants sequestered on hepatocyte, with hepatocyte-derived apoE, facilitating their receptor-mediated internalization.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University	Weisgraber, KH (corresponding author), Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Hasty, Alyssa/AAA-2757-2020	Hasty, Alyssa/0000-0001-7302-8045	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660, R01HL057986] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660, R01 HL057986] Funding Source: Medline; PHS HHS [57986, 53989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Burgess JW, 2001, J LIPID RES, V42, P1413; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; Dichek HL, 2001, J LIPID RES, V42, P201; Ebara T, 2000, J CLIN INVEST, V105, P1807, DOI 10.1172/JCI8283; HAMILTON RL, 1990, J LIPID RES, V31, P1589; Hasty AH, 1999, J LIPID RES, V40, P1529; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 2001, METABOLIC MOL BASES, V2, P2835; Maugeais C, 2000, J LIPID RES, V41, P1673; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Raffai RL, 2002, J BIOL CHEM, V277, P11064, DOI 10.1074/jbc.M111222200; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; SHAFI S, 1994, J LIPID RES, V35, P709; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Windler E, 1996, HEPATOLOGY, V24, P344; Yu KCW, 2000, J LIPID RES, V41, P1715; Yu KCW, 2001, J CLIN INVEST, V107, P1387, DOI 10.1172/JCI11750; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	38	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11670	11675		10.1074/jbc.M212873200	http://dx.doi.org/10.1074/jbc.M212873200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551940	hybrid			2022-12-27	WOS:000181855400101
J	Shiraki, T; Sakai, N; Kanaya, E; Jingami, H				Shiraki, T; Sakai, N; Kanaya, E; Jingami, H			Activation of orphan nuclear constitutive androstane receptor requires subnuclear targeting by peroxisome proliferator-activated receptor gamma coactivator-1 alpha - Possible link between xenobiotic response and nutritional state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; HORMONE-RECEPTOR; SPLICING FACTOR; SR PROTEINS; CYP2B GENE; PGC-1; CAR; ALPHA	In contrast to the classical nuclear receptors, the constitutive androstane receptor (CAR) is transcriptionally active in the absence of ligand. In the course of searching for the mediator of CAR activation, we found that ligand-independent activation of CAR was achieved in cooperation with the peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha). PGC-1beta, a PGC-1alpha homologue, also activated CAR to less of an extent than PGC-1alpha. Coexpression of the ligand-binding domain of a heterodimerization partner, retinoid X receptor alpha, enhanced the PGC-1alpha-mediated activation of CAR, although it had a weak effect on the basal activity of CAR in the absence of PGC-1alpha. Both the N-terminal region, with the LXXLL motif, and the C-terminal region, with a serine/arginine-rich domain (RS domain), in PGC-1alpha were required for full activation of CAR. Pull-down experiments using recombinant proteins revealed that CAR directly interacted with both the LXXLL motif and the RS domain. Furthermore, we demonstrated that the RS domain of PGC-1alpha was required for CAR localization at nuclear speckles. These results indicate that PGC-1alpha mediates the ligand-independent activation of CAR by means of subnuclear targeting through the RS domain of PGC-1alpha.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan		Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.							Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Dussault I, 2002, MOL CELL BIOL, V22, P5270, DOI 10.1128/MCB.22.15.5270-5280.2002; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Glass CK, 2000, GENE DEV, V14, P121; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	35	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11344	11350		10.1074/jbc.M212859200	http://dx.doi.org/10.1074/jbc.M212859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551939	Green Submitted, hybrid			2022-12-27	WOS:000181855400062
J	Taheri, M; Saragovi, HU; Stanners, CP				Taheri, M; Saragovi, HU; Stanners, CP			The adhesion and differentiation-inhibitory activities of the immunoglobulin superfamily member, carcinoembryonic antigen, can be independently blocked	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TUMOR-MARKER; IG SUPERFAMILY; CEA; IDENTIFICATION; FIBRONECTIN; SPECIFICITY; EXPRESSION; MOLECULES; PROTEINS; DOMAINS	The external domains of Ig superfamily members are involved in multiple binding interactions, both homophilic and heterophilic, that initiate molecular events leading to the execution of diverse cell functions. Human carcinoembryonic antigen (CEA), an Ig superfamily cell surface glycoprotein used widely as a clinical tumor marker, undergoes homophilic interactions that mediate intercellular adhesion. Recent evidence supports the view that deregulated overexpression of CEA has an instrumental role in tumorigenesis through the inhibition of cell differentiation and the disruption of tissue architecture. The CEA-mediated block of the myogenic differentiation of rat L6 myoblasts depends on homophilic binding of its external domains. We show here that L6 transfectant cells expressing CEA can "trans-block" the myogenesis of juxtaposed differentiation-competent L6 transfectant cells expressing a deletion mutant of CEA (DeltaNCEA). This result implies the efficacy of antiparallel CEA-CEA interactions between cells in the differentiation block. In addition, DeltaNCEA can acquire differentiation blocking activity by cross-linking with specific anti-CEA antibodies, thus implying the efficacy of parallel CEA-CEA interactions on the same cell surface. The myogenic differentiation blocking activity of CEA was demonstrated by site-directed mutations to involve three subdomains of the amino-terminal domain, shown previously to be critical for its intercellular adhesion function. Monovalent Fab fragments of monoclonal antibodies binding to the region bridging subdomains 1 and 2 could both inhibit intercellular adhesion and release the myogenic differentiation block. Amino acid substitutions Q80A, Q80R, and D82N in subdomain 3, QNDTG, however, were found to completely ablate the differentiation blocking activity of CEA but had no effect on intercellular adhesion activity. A cyclized peptide representing this subdomain was the most effective at releasing the differentiation block.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; McGill University	Stanners, CP (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	cliff.stanners@mcgill.ca						AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; DEGIOVANNI C, 1993, BRIT J CANCER, V67, P674, DOI 10.1038/bjc.1993.125; Draber P, 1998, CELL ADHES COMMUN S, V5, P121; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GULLBERG D, 1995, EXP CELL RES, V220, P112, DOI 10.1006/excr.1995.1297; HAUCK W, 1991, CANCER RES, V51, P3526; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Ilantzis C, 1997, LAB INVEST, V76, P703; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; Ordonez C, 2000, CANCER RES, V60, P3419; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P141; Taheri M, 2000, J BIOL CHEM, V275, P26935; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; Tan KM, 2002, EMBO J, V21, P2076, DOI 10.1093/emboj/21.9.2076; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU H, 1993, CANCER RES, V53, P3817; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	38	30	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14632	14639		10.1074/jbc.M212500200	http://dx.doi.org/10.1074/jbc.M212500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12571231	hybrid			2022-12-27	WOS:000182516100009
J	Huang, ZD; Ling, J; Traugh, JA				Huang, ZD; Ling, J; Traugh, JA			Localization of p21-activated protein kinase gamma-PAK/Pak2 in the endoplasmic reticulum is required for induction of cytostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-PAK; ADAPTER PROTEIN; CELL-CYCLE; C-ABL; ACTIVATION; MECHANISM; ACTIN; AUTOPHOSPHORYLATION; PHOSPHORYLATION; CLEAVAGE	The intracellular localization and physiological functions of the p21-activated protein kinase gamma-PAK have been examined in human embryonic kidney 293T and COS-7 cells. At 1-4 days post-transfection, cell division is inhibited by the expression of wild type (WT) gamma-PAK and the mutant S490A, whereas cells expressing S490D and the inactive mutants K278R and T402A grow exponentially, indicating a role for gamma-PAK in the induction of cytostasis. WT gamma-PAK and S490A are localized in a region surrounding the nucleus identified as the endoplasmic reticulum (ER), as determined by immunofluorescence, whereas K278R, T402A, and S490D lack localization. As shown by sucrose density gradient centrifugation, WT gamma-PAK, S490A, and endogenous gamma-PAK are distributed among the high density (ER-associated), intermediate density, and low density fractions, whereas the mutants that do not inhibit cell division are present only as soluble enzyme. The amount of endogenousy-PAK associated with the particulate fractions is increased 4-fold when cell division is inhibited by ionizing radiation.,gamma-PAK in the ER and intermediate density fractions has high specific activity and is active, whereas the soluble form of gamma-PAK has low activity and is activable. The importance of localization of gamma-PAK is supported by data with the C-terminal mutants S490D and Delta488; these mutants have high levels of protein kinase activity but do not induce cytostasis and are not bound to the ER. A model for the induction of cytostasis by gamma-PAK through targeting of gamma-PAK to the ER is presented in which gamma-PAK activity and Ser-490 are implicated in the regulation of cytostasis.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; DELGRANDE RW, 1982, EUR J BIOCHEM, V123, P421; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Dutartre H, 1996, J CELL SCI, V109, P367; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; GOGA A, 1995, ONCOGENE, V11, P791; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Roig J, 2001, FEBS LETT, V507, P195, DOI 10.1016/S0014-5793(01)02965-9; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1998, J IMMUNOL, V160, P7; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SFEIR C, 1995, J BONE MINER RES, V10, P607; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733	39	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13101	13109		10.1074/jbc.M212557200	http://dx.doi.org/10.1074/jbc.M212557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560339	hybrid			2022-12-27	WOS:000182189500066
J	Kwon, O; Georgellis, D; Lin, ECC				Kwon, O; Georgellis, D; Lin, ECC			Rotational on-off switching of a hybrid membrane sensor kinase Tar-ArcB in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; SIGNAL-TRANSDUCTION SYSTEM; ASPARTATE RECEPTOR; 2-COMPONENT SYSTEM; BACTERIAL CHEMOTAXIS; ANAEROBIC REPRESSION; AEROBIC PATHWAYS; GENE-EXPRESSION; IN-VITRO; PROTEIN	Signal transduction in biological systems typically involves receptor proteins that possess an extracytosolic sensory domain connected to a cytosolic catalytic domain. Relatively little is known about the mechanism by which the signal is transmitted from the sensory site to the catalytic site. At least in the case of Tar (methyl-accepting chemotaxis protein for sensing aspartate) of Escherichia coli, vertical piston-like displacements of one transmembrane segment relative to the other within the monomer induced by ligand binding has been shown to modulate the catalytic activity of the cytosolic domain. The ArcB sensor kinase of E. coli is a transmembrane protein without a significant periplasmic domain. Here, we explore how the signal is conveyed to the catalytic site by analyzing the property of various Tar-ArcB hybrids. Our results suggest that, in contrast to the piston-like displacement that operates in Tar, the catalytic activity of ArcB is set by altering the orientation of the cytosolic domain of one monomer relative to the other in the homodimer. Thus, ArcB represents a distinct family of membrane receptor proteins whose catalytic activity is determined by rotational movements of the cytosolic domain.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Mol Genet, Mexico City 04510, DF, Mexico; Korea Res Inst Biosci & Biotechnol, Lab Met Engn, Yusong Gu, Taejon 305333, South Korea	Harvard University; Harvard Medical School; Universidad Nacional Autonoma de Mexico; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.		Georgellis, Dimitris/U-2517-2017	Georgellis, Dimitris/0000-0002-6114-795X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRONDSTED L, 1994, J BACTERIOL, V176, P5423; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; DONG JM, 1993, J BACTERIOL, V175, P6671, DOI 10.1128/jb.175.20.6671-6678.1993; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FALKE JJ, 1987, SCIENCE, V237, P1597; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1992, J BACTERIOL, V174, P3972, DOI 10.1128/jb.174.12.3972-3980.1992; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; IUCHI S, 1990, MOL MICROBIOL, V4, P715, DOI 10.1111/j.1365-2958.1990.tb00642.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; KIM SH, 1994, PROTEIN SCI, V3, P159; Kwon O, 2000, J BACTERIOL, V182, P3858, DOI 10.1128/JB.182.13.3858-3862.2000; Kwon O, 2000, J BACTERIOL, V182, P2960, DOI 10.1128/JB.182.10.2960-2966.2000; LEE GF, 1994, J BIOL CHEM, V269, P29920; Lin ECC, 1996, ESCHERICHIA COLI SAL, P1526; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Lynch A. Simon, 1996, P361; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x	29	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13192	13195		10.1074/jbc.M210647200	http://dx.doi.org/10.1074/jbc.M210647200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562763	Green Submitted, hybrid			2022-12-27	WOS:000182189500077
J	Zhang, YG; Cho, YY; Petersen, BL; Bode, AM; Zhu, F; Dong, ZG				Zhang, YG; Cho, YY; Petersen, BL; Bode, AM; Zhu, F; Dong, ZG			Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; SERINE PHOSPHORYLATION; SIGNAL TRANSDUCER; TYROSINE PHOSPHORYLATION; MAXIMAL ACTIVATION; TRANSCRIPTION; REQUIREMENT; PATHWAYS; TARGET; ATM	Phosphorylation at Ser(727) is known to be required for complete activation of STAT3 by diverse stimuli including UV irradiation, but the kinase(s) responsible for phosphorylating STAT3 (Ser(727)) is still not well discerned. In the present study, we observed that activation of ATM is required for a UVA-stimulated increase in Ser(727) phosphorylation of STAT3 as well as in activation and phosphorylation of p90 ribosomal protein S6 kinases (RSKs). Moreover, UVA-stimulated activation of upstream kinases, such as c-Jun N-terminal kinases (JNKs) and ERKs, involved in mediating phosphorylation of RSKs and STAT3 was defective or delayed in ATM-deficient cells. Furthermore, we provide evidence that RSK2-deficient cells were defective for UV-induced Ser(727) phosphorylation of STAT3, and the defect was restored after ectopic expression of transfected full-length RSK2. In vitro experiments showed that active RSK2 and JNK1 induce the phosphorylation of STAT3 precipitates from immunoprecipitation but not from glutathione S-transferase (GST) pull-down. Interestingly, the GST fusion STAT3 proteins mixed together with STAT3 immunoprecipitates can be phosphorylated by JNK. However, the in vitro phosphorylation of STAT3 was reduced by the GST-STAT3beta protein, a dominant negative form of STAT3. Taken together, our results demonstrate that the STAT3 phosphorylation at Ser(727) is triggered by active RSK2 or JNK1 in the presence of a downstream kinase or a cofactor, and thereby the intracellular phosphorylation process is stimulated through a signaling pathway involving ATM, MAPKs, RSK2, and an as yet unidentified kinase or cofactor. Additionally, RSK2-mediated phosphorylation of STAT3 (Ser(727)) was further determined to be required for basal and UVA-stimulated STAT3 transcriptional activities.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020; ZHU, Feng/G-3567-2010; ZHU, Feng/C-1303-2010	Cho, Yong-Yeon/0000-0003-1107-2651; Zhu, Feng/0000-0003-1172-0102; Zhang, Yiguo/0000-0003-3910-2779	NCI NIH HHS [CA77646, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081064, R01CA077646, R37CA081064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Frank DA, 1999, MOL MED, V5, P432; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukuzawa M, 2001, MOL CELL, V7, P779, DOI 10.1016/S1097-2765(01)00222-2; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 2000, J BIOL CHEM, V275, P27634; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	54	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12650	12659		10.1074/jbc.M210368200	http://dx.doi.org/10.1074/jbc.M210368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562765	hybrid			2022-12-27	WOS:000182189500010
J	Que-Gewirth, NLS; Lin, SH; Cotter, RJ; Raetz, CRH				Que-Gewirth, NLS; Lin, SH; Cotter, RJ; Raetz, CRH			An outer membrane enzyme that generates the 2-amino-2-deoxy-gluconate moiety of Rhizobium leguminosarum lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN GLUCOSE-DEHYDROGENASE; ACID-DEFICIENT MUTANT; ESCHERICHIA-COLI; CELLOBIOSE DEHYDROGENASE; LIPOPOLYSACCHARIDE CORE; SALMONELLA-TYPHIMURIUM; NODULE DEVELOPMENT; RESPIRATORY-CHAIN; SYMBIOTIC NODULE; CLONING	The structures of Rhizobium leguminosarum and Rhizobium etli lipid A are distinct from those found in other Gram-negative bacteria. Whereas the more typical Escherichia coli lipid A is a hexa-acylated disaccharide of glucosamine that is phosphorylated at positions 1 and 4', R. etli and R. leguminosarum lipid A consists of a mixture of structurally related species (designated A-E) that lack phosphate. A conserved distal unit, comprised of a diacylated glucosamine moiety with galacturonic acid residue at position 4' and a secondary 27-hydroxyoctacosanoyl (27-OH-C28) as part of a 2' acyloxyacyl moiety, is present in all five components. The proximal end is heterogeneous, differing in the number and lengths of acyl chains and in the identity of the sugar itself. A proximal glucosamine unit is present in B and C, but an unusual 2-amino-2-deoxy-gluconate moiety is found in D-1 and E. We now demonstrate that membranes of R. leguminosarum and R. etli can convert B to D-1 in a reaction that requires added detergent and is inhibited by EDTA. Membranes of Sinorhizobium meliloti and E. coli lack this activity. Mass spectrometry demonstrates that B is oxidized in vitro to a substance that is 16 atomic mass units larger, consistent with the formation of D-1. The oxidation of the lipid A proximal unit is also demonstrated by matrix-assisted laser desorption ionization time-of-flight mass spectrometry in the positive and negative modes using the model substrate, 1-dephospho-lipid IVA. With this material, an additional intermediate (or by product) is detected that is tentatively identified as a lactone derivative of 1-dephospho-lipid IVA. The enzyme, presumed to be an oxidase, is located exclusively in the outer membrane of R leguminosarum as judged by sucrose gradient analysis. To our knowledge, an oxidase associated with the outer membranes of Gram-negative bacteria has not been reported previously.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R37GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM-51796, GM-54882, R37 GM051796, R37 GM051796-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony C, 1996, BIOCHEM J, V320, P697, DOI 10.1042/bj3200697; ANTHONY C, 1992, INT J BIOCHEM, V24, P29, DOI 10.1016/0020-711X(92)90226-Q; BAO WJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P705, DOI 10.1006/abbi.1993.1098; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; Becker A, 2002, J MOL MICROB BIOTECH, V4, P187; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Brade H., 1999, ENDOTOXIN HLTH DIS; BREEDVELD MW, 1994, MICROBIOL REV, V58, P145, DOI 10.1128/MMBR.58.2.145-161.1994; Bright H.B., 1975, ENZYMES, V12B, P421; Broughton WJ, 2000, J BACTERIOL, V182, P5641, DOI 10.1128/JB.182.20.5641-5652.2000; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; CARLSON FW, 1992, PLANT BIOTECHNOLOGY, P33; CARLSON RW, 1989, CARBOHYD RES, V195, P101, DOI 10.1016/0008-6215(89)85092-X; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CLETONJANSEN AM, 1989, MOL GEN GENET, V217, P430, DOI 10.1007/BF02464914; COLLYER CA, 1990, J MOL BIOL, V212, P211, DOI 10.1016/0022-2836(90)90316-E; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; DOKTER P, 1988, BIOCHEM J, V254, P131, DOI 10.1042/bj2540131; Downie JA, 1999, CURR OPIN PLANT BIOL, V2, P483, DOI 10.1016/S1369-5266(99)00018-7; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; Gage DJ, 2000, CURR OPIN MICROBIOL, V3, P613, DOI 10.1016/S1369-5274(00)00149-1; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GEIGER O, 1986, BIOCHEMISTRY-US, V25, P6043, DOI 10.1021/bi00368a031; Goodwin PM, 1998, ADV MICROB PHYSIOL, V40, P1, DOI 10.1016/S0065-2911(08)60129-0; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; He XM, 2000, CHEM REV, V100, P4615, DOI 10.1021/cr9902998; Henriksson G, 2000, J BIOTECHNOL, V78, P93, DOI 10.1016/S0168-1656(00)00206-6; HIGHAM CW, 1994, FEBS LETT, V351, P128, DOI 10.1016/0014-5793(94)00847-7; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kereszt A, 1998, J BACTERIOL, V180, P5426, DOI 10.1128/JB.180.20.5426-5431.1998; KREMER SM, 1992, EUR J BIOCHEM, V205, P133, DOI 10.1111/j.1432-1033.1992.tb16760.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Li B, 1996, APPL ENVIRON MICROB, V62, P1329, DOI 10.1128/AEM.62.4.1329-1335.1996; MATSUSHITA K, 1989, BIOCHEMISTRY-US, V28, P6276, DOI 10.1021/bi00441a020; MATSUSHITA K, 1989, AGR BIOL CHEM TOKYO, V53, P2895, DOI 10.1080/00021369.1989.10869793; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Niehaus K, 1998, Subcell Biochem, V29, P73; Niner BM, 1998, SYMBIOSIS, V24, P51; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; NOEK KD, 2000, PROKARYOTIC NITROGEN, P415; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Noel KD, 2000, J BACTERIOL, V182, P5317, DOI 10.1128/JB.182.19.5317-5324.2000; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que NLS, 1998, FASEB J, V12, pA1284; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; Rotsaert FAJ, 2001, ARCH BIOCHEM BIOPHYS, V390, P206, DOI 10.1006/abbi.2001.2362; SCHRAY KJ, 1971, BIOCHEMISTRY-US, V10, P1058, DOI 10.1021/bi00782a019; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Stacey G., 1992, BIOL NITROGEN FIXATI; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Triplett E. W, 2000, PROKARYOTIC NITROGEN, V1st; VANBASTELAERE PBM, 1992, BIOCHEM J, V286, P729, DOI 10.1042/bj2860729; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; WHITLOW M, 1991, PROTEINS, V9, P153, DOI 10.1002/prot.340090302; Xu F, 2001, ENZYME MICROB TECH, V28, P744, DOI 10.1016/S0141-0229(01)00319-2; YAMADA M, 1993, J BIOL CHEM, V268, P12812; Young JPW, 1996, NEW PHYTOL, V133, P87, DOI 10.1111/j.1469-8137.1996.tb04344.x	88	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12109	12119		10.1074/jbc.M300378200	http://dx.doi.org/10.1074/jbc.M300378200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531907	Green Accepted, hybrid			2022-12-27	WOS:000182015700052
J	Westheimer, FH				Westheimer, FH			Musings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Westheimer, FH (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.								0	5	5	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11729	11730		10.1074/jbc.X300001200	http://dx.doi.org/10.1074/jbc.X300001200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556464	hybrid			2022-12-27	WOS:000182015700001
J	Cilenti, L; Lee, Y; Hess, S; Srinivasula, S; Park, KM; Junqueira, D; Davis, H; Bonventre, JV; Alnemri, ES; Zervos, AS				Cilenti, L; Lee, Y; Hess, S; Srinivasula, S; Park, KM; Junqueira, D; Davis, H; Bonventre, JV; Alnemri, ES; Zervos, AS			Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SERINE-PROTEASE; PROTEINS; DROSOPHILA; HTRA2; GENE; XIAP; IDENTIFICATION; MITOCHONDRIA; INTERACTS	Omi/HtrA2 is a mammalian serine protease with high homology to bacterial HtrA chaperones. Omi/HtrA2 is localized in mitochondria and is released to the cytoplasm in response to apoptotic stimuli. Omi/HtrA2 induces cell death in a caspase-dependent manner by interacting with the inhibitor of apoptosis protein as well as in a caspase-independent manner that relies on its protease activity. We describe the identification and characterization of a novel compound as a specific inhibitor of the proteolytic activity of Omi/HtrA2. This compound (ucf-101) was isolated in a high throughput screening of a combinatorial library using bacterially made Omi-(134-458) protease and fluorescein-casein as a generic substrate. ucf-101 showed specific activity against Omi/HtrA2 and very little activity against various other serine proteases. This compound has a natural fluorescence that was used to monitor its ability to enter mammalian cells. ucf-101, when tested in caspase-9 (-/-) null fibroblasts, was found to inhibit Omi/HtrA2-induced cell death.	Univ Cent Florida, Biomol Sci Ctr, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Morphochem AG, D-81379 Munich, Germany	State University System of Florida; University of Central Florida; Jefferson University; Harvard University; Brigham & Women's Hospital	Zervos, AS (corresponding author), Univ Cent Florida, Biomol Sci Ctr, Dept Mol Biol & Microbiol, 12722 Res Pkwy, Orlando, FL 32826 USA.		Alnemri, Emad S/B-4526-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13487] Funding Source: Medline; NIDDK NIH HHS [R01 DK55734-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Faccio L, 2000, GENOMICS, V68, P343, DOI 10.1006/geno.2000.6263; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300	21	101	111	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11489	11494		10.1074/jbc.M212819200	http://dx.doi.org/10.1074/jbc.M212819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529364	hybrid, Green Published			2022-12-27	WOS:000181855400080
J	Luttichau, HR; Clark-Lewis, I; Jensen, PO; Moser, C; Gerstoft, J; Schwartz, TW				Luttichau, HR; Clark-Lewis, I; Jensen, PO; Moser, C; Gerstoft, J; Schwartz, TW			A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SARCOMA-ASSOCIATED HERPESVIRUS; C-C CHEMOKINES; MULTIPLE-SCLEROSIS; KAPOSIS-SARCOMA; CYTOMEGALOVIRUS ENCODES; INTERNATIONAL UNION; CX3C CHEMOKINE; VMIP-II	The chemokine-like, secreted protein product of the U83 gene from human herpesvirus 6, here named vCCL4, was chemically synthesized to be characterized in a complete library of the 18 known human chemokine receptors expressed individually in stably transfected cell lines. vCCL4 was found to cause calcium mobilization as efficiently as the endogenous chemokine ligand CCL2 through the CCR2 receptor, whereas the virally encoded chemokine did not affect any of the other 17 human chemokine receptors tested. Mutual cross-desensitization between CCL2 and vCCL4 was demonstrated in the CCR2-transfected cells. The affinity of vCCL4 for the CCR2 receptor was 79 nm as determined in competition binding against radioactively labeled CCL2. In the murine pre-B lymphocyte cell line L1.2 stably transfected with the CCR2 receptor, vCCL4 acted as a relatively low potency but highly efficacious chemoattractant being equally or more efficacious in causing cell migration than CCL2 and CCL7 and considerably more efficacious than CCL8 and CCL13. It is concluded that human herpesvirus 6 encodes a highly selective and efficacious CCR2 agonist, which will attract CCR2 expressing cells, for example macrophages and monocytes, conceivably for the virus to infect and to establish latency in. It is suggested that vCCL4 during reactivation of the virus in for example monocyte-derived microglia could perhaps be involved in the pathogenesis of the CCR2-dependent disease, multiple sclerosis.	Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z4, Canada; Rigshosp, Dept Clin Microbiol, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of British Columbia; Rigshospitalet; University of Copenhagen	Luttichau, HR (corresponding author), Panum Inst, Mol Pharmacol Lab, 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.		Jensen, Peter Ostrup/HGD-7725-2022; Moser, Claus Ernst/GPK-5546-2022; Moser, Claus Ernst/N-5951-2017	Moser, Claus Ernst/0000-0002-7664-8570; Moser, Claus Ernst/0000-0002-7664-8570; Luttichau, Hans Rudolf/0000-0002-5428-4075; Schwartz, Thue W./0000-0002-0261-6904; Jensen, Peter Ostrup/0000-0003-1648-7186				Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521; Carrigan DR, 1996, NEUROLOGY, V47, P145, DOI 10.1212/WNL.47.1.145; Cha TA, 1996, J VIROL, V70, P78, DOI 10.1128/JVI.70.1.78-83.1996; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; French C, 1999, VIROLOGY, V262, P139, DOI 10.1006/viro.1999.9875; Friedman JE, 1999, MULT SCLER, V5, P355, DOI 10.1177/135245859900500509; Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Kamei A, 1997, EUR J PEDIATR, V156, P709, DOI 10.1007/s004310050695; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KONDO K, 1991, J GEN VIROL, V72, P1401, DOI 10.1099/0022-1317-72-6-1401; Liu Y, 1997, J IMMUNOL, V158, P604; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Luttichau HR, 2001, EUR J IMMUNOL, V31, P1217; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2002, PHARMACOL REV, V54, P227, DOI 10.1124/pr.54.2.227; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Osborne J, 1999, HUM IMMUNOL, V60, P921, DOI 10.1016/S0198-8859(99)00083-X; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; Tran EH, 2000, EUR J IMMUNOL, V30, P1410, DOI 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Xu L, 1997, J LEUKOCYTE BIOL, V62, P653, DOI 10.1002/jlb.62.5.653; Yamagami S, 1997, FEBS LETT, V400, P329, DOI 10.1016/S0014-5793(96)01411-1; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918; Zou P, 1999, J VIROL, V73, P5926, DOI 10.1128/JVI.73.7.5926-5933.1999	54	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10928	10933		10.1074/jbc.M211329200	http://dx.doi.org/10.1074/jbc.M211329200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12554737	hybrid			2022-12-27	WOS:000181855400009
J	Barr, SD; Gedamu, L				Barr, SD; Gedamu, L			Role of peroxidoxins in Leishmania chagasi survival - Evidence of an enzymatic defense against nitrosative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; ALKYL HYDROPEROXIDE REDUCTASE; NITRIC-OXIDE; HYDROGEN-PEROXIDE; IN-VIVO; MURINE MACROPHAGES; DONOVANI PROMASTIGOTES; ACTIVATED MACROPHAGES; REACTIVE NITROGEN; CELL-LINE	The mechanisms by which Leishmania parasites survive exposure to highly reactive oxygen (ROS) and nitrogen (RNS) species within phagosomes of macrophages are not well known. Recently it has been shown that RNS alone is sufficient and necessary to control Leishmania donovani infection in mice (Murray, H. W., and Nathan, C. F. (1999) J. Exp. Med. 189, 741-746). No enzymatic defense against RNS has been discovered in Leishmania to date. We have previously isolated two peroxidoxins (LcPxn1 and LcPxn2) from Leishmania chagasi and showed that recombinant LcPxn1 protein was capable of detoxifying hydrogen peroxide, hydroperoxide, and hydroxyl radicals (Barr, S. D., and Gedamu, L. (2001) J. Biol. Chem 276, 34279-34287). In further characterizing the physiological role of peroxidoxins in Leishmania survival, we show here that recombinant LcPxn1 protein can detoxify RNS in addition to ROS, whereas recombinant LcPxn2 protein can only detoxify hydrogen peroxide. LcPxn1 and LcPxn2 are localized to the cytoplasm, and overexpression of LcPxn1 in L chagasi parasites enhanced survival when exposed to exogenous ROS and RNS and enhanced survival within U937 macrophage cells. Site-directed mutagenesis studies revealed that the conserved Cys-52 residue is essential for detoxifying hydrogen peroxide, t-butyl hydroperoxide, and hydroxyl radicals, whereas the conserved Cys-173 residue is essential for detoxifying t-butyl hydroperoxide and peroxynitrite. This is the first report of an enzymatic defense against RNS in Leishmania.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Gedamu, L (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	lgedamu@ucalgary.ca		Barr, Stephen/0000-0002-0028-7430				Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Balavoine GGA, 1999, NITRIC OXIDE-BIOL CH, V3, P40, DOI 10.1006/niox.1999.0206; Barr SD, 2001, J BIOL CHEM, V276, P34279, DOI 10.1074/jbc.M104406200; Bhat VB, 2001, BIOCHEM BIOPH RES CO, V285, P262, DOI 10.1006/bbrc.2001.5195; Bhattacharyya S, 2002, J INFECT DIS, V185, P1704, DOI 10.1086/340820; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Butterfield LH, 1999, ANTIOXID REDOX SIGN, V1, P385, DOI 10.1089/ars.1999.1.4-385; Castro H, 2002, FREE RADICAL BIO MED, V33, P1563, DOI 10.1016/S0891-5849(02)01088-2; Castro H, 2002, FREE RADICAL BIO MED, V33, P1552, DOI 10.1016/S0891-5849(02)01089-4; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHANNON JY, 1985, PARASITOLOGY, V91, P197, DOI 10.1017/S0031182000057309; CHANNON JY, 1985, PARASITOLOGY, V91, P207, DOI 10.1017/S0031182000057310; CHANNON JY, 1984, IMMUNOLOGY, V53, P345; Chen L, 1998, MOL CELL, V1, P795, DOI 10.1016/S1097-2765(00)80079-9; CLEMENT LT, 1983, J IMMUNOL, V130, P2763; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ekman P, 1999, INFECT IMMUN, V67, P3670, DOI 10.1128/IAI.67.7.3670-3673.1999; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; EVANS TG, 1993, J IMMUNOL, V151, P907; Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893; GREEN SJ, 1990, J IMMUNOL, V144, P278; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; Jagannath C, 1998, NITRIC OXIDE-BIOL CH, V2, P174, DOI 10.1006/niox.1998.9999; JOYCE DA, 1992, AGENTS ACTIONS, V37, P305, DOI 10.1007/BF02028124; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIMURA T, 1993, FEBS LETT, V326, P232, DOI 10.1016/0014-5793(93)81797-4; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; LIEW FY, 1990, J IMMUNOL, V144, P4794; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Logan C, 2000, J BIOL CHEM, V275, P30019, DOI 10.1074/jbc.M004161200; MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73, DOI 10.1002/jlb.49.1.73; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; Miller MA, 2000, J BIOL CHEM, V275, P33883, DOI 10.1074/jbc.M003671200; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; MURRAY HW, 1982, J IMMUNOL, V129, P351; Muyombwe A, 1997, EXP PARASITOL, V85, P35, DOI 10.1006/expr.1996.4115; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nims RW, 1996, METHOD ENZYMOL, V268, P93; Paramchuk WJ, 1997, MOL BIOCHEM PARASIT, V90, P203, DOI 10.1016/S0166-6851(97)00141-2; PEARSON RD, 1982, J IMMUNOL, V129, P1282; PEARSON RD, 1983, J IMMUNOL, V131, P1994; Peshenko IV, 2001, J OCUL PHARMACOL TH, V17, P93, DOI 10.1089/108076801750125775; ROACH TIA, 1991, INFECT IMMUN, V59, P3935, DOI 10.1128/IAI.59.11.3935-3944.1991; Romao PRT, 1999, PARASITOLOGY, V118, P559, DOI 10.1017/S0031182099004278; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Streit JA, 1996, INFECT IMMUN, V64, P1810, DOI 10.1128/IAI.64.5.1810-1818.1996; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Uppu RM, 1996, METHOD ENZYMOL, V269, P322; VOULDOUKIS I, 1995, P NATL ACAD SCI USA, V92, P7804, DOI 10.1073/pnas.92.17.7804; Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998; WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	66	86	92	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10816	10823		10.1074/jbc.M212990200	http://dx.doi.org/10.1074/jbc.M212990200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529367	hybrid			2022-12-27	WOS:000181777500107
J	Zhang, YQ; Han, H; Wang, JX; Wang, HZ; Yang, BF; Wang, ZG				Zhang, YQ; Han, H; Wang, JX; Wang, HZ; Yang, BF; Wang, ZG			Impairment of human ether-a-Go-Go-related gene (HERG) K+ channel function by hypoglycemia and hyperglycemia - Similar phenotypes but different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH GLUCOSE; OXIDATIVE STRESS; QT INTERVAL; PREFERENTIAL REGULATION; SIGNALING PATHWAYS; POTENTIAL ROLE; DYSFUNCTION; CELLS; EXPRESSION; ATP	Hyperglycemia and hypoglycemia both can cause prolongation of the Q-T interval and ventricular arrhythmias. Here we studied modulation of human ether-A-go-go-related gene (HERG) K+ channel, the major molecular component of delayed rectifier K+ current responsible for cardiac repolarization, by glucose in HEK293 cells using whole-cell patch clamp techniques. We found that both hyperglycemia (extracellular glucose concentration [Glu], = 10 or 20 mm) and hypoglycemia ([Glu], = 2.5, 1, or 0 mm) impaired HERG function by reducing HERG current (I-HERG) density, as compared with normoglycemia ([Glu], = 5 mM). Complete inhibition of glucose metabolism (glycolysis and oxidative phosphorylation) by 2-deoxy-D-glucose mimicked the effects of hypoglycemia, but inhibition of glycolysis or oxidative phosphorylation alone did not cause IHERG depression. Depletion of intracellular ATP mimicked the effects of hypoglycemia, and replacement of ATP by GTP or non-hydrolysable ATP failed to prevent the effects. Inhibition of oxidative phosphorylation by NaCN or application of antioxidants vitamin E or superoxide dismutase mimetic (Mn(III) tetrakis(4-benzoic acid) porphyrin chloride) abrogated and incubation with xanthine/xanthine oxidase mimicked the effects of hyperglycemia. Hyperglycemia or xanthine/xanthine oxidase markedly increased intracellular levels of reactive oxygen species, as measured by 5-(and-6)chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H(2)DCFDA) fluorescence dye, and this increase was prevented by NaCN, vitamin E, or Mn(III) tetrakis(4-benzoic acid) porphyrin chloride. We conclude that ATP, derived from either glycolysis or oxidative phosphorylation, is critical for normal HERG function; depression of I-HERG in hypoglycemia results from underproduction of ATP and in hyperglycemia from overproduction of reactive oxygen species. Impairment of HERG function might contribute to Q-T prolongation caused by hypoglycemia and hyperglycemia.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Harbin Med Univ, Dept Pharmacol, Harbin 150086, Heilongjiang, Peoples R China	Universite de Montreal; Universite de Montreal; Harbin Medical University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.	wangz@icm.umontreal.ca	Zhang, Yiqiang/D-9613-2012; wang, zhiguo/AAN-4182-2021; Wang, Zhiguo/GRS-4339-2022; Han, Ho Jae/M-1476-2016	Zhang, Yiqiang/0000-0003-0691-6645; Wang, Zhiguo/0000-0002-0811-2045; Han, Ho Jae/0000-0002-0657-1766; Zheng, Jie/0000-0001-6524-6800				Abo K, 1996, DIABETES CARE, V19, P1010, DOI 10.2337/diacare.19.9.1010; AIELLO EA, 1995, CIRC RES, V77, P153, DOI 10.1161/01.RES.77.1.153; BARRINGTON PL, 1988, J MOL CELL CARDIOL, V20, P1163, DOI 10.1016/0022-2828(88)90596-2; Berube J, 2001, J PHARMACOL EXP THER, V297, P96; Chelliah YR, 2000, ANAESTH INTENS CARE, V28, P698, DOI 10.1177/0310057X0002800617; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Eckert B, 1998, CLIN PHYSIOL, V18, P570, DOI 10.1046/j.1365-2281.1998.00138.x; Esposito K, 2002, J ENDOCRINOL INVEST, V25, P485, DOI 10.1007/BF03344043; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; Graier WF, 1997, HORM METAB RES, V29, P622, DOI 10.1055/s-2007-979113; Graier WF, 1999, DIABETES RES CLIN PR, V45, P153, DOI 10.1016/S0168-8227(99)00045-5; HAZEN SL, 1994, FEBS LETT, V339, P213, DOI 10.1016/0014-5793(94)80418-4; Hsieh TJ, 2002, ENDOCRINOLOGY, V143, P2975, DOI 10.1210/en.143.8.2975; KAHN JK, 1987, J CLIN ENDOCR METAB, V64, P751, DOI 10.1210/jcem-64-4-751; Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282; Koo JR, 2002, CLIN EXP HYPERTENS, V24, P333, DOI 10.1081/CEH-120004795; Landstedt-Hallin L, 1999, J INTERN MED, V246, P299, DOI 10.1046/j.1365-2796.1999.00528.x; Li PA, 1999, FREE RADICAL BIO MED, V27, P1033, DOI 10.1016/S0891-5849(99)00152-5; LINDSTROM T, 1992, DIABETIC MED, V9, P536, DOI 10.1111/j.1464-5491.1992.tb01834.x; Liu YP, 2002, CLIN EXP PHARMACOL P, V29, P305, DOI 10.1046/j.1440-1681.2002.03649.x; Liu YP, 2001, CIRC RES, V89, P146, DOI 10.1161/hh1401.093294; Losito VA, 1998, J PHYSIOL-LONDON, V511, P67, DOI 10.1111/j.1469-7793.1998.067bi.x; Ludwig B, 2001, CHEMBIOCHEM, V2, P392, DOI 10.1002/1439-7633(20010601)2:6<392::AID-CBIC392>3.3.CO;2-E; Marfella R, 2001, DIABETES NUTR METAB, V14, P63; Marfella R, 2001, J CLIN INVEST, V108, P635, DOI 10.1172/JCI13727; Marques JLB, 1997, DIABETIC MED, V14, P648, DOI 10.1002/(SICI)1096-9136(199708)14:8<648::AID-DIA418>3.3.CO;2-T; MIKI S, 1988, J MOL CELL CARDIOL, V20, P1009, DOI 10.1016/0022-2828(88)90578-0; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; ODA A, 1994, HORM METAB RES, V26, P1, DOI 10.1055/s-2007-1000762; Patane G, 2002, DIABETES, V51, P2749, DOI 10.2337/diabetes.51.9.2749; Sanguinetti MC, 1999, ANN NY ACAD SCI, V868, P406, DOI 10.1111/j.1749-6632.1999.tb11302.x; SHIMADA R, 1984, ARCH INTERN MED, V144, P1068, DOI 10.1001/archinte.144.5.1068; Siraki AG, 2002, FREE RADICAL BIO MED, V32, P2, DOI 10.1016/S0891-5849(01)00764-X; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Srivastava AK, 2002, INT J MOL MED, V9, P85; Taglialatela M, 1998, BIOCHEM PHARMACOL, V55, P1741, DOI 10.1016/S0006-2952(98)00002-1; Taglialatela M, 1997, P NATL ACAD SCI USA, V94, P11698, DOI 10.1073/pnas.94.21.11698; Takigawa T, 2000, NEUROREPORT, V11, P2547, DOI 10.1097/00001756-200008030-00040; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; vanDam PS, 1998, FREE RADICAL BIO MED, V24, P18, DOI 10.1016/S0891-5849(97)00122-6; Veglio M, 1999, DIABETOLOGIA, V42, P68, DOI 10.1007/s001250051115; Wallace D C, 2001, Novartis Found Symp, V235, P247; Wallace Douglas C, 2002, Methods Mol Biol, V197, P3, DOI 10.1385/1-59259-284-8:003; Wang HZ, 2001, J BIOL CHEM, V276, P40811, DOI 10.1074/jbc.M105572200; Wang JX, 2001, CIRCULATION, V104, P2645, DOI 10.1161/hc4701.100513; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; XU Z, 1998, AM J PHYSIOL, V271, pH2190; Yazawa K, 1997, PFLUG ARCH EUR J PHY, V433, P557, DOI 10.1007/s004240050314; YTREHUS K, 1986, CARDIOVASC RES, V20, P597, DOI 10.1093/cvr/20.8.597; Zhang YQ, 2003, FEBS LETT, V534, P125, DOI 10.1016/S0014-5793(02)03804-8; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	53	157	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10417	10426		10.1074/jbc.M211044200	http://dx.doi.org/10.1074/jbc.M211044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531891	hybrid			2022-12-27	WOS:000181777500058
J	Espanel, X; Walchli, S; Ruckle, T; Harrenga, A; Huguenin-Reggiani, M; van Huijsduijnen, RH				Espanel, X; Walchli, S; Ruckle, T; Harrenga, A; Huguenin-Reggiani, M; van Huijsduijnen, RH			Mapping of synergistic components of weakly interacting protein-protein motifs using arrays of paired peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; SIGNAL-REGULATED KINASE; YES-ASSOCIATED PROTEIN; INSULIN-RECEPTOR; CATALYTIC ACTIVATION; MEMBRANE SUPPORTS; MAP KINASES; SUBSTRATE; DOMAINS; BINDING	Protein-protein recognition usually involves multiple interactions among different motifs that are scattered over protein surfaces. To identify such weak interactions, we have developed a novel double peptide synthesis (DS) method. This method allows us to map protein-protein interactions that involve two linear discontinuous components from a polypeptide by the use of spatially addressable synergistic pairs of synthetic peptides. The DS procedure is based on the "SPOT" membrane-bound peptide synthesis technique, but to synthesize a mixture of two peptides, it uses both Fmoc (N-(9-fluorenyl)methoxycarbonyl))-alanine and Alloc-alanine at the first cycle. This allows their selective deprotection by either piperidine or tributyltin/palladium treatment, respectively. Using SPOT DS, we confirmed as a proof of principle that Elk-1 Ser(383) phosphorylation by ERK-2 kinase is stimulated by the presence of the Elk-1-docking domain. SPOT DS can also be used to dissect protein-protein motifs that define phosphatase substrate affinity. Using this technique, we identified three new regions in the insulin receptor that stimulate the dephosphorylation of the receptor by protein-tyrosine phosphatase (PTP) 1B and presumably increase the selectivity of PTP for this substrate. These data demonstrate that the SPOT DS technique allows the identification of non-linear weakly interacting protein motifs, which are an important determinant of protein, kinase and phosphatase substrate specificity and of protein-protein interactions in general.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland		van Huijsduijnen, RH (corresponding author), Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland.		van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424; Walchli, Sebastien/0000-0001-5869-1746				Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Dadke SS, 2000, BIOCHEM BIOPH RES CO, V274, P583, DOI 10.1006/bbrc.2000.3188; DANGLES O, 1987, J ORG CHEM, V52, P4984, DOI 10.1021/jo00231a027; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Espanel X, 2002, PROTEIN SCI, V11, P2326, DOI 10.1110/ps.0213402; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KRAMER A, 1993, PEPTIDE RES, V6, P314; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pawson T, 2000, GENE DEV, V14, P1027; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	20	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15162	15167		10.1074/jbc.M211887200	http://dx.doi.org/10.1074/jbc.M211887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12551909	hybrid			2022-12-27	WOS:000182516100075
J	Milutinovic, S; Zhuang, QL; Niveleau, A; Szyf, M				Milutinovic, S; Zhuang, QL; Niveleau, A; Szyf, M			Epigenomic stress response - Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-REGULATION; TUMOR-ANTIGEN; LUNG-CANCER; METHYLATION; INHIBITION; EXPRESSION; COMPLEX; TRANSCRIPTION; FAMILY; DIFFERENTIATION	The DNA methylation pattern is an important component of the epigenome that regulates and maintains gene expression programs. In this paper, we test the hypothesis that vertebrate cells possess mechanisms protecting them from epigenomic stress similar to DNA damage checkpoints. We show that knockdown of DNMT1 (DNA methyltransferase 1) by an antisense oligonucleotide triggers an intra-S-phase arrest of DNA replication that is not observed with control oligonucleotide. The cells are arrested at different positions throughout the S-phase of the cell cycle, suggesting that this response is not specific to distinct classes of origins of replication. The intra-S-phase arrest of DNA replication is proposed to protect the genome from extensive DNA demethylation that could come about by replication in the absence of DNMT1. This protective mechanism is not induced by 5-aza-2'-deoxycytidine, a nucleoside analog that inhibits DNA methylation by trapping DNMT1 in the progressing replication fork, but does not reduce de novo synthesis of DNMT1. Our data therefore suggest that the intra-S-phase arrest is triggered by a reduction in DNMT1 and not by demethylation of DNA. DNMT1 knockdown also leads to an induction of a set of genes that are implicated in genotoxic stress response such as NF-kappaB, JunB, ATF-3, and GADD45beta (growth arrest DNA damage 45beta gene). Based on these data, we suggest that this stress response mechanism evolved to guard against buildup of DNA methylation errors and to coordinate inheritance of genomic and epigenomic information.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Grenoble 1, Fac Med & Pharm, Lab Virol Mol & Structurale, EA 2939, F-38706 La Tronche, France	McGill University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.							Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Barbot W, 2002, NUCLEIC ACIDS RES, V30, P2365, DOI 10.1093/nar/30.11.2365; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bender CM, 1998, CANCER RES, V58, P95; Bender J, 1998, TRENDS BIOCHEM SCI, V23, P252, DOI 10.1016/S0968-0004(98)01225-0; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cilensek ZM, 2002, CANCER BIOL THER, V1, P380; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Habib M, 1999, EXP CELL RES, V249, P46, DOI 10.1006/excr.1999.4434; HARPER JW, 1993, CELL, V75, P805; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; JONES PA, 1985, PHARMACOL THERAPEUT, V28, P17, DOI 10.1016/0163-7258(85)90080-4; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; MERIO A, 1995, NAT MED, V1, P686; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; ORMEROD EJ, 1986, CANCER RES, V46, P884; Palmisano WA, 2000, CANCER RES, V60, P5954; Piyathilake CJ, 2001, HUM PATHOL, V32, P856, DOI 10.1053/hupa.2001.26471; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; RUSSO V, 1995, INT J CANCER, V64, P216, DOI 10.1002/ijc.2910640313; Scanlan MJ, 2002, CANCER RES, V62, P4041; Serrano A, 1996, INT J CANCER, V68, P464, DOI 10.1002/(SICI)1097-0215(19961115)68:4<464::AID-IJC11>3.0.CO;2-5; Shichijo S, 1996, JPN J CANCER RES, V87, P751, DOI 10.1111/j.1349-7006.1996.tb00288.x; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; SUZUKI H, 2001, MOL CANCER THER, V1, P95; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 2001, FRONT BIOSCI-LANDMRK, V6, pD599, DOI 10.2741/szyf; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; VANDERLAAN M, 1985, CYTOMETRY, V6, P501, DOI 10.1002/cyto.990060603; Wang XM, 1998, ANN SURG, V227, P922, DOI 10.1097/00000658-199806000-00016; WEBER J, 1994, CANCER RES, V54, P1766	61	93	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14985	14995		10.1074/jbc.M213219200	http://dx.doi.org/10.1074/jbc.M213219200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576480	hybrid			2022-12-27	WOS:000182516100054
J	Yegneswaran, S; Deguchi, H; Griffin, JH				Yegneswaran, S; Deguchi, H; Griffin, JH			Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein C with negatively charged phospholipid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR VA; ENERGY-TRANSFER; PROTHROMBIN ACTIVATION; FACTOR-XA; BINDING; FLUORESCENCE; SURFACE; SITE; PHOSPHATIDYLSERINE; INACTIVATION	The effect of glucosylceramide (GlcCer) on activated protein C (APC)-phospholipid interactions was examined using fluorescence resonance energy transfer. Human APC, labeled with either fluorescein (F1-APC) or dansyl (DEGR-APC) donor, bound to phosphatidylcholine/phosphatidylserine (PC/PS, 9:1 w/w) vesicles containing octadecylrhodamine (OR) acceptor with a K-d app = 16 mug/ml, whereas Fl-APC (or DEGR-APC) bound to PC/ PS/GlcCer(OR) (8:1:1) vesicles with a Kd app = 3 mug/ml. This 5-fold increase in apparent affinity was not species-specific since bovine DEGR-APC also showed a similar GlcCer-dependent enhancement of binding of APC to PC/PS vesicles. From the efficiency of fluorescence resonance energy transfer, distances of closest approach of similar to63 and similar to64 Angstrom were estimated between the dansyl on DEGR-APC and rhodamine in PC/PS/Glc-Cer(OR) and PC/PS(OR), respectively, assuming K-2 = 2/3. DEGR-APC bound to short chain C8-GIcCer with an apparent K-d of 460 nm. The presence of C8-GlcCer selectively enhanced the binding of C16,6-NBD-phosphatidylserine but not C16,6-7-nitrobenz-2-oxa-1,3-diazole (N-BD)-phosphatidylcholine to coumarin-labeled APC. These data suggest that APC binds to GlcCer, that PC/ PS/GlcCer vesicles like PUPS vesicles bind to the N-terminal gamma-carboxyglutamic acid domain of APC, and that one mechanism by which GlcCer enhances the activity of APC is by increasing its affinity for membrane surfaces containing negatively charged phospholipids.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM-180, La Jolla, CA 92037 USA.	jgriffin@scripps.edu		Griffin, John/0000-0002-4302-2547; Deguchi, Hiroshi/0000-0002-7721-1207	NCRR NIH HHS [M01-RR00833] Funding Source: Medline; NHLBI NIH HHS [HL52246, HL21544] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052246, R37HL052246, R01HL021544] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Deguchi H, 2002, J BIOL CHEM, V277, P8861, DOI 10.1074/jbc.M110252200; Deguchi H, 2001, BLOOD, V97, P1907, DOI 10.1182/blood.V97.7.1907; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; Esmon CT, 2001, CRIT CARE MED, V29, pS48, DOI 10.1097/00003246-200107001-00018; Fernandez JA, 2000, BLOOD CELL MOL DIS, V26, P115, DOI 10.1006/bcmd.2000.0285; Gilbert GE, 1997, BIOCHEMISTRY-US, V36, P10768, DOI 10.1021/bi970537y; Griffin JH, 1999, J CLIN INVEST, V103, P219, DOI 10.1172/JCI5006; Hackeng TM, 2000, BIOCHEM J, V349, P757, DOI 10.1042/bj3490757; HEMKER HC, 1967, NATURE, V215, P248, DOI 10.1038/215248a0; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; Koppaka V, 1996, BIOPHYS J, V70, P2930, DOI 10.1016/S0006-3495(96)79863-6; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8193, DOI 10.1021/bi960280o; LUNDBLAD RL, 1964, BIOCHEMISTRY-US, V3, P1720, DOI 10.1021/bi00899a022; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PAPAHADJOPOULOS D, 1964, BIOCHIM BIOPHYS ACTA, V90, P436, DOI 10.1016/0304-4165(64)90220-X; PEI G, 1993, J BIOL CHEM, V268, P3226; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Srivastava A, 2002, J BIOL CHEM, V277, P1855, DOI 10.1074/jbc.M105697200; STEVENSON KJ, 1982, THROMB RES, V26, P341, DOI 10.1016/0049-3848(82)90252-3; VANDERMEER BW, 1994, RESONANCE ENERGY TRA, P159; WEBER G, 1960, BIOCHEM J, V75, P335, DOI 10.1042/bj0750335; YE J, 1991, J BIOL CHEM, V266, P23016; Yegneswaran S, 1996, FASEB J, V10, P663; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1; YEGNESWARAN S, 1997, THESIS TEXAS A M U	42	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14614	14621		10.1074/jbc.M206746200	http://dx.doi.org/10.1074/jbc.M206746200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12560338	hybrid			2022-12-27	WOS:000182516100007
J	Srinivasan, P; Piano, F; Shatkin, AJ				Srinivasan, P; Piano, F; Shatkin, AJ			mRNA capping enzyme requirement for Caenorhabditis elegans viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA GUANYLYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; GENETIC INTERFERENCE; YEAST; TRANSCRIPTION; MECHANISM; 5'-TRIPHOSPHATASE; EXPRESSION; APPARATUS; EVOLUTION	Capping of the initiated 5' ends of RNA polymerase II products is evolutionarily and functionally conserved from yeasts to humans. The m 7 GpppN cap promotes RNA stability, processing, transport, and translation. Deletion of capping enzymes in yeasts was shown to be lethal due to rapid exonucleolytic degradation of un-capped transcripts or failure of capped but unmethylated RNA to initiate protein synthesis. Using RNA interference and Caenorhabditis elegans we have found that RNA capping is also essential for metazoan viability. C. elegans bifunctional capping enzyme was cloned, and capping activity by the expressed protein as well as growth complementation of yeast deletion strains missing either RNA triphosphatase or guanylyltransferase required terminal sequences not present in the previously isolated cel-1 clone. By RNA interference analysis we show that cel-1 is required for embryogenesis. cel-1(RNAi) embryos formed cytoplasmic granules characteristic of a phenocluster of RNA processing genes and died early in development.	Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Grad Sch Biomed Sci, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Program Biochem, Grad Sch Biomed Sci, Piscataway, NJ 08854 USA; NYU, Dept Biol, New York, NY 10012 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; New York University	Shatkin, AJ (corresponding author), Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Grad Sch Biomed Sci, 679 Hoes Lane, Piscataway, NJ 08854 USA.	shatkin@cabm.rutgers.edu						Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Hausmann S, 2001, J BIOL CHEM, V276, P36116, DOI 10.1074/jbc.M105856200; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Manley JL, 2002, NAT STRUCT BIOL, V9, P790, DOI 10.1038/nsb1102-790; MAO XD, 1995, MOL CELL BIOL, V15, P4167; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; PIANO F, 2002, CURR BIO, V12, P1; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	30	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14168	14173		10.1074/jbc.M212102200	http://dx.doi.org/10.1074/jbc.M212102200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576475	hybrid			2022-12-27	WOS:000182405000078
J	Albertsen, M; Bellahn, I; Kramer, R; Waffenschmidt, S				Albertsen, M; Bellahn, I; Kramer, R; Waffenschmidt, S			Localization and function of the yeast multidrug transporter Tpo1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR-MEMBRANE-VESICLES; SACCHAROMYCES-CEREVISIAE; POLYAMINE TRANSPORT; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; AMINO-ACIDS; GENE; RESISTANCE; IDENTIFICATION; SYSTEMS	In Saccharomyces cerevisiae four transporters, Tpo1p-Tpo4p, all members of the major facilitator superfamily, have been shown to confer resistance to polyamines. It was suggested that they act by pumping their respective substrate into the lumen of the vacuole depending on the proton gradient generated by the VATPase. Using sucrose gradient ultracentrifugation we found that an hemagglutinin (RA)-tagged Tpo1p as well as its HA-tagged Tpo2p-4p homologues co-localize with plasma membrane markers. Because the RA-tagged Tpo1p carrier protein proved to be functional in conferring resistance to polyamines in TPO1 knockouts, a function of Tpo1p in transport of polyamines across the plasma membrane seemed to be likely. The polyamine transport activity of wild type cells was compared with the respective activity of a TPO1 knockout strain. The results obtained strongly suggest that Tpo1p is a plasma membrane-bound exporter, involved in the detoxification of excess spermidine in yeast. When studying polyamine transport of wild type cells, we furthermore found that S. cerevisiae is excreting putrescine during the fermentative growth phase.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	University of Cologne	Waffenschmidt, S (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	waff@uni-koeln.de						BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; Bianchi MM, 1999, YEAST, V15, P513, DOI 10.1002/(SICI)1097-0061(199904)15:6<513::AID-YEA370>3.3.CO;2-G; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; Buziol S, 2002, FEMS YEAST RES, V2, P283, DOI 10.1016/S1567-1356(02)00113-7; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; Desmoucelles C, 2002, J BIOL CHEM, V277, P27036, DOI 10.1074/jbc.M111433200; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; Matta MAD, 2001, GENE, V272, P111, DOI 10.1016/S0378-1119(01)00558-3; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; PRICE NPJ, 1992, J CHROMATOGR, V598, P51, DOI 10.1016/0021-9673(92)85113-8; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SATO T, 1984, J BIOL CHEM, V259, P1505; Schiller D, 2000, J BACTERIOL, V182, P6247, DOI 10.1128/JB.182.21.6247-6249.2000; Sorin A, 1997, J BIOL CHEM, V272, P9895; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Teixeira MC, 2002, BIOCHEM BIOPH RES CO, V292, P530, DOI 10.1006/bbrc.2002.6691; TJANDRAWINATA RR, 1994, J IMMUNOL, V152, P3039; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; Woolridge DP, 1997, J BIOL CHEM, V272, P8864	29	59	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12820	12825		10.1074/jbc.M210715200	http://dx.doi.org/10.1074/jbc.M210715200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562762	hybrid			2022-12-27	WOS:000182189500031
J	Didierjean, C; Corbier, C; Fatih, M; Favier, F; Boschi-Muller, S; Branlant, G; Aubry, A				Didierjean, C; Corbier, C; Fatih, M; Favier, F; Boschi-Muller, S; Branlant, G; Aubry, A			Crystal structure of two ternary complexes of phosphorylating glyceraldehyde-3-phosphate dehydrogenase from Bacillus stearothermophilus with NAD and D-glyceraldehyde 3-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOBSTER D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SITE-DIRECTED MUTAGENESIS; PHOSPHATE-BINDING SITES; HOLO-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ANGSTROM RESOLUTION; KINETIC MECHANISM; ESCHERICHIA-COLI; RABBIT MUSCLE; DESIGN	The crystal structure of the phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from Bacillus stearothermophilus was solved in complex with its cofactor, NAD, and its physiological substrate, D-glyceraldehyde 3-phosphate (D-G3P). To isolate a stable ternary complex, the nucleophilic residue of the active site, Cys(149), was substituted with alanine or serine. The C149A and C149S GAPDH ternary complexes were obtained by soaking the crystals of the corresponding binary complexes (enzyme(.)NAD) in a solution containing G3P. The structures of the two binary and the two ternary complexes are presented. The D-G3P adopts the same conformation in the two ternary complexes. It is bound in a non-covalent way, in the free aldehyde form, its C-3 phosphate group being positioned in the P-s site and not in the P-i site. Its C-1 carbonyl oxygen points toward the essential His(176), which supports the role proposed for this residue along the two steps of the catalytic pathway. Arguments are provided that the structures reported here are representative of a productive enzyme(.)NAD(.)D-G3P complex in the ground state (Michaelis complex).	UHP, CNRS, Fac Sci, Maturat ARN & Enzymol Mol UMR 7567, F-54506 Vandoeuvre Les Nancy, France; Univ Henri Poincare, CNRS, Fac Sci,Grp Biocristallog,UMR 7036, Lab Cristallog & Modelisat Mat Mineraux & Biol, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Lorraine	Branlant, G (corresponding author), UHP, CNRS, Fac Sci, Maturat ARN & Enzymol Mol UMR 7567, F-54506 Vandoeuvre Les Nancy, France.		Favier, Frederique/B-3090-2013; DIDIERJEAN, Claude/L-1493-2013	Favier, Frederique/0000-0003-3249-997X; DIDIERJEAN, Claude/0000-0002-3176-8974; Boschi, Sandrine/0000-0001-8962-4749				Boschi-Muller S, 1999, ARCH BIOCHEM BIOPHYS, V363, P259, DOI 10.1006/abbi.1998.1080; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUEHNER M, 1974, J MOL BIOL, V82, P563, DOI 10.1016/0022-2836(74)90249-6; BYERS LD, 1978, ARCH BIOCHEM BIOPHYS, V186, P335, DOI 10.1016/0003-9861(78)90443-5; CANELLAS PF, 1991, BIOCHEMISTRY-US, V30, P8871, DOI 10.1021/bi00100a021; CHAKRABARTI P, 1993, J MOL BIOL, V234, P463, DOI 10.1006/jmbi.1993.1599; COPLEY RR, 1994, J MOL BIOL, V242, P321; CORBIER C, 1994, BIOCHEMISTRY-US, V33, P3260, DOI 10.1021/bi00177a017; CORBIER C, 1992, BIOCHEMISTRY-US, V31, P12532, DOI 10.1021/bi00164a033; CROW VL, 1979, J BIOL CHEM, V254, P1134; DALZIEL K, 1981, PHILOS T ROY SOC B, V293, P105, DOI 10.1098/rstb.1981.0064; Duee E, 1996, J MOL BIOL, V257, P814, DOI 10.1006/jmbi.1996.0204; DUGGLEBY RG, 1974, J BIOL CHEM, V249, P167; GRIFFITH JP, 1983, J MOL BIOL, V169, P963, DOI 10.1016/S0022-2836(83)80145-4; HARRIGAN PJ, 1974, BIOCHEM J, V143, P353, DOI 10.1042/bj1430353; HARRIS JI, 1976, ENZYMES, V13, P1; KIM HD, 1995, BIOCHEMISTRY-US, V34, P14975, DOI 10.1021/bi00046a004; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU L, 1992, BIOCHEMISTRY-US, V31, P6898, DOI 10.1021/bi00145a005; MACPHERSON A, 1999, CRYSTALLIZATION BIOL, P165; MERCER WD, 1976, J MOL BIOL, V104, P277, DOI 10.1016/0022-2836(76)90013-9; MEUNIER JC, 1978, EUR J BIOCHEM, V82, P483, DOI 10.1111/j.1432-1033.1978.tb12042.x; Michels S, 1996, EUR J BIOCHEM, V235, P641, DOI 10.1111/j.1432-1033.1996.00641.x; MORAS D, 1975, J BIOL CHEM, V250, P9137; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORSI BA, 1972, BIOCHEMISTRY-US, V11, P102, DOI 10.1021/bi00751a018; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Roussel P. A., 1991, TURBO FRODO SILICON; SEGAL HL, 1953, J BIOL CHEM, V204, P265; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; Song SY, 1998, ACTA CRYSTALLOGR D, V54, P558, DOI 10.1107/S090744499701620X; Souza DHF, 1998, FEBS LETT, V424, P131, DOI 10.1016/S0014-5793(98)00154-9; Talfournier F, 1998, EUR J BIOCHEM, V252, P447, DOI 10.1046/j.1432-1327.1998.2520447.x; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; TRENTHAM DR, 1971, BIOCHEM J, V122, P71, DOI 10.1042/bj1220071; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; Yun M, 2000, BIOCHEMISTRY-US, V39, P10702, DOI 10.1021/bi9927080	40	30	32	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12968	12976		10.1074/jbc.M211040200	http://dx.doi.org/10.1074/jbc.M211040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569100	hybrid, Green Published			2022-12-27	WOS:000182189500049
J	Lim, K; Tempczyk, A; Bonander, N; Toedt, J; Howard, A; Eisenstein, E; Herzberg, O				Lim, K; Tempczyk, A; Bonander, N; Toedt, J; Howard, A; Eisenstein, E; Herzberg, O			A catalytic mechanism for D-Tyr-tRNA(Tyr) deacylase based on the crystal structure of Hemophilus influenzae HI0670	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; PROTEIN; METABOLISM; ALIGNMENT	D-Tyr-tRNA(Tyr) deacylase is an editing enzyme that removes D-tyrosine and other D-amino acids from charged tRNAs, thereby preventing incorrect incorporation of D-amino acids into proteins. A model for the catalytic mechanism of this enzyme is proposed based on the crystal structure of the enzyme from Haemophilus influenzae determined at a 1.64-Angstrom resolution. Structural comparison of this dimeric enzyme with the very similar structure of the enzyme from Escherichia coli together with sequence analyses indicate that the active site is located in the dimer interface within a depression that includes an invariant threonine residue, Thr-80. The active site contains an oxyanion hole formed by the main chain nitrogen atoms of Thr-80 and Phe-79 and the side chain amide group of the invariant Gln-78. The Michaelis complex between the enzyme and D-Tyr-tRNA was modeled assuming a nucleophilic attack on the carbonyl carbon of D-Tyr by the Thr-80 O-gamma atom and a role for the oxyanion hole in stabilizing the negatively charged tetrahedral transition states. The model is consistent with all of the available data on substrate specificity. Based on this model, we propose a substrate-assisted acylation/deacylation-catalytic mechanism in which the amino group of the D-Tyr is deprotonated and serves as the general base.	Univ Maryland, Biotechnol Inst, Ctr Adv Res In Biotechnol, Rockville, MD 20850 USA; NIST, Gaithersburg, MD 20899 USA; Argonne Natl Lab, Argonne, IL 60439 USA; IIT, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA	National Institute of Standards & Technology (NIST) - USA; United States Department of Energy (DOE); Argonne National Laboratory; Illinois Institute of Technology; University System of Maryland; University of Maryland Baltimore County	Herzberg, O (corresponding author), Univ Maryland, Biotechnol Inst, Ctr Adv Res In Biotechnol, Rockville, MD 20850 USA.	osnat@carb.nist.gov	ID, IMCACAT/D-5867-2014	Herzberg, Osnat/0000-0003-2823-7627	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57890, P01 GM057890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; ROUSSEL A, 1989, TURBO FRODO VERSION; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)80195-Z; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	26	19	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13496	13502		10.1074/jbc.M213150200	http://dx.doi.org/10.1074/jbc.M213150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571243	hybrid, Green Accepted			2022-12-27	WOS:000182189500113
J	Lin, SS; Manchester, JK; Gordon, JI				Lin, SS; Manchester, JK; Gordon, JI			Sip2, an N-myristoylated beta subunit of Snf1 kinase, regulates aging in Saccharomyces cerevisiae by affecting cellular histone kinase activity, recombination at rDNA loci, and silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SUBCELLULAR-LOCALIZATION; GLUCOSE REPRESSION; YEAST GENE; SIR2; ACTIVATION; PHOSPHORYLATION; LONGEVITY; SUBSTRATE; BINDING	Saccharomyces cerevisiae has evolved a number of mechanisms for sensing glucose. In the present study we examine the mechanism by which one of these pathways, involving Snf1, regulates cellular aging. Snf1 is a heterotrimer composed of a catalytic alpha subunit (Snf1p) that phosphorylates target proteins at Ser/Thr residues, an activating gamma subunit (Snf4p), and a beta subunit (Sip1p, Sip2p, or Gal83). We previously showed that forced expression of Snf1p or loss of Sip2p, but not the other 13 subunits, causes accelerated aging, while removal of Snf4p extends life span (Ashrafi, K., Lin, S. S., Manchester, J. K., and Gordon, J. I. (2000) Genes Dev. 14, 18721885). We now demonstrate that in wild type cells, there is an age-associated shift in Sip2p from the plasma membrane to the cytoplasm, a prominent redistribution of Snf4p from the plasma membrane to the nucleus, a modest increase in nuclear Snflp, and a concomitant increase in cellular Snf1 histone H3 kinase activity. Covalent attachment of myristate to the N-terminal Gly of Sip2p is essential for normal cellular life span. When plasma membrane association of Sip2p is abolished by a mutation that blocks its N-myristoylation, Snf4p is shifted to the nucleus. Rapidly aging sip2Delta cells have higher levels of histone H3 kinase activity than their generation-matched isogenic wild type counterparts. Increased Snf1 activity is associated with augmented recombination at rDNA loci, plus desilencing at sites affected by Snf1-catalyzed Ser(10) phosphorylation of historic H3 (the INO1 promoter plus targets of the transcription factor Adr1p). The rapid-aging phenotype of sip2Delta cells is fully rescued by blocking recombination at rDNA loci with a fob1Delta allele; rescue is not accompanied by amelioration of an age-associated shift toward gluconeogenesis and glucose storage. Together, these findings suggest that Sip2p acts as a negative regulator of nuclear Snf1 activity in young cells by sequestering its activating gamma subunit at the plasma membrane and that loss of Sip2p from the plasma membrane to the cytoplasm in aging cells facilities Snf4p entry into the nucleus so that Snf1 can modify chromatin structure.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu			NIAID NIH HHS [AI38200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Ashrafi K, 2000, GENE DEV, V14, P1872; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; BARBEHENN EK, 1976, ANAL BIOCHEM, V70, P554, DOI 10.1016/0003-2697(76)90482-6; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Farazi TA, 2000, BIOCHEMISTRY-US, V39, P15807, DOI 10.1021/bi002074t; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1016/S0168-6445(00)00059-0; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Lodge JK, 1998, J BIOL CHEM, V273, P12482, DOI 10.1074/jbc.273.20.12482; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MULLER I, 1971, ARCH MIKROBIOL, V77, P20, DOI 10.1007/BF00407985; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PASSONEAU JV, 1993, ENZYMATIC ANAL PRACT; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Young ET, 2002, J BIOL CHEM, V277, P38095, DOI 10.1074/jbc.M206158200	41	71	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13390	13397		10.1074/jbc.M212818200	http://dx.doi.org/10.1074/jbc.M212818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562756	hybrid			2022-12-27	WOS:000182189500101
J	Ray, RM; McCormack, SA; Covington, C; Viar, MJ; Zheng, Y; Johnson, LR				Ray, RM; McCormack, SA; Covington, C; Viar, MJ; Zheng, Y; Johnson, LR			The requirement for polyamines for intestinal epithelial cell migration is mediated through Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IEC-6 CELLS; FOCAL ADHESIONS; RHO-PROTEINS; F-ACTIN; DEPLETION; GROWTH; INHIBITORS; EXPRESSION; ACTIVATION; MECHANISM	The rapid migration of intestinal epithelial cells is important to the healing 4 mucosal ulcers and wounds. This cell migration requires the presence of polyamines and the activation of RhoA. RhoA activity, however, is not sufficient for migration because polyamine depletion inhibited the migration of IEC-6 cells expressing constitutively active RhoA. The current study examines the role of Rac1 and Cdc42 in cell migration and whether their activities are polyamine-dependent. Polyamine depletion with alpha-difluoromethylornithine inhibited the activities of RhoA, Rac1, and Cdc42. This inhibition was prevented by supplying exogenous putrescine in the presence of a-difluoromethylornithine. IEC-6 cells transfected with constitutively active Rac1 and Cdc42 migrated more rapidly than vector-transfected cells, whereas cells expressing dominant negative Rac1 and Cdc42 migrated more slowly. Polyamine depletion had no effect on the migration of cells expressing Rac1 and only partially inhibited the migration of those expressing Cdc42. Although polyamine depletion caused the disappearance of actin stress fibers in cells transfected with empty vector, it had no effect on cells expressing Rac1. Constitutively active Rac1 increased RhoA and Cdc42 activity in both normal and polyamine-depleted cells. These results demonstrate that Rac1, RhoA, and Cdc42 are required for optimal epithelial cell migration and that Rac1 activity is sufficient for cell migration in the absence of polyamines due to its ability to activate RhoA and Cdc42 as well as its own effects on the process of cell migration. These data imply that the involvement of polyamines in cell migration occurs either at Rac1 itself or upstream from Rac1.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Johnson, LR (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIDDK NIH HHS [DK 52784] Funding Source: Medline; NIGMS NIH HHS [GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham VC, 1999, BIOPHYS J, V77, P1721, DOI 10.1016/S0006-3495(99)77018-9; Bachrach U, 2001, NEWS PHYSIOL SCI, V16, P106, DOI 10.1152/physiologyonline.2001.16.3.106; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; EDELMAN GM, 1992, DEV DYNAM, V192, P2; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GOKE M, 1996, AM J PHYSIOL, V271, P729; GRANT NJ, 1983, EUR J CELL BIOL, V30, P67; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KAMINSKA B, 1992, FEBS LETT, V304, P198, DOI 10.1016/0014-5793(92)80618-Q; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MARQUET R, 1998, BIOCHEM PHARMACOL, V37, P1857; MCCORMACK SA, 1994, AM J PHYSIOL, V267, pC715, DOI 10.1152/ajpcell.1994.267.3.C715; McCormack SA, 1999, AM J PHYSIOL-CELL PH, V276, pC459, DOI 10.1152/ajpcell.1999.276.2.C459; MCCORMACK SA, 1992, AM J PHYSIOL-GASTR L, V263, P426; MCCORMACK SA, 1993, AM J PHYSIOL-GASTR L, V264, P367; MCLEAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V950, P243, DOI 10.1016/0167-4781(88)90120-0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOORE R, 1989, LAB INVEST, V60, P227; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Patel AR, 1998, AM J PHYSIOL-CELL PH, V275, pC590, DOI 10.1152/ajpcell.1998.275.2.C590; Pfeffer LM, 2001, J BIOL CHEM, V276, P45909, DOI 10.1074/jbc.M108097200; POHJANPELTO P, 1981, NATURE, V293, P475, DOI 10.1038/293475a0; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rao JN, 2001, AM J PHYSIOL-CELL PH, V280, pC993, DOI 10.1152/ajpcell.2001.280.4.C993; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAKAMAKI Y, 1989, BIOCHEM PHARMACOL, V38, P1083, DOI 10.1016/0006-2952(89)90252-9; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; SCHUBER F, 1989, BIOCHEM J, V260, P1; SHINDLER M, 1980, P NATL ACAD SCI USA, V77, P1457; SILEN W, 1985, ANNU REV PHYSIOL, V47, P217; WANG JY, 1991, GASTROENTEROLOGY, V100, P333, DOI 10.1016/0016-5085(91)90200-5; Wang JY, 1996, AM J PHYSIOL-GASTR L, V270, pG355, DOI 10.1152/ajpgi.1996.270.2.G355; Wang JY, 2000, AM J PHYSIOL-CELL PH, V278, pC303, DOI 10.1152/ajpcell.2000.278.2.C303; WANG JY, 1990, AM J PHYSIOL, V259, P584; Yuan Q, 2000, AM J PHYSIOL-GASTR L, V278, pG49, DOI 10.1152/ajpgi.2000.278.1.G49	42	66	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13039	13046		10.1074/jbc.M208741200	http://dx.doi.org/10.1074/jbc.M208741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574162	hybrid			2022-12-27	WOS:000182189500058
J	Tremblay, M; Herblot, S; Lecuyer, E; Hoang, T				Tremblay, M; Herblot, S; Lecuyer, E; Hoang, T			Regulation of pT alpha gene expression by a dosage of E2A, HEB, and SCL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL DEVELOPMENT; LOOP-HELIX PROTEINS; TRANSGENIC MICE; LYMPHOCYTE DEVELOPMENT; THYMOCYTE DEVELOPMENT; SIGNALING PATHWAY; B-LYMPHOCYTE; IN-VIVO; TRANSCRIPTION; ENHANCER	The expression of the pTalpha gene is required for effective selection, proliferation, and survival of beta T-cell receptor (betaTCR)-expressing immature thymocytes. Here, we have identified two phylogenetically conserved E-boxes within the pTalpha enhancer sequence that are required for optimal enhancer activity and for its stage-specific activity in immature T cells. We have shown that the transcription factors E2A and HEB associate with high affinity to these E-boxes. Moreover, we have identified pTalpha as a direct target of E2A-HEB heterodimers in immature thymocytes because they specifically occupy the enhancer in vivo. In these cells, pTalpha mRNA levels are determined by the presence of one or two functional E2A or HEB alleles. Furthermore, E2A/HEB transcriptional activity is repressed by heterodimerization with SCL, a transcription factor that is turned off in differentiating thymocytes exactly at a stage when pTalpha is up-regulated. Taken together, our observations suggest that the dosage of E2A, HEB, and SCL determines pTalpha gene expression in immature T cells.	Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Program Mol Biol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Hoang, T (corresponding author), Inst Rech Clin Montreal, 110 Ave Pins Oueset, Montreal, PQ H2W 1R7, Canada.							Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; Barndt R, 1999, J IMMUNOL, V163, P3331; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Blom B, 1999, EMBO J, V18, P2793, DOI 10.1093/emboj/18.10.2793; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Goardon N, 2002, BLOOD, V100, P491, DOI 10.1182/blood.V100.2.491; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gounari F, 2002, NAT IMMUNOL, V3, P489, DOI 10.1038/ni778; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Liu XD, 1999, J BIOL CHEM, V274, P3285, DOI 10.1074/jbc.274.6.3285; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pan LH, 2002, J IMMUNOL, V168, P3923, DOI 10.4049/jimmunol.168.8.3923; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Petersson K, 2002, EUR J IMMUNOL, V32, P911, DOI 10.1002/1521-4141(200203)32:3<911::AID-IMMU911>3.0.CO;2-H; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Rabbitts T. H., 1997, Leukemia (Basingstoke), V11, P271; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Takeuchi A, 2001, J IMMUNOL, V167, P2157, DOI 10.4049/jimmunol.167.4.2157; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang BP, 1997, IMMUNOL REV, V157, P53, DOI 10.1111/j.1600-065X.1997.tb00973.x; Wang NH, 1998, INT IMMUNOL, V10, P1777, DOI 10.1093/intimm/10.12.1777; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	52	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12680	12687		10.1074/jbc.M209870200	http://dx.doi.org/10.1074/jbc.M209870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566462	hybrid			2022-12-27	WOS:000182189500013
J	Fourgeaud, L; Bessis, AS; Rossignol, F; Pin, JP; Olivo-Marin, JC; Hemar, A				Fourgeaud, L; Bessis, AS; Rossignol, F; Pin, JP; Olivo-Marin, JC; Hemar, A			The metabotropic glutamate receptor mGluR5 is endocytosed by a clathrin-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-2 MUSCARINIC ACETYLCHOLINE; SPLICE VARIANTS; LIPID RAFTS; G-PROTEINS; DYNAMIN; INTERNALIZATION; AGONIST; RAT; CAVEOLAE; EXPRESSION	Metabotropic glutamate receptors 5 (mGluR5) are members of the growing group C G protein-coupled receptor family. Widely expressed in mammalian brain, they are involved in modulation of the glutamate transmission. By means of transfection of mGluR5 receptors in COS-7 cells and primary hippocampal neurons in culture followed by immunocytochemistry and quantitative image analysis and by a biochemical assay, we have studied the internalization of mGluR5 splice variants. mGluR5a and -5b were endocytosed in COS-7 cells as well as in axons and dendrites of cultured neurons. Endocytosis occurred even in the absence of receptor activity, because receptors mutated in the glutamate binding site were still internalized as well as receptors in which endogenous activity had been inhibited by an inverse agonist. We have measured a constitutive rate of endocytosis of 11.7%/min for mGluR5a. We report for the first time the endocytosis pathway of mGluR5. Internalization of mGluR5 is not mediated by clathrin-coated pits. Indeed, inhibition of this pathway by Eps15 dominant negative mutants did not disturb their endocytosis. However, the large GTPase dynamin 2 is implicated in the endocytosis of mGluR5 in COS-7. mGluR5 is the first shown member of the group C G-protein coupled receptor family internalized by a nonconventional pathway.	Univ Bordeaux 2, Inst Francois Magendie, CNRS, Physiol Cellulaire Synapse UMR 5091, F-33077 Bordeaux, France; CNRS, CCIPE, Mecan Mol Commun Cellulaires UPR 9023, F-34094 Montpellier 5, France; Inst Pasteur, CNRS, Anal Images Quantitat URA 1947, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hemar, A (corresponding author), Univ Bordeaux 2, Inst Francois Magendie, CNRS, Physiol Cellulaire Synapse UMR 5091, Rue Camille St Saens, F-33077 Bordeaux, France.	ahemar@u-bordeaux2.fr	Olivo-Marin, Jean-Christophe/K-4428-2015; Pin, Jean-Philippe/Y-6668-2019	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; Pin, Jean-Philippe/0000-0002-1423-345X				Albasanz JL, 2002, MOL BRAIN RES, V99, P54; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Ango F, 2000, J NEUROSCI, V20, P8710; Becher A, 2001, J NEUROCHEM, V79, P787, DOI 10.1046/j.1471-4159.2001.00614.x; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Cinar H, 2001, BIOCHEMISTRY-US, V40, P14030, DOI 10.1021/bi011025t; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAUTRYVARSAT A, 2001, ENDOCYTOSIS, P27; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Doherty AJ, 1999, BIOCHEM J, V341, P415, DOI 10.1042/0264-6021:3410415; Francesconi A, 2002, J NEUROSCI, V22, P2196, DOI 10.1523/JNEUROSCI.22-06-02196.2002; Garrido JJ, 2001, EMBO J, V20, P5950, DOI 10.1093/emboj/20.21.5950; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Goslin K., 1991, CULTURING NERVE CELL, P251; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Hemar A, 1997, J NEUROSCI, V17, P9026; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Hubert GW, 2001, J NEUROSCI, V21, P1838, DOI 10.1523/JNEUROSCI.21-06-01838.2001; JOLY C, 1995, J NEUROSCI, V15, P3970; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Liu MT, 2000, J NEUROSCI, V20, P3200, DOI 10.1523/JNEUROSCI.20-09-03200.2000; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Martin-Negrier ML, 2000, NEUROSCIENCE, V99, P257, DOI 10.1016/S0306-4522(00)00187-1; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mundell SJ, 2001, J NEUROCHEM, V78, P546, DOI 10.1046/j.1471-4159.2001.00421.x; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Olivo-Marin JC, 2002, PATTERN RECOGN, V35, P1989, DOI 10.1016/S0031-3203(01)00127-3; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; Romano C, 1996, J COMP NEUROL, V367, P403, DOI 10.1002/(SICI)1096-9861(19960408)367:3<403::AID-CNE6>3.0.CO;2-9; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Roseberry AG, 2001, J CELL SCI, V114, P739; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; SUBTIL A, 1994, J CELL SCI, V107, P3461; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	63	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12222	12230		10.1074/jbc.M205663200	http://dx.doi.org/10.1074/jbc.M205663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529370	hybrid			2022-12-27	WOS:000182015700066
J	Henderson, C; Mizzau, M; Paroni, G; Maestro, R; Schneider, C; Brancolini, C				Henderson, C; Mizzau, M; Paroni, G; Maestro, R; Schneider, C; Brancolini, C			Role of caspases, bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) suberoylanilide hydroxamic acid and (SAHA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-CYCLE; ACTIVATION; CANCER; PROTEINS; DIFFERENTIATION; MITOCHONDRIA; APOPTOSOME; INDUCTION; MECHANISM	Histone deacetylase activity is potently inhibited by hydroaximc acid derivatives such as suberoylanilide hydroxamic acid (SARA) and trichostatin-A (TSA). These inhibitors specifically induce differentiation/apoptosis of transformed cells in vitro and suppress tumor growth in vivo. Because of its low toxicity, SARA is currently evaluated in clinical trials for the treatment of cancer. SARA and TSA induce apoptosis, which is characterized by mitochondrial stress, but so far, the critical elements of this apoptotic program remain poorly defined. To characterize in more detail this apoptotic program, we used human cell lines containing alterations in important elements of apoptotic response such as: p53, Bcl-2, caspase-9, and caspase-3. We demonstrate that caspase-9 is critical for apoptosis induced by SARA and TSA and that efficient proteolytic activation of caspase-2, caspase-8, and caspase-7 strictly depends on caspase-9. Bcl-2 efficiently antagonizes cytochrome c release and apoptosis in response to both histone deacetylase inhibitors. We provide evidences that translocation into the mitochondria of the Bcl-2 family member Bid depends on caspase-9 and that this translocation is a late event during TSA-induced apoptosis. We also demonstrate that the susceptibility to TSA- and SARA-induced cell death is regulated by p53.	Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, I-33100 Udine, Italy; Lab Nazl Consorzio Interuniv Biotecnol AREA, I-34142 Trieste, Italy; IRCCS, CRO, MMNP Unit Expt Oncol, Natl Canc Inst, I-33081 Aviano, PN, Italy; Univ Udine, MATI Ctr Excellence, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; IRCCS Aviano (CRO); University of Udine	Brancolini, C (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, P Kolbe 4, I-33100 Udine, Italy.	cbrancolini@makek.dstb.uniud.it	Maestro, Roberta/P-9748-2019; Paroni, Gabriela/J-4848-2018; Maestro, Roberta/M-1846-2015	Maestro, Roberta/0000-0002-6642-5592; Paroni, Gabriela/0000-0003-0132-0869; Maestro, Roberta/0000-0002-6642-5592; BRANCOLINI, Claudio/0000-0002-6597-5373				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Bouillet P, 2002, J CELL SCI, V115, P1567; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuvillier O, 1999, BLOOD, V94, P3583, DOI 10.1182/blood.V94.10.3583.422k31_3583_3592; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Liu JR, 2002, CANCER RES, V62, P924; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Medina V, 1997, CANCER RES, V57, P3697; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sawa H, 2001, Brain Tumor Pathol, V18, P109, DOI 10.1007/BF02479423; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang JX, 1999, CANCER RES, V59, P2766; Wang XD, 2001, GENE DEV, V15, P2922; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhu WG, 2001, CANCER RES, V61, P1327	51	143	152	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12579	12589		10.1074/jbc.M213093200	http://dx.doi.org/10.1074/jbc.M213093200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556448	hybrid			2022-12-27	WOS:000182015700111
J	Thannickal, VJ; Lee, DY; White, ES; Cui, Z; Larios, JM; Chacon, R; Horowitz, JC; Day, RM; Thomas, PE				Thannickal, VJ; Lee, DY; White, ES; Cui, Z; Larios, JM; Chacon, R; Horowitz, JC; Day, RM; Thomas, PE			Myofibroblast differentiation by transforming growth factor-beta 1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG FIBROBLASTS; SMOOTH MUSCLE ACTIN; FACTOR-BETA; EXTRACELLULAR-MATRIX; GRANULATION-TISSUE; WOUND CONTRACTION; GENE-EXPRESSION; GROWTH-FACTOR-BETA-1; INDUCTION; FIBROSIS	Myofibroblast differentiation and activation by transforming growth factor-beta1 (TGF-beta1) is a critical event in the pathogenesis of human fibrotic diseases, but regulatory mechanisms for this effect are unclear. In this report, we demonstrate that stable expression of the myofibroblast phenotype requires both TGF-beta1 and adhesion-dependent signals. TGF-beta1-induced myofibroblast differentiation of lung fibroblasts is blocked in non-adherent cells despite the preservation of TGF-beta receptor(s)-mediated signaling of Smad2 phosphorylation. TGF-beta1 induces tyrosine phosphorylation of focal adhesion kinase (FAK) including that of its autophosphorylation site, Tyr-397, an effect that is dependent on cell adhesion and is delayed relative to early Smad signaling. Pharmacologic inhibition of FAR or expression of kinase-deficient FAK, mutated by substituting Tyr-397 with Phe, inhibit TGF-beta1-induced alpha-smooth muscle actin expression, stress fiber formation, and cellular hypertrophy. Basal expression of a-smooth muscle actin is elevated in cells grown on fibronectin-coated dishes but is decreased on laminin and poly-D-lysine, a nonintegrin binding polypeptide. TGF-beta1 up-regulates expression of integrins and fibronectin, an effect that is associated with autophosphorylation/activation of FAK. Thus, a safer and more effective therapeutic strategy for fibrotic diseases characterized by persistent myofibroblast activation may be to target this integrin/FAK pathway while not interfering with tumor-suppressive functions of TGF-beta1/Smad signaling.	Univ Michigan, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, Ann Arbor, MI 48109 USA; Tufts Univ, New England Med Ctr, Div Pulm & Crit Care, Dept Med, Boston, MA 02111 USA	University of Michigan System; University of Michigan; Tufts Medical Center; Tufts University	Thannickal, VJ (corresponding author), Univ Michigan, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.			Horowitz, Jeffrey/0000-0002-1505-2837; White, Eric/0000-0003-4060-8443	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007749, R01HL067967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67967, T32 HL007749] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dugina V, 2001, J CELL SCI, V114, P3285; Finlay GA, 2000, J BIOL CHEM, V275, P27650; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEINO J, 1989, J BIOL CHEM, V264, P380; Hubbard R, 2000, AM J RESP CRIT CARE, V161, P5, DOI 10.1164/ajrccm.161.1.9906062; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Larios JM, 2001, J BIOL CHEM, V276, P17437, DOI 10.1074/jbc.M100426200; LIKE B, 1986, J BIOL CHEM, V261, P3426; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SAPPINO AP, 1990, LAB INVEST, V63, P144; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; SKALLI O, 1989, LAB INVEST, V60, P275; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wang QJ, 1999, THORAX, V54, P805, DOI 10.1136/thx.54.9.805; ZHANG K, 1994, AM J PATHOL, V145, P114	39	464	490	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12384	12389		10.1074/jbc.M208544200	http://dx.doi.org/10.1074/jbc.M208544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531888	hybrid			2022-12-27	WOS:000182015700086
J	Ching, YP; Wong, CM; Chan, SF; Leung, THY; Ng, DCH; Jin, DY; Ng, IOL				Ching, YP; Wong, CM; Chan, SF; Leung, THY; Ng, DCH; Jin, DY; Ng, IOL			Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GENOMIC INSTABILITY; CHROMOSOME 13Q; SAM DOMAIN; GENE; MUTATIONS; HETEROZYGOSITY; PATHWAYS; EFFECTOR; CDC42HS	Hepatocellular carcinoma (HCC) is a major malignancy in many parts of the world, especially in Asia and Africa. Loss of heterozygosity (LOH) on the long arm of chromosome 13 has been reported in HCC. In search of tumor suppressor genes in this region, here we have identified DLC2 (for deleted in liver cancer 2) at 13q12.3 encoding a novel Rho family GTPase-activating protein (GAP). DLC2 mRNA is ubiquitously expressed in normal tissues but was significantly underexpressed in 18% (8/45) of human HCCs. DLC2 is homologous to DLC1, a previously identified tumor suppressor gene at 8p22-p21.3 frequently deleted in HCC. DLC2 encodes a novel protein with a RhoGAP domain, a SAM (sterile alpha motif) domain related to p73/p63, and a lipid-binding StAR-related lipid transfer (START) domain. Biochemical analysis indicates that DLC2 protein has GAP activity specific for small GTPases RhoA and Cdc42. Expression of the GAP domain of DLC2 sufficiently inhibits the Rho-mediated formation of actin stress fibers. Introduction of human DLC2 into mouse fibroblasts suppresses Ras signaling and Ras-induced cellular transformation in a GAP-dependent manner. Taken together, our findings suggest a role for DLC2 in growth suppression and hepatocarcinogenesis.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China.	dyjin@hkucc.hku.hk; iolng@hku.hk	WONG, Chun-Ming/A-6739-2009; Ching, Yick Pang/C-4244-2009	WONG, Chun-Ming/0000-0002-2497-7858; CHING, Yick Pang/0000-0002-6461-8358; Ng, Irene Oi-lin/0000-0001-7532-2029				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1995, METHOD ENZYMOL, V256, P114; ANGEL P, 1989, New Biologist, V1, P35; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bosch FX, 1997, LIVER CANCER, P13; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kawai H, 2000, HEPATOLOGY, V31, P1246, DOI 10.1053/jhep.2000.7298; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Ng IOL, 2000, CANCER RES, V60, P6581; NG IOL, 1994, ONCOGENE, V9, P985; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SCORSONE KA, 1992, CANCER RES, V52, P1635; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wong CM, 2002, CLIN CANCER RES, V8, P2266; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wong N, 2000, HEPATOLOGY, V32, P1060, DOI 10.1053/jhep.2000.19349; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhou HJ, 2001, J BIOL CHEM, V276, P28933, DOI 10.1074/jbc.M103893200; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	53	154	159	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10824	10830		10.1074/jbc.M208310200	http://dx.doi.org/10.1074/jbc.M208310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531887	hybrid			2022-12-27	WOS:000181777500108
J	Miller, M; Shuman, JD; Sebastian, T; Dauter, Z; Johnson, PF				Miller, M; Shuman, JD; Sebastian, T; Dauter, Z; Johnson, PF			Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; C/EBP-ALPHA; CRYSTAL-STRUCTURE; COMPLEX; IDENTIFICATION; DOMAIN; GCN4; GENE; GRANULOPOIESIS; ADIPOGENESIS	CCAAT/enhancer-binding proteins (C/EBPs) are basic region leucine zipper (bZIP) transcription factors that regulate cell differentiation, growth, survival, and inflammation. To understand the molecular basis of DNA recognition by the C/EBP family we determined the x-ray structure of a C/EBPalpha bZIP polypeptide bound to its cognate DNA site (A(-5)T(-4)T(-3)G(-2)C(-1)G(1)A(3)T(5)) and characterized several basic region mutants. Binding specificity is provided by interactions of basic region residues Arg(289), Asn(292), Ala(295), Val(296), Ser(299), and Arg(300) with DNA bases. A striking feature of the C/EBPalpha protein-DNA interface that distinguishes it from known 89 bZIP-DNA complexes is the central role of Are, which is hydrogen-bonded to base A(3), phosphate, Asn(292) (invariant in bZlPs), and Asn(293). The conformation of Arg(289) is also restricted by Tyr(285). In accordance with the structural model, mutation of Arg(289) or a pair of its interacting partners (Tyr(285) and Asn(293)) abolished C/EBPalpha binding activity. Val(296) (Ala in most other bZlPs) contributes to C/EBPalpha specificity by discriminating against purines at position -3 and imposing steric restraints on the invariant Arg(300). Mutating Val(296) to Ala strongly enhanced C/EBPalpha binding to cAMP response element (CRE) sites while retaining affinity for C/EBP sites. Thus, Arg(289) is essential for formation of the complementary protein-DNA interface, whereas Val(296) functions primarily to restrict interactions with related sequences such as CRE sites rather than specifying binding to C/EBP sites. Our studies also help to explain the phenotypes of mice carrying targeted mutations in the C/EBPalpha bZIP region.	NCI, Macromol Crystallog Lab, Prot Struct Sect, Frederick, MD 21702 USA; NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA; Natl Canc Inst, Macromol Crystallog Lab, Synchrotron Radiat Res Sect, Upton, NY 11973 USA; Brookhaven Natl Lab, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Brookhaven National Laboratory	Miller, M (corresponding author), NCI, Macromol Crystallog Lab, Prot Struct Sect, Frederick, MD 21702 USA.		Miller, Maria/I-1636-2013; Johnson, Peter/A-1940-2012	Miller, Maria/0000-0003-0252-5348; Shuman, Jon/0000-0001-8412-9087; Johnson, Peter/0000-0002-4145-4725	NATIONAL CANCER INSTITUTE [Z01BC010328, ZIABC010378, Z01BC010378, ZIABC010328] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Falvey E, 1996, BIOL CHEM, V377, P797; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Fujii Y, 2000, NAT STRUCT BIOL, V7, P889; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; Osada S, 1996, J BIOL CHEM, V271, P3891; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tenen DG, 2001, LEUKEMIA, V15, P688, DOI 10.1038/sj.leu.2402088; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	40	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15178	15184		10.1074/jbc.M300417200	http://dx.doi.org/10.1074/jbc.M300417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578822	hybrid			2022-12-27	WOS:000182516100077
J	Kim, KH; Min, YK; Baik, JH; Lau, LF; Chaqour, B; Chung, KC				Kim, KH; Min, YK; Baik, JH; Lau, LF; Chaqour, B; Chung, KC			Expression of angiogenic factor cyr61 during neuronal cell death via the activation of c-Jun N-terminal kinase and serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; SIGNAL-TRANSDUCTION; CCN FAMILY; APOPTOSIS; PRODUCT; JNK; PROLIFERATION; DIFFERENTIATION; CHONDROGENESIS; SURVIVAL	The immediate early gene, cyr61, is transcriptionally activated within minutes by serum and serum growth factors. The encoded Cyr61 protein is secreted into the extracellular matrix and promotes cell adhesion and migration. In this study, we sought to examine the expression profile of cyr61 gene during neuronal cell death induced by various toxic stimuli and the mechanisms involved. Our data show that toxic stimuli, such as etoposide, significantly increased cyr61 mRNA levels in immortalized hippocampal progenitor (H19-7) cells. Cyr61 transcriptional activation was corroborated at the protein level as well. To identify the upstream signaling cascades involved in cyr61 gene induction, the blocking effect of either JNK or p38 kinase-signaling pathway on cyr61 induction in response to etoposide was tested. Transfection of the cells with a kinase-deficient mutant MEKK, an upstream activator of JNK, significantly decreased the cyr61 expression induced by etoposide. In contrast, cyr61 mRNA levels did not change after pretreatment with SB203580, the p38 kinase inhibitor. When the induction of cyr61 was tested by using several of its deleted promoters driving the expression of reporter gene, the promoter activation occurred primarily within the region containing an SRE-like CArG box. In addition, the SRF, which binds to the CArG site, was directly phosphorylated by active JNK. Furthermore, the blockade of cyr61 gene expression using an antisense encoding cyr61 sequence significantly inhibited the cell death induced by etoposide. Overall, these results suggest that the induction of the immediate early gene, cyr61, is important for neuronal cell death in the central nervous system hippocampal progenitor cells, and JNR activation, but not of p38, as well as the subsequent SRF phosphorylation are involved in cyr61 gene induction.	Yonsei Univ, Coll Sci, Dept Biol, Seodaemun Gu, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seodaemun Gu, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seodaemun Gu, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Mol Biol Lab, Med Res Ctr,Seodaemun Gu, Seoul 120749, South Korea; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pennsylvania	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Seodaemun Gu, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr	Chaqour, Brahim/AEH-1314-2022	Chaqour, Brahim/0000-0002-8516-4324; Lau, Lester/0000-0002-4364-2914	NIDDK NIH HHS [R01 DK060572-03, R01 DK060572, R01 DK-60572] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Chung KC, 1998, NEUROSCI LETT, V255, P155, DOI 10.1016/S0304-3940(98)00733-2; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Fluck M, 2000, BIOCHEM BIOPH RES CO, V270, P488, DOI 10.1006/bbrc.2000.2457; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LYONS AB, 1992, CYTOMETRY, V13, P809; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Tamura I, 2001, AM J PHYSIOL-CELL PH, V281, pC1524, DOI 10.1152/ajpcell.2001.281.5.C1524; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	45	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13847	13854		10.1074/jbc.M210128200	http://dx.doi.org/10.1074/jbc.M210128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576482	hybrid			2022-12-27	WOS:000182405000037
J	Lah, J; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Kinne, J; Wyns, L; Loris, R				Lah, J; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Kinne, J; Wyns, L; Loris, R			Recognition of the intrinsically flexible addiction antidote MazE by a dromedary single domain antibody fragment - Structure, thermodynamics of binding, stability, and influence on interactions with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HEAT-CAPACITY CHANGES; ESCHERICHIA-COLI; F-PLASMID; PROTEIN-STRUCTURE; TOXIN-ANTITOXIN; CCD OPERON; SYSTEM; ENERGETICS; AUTOREGULATION	The Escherichia coli mazEF operon defines a chromosomal addiction module that programs cell death under various stress conditions. It encodes the toxic and long-lived MazF and the labile antidote MazE. The denaturation of MazE is a two-state reversible dimer-monomer transition. At lower concentrations the denatured state is significantly populated. This leads to a new aspect of the regulation of MazE concentration, which may decide about the life and death of the cell. Interactions of MazE with a dromedary antibody domain, cAbMaz1 (previously used as a crystallization aid), as well as with promoter DNA were studied using microcalorimetric and spectroscopic techniques. Unique features of cAbMaz1 enable a specific enthalpy-driven recognition of MazE and, thus, a significant stabilization of its dimeric native conformation. The MazE dimer and the MazE dimer-cAbMaz1 complex show very similar binding characteristics with promoter DNA, i.e. three binding sites with apparent affinities in micromolar range and highly exothermic binding accompanied by large negative entropy contributions. A working model for the MazE-DNA assembly is proposed on the basis of the structural and binding data. Both binding and stability studies lead to a picture of MazE solution structure that is significantly more unfolded than the structure observed in a crystal of the MazE-cAbMaz1 complex.	Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia; Free Univ Brussels, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biol Mol, IL-91120 Jerusalem, Israel; Cent Vet Res Labs, Dubai, U Arab Emirates	University of Ljubljana; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Lah, J (corresponding author), Univ Ljubljana, Fac Chem & Chem Technol, Askerceva 5, Ljubljana 1000, Slovenia.		Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; Brady GP, 1997, BIOPHYS J, V72, P913, DOI 10.1016/S0006-3495(97)78725-3; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Cole JL, 2001, BIOCHEMISTRY-US, V40, P5633, DOI 10.1021/bi010085w; Couturier M, 1998, TRENDS MICROBIOL, V6, P269, DOI 10.1016/S0966-842X(98)01311-0; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; EBERL L, 1992, MOL MICROBIOL, V6, P1969, DOI 10.1111/j.1365-2958.1992.tb01370.x; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Engelberg-Kulka H, 2001, ASM NEWS, V67, P617; Ewert S, 2002, BIOCHEMISTRY-US, V41, P3628, DOI 10.1021/bi011239a; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FREIRE E, 1989, COMMENTS MOL CELL BI, V6, P123; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Green MC, 2000, CANCER TREAT REV, V26, P269, DOI 10.1053/ctrv.2000.0176; Gurney R.W., 1953, IONIC PROCESSES SOLU; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hazan R, 2001, J BACTERIOL, V183, P2046, DOI 10.1128/JB.183.6.2046-2050.2001; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Lah J, 2001, J PHYS CHEM B, V105, P1670, DOI 10.1021/jp002304d; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200; MASUDA Y, 1994, J BACTERIOL, V176, P5861, DOI 10.1128/JB.176.18.5861-5863.1994; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; Press W.H., 1992, NUMERICAL RECIPES, V2, P650; Privalov P L, 1986, Methods Enzymol, V131, P4; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rawlings DE, 1999, FEMS MICROBIOL LETT, V176, P269, DOI 10.1111/j.1574-6968.1999.tb13672.x; RUIZ-ECHEVARRIA M J, 1991, Molecular and General Genetics, V225, P335; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; Sat B, 2001, J BACTERIOL, V183, P2041, DOI 10.1128/JB.183.6.2041-2045.2001; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528	67	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14101	14111		10.1074/jbc.M209855200	http://dx.doi.org/10.1074/jbc.M209855200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12533537	hybrid			2022-12-27	WOS:000182405000071
J	Yu, H; Stasinopoulos, S; Leedman, P; Medcalf, RL				Yu, H; Stasinopoulos, S; Leedman, P; Medcalf, RL			Inherent instability of plasminogen activator inhibitor type 2 mRNA is regulated by tristetraprolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RNA-BINDING PROTEIN; CONTAINING MESSENGER-RNAS; ALPHA-INDUCED APOPTOSIS; 3' UNTRANSLATED REGION; YEAST 3-HYBRID SYSTEM; PHORBOL ESTER; GENE PROMOTER; TRANSCRIPTION FACTOR; RICH ELEMENTS	Plasminogen activator inhibitor type 2 (PAI-2) is a serine protease inhibitor that is subject to regulation at the post-transcriptional level. At least two mRNA instability elements reside within the PAI-2 transcript; one in the coding region and another within the 3'-untranslated region (UTR). For the latter, a functional AU-rich motif (ARE) has been identified that provides a binding site for a number of cellular proteins, including the mRNA stability protein, HuR. In this study, we used the yeast three-hybrid system to screen a human leukocyte cDNA library to identify other proteins that associate with the PAI-2 ARE. This screen identified tristetraprolin (TTP) as a PAI-2 mRNA ARE-binding protein. UV cross-linking and immunoprecipitation experiments showed that TTP expressed in HEK293 cells could associate with the PAI-2 ARE in vitro. Co-transfection of plasmids expressing TTP and PAI-2 in HEK293 cells resulted in an increase in the decay rate of PAI-2 mRNA and loss of PAI-2 protein in a process that was dependent upon the PAI-2 3'-UTR. The 29-nt PAI-2 AU-rich element alone was also capable of conferring TTP-dependent mRNA instability to a reporter transcript. The extent of PAI-2 mRNA stability was remarkably sensitive to TTP since TTP-dependent PAI-2 mRNA decay occurred at TTP levels that were below Western blot detection limits. This study identifies TTP as a functional PAI-2 ARE-binding protein that modulates the post-transcriptional regulation of the PAI-2 gene.	Monash Univ, Box Hill Hosp, Dept Med, Box Hill, Vic 3128, Australia; Univ Western Australia, Western Australian Inst Med Res, Sch Med & Pharmacol,Ctr Med Res, Royal Perth Hosp Unit,Lab Canc Med, Perth, WA 6000, Australia	Box Hill Hospital; Monash University; Royal Perth Hospital; University of Western Australia	Medcalf, RL (corresponding author), Monash Univ, Box Hill Hosp, Dept Med, Box Hill, Vic 3128, Australia.	Robert.Medcalf@med.monash.edu.au	Medcalf, Robert L/E-9632-2011; Leedman, Peter J/O-4044-2014					BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costa M, 1996, EUR J BIOCHEM, V237, P532, DOI 10.1111/j.1432-1033.1996.00532.x; Costa M, 1998, EUR J BIOCHEM, V258, P123, DOI 10.1046/j.1432-1327.1998.2580123.x; Dear AE, 1997, FEBS LETT, V402, P265, DOI 10.1016/S0014-5793(97)00002-1; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; Hibino T, 1999, J INVEST DERMATOL, V112, P85, DOI 10.1046/j.1523-1747.1999.00466.x; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; MA QF, 1991, ONCOGENE, V6, P1277; Mahony D, 1998, EUR J BIOCHEM, V256, P550, DOI 10.1046/j.1432-1327.1998.2560550.x; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; Maurer F, 1996, J BIOL CHEM, V271, P26074, DOI 10.1074/jbc.271.42.26074; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; MEDCALF RL, 1988, J EXP MED, V168, P751, DOI 10.1084/jem.168.2.751; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; Park YW, 1999, BIOTECHNIQUES, V26, P1102, DOI 10.2144/99266st01; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SCHWARTZ BS, 1989, BLOOD, V73, P2188; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Shafren DR, 1999, J VIROL, V73, P7193, DOI 10.1128/JVI.73.9.7193-7198.1999; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Snee M, 2002, J CELL SCI, V115, P4661, DOI 10.1242/jcs.00137; Tierney MJ, 2001, J BIOL CHEM, V276, P13675, DOI 10.1074/jbc.M010627200; VARNUM BC, 1989, ONCOGENE, V4, P119; Yu H, 2002, BLOOD, V99, P2810, DOI 10.1182/blood.V99.8.2810; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	49	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13912	13918		10.1074/jbc.M213027200	http://dx.doi.org/10.1074/jbc.M213027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578825	hybrid			2022-12-27	WOS:000182405000046
J	Chauhan, A; Turchan, J; Pocernich, C; Bruce-Keller, A; Roth, S; Butterfield, DA; Major, EO; Nath, A				Chauhan, A; Turchan, J; Pocernich, C; Bruce-Keller, A; Roth, S; Butterfield, DA; Major, EO; Nath, A			Intracellular human immunodeficiency virus tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; REGULATORY PROTEIN TAT; OXIDATIVE STRESS; HIV-1; CELLS; ACTIVATION; TRANSACTIVATION; MECHANISMS; DAMAGE; BRAIN	The human immunodeficiency virus (HM-Tat protein has been implicated in the neuropathogenesis of HrV infection. However, its role in modulating astroglial-neuronal relationships is poorly understood. Astrocyte infection with HIV has been associated with rapid progression of dementia. We thus initially transfected astrocytes with HIV proviral. DNA and confirmed Tat production in. these cells. Subsequently, using stably Tat-producing asytocyte cell lines, we observed that Tat promoted astrocyte survival by causing a prominent antioxidant effect and resistance to cell injury in these cells. Tat was released extracellularly where it could be taken up by other cells. Tat remained functionally active following uptake and caused long terminal repeat (LTR) transactivation in lymphocytic and astrocytic cell lines. Tat released from astrocytes caused mitochondrial dysfunction, trimming of neurites, and cell death in neurons. Tat neurotoxicity was attenuated by antiTat antibodies, kynurenate or heparan sulfate. The neurotoxic effects of Tat were caused at concentrations lower than that needed to cause LTR transactivation. When Tat-expressing cells were injected into the rat dentate gyrus, Tat was taken up by granule cells and transported along neuronal pathways to the CA3 region where it caused glial cell activation and neurotoxicity. The arginine-rich domain of Tat was essential for both the LTR transactivation and the neurotoxic properties of Tat. Thus HIV-Tat is a potent neurotoxin that may act at distant sites while at the same time it assures its production by preventing cell death in astrocytes where it is produced.	Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA; Univ Kentucky, Dept Chem Anat, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Kentucky; University of Kentucky; University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Nath, A (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, 600 N Wolfe St,Pathol 509, Baltimore, MD 21287 USA.		Bruce-Keller, Annadora/N-1954-2017		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002851, ZIANS002851] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barton CH, 1996, J GEN VIROL, V77, P1643, DOI 10.1099/0022-1317-77-8-1643; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Cheng J, 1998, NEUROSCIENCE, V82, P97, DOI 10.1016/S0306-4522(97)00174-7; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Dorsky DI, 1999, J ACQ IMMUN DEF SYND, V22, P213; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Foga IO, 1997, J ACQ IMMUN DEF SYND, V16, P223, DOI 10.1097/00042560-199712010-00001; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Hudson L, 2000, J NEUROVIROL, V6, P145, DOI 10.3109/13550280009013158; Johnston JB, 2001, ANN NEUROL, V49, P230, DOI 10.1002/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O; Koller H, 2001, EUR J NEUROSCI, V14, P1793, DOI 10.1046/j.0953-816x.2001.01808.x; KOLSON DL, 1994, J GEN VIROL, V75, P1927, DOI 10.1099/0022-1317-75-8-1927; Liu W, 2000, J CELL SCI, V113, P635; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MASLIAH E, 1992, LAB INVEST, V66, P285; Mori I, 1999, J NEUROVIROL, V5, P355, DOI 10.3109/13550289909029476; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1; NATH A, 1995, J NEUROPATH EXP NEUR, V54, P320, DOI 10.1097/00005072-199505000-00005; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Nicolini A, 2001, J NEUROCHEM, V79, P713, DOI 10.1046/j.1471-4159.2001.00568.x; Picklo MJ, 1999, J NEUROCHEM, V72, P1617, DOI 10.1046/j.1471-4159.1999.721617.x; Rappaport J, 1999, J LEUKOCYTE BIOL, V65, P458, DOI 10.1002/jlb.65.4.458; RUBEN S, 1989, J VIROL, V63, P1; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Turchan J, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-3; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Wilt SG, 2000, J NEUROSCI RES, V62, P440, DOI 10.1002/1097-4547(20001101)62:3<440::AID-JNR14>3.3.CO;2-D; Wu SY, 2002, NEOPLASIA, V4, P486, DOI 10.1038/sj.neo.7900264; Yang LP, 1997, VIROLOGY, V235, P48, DOI 10.1006/viro.1997.8672	43	142	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13512	13519		10.1074/jbc.M209381200	http://dx.doi.org/10.1074/jbc.M209381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551932	hybrid			2022-12-27	WOS:000182189500115
J	Condliffe, SB; Carattino, MD; Frizzell, RA; Zhang, H				Condliffe, SB; Carattino, MD; Frizzell, RA; Zhang, H			Syntaxin 1A regulates ENaC via domain-specific interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; SODIUM-CHANNEL; CRYSTAL-STRUCTURE; LIDDLES SYNDROME; COMPLEX; TRAFFICKING; MUTATIONS; INHIBITION; EXOCYTOSIS; EXPRESSION	The epithelial sodium channel (ENaC) is a heterotrimeric protein responsible for Na+ absorption across the apical membranes of several absorptive epithelia. The rate of Na+ absorption is governed in part by regulated membrane trafficking mechanisms that control the apical membrane ENaC density. Previous reports have implicated a role for the t-SNARE protein, syntaxin 1A (S1A), in the regulation of ENaC current (I-Na). In the present study, we examine the structure-function relations influencing S1A-ENaC interactions. In vitro pull-down assays demonstrated that S1A directly interacts with the C termini of the alpha-, beta-, and gamma-ENaC subunits but not with the N terminus of any ENaC subunit. The H3 domain of S1A is the critical motif mediating S1A-ENaC binding. Functional studies in ENaC expressing Xenopus oocytes revealed that deletion of the H3 domain of co-expressed S1A eliminated its inhibition of I-Na, and acute injection of a GST-H3 fusion protein into ENaC expressing oocytes inhibited I-Na to the same extent as S1A co-expression. In cell surface ENaC labeling experiments, reductions in plasma membrane ENaC accounted for the H3 domain inhibition Of I-Na. Individually substituting C terminus-truncated alpha-, beta-, or gamma-ENaC subunits for their wild-type counterparts reversed the S1A-induced inhibition of I-Na, and oocytes expressing ENaC comprised of three C terminus-truncated subunits showed no S1A inhibition Of I-Na. C terminus truncation or disruption of the C terminus beta-subunit PY motif increases I-Na by interfering with ENaC endocytosis. In contrast to subunit truncation, a beta-ENaC PY mutation did not relieve S1A inhibition of I-Na, suggesting that S1A does not perturb Nedd4 interactions that lead to ENaC endocytosis/degradation. This study provides support for the concept that S1A inhibits ENaC-mediated Na+ transport by decreasing cell surface channel number via direct protein-protein interactions at the ENaC C termini.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu; Zhangh@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Betz A, 1997, J BIOL CHEM, V272, P2520; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rettig J, 1997, J NEUROSCI, V17, P6647; Rotin D, 2000, CURR OPIN NEPHROL HY, V9, P529, DOI 10.1097/00041552-200009000-00012; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200	40	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12796	12804		10.1074/jbc.M210772200	http://dx.doi.org/10.1074/jbc.M210772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562778	hybrid			2022-12-27	WOS:000182189500028
J	Corbit, KC; Trakul, N; Eves, EM; Diaz, B; Marshall, M; Rosner, MR				Corbit, KC; Trakul, N; Eves, EM; Diaz, B; Marshall, M; Rosner, MR			Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; NF-KAPPA-B; GROWTH-FACTOR ACTIVATION; CRYSTAL-STRUCTURE; PATHWAY; ZETA; PHOSPHORYLATION; SUPPRESSION; SCAFFOLD; COMPLEX	Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1, whereas mutant RKIP (S153V or S153E) remains bound. Increased expression of PKC can rescue inhibition of the mitogen-activated protein (MAP) kinase signaling cascade by wild-type but not mutant S153V RKIP. Taken together, these results constitute the first model showing how phosphorylation by PKC relieves a key inhibitor of the Raf/MAP kinase signaling cascade and may represent a general mechanism for the regulation of MAP kinase pathways.	Univ Chicago, Ben May Canc Inst Canc Res, Chicago, IL 60637 USA; Lilly Res Labs, Indianapolis, IN 46285 USA; Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago; Eli Lilly; University of Chicago; University of Chicago	Rosner, MR (corresponding author), Univ Chicago, Ben May Canc Inst Canc Res, 5841 S Maryland Ave, Chicago, IL 60637 USA.	m-rosner@uchicago.edu			NATIONAL CANCER INSTITUTE [T32CA009594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS038846] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09594] Funding Source: Medline; NIGMS NIH HHS [T32GM07151] Funding Source: Medline; NINDS NIH HHS [NS38846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Corbit KC, 2000, MOL CELL BIOL, V20, P5392, DOI 10.1128/MCB.20.15.5392-5403.2000; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Morrison DK, 2001, J CELL SCI, V114, P1609; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ojika K, 2000, PROG NEUROBIOL, V60, P37, DOI 10.1016/S0301-0082(99)00021-0; OJIKA K, 1992, BRAIN RES, V572, P164, DOI 10.1016/0006-8993(92)90465-L; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; Serre L, 2001, J MOL BIOL, V310, P617, DOI 10.1006/jmbi.2001.4784; Simister PC, 2002, ACTA CRYSTALLOGR D, V58, P1077, DOI 10.1107/S090744490200522X; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Yuasa H, 2001, DEV BRAIN RES, V127, P1, DOI 10.1016/S0165-3806(01)00097-9; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	42	275	302	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13061	13068		10.1074/jbc.M210015200	http://dx.doi.org/10.1074/jbc.M210015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551925	hybrid			2022-12-27	WOS:000182189500061
J	Muhlenhoff, M; Stummeyer, K; Grove, M; Sauerborn, M; Gerardy-Schahn, R				Muhlenhoff, M; Stummeyer, K; Grove, M; Sauerborn, M; Gerardy-Schahn, R			Proteolytic processing and oligomerization of bacteriophage-derived endosialidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-N-ACETYLNEURAMINIDASE; COMPLETE NUCLEOTIDE-SEQUENCE; CELL-ADHESION MOLECULE; LONG-TERM POTENTIATION; ESCHERICHIA-COLI; POLYSIALIC ACID; CAPSULAR POLYSACCHARIDE; K1E ENDOSIALIDASE; TAIL-FIBER; LTF GENE	Bacteriophages infecting the neuroinvasive pathogen Escherichia coli K1 require an endosialidase to penetrate the polysialic acid capsule of the host. Sequence information is available for the endosialidases endoNE, endoNF, and endoN63D of the K1-specific phages phiK1E, phiK1F, and 63D, respectively. The cloned sequences share a highly conserved catalytic domain but differ in the length of the N- and C-terminal parts. Although the expression of active recombinant enzyme succeeded in the case of endoNE, it failed for endoNF. Protein alignments of all three endosialidase sequences gave rise to the assumption that inactivity of the cloned endoNF is caused by a C-terminal truncation. By reinvestigation of the respective gene locus in the, phiK1F genome, we identified an extended open reading frame of 3195 bp, encoding a 119-kDa protein. Full-length endoNF contains the C-terminal domain conserved in all endosialidases, which may act as an intramolecular chaperone. Comparative studies carried out with endoNE and endoNF demonstrate that endosialidases are proteolytically processed, releasing the C-terminal domain. Using a mutational approach in combination with protein analytical techniques we demonstrate that (i) the C-terminal domain is a common feature of endosialidases and other tail fiber proteins; (ii) the integrity of the C-terminal domain and its presence in the nascent protein are crucial for the formation of active enzymes; (iii) proteolytic processing is not essential for enzymatic activity; and (iv) functional folding is a prerequisite for trimerization of endoNF.	Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, D-30625 Hannover, Germany; Univ Giessen, Inst Mikro & Mol Biol, D-35390 Giessen, Germany	Hannover Medical School; Justus Liebig University Giessen	Muhlenhoff, M (corresponding author), Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrow P, 1998, CLIN DIAGN LAB IMMUN, V5, P294, DOI 10.1128/CDLI.5.3.294-298.1998; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; Clarke BR, 2000, J BACTERIOL, V182, P3761, DOI 10.1128/JB.182.13.3761-3766.2000; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Daniel L, 2001, ONCOGENE, V20, P997, DOI 10.1038/sj.onc.1204176; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GROSS RJ, 1977, J CLIN MICROBIOL, V6, P548; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; Hanfling P, 1996, J BACTERIOL, V178, P4747; HELLER KJ, 1986, J BACTERIOL, V167, P1071, DOI 10.1128/jb.167.3.1071-1073.1986; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; KALIMAN AV, 1995, FEBS LETT, V366, P46, DOI 10.1016/0014-5793(95)00482-O; Kanamaru S, 2002, NATURE, V415, P553, DOI 10.1038/415553a; KWIATKOWSKI B, 1982, J VIROL, V43, P697, DOI 10.1128/JVI.43.2.697-704.1982; Leggate DR, 2002, MOL MICROBIOL, V44, P749, DOI 10.1046/j.1365-2958.2002.02908.x; Legoux R, 1996, J BACTERIOL, V178, P7260, DOI 10.1128/jb.178.24.7260-7264.1996; LIFELY MR, 1986, CARBOHYD RES, V156, P123, DOI 10.1016/S0008-6215(00)90104-6; LONG GS, 1995, BIOCHEM J, V309, P543, DOI 10.1042/bj3090543; Machida Y, 2000, FEMS MICROBIOL LETT, V182, P333, DOI 10.1111/j.1574-6968.2000.tb08917.x; Miyake K, 1997, J FERMENT BIOENG, V84, P90, DOI 10.1016/S0922-338X(97)82793-6; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Muller D, 2000, P NATL ACAD SCI USA, V97, P4315, DOI 10.1073/pnas.070022697; NAKANO Y, 1995, GENE, V162, P157, DOI 10.1016/0378-1119(95)00320-6; Pajunen MI, 2001, J BACTERIOL, V183, P1928, DOI 10.1128/JB.183.6.1928-1937.2001; PELKONEN S, 1988, J BACTERIOL, V170, P2646, DOI 10.1128/jb.170.6.2646-2653.1988; PELKONEN S, 1989, J VIROL, V63, P4409, DOI 10.1128/JVI.63.10.4409-4416.1989; PETTER JG, 1993, J BACTERIOL, V175, P4354, DOI 10.1128/JB.175.14.4354-4363.1993; ROHR TE, 1980, J BIOL CHEM, V255, P2332; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Scholl D, 2001, J VIROL, V75, P2509, DOI 10.1128/JVI.75.6.2509-2515.2001; SKOZA L, 1976, BIOCHEM J, V159, P457, DOI 10.1042/bj1590457; SMITH HW, 1982, J GEN MICROBIOL, V128, P307; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STEVEN AC, 1988, J MOL BIOL, V200, P351, DOI 10.1016/0022-2836(88)90246-X; TOMLINSON S, 1985, J VIROL, V55, P374, DOI 10.1128/JVI.55.2.374-378.1985; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020	37	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12634	12644		10.1074/jbc.M212048200	http://dx.doi.org/10.1074/jbc.M212048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556457	hybrid			2022-12-27	WOS:000182189500008
J	Tani, K; Shibata, M; Kawase, K; Kawashima, H; Hatsuzawa, K; Nagahama, M; Tagaya, M				Tani, K; Shibata, M; Kawase, K; Kawashima, H; Hatsuzawa, K; Nagahama, M; Tagaya, M			Mapping of functional domains of gamma-SNAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; NSF ATTACHMENT PROTEINS; MEMBRANE-FUSION; ALPHA-SNAP; ATPASE ACTIVITY; VESICULAR TRANSPORT; BINDING PROTEIN; COMPLEX; FAMILY; IDENTIFICATION	gamma-Soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein (gamma-SNAP) is capable of stabilizing a 20 S complex consisting of NSF, alpha-SNAP, and SNAP receptors (SNAREs), but its function in vesicular transport is not fully understood. Our two-hybrid analysis revealed that gamma-SNAP, unlike alpha-SNAP, interacts directly with NSF, as well as Gaf-1/Rip11, but not with SNAREs. Gaf1/Rip11 is a gamma-SNAP-associated factor that belongs to the Rab11-interacting protein family. To gain insight into the molecular basis for the interactions of gamma-SNAP with NSF and Gaf-1/Rip11, we determined the regions of the three proteins involved in protein-protein interactions. gamma-SNAP bound to NSF via its extreme C-terminal region, and the full-length NSF was needed to interact with gamma-SNAP. Both the N-terminal and C-terminal regions of gamma-SNAP were required for the binding to Gaf-1/Rip11. Gaf-1/Rip11 bound to gamma-SNAP via its C-terminal domain comprising a putative coiled-coil region. Although the C-terminal domain of Gaf-1/Rip11 also interacts with Rab11, the binding of gamma-SNAP and Rab11 to Gaf-1/Rip11 was not mutually exclusive. Rather, Gaf-1/Rip11 was capable of serving a link between gamma-SNAP and Rab11. A complex comprising gamma-SNAP and Gaf-1/Rip11 was disassembled in a process coupled to NSF-mediated ATP hydrolysis, suggesting that the interaction between gamma-SNAP and Gaf-1/Rip11 is of functional significance.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Tagaya, M (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan.							Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Chen D, 2001, J BIOL CHEM, V276, P13127, DOI 10.1074/jbc.M009424200; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Cullis DN, 2002, J BIOL CHEM, V277, P49158, DOI 10.1074/jbc.M206316200; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hatsuzawa K, 2000, J BIOL CHEM, V275, P13713, DOI 10.1074/jbc.275.18.13713; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Haynes LP, 1998, FEBS LETT, V436, P1, DOI 10.1016/S0014-5793(98)01088-6; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Mayer A, 2002, ANNU REV CELL DEV BI, V18, P289, DOI 10.1146/annurev.cellbio.18.032202.114809; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Meyers JM, 2002, J BIOL CHEM, V277, P49003, DOI 10.1074/jbc.M205728200; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Peter F, 1998, J CELL SCI, V111, P2625; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	40	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13531	13538		10.1074/jbc.M213205200	http://dx.doi.org/10.1074/jbc.M213205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12554740	hybrid			2022-12-27	WOS:000182189500117
J	Carroll, SS; Tomassini, JE; Bosserman, M; Getty, K; Stahlhut, MW; Eldrup, AB; Bhat, B; Hall, D; Simcoe, AL; LaFemina, R; Rutkowski, CA; Wolanski, B; Yang, ZC; Migliaccio, G; De Francesco, R; Kuo, LC; MacCoss, M; Olsen, DB				Carroll, SS; Tomassini, JE; Bosserman, M; Getty, K; Stahlhut, MW; Eldrup, AB; Bhat, B; Hall, D; Simcoe, AL; LaFemina, R; Rutkowski, CA; Wolanski, B; Yang, ZC; Migliaccio, G; De Francesco, R; Kuo, LC; MacCoss, M; Olsen, DB			Inhibition of hepatitis C virus RNA replication by 2 '-modified nucleoside analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA-2B PLUS RIBAVIRIN; INITIAL TREATMENT; NON-A; POLYMERASE; ELONGATION; INFECTION; NS5B	The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is essential for the replication of viral RNA and thus constitutes a valid target for the chemotherapeutic intervention of HCV infection. In this report, we describe the identification of 2'-substituted nucleosides as inhibitors of HCV replication. The 5'- triphosphates of 2'-C-methyladenosine and 2'-O-methylcytidine are found to inhibit NS5B-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate. NS5B is able to incorporate either nucleotide analog into RNA as determined with gel-based incorporation assays but is impaired in its ability to extend the incorporated analog by addition of the next nucleotide. In a subgenomic replicon cell line, 2-C-methyladenosine and 2'-O-methylcytidine inhibit HCV RNA replication. The 5'-triphosphates of both nucleosides are detected intracellularly following addition of the nucleosides to the media. However, significantly higher concentrations of 2'-C-methyladenosine triphosphate than 2'-O-methylcytidine triphosphate are detected, consistent with the greater potency of 2'-C-methyladenosine in the replicon assay, despite similar inhibition of NS5B by the triphosphates in the in vitro enzyme assays. Thus, the 2'-modifications of natural substrate nucleosides transform these molecules into potent inhibitors of HCV replication.	Merck Sharp & Dohme Ltd, Res Lab, Dept Biol Chem, West Point, PA 19486 USA; Merck Sharp & Dohme Ltd, Res Lab, Dept Biol Struct, West Point, PA 19486 USA; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, Roma, Italy; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Isis Pharmaceuticals Inc	Carroll, SS (corresponding author), Merck Sharp & Dohme Ltd, Res Lab, Dept Biol Chem, WP26-265, West Point, PA 19486 USA.	steve_carroll@merck.com	De Francesco, Raffaele/J-6003-2012	De Francesco, Raffaele/0000-0001-8754-5123; olsen, david/0000-0001-5521-0206				Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; Burgess K, 2000, CHEM REV, V100, P2047, DOI 10.1021/cr990045m; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; De Clercq E, 2001, J CLIN VIROL, V22, P73, DOI 10.1016/S1386-6532(01)00167-6; DeFrancesco R, 1996, METHOD ENZYMOL, V275, P58; Franchetti P, 1998, J MED CHEM, V41, P1708, DOI 10.1021/jm9707737; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229; OHNO Y, 1989, CANCER RES, V49, P2077; OHNO Y, 1988, CANCER RES, V48, P1494; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; WALTON E, 1969, J MED CHEM, V12, P306, DOI 10.1021/jm00302a025; Wang TSF, 1995, METHOD ENZYMOL, V262, P77; Wright M, 2001, ANTIVIR CHEM CHEMOTH, V12, P201, DOI 10.1177/095632020101200401; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	30	286	337	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11979	11984		10.1074/jbc.M210914200	http://dx.doi.org/10.1074/jbc.M210914200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12554735	hybrid			2022-12-27	WOS:000182015700035
J	da Costa, CA; Mattson, MP; Ancolio, K; Checler, F				da Costa, CA; Mattson, MP; Ancolio, K; Checler, F			The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; ENDOPLASMIC-RETICULUM; PARKINSONS-DISEASE; NEURONAL CELLS; APP-ALPHA; WILD-TYPE; CLEAVAGE; BETA	Mutations on presenilins are responsible for most of familial forms of Alzheimer's disease. These holoproteins undergo rapid maturation by presenilinase mainly in the endoplasmic reticulum, leading to the production of N- and C-terminal fragments. We show first that overexpression of the presenilinase-derived maturation product of presenilin 2 (CTF-PS2) increases Abeta recovery, the production of which is almost abolished by a caspase 3 inhibitor and increased by staurosporine. This and the observation that the apoptotic inducer staurosporine enhances CTF-PS2 degradation clearly link CTF-PS2 to apoptotic cascade effectors. This prompted us to analyze the putative ability of CTF-PS2 to modulate cell death. CTF-PS2 overexpression decreases cell viability and augments both caspase 3 activity and immunoreactivity. This is accompanied by lowered bcl2-like immunoreactivity and increased poly(ADP-ribose) polymerase cleavage and cytochrome c translocation into the cytosol. Interestingly, CTF-PS2-induced caspase 3 activation is prevented by pifithrin-alpha, a selective blocker of p53 transcriptional activity. On line with the latter data, CTF-PS2 drastically increases p53 immunoreactivity and transcriptional activity. Of most interest is our observation that CTF-PS2 expression also triggers increased caspase 3 activity and immunoreactivity in fibroblasts in which presenilins had been deleted. Therefore, CTF-PS2 could modulate cell death out of the NTF/CTF heterodimeric complex thought to correspond to the biologically functional entity. This is the first direct demonstration that CTF-PS2 could exhibit some of its functions in the absence of the presenilin 2 N-terminal fragment (NTF-PS2) counterpart derived from the presenilinase cleavage.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, F-06560 Valbonne, France; NIA, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, 660 Route des Lucioles,Sophia Antipolis, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; Mattson, Mark P/F-6038-2012; da Costa, Cristine Alves/G-8075-2011	Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X	NATIONAL INSTITUTE ON AGING [Z01AG000312, ZIAAG000312, Z01AG000313, ZIAAG000317, ZIAAG000313, Z01AG000317] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Baumann K, 1997, NEUROBIOL AGING, V18, P181, DOI 10.1016/S0197-4580(97)00004-3; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Checler F, 1999, MOL NEUROBIOL, V19, P255, DOI 10.1007/BF02821716; Checler F, 1999, IUBMB LIFE, V48, P33, DOI 10.1080/152165499307396; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; da Costa CA, 1999, MOL MED, V5, P160, DOI 10.1007/BF03402059; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Marambaud P, 1998, BIOCHEM BIOPH RES CO, V252, P134, DOI 10.1006/bbrc.1998.9619; Mattson MP, 1998, J NEUROCHEM, V70, P1; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shirotani K, 1997, BIOCHEM BIOPH RES CO, V240, P728, DOI 10.1006/bbrc.1997.7730; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Ward RV, 1996, NEURODEGENERATION, V5, P293, DOI 10.1006/neur.1996.0040; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710	38	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12064	12069		10.1074/jbc.M212379200	http://dx.doi.org/10.1074/jbc.M212379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556443	hybrid			2022-12-27	WOS:000182015700046
J	Girrbach, V; Strahl, S				Girrbach, V; Strahl, S			Members of the evolutionarily conserved PMT family of protein O-mannosyltransferases form distinct protein complexes among themselves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PATHOGEN CANDIDA-ALBICANS; SACCHAROMYCES-CEREVISIAE; MANNOSYL-TRANSFERASE; ENDOPLASMIC-RETICULUM; SHUTTLE VECTORS; GENE FAMILY; YEAST; GLYCOSYLATION; PURIFICATION	Protein O-mannosyltransferases (PMTs) initiate the assembly of O-mannosyl glycans, an essential protein modification. Since PMTs are evolutionarily conserved in fungi but are absent in green plants, the PMT family is a putative target for new antifungal drugs, particularly in fighting the threat of phytopathogenic fungi. The PMT family is phylogenetically classified into PMT1, PMT2, and PMT4 subfamilies, which differ in protein substrate specificity. In the model organism Saccharomyces cerevisiae as well as in many other fungi the PMT family is highly redundant, and only the simultaneous deletion of PMT1/PMT2 and PMT4 subfamily members is lethal. In this study we analyzed the molecular organization of PMT family members in S. cerevisiae. We show that members of the PMT1 subfamily (Pmt1p and Pmt5p) interact in pairs with members of the PMT2 subfamily (Pmt2p and Pmt3p) and that Pmt1p-Pmt2p and Pmt5p-Pmt3p complexes represent the predominant forms. Under certain physiological conditions, however, Pmt1p interacts also with Pmt3p, and Pmt5p with Pmt2p, suggesting a compensatory cooperation that guarantees the maintenance of O-mannosylation. Unlike the PMT1/PMT2 subfamily members, the single member of the PMT4 subfamily (Pmt4p) acts as a homomeric complex. Using mutational analyses we demonstrate that the same conserved protein domains underlie both heteromeric and homomeric interactions, and we identify an invariant arginine residue of transmembrane domain two as essential for the formation and/or stability of PMT complexes in general. Our data suggest that protein-protein interactions between the PMT family members offer a point of attack to shut down overall protein O-mannosylation in fungi.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Strahl, S (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany.	sabine.strahlbolsinger@biologie.uni-regensburg.de						Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Ernst JF, 2001, MED MYCOL, V39, P67, DOI 10.1080/744118884; FRANK C, 2000, THESIS U REGENSBURY; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girrbach V, 2000, J BIOL CHEM, V275, P19288, DOI 10.1074/jbc.M001771200; Harlow E., 1988, ANTIBODIES LAB MANUA; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kaiser C., 1994, METHODS YEAST GENETI; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; LARRIBA G, 1976, FEBS LETT, V71, P316, DOI 10.1016/0014-5793(76)80960-X; Lodder AL, 1999, GENETICS, V152, P1487; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Mrsa V, 1997, YEAST, V13, P1145; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Ponting CP, 2000, TRENDS BIOCHEM SCI, V25, P48; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanders SL, 1999, J CELL BIOL, V145, P1177, DOI 10.1083/jcb.145.6.1177; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; Timpel C, 2000, J BACTERIOL, V182, P3063, DOI 10.1128/JB.182.11.3063-3071.2000; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Truernit E, 1996, PLANT CELL, V8, P2169, DOI 10.1105/tpc.8.12.2169; Willer T, 2002, GLYCOBIOLOGY, V12, P771, DOI 10.1093/glycob/cwf086; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	53	118	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12554	12562		10.1074/jbc.M212582200	http://dx.doi.org/10.1074/jbc.M212582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551906	hybrid			2022-12-27	WOS:000182015700108
J	Ulloa, F; Real, FX				Ulloa, F; Real, FX			Benzyl-N-acetyl-alpha-D-galactosaminide induces a storage disease-like phenotype by perturbing the endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID; INTRACELLULAR-TRANSPORT; SUCRASE-ISOMALTASE; MATURE LYSOSOMES; HT-29; CELLS; GLYCOSYLATION; CANCER; GALNAC; MUCINS	The sugar analog O-benzyl-N-acetyl-alpha-D-galactosaminide (BG) is an inhibitor of glycan chain elongation and inhibits alpha2,3-sialylation in mucus-secreting HT-29 cells. Long-term exposure of these cells to BG is associated with the accumulation of apical glycoproteins in cytoplasmic vesicles. The mechanisms involved therein and the nature of the vesicles have not been elucidated. In these cells, a massive amount of BG metabolites is synthesized. Because sialic acid is mainly distributed apically in epithelial cells, it has been proposed that the BG-induced undersialylation of apical membrane glycoproteins is responsible for their intracellular accumulation due to a defect in anterograde traffic and that sialic acid may constitute an apical targeting signal. In this work, we demonstrate that the intracellular accumulation of membrane glycoproteins does not result mainly from defects in anterograde traffic. By contrast, in BG-treated cells, endocytosed membrane proteins were retained intracellularly for longer periods of time than in control cells and colocalized with accumulated MUC1 and beta(1) integrin in Rab7/lysobisphosphatidic acid(+) vesicles displaying features of late endosomes. The phenotype of BG-treated cells is reminiscent of that observed in lysosomal storage disorders. Sucrose induced a BG-like, lysosomal storage disease-like phenotype without affecting sialylation, indicating that undersialylation is not a requisite for the intracellular accumulation of membrane glycoproteins. Our findings strongly support the notion that the effects observed in BG-treated cells result from the accumulation of BG-derived metabolites and from defects in the endosomal pathway. We propose that abnormal subcellular distribution of membrane glycoproteins involved in cellular communication and/or signaling may also take place in lysosomal storage disorders and may contribute to their pathogenesis.	Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Celular & Mol, Barcelona 08003, Spain	Pompeu Fabra University	Real, FX (corresponding author), Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Celular & Mol, Barcelona 08003, Spain.	preal@imim.es	Arribas, Francisco X Real/H-5275-2015; Ulloa, Fausto/AAB-2787-2019	Arribas, Francisco X Real/0000-0001-9501-498X; 				AITSLIMANE T, 2000, EXP CELL RES, V258, P184; Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; Delannoy P, 1996, GLYCOCONJUGATE J, V13, P717, DOI 10.1007/BF00702335; DIIULIO NA, 1995, GLYCOBIOLOGY, V5, P195; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Franci C, 1996, BIOCHEM J, V314, P33, DOI 10.1042/bj3140033; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gouyer V, 2001, J CELL SCI, V114, P1455; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; HUET G, 1995, J CELL SCI, V108, P1275; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Karageorgos LE, 1997, EXP CELL RES, V234, P85, DOI 10.1006/excr.1997.3581; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LEBIVIC A, 1993, J BIOL CHEM, V268, P6909; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; MCILHINNEY RAJ, 1985, BIOCHEM J, V227, P155, DOI 10.1042/bj2270155; MERESSE S, 1995, J CELL SCI, V108, P3349; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Schmid JA, 1999, J BIOL CHEM, V274, P19063, DOI 10.1074/jbc.274.27.19063; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; TIETZE F, 1989, J BIOL CHEM, V264, P15316; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; Ulloa F, 2001, J HISTOCHEM CYTOCHEM, V49, P501, DOI 10.1177/002215540104900410; Ulloa F, 2000, J BIOL CHEM, V275, P18785, DOI 10.1074/jbc.M000510200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki A., 1999, ESSENTIALS GLYCOBIOL; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; VILA MR, 1995, LAB INVEST, V72, P395; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Zanetta JP, 2000, GLYCOBIOLOGY, V10, P565, DOI 10.1093/glycob/10.6.565	50	16	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12374	12383		10.1074/jbc.M211909200	http://dx.doi.org/10.1074/jbc.M211909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538583	hybrid			2022-12-27	WOS:000182015700085
J	Liu, XB; Singh, BB; Ambudkar, IS				Liu, XB; Singh, BB; Ambudkar, IS			TRPC1 is required for functional store-operated Ca2+ channels - Role of acidic amino acid residues in the S5-S6 region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINUS; RELEASE; PROTEIN; CAT1; ENTRY; EXPRESSION; RETICULUM; DEPLETION; SUBUNIT; FAMILY	The exact role of TRPC1 in store-operated calcium influx channel (SOCC) function is not known. We have examined the effect of overexpression of full-length TRPC1, depletion of endogenous TRPC1, and expression of TRPC1 in which the proposed pore region (S5-S6, amino acids (aa) 557-620) was deleted or modified by site-directed mutagenesis on thapsigargin- and carbachol-stimulated SOCC activity in HSG. cells. TRPC1 overexpression induced channel activity that was indistinguishable from the endogenous SOCC activity. Transfection with antisense hTRPC1 decreased SOCC activity although characteristics of SOCC-mediated current, I-SOC, were not altered. Expression of TRPC1Delta567-793, but not TRPC1Delta664-793, induced a similar decrease in SOCC activity. Furthermore, TRPC1Delta567-793 was coimmunoprecipitated with endogenous TRPC1. Simultaneous substitutions of seven acidic as in the S5-S6 region (Asp --> Asn and Glu --> Gln) decreased SOCC-mediated Ca2+, but not Na+, current and induced a left shift in E-rev. Similar effects were induced by E576K or D581K, but not D581N or E615K, substitution. Furthermore, expressed TRPC1 proteins interacted with each other. Together, these data demonstrate that TRPC1 is required for generation of functional SOCC in HSG cells. We suggest that TRPC1 monomers co-assemble to form SOCC and that specific acidic as residues in the proposed pore region of TRPC1 contribute to Ca2+ influx.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov		Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Antoniotti S, 2002, FEBS LETT, V510, P189, DOI 10.1016/S0014-5793(01)03256-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; ENGELKE M, 2002, FEBS LETT, V17, P523; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MONTELL C, 2001, SCIENCE STKE; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; PUTNEY JW, 1990, PHARMACOL THERAPEUT, V48, P427, DOI 10.1016/0163-7258(90)90059-B; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	37	145	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11337	11343		10.1074/jbc.M213271200	http://dx.doi.org/10.1074/jbc.M213271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536150	hybrid			2022-12-27	WOS:000181855400061
J	Hughes, E; Middleton, DA				Hughes, E; Middleton, DA			Solid-state NMR reveals structural changes in phospholamban accompanying the functional regulation of Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; DEPENDENT PROTEIN-KINASE; CA-ATPASE; TRANSMEMBRANE DOMAIN; INHIBITORY FUNCTION; INTERACTION SITE; LIPID BILAYERS; CALCIUM-PUMP; SF21 CELLS; PHOSPHORYLATION	Calcium transport across the sarcoplasmic reticulum of cardiac myocytes is regulated by a reversible inhibitory interaction between the Ca2+-ATPase and the small transmembrane protein phospholamban (PLB). A null-cysteine analogue of PLB, containing isotope labels in the transmembrane domain or cytoplasmic domain, was reconstituted into membranes in the absence and presence of the SERCA1 isoform of Ca2+-ATPase for structural investigation by cross-polarization magic-angle spinning (CP-MAS) NMR. PLB lowered the maximal hydrolytic activity of SERCA1 and its affinity for calcium in membrane preparations suitable for structural analysis by NMR. Novel backbone amide proton-deuterium exchange CP-MAS NMR experiments on the two PLB analogues co-reconstituted with SERCA1 indicated that labeled residues Leu(42) and Leu(44) were situated well within the membrane interior, whereas Pro(21) and Ala(24) lie exposed outside the membrane. Internuclear distance measurements on PLB using rotational resonance NMR indicated that the sequences Pro(21)-Ala(24) and Leu(42)-Leu(44) adopt an alpha-helical structure in pure lipid bilayers, which is unchanged in the presence of Ca2+-ATPase. By contrast, rotational echo double resonance (REDOR) NMR experiments revealed that the sequence Ala(24)-Gln(26) switches from an alpha-helix in pure lipid membranes to a more extended structure in the presence of SERCA1, which may reflect local structural distortions which change the orientations of the transmembrane and cytoplasmic domains. These results suggest that Ca2+-ATPase has a long-range effect on the structure of PLB around residue 25, which promotes the functional association of the two proteins.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Manchester	Middleton, DA (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.							Ahmed Z, 2000, BBA-BIOMEMBRANES, V1468, P187, DOI 10.1016/S0005-2736(00)00257-1; Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Asahi M, 2000, J BIOL CHEM, V275, P15034, DOI 10.1074/jbc.275.20.15034; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Chen BW, 2002, BIOCHEMISTRY-US, V41, P13965, DOI 10.1021/bi0266030; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; Ferrington DA, 2002, BIOCHEMISTRY-US, V41, P13289, DOI 10.1021/bi026407t; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; Gullion T, 2000, J MAGN RESON, V146, P220, DOI 10.1006/jmre.2000.2164; Hughes G, 1996, BIOCHEM J, V318, P973, DOI 10.1042/bj3180973; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; Kargacin ME, 1998, BIOCHEM J, V331, P245, DOI 10.1042/bj3310245; Karim CB, 2000, BIOCHEMISTRY-US, V39, P10892, DOI 10.1021/bi0003543; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Lamberth S, 2000, HELV CHIM ACTA, V83, P2141, DOI 10.1002/1522-2675(20000906)83:9<2141::AID-HLCA2141>3.0.CO;2-W; LEVITT MH, 1990, J CHEM PHYS, V92, P6347, DOI 10.1063/1.458314; Mahaney JE, 2000, BIOPHYS J, V78, P1306, DOI 10.1016/S0006-3495(00)76686-0; Mascioni A, 2002, J AM CHEM SOC, V124, P9392, DOI 10.1021/ja026507m; Middleton DA, 2000, J MAGN RESON, V147, P366, DOI 10.1006/jmre.2000.2187; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Negash S, 2000, BIOCHEM J, V351, P195, DOI 10.1042/0264-6021:3510195; Negash S, 1996, BIOCHEMISTRY-US, V35, P11247, DOI 10.1021/bi960864q; PAN Y, 1990, J MAGN RESON, V90, P330, DOI 10.1016/0022-2364(90)90138-Y; Pollesello P, 1999, BIOPHYS J, V76, P1784, DOI 10.1016/S0006-3495(99)77339-X; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; REDDY LG, 2002, BIOPH J ANN M ABSTR, V82, P263; SASAKI T, 1992, J BIOL CHEM, V267, P1674; Schmidt AG, 2001, CARDIOVASC DRUG THER, V15, P387, DOI 10.1023/A:1013381204658; SILVER B, 1985, PHYSICAL CHEM MEMBRA; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Smith SO, 2001, J MOL BIOL, V313, P1139, DOI 10.1006/jmbi.2001.5101; TADA M, 1983, J MOL CELL CARDIOL, V15, P565, DOI 10.1016/0022-2828(83)90267-5; Tatulian SA, 2002, BIOCHEMISTRY-US, V41, P741, DOI 10.1021/bi011148d; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Waterborg Jakob H., 1996, P7, DOI 10.1007/978-1-60327-259-9_2; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; Yao Q, 2001, BIOCHEMISTRY-US, V40, P6406, DOI 10.1021/bi002891t; Young HS, 2001, BIOPHYS J, V81, P884, DOI 10.1016/S0006-3495(01)75748-7; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	47	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20835	20842		10.1074/jbc.M212208200	http://dx.doi.org/10.1074/jbc.M212208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12556441	hybrid			2022-12-27	WOS:000183230500052
J	Janz, JM; Fay, JF; Farrens, DL				Janz, JM; Fay, JF; Farrens, DL			Stability of dark state rhodopsin is mediated by a conserved ion pair in intradiscal loop E-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; SCHIFF-BASE COUNTERION; HELICAL MEMBRANE-PROTEINS; CYSTEINE RESIDUE-110; DISULFIDE BOND; CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; METARHODOPSIN-III; VISUAL PIGMENTS; BOVINE	The rhodopsin crystal structure reveals that intradiscal loop E-2 covers the 11-cis-retinal, creating a "retinal plug." Recently, we noticed the ends of loop E-2 are linked by an ion pair between residues Arg-177 and Asp-190, near the highly conserved disulfide bond. This ion pair appears biologically significant; it is conserved in almost all vertebrate opsins and may occur in other G-protein-coupled receptors. We report here that the Arg-177/Asp-190 ion pair is critical for the folding and stability of dark state rhodopsin. We find ion pair mutants that regenerate with retinal are functionally and spectrally wild-type-like yet thermally unstable in their dark state because of rapid hydrolysis of the retinal Schiff base linkage. Surprisingly, Arrhenius analysis indicates that the activation energies for the hydrolysis process are similar between the ion pair mutants and wild-type rhodopsin. Furthermore, the ion pair mutants do not show increased reactivity toward hydroxylamine, suggesting that their instability is not caused by an increased exposure to bulk solvent. Our results indicate that the loop E-2 ion pair is important for rhodopsin stability and thus suggest that retinitis pigmentosa observed in patients with Asp-190 mutations may in part be the result of thermally unstable rhodopsin proteins.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Farrens, DL (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Mail Code L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	farrensd@ohsu.edu			NEI NIH HHS [EY12095-01, T32-EY07123-09] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007123, R01EY012095] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Albert AD, 2002, BBA-BIOMEMBRANES, V1565, P183, DOI 10.1016/S0005-2736(02)00568-0; Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; BAEHR W, 1982, J BIOL CHEM, V257, P6452; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; COOPER A, 1976, BIOCHEMISTRY-US, V15, P2970, DOI 10.1021/bi00659a006; COOPER A, 1987, J AM CHEM SOC, V109, P7254, DOI 10.1021/ja00258a002; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Fahmy K, 1996, BIOCHEMISTRY-US, V35, P15065, DOI 10.1021/bi961486s; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FONG TM, 1999, REC BIOCH M, P1; FUKUDA MN, 1982, METHOD ENZYMOL, V81, P214; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HAROSI FI, 1995, PHOTOCHEM PHOTOBIOL, V61, P510; HUBBARD R, 1965, COLD SPRING HARB SYM, V30, P301, DOI 10.1101/SQB.1965.030.01.032; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1999, P NATL ACAD SCI USA, V96, P1932, DOI 10.1073/pnas.96.5.1932; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; JACOBSON SG, 1991, AM J OPHTHALMOL, V112, P256, DOI 10.1016/S0002-9394(14)76726-1; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; Jung KH, 1999, BIOCHEMISTRY-US, V38, P13270, DOI 10.1021/bi991180w; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KEMP CM, 1992, AM J OPHTHALMOL, V113, P165, DOI 10.1016/S0002-9394(14)71529-6; KHORANA HG, 1992, J BIOL CHEM, V267, P1; Kochendoerfer GG, 1999, TRENDS BIOCHEM SCI, V24, P300, DOI 10.1016/S0968-0004(99)01432-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landin JS, 2001, BIOCHEMISTRY-US, V40, P11176, DOI 10.1021/bi0100539; Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1; Lewis JW, 2000, METHOD ENZYMOL, V315, P164; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; MATSUMOTO H, 1978, BIOCHIM BIOPHYS ACTA, V501, P257, DOI 10.1016/0005-2728(78)90031-2; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; REUTER T, 1976, VISION RES, V16, P909, DOI 10.1016/0042-6989(76)90220-0; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Segel I. H., 1975, ENZYME KINETICS, P931; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; SWINBOURNE ES, 1971, ANAL KINETIC DATA, P60; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3536, DOI 10.1021/bi016024f; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Yan ECY, 2002, BIOCHEMISTRY-US, V41, P3620, DOI 10.1021/bi0160011; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; Zvyaga TA, 1996, BIOCHEMISTRY-US, V35, P7536, DOI 10.1021/bi960391n	79	69	70	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16982	16991		10.1074/jbc.M210567200	http://dx.doi.org/10.1074/jbc.M210567200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12547830	hybrid			2022-12-27	WOS:000182818600073
J	Carneiro, FA; Stauffer, F; Lima, CS; Juliano, MA; Juliano, L; Da Poian, AT				Carneiro, FA; Stauffer, F; Lima, CS; Juliano, MA; Juliano, L; Da Poian, AT			Membrane fusion induced by vesicular stomatitis virus depends on histidine protonation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; N-TERMINAL PEPTIDES; ENVELOPE GLYCOPROTEIN; LOW-PH; HEPTAD-REPEAT; CELL-FUSION; PHOSPHOLIPID INTERACTIONS; SYNTHETIC PEPTIDES; PROTEIN; DOMAIN	Entry of enveloped animal viruses into their host cells always depends on a step of membrane fusion triggered by conformational changes in viral envelope glycoproteins. Vesicular stomatitis virus (VSV) infection is mediated by virus spike glycoprotein G, which induces membrane fusion at the acidic environment of the endosomal compartment. VSV-induced membrane fusion occurs at a very narrow pH range, between 6.2 and 5.8, suggesting that His protonation. is required for this process. To investigate the role of His in VSV fusion, we chemically modified these residues using diethylpyrocarbonate (DEPC). We found that DEPC treatment inhibited membrane fusion mediated by VSV in a concentration-dependent manner and that the complete inhibition of fusion was fully reversed by incubation of modified virus with hydroxylamine. Fluorescence measurements showed that VSV modification with DEPC abolished pH-induced conformational changes in G protein, suggesting that His protonation drives G protein interaction with the target membrane at acidic pH. Mass spectrometry analysis of tryptic fragments of modified G protein allowed the identification of the putative active His residues. Using synthetic peptides, we showed that the modification of His-148 and His-149 by DEPC, as well as the substitution of these residues by Ala, completely inhibited peptide-induced fusion, suggesting the direct participation of these His in VSV fusion.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941 Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP)	Da Poian, AT (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941 Rio De Janeiro, Brazil.	dapoian@bioqmed.ufrj.br	CARNEIRO, FABIANA A/S-4525-2018; Da Poian, Andrea T./V-1699-2019; Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822; Da Poian, Andrea/0000-0002-3969-704X; Carneiro, Fabiana/0000-0002-6584-4875				Ben-Efraim I, 1999, J MOL BIOL, V285, P609, DOI 10.1006/jmbi.1998.2370; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Carneiro FA, 2001, J BIOL CHEM, V276, P62, DOI 10.1074/jbc.M008753200; Carneiro FA, 2002, J VIROL, V76, P3756, DOI 10.1128/JVI.76.8.3756-3764.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Coll JM, 1997, ARCH VIROL, V142, P2089, DOI 10.1007/s007050050227; COLL JM, 1995, VIRUS GENES, V10, P107, DOI 10.1007/BF01702591; Da Poian AT, 1998, J VIROL METHODS, V70, P45, DOI 10.1016/S0166-0934(97)00166-3; DaPoian AT, 1996, P NATL ACAD SCI USA, V93, P8268, DOI 10.1073/pnas.93.16.8268; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Estepa A, 1996, J VIROL METHODS, V61, P37, DOI 10.1016/0166-0934(96)02067-8; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FREDERICKSEN BL, 1995, J VIROL, V69, P1435, DOI 10.1128/JVI.69.3.1435-1443.1995; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; Gaudin Y, 1999, MOL MEMBR BIOL, V16, P21, DOI 10.1080/096876899294724; GAUDIN Y, 1993, J VIROL, V67, P1365, DOI 10.1128/JVI.67.3.1365-1372.1993; Ghosh JK, 1998, J BIOL CHEM, V273, P27182, DOI 10.1074/jbc.273.42.27182; Ghosh JK, 1999, J MOL BIOL, V292, P531, DOI 10.1006/jmbi.1999.3097; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LI Y, 1993, J VIROL, V67, P4070, DOI 10.1128/JVI.67.7.4070-4077.1993; MARTIN I, 1994, J VIROL, V68, P1139, DOI 10.1128/JVI.68.2.1139-1148.1994; Martin I, 1999, ADV DRUG DELIVER REV, V38, P233, DOI 10.1016/S0169-409X(99)00031-9; Miles E W, 1977, Methods Enzymol, V47, P431; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Nunez E, 1998, VIROLOGY, V243, P322, DOI 10.1006/viro.1998.9076; PAL R, 1988, BIOCHEMISTRY-US, V27, P30, DOI 10.1021/bi00401a006; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; Saez-Cirion A, 2002, BBA-BIOMEMBRANES, V1564, P57, DOI 10.1016/S0005-2736(02)00400-5; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; TAKAHASHI S, 1990, BIOCHEMISTRY-US, V29, P6257, DOI 10.1021/bi00478a021; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994	40	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13789	13794		10.1074/jbc.M210615200	http://dx.doi.org/10.1074/jbc.M210615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571240	hybrid			2022-12-27	WOS:000182405000030
J	Mori, H; Tsukazaki, T; Masui, R; Kuramitsu, S; Yokoyama, S; Johnson, AE; Kimura, Y; Akiyama, Y; Ito, K				Mori, H; Tsukazaki, T; Masui, R; Kuramitsu, S; Yokoyama, S; Johnson, AE; Kimura, Y; Akiyama, Y; Ito, K			Fluorescence resonance energy transfer analysis of protein translocase - SecYE from Thermus thermophilus HB8 forms a constitutive oligomer in membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PREPROTEIN TRANSLOCATION; COMPLEX; SECRETION; INSERTION; CHANNEL; SYSTEM	SecY and SecE are the two principal translocase subunits that create a channel-like pathway for the transit of preprotein across the bacterial cytoplasmic membrane. Here we report the cloning, expression, and purification of the SecYE complex (TSecYE) from a thermophilic bacterium, Thermus thermophilus HB8. Purified TSecYE can be reconstituted into proteoliposomes that function in T. thermophilus SecA (TSecA) dependent preprotein translocation. After the mixing of TSecYE derivatives labeled with either a donor or an acceptor fluorophore during reconstitution, fluorescence resonance energy transfer experiments demonstrated that 2 or more units of TSecYE in the lipid bilayer associate to form a largely non-exchangeable oligomeric structure.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; Osaka Univ, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan; Univ Tokyo, Grad Sch Sci, Tokyo 1130033, Japan; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan	Kyoto University; Osaka University; University of Tokyo; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp	Tsukazaki, Tomoya/N-2299-2019; Johnson, Arthur E/G-3457-2012; Yokoyama, Shigeyuki/N-6911-2015	Tsukazaki, Tomoya/0000-0002-6386-723X; Yokoyama, Shigeyuki/0000-0003-3133-7338; Mori, Hiroyuki/0000-0002-0429-1269	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Heuck AP, 2002, CELL BIOCHEM BIOPHYS, V36, P89, DOI 10.1385/CBB:36:1:89; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Matsuo E, 1998, J BIOL CHEM, V273, P18835, DOI 10.1074/jbc.273.30.18835; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mori H, 2001, P NATL ACAD SCI USA, V98, P5128, DOI 10.1073/pnas.081617398; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shimohata N, 2002, GENES CELLS, V7, P653, DOI 10.1046/j.1365-2443.2002.00554.x; WATSON BS, 1995, BIOCHEMISTRY-US, V34, P7904, DOI 10.1021/bi00024a015; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429	27	47	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14257	14264		10.1074/jbc.M300230200	http://dx.doi.org/10.1074/jbc.M300230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12533543	hybrid			2022-12-27	WOS:000182405000088
J	Son, M; Cloyd, CD; Rothstein, JD; Rajendran, B; Elliott, JL				Son, M; Cloyd, CD; Rothstein, JD; Rajendran, B; Elliott, JL			Aggregate formation in Cu,Zn superoxide dismutase-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; COPPER CHAPERONE; TRANSGENIC MICE; PRION PROTEIN; ALPHA-SYNUCLEIN; BINDS COPPER; DISEASE; SOD1; ZINC	Aggregation of Cu,Zn superoxide dismutase (SOD1) protein is a pathologic hallmark of familial amyotrophic lateral sclerosis linked to mutations in the SOD1 gene, although the structural motifs within mutant SOD1 that are responsible for its aggregation are unknown. Copper chaperone for SOD1 (CCS) and extracellular Cu,Zn superoxide dismutase (SOD3) have some sequence identity with SOD1, particularly in the regions of metal binding, but play no significant role in mutant SOD1-induced disease. We hypothesized that it would be possible to form CCS- or SOD3-positive aggregates by making these molecules resemble mutant SOD1 via the introduction of point mutations in codons homologous to a disease causing G85R SOD1 mutation. Using an in vitro assay system, we found that expression of wild type human CCS or a modified intracellular wild type SOD3 does not result in significant aggregate formation. In contrast, expression of G16SR CCS or G146R SOD3 produced aggregates as evidenced by the presence of high molecular weight protein complexes on Western gels or inclusion bodies on immunofluorescence. CCS- and SOD3-positive inclusions appear to be ubiquitinated and localized to aggresomes. These results suggest that proteins sharing structural similarities to mutant SOD1 are also at risk for aggregate formation.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	Elliott, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		rothstein, jeffrey d/C-9470-2013					Bartnikas TB, 2000, MAMM GENOME, V11, P409, DOI 10.1007/s003350010078; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bowler RP, 2002, J BIOL CHEM, V277, P16505, DOI 10.1074/jbc.M105409200; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Elliott JL, 2001, PROG NEURO-PSYCHOPH, V25, P1169, DOI 10.1016/S0278-5846(01)00185-3; Elliott JL, 1999, NEUROBIOL DIS, V6, P310, DOI 10.1006/nbdi.1999.0266; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FOLZ RJ, 1994, GENOMICS, V22, P162, DOI 10.1006/geno.1994.1357; Gaudette M, 2000, AMYOTROPH LATERAL SC, V1, P83, DOI 10.1080/14660820050515377; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Puttaparthi K, 2002, J NEUROSCI, V22, P8790; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Worrall BB, 2000, ARCH NEUROL-CHICAGO, V57, P33, DOI 10.1001/archneur.57.1.33	38	34	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14331	14336		10.1074/jbc.M211698200	http://dx.doi.org/10.1074/jbc.M211698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12551935	hybrid			2022-12-27	WOS:000182405000097
J	Darbandi-Tonkabon, R; Hastings, WR; Zeng, CM; Akk, G; Manion, BD; Bracamontes, JR; Steinbach, JH; Mennerick, SJ; Covey, DF; Evers, AS				Darbandi-Tonkabon, R; Hastings, WR; Zeng, CM; Akk, G; Manion, BD; Bracamontes, JR; Steinbach, JH; Mennerick, SJ; Covey, DF; Evers, AS			Photoaffinity Labeling with a neuroactive steroid analogue - 6-AZI-Pregnanolone labels voltage-dependent anion channel-1 in rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; A RECEPTOR; GABA(A) RECEPTOR; LIGAND-BINDING; ALPHA-SUBUNIT; MODULATION; ANESTHETICS; SITES; CELLS; PROTEIN	Neuroactive steroids modulate the function of gamma-aminobutyric acid, type A (GABA(A)) receptors in the central nervous system by an unknown mechanism. In this study we have used a novel neuroactive steroid analogue, 3alpha,5beta-6-azi-3-hydroxypregnan-20-one (6-AziP), as a photoaffinity labeling reagent to identify neuroactive steroid binding sites in rat brain. 6-AziP is an effective modulator of GABA(A) receptors as evidenced by its ability to inhibit binding of [S-35]t-butylbicyclophosphoro-thionate to rat brain membranes and to potentiate GABA-elicited currents in Xenopus oocytes and human endothelial kidney 293 cells expressing GABA(A) receptor subunits (alpha(1)beta(2)gamma(2)). [H-3]6-AziP produced time- and concentration-dependent photolabeling of protein bands of similar to35 and 60 kDa in rat brain membranes. The 35-kDa band was half-maximally labeled at a [H-3]6-AziP concentration of 1.9 muM, whereas the 60-kDa band was labeled at higher concentrations. The photolabeled 35-kDa protein was isolated from rat brain by two-dimensional PAGE and identified as voltage-dependent anion channel-1 (VDAC-1) by both matrix-assisted laser desorption ionization time-of-flight and ESI-tandem mass spectrometry. Monoclonal antibody directed against the N terminus of VDAC-1 immunoprecipitated labeled 35-kDa protein from a lysate of rat brain membranes, confirming that VDAC-1 is the species labeled by [H-3]6-AziP. The 132 and 133 subunits of the GABAA receptor were co-immunoprecipitated by the VDAC-1 antibody suggesting a physical association between VDAC-1 and GABAA receptors in rat brain membranes. These data suggest that neuroactive steroid effects on the GABAA receptor may be mediated by binding to an accessory protein, VDAC-1.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Evers, AS (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, 660 S Euclid Ave,Campus Box 8054, St Louis, MO 63110 USA.		Mennerick, Steven/O-2806-2017; Akk, Gustav/CAG-1703-2022	Mennerick, Steven/0000-0003-0868-0664; Evers, Alex/0000-0002-0342-0575	NIAAA NIH HHS [AA12952] Funding Source: Medline; NIGMS NIH HHS [P01 GM047969, P01-GM47969] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012952] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Anflous K, 2001, J BIOL CHEM, V276, P1954, DOI 10.1074/jbc.M006587200; ANTONUCCI R, 1952, J ORG CHEM, V17, P1369, DOI 10.1021/jo50010a014; ATKINSON RM, 1965, J MED CHEM, V8, P426, DOI 10.1021/jm00328a004; BARKER JL, 1987, J PHYSIOL-LONDON, V386, P485, DOI 10.1113/jphysiol.1987.sp016547; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; Bathori G, 2000, J BIOENERG BIOMEMBR, V32, P79, DOI 10.1023/A:1005516513313; BELLELI D, 1997, P NATL ACAD SCI USA, V94, P11031; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CALLACHAN H, 1987, PROC R SOC SER B-BIO, V231, P359, DOI 10.1098/rspb.1987.0049; Colombini M, 1996, Ion Channels, V4, P169; COTTRELL GA, 1987, BRIT J PHARMACOL, V90, P491, DOI 10.1111/j.1476-5381.1987.tb11198.x; Covey DF, 2000, J PHARMACOL EXP THER, V293, P1009; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Fountoulakis M, 1999, ELECTROPHORESIS, V20, P3572; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Greenblatt EP, 2001, ANESTHESIOLOGY, V94, P1026, DOI 10.1097/00000542-200106000-00017; HARRISON NL, 1987, J NEUROSCI, V7, P604; HARRISON NL, 1984, BRAIN RES, V323, P287, DOI 10.1016/0006-8993(84)90299-3; HARRISON NL, 1987, J PHARMACOL EXP THER, V241, P346; Hatzimanikatis V, 1999, BIOTECHNOL PROGR, V15, P312, DOI 10.1021/bp990004b; HAWKINSON JE, 1994, MOL PHARMACOL, V46, P977; Hawkinson JE, 1996, MOL PHARMACOL, V49, P897; HillVenning C, 1997, BRIT J PHARMACOL, V120, P749, DOI 10.1038/sj.bjp.0700927; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; JIMENEZ CR, 2000, CURRENT PROTOCOLS PR; KATZENELLENBOGEN JA, 1974, BIOCHEMISTRY-US, V13, P2986, DOI 10.1021/bi00711a031; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZCOLOME AM, 1990, EUR J PHARMACOL, V176, P297; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MOHLER H, 1980, P NATL ACAD SCI-BIOL, V77, P1666, DOI 10.1073/pnas.77.3.1666; Moon JI, 1999, NEUROREPORT, V10, P443, DOI 10.1097/00001756-199902250-00001; Paradiso K, 2000, MOL PHARMACOL, V58, P341, DOI 10.1124/mol.58.2.341; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Rick CE, 1998, NEUROREPORT, V9, P379, DOI 10.1097/00001756-199802160-00004; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Sabey K, 1999, MOL PHARMACOL, V55, P58, DOI 10.1124/mol.55.1.58; Sanna E, 1997, MOL PHARMACOL, V51, P484; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Steinbach JH, 2001, J PHYSIOL-LONDON, V537, P715; Tao YX, 2001, ANESTHESIOLOGY, V94, P1010, DOI 10.1097/00000542-200106000-00015; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; Ueno S, 1996, MOL PHARMACOL, V50, P931; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8; Wittmer LL, 1996, MOL PHARMACOL, V50, P1581; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23	57	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13196	13206		10.1074/jbc.M213168200	http://dx.doi.org/10.1074/jbc.M213168200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560326	hybrid			2022-12-27	WOS:000182189500078
J	Freedman, SJ; Song, HK; Xu, YW; Sun, ZYJ; Eck, MJ				Freedman, SJ; Song, HK; Xu, YW; Sun, ZYJ; Eck, MJ			Homotetrameric structure of the SNAP-23 N-terminal coiled-coil domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC SNARE COMPLEX; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; SYNTAXIN 1A; PROTEIN; EXOCYTOSIS; IDENTIFICATION; ASSOCIATION; RECEPTORS; INSIGHTS	SNARE proteins mediate intracellular membrane fusion by forming a coiled-coil complex to merge opposing membranes. A "fusion-active" neuronal SNARE complex is a parallel four-helix bundle containing two coiled-coil domains from SNAP-25 and one coiled-coil domain each from syntaxin-1a and VAMP-2. "Prefusion" assembly intermediate complexes can also form from these SNAREs. We studied the N-terminal coiled-coil domain of SNAP-23 (SNAP-23N), a non-neuronal homologue of SNAP-25, and its interaction with other coiled-coil domains. SNAP-23N can assemble spontaneously with the coiled-coil domains from SNAP-23C, syntaxiln-4. and VAMP-3 to form a heterotetrameric complex. Unexpectedly, pure SNAP-23N crystallizes as a coiled-coil homotetrameric complex. The four helices have a parallel orientation and are symmetrical about the long axis. The complex is stabilized through the interaction of conserved hydrophobic residues comprising the a and d positions of the coiled-coil heptad repeats. In addition, a central, highly conserved glutamine residue (Gln-48) is buried within the interface by hydrogen bonding between glutamine side chains derived from adjacent subunits and to solvent molecules. A comparison of the SNAP-23N structure to other SNARE complex structures reveals how a simple coiled-coil motif can form diverse SNARE complexes.	Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Freedman, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis, 41 Ave Louis Pasteur, Boston, MA 02115 USA.		Song, Hyun Kyu/D-6763-2016	Song, Hyun Kyu/0000-0001-5684-4059	PHS HHS [K08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akey DL, 2001, BIOCHEMISTRY-US, V40, P6352, DOI 10.1021/bi002829w; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bracher A, 2002, J BIOL CHEM, V277, P26517, DOI 10.1074/jbc.M203460200; Brunger AT, 2001, CURR OPIN STRUC BIOL, V11, P163, DOI 10.1016/S0959-440X(00)00186-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Misura KMS, 2001, J BIOL CHEM, V276, P13273, DOI 10.1074/jbc.M009636200; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; Pinxteren JA, 2000, BIOCHIMIE, V82, P385, DOI 10.1016/S0300-9084(00)00197-8; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	33	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13462	13467		10.1074/jbc.M210483200	http://dx.doi.org/10.1074/jbc.M210483200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556468	hybrid			2022-12-27	WOS:000182189500109
J	Sanes, JR				Sanes, JR			The basement membrane/basal lamina of skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MOTOR-NERVE TERMINALS; BASAL LAMINA; NEUROMUSCULAR-JUNCTION; SYNAPTIC CLEFT; COLLAGEN-IV; ACETYLCHOLINESTERASE; ABSENCE; AGRIN; DIFFERENTIATION; MYOGENESIS		Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	sanesj@pcg.wustl.edu						Akaaboune M, 2002, NEURON, V34, P865, DOI 10.1016/S0896-6273(02)00739-0; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Benjamin M, 2000, INT REV CYTOL, V196, P85; BETZ W, 1973, J PHYSIOL-LONDON, V230, P673, DOI 10.1113/jphysiol.1973.sp010211; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BOWMAN JW, 1840, PHILOS T R SOC LOND, V130, P457; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; CAJAL SRY, 1928, DEGENERATION REGENER, P265; Cohen I, 1997, MOL CELL NEUROSCI, V9, P237, DOI 10.1006/mcne.1997.0623; Cohen MW, 2000, J NEUROSCI, V20, P4912; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; Dunaevsky A, 1998, DEV BIOL, V194, P61, DOI 10.1006/dbio.1997.8805; Edwards JP, 1998, BRAIN RES, V788, P262, DOI 10.1016/S0006-8993(98)00010-9; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HALL ZW, 1971, NATURE-NEW BIOL, V232, P62, DOI 10.1038/newbio232062a0; HAUSCHKA SD, 1966, P NATL ACAD SCI USA, V55, P119, DOI 10.1073/pnas.55.1.119; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; Jones G, 1997, P NATL ACAD SCI USA, V94, P2654, DOI 10.1073/pnas.94.6.2654; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; LAND BR, 1984, P NATL ACAD SCI-BIOL, V81, P1594, DOI 10.1073/pnas.81.5.1594; Martin PT, 1999, MOL CELL NEUROSCI, V13, P105, DOI 10.1006/mcne.1999.0737; MARTIN PT, 1995, SCIENCE, V269, P413, DOI 10.1126/science.7618109; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MICHELE DE, 2003, J BIOL CHEM     0129, V278; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Nguyen QT, 2002, NAT NEUROSCI, V5, P861, DOI 10.1038/nn905; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; Patton BL, 2000, MICROSC RES TECHNIQ, V51, P247, DOI 10.1002/1097-0029(20001101)51:3<247::AID-JEMT5>3.0.CO;2-Z; Patton BL, 2001, NAT NEUROSCI, V4, P597, DOI 10.1038/88414; Patton BL, 1998, NATURE, V393, P698, DOI 10.1038/31502; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Pedrosa-Domellof F, 2000, J HISTOCHEM CYTOCHEM, V48, P201, DOI 10.1177/002215540004800205; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Pirskanen A, 2000, DEV BIOL, V224, P189, DOI 10.1006/dbio.2000.9784; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; Sanes Joshua R., 1995, Seminars in Developmental Biology, V6, P163, DOI 10.1016/S1044-5781(06)80026-5; SANES JR, 1982, J CELL BIOL, V93, P442, DOI 10.1083/jcb.93.2.442; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SANES JR, 1994, MYOLOGY, P242; Shapira YA, 2002, NEUROLOGY, V58, P603, DOI 10.1212/WNL.58.4.603; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Son YJ, 1999, EUR J NEUROSCI, V11, P3457, DOI 10.1046/j.1460-9568.1999.00766.x; Son YJ, 2000, J BIOL CHEM, V275, P451, DOI 10.1074/jbc.275.1.451; Sunderland WJ, 2000, J NEUROSCI, V20, P1009, DOI 10.1523/JNEUROSCI.20-03-01009.2000; TIDBALL JG, 1986, BIOPHYS J, V50, P1127, DOI 10.1016/S0006-3495(86)83557-3; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TIMPL R, MOL CELLULAR ASPECTS; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; VRACKO R, 1972, J CELL BIOL, V55, P406, DOI 10.1083/jcb.55.2.406; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297	69	277	282	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12601	12604		10.1074/jbc.R200027200	http://dx.doi.org/10.1074/jbc.R200027200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556454	hybrid			2022-12-27	WOS:000182189500002
J	Shao, E; Nishi, T; Kawasaki-Nishi, S; Forgac, M				Shao, E; Nishi, T; Kawasaki-Nishi, S; Forgac, M			Mutational analysis of the non-homologous region of subunit a of the yeast V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON PUMP; LUMINAL ACIDIFICATION; CATALYTIC SUBUNIT; CROSS-LINKING; A-SUBUNIT; ROTATION; SYNTHASE; MEMBRANES; OLIGOMER	Subunit A is the catalytic nucleotide binding subunit of the vacuolar proton-translocating ATPase (or V-ATPase) and is homologous to subunit beta of the-F1F0 ATP synthase (or F-ATPase). Amino acid sequence alignment of these subunits reveals a 90-amino acid insert in subunit A (termed the non-homologous region) that is absent from subunit beta. To investigate the functional role of this region, site-directed mutagenesis has been performed on the VMA1 gene that encodes subunit A in yeast. Substitutions were, performed on 13 amino acid residues within this region that are conserved in all available A subunit sequences. Most of the 18 mutations introduced showed normal assembly of the V-ATPase. Of these, one (R219K) greatly reduced both proton transport and ATPase activity. By contrast, the P217V mutant showed significantly reduced ATPase activity but higher than normal levels of proton transport, suggesting an increase in coupling efficiency. Two other mutations in the same region (P223V and P233V) showed decreased coupling efficiency, suggesting that changes in the non-homologous region can alter coupling of proton transport and ATP hydrolysis. It was previously shown that the V-ATPase must possess at least 5-10% activity relative to wild type to undergo in vivo dissociation in response to glucose withdrawal. However, four of the mutations studied (G150A, D157E, P177V, and P223V) were partially or completely blocked in dissociation despite having greater than 30% of wild type levels of activity. These results suggest that changes in the non-homologous region can also alter in vivo dissociation of the V-ATPase independent of effects on activity.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM 34478, R37 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P960; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; Brown D, 2000, J EXP BIOL, V203, P137; Capaldi RA, 2000, J EXP BIOL, V203, P29; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 2000, J EXP BIOL, V203, P9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graham LA, 2000, J EXP BIOL, V203, P61; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Muller ML, 1997, J BIOL CHEM, V272, P12762, DOI 10.1074/jbc.272.19.12762; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Wieczorek H, 2000, J EXP BIOL, V203, P127; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	75	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12985	12991		10.1074/jbc.M212096200	http://dx.doi.org/10.1074/jbc.M212096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569096	hybrid			2022-12-27	WOS:000182189500051
J	Zhu, H; Takahashi, Y; Xu, WP; Kawajiri, H; Murakami, T; Yamamoto, M; Iseki, S; Iwasaki, T; Hattori, H; Yoshimoto, T				Zhu, H; Takahashi, Y; Xu, WP; Kawajiri, H; Murakami, T; Yamamoto, M; Iseki, S; Iwasaki, T; Hattori, H; Yoshimoto, T			Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR; MOLECULAR-BIOLOGY; 15-LIPOXYGENASE; EXPRESSION; 12-LIPOXYGENASE; DOMAIN; GENE; LDL; ATHEROSCLEROSIS; LIPOXYGENASES	Oxidation of low density lipoprotein (LDL) is the key step for the development of atherosclerosis. The 12/15-lipoxygenase expressed in macrophages is capable of oxygenating linoleic acid esterified to cholesterol in the LDL particle, and thus this enzyme is presumed to initiate LDL oxidation. We recently reported that LDL receptor-related protein (LRP) was required for the enzyme-mediated LDL oxidation by macrophages and suggested the selective uptake of cholesterol ester from LDL to the plasma membrane (Xu, W., Takahashi, Y., Sakashita, T., Iwasaki, T., Hattori, H., and Yoshimoto. T. (2001) J. Biol. Chem 276,36454-36459). To elucidate precise mechanisms of lipoxygenase-mediated LDL oxidation, we investigated the intracellular localization of 12/15-lipoxygenase. The 12/15-lipoxygenase was predominantly detected in cytosol of resting peritoneal macrophages and of macrophage-like J774A.1 cells permanently transfected with the cDNA for the enzyme. When the cells were treated with LDL and subjected to subcellular fractionation, the 12/15-lipoxygenase was detected in the membranes with a concomitant decrease in cytosol as shown by Western blot analysis. The levels of the enzyme associated with the membrane reached maximum in 15 min after LDL addition and then decreased. However, the enzymatic activity of 12/15-lipoxygenase in the membrane fraction was very weak even after LDL treatment. This fact supports the suicide inactivation of the enzyme by the oxygenation of cholesterol ester transferred from the LDL particle to the plasma membrane. Immunohistochemical analysis using an antibody against 12/15-lipoxygenase revealed that the plasma membrane was the major site of the enzyme translocation by the LDL treatment. LDL-dependent 12/15-lipoxygenase translocation was inhibited by a blocking antibody against LRP. Furthermore, an enzyme translocation inhibitor, L655238, inhibited the LDL oxidation caused by the 12/15-lipoxygenase. We propose that cholesterol ester selectively transferred from the LDL particle to the plasma membrane via LRP is oxygenated by 12/15-lipoxygenase translocated to this membrane.	Kanazawa Univ, Grad Sch Med Sci, Dept Mol Pharmacol, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Mol Funct Anal, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University; Kanazawa University	Yoshimoto, T (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Mol Pharmacol, Kanazawa, Ishikawa 9208640, Japan.	yoshimot@med.kanazawa-u.ac.jp						Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Belkner J, 1998, J BIOL CHEM, V273, P23225, DOI 10.1074/jbc.273.36.23225; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; EVANS JF, 1991, MOL PHARMACOL, V40, P22; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Funk CD, 2001, TRENDS CARDIOVAS MED, V11, P116; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiltunen TP, 1998, ATHEROSCLEROSIS, V137, pS81, DOI 10.1016/S0021-9150(97)00307-9; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kawajiri H, 1997, BIOCHEM BIOPH RES CO, V238, P229, DOI 10.1006/bbrc.1997.7213; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Miller YI, 2001, J BIOL CHEM, V276, P19431, DOI 10.1074/jbc.M011276200; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Ozeki Y, 1999, BRIT J PHARMACOL, V128, P1699, DOI 10.1038/sj.bjp.0702976; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sakashita T, 1999, EUR J BIOCHEM, V265, P825, DOI 10.1046/j.1432-1327.1999.00803.x; Shen JH, 1995, FASEB J, V9, P1623, DOI 10.1096/fasebj.9.15.8529842; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; TAKAHASHI Y, 2002, RES ADV CANC, V2, P221; Walther M, 2002, J BIOL CHEM, V277, P27360, DOI 10.1074/jbc.M203234200; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Xu WP, 2001, J BIOL CHEM, V276, P36454, DOI 10.1074/jbc.M105093200; Yamamoto M, 2001, ANAT REC, V262, P213, DOI 10.1002/1097-0185(20010201)262:2<213::AID-AR1031>3.0.CO;2-W; YOSHIMOTO T, 1995, J LIPID MEDIAT CELL, V12, P195, DOI 10.1016/0929-7855(95)00019-M; Zhuang DM, 2000, J BIOCHEM, V127, P451, DOI 10.1093/oxfordjournals.jbchem.a022627	40	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13350	13355		10.1074/jbc.M212104200	http://dx.doi.org/10.1074/jbc.M212104200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566436	hybrid, Green Submitted			2022-12-27	WOS:000182189500096
J	Blom, WM; de Bont, HJGM; Nagelkerke, JF				Blom, WM; de Bont, HJGM; Nagelkerke, JF			Regional loss of the mitochondrial membrane potential in the hepatocyte is rapidly followed by externalization of phosphatidylserines at that specific site during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; PERMEABILITY TRANSITION; CYTOCHROME-C; OXIDATIVE STRESS; DEATH; ATP; RECOGNITION; ACTIVATION; MECHANISM; EXPOSURE	The spatio-temporal relationship between a decrease in the mitochondrial membrane potential (MMP) and externalization of phosphatidylserines (PS) during induction of apoptosis was investigated in single freshly isolated hepatocytes. Apoptosis was induced in the hepatocytes in three different ways: attack by activated Natural Killer cells, exposure to ATP, or exposure to the inhibitor of protein synthesis cycloheximide. Fluorescence microscopy showed staining of externalized PS at those areas where the staining for MMP was lost whereas in other areas the mitochondria remained intact for longer periods of time, indicating coupling between local loss of MMP and local PS exposure. To discriminate whether the decrease in MMP itself or a decrease in ATP induced PS externalization, hepatocytes were treated with rotenone, which resulted in a rapid collapse of cellular ATP but left the MMP intact for a much longer period. Addition of fructose prevented the decrease of ATP to similar to30% and also delayed the collapse of the MMP. This indicates that ATP was needed for the maintenance of the MMP probably via reverse action of the ATP synthase. In a subsequent study hepatocytes were incubated with Natural Killer cells for induction of apoptosis followed by addition of rotenone to deplete ATP. Under these conditions the PS staining co-localized with mitochondrial MMP indicating that PS externalization does not require a collapse in AMP. Moreover, exposure of PS was evenly distributed over the whole plasma membrane. In conclusion, we propose that after an apoptotic stimulus some mitochondria start to loose their MMP, which results in cessation of ATP production and perhaps even consumption of ATP. This results in an overall decrease in cellular ATP. ATP-consuming enzyme reactions most distal from still intact mitochondria will be most sensitive to such a decrease. Apparently the translocase that keeps phosphatidylserines inward-oriented is such a sensitive enzyme.	Leiden Univ, Div Toxicol, Gorlaeus Labs, LACDR, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Nagelkerke, JF (corresponding author), Leiden Univ, Div Toxicol, Gorlaeus Labs, LACDR, POB 9502, NL-2300 RA Leiden, Netherlands.	nagelker@lacdr.Leidenuniv.nl		Blom, W.M./0000-0002-6853-0900				ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; Bernardi P, 1998, BBA-BIOENERGETICS, V1366, P1; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Blom WM, 1999, BIOCHEM PHARMACOL, V58, P1891, DOI 10.1016/S0006-2952(99)00268-3; Blom WM, 1999, HEPATOLOGY, V29, P785, DOI 10.1002/hep.510290303; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Castedo M, 1996, J IMMUNOL, V157, P512; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; FADOK VA, 1992, J IMMUNOL, V148, P2207; GiezemanSmits KM, 1997, IMMUNOBIOLOGY, V197, P429, DOI 10.1016/S0171-2985(97)80077-0; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KOOP A, 1993, BIOCHEM J, V295, P165, DOI 10.1042/bj2950165; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUMBLE KD, 1991, J CELL SCI, V99, P751; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Nagelkerke JF, 1996, J MICROSC-OXFORD, V184, P58; NAGELKERKE JF, 2001, MITOCHONDRIA PATHOGE, P449; Nicotera P, 1998, TOXICOL LETT, V103, P139; Pelassy C, 2001, BBA-MOL CELL RES, V1539, P256, DOI 10.1016/S0167-4889(01)00113-6; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Porcelli AM, 2001, METHOD CELL BIOL, V65, P353, DOI 10.1016/S0091-679X(01)65021-0; Rolstad B, 1998, SCAND J IMMUNOL, V47, P412; SMALLCOMBE A, 1996, 11 BIOR; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207	42	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12467	12474		10.1074/jbc.M201264200	http://dx.doi.org/10.1074/jbc.M201264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538597	hybrid, Green Published			2022-12-27	WOS:000182015700097
J	Ko, YH; Delannoy, M; Hullihen, J; Chiu, W; Pedersen, PL				Ko, YH; Delannoy, M; Hullihen, J; Chiu, W; Pedersen, PL			Mitochondrial ATP synthasome - Cristae-enriched membranes and a multiwell detergent screening assay yield dispersed single complexes containing the ATP synthase and carriers for P-i and ADP/ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; RESPIRATORY-CHAIN; CRYSTAL-STRUCTURE; MECHANISM; SUBUNIT; MOTOR	The terminal step of ATP synthesis in intact mitochondria is catalyzed by the ATP synthase (F0F1) that works in close synchrony with the P-i and ADP/ATP carriers. Each carrier consists of only a single polypeptide chain in dimeric form, while the ATP synthase is highly complex consisting in animals of 17 known subunit types and more than 30 total subunits. Although structures at high resolution have been obtained for the water-soluble F-1 part of the ATP synthase consisting of only five subunit types, such structures have not been obtained for either the complete ATP synthase or the P-i and ADP/ ATP carriers. Here, we report that all three proteins are localized in highly purified cristae-like vesicles obtained by extensive subfractionation of the mitochondrial inner membrane. Moreover, using a multiwell detergent screening assay, 4 nonionic detergents out of 80 tested were found to disperse these cristae-like vesicles into single soluble complexes or "ATP synthasomes" that contain the ATP synthase in association with the P-i and ADP/ATP carriers. These studies offer new mechanistic insights into the terminal steps of oxidative phosphorylation in mitochondria and set the stage for future structural efforts designed to visualize in atomic detail the entire complex involved. They also provide evidence that the cristae are a subcompartment of the inner membrane.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Natl Ctr Macromol Inaging, Houston, TX 77030 USA; Baylor Coll Med, Program Struct & COmputat Biol & Mol Biophys, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Baylor College of Medicine; Baylor College of Medicine	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	ppederse@jhmi.edu			NCI NIH HHS [CA 10951] Funding Source: Medline; NCRR NIH HHS [P41RR02250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Belogrudov GI, 2002, J BIOL CHEM, V277, P6097, DOI 10.1074/jbc.M111256200; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; CHAN TL, 1970, J CELL BIOL, V45, P291, DOI 10.1083/jcb.45.2.291; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; Frey TG, 2002, BBA-BIOENERGETICS, V1555, P196, DOI 10.1016/S0005-2728(02)00278-5; JACOBS EE, 1956, J BIOL CHEM, V223, P147; KAGAWA Y, 1966, J BIOL CHEM, V241, P2475; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Ko YH, 2000, J BIOL CHEM, V275, P32931, DOI 10.1074/jbc.M004453200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ostermeier C, 1997, CURR OPIN STRUC BIOL, V7, P697, DOI 10.1016/S0959-440X(97)80080-2; PALADE GE, 1952, ANAT RECORD, V114, P427, DOI 10.1002/ar.1091140304; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P423, DOI 10.1023/A:1005652605340; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SOPER JW, 1976, BIOCHEMISTRY-US, V15, P2682, DOI 10.1021/bi00657a031; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; ZIEGLER M, 1993, J BIOL CHEM, V268, P25320	28	149	151	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12305	12309		10.1074/jbc.C200703200	http://dx.doi.org/10.1074/jbc.C200703200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560333	hybrid			2022-12-27	WOS:000182015700076
J	Li, JM; Shah, AM				Li, JM; Shah, AM			Mechanism of endothelial cell NADPH oxidase activation by angiotensin II - Role of the p47(Phox) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SUPEROXIDE PRODUCTION; NAD(P)H OXIDASE; CYTOSOLIC COMPONENT; OXIDATIVE STRESS; RENAL DISEASES; MICE; PHOSPHORYLATION; MEMBRANE; HYPERTROPHY	Endothelial cells express a constitutively active phagocyte-type NADPH oxidase whose activity is augmented by agonists such as angiotensin II. We recently reported (Li, J.-M., and Shah, A. M. (2002) J. Biol. Chem. 277, 19952-19960) that in contrast to neutrophils a substantial proportion of the NADPH oxidase in unstimulated endothelial cells exists as preassembled intracellular complexes. Here, we investigate the mechanism of angiotensin II-induced endothelial NADPH oxidase activation. Angiotensin II (100 nmol/liter)-induced reactive oxygen species production (as measured by dichloro-hydrofluorescein fluorescence or lucigenin chemiluminescence) was completely absent in coronary microvascular endothelial cells isolated from p47(phox) knockout mice. Transfection of p47(phox) cDNA into p47(phox-/-) cells restored the angiotensin II response, whereas transfection of antisense p47(phox) cDNA into wild-type cells depleted p47(phox) and inhibited the angiotensin II response. In unstimulated human microvascular endothelial cells, there was significant p47(phox)-p22(phox) complex formation but minimal detectable p47(phox) phosphorylation. Angiotensin II induced rapid serine phosphorylation of P47(phox) (within 1 min, peaking at similar to15 min), a 1.9 +/- 0.1-fold increase in p47(phox)-p22(phox) complex formation and a 1.6 +/- 0.2-fold increase in NADPH-dependent O-2(radical anion) production (p < 0.05). p47(phox) was redistributed to "nuclear" and membrane-enriched cell fractions. These data indicate that angiotensin II-stimulated endothelial NADPH oxidase activity is regulated through serine phosphorylation of p47(phox) and its enhanced binding to p22(phox).	Kings Coll London, Dept Cardiol, Guys Kings & St Thomass Sch Med, London SE5 9PJ, England	University of London; King's College London	Shah, AM (corresponding author), Kings Coll London, Dept Cardiol, Guys Kings & St Thomass Sch Med, Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk		Shah, Ajay/0000-0002-6547-0631				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Bendall JK, 2002, CIRCULATION, V105, P293, DOI 10.1161/hc0302.103712; Cifuentes ME, 2000, AM J PHYSIOL-HEART C, V279, pH2234, DOI 10.1152/ajpheart.2000.279.5.H2234; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kim S, 2000, PHARMACOL REV, V52, P11; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Lang D, 2000, CIRC RES, V86, P463, DOI 10.1161/01.RES.86.4.463; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lavigne MC, 2001, CIRCULATION, V104, P79, DOI 10.1161/01.CIR.104.1.79; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2; Li JM, 2001, J MOL CELL CARDIOL, V33, P1119, DOI 10.1006/jmcc.2001.1372; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Morozov I, 1998, J BIOL CHEM, V273, P15435, DOI 10.1074/jbc.273.25.15435; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; Pueyo ME, 1997, GEN PHARMACOL-VASC S, V29, P691, DOI 10.1016/S0306-3623(97)00021-9; Pueyo ME, 2000, ARTERIOSCL THROM VAS, V20, P645, DOI 10.1161/01.ATV.20.3.645; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Schieffer B, 2000, CIRC RES, V87, P1195, DOI 10.1161/01.RES.87.12.1195; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2	34	248	263	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12094	12100		10.1074/jbc.M209793200	http://dx.doi.org/10.1074/jbc.M209793200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560337	hybrid			2022-12-27	WOS:000182015700050
J	De Lean, A; McNicoll, N; Labrecque, J				De Lean, A; McNicoll, N; Labrecque, J			Natriuretic peptide receptor A activation stabilizes a membrane-distal dimer interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; FACTOR-R1 RECEPTOR; BINDING DOMAIN; ANP RECEPTOR; COMPLEX; MUTANT; IDENTIFICATION; HYPERTENSION	We have shown previously (Rondeau, J.-J., McNicoll, N., Gagnon, J., Bouchard, N., Ong, H., and De Lean, A. (1995) Biochemistry 34,2130-2136) that atrial natriuretic peptide (ANP) stabilizes a dimeric form of the natriuretic peptide receptor A (NPRA) by simultaneously interacting with both receptor subunits. However, the first crystallographic study of unliganded NPRA extracellular domain documented a V-shaped dimer involving a membrane-proximal dimer interface and separate binding sites for ANP on each monomer. We explored the possibility of an alternative A-shaped dimer involving a membrane-distal dimer interface by substituting an unpaired solvent-exposed cysteine for Trp74 in the amino-terminal lobe of full-length NPRA. The predicted spacing between Trp(74) from both subunits drastically differs, depending on whether the V-shaped (84 Angstrom) or the A-shaped (8 Angstrom) dimer model is considered. In contrast with the expected results for the reported V-shaped dimer, the NPRA(W74C) mutant was constitutively covalently dimeric. Also, the"subunits spontaneously associated following transient disulfide reduction by dithiothreitol and reoxidation. However, ANP could neither bind to nor activate NPRA(W74C). Permanent disulfide opening by reduction with dithiothreitol and alkylation with N-ethylmaleimide rescued ANP binding to NPRA(W74C). The NPRA mutant could be maintained as a covalent dimer while preserving its function by crosslinking with the bifunctional alkylating agent phenylenedimaleimides (PDM), the ortho-substituted oPDM being more efficient than mPDM or pPDM. These results indicate that the membrane-distal lobe of the NPRAM extracellular domains are dynamically interfacing in the unliganded state and that ANP binding stabilizes the receptor dimer with more stringent spacing at the dimer interface.	Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3T 1J4, Canada	Universite de Montreal	De Lean, A (corresponding author), Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3T 1J4, Canada.							CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; FETHIERE J, 1989, MOL PHARMACOL, V35, P584; Foster D C, 1999, Rev Physiol Biochem Pharmacol, V135, P1, DOI 10.1007/BFb0033668; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; Hashimoto M, 1999, BIOCHEMISTRY-US, V38, P1050, DOI 10.1021/bi9822978; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Labrecque J, 1999, J BIOL CHEM, V274, P9752, DOI 10.1074/jbc.274.14.9752; Labrecque J, 2001, J BIOL CHEM, V276, P8064, DOI 10.1074/jbc.M005550200; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; LIU B, 1989, BIOCHEMISTRY-US, V28, P5599, DOI 10.1021/bi00439a039; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Lucas KA, 2000, PHARMACOL REV, V52, P375; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Marquis M, 1999, MOL CELL BIOCHEM, V194, P23, DOI 10.1023/A:1006835808554; McNicoll N, 1996, BIOCHEMISTRY-US, V35, P12950, DOI 10.1021/bi960818q; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; RONDEAU JJ, 1995, BIOCHEMISTRY-US, V34, P2130, DOI 10.1021/bi00007a005; Suzuki T, 2001, CARDIOVASC RES, V51, P489, DOI 10.1016/S0008-6363(01)00238-3; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKASHIMA A, 1995, EUR J BIOCHEM, V227, P673, DOI 10.1111/j.1432-1033.1995.tb20187.x; van den Akker F, 2001, J MOL BIOL, V311, P923, DOI 10.1006/jmbi.2001.4922; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	34	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11159	11166		10.1074/jbc.M212862200	http://dx.doi.org/10.1074/jbc.M212862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547834	hybrid			2022-12-27	WOS:000181855400040
J	Engedal, N; Blomhoff, HK				Engedal, N; Blomhoff, HK			Combined action of ERK and NF kappa B mediates the protective effect of phorbol ester on fas-induced apoptosis in Jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN T-CELLS; CD95-MEDIATED APOPTOSIS; SIGNALING COMPLEX; UP-REGULATION; DEATH DOMAIN; ACTIVATION; CD95; INHIBITOR; RECRUITMENT	The mechanisms whereby phorbol esters antagonize Fas-induced apoptosis in Jurkat T cells are poorly defined. In the present study, we report that protection from Fas-induced apoptosis by 12-O-tetradecanoylphorbol 13-acetate (TPA) is dependent on both ERK and NFkappaB activation. First, we showed that two specific mitogen-activated protein kinase/ERK kinase-inhibitors, PD98059 and U0126, both counteracted TPA-mediated suppression of Fas-induced apoptosis. Moreover, the dose-dependence of U0126-mediated inhibition of ERK phosphorylation correlated with that of reversion of the anti-apoptotic effect of TPA. Second, we observed an excellent correlation between repression of TPA-induced NFkappaB activation by an irreversible inhibitor of IkappaBalpha phosphorylation, BAY11-7082, and its ability to abrogate TPA-induced suppression of Fas-mediated apoptosis. Furthermore, we located the anti-apoptotic effect of both ERK and NFkappaB to lie upstream of the mitochondrial membrane potential depolarization event. Finally, although each inhibitor at optimal, non-toxic concentration by itself only partly reversed TPA-mediated repression of apoptosis, the combination of U0126 and BAY11-7082 completely abolished the anti-apoptotic effect of TPA. Together these findings suggest that TPA-induced activation of ERK and NFkappaB are parallel events that are both required for maximal inhibition of Fas-induced apoptosis in Jurkat T cells.	Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway	University of Oslo	Blomhoff, HK (corresponding author), Univ Oslo, Inst Med Biochem, POB 1112,Blindern, N-0317 Oslo, Norway.	h.k.blomhoff@basalmed.uio.no	Engedal, Nikolai/AAJ-8951-2020	Engedal, Nikolai/0000-0003-3718-3464				Ahn NG, 2001, METHOD ENZYMOL, V332, P417; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; McLeod JD, 1998, J IMMUNOL, V160, P2072; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; WEISS A, 1984, J IMMUNOL, V133, P123; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	47	37	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10934	10941		10.1074/jbc.M211556200	http://dx.doi.org/10.1074/jbc.M211556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551910	hybrid			2022-12-27	WOS:000181855400010
J	Picher, M; Boucher, RC				Picher, M; Boucher, RC			Human airway ecto-adenylate kinase - A mechanism to propagate ATP signaling on airway surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-CHANNEL EXPRESSION; NASAL EPITHELIAL-CELLS; EXTRACELLULAR ATP; NUCLEOSIDE DIPHOSPHOKINASE; RELEASE; ADENOSINE; VOLUME; METABOLISM; PHOSPHOTRANSFERASE; DIFFERENTIATION	Mechanically induced ATP release from human airway epithelial cells regulates mucociliary clearance through cell surface nucleotide receptors. Ectoenzymes detected on these cells were recently shown to terminate ATP-mediated responses by sequential dephosphorylation of extracellular ATP into ADP, AMP, and adenosine. We now demonstrate that an ecto-adenylate kinase (ecto-AK) contributes to the metabolism of adenine nucleotides on human airway epithelial surfaces by the reversible reaction: ATP + AMP reversible arrow 2ADP. This phosphotransferase exhibited a bilateral distribution on polarized primary cultures of human bronchial epithelial cells with a 4-fold higher activity on the mucosal surface. Ecto-AK presented an absolute requirement for magnesium and adenine-based nucleotides. UMP, GMP, and CMP could not substitute for AMP as gamma-phosphate acceptor, and UDP could not replace ADP. Apparent K-m and V-max values were 23 +/- 5 muM and 1.1 +/- 0.1 nmol.min(-1).cm(-2) for ATP and 43 +/- 6 muM and 0.5 +/- 0.1 nmol.min(-1).cm(-2) for ADP. Ecto-AK accounted for 20% of [gamma-P-32]ATP dephosphorylation, and the impermeant AK inhibitor, diadenosine pentaphosphate, reduced ADPase activity by more than 70% on both epithelial surfaces. Time course experiments on ATP metabolism demonstrated that ecto-AK significantly prolongs effective ATP and ADP concentrations on airway epithelial surfaces for P2 receptor signaling and reduces by 6-fold adenosine production. Our data suggest a role for this nucleotide entrapment cycle in the propagation of purine-mediated mucociliary clearance on human airway epithelial surfaces.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulmonary Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Picher, M (corresponding author), Univ N Carolina, Sch Med, 7010 Thurston Bowles Bldg, Chapel Hill, NC 27510 USA.	pichm@med.unc.edu						Beaudoin A.R, 1996, BIOMEMBRANES, V5, P369; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; CASCALHEIRA JF, 1992, EUR J PHARMACOL, V222, P49, DOI 10.1016/0014-2999(92)90462-D; CLANCY JP, 1999, AM J PHYSIOL, V267, pC361; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; DONALDSON SH, 1998, P2 NUCLEOTIDE RECEPT, P413; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUNKLEY CR, 1966, J CELL PHYSIOL, V68, P241, DOI 10.1002/jcp.1040680305; FEDDE KN, 1988, ARCH BIOCHEM BIOPHYS, V264, P400, DOI 10.1016/0003-9861(88)90305-0; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HAMADA M, 1982, J BIOL CHEM, V257, P3120; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; KUBY SA, 1978, ARCH BIOCHEM BIOPHYS, V187, P34, DOI 10.1016/0003-9861(78)90004-8; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lange K, 2000, J CELL PHYSIOL, V185, P21, DOI 10.1002/1097-4652(200010)185:1<21::AID-JCP2>3.3.CO;2-4; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; LAZAROWSKI ER, 2001, PEDIAT PULMONOLOGY S, V22, P193; LAZAROWSKI ER, 1997, BRIT J PHARMACOL, V127, P1272; Le KT, 1998, J NEUROSCI, V18, P7152; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LEHIR M, 1993, AM J PHYSIOL, V264, pF377, DOI 10.1152/ajprenal.1993.264.3.F377; LIEB T, 2001, J PHYSL, V538, P633; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485, DOI 10.1152/ajpcell.2001.280.6.C1485; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; NAGY AK, 1989, J NEUROCHEM, V53, P1166, DOI 10.1111/j.1471-4159.1989.tb07410.x; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Picher M, 2000, AM J RESP CELL MOL, V23, P255, DOI 10.1165/ajrcmb.23.2.4088; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; Picher M, 2001, DRUG DEVELOP RES, V52, P66, DOI 10.1002/ddr.1099; PICHER M, 1999, PEDIAT PULMONOLOGY S, V19, P311; Ramirez AN, 2002, AM J PHYSIOL-HEART C, V282, pH2106, DOI 10.1152/ajpheart.00892.2001; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; Van Rompay AR, 2000, PHARMACOL THERAPEUT, V87, P189, DOI 10.1016/S0163-7258(00)00048-6; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Williams M, 2000, BIOCHEM PHARMACOL, V59, P1173, DOI 10.1016/S0006-2952(99)00341-X; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; WU R, 1985, AM REV RESPIR DIS, V132, P311; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	63	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11256	11264		10.1074/jbc.M208071200	http://dx.doi.org/10.1074/jbc.M208071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551890	hybrid			2022-12-27	WOS:000181855400052
J	So, SP; Wu, JX; Huang, GX; Huang, AM; Li, DW; Ruan, KH				So, SP; Wu, JX; Huang, GX; Huang, AM; Li, DW; Ruan, KH			Identification of residues important for ligand binding of thromboxane A(2) receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; CDNA; ISOFORMS; SUBTYPE; CHAIN; SITE	The second extracellular loop (eLP2) of the thromboxane A(2) receptor (TP) had been proposed to be involved in ligand binding. Through two-dimensional H-1 NMR experiments, the overall three-dimensional structure of a constrained synthetic peptide mimicking the eLP2 had been determined by our group (Ruan, K: H., So, S.-P., Wu, J., Li, D., Huang, A., and Kung, J. (2001) Biochemistry 40, 275-280). To further identify the residues involved in ligand binding, a TP receptor antagonist, SQ29,548 was used to interact with the synthetic peptide. High resolution two-dimensional H-1 NMR experiments, NOESY, and TOCSY were performed for the peptide, SQ29,548, and peptide with SQ29,548, respectively. Through completed H-1 NMR assignment and by comparing the different spectra, extra peaks were observed on the NOESY spectrum of the peptide with SQ29,548, which implied the contacts between residues of eLP2 at Val(176), Leu(185), Thr(186), and Leu(187) with SQ29,548 at position H2, H7, and H8. Site-directed mutagenesis was used to confirm the possible ligand-binding sites on native human TP receptor. Each of the four residues was mutated to the residues either in the same group, with different structure or different charged. The mutated receptors were then tested for their ligand binding activity. The receptor with V176L mutant retained binding activity to SQ29,548. All other mutations resulted in decreased or lost binding activity to SQ29,548. These mutagenesis results supported the prediction from NMR experiments in which Val(176), Leu(185), Thr(186), and Leu(187) are the possible residues involved in ligand binding. This information facilitates the understanding of the molecular mechanism of thromboxane A(2) binding to the important receptor and its signal transduction.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Ruan, KH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.	kruan@uth.tmc.edu		Huang, Gangxiong/0000-0002-0117-5457	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056712, R29HL056712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56712] Funding Source: Medline; NINDS NIH HHS [NS 23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; FUNK CD, 1993, J BIOL CHEM, V268, P26767; FUNK CD, 1993, MOL PHARMACOL, V44, P934; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; KATSUYAMA M, 1994, FEBS LETT, V344, P74, DOI 10.1016/0014-5793(94)00355-6; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; REGAN JW, 1994, BRIT J PHARMACOL, V112, P377, DOI 10.1111/j.1476-5381.1994.tb13082.x; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Turek JW, 2002, J BIOL CHEM, V277, P16791, DOI 10.1074/jbc.M105872200; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JH, 1994, BIOCHEM BIOPH RES CO, V198, P999, DOI 10.1006/bbrc.1994.1142	28	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10922	10927		10.1074/jbc.M209337200	http://dx.doi.org/10.1074/jbc.M209337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551898	hybrid			2022-12-27	WOS:000181855400008
J	Anestal, K; Arner, ESJ				Anestal, K; Arner, ESJ			Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; GENE-EXPRESSION; GLUTATHIONE-REDUCTASE; INSERTION-SEQUENCE; REDOX REGULATION; HUMAN PLACENTA; CYTOCHROME-C; INTERFERON; APOPTOSIS; MECHANISM	Mammalian thioredoxin reductases are selenoproteins. For native catalytic activity, these enzymes utilize a C-terminal -Gly-Cys-Sec-Gly-COOH sequence (where Sec is selenocysteine) forming a redox active selenenyl-sulfide/selenolthiol motif. A range of cellular systems depend upon or are regulated by thioredoxin reductase and its major protein substrate thioredoxin, including apoptosis signal-regulating kinase 1, peroxiredoxins, methionine sulfoxide reductase, and several transcription factors. Cytosolic thioredoxin reductase 1 (TrxR1) is moreover inhibited by various electrophilic anticancer compounds. TrxR1 is hence generally considered to promote cell viability. However, several recent studies have suggested that TrxR1 may promote apoptosis, and the enzyme was identified as GRIM-12 (gene associated with retinoid interferon-induced mortality 12). Transient transfection with GRIM-12/TrxR1 was also shown to directly, induce cell death. To further analyze such effects, we have here employed lipid-mediated delivery of recombinant TrxR1 preparations into human A549 cells, thereby bypassing selenoprotein translation to facilitate assessment of the protein-related effects on cell viability. We found that selenium-deficient TrxR1, having a two-amino acid-truncated C-terminal -Gly-Cys-COOH motif, rapidly induced cell death (38 +/- 29% apoptotic cells after 4 h; p < 0.005 compared with controls). Cell death induction was also promoted by selenium-compromised TrxR1 derivatized with either cis-diam-minedichloroplatinum (H) (cisplatin) or dinitrophenyl moieties but not by the structurally related non-selenoprotein glutathione reductase. In contrast, TrxR1 with intact selenocysteine could not promote cell death. The direct cellular effects of selenium-compromised forms of TrxR1 may be important for the pathophysiology of selenium deficiency as well as for the efficacy of antipro-liferative drugs targeting the selenocysteine moiety of this enzyme.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Arner, ESJ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.	Elias.Arner@mbb.ki.se	Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; ARNER ESJ, 2000, CURRENT PROTOCOLS TO; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Berggren M, 1996, ANTICANCER RES, V16, P3459; BROT N, 1991, BIOFACTORS, V3, P91; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chang SH, 2000, AM J PATHOL, V156, P637, DOI 10.1016/S0002-9440(10)64768-2; Fujiwara N, 1999, BIOCHEM J, V340, P439, DOI 10.1042/0264-6021:3400439; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gilmore KJ, 2001, CELL DEATH DIFFER, V8, P631, DOI 10.1038/sj.cdd.4400858; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lindner DJ, 2002, CLIN CANCER RES, V8, P3210; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Ma XR, 2002, J BIOL CHEM, V277, P22460, DOI 10.1074/jbc.M202286200; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1613, DOI 10.1016/0006-2952(92)90220-D; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1621; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Yarimizu J, 2000, ANTIOXID REDOX SIGN, V2, P643, DOI 10.1089/ars.2000.2.4-643; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	48	133	141	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15966	15972		10.1074/jbc.M210733200	http://dx.doi.org/10.1074/jbc.M210733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12574159	hybrid			2022-12-27	WOS:000182680000066
J	Carvalho, RN; Solstad, T; Bjorgo, E; Barroso, JF; Flatmark, T				Carvalho, RN; Solstad, T; Bjorgo, E; Barroso, JF; Flatmark, T			Deamidations in recombinant human phenylalanine hydroxylase - Identification of labile asparagine residues and functional characterization of ASN -> ASP mutant forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; AMINO-ACID-SEQUENCE; PROTEIN DEAMIDATION; SUBSTRATE-BINDING; WILD-TYPE; PEPTIDES; ENZYME; DEGRADATION; GENE; PHENYLKETONURIA	Recombinant human phenylalanine hydroxylase (hPAH) expressed in Escherichia coli for 24 h at 28 degreesC has been found by two-dimensional electrophoresis to exist as a mixture of four to five molecular forms as a result of nonenzymatic deamidation of labile Asn residues. The multiple deamidations alter the functional properties of the enzyme including its affinity for L-phenylalanine and tetrahydrobiopterin, catalytic efficiency, and substrate inhibition and also result in enzyme forms more susceptible to limited tryptic proteolysis. Asn(32) in the regulatory domain deamidates very rapidly because of its nearest neighbor amino acid Gly(33) (Solstad, T., Carvalho, R. N., Andersen, O. A., Waidelich, D., and Flatmark, T. (2003) Eur. J. Biochem., in press). Matrix-assisted laser desorption/ionization time of flight-mass spectrometry of the tryptic peptides in the catalytic domain of a 24-h (28 degreesC) expressed enzyme has shown Asn(376) and Asn(133) to be labile residues. Site-directed mutagenesis of nine Asn residues revealed that the deamidations of Asn(32) and Asn(376) are the main determinants for the functional and regulatory differences observed between the 2- and 24-h-induced wild-type (wt) enzyme. The Asn(32) --> Asp, Asn(376) --> Asp, and the double mutant forms expressed for 2 h at 28 degreesC revealed qualitatively similar regulatory properties as the highly deamidated 24-h expressed wt-hPAH. Moreover, deamidation of Asn(32) in the wt-hPAH (24 h expression at 28 C) and the Asn(32) --> Asp mutation both increase the initial rate of phosphorylation of Serfs by cAMP-dependent protein kinase (p < 0.005). By contrast, the substitution of Gly(33) with Ala or Val, both preventing the deamidation of Asn(32), resulted in enzyme forms that were phosphorylated at a similar rate as nondeamidated wt-hPAH, even on 24-h expression. The other Asn --> Asp substitutions (in the catalytic domain) revealed that Asn(207) and Asn(223) have an important stabilizing structural function. Finally, two recently reported phenylketonuria mutations at Asn residues in the catalytic domain were studied, i.e. Asn(167) --> Ile and Asn(207) --> Asp, and their phenotypes were characterized.	Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Prote Unit, N-5009 Bergen, Norway; Univ Oslo, Ctr Biotechnol, N-0317 Oslo, Norway	University of Bergen; University of Bergen; University of Oslo	Flatmark, T (corresponding author), Univ Bergen, Dept Biochem & Mol Biol, Arstadveien 19, N-5009 Bergen, Norway.	torgeir.flatmark@ibmb.uib.no						BISCHOFF R, 1994, J CHROMATOGR B, V662, P261, DOI 10.1016/0378-4347(94)00203-7; Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; Bjorgo E, 2001, EUR J BIOCHEM, V268, P997, DOI 10.1046/j.1432-1327.2001.01958.x; CARVALHO RMN, 2002, CHEM BIOL PTERIDINES, P103; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Doskeland AP, 1996, BIOCHEM J, V319, P941, DOI 10.1042/bj3190941; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; Eiken HG, 1996, HUM MUTAT, V7, P228, DOI 10.1002/(SICI)1098-1004(1996)7:3<228::AID-HUMU7>3.0.CO;2-6; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; FLATMARK T, 1968, J BIOL CHEM, V243, P1623; FLATMARK T, 1967, J BIOL CHEM, V242, P2454; FLATMARK T, 1966, ACTA CHEM SCAND, V20, P1487, DOI 10.3891/acta.chem.scand.20-1487; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; Flatmark T, 2001, ANAL BIOCHEM, V294, P95, DOI 10.1006/abio.2001.5163; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; GEIGER T, 1987, J BIOL CHEM, V262, P785; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KNACK I, 1981, H-S Z PHYSIOL CHEM, V362, P1119, DOI 10.1515/bchm2.1981.362.2.1119; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Knappskog PM, 1996, HUM MUTAT, V8, P236, DOI 10.1002/(SICI)1098-1004(1996)8:3<236::AID-HUMU7>3.0.CO;2-7; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Kosky AA, 1999, PROTEIN SCI, V8, P2519; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LiCata VJ, 1997, BIOPHYS CHEM, V64, P225, DOI 10.1016/S0301-4622(96)02204-1; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Park YS, 1998, HUM MUTAT, pS121; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P4367, DOI 10.1073/pnas.071066498; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P944, DOI 10.1073/pnas.98.3.944; Robinson NE, 2001, J PEPT RES, V57, P483, DOI 10.1034/j.1399-3011.2001.00863.x; Scriver CR, 2000, HUM MUTAT, V15, P99, DOI 10.1002/(SICI)1098-1004(200001)15:1<99::AID-HUMU18>3.0.CO;2-P; SMITH SC, 1984, J BIOL CHEM, V259, P1284; Solstad T, 2000, EUR J BIOCHEM, V267, P6302, DOI 10.1046/j.1432-1327.2000.01715.x; Solstad T, 2003, EUR J BIOCHEM, V270, P929, DOI 10.1046/j.1432-1033.2003.03455.x; SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X; Tyfield LA, 1997, AM J HUM GENET, V60, P388; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; Waters PJ, 1998, HUM MUTAT, V12, P344, DOI 10.1002/(SICI)1098-1004(1998)12:5<344::AID-HUMU8>3.0.CO;2-D; Wehofsky M, 2001, EUR J MASS SPECTROM, V7, P39, DOI 10.1255/ejms.387; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	44	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15142	15152		10.1074/jbc.M212180200	http://dx.doi.org/10.1074/jbc.M212180200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12554741	hybrid			2022-12-27	WOS:000182516100073
J	Hino, S; Michiue, T; Asashima, M; Kikuchi, A				Hino, S; Michiue, T; Asashima, M; Kikuchi, A			Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; F-BOX PROTEIN; NEGATIVE REGULATOR; AXIN; PHOSPHORYLATION; DEGRADATION; INHIBITION; ACTIVATION; DOMAINS; COMPLEX	We demonstrate that Dvl-1, casein kinase Iepsilon (CKIepsilon), and Frat-1 activate the Wnt signaling pathway cooperatively. The amino acid region 228-250 of Dvl-1 was necessary for its binding to Frat-1, and the interaction of Dvl-1 with Frat-1 was enhanced by CKIepsilon. Coexpression of Dvl-1 and Frat-1 caused accumulation of beta-catenin synergistically in L cells. Both proteins also activated the transcriptional activity of T-cell factor-4 (Tcf-4) synergistically in human embryonic kidney 293 cells, but coexpression of Dvl-1-(Delta228-250), which lacks the amino acid region 228-250 from Dvl-1, and Frat-1 did not. Dvl-1, but not Dvl-1-(Delta228-250), acted synergistically with CKIepsilon to activate Tcf-4. Depletion of CKIepsilon by double-stranded RNA interference in HeLa S3 cells led to the inhibition of Wnt-3a-induced phosphorylation of Dvl and the binding of Dvl-1 to Frat-1. Furthermore, depletion of CKIepsilon reduced the Wnt-3a-induced accumulation of beta-catenin, although it did not affect the basal level of beta-catenin. These results indicate that CKIepsilon-dependent phosphorylation of Dvl enhances the formation of a complex of Dvl-1 with Frat-1 and that this complex leads to the activation of the Wnt signaling pathway.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Sorst Project, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan	Hiroshima University; University of Tokyo; University of Tokyo	Kikuchi, A (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Penton A, 2002, GENETICS, V161, P747; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	43	93	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14066	14073		10.1074/jbc.M213265200	http://dx.doi.org/10.1074/jbc.M213265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556519	hybrid			2022-12-27	WOS:000182405000066
J	Levy, Y; Ronen, D; Bershadsky, AD; Zick, Y				Levy, Y; Ronen, D; Bershadsky, AD; Zick, Y			RETRACTED: Sustained induction of ERK, protein kinase B, and p70 S6 kinase regulates cell spreading and formation of F-actin microspikes upon ligation of integrins by galectin-8, a mammalian lectin (Retracted article. See vol. 293, pg. 7265, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							SIGNAL-TRANSDUCTION; ADHESION RECEPTORS; FASCIN SPIKES; RHO GTPASES; T-CELLS; ACTIVATION; BINDING; FAMILY; EXPRESSION; FIBRONECTIN	Galectin-8, a member of the galectin family of mammalian lectins, is a secreted protein that promotes cell adhesion and migration upon binding to a subset of integrins through sugar-protein interactions. Ligation of integrins by galectin-8 triggers a distinct pattern of cytoskeletal organization, including formation of F-actin-containing microspikes. This is associated with activation of integrin-mediated signaling cascades (ERK and phosphatidylinositol 3 kinase (PI3K)) that are much more robust and are of longer duration than those induced upon cell adhesion to fibronectin. Indeed, formation of microspikes is enhanced 40% in cells that overexpress protein kinase B, the downstream effector of PI3K. Inhibition of PI3K activity induced by wortmannin partially inhibits cell adhesion and spreading while largely inhibiting microspike formation in cells adherent to galectin-8. Furthermore, the inhibitory effects of wortmannin are markedly accentuated in cells overexpressing PKB or p70S6K (CHOPKB and CHOp70S6K cells), whose adhesion and spreading on galectin-8 (but not on fibronectin) is inhibited similar to25-35% in the presence of wortmannin. The above results suggest that galectin-8 is an extracellular matrix protein that triggers a unique repertoire of integrin-mediated signals, which leads to a distinctive cytoskeletal organization and microspike formation. They further suggest that downstream effectors of PI3K, including PKB and p70 S6 kinase, in part mediate cell adhesion, spreading, and microspike formation induced by galectin-8.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	yehiel.zick@weizmann.ac.il	Zick, Yehiel/K-1479-2012	Bershadsky, Alexander/0000-0002-9571-7375				Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; ADAMS JC, 1995, J CELL SCI, V108, P1977; ADLER R, 1985, DEV BIOL, V112, P100, DOI 10.1016/0012-1606(85)90124-1; ALBRECHTBUEHLER G, 1976, J CELL BIOL, V71, P370, DOI 10.1083/jcb.71.2.370; Aplin AE, 1998, PHARMACOL REV, V50, P197; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4; Camby I, 2001, BRAIN PATHOL, V11, P12; CHIQUETEHRISMANN R, 1995, CURR OPIN CELL BIOL, V7, P715, DOI 10.1016/0955-0674(95)80114-6; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; Feizi T, 1999, TRENDS BIOCHEM SCI, V24, P369, DOI 10.1016/S0968-0004(99)01458-9; Fischer D, 1997, MOL BIOL CELL, V8, P2055, DOI 10.1091/mbc.8.10.2055; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guvakova MA, 2002, J CELL SCI, V115, P4149, DOI 10.1242/jcs.00104; Guvakova MA, 2002, INT J BIOCHEM CELL B, V34, P685, DOI 10.1016/S1357-2725(01)00160-1; Hadari YR, 2000, J CELL SCI, V113, P2385; Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Hughes RC, 2001, BIOCHIMIE, V83, P667; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; IZZARD CS, 1980, J CELL SCI, V42, P81; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kawano K, 2001, EXP CELL RES, V262, P180, DOI 10.1006/excr.2000.5083; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rabinovich GA, 2002, J LEUKOCYTE BIOL, V71, P741; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; Woods ML, 2000, EUR J IMMUNOL, V30, P38, DOI 10.1002/1521-4141(200001)30:1<38::AID-IMMU38>3.3.CO;2-2; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	57	70	73	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14533	14542		10.1074/jbc.M207380200	http://dx.doi.org/10.1074/jbc.M207380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12569102	hybrid, Green Published			2022-12-27	WOS:000182405000121
J	Marchesini, N; Luberto, C; Hannun, YA				Marchesini, N; Luberto, C; Hannun, YA			Biochemical properties of mammalian neutral sphingomyelinase2 and its role in sphingolipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INDUCED CELL-DEATH; P55 TNF RECEPTOR; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; LYSOSOMAL SPHINGOMYELINASE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL REQUIREMENTS; ACID SPHINGOMYELINASE	Neutral sphingomyelinase (N-SMase) is one of the key enzymes involved in the generation of ceramide; however, the gene(s) encoding for the mammalian N-SMase is still not well defined. Previous studies on the cloned nSMase1 had shown that the protein acts primarily as lyso-platelet-activating factor-phospholipase C. Recently the cloning of another putative N-SMase, nSMase2, was reported. In this study, biochemical characterization of the mouse nSMase2 was carried out using the overexpressed protein in yeast cells in which the inositol phosphosphingolipid phospholipase C (Isc1p) was deleted. N-SMase activity was dependent on Mg2+ and was activated by phosphatidylserine and inhibited by GW4869. The ability of nSMase2 to recognize endogenous sphingomyelin (SM) as substrate was investigated by overexpressing nSMase2 in MCF7 cells. Mass measurements showed a 40% decrease in the SM levels in the overexpressor cells, and labeling studies demonstrated that nSMase2 accelerated SM catabolism. Accordingly, ceramide measurement showed a 60 +/- 15% increase in nSMase2-overexpressing cells compared with the vector-transfected MCF7. The role of nSMase2 in cell growth was next investigated. Stable overexpression of nSMase2 resulted in a 30-40% decrease in the rate of growth at the late exponential phase. Moreover, tumor necrosis factor induced similar to50% activation of nSMase2 in MCF7 cells overexpressing the enzyme, demonstrating that nSMase2 is a tumor necrosis factor-responsive enzyme. In conclusion, these results 1) show that nSMase2 is a structural gene for nSMase, 2) suggest that nSMase2 acts as a bona fide N-SMase in cells, and 3) implicate nSMase2 in the regulation of cell growth and cell signaling.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; Bezombes C, 2001, FASEB J, V15, P297; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Chatterjee S, 1999, CHEM PHYS LIPIDS, V102, P79, DOI 10.1016/S0009-3084(99)00077-8; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; Fensome AC, 2002, BIOCHEM J, V365, P69, DOI 10.1042/BJ20020120; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hayashi Y, 1997, J BIOL CHEM, V272, P18082, DOI 10.1074/jbc.272.29.18082; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Koppenhoefer U, 1997, FEBS LETT, V414, P444, DOI 10.1016/S0014-5793(97)01035-1; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; Mizutani Y, 2000, BBA-MOL CELL BIOL L, V1485, P236, DOI 10.1016/S1388-1981(00)00059-7; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Perry DK, 2000, METHOD ENZYMOL, V312, P22; PETTUS B, 2003, BIOCHIM BIOPHYS ACTA, V1585, P114; RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; Sawai H, 1997, J BIOL CHEM, V272, P2452; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Tanaka M, 1999, J ANTIBIOT, V52, P670, DOI 10.7164/antibiotics.52.670; Tcherkasowa AE, 2002, J IMMUNOL, V169, P5161, DOI 10.4049/jimmunol.169.9.5161; Tepper AD, 2001, BIOCHEM BIOPH RES CO, V280, P634, DOI 10.1006/bbrc.2000.4166; Tomiuk S, 2000, J BIOL CHEM, V275, P5710, DOI 10.1074/jbc.275.8.5710; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	51	155	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13775	13783		10.1074/jbc.M212262200	http://dx.doi.org/10.1074/jbc.M212262200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566438	hybrid			2022-12-27	WOS:000182405000028
J	Noorwez, SM; Kuksa, V; Imanishi, Y; Zhu, L; Filipek, S; Palczewski, K; Kaushal, S				Noorwez, SM; Kuksa, V; Imanishi, Y; Zhu, L; Filipek, S; Palczewski, K; Kaushal, S			Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CYSTIC-FIBROSIS; FRAMESHIFT MUTATION; MOLECULAR-GENETICS; RHODOPSIN MUTANTS; MOUSE MODEL; ACTIVATION; MECHANISM; RETINALS; DISEASE	Protein conformational disorders, which include certain types of retinitis pigmentosa, are a set of inherited human diseases in which mutant proteins are misfolded and often aggregated. Many opsin mutants associated with retinitis pigmentosa, the most common being P23H, are misfolded and retained within the cell. Here, we describe a pharmacological chaperone, 11-cis-7-ring retinal, that quantitatively induces the in vivo folding of P23H-opsin. The rescued protein forms pigment, acquires mature glycosylation, and is transported to the cell surface. Additionally, we determined the temperature stability of the rescued protein as well as the reactivity of the retinal-opsin Schiff base to hydroxylamine. Our study unveils novel properties of P23H-opsin and its interaction with the chromophore. These properties suggest that 11-cis-7-ring retinal may be a useful therapeutic agent for the rescue of P23H-opsin and the prevention of retinal degeneration.	Univ Florida, Dept Ophthalmol, Gainesville, FL USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Warsaw, Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Univ Warsaw, Dept Chem, PL-02109 Warsaw, Poland	State University System of Florida; University of Florida; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Warsaw; University of Warsaw	Kaushal, S (corresponding author), Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.	skaushal@eye.ufl.edu	Imanishi, Yoshikazu/E-8178-2010; Filipek, Slawomir/A-2985-2008	Imanishi, Yoshikazu/0000-0003-4696-4836; Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY013385, P30EY001730, R01EY009339] Funding Source: NIH RePORTER; NEI NIH HHS [EY09339, EY13385, R01 EY013385, P30 EY001730, R01 EY009339, EY01730] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; Bai CX, 1998, J PHARMACOL TOX MET, V40, P39, DOI 10.1016/S1056-8719(98)00034-3; Ballesteros J, 2001, Curr Opin Drug Discov Devel, V4, P561; BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; CALDWELL CG, 1993, J ORG CHEM, V58, P3533, DOI 10.1021/jo00065a014; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Frederick J, 2000, METHOD ENZYMOL, V316, P515; Fujimoto Y, 2002, CHIRALITY, V14, P340, DOI 10.1002/chir.10076; GOVARDHAN CP, 1994, J BIOL CHEM, V269, P6524; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kuksa V, 2002, J BIOL CHEM, V277, P42315, DOI 10.1074/jbc.M206014200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Lou JH, 2000, METHOD ENZYMOL, V315, P219; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Papermaster DS, 2002, INVEST OPHTH VIS SCI, V43, P1300; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; Saliba RS, 2002, J CELL SCI, V115, P2907; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Yang T, 1997, P NATL ACAD SCI USA, V94, P13559, DOI 10.1073/pnas.94.25.13559; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	45	167	193	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14442	14450		10.1074/jbc.M300087200	http://dx.doi.org/10.1074/jbc.M300087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566452	hybrid, Green Accepted			2022-12-27	WOS:000182405000111
J	Zhout, PC; Fernandes, N; Dodge, IL; Reddi, AL; Rao, N; Safran, H; Dipetrillo, TA; Wazer, DE; Band, V; Band, H				Zhout, PC; Fernandes, N; Dodge, IL; Reddi, AL; Rao, N; Safran, H; Dipetrillo, TA; Wazer, DE; Band, V; Band, H			ErbB2 degradation mediated by the co-chaperone protein CHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; TYROSINE KINASES; RING FINGER; CBL; RECEPTOR; GELDANAMYCIN; IDENTIFICATION; TARGET; DOMAIN; UBIQUITYLATION	ErbB2 overexpression contributes to the evolution of a substantial group of human cancers and signifies a poor clinical prognosis. Thus, down-regulation of ErbB2 signaling has emerged as a new anti-cancer strategy. Ubiquitinylation, mediated by the Cbl family of ubiquitin ligases, has emerged as a physiological mechanism of ErbB receptor down-regulation, and this mechanism appears to contribute to ErbB2 down-regulation induced by therapeutic anti-ErbB2 antibodies. Hsp90 inhibitory ansamycin antibiotics such as geldanamycin (GA) induce rapid ubiquitinylation and down-regulation of ErbB2. However, the ubiquitin ligase(s) involved has not been identified. Here, we show that ErbB2 serves as an in vitro substrate for the Hsp70/Hsp90-associated U-box ubiquitin ligase CHIP. Overexpression of wild type CHIP, but not its U-box mutant H260Q, induced ubiquitinylation and reduction in both cell surface and total levels of ectopically expressed or endogenous ErbB2 in vivo, and this effect was additive with that of 17-allylamino-geldanamycin (17-AAG). The CHIP U-box mutant H260Q reduced 17-AAG-induced ErbB2 ubiquitinylation. Wild type ErbB2 and a mutant incapable of association with Cbl (ErbB2 Y1112F) were equally sensitive to CHIP and 17-AAG, implying that Cbl does not play a major role in geldanamycin-induced ErbB2 down-regulation. Both endogenous and ectopically expressed CHIP and ErbB2 coimmunoprecipitated with each other, and this association was enhanced by 17-AAG. Notably, CHIP H260Q induced a dramatic elevation of ErbB2 association with Hsp70 and prevented the 17-AAG-induced dissociation of Hsp90. Our results demonstrate that ErbB2 is a target of CHIP ubiquitin ligase activity and suggest a role for CHIP E3 activity in controlling both the association of Hsp70/Hsp90 chaperones with ErbB2 and the down-regulation of ErbB2 induced by inhibitors of Hsp90.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Brown Univ, Miriam Hosp, Oncol Grp, Providence, RI 02906 USA; Tufts Univ, New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Miriam Hospital; Tufts Medical Center; Tufts University	Band, H (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Smith Bldg,Rm 538C,1 Jimmy Fund Way, Boston, MA 02115 USA.	hband@rics.bwh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA081076, R01CA075075, R01CA076118, R01CA070195, R01CA087986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75075, CA 76118, CA70195, CA 87986, CA 81076] Funding Source: Medline; NIAMS NIH HHS [T32AR07530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kimmins S, 2000, CELL STRESS CHAPERON, V5, P76, DOI 10.1379/1466-1268(2000)005<0076:MOSRAE>2.0.CO;2; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klapper LN, 2000, CANCER RES, V60, P3384; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng FF, 2000, CANCER RES, V60, P2090	42	158	174	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13829	13837		10.1074/jbc.M209640200	http://dx.doi.org/10.1074/jbc.M209640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574167	hybrid			2022-12-27	WOS:000182405000035
J	Androutsellis-Theotokis, A; Goldberg, NR; Ueda, K; Beppu, T; Beckman, ML; Das, S; Javitch, JA; Rudnick, G				Androutsellis-Theotokis, A; Goldberg, NR; Ueda, K; Beppu, T; Beckman, ML; Das, S; Javitch, JA; Rudnick, G			Characterization of a functional bacterial homologue of sodium-dependent neurotransmitter transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; TRANSMEMBRANE DOMAIN-I; OBLIGATELY SYMBIOTIC THERMOPHILE; HUMAN DOPAMINE TRANSPORTER; COMPLETE GENOME SEQUENCE; SEROTONIN TRANSPORTER; ESCHERICHIA-COLI; SYMBIOBACTERIUM-THERMOPHILUM; RAT-BRAIN; ORPHAN TRANSPORTERS	The tnaT gene of Symbiobacterium thermophilum encodes a protein homologous to sodium-dependent neurotransmitter transporters. Expression of the tnaT gene product in Escherichia coli conferred the ability to accumulate tryptophan from the medium and the ability to grow on tryptophan as a sole source of carbon. Transport was Na+-dependent and highly selective. The K-m for tryptophan was similar to145 nM, and tryptophan transport was unchanged in the presence of 100 muM concentrations of other amino acids. Tryptamine and serotonin were weak inhibitors with K-I values of 200 and 440 muM, respectively. By using a T7 promoter-based system, TnaT with an N-terminal His(6) tag was expressed at high levels in the membrane and was purified to near-homogeneity in high yield.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, Ctr Mol Recognit, New York, NY 10032 USA; Nihon Univ, Dept Appl Biol Sci, Kanagawa 2528510, Japan	Yale University; Columbia University; Columbia University; Nihon University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,POB 3333, New Haven, CT 06510 USA.	gary.rudnick@yale.edu		Androutsellis-Theotokis, Andreas/0000-0002-1985-4589; Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014942] Funding Source: NIH RePORTER; NIDA NIH HHS [DA014942] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; ASBERG M, 1993, CLIN NEUROPHARMACOL, V16, pS32; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BARZU O, 1994, PROG NUCLEIC ACID RE, V49, P241; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; BRILEY M, 1993, CLIN NEUROPHARMACOL, V16, P387, DOI 10.1097/00002826-199310000-00002; CAIRNEY J, 1984, J BACTERIOL, V160, P22, DOI 10.1128/JB.160.1.22-27.1984; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Charney DS, 1998, J CLIN PSYCHIAT, V59, P11; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; ELMESTIKAWY S, 1994, J NEUROCHEM, V62, P445; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Farmer MK, 2000, GENOMICS, V70, P241, DOI 10.1006/geno.2000.6387; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; HIRAHARA T, 1992, APPL ENVIRON MICROB, V58, P2633, DOI 10.1128/AEM.58.8.2633-2642.1992; HIRAHARA T, 1993, APPL MICROBIOL BIOT, V39, P341, DOI 10.1007/BF00192089; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HRDINA PD, 1990, J PHARMACOL EXP THER, V252, P410; Johnson K, 1999, DEV BIOL, V212, P440, DOI 10.1006/dbio.1999.9351; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Jones SR, 1998, J NEUROSCI, V18, P1979; KABACK HR, 1974, SCIENCE, V186, P882, DOI 10.1126/science.186.4167.882; Kanner Baruch I., 2002, P235; KUGENHOLTZ J, 1981, P NATL ACAD SCI USA, V78, P3446; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LIU QR, 1993, FEBS LETT, V315, P114, DOI 10.1016/0014-5793(93)81145-P; Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281; Martin K, 1998, J BACTERIOL, V180, P107, DOI 10.1128/JB.180.1.107-118.1998; Ni YG, 2001, J BIOL CHEM, V276, P30942, DOI 10.1074/jbc.M104653200; Ohno M, 2000, INT J SYST EVOL MICR, V50, P1829, DOI 10.1099/00207713-50-5-1829; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PADAN E, 1994, J EXP BIOL, V196, P443; Pifl C, 2000, PURE APPL CHEM, V72, P1045, DOI 10.1351/pac200072061045; Pifl C, 1999, NEUROPHARMACOLOGY, V38, P157, DOI 10.1016/S0028-3908(98)00155-5; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; Rudnick Gary, 2002, P25; Saier MH, 1999, J CELL BIOCHEM, P84; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Soehnge H, 1996, P NATL ACAD SCI USA, V93, P13262, DOI 10.1073/pnas.93.23.13262; SULZER D, 1995, J NEUROSCI, V15, P4102; SUZUKI S, 1988, J GEN MICROBIOL, V134, P2353; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Tate CG, 2001, FEBS LETT, V504, P94, DOI 10.1016/S0014-5793(01)02711-9; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; UHL GR, 1992, MOL BRAIN RES, V16, P353, DOI 10.1016/0169-328X(92)90246-8; VERSAW WK, 1995, P NATL ACAD SCI USA, V92, P3884, DOI 10.1073/pnas.92.9.3884; WALL SC, 1993, MOL PHARMACOL, V43, P264; WALL SC, 1995, MOL PHARMACOL, V47, P544; WANG JB, 1995, J NEUROCHEM, V64, P1416; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991	73	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12703	12709		10.1074/jbc.M206563200	http://dx.doi.org/10.1074/jbc.M206563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569103	hybrid			2022-12-27	WOS:000182189500016
J	Goyal, K; Tisi, L; Basran, A; Browne, J; Burnell, A; Zurdo, J; Tunnacliffe, A				Goyal, K; Tisi, L; Basran, A; Browne, J; Burnell, A; Zurdo, J; Tunnacliffe, A			Transition from natively unfolded to folded state induced by desiccation in an anhydrobiotic nematode protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT CRATEROSTIGMA-PLANTAGINEUM; EMBRYOGENESIS-ABUNDANT PROTEIN; SECONDARY STRUCTURE; WATER-DEFICIT; LEA PROTEINS; TOLERANCE; SURVIVAL; STRESS; PURIFICATION; CONFORMATION	Late embryogenesis abundant (LEA) proteins are associated with desiccation tolerance in resurrection plants and in plant seeds, and the recent discovery of a dehydration-induced Group 3 LEA-like gene in the nematode Aphelenchus avenae suggests a similar association in anhydrobiotic animals. Despite their importance, little is known about the structure of Group 3 LEA proteins, although computer modeling and secondary structure algorithms predict a largely a-helical monomer that forms coiled coil oligomers. We have therefore investigated the structure of the nematode protein, Aav-LEA1, in the first such analysis of a well characterized Group 3 LEA-like protein. Immunoblotting and subunit cross-linking experiments demonstrate limited oligomerization of AavLEA1, but analytical ultracentrifugation and gel filtration show that the vast majority of the protein is monomeric. Moreover, CD, fluorescence emission, and Fourier transform-infrared spectroscopy indicate an unstructured conformation for the nematode protein. Therefore, in solution, no evidence was found to support structure predictions; instead, AavLEA1 seems to be natively unfolded with a high degree of hydration and low compactness. Such proteins can, however, be induced to fold into more rigid structures by partner molecules or by altered physiological conditions. Because AavLEA1 is associated with desiccation stress, its Fourier transform-infrared spectrum in the dehydrated state was examined. A dramatic but reversible increase in a-helix and, possibly, coiled coil formation was observed on drying, indicating that computer predictions of secondary structure may be correct for the solid state. This unusual finding offers the possibility that structural shifts in Group 3 LEA proteins occur on dehydration, perhaps consistent with their role in anhydrobiosis.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Natl Univ Ireland Maynooth, Dept Biol, Inst Bioengn & Agroecol, Maynooth, Kildare, Ireland; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge; Maynooth University; University of Cambridge	Tunnacliffe, A (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.	at10004@biotech.cam.ac.uk	Zurdo, Jesús/C-3110-2015	Zurdo, Jesús/0000-0001-5186-8633; Tunnacliffe, Alan/0000-0001-8570-125X				BAKER J, 1988, PLANT MOL BIOL, V11, P277, DOI 10.1007/BF00027385; Bartels D, 2001, PLANT PHYSIOL, V127, P1346, DOI 10.1104/pp.010765; Battista JR, 2001, CRYOBIOLOGY, V43, P133, DOI 10.1006/cryo.2001.2357; BLACKMAN SA, 1995, PHYSIOL PLANTARUM, V93, P630, DOI 10.1111/j.1399-3054.1995.tb05110.x; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Boothe JG, 1997, PLANT PHYSIOL, V113, P367, DOI 10.1104/pp.113.2.367; BRAY EA, 1993, PLANT PHYSIOL, V103, P1035, DOI 10.1104/pp.103.4.1035; Browne J, 2002, NATURE, V416, P38, DOI 10.1038/416038a; BURGESS AW, 1974, ISRAEL J CHEM, V12, P239; Burke MJ., 1986, MEMBRANES METABOLISM, P358; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CECCARDI TL, 1994, PROTEIN EXPRES PURIF, V5, P266, DOI 10.1006/prep.1994.1040; Clegg JS, 2001, COMP BIOCHEM PHYS B, V128, P613, DOI 10.1016/S1096-4959(01)00300-1; COGGINS JR, 1977, BIOCHEMISTRY-US, V16, P1111, DOI 10.1021/bi00625a013; COLACO C, 1992, BIO-TECHNOL, V10, P1007, DOI 10.1038/nbt0992-1007; Cole J L, 1999, J Biomol Tech, V10, P163; CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001; Crowe JH, 1998, ANNU REV PHYSIOL, V60, P73, DOI 10.1146/annurev.physiol.60.1.73; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; Crowe JH, 1997, CRYOBIOLOGY, V35, P20, DOI 10.1006/cryo.1997.2020; Cuming AC, 1999, SEED PROTEINS, P753; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; Denning DP, 2002, J BIOL CHEM, V277, P33447, DOI 10.1074/jbc.M203499200; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong CN, 2002, PLANT PHYSIOL, V129, P1368, DOI 10.1104/pp.001925; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; DURE L, 1981, BIOCHEMISTRY-US, V20, P4162, DOI 10.1021/bi00517a033; DURE L, 1993, PLANT J, V3, P363, DOI 10.1046/j.1365-313X.1993.t01-18-00999.x; Dure L, 2001, PROTEIN PEPTIDE LETT, V8, P115, DOI 10.2174/0929866013409643; EVANS AAF, 1970, J NEMATOL, V2, P99; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GALAU GA, 1986, PLANT MOL BIOL, V7, P155, DOI 10.1007/BF00021327; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARNIER J, 1996, METHOD ENZYMOL, V266, P97; GRZELCZAK ZF, 1982, CAN J BIOCHEM CELL B, V60, P389, DOI 10.1139/o82-046; Hara M, 2001, J PLANT PHYSIOL, V158, P1333, DOI 10.1078/0176-1617-00600; Heimburg T, 1999, BIOCHEMISTRY-US, V38, P12727, DOI 10.1021/bi983079h; HIGA LM, 1993, J EXP ZOOL, V267, P120, DOI 10.1002/jez.1402670205; Hoekstra FA, 2001, TRENDS PLANT SCI, V6, P431, DOI 10.1016/S1360-1385(01)02052-0; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; Honjoh K, 2000, BIOSCI BIOTECH BIOCH, V64, P1656, DOI 10.1271/bbb.64.1656; Honjoh KI, 1996, J PLANT PHYSL, V155, P509; Imai R, 1996, GENE, V170, P243, DOI 10.1016/0378-1119(95)00868-3; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; Ismail AM, 1999, PLANT PHYSIOL, V120, P237, DOI 10.1104/pp.120.1.237; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; KING RD, 1990, J MOL BIOL, V216, P441, DOI 10.1016/S0022-2836(05)80333-X; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lisse T, 1996, BIOL CHEM, V377, P555, DOI 10.1515/bchm3.1996.377.9.555; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; MCCUBBIN WD, 1985, CAN J BIOCHEM CELL B, V63, P803, DOI 10.1139/o85-102; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Oliver MJ, 2000, PLANT ECOL, V151, P85, DOI 10.1023/A:1026550808557; Perry RN, 1999, PARASITOLOGY, V119, pS19, DOI 10.1017/S0031182000084626; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; ROBERTS JK, 1993, PLANT CELL, V5, P769, DOI 10.1105/tpc.5.7.769; Rowe A. J., 1992, ANAL ULTRACENTRIFUGA, P394, DOI DOI 10.1007/S00249-009-0425-1; ROWE AJ, 1977, BIOPOLYMERS, V16, P2595, DOI 10.1002/bip.1977.360161202; Russouw PS, 1997, SEED SCI RES, V7, P117, DOI 10.1017/S0960258500003457; RUSSOUW PS, 1995, SEED SCI RES, V5, P137, DOI 10.1017/S0960258500002750; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Sivamani E, 2000, PLANT SCI, V155, P1, DOI 10.1016/S0168-9452(99)00247-2; Solomon A, 2000, PARASITOLOGY, V121, P409, DOI 10.1017/S0031182099006563; Soulages JL, 2002, PLANT PHYSIOL, V128, P822, DOI 10.1104/pp.010521; STELLWAGEN E, 1972, J BIOL CHEM, V247, P8074; Stetefeld J, 2000, NAT STRUCT BIOL, V7, P772, DOI 10.1038/79006; Sun WQ, 1997, COMP BIOCHEM PHYS A, V117, P327, DOI 10.1016/S0300-9629(96)00271-X; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Swire-Clark GA, 1999, PLANT MOL BIOL, V39, P117, DOI 10.1023/A:1006106906345; TUNNACLIFFE A, 2003, IN PRESS PHILOS T B; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Walters C, 1997, SEED SCI RES, V7, P125, DOI 10.1017/S0960258500003469; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wolfe J, 1986, MEMBRANES METABOLISM, P286; Wolkers WF, 1998, BBA-GEN SUBJECTS, V1425, P127, DOI 10.1016/S0304-4165(98)00059-2; Wolkers WF, 2001, BBA-PROTEIN STRUCT M, V1544, P196, DOI 10.1016/S0167-4838(00)00220-X; Womersley CZ, 1998, NEMATOLOGICA, V44, P269, DOI 10.1163/005425998X00044; Xu DP, 1996, PLANT PHYSIOL, V110, P249, DOI 10.1104/pp.110.1.249; Zhang L, 2000, J BIOCHEM, V127, P611, DOI 10.1093/oxfordjournals.jbchem.a022648; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	83	166	182	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12977	12984		10.1074/jbc.M212007200	http://dx.doi.org/10.1074/jbc.M212007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569097	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000182189500050
J	Kraus, TA; Lau, JF; Parisien, JP; Horvath, CM				Kraus, TA; Lau, JF; Parisien, JP; Horvath, CM			A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; GAMMA(1)34.5 PROTEIN; ESTABLISHED TUMORS; ALPHA-INTERFERON; BINDING DOMAIN; STAT PROTEINS; THERAPY; TRANSCRIPTION; SIGNAL; TRANSACTIVATION	Type I interferon (IFN) signaling induces the heterotrimeric transcription complex, IFN-stimulated gene factor (ISGF) 3, which contains STAT1, STAT2, and the DNA binding subunit, interferon regulatory factor (IRF) 9. Because IRF9 is targeted to the nucleus in the absence of IFN stimulation, the potential of IRF9 protein for gene regulation was examined using a GAL4 DNA binding domain fusion system. GAL4-IRF9 was transcriptionally active in reporter gene assays but not in the absence of cellular STAT1 and STAT2. However, the inert IRF9 protein was readily converted to a constitutively active ISGF3-like activator by fusion with the C-terminal transcriptional activation domain of STAT2 or the acidic activation domain of herpesvirus VP16. The IRF9 hybrids are targeted to endogenous ISGF3 target loci and can activate their transcription. Moreover, expression of the IRF9-STAT2 fusion can recapitulate the type I IFN biological response, producing a cellular antiviral state that protects cells from virus-induced cytopathic effects and inhibits virus replication. The antiviral state generated by regulated IRF9-STAT2 hybrid protein expression is independent of autocrine IFN signaling and inhibits both RNA and DNA viruses.	Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Horvath, CM (corresponding author), Box 1630,E Bldg,Rm 12-20D,1 Gustave L Levy Pl, New York, NY 10029 USA.	curt.horvath@mssm.edu		Horvath, Curt/0000-0003-2449-225X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048722, R01AI048722] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48722] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albini A, 2000, AM J PATHOL, V156, P1381, DOI 10.1016/S0002-9440(10)65007-9; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Brassard DL, 2002, J LEUKOCYTE BIOL, V71, P565; Cassady KA, 1998, J VIROL, V72, P7005; Cheng GF, 2001, VIROLOGY, V290, P115, DOI 10.1006/viro.2001.1148; Coleman M, 1998, HUM GENE THER, V9, P2223, DOI 10.1089/hum.1998.9.15-2223; Didcock L, 1999, J VIROL, V73, P9928, DOI 10.1128/JVI.73.12.9928-9933.1999; Ferrantini M, 2000, SEMIN CANCER BIOL, V10, P145, DOI 10.1006/scbi.2000.0333; FRIEDMAN RM, 1981, INTERFERONS PRIMER; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Horton HM, 1999, P NATL ACAD SCI USA, V96, P1553, DOI 10.1073/pnas.96.4.1553; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levy DE, 2002, J EXP MED, V195, pF15, DOI 10.1084/jem.20020075; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Luker KE, 2001, CANCER RES, V61, P6540; Majumder S, 1998, J IMMUNOL, V161, P4736; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Mendiratta SK, 2000, HUM GENE THER, V11, P1851, DOI 10.1089/10430340050129477; Mossman KL, 2002, J VIROL, V76, P1995, DOI 10.1128/JVI.76.4.1995-1998.2002; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Parisien JP, 2002, J VIROL, V76, P6435, DOI 10.1128/JVI.76.13.6435-6441.2002; Parisien JP, 2002, J VIROL, V76, P4190, DOI 10.1128/JVI.76.9.4190-4198.2002; Park C, 1999, NUCLEIC ACIDS RES, V27, P4191, DOI 10.1093/nar/27.21.4191; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Shen Y, 2001, J VIROL, V75, P2627, DOI 10.1128/JVI.75.6.2627-2633.2001; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	42	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13033	13038		10.1074/jbc.M212972200	http://dx.doi.org/10.1074/jbc.M212972200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574168	hybrid			2022-12-27	WOS:000182189500057
J	Luo, ZQ; Smyth, AJ; Gao, P; Qin, YP; Farrand, SK				Luo, ZQ; Smyth, AJ; Gao, P; Qin, YP; Farrand, SK			Mutational analysis of TraR - Correlating function with molecular structure of a quorum-sensing transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISCHERI LUXR PROTEIN; GRAM-NEGATIVE BACTERIA; C-TERMINAL REGION; VIBRIO-FISCHERI; AGROBACTERIUM-TUMEFACIENS; AUTOINDUCER-BINDING; DNA-BINDING; RHIZOBIUM-LEGUMINOSARUM; SYSTEM; GENES	TraR, the quorum-sensing activator of the Agrobacterium tumefaciens Ti plasmid conjugation system, induces gene expression in response to its quormone, N-(3-oxooctanoyl)-L-homoserine lactone. Ligand binding results in dimerization of TraR and is required for its activity. Analysis of N- and C-terminal deletion mutants of TraR localized the quormone-binding domain to a region between residues 39 and 140 and the primary dimerization domain to a region between residues 119 and 156. The dominant-negative properties of these mutants predicted a second dimerization domain at the C terminus of the protein. Analysis of fusions of N-terminal fragments of TraR to lambdacI' confirmed the dimerization activity of these two domains. Fifteen single amino acid substitution mutants of TraR defective in dimerization were isolated. According to the analysis of these mutants, Asp-70 and Gly-113 are essential for quormone binding, whereas Ala-38 and Ala-105 are important, but not essential. Additional residues located within the N-terminal half of TraR, including three located in a-helix 9, contribute to dimerization, but are not required for ligand binding. These results and the recently reported crystal structure of TraR are consistent with and complement each other and together define some of the structural and functional relationships of this quorum-sensing activator.	Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Farrand, SK (corresponding author), Univ Illinois, Dept Crop Sci, 240 ERML,1201 W Gregory Dr, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052465] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cangelosi GA, 1991, METHOD ENZYMOL, V145, P177; Cha C, 1998, MOL PLANT MICROBE IN, V11, P1119, DOI 10.1094/MPMI.1998.11.11.1119; CHILTON MD, 1974, P NATL ACAD SCI USA, V71, P3672, DOI 10.1073/pnas.71.9.3672; CHOI SH, 1992, J BACTERIOL, V174, P4064, DOI 10.1128/jb.174.12.4064-4069.1992; CHOI SH, 1991, P NATL ACAD SCI USA, V88, P11115, DOI 10.1073/pnas.88.24.11115; COOK DM, 1992, J BACTERIOL, V174, P6238, DOI 10.1128/JB.174.19.6238-6246.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; Egland KA, 2001, J BACTERIOL, V183, P382, DOI 10.1128/JB.183.1.382-386.2001; Farrand S. K, 1998, RHIZOBIACEAE MOL BIO, P199, DOI DOI 10.1007/978-94-011-5060-6; Farrand SK, 1996, J BACTERIOL, V178, P4233, DOI 10.1128/jb.178.14.4233-4247.1996; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; FUQUA WC, 1994, J BACTERIOL, V176, P2796, DOI 10.1128/JB.176.10.2796-2806.1994; Gray KM, 1996, J BACTERIOL, V178, P372, DOI 10.1128/jb.178.2.372-376.1996; HANZELKA BL, 1995, J BACTERIOL, V177, P815, DOI 10.1128/jb.177.3.815-817.1995; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kiratisin P, 2002, J BACTERIOL, V184, P4912, DOI 10.1128/JB.184.17.4912-4919.2002; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Lithgow JK, 2000, MOL MICROBIOL, V37, P81, DOI 10.1046/j.1365-2958.2000.01960.x; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; Luo ZQ, 1999, P NATL ACAD SCI USA, V96, P9009, DOI 10.1073/pnas.96.16.9009; Luo ZQ, 2001, MOL PLANT MICROBE IN, V14, P98, DOI 10.1094/MPMI.2001.14.1.98; McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703; Miller J. H, 1972, EXPT MOL GENETICS; Minogue TD, 2002, MOL MICROBIOL, V44, P1625, DOI 10.1046/j.1365-2958.2002.02987.x; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; Qin YP, 2000, EMBO J, V19, P5212, DOI 10.1093/emboj/19.19.5212; Reverchon S, 1998, MOL MICROBIOL, V29, P1407, DOI 10.1046/j.1365-2958.1998.01023.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schripsema J, 1996, J BACTERIOL, V178, P366, DOI 10.1128/jb.178.2.366-371.1996; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; Shaw PD, 1997, P NATL ACAD SCI USA, V94, P6036, DOI 10.1073/pnas.94.12.6036; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SITNIKOV DM, 1995, MOL MICROBIOL, V17, P801, DOI 10.1111/j.1365-2958.1995.mmi_17050801.x; SLOCK J, 1990, J BACTERIOL, V172, P3974, DOI 10.1128/jb.172.7.3974-3979.1990; Trott AE, 2001, J BACTERIOL, V183, P387, DOI 10.1128/JB.183.1.387-392.2001; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832; Zhu J, 1998, J BACTERIOL, V180, P5398, DOI 10.1128/JB.180.20.5398-5405.1998	44	39	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13173	13182		10.1074/jbc.M210035200	http://dx.doi.org/10.1074/jbc.M210035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569101	hybrid			2022-12-27	WOS:000182189500075
J	Mulligan, JD; Flowers, MT; Tebon, A; Bitgood, JJ; Wellington, C; Hayden, MR; Attie, AD				Mulligan, JD; Flowers, MT; Tebon, A; Bitgood, JJ; Wellington, C; Hayden, MR; Attie, AD			ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTOR; DENSITY-LIPOPROTEIN DEFICIENCY; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; PLASMA-MEMBRANE; BINDING; TRANSPORTER; GENE; MUTATIONS; ABCG5	The ATP-binding cassette transporter A1 (ABCA1) participates in the efflux of cholesterol from cells. It remains unclear whether ABCA1 functions to efflux cholesterol across the basolateral or apical membrane of the intestine. We used. a chicken model of ABCA1 dysfunction, the Wisconsin hypoalpha mutant (WHAM) chicken, to address this issue. After an oral gavage of radioactive cholesterol, the percentage appearing in the bloodstream was reduced by 79% in the WHAM chicken along with a 97% reduction in the amount of tracer in high density lipoprotein. In contrast, the percentage of radioactive cholesterol absorbed from the lumen into the intestine was not affected by the ABCA1 mutation. Liver X receptor (LXR) agonists have been inferred to decrease cholesterol absorption through activation of ABCA1 expression. However, the LXR agonist T0901317 decreased cholesterol absorption equally in both wild type and WHAM chickens, indicating that the effect of LXR activation on cholesterol absorption is independent of ABCA1 The ABCA1 mutation resulted in accumulation of radioactive cholesterol ester in the intestine and the liver of the WHAM chicken (5.0- and 4.4-fold, respectively), whereas biliary lipid concentrations were unaltered by the WHAM mutation. In summary, ABCA1 regulates the efflux of cholesterol from the basolateral but not apical membrane in the intestine and the liver.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Anim Sci, Madison, WI 53706 USA; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V65Z 4H4, Canada; Xenon Genet, Burnaby, BC V5G 4W8, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of British Columbia	Attie, AD (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		Eckhardt, Erik/G-1567-2010; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419	NHLBI NIH HHS [HL56593] Funding Source: Medline; NIA NIH HHS [T32-AG00213] Funding Source: Medline; NIGMS NIH HHS [T32-GM07215-25] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200; Attie AD, 2001, J LIPID RES, V42, P1717; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Clee SM, 2001, CIRCULATION, V103, P1198; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Dean M, 2001, J LIPID RES, V42, P1007; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; GREEN PHR, 1978, J CLIN INVEST, V61, P528, DOI 10.1172/JCI108963; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee J, 2002, BIOCHEM J, V364, P475, DOI 10.1042/BJ20011493; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu KM, 2001, AM J HUM GENET, V69, P278, DOI 10.1086/321294; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; MARSH JB, 1974, J LIPID RES, V15, P544; MCGIBBON WH, 1981, J HERED, V72, P139, DOI 10.1093/oxfordjournals.jhered.a109450; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Neufeld EB, 2002, BIOCHEM BIOPH RES CO, V297, P974, DOI 10.1016/S0006-291X(02)02274-X; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Ohama T, 2002, BIOCHEM BIOPH RES CO, V296, P625, DOI 10.1016/S0006-291X(02)00853-7; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; POERNAMA F, 1990, J LIPID RES, V31, P955; QUINTAO E, 1971, J LIPID RES, V12, P221; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; Schmitz G, 2001, J LIPID RES, V42, P1513; SCHREYER SA, 1994, ARTERIOSCLER THROMB, V14, P2053, DOI 10.1161/01.ATV.14.12.2053; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; STURKIE PD, 1965, AVIAN PHYSL, P109; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; 2001, APPL BIOSYSTEMS USER, V2	73	94	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13356	13366		10.1074/jbc.M212377200	http://dx.doi.org/10.1074/jbc.M212377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551945	hybrid			2022-12-27	WOS:000182189500097
J	Yang, Y; Borset, M; Langford, JK; Sanderson, RD				Yang, Y; Borset, M; Langford, JK; Sanderson, RD			Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEOGLYCAN; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; EPITHELIAL-CELLS; FINE-STRUCTURE; MYELOMA CELLS; EXPRESSION; RECEPTOR; GLYPICAN; BINDING	In polarized B lymphoid cells, syndecan-1 is targeted specifically to a discrete membrane domain termed the uropod that is located at the cell's trailing edge. Within this functional domain, syndecan-1 promotes cell-cell adhesion and concentration of heparin binding growth factors. The present study reveals the surprising finding that targeting of syndecan-1 to uropods is mediated by its heparan sulfate chains and that targeting is regulated by cell surface events rather than solely by intracellular mechanisms. The addition of exogenous heparin or the treatment of polarized cells with heparitinase initiates a rapid and dramatic redistribution of uropod syndecan-1 over the entire cell surface, and a mutated syndecan-1 lacking heparan sulfate chains fails to concentrate within uropods. Interestingly, the heparan sulfate-bearing proteoglycans glypican-1 and betaglycan fail to concentrate in uropods, indicating that targeting may require heparan sulfate structural motifs unique to syndecan-1 or that the core protein of syndecan-1 participates in specific interactions that promote heparan sulfate-mediated targeting. These findings suggest functional specificity for syndecan-1 within uropods and, in addition, reveal a novel mechanism for the targeting of molecules to discrete membrane subcellular domains via heparan sulfate.	Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Anat & Neurobiol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Sanderson, RD (corresponding author), Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Pathol, Slot 517,4301 W Markham, Little Rock, AR 72205 USA.		Borset, Magne/AAY-1713-2021	Borset, Magne/0000-0001-5179-2835	NATIONAL CANCER INSTITUTE [R01CA068494] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Borset M, 2000, BLOOD, V96, P2528; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; del Pozo MA, 1998, CELL ADHES COMMUN, V6, P125, DOI 10.3109/15419069809004468; delPozo MA, 1997, J CELL BIOL, V137, P493; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P18881; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; LITWACK ED, 1994, J NEUROSCI, V14, P3713; Litwack ED, 1998, DEV DYNAM, V211, P72, DOI 10.1002/(SICI)1097-0177(199801)211:1<72::AID-AJA7>3.3.CO;2-8; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MIETTINEN HM, 1994, J CELL SCI, V107, P1571; Millan J, 2002, BLOOD, V99, P978, DOI 10.1182/blood.V99.3.978; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood-2002-04-1190; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Wijdenes J, 1996, BRIT J HAEMATOL, V94, P318, DOI 10.1046/j.1365-2141.1996.d01-1811.x; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	37	26	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12888	12893		10.1074/jbc.M209440200	http://dx.doi.org/10.1074/jbc.M209440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566461	hybrid			2022-12-27	WOS:000182189500039
J	Zako, M; Dong, JY; Goldberger, O; Bernfield, M; Gallagher, JT; Deakin, JA				Zako, M; Dong, JY; Goldberger, O; Bernfield, M; Gallagher, JT; Deakin, JA			Syndecan-1 and-4 synthesized simultaneously by mouse mammary gland epithelial cells bear heparan sulfate chains that are apparently structurally indistinguishable	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; FINE-STRUCTURE; SURFACE; PROTEOGLYCANS; ADHESION; DOMAIN; TETRASACCHARIDES; IDENTIFICATION; ECTODOMAINS; AFFINITY	Many of the biological functions attributed to cell surface heparan sulfate (HS) proteoglycans, including the Syndecan family, are elicited through the interaction of their HS chains with soluble extracellular molecules. Tightly controlled, cell-specific sulfation and epimerization of HS precursors endows these chains with highly sulfated, iduronate-rich regions, which are major determinants of cytokine and matrix-protein binding and which are interspersed by N-acetylated, poorly sulfated regions. Until this study, there have been no comprehensive structural comparisons made on HS chains decorating simultaneously expressed, but different, syndecan core proteins. In this paper we demonstrate that the HS chains on affinity-purified syndecan-1 and -4 from murine mammary gland cells are essentially identical by a number of parameters. Size determination, disaccharide analyses, enzymatic and chemical scission methods, and affinity co-electrophoresis all failed to reveal any significant differences in fine structure, domain organization, or ligand-binding properties of these HS species. These findings lead us to suggest that the imposition of the fine structure onto HS occurs independently of the core protein to which it is attached and that these core proteins, in addition to the HS chains, may play a pivotal role in the various biological functions ascribed to these macromolecules.	Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med, Boston, MA 02215 USA; Univ Manchester, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England	Harvard University; Boston Children's Hospital; Harvard Medical School; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Zako, M (corresponding author), Aichi Med Univ, Dept Ophthalmol, Nagakute Cho, Aichi 4801195, Japan.	zako@aichi-med-u.ac.jp						Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Carey DJ, 1997, BIOCHEM J, V327, P1; DAVID G, 1981, J NATL CANCER I, V67, P719; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; Fitzgerald M. L., 1999, SYNDECANS GUIDEBOOK, P306; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KATO M, 1994, J BIOL CHEM, V269, P18881; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinnunen A, 1998, EUR J NEUROSCI, V10, P635, DOI 10.1046/j.1460-9568.1998.00082.x; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; McFall AJ, 1997, J BIOL CHEM, V272, P12901, DOI 10.1074/jbc.272.20.12901; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; MERTENS G, 1992, J BIOL CHEM, V269, P2270; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Stringer SE, 1999, J BIOL CHEM, V274, P25455, DOI 10.1074/jbc.274.36.25455; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; Yamashita Y, 1999, J IMMUNOL, V162, P5940; Zimmermann P, 1999, FASEB J, V13, pS91	56	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13561	13569		10.1074/jbc.M209658200	http://dx.doi.org/10.1074/jbc.M209658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571251	hybrid			2022-12-27	WOS:000182189500121
J	Kweon, DH; Kim, CS; Shin, YK				Kweon, DH; Kim, CS; Shin, YK			Insertion of the membrane-proximal region of the neuronal SNARE coiled coil into the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC EXOCYTOSIS; PENETRATION DEPTH; PROTEIN-STRUCTURE; SIDE-CHAINS; SPIN; COMPLEX; FUSION; BINDING; MECHANISM; SYNTAXIN	In the neuron, soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins assemble into an a-helical coiled coil that bridges the synaptic vesicle to the plasma membrane and drives membrane fusion, a required process for neurotransmitter release at the nerve terminal. How does coiled coil formation drive membrane fusion? To investigate the structural and energetic coupling between the coiled coil and membrane, the recombinant SNARE complex in the phospholipid bilayer was studied using fluorescence quenching and site-directed spin labeling EPR. Fluorescence analysis revealed that two native Trp residues at the membrane-proximal region of the coiled coil are inserted into the membrane, tightly coupling the coiled coil to the membrane. The EPR results indicate that the coiled coil penetrates into the membrane with an oblique angle, providing a favorable geometry for the basic residues to interact with negatively charged lipids. The result supports the proposition that core complex formation directly leads to the apposition of two membranes, which could facilitate lipid mixing. Trp residues and basic residues are abundant at the membrane-proximal region of transmembrane SNARE proteins, suggesting the generality of the proposed mechanism for the SNARE complex-membrane coupling.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Shin, YK (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	colishin@iastate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051290, R29GM051290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; Brunger AT, 2001, CURR OPIN STRUC BIOL, V11, P163, DOI 10.1016/S0959-440X(00)00186-X; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kim CS, 2002, BIOCHEMISTRY-US, V41, P10928, DOI 10.1021/bi026266v; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Kuzmin PI, 2001, P NATL ACAD SCI USA, V98, P7235, DOI 10.1073/pnas.121191898; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P9264, DOI 10.1021/bi025934+; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mayer A, 2001, TRENDS BIOCHEM SCI, V26, P717, DOI 10.1016/S0968-0004(01)01984-3; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Quetglas S, 2002, EMBO J, V21, P3970, DOI 10.1093/emboj/cdf404; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; RAND RP, 1986, ANNU REV PHYSIOL, V48, P201; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Russell CJ, 1999, BIOCHEMISTRY-US, V38, P337, DOI 10.1021/bi981179h; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorgeirsson TE, 1996, BIOCHEMISTRY-US, V35, P1803, DOI 10.1021/bi952300c; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200	52	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12367	12373		10.1074/jbc.M211123200	http://dx.doi.org/10.1074/jbc.M211123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529381	hybrid			2022-12-27	WOS:000182015700084
J	Burkart, EM; Sumandea, MP; Kobayashi, T; Nili, M; Martin, AF; Homsher, E; Solaro, RJ				Burkart, EM; Sumandea, MP; Kobayashi, T; Nili, M; Martin, AF; Homsher, E; Solaro, RJ			Phosphorylation or glutamic acid substitution at protein kinase C sites on cardiac troponin I differentially depress myofilament tension and shortening velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE VENTRICULAR MYOCYTES; ISOMETRIC FORCE; EXPRESSION; HEART; STIMULATION; MICE; HYPERTROPHY; ACTIVATION; MGATPASE; EPSILON	There is evidence that multi-site phosphorylation of cardiac troponin I (cTnI) by protein kinase C is important in both long- and short-term regulation of cardiac function. To determine the specific functional effects of these phosphorylation sites (Ser-43, Ser-45, and Thr-144), we measured tension and sliding speed of thin filaments in reconstituted preparations in which endogenous cTnI was replaced with cTnI phosphorylated by protein kinase C-a or mutated to cTnI-S43E/S45E/T144E, cTnI-S43E/S45E, or cTnI-T144E. We used detergent-skinned mouse cardiac fiber bundles to measure changes in Ca2+-dependence of force. Compared with controls, fibers reconstituted with phosphorylated cTnI, cTnI-S43E/S45E/T144E, or cTnI-S43E/S45E were desensitized to Ca2+, and maximum tension was as much as 27% lower, whereas fibers reconstituted with cTnI-T144E showed no change. In the in vitro motility assay actin filaments regulated by troponin complexes containing phosphorylated cTnI or cTnI-S43E/S45E/T144E showed both a decrease in Ca2+ sensitivity and maximum sliding speed compared with controls, whereas filaments regulated by cTnI-S43E/S45E showed only decreased maximum sliding speed and filaments regulated by cTnI-T144E demonstrated only desensitization to Ca2+. Our results demonstrate novel site specificity of effects of PKC phosphorylation on cTnI function and emphasize the complexity of modulation of the actin-myosin interaction by specific changes in the thin filament.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Program Cardiovasc Sci, Chicago, IL 60612 USA; Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci, Dept Physiol, Los Angeles, CA 90025 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Solaro, RJ (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, Program Cardiovasc Sci, M-C 901,835 S Wolcott Ave, Chicago, IL 60612 USA.	SolaroRJ@uic.edu			NHLBI NIH HHS [R01 HL 64035, P01 HL 62426, F32 HL 10409] Funding Source: Medline; NIAMS NIH HHS [R01 AR-30988] Funding Source: Medline; PHS HHS [T3207692] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062426, R01HL064035, F32HL010409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; Chandra M, 1999, BIOCHEM BIOPH RES CO, V263, P219, DOI 10.1006/bbrc.1999.1341; Chandra M, 2001, AM J PHYSIOL-HEART C, V280, pH705, DOI 10.1152/ajpheart.2001.280.2.H705; de Tombe PP, 2000, ANN BIOMED ENG, V28, P991, DOI 10.1114/1.1312189; EDMAN KAP, 1981, J MUSCLE RES CELL M, V2, P321, DOI 10.1007/BF00713270; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; Goekjian PG, 1999, CURR MED CHEM, V6, P877; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; GORDON AM, 1966, J PHYSIOL-LONDON, V184, P170, DOI 10.1113/jphysiol.1966.sp007909; GUO XD, 1994, J BIOL CHEM, V269, P15210; HATAKENAKA M, 1991, BIOCHEM BIOPH RES CO, V181, P1022, DOI 10.1016/0006-291X(91)92039-M; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; Huang L, 2001, AM J PHYSIOL-CELL PH, V280, pC1114, DOI 10.1152/ajpcell.2001.280.5.C1114; Jideama NM, 1996, J BIOL CHEM, V271, P23277, DOI 10.1074/jbc.271.38.23277; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Knollmann BC, 2001, J BIOL CHEM, V276, P10039, DOI 10.1074/jbc.M006745200; Knott A, 2002, J MOL CELL CARDIOL, V34, P469, DOI 10.1006/jmcc.2002.1528; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Lester JW, 2000, AM J PHYSIOL-HEART C, V279, pH2685, DOI 10.1152/ajpheart.2000.279.6.H2685; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; MacGowan GA, 2001, AM J PHYSIOL-HEART C, V280, pH835, DOI 10.1152/ajpheart.2001.280.2.H835; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Montgomery DE, 2002, AM J PHYSIOL-HEART C, V282, pH2397, DOI 10.1152/ajpheart.00714.2001; Morimoto S, 2001, BIOCHEM BIOPH RES CO, V282, P811, DOI 10.1006/bbrc.2001.4647; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; Noland TA, 1996, BIOCHEMISTRY-US, V35, P14923, DOI 10.1021/bi9616357; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; Pi YQ, 2002, CIRC RES, V90, P649, DOI 10.1161/01.RES.0000014080.82861.5F; Pyle WG, 2002, AM J PHYSIOL-HEART C, V283, pH1215, DOI 10.1152/ajpheart.00128.2002; Rarick HM, 1999, J MOL CELL CARDIOL, V31, P363, DOI 10.1006/jmcc.1998.0870; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; Solaro RJ, 2002, J MOL CELL CARDIOL, V34, P689, DOI 10.1006/jmcc.2002.2028; SOLARO RJ, 1993, CIRC RES, V73, P981, DOI 10.1161/01.RES.73.6.981; SOLARO RJ, 2001, HDB PHYSL 2, V1, P264; STRANG KT, 1995, CIRC RES, V77, P114, DOI 10.1161/01.RES.77.1.114; STRANG KT, 1994, CIRC RES, V74, P542, DOI 10.1161/01.RES.74.3.542; Takeda S, 2002, BIOPHYS J, V82, p170A; Takeishi Y, 1998, J CLIN INVEST, V102, P72, DOI 10.1172/JCI2709; Takeishi Y, 2000, CIRC RES, V86, P1218, DOI 10.1161/01.RES.86.12.1218; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; VENEMA RC, 1993, BIOCHEM J, V294, P401, DOI 10.1042/bj2940401; Wang X, 2001, J BIOL CHEM, V276, P25456, DOI 10.1074/jbc.M102418200; Wolska BM, 2002, CIRC RES, V90, P882, DOI 10.1161/01.RES.0000016962.36404.04; Wu GY, 2000, J BIOL CHEM, V275, P29927, DOI 10.1074/jbc.C000380200; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	49	133	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11265	11272		10.1074/jbc.M210712200	http://dx.doi.org/10.1074/jbc.M210712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551921	hybrid			2022-12-27	WOS:000181855400053
J	Li, H; Xu, HM; Graham, DE; White, RH				Li, H; Xu, HM; Graham, DE; White, RH			The Methanococcus jannaschii dCTP deaminase is a bifunctional deaminase and diphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; CYTIDINE DEAMINASE; DEOXYURIDINE TRIPHOSPHATASE; DUTP PYROPHOSPHATASE; ADENOSINE-DEAMINASE; ESCHERICHIA-COLI; DNA-POLYMERASES; PYRIMIDINE; EVOLUTION	Most bacteria produce the dUMP precursor for thymine nucleotide biosynthesis using two enzymes: a dCTP deaminase catalyzes the formation of dUTP and a dUTP diphosphatase catalyzes pyrophosphate release. Although these two hydrolytic enzymes appear to catalyze very different reactions, they are encoded by homologous genes. The hyperthermophilic archaeon Methanococcus jannaschii has two members of this gene family. One gene, at locus MJ1102, encodes a dUTP diphosphatase, which can scavenge deoxyuridine nucleotides that inhibit archaeal DNA polymerases. The second gene, at locus MJ0430, encodes a novel dCTP deaminase that releases dUMP, ammonia, and pyrophosphate. Therefore this enzyme can singly catalyze both steps in dUMP biosynthesis, precluding the formation of free, mutagenic dUTP. Besides differing from the previously characterized Salmonella typhimurium dCTP deaminase in its reaction products, this archaeal enzyme has a higher affinity for dCTP and its steady-state turnover is faster than the bacterial enzyme. Kinetic studies suggest: 1) the archaeal enzyme specifically recognizes dCTP; 2) dCTP deamination and dUTP diphosphatase activities occur independently at the same active site, and 3) both activities depend on Mg2+. The bifunctional activity of this M. jannaschii enzyme illustrates the evolution of a suprafamily of related enzymes that catalyze mechanistically distinct reactions.	Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	White, RH (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA.	rhwhite@vt.edu	Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344				Baldo AM, 1999, J VIROL, V73, P7710, DOI 10.1128/JVI.73.9.7710-7721.1999; BECK CF, 1975, J BIOL CHEM, V250, P609; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cardenas ML, 2001, METHODS, V24, P175, DOI 10.1006/meth.2001.1178; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; DAWSON RM, 1985, DATA BIOCH RES, P103; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Graham DE, 2002, BIOCHEMISTRY-US, V41, P15074, DOI 10.1021/bi0268798; Graupner M, 2000, J BACTERIOL, V182, P3688, DOI 10.1128/JB.182.13.3688-3692.2000; Harris JM, 1999, J MOL BIOL, V288, P275, DOI 10.1006/jmbi.1999.2680; Hogrefe HH, 2002, P NATL ACAD SCI USA, V99, P596, DOI 10.1073/pnas.012372799; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MOORE JT, 1993, J BIOL CHEM, V268, P2288; NEUHARD J, 1968, J BACTERIOL, V96, P1519, DOI 10.1128/JB.96.5.1519-1527.1968; PENVERNE B, 1994, ARCH BIOCHEM BIOPHYS, V309, P85, DOI 10.1006/abbi.1994.1089; PHAM DN, 1993, BIOCHEMISTRY-US, V32, P13725, DOI 10.1021/bi00212a043; Poole A, 2001, NAT REV MOL CELL BIO, V2, P147, DOI 10.1038/35052091; Poyner RR, 2001, BIOCHEMISTRY-US, V40, P8009, DOI 10.1021/bi0103922; Prangishvili D, 1998, J BIOL CHEM, V273, P6024, DOI 10.1074/jbc.273.11.6024; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2001, CURR PROTEIN PEPT SC, V2, P301, DOI 10.2174/1389203013381017; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; Serre V, 1998, J MOL BIOL, V281, P363, DOI 10.1006/jmbi.1998.1856; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; SLUPPHAUG G, 1993, ANAL BIOCHEM, V211, P164, DOI 10.1006/abio.1993.1248; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; WILSON DK, 1993, BIOCHEMISTRY-US, V32, P1689, DOI 10.1021/bi00058a001; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Xiang SB, 1997, BIOCHEMISTRY-US, V36, P4768, DOI 10.1021/bi963091e	38	26	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11100	11106		10.1074/jbc.M212460200	http://dx.doi.org/10.1074/jbc.M212460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538648	hybrid			2022-12-27	WOS:000181855400032
J	Makino, R; Obayashi, E; Homma, N; Shiro, Y; Hori, H				Makino, R; Obayashi, E; Homma, N; Shiro, Y; Hori, H			YC-1 facilitates release of the proximal his residue in the NO and CO complexes of soluble guanylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NITRIC-OXIDE COMPLEXES; CARBON-MONOXIDE; BOVINE LUNG; LIGAND-BINDING; SMOOTH-MUSCLE; HEME-PROTEINS; CYCLIC-GMP; ACTIVATION; RAMAN	The benzylindazole compound YC-1 has been shown to activate soluble guanylate cyclase by increasing the sensitivity toward NO and CO. Here we report the action of YC-1 on the coordination of CO- and NO-hemes in the enzyme and correlate the events with the activation of enzyme catalysis. A single YC-1-binding site on the heterodimeric enzyme was identified by equilibrium dialysis. To explore the affect of YC-1 on the NO-heme coordination, the six-coordinate NO complex of the enzyme was stabilized by dibromodeuteroheme substitution. Using the dibromodeuteroheme enzyme, YC-1 converted the six-coordinate NO-heme to a five-coordinate NO-heme with a characteristic EPR signal that differed from that in the absence of YC-1. These results revealed that YC-1 facilitated cleavage of the proximal His-iron bond and caused geometrical distortion of the five-coordinate NO-heme. Resonance Raman studies demonstrated the presence of two iron-CO stretch modes at 488 and 521 cm(-1) specific to the YC-1-bound CO complex of the native enzyme. Together with the infrared C-O stretching measurements, we assigned the 488-cm(-1) band to the iron-CO stretch of a six-coordinate CO-heme and the 521-cm(-1) band to the iron-CO stretch of a five-coordinate CO-heme. These results indicate that YC-1 stimulates enzyme activity by weakening or cleaving the proximal His-iron bond in the CO complex as well as the NO complex.	Rikkyo Univ, Coll Sci, Dept Life Sci, Toshima Ku, Tokyo 1718501, Japan; RIKEN, Harima Inst, Inst Phys & Chem Res, Sayo, Hyogo 6795143, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Toyonaka, Osaka 5608531, Japan	Rikkyo University; RIKEN; Osaka University	Makino, R (corresponding author), Rikkyo Univ, Coll Sci, Dept Life Sci, Toshima Ku, Nishiikebukoro 3-34-1, Tokyo 1718501, Japan.	rmakino@rikkyo.net.jp	Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327				BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Chu GC, 2000, J BIOL CHEM, V275, P17494, DOI 10.1074/jbc.M000830200; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Kharitonov VG, 1999, BIOCHEMISTRY-US, V38, P10699, DOI 10.1021/bi990277f; Kim SY, 1996, J AM CHEM SOC, V118, P8769, DOI 10.1021/ja961411b; KON H, 1969, BIOCHEMISTRY-US, V8, P4757, DOI 10.1021/bi00840a016; KON H, 1968, J BIOL CHEM, V243, P4350; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; Makino R., 1982, OXYGENASES OXYGEN ME, P467; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEIDT WR, 1977, J AM CHEM SOC, V99, P7315, DOI 10.1021/ja00464a035; SEYBERT DW, 1977, J BIOL CHEM, V252, P4225; Sharma VS, 1999, BIOCHEM BIOPH RES CO, V254, P188, DOI 10.1006/bbrc.1998.9812; SHIRO Y, 1995, BIOCHEMISTRY-US, V34, P9052, DOI 10.1021/bi00028a014; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4535, DOI 10.1021/bi00388a055; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4527, DOI 10.1021/bi00388a054; UNO T, 1985, J BIOL CHEM, V260, P2023; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; WALCH A, 1989, J AM CHEM SOC, V111, P2767; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WALKER FA, 1976, J AM CHEM SOC, V98, P3484, DOI 10.1021/ja00428a016; WAYLAND BB, 1974, J AM CHEM SOC, V96, P6037, DOI 10.1021/ja00826a013; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; WU CC, 1995, BRIT J PHARMACOL, V116, P1973, DOI 10.1111/j.1476-5381.1995.tb16400.x; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P344, DOI 10.1016/0003-9861(75)90350-1; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YOSHIMURA T, 1991, B CHEM SOC JPN, V64, P2819, DOI 10.1246/bcsj.64.2819; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	55	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11130	11137		10.1074/jbc.M209026200	http://dx.doi.org/10.1074/jbc.M209026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540839	hybrid			2022-12-27	WOS:000181855400036
J	Seck, T; Baron, R; Horne, WC				Seck, T; Baron, R; Horne, WC			Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; INTRACELLULAR TRAFFICKING; TONIC INTERNALIZATION; ANGIOTENSIN-II; PROTEIN; ENDOCYTOSIS; PHOSPHORYLATION; DESENSITIZATION; MODULATION; CYTOSKELETON	Many G protein-coupled receptors undergo endocytosis, but the mechanisms involved in endocytic sorting and recycling remain to be fully elucidated. We found that the G protein-coupled calcitonin receptor (CTR) undergoes tonic internalization and accumulates within the cell. Using a fluorescence loss in photobleaching assay, we classified these vesicles functionally as recycling vesicles. In a two-hybrid screening, we found that the actin-binding protein filamin interacted with the C-terminal tail of the CTR. The degradation of the receptor was profoundly increased in the absence of filamin or the CTR-filamin interaction. The absence of filamin was also associated with a marked decrease in recycling of the receptor from the endosomes to the cell surface. In contrast, calcitonin-induced inhibition of spontaneous filamin proteolysis was associated with increased recycling of the receptor to the cell surface and decreased degradation of the CTR, suggesting an important role for filamin in the endocytic sorting and recycling of the internalized CTR.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthoped, New Haven, CT 06510 USA	Yale University; Yale University	Seck, T (corresponding author), Berufsgenossenschaftliche Klin Bergmannsheil, Burkle Camp Pl 1, D-44789 Bochum, Germany.	thomas_seck@hotmail.com			NIDCR NIH HHS [DE-0724] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Azria M., 1989, CALCITONINS PHYSL PH; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN M, 1989, J BIOL CHEM, V264, P14282; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; MARZIA M, 2002, J BONE MINER RES  S1, V17, P231; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Shyu JF, 1999, EUR J BIOCHEM, V262, P95, DOI 10.1046/j.1432-1327.1999.00346.x; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093	34	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10408	10416		10.1074/jbc.M209655200	http://dx.doi.org/10.1074/jbc.M209655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531889	hybrid			2022-12-27	WOS:000181777500057
J	Van Lanen, SG; Kinzie, SD; Matthieu, S; Link, T; Culp, J; Iwata-Reuyl, D				Van Lanen, SG; Kinzie, SD; Matthieu, S; Link, T; Culp, J; Iwata-Reuyl, D			tRNA modification by S-adenosylmethionine : tRNA ribosyltransferase-isomerase - Assay development and characterization of the recombinant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PREPARATIVE-SCALE PURIFICATION; ESCHERICHIA-COLI; GUANINE TRANSGLYCOSYLASE; WOBBLE BASE; HELA-CELLS; ADENINE PHOSPHORIBOSYLTRANSFERASE; MODIFYING ENZYME; NUTRIENT FACTOR; QUEUINE	The enzyme S-adenosylmethionine:tRNA ribosyltransferase-isomerase catalyzes the penultimate step in the biosynthesis of the hypermodified tRNA nucleoside queuosine (Q), an unprecedented ribosyl transfer from the cofactor S-adenosylmethionine (AdoMet) to a modified-tRNA precursor to generate epoxyqueuosine (oQ). The complexity of the reaction makes it an especially interesting mechanistic problem, and as a foundation for detailed kinetic and mechanistic studies we have carried out the basic characterization of the enzyme. Importantly, to allow for the direct measurement of oQ formation, we have developed protocols for the preparation of homogeneous substrates; specifically, an overexpression system was constructed for tRNATyr in an E. coli queA deletion mutant to allow for the isolation of large quantities of substrate tRNA, and [U-ribosyl-C-14]AdoMet was synthesized. The enzyme shows optimal activity at pH 8.7 in buffers containing various oxyanions, including acetate, carbonate, EDTA, and phosphate. Unexpectedly, the enzyme was inhibited by Mg2+ and Mn2+ in millimolar concentrations. The steady-state kinetic parameters were determined to be K-m(AdoMet) = 101.4 muM, K-m(tRNA) = 1.5 muM, and k(cat) = 2.5 min(-1). A short minihelix RNA was synthesized and modified with the precursor 7-aminomethyl-7-deazaguanine, and this served as an efficient substrate for the enzyme (K-m(RNA) = 37.7 muM and k(cat) = 14.7 min(-1)), demonstrating that the anticodon stem-loop is sufficient for recognition and catalysis by QueA.	Portland State Univ, Dept Chem, Portland, OR 97207 USA	Portland State University	Iwata-Reuyl, D (corresponding author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA.	iwatareuyld@pdx.edu		Link, Todd/0000-0003-1939-9755				AKIMOTO H, 1988, J CHEM SOC P1, V7, P1637; Alfonzo JD, 1997, BBA-PROTEIN STRUCT M, V1341, P173, DOI 10.1016/S0167-4838(97)00068-X; Alfonzo JD, 1999, J BACTERIOL, V181, P347, DOI 10.1128/JB.181.1.347-352.1999; Altman Sidney, 1995, P67; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BARANOWSKI W, 1994, CANCER RES, V54, P4468; Bjork GR, 1995, TRNA STRUCTURE BIOSY, P165; BOYLE SM, 1984, GENE, V30, P129, DOI 10.1016/0378-1119(84)90113-6; BRAVEN J, 1984, ANN CLIN BIOCHEM, V21, P366, DOI 10.1177/000456328402100505; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cunningham L, 1996, NUCLEIC ACIDS RES, V24, P3647, DOI 10.1093/nar/24.18.3647; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DAVOLL J, 1960, J CHEM SOC, P131, DOI 10.1039/jr9600000131; Deutscher Murray P., 1995, P51; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EMMERICH B, 1985, CANCER RES, V45, P4308; FRENCH BT, 1991, P NATL ACAD SCI USA, V88, P370, DOI 10.1073/pnas.88.2.370; GARCIA GA, 1998, MODIFICATION EDITING, P135; GILLAM IC, 1971, METHOD ENZYMOL, V20, P55; HATFIELD D, 1989, VIROLOGY, V173, P736, DOI 10.1016/0042-6822(89)90589-8; Hochstadt J, 1978, Methods Enzymol, V51, P558; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; HOOPS GC, 1995, BIOCHEMISTRY-US, V34, P15381, DOI 10.1021/bi00046a047; HUANG BS, 1992, CANCER RES, V52, P4696; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KERSTEN H, 1988, Biofactors, V1, P27; Kersten H., 1990, CHROMATOGRAPHY MODIF, V45, pB69; Kinzie SD, 2000, ORG LETT, V2, P1307, DOI 10.1021/ol005756h; KIRTLAND GM, 1988, J BACTERIOL, V170, P5633, DOI 10.1128/jb.170.12.5633-5641.1988; Kittendorf JD, 2001, BIOCHEMISTRY-US, V40, P14123, DOI 10.1021/bi0110589; KUCHINO Y, 1976, NUCLEIC ACIDS RES, V3, P393, DOI 10.1093/nar/3.2.393; LANGGUT W, 1990, FEBS LETT, V265, P33, DOI 10.1016/0014-5793(90)80877-L; LANGGUT W, 1993, FEBS LETT, V336, P137, DOI 10.1016/0014-5793(93)81627-C; LANGGUT W, 1995, BIOCHEM BIOPH RES CO, V207, P306, DOI 10.1006/bbrc.1995.1188; LANGGUT W, 1993, ONCOGENE, V8, P3141; LIM CK, 1989, J CHROMATOGR, V461, P259, DOI 10.1016/S0021-9673(00)94291-2; MAHR U, 1990, Biofactors, V2, P185; Maniatis T., 1982, MOL CLONING; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; Marks T, 1997, BIOCHEM BIOPH RES CO, V230, P233, DOI 10.1006/bbrc.1996.5768; MARTIN F, 1993, J MOL BIOL, V234, P965, DOI 10.1006/jmbi.1993.1651; MATOS JR, 1987, BIOTECHNOL APPL BIOC, V9, P39; MATOS JR, 1988, THESIS TEXAS A M U C; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Misra VK, 2000, J MOL BIOL, V299, P813, DOI 10.1006/jmbi.2000.3769; Moore JA, 1997, BIOCHEMISTRY-US, V36, P604, DOI 10.1021/bi962225l; MUELLER SO, 1995, FEBS LETT, V361, P259, DOI 10.1016/0014-5793(95)00169-A; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NISHIMURA S, 1967, BIOCHIM BIOPHYS ACTA, V142, P133, DOI 10.1016/0005-2787(67)90522-9; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P2931, DOI 10.1093/nar/4.8.2931; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; OKADA N, 1979, J BIOL CHEM, V254, P3061; Park J, 1996, BIOORGAN MED CHEM, V4, P2179, DOI 10.1016/S0968-0896(96)00228-3; PARKIN DW, 1984, J BIOL CHEM, V259, P9411; PEARSON JD, 1983, J LIQ CHROMATOGR, V6, P1441, DOI 10.1080/01483918308064863; REISSER T, 1993, BIOCHEM BIOPH RES CO, V197, P1319, DOI 10.1006/bbrc.1993.2621; REISSER T, 1994, EUR J BIOCHEM, V221, P979, DOI 10.1111/j.1432-1033.1994.tb18814.x; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; ROMER R, 1975, EUR J BIOCHEM, V55, P271, DOI 10.1111/j.1432-1033.1975.tb02160.x; Romier C, 1996, BIOCHEMISTRY-US, V35, P15734, DOI 10.1021/bi962003n; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; SCHLAX PE, 1995, BIOTECHNIQUES, V18, P94; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SLANY RK, 1994, BIOCHIMIE, V76, P389, DOI 10.1016/0300-9084(94)90113-9; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; TANNER NK, 1989, METHOD ENZYMOL, V180, P25; THOMPSON JA, 1983, METHOD ENZYMOL, V100, P368; Westaway Shawn K., 1995, P79; WHITE BN, 1973, J MOL BIOL, V74, P635, DOI 10.1016/0022-2836(73)90054-5	72	36	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10491	10499		10.1074/jbc.M207727200	http://dx.doi.org/10.1074/jbc.M207727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533518	hybrid			2022-12-27	WOS:000181777500067
J	Krell, T; Renauld-Mongenie, G; Nicolai, MC; Fraysse, S; Chevalier, M; Berard, Y; Oakhill, J; Evans, RW; Gorringe, A; Lissolo, L				Krell, T; Renauld-Mongenie, G; Nicolai, MC; Fraysse, S; Chevalier, M; Berard, Y; Oakhill, J; Evans, RW; Gorringe, A; Lissolo, L			Insight into the structure and function of the transferrin receptor from Neisseria meningitidis using microcalorimetric techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-B; DIFFERENTIAL SCANNING CALORIMETRY; ISOTHERMAL TITRATION CALORIMETRY; ESCHERICHIA-COLI; BACTERICIDAL ANTIBODIES; DOMAIN INTERACTIONS; IDENTIFICATION; VACCINE; GENES; TBPB	The transferrin receptor of Neisseria meningitidis is composed of the transmembrane protein TbpA and the outer membrane protein TbpB. Both receptor proteins have the capacity to independently bind their ligand human transferrin (htf). To elucidate the specific role of these proteins in receptor function, isothermal titration calorimetry was used to study the interaction between purified TbpA, TbpB or the entire receptor (TbpA + TbpB) with holo- and apo-htf. The entire receptor was shown to contain a single high affinity htf-binding site on TbpA and approximately two lower affinity binding sites on TbpB. The binding sites appear to be independent. Purified ThpA was shown to have strong ligand preference for apo-htf, whereas TbpA in the receptor complex with TbpB preferentially binds the holo form of htf. The orientation of the ligand specificity of TbpA toward holo-htf is proposed to be the physiological function of TbpB. Furthermore, the thermodynamic mode of htf binding by TbpB of isotypes I and II was shown to be different. A protocol for the generation of active, histidine-tagged TbpB as well as its individual N- and C-terminal domains is presented. Both domains are shown to strongly interact with each other, and isothermal titration calorimetry and circular dichroism experiments provide clear evidence for this interaction causing conformational changes. The N-terminal domain of TbpB was shown to be the site of htf binding, whereas the C-terminal domain is not involved in binding. Furthermore, the interactions between ThpA and the different domains of TbpB have been demonstrated.	Aventis Pasteur, F-69280 Marcy Letoile, France; Kings Coll London, Randall Ctr Mol Mechanisms Cell Funct, Metalloprot Res Grp, London SE1 1UL, England; Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England	Sanofi-Aventis; Sanofi France; University of London; King's College London	Krell, T (corresponding author), Aventis Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.	tino.krell@aventis.com	Gorringe, Andrew R/L-6022-2017; Oakhill, Jonathan S/F-5724-2011; Krell, Tino/G-7296-2015	Gorringe, Andrew R/0000-0003-2193-7954; Oakhill, Jonathan S/0000-0002-9475-1440; Krell, Tino/0000-0002-9040-3166				ALAALDEEN DAA, 1994, INFECT IMMUN, V62, P2984, DOI 10.1128/IAI.62.7.2984-2990.1994; ANDERSON JE, 1994, J BACTERIOL, V176, P3162, DOI 10.1128/jb.176.11.3162-3170.1994; Begg N, 1999, J INFECTION, V39, P1, DOI 10.1016/S0163-4453(99)90095-6; Boulton IC, 1997, FEBS LETT, V414, P409, DOI 10.1016/S0014-5793(97)01025-9; Boulton IC, 1998, BIOCHEM J, V334, P269, DOI 10.1042/bj3340269; Boulton IC, 1999, J THEOR BIOL, V198, P497, DOI 10.1006/jtbi.1999.0928; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CHANG BS, 1993, PHARMACEUT RES, V10, P1478, DOI 10.1023/A:1018979410338; Cooper A., 1999, PROTEIN C T, P217; Cornelissen CN, 1997, INFECT IMMUN, V65, P822, DOI 10.1128/IAI.65.2.822-828.1997; Cornelissen CN, 1996, J BACTERIOL, V178, P1437, DOI 10.1128/jb.178.5.1437-1444.1996; Cornelissen CN, 1997, MOL MICROBIOL, V26, P25, DOI 10.1046/j.1365-2958.1997.5381914.x; CORNELISSEN CN, 1994, MOL MICROBIOL, V14, P843, DOI 10.1111/j.1365-2958.1994.tb01320.x; DANVE B, 1993, VACCINE, V11, P1214, DOI 10.1016/0264-410X(93)90045-Y; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Freire Ernesto, 1995, V40, P191; Fuller CA, 1998, MICROB PATHOGENESIS, V24, P75, DOI 10.1006/mpat.1997.0174; GORRINGE AR, 1995, VACCINE, V13, P1207, DOI 10.1016/0264-410X(95)00055-6; GRAYOWEN SD, 1995, INFECT IMMUN, V63, P1201, DOI 10.1128/IAI.63.4.1201-1210.1995; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; IRWIN SW, 1993, MOL MICROBIOL, V8, P1125, DOI 10.1111/j.1365-2958.1993.tb01657.x; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; Krell T, 2002, PROTEIN EXPRES PURIF, V24, P323, DOI 10.1006/prep.2001.1593; LEGRAIN M, 1993, GENE, V130, P73, DOI 10.1016/0378-1119(93)90348-7; LEGRAIN M, 1995, PROTEIN EXPRES PURIF, V6, P570, DOI 10.1006/prep.1995.1075; LISSOLO L, 1995, INFECT IMMUN, V63, P884, DOI 10.1128/IAI.63.3.884-890.1995; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Luke NR, 1999, INFECT IMMUN, V67, P5815, DOI 10.1128/IAI.67.11.5815-5819.1999; MAZARIN V, 1995, GENE, V158, P145, DOI 10.1016/0378-1119(95)00151-U; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; Myers LE, 1998, INFECT IMMUN, V66, P4183; OAKHILL JS, 2002, PROTEIN EXPRES PURIF, V364, P613; Pintor M, 1998, J MED MICROBIOL, V47, P757, DOI 10.1099/00222615-47-9-757; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; Powell NBL, 1998, J MED MICROBIOL, V47, P257, DOI 10.1099/00222615-47-3-257; Remmele RL, 1999, BIOCHEMISTRY-US, V38, P5241, DOI 10.1021/bi982881g; Renauld-Mongenie G, 1998, FEMS MICROBIOL LETT, V169, P171; RenauldMongenie G, 1997, J BACTERIOL, V179, P6400, DOI 10.1128/jb.179.20.6400-6407.1997; Retzer MD, 1999, MOL MICROBIOL, V32, P111, DOI 10.1046/j.1365-2958.1999.01331.x; Rokbi B, 2000, INFECT IMMUN, V68, P4938, DOI 10.1128/IAI.68.9.4938-4947.2000; ROKBI B, 1993, FEMS MICROBIOL LETT, V110, P51, DOI 10.1016/0378-1097(93)90241-S; Ronpirin C, 2001, INFECT IMMUN, V69, P6336, DOI 10.1128/IAI.69.10.6336-6347.2001; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; VONDERHAAR RA, 1994, J BACTERIOL, V176, P6207, DOI 10.1128/jb.176.20.6207-6213.1994; WARD JH, 1987, INVEST RADIOL, V22, P74, DOI 10.1097/00004424-198701000-00017; West D, 2001, INFECT IMMUN, V69, P1561, DOI 10.1128/IAI.69.3.1561-1567.2001; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	55	32	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14712	14722		10.1074/jbc.M204461200	http://dx.doi.org/10.1074/jbc.M204461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12571247	hybrid			2022-12-27	WOS:000182516100018
J	Yueh, MF; Huang, YH; Hiller, A; Chen, SJ; Nguyen, N; Tukey, RH				Yueh, MF; Huang, YH; Hiller, A; Chen, SJ; Nguyen, N; Tukey, RH			Involvement of the xenobiotic response element (XRE) in ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; CACO-2 CELLS; HUMAN BILIRUBIN; GASTROINTESTINAL-TRACT; METABOLIZING-ENZYMES; FLAVONOID CHRYSIN; NUCLEAR RECEPTOR; COMPLEX LOCUS; CYP1A1 GENE; EXPRESSION	UDP-glucuronosyltransferase 1A1 (UGT1A1) plays an important physiological role by contributing to the metabolism of endogenous substances such as bilirubin in addition to xenobiotics and drugs. The UGT1A1 gene has been shown to be inducible by nuclear receptors steroid xenobiotic receptor (SXR) and the constitutive active receptor, CAR. In this report, we show that in human hepatoma HepG2 cells the UGT1A1 gene is also inducible with aryl hydrocarbon receptor (Ah receptor) ligands such as 2,3,7,8-tetrachlodibenzo-p-dioxin (TCDD), beta-naphthoflavone, and benzo[a]pyrene metabolites. Induction was monitored by increases in protein and catalytic activity as well as UGT1A1 mRNA. To examine the molecular interactions that control UGT1A1 expression, the gene was characterized and induction by Ah receptor ligands was regionalized to bases -3338 to -3287. Nucleotide sequence analysis of this UGT1A1 enhancer region revealed a xenobiotic response element (XRE) at -3381/-3299. The dependence of the XRE on UGT1A1-luciferase activity was demonstrated by a loss of Ah receptor ligand inducibility when the XRE core region (CACGCA) was deleted or mutated. Gel mobility shift analysis confirmed that TCDD induction of nuclear proteins specifically bound to the UGT1A1-XRE, and competition experiments with Ah receptor and Arnt antibodies demonstrated that the nuclear protein was the Ah receptor. These observations reveal that the Ah receptor is involved in human UGT1A1 induction.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Lab Environm Toxicol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10337] Funding Source: Medline; NIGMS NIH HHS [GM49135] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen SW, 2001, DRUG METAB DISPOS, V29, P1074; Anderson JW, 1999, MAR ENVIRON RES, V48, P389, DOI 10.1016/S0141-1136(99)00054-9; BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bock KW, 2000, BIOCHEM PHARMACOL, V59, P467, DOI 10.1016/S0006-2952(99)00366-4; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Dutton G.F., 1980, GLUCURONIDATION DRUG; Galijatovic A, 2000, PHARMACEUT RES, V17, P21, DOI 10.1023/A:1007506222436; Galijatovic A, 2001, PHARMACEUT RES, V18, P374, DOI 10.1023/A:1011019417236; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grams B, 2000, ARCH BIOCHEM BIOPHYS, V377, P255, DOI 10.1006/abbi.2000.1777; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kashfi K, 1995, CLIN PHARMACOL THER, V58, P625, DOI 10.1016/0009-9236(95)90018-7; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V292, P250, DOI 10.1016/0003-9861(92)90076-9; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; Munzel PA, 1999, DRUG METAB DISPOS, V27, P569; Munzel PA, 1998, ARCH BIOCHEM BIOPHYS, V350, P72, DOI 10.1006/abbi.1997.0485; PETERS WHM, 1987, GASTROENTEROLOGY, V93, P162, DOI 10.1016/0016-5085(87)90329-5; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; Ritter JK, 1999, HEPATOLOGY, V30, P476, DOI 10.1002/hep.510300205; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Soucek P, 1995, BIOCHEMISTRY-US, V34, P16013, DOI 10.1021/bi00049a015; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Walle T, 2000, DRUG METAB DISPOS, V28, P1077; Walle UK, 2002, DRUG METAB DISPOS, V30, P564, DOI 10.1124/dmd.30.5.564; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245; XIE W, 2003, IN PRESS P NATL ACAD; Ziccardi MH, 2002, ENVIRON TOXICOL CHEM, V21, P2027, DOI 10.1897/1551-5028(2002)021<2027:AOTLRC>2.0.CO;2	38	139	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15001	15006		10.1074/jbc.M300645200	http://dx.doi.org/10.1074/jbc.M300645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12566446	hybrid			2022-12-27	WOS:000182516100056
J	Deng, Y; Pang, A; Wang, JH				Deng, Y; Pang, A; Wang, JH			Regulation of mammalian STE20-like kinase 2 (MST2) by protein phophorylation/dephosphorylation and proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED ACTIVATION; PHOSPHORYLATION; APOPTOSIS; MST/KRS; CLEAVAGE; CLONING	Mammalian STE20-like kinase 2 (MST2), a member of the STE20-like kinase family, has been shown in previous studies to undergo proteolytic activation by caspase-3 during cell apoptosis. A few studies have also implicated protein phosphorylation reactions in MST2 regulation. In this study, we examined the mechanism of MST2 regulation with an emphasis on the relationship between caspase-3 cleavage and protein phosphorylation. Both the full-length MST2 and the caspase-3 truncated form of MST2 overexpressed in 293T cells exist in a phosphorylated state. On the other hand, the endogenous full-length MST2 from rat thymus or from proliferating cells is mainly unphosphorylated whereas the caspase-3-truncated endogenous MST2 from apoptotic cells is highly phosphorylated. Cell transfection studies using mutant MST2 constructs indicate that MST2 depends on the autophosphorylation of a unique threonine residue, Thr(180), for kinase activity. The autophosphorylation reaction shows strong dependence on MST2 concentration suggesting that it is an intermolecular reaction. While both the full-length MST2 and the caspase-3-truncated form of MST2 undergo autophosphorylation, the two forms of the phosphorylated MST2 display marked difference in susceptibility to protein phosphatases. The full-length phospho-MST2 is rapidly dephosphorylated by protein phosphatase 1 or protein phosphatase 2A whereas the truncated MST2 is remarkably resistant to the dephosphorylation. Based on the present results, a novel molecular mechanism for MST2 regulation in apoptotic cells is postulated. In normal cells, because of the low concentration and the ready reversal of the autophosphorylation by protein phosphatases, MST2 is present mainly in the unphosphorylated and inactive state. During cell apoptosis, MST2 is cleaved by caspase-3 and undergoes irreversible autophosphorylation, thus resulting in the accumulation of active MST2.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	jerwang@ust.hk						Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Kakeya H, 1998, CANCER RES, V58, P4888; Kakeya H, 1999, ANN NY ACAD SCI, V886, P273, DOI 10.1111/j.1749-6632.1999.tb09434.x; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lian JP, 2001, J IMMUNOL, V166, P6349, DOI 10.4049/jimmunol.166.10.6349; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; Watabe M, 2000, J BIOL CHEM, V275, P8766, DOI 10.1074/jbc.275.12.8766	23	54	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11760	11767		10.1074/jbc.M211085200	http://dx.doi.org/10.1074/jbc.M211085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12554736	hybrid			2022-12-27	WOS:000182015700007
J	Khoshbouei, H; Wang, HW; Lechleiter, JD; Javitch, JA; Galli, A				Khoshbouei, H; Wang, HW; Lechleiter, JD; Javitch, JA; Galli, A			Amphetamine-induced dopamine efflux - A voltage-sensitive and intracellular Na+-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; CARRIER-MEDIATED RELEASE; PROTEIN-KINASE-C; SEROTONIN TRANSPORTERS; EXCHANGE DIFFUSION; TRANSFECTED CELLS; MICE LACKING; COCAINE; NEURONS; CALCIUM	Amphetamine (AMPH) elicits its behavioral effects by acting on the dopamine (DA) transporter (DAT) to induce DA overflow into the synaptic cleft. Facilitated exchange diffusion is the classical model used to describe AMPH-induced DA efflux. This model hypothesizes that AMPH-induced DA efflux is mediated by DAT and results from the transport of AMPH into the cell followed by a counter movement of DA out to the extracellular compartment. To further characterize the action of AMPH, we used the patch clamp technique in the whole-cell configuration combined with amperometry on human embryonic kidney HEK-293 cells stably transfected with the human DAT (DAT cells). In DAT cells, AMPH-induced DAT-mediated currents were blocked by cocaine. We demonstrate that DA efflux mediated by DAT is voltage-dependent, electrogenic, and dependent on intracellular Na+ concentration in the recording electrode. Intracellular Na+ fluorescence, as measured by confocal microscopy using a Na+-sensitive dye, was enhanced by AMPH application. Furthermore, the ability of AMPH to induce DA efflux was regulated by intracellular Na+ concentration and correlated with the size of the DAT-mediated, AMPH-induced ion flux across the plasma membrane. In the absence of intracellular Na+ but the presence of high intracellular Cl-, AMPH-induced inward currents elicited DA efflux proportionally to their dimension and duration. Thus, we propose that AMPH-induced DA efflux depends on two correlated transporter processes. First, AMPH binds to the DAT and is transported, thereby causing an inward current. Second, because of this AMPH-induced inward current, Na+ becomes more available intracellularly to the DAT, thereby enhancing DAT-mediated reverse transport of DA.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Health San Antonio; Columbia University; Columbia University; Columbia University	Galli, A (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	Aurelio.Galli@Vanderbilt.edu		Javitch, Jonathan/0000-0001-7395-2967; Khoshbouei, Habibeh/0000-0002-1533-8771	NIDA NIH HHS [DA-14684, DA-13975] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013975, R01DA014684] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BONISCH H, 1986, N-S ARCH PHARMACOL, V332, P135, DOI 10.1007/BF00511403; Burnette WB, 1996, ANAL CHEM, V68, P2932, DOI 10.1021/ac960022x; Chen NH, 1998, J NEUROCHEM, V71, P653; Chen NH, 2000, MOL BRAIN RES, V75, P208, DOI 10.1016/S0169-328X(99)00288-0; Cowell RM, 2000, EUR J PHARMACOL, V389, P59, DOI 10.1016/S0014-2999(99)00828-6; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; Jones SR, 1998, J NEUROSCI, V18, P1979; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Kantor L, 2001, J PHARMACOL EXP THER, V297, P1016; LIANG NY, 1983, EUR J PHARMACOL, V89, P153, DOI 10.1016/0014-2999(83)90621-0; NELSON PJ, 1982, J BIOL CHEM, V257, P6151; Pierce RC, 1997, J NEUROSCI, V17, P3254; Pifl C, 1999, MOL PHARMACOL, V56, P1047, DOI 10.1124/mol.56.5.1047; Pifl C, 1999, NEUROPHARMACOLOGY, V38, P157, DOI 10.1016/S0028-3908(98)00155-5; POWIS DA, 1988, N-S ARCH PHARMACOL, V337, P273; Prasad BM, 2001, J NEUROSCI, V21, P7561, DOI 10.1523/JNEUROSCI.21-19-07561.2001; RAITERI M, 1979, J PHARMACOL EXP THER, V208, P195; Rees S, 1996, BIOTECHNIQUES, V20, P102; RUDNICK G, 1992, BIOCHEMISTRY-US, V31, P6710, DOI 10.1021/bi00144a010; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; SULZER D, 1995, J NEUROSCI, V15, P4102; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; SULZER D, 1992, ANN NY ACAD SCI, V654, P525, DOI 10.1111/j.1749-6632.1992.tb26020.x	31	143	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12070	12077		10.1074/jbc.M212815200	http://dx.doi.org/10.1074/jbc.M212815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556446	hybrid			2022-12-27	WOS:000182015700047
J	Shoji, H; Nishi, N; Hirashima, M; Nakamura, T				Shoji, H; Nishi, N; Hirashima, M; Nakamura, T			Characterization of the Xenopus galectin family - Three structurally different types as in mammals and regulated expression during embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; PERIPHERAL-NERVES; ANIMAL LECTINS; CDNA CLONING; LAEVIS; GENE; PEPTIDE; GROWTH; DEATH; BONES	We have isolated six novel galectin cDNAs from a Xenopus laevis kidney cDNA library. The newly identified X. laevis galectins (xgalectins) comprise one proto type (xgalectin-Vb), one chimera type (xgalectin-VIIa), and four tandem repeat types (xgalectin-IIb, -IIIb, -VIa, and -VIIIa). Thus, together with those mentioned in our previous work (Shoji, H., Nishi, N., Hirashima, M., and Nakamura, T. (2002) Glycobiology 12, 163-172), the 12 xgalectins are classified into three types based on their domain structures, as in mammals. The xgalectins whose counterparts in other species have not been identified (xgalectin-IVa, -Vb, and -VIa) were confirmed to possess lactose-binding activity by expression of their recombinant forms. This shows that they truly function as animal lectins. The protein purification study revealed that the major xgalectins in kidney are xgalectin-Ib, -IIa, -IIb, -IIIa, and -VIIa. The mRNAs of xgalectin-IIb, -IIIb, -Vb, and -VIa were localized to specific adult tissues, whereas those of xgalectin-VIIa and -VIIIa were broadly distributed. The temporal expression patterns of the mRNAs of the 12 xgalectins during embryogenesis were analyzed and categorized into three groups: 1) mRNA observed to exist throughout embryogenesis, i.e. maternal mRNA also exists (xgalectin-Ia, -IIa, -IIIa, -IIIb, -Va, -VIIa, and -VIIIa); 2) mRNA observed from the gastrula stage (xgalectin-VIa); and 3) mRNA observed from the tail bud or the tadpole stage (xgalectin-Ib, -IIb, -IVa, and -Vb). The mRNA of the most abundant xgalectin in embryos, xgalectin-VIIa, was localized to the surface layer of embryos, the epidermis, the cement gland, and various placodes. Xgalectin-VIIa protein was also observed to exist throughout embryogenesis by Western blot analysis with specific antiserum. These results show that the expression of each member is spatiotemporally regulated from eggs to adulthood, suggesting that galectins play multiple roles not only in adults, but also in development.	Kagawa Med Univ, Dept Endocrinol, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Immunol & Immunopathol, Kagawa 7610793, Japan; Galpharma Co Ltd, Kagawa 7610301, Japan	Kagawa University; Kagawa University	Nakamura, T (corresponding author), Kagawa Med Univ, Dept Endocrinol, 1750-1 Miki Cho, Kagawa 7610793, Japan.			Nishi, Nozomu/0000-0001-7050-3226				BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; Colnot C, 2001, DEV BIOL, V229, P203, DOI 10.1006/dbio.2000.9933; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; Dunphy JL, 2000, J BIOL CHEM, V275, P32106, DOI 10.1074/jbc.M003739200; Dunphy JL, 2002, J BIOL CHEM, V277, P14916, DOI 10.1074/jbc.M200214200; Evanson JE, 1996, J CRAN GENET DEV BIO, V16, P74; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; FRUNCHAK YN, 1993, ANAT EMBRYOL, V187, P299; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; Gopalkrishnan RV, 2000, ONCOGENE, V19, P4405, DOI 10.1038/sj.onc.1203767; Horie H, 1999, J NEUROSCI, V19, P9964; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Inagaki Y, 2000, EUR J BIOCHEM, V267, P2955, DOI 10.1046/j.1432-1033.2000.01311.x; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; Murphy KM, 1999, DEV DYNAM, V215, P248, DOI 10.1002/(SICI)1097-0177(199907)215:3<248::AID-AJA7>3.3.CO;2-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishi N, 1996, PROSTATE, V28, P139; Okabayashi K, 1999, BIOCHEM BIOPH RES CO, V254, P42, DOI 10.1006/bbrc.1998.9892; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; POIRIER F, 1992, DEVELOPMENT, V115, P143; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; Sato M, 2002, J BIOCHEM, V131, P255, DOI 10.1093/oxfordjournals.jbchem.a003096; Sato M, 2002, GLYCOBIOLOGY, V12, P191, DOI 10.1093/glycob/12.3.191; Shoji H, 2002, GLYCOBIOLOGY, V12, P163, DOI 10.1093/glycob/12.3.163; Visegrady B, 2001, PROTEIN ENG, V14, P875, DOI 10.1093/protein/14.11.875; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Yamada K, 1999, DEV BIOL, V214, P318, DOI 10.1006/dbio.1999.9412; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200	38	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12285	12293		10.1074/jbc.M209008200	http://dx.doi.org/10.1074/jbc.M209008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538594	hybrid			2022-12-27	WOS:000182015700074
J	Kalant, D; Cain, SA; Maslowska, M; Sniderman, AD; Cianflone, K; Monk, PN				Kalant, D; Cain, SA; Maslowska, M; Sniderman, AD; Cianflone, K; Monk, PN			The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg(77)/acylation-stimulating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLATION-STIMULATING PROTEIN; HUMAN C5A RECEPTOR; ANAPHYLATOXIN C3A; U937 CELLS; COMPLEMENT; C3A(DESARG); EXPRESSION; NEUTROPHILS; CHEMOTAXIN; ACTIVATION	The orphan receptor C5L2 has recently been described as a high affinity binding protein for complement fragments C5a and C3a that, unlike the previously described C5a receptor (CD88), couples only weakly to G; like G proteins (Cain, S. A., and Monk, P. N. (2002) J. Biol. Chem. 277, 7165-7169). Here we demonstrate that C5L2 binds the metabolites of C4a and C3a, C4a des-Arg(77), and C3a des-Arg(77) (also known as the acylation-stimulating protein or ASP) at a site distinct from the C5a binding site. The binding of these metabolites to C5L2 does not stimulate the degranulation of transfected rat basophilic leukemia cells either through endogenous rat G proteins or when co-transfected with human G(alpha16). C3a des-Arg(77)/ASP and C3a can potently stimulate triglyceride synthesis in human skin fibroblasts and 3T3-L1 preadipocytes. Here we show that both cell types and human adipose tissue express C5L2 mRNA and that the human fibroblasts express C5L2 protein at the cell surface. This is the first demonstration of the expression of C5L2 in cells that bind and respond to C3a des-Arg(77)/ASP and C3a. Thus C5L2, a promiscuous complement fragment-binding protein with a high affinity site that binds C3a des-Arg /ASP, may mediate the acylation-stimulating properties of this peptide.	Univ Sheffield, Sch Med, Dept Neurol, Sheffield S10 2RX, S Yorkshire, England; McGill Univ, Ctr Hlth, Div Med, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada	University of Sheffield; McGill University	Monk, PN (corresponding author), Univ Sheffield, Sch Med, Dept Neurol, E Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.		Monk, Peter/C-6155-2008; Cain, Stuart A/G-2836-2017	Monk, Peter/0000-0003-4637-3059; Cain, Stuart/0000-0001-8417-1058				BALDO A, 1995, J LIPID RES, V36, P1415; Bhatia M, 2000, J PATHOL, V190, P117; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; CHARRIAUT C, 1982, P NATL ACAD SCI-BIOL, V79, P6003, DOI 10.1073/pnas.79.19.6003; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; CIANFLONE K, 1989, J LIPID RES, V30, P1727; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Fischer WH, 1997, J IMMUNOL, V159, P4279; Fischer WH, 1999, J IMMUNOL, V162, P453; KLOS A, 1992, BIOCHEMISTRY-US, V31, P11274, DOI 10.1021/bi00161a003; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; MONK PN, 1994, BBA-MOL CELL RES, V1221, P323, DOI 10.1016/0167-4889(94)90257-7; MONK PN, 1995, J BIOL CHEM, V270, P16625, DOI 10.1074/jbc.270.28.16625; MOUSLI M, 1992, J IMMUNOL, V148, P2456; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Murray I, 1997, J LIPID RES, V38, P2492; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; Puschel GP, 1996, HEPATOLOGY, V24, P685, DOI 10.1053/jhep.1996.v24.pm0008781343; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; SCHUPF N, 1989, Brain Behavior and Immunity, V3, P28, DOI 10.1016/0889-1591(89)90003-2; SHETH B, 1991, BIOCHEM J, V275, P809, DOI 10.1042/bj2750809; SHUM JK, 1995, BIOCHEM BIOPH RES CO, V208, P223, DOI 10.1006/bbrc.1995.1327; Wilken HC, 1999, J IMMUNOL METHODS, V226, P139, DOI 10.1016/S0022-1759(99)00064-2; Zwirner J, 1998, EUR J IMMUNOL, V28, P1570, DOI 10.1002/(SICI)1521-4141(199805)28:05<1570::AID-IMMU1570>3.3.CO;2-Y	33	151	168	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11123	11129		10.1074/jbc.M206169200	http://dx.doi.org/10.1074/jbc.M206169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540846	hybrid			2022-12-27	WOS:000181855400035
J	Silvis, MR; Picciano, JA; Bertrand, C; Weixel, K; Bridges, RJ; Bradbury, NA				Silvis, MR; Picciano, JA; Bertrand, C; Weixel, K; Bridges, RJ; Bradbury, NA			A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-TRANSPORT; CFTR; IDENTIFICATION; LOCALIZATION; TAIL; GENE	Cystic fibrosis is a common lethal genetic disease among Caucasians. The cystic fibrosis gene encodes a cyclic adenosine monophosphate-activated chloride channel (cystic fibrosis transmembrane conductance regulator (CFTR)) that mediates electrolyte transport across the luminal surfaces of a variety of epithelial cells. Mutations in CFTR fall into two broad categories; those that affect protein biosynthesis/stability and traffic to the cell surface and those that cause altered channel kinetics in proteins that reach the cell surface. Here we report a novel mechanism by which mutations in CFTR give rise to disease. N287Y, a mutation within an intracellular loop of CFTR, increases channel endocytosis from the cell surface without affecting either biosynthesis or channel gating. The sole consequence of this novel mutation is to generate a novel tyrosine-based endocytic sequence within an intracellular loop in CFTR leading to increased removal from the cell surface and a reduction in the steady-state level of CFTR at the cell surface.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bradbury, NA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, S306 BST S,3500 Terrace St, Pittsburgh, PA 15261 USA.	nabrad@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490, R01DK057583] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50DK56490, DK57583] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Bradbury Neil A., 1999, Physiological Reviews, V79, pS175; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; FEREC C, 1995, MOL CELL PROBE, V9, P135, DOI 10.1016/S0890-8508(95)80038-7; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; RIORDAN JR, 1989, SCIENCE, V245, P1066; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Seibert FS, 1997, BIOCHEMISTRY-US, V36, P11966, DOI 10.1021/bi9712652; Shrimpton AE, 1997, HUM MUTAT, V10, P436, DOI 10.1002/(SICI)1098-1004(1997)10:6<436::AID-HUMU4>3.0.CO;2-B; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WARD CL, 1994, J BIOL CHEM, V269, P25710; Weixel Kelly, 2002, Methods Mol Med, V70, P323; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; XIE JX, 1995, J BIOL CHEM, V270, P28084; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	30	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11554	11560		10.1074/jbc.M212843200	http://dx.doi.org/10.1074/jbc.M212843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529365	hybrid			2022-12-27	WOS:000181855400088
J	Fischer, H; Dias, SMG; Santos, MAM; Alves, AC; Zanchin, N; Craievich, AF; Apriletti, JW; Baxter, JD; Webb, P; Neves, FAR; Ribeiro, RCJ; Polikarpov, I				Fischer, H; Dias, SMG; Santos, MAM; Alves, AC; Zanchin, N; Craievich, AF; Apriletti, JW; Baxter, JD; Webb, P; Neves, FAR; Ribeiro, RCJ; Polikarpov, I			Low resolution structures of the retinoid X receptor DNA-binding and ligand-binding domains revealed by synchrotron x-ray solution scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT SHAPE DETERMINATION; THYROID-HORMONE RECEPTORS; SMALL-ANGLE SCATTERING; NUCLEAR RECEPTORS; BIOLOGICAL MACROMOLECULES; TETRAMER FORMATION; CRYSTAL-STRUCTURE; RXR-ALPHA; ACID; HETERODIMERS	Nuclear receptors are ligand-inducible transcription factors that share structurally related DNA-binding (DBD) and ligand-binding (LBD) domains. Biochemical and structural studies have revealed the modular nature of DBD and LBD. Nevertheless, the domains function in concert in vivo. While high-resolution crystal structures of nuclear receptor DBDs and LBDs are available, there are no x-ray structural studies of nuclear receptor proteins containing multiple domains. We report the solution structures of the human retinoid X receptor DBD-LBD (hRXRalphaDeltaAB) region. We obtained ab initio shapes of hRXRalphaDeltaAB dimer and tetramer to 3.3 and 1.7 nm resolutions, respectively, and established the position and orientation of the DBD and LBD by fitting atomic coordinates of hRXRalpha DBD and LBD. The dimer is U-shaped with DBDs spaced at similar to2 nm in a head to head orientation forming an angle of about 10degrees with respect to each other and with an extensive interface area provided by the LBD. The tetramer is a more elongated X-shaped molecule formed by two dimers in head to head arrangement in which the DBDs are extended from the structure and spaced at about 6 nm. The close proximity of DBDs in dimers may facilitate homodimer formation on DNA, however, for the homodimer to bind to a DNA element containing two directly repeated half-sites, one of the DBDs would need to rotate with respect to the other element. By contrast, the separation of DBDs in the tetramers may account for their decreased ability to recognize DNA.	Univ Sao Paulo, Dept Fis & Informat, Inst Fis Sao Carlos, BR-13560970 Sao Carlos, SP, Brazil; Univ Sao Paulo, Inst Fis, BR-05508900 Sao Paulo, Brazil; Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Brasilia, Dept Ciencias Farmaceut, BR-70900910 Brasilia, DF, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Laboratorio Nacional de Luz Sincrotron (LNLS); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia	Polikarpov, I (corresponding author), Univ Sao Paulo, Dept Fis & Informat, Inst Fis Sao Carlos, Av Trabalhador Sao Carlense 400, BR-13560970 Sao Carlos, SP, Brazil.		Fischer, Hannes/C-2215-2012; Polikarpov, Igor/D-2575-2012; Craievich, Aldo F/A-2852-2013; Zanchin, Nilson Ivo Tonin/AAB-4907-2019; Dias, Sandra/AAB-7042-2019	Fischer, Hannes/0000-0003-2984-2028; Craievich, Aldo F/0000-0002-5103-0248; Zanchin, Nilson Ivo Tonin/0000-0002-1153-0694; Polikarpov, Igor/0000-0001-9496-4174	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009516, R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41842, DK 09516] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; Chen ZP, 1998, J MOL BIOL, V275, P55, DOI 10.1006/jmbi.1997.1413; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Egea PF, 2001, J MOL BIOL, V307, P557, DOI 10.1006/jmbi.2000.4409; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P839; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Guinier A., 1955, SMALL ANGLE SCATTERI; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lin BC, 1997, J BIOL CHEM, V272, P9860; Magli E, 2000, RRD PATTERN RECOGNIT, V1, P1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; Shannon C. E., 1949, MATH THEORY COMMUNIC; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STURMANN HB, 1970, J PHYS CHEM-US, V72, P177; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; SVERGUN DI, 1991, ACTA CRYSTALLOGR A, V47, P736, DOI 10.1107/S0108767391006414; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YEN PM, 1992, J BIOL CHEM, V267, P3565; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	49	14	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16030	16038		10.1074/jbc.M206953200	http://dx.doi.org/10.1074/jbc.M206953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12533536	Green Published, hybrid			2022-12-27	WOS:000182680000074
J	Gooding, C; Kemp, P; Smith, CWJ				Gooding, C; Kemp, P; Smith, CWJ			A novel polypyrimidine tract-binding protein paralog expressed in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; EXON; SELECTION; GENE; PTB; ANTAGONIZES; INVOLVEMENT; REPRESSION; DIVERSITY; UPSTREAM	Polypyrimidine tract-binding protein (PTB) is an abundant widespread RNA-binding protein with roles in regulation of pre-mRNA alternative splicing and 3'-end processing, internal ribosomal entry site-driven translation, and mRNA localization. Tissue-restricted paralogs of PTB have previously been reported in neuronal and hematopoietic cells. These proteins are thought to replace many general functions of PTB, but to have some distinct activities, e.g. in the tissue-specific regulation of some alternative splicing events. We report the identification and characterization of a fourth rodent PTB paralog (smPTB) that is expressed at high levels in a number of smooth muscle tissues. Recombinant smPTB localized to the nucleus, bound to RNA, and was able to regulate alternative splicing. We suggest that replacement of PTB by smPTB might be important in controlling some pre-mRNA alternative splicing events.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Smith, CWJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	cwjs1@mole.bio.cam.ac.uk		Kemp, Paul/0000-0001-8975-7293				Ashiya M, 1997, RNA, V3, P996; Back SH, 2002, J BIOL CHEM, V277, P27200, DOI 10.1074/jbc.M203887200; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; Goldberg, 1995, Fold Des, V1, P21; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; Jin W, 2000, CANCER RES, V60, P1221; Kaminski A, 1995, RNA, V1, P924; KEMP PR, 1991, BIOCHEM J, V277, P285, DOI 10.1042/bj2770285; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LIN CH, 1995, RNA, V1, P234; Lou H, 1999, MOL CELL BIOL, V19, P78; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Perez I, 1997, RNA, V3, P764; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Sambrook J., 2001, MOL CLONING LAB MANU; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Southby J, 1999, MOL CELL BIOL, V19, P2699; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; WAITES GT, 1992, J BIOL CHEM, V267, P6263; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214; Yamamoto H, 1999, MOL CELL BIOL, V19, P3829; Zhang L, 1999, RNA, V5, P117, DOI 10.1017/S1355838299981530	49	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15201	15207		10.1074/jbc.M210131200	http://dx.doi.org/10.1074/jbc.M210131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578833	hybrid			2022-12-27	WOS:000182516100080
J	Reddy, KV; Serio, KJ; Hodulik, CR; Bigby, TD				Reddy, KV; Serio, KJ; Hodulik, CR; Bigby, TD			5-lipoxygenase-activating protein gene expression - Key role of CCAAT/enhancer-binding proteins (C/EBP) in constitutive and tumor necrosis factor (TNF) alpha-induced expression in THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TRANSCRIPTIONAL ACTIVATOR PROTEIN; LEUCINE-ZIPPER; MESSENGER-RNA; DEVELOPMENTAL REGULATION; SYNTHASE GENE; FAMILY; ISOFORMS; DELTA; BETA	We examined expression of the 5-lipoxygenase activating protein (FLAP), which is critical for inflammatory cell leukotriene synthesis. A 3.4-kb segment of the FLAP gene 5'-untranslated region accounted for a 22-fold increase in promoter activity when transfected into the monocyte-like cell line, THP-1, and demonstrated no activity in non-inflammatory cells. Virtually all of the promoter activity was mediated by the first 134 bp upstream of the transcription start site, a region that contains CCAAT/enhancer-binding proteins (C/EBP) consensus binding sites, at -36 to -28 bp (distal) and -25 to -12 bp (proximal). DNase I footprint analyses demonstrated THP-1 nuclear extract proteins bind to the proximal site. Electrophoretic mobility shift assay analyses revealed that C/EBPalpha, delta, and epsilon bind to the proximal site and C/EBPalpha and epsilon bind to the distal site, constitutively. Transfection studies indicated that mutation of both the proximal and distal sites decreased constitutive FLAP promoter activity. Overexpression of C/EBPalpha, delta, and epsilon transactivated promoter activity and increased native FLAP mRNA accumulation. Mutation of both C/EBP sites essentially abolished promoter induction by C/EBP overexpression. Tumor necrosis factor (TNF) alpha induced FLAP mRNA expression, FLAP promoter activity, and C/EBPalpha, delta, and epsilon binding to the proximal and distal promoter consensus sites. Chromatin immunoprecipitation assays demonstrated that C/EBPalpha, delta, and epsilon bound to this region of the 5'-untranslated region, whereas C/EBPbeta does not bind even under conditions of overexpression and stimulation. We conclude that the FLAP gene is transactivated by members of the C/EBP family of transcription factors in inflammatory cells and that these factors play an important role in FLAP gene induction by TNFalpha.	Vet Affairs San Diego Healthcare Syst, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, San Diego, CA 92161 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego	Bigby, TD (corresponding author), Vet Affairs San Diego Healthcare Syst, Dept Med, Mail Code 111-J,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	tbigby@UCSD.edu						ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; AVITAHL N, 1994, J BIOL CHEM, V269, P23553; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; CLEUTJENS CBJM, 1993, GENOMICS, V16, P520, DOI 10.1006/geno.1993.1220; Coffey MJ, 1999, BLOOD, V94, P3897, DOI 10.1182/blood.V94.11.3897.423k12_3897_3905; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORDHUTCHINSON AW, 1989, ADV PROSTAG THROMB L, V19, P507; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HOUGLUM K, 1994, J CLIN INVEST, V94, P808, DOI 10.1172/JCI117400; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; KENNEDY BP, 1991, J BIOL CHEM, V266, P8511; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Koshino T, 1999, Mol Cell Biol Res Commun, V2, P32, DOI 10.1006/mcbr.1999.0147; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Osada S, 1996, J BIOL CHEM, V271, P3891; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PALMANTIER R, 1994, LAB INVEST, V70, P696; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; PAUWELS RA, 1995, ALLERGY, V50, P615, DOI 10.1111/j.1398-9995.1995.tb02578.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pope RM, 1999, CLIN IMMUNOL, V91, P271, DOI 10.1006/clim.1999.4723; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; RIFAI A, 1993, KIDNEY INT, V43, pS95; Ring WL, 1996, J CLIN INVEST, V97, P1293, DOI 10.1172/JCI118545; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCOTT LM, 1992, BLOOD, V80, P1725; Serio KJ, 2000, AM J RESP CELL MOL, V23, P234, DOI 10.1165/ajrcmb.23.2.4042; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEINHILBER D, 1993, BIOCHEM BIOPH RES CO, V193, P1083, DOI 10.1006/bbrc.1993.1736; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	56	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13810	13818		10.1074/jbc.M211102200	http://dx.doi.org/10.1074/jbc.M211102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571239	hybrid			2022-12-27	WOS:000182405000033
J	Rudolph, MJ; Wuebbens, MM; Turque, O; Rajagopalan, KV; Schindelin, H				Rudolph, MJ; Wuebbens, MM; Turque, O; Rajagopalan, KV; Schindelin, H			Structural studies of molybdopterin synthase provide insights into its catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; MOLECULAR REPLACEMENT; MOLYBDENUM COFACTOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURES; UBIQUITIN ACTIVATION; MAXIMUM-LIKELIHOOD; BIOSYNTHESIS; PROGRAM	Molybdenum cofactor biosynthesis is an evolutionarily conserved pathway present in eubacteria, archaea, and eukaryotes, including humans. Genetic deficiencies of enzymes involved in cofactor biosynthesis in humans lead to a severe and usually fatal disease. The molybdenum cofactor contains a tricyclic pyranopterin, termed molybdopterin, that bears the cis-dithiolene group responsible for molybdenum ligation. The dithiolene group of molybdopterin is generated by molybdopterin synthase, which consists of a large (MoaE) and small (MoaD) subunit. The crystal structure of molybdopterin synthase revealed a heterotetrameric enzyme in which the C terminus of each MoaD subunit is deeply inserted into a MoaE subunit to form the active site. In the activated form of the enzyme, the MoaD C terminus is present as a thiocarboxylate. The present study identified the position of the thiocarboxylate sulfur by exploiting the anomalous signal originating from the sulfur atom. The structure of molybdopterin synthase in a novel crystal form revealed a binding pocket for the terminal phosphate of molybdopterin, the product of the enzyme, and suggested a binding site for the pterin moiety present in precursor Z and molybdopterin. Finally, the crystal structure of the MoaE homodimer provides insights into the conformational changes accompanying bindin of the MoaD subunit.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Duke University	Schindelin, H (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019	Turque, Oliver/0000-0001-8987-8546	NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM00091] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Li HK, 2000, J AM CHEM SOC, V122, P7673, DOI 10.1021/ja000643e; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698	37	44	48	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14514	14522		10.1074/jbc.M300449200	http://dx.doi.org/10.1074/jbc.M300449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571227	hybrid			2022-12-27	WOS:000182405000119
J	Stahelin, RV; Burian, A; Bruzik, KS; Murray, D; Cho, WW				Stahelin, RV; Burian, A; Bruzik, KS; Murray, D; Cho, WW			Membrane binding mechanisms of the PX domains of NADPH oxidase p40(phox) and p47(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; CYTOSOLIC PHOSPHOLIPASE A(2); C2 DOMAIN; MOLECULAR-BASIS; CELL MEMBRANES; ROLES; ACTIVATION; PRESSURE; RESIDUES; LOCATION	Phox (PX) domains are phosphoinositide (PI)-binding domains with broad PI specificity. Two cytosolic components of NADPH oxidase, p40(phox) and p47(phox), contain PX domains. The PX domain of p40(phox) specifically binds phosphatidylinositol 3-phosphate, whereas the PX domain of p47(phox) has two lipid binding sites, one specific for phosphatidylinositol 3,4-bisphosphate and the other with affinity for phosphatidic acid or phosphatidylserine. To delineate the mechanisms by which these PX domains interact with PI-containing membranes, we measured the membrane binding of these domains and respective mutants by surface plasmon resonance and monolayer techniques and also calculated the electrostatic potentials of the domains as a function of PI binding. Results indicate that membrane binding of both PX domains is initiated by nonspecific electrostatic interactions, which is followed by the membrane penetration of hydrophobic residues. The membrane penetration of the p40(phox) PX domain is induced by phosphatidylinositol 3-phosphate, whereas that of the p47(phox) PX domain is triggered by both phosphatidylinositol 3,4-bisphosphate and phosphatidic acid (or phosphatidylserine). Studies of enhanced green fluorescent protein-fused PX domains in HEK293 cells indicate that this specific membrane penetration is also important for subcellular localization of the two PX domains. Further studies on the full-length p40(phox) and p47(phox) proteins showed that an intramolecular interaction between the C-terminal Src homology 3 domain and the PX domain prevents the nonspecific monolayer penetration of p47(phox), whereas such an interaction is absent in p40(phox).	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University	Cho, WW (corresponding author), Univ Illinois, Dept Chem, M C 111,845 W Taylor St, Chicago, IL USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598, R01GM057568, R01GM066147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52598, GM53987, GM57568, GM66147] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200	43	122	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14469	14479		10.1074/jbc.M212579200	http://dx.doi.org/10.1074/jbc.M212579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556460	hybrid			2022-12-27	WOS:000182405000114
J	Xu, Y; Johnson, J; Kohn, H; Widger, WR				Xu, Y; Johnson, J; Kohn, H; Widger, WR			ATP binding to Rho transcription termination factor - Mutant F355W ATP-induced fluorescence quenching reveals dynamic ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICYCLOMYCIN-RESISTANT MUTANTS; ESCHERICHIA-COLI F1-ATPASE; RNA-BINDING; PROTEIN-RHO; SITES; SEQUENCE; HELICASE; MUTATIONS; AFFINITY; DOMAIN	Rho transcription termination factor mutant, F355W, showed tryptophan fluorescence intensity approximately twice that of wild-type Rho at equivalent protein concentrations and underwent a decrease in relative fluorescence intensity at 350 nm when 100 muM ATP was added in the presence or absence of RNA. Titration of this fluorescence quenching with varying concentrations of ATP (0-600 muM), where Rho is shown to exist as a hexamer (400 nm Rho), revealed tight and loose ATP-binding sites. Bicyclomycin, a specific inhibitor of Rho, increased the tight ATP binding and was used to calibrate ATP-induced fluorescence quenching by using [gamma-P-32]ATP filter binding. For the Rho mutant F355W, three tight (K-d1, = 3 +/- 0.3 muM) and three loose (K-d2 = 58 +/- 3 muM) ATP-binding sites per hexamer were seen on Scatchard analysis in the absence of bicyclomycin and poly(C). In the presence of bicyclomycin, the K-d1 changed from 3.0 to 1.4 muM, but K-d2 underwent a lesser change. The non-hydrolyzable ATP analogue, gamma-S-ATP, gave a similar profile with three tight (K-d1 = 0.2 muM) and three loose (K-d2 = 70 pm) ATP-binding sites per hexamer. Adding poly(C) to F355W did not alter the K-d1 or K-d2 for ATP or for gamma-S-ATP. ADP-induced quenching produced 5.5 loose (K-d = 92 muM) binding sites in the absence of poly(C), and the binding became weaker (K-d = 175 muM) in the presence of poly(C). The data suggest that in the presence of ADP Rho has six equivalent nucleotide-binding sites. When ATP was added these sites converted to three tight and three loose binding loci. We propose an alternating ATP site mechanism where ATP binding creates heterogeneity in the ATP binding in adjacent subunits, and we suggest that ATP binding to a neighboring loose site stimulates hydrolysis at a neighboring tight binding site such that all six subunits can be potential "active" sites for ATP hydrolysis. The dynamic nature of the ATP binding to Rho is discussed in the terms of the mechanism of RNA tracking driven by ATP hydrolysis.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA	University of Houston System; University of Houston; University of North Carolina; University of North Carolina Chapel Hill	Widger, WR (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.				NIGMS NIH HHS [GM37934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; Boyer PD, 1998, ANGEW CHEM INT EDIT, V37, P2297, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2296::AID-ANIE2296>3.0.CO;2-W; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CROSS RL, 1975, BIOCHEMISTRY-US, V14, P392, DOI 10.1021/bi00673a028; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; Kim DE, 1999, J BIOL CHEM, V274, P32667, DOI 10.1074/jbc.274.46.32667; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; Koshland DE, 2002, J BIOL CHEM, V277, P46841, DOI 10.1074/jbc.R200014200; Magyar A, 1999, J BIOL CHEM, V274, P7316, DOI 10.1074/jbc.274.11.7316; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; Moyse KA, 2001, BBA-GENE STRUCT EXPR, V1520, P223, DOI 10.1016/S0167-4781(01)00271-8; Moyse KA, 2000, J MOL BIOL, V302, P565, DOI 10.1006/jmbi.2000.4090; ODA T, 1972, J MOL BIOL, V71, P799; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; Vincent F, 2000, BIOCHEMISTRY-US, V39, P9077, DOI 10.1021/bi000504+; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Walstrom KM, 1998, J MOL BIOL, V279, P713, DOI 10.1006/jmbi.1998.1814; WANG Y, 1993, J BIOL CHEM, V268, P13940; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Wei RR, 2001, J MOL BIOL, V314, P1007, DOI 10.1006/jmbi.2000.5207; Xu Y, 2002, J BIOL CHEM, V277, P30023, DOI 10.1074/jbc.M111009200; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810	47	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13719	13727		10.1074/jbc.M212979200	http://dx.doi.org/10.1074/jbc.M212979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12551938	hybrid			2022-12-27	WOS:000182405000022
J	Bondarava, N; De Pascalis, L; Al-Babili, S; Goussias, C; Golecki, JR; Beyer, P; Bock, R; Krieger-Liszkay, A				Bondarava, N; De Pascalis, L; Al-Babili, S; Goussias, C; Golecki, JR; Beyer, P; Bock, R; Krieger-Liszkay, A			Evidence that cytochrome b(559) mediates the oxidation of reduced plastoquinone in the dark	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; II REACTION-CENTER; PHOTOSYSTEM-II; THYLAKOID MEMBRANE; AXIAL LIGANDS; FLUORESCENCE; CHLOROPLASTS; B-559; CHLOROPHYLL; COMPLEX	The function of cytochrome b(559) in photosystem II (PSII) was investigated using a mutant created in tobacco in which the conserved phenylalanine at position 26 in the beta-subunit (PsbF) was changed to serine (Bock, R., Kossel, H., and Maliga, P. (1994) EMBO J. 13, 4623-4628). The mutant grew photoautotrophically, but the amount of PSII was reduced and the ultrastructure of the chloroplast was dramatically altered. Very few grana stacks were formed in the mutant. Although isolated PSII-enriched membrane fragments showed low PSII activity, electron paramagnetic resonance indicated the presence of functional PSII Difference absorption spectra showed that the cytochrome b(559) contained heme. The plastoquinone pool was largely reduced in dark-adapted leaves of the mutant, based on chlorophyll fluorescence and thermoluminescence measurements. We therefore propose that cytochrome b(559) plays an important role in PSII by keeping the plastoquinone pool and thereby the acceptor side of PSII oxidized in the dark. Structural alterations as induced by the single Phe --> Ser point mutation in the transmembrane domain of PsbF evidently inhibit this function.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Freiburg, Inst Biochem Pflanzen, D-79104 Freiburg, Germany; Univ Freiburg, Inst Zellbiol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Mikrobiol, D-79104 Freiburg, Germany; CNRS, URA 2096, Serv Bioenerget, Commissariat Energie Atom Saclay, F-91191 Gif Sur Yvette, France; Univ Munster, Inst Biochem & Biotechnol, D-48143 Munster, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Munster	Krieger-Liszkay, A (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.		Bock, Ralph/B-4352-2009	Bock, Ralph/0000-0001-7502-6940; Al-Babili, Salim/0000-0003-4823-2882; Krieger-Liszkay, Anja/0000-0001-7141-4129				ALBERTSSON PA, 1990, FEBS LETT, V273, P36, DOI 10.1016/0014-5793(90)81045-P; Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; ANANYEV G, 1994, PHOTOSYNTH RES, V41, P327, DOI 10.1007/BF00019410; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BERGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V682, P452, DOI 10.1016/0005-2728(82)90060-3; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/j.1460-2075.1994.tb06784.x; BUTLER WL, 1973, BIOCHIM BIOPHYS ACTA, V292, P140, DOI 10.1016/0005-2728(73)90258-2; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; DUCRUET JM, 1992, PHOTOSYNTH RES, V33, P15, DOI 10.1007/BF00032979; Fiege R, 1996, FEBS LETT, V387, P33, DOI 10.1016/0014-5793(96)00458-9; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; Joet T, 2002, J BIOL CHEM, V277, P31623, DOI 10.1074/jbc.M203538200; Kieselbach T, 1998, J BIOL CHEM, V273, P6710, DOI 10.1074/jbc.273.12.6710; Krieger A, 1998, PLANTA, V205, P587, DOI 10.1007/s004250050360; Kruk J, 2001, J BIOL CHEM, V276, P86, DOI 10.1074/jbc.M003602200; Kruk J, 1999, PHOTOSYNTH RES, V62, P273, DOI 10.1023/A:1006374319191; LAASCH H, 1987, PLANTA, V171, P220, DOI 10.1007/BF00391097; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; Morais F, 2001, J BIOL CHEM, V276, P31986, DOI 10.1074/jbc.M103935200; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEWMAN GR, 1983, HISTOCHEM J, V15, P543, DOI 10.1007/BF01954145; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; TAE GS, 1994, BIOCHEMISTRY-US, V33, P10060, DOI 10.1021/bi00199a033; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; VANDORSSEN RJ, 1987, BIOCHIM BIOPHYS ACTA, V890, P134, DOI 10.1016/0005-2728(87)90014-4; VASS I, 1992, PHOTOSYSTEMS STRUCTU, P259; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WATSON ML, 1958, J BIOPHYS BIOCHEM CY, V4, P475, DOI 10.1083/jcb.4.4.475; WHITMARSH J, 1978, BIOCHIM BIOPHYS ACTA, V501, P83, DOI 10.1016/0005-2728(78)90097-X; ZIMMERMANN JL, 1986, BIOCHIM BIOPHYS ACTA, V851, P416, DOI 10.1016/0005-2728(86)90078-2; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	41	70	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13554	13560		10.1074/jbc.M212842200	http://dx.doi.org/10.1074/jbc.M212842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571242	hybrid			2022-12-27	WOS:000182189500120
J	Chikamori, K; Grabowski, DR; Kinter, M; Willard, BB; Yadav, S; Aebersold, RH; Bukowski, RM; Hickson, ID; Andersen, AH; Ganapathi, R; Ganapathi, MK				Chikamori, K; Grabowski, DR; Kinter, M; Willard, BB; Yadav, S; Aebersold, RH; Bukowski, RM; Hickson, ID; Andersen, AH; Ganapathi, R; Ganapathi, MK			Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; METABOTROPIC GLUTAMATE RECEPTORS; DNA TOPOISOMERASE; CELL-CYCLE; MITOTIC PHOSPHORYLATION; PROTEIN PHOSPHATASES; TERMINAL DOMAIN; HL-60 CELLS; EXPRESSION; ETOPOSIDE	Topoisomerases alter DNA topology and are vital for the maintenance of genomic integrity. Topoisomerases I and II are also targets for widely used antitumor agents. We demonstrated previously that in the human leukemia cell line, HL-60, resistance to topoisomerase (topo) II-targeting drugs such as etoposide is associated with site-specific hypophosphorylation of topo IIalpha. This effect can be mimicked in sensitive cells treated with the intracellular Ca2+ chelator, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM). Here we identify Ser-1106 as a major phosphorylation site in the catalytic domain of topo IIalpha. This site lies within the consensus sequence for the acidotrophic kinases, casein kinase I and casein kinase II. Mutation of serine 1106 to alanine (S1106A) abrogates phosphorylation of phosphopeptides that were found to be hypophosphorylated in resistant HL-60 cells or sensitive cells treated with BAPTA-AM. Purified topo IIalpha containing a S1106A substitution is 4-fold less active than wild type topo IIalpha in decatenating kinetoplast DNA and also exhibits a 2-4-fold decrease in the level of etoposide-stabilized DNA cleavable complex formation. Saccharomyces cerevisiae (JN394t2-4) cells expressing S1106A mutant topo IIalpha protein are more resistant to the cytotoxic effects of etoposide or amsacrine. These results demonstrate that Ca2+-regulated phosphorylation of Ser-1106 in the catalytic domain of topo IIalpha modulates the enzymatic activity of this protein and sensitivity to topo II-targeting drugs.	Cleveland Clin Fdn, Taussig Canc Ctr, Expt Therapeut Program, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Inst Syst Biol, Seattle, WA 98103 USA; Canc Res UK, Oxford Canc Ctr, Oxford OX3 9DS, England; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Institute for Systems Biology (ISB); Cancer Research UK; Aarhus University	Ganapathi, MK (corresponding author), Cleveland Clin Fdn, Taussig Canc Ctr, Expt Therapeut Program, R40,9500 Euclid Ave, Cleveland, OH 44195 USA.	ganapam@ccf.org	Andersen, Anni/O-1162-2017; Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X; Kinter, Michael/0000-0001-7409-8918; Andersen, Anni/0000-0001-7194-3258	NATIONAL CANCER INSTITUTE [R01CA074939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056917] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA74939] Funding Source: Medline; NIDDK NIH HHS [R01 DK56917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; Aoyama M, 1998, BIOCHEM J, V336, P727, DOI 10.1042/bj3360727; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DEVORE RF, 1992, CANCER RES, V52, P2156; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Ganapathi R, 1996, MOL PHARMACOL, V50, P243; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; HECK MMS, 1989, J BIOL CHEM, V264, P15161; Hsiung Y, 1996, CANCER RES, V56, P91; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; Jensen S, 1996, MOL CELL BIOL, V16, P3866; Kellner U, 2002, LANCET ONCOL, V3, P235, DOI 10.1016/S1470-2045(02)00715-5; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; KINTER M, 2000, PROTEIN SEQUENCING I, P147, DOI DOI 10.1002/0471721980; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Liu F, 2002, J BIOL CHEM, V277, P45393, DOI 10.1074/jbc.M204499200; Liu F, 2001, P NATL ACAD SCI USA, V98, P11062, DOI 10.1073/pnas.191353898; MARINI JC, 1980, J BIOL CHEM, V255, P4976; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; RITKE MK, 1995, MOL PHARMACOL, V48, P798; Ruse CI, 2002, ANAL CHEM, V74, P1658, DOI 10.1021/ac0157122; TAKANO H, 1991, CANCER RES, V51, P3951; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	41	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12696	12702		10.1074/jbc.M300837200	http://dx.doi.org/10.1074/jbc.M300837200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569090	hybrid			2022-12-27	WOS:000182189500015
J	Darst, RP; Dasgupta, A; Zhu, CM; Hsu, JY; Vroom, A; Muldrow, T; Auble, DT				Darst, RP; Dasgupta, A; Zhu, CM; Hsu, JY; Vroom, A; Muldrow, T; Auble, DT			Mot1 regulates the DNA binding activity of free TATA-binding protein in an ATP-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; POLYMERASE-II TRANSCRIPTION; GENE-EXPRESSION; BOX-BINDING; IN-VIVO; TBP BINDING; CRYSTAL-STRUCTURE; NUCLEAR IMPORT; FAMILY MEMBER; COMPLEX	Mot1 is an essential Snf2/Swi2-related Saccharomyces cerevisiae protein that binds the TATA-binding protein (TBP) and removes TBP from DNA using ATP hydrolysis. Mot1 functions in vivo both as a repressor and as an activator of transcription. Mot1 catalysis of TBP-DNA disruption is consistent with its function as a repressor, but the Mot1 mechanism of activation is unknown. To better understand the physiologic role of Mot1 and its enzymatic mechanism, MOT1 mutants were generated and tested for activity in vitro and in vivo. The results demonstrate a close correlation between the TBP(.)DNA disruption activity of Mot1 and its essential in vivo function. Previous results demonstrated a large overlap in the gene sets controlled by Mot1 and NC2. Mot1 and NC2 can co-occupy TBP-DNA in vitro, and NC2 binding does not impair Mot1-catalyzed disruption of the complex. Residues on the DNA-binding surface of TBP are important for Mot1 binding and the Mot1(.)TBP binary complex binds very poorly to DNA and does not dissociate in the presence of ATP. However, the binary complex binds DNA well in the presence of the transition state analog ADP-AlF4. A model for Mot1 action is proposed in which ATP hydrolysis causes the Mot1 N terminus to displace the TATA box, leading to ejection of Mot1 and TBP from DNA.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Auble, DT (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055763] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55763, R01 GM055763] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamkewicz JI, 2000, J BIOL CHEM, V275, P21158, DOI 10.1074/jbc.M002639200; Adamkewicz JI, 2001, J BIOL CHEM, V276, P11883, DOI 10.1074/jbc.M010665200; Andrade MA, 2000, J MOL BIOL, V298, P521, DOI 10.1006/jmbi.2000.3684; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrau JC, 2002, EMBO J, V21, P5173, DOI 10.1093/emboj/cdf485; Auble DT, 1999, MOL CELL BIOL, V19, P412; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; Banik U, 2001, J BIOL CHEM, V276, P49100, DOI 10.1074/jbc.M109246200; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Darst RP, 2001, EMBO J, V20, P2028, DOI 10.1093/emboj/20.8.2028; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Geisberg JV, 2001, MOL CELL BIOL, V21, P2736, DOI 10.1128/MCB.21.8.2736-2742.2001; GoldmanLevi R, 1996, NUCLEIC ACIDS RES, V24, P3121, DOI 10.1093/nar/24.16.3121; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guthrie C., 1991, GUIDE YEAST GENETICS, P194; Guyon JR, 2001, MOL CELL BIOL, V21, P1132, DOI 10.1128/MCB.21.4.1132-1144.2001; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; KARNITZ L, 1992, GENETICS, V132, P351; Kim TK, 1997, J BIOL CHEM, V272, P7540, DOI 10.1074/jbc.272.11.7540; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lemaire M, 2000, MOL MICROBIOL, V36, P163, DOI 10.1046/j.1365-2958.2000.01839.x; Leung DW, 1989, TECHNIQUE, V1, P11; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MARUTA S, 1993, J BIOL CHEM, V268, P7093; Morehouse H, 1999, P NATL ACAD SCI USA, V96, P12542, DOI 10.1073/pnas.96.22.12542; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; Pereira LA, 2001, MOL CELL BIOL, V21, P7523, DOI 10.1128/MCB.21.21.7523-7534.2001; PIATTI S, 1992, CHROMOSOMA, V102, P107; POON D, 1994, J BIOL CHEM, V269, P23135; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIKORSKI RS, 1989, GENETICS, V122, P19; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7	56	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13216	13226		10.1074/jbc.M211445200	http://dx.doi.org/10.1074/jbc.M211445200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571241	hybrid			2022-12-27	WOS:000182189500080
J	Chandrasekera, CP; Lytton, J				Chandrasekera, CP; Lytton, J			Inhibition of human SERCA3 by PL/IM430 - Molecular analysis of the interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM CA-ATPASE; SARCOPLASMIC-RETICULUM; MESSENGER-RNA; CALCIUM PUMPS; DEPENDENT RELAXATION; SMOOTH-MUSCLE; CA-2+ PUMP; CA2+-ATPASE; GENE; EXPRESSION	The monoclonal antibody PL/IM430 has previously been reported to uncouple Ca2+ transport from ATP hydrolysis in platelet membranes (Hack, N., Wilkinson, J. M., and Crawford, N. (1988) Biochem. J. 250,355-361). More recently, we have demonstrated that this antibody is specific for human SERCA3 (Poch, E., Leach, S., Snape, S., Cacic, T., MacLennan, D. H., and Lytton, J. (1998) Am. J. Physiol. 275, C1449-CI458). In this paper, we have extended the analysis of the PL/IM430-SERCA3 interaction. Using HEK293 cells to express human SERCA3a, we were able to measure bot ATP-mediated, oxalate-dependent Ca-45(2+) uptake and Ca2+-dependent ATP hydrolysis activities due exclusively to SERCA3. Treatment with PL/IM430 inhibited both activities almost identically, with a maximal inhibition of 81 and 73% and a half-maximal concentration of 8.3 and 5.9 mug/ml, for Ca2+ uptake and ATP hydrolysis, respectively. We conclude that PL/IM430 does inhibit SERCA3 activity but does not uncouple Ca2+ transport from ATP hydrolysis. Using a combination of partial proteolysis, GST fusion protein expression, and mutation of residues that differ between rat and human SERCA3, we have identified human SERCA3 amino acids Pros and Glu(192) as essential to forming the PL/IM430 epitope. PL/IM430 thus recognizes a linearly noncontiguous set of amino acids within the actuator domain of human SERCA3. We propose that PL/IM430 inhibits SERCA3 activity by sterically preventing movement of the actuator domain into a catalytically critical position in the E2 conformation of the enzyme.	Univ Calgary, Hlth Sci Ctr, Cardiovasc Res Grp, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Cardiovasc Res Grp, Dept Biochem & Mol Biol, Rm 2518,3330 Hosp Dr,NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Lytton, Jonathan/0000-0003-4770-2512				ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANGER M, 1993, FEBS LETT, V334, P45, DOI 10.1016/0014-5793(93)81677-R; ANGER M, 1994, J MOL CELL CARDIOL, V26, P539, DOI 10.1006/jmcc.1994.1064; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; East JM, 2000, MOL MEMBR BIOL, V17, P189, DOI 10.1080/09687680010009646; FRASSETTO SS, 1993, MOL CELL BIOCHEM, V129, P47, DOI 10.1007/BF00926575; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Martin V, 2002, J BIOL CHEM, V277, P24442, DOI 10.1074/jbc.M202011200; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; PAPP B, 1991, J BIOL CHEM, V266, P14593; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; ROE MW, 1994, J BIOL CHEM, V269, P18279; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775	33	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12482	12488		10.1074/jbc.M212745200	http://dx.doi.org/10.1074/jbc.M212745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540840	hybrid			2022-12-27	WOS:000182015700099
J	Koizumi, H; Yamaguchi, N; Hattori, M; Ishikawa, TO; Aoki, J; Taketo, MM; Inoue, K; Arai, H				Koizumi, H; Yamaguchi, N; Hattori, M; Ishikawa, TO; Aoki, J; Taketo, MM; Inoue, K; Arai, H			Targeted disruption of intracellular type I platelet activating factor-acetylhydrolase catalytic subunits causes severe impairment in spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIEKER LISSENCEPHALY GENE; NEURONAL MIGRATION; LIS1; PROTEIN; PURIFICATION; EXPRESSION; REDUCTION; SUBSTRATE; MOUSE	Intracellular type I platelet activating factor-acetylhydrolase is a phospholipase that consists of a dimer of two homologous catalytic subunits alpha1 and alpha2 as well as LIS1, a product of the causative gene for type I lissencephaly. LIS1 plays an important role in neuronal migration during brain development, but the in vivo function of the catalytic subunits remains unclear. In this study, we generated alpha1- and alpha2-deficient mice by targeted disruption. alpha1(-/-) mice are indistinguishable from wild-type mice, whereas alpha2(-/-) male mice show a significant reduction in testis size. Double-mutant male mice are sterile because of severe impairment of spermatogenesis. Histological examination revealed marked degeneration at the spermatocyte stage and an increase of apoptotic cells in the seminiferous tubules. The catalytic subunits are expressed at high levels in testis as well as brain in mice. In wild-type mice, alpha2 is expressed in all seminiferous tubule cell types, whereas alpha1 is expressed only in the spermatogonia. This expression pattern parallels the finding that deletion of both subunits induces a marked loss of germ cells at an early spermatogenic stage. We also found that the LIS1 protein levels, but not the mRNA levels, were significantly reduced in alpha2(-/-) and double-mutant mice, suggesting that the catalytic subunits, especially alpha2, are a determinant of LIS1 expression level.	Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Lab Biomed Genet, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Banyu Tsukuba Res Inst, Merck, Tsukuba, Ibaraki 3000026, Japan	University of Tokyo; University of Tokyo; Merck & Company	Arai, H (corresponding author), Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	harai@mol.f.u-tokyo.ac.jp	Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969; Aoki, Junken/0000-0001-9435-1896				Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; Bazan NG, 1998, PROG BRAIN RES, V118, P281; Chiarini-Garcia H, 2001, BIOL REPROD, V65, P1179, DOI 10.1095/biolreprod65.4.1179; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1; Lecointe N, 1999, ONCOGENE, V18, P2852, DOI 10.1038/sj.onc.1202645; Levine AS, 2002, J ANDROL, V23, P471; Maclennan KM, 1996, PROG NEUROBIOL, V50, P585, DOI 10.1016/S0301-0082(96)00047-0; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Minhas BS, 1996, AM J REPROD IMMUNOL, V35, P267; Mori C, 1997, DEV DYNAM, V208, P125; Nagano M, 1999, BIOL REPROD, V60, P1429, DOI 10.1095/biolreprod60.6.1429; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nothwang HG, 2001, HUM MOL GENET, V10, P797, DOI 10.1093/hmg/10.8.797; Parreira GG, 1998, BIOL REPROD, V59, P1360, DOI 10.1095/biolreprod59.6.1360; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RICKER DD, 1989, FERTIL STERIL, V52, P655; Roudebush WE, 2000, FERTIL STERIL, V74, P257, DOI 10.1016/S0015-0282(00)00646-4; Roudebush WE, 2001, THERIOGENOLOGY, V55, P1633, DOI 10.1016/S0093-691X(01)00508-8; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0	34	69	72	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12489	12494		10.1074/jbc.M211836200	http://dx.doi.org/10.1074/jbc.M211836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551946	hybrid			2022-12-27	WOS:000182015700100
J	Guillard, C; Chretien, S; Pelus, AS; Porteu, F; Muller, O; Mayeux, P; Duprez, V				Guillard, C; Chretien, S; Pelus, AS; Porteu, F; Muller, O; Mayeux, P; Duprez, V			Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i) protein beta gamma-subunit-initiated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ERYTHROID-DIFFERENTIATION; TYROSINE-PHOSPHORYLATED PROTEIN; NUCLEOTIDE EXCHANGE FACTOR; RAS-DEPENDENT ACTIVATION; AIRWAY SMOOTH-MUSCLE; MAP KINASE; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO	We have recently shown that a heterotrimeric G(i) protein is coupled to the erythropoietin (Epo) receptor. The G(i) protein constitutively associates in its heterotrimeric form with the intracellular domain of Epo receptor (EpoR). After Epo stimulation G(i) is released from the receptor and activated. In the present study we have investigated the functional role of the heterotrimeric G(i) protein bound to EpoR. In Chinese hamster ovary cells expressing EpoR, the G(i) inhibitor pertussis toxin blocked mitogen-activated protein kinase (MAPK) Erk1/2 activation induced by Epo. Epo-dependent MAPK activation was also sensitive to the Gbetagamma competitive inhibitor betaARK1-ct (C-terminal fragment of the beta-adrenergic receptor kinase), to the Ras dominant negative mutant RasN17, and to the phosphoinositide 3-kinase (PI3K) inhibitor LY 294002. A region of 7 amino acids (469-475) in the C-terminal end of EpoR was shown to be required for G(i) binding to EpoR in vivo. Deletion of this region in EpoR abolished both MAPK and PI3K activation in response to Epo. We conclude that in Chinese hamster ovary cells, Epo activates MAPK via a novel pathway dependant on G(i) association to EpoR, Gbetagamma subunit, Ras, and PI3K. The tyrosine kinase Jak2 also contributes to this new pathway, more likely downstream of betagamma and upstream of Ras and PI3K. This pathway is similar to the best characterized pathway used by seven transmembrane receptors coupled to G(i) to activate MAPK and may cooperate with other described Epo-dependent MAPK activation pathways in hematopoietic cells.	Univ Paris 05, CNRS UMR 8104, INSERM U567, Inst Cochin,Dept Hematol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Duprez, V (corresponding author), Univ Paris 05, CNRS UMR 8104, INSERM U567, Inst Cochin,Dept Hematol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		PORTEU, Françoise/I-8445-2016; Chretien, Stany/M-5166-2018	PORTEU, Françoise/0000-0002-2403-4163; 				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN J, 1992, BLOOD, V80, P1923; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Devemy E, 1997, CELL SIGNAL, V9, P41, DOI 10.1016/S0898-6568(96)00095-2; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duprez V, 1998, J BIOL CHEM, V273, P33985, DOI 10.1074/jbc.273.51.33985; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Guillard C, 2001, J BIOL CHEM, V276, P2007, DOI 10.1074/jbc.M003527200; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; MILLER BA, 1991, BLOOD, V77, P486; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TORTI M, 1992, J BIOL CHEM, V267, P8293; VAN BT, 1995, NATURE, V376, P781; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Yu XB, 2002, DEVELOPMENT, V129, P505	69	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11050	11056		10.1074/jbc.M208834200	http://dx.doi.org/10.1074/jbc.M208834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538595	hybrid			2022-12-27	WOS:000181855400025
J	Hara, N; Yamada, K; Terashima, M; Osago, H; Shimoyama, M; Tsuchiya, M				Hara, N; Yamada, K; Terashima, M; Osago, H; Shimoyama, M; Tsuchiya, M			Molecular identification of human glutamine- and ammonia-dependent NAD synthetases - Carbon-nitrogen hydrolase domain confers glutamine dependency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ADP-RIBOSE; GENE; ENZYME; EXPRESSION; NITRILASE; CLONING; FAMILY; BIOSYNTHESIS	NAD synthetase catalyzes the final step in the biosynthesis of NAD. In the present study, we obtained cDNAs for two types of human NAD synthetase (referred as NADsyn1 and NADsyn2). Structural analysis revealed in both NADsyn1 and NADsyn2 a domain required for NAD synthesis from ammonia and in only NADsyn1 an additional carbon-nitrogen hydrolase domain shared with enzymes of the nitrilase family that cleave nitriles as well as amides to produce the corresponding acids and ammonia. Consistent with the domain structures, biochemical assays indicated (i) that both NADsyn1 and NADsyn2 have NAD synthetase activity, (ii) that NADsyn1 uses glutamine as well as ammonia as an amide donor, whereas NADsyn2 catalyzes only ammonia-dependent NAD synthesis, and (iii) that mutant NADsyn1 in which Cys-175 corresponding to the catalytic cysteine residue in nitrilases was replaced with Ser does not use glutamine. Kinetic studies suggested that glutamine and ammonia serve as physiological amide donors for NADsyn1 and NADsyn2, respectively. Both synthetases exerted catalytic activity in a multimeric form. In the mouse, NADsyn1 was seen to be abundantly expressed in the small intestine, liver, kidney, and testis but very weakly in the skeletal muscle and heart. In contrast, expression of NADsyn2 was observed in all tissues tested. Therefore, we conclude that humans have two types of NAD synthetase exhibiting different amide donor specificity and tissue distributions. The ammonia-dependent synthetase has not been found in eucaryotes until this study. Our results also indicate that the carbon-nitrogen hydrolase domain is the functional domain of NAD synthetase to make use of glutamine as an amide donor in NAD synthesis. Thus, glutamine-dependent NAD synthetase may be classified as a possible glutamine amidase in the nitrilase family. Our molecular identification of NAD synthetases may prove useful to learn more of mechanisms regulating cellular NAD metabolism.	Shimane Med Univ, Dept Biochem, Izumo, Shimane 6938501, Japan	Shimane University	Tsuchiya, M (corresponding author), Shimane Med Univ, Dept Biochem, 89-1, Izumo, Shimane 6938501, Japan.							Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; BORK P, 1994, PROTEIN SCI, V3, P1344, DOI 10.1002/pro.5560030821; Cantoni R, 1998, J BACTERIOL, V180, P3218, DOI 10.1128/JB.180.12.3218-3221.1998; Elgadi KM, 1999, PHYSIOL GENOMICS, V1, P51, DOI 10.1152/physiolgenomics.1999.1.2.51; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; FOSTER JW, 1980, MICROBIOL REV, V44, P83, DOI 10.1128/MMBR.44.1.83-105.1980; Fukuoka S, 1998, BBA-GENE STRUCT EXPR, V1395, P192, DOI 10.1016/S0167-4781(97)00143-7; Haag F, 1998, J BIOL REG HOMEOS AG, V12, P53; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; NESSI C, 1995, J BIOL CHEM, V270, P6181, DOI 10.1074/jbc.270.11.6181; NOVO C, 1995, FEBS LETT, V367, P275, DOI 10.1016/0014-5793(95)00585-W; Okazaki IJ, 1998, J BIOL CHEM, V273, P23617, DOI 10.1074/jbc.273.37.23617; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; SPENCER RL, 1967, J BIOL CHEM, V242, P385; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TRITZ GJ, 1987, ESCHERICHIA COLI SAL, P557; White III H. B., 1982, PYRIDINE NUCLEOTIDE, P1; WILLISON JC, 1994, J BACTERIOL, V176, P3400, DOI 10.1128/jb.176.11.3400-3402.1994; YU CK, 1972, J BIOL CHEM, V247, P4794; ZALKIN H, 1985, METHOD ENZYMOL, V113, P297; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; ZEREZ CR, 1990, BLOOD, V75, P1576	31	55	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10914	10921		10.1074/jbc.M209203200	http://dx.doi.org/10.1074/jbc.M209203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547821	hybrid			2022-12-27	WOS:000181855400007
J	Koprowski, P; Kubalski, A				Koprowski, P; Kubalski, A			C termini of the Escherichia coli mechanosensitive ion channel (MscS) move apart upon the channel opening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; CRYSTAL-STRUCTURE; GATING MECHANISM; ACTIVATION; SUBUNIT; PROTEIN; IDENTIFICATION; ADAPTATION; DOMAINS; BINDING	Heptameric YggB is a mechanosensitive ion channel (MscS) from the inner membrane of Escherichia coli. We demonstrate, using the patch clamp technique, that cross-linking of the YggB C termini led to irreversible inhibition of the channel activities. Application of Ni2+ to the YggB-His, channels with the hexahistidine tags added to the ends of their C termini also resulted in a marked but reversible decrease of activities. Western blot revealed that YggB-His, oligomers are more stable in the presence of Ni2+, providing evidence that Ni2+ is coordinated between C termini from different subunits of the channel. Intersubunit coordination of Ni2+ affecting channel activities occurred in the channel closed conformation and not in the open state. This may suggest that the C termini move apart upon channel opening and are involved in the channel activation. We propose that the as yet undefined C-terminal region may form a cytoplasmic gate of the channel. The results are discussed and interpreted based on the recently released quaternary structure of the channel.	M Nencki Inst Expt Biol, Dept Cell Biol, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kubalski, A (corresponding author), M Nencki Inst Expt Biol, Dept Cell Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	kubalski@nencki.gov.pl	Koprowski, Piotr R/R-4088-2016	Koprowski, Piotr R/0000-0002-7571-2446				Ajouz B, 1998, J BIOL CHEM, V273, P26670, DOI 10.1074/jbc.273.41.26670; Anishkin A, 2002, BIOPHYS J, V82, p269A; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Batiza AF, 2002, P NATL ACAD SCI USA, V99, P5643, DOI 10.1073/pnas.082092599; Batiza AF, 1999, STRUCTURE, V7, pR99, DOI 10.1016/S0969-2126(99)80061-6; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Bezanilla F, 2002, SCIENCE, V298, P1562, DOI 10.1126/science.1079369; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kloda A, 2001, BIOPHYS J, V80, P229, DOI 10.1016/S0006-3495(01)76009-2; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; Koprowski P, 1998, J MEMBRANE BIOL, V164, P253, DOI 10.1007/s002329900410; Koprowski P, 2001, BIOESSAYS, V23, P1148, DOI 10.1002/bies.10017; KUBALSKI A, 1995, BBA-BIOMEMBRANES, V1238, P177, DOI 10.1016/0005-2736(95)00126-N; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; McLaggan D, 2002, MOL MICROBIOL, V43, P521, DOI 10.1046/j.1365-2958.2002.02764.x; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; Okada K, 2002, J BIOL CHEM, V277, P27682, DOI 10.1074/jbc.M202497200; Paar JM, 2002, J IMMUNOL, V169, P856, DOI 10.4049/jimmunol.169.2.856; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; SILLEN LG, 1971, STABILITY CONSTAN S, V1; Sukharev S, 2002, BIOPHYS J, V83, P290, DOI 10.1016/S0006-3495(02)75169-2; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; Zhou BY, 1998, J GEN PHYSIOL, V111, P555, DOI 10.1085/jgp.111.4.555	38	59	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11237	11245		10.1074/jbc.M212073200	http://dx.doi.org/10.1074/jbc.M212073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551944	hybrid			2022-12-27	WOS:000181855400050
J	Takahashi, S; Saito, T; Hisanaga, S; Pant, HC; Kulkarni, AB				Takahashi, S; Saito, T; Hisanaga, S; Pant, HC; Kulkarni, AB			Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK5 ACTIVATOR P35; PROTEIN-KINASE; NEURITE OUTGROWTH; ABNORMAL PHOSPHORYLATION; REGULATORY SUBUNIT; RECOMBINANT TAU; MESSENGER-RNA; FETAL-TAU; EXPRESSION; LOCALIZATION	The microtubule-associated protein tau is a developmentally regulated neuronal phosphoprotein. The phosphorylation of tau reduces its ability to bind and stabilize axonal microtubules during axonal growth. Although tau is phosphorylated by cyclin-dependent kinase 5 (Cdk5) in vitro, its in vivo roles remain unclear. Here, we show that tau is phosphorylated by Cdk5/p39 during brain development, resulting in a reduction of its affinity for microtubules. The activity of Cdk5 is tightly regulated by association with its neuronal activators, p35 or p39. The p35 and p39 expression levels were investigated in the developing mouse brain; the p39 expression level was higher in embryonic hind brain and spinal cord and in postnatal cerebral cortex, whereas that of p35 was most prominent in cerebral cortex at earlier stages of development. The ability of Cdk5 to phosphorylate tau was higher when in association with p39 than in association with p35. Tau phosphorylation at Ser-202 and Thr-205 was decreased in Cdk5-/- mouse brain but not in p35-/- mouse brain, suggesting that Cdk5/p39 is responsible for the in vivo phosphorylation of tau at these sites. Our data suggest that tau phosphorylation by Cdk5 may provide the neuronal microtubules with dynamic properties in a region-specific and developmentally regulated manner.	NIDCR, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; Tokyo Metropolitan Univ, Dept Biol Sci, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Tokyo Metropolitan University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Kulkarni, AB (corresponding author), NIDCR, Funct Genom Unit, NIH, Bldg 30,Rm 527,30 Convent Dr, Bethesda, MD 20892 USA.	ak40m@nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000698, Z01DE000698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002725, Z01NS002725] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; AVILA J, 1994, INT J DEV BIOL, V38, P13; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1994, NEUROSCIENCE, V63, P895, DOI 10.1016/0306-4522(94)90533-9; BRION JP, 1993, J NEUROCHEM, V61, P2071, DOI 10.1111/j.1471-4159.1993.tb07444.x; CACERES A, 1991, J NEUROSCI, V11, P1515; Cai XH, 1997, NEUROSCI RES, V28, P355, DOI 10.1016/S0168-0102(97)00063-1; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Humbert S, 2000, NEUROREPORT, V11, P2213, DOI 10.1097/00001756-200007140-00030; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KENESSEY A, 1993, BRAIN RES, V629, P40, DOI 10.1016/0006-8993(93)90478-6; Ko J, 2001, J NEUROSCI, V21, P6758; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ohshima T, 2002, J NEUROSCI, V22, P4036, DOI 10.1523/JNEUROSCI.22-10-04036.2002; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; Ohshima T, 1996, GENOMICS, V35, P372, DOI 10.1006/geno.1996.0370; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PIERRE M, 1983, BIOCHEM BIOPH RES CO, V115, P212, DOI 10.1016/0006-291X(83)90991-9; Pigino G, 1997, J CELL SCI, V110, P257; RIEDERER BM, 1992, HISTOCHEM J, V24, P783, DOI 10.1007/BF01046350; RIEDERER BM, 1994, BRAIN RES BULL, V33, P155, DOI 10.1016/0361-9230(94)90245-3; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; TAKEMURA R, 1991, NEUROSCIENCE, V44, P393, DOI 10.1016/0306-4522(91)90064-U; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Town T, 2002, J NEUROSCI RES, V69, P362, DOI 10.1002/jnr.10299; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wu DC, 2000, NEUROCHEM RES, V25, P923, DOI 10.1023/A:1007544106645; Wullner U, 1998, DEV BRAIN RES, V110, P1, DOI 10.1016/S0165-3806(98)00079-0; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	59	64	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10506	10515		10.1074/jbc.M211964200	http://dx.doi.org/10.1074/jbc.M211964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12536148	hybrid, Green Submitted			2022-12-27	WOS:000181777500069
J	Nieto, N; Cederbaum, AI				Nieto, N; Cederbaum, AI			Increased Sp1-dependent transactivation of the LAM gamma 1 promoter in hepatic stellate cells co-cultured with HepG2 cells overexpressing cytochrome P450 2E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; BASEMENT-MEMBRANES; LIPID-PEROXIDATION; OXIDATIVE STRESS; RECEPTOR LBP-32; FISH-OIL; LAMININ; EXPRESSION; LIVER; GENE	Laminin is a basement-membrane protein that increases in liver fibrosis. To study the role of oxidative stress on laminin expression, hepatic stellate cells (HSC) were co-cultured with HepG2 cells that do or do not express (E47 or C34 cells, respectively) CYP2E1, a potent generator of oxygen radicals. Co-incubation of HSC with E47 cells increased laminin beta1 and gamma1 proteins compared with co-incubation with C34 cells; this increase was prevented by antioxidants and CYP2E1 inhibitors. Similar results were observed in co-culture with primary hepatocytes from saline- or pyrazole-treated (with high levels of CYP2E1) rats. Laminin alpha1 chain was not detectable in the HSC in any of the systems; however, laminin alpha2 chain increased in HSC co-cultured with E47 cells. Synthesis but not turnover of laminin beta1 and gamma1 proteins was increased in HSC in the E47 co-culture. Laminin beta1 and gamma1 mRNAs were up-regulated in HSC in the E47. co-culture because of transcriptional activation of both genes. Transfection experiments in HSC with reporter constructs driven by the laminin gamma1 promoter showed maximal responsiveness with the -230/+106 and the -1400/+106 constructs in the E47 system. Gelshift assays demonstrated an increase in Sp1 binding to the laminin gamma1 promoter in HSC when co-incubated with E47 cells, which was blocked by an anti-Sp1 antibody. Co-transfection of a Sp1 expression vector further increased the responsiveness of the -330LAMgamma1-CAT reporter vector in HSC in the HSC/E47 system. These results show that diffusable CYP2E1-derived oxidative-stress mediators induce synthesis of laminins by a transcriptional mechanism in HSC. Such interactions between hepatocytes and HSC may be important during liver fibrosis.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Nieto, N (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	ny2000@hotmail.com			NIAAA NIH HHS [AA03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA003312, R56AA003312] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALBRECHTSEN R, 1988, HEPATOLOGY, V8, P538, DOI 10.1002/hep.1840080318; BOOTHANDFORD RP, 1987, J BIOL CHEM, V262, P12475; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1524, DOI 10.1016/S0891-5849(01)00741-9; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLEMENT B, 1988, HEPATOLOGY, V8, P794, DOI 10.1002/hep.1840080417; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Engvall E, 1996, J CELL BIOCHEM, V61, P493; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; Kedar V, 1997, MOL BRAIN RES, V47, P87, DOI 10.1016/S0169-328X(97)00062-4; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LEVAVASSEUR F, 1994, J CELL PHYSIOL, V161, P257, DOI 10.1002/jcp.1041610210; Lietard J, 1997, AM J PATHOL, V151, P1663; LIOTTA LA, 1983, LAB INVEST, V49, P636; MAHER JJ, 1994, HEPATOLOGY, V19, P764, DOI 10.1002/hep.1840190332; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; Nieto N, 2002, HEPATOLOGY, V35, P62, DOI 10.1053/jhep.2002.30362; Nieto N, 2002, J BIOL CHEM, V277, P9853, DOI 10.1074/jbc.M110506200; Nieto N, 2001, HEPATOLOGY, V33, P597, DOI 10.1053/jhep.2001.22520; Nieto N, 2000, J BIOL CHEM, V275, P20136, DOI 10.1074/jbc.M001422200; OGAWA K, 1988, J BIOL CHEM, V263, P8384; ONeill BC, 1997, AM J PHYSIOL-RENAL, V273, pF411, DOI 10.1152/ajprenal.1997.273.3.F411; RESCAN PY, 1991, HEPATOLOGY, V13, P289, DOI 10.1016/0270-9139(91)92442-B; RESCAN PY, 1990, AM J PATHOL, V137, P701; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; WEINER FR, 1992, MATRIX, V12, P36, DOI 10.1016/S0934-8832(11)80102-2; WEVER UM, 1992, VIRCHOWS ARCH A, V421, P87; Wu DF, 2001, MOL PHARMACOL, V59, P795, DOI 10.1124/mol.59.4.795; WU DF, 1993, J PHARMACOL EXP THER, V264, P1468; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; Yurchenco P. D., 1994, EXTRACELLULAR MATRIX; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15360	15372		10.1074/jbc.M206790200	http://dx.doi.org/10.1074/jbc.M206790200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12529372	hybrid			2022-12-27	WOS:000182516100101
J	Guo, FK; Gao, Y; Wang, L; Zheng, Y				Guo, FK; Gao, Y; Wang, L; Zheng, Y			P19(Arf)-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; WILD-TYPE P53; RHO-GTPASES; GENE-EXPRESSION; ACTIVATION; GROWTH; BINDING; RAS; FIBROBLASTS; APOPTOSIS	The p19(Arf)-p53 tumor suppressor pathway plays a critical role in cell-cycle checkpoint control and apoptosis, whereas Rho family small GTPases are key regulators of actin structure and cell motility. By using primary mouse embryonic fibroblasts that lack Arf, p53, or both, we studied the involvement of the p19(Arf)-p53 pathway in the regulation of cell motility and its relationship with Rho GTPases. Deletion of Arf and/or p53 led to actin cytoskeleton reorganization and a significant increase in cell motility. The endogenous phosphoinositide (PI) 3-kinase and Rac1 activities were elevated in Arf(-/-) and p53(-/-) cells, and these activities are required for p19(Arf)- and p53-regulated migration. Reintroduction of the wild type Arf or p53 genes into Arf(-/-) or p53(-/-) cells reversed the PI 3-kinase and Rho GTPase activities as well as the migration phenotype. These results suggest a functional relationship between an established tumor suppressor pathway and a signaling module that controls actin structure and cell motility and show that p19(Arf) and p53 negatively regulate cell migration by suppression of PI 3-kinase and Rac1 activities.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM53943] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; Williams DA, 2000, BLOOD, V96, P1646; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao RB, 2000, GENE DEV, V14, P981; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	36	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14414	14419		10.1074/jbc.M300341200	http://dx.doi.org/10.1074/jbc.M300341200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578823	hybrid			2022-12-27	WOS:000182405000108
J	Cao, C; Leng, YM; Li, CF; Kufe, D				Cao, C; Leng, YM; Li, CF; Kufe, D			Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; APOPTOTIC RESPONSE; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; DROSOPHILA-ABL; ACTIVATION; NUCLEAR; BINDING; GENE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE	The AbI family of mammalian nonreceptor tyrosine kinases consists of c-Abl and Arg. Recent work has shown that c-Abl and Arg are activated in the cellular response to oxidative stress. The present studies demonstrate that reactive oxygen species (ROS) induce the formation of c-Abl and Arg heterodimers. The results show that the c-Abl SH3 domain binds directly to a proline-rich site (amino acids 567-576) in the Arg C-terminal region. Formation of c-Abl(.)Arg heterodimers also involves direct binding of the Arg Src homology 3 domain to the C-terminal region of c-Abl. The results further demonstrate that the interaction between c-Abl and Arg involves c-Abl-mediated phosphorylation of Arg. The functional significance of the c-Abl-Arg interaction is supported by the demonstration that both c-Abl and Arg are required for ROS-induced apoptosis. These findings indicate that ROS induce c-Abl(.)Arg heterodinters and that both c-Abl and Arg are necessary as effectors in the apoptotic response to oxidative stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Beijing Inst Biotechnol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.							Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; Gong JG, 1999, NATURE, V399, P806; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Klohn PC, 1997, CHEM-BIOL INTERACT, V106, P15, DOI 10.1016/S0009-2797(97)00052-5; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; MATTIONI T, 1995, ONCOGENE, V10, P1325; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Walkenhorst J, 1996, ONCOGENE, V12, P1513; Wang BL, 1996, ONCOGENE, V13, P193; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	48	33	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12961	12967		10.1074/jbc.M300058200	http://dx.doi.org/10.1074/jbc.M300058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569093	hybrid			2022-12-27	WOS:000182189500048
J	Llamazares, M; Cal, S; Quesada, V; Lopez-Otin, C				Llamazares, M; Cal, S; Quesada, V; Lopez-Otin, C			Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-CLEAVING PROTEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; GENE FAMILY; CLONING; MATRIX; MEMBER; ADAM; AGGRECANASE-1; MUTATIONS; PROTEINS	We have cloned a mouse brain cDNA encoding a new protein of the ADAMTS family (A disintegrin and metalloproteinase domain, with thrombospondin type-1 repeats), which has been called ADAMTS-20. This protein shows a domain organization similar to that described for other ADAMTSs including signal sequence, propeptide, metalloproteinase domain, disintegrin domain, central TS-1 motif, cysteine-rich region, and C-terminal TS module. However, this last module is more complex than that of other ADAMTSs, being composed of a total of 14 repeats. The structural complexity of ADAMTS-20 is further increased by the presence of an additional domain 200 residues long and located immediately adjacent to the TS module. This domain has been tentatively called GON domain and can also be recognized in some ADAMTSs such as gon-1 from Caenorhabditis elegans and human and mouse ADAMTS-9. The presence of this domain is a hallmark of a novel subfamily of structurally and evolutionarily related ADAMTSs, called GON-ADAMTSs. Expression analysis demonstrated that ADAMTS-20 transcripts can be detected at low levels in several human and mouse tissues, especially in testis. This gene is also overexpressed in some human malignant tumors, including brain, colon, and breast carcinomas. Western blot analysis using polyclonal antibodies raised against recombinant ADAMTS-20 produced in Escherichia coli showed the presence of a 70-kDa band in mouse brain and testis extracts. This recombinant ADAMTS-20 hydrolyzed a synthetic peptide used for assaying matrix metalloproteinases. These data suggest that this novel enzyme may play a role in the tissue remodeling process occurring in both normal and pathological conditions.	Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, Inst Oncol, E-33006 Oviedo, Spain	University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, Inst Oncol, E-33006 Oviedo, Spain.	CLO@correo.uniovi.es	López-Otín, Carlos/AAB-2106-2020; Quesada, Víctor/B-6557-2014	López-Otín, Carlos/0000-0001-6964-1904; Quesada, Víctor/0000-0002-8398-3457; Llamazares Prada, Maria/0000-0001-6559-9374				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Cin PD, 1999, GENE CHROMOSOME CANC, V24, P94, DOI 10.1002/(SICI)1098-2264(199901)24:1<94::AID-GCC14>3.0.CO;2-2; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; El-Rifai W, 2001, NEOPLASIA, V3, P173, DOI 10.1038/sj.neo.7900158; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Hough RE, 2001, BRIT J CANCER, V84, P499, DOI 10.1054/bjoc.2000.1638; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Llano E, 1999, CANCER RES, V59, P2570; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Northrop DB, 1999, ADV ENZYMOL RAMB, V73, P25, DOI 10.1002/9780470123195.ch2; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEDEUTOUR F, 1994, GENOMICS, V22, P512, DOI 10.1006/geno.1994.1424; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200	41	71	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13382	13389		10.1074/jbc.M211900200	http://dx.doi.org/10.1074/jbc.M211900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562771	hybrid, Green Published			2022-12-27	WOS:000182189500100
J	Moriuchi, M; Moriuchi, H				Moriuchi, M; Moriuchi, H			YY1 transcription factor down-regulates expression of CCR5, a major coreceptor for HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROMOTER ACTIVITY; T-LYMPHOCYTES; ENTRY; INFECTION; PROTEIN; REPLICATION; INCREASES; CXCR4; CELLS	Expression of CCR5, a major coreceptor for human immunodeficiency virus type 1 (HIV-1), is regulated by a number of transcription factors. Here we report that the YY1 transcription factor down-regulates CCR5 promoter activity and that overexpression of YY1 reduces cell surface CCR5 expression and infectibility by R5-HIV-1. Because YY1 also down-regulates promoter activities of CXCR4, another major coreceptor for HIV-1 and HIV-1 long terminal repeat, this transcription factor may play a critical role in the pathogenesis of HIV-1 disease.	Nagasaki Univ Hosp, Dept Pediat, Nagasaki 8528501, Japan; Nagasaki Univ, Sch Biomed Sci, Div Med Virol, Dept Mol Microbiol & Immunol, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University	Moriuchi, H (corresponding author), Nagasaki Univ Hosp, Dept Pediat, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Liu R, 1998, AIDS RES HUM RETROV, V14, P1509, DOI 10.1089/aid.1998.14.1509; Lusso P, 2000, VIROLOGY, V273, P228, DOI 10.1006/viro.2000.0443; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MORIUCHI H, 1995, J VIROL, V69, P4693, DOI 10.1128/JVI.69.8.4693-4701.1995; Moriuchi H, 1998, J EXP MED, V187, P1689, DOI 10.1084/jem.187.10.1689; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Moriuchi M, 2001, J BIOL CHEM, V276, P8639, DOI 10.1074/jbc.M008391200; Moriuchi M, 1999, BLOOD, V93, P1433, DOI 10.1182/blood.V93.4.1433.404a36c_1433_1435; Reynes J, 2001, AIDS, V15, P1627, DOI 10.1097/00002030-200109070-00004; Rosati M, 2001, J IMMUNOL, V167, P1654, DOI 10.4049/jimmunol.167.3.1654; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439; Thivierge M, 1998, BLOOD, V92, P40, DOI 10.1182/blood.V92.1.40.413k43_40_45; Tuttle DL, 1998, J VIROL, V72, P4962, DOI 10.1128/JVI.72.6.4962-4969.1998; Wang JH, 1998, J VIROL, V72, P7642, DOI 10.1128/JVI.72.9.7642-7647.1998; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187	22	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13003	13007		10.1074/jbc.M204980200	http://dx.doi.org/10.1074/jbc.M204980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571248	hybrid			2022-12-27	WOS:000182189500053
J	Nishigaki, K; Thompson, D; Yugawa, T; Rulli, K; Hanson, C; Cmarik, J; Gutkind, JS; Teramoto, H; Ruscetti, S				Nishigaki, K; Thompson, D; Yugawa, T; Rulli, K; Hanson, C; Cmarik, J; Gutkind, JS; Teramoto, H; Ruscetti, S			Identification and characterization of a novel Ste20/germinal center kinase-related kinase, polyploidy-associated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; ANCHORAGE-INDEPENDENT GROWTH; HUMAN STE20-LIKE KINASE; C-JUN; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; CELLULAR STRESSES; MOLECULAR-CLONING; PATHWAY	A novel protein kinase, polyploidy-associated protein kinase (PAPK), was isolated using a subtraction cDNA library approach from a mouse erythroleukemia cell line that had been induced to polyploidy after serum withdrawal. PAPK shares homology with members of the Ste20/germinal center kinase family of protein kinases and is ubiquitously expressed as two spliced forms, PAPK-A and PAPK-B, that encode for proteins of 418 and 189 amino acids, respectively. The expression of endogenous PAPK-A protein increased after growth factor withdrawal in murine hematopoietic and fibroblast cells. When tested in an in vitro kinase assay, PAPK-A was activated in response to the stress-inducing agent hydrogen peroxide and slightly by fetal calf serum. Biochemical characterization of the PAPK-A-initiated pathway revealed that this novel kinase does not affect MAP kinase activity but can stimulate both c-Jun N-terminal kinase 1 (JNK1) and ERK6/p38gamma. The kinase activity of PAPK appears to be required for the activation of ERK6/p38gamma but not JNK1. When an inducible construct of PAPK-A was expressed in stably transfected NIH3T3 cells, the cells exhibited distinct cytoskeletal changes and became resistant to apoptotic cell death induced by serum withdrawal, effects of PAPK that require its kinase activity. These data suggest that PAPK is a new member of the Ste20/germinal center kinase family that modulates cytoskeletal organization and cell survival.	NCI Frederick, Basic Res Lab, NIH, Ft Detrick, MD 21702 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Nishigaki, K (corresponding author), NCI Frederick, Basic Res Lab, NIH, Bldg 469,Rm 205, Ft Detrick, MD 21702 USA.	nishigakik@mail.ncifcrf.gov; ruscetti@ncifcrf.gov	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Court NW, 2002, J MOL CELL CARDIOL, V34, P413, DOI 10.1006/jmcc.2001.1523; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kanai-Azuma M, 1999, MECH DEVELOP, V89, P155, DOI 10.1016/S0925-4773(99)00193-8; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Schrick K, 1997, GENETICS, V147, P19; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736; Vannucchi AM, 2000, BLOOD, V95, P2559; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yamada E, 2000, BBA-MOL CELL RES, V1495, P250, DOI 10.1016/S0167-4889(99)00164-0; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang WP, 2000, BIOCHEM BIOPH RES CO, V274, P872, DOI 10.1006/bbrc.2000.3244; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	73	13	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13520	13530		10.1074/jbc.M208601200	http://dx.doi.org/10.1074/jbc.M208601200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574163	hybrid			2022-12-27	WOS:000182189500116
J	Stein, EG; Ghirlando, R; Hubbard, SR				Stein, EG; Ghirlando, R; Hubbard, SR			Structural basis for dimerization of the Grb10 Src homology 2 domain - Implications for ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTORS; INSULIN-RECEPTOR; SH2 DOMAIN; CRYSTAL-STRUCTURE; CATALYTIC ACTIVITY; ADAPTER GRB14; PROTEIN	Grb7, Grb10, and Grb14 are members of a distinct family of adapter proteins that interact with various receptor tyrosine kinases upon receptor activation. Proteins in this family contain several modular signaling domains including a pleckstrin homology (PH) domain, a BPS (between PH and SH2) domain, and a C-terminal Src homology 2 (SH2) domain. Although SH2 domains are typically monomeric, we show that the Grb10 SH2 domain and also full-length Grb10gamma are dimeric in solution under physiologic conditions. The crystal structure of the Grb10 SH2 domain at 1.65-Angstrom resolution reveals a non-covalent dimer whose interface comprises residues within and flanking the C-terminal a helix, which are conserved in the Grb7/Grb10/Grb14 family but not in other SH2 domains. Val-522 in the BG loop (BG3) and Asp-500 in the EF loop (EF1) are positioned to interfere with the binding of the P+3 residue of a phosphopeptide ligand. These structural features of the Grb10 SH2 domain will favor binding of dimeric, turn-containing phosphotyrosine sequences, such as the phosphorylated activation loops in the two Beta subunits of the insulin and insulin-like growth factor-1 receptors. Moreover, the structure suggests the mechanism by which the Grb7 SH2 domain binds selectively to pTyr-1139 (pYVNQ) in Her2, which along with Grb7 is co-amplified in human breast cancers.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	New York University; New York University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hubbard, SR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 540 1st Ave, New York, NY 10016 USA.	hubbard@saturn.med.nyu.edu	Ghirlando, Rodolfo/A-8880-2009	Hubbard, Stevan/0000-0002-2707-9383	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052916] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52916] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newcomer ME, 2002, CURR OPIN STRUC BIOL, V12, P48, DOI 10.1016/S0959-440X(02)00288-9; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Pero SC, 2002, J BIOL CHEM, V277, P11918, DOI 10.1074/jbc.M111816200; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Rety S, 1996, PROTEIN SCI, V5, P405; Schiering N, 2000, BIOCHEMISTRY-US, V39, P13376, DOI 10.1021/bi0012336; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wang J, 1999, MOL CELL BIOL, V19, P6217; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13257	13264		10.1074/jbc.M212026200	http://dx.doi.org/10.1074/jbc.M212026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551896	hybrid			2022-12-27	WOS:000182189500084
J	Wu, WS; Xu, ZX; Hittelman, WN; Salomoni, P; Pandolfi, PP; Chang, KS				Wu, WS; Xu, ZX; Hittelman, WN; Salomoni, P; Pandolfi, PP; Chang, KS			Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappa B survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML-RAR-ALPHA; CYTOCHROME-C; FACTOR RECEPTOR; NUCLEAR-BODIES; CELL-DEATH; GROWTH; DAXX; TRANSCRIPTION; EXPRESSION; INDUCTION	The promyelocytic leukemia protein (PML) is a growth/tumor suppressor essential for induction of apoptosis by diverse apoptotic stimuli. The mechanism by which PML regulates cell death remains unclear. In this study we found that ectopic expression of PML potentiates cell death by apoptosis in the tumor necrosis factor alpha (TNFalpha)-resistant cell line U2OS and other cell lines. Treatment with TNFa significantly sensitized these cells to apoptosis in a p53-independent manner. PML/TNFalpha-induced cell death is associated with DNA fragmentation, activation of caspase-3, -7, and -8, and degradation of DNA fragmentation factor/inhibitor of CAD. PML/TNFalpha-induced cell death could be blocked by the caspase-8 inhibitors Crm-A and c-FLIP but not by Bcl-2. These findings indicate that this cell death event is initiated through the death receptor-dependent apoptosis pathway. PML is a transcriptional repressor of NF-kappaB by interacting with RelA/p65 and prevents its binding to the cognate enhancer through the C terminus. Coimmunoprecipitation and double-color immunofluorescence staining demonstrated that PML physically interacts with RelA/p65 in vivo and the two proteins colocalized at the endogenous levels. Overexpression of NF-kappaB rescued cell death induced by PML TNFalpha. Furthermore, PML-/- mouse embryo fibroblasts are more resistant to TNFalpha-induced apoptosis. Together this study defines a novel mechanism by which PML induces apoptosis through repression of the NF-kappaB survival pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holocombe Blvd,Unit 89, Houston, TX 77030 USA.	kchang@mail.mdanderson.org	Wu, Wen-Shu/I-1258-2014	Wu, Wen-Shu/0000-0002-0225-2522	NCI NIH HHS [CA 55577, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA055577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; Chan JYH, 1998, EUR J CANCER, V34, P1015, DOI 10.1016/S0959-8049(97)10138-1; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gastman BR, 2000, CANCER RES, V60, P6811; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; IRMIER M, 1997, NATURE, V388, P190; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson BW, 1999, J BIOL CHEM, V274, P18552, DOI 10.1074/jbc.274.26.18552; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Min W, 1996, MOL CELL BIOL, V16, P359; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Stadler M, 1995, ONCOGENE, V11, P2565; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wilkinson GWG, 1998, J GEN VIROL, V79, P1233, DOI 10.1099/0022-1317-79-5-1233; Wu WS, 2002, J BIOL CHEM, V277, P31734, DOI 10.1074/jbc.M201648200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	68	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12294	12304		10.1074/jbc.M211849200	http://dx.doi.org/10.1074/jbc.M211849200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540841	hybrid			2022-12-27	WOS:000182015700075
J	de Valencia, FF; Paulucci, AA; Quaggio, RB; da Silva, ACR; Farah, CS; Reinach, FD				de Valencia, FF; Paulucci, AA; Quaggio, RB; da Silva, ACR; Farah, CS; Reinach, FD			Parallel measurement of Ca2+ binding and fluorescence emission upon Ca2+ titration of recombinant skeletal muscle troponin C - Measurement of sequential calcium binding to the regulatory sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; TRYPTOPHAN ANALOGS; BIOSYNTHETIC INCORPORATION; STAPHYLOCOCCAL NUCLEASE; CA-2+-SPECIFIC SITES; DIRECTED MUTAGENESIS; MAGNESIUM BINDING; DISULFIDE BOND; RNA-POLYMERASE; HIGH-AFFINITY	Calcium binding to chicken recombinant skeletal muscle TnC (TnC) and its mutants containing tryptophan (F29W), 5-hydroxytryptophan (F29 (H) under barW), or 7-azatryptophan (F29 (Z) under barW) at position 29 was measured by flow dialysis and by fluorescence. Comparative analysis of the results allowed us to determine the influence of each amino acid on the calcium binding properties of the N-terminal regulatory domain of the protein. Compared with TnC, the Ca2+ affinity of N-terminal sites was: 1) increased 6-fold in F29W, 2) increased 3-fold in F29 (Z) under barW, and 3) decreased slightly in F29 (H) under barW. The Ca2+ titration of F29 (H) under barW monitored by fluorescence displayed a bimodal curve related to sequential Ca2+ binding to the two N-terminal Ca2+ binding sites. Single and double mutants of TnC, F29W, F29 (H) under barW, and F29 (Z) under barW were constructed by replacing aspartate by alanine at position 30 (site I) or 66 (site II) or both. Ca2+ binding data showed that the Asp --> Ala mutation at position 30 impairs calcium binding to site I only, whereas the Asp --> Ala mutation at position 66 impairs calcium binding to both sites I and II. Furthermore, the Asp --> Ala mutation at position 30 eliminates the differences in Ca2+ affinity observed for replacement of Phe at position 29 by Trp, 5-hydroxytryptophan, or 7-azatryptophan. We conclude that position 29 influences the affinity of site I and that Ca2+ binding to site I is dependent on the previous binding of metal to site II.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil	Universidade de Sao Paulo	de Valencia, FF (corresponding author), Univ Brasilia, Inst Ciencias Biol, Dept Cellular Biol, ICC SUL, Campus Univ,Asa Norte, BR-7091997 Brasilia, DF, Brazil.		Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302				BARLATI S, 1970, J BACTERIOL, V101, P166, DOI 10.1128/JB.101.1.166-172.1970; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DRAPEAU GR, 1968, J MOL BIOL, V35, P357, DOI 10.1016/S0022-2836(68)80030-0; ELLIS PD, 1988, J BIOL CHEM, V263, P10284; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Fredricksen RS, 1996, BIOCHEMISTRY-US, V35, P14012, DOI 10.1021/bi961270q; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; GRABAREK Z, 1983, J BIOL CHEM, V258, P4098; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GRIFFITHS PJ, 1984, FEBS LETT, V176, P144, DOI 10.1016/0014-5793(84)80929-1; GUSEV NB, 1991, J BIOL CHEM, V266, P16622; GUTH K, 1987, J BIOL CHEM, V262, P13627; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOGUE CWV, 1992, FEBS LETT, V310, P269, DOI 10.1016/0014-5793(92)81346-N; HOGUE CWV, 1993, BIOPHYS CHEM, V48, P159, DOI 10.1016/0301-4622(93)85007-5; IIDA S, 1988, J BIOCHEM-TOKYO, V103, P482, DOI 10.1093/oxfordjournals.jbchem.a122296; JOHNSON JD, 1978, J BIOL CHEM, V253, P6451; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P9703, DOI 10.1021/bi00155a025; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; Pearlstone JR, 2000, J BIOL CHEM, V275, P35106, DOI 10.1074/jbc.M001000200; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1981, FED PROC, V40, P2653; REINACH FC, 1988, J BIOL CHEM, V263, P2371; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; ROSS JBA, 1992, P NATL ACAD SCI USA, V89, P12023, DOI 10.1073/pnas.89.24.12023; Ross JBA, 1997, METHOD ENZYMOL, V278, P151; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TELEMAN O, 1983, EUR J BIOCHEM, V134, P453, DOI 10.1111/j.1432-1033.1983.tb07588.x; Tikunova SB, 2002, BIOCHEMISTRY-US, V41, P6697, DOI 10.1021/bi011763h; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TRIGOGONZALEZ G, 1992, BIOCHEMISTRY-US, V31, P7009, DOI 10.1021/bi00146a001; Wong CY, 1997, PROTEIN SCI, V6, P689; Wong CY, 1998, BIOCHEMISTRY-US, V37, P8947, DOI 10.1021/bi971863g; Yu A, 1999, BBA-PROTEIN STRUCT M, V1431, P53, DOI 10.1016/S0167-4838(99)00043-6; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031; ZOT AS, 1987, J BIOL CHEM, V262, P1966; ZOT HG, 1986, J BIOL CHEM, V261, P5883	57	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11007	11014		10.1074/jbc.M209943200	http://dx.doi.org/10.1074/jbc.M209943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531902	hybrid			2022-12-27	WOS:000181855400019
J	Liu, M; Barth, A				Liu, M; Barth, A			Mapping interactions between the Ca2+-ATPase and its substrate ATP with infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONSERVED PHOSPHORYLATION LOOP; NUCLEAR-MAGNETIC-RESONANCE; NUCLEOTIDE-BINDING; STRUCTURAL-CHANGES; CATALYTIC SITE; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGE; REACTION-MECHANISM	Infrared spectroscopy has been used to map substrate-protein interactions: the conformational changes of the sarcoplasmic reticulum Ca2+-ATPase upon nucleotide binding and ATPase phosphorylation were monitored using the substrate ATP and ATP analogues (2'-deoxy-ATP, 3'-deoxy-ATP, and inosine 5'-triphosphate), which were modified at specific functional groups of the substrate. Modifications to the 2'-OH, the X-OH, and the amino group of adenine reduce the extent of binding-induced conformational change of the ATPase, with particularly strong effects observed for the latter two. This demonstrates the structural sensitivity of the nucleotide-ATPase complex to individual interactions between nucleotide and ATPase. All groups studied are important for binding and interactions of a given ligand group with the ATPase depend on interactions of other ligand groups. Phosphorylation of the ATPase was observed for ITP and 2'-deoxy-ATP, but not for 3'-deoxy-ATP. There is no direct link between the extent of conformational change upon nucleotide binding and the rate of phosphorylation showing that the full extent of the ATP-induced conformational change is not mandatory for phosphorylation. As observed for the nucleotide-ATPase complex, the conformation of the first phosphorylated ATPase intermediate E1PCa(2) also depends on the nucleotide, indicating that ATPase states have a less uniform conformation than previously anticipated.	Goethe Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Barth, A (corresponding author), Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	Andreas.Barth@dbb.su.se	Liu, Man/GXH-3184-2022; Barth, Andreas/N-8872-2013	Liu, Man/0000-0002-1390-7862; Barth, Andreas/0000-0001-5784-7673				Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1992, ACTA PHYSIOL SCAND, V146, P151; BAENZIGER JE, 1993, BIOCHEMISTRY-US, V32, P5448, DOI 10.1021/bi00071a022; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1998, BIOPHYS J, V75, P538, DOI 10.1016/S0006-3495(98)77543-5; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; Barth A, 2000, FEBS LETT, V477, P151, DOI 10.1016/S0014-5793(00)01782-8; BELASCO JG, 1980, BIOCHEMISTRY-US, V19, P472, DOI 10.1021/bi00544a012; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CAREY PR, 1995, ACCOUNTS CHEM RES, V28, P8, DOI 10.1021/ar00049a002; Cepus V, 1998, BIOCHEMISTRY-US, V37, P10263, DOI 10.1021/bi973183j; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; CLORE GM, 1982, EUR J BIOCHEM, V128, P113; COAN C, 1993, J BIOL CHEM, V268, P6917; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DAVIES DB, 1974, BIOCHEMISTRY-US, V13, P4417, DOI 10.1021/bi00718a027; Davis AM, 1999, ANGEW CHEM INT EDIT, V38, P737, DOI 10.1002/(SICI)1521-3773(19990315)38:6<736::AID-ANIE736>3.0.CO;2-R; de Meis L, 1973, J Biol Chem, V248, P3691; Deng H, 1999, METHOD ENZYMOL, V308, P176; Ettrich R, 2001, J MOL MODEL, V7, P184; FERREIRA ST, 1988, J BIOL CHEM, V263, P9973; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Hasselbach W, 1979, Top Curr Chem, V78, P1; HASSELBACH W, 1974, ENZYMES, P431; HASSELBACH W, 1981, MEMBRANE TRANSPORT, P183; HOBBS AS, 1985, J BIOL CHEM, V260, P2035; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Huang SH, 1998, BIOCHEMISTRY-US, V37, P18064, DOI 10.1021/bi981997+; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; JONA I, 1990, BIOCHIM BIOPHYS ACTA, V1028, P183, DOI 10.1016/0005-2736(90)90153-F; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; Liu M, 2002, BIOPOLYMERS, V67, P267, DOI 10.1002/bip.10113; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MacLennan DH, 2000, NATURE, V405, P633, DOI 10.1038/35015206; MATA AM, 1993, BIOCHIM BIOPHYS ACTA, V1147, P6, DOI 10.1016/0005-2736(93)90309-N; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; OUALI M, 1993, J AM CHEM SOC, V115, P4264, DOI 10.1021/ja00063a049; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETRETSKI JH, 1989, J BIOL CHEM, V264, P20339; RUBTSOV AM, 1988, FEBS LETT, V238, P240, DOI 10.1016/0014-5793(88)80487-3; SCHLEICH T, 1972, BIOCHEMISTRY-US, V11, P137, DOI 10.1021/bi00752a001; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P6095, DOI 10.1021/bi00074a022; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; TAILLANDIER E, 1987, BIOCHEMISTRY-US, V26, P3361, DOI 10.1021/bi00386a017; THE R, 1975, EUR J BIOCHEM, V53, P105, DOI 10.1111/j.1432-1033.1975.tb04047.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; von Germar F, 2000, BIOPHYS J, V78, P1531, DOI 10.1016/S0006-3495(00)76705-1; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WARTELL RM, 1986, BIOCHEMISTRY-US, V25, P2664, DOI 10.1021/bi00357a056; Wharton CW, 2000, NAT PROD REP, V17, P447, DOI 10.1039/b002066o; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	66	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10112	10118		10.1074/jbc.M212403200	http://dx.doi.org/10.1074/jbc.M212403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12538577	hybrid			2022-12-27	WOS:000181777500018
J	Muradov, KG; Boyd, KK; Martinez, SE; Beavo, JA; Artemyev, NO				Muradov, KG; Boyd, KK; Martinez, SE; Beavo, JA; Artemyev, NO			The GAFa domains of rod cGMP-phosphodiesterase 6 determine the selectivity of the enzyme dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR CGMP-PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; GENE FAMILY; BINDING; SUBUNIT; PHOSPHORYLATION; PURIFICATION; INHIBITION; EXPRESSION; PROTEINS	Retinal rod cGMP phosphodiesterase (PDE6 family) is the effector enzyme in the vertebrate visual transduction cascade. Unlike other known PDEs that form catalytic homodimers, the rod PDE6 catalytic core is a heterodimer composed of alpha and beta subunits. A system for efficient expression of rod PDE6 is not available. Therefore, to elucidate the structural basis for specific dimerization of rod PDE6, we constructed a series of chimeric proteins between PDE6alphabeta and PDE5, which contain the N-terminal GAFa/GAFb domains, or portions thereof, of the rod enzyme. These chimeras were co-expressed in Sf9 cells in various combinations as His-, myc-, or FLAG-tagged proteins. Dimerization of chimeric PDEs was assessed using gel filtration and sucrose gradient centrifugation. The composition of formed dimeric enzymes was analyzed with Western blotting and immunoprecipitation. Consistent with the selectivity of PDE6 dimerization in vivo, efficient heterodimerization was observed between the GAF regions of PDE6alpha and PDE6beta with no significant homodimerization. In addition, PDE6alpha was able to form dimers with the cone PDE6alpha' subunit. Furthermore, our analysis indicated that the PDE6 GAFa domains contain major structural determinants for the affinity and selectivity of dimerization of PDE6 catalytic subunits. The key dimerization selectivity module of PDE6 has been localized to a small segment within the GAFa domains, PDE6alpha-59-74/PDE6beta-57-72. This study provides tools for the generation of the homodimeric alphaalpha and betabeta enzymes that will allow us to address the question of functional significance of the unique heterodimerization of rod PDE6.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Iowa; University of Washington; University of Washington Seattle	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	nikolai-artemyev@uiowa.edu		Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Cook TA, 2001, J BIOL CHEM, V276, P5248, DOI 10.1074/jbc.M004690200; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; Institutionen B Universitet Uppsala S, 1963, PURE APPL CHEM, V233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Natochin M, 2000, METHOD ENZYMOL, V315, P539; Okada D, 2002, BIOCHEMISTRY-US, V41, P9672, DOI 10.1021/bi025727+; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; QIN N, 1994, J BIOL CHEM, V269, P3265; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; STROOP SD, 1991, J BIOL CHEM, V266, P23802; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	45	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10594	10601		10.1074/jbc.M208456200	http://dx.doi.org/10.1074/jbc.M208456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531898	hybrid, Green Published			2022-12-27	WOS:000181777500080
J	Barry, JB; Leong, GM; Church, WB; Issa, LL; Eisman, JA; Gardiner, EM				Barry, JB; Leong, GM; Church, WB; Issa, LL; Eisman, JA; Gardiner, EM			Interactions of SKIP/NCoA-62, TFIIB, and retinoid X receptor with vitamin D receptor helix H10 residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIB; D-MEDIATED TRANSCRIPTION; CRYSTAL-STRUCTURE; NUCLEAR RECEPTORS; PROTEIN; BINDING; LIGAND; DOMAIN; SKIP; ACTIVATION	The vitamin D receptor (VDR) is a ligand-dependent transcription factor that heterodimerizes with retinoid X receptor (RXR) and interacts with the basal transcription machinery and transcriptional cofactors to regulate target gene activity. The p160 coactivator GRIP1 and the distinct coregulator Ski-interacting protein (SKIP)/NCoA-62 synergistically enhance ligand-dependent VDR transcriptional activity. Both coregulators bind directly to and form a ternary complex with VDR, with GRIP1 contacting the activation function-2 (AF-2) domain and SKIP/NCoA-62 interacting through an AF-2 independent interface. It was previously reported that SKIP/NCoA-62 interaction with VDR was independent of the heterodimerization interface (specifically, helices H10/H11). In contrast, the present study defines specific residues within a conserved and surface-exposed region of VDR helix H10 that are required for interaction with SKIP/NCoA-62 and for full ligand-dependent transactivation activity. SKIP/NCoA-62, the basal transcription factor TFIIB, and RXR all interacted with VDR helix H10 mutants at reduced levels compared with wild type in the absence of ligand and exhibited different degrees of increased interaction upon ligand addition. Thus, SKIP/NCoA-62 interacts with VDR at a highly conserved region not previously associated with coregulator binding to regulate transactivation by a molecular mechanism distinct from that of p160 coactivators.	Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia; Garvan Inst Med Res, Mol Modeling Facil, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research	Gardiner, EM (corresponding author), Garvan Inst Med Res, Bone & Mineral Res Program, 384 Victoria St,Darlinghurst, Sydney, NSW 2010, Australia.		Church, William/H-6040-2013; Eisman, John A/C-2886-2014	Church, William/0000-0002-8033-5518; 				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Glass CK, 2000, GENE DEV, V14, P121; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Issa LL, 2001, ENDOCRINOLOGY, V142, P1606, DOI 10.1210/en.142.4.1606; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leong GM, 1998, J BIOL CHEM, V273, P2296, DOI 10.1074/jbc.273.4.2296; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; LEONG GM, 1998, BONE, V23, pS256; Lu ZJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P99, DOI 10.1006/abbi.1996.9864; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; NISHIKAWA J, 1995, NUCLEIC ACIDS RES, V23, P606, DOI 10.1093/nar/23.4.606; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; Prathapam T, 2001, ONCOGENE, V20, P7677, DOI 10.1038/sj.onc.1204960; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000; Zhou SF, 2000, J VIROL, V74, P1939, DOI 10.1128/JVI.74.4.1939-1947.2000	31	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8224	8228		10.1074/jbc.C200712200	http://dx.doi.org/10.1074/jbc.C200712200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12529369	hybrid			2022-12-27	WOS:000181466800062
J	Cobucci-Ponzano, B; Trincone, A; Giordano, A; Rossi, M; Moracci, M				Cobucci-Ponzano, B; Trincone, A; Giordano, A; Rossi, M; Moracci, M			Identification of an archaeal alpha-L-fucosidase encoded by an interrupted gene - Production of a functional enzyme by mutations mimicking programmed-1 frameshifting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SOLFATARICUS; FUCOSYL-TRANSFERASE; BETA-GLYCOSIDASE; N-GLYCANS; SEQUENCE; PROTEIN; GLUCOSIDASE; PREDICTION; BACTERIA; GENOME	The analysis of the complete genome of the thermoacidophilic Archaeon Sulfolobus solfataricus revealed two open reading frames (ORF), named SSO11867 and SSO3060, interrupted by a -1 frameshift and encoding for the N- and the C-terminal fragments, respectively, of an alpha-L-fucosidase. We report here that these ORFs are actively transcribed in vivo, and we confirm the presence of the -1 frameshift between them at the cDNA level, explaining why we could not find a-fucosidase activity in S. solfataricus extracts. Detailed analysis of the region of overlap between the two ORFs revealed the presence of the consensus sequence for a programmed -1 frameshifting. Two specific mutations, mimicking this regulative frameshifting event, allow the expression, in Escherichia coli, of a fully active thermophilic and thermostable alpha-L-fucosidase (EC 3.2.1.51) with micromolar substrate specificity and showing transfucosylating activity. The analysis of the fucosylated products of this enzyme allows, for the first time, assigning a retaining reaction mechanism to family 29 of glycosyl hydrolases. The presence of an alpha-fucosidase putatively regulated by programmed -1 frameshifting is intriguing both with respect to the regulation of gene expression and, in post-genomic era, for the definition of gene function in Archaea.	CNR, Inst Prot Biochem, I-80131 Naples, Italy; CNR, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy; Univ Naples Federico II, Dipartimento Chim Biol, I-80134 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Naples Federico II	Moracci, M (corresponding author), CNR, Inst Prot Biochem, Via P Castellino 111, I-80131 Naples, Italy.	moracci@dafne.ibpe.na.cnr.it	Trincone, Antonio/B-4323-2010; Cobucci Ponzano, Beatrice/G-8536-2013; giordano, assunta/E-3574-2012; Moracci, Marco/B-8444-2015; Cobucci-Ponzano, Beatrice/B-7654-2015; Cobucci-Ponzano, Beatrice/AAX-7630-2020	Trincone, Antonio/0000-0003-4191-7280; Moracci, Marco/0000-0002-9846-2531; Cobucci-Ponzano, Beatrice/0000-0002-8211-2297; GIORDANO, ASSUNTA/0000-0001-8139-407X				AbdelAleem H, 1996, INT J GYNECOL OBSTET, V55, P273, DOI 10.1016/S0020-7292(96)02770-1; Baranov PV, 2001, NUCLEIC ACIDS RES, V29, P264, DOI 10.1093/nar/29.1.264; Cobucci-Ponzano B, 2002, PROTEINS, V48, P98, DOI 10.1002/prot.10128; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Crombie HJ, 1998, PLANT J, V15, P27, DOI 10.1046/j.1365-313X.1998.00182.x; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; de la Torre F, 2002, PLANT PHYSIOL, V128, P247, DOI 10.1104/pp.010508; DEROSA M, 1975, J GEN MICROBIOL, V86, P156, DOI 10.1099/00221287-86-1-156; Eneyskaya EV, 2001, GLYCOCONJUGATE J, V18, P827, DOI 10.1023/A:1021163720282; Farabaugh PJ, 1996, ANNU REV GENET, V30, P507, DOI 10.1146/annurev.genet.30.1.507; Farkas E, 2000, CARBOHYD RES, V328, P293, DOI 10.1016/S0008-6215(00)00113-0; Fernandez-Rodriguez J, 2000, CANCER DETECT PREV, V24, P143; Fischer L, 1996, BIO-TECHNOL, V14, P88, DOI 10.1038/nbt0196-88; Hammell AB, 1999, GENOME RES, V9, P417; Hao B, 2002, SCIENCE, V296, P1462, DOI 10.1126/science.1069556; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Ishizuka H, 1999, INTERNAL MED, V38, P927, DOI 10.2169/internalmedicine.38.927; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Listinsky JJ, 1998, AM J CLIN PATHOL, V110, P425; Lower BH, 2002, J BACTERIOL, V184, P2614, DOI 10.1128/JB.184.10.2614-2619.2002; Michalski JC, 1999, BBA-MOL BASIS DIS, V1455, P69, DOI 10.1016/S0925-4439(99)00077-0; Moracci M, 2000, J BIOL CHEM, V275, P22082, DOI 10.1074/jbc.M910392199; Mori E, 1998, GLYCOCONJUGATE J, V15, P447, DOI 10.1023/A:1006926801717; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Noda K, 1998, INT J CANCER, V75, P444; PRISCO A, 1995, J BACTERIOL, V177, P1614, DOI 10.1128/jb.177.6.1614-1619.1995; Rapoport E, 1999, GLYCOBIOLOGY, V9, P1337, DOI 10.1093/glycob/9.12.1337; Russell L, 1998, BIOCHEM BIOPH RES CO, V250, P449, DOI 10.1006/bbrc.1998.9337; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Stahl B, 2001, ADV EXP MED BIOL, V501, P299; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; Tolstrup N, 2000, EXTREMOPHILES, V4, P175, DOI 10.1007/s007920070032; Trincone A, 2000, BIOORG MED CHEM LETT, V10, P365, DOI 10.1016/S0960-894X(99)00700-3; WANG LX, 1991, CARBOHYD RES, V219, P133, DOI 10.1016/0008-6215(91)89048-K; Wiese TJ, 1997, BBA-GEN SUBJECTS, V1335, P61, DOI 10.1016/S0304-4165(96)00123-7; XIANG JM, 1992, BIOCHEM BIOPH RES CO, V189, P27, DOI 10.1016/0006-291X(92)91520-Z	38	40	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14622	14631		10.1074/jbc.M211834200	http://dx.doi.org/10.1074/jbc.M211834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12569098	hybrid			2022-12-27	WOS:000182516100008
J	Fukuda, M				Fukuda, M			Distinct Rab binding specificity of Rim1, Rim2, rabphilin, and Noc2 - Identification of a critical determinant of Rab3A/Rab27A recognition by Rim2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-VESICLE FUSION; SLP HOMOLOGY DOMAIN; PC12 CELLS; C2 DOMAINS; MYOSIN-VA; MELANOSOME TRANSPORT; PHOSPHOLIPID-BINDING; SYNAPTOTAGMIN FAMILY; REGULATED SECRETION; PROTEIN	Rabphilin, Rim, and Noc2 have generally been believed to be the Rab3 isoform (Rab3A/B/C/D)-specific effectors that regulate secretory vesicle exocytosis in neurons and in some endocrine cells. The results of recent genetic analysis of rabphilin knock-out animals, however, strongly refute this notion, because there are no obvious genetic interactions between Rab3 and rabphilin in nematoda (Staunton, J., Ganetzky, B., and Nonet, M. L. (2001) J. Neurosci. 21, 9255-9264), suggesting that Rab3 is not a major ligand of rabphilin in vivo. In this study, I tested the interaction of rabphilin, Rim1, Rim2, and Noc2 with 42 different Rab proteins by cotransfection assay and found differences in rabphilin, Rim1, Rim2, and Noc2 binding to several Rab proteins that belong to the Rab functional group III (Rab3A/B/C/D, Rab26, Rab27A/B, and Rab37) and/or VIII (Rab8A and Rab10). Riml interacts with Rab3A/B/C/D, Rab10, Rab26, and Rab37; Rim2 interacts with Rab3A/B/C/D and Rab8A, and rabphilin and Noc2 interact with Rab3A/B/ C/D, Rab8A, and Rab27A/B. By contrast, the synaptotagmin-like protein homology domain of Slp homologue lacking C2 domains-a (Slac2-a)/melanophilin specifically recognizes Rab27A/B but not other Rabs. I also found that alternative splicing events in the first alpha-helical region (alpha(1)) of the Rab binding domain of Rim1 alter the Rab binding specificity of Rim1. Site-directed mutagenesis and chimeric analyses of Rim2 and Slac2-a indicate that the acidic cluster (Glu-50, Glu-51, and Glu-52) in the a, region of the Rab binding domain of Rim2, which is not conserved in the synaptotagmin-like pro tein homology domain of Slac2-a, is a critical determinant of Rab3A recognition. Based on these results, I propose that Rim, rabphilin, and Noc2 function differently in concert with functional group III and/or VIII Rab proteins, including Rab3 isoforms.	RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; Chen S, 2001, J BIOL CHEM, V276, P13209, DOI 10.1074/jbc.M010798200; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 2001, J BIOL CHEM, V276, P9726, DOI 10.1074/jbc.M006959200; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Joberty G, 1999, J CELL SCI, V112, P3579; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Masuda ES, 2000, FEBS LETT, V470, P61, DOI 10.1016/S0014-5793(00)01288-6; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Staunton J, 2001, J NEUROSCI, V21, P9255, DOI 10.1523/JNEUROSCI.21-23-09255.2001; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Yoshie S, 2000, HISTOCHEM CELL BIOL, V113, P259, DOI 10.1007/s004180000130; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	49	149	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15373	15380		10.1074/jbc.M212341200	http://dx.doi.org/10.1074/jbc.M212341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578829	hybrid			2022-12-27	WOS:000182516100102
J	Boucrot, E; Beuzon, CR; Holden, DW; Gorvel, JP; Meresse, S				Boucrot, E; Beuzon, CR; Holden, DW; Gorvel, JP; Meresse, S			Salmonella typhimurium SifA effector protein requires its membrane-anchoring C-terminal hexapeptide for its biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III SECRETION SYSTEM; PATHOGENICITY ISLAND 2; EPITHELIAL-CELLS; IN-VIVO; FILAMENTOUS STRUCTURES; CONTAINING VACUOLES; MURINE MACROPHAGES; RAB GTPASES; VIRULENCE; GENES	SifA is a Salmonella typhimurium effector protein that is translocated across the membrane of the Salmonella-containing vacuole by the Salmonella pathogenicity island 2-encoded type III secretion system. SifA is necessary for the formation of Salmonella-induced filaments and for the maintenance of the vacuolar membrane enclosing the pathogen. We have investigated the role of the C-terminal hexapeptide of SifA as a potential site for membrane anchoring. An S. typhimurium strain carrying a deletion of the sequence encoding this hexapeptide (sifADelta6) was found to be attenuated for systemic virulence in mice. In mouse macrophages, sifADelta6 mutant bacteria displayed a reduced association with vacuolar markers, similar to that of sifA null mutant bacteria, and exhibited a dramatic replication defect. Expression of SifA in epithelial cells results in the mobilization of lysosomal glycoproteins in large vesicular structures and Sif-like tubules. This process requires the presence of the C-terminal hexapeptide domain of SifA. Ectopic expression of truncated or mutated versions of SifA affecting the C-terminal hexapeptide revealed a strong correlation between the membrane binding capability and the biological activity of the protein. Finally, the eleven C-terminal residues of SifA are shown to be sufficient to target the Aequorea green fluorescent protein to membranes. Altogether, our results indicate that membrane anchoring of SifA requires its C-terminal hexapeptide domain, which is important for the biological function of this bacterial effector.	Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, F-13288 Marseille 9, France; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ctr Mol Microbiol & Infect, Dept Infect Dis, London SW7 2AZ, England	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Imperial College London	Meresse, S (corresponding author), Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, Case 906, F-13288 Marseille 9, France.		Meresse, Stephane/E-2192-2012; Beuzon, Carmen/G-7302-2011; Gorvel, Jean-Pierre/O-1332-2018	Meresse, Stephane/0000-0001-6578-5177; Beuzon, Carmen/0000-0002-6888-3845; Gorvel, Jean-Pierre/0000-0002-2829-9804				Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2001, MICROBES INFECT, V3, P1345, DOI 10.1016/S1286-4579(01)01496-4; Beuzon CR, 2001, INFECT IMMUN, V69, P7254, DOI 10.1128/IAI.69.12.7254-7261.2001; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Brumell JH, 2002, TRAFFIC, V3, P407, DOI 10.1034/j.1600-0854.2002.30604.x; Brumell JH, 2001, TRAFFIC, V2, P643, DOI 10.1034/j.1600-0854.2001.20907.x; Brumell JH, 2001, CELL MICROBIOL, V3, P75, DOI 10.1046/j.1462-5822.2001.00087.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Freeman JA, 2003, INFECT IMMUN, V71, P418, DOI 10.1128/IAI.71.1.418-427.2003; FRETER R, 1981, INFECT IMMUN, V34, P234, DOI 10.1128/IAI.34.1.234-240.1981; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; Gordon MA, 2001, J INFECTION, V42, P44, DOI 10.1053/jinf.2000.0779; Guy RL, 2000, MOL MICROBIOL, V37, P1417, DOI 10.1046/j.1365-2958.2000.02092.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hansen-Wester I, 2002, INFECT IMMUN, V70, P1403, DOI 10.1128/IAI.70.3.1403-1409.2002; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; Jensen FB, 1998, AM J PHYSIOL-REG I, V274, pR661, DOI 10.1152/ajpregu.1998.274.3.R661; Knodler LA, 2002, MOL MICROBIOL, V43, P1089, DOI 10.1046/j.1365-2958.2002.02820.x; LEUNG KY, 1991, P NATL ACAD SCI USA, V88, P11470, DOI 10.1073/pnas.88.24.11470; LEVINE WC, 1991, J INFECT DIS, V164, P81, DOI 10.1093/infdis/164.1.81; Meresse S, 1997, ELECTROPHORESIS, V18, P2682, DOI 10.1002/elps.1150181425; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; Ruiz-Albert J, 2002, MOL MICROBIOL, V44, P645, DOI 10.1046/j.1365-2958.2002.02912.x; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	38	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14196	14202		10.1074/jbc.M207901200	http://dx.doi.org/10.1074/jbc.M207901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574170	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000182405000081
J	Duchesne, C; Charland, S; Asselin, C; Nahmias, C; Rivard, N				Duchesne, C; Charland, S; Asselin, C; Nahmias, C; Rivard, N			Negative regulation of beta-catenin signaling by tyrosine phosphatase SHP-1 in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; PROTEIN-KINASE; CYCLIN D1; GROWTH-REGULATION; BINDING PROTEIN; COLON-CARCINOMA; GENE-EXPRESSION; CACO-2 CELLS; MOTH-EATEN; DNA-DAMAGE	Protein-tyrosine phosphatase SHP-1 is expressed at high levels in hematopoietic cells and at moderate levels in many other cell types including epithelial cells. Although SHP-1 has been shown to be a negative regulator of multiple signaling pathways in hematopoietic cells, very little is known about the biological role of SHP-1 in epithelial cells. In order to elucidate the mechanism(s) responsible for the loss of proliferative potential once committed intestinal epithelial cells begin to differentiate, the role and regulation of SHP-1 were analyzed in both intact epithelium as well as in well established intestinal cell models recapitulating the crypt-villus axis in vitro. Results show that SHP-1 was expressed in the nuclei of all intestinal epithelial cell models as well as in epithelial cells of intact human fetal jejunum and colon. Expression and phosphatase activity levels of SHP-1 were much more elevated in confluent growth-arrested intestinal epithelial cells and in differentiated enterocytes as well. Overexpression of SHP-1 in intestinal epithelial crypt cells significantly inhibited dhfr, c-myc, and cyclin D1 gene expression but did not interfere with c-fos gene expression. In contrast, a mutated inactive form of SHP-1 had no effect on these genes. SHP-1 expression significantly decreased beta-catenin/TCF-dependent transcription in intestinal epithelial crypt cells. Immunoprecipitation experiments revealed that beta-catenin is one of the main binding partners and a substrate for SHP-1. Taken together, our results indicate that SHP-1 may be involved in the regulation of beta-catenin transcriptional function and in the negative control of intestinal epithelial cell proliferation.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada; Inst Cochin, Dept Cell Biol, F-75014 Paris, France	University of Sherbrooke; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada.							Adachi M, 1996, CELL, V85, P15; Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; [Anonymous], 1920, CONTRIBUTIONS EMBRYO; BABYATSKY MW, 1999, GROWTH DEV GASTROINT, P547; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chiang GG, 2001, J BIOL CHEM, V276, P23173, DOI 10.1074/jbc.M101219200; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Engle MJ, 1998, J CELL PHYSIOL, V174, P362, DOI 10.1002/(SICI)1097-4652(199803)174:3<362::AID-JCP10>3.0.CO;2-B; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Gallet A, 1999, EMBO J, V18, P2208, DOI 10.1093/emboj/18.8.2208; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hiscox S, 1999, ANTICANCER RES, V19, P509; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Ilan N, 1999, J CELL SCI, V112, P3005; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; Kim K, 2001, CELL BIOL INT, V25, P421, DOI 10.1006/cbir.2000.0650; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mariadason JM, 2001, CANCER RES, V61, P3465; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Qu CK, 2000, CELL RES, V10, P279, DOI 10.1038/sj.cr.7290055; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shackney SE, 1999, CYTOMETRY, V35, P97, DOI 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.3.CO;2-X; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Treisman R, 1990, Semin Cancer Biol, V1, P47; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UMBAS R, 1992, CANCER RES, V52, P5104; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; VACHON PH, 1995, AM J PHYSIOL, V268, P857; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	75	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14274	14283		10.1074/jbc.M300425200	http://dx.doi.org/10.1074/jbc.M300425200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571228	hybrid			2022-12-27	WOS:000182405000090
J	Lim, ST; Longley, RL; Couchman, JR; Woods, A				Lim, ST; Longley, RL; Couchman, JR; Woods, A			Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; PHOSPHORYLATION; CASK/LIN-2; ACTIVATION; CONTACTS; PICK1	Syndecan-4 is a transmembrane heparan sulfate proteoglycan that, acts as a coreceptor with integrins in focal adhesion formation. The central region of syndecan-4 cytoplasmic domain (4V, LGKKPIYKK) binds phosphatidylinositol 4,5-bisphosphate, and together they regulate protein kinase Calpha (PKCalpha) activity. Syndecan 4V peptide directly potentiates PKCalpha activity, leading to "superactivation" of the enzyme, apparently through an interaction with its catalytic domain. We now have performed yeast two-hybrid and in vitro binding assays to determine the interaction sites between 4V and PKCalpha. Full-length PKCa weakly interacted with 4V by yeast two-hybrid assays, but PKCalpha constructs that lack the pseudosubstrate region or constructs of the whole catalytic domain interacted more strongly. A mu tated 4V sequence (4V(YF): LGKKPIFKK) did not interact with PKCalpha, indicating that tyrosine 192 in the syndecan-4 cytoplasmic domain might be critical for this interaction. Further assays identified a novel interaction site in the C terminus of the catalytic domain of PKCalpha (amino acid sequence 513-672). This encompasses the autophosphorylation sites, which are implicated in activation and stability. Yeast two-hybrid data were confirmed by in vitro binding and coimmunoprecipitation assays. The interaction of syndecan-4 with PKCa appears unique since PKCS and E did not interact with 4V in yeast two-hybrid assays or coimmunoprecipitate with syndecan-4. Finally, overexpression of syndecan-4 in rat embryo fibroblast cells, but not expression of the YF mutant, increased PKCalpha localization to focal adhesions. The data support a mechanism where syndecan-4 binds PKCalpha and localizes it to focal adhesions, whose assembly may be regulated by the kinase.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Schering Plough Res Inst, Union, NJ 07083 USA; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AZ, England	University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering-Plough Research Institute; Imperial College London	Woods, A (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, THT 946,1530 3rd Ave S, Birmingham, AL 35294 USA.	anwoods@ab.edu		Lim, Steve/0000-0003-0323-8607	NIGMS NIH HHS [GM50194] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, P1503; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Carey DJ, 1997, BIOCHEM J, V327, P1; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Ethell IM, 2000, J CELL BIOL, V151, P53, DOI 10.1083/jcb.151.1.53; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Haller H, 1998, CIRC RES, V82, P157; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; Longley RL, 1999, J CELL SCI, V112, P3421; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Shin J, 2001, BIOCHEMISTRY-US, V40, P8471, DOI 10.1021/bi002750r; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; VUORI K, 1993, J BIOL CHEM, V268, P21459; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; WOODS A, 1992, J CELL SCI, V101, P277; Zimmermann P, 1999, FASEB J, V13, pS91	37	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13795	13802		10.1074/jbc.M208300200	http://dx.doi.org/10.1074/jbc.M208300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571249	hybrid			2022-12-27	WOS:000182405000031
J	Boehr, DD; Jenkins, SI; Wright, GD				Boehr, DD; Jenkins, SI; Wright, GD			The molecular basis of the expansive substrate specificity of the antibiotic resistance enzyme aminoglycoside acetyltransferase-6 '-aminoglycoside phosphotransferase-2 '' - The role of Asp-99 as an active site base important for acetyl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; MAGNETIC-RESONANCE SPECTROSCOPY; SACCHAROMYCES-CEREVISIAE GNA1; CATALYTIC MECHANISM; KINASE APH(3')-IIIA; ANGSTROM RESOLUTION; MODIFYING ENZYMES; KINETIC MECHANISM; CRYSTAL-STRUCTURE; COENZYME-A	The most frequent determinant of aminoglycoside antibiotic resistance in Gram-positive bacterial pathogens is a bifunctional enzyme, aminoglycoside acetyltransferase-6'-aminoglycoside phosphotransferase-2" (AAC(6')-aminoglycoside phosphotransferase-2", capable of modifying a wide selection of clinically relevant antibiotics through its acetyltransferase and kinase activities. The aminoglycoside acetyltransferase domain of the enzyme, AAC(6')-Ie, is the only member of the large AAC(6') subclass known to modify fortimicin A and catalyze O-acetylation. We have demonstrated through solvent isotope, pH, and site-directed mutagenesis effects that Asp-99 is responsible for the distinct abilities of AAC(6')le. Moreover, we have demonstrated that small planar molecules such as 1-(bromomethyl)phenanthrene can inactivate the enzyme through covalent modification of this residue. Thus, Asp-99 acts as an active site base in the molecular mechanism of AAC(6')-Ie. The prominent role of this residue in aminoglycoside modification can be exploited as an anchoring site for the development of compounds capable of reversing antibiotic resistance in vivo.	McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University	Wright, GD (corresponding author), McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada.		Boehr, David/A-2068-2010; Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				Azucena E, 2001, DRUG RESIST UPDATE, V4, P106, DOI 10.1054/drup.2001.0197; Azucena E, 1997, J AM CHEM SOC, V119, P2317, DOI 10.1021/ja964278w; Boehr DD, 2001, CHEM BIOL, V8, P791, DOI 10.1016/S1074-5521(01)00051-5; Boehr DD, 2001, J BIOL CHEM, V276, P23929, DOI 10.1074/jbc.M100540200; BOTTO RE, 1983, J AM CHEM SOC, V105, P1021, DOI 10.1021/ja00342a062; Burk DL, 2001, BIOCHEMISTRY-US, V40, P8756, DOI 10.1021/bi010504p; Culebras Esther, 1999, Frontiers in Bioscience, V4, pD1, DOI 10.2741/culebras; Daigle DM, 1999, CHEM BIOL, V6, P99, DOI 10.1016/S1074-5521(99)80006-4; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DORMAN DE, 1976, J AM CHEM SOC, V98, P6885, DOI 10.1021/ja00438a020; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; LEATHERBARROW RJ, 2000, GRAFIT VERSION 4 0; Llano-Sotelo B, 2002, CHEM BIOL, V9, P455, DOI 10.1016/S1074-5521(02)00125-4; Magnet S, 2001, BIOCHEMISTRY-US, V40, P3700, DOI 10.1021/bi002736e; MARTEL A, 1983, EUR J BIOCHEM, V133, P515, DOI 10.1111/j.1432-1033.1983.tb07494.x; MILLER GH, 1997, CLIN INFECT DIS, V24, P46; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Peneff C, 2001, J BIOL CHEM, V276, P16328, DOI 10.1074/jbc.M009988200; RADIKA K, 1984, J BIOL CHEM, V259, P2543; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Shmara A, 2001, ANTIMICROB AGENTS CH, V45, P3287, DOI 10.1128/AAC.45.12.3287-3292.2001; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thompson PR, 2002, BIOCHEMISTRY-US, V41, P7001, DOI 10.1021/bi0256680; Vetting MW, 2002, NAT STRUCT BIOL, V9, P653, DOI 10.1038/nsb830; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; WRIGHT GD, 1990, BIOCHIM BIOPHYS ACTA, V1040, P95, DOI 10.1016/0167-4838(90)90151-5; Wright GD, 1998, ADV EXP MED BIOL, V456, P27; Wright Gerard D., 1999, Frontiers in Bioscience, V4, pD9, DOI 10.2741/Wright; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5	40	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12873	12880		10.1074/jbc.M211680200	http://dx.doi.org/10.1074/jbc.M211680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566434	hybrid			2022-12-27	WOS:000182189500037
J	Chen, R; Lee, JC				Chen, R; Lee, JC			Functional roles of loops 3 and 4 in the cyclic nucleotide binding domain of cyclic AMP receptor protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; REGULATORY SUBUNIT; FOOTPRINTING TECHNIQUE; PREDICTED STRUCTURES; CRYSTAL-STRUCTURE; CAMP; SITES; KINASE; ACTIVATION; MUTAGENESIS	Cyclic AMP is a ubiquitous secondary message that regulates a large variety of functions. The protein structural motif that binds cAMP is highly conserved with the exception of loops 3 and 4, whose structure and length are variable. The cAMP receptor protein of Escherichia coli, CRP, was employed as a model system to elucidate the functional roles of these loops. Based on the sequence differences between CRP and cyclic nucleotide gated channel, three mutants of CRP were constructed: deletion (residues 54-56 in loop 3 were deleted), insertion (loop 4 was lengthened by 5 residues between Glu-78 and Gly-79) and double mutants. The effects of these mutations on the structure and function of CRP were monitored. Results show that the deletion and insertion mutations do not significantly change the secondary structure of CRP, although the tertiary and quaternary structures are perturbed. The functional data indicate that loop 3 modulates the binding affinities of cAMP and DNA. Although the lengthened loop 4 may have some fine-tuning functions, the specific function of the original loop 4 of CRP remains uncertain. The function consequences of mutation in loop 3 of CRP are similar to that of site A and site B in the regulatory subunits of cyclic AMP-dependent protein kinases. Thus, the roles played by loop 3 in CRP may represent a more common mechanism employed by cyclic nucleotide binding domain in modulating ligand binding affinity and intramolecular communication.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lee, JC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	jelee@utmb.edu	Lee, James C/A-7849-2009		NIGMS NIH HHS [GM-45579] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baichoo N, 1999, PROTEIN SCI, V8, P518; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Cheng XD, 1998, BIOCHEMISTRY-US, V37, P51, DOI 10.1021/bi9719455; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; Chu SY, 2001, J BIOL CHEM, V276, P11230, DOI 10.1074/jbc.M010428200; COHN EJ, 1943, PROTEINS AMINO ACIDS, P372; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; DEGRAZIA H, 1990, BIOCHEMISTRY-US, V29, P3557, DOI 10.1021/bi00466a019; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; GRONENBORN AM, 1988, BIOCHEM J, V253, P801, DOI 10.1042/bj2530801; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Lee J C, 1979, Methods Enzymol, V61, P49; Lin SH, 2002, BIOCHEMISTRY-US, V41, P11857, DOI 10.1021/bi026099z; Lin SH, 2002, BIOCHEMISTRY-US, V41, P2946, DOI 10.1021/bi0119215; Malecki J, 2000, J BIOL CHEM, V275, P8480, DOI 10.1074/jbc.275.12.8480; Minard P, 2001, PROTEIN SCI, V10, P129, DOI 10.1110/ps.32401; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1982, FEBS LETT, V150, P161, DOI 10.1016/0014-5793(82)81326-4; OGREID D, 1983, J BIOL CHEM, V258, P1041; Pan H, 2000, P NATL ACAD SCI USA, V97, P12020, DOI 10.1073/pnas.220240297; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Richards MJ, 2000, BIOCHEMISTRY-US, V39, P14003, DOI 10.1021/bi001639i; ROBINSONSTEINER AM, 1983, J BIOL CHEM, V258, P1032; SAMBROOOK J, 2001, MOL CLONING LAB MANU, V2; Scott SP, 2001, BIOCHEMISTRY-US, V40, P7464, DOI 10.1021/bi002804x; Scott SP, 1996, PROTEIN ENG, V9, P333, DOI 10.1093/protein/9.4.333; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAN GS, 1991, BIOCHEMISTRY-US, V30, P5076, DOI 10.1021/bi00234a034; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Tibbs GR, 1998, J BIOL CHEM, V273, P4497, DOI 10.1074/jbc.273.8.4497; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; WASYLEWSKI M, 1995, J PROTEIN CHEM, V14, P299, DOI 10.1007/BF01886787; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; Won HS, 2002, J BIOL CHEM, V277, P11450, DOI 10.1074/jbc.M112411200; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	48	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13235	13243		10.1074/jbc.M211551200	http://dx.doi.org/10.1074/jbc.M211551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551924	hybrid			2022-12-27	WOS:000182189500082
J	Krohn, NM; Stemmer, C; Fojan, P; Grimm, R; Grasser, KD				Krohn, NM; Stemmer, C; Fojan, P; Grimm, R; Grasser, KD			Protein kinase CK2 phosphorylates the high mobility group domain protein SSRP1, inducing the recognition of UV-damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; GROUP BOX PROTEIN; SACCHAROMYCES-CEREVISIAE; HMG DOMAIN; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME-BINDING; POLYMERASE-ALPHA; CHROMATIN; MAIZE; POB3	The structure-specific recognition protein SSRP1 plays a role in transcription and replication in the chromatin context. Mediated by its C-terminal high mobility group (HMG) box domain, SSRP1 binds DNA non-sequence specifically but recognizes certain DNA structures. Using acetic acid urea polyacrylamide gel electrophoresis and mass spectrometry, we have examined the phosphorylation of maize SSRP1 by protein kinase CK2alpha. The kinase phosphorylated several amino acid residues in the C-terminal part of the SSRP1 protein. Two phosphorylation sites were mapped in the very C-terminal region next to the HMG box domain, and about seven sites are localized within the acidic domain. Circular dichroism showed that the phosphorylation of the two C-terminal sites by CK2alpha resulted in a structural change in the region of HMG box domain, because the negative peak of the CD spectrum at 222 nm was decreased by similar to10%. In parallel, the phosphorylation induced the recognition of UV-damaged DNA, whereas the non-phosphorylated protein does not discriminate between UV-damaged DNA and control DNA. The affinity of CK2alpha-phosphorylated SSRP1 for the DNA correlates with the degree of UV-induced DNA damage. Moreover, maize SSRP1 can restore the increased UV-sensitivity of a yeast strain lacking the NHP6A/B HMG domain proteins to levels of the control strain. Collectively, these findings indicate a role for SSRP1 in the UV response of eukaryotic cells.	Aalborg Univ, Inst Life Sci, DK-9000 Aalborg, Denmark; Agilent Technol, D-76337 Waldbronn, Germany	Aalborg University; Agilent Technologies	Grasser, KD (corresponding author), Aalborg Univ, Inst Life Sci, Sohngaardsholmsvej 49, DK-9000 Aalborg, Denmark.	kdg@bio.auc.dk		Fojan, Peter/0000-0002-0626-4766				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Birrell GW, 2001, P NATL ACAD SCI USA, V98, P12608, DOI 10.1073/pnas.231366398; Brenneisen P, 2002, BIOCHEM J, V365, P31, DOI 10.1042/BJ20020110; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; Dyer MA, 1998, MOL CELL BIOL, V18, P2617, DOI 10.1128/MCB.18.5.2617; Espunya MC, 1997, PLANT SCI, V124, P131, DOI 10.1016/S0168-9452(96)04599-2; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Gariglio M, 1997, EXP CELL RES, V236, P472, DOI 10.1006/excr.1997.3742; Grasser KD, 1996, J BIOL CHEM, V271, P32900, DOI 10.1074/jbc.271.51.32900; Grasser KD, 2000, PHYSIOL PLANTARUM, V110, P427, DOI 10.1111/j.1399-3054.2000.1100401.x; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; Hertel L, 1999, EXP CELL RES, V250, P313, DOI 10.1006/excr.1999.4495; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; LENNOX RW, 1989, METHOD ENZYMOL, V170, P532; Lichota J, 2001, BIOCHEMISTRY-US, V40, P7860, DOI 10.1021/bi010548y; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lysetska M, 2002, NUCLEIC ACIDS RES, V30, P2686, DOI 10.1093/nar/gkf378; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Riera M, 2001, MOL CELL BIOCHEM, V227, P119, DOI 10.1023/A:1013141713277; Rottgers K, 2000, PLANT J, V23, P395, DOI 10.1046/j.1365-313x.2000.00801.x; Schlesinger MB, 2000, GENETICS, V155, P1593; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Spencer JA, 1999, J BIOL CHEM, V274, P15686, DOI 10.1074/jbc.274.22.15686; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; WHITTAKER PA, 1986, GENE, V41, P129, DOI 10.1016/0378-1119(86)90276-3; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Yarnell AT, 2001, J BIOL CHEM, V276, P25736, DOI 10.1074/jbc.M101208200	47	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12710	12715		10.1074/jbc.M300250200	http://dx.doi.org/10.1074/jbc.M300250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571244	hybrid			2022-12-27	WOS:000182189500017
J	Chavey, C; Mari, B; Monthouel, MN; Bonnafous, S; Anglard, P; Van Obberghen, E; Tartare-Deckert, S				Chavey, C; Mari, B; Monthouel, MN; Bonnafous, S; Anglard, P; Van Obberghen, E; Tartare-Deckert, S			Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; TNF-ALPHA; CELLS; MICE; ADIPOGENESIS; PROLIFERATION; INHIBITOR; LEPTIN; GENE; PREADIPOCYTES	Matrix metalloproteinases (MMPs) are essential for proper extracellular matrix remodeling, a process that takes place during obesity-mediated adipose tissue formation. Here, we examine expression profiles and the potential role of MMPs and their tissue inhibitors (TIMPs) in adipose tissue remodeling during obesity. Expression patterns are studied by Northern blot and real-time PCR in two genetic models of obesity (ob/ob and db/db mice) and in a diet-induced model of obesity (AKR mice). Of the MMPs and TIMPs studied, mRNA levels for MMP-2, MMP-3, MMP-12, MNW-14, MMP-19, and TIMP-1 are strongly induced in obese adipose tissues compared with lean tissues. In contrast, MMP-7 and TIMP-3 mRNAs are markedly decreased in obesity. Interestingly, enzymatic activities of MMP-12 and of a new identified adipocyte-derived 30-kDa metalloproteinase are enhanced in obese adipose tissue fractions, demonstrating that MMP/TIMP balance is shifted toward increased matrix degradation in obesity. Finally, we analyze the modulation of MMP-2, MMP-19, and TIMP-1 during 3T3-L1 preadipocyte differentiation, and we explore the effect of inhibition of MMP activity on in vitro adipogenesis. We find that the synthetic MMP inhibitor BB-94 (Batimastat) decreases adipose conversion of 3T3-L1 and primary rat preadipocytes. BB-94 represses differentiation without affecting mitotic clonal expansion but prevents the early expression of CCAAT/enhancer-binding protein beta, a transcription factor that is thought to play a major role in the adipogenic program. Such findings support a role for the MMP/TIMP system in the control of proteolytic events and adipogenesis during obesity-mediated fat mass development.	INSERM, U145, IFR 50, F-06107 Nice, France; INSERM, U385, Fac Med, F-06107 Nice 2, France; INSERM, U526, IFR 50, F-06107 Nice, France; UMR 7104, Inst Genet & Biol Mol, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm)	Tartare-Deckert, S (corresponding author), INSERM, U385, Fac Med, Ave Valombrose, F-06107 Nice 2, France.		Anglard, Patrick/M-6618-2019; Mari, Bernard/Q-5832-2019; Mari, Bernard P/F-8960-2013; Mari, Bernard P/GVS-3100-2022; TARTARE-DECKERT, Sophie/P-6057-2015; Mari, Bernard P/D-7445-2015	Anglard, Patrick/0000-0001-5701-441X; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Mari, Bernard P/0000-0002-0422-9182; Chavey, Carine/0000-0002-5267-5638				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Alessi MC, 2000, HORM METAB RES, V32, P504, DOI 10.1055/s-2007-978677; Alexander CM, 2001, J CELL BIOL, V152, P693, DOI 10.1083/jcb.152.4.693; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Bouloumie A, 2001, DIABETES, V50, P2080, DOI 10.2337/diabetes.50.9.2080; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown LM, 1997, AM J PHYSIOL-CELL PH, V272, pC937, DOI 10.1152/ajpcell.1997.272.3.C937; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Curci JA, 1998, J CLIN INVEST, V102, P1900, DOI 10.1172/JCI2182; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Kawaguchi N, 2002, AM J PATHOL, V160, P1895, DOI 10.1016/S0002-9440(10)61136-4; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Lijnen HR, 2002, ARTERIOSCL THROM VAS, V22, P374, DOI 10.1161/hq0302.104522; Lijnen HR, 2001, THROMB HAEMOSTASIS, V85, P1111; Lijnen HR, 2002, THROMB HAEMOSTASIS, V87, P530; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Maquoi E, 2002, DIABETES, V51, P1093, DOI 10.2337/diabetes.51.4.1093; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Pierleoni C, 1998, EUR J HISTOCHEM, V42, P183; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Selvarajan S, 2001, NAT CELL BIOL, V3, P267, DOI 10.1038/35060059; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P22231, DOI 10.1074/jbc.M010634200; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	42	340	353	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11888	11896		10.1074/jbc.M209196200	http://dx.doi.org/10.1074/jbc.M209196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529376	hybrid			2022-12-27	WOS:000182015700023
J	Golovleva, I; Bhattacharya, S; Wu, ZP; Shaw, N; Yang, YW; Andrabi, H; West, KA; Burstedt, MSI; Forsman, K; Holmgren, G; Sandgren, O; Noy, N; Qin, J; Crabb, JW				Golovleva, I; Bhattacharya, S; Wu, ZP; Shaw, N; Yang, YW; Andrabi, H; West, KA; Burstedt, MSI; Forsman, K; Holmgren, G; Sandgren, O; Noy, N; Qin, J; Crabb, JW			Disease-causing mutations in the cellular retinaldehyde binding protein tighten and abolish ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; RETINITIS-PIGMENTOSA; BOTHNIA DYSTROPHY; CYCLE; RLBP1; SPECIFICITY	Mutations in the human cellular retinaldehyde binding Protein (CRALBP) gene cause retinal pathology. To understand the molecular basis of impaired CRALBP function, we have characterized human recombinant CRALBP containing the disease causing mutations R233W or M225K Protein structures were verified by amino acid analysis and mass spectrometry, retinoid binding properties were evaluated by UV-visible and fluorescence spectroscopy and substrate carrier functions were assayed for recombinant 11-cis-retinol dehydrogenase (rRDH5). The M225K mutant was less soluble than the R233W mutant and lacked retinoid binding capability and substrate carrier function. In contrast, the R233W mutant exhibited solubility comparable to wild type rCRALBP and bound stoichiometric amounts of 11-cis- and 9-cis-retinal with at least 2-fold higher affinity than wild type rCRALBP. Holo-R233W significantly decreased the apparent affinity of rRDH5 for 11-cis-retinoid relative to wild type rCRALBP. Analyses by heteronuclear single quantum correlation NMR demonstrated that the R233W protein exhibits a different conformation than wild type rCRALBP, including a different retinoid-binding pocket conformation. The R233W mutant also undergoes less extensive structural changes upon photoisomerization of bound ligand, suggesting a more constrained structure than that of the wild type protein. Overall, the results show that the M225K mutation abolishes and the R233W mutation tightens retinoid binding and both impair CRALBP function in the visual cycle as an 11-cis-retinol acceptor and as a substrate carrier.	Umea Univ, Dept Med Biosci, S-90185 Umea, Sweden; Umea Univ, Dept Ophthalmol, S-90185 Umea, Sweden; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Umea University; Umea University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cornell University; University System of Ohio; Cleveland State University	Crabb, JW (corresponding author), Umea Univ, Norrlands Univ Hosp, S-90185 Umea, Sweden.	crabbj@ccf.org		Qin, Jun/0000-0002-2647-9270; Golovleva, Irina/0000-0001-8741-0616; andrabi, Khurshid/0000-0003-0314-5662	NCI NIH HHS [CA68150] Funding Source: Medline; NEI NIH HHS [EY6603, EY14239] Funding Source: Medline; NHLBI NIH HHS [HL58758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhattacharya SK, 2002, FASEB J, V16, pA14; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budhu A, 2001, J MOL BIOL, V305, P939, DOI 10.1006/jmbi.2000.4340; Burstedt MSI, 1999, INVEST OPHTH VIS SCI, V40, P995; Burstedt MSL, 2001, ARCH OPHTHALMOL-CHIC, V119, P260; Crabb JW, 1998, METH MOL B, V89, P91; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; Crabb JW, 2001, INVEST OPHTH VIS SCI, V42, pS655; CRABB JW, 1997, CURRENT PROTOCOLS S, V7; Crouch RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P613, DOI 10.1111/j.1751-1097.1996.tb03114.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; Eichers ER, 2002, AM J HUM GENET, V70, P955, DOI 10.1086/339688; FUTTERMAN S, 1961, J BIOL CHEM, V236, P1652; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Jang GF, 2000, J BIOL CHEM, V275, P28128; Katsanis N, 2001, CLIN GENET, V59, P424, DOI 10.1034/j.1399-0004.2001.590607.x; Kennedy B N, 1998, Mol Vis, V4, P14; Luck LA, 1997, TECH PROT CHEM, V8, P439, DOI 10.1016/S1080-8914(97)80044-0; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; NOY N, 1999, HANDB EXP PHARM, V139, P3; Phelan JK, 2000, MOL VIS, V6, P116; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; Saari John C., 1994, P351; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058; Wu ZP, 2003, J BIOL CHEM, V278, P12390, DOI 10.1074/jbc.M212775200	35	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12397	12402		10.1074/jbc.M207300200	http://dx.doi.org/10.1074/jbc.M207300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12536144	hybrid			2022-12-27	WOS:000182015700088
J	Hoyt, MA; Zhang, MS; Coffino, P				Hoyt, MA; Zhang, MS; Coffino, P			Ubiquitin-independent mechanisms of mouse ornithine decarboxylase degradation are conserved between mammalian and fungal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; DOA4 DEUBIQUITINATING ENZYME; IN-VIVO DEGRADATION; SACCHAROMYCES-CEREVISIAE; 26S PROTEASOME; INTRACELLULAR DEGRADATION; REGULATED DEGRADATION; ACTIVATING ENZYME; ANTIZYME; GENE	The polyamine biosynthetic enzyme ornithine decarboxylase (ODC) is degraded by the 26 S proteasome via a ubiquitin-independent pathway in mammalian cells. Its degradation is greatly accelerated by association with the polyamine-induced regulatory protein antizyme I (AZ1). Mouse ODC (mODC) that is expressed in the yeast Saccharomyces cerevisiae is also rapidly degraded by the proteasome of that organism. We have now carried out in vivo and in vitro studies to determine whether S. cerevisiae proteasomes recognize mODC degradation signals. Mutations of mODC that stabilized the protein in animal cells also did so in the fungus. Moreover, the mODC degradation signal was able to destabilize a GFP or Ura3 reporter in GFP-mODC and Ura3-mODC fusion proteins. Co-expression of AZ1 accelerated mODC degradation 2-3-fold in yeast cells. The degradation of both mODC and the endogenous yeast ODC (yODC) was unaffected in S. cerevisiae mutants with various defects in ubiquitin metabolism, and ubiquitinylated forms of mODC were not detected in yeast cells. In addition, recombinant mODC was degraded in an ATP-dependent manner by affinity-purified yeast 26 S proteasomes in the absence of ubiquitin. Degradation by purified yeast proteasomes was sensitive to mutations that stabilized mODC in vivo, but was not accelerated by recombinant AZ1. These studies demonstrate that cell constituents required for mODC degradation are conserved between animals and fungi, and that both mammalian and fungal ODC are subject to proteasome-mediated proteolysis by ubiquitin-independent mechanisms.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.			Coffino, Philip/0000-0003-0344-5083	NIGMS NIH HHS [GM45335, GM20527] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Brachmann CB, 1998, YEAST, V14, P115; Chattopadhyay MK, 2001, J BIOL CHEM, V276, P21235, DOI 10.1074/jbc.M010643200; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; FONZI WA, 1987, J BIOL CHEM, V262, P10127; FONZI WA, 1989, J BIOL CHEM, V264, P18110; Gandre S, 2002, BIOCHEM BIOPH RES CO, V293, P139, DOI 10.1016/S0006-291X(02)00194-8; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GHODA L, 1990, J BIOL CHEM, V265, P11823; GLASS JR, 1986, BIOCHEM J, V236, P351, DOI 10.1042/bj2360351; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GUPTA M, 1985, J BIOL CHEM, V260, P2941; Gupta R, 2001, P NATL ACAD SCI USA, V98, P10620, DOI 10.1073/pnas.181341298; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Ivanov IP, 1998, MOL CELL BIOL, V18, P1553, DOI 10.1128/MCB.18.3.1553; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; MAMROUDKIDRON E, 1994, FEBS LETT, V356, P162, DOI 10.1016/0014-5793(94)01260-1; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Toth C, 1999, J BIOL CHEM, V274, P25921, DOI 10.1074/jbc.274.36.25921; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Zhu C, 2000, BIOINFORMATICS, V16, P478, DOI 10.1093/bioinformatics/16.5.478	59	60	61	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12135	12143		10.1074/jbc.M211802200	http://dx.doi.org/10.1074/jbc.M211802200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12562772	hybrid			2022-12-27	WOS:000182015700055
J	Leckie, C; Empson, R; Becchetti, A; Thomas, J; Galione, A; Whitaker, M				Leckie, C; Empson, R; Becchetti, A; Thomas, J; Galione, A; Whitaker, M			The NO pathway acts late during the fertilization response in sea urchin eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; PHOSPHOLIPASE C-GAMMA; FREE CALCIUM LEVELS; NITRIC-OXIDE; INOSITOL 1,4,5-TRISPHOSPHATE; CA2+ OSCILLATIONS; SIGNALING PATHWAY; INTRACELLULAR PH; STARFISH EGGS; ACTIVATION	Both the inositol 1,4,5-trisphosphate (InsP(3)) and ryanodine receptor pathways contribute to the Ca2+ transient at fertilization in sea urchin eggs. To date, the precise contribution of each pathway has been difficult to ascertain. Evidence has accumulated to suggest that the InsP(3) receptor pathway has a primary role in causing Ca2+ release and egg activation. However, this was recently called into question by a report implicating NO as the primary egg activator. In the present study we pursue the hypothesis that NO is a primary egg activator in sea urchin eggs and build on previous findings that an NO/cGMP/cyclic ADP-ribose (cADPR) pathway is active at fertilization in sea urchin eggs to define its role. Using a fluorescence indicator of NO levels, we have measured both NO and Ca2+ at fertilization and establish that NO levels rise after, not before, the Ca2+ wave is initiated and that this rise is Ca2+-dependent. By inhibiting the increase in NO at fertilization, we find not that the Ca2+ transient is abolished but that the duration of the transient is significantly reduced. The latency and rise time of the transient are unaffected. This effect is mirrored by the inhibition of cGMP and cADPR signaling in sea urchin eggs at fertilization. We establish that cADPR is generated at fertilization, at a time comparable to the time of the rise in NO levels. We conclude that NO is unlikely to be a primary egg activator but, rather, acts after the initiation of the Ca2+ wave to regulate the duration of the fertilization Ca2+ transient.	Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	Newcastle University - UK; University of Oxford	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Galione, Antony/E-5884-2011; Becchetti, Andrea/AAF-7821-2020	Becchetti, Andrea/0000-0002-9297-0527; Galione, Antony/0000-0002-4132-7646; Empson, Ruth/0000-0002-0415-6083				Abassi YA, 2000, DEV BIOL, V218, P206, DOI 10.1006/dbio.1999.9582; AYABE T, 1995, DEVELOPMENT, V121, P2233; Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; Carroll DJ, 1999, DEV BIOL, V206, P232, DOI 10.1006/dbio.1998.9145; Carroll J, 2001, SEMIN CELL DEV BIOL, V12, P37, DOI 10.1006/scdb.2000.0215; Ciapa B, 1996, BIOCHEM BIOPH RES CO, V223, P633, DOI 10.1006/bbrc.1996.0946; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CROSSLEY I, 1991, CELL REGUL, V2, P121, DOI 10.1091/mbc.2.2.121; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Giusti AF, 2000, J BIOL CHEM, V275, P16788, DOI 10.1074/jbc.M001091200; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; HOFMANN F, 1985, EUR J BIOCHEM, V150, P85, DOI 10.1111/j.1432-1033.1985.tb08991.x; Hyslop LA, 2001, DEV BIOL, V234, P216, DOI 10.1006/dbio.2001.0252; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Kinsey WH, 2000, DEV BIOL, V225, P253, DOI 10.1006/dbio.2000.9830; Kojima H, 2001, J NEUROCHEM, V76, P1404, DOI 10.1046/j.1471-4159.2001.00161.x; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Kuo RK, 2000, NATURE, V406, P633, DOI 10.1038/35020577; Kuroda R, 2001, DEVELOPMENT, V128, P4405; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Lee SJ, 1996, DEV BIOL, V180, P324, DOI 10.1006/dbio.1996.0304; Lee SJ, 1998, DEV BIOL, V193, P195, DOI 10.1006/dbio.1997.8792; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MILLER AL, 1993, J CELL SCI, V106, P523; MIYAZAKI S, 1993, BIOMED RES-TOKYO, V14, P35; MOHRI T, 1995, DEV BIOL, V172, P139, DOI 10.1006/dbio.1995.0011; NUCCITELLI R, 1993, DEV BIOL, V158, P200, DOI 10.1006/dbio.1993.1179; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; REES BB, 1995, DEV BIOL, V169, P683, DOI 10.1006/dbio.1995.1179; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Sethi JK, 1996, BIOCHEM J, V319, P613, DOI 10.1042/bj3190613; Shearer J, 1999, DEVELOPMENT, V126, P2273; SHEN SS, 1993, DEV BIOL, V157, P157, DOI 10.1006/dbio.1993.1120; SHEN SS, 1978, NATURE, V272, P253, DOI 10.1038/272253a0; Shiwa M, 2002, AM J PHYSIOL-REG I, V282, pR727, DOI 10.1152/ajpregu.00519.2001; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; SWANN K, 1985, NATURE, V314, P274, DOI 10.1038/314274a0; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WENNMALM A, 1992, BRIT J PHARMACOL, V106, P507, DOI 10.1111/j.1476-5381.1992.tb14365.x; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER MJ, 1982, Q REV BIOPHYS, V15, P593, DOI 10.1017/S0033583500003760; Willmott N, 1996, J BIOL CHEM, V271, P3699; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Yoshida M, 1998, DEV BIOL, V203, P122, DOI 10.1006/dbio.1998.9037; ZUCKER RS, 1978, BIOCHIM BIOPHYS ACTA, V541, P459, DOI 10.1016/0304-4165(78)90155-1	58	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12247	12254		10.1074/jbc.M210770200	http://dx.doi.org/10.1074/jbc.M210770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540836	hybrid			2022-12-27	WOS:000182015700069
J	Mukherjee, TK; Nathan, L; Dinh, H; Reddy, ST; Chaudhuri, G				Mukherjee, TK; Nathan, L; Dinh, H; Reddy, ST; Chaudhuri, G			17-epiestriol, an estrogen metabolite, is more potent than estradiol in inhibiting vascular cell adhesion molecule 1 (VCAM-1) mRNA expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA MESSENGER-RNA; RECEPTOR-BETA; NITRIC-OXIDE; ENDOTHELIAL-CELLS; INJURY RESPONSE; SMOOTH-MUSCLE; E-SELECTIN; ALPHA; ATHEROSCLEROSIS; 17-BETA-ESTRADIOL	17-beta estradiol (17-beta E-2) attenuates the expression of vascular cell adhesion molecule 1 (VCAM-1) in vivo at physiological levels (pg/ml), whereas supraphysiological concentrations of 17-beta E-2 (ng/ml) are required in vitro. We assessed whether a metabolite of estrogen, which could only be generated in vivo, might be a more potent inhibitor of VCAM-1 expression and thereby explain this discrepancy. We report here that 17-epiestriol, an estrogen metabolite and a selective estrogen receptor (ER) 13 agonist, is similar to400X more potent than 17-beta E-2 in suppressing tumor necrosis factor (TNF) alpha-induced VCAM-1 mRNA as well as protein expression in human umbilical vein endothelial cells. Genistein, an ERbeta agonist, at low concentrations (1 and 10 nm) also suppressed TNFalpha-induced VCAM-1 mRNA expression. These actions of 17-epiestriol and genistein were significantly attenuated in the presence of the estrogen receptor antagonist ICI-182780. Other estrogenic compounds such as ethinyl estradiol and estrone did not have any effect on TNFalpha-induced VCAM-1 expression at the concentrations tested. We further show that, 1) 17-epiestriol induces the expression of endothelial nitric-oxide synthase mRNA and protein, 2) 17-epiestriol prevents TNFa-induced migration of NFkappaB into the nucleus, 3) N-G-nitro-L-arginine methyl ester, an inhibitor of NO synthesis, abolishes 17-epiestriol-mediated inhibition of TNFalpha-induced VCAM-1 expression and migration of NFkappaB from the cytoplasm to the nucleus. Our results indicate that 17-epiestriol is more potent than 17-beta E-2 in suppressing TNFalpha-induced VCAM-1 expression and that this action is modulated at least in part through NO.	Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Chaudhuri, G (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Dept Obstet & Gynecol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Mukherjee, Tapan/0000-0001-6737-8321	NIA NIH HHS [AG-15857] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015857] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aziz KE, 1996, CELL IMMUNOL, V167, P79, DOI 10.1006/cimm.1996.0010; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; CaulinGlaser T, 1997, CIRC RES, V81, P885; CaulinGlaser T, 1996, J CLIN INVEST, V98, P36, DOI 10.1172/JCI118774; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CID MC, 1994, J CLIN INVEST, V93, P17, DOI 10.1172/JCI116941; DE CR, 1995, J CLIN INVEST, V96, P60; DECATERINA R, 1995, N 3 FATTY ACIDS PREV, P9; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; Haynes MP, 2000, J NUCL CARDIOL, V7, P500, DOI 10.1067/mnc.2000.109958; Hodges YK, 2000, CIRCULATION, V101, P1792, DOI 10.1161/01.CIR.101.15.1792; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; Karas RH, 1999, P NATL ACAD SCI USA, V96, P15133, DOI 10.1073/pnas.96.26.15133; Katsuyama K, 1998, ARTERIOSCL THROM VAS, V18, P1796, DOI 10.1161/01.ATV.18.11.1796; KUIPER GG, 1996, P NATL ACAD SCI USA, V90, P5925; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Lindner V, 1998, CIRC RES, V83, P224, DOI 10.1161/01.RES.83.2.224; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; Mukherjee TK, 2002, P NATL ACAD SCI USA, V99, P4055, DOI 10.1073/pnas.052703199; NAKAI K, 1994, LIFE SCI, V54, P221; Nathan L, 1997, ANNU REV PHARMACOL, V37, P477, DOI 10.1146/annurev.pharmtox.37.1.477; Nathan L, 1999, CIRC RES, V85, P377, DOI 10.1161/01.RES.85.4.377; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Register TC, 1998, J STEROID BIOCHEM, V64, P187, DOI 10.1016/S0960-0760(97)00155-6; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Simoncini T, 2000, CIRC RES, V87, P19, DOI 10.1161/01.RES.87.1.19; Singh R, 2000, CANCER RES, V60, P3305; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	32	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11746	11752		10.1074/jbc.M207800200	http://dx.doi.org/10.1074/jbc.M207800200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547825	hybrid			2022-12-27	WOS:000182015700005
J	Pudi, R; Abhiman, S; Srinivasan, N; Das, S				Pudi, R; Abhiman, S; Srinivasan, N; Das, S			Hepatitis C virus internal ribosome entry site-mediated translation is stimulated by specific interaction of independent regions of human La autoantigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TERMINATION FACTOR LA; MESSENGER-RNA; TRANSCRIPTION TERMINATION; CRYSTAL-STRUCTURE; BINDING PROTEIN; POLIOVIRUS RNA; RECOGNITION MOTIF; INITIATION CODON; LEADER RNA	The human La autoantigen has been shown to interact with the internal ribosome entry site (IRES) of hepatitis C virus (HCV) in vitro. Using a yeast three-hybrid system, we demonstrated that, in addition to full-length La protein, both N- and C-terminal halves were able to interact with HCV IRES in vivo. The exogenous addition of purified full-length and truncated La proteins in rabbit reticulocyte lysate showed dose-dependent stimulation of HCV IRES-mediated translation. However, an additive effect was achieved adding the terminal halves together in the reaction, suggesting that both might play critical roles in achieving full stimulatory activity of the full-length La protein. Using computational analysis, three-dimensional structures of the RNA recognition motifs (RRM) of the La protein were independently modeled. Of the three putative RRMs, RRM2 was predicted to have a good binding pocket for the interaction with the HCV IRES around the GCAC motif near the initiator AUG and RRM3 binds perhaps in a different location. This observation was further investigated by the filter-binding and toe-printing assays. The results presented here strongly suggest that both the N- and C-terminal halves can interact independently with the HCV IRES and are involved in stimulating internal initiation of translation.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in		Limgala, Renuka/0000-0001-6957-6284				Ali N, 2000, J BIOL CHEM, V275, P27531; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; FRANCOEUR AM, 1982, P NATL ACAD SCI-BIOL, V79, P6772, DOI 10.1073/pnas.79.22.6772; Fukushi S, 2001, VIRUS RES, V73, P67, DOI 10.1016/S0168-1702(00)00228-8; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; Hahn B, 1998, J VIROL, V72, P8782, DOI 10.1128/JVI.72.11.8782-8788.1998; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Isoyama T, 1999, J GEN VIROL, V80, P2319, DOI 10.1099/0022-1317-80-9-2319; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kim YK, 1999, J GEN VIROL, V80, P3159, DOI 10.1099/0022-1317-80-12-3159; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; Martin F, 2000, NUCLEIC ACIDS RES, V28, P1594, DOI 10.1093/nar/28.7.1594; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Ohndorf UM, 2001, J BIOL CHEM, V276, P27188, DOI 10.1074/jbc.M102891200; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; PARK YW, 1995, J BIOL CHEM, V270, P28433; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Reynolds JE, 1996, RNA, V2, P867; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; SRINIVASAN N, 1993, PROTEIN ENG, V6, P501, DOI 10.1093/protein/6.5.501; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P385, DOI 10.1093/protein/1.5.385; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TOPHAM CM, 1993, J MOL BIOL, V229, P194, DOI 10.1006/jmbi.1993.1018; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; ZHU ZY, 1992, PROTEIN ENG, V5, P43, DOI 10.1093/protein/5.1.43	61	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12231	12240		10.1074/jbc.M210287200	http://dx.doi.org/10.1074/jbc.M210287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540850	hybrid			2022-12-27	WOS:000182015700067
J	Dhar-Mascareno, M; Chen, J; Zhang, RH; Carcamo, JM; Golde, DW				Dhar-Mascareno, M; Chen, J; Zhang, RH; Carcamo, JM; Golde, DW			Granulocyte-macrophage colony-stimulating factor signals for increased glucose transport via phosphatidylinositol 3-kinase- and hydrogen peroxide-dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; HUMAN-ENDOTHELIAL CELLS; RECEPTOR-ALPHA-SUBUNIT; GM-CSF RECEPTOR; HEMATOPOIETIC-CELLS; HEXOSE-TRANSPORT; VITAMIN-C; GLUT4 TRANSLOCATION; CYTOPLASMIC DOMAIN; INSULIN ACTION	Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates cellular glucose uptake by decreasing the apparent Km for substrate transport through facilitative glucose transporters on the plasma membrane. Little is known about this signal transduction pathway and the role of the a subunit of the GM-CSF receptor (alphaGMR) in modulating transporter activity. We examined the function of phosphatidylinositol 3-kinase (PI 3-kinase) in GM-CSF-stimulated glucose uptake and found that PI 3-kinase inhibitors, wortmannin and LY294002, completely blocked the GM-CSF-dependent increase of glucose uptake in Xenopus oocytes expressing the low affinity aGMR and in human cells expressing the high affinity alphabetaGMR complex. We identified a Src homology 3 domain-binding motif in aGMR at residues 358-361 as a potential interaction site for the PI 3-kinase regulatory subunit, p85. Physical evidence for p85 binding to aGMR was obtained by co-immunoprecipitation with antibodies to aGMR and p85, and an aGMR mutant with alteration of the Src homology 3 binding domain lost the ability to bind p85. Experiments with a construct eliminating most of the intracellular portion of aGMR showed a 50% reduction in GM-CSF-stimulated glucose uptake with residual activity blocked by wortmannin. Searching for a proximally generated diffusible factor capable of activating PI 3-kinase, we identified hydrogen peroxide (H2O2), generated by ligand or antibody binding to aGMR, as the initiating factor. Catalase treatment abrogated GM-CSF- or anti-aGMR antibody-stimulated glucose uptake in alphaGMR-expressing oocytes, and H2O2 activated PI 3-kinase and led to some stimulation of glucose uptake in uninjected oocytes. Human myeloid cell lines and primary explant human lymphocytes expressing high affinity GM-CSF receptors responded to aGMR antibody with increased glucose uptake. These results identify the early events in the stimulation of glucose uptake by GM-CSF as involving local H2O2 generation and requiring PI 3-kinase activation. Our findings also provide a mechanistic explanation for signaling through the isolated a subunit of the GM-CSF receptor.	Mem Sloan Kettering Canc Ctr, Dept Clin Chem, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA; CUNY, Weill Grad Sch Med Sci, Dept Pharmacol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; City University of New York (CUNY) System; Cornell University	Golde, DW (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA.	d-golde@ski.mskcc.org	Dhar-Mascareno, Manya/S-9392-2019		NCI NIH HHS [2P30 CA08748-28, CA30388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA030388, R37CA030388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed N, 1997, BIOCHEM J, V327, P369, DOI 10.1042/bj3270369; AVALOS BR, 1990, BLOOD, V75, P851; BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; BIRD TA, 1990, J BIOL CHEM, V265, P13578; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Carcamo JM, 2002, BLOOD, V99, P3205, DOI 10.1182/blood.V99.9.3205; CORKEY RF, 1981, J CELL PHYSIOL, V106, P425, DOI 10.1002/jcp.1041060312; Cushman SW, 1998, ADV EXP MED BIOL, V441, P63; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEXTER TM, 1984, DIFFERENTIATION, V27, P163, DOI 10.1111/j.1432-0436.1984.tb01423.x; DING DXH, 1994, P NATL ACAD SCI USA, V91, P2537, DOI 10.1073/pnas.91.7.2537; DIPERSIO JF, 1990, INT J CELL CLONING, V8, P63, DOI 10.1002/stem.5530080707; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Egert S, 1997, CARDIOVASC RES, V35, P283, DOI 10.1016/S0008-6363(97)00133-8; Evans CA, 2002, BLOOD, V100, P3164, DOI 10.1182/blood-2001-12-0235; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; FREEDMAN MH, 1993, BLOOD, V81, P3068; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Geijsen N, 2001, CYTOKINE GROWTH F R, V12, P19, DOI 10.1016/S1359-6101(00)00019-8; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; GOULD GW, 1994, J BIOL CHEM, V269, P26622; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HAMILTON JA, 1988, J CELL PHYSIOL, V134, P405, DOI 10.1002/jcp.1041340311; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRSCH T, 1995, BIOCHEM BIOPH RES CO, V217, P138, DOI 10.1006/bbrc.1995.2755; Ishizuka T, 1999, AM J PHYSIOL-ENDOC M, V276, pE196, DOI 10.1152/ajpendo.1999.276.1.E196; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kozlovsky N, 1997, FREE RADICAL BIO MED, V23, P859, DOI 10.1016/S0891-5849(97)00069-5; LEE SC, 1993, J IMMUNOL, V150, P594; Lilly MB, 2001, BLOOD, V97, P1662, DOI 10.1182/blood.V97.6.1662; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; Medina RA, 2002, BIOL RES, V35, P9, DOI 10.4067/S0716-97602002000100004; MIYAJIMA A, 1993, BLOOD, V82, P1960; Moon BG, 2001, IMMUNOLOGY, V102, P289, DOI 10.1046/j.1365-2567.2001.01196.x; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Robertson SA, 2001, BIOL REPROD, V64, P1206, DOI 10.1095/biolreprod64.4.1206; Sattler M, 1999, BLOOD, V93, P2928; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Scott CL, 1998, BLOOD, V92, P4119, DOI 10.1182/blood.V92.11.4119.423k40_4119_4127; SIEGERT W, 1981, BLUT, V43, P297, DOI 10.1007/BF00320953; SPIELHOLZ C, 1995, BLOOD, V85, P973, DOI 10.1182/blood.V85.4.973.bloodjournal854973; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TAKETAZU F, 1991, J CELL PHYSIOL, V146, P251, DOI 10.1002/jcp.1041460209; Tan AS, 1998, BLOOD, V91, P649, DOI 10.1182/blood.V91.2.649.649_649_655; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TOMONAGA M, 1986, BLOOD, V67, P1433; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vera JC, 1998, BLOOD, V91, P2536, DOI 10.1182/blood.V91.7.2536.2536_2536_2546; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; Zambrano A, 2001, J CELL BIOCHEM, V80, P625, DOI 10.1002/1097-4644(20010315)80:4<625::AID-JCB1017>3.0.CO;2-9	64	29	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11107	11114		10.1074/jbc.M212541200	http://dx.doi.org/10.1074/jbc.M212541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538575	hybrid			2022-12-27	WOS:000181855400033
J	Machius, M; Declerck, N; Huber, R; Wiegand, G				Machius, M; Declerck, N; Huber, R; Wiegand, G			Kinetic stabilization of Bacillus licheniformis alpha-amylase through introduction of hydrophobic residues at the surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; ELECTRON-DENSITY MAPS; METAL-BINDING SITES; COLD-SHOCK PROTEIN; CRYSTAL-STRUCTURE; HYPERTHERMOSTABLE MUTANTS; ANGSTROM RESOLUTION; STABILITY; THERMOSTABILITY; DETERMINANTS	It is generally assumed that in proteins hydrophobic residues are not favorable at solvent-exposed sites, and that amino acid substitutions on the surface have little effect on protein thermostability. Contrary to these assumptions, we have identified hyperthermostable variants of Bacillus licheniformis alpha-amylase (BLA) that result from the incorporation of hydrophobic residues at the surface. Under highly destabilizing conditions, a variant combining five stabilizing mutations unfolds 32 times more slowly and at a temperature 13 degreesC higher than the wild-type. Crystal structure analysis at 1.7 Angstrom resolution suggests that stabilization is achieved through (a) extension of the concept of increased hydrophobic packing, usually applied to cavities, to surface indentations, (b) introduction of favorable aromatic-aromatic interactions on the surface, (c) specific stabilization of intrinsic metal binding sites, and (d) stabilization of a beta-sheet by introducing a residue with high beta-sheet forming propensity. All mutated residues are involved in forming complex, cooperative interaction networks that extend from the interior of the protein to its surface and which may therefore constitute "weak points" where BLA unfolding is initiated. This might explain the unexpectedly large effect induced by some of the substitutions on the kinetic stability of BLA. Our study shows that substantial protein stabilization can be achieved by stabilizing surface positions that participate in underlying cooperatively formed substructures. At such positions, even the apparently thermodynamically unfavorable introduction of hydrophobic residues should be explored.	Univ Texas, SW Med Ctr Dallas, Dallas, TX 75390 USA; INAP G, CNRS, URA 1925, INRA UMR 216, F-78850 Thiverval Grignon, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Centre National de la Recherche Scientifique (CNRS); INRAE; Max Planck Society	Machius, M (corresponding author), Univ Texas, SW Med Ctr Dallas, Dallas, TX 75390 USA.			Declerck, Nathalie/0000-0003-1551-1607				Bertoldo C, 2002, CURR OPIN CHEM BIOL, V6, P151, DOI 10.1016/S1367-5931(02)00311-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryan PN, 2000, BBA-PROTEIN STRUCT M, V1543, P203, DOI 10.1016/S0167-4838(00)00235-1; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; CONRAD B, 1995, EUR J BIOCHEM, V230, P481; DECLERCK M, 2002, IN PRESS BIOL BRAT S, V57; Declerck N, 1997, PROTEIN ENG, V10, P541, DOI 10.1093/protein/10.5.541; DECLERCK N, 1990, J BIOL CHEM, V265, P15481; Declerck N, 2000, J MOL BIOL, V301, P1041, DOI 10.1006/jmbi.2000.4025; Declerck N, 1995, PROTEIN ENG, V8, P1029, DOI 10.1093/protein/8.10.1029; Demirjian DC, 2001, CURR OPIN CHEM BIOL, V5, P144, DOI 10.1016/S1367-5931(00)00183-6; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fitter J, 2001, BIOCHEMISTRY-US, V40, P10723, DOI 10.1021/bi010808b; Frigerio F, 1996, PROTEIN ENG, V9, P439, DOI 10.1093/protein/9.5.439; Gu H, 1999, PROTEIN SCI, V8, P2734; Harris GW, 1997, PROTEINS, V29, P77, DOI 10.1002/(SICI)1097-0134(199709)29:1<77::AID-PROT6>3.3.CO;2-K; Hartley BS, 2000, BBA-PROTEIN STRUCT M, V1543, P294, DOI 10.1016/S0167-4838(00)00246-6; HUBBARD SJ, 1995, CURR OPIN BIOTECH, V6, P375, DOI 10.1016/0958-1669(95)80065-4; Hwang KY, 1997, MOL CELLS, V7, P251; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYET P, 1992, BIO-TECHNOL, V10, P1579, DOI 10.1038/nbt1292-1579; Knegtel RMA, 1996, J MOL BIOL, V256, P611, DOI 10.1006/jmbi.1996.0113; Kwok SC, 2002, PROTEIN SCI, V11, P1519, DOI 10.1110/ps.4170102; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee B, 1997, CURR OPIN BIOTECH, V8, P423, DOI 10.1016/S0958-1669(97)80063-8; Lu Y, 1997, CURR OPIN STRUC BIOL, V7, P495, DOI 10.1016/S0959-440X(97)80112-1; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; Machius M, 1998, STRUCTURE, V6, P281, DOI 10.1016/S0969-2126(98)00032-X; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; Munson M, 1996, PROTEIN SCI, V5, P1584, DOI 10.1002/pro.5560050813; Nielsen JE, 2000, BBA-PROTEIN STRUCT M, V1543, P253, DOI 10.1016/S0167-4838(00)00240-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Poso D, 2000, J BIOL CHEM, V275, P35723, DOI 10.1074/jbc.M001747200; Predki PF, 1996, NAT STRUCT BIOL, V3, P54, DOI 10.1038/nsb0196-54; Schindler T, 1998, PROTEINS, V30, P401, DOI 10.1002/(SICI)1097-0134(19980301)30:4<401::AID-PROT7>3.3.CO;2-G; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; Shaw A, 1999, CURR OPIN BIOTECH, V10, P349, DOI 10.1016/S0958-1669(99)80063-9; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; Suvd D, 2001, J BIOCHEM, V129, P461, DOI 10.1093/oxfordjournals.jbchem.a002878; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; Tanaka A, 2002, BIOCHEM J, V364, P635, DOI 10.1042/BJ20011436; Terashima M, 1996, ANN NY ACAD SCI, V799, P65, DOI 10.1111/j.1749-6632.1996.tb33179.x; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; VANDENBURG B, 1994, EUR J BIOCHEM, V220, P981; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	54	99	108	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11546	11553		10.1074/jbc.M212618200	http://dx.doi.org/10.1074/jbc.M212618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540849	hybrid			2022-12-27	WOS:000181855400087
J	Miyake, Y; Kakeya, H; Kataoka, T; Osada, H				Miyake, Y; Kakeya, H; Kataoka, T; Osada, H			Epoxycyclohexenone inhibits Fas-mediated apoptosis by blocking activation of pro-caspase-8 in the death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; CASPASE INHIBITOR; CD95; RECEPTOR; CELLS; FADD; NEUROPROTECTION; RECRUITMENT; MODULATION	Death receptors belong to the tumor necrosis factor receptor family. They can induce apoptosis following engagement with specific ligands and are known to play an important role in the regulation of the immune system. Here we report that epoxycyclohexenone (ECH) inhibits apoptosis induced by anti-Fas antibody, Fas ligand (FasL), or tumor necrosis factor-alpha but not by staurosporine, MG-132, C2-ceramide, or UV irradiation. These results suggest that ECH specifically blocks death receptor-mediated apoptosis. Neither the surface expression of Fas nor the Fas-FasL interaction was influenced by ECH. However, ECH did block the activation of pro-caspase-8 in the death-inducing signaling complex, although recruitment of Fas-associating death domain (FADD) and pro-caspase-8 was not affected. ECH inhibited the enzymatic activity of recombinant active caspase-8 at slightly lower concentrations than it did for active caspase-3 and active caspase-9 in vitro. However, in FasL-treated cells, ECH was only able to inhibit the activation of pro-caspase-8, and it had no effect on the already activated caspase-8 at a concentration that is effective at inhibiting Fas-induced apoptosis. ECH directly bound the large subunit of active caspase-8 that contains the active center cysteine and had a relatively higher affinity to pro-caspase-8. Moreover, compared with pro-caspase-3 and pro-caspase-9, pro-caspase-8 was predominantly depleted by biotinylated ECH with avidin beads in the cell lysates, suggesting that ECH preferentially affects pro-caspase-8. Thus, our results suggest that ECH blocks the self-activation of pro-caspase-8 in the death-inducing signaling complex and thus selectively inhibits death receptor-mediated apoptosis.	RIKEN, Discovery Res Inst, Antibiot Lab, Wako, Saitama 3510198, Japan; Tokyo Inst Technol, Res Ctr Expt Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	RIKEN; Tokyo Institute of Technology	Osada, H (corresponding author), RIKEN, Discovery Res Inst, Antibiot Lab, Wako, Saitama 3510198, Japan.	antibiot@postman.riken.go.jp	Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014; Kakeya, Hideaki/B-3527-2012	Kakeya, Hideaki/0000-0002-4293-7331				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Arakaki N, 1999, J BIOL CHEM, V274, P13541, DOI 10.1074/jbc.274.19.13541; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Osada H, 2000, BIOPROBES, P1; OSADA H, 1990, J ANTIBIOT, V43, P163, DOI 10.7164/antibiotics.43.163; Patel M, 1998, J NEUROCHEM, V71, P1068, DOI 10.1046/j.1471-4159.1998.71031068.x; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; 1999, Patent No. 11222456	38	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11213	11220		10.1074/jbc.M209610200	http://dx.doi.org/10.1074/jbc.M209610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551927	hybrid			2022-12-27	WOS:000181855400047
J	Yanofsky, C				Yanofsky, C			Using studies on tryptophan metabolism to answer basic biological questions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							OPERON LEADER REGION; BINDING ATTENUATION PROTEIN; IN-VITRO TRANSCRIPTION; ESCHERICHIA-COLI K-12; TRP REPRESSOR; TRANSFER-RNA; MESSENGER-RNA; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; GENE-EXPRESSION		Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.							Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BAKER RF, 1968, NATURE, V219, P26, DOI 10.1038/219026a0; BAUERLE RH, 1967, J MOL BIOL, V26, P423, DOI 10.1016/0022-2836(67)90313-0; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; Benzer S., 1957, Proceedings of the International Genetics Symposia, 1956. Tokyo & Kyoto, September 1956, pp; Berg P, 1973, Harvey Lect, V67, P247; BRODY S, 1963, P NATL ACAD SCI USA, V50, P9, DOI 10.1073/pnas.50.1.9; CARBON J, 1966, COLD SPRING HARB SYM, V31, P487, DOI 10.1101/SQB.1966.031.01.063; COX EC, 1967, P NATL ACAD SCI USA, V58, P1895, DOI 10.1073/pnas.58.5.1895; CRAWFORD IP, 1958, P NATL ACAD SCI USA, V44, P1161, DOI 10.1073/pnas.44.12.1161; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; DAS A, 1989, NUCLEIC ACIDS RES, V17, P9333, DOI 10.1093/nar/17.22.9333; Di Martino P, 2002, CAN J MICROBIOL, V48, P132, DOI 10.1139/W02-001; DOOLITTLE WF, 1968, J BACTERIOL, V95, P1283, DOI 10.1128/JB.95.4.1283-1294.1968; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; FISHER R, 1983, J BIOL CHEM, V258, P9208; FISHER RF, 1985, J MOL BIOL, V182, P397, DOI 10.1016/0022-2836(85)90199-8; FRANKLIN NC, 1965, BIOCHEM BIOPH RES CO, V18, P898; GOLDBERG ME, 1966, J MOL BIOL, V21, P71, DOI 10.1016/0022-2836(66)90080-5; Gollnick P., 2002, BACILLUS SUBTILIS IT, P233; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; Gong F, 2002, J BIOL CHEM, V277, P17095, DOI 10.1074/jbc.M201213200; Grundy FJ, 2002, P NATL ACAD SCI USA, V99, P11121, DOI 10.1073/pnas.162366799; GUEST JR, 1965, J MOL BIOL, V12, P793, DOI 10.1016/S0022-2836(65)80328-X; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; GUPTA NK, 1966, P NATL ACAD SCI USA, V56, P772, DOI 10.1073/pnas.56.2.772; HELINSKI DR, 1963, J BIOL CHEM, V238, P1043; Henkin TM, 2000, CURR OPIN MICROBIOL, V3, P149, DOI 10.1016/S1369-5274(00)00067-9; Henkin TM, 2002, BIOESSAYS, V24, P700, DOI 10.1002/bies.10125; Henner Dennis, 1993, P269; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; HERSHFIE.V, 1974, P NATL ACAD SCI USA, V71, P3455, DOI 10.1073/pnas.71.9.3455; HOGNESS DS, 1954, J GEN MICROBIOL, V11, P401, DOI 10.1099/00221287-11-3-401; HOROWITZ H, 1982, J MOL BIOL, V156, P257, DOI 10.1016/0022-2836(82)90327-8; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IMAMOTO F, 1967, J MOL BIOL, V28, P1, DOI 10.1016/S0022-2836(67)80073-1; IMAMOTO F, 1966, COLD SPRING HARB SYM, V31, P235, DOI 10.1101/SQB.1966.031.01.032; INGRAM VM, 1958, BIOCHIM BIOPHYS ACTA, V28, P539, DOI 10.1016/0006-3002(58)90516-X; JACKSON DA, 1969, J BIOL CHEM, V244, P4539; JACKSON EN, 1973, J MOL BIOL, V76, P89, DOI 10.1016/0022-2836(73)90082-X; JACKSON EN, 1972, J MOL BIOL, V69, P307, DOI 10.1016/0022-2836(72)90232-X; Jurgens C, 2000, P NATL ACAD SCI USA, V97, P9925, DOI 10.1073/pnas.160255397; KASAI T, 1974, NATURE, V249, P523, DOI 10.1038/249523a0; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LANDICK R, 1985, P NATL ACAD SCI USA, V82, P4663, DOI 10.1073/pnas.82.14.4663; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; LEE F, 1976, J MOL BIOL, V103, P383, DOI 10.1016/0022-2836(76)90318-1; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; MERINO E, 2002, BACILLUS SUBTILIS IT, P323; Miles E W, 1995, Subcell Biochem, V24, P207; MITCHELL HK, 1948, J BIOL CHEM, V175, P481; MORSE DE, 1976, J MOL BIOL, V103, P209, DOI 10.1016/0022-2836(76)90310-7; MORSE DE, 1969, COLD SPRING HARB SYM, V34, P725, DOI 10.1101/SQB.1969.034.01.082; NAGATA S, 1989, J BIOL CHEM, V264, P6288; OPPENHEIM DS, 1980, GENETICS, V95, P785; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; ROSE JK, 1973, NATURE-NEW BIOL, V245, P133, DOI 10.1038/newbio245133a0; ROTH JR, 1966, COLD SPRING HARB SYM, V31, P383, DOI 10.1101/SQB.1966.031.01.050; ROTHMAN FG, 1987, PHOSPHATE METABOLISM, P307; SANGER F, 1952, ADV PROTEIN CHEM, V7, P1, DOI 10.1016/S0065-3233(08)60017-0; SARABHAI AS, 1964, NATURE, V201, P13, DOI 10.1038/201013a0; Sarsero JP, 2000, P NATL ACAD SCI USA, V97, P2656, DOI 10.1073/pnas.050578997; SCHNEIDER WP, 1981, P NATL ACAD SCI-BIOL, V78, P2169, DOI 10.1073/pnas.78.4.2169; SOMERVILLE RL, 1964, J MOL BIOL, V8, P616, DOI 10.1016/S0022-2836(64)80019-X; SQUIRES CL, 1975, J MOL BIOL, V92, P93, DOI 10.1016/0022-2836(75)90093-5; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; SUSKIND Sr, 1955, P NATL ACAD SCI USA, V41, P577, DOI 10.1073/pnas.41.8.577; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; UMBREIT WW, 1946, J BIOL CHEM, V165, P731; Valbuzzi A, 2002, J BIOL CHEM, V277, P10608, DOI 10.1074/jbc.M111813200; Valbuzzi A, 2001, SCIENCE, V293, P2057, DOI 10.1126/science.1062187; Wang DD, 2001, J BACTERIOL, V183, P4210, DOI 10.1128/JB.183.14.4210-4216.2001; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WINKLER ME, 1981, BIOCHEMISTRY-US, V20, P3738, DOI 10.1021/bi00516a011; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; YANOFSKY C, 1984, MOL BIOL EVOL, V1, P143; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; YANOFSKY C, 1964, P NATL ACAD SCI USA, V51, P266, DOI 10.1073/pnas.51.2.266; YANOFSKY C, 1959, VIROLOGY, V8, P425, DOI 10.1016/0042-6822(59)90046-7; Yanofsky C, 2001, ANNU REV BIOCHEM, V70, P1, DOI 10.1146/annurev.biochem.70.1.1; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; YANOFSKY C, 1952, P NATL ACAD SCI USA, V38, P215, DOI 10.1073/pnas.38.3.215; YANOFSKY C, 1954, J BACTERIOL, V68, P577, DOI 10.1128/JB.68.5.577-584.1954; YANOFSKY C, 1977, J MOL BIOL, V113, P663, DOI 10.1016/0022-2836(77)90229-7; Yanofsky C, 2000, J BACTERIOL, V182, P1, DOI 10.1128/JB.182.1.1-8.2000; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991; YANOFSKY C, 1984, J BACTERIOL, V158, P1018, DOI 10.1128/JB.158.3.1018-1024.1984; YANOFSKY C, 1967, P NATL ACAD SCI USA, V57, P296, DOI 10.1073/pnas.57.2.296; YANOFSKY C, 1956, H FORD HOSP INT S EN, P147; YANOFSKY C, 1963, COLD SPRING HARB SYM, V28, P296; YANOFSKY C, 1969, 12TH P INT C GEN, V3, P155; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P641; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317	101	32	35	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10859	10878		10.1074/jbc.X200012200	http://dx.doi.org/10.1074/jbc.X200012200			20	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12556463	hybrid			2022-12-27	WOS:000181855400001
J	Cabral, WA; Mertts, MV; Makareeva, E; Colige, A; Tekin, M; Pandya, A; Leikin, S; Marin, JC				Cabral, WA; Mertts, MV; Makareeva, E; Colige, A; Tekin, M; Pandya, A; Leikin, S; Marin, JC			Type I collagen triplet duplication mutation in lethal osteogenesis imperfecta shifts register of alpha chains throughout the helix and disrupts incorporation of mutant helices into fibrils and extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE LABELING REAGENTS; N-PROTEINASE; PRO-ALPHA-1(I) CHAIN; POINT MUTATION; PROCOLLAGEN; CLEAVAGE; DELETION; COL1A1; HETEROGENEITY; TRANSLATION	The majority of collagen mutations causing osteogenesis imperfecta (OI) are glycine substitutions that disrupt formation of the triple helix. A rare type of collagen mutation consists of a duplication or deletion of one or two Gly-X-Y triplets. These mutations shift the register of collagen chains with respect to each other in the helix but do not interrupt the triplet sequence, yet they have severe clinical consequences. We investigated the effect of shifting the register of the collagen helix by a single Gly-X-Y triplet on collagen assembly, stability, and incorporation into fibrils and matrix. These studies utilized a triplet duplication in COL1A1 exon 44 that occurred in the cDNA and gDNA of two siblings with lethal OI. The normal allele encodes three identical Gly-Ala-Hyp triplets at aa 868-876, whereas the mutant allele encodes four. The register shift delays helix formation, causing overmodification. Differential scanning calorimetry yielded a decrease in T-m of 2 degreesC for helices with one mutant chain and a 6 degreesC decrease in helices with two mutant chains. An in vitro binary co-processing assay of N-proteinase cleavage demonstrated that procollagen with the triplet duplication has slower N-propeptide cleavage than in normal controls or procollagen with proalpha1(I) G832S, G898S, or G997S substitutions, showing that the register shift persists through the entire helix. The register shift disrupts incorporation of mutant collagen into fibrils and matrix. Proband fibrils formed inefficiently in vitro and contained only normal helices and helices with a single mutant chain. Helices with two mutant chains and a significant portion of helices with one mutant chain did not form fibrils. In matrix deposited by proband fibroblasts, mutant chains were abundant in the immaturely cross-linked fraction but constituted a minor fraction of maturely cross-linked chains. The profound effects of shifting the collagen triplet register on chain interactions in the helix and on fibril formation correlate with the severe clinical consequences.	NICHD, Sect Connect Tissue Disorders, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; NICHD, Sect Phys Biochem, NIH, Bethesda, MD 20892 USA; Univ Liege, Connect Tissue Res Labs, Liege, Belgium; Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Liege; Virginia Commonwealth University	Marin, JC (corresponding author), NICHD, Sect Connect Tissue Disorders, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241,9000 Rockville Pike, Bethesda, MD 20892 USA.	oidoc@helix.nih.gov	Leikin, Sergey/A-5518-2008; Tekin, Mustafa/ABG-7627-2020; Makareeva, Elena/F-5183-2011	Leikin, Sergey/0000-0001-7095-0739; Makareeva, Elena/0000-0002-5815-0760; Tekin, Mustafa/0000-0002-3525-7960	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000256, ZIAHD000408] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000408, Z01HD000256] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; BONADIO J, 1985, J BIOL CHEM, V260, P1734; Byers Peter H., 1993, P317; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Dalgleish R, 1998, NUCLEIC ACIDS RES, V26, P253, DOI 10.1093/nar/26.1.253; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; FIEDLERNAGY C, 1981, ARCH BIOCHEM BIOPHYS, V212, P668, DOI 10.1016/0003-9861(81)90411-2; FILIE JD, 1993, HUM MUTAT, V2, P380, DOI 10.1002/humu.1380020510; FORLINO A, 1994, HUM MOL GENET, V3, P2201, DOI 10.1093/hmg/3.12.2201; GRANGE DK, 1990, NUCLEIC ACIDS RES, V18, P4227, DOI 10.1093/nar/18.14.4227; HAWKINS JR, 1991, J BIOL CHEM, V266, P22370; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; MARINI JC, 1989, J BIOL CHEM, V264, P11893; MARINI JC, 2001, MANAGEMENT GENETIC S, P281; MCBRIDE DJ, 1992, MATRIX, V12, P256; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; Pace JM, 2001, HUM MUTAT, V18, P319, DOI 10.1002/humu.1193; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Sacca B, 2002, CHEMBIOCHEM, V3, P904, DOI 10.1002/1439-7633(20020902)3:9<904::AID-CBIC904>3.0.CO;2-I; Sacca B, 2002, J MOL BIOL, V324, P309, DOI 10.1016/S0022-2836(02)01065-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; TIFFANY ML, 1969, BIOPOLYMERS, V8, P347, DOI 10.1002/bip.1969.360080306; Van der Hoeve J., 1918, ARCH OPHTHALMOL-CHIC, V95, P81, DOI DOI 10.1007/BF01928336; VOGEL BE, 1987, J BIOL CHEM, V262, P14737; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WALLIS GA, 1992, J BIOL CHEM, V267, P25529; Ward L M, 2001, Hum Mutat, V17, P434, DOI 10.1002/humu.1124; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; WILLING MC, 1994, AM J HUM GENET, V55, P638	39	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10006	10012		10.1074/jbc.M212523200	http://dx.doi.org/10.1074/jbc.M212523200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12538651	hybrid			2022-12-27	WOS:000181777500003
J	Corcoran, EE; Joseph, JD; MacDonald, JA; Kane, CD; Haystead, TAJ; Means, AR				Corcoran, EE; Joseph, JD; MacDonald, JA; Kane, CD; Haystead, TAJ; Means, AR			Proteomic analysis of calcium/calmodulin-dependent protein kinase I and IV in vitro substrates reveals distinct catalytic preferences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MAPKAP KINASE-2; CONSTITUTIVE EXPRESSION; MEDIATED TRANSCRIPTION; CELLULAR-LOCALIZATION; PHOSPHORYLATION SITES; RECOGNITION MOTIFS; NERVOUS-SYSTEM; CALMODULIN; ACTIVATION	The multifunctional calcium/calmodulin-dependent protein kinases I and TV (CaMKI and CaMKIV) are closely related by primary sequence and predicted to have similar substrate specificities based on peptide studies. We identified a fragment of p300-(1-117) that is a substrate of both kinases, and through both mutagenesis and Edman phosphate (P-32) release sequencing, established that CaMKI and CaMKIV phosphorylate completely different sites. The CaMKI site, Ser(89) ((84)LLRSGSSPNL(93)), fits the expected consensus whereas the CaMKIV site, Ser(24) ((19)SSpALSASAS(28)) is novel. To compare kinase substrate preferences more generally, we employed a proteomic display technique that allowed comparison of complex cell extracts phosphorylated by each kinase in a rapid in vitro assay, thereby demonstrating substrate preferences that overlapped but were clearly distinct. To validate this approach, one of the proteins labeled in this assay was identified by microsequencing as HSP25, purified as a recombinant protein, and examined as a substrate for both CaMKI and CaMKIV. Again, CaMKI and CaMKIV were different, this time in kinetics and stoichiometry of the phosphorylation sites, with CaMKI preferring Ser(15) ((10)LLRTPSWGPF(19)) to Ser(85) ((80)LNRQLSSGVS(89)) 3:1, but CaMKIV phosphorylating the two sites equally. These differences in substrate specificities emphasize the need to consider these protein kinases independently despite their close homology.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.	means001@mc.duke.edu	Kane, Christopher/C-8256-2019	Kane, Christopher/0000-0002-0469-1668; MacDonald, Justin/0000-0002-9238-8473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07503-24] Funding Source: Medline; NIDDK NIH HHS [DK52378-06] Funding Source: Medline; NIGMS NIH HHS [GM33976-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed BY, 2000, NEUROSCI LETT, V290, P149, DOI 10.1016/S0304-3940(00)01347-1; ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Armstrong CL, 2000, J COMP NEUROL, V416, P383, DOI 10.1002/(SICI)1096-9861(20000117)416:3<383::AID-CNE9>3.0.CO;2-M; Armstrong CL, 2001, J COMP NEUROL, V434, P262, DOI 10.1002/cne.1176; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Geier A, 1997, IN VITRO CELL DEV-AN, V33, P129; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Guo ZY, 2000, BIOCHEM BIOPH RES CO, V270, P183, DOI 10.1006/bbrc.2000.2401; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Loones MT, 2000, CELL STRESS CHAPERON, V5, P291, DOI 10.1379/1466-1268(2000)005<0291:TDOHSP>2.0.CO;2; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; Mackey AJ, 2002, MOL CELL PROTEOMICS, V1, P139, DOI 10.1074/mcp.M100004-MCP200; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Means AR, 2000, PRINCIPLES OF MOLECULAR REGULATION, P187; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Wakayama T, 1998, CELL BIOL INT, V22, P295, DOI 10.1006/cbir.1998.0252; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	38	15	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10516	10522		10.1074/jbc.M210642200	http://dx.doi.org/10.1074/jbc.M210642200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12538590	hybrid			2022-12-27	WOS:000181777500070
J	Nishizuka, M; Arimoto, E; Tsuchiya, T; Nishihara, T; Imagawa, M				Nishizuka, M; Arimoto, E; Tsuchiya, T; Nishihara, T; Imagawa, M			Crucial role of TCL/TC10 beta L, a subfamily of Rho GTPase, in adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; INSULIN-RESISTANCE; GENE-EXPRESSION; BINDING-PROTEIN; ADIPOSE-TISSUE; 3T3-L1 CELLS; EARLY-STAGE; ADIPOGENESIS; OBESITY	The events at the beginning of adipocyte differentiation are not well known. We previously cloned the genes expressed early in the differentiation of mouse 3T3-L1 preadipocyte cells. One of them, similar in sequence to human TC10, was identified as TC10-like/TC10betaLong (TCL/TC10betaL), a new Rho GTPase by the cloning of full-length cDNA. The expression of TCL/TC10betaL increased rapidly right after the addition of inducers for differentiation, whereas the levels of other Rho family genes were unchanged at this stage. The antisense TCL/TC10betaL-expressing experiment revealed that the differentiation of 3T3-L1 cells into adipocytes was inhibited. Moreover, the sense TCL/TC10betaL-expressing experiment using NIH-3T3 cells, which do not usually differentiate into adipocytes, clearly showed the accumulation of oil droplets as well as the elevated expression of various adipogenic marker genes in the presence of the ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). These results strongly indicated that TCL/TC10betaL has a crucial role in the early stage of adipocyte differentiation, probably linked to the PPARgamma pathway. Using a subtraction protocol, the genes specifically regulated by TCL/TC10betaL were also isolated. The expression pattern of some of them was similar to TCL/TC10betaL expression in adipogenesis, suggesting that the expression of these genes would be regulated by TCL/TC10betaL.	Nagoya City Univ, Dept Mol Biol, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Environm Biochem, Suita, Osaka 5650871, Japan	Nagoya City University; Osaka University	Imagawa, M (corresponding author), Nagoya City Univ, Dept Mol Biol, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.							Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Imagawa M, 1999, BIOCHEM BIOPH RES CO, V254, P299, DOI 10.1006/bbrc.1998.9937; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lee YH, 1996, BIOCHEM BIOPH RES CO, V222, P839, DOI 10.1006/bbrc.1996.0831; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Nishizuka M, 2002, BIOCHEM J, V361, P629, DOI 10.1042/0264-6021:3610629; Nishizuka M, 2001, J BIOL CHEM, V276, P29625, DOI 10.1074/jbc.C100272200; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VAN AL, 1997, GENE DEV, V11, P2295; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; WARDEN CH, 1994, GENOMICS, V24, P14, DOI 10.1006/geno.1994.1576; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8	33	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15279	15284		10.1074/jbc.M211479200	http://dx.doi.org/10.1074/jbc.M211479200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578843	hybrid			2022-12-27	WOS:000182516100090
J	Qi, HY; Li, TK; Kuo, D; Nur-E-Kamal, A; Liu, LF				Qi, HY; Li, TK; Kuo, D; Nur-E-Kamal, A; Liu, LF			Inactivation of Cdc13p triggers MEC1-dependent apoptotic signals in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; TELOMERE MAINTENANCE; OXIDATIVE STRESS; BINDING PROTEIN; CASPASE ACTIVATION; CHECKPOINT GENES; BUDDING YEAST; CELLS	Inactivation of the budding yeast telomere binding protein Cdc13 results in abnormal telomeres (exposed long G-strands) and activation of the DNA damage checkpoint. In the current study, we show that inactivation of Cdc13p induces apoptotic signals in yeast, as evidenced by caspase activation, increased reactive oxygen species production, and flipping of phosphatidylserine in the cytoplasmic membrane. These apoptotic signals were suppressed in a mitochondrial (rho(0)) mutant. Moreover, mitochondrial proteins (e.g. MTCO3) were identified as multicopy suppressors of edc13-1, suggesting the involvement of mitochondrial functions in telomere-initiated apoptotic signaling. These telomere-initiated apoptotic signals were also shown to depend on MEC1, but not TELL, and were antagonized by MRE11. Our results are consistent with a model in which single-stranded G-tails in the cdc13-1 mutant trigger MEC1-dependent apoptotic signaling in yeast.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Qi, HY (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.			LI, TSAI-KUN/0000-0003-0393-2340; Liu, Leroy/0000-0001-9396-763X	NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Bhattacharya R, 1997, TOXICOLOGY, V123, P207, DOI 10.1016/S0300-483X(97)00130-3; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CERBON J, 1991, BIOCHIM BIOPHYS ACTA, V1067, P139, DOI 10.1016/0005-2736(91)90035-7; Craven RJ, 2000, MOL CELL BIOL, V20, P2378, DOI 10.1128/MCB.20.7.2378-2384.2000; Diede SJ, 2001, CURR BIOL, V11, P1336, DOI 10.1016/S0960-9822(01)00400-6; Enomoto S, 2002, MOL BIOL CELL, V13, P2626, DOI 10.1091/mbc.02-02-0012; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Grandin N, 2001, EMBO J, V20, P6127, DOI 10.1093/emboj/20.21.6127; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green-Willms NS, 1998, MOL CELL BIOL, V18, P1826, DOI 10.1128/MCB.18.4.1826; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; GUTHRIE G, 1991, METHOD ENZYMOL, V194, P150; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LIU HP, 1992, GENETICS, V132, P665; Longhese MP, 2000, GENETICS, V155, P1577; Lydall D, 1997, METHOD ENZYMOL, V283, P410; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Manon S, 2001, BIOCHEM BIOPH RES CO, V289, P1314, DOI 10.1006/bbrc.2001.6120; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mills EM, 1996, J NEUROCHEM, V67, P1039; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Qi HY, 2000, GENE DEV, V14, P1777; Ritchie KB, 2000, GENETICS, V155, P475; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; WRIGHT RM, 1990, MOL CELL BIOL, V10, P1297, DOI 10.1128/MCB.10.3.1297; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	46	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15136	15141		10.1074/jbc.M212808200	http://dx.doi.org/10.1074/jbc.M212808200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12569108	hybrid			2022-12-27	WOS:000182516100072
J	Wu, LY; Wu, YL; Gathings, B; Wan, M; Li, XL; Grizzle, W; Liu, ZY; Lu, CY; Mao, ZK; Cao, X				Wu, LY; Wu, YL; Gathings, B; Wan, M; Li, XL; Grizzle, W; Liu, ZY; Lu, CY; Mao, ZK; Cao, X			Smad4 as a transcription corepressor for estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATION FUNCTION AF-2; BREAST-CANCER; NUCLEAR RECEPTORS; POSTMENOPAUSAL WOMEN; MOLECULAR-CLONING; BINDING DOMAINS; CROSS-TALK; EXPRESSION; COACTIVATOR	Antiestrogen compounds exhibit a variety of different effects in different tissues and are widely used for the treatment of osteoporosis, breast cancer, and other diseases. Upon examining the molecular mechanisms, we found that Smad4, a common signal transducer in the bone morphogenetic protein (BMP)/transforming growth factor-beta (TGF-beta) signaling pathway, functions as a transcription corepressor for human estrogen receptor alpha (ERalpha). Endogenous ERalpha was co-immunoprecipitated with Smad4, and the interaction was induced by antiestrogen ligands such as tamoxifen, raloxifene, and droloxifen, which was confirmed in chromatin immunoprecipitation assays. Smad4 and ERalpha form a complex when ERalpha binds to the estrogen-responsive element within the estrogen target gene promoter. Importantly, the expression of Smad4 inhibits both antiestrogen-induced luciferase activity and estrogen downstream target gene transcription in breast cancer cells. Mapping of the interaction domains indicates that the activation function 1 (AF1) domain of ERalpha is essential for its interaction with Smad4, while the MH1 domain and linker region of Smad4 are essential for the interaction. Our findings represent a novel mechanism that TGF-beta may regulate cell fate through Smad4-mediated crosstalk with estrogen.	Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL 35294 USA; Univ Alabama, Consortium Mat Dev Space, Huntsville, AL 35899 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Huntsville	Cao, X (corresponding author), Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL 35294 USA.	cao@path.uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060913] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60913, DK57501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fuqua SAW, 1999, CANCER RES, V59, P5425; Goggins M, 1998, CANCER RES, V58, P5329; Grady WM, 1998, CANCER RES, V58, P3101; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; He W, 2001, ONCOGENE, V20, P471, DOI 10.1038/sj.onc.1204117; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; JORDAN VC, 1992, CANCER, V70, P977; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang HY, 2002, J BIOL CHEM, V277, P43749, DOI 10.1074/jbc.M205603200; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LHorset F, 1996, MOL CELL BIOL, V16, P6029; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; MUSS HB, 1992, BREAST CANCER RES TR, V21, P15, DOI 10.1007/BF01811960; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Speirs V, 1999, CANCER RES, V59, P5421; Speirs V, 2000, BRIT J SURG, V87, P405, DOI 10.1046/j.1365-2168.2000.01402.x; Stoica A, 1997, ENDOCRINOLOGY, V138, P1498, DOI 10.1210/en.138.4.1498; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	71	86	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15192	15200		10.1074/jbc.M212332200	http://dx.doi.org/10.1074/jbc.M212332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576474	hybrid			2022-12-27	WOS:000182516100079
J	Burnett, JR; Shan, J; Miskie, BA; Whitfield, AJ; Yuan, J; Tran, K; McKnight, CJ; Hegele, RA; Yao, ZM				Burnett, JR; Shan, J; Miskie, BA; Whitfield, AJ; Yuan, J; Tran, K; McKnight, CJ; Hegele, RA; Yao, ZM			A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; HUMAN APOLIPOPROTEIN-B; CARBOXYL-TERMINAL TRUNCATION; MCA-RH7777 CELLS; DECREASED PRODUCTION; LIPID RECRUITMENT; AMINO-TERMINUS; FATTY LIVER; SECRETION	Familial hypobetalipoproteinemia (FHBL), an autosomal co-dominant disorder, is associated with reduced plasma concentrations (<5th percentile for age and sex) of apolipoprotein (apo) B and beta-migrating lipoproteins. To date, only mutations in APOB encoding prematurely truncated apoB have been found in FHBL. We discovered a novel APOB gene mutation, namely R463W, in an extended Christian Lebanese FHBL kindred. Heterozygotes for R463W had the typical FHBL phenotype, whereas homozygotes had barely detectable apoB-100. The effect of the R463W mutation on apoB secretion was examined using transfected McA-RH7777 cells that expressed one of two recombinant human apoBs, namely B48 and B17. In both cases, the mutant proteins (B48RW and B17RW) were retained within the endoplasmic reticulum and were secreted poorly compared with their wild-type counterparts. Pulse-chase analysis showed that secretion efficiencies of B48RW and B17RW were, respectively, 45 and 40% lower than those of the wild-types. Substitution of Arg(463) with Ala in apoB-17 (B17RA) decreased secretion efficiency by similar to50%, but substitution with Lys (B17RK) had no effect on secretion, indicating that the positive charge was important. Molecular modeling of apoB predicted that Arg(463) was in close proximity to Glu(756) and Asp(456). Substitution of Glu(756) with Gln (B17EQ) had no effect on secretion, but substitution of Asp456 with Asn (Bl7DN) decreased secretion to the same extent as B17RW. In co-transfection experiments, the mutant B17RW showed increased binding to microsomal triglyceride transfer protein as compared with wild-type B17. Thus, the naturally occurring R463W mutant reveals a key local domain governing assembly and secretion of apoB-containing lipoproteins.	Univ Western Australia, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia; Univ Western Australia, Dept Pathol, Perth, WA 6847, Australia; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada; John P Robarts Res Inst, London, ON N6A 5K8, Canada; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; Western University (University of Western Ontario); Boston University	Burnett, JR (corresponding author), Univ Western Australia, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia.		Hegele, Robert/G-3301-2011; Hooper, Amanda J/H-7757-2014; Hegele, Robert/AAF-6482-2020	Hegele, Robert/0000-0003-2861-5325; McKnight, Christopher/0000-0002-3237-0896				AGUILARSALINAS CA, 1995, ARTERIOSCL THROM VAS, V15, P71, DOI 10.1161/01.ATV.15.1.71; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; BURGESS WH, 2000, J BIOL CHEM, V275, P16267; BURNETT JR, 1993, MED J AUSTRALIA, V159, P272, DOI 10.5694/j.1326-5377.1993.tb137834.x; Cham BE, 1999, CLIN CHIM ACTA, V287, P45, DOI 10.1016/S0009-8981(99)00117-5; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; Elias N, 1999, ARTERIOSCL THROM VAS, V19, P2714, DOI 10.1161/01.ATV.19.11.2714; ELOVSON J, 1988, J LIPID RES, V29, P1461; Gabelli C, 1996, ARTERIOSCL THROM VAS, V16, P1189, DOI 10.1161/01.ATV.16.9.1189; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hegele RA, 2001, AM J HUM GENET, V69, P1161, DOI 10.1086/324647; Herscovitz H, 2001, J LIPID RES, V42, P51; HIXSON JE, 1990, J LIPID RES, V31, P545; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Kane JP, 2001, METABOLIC MOL BASES; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LINTON MF, 1993, J LIPID RES, V34, P521; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MCCORMICK SPA, 1992, BIOCHIM BIOPHYS ACTA, V1138, P290, DOI 10.1016/0925-4439(92)90006-9; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; Ogata H, 1997, AM J GASTROENTEROL, V92, P339; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; Parhofer KG, 1996, J LIPID RES, V37, P844; Pulai JI, 1998, AM J MED GENET, V76, P79, DOI 10.1002/(SICI)1096-8628(19980226)76:1<79::AID-AJMG15>3.3.CO;2-E; RICKWOOD D, 1982, ANAL BIOCHEM, V123, P23, DOI 10.1016/0003-2697(82)90618-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARROCK WJ, 1992, J MOL BIOL, V226, P903, DOI 10.1016/0022-2836(92)90642-W; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Tarugi P, 2000, J HEPATOL, V33, P361, DOI 10.1016/S0168-8278(00)80270-6; Tarugi P, 2001, J LIPID RES, V42, P1552; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Welty FK, 1997, ARTERIOSCL THROM VAS, V17, P881, DOI 10.1161/01.ATV.17.5.881; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yao ZM, 1997, J LIPID RES, V38, P1937; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	57	66	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13442	13452		10.1074/jbc.M300235200	http://dx.doi.org/10.1074/jbc.M300235200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551903	hybrid			2022-12-27	WOS:000182189500107
J	Ju, M; Stevens, L; Leadbitter, E; Wray, D				Ju, M; Stevens, L; Leadbitter, E; Wray, D			The roles of N- and C-terminal determinants in the activation of the Kv2.1 potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; TETRAMERIZATION DOMAIN; T1 DOMAIN; RAT-BRAIN; VOLTAGE; PERSPECTIVE; EXPRESSION; RESIDUES; MOVEMENT; CLONING	The human and rat forms of the Kv2.1 channel have identical amino acids over the membrane-spanning regions and differ only in the N- and C-terminal intracellular regions. Rat Kv2.1 activates much faster than human Kv2.1. Here we have studied the role of the N- and C-terminal residues that determine this difference in activation kinetics between the two channels. For this, we constructed mutants and chimeras between the two channels, expressed them in oocytes, and recorded currents by two-electrode voltage clamping. In the N-terminal region, mutation Q67E in the rat channel displayed a slowing of activation relative to rat wild type, whereas mutation D75E in the human channel showed faster activation than human wild type. In the C-terminal region, we found that some residues within the region of amino acids 740-853 ("CTA" domain) were also involved in determining activation kinetics. The electrophysiological data also suggested interactions between the N and C termini. Such an interaction was confirmed directly by using a glutathione S-transferase (GST) fusion protein with the N terminus of Kv2.1, which we showed to bind to the C terminus of Kv2.1. Taken together, these data suggest that exposed residues in the T1 domain of the N terminus, as well as the CTA domain in the C terminus, are important in determining channel activation kinetics and that these N- and C-terminal regions interact.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Wray, D (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.							ALBRECHT B, 1993, RECEPTOR CHANNEL, V1, P99; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; Bezanilla F, 2002, J GEN PHYSIOL, V120, P465, DOI 10.1085/jgp.20028660; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; CATTERALL WA, 2002, IUPHAR COMPENDIUM VO, P86; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Elkes DA, 1997, NEURON, V19, P165, DOI 10.1016/S0896-6273(00)80356-6; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Jones PA, 2001, FEBS LETT, V508, P85, DOI 10.1016/S0014-5793(01)03023-X; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kurata HT, 2002, J BIOL CHEM, V277, P29045, DOI 10.1074/jbc.M111470200; Liu TI, 2001, J NEUROPHYSIOL, V85, P61, DOI 10.1152/jn.2001.85.1.61; Marten I, 1997, P NATL ACAD SCI USA, V94, P3448, DOI 10.1073/pnas.94.7.3448; Milligan CJ, 2000, BIOPHYS J, V78, P1852, DOI 10.1016/S0006-3495(00)76734-8; Minor DL, 2001, CURR OPIN STRUC BIOL, V11, P408, DOI 10.1016/S0959-440X(00)00225-6; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Packer Jeremy, 2000, Trends in Pharmacological Sciences, V21, P327, DOI 10.1016/S0165-6147(00)01527-3; Pascual JM, 1997, AM J PHYSIOL-CELL PH, V273, pC1849, DOI 10.1152/ajpcell.1997.273.6.C1849; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; WRAY D, 2001, PHARM NEWS, V8, P12; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797	30	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12769	12778		10.1074/jbc.M212973200	http://dx.doi.org/10.1074/jbc.M212973200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560340	hybrid			2022-12-27	WOS:000182189500025
J	Picher, M; Burch, LH; Hirsh, AJ; Spychala, J; Boucher, RC				Picher, M; Burch, LH; Hirsh, AJ; Spychala, J; Boucher, RC			Ecto 5 '-nucleotidase and nonspecific alkaline phosphatase - Two amp-hydrolyzing ectoenzymes with distinct roles in human airways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASAL EPITHELIAL-CELLS; CYSTIC-FIBROSIS; ATP RELEASE; CHLORIDE SECRETION; EXTRACELLULAR ATP; MUCIN SECRETION; APICAL MEMBRANE; ION-TRANSPORT; HUMAN-LUNG; ADENOSINE	In human airways, extracellular adenosine regulates epithelial functions supporting mucociliary clearance, an important airway defense mechanism against bacterial infection. Thus, defining the mechanisms of adenosine generation is critical for elucidating the role of this nucleoside in airway homeostasis. In this study, we identified the source of adenosine on the mucosal surface of human airway epithelia. Polarized primary cultures of human nasal or bronchial epithelial cells were assayed for transepithelial transport, cytosolic and cell surface adenosine production. Ussing chamber experiments indicated that serosal 1 muM [H-3]adenosine was not transported to the mucosal compartment. Messenger RNA for the cytosolic AMP-specific 5'-nucleotidase (CN-I) was not detected in human bronchial epithelial cells, suggesting that mucosal adenosine did not originate from intracellular pools. In contrast, extracellular 0.1 mM ATP was rapidly dephosphorylated into adenosine on the mucosal epithelial surface. We identified two ectonucleotidases that mediated the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline phosphatase (AP). Both mucosal and serosal epithelial surfaces displayed ecto 5'-NT activity (K-m = 14 muM, V-max = 0.5 nmol.min(-1) .cm(-2)), whereas AP activity was restricted to the mucosal surface (K-m,high = 36 muM, V-max = = 717 muM, V-max = 2.8 nmol.min(-1).cm(-2) K-m,K-low = min(-1).cm(-2)). In bronchial cultures and tissues, ecto 5'-NT accounted for >80% of total activity toward 0.01 mM AMP, compared with < 15% for 5 mm AMP. The proximal airway AP isoform was identified as nonspecific AP (NS AP) by levamisole sensitivity and mRNA expression. The two ectoenzymes presented opposite airway distributions, ecto 5'-NT and NS AP mRNA dominating in higher and lower airways, respectively. Collectively, these experiments support a major role for extracellular nucleotide catalysis and for ecto 5'-NT and NS AP in the regulation of adenosine concentrations on airway surfaces.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Dept Pulm & Crit Care Med, Durham, NC 27710 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University; University of North Carolina; University of North Carolina Chapel Hill	Picher, M (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, 7010 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.				PHS HHS [34322] Funding Source: Medline; ODCDC CDC HHS [CCF R026, CCF R001] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ODCDC CDC HHS		Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; BELFIELD A, 1968, NATURE, V219, P73, DOI 10.1038/219073a0; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Braun N, 1998, J COMP NEUROL, V393, P528, DOI 10.1002/(SICI)1096-9861(19980420)393:4<528::AID-CNE10>3.0.CO;2-L; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; Capelli A, 1997, AM J RESP CRIT CARE, V155, P249, DOI 10.1164/ajrccm.155.1.9001320; Cass C E, 1999, Pharm Biotechnol, V12, P313; Chandrasena G, 1997, BIOCHEM PHARMACOL, V53, P1909, DOI 10.1016/S0006-2952(97)00170-6; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; Clancy JP, 1999, AM J PHYSIOL-CELL PH, V276, pC361, DOI 10.1152/ajpcell.1999.276.2.C361; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; Davis CW, 1997, PULM PHARMACOL THER, V10, P145, DOI 10.1006/pupt.1997.0088; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; EVANS WH, 1973, BIOCHEM J, V133, P189, DOI 10.1042/bj1330189; FEDDE KN, 1988, ARCH BIOCHEM BIOPHYS, V264, P400, DOI 10.1016/0003-9861(88)90305-0; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; FORTUNA R, 1980, CALCIFIED TISSUE INT, V30, P217, DOI 10.1007/BF02408631; FYFE GK, 1994, BBA-MOL CELL RES, V1224, P355, DOI 10.1016/0167-4889(94)90268-2; GALIETTA LJV, 1992, FEBS LETT, V304, P61, DOI 10.1016/0014-5793(92)80589-9; GATZY JT, 1975, AM J PHYSIOL, V228, P1162, DOI 10.1152/ajplegacy.1975.228.4.1162; GOLDSTEIN DJ, 1982, CLIN CHIM ACTA, V125, P63, DOI 10.1016/0009-8981(82)90046-8; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; HENDERSON RF, 1984, ENVIRON HEALTH PERSP, V56, P115, DOI 10.2307/3429841; HIRSH AJ, 2001, PEDIATR PULM, V22, P241; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; LAZAROWSKI ER, 2001, PEDIATR PULM, V22, P239; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LEHIR M, 1989, ENZYME, V41, P87, DOI 10.1159/000469058; LEHIR M, 1985, RENAL PHYSIOL BIOCH, V8, P321; LEHIR M, 1993, AM J PHYSIOL, V264, pF377, DOI 10.1152/ajprenal.1993.264.3.F377; LIEB T, 2001, J PHYSL, V538, P633; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485, DOI 10.1152/ajpcell.2001.280.6.C1485; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; NOUWEN EJ, 1986, CANCER RES, V46, P866; NOUWEN EJ, 1990, CELL TISSUE RES, V260, P321, DOI 10.1007/BF00318635; Orlati S, 2000, ARCH BIOCHEM BIOPHYS, V375, P69, DOI 10.1006/abbi.1999.1589; Otero M, 2000, MOL CELL BIOCHEM, V205, P115, DOI 10.1023/A:1007018001735; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314, DOI 10.1152/ajpgi.1997.272.6.G1314; PICHER M, 2001, DRUG DEVELOP RES, V23, P255; PICHER M, 2001, PEDIATR PULM, V22, P242; PIZAURO JM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P22, DOI 10.1016/0167-4838(93)90058-Y; Poelstra K, 1997, LAB INVEST, V76, P319; Polosa R, 2002, THORAX, V57, P649, DOI 10.1136/thorax.57.7.649; Pragnacharyulu PVP, 2000, J MED CHEM, V43, P4694, DOI 10.1021/jm0002533; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; SONG CS, 1967, J BIOL CHEM, V242, P694; STEFANOVIC V, 1988, RENAL PHYSIOL BIOCH, V11, P89; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; STUTTS MJ, 1994, AM J PHYSIOL, V267, pC1444; SUGIURA M, 1975, CHEM PHARM BULL, V23, P2369; SUGIURA M, 1976, CHEM PHARM BULL, V2, P1698; SUNDERMAN FW, 1990, ANN CLIN LAB SCI, V20, P123; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; TURNAY J, 1992, MOL CELL BIOCHEM, V117, P23; VANBELLE H, 1976, CLIN CHEM, V22, P972; VANHOOF VO, 1994, CRIT REV CL LAB SCI, V31, P197, DOI 10.3109/10408369409084677; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watkins DN, 1997, BRIT J PHARMACOL, V121, P1482; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; WU R, 1985, AM REV RESPIR DIS, V132, P311; YOUNG GP, 1981, BIOCHIM BIOPHYS ACTA, V676, P257, DOI 10.1016/0304-4165(81)90194-X; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	79	147	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13468	13479		10.1074/jbc.M300569200	http://dx.doi.org/10.1074/jbc.M300569200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560324	hybrid			2022-12-27	WOS:000182189500110
J	Sarandeses, CS; Covelo, G; Diaz-Jullien, C; Freire, M				Sarandeses, CS; Covelo, G; Diaz-Jullien, C; Freire, M			Prothymosin alpha is processed to thymosin alpha(1) and thymosin alpha(11) by a lysosomal asparaginyl endopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MESSENGER-RNA; HISTONE H1; THYMOSIN; THYMUS; CLEAVAGE; PEPTIDE; IDENTIFICATION; PURIFICATION; LEGUMAIN	Thymosin alpha(1) (Talpha(1)) and thymosin Talpha(11) (Talpha(11)) are polypeptides with immunoregulatory properties first isolated from thymic extracts, corresponding to the first 28 and 35 amino acid residues, respectively, of prothymosin a (ProTalpha), a protein involved in chromatin remodeling. It has been widely supposed that these polypeptides are not natural products of the in vivo processing of ProTalpha, since neither was found in extracts in which proteolysis was prevented. Here we show that a lysosomal asparaginyl endopeptidase is able to process ProTalpha to generate Talpha(1) and Talpha(11). In view of its catalytic properties and structural and immunological analyses, this protease was identified as mammalian legumain. It selectively cleaves some of the asparaginyl-glycine residues in the ProTa sequence; specifically, Asn(28)-Gly(29) and Asn(35)-Gly(36) residues are cleaved with similar efficiency in vitro to generate Talpha(1) and Talpha(11), respectively. By contrast Talpha(1) is the main product detected in vivo, free in the cytosol, at concentrations similar to that of ProTalpha. The data here reported demonstrate that Talpha(1) is not an artifact but rather is naturally present in diverse mammalian tissues and raise the possibility that it has a functional role.	Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain	Universidade de Santiago de Compostela	Freire, M (corresponding author), Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain.	bnfreire@usc.es	Diaz-Jullien, Cristina/L-4575-2018	Diaz-Jullien, Cristina/0000-0002-4307-8129; Sarandeses da Costa, Concepcion Sofia/0000-0002-0299-7129				BARCIA MG, 1993, J BIOL CHEM, V268, P4704; CALDARELLA J, 1983, P NATL ACAD SCI-BIOL, V80, P7424, DOI 10.1073/pnas.80.24.7424; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Enkemann SA, 2000, J CELL PHYSIOL, V182, P256, DOI 10.1002/(SICI)1097-4652(200002)182:2<256::AID-JCP15>3.0.CO;2-N; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; Evstafieva AG, 2000, FEBS LETT, V467, P150, DOI 10.1016/S0014-5793(00)01139-X; FRANCO FJ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P43, DOI 10.1016/0167-4838(92)90422-A; Freire J, 2001, BIOCHEM CELL BIOL, V79, P123, DOI 10.1139/bcb-79-2-123; FREIRE M, 1985, ARCH BIOCHEM BIOPHYS, V239, P480, DOI 10.1016/0003-9861(85)90715-5; FREIRE M, 1981, P NATL ACAD SCI-BIOL, V78, P192, DOI 10.1073/pnas.78.1.192; FREIRE M, 1978, P NATL ACAD SCI USA, V75, P6007, DOI 10.1073/pnas.75.12.6007; FREIRE M, 2002, RECENT RES DEV PROTE, V1, P257; GOLDSTEIN AL, 1977, P NATL ACAD SCI USA, V74, P725, DOI 10.1073/pnas.74.2.725; GOLDSTEIN AL, 1972, P NATL ACAD SCI USA, V69, P1800, DOI 10.1073/pnas.69.7.1800; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW TLK, 1979, J BIOL CHEM, V254, P981; LOW TLK, 1985, METHOD ENZYMOL, V116, P213; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; MANROW RE, 1991, J BIOL CHEM, V266, P3916; PAN LX, 1986, ARCH BIOCHEM BIOPHYS, V250, P197, DOI 10.1016/0003-9861(86)90717-4; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Perez-Estevez A, 2000, MOL CELL BIOCHEM, V208, P111, DOI 10.1023/A:1007050206653; PerezEstevez A, 1997, J BIOL CHEM, V272, P10506; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9	37	63	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13286	13293		10.1074/jbc.M213005200	http://dx.doi.org/10.1074/jbc.M213005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12554742	hybrid			2022-12-27	WOS:000182189500088
J	Basuroy, S; Sheth, P; Kuppuswamy, D; Balasubramanian, S; Ray, RM; Rao, RK				Basuroy, S; Sheth, P; Kuppuswamy, D; Balasubramanian, S; Ray, RM; Rao, RK			Expression of kinase-inactive c-Src delays oxidative stress-induced disassembly and accelerates calcium-mediated reassembly of tight junctions in the Caco-2 cell monolayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; INDUCED DISRUPTION; HYDROGEN-PEROXIDE; BARRIER FUNCTION; GROWTH-FACTOR; ACTIVATION; OCCLUDIN; PERMEABILITY; DISSOCIATION; ORGANIZATION	The activity of Src kinases appears to play a role in both assembly and disassembly of tight junction. However, the robe of a specific isoform. of Src kinase in regulation of tight junction is not known. In the present study the role of c-Src in regulation of epithelial tight junction was investigated in Caco-2 cell monolayers. Oxidative stress (xanthine oxidase + xanthine) induced an activation and membrane translocation of c-Src. The oxidative stress-induced decrease in transepithelial electrical resistance, increase in inulin permeability, and redistribution of occludin and ZO-1 from the intercellular junctions were prevented by PP2. The rates of oxidative stress-induced activation of c-Src, tyrosine phosphorylation of ZO-1 and beta-catenin, decrease in resistance, increase in permeability to inulin, and redistribution of occludin and ZO-1 were significantly greater in cells transfected with wild type c-Src, whereas it was low in cells transfected with kinase-inactive c-SrcK297R mutant, when compared with those in empty vector-transfected cells. The rates of recovery of resistance, increase in barrier to inulin, and reorganization of occludin and ZO-1 into the intercellular junctions during the calcium-induced reassembly of tight junction were much greater in Caco-2 cells transfected with c-SrcK297R as compared with those in cells transfected with empty vector or wild type c-Src. These results show that the dominant-negative expression of kinase-inactive c-Src delays the oxidative stress-induced disruption of tight junction and accelerates calcium induced assembly of tight junction in Caco-2 cells and demonstrate that oxidative stress-induced disruption of tight junction is mediated by the activation of c-Src.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, RK (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Rm 426, Memphis, TN 38163 USA.	rkrao@physio1.utmem.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012307] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA012307, R01-AA12307] Funding Source: Medline; NIDDK NIH HHS [R01-DK55532, R01 DK055532] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Atkinson KJ, 2001, AM J PHYSIOL-GASTR L, V280, pG1280, DOI 10.1152/ajpgi.2001.280.6.G1280; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V91, P83; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Collares-Buzato CB, 1998, EUR J CELL BIOL, V76, P85, DOI 10.1016/S0171-9335(98)80020-4; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gomez S, 1999, BBA-MOL CELL RES, V1452, P121, DOI 10.1016/S0167-4889(99)00124-X; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Grisendi S, 1998, J CELL PHYSIOL, V176, P465, DOI 10.1002/(SICI)1097-4652(199809)176:3<465::AID-JCP3>3.0.CO;2-M; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Ihara Y, 2002, BIOCHEM BIOPH RES CO, V297, P353, DOI 10.1016/S0006-291X(02)02195-2; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Meyer TN, 2001, J BIOL CHEM, V276, P22048, DOI 10.1074/jbc.M011477200; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rao RK, 1997, AM J PHYSIOL-GASTR L, V273, pG812, DOI 10.1152/ajpgi.1997.273.4.G812; Rao RK, 2000, AM J PHYSIOL-GASTR L, V279, pG332, DOI 10.1152/ajpgi.2000.279.2.G332; Ries J, 1997, AM J PHYSIOL-CELL PH, V272, pC794, DOI 10.1152/ajpcell.1997.272.3.C794; Sato K, 2001, DEV GROWTH DIFFER, V43, P55; STADDON JM, 1995, J CELL SCI, V108, P609; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Trischitta F, 2001, J COMP PHYSIOL B, V171, P85, DOI 10.1007/s003600000152; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yap AS, 1997, ENDOCRINOLOGY, V138, P2315, DOI 10.1210/en.138.6.2315	41	139	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11916	11924		10.1074/jbc.M211710200	http://dx.doi.org/10.1074/jbc.M211710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547828	hybrid			2022-12-27	WOS:000182015700027
J	Lanning, CC; Ruiz-Velasco, R; Williams, CL				Lanning, CC; Ruiz-Velasco, R; Williams, CL			Novel mechanism of the co-regulation of nuclear transport of SmgGDS and rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; GTP EXCHANGE PROTEIN; RHO-FAMILY; ACTIVATION; INTERACTS; CATENIN; IDENTIFICATION; LOCALIZATION; PRENYLATION; REPEATS	The armadillo protein SmgGDS promotes guanine nucleotide exchange by small GTPases containing a C-terminal polybasic region (PBR), such as Rac1 and RhoA. Because the PBR resembles a nuclear localization signal (NLS) sequence, we investigated the nuclear transport of SmgGDS with Rac1 or RhoA. We show that the Rac1 PBR has significant NLS activity when it is fused to green fluorescent protein (GFP) or in the context of full-length Rac1. In contrast, the RhoA PBR has very poor NLS activity when it is fused to GFP or in the context of full-length RhoA. The nuclear accumulation of both Rac1 and SmgGDS is enhanced by Rac1 activation and diminished by mutation of the Rac1 PBR. Conversely, SmgGDS nuclear accumulation is diminished by interactions with RhoA. An SmgGDS nuclear export signal sequence that we identified promotes SmgGDS nuclear export. These results suggest that SmgGDS-Rac1 complexes accumulate in the nucleus because the Rac1 PBR has NLS activity and because Rac1 supplies the appropriate GTP-dependent signal. In contrast, SmgGDS(.)RhoA complexes accumulate in the cytoplasm because the RhoA PBR does not have NLS activity. This model may be applicable to other armadillo proteins in addition to SmgGDS, because we demonstrate that activated Rac1 and RhoA also provide stimulatory and inhibitory signals, respectively, for the nuclear accumulation of p120 catenin. These results indicate that small GTPases with a PBR can regulate the nuclear transport of armadillo proteins.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, 1 Guthrie Square, Sayre, PA 18840 USA.	williams_carol@guthrie.org			NHLBI NIH HHS [R01 HL063921, R01 HL63921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Goodwin DJ, 2001, J BIOL CHEM, V276, P19905, DOI 10.1074/jbc.M009513200; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P237; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; KOTANI K, 1992, ONCOGENE, V7, P1699; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; KUDO N, 1996, P NTL ACAD SCI US, V96, P9112; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; ORITA S, 1993, J BIOL CHEM, V268, P25542; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Ruiz-Velasco R, 2002, J BIOL CHEM, V277, P33081, DOI 10.1074/jbc.M202664200; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Shafer SH, 1999, EXP CELL RES, V248, P148, DOI 10.1006/excr.1998.4385; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Strassheim D, 1999, J BIOL CHEM, V274, P18675, DOI 10.1074/jbc.274.26.18675; Strassheim D, 2000, J BIOL CHEM, V275, P6699, DOI 10.1074/jbc.275.10.6699; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Vithalani KK, 1998, MOL BIOL CELL, V9, P3095, DOI 10.1091/mbc.9.11.3095; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	38	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12495	12506		10.1074/jbc.M211286200	http://dx.doi.org/10.1074/jbc.M211286200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551911	hybrid			2022-12-27	WOS:000182015700101
J	Gotte, G; Vottariello, F; Libonati, M				Gotte, G; Vottariello, F; Libonati, M			Thermal aggregation of ribonuclease A - A contribution to the understanding of the role of 3D domain swapping in protein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; RNASE; DIMER	By lyophilizing RNase A from 40% acetic acid solutions, two dimeric aggregates, the "minor" and "major" dimers (named here N-dimer and C-dimer, respectively), form by 3D domain swapping at. a ratio of 1:4. Trimeric and tetrameric aggregates are also obtained. The two dimers and the higher oligomers also form without a lyophilization step. By keeping IRNase A dissolved at a high concentration (generally 200 mg/ml) in various media at temperatures ranging from 23 to 70 degreesC for times varying from a few minutes to 2 h, various oligomers, in particular the two dimeric conformers, formed in quite different amounts, often inverting their relative quantities depending on the more or less severe unfolding conditions. When unfolding mainly concerned the N terminus of the protein, richer in hydrophilic residues, the N-dimer, formed by 3D domain swapping of the N-terminal alpha-helix of each monomer, prevailed over the C-dimer. Under more vigorous denaturing conditions, where also the C terminus of RNase A, richer in hydrophobic amino acids, unfolded, the C-dimer, formed by 3D domain swapping of the C-terminal beta-strand, prevailed over the other, possibly because of the induction to aggregation promoted by the hydrophobic residues present in the C termini of the two monomers.	Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Visione, I-87134 Verona, Italy	University of Verona	Libonati, M (corresponding author), Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Visione, Strada Grazie 8, I-87134 Verona, Italy.	massimo.libonati@univr.it		Gotte, Giovanni/0000-0003-3179-7158				BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Juminaga D, 1997, BIOCHEMISTRY-US, V36, P10131, DOI 10.1021/bi970711i; Juneja J, 2002, BIOCHEMISTRY-US, V41, P2641, DOI 10.1021/bi011480p; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; LIBONATI M, 1969, Italian Journal of Biochemistry (English Edition), V18, P407; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; MARZOTTO A, 1970, ARCH BIOCHEM BIOPHYS, V137, P373, DOI 10.1016/0003-9861(70)90451-0; Neira JL, 1999, J MOL BIOL, V285, P627, DOI 10.1006/jmbi.1998.2365; Nenci A, 2001, PROTEIN SCI, V10, P2017, DOI 10.1110/ps.14101; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; Park C, 2000, PROTEIN SCI, V9, P2026, DOI 10.1110/ps.9.10.2026; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; RICO M, 1990, P 2 INT M STRUCT MEC, P9; SHINDO H, 1976, J BIOL CHEM, V251, P2648; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; TSONG TY, 1972, P NATL ACAD SCI USA, V69, P1809, DOI 10.1073/pnas.69.7.1809; TSONG TY, 1972, J MOL BIOL, V63, P453, DOI 10.1016/0022-2836(72)90440-8	28	66	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10763	10769		10.1074/jbc.M213146200	http://dx.doi.org/10.1074/jbc.M213146200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533538	hybrid			2022-12-27	WOS:000181777500100
J	Le Guiner, C; Gesnel, MC; Breathnach, R				Le Guiner, C; Gesnel, MC; Breathnach, R			TIA-1 or TUR is required for DT40 cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; GENE-EXPRESSION; MESSENGER-RNA; INTRON SEQUENCES; BINDING; APOPTOSIS; CLEAVAGE; IDENTIFICATION	TIA-1 and TIAR are a pair of related RNA-binding proteins which have been implicated in apoptosis. We show that chicken DT40 cells with both tia-1 alleles and one tiar allele disrupted (tia-1(-/-)tiar(-/+) cells) are viable. However, their growth and survival in medium containing low serum levels is significantly reduced compared with DT40 cells. The remaining intact tiar allele in tia-1(-/-)tiar(-/+) cells can only be disrupted if TIA-1 expression is first restored to the cells by transfection of a TIA-1 expression vector. We conclude that DT40 cells require either TIA-1 or TIAR for viability. TIA-1 overexpression in tia-1(-/-)tiar(-/+) cells leads to a radical drop in TIAR levels, by inducing efficient splicing of two tiar alternative exons carrying in-frame stop codons. In wild-type DT40 cells, tiar transcripts including these exons can also be detected. These transcripts increase significantly in abundance in cycloheximide-treated cells, suggesting that splicing of the exons exposes mRNAs to nonsense-mediated mRNA decay. TIA-1 or TIAR depletion leads to a marked drop in splicing of the exons. The human tiar gene contains a corresponding pair of TIA-1-inducible alternative exons, and we show that there is very high sequence conservation between chickens and humans of the exon pair and parts of the flanking introns. The TIA-1/TIAR responsiveness of these alternative tiar exons is likely to be of physiological importance for controlling TIAR levels.	CHR, INSERM, U463, Inst Biol, F-44093 Nantes 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	Breathnach, R (corresponding author), CHR, INSERM, U463, Inst Biol, 9 Quai Moncousu, F-44093 Nantes 1, France.	breathna@nantes.inserm.fr	Breathnach, Richard/K-7599-2015					Anderson P, 1995, Curr Top Microbiol Immunol, V198, P131; Anderson P, 2002, CELL STRESS CHAPERON, V7, P213, DOI 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2; Anderson P, 2002, J CELL SCI, V115, P3227; Anderson P, 2000, ANN RHEUM DIS, V59, P3; Beck ARP, 1998, P NATL ACAD SCI USA, V95, P2331, DOI 10.1073/pnas.95.5.2331; Buerstedde JM, 2002, NUCLEIC ACIDS RES, V30, P230, DOI 10.1093/nar/30.1.230; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Degen WGJ, 2000, CELL DEATH DIFFER, V7, P70, DOI 10.1038/sj.cdd.4400617; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2001, RNA, V7, P1185, DOI 10.1017/S1355838201010536; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; Iseni F, 2002, EMBO J, V21, P5141, DOI 10.1093/emboj/cdf513; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Jin KL, 2001, ANN NEUROL, V50, P93, DOI 10.1002/ana.1073; KAWAKAMI A, 1994, J IMMUNOL, V152, P4937; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Li W, 2002, J VIROL, V76, P11989, DOI 10.1128/JVI.76.23.11989-12000.2002; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; Osborne NN, 1997, INVEST OPHTH VIS SCI, V38, P1390; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Saito K, 2001, ARTHRITIS RHEUM-US, V44, P2879, DOI 10.1002/1529-0131(200112)44:12<2879::AID-ART476>3.0.CO;2-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sonoda E, 2001, PHILOS T ROY SOC B, V356, P111, DOI 10.1098/rstb.2000.0755; Sureau A, 2001, EMBO J, V20, P1785, DOI 10.1093/emboj/20.7.1785; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Tsuzuki S, 2001, INSECT BIOCHEM MOLEC, V31, P321, DOI 10.1016/S0965-1748(00)00124-7; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; Yu Q, 2003, J BIOL CHEM, V278, P1579, DOI 10.1074/jbc.M203526200	46	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10465	10476		10.1074/jbc.M212378200	http://dx.doi.org/10.1074/jbc.M212378200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533540	hybrid			2022-12-27	WOS:000181777500064
J	Staudinger, R; Phogat, SK; Xiao, XD; Wang, XH; Dimitrov, DS; Zolla-Pazner, S				Staudinger, R; Phogat, SK; Xiao, XD; Wang, XH; Dimitrov, DS; Zolla-Pazner, S			Evidence for CD4-enchanced signaling through the chemokine receptor CCR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1; INFECTION; FUSION; CD4; IDENTIFICATION; CORECEPTOR; COMPONENT; DOPAMINE; ANTIGEN; BINDING	The chemokine receptor CCR5 is constitutively associated with the T cell co-receptor CD4 in plasma cell membranes, but the physiological role of this interaction has not been elucidated. Here we show that detergent-solubilized, purified CCR5 can directly associate with purified soluble fragments of the extracellular portion of CD4. We further demonstrate that the physical association of CCR5 and CD4 in membrane vesicles results in the formation of a receptor complex that exhibits macrophage inflammatory protein 1beta (MIP-1beta) binding properties that are distinct from CCR5. The affinity of the CD4-CCR5 complex for MIP-1beta was 3.5-fold lower than for CCR5, but the interaction of CD4 and CCR5 resulted in a receptor complex that exhibited enhanced G-protein signaling as compared with CCR5 alone. MIP1beta-induced G-protein activation was further increased by simultaneous stimulation of CD4 with its natural agonist, interleukin-16. Thus, the physical association of CD4 and CCR5 results in receptor cross-talk with allosteric CD4-dependent regulation of the binding and signaling properties of CCR5. Although the precise physiological role of the CD4 effects on CCR5-mediated signaling remains unknown, one can speculate that the cross-talk is a component of mechanisms involved in the fine tuning of immune system cell responses.	NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, NIH, Ft Detrick, MD 21702 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Vet Affairs New York Harbor Healthcare Syst, New York, NY 10016 USA	New York University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; New York University; New York University	Staudinger, R (corresponding author), NYU, Sch Med, Dept Neurol, 550 1st Ave,NBV 7W11, New York, NY 10016 USA.	robert.staudinger@med.nyu.edu	Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036085, P30AI027742] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59725] Funding Source: Medline; NIAID NIH HHS [AI27742, AI36085] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Beckner SK, 1997, METHOD ENZYMOL, V288, P309; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; EVANS SW, 1987, NATURE, V325, P166, DOI 10.1038/325166a0; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; Mashikian MV, 1999, J IMMUNOL, V163, P3123; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Mueller A, 2002, BRIT J PHARMACOL, V135, P1033, DOI 10.1038/sj.bjp.0704540; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Staudinger R, 2001, BIOCHEM BIOPH RES CO, V286, P41, DOI 10.1006/bbrc.2001.5345; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Willett BJ, 1997, NATURE, V385, P587, DOI 10.1038/385587a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496	29	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10389	10392		10.1074/jbc.M212013200	http://dx.doi.org/10.1074/jbc.M212013200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531905	hybrid			2022-12-27	WOS:000181777500054
J	Peng, AM; Chen, PL				Peng, AM; Chen, PL			NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY PARTICIPANT; HISTONE H2AX; PROTEIN; REPAIR; BRCT; RAD9	Signaling pathways in response to DNA double strand breaks involve molecular cascades consisting of sensors, transducers, and effector proteins that activate cell cycle checkpoints and recruit repair machinery proteins. NFBD1 (a nuclear factor with BRCT domains protein 1) contains FRA ((f) under bar ork (h) under bar ead-(a) under bar ssociated), BRCT ((br) under bar east cancer susceptibility gene 1 carboxyl terminus) domains, and internal repeats and is an early participant in nuclear foci in response to IR. To elucidate its role in the response pathways, small interfering RNA (siRNA) directed against NFDB1 in human cells demonstrated that its absence is associated with increased radio-sensitivity and delayed G(2)/M transition, but not G(1) to S. NFBD1 associates with nuclear foci within minutes following 111, a property similar to histone H2AX, 53BP1, and Chk2, which are all early participants in the DNA damage signaling cascade. Temporal studies show that H2AX is required for the foci positive for NFBD1, but NFBD1 is not needed for 53BP1- and H2AX-positive foci. NFBD1, together with 53BP1, plays a partially redundant role in regulating phosphorylation of the downstream effector protein, Chk2; since abrogation of both diminishes phosphorylated Chk2 in IR-induced foci. These results place NFBD1 parallel to 53BP1 in regulating Chk2 and downstream of H2AX in the recruitment of repair and signaling proteins to sites of DNA damage.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	chenp0@uthscsa.edu		Chen, Phang-Lang/0000-0002-0357-9017	NATIONAL CANCER INSTITUTE [R01CA085605] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	21	83	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8873	8876		10.1074/jbc.C300001200	http://dx.doi.org/10.1074/jbc.C300001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12551934	hybrid			2022-12-27	WOS:000181524000002
J	Goto, E; Ishido, S; Sato, Y; Ohgimoto, S; Ohgimoto, K; Nagano-Fujii, M; Hotta, H				Goto, E; Ishido, S; Sato, Y; Ohgimoto, S; Ohgimoto, K; Nagano-Fujii, M; Hotta, H			C-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; MHC CLASS-I; T-CELLS; IMMUNOLOGICAL SYNAPSE; DOWN-REGULATION; IMMUNE EVASION; VIRAL PROTEIN; PHD DOMAIN; K5 PROTEIN; NK CELLS	Kaposi's sarcoma associated-herpes virus encodes two proteins, MIR (modulator of immune recognition) 1 and 2, which are involved in the evasion of host immunity. MIR1 and 2 have been shown to function as an E3 ubiquitin ligase for immune recognition-related molecules (e.g. major histocompatibility complex class 1, B7-2, and ICAM-1) through the BKS (bovine herpesvirus 4, Kaposi's sarcoma associated-herpes virus, and Swinepox virus) subclass of plant homeodomain (PHD) domain, termed the BKS-PHD domain. Here we show that the human genome also encodes a novel BKS-PHD domain-containing protein that functions as an E3 ubiquitin ligase and whose putative substrate is the B7-2 co-stimulatory molecule. This novel E3 ubiquitin ligase was designated as c-MIR (cellular MIR) based on its functional and structural similarity to MIR1 and 2. Forced expression of c-MIR induced specific down-regulation of B7-2 surface expression through ubiquitination, rapid endocytosis, and lysosomal degradation of the target molecule. This specific targeting was dependent upon the binding of c-MIR to B7-2. Replacing the BKS-PHD domain of MIR1 with the corresponding domain of cMIR did not alter MIR1 function. The discovery of cMIR, a novel E3 ubiquitin ligase, highlights the possibility that viral immune regulatory proteins originated in the host genome and presents unique functions of BKS-PHD domain-containing proteins in mammals.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Microbiol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Ishido, S (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Microbiol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Choi JK, 2001, CYTOKINE GROWTH F R, V12, P245, DOI 10.1016/S1359-6101(00)00029-0; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Coscoy L, 2000, P NATL ACAD SCI USA, V97, P8051, DOI 10.1073/pnas.140129797; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Coscoy L, 2001, J CLIN INVEST, V107, P1599, DOI 10.1172/JCI12432; Davis DM, 2002, TRENDS IMMUNOL, V23, P356, DOI 10.1016/S1471-4906(02)02243-3; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gao JX, 2002, J EXP MED, V195, P959, DOI 10.1084/jem.20011948; Haque M, 2001, J GEN VIROL, V82, P1175, DOI 10.1099/0022-1317-82-5-1175; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Ishido S, 2000, IMMUNITY, V13, P365, DOI 10.1016/S1074-7613(00)00036-4; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; ITOH, 2002, J IMMUNOL, V168, P541; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Luhder F, 2000, P NATL ACAD SCI USA, V97, P12204, DOI 10.1073/pnas.200348397; Means RE, 2002, EMBO J, V21, P1638, DOI 10.1093/emboj/21.7.1638; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Sanchez DJ, 2002, J BIOL CHEM, V277, P6124, DOI 10.1074/jbc.M110265200; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741	34	123	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14657	14668		10.1074/jbc.M211285200	http://dx.doi.org/10.1074/jbc.M211285200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582153	hybrid			2022-12-27	WOS:000182516100012
J	Hausmann, S; Shuman, S				Hausmann, S; Shuman, S			Defining the active site of Schizosaccharomyces pombe C-terminal domain phosphatase fcp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROTEIN PHOSPHATASE; PHOSPHOSERINE PHOSPHATASE; MUTATIONAL ANALYSIS; CATALYTIC DOMAIN; CTD PHOSPHATASE; TRANSCRIPTION; SUBUNIT; DEPHOSPHORYLATION; PURIFICATION	Fcp1 is an essential protein serine phosphatase that dephosphorylates the C-terminal domain (CTD) of RNA polymerase 11. By testing the effects of serial N- and C-terminal deletions of the 723-amino acid Schizosaccharomyces pombe Fcp1, we defined a minimal phosphatase domain spanning amino acids 156-580. We employed site-directed mutagenesis (introducing 24 mutations at 14 conserved positions) to locate candidate catalytic residues. We found that alanine substitutions for Arg(223), Asp(258), Lys(280), Asp(297), and Asp(298) abrogated the phosphatase activity with either p-nitrophenyl phosphate or CTD-PO4 as substrates. Structure-activity relationships were determined by introducing conservative substitutions at each essential position. Our results, together with previous mutational studies, highlight a constellation of seven amino acids (Asp(170), Asp(172), Arg(223), Asp(258), Lys(280), Asp(297), and Asp(298)) that are conserved in all Fcp1 orthologs and likely comprise the active site. Five of these residues (Asp(170), Asp(172) Lys(280), Asp(297), and Asp (298)) are conserved at the active site of T4 polynucleotide X-phosphatase, suggesting that Fcp1 and T4 phosphatase are structurally and mechanistically related members of the DXD phosphotransferase superfamily.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hirose Y, 2000, GENE DEV, V14, P1415; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; Mandal SS, 2002, MOL CELL BIOL, V22, P7543, DOI 10.1128/MCB.22.21.7543-7552.2002; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8	29	22	22	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13627	13632		10.1074/jbc.M213191200	http://dx.doi.org/10.1074/jbc.M213191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556522	hybrid			2022-12-27	WOS:000182405000010
J	Kuai, J; Nickbarg, E; Wooters, J; Qiu, YC; Wang, J; Lin, LL				Kuai, J; Nickbarg, E; Wooters, J; Qiu, YC; Wang, J; Lin, LL			Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; NONOBESE DIABETIC MICE; CELL-DEATH; SIGNALING COMPLEX; LYMPHOID-TISSUES; DEFICIENT MICE; CYTOCHROME-C; ABNORMAL-DEVELOPMENT; SMAC/DIABLO RELEASE	Lymphotoxin-beta receptor (LTbetaR) is a member of tumor necrosis factor receptor family and plays essential roles in the embryonic development and organization of secondary lymphoid tissues. It binds two types of tumor necrosis factor family cytokines, heterotrimer LTalpha1beta2 and homotrimer LIGHT, and activates multiple signaling pathways including transcriptional factor NFkappaB, c-Jun N-terminal kinase, and cell death. However, the molecular mechanism of the activation of these signaling pathways by LTbetaR is not clear. Because there is no enzymatic activity associated with the receptor itself, the signal transduction of LTbetaR is mediated by cytoplasmic proteins recruited to receptors. To identify these proteins, we took a proteomic approach. The endogenous LIGHT-LTbetaR complex was affinity-purified from U937 cells, and proteins associated with the complex were identified by mass spectrometry. Four of five proteins identified, TRAF2, TRAF3, cIAP1, and Smac, are reported here. Their association with LTbetaR was further confirmed by coimmunoprecipitation in U937 cells and HEK293 cells. The presence of cIAP1 and Smac in LIGHT-LTbetaR complex revealed a novel mechanism of LIGHT-LTbetaR-induced apoptosis.	Wyeth Ayerst Res, Musculoskeletal Sci, Cambridge, MA 02140 USA; Wyeth Ayerst Res, Prot Chem & Proteom, Cambridge, MA 02140 USA	Pfizer; Pfizer	Lin, LL (corresponding author), Wyeth Ayerst Res, Musculoskeletal Sci, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	llin@wyeth.com						Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; BANKS TA, 1995, J IMMUNOL, V155, P1685; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Ettinger R, 2001, J EXP MED, V193, P1333, DOI 10.1084/jem.193.11.1333; FAVA R, 1998, J INTERFERON CYTOKIN, V18, P95; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Herrera B, 2002, FEBS LETT, V520, P93, DOI 10.1016/S0014-5793(02)02774-6; Houthaeve T, 1997, J PROTEIN CHEM, V16, P343, DOI 10.1023/A:1026372302560; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Krajewska M, 1998, AM J PATHOL, V152, P1549; Kuprash DV, 1999, J IMMUNOL, V163, P6575; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mackay F, 1996, J BIOL CHEM, V271, P24934, DOI 10.1074/jbc.271.40.24934; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Murphy M, 1998, CELL DEATH DIFFER, V5, P497, DOI 10.1038/sj.cdd.4400374; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wajant H, 1999, CYTOKINE GROWTH F R, V10, P15, DOI 10.1016/S1359-6101(98)00023-9; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Wu Q, 2001, J EXP MED, V193, P1327, DOI 10.1084/jem.193.11.1327; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoshikawa H, 2001, J IMMUNOL, V167, P2487, DOI 10.4049/jimmunol.167.5.2487; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492; Zhang XD, 2001, CANCER RES, V61, P7339	50	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14363	14369		10.1074/jbc.M208672200	http://dx.doi.org/10.1074/jbc.M208672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571250	hybrid			2022-12-27	WOS:000182405000101
J	Park, B; Ahn, K				Park, B; Ahn, K			An essential function of tapasin in quality control of HLA-G molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; NATURAL-KILLER-CELLS; ANTIGEN PRESENTATION; ENDOPLASMIC-RETICULUM; PEPTIDE REPERTOIRE; SURFACE EXPRESSION; RECYCLING PATHWAY; COMPLEX; TAP; PROTEINS	Tapasin plays an important role in the quality control of major histocompatibility complex (MHC) class I assembly, but its precise function in this process remains controversial. Whether tapasin participates in the assembly of HILA-G has not been studied. HIA-G, an MHC class Ib molecule that binds a more restricted set of peptides than class la molecules, is a particularly interesting molecule, because during assembly, it recycles between the endoplasmic reticulum (ER) and the cis-Golgi until it is loaded with a high affinity peptide. We have taken advantage of this unusual trafficking property of HILA-G and its requirement for high affinity peptides to demonstrate that a critical function of tapasin is to transform class I molecules into a high affinity, peptide-receptive form. In the absence of tapasin, HIA-G molecules cannot bind high affinity peptides, and an abundant supply of peptides cannot overcome the tapasin requirement for high affinity peptide loading. The addition of tapasin renders HILA-G molecules capable of loading high affinity peptides and of transporting to the surface, suggesting that tapasin is a prerequisite for the binding of high-affinity ligands. Interestingly, the "tapasin-dependent" HILA-G molecules are not empty in the absence of tapasin but are in fact associated with suboptimal peptides and continue to recycle between the ER and the cis-Golgi. Together with the finding that empty HIA-G heterodimers are strictly retained in the ER and degraded, our data suggest that MHC class I molecules bind any available peptides to avoid ER-mediated degradation and that the peptides are in turn replaced by higher affinity peptides with the aid of tapasin.	Korea Univ, Grad Sch Biotechnol, Sungbuk Gu, Seoul 136701, South Korea	Korea University	Park, B (corresponding author), Korea Univ, Grad Sch Biotechnol, Sungbuk Gu, 1,5-Ka,Anam Dong, Seoul 136701, South Korea.							Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; CARRENO BM, 1995, J IMMUNOL, V155, P4726; Chun T, 2001, J IMMUNOL, V167, P1507, DOI 10.4049/jimmunol.167.3.1507; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Diehl M, 1996, CURR BIOL, V6, P305, DOI 10.1016/S0960-9822(02)00481-5; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HOWELL DN, 1986, HUM IMMUNOL, V17, P443, DOI 10.1016/0198-8859(86)90303-4; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jun Y, 2000, J IMMUNOL, V164, P805, DOI 10.4049/jimmunol.164.2.805; Kropshofer H, 1999, IMMUNOL REV, V172, P267, DOI 10.1111/j.1600-065X.1999.tb01371.x; Kropshofer H, 1997, IMMUNOL TODAY, V18, P77, DOI 10.1016/S0167-5699(97)01006-2; LEE N, 1995, IMMUNITY, V3, P591, DOI 10.1016/1074-7613(95)90130-2; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Li SL, 2000, J BIOL CHEM, V275, P1581, DOI 10.1074/jbc.275.3.1581; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; Munz C, 1997, J EXP MED, V185, P385, DOI 10.1084/jem.185.3.385; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; Sijts AJAM, 1997, J EXP MED, V185, P1403, DOI 10.1084/jem.185.8.1403; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Yu YYL, 1999, J IMMUNOL, V163, P4427	45	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14337	14345		10.1074/jbc.M212882200	http://dx.doi.org/10.1074/jbc.M212882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582157	hybrid			2022-12-27	WOS:000182405000098
J	Ridyard, MS; Robbins, SM				Ridyard, MS; Robbins, SM			Fibroblast growth factor-2-induced signaling through lipid raft-associated fibroblast growth factor receptor substrate 2 (FRS2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCKING-PROTEIN FRS2-ALPHA; TYROSINE KINASE-ACTIVITY; PC12 CELLS; EARLY EMBRYOGENESIS; ADAPTER PROTEINS; FGF RECEPTORS; SH2 DOMAIN; CAVEOLAE; MEMBRANE; ACTIVATION	The plasma membrane is not homogenous but contains specific subcompartments characterized by their unique lipid and protein composition. Based on their enrichment in various signaling molecules, these membrane microdomains are recognized to be sites of localized signal transduction for a number of extracellular stimuli. We have previously shown that fibroblast growth factor-2 (FGF2) induced a specific signaling response within a lipid raft membrane microdomain in human neuroblastoma cells characterized by the tyrosine phosphorylation of a p,80 phosphoprotein. Herein, we show that this protein is the signaling adaptor FRS2 and that it is localized exclusively to lipid rafts in vitro and in vivo. We have examined how the tyrosine phosphorylation and serine-threonine phosphorylation of FRS2 within lipid rafts affect the response of cells to FGF2 signaling. Our data suggest that activation of protein kinase C, Src family kinases, and MEK1/2 are involved in regulating serine-threonine phosphorylation of FRS2, which can indirectly affect FRS2 phosphotyrosine levels. We also show that Grb2 is recruited to lipid rafts during signaling events and that activation of MEK1/2 by different mechanisms within lipid rafts may lead to different cellular responses. This work suggests that compartmentalized signaling within lipid rafts may provide a level of specificity for growth factor signaling.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr,NW, Calgary, AB T2N 4N1, Canada.							ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Bansal R, 1996, MOL CELL NEUROSCI, V7, P263, DOI 10.1006/mcne.1996.0020; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Davy A, 2000, J NEUROCHEM, V74, P676, DOI 10.1046/j.1471-4159.2000.740676.x; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Gritti A, 1996, J NEUROSCI, V16, P1091; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hama J, 2002, J BIOL CHEM, V277, P19806, DOI 10.1074/jbc.M110637200; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kusakabe M, 2001, EMBO REP, V2, P727, DOI 10.1093/embo-reports/kve152; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Llosas MD, 1996, BIOCHEM J, V315, P1049; McDougall K, 2001, MECH DEVELOP, V103, P145, DOI 10.1016/S0925-4773(01)00337-9; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; ORNITZ DM, 1996, J BIOL CHEM, V271, P1592; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schnitzer J. E., 1997, VASCULAR ENDOTHELIUM, P77; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	51	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13803	13809		10.1074/jbc.M210245200	http://dx.doi.org/10.1074/jbc.M210245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571252	hybrid			2022-12-27	WOS:000182405000032
J	Lee, M; Metso, J; Jauhiainen, M; Kovanen, PT				Lee, M; Metso, J; Jauhiainen, M; Kovanen, PT			Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; APOLIPOPROTEIN-B; HDL; ATHEROSCLEROSIS; PARTICLES; SECRETION; RESISTANT; TRANSPORT; GRANULES; ABILITY	Human atherosclerotic lesions contain mast cells filled with the neutral protease chymase. Here we studied the effect of human chymase on W phospholipid transfer protein (PLTP)-mediated phospholipid (PL) transfer activity, and (ii) the ability of PLTP to generate pre-beta-high density lipoprotein (HDL). Immunoblot analysis of PLTP after incubation with chymase for 6 h revealed, in addition to the original 80-kDa band, four specific proteolytic fragments of PLTP with approximate molecular masses of 70, 52, 48, and 31 kDa. This specific pattern of PLTP degradation remained stable for at least 24 h of incubation with chymase. Such proteolyzed PLTP had reduced ability (i) to transfer PL from liposome donor particles to acceptor HDL3 particles, and (ii) to facilitate the formation of pre-beta-HDL. However, when PLTP was incubated with chymase in the presence of HDL3 only one major cleavage product of PLTP (48 kDa) was generated, and PL, transfer activity was almost fully preserved. Moreover, chymase effectively depleted the pre-beta-HDL particles generated from HDL3 by PLTP and significantly inhibited the high affinity component of cholesterol efflux from macrophage foam cells. These results suggest that the mast cells in human atherosclerotic lesions, by secreting chymase, may prevent PLTP-dependent formation of pre-beta-HDL particles from HDL3 and so impair the anti-atherogenic function of PLTP.	Wihuri Res Inst, Helsinki 00140, Finland; Univ Havana, Fac Biol, Havana 10400, Cuba; Natl Publ Hlth Inst, Dept Mol Med, FIN-00290 Helsinki, Finland	Wihuri Research Institute; Universidad de la Habana; Finland National Institute for Health & Welfare	Kovanen, PT (corresponding author), Wihuri Res Inst, Kalliolinnatie 4, Helsinki 00140, Finland.	petri.kovanen@wri.fi						BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CAUGHEY GH, 1998, HDB PROTEOLYTIC ENZY, P66; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DAY JR, 1994, J BIOL CHEM, V269, P9388; Desrumaux C, 2001, J BIOL CHEM, V276, P5908, DOI 10.1074/jbc.M008420200; Dullaart RPF, 2001, SCAND J CLIN LAB INV, V61, P69; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Huuskonen J, 1998, J LIPID RES, V39, P2021; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2001, ATHEROSCLEROSIS, V155, P269, DOI 10.1016/S0021-9150(01)00447-6; Huuskonen J, 1998, BBA-LIPID LIPID MET, V1391, P181, DOI 10.1016/S0005-2760(98)00008-3; Jaari S, 2001, COMP BIOCHEM PHYS B, V128, P781, DOI 10.1016/S1096-4959(01)00297-4; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; Karkkainen M, 2002, J BIOL CHEM, V277, P15413, DOI 10.1074/jbc.M112247200; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee M, 1999, ARTERIOSCL THROM VAS, V19, P1066, DOI 10.1161/01.ATV.19.4.1066; Lee M, 2002, ARTERIOSCL THROM VAS, V22, P1475, DOI 10.1161/01.ATV.0000029782.84357.68; Lee M, 2000, J LIPID RES, V41, P975; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; Lindstedt L, 2001, ATHEROSCLEROSIS, V155, P87, DOI 10.1016/S0021-9150(00)00544-X; MarquesVidal P, 1997, ATHEROSCLEROSIS, V133, P87, DOI 10.1016/S0021-9150(97)00120-2; Oka T, 2000, J LIPID RES, V41, P1651; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Haperen R, 2000, ARTERIOSCL THROM VAS, V20, P1082, DOI 10.1161/01.ATV.20.4.1082; van Haperen R, 2002, J BIOL CHEM, V277, P48938, DOI 10.1074/jbc.M209128200; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; vonEckardstein A, 1996, BBA-LIPID LIPID MET, V1301, P255, DOI 10.1016/0005-2760(96)00050-1; Wolfbauer G, 1999, BBA-MOL CELL BIOL L, V1439, P65, DOI 10.1016/S1388-1981(99)00077-3; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	43	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13539	13545		10.1074/jbc.M210847200	http://dx.doi.org/10.1074/jbc.M210847200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12531890	hybrid			2022-12-27	WOS:000182189500118
J	Rai, R; Tate, JJ; Cooper, TG				Rai, R; Tate, JJ; Cooper, TG			Ure2, a prion precursor with homology to glutathione S-transferase, protects Saccharomyces cerevisiae cells from heavy metal ion and oxidant toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; GENE-EXPRESSION; YEAST; ALPHA; MKS1; TRANSCRIPTION; BIOSYNTHESIS; GENERATION; ENCODES; REGION	Ure2, the protein that negatively regulates GATA factor (GIn3, Gat1)-mediated transcription in Saccharomyces cerevisiae, possesses prion-like characteristics. Identification of metabolic and environmental factors that influence prion formation as well as any activities that prions or prion precursors may possess are important to understanding them and developing treatment strategies for the diseases in which they participate. Ure2 exhibits primary sequence and three-dimensional homologies to known glutathione S-transferases. However, multiple attempts over nearly 2 decades to demonstrate Ure2-mediated S-transferase activity have been unsuccessful, leading to the possibility that Ure2 may wen not participate in glutathionation reactions. Here we show that Ure2 is required for detoxification of glutathione S-transferase substrates and cellular oxidants. ure2Delta mutants are hypersensitive to cadmium and nickel ions and hydrogen peroxide. They are only slightly hypersensitive to diamide, which is nitrogen source-dependent, and minimally if at all hypersensitive to 1-chloro-2,4-dinitrobenzene, the most commonly used substrate for glutathione S-transferase enzyme assays. Therefore, Ure2 shares not only structural homology with various glutathione S-transferases, but ure2 mutations possess the same phenotypes as mutations in known S. cerevisiae and Schizosaccharomyces pombe glutathione S-transferase genes. These findings are consistent with Ure2 serving as a glutathione S-transferase in S. cerevisiae.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avendano A, 1997, J BACTERIOL, V179, P5594, DOI 10.1128/jb.179.17.5594-5597.1997; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cunningham TS, 2000, J BACTERIOL, V182, P6584, DOI 10.1128/JB.182.23.6584-6591.2000; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Fraser JA, 2002, APPL ENVIRON MICROB, V68, P2802, DOI 10.1128/AEM.68.6.2802-2808.2002; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LACROUTE F, 1968, J BACTERIOL, V95, P824, DOI 10.1128/JB.95.3.824-832.1968; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MAGASANIK B, 1993, MOL CELLULAR BIOL YE, P2853; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Sherratt PJ, 1997, BIOCHEM J, V326, P837, DOI 10.1042/bj3260837; Shin YH, 2002, BBA-GENE STRUCT EXPR, V1577, P164, DOI 10.1016/S0167-4781(02)00422-0; Tan KL, 1996, BIOCHEM J, V315, P727, DOI 10.1042/bj3150727; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Veal EA, 2002, J BIOL CHEM, V277, P35523, DOI 10.1074/jbc.M111548200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	39	54	54	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12826	12833		10.1074/jbc.M212186200	http://dx.doi.org/10.1074/jbc.M212186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562760	Green Accepted, hybrid			2022-12-27	WOS:000182189500032
J	Masuda, Y; Ohmae, M; Masuda, K; Kamiya, K				Masuda, Y; Ohmae, M; Masuda, K; Kamiya, K			Structure and enzymatic properties of a stable complex of the human REV1 and REV7 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ZETA; DEOXYCYTIDYL TRANSFERASE-ACTIVITY; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; DCMP TRANSFERASE; UV MUTAGENESIS; HUMAN HOMOLOG; ABASIC SITES; ERROR-PRONE; YEAST	With yeast Saccharomyces cerevisiae, results from a variety of genetic and biochemical investigations have demonstrated that the REV genes play a major role in induction of mutations through replication processes that directly copy the damaged DNA template during DNA replication. However, in higher eucaryotes functions of homologues are poorly understood and appear somewhat different from the yeast case. It has been suggested that human REV1 interacts with human REV7, this being specific to higher eucaryotes. Here we show that purified human REV1 and REV7 proteins form a heterodimer in solution, which is stable through intensive purification steps. Results from biochemical analysis of the transferase reactions of the REV1-REV7 complex demonstrated, in contrast to the case of yeast Rev3 whose polymerase activity is stimulated by assembly with yeast Rev7, that human REV7 did not influence the stability, substrate specificity, or kinetic parameters of the transferase reactions of REV1 protein. The possible role of human REV7 is discussed.	Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Kamiya, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.		Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988				Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo DY, 2001, NUCLEIC ACIDS RES, V29, P2875, DOI 10.1093/nar/29.13.2875; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; LAWRENCE CW, 1985, MOL GEN GENET, V200, P80, DOI 10.1007/BF00383316; Lawrence CW, 1996, CANCER SURV, V28, P21; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; LAWRENCE CW, 1976, GENETICS, V82, P207; LEMONTT JF, 1971, GENETICS, V68, P21; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Masuda Y, 2002, FEBS LETT, V520, P88, DOI 10.1016/S0014-5793(02)02773-4; Masuda Y, 2002, J BIOL CHEM, V277, P3040, DOI 10.1074/jbc.M110149200; Masuda Y, 2001, J BIOL CHEM, V276, P15051, DOI 10.1074/jbc.M008082200; MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Otsuka C, 2002, MUTAT RES-FUND MOL M, V502, P53, DOI 10.1016/S0027-5107(02)00023-4; Sambrook J., 2002, MOL CLONING LAB MANU; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Xiao W, 2000, GENETICS, V155, P1633; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630	33	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12356	12360		10.1074/jbc.M211765200	http://dx.doi.org/10.1074/jbc.M211765200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529368	hybrid			2022-12-27	WOS:000182015700082
J	Samaras, SE; Zhao, L; Means, A; Henderson, E; Matsuoka, T; Stein, R				Samaras, SE; Zhao, L; Means, A; Henderson, E; Matsuoka, T; Stein, R			The islet beta cell-enriched RIPE3b1/Maf transcription factor regulates pdx-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR 3-BETA; DNA-BINDING ACTIVITY; INSULIN-II GENE; C-MAF; LENS DEVELOPMENT; FACTOR IDX1/IPF1; DISTINCT ROLES; NEURAL CELLS; PAX6; DIFFERENTIATION	Pancreatic duodenal homeobox factor-1, PDX-1, is required for pancreas development, islet cell differentiation, and the maintenance of 0 cell function. Selective expression in the pancreas appears to be principally regulated by Area II, one of four conserved regulatory sequence domains found within the 5'-flanking region of the pdx-1 gene. Detailed mutagenesis studies have identified potential sites of interaction for both positive- and negative-acting factors within the conserved sequence blocks of Area II. The islet beta cell-enriched RIPE3b1 transcription factor, the activator of insulin C1 element-driven expression, was shown here to also stimulate Area II by binding to sequence blocks 4 and 5 (termed B4/5). Accordingly, B4/5 DNA-binding protein's molecular mass (i.e. 46 kDa), binding specificity, and islet beta cell-enriched distribution were identical to RIPE3b1. Area II-mediated activation was also unaffected upon replacing B4/5 with the insulin C1/RIPE3b1 binding site. In addition, the chromatin immunoprecipitation assay showed that the Area II region of the endogenous pdx-1 gene was precipitated by an antiserum that recognizes the large Maf protein that comprises the RIPE3b1 transcription factor. These results strongly suggest that RIPE3b1/Maf has an important role in generating and maintaining physiologically functional beta cells.	Vanderbilt Univ, Dept Physiol & Mol Biophys, Ctr Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Surg Oncol, Ctr Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Dept Physiol & Mol Biophys, Ctr Med, 221 Kirkland Hall, Nashville, TN 37232 USA.	Roland.Stein@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042502, R01DK050203, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK42502, R01 DK50203, P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Brink C, 2001, MECH DEVELOP, V100, P37, DOI 10.1016/S0925-4773(00)00500-1; Civil A, 2002, NUCLEIC ACIDS RES, V30, P975, DOI 10.1093/nar/30.4.975; Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DEWIT L, 1993, BIOCHEM BIOPH RES CO, V192, P840, DOI 10.1006/bbrc.1993.1491; Gannon M, 2001, DEV BIOL, V238, P185, DOI 10.1006/dbio.2001.0359; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Ishibashi S, 2001, MECH DEVELOP, V101, P155, DOI 10.1016/S0925-4773(00)00585-2; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KATO K, 1981, BIOCHIM BIOPHYS ACTA, V660, P30, DOI 10.1016/0005-2744(81)90104-2; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Lee CS, 2002, DIABETES, V51, P2546, DOI 10.2337/diabetes.51.8.2546; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; Marshak S, 2001, DIABETES, V50, pS37, DOI 10.2337/diabetes.50.2007.S37; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; Matsuoka T, 2001, J BIOL CHEM, V276, P22071, DOI 10.1074/jbc.M010321200; MOSSELMAN S, 1990, FEBS LETT, V271, P33, DOI 10.1016/0014-5793(90)80365-P; Muta M, 2002, GENES CELLS, V7, P791, DOI 10.1046/j.1365-2443.2002.00560.x; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Perez-Villamil B, 1999, ENDOCRINOLOGY, V140, P3857, DOI 10.1210/en.140.8.3857; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Reza HM, 2002, MECH DEVELOP, V116, P61, DOI 10.1016/S0925-4773(02)00137-5; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; Samaras SE, 2002, MOL CELL BIOL, V22, P4702, DOI 10.1128/MCB.22.13.4702-4713.2002; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz PT, 2000, J BIOL CHEM, V275, P19106, DOI 10.1074/jbc.M000655200; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; WEST RE, 1982, LIFE SCI, V31, P1335, DOI 10.1016/0024-3205(82)90375-7; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xu PX, 1999, DEVELOPMENT, V126, P383; Xu ZP, 1997, J BIOL CHEM, V272, P3430, DOI 10.1074/jbc.272.6.3430; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	64	51	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12263	12270		10.1074/jbc.M210801200	http://dx.doi.org/10.1074/jbc.M210801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551916	hybrid			2022-12-27	WOS:000182015700071
J	Speare, JO; Rush, TS; Bloom, ME; Caughey, B				Speare, JO; Rush, TS; Bloom, ME; Caughey, B			The role of helix 1 aspartates and salt bridges in the stability and conversion of prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; CELL-FREE CONVERSION; SECONDARY STRUCTURE; PRP 27-30; PURIFICATION; AGGREGATION; SIMULATIONS; SPECIFICITY; DISEASES; BINDING	A key event in the pathogenesis of transmissible spongiform encephalopathies is the conversion of PrP-sen to PrP-res. Morrissey and Shakhnovich (Morrissey, M. P., and Shakhnovich, E. I. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11293-11298) proposed that the conversion mechanism involves critical interactions at helix 1 (residues 144-153) and that the helix is stabilized on PrP-sen by intra-helix salt bridges between two aspartic acid-arginine ion pairs at positions 144 and 148 and at 147 and 151, respectively. Mutants of the hamster prion protein were constructed by replacing the aspartic acids with either asparagines or alanines to destabilize the proposed helix 1 salt bridges. Thermal and chemical denaturation experiments using circular dichroism spectroscopy indicated the overall structures of the mutants are not substantially destabilized but appear to unfold differently. Cell-free conversion reactions per. formed using ionic denaturants, detergents, and salts (conditions unfavorable to salt bridge formation) showed no significant differences between conversion efficiencies of mutant and wild type proteins. Using conditions more favorable to salt bridge formation, the mutant proteins converted with up to 4-fold higher efficiency than the wild type protein. Thus, although spectroscopic data indicate the salt bridges do not substantially stabilize PrP-sen, the cell-free conversion data suggest that Asp-144 and Asp-147 and their respective salt bridges stabilize PrP-sen from converting to PrP-res.	NIAID, Rocky Mt Lab, Lab Persistent Viral Dis, NIH, Hamilton, MT 59840 USA; Univ Montana, Dept Chem, Missoula, MT 59812 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Montana System; University of Montana	Caughey, B (corresponding author), NIAID, Rocky Mt Lab, Lab Persistent Viral Dis, NIH, Hamilton, MT 59840 USA.	bcaughey@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000580, ZIAAI000580, Z01AI000908] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso DOV, 2001, ADV PROTEIN CHEM, V57, P107; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Caughey B, 2001, ADV PROTEIN CHEM, V57, P139; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morrissey MP, 1999, P NATL ACAD SCI USA, V96, P11293, DOI 10.1073/pnas.96.20.11293; Nakamura H, 1996, Q REV BIOPHYS, V29, P1, DOI 10.1017/S0033583500005746; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Rezaei H, 2000, EUR J BIOCHEM, V267, P2833, DOI 10.1046/j.1432-1033.2000.01347.x; ROBERTSON MN, 1992, J VIROL, V66, P3271, DOI 10.1128/JVI.66.6.3271-3277.1992; RUBENSTEIN R, 1986, J GEN VIROL, V67, P671, DOI 10.1099/0022-1317-67-4-671; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Vorberg I, 2001, J VIROL, V75, P10024, DOI 10.1128/JVI.75.21.10024-10032.2001; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Zuegg J, 1999, BIOCHEMISTRY-US, V38, P13862, DOI 10.1021/bi991469d	46	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12522	12529		10.1074/jbc.M211599200	http://dx.doi.org/10.1074/jbc.M211599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551897	hybrid			2022-12-27	WOS:000182015700104
J	Wouters, J; Oudjama, Y; Barkley, SJ; Tricot, C; Stalon, V; Droogmans, L; Poulter, CD				Wouters, J; Oudjama, Y; Barkley, SJ; Tricot, C; Stalon, V; Droogmans, L; Poulter, CD			Catalytic mechanism of Escherichia coli isopentenyl diphosphate isomerase involves Cys-67, Glu-116, and Tyr-104 as suggested by crystal structures of complexes with transition state analogues and irreversible inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYLALLYL DIPHOSPHATE; ACTIVE-SITE; IDENTIFICATION; BIOSYNTHESIS; GENE; TRP	Isopentenyl diphosphate (IPP):dimethylallyl diphosphate (DMAPP) isomerase is a key enzyme in the biosynthesis of isoprenoids. The reaction involves protonation and deprotonation of the isoprenoid unit and proceeds through a carbocationic transition state. Analysis of the crystal structures (2 Angstrom) of complexes of Escherichia coli IPP(.)DMAPPs isomerase with a transition state analogue (N,N-dimethyl-2-amino-1-ethyl diphosphate) and a covalently attached irreversible inhibitor (3,4-epoxy-3methyl-1-butyl diphosphate) indicates that Glu-116, Tyr-104, and Cys-67 are involved in the antarafacial addition/elimination of protons during isomerization. This work provides a new perspective about the mechanism of the reaction.	Inst Rech Microbiol JM Wiame, B-1070 Brussels, Belgium; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium; Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Utah System of Higher Education; University of Utah	Wouters, J (corresponding author), Inst Rech Microbiol JM Wiame, 1 Av E Gryzon, B-1070 Brussels, Belgium.			Wouters, Johan/0000-0002-4920-6857	NIGMS NIH HHS [GM25521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025521] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonanno JB, 2001, P NATL ACAD SCI USA, V98, P12896, DOI 10.1073/pnas.181466998; CLIFFORD K, 1971, J CHEM SOC CHEM COMM, P1699; CORNFORTH RH, 1969, METHOD ENZYMOL, V15, P359; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Durbecq V, 2001, EMBO J, V20, P1530, DOI 10.1093/emboj/20.7.1530; Hahn FM, 1999, J BACTERIOL, V181, P4499, DOI 10.1128/JB.181.15.4499-4504.1999; Hoeffler JF, 2002, BIOCHEM J, V366, P573, DOI 10.1042/BJ20020337; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leyes AE, 1999, CHEM COMMUN, P717, DOI 10.1039/a900621d; LU XJ, 1992, BIOCHEMISTRY-US, V31, P9955, DOI 10.1021/bi00156a014; MUELBACHER M, 1988, BIOCHEMISTRY-US, V27, P7315; Oudjama Y, 2001, ACTA CRYSTALLOGR D, V57, P287, DOI 10.1107/S0907444900017571; POULTER CD, 1989, J AM CHEM SOC, V111, P3740, DOI 10.1021/ja00192a037; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, V1, P162; REARDON JE, 1986, BIOCHEMISTRY-US, V25, P5609, DOI 10.1021/bi00367a040; Roussel A, 1992, TURBO FRODO BIOGRAPH; SATTERWHITE DM, 1985, METHOD ENZYMOL, V110, P92; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; STREET IP, 1994, BIOCHEMISTRY-US, V33, P4212, DOI 10.1021/bi00180a014; STREET IP, 1990, J AM CHEM SOC, V112, P8577, DOI 10.1021/ja00179a049; Wouters J, 1998, PROTEIN SCI, V7, P2472, DOI 10.1002/pro.5560071127	22	67	70	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11903	11908		10.1074/jbc.M212823200	http://dx.doi.org/10.1074/jbc.M212823200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540835	hybrid			2022-12-27	WOS:000182015700025
J	Coulthard, VH; Matsuda, S; Heery, DM				Coulthard, VH; Matsuda, S; Heery, DM			An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; THYROID-HORMONE RECEPTOR; ESTROGEN-RECEPTOR; LIGAND-BINDING; COACTIVATOR COMPLEX; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; PROTEIN; ALPHA; BETA	The interaction of coactivators with the ligand-binding domain of nuclear receptors (NRs) is mediated by amphipathic a-helices containing the signature motif LXXLL. TRAP220 contains two LXXLL motifs (LXM1 and LXM2) that are required for its interaction with NRs. Here we show that the nuclear receptor interaction domain (NID) of TRAP220 interacts weakly with Class I NRs. In contrast, SRC1 NID binds strongly to both Class I and Class II NRs. Interaction assays using nine amino acid LXXLL core motifs derived from SRC1 and TRAP220 revealed no discriminatory NR binding preferences. However, an extended LXMl sequence containing amino acids -4 to +9, (where the first conserved leucine is +1) showed selective binding to thyroid hormone receptor and reduced binding to estrogen receptor. Replacement of either TRAP220 LXXLL motif with the corresponding 13 amino acids of SRC1 LXM2 strongly enhanced the interaction of the TRAP220 NID with the estrogen receptor. Mutational analysis revealed combinatorial effects of the LXMl core and flanking sequences in the determination of the NR binding specificity of the TRAP220 NID. In contrast, a mutation that increased the spacing between TRAP220 LXM1 and LXM2 had little effect on the binding properties of this domain. Thus, a 13-amino acid sequence comprising an extended LXXLL motif acts as the key determinant of the NR binding specificity of TRAP220. Finally, we show that the NR binding specificity of full-length TRAP220 can be altered by swapping extended LXM sequences.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Heery, DM (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Heery, David/0000-0002-5035-2392				Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2002, EMBO J, V21, P3464, DOI 10.1093/emboj/cdf348; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Ko L, 2002, MOL ENDOCRINOL, V16, P128, DOI 10.1210/me.16.1.128; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Le Douarin B, 2001, METH MOL B, V176, P227; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Li DS, 1999, MOL CELL BIOL, V19, P7191; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Mak HY, 1999, MOL CELL BIOL, V19, P3895; Malik S, 2002, MOL CELL BIOL, V22, P5626, DOI 10.1128/MCB.22.15.5626-5637.2002; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suzuki T, 2001, P NATL ACAD SCI USA, V98, P12403, DOI 10.1073/pnas.221552998; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	58	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10942	10951		10.1074/jbc.M212950200	http://dx.doi.org/10.1074/jbc.M212950200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12556447	hybrid			2022-12-27	WOS:000181855400011
J	Minoguchi, M; Minoguchi, S; Aki, D; Joo, A; Yamamoto, T; Yumioka, T; Matsuda, T; Yoshimura, A				Minoguchi, M; Minoguchi, S; Aki, D; Joo, A; Yamamoto, T; Yumioka, T; Matsuda, T; Yoshimura, A			STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TYROSINE KINASE; CELLULAR-TRANSFORMATION; MOLECULAR-CLONING; JAK/STAT PATHWAY; DOCKING PROTEIN; GENE-REGULATION; SH2 DOMAINS; RECEPTOR; FAMILY	As a c-fins-interacting protein, we cloned a novel adaptor molecule, signal-transducing adaptor protein-2 (STAP-2), which contains pleckstrin homology- and Src homology 2-like (PH and SRC) domains and a proline-rich region. STAP-2 is structurally related to STAP-1/BRDG1 (BCR downstream signaling-1), which we had cloned previously from hematopoietic stem cells. STAP-2 is a murine homologue of a recently identified adaptor molecule, BKS, a substrate of BRK tyrosine kinase. STAP-2 was tyrosine-phosphorylated and translocated to the plasma membrane in response to epidermal growth factor when overexpressed in fibroblastic cells. To define the function of STAP-2, we generated mice lacking the STAP-2 gene. STAP-2 mRNA was strongly induced in the liver in response to lipopolysaccharide and in isolated hepatocytes in response to interleukin-6. In the STAP-2(-/-) hepatocytes, the interleukin-6-induced expression of acute-phase (AP) genes and the tyrosine-phosphorylation level of STAT3 were reduced specifically at the late phase (6-24 h) of the response. These data indicate that STAP-2 plays a regulatory role in the AP response in systemic inflammation. STAP-2 contains a YXXQ motif in the C-terminal region that is a potential STAT3-binding site. Overexpression of wild-type STAP-2, but not of mutants lacking this motif, enhanced the AP response element reporter activity and an AP protein production. These data suggest that STAP-2 is a new class of adaptor molecule that modulates STAT3 activity through its YXXQ motif.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Sapporo, Hokkaido 0600812, Japan	Kyushu University; Hokkaido University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Yoshimura, Akihiko/K-5515-2013; Matsuda, Tadashi/A-3835-2012	Matsuda, Tadashi/0000-0002-3089-3757				Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Alonzi T, 1998, CYTOKINE, V10, P13, DOI 10.1006/cyto.1997.0250; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Burack WR, 2002, CURR OPIN IMMUNOL, V14, P312, DOI 10.1016/S0952-7915(02)00347-3; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Masuhara M, 2000, BIOCHEM BIOPH RES CO, V268, P697, DOI 10.1006/bbrc.2000.2223; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; Ohtsuka S, 2002, MOL CELL BIOL, V22, P3066, DOI 10.1128/MCB.22.9.3066-3077.2002; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; ROHRSCHNEIDER LR, 1995, GUIDEBOOK CYTOKINES, P168; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	36	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11182	11189		10.1074/jbc.M211230200	http://dx.doi.org/10.1074/jbc.M211230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540842	hybrid			2022-12-27	WOS:000181855400043
J	Mayer, U				Mayer, U			Integrins: Redundant or important players in skeletal muscle?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DYSTROPHIN-GLYCOPROTEIN COMPLEX; MUSCULAR-DYSTROPHY; CYTOPLASMIC DOMAINS; CELL-ADHESION; ALPHA-7-BETA-1 INTEGRIN; MYOTENDINOUS JUNCTION; SPLICE VARIANTS; ANIMAL-MODELS; EXPRESSION; LAMININ		Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Mayer, U (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, 3-239 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Ulrike.Mayer@man.ac.uk		Mayer, Ulrike/0000-0003-2328-0052				Allamand V, 2000, HUM MOL GENET, V9, P2459, DOI 10.1093/hmg/9.16.2459; Arnold HH, 2000, CURR TOP DEV BIOL, V48, P129; BAO ZZ, 1993, J CELL SCI, V106, P579; Baudoin C, 1998, GENE DEV, V12, P1202, DOI 10.1101/gad.12.8.1202; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; BLASCHUK KL, 1994, DEV BIOL, V164, P475, DOI 10.1006/dbio.1994.1217; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; BRABANT MC, 1993, DEV BIOL, V157, P49, DOI 10.1006/dbio.1993.1111; BRONNERFRASER M, 1992, DEVELOPMENT, V115, P197; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Burton EA, 2002, CELL, V108, P5, DOI 10.1016/S0092-8674(01)00626-2; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Cohn RD, 1999, J NEUROL SCI, V163, P140, DOI 10.1016/S0022-510X(99)00012-X; COLLO G, 1993, J BIOL CHEM, V268, P19019; Crawley S, 1997, EXP CELL RES, V235, P274, DOI 10.1006/excr.1997.3671; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; Gullberg G, 1999, CELL MOL LIFE SCI, V56, P442, DOI 10.1007/PL00000616; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Hirsch E, 1998, J CELL SCI, V111, P2397; Hodges BL, 1997, J CELL SCI, V110, P2873; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; Kikkawa Y, 2000, J CELL SCI, V113, P869; Klaffky E, 2001, DEV BIOL, V239, P161, DOI 10.1006/dbio.2001.0404; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KUHL U, 1986, DEV BIOL, V117, P628, DOI 10.1016/0012-1606(86)90331-3; Leung E, 1998, BIOCHEM BIOPH RES CO, V243, P317, DOI 10.1006/bbrc.1998.8092; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; McDonald Kevin A., 1995, Seminars in Developmental Biology, V6, P105, DOI 10.1016/S1044-5781(06)80020-4; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; Miosge N, 1999, LAB INVEST, V79, P1591; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Pegoraro E, 2002, AM J PATHOL, V160, P2135, DOI 10.1016/S0002-9440(10)61162-5; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Ringelmann B, 1999, EXP CELL RES, V246, P165, DOI 10.1006/excr.1998.4244; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Sasaki T, 1998, EXP CELL RES, V238, P70, DOI 10.1006/excr.1997.3837; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Schober S, 2000, EXP CELL RES, V255, P303, DOI 10.1006/excr.2000.4806; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; Sorokin LM, 2000, EXP CELL RES, V256, P500, DOI 10.1006/excr.2000.4842; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Taverna D, 1998, J CELL BIOL, V143, P849, DOI 10.1083/jcb.143.3.849; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Velling T, 1996, DEV DYNAM, V207, P355, DOI 10.1002/(SICI)1097-0177(199612)207:4<355::AID-AJA1>3.0.CO;2-G; Vignier N, 1999, BIOCHEM BIOPH RES CO, V260, P357, DOI 10.1006/bbrc.1999.0916; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; von der Mark H, 2002, J BIOL CHEM, V277, P6012, DOI 10.1074/jbc.M102188200; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Werner A, 2000, J NEUROSCI, V20, P1822; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yang JT, 1996, J CELL BIOL, V135, P829, DOI 10.1083/jcb.135.3.829; YANG JT, 1993, DEVELOPMENT, V119, P1093; Yao CC, 1997, J CELL SCI, V110, P1477; Yao CC, 1996, J CELL SCI, V109, P3139; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598; Ziober BL, 1997, MOL BIOL CELL, V8, P1723, DOI 10.1091/mbc.8.9.1723; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773	78	136	137	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14587	14590		10.1074/jbc.R200022200	http://dx.doi.org/10.1074/jbc.R200022200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12556453	hybrid			2022-12-27	WOS:000182516100001
J	Seabold, GK; Burette, A; Lim, IA; Weinberg, RJ; Hell, JW				Seabold, GK; Burette, A; Lim, IA; Weinberg, RJ; Hell, JW			Interaction of the tyrosine kinase Pyk2 with the N-methyl-D-aspartate receptor complex via the Src homology 3 domains of PSD-95 and SAP102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; FOCAL ADHESION KINASE; SYNAPSE-ASSOCIATED PROTEIN-97; CENTRAL NERVOUS-SYSTEM; AMINO-ACID RECEPTORS; NMDA-RECEPTOR; POSTSYNAPTIC DENSITY; INTRAMOLECULAR INTERACTION; GLUTAMATE RECEPTORS	The protein-tyrosine kinase Pyk2/CAKbeta/CADTK is a key activator of Src in many cells. At hippocampal synapses, induction of long term potentiation requires the Pyk2/Src signaling pathway, which up-regulates the activity of N-methyl-D-aspartate-type glutamate receptors. Because localization of protein kinases close to their substrates is crucial for effective phosphorylation, we investigated how Pyk2 might be recruited to the N-methyl-D-aspartate receptor complex. This interaction is mediated by PSD-95 and its homolog SAP102. Both proteins colocalize with Pyk2 at postsynaptic dendritic spines in the cerebral cortex. The proline-rich regions in the C-terminal half of Pyk2 bind to the SH3 domain of PSD-95 and SAP102. The SH3 and guanylate kinase homology (GK) domain of PSD-95 and SAP102 interact intramolecularly, but the physiological significance of this interaction has been unclear. We show that Pyk2 effectively binds to the Src homology 3 (SH3) domain of SAP102 only when the GK domain is removed from the SH3 domain. Characterization of PSD-95 and SAP102 as adaptor proteins for Pyk2 fills a critical gap in the understanding of the spatial organization of the Pyk2-Src signaling pathway at the postsynaptic site and reveals a physiological function of the intramolecular SH3-GK domain interaction in SAP102.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA	University of Iowa; University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Hell, JW (corresponding author), Univ Iowa, Dept Pharmacol, 51 Newton Rd, Iowa City, IA 52242 USA.		Hell, Johannes W./P-5085-2019; Weinberg, Richard/AAC-1898-2020	Weinberg, Richard/0000-0001-9689-7278	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563, R01NS039444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017502, R56AG017502] Funding Source: NIH RePORTER; NIA NIH HHS [AG17502] Funding Source: Medline; NINDS NIH HHS [NS35563, NS39444] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Burette A, 1999, J COMP NEUROL, V411, P601; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; Cheung HH, 2001, J NEUROCHEM, V78, P524, DOI 10.1046/j.1471-4159.2001.00433.x; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, J BIOL CHEM, V270, P28440; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Heidinger V, 2002, J NEUROSCI, V22, P5452; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Hunyady B, 1996, J HISTOCHEM CYTOCHEM, V44, P1353, DOI 10.1177/44.12.8985127; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KINGSTON R, 1997, CURRENT PROTOCOLS MO, V1; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lan JY, 2001, J NEUROSCI, V21, P6058, DOI 10.1523/JNEUROSCI.21-16-06058.2001; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Logan SM, 1999, J NEUROSCI, V19, P974; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; Paarmann I, 2002, J BIOL CHEM, V277, P40832, DOI 10.1074/jbc.M205618200; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Raja S, 1997, J BIOL CHEM, V272, P10941; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; Tapia JA, 1999, J BIOL CHEM, V274, P31261, DOI 10.1074/jbc.274.44.31261; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Thomas U, 2000, CURR BIOL, V10, P1108, DOI 10.1016/S0960-9822(00)00696-5; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Xiong WC, 1998, J CELL SCI, V111, P1981; Xiong ZG, 1998, MOL PHARMACOL, V54, P1055, DOI 10.1124/mol.54.6.1055; Xiong ZG, 1999, J NEUROSCI, V19; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zheng F, 1998, NAT NEUROSCI, V1, P185, DOI 10.1038/634; Zheng X, 1999, P NATL ACAD SCI USA, V96, P15262, DOI 10.1073/pnas.96.26.15262	101	61	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15040	15048		10.1074/jbc.M212825200	http://dx.doi.org/10.1074/jbc.M212825200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576483	Green Published, hybrid			2022-12-27	WOS:000182516100061
J	Hill, KE; Zhou, JD; McMahan, WJ; Motley, AK; Atkins, JF; Gesteland, RF; Burk, RF				Hill, KE; Zhou, JD; McMahan, WJ; Motley, AK; Atkins, JF; Gesteland, RF; Burk, RF			Deletion of selenoprotein P alters distribution of selenium in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE-ACTIVITY; DEFICIENT RAT-LIVER; MESSENGER-RNA; SELENOCYSTEINE; PLASMA; PROTEIN; CELLS; EXPRESSION; RESIDUES; TISSUES	Selenoprotein P (Se-P) contains most of the selenium in plasma. Its function is not known. Mice with the Se-P gene deleted (Sepp(-/-)) were generated. Two phenotypes were observed: 1) Sepp(-/-) mice lost weight and developed poor motor coordination when fed diets with selenium below 0.1 mg/kg, and 2) male Sepp(-/-) mice had sharply reduced fertility. Weanling male Sepp(+/+), Sepp(+/-), and Sepp(-/-) mice were fed diets for 8 weeks containing <0.02-2 mg selenium/kg. Sepp(+/+) and Sepp(+/-) mice had similar selenium concentrations in all tissues except plasma where a gene-dose effect on Se-P was observed. Liver selenium was unaffected by Se-P deletion except that it increased when dietary selenium was below 0.1 mg/kg. Selenium in other tissues exhibited a continuum of responses to Se-P deletion. Testis selenium was depressed to 19% in mice fed an 0.1 mg selenium/kg diet and did not rise to Sepp(+/+) levels even with a dietary selenium of 2 mg/kg. Brain selenium was depressed to 43%, but feeding 2 mg selenium/kg diet raised it to Sepp(+/+) levels. Kidney was depressed to 76% and reached Sepp(+/+) levels on an 0.25 mg selenium/kg diet. Heart selenium was not affected. These results suggest that the Sepp(-/-) phenotypes were caused by low selenium in testis and brain. They strongly suggest that Se-P from liver provides selenium to several tissues, especially testis and brain. Further, they indicate that transport forms of selenium other than Se-P exist because selenium levels of all tissues except testis responded to increases of dietary selenium in Sepp(-/-) mice.	Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA; Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA	Vanderbilt University; Utah System of Higher Education; University of Utah	Burk, RF (corresponding author), Vanderbilt Univ Sch Med, N Med Ctr, C-2104, Nashville, TN 37232 USA.			Atkins, John/0000-0001-7933-0165	NIEHS NIH HHS [R01 ES02497, P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM48152, GM61200] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061200, R01GM048152] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson JB, 2001, LAB INVEST, V81, P193, DOI 10.1038/labinvest.3780227; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; BURK RF, 1972, J NUTR, V102, P1049, DOI 10.1093/jn/102.8.1049; BURK RF, 1991, AM J PHYSIOL, V261, pE26, DOI 10.1152/ajpendo.1991.261.1.E26; Burk RF, 1997, HISTOCHEM CELL BIOL, V108, P11, DOI 10.1007/s004180050141; BURK RF, 1995, HEPATOLOGY, V21, P561; BURK RF, 1987, METHOD ENZYMOL, V143, P307; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; ESAKI N, 1981, BIOCHEMISTRY-US, V20, P4492, DOI 10.1021/bi00518a039; Greer JM, 2002, NEURON, V33, P23, DOI 10.1016/S0896-6273(01)00564-5; Hill KE, 1996, J NUTR, V126, P138, DOI 10.1093/jn/126.1.138; Hill KE, 1996, BBA-MOL CELL RES, V1313, P29, DOI 10.1016/0167-4889(96)00047-X; HILL KE, 1991, J BIOL CHEM, V266, P10050; Hondal RJ, 2001, J BIOL CHEM, V276, P15823, DOI 10.1074/jbc.M010405200; KATO T, 1992, AM J PHYSIOL, V262, pG854, DOI 10.1152/ajpgi.1992.262.5.G854; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kryukov GV, 2000, GENES CELLS, V5, P1049, DOI 10.1046/j.1365-2443.2000.00392.x; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MOTSENBOCKER MA, 1982, BIOCHIM BIOPHYS ACTA, V719, P147, DOI 10.1016/0304-4165(82)90318-X; PROHASKA JR, 1993, COMP BIOCHEM PHYS B, V105, P111, DOI 10.1016/0305-0491(93)90176-6; READ R, 1990, J BIOL CHEM, V265, P17899; Saito Y, 2002, EUR J BIOCHEM, V269, P5746, DOI 10.1046/j.1432-1033.2002.03298.x; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Steinert P, 1998, BIOL CHEM, V379, P683, DOI 10.1515/bchm.1998.379.6.683; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Weiss SL, 1996, J NUTR, V126, P2260, DOI 10.1093/jn/126.9.2260; Yan J, 1998, J NEUROSCI, V18, P8682	34	356	369	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13640	13646		10.1074/jbc.M300755200	http://dx.doi.org/10.1074/jbc.M300755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574155	hybrid			2022-12-27	WOS:000182405000012
J	Mazin, AV; Alexeev, AA; Kowalczykowski, SC				Mazin, AV; Alexeev, AA; Kowalczykowski, SC			A novel function of Rad54 protein - Stabilization of the Rad51 nucleoprotein filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE RAD51; PRESYNAPTIC COMPLEX-FORMATION; MATING-TYPE HETEROZYGOSITY; RECA PROTEIN; YEAST RAD51; HOMOLOGOUS RECOMBINATION; ESCHERICHIA-COLI; ATP HYDROLYSIS; REPAIR PROTEIN	Homologous recombination is important for the repair of double-stranded DNA breaks in all organisms. Rad51. and Rad54 proteins are two key components of the homologous recombination machinery in eukaryotes. In vitro, Rad51. protein assembles with single-stranded DNA to form the helical nucleoprotein filament that promotes DNA strand exchange, a basic step of homologous recombination. Rad54 protein interacts with this Rad51. nucleoprotein filament and stimulates its DNA pairing activity, suggesting that Rad54 protein is a component of the nucleoprotein complex involved in the DNA homology search. Here, using physical criteria, we demonstrate directly the formation of Rad54-Rad51-DNA nucleoprotein co-complexes that contain equimolar amounts of each protein. The binding of Rad54 protein significantly stabilizes the Rad51 nucleoprotein filament formed on either single-stranded DNA or double-stranded DNA. The Rad54-stabilized nucleoprotein filament is more competent in DNA strand exchange and acts over a broader range of solution conditions. Thus, the co-assembly of an interacting partner with the Rad51. nucleoprotein filament represents a novel means of stabilizing the biochemical entity central to homologous recombination, and reveals a new function of Rad54 protein.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, Briggs Hall, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM062653, R01GM062653] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-62653] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Clever B, 1999, YEAST, V15, P721, DOI 10.1002/(SICI)1097-0061(19990630)15:9<721::AID-YEA414>3.0.CO;2-W; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Essers J, 2002, DNA REPAIR, V1, P779, DOI 10.1016/S1568-7864(02)00110-6; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Game JC, 2000, MUTAT RES-FUND MOL M, V451, P277, DOI 10.1016/S0027-5107(00)00055-5; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kiianitsa K, 2002, J BIOL CHEM, V277, P46205, DOI 10.1074/jbc.M207967200; Kim PM, 2002, NUCLEIC ACIDS RES, V30, P2727, DOI 10.1093/nar/gkf413; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAUDER SD, 1993, J MOL BIOL, V234, P72, DOI 10.1006/jmbi.1993.1564; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Mazin AV, 1996, P NATL ACAD SCI USA, V93, P10673, DOI 10.1073/pnas.93.20.10673; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Morgan EA, 2002, MOL CELL BIOL, V22, P6336, DOI 10.1128/MCB.22.18.6336-6343.2002; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RATTRAY AJ, 1995, GENETICS, V139, P45; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SCHILD D, 1995, GENETICS, V140, P115; Seitz EM, 2001, ADV APPL MICROBIOL, V50, P101, DOI 10.1016/S0065-2164(01)50005-2; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	57	132	135	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14029	14036		10.1074/jbc.M212779200	http://dx.doi.org/10.1074/jbc.M212779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566442	hybrid, Green Published			2022-12-27	WOS:000182405000061
J	Wang, HB; Faucette, S; Sueyoshi, T; Moore, R; Ferguson, S; Negishi, M; LeCluyse, EL				Wang, HB; Faucette, S; Sueyoshi, T; Moore, R; Ferguson, S; Negishi, M; LeCluyse, EL			A novel distal enhancer module regulated by pregnane x receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME P4502B6; HUMAN HEPATOCYTES; TRANSCRIPTIONAL REGULATION; NUCLEAR TRANSLOCATION; CATALYTIC-ACTIVITY; CAR; LIVER; METABOLISM; ACTIVATION; HYDROXYLATION	CYP2B6 plays an important role in the metabolism of a variety of structurally unrelated xenobiotics, including the anticancer drugs cyclophosphamide and ifosfamide. Previous studies have shown that the nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are involved in the transcriptional regulation of CYP2B genes through the phenobarbital-responsive enhancer module (PBREM). However, for human CYP2B6 the relatively weak response of the PBREM to PXR and CAR activation in transfection assays fails to describe the potent induction observed in primary human hepatocyte cultures. In this report, a novel nuclear receptor response module located -8.5 kilobases upstream from the CYP2B6 encoding region is described. Several potential PXR/CAR binding motifs were identified within the distal regulatory cluster. In electrophoretic mobility shift assays, one DR4 motif showed the strongest binding to both PXR and CAR. Transient transfection assays in HepG2 cells demonstrated that the novel distal response cluster could be activated by PXR and CAR. In primary human hepatocytes, both PBREM and the distal responsive element were activated individually by endogenous nuclear receptors upon exposure to prototypical inducers. However, in both HepG2 cells and primary human hepatocytes maximal reporter activation was observed in a construct containing both PBREM and the distal responsive element. In mouse tail-vein injection experiments, a construct containing both the distal responsive element and the proximal PBREM exhibited a strong synergistic expression in phenobarbital-treated mice. These results show that a novel xenobiotic-responsive enhancer module in the distal region of the CYP2B6 promoter (CYP2B6-XREM) together with the PBREM mediates optimal drug-induced expression of CYP2B6.	Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	LeCluyse, EL (corresponding author), Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA.	ed_lecluyse@une.edu	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; LeCluyse, Edward/0000-0002-2149-8990	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040, P30ES010126, Z01ES071005, Z01ES021024] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34987] Funding Source: Medline; NIEHS NIH HHS [P30 ES10126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Code EL, 1997, DRUG METAB DISPOS, V25, P985; Court MH, 2001, ANESTHESIOLOGY, V94, P110, DOI 10.1097/00000542-200101000-00021; Ekins S, 1998, J PHARMACOL EXP THER, V286, P1253; Erickson DA, 1999, DRUG METAB DISPOS, V27, P1488; Ferguson SS, 2002, MOL PHARMACOL, V62, P737, DOI 10.1124/mol.62.3.737; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Gervot L, 1999, PHARMACOGENETICS, V9, P295, DOI 10.1097/00008571-199906000-00004; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2002, MOL PHARMACOL, V62, P359, DOI 10.1124/mol.62.2.359; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Hamilton GA, 2001, CELL TISSUE RES, V306, P85; Hanna IH, 2000, ARCH BIOCHEM BIOPHYS, V376, P206, DOI 10.1006/abbi.2000.1708; Hesse LM, 2000, DRUG METAB DISPOS, V28, P1176; Hidestrand M, 2001, DRUG METAB DISPOS, V29, P1480; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kobayashi K, 1999, DRUG METAB DISPOS, V27, P1429; LeCluyse EL, 2001, EUR J PHARM SCI, V13, P343, DOI 10.1016/S0928-0987(01)00135-X; Li AP, 1997, CHEM-BIOL INTERACT, V107, P5, DOI 10.1016/S0009-2797(97)00070-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maurel P, 1996, ADV DRUG DELIVER REV, V22, P105, DOI 10.1016/S0169-409X(96)00417-6; Oda Y, 2001, BRIT J CLIN PHARMACO, V51, P281, DOI 10.1046/j.1365-2125.2001.00344.x; PARKINSON A, 2001, BASIC SCI POISONS, V5, P113; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Roy P, 1999, DRUG METAB DISPOS, V27, P655; Sahi J, 2000, XENOBIOTICA, V30, P273, DOI 10.1080/004982500237668; Sridar C, 2002, J PHARMACOL EXP THER, V301, P945, DOI 10.1124/jpet.301.3.945; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; van Heeswijk RPG, 2001, ANTIVIR THER, V6, P201; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001	38	131	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14146	14152		10.1074/jbc.M212482200	http://dx.doi.org/10.1074/jbc.M212482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571232	hybrid			2022-12-27	WOS:000182405000075
J	Dussmann, H; Kogel, D; Rehm, M; Prehn, JHM				Dussmann, H; Kogel, D; Rehm, M; Prehn, JHM			Mitochondrial membrane permeabilization and superoxide production during apoptosis - A single-cell analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; RAT HIPPOCAMPAL-NEURONS; INTERMEMBRANE SPACE; DEATH; GENERATION; HYDROETHIDINE; DYSFUNCTION; BINDING; PROTEIN; CHAIN	The temporal relationship between mitochondrial membrane permeabilization and reactive oxygen species production during apoptosis remains unknown. We analyzed the rate of superoxide production of human breast carcinoma cells expressing a cytochrome c-green fluorescent protein (cyt-c-GFP) fusion protein at the single-cell level during apoptosis. In cells treated with the proapoptotic agents stattrosporine (3 mum) or tumor necrosis factor-alpha (100 ng/ml), the release of cyt-c-GFP was individually set for each cell, and the majority of the fusion protein was released in less than 10 min. Prior to the release of the fusion protein, cells demonstrated a constant rate of superoxide production determined with the probe hydroethidine. After the release was completed, the superoxide concentration increased rapidly to a level more than 3-fold above baseline. Treatment with the broad spectrum caspase inhibitor z-Val-Ala-Asp(O-methyl)-fluoromethylketone (z-VAD-fink; 200 mum) did not alter the kinetics of the cyt-c-GFP release but significantly reduced superoxide concentration after the release of cyt-c-GFP. Interestingly, treatment with z-VAD-fink also reduced the increase in superoxide concentration in response to menadione in the absence of mitochondrial cyt-c-GFP release. Mitochondrial depolarization with the protonophore carbonyl cyanide p-trifluoromethoxy-phenylhydrazone per se did not trigger cyt-c-GFP release or an increase in superoxide production. Our data suggest that mitochondria increase their superoxide production during apoptosis directly after the quantitative release of soluble intermembrane proteins and demonstrate novel antioxidative effects of the commonly used caspase inhibitor z-VAD-frnk.	Westphalian Wilhelms Univ, Interdisciplinary Ctr Clin Res, IZKF, D-48149 Munster, Germany; Westphalian Wilhelms Univ, Dept Pharmacol & Toxicol, D-48149 Munster, Germany	University of Munster; University of Munster	Prehn, JHM (corresponding author), Klinikum Johann Wolfgang Goethe Univ, Haus 25 B,4-OG,Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Prehn, Jochen HM/A-3928-2010; Rehm, Markus/C-3398-2012	Prehn, Jochen HM/0000-0003-3479-7794; Rehm, Markus/0000-0001-6149-9261; Kogel, Donat/0000-0003-1209-0210; Dussmann, Heiko/0000-0002-3582-8057				Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; Cadenas E, 1985, Adv Enzyme Regul, V23, P217, DOI 10.1016/0065-2571(85)90049-4; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CORTESE JD, 1995, BBA-BIOENERGETICS, V1228, P216, DOI 10.1016/0005-2728(94)00178-8; D'Herde K, 2000, CELL DEATH DIFFER, V7, P331, DOI 10.1038/sj.cdd.4400655; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; JORDAN J, 1995, MOL PHARMACOL, V47, P1095; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Luetjens CM, 2001, MOL PHARMACOL, V60, P1008, DOI 10.1124/mol.60.5.1008; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wang XD, 2001, GENE DEV, V15, P2922; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	34	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12645	12649		10.1074/jbc.M210826200	http://dx.doi.org/10.1074/jbc.M210826200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560329	hybrid			2022-12-27	WOS:000182189500009
J	Gille, A; Seifert, R				Gille, A; Seifert, R			2 '(3 ')-O-(N-methylanthraniloyl)-substituted GTP analogs: A novel class of potent competitive adenylyl cyclase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; GUANINE-NUCLEOTIDE ANALOGS; SITE-MEDIATED INHIBITION; RETINAL G-PROTEIN; CRYSTAL-STRUCTURE; SF9 CELLS; CYTOSOLIC DOMAINS; LYMPHOMA-CELLS; RECEPTOR; TRANSDUCIN	2'(3')-O-(N-Methylanthraniloyl)-(MANT)-substituted nucleotides are fluorescent and widely used for the kinetic analysis of enzymes and signaling proteins. We studied the effects of MANT-guanosine 5'-[gamma-thio]triphosphate (MANT-GTPgammaS) and MANT-guanosine 5'-[beta,gamma-imido]triphosphate (MANT-GppNHp) on Galpha(s)- and Galpha(i)-protein-mediated signaling. MANT-GTPgammaS/MANT-GppNHp had lower affinities for Galpha(s) and Galpha(i) than GTPgammaS/GppNHp as assessed by inhibition of GTP hydrolysis of receptor-Galpha fusion proteins. MANT-GTPgammaS was much less effective than GTPgammaS at disrupting the ternary complex between the formyl peptide receptor and Galpha(12). MANT-GTPgammaS/MANT-GppNHp non-competitively inhibited GTPgammaS/GppNHp-, AlF4--, beta(2)-adrenoceptor plus GTP-, cholera toxin plus GTP-, and forskolin-stimulated adenylyl cyclase (AC) in Galpha(s)-expressing Sf9 insect cell membranes and S49 wild-type lymphoma cell membranes. AC inhibition by MANT-GTPgammaS/MANT-GppNHp was not due to Galpha(s) inhibition because it was also observed in Galpha(s)-deficient S49 cyc(-) lymphoma cell membranes. Mn2+ blocked AC inhibition by GTPgammaS/ GppNHp in S49 cyc(-) membranes but enhanced the potency of MANT-GTPgammaS/MANT-GppNHp at inhibiting AC by similar to4-8-fold. MANT-GTPgammaS and MANT-GppNHp competitively inhibited forskolin/Mn2+-stimulated AC in S49 cyc(-) membranes with K-i values of 53 and 160 lam, respectively. The K-i value for MANT-GppNHp at insect cell AC was 155 nm. Collectively, MANT-GTPgammaS/MANT-GppNHp bind to Galpha(s)- and Galpha(i)-proteins with low affinity and are ineffective at activating Galpha. Instead, MANT-GTPgammaS/MANT-GppNHp constitute a novel class of potent competitive AC inhibitors.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	University of Kansas	Seifert, R (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 1251 Wescoe Hall Dr,Malott Hall,Rm 5064, Lawrence, KS 66045 USA.		Seifert, Roland/G-3189-2013; Gille, Andreas/E-1531-2011	Gille, Andreas/0000-0001-5235-8897				ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CASSEL D, 1979, J BIOL CHEM, V254, P9835; Coleman DE, 1999, J BIOL CHEM, V274, P16669, DOI 10.1074/jbc.274.24.16669; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; GETHER U, 1995, J BIOL CHEM, V270, P28268; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; Gille A, 2002, J BIOL CHEM, V277, P34434, DOI 10.1074/jbc.M204259200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; Houston C, 2002, J NEUROCHEM, V80, P678, DOI 10.1046/j.0022-3042.2001.00746.x; JAKOBS KH, 1983, EUR J BIOCHEM, V130, P605, DOI 10.1111/j.1432-1033.1983.tb07192.x; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Kawabe J, 1996, J BIOL CHEM, V271, P20132, DOI 10.1074/jbc.271.33.20132; Klinker JF, 1997, BIOCHEM PHARMACOL, V54, P551, DOI 10.1016/S0006-2952(97)00205-0; Klinker JF, 1999, BIOCHEM BIOPH RES CO, V262, P341, DOI 10.1006/bbrc.1999.1203; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; LONDOS C, 1977, J BIOL CHEM, V252, P5951; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Remmers AE, 1996, J BIOL CHEM, V271, P4791; Remmers AE, 1998, ANAL BIOCHEM, V257, P89, DOI 10.1006/abio.1997.2533; SARFATI RS, 1990, J BIOL CHEM, V265, P18902; SCHEIDIG AJ, 1995, J MOL BIOL, V253, P132, DOI 10.1006/jmbi.1995.0541; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SVOBODA M, 1980, FEBS LETT, V109, P275, DOI 10.1016/0014-5793(80)81104-5; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TAO M, 1970, ARCH BIOCHEM BIOPHYS, V141, P236, DOI 10.1016/0003-9861(70)90127-X; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WATSON PA, 1994, J BIOL CHEM, V269, P28893; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; WENZELSEIFERT K, 1998, J BIOL CHEM, V273; Zera EM, 1996, J BIOL CHEM, V271, P12925, DOI 10.1074/jbc.271.22.12925	51	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12672	12679		10.1074/jbc.M211292200	http://dx.doi.org/10.1074/jbc.M211292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566433	hybrid			2022-12-27	WOS:000182189500012
J	Kawashima, H; Watanabe, N; Hirose, M; Sun, X; Atarashi, K; Kimura, T; Shikata, K; Matsuda, M; Ogawa, D; Hejasvaara, R; Rehn, M; Pihlajaniemi, T; Miyasaka, M				Kawashima, H; Watanabe, N; Hirose, M; Sun, X; Atarashi, K; Kimura, T; Shikata, K; Matsuda, M; Ogawa, D; Hejasvaara, R; Rehn, M; Pihlajaniemi, T; Miyasaka, M			Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC DIFFERENCES; CHONDROITIN SULFATE; P-SELECTIN; CORRESPONDING TRANSCRIPTS; DEFICIENT MICE; EXPRESSION; IDENTIFICATION; LIGANDS; LECAM-1; KIDNEY	Leukocyte infiltration during inflammation is mediated by the sequential actions of adhesion molecules and chemokines. By using a rat ureteral obstruction model, we showed previously that L-selectin plays an important role in leukocyte infiltration into the kidney. Here we report the purification, identification, and characterization of an L-selectin-binding heparan sulfate proteoglycan (HSPG) expressed in the rat kidney. Partial amino acid sequencing and Western blotting analyses showed that the L-selectin-binding HSPG is collagen XVIII, a basement membrane HSPG. The binding of L-selectin to isolated collagen XVIII was specifically inhibited by an anti-L-selectin monoclonal antibody, EDTA, treatment of the collagen XVIII with heparitinase or heparin but not by chemically desulfated heparin. A cell binding assay showed that the L-selectin-collagen XVIII interaction mediates cell adhesion. Interestingly, collagen XVIII also interacted with a chemokine, monocyte chemoattractant protein-1, and presented it to a monocytic cell line, THP-1, which enhanced the alpha(4)beta(1) integrin-mediated binding of the THP-1 cells to vascular cell adhesion molecule-1. Thus, collagen XVIII may provide a link between selectin-mediated cell adhesion and chemokine-induced cellular activation and accelerate the progression of leukocyte infiltration in renal inflammation.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr, FIN-90014 Oulu, Finland; Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, Okayama 7008558, Japan; Osaka Univ, Grad Sch Med, Lab MOl & Cellular Recognit, Suita, Osaka 5650871, Japan	University of Oulu; University of Oulu; Okayama University; Osaka University	Kawashima, H (corresponding author), Burnham Inst, Glycobiol Program, Canc Res Ctr, La Jolla, CA 92037 USA.	hkawashima@burnham.org	まゆみ, 廣瀬/AAK-5735-2020; Miyasaka, Masayuki/AAM-6343-2020	Atarashi, Kazuyuki/0000-0002-4166-7114; Heljasvaara, Ritva/0000-0003-4763-3844; Pihlajaniemi, Taina/0000-0002-1664-9045; Kimura, Tetsuya/0000-0001-6367-7818				ABE N, 1993, BIOCHEM BIOPH RES CO, V196, P576, DOI 10.1006/bbrc.1993.2288; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KRISKO I, 1977, KIDNEY INT, V12, P238, DOI 10.1038/ki.1977.108; LEY K, 1991, BLOOD, V77, P2553; Li YF, 1999, FEBS LETT, V444, P201, DOI 10.1016/S0014-5793(99)00046-0; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; NELSON RM, 1993, BLOOD, V82, P3253; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PRODJOSUDJADI W, 1995, CLIN NEPHROL, V44, P148; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; ROVIN BH, 1994, LAB INVEST, V71, P536; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Schlondorff D, 1997, KIDNEY INT, V51, P610, DOI 10.1038/ki.1997.90; Shikata K, 1999, J PATHOL, V188, P93, DOI 10.1002/(SICI)1096-9896(199905)188:1<93::AID-PATH305>3.0.CO;2-#; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; TAMATANI T, 1993, J IMMUNOL, V150, P1735; TAMATANI T, 1993, EUR J IMMUNOL, V23, P2181, DOI 10.1002/eji.1830230920; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; Tesch GH, 1999, J CLIN INVEST, V103, P73, DOI 10.1172/JCI4876; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Watanabe N, 1999, J BIOCHEM-TOKYO, V125, P826, DOI 10.1093/oxfordjournals.jbchem.a022355; WATANABE T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P321, DOI 10.1016/0167-4781(92)90033-V; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	40	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13069	13076		10.1074/jbc.M212244200	http://dx.doi.org/10.1074/jbc.M212244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556525	hybrid			2022-12-27	WOS:000182189500062
J	Kiba, A; Yabana, N; Shibuya, M				Kiba, A; Yabana, N; Shibuya, M			A set of loop-1 and-3 structures in the novel vascular endothelial growth factor (VEGF) family member, VEGF-ENZ-7, is essential for the activation of VEGFR-2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING SITE; TYROSINE KINASE; CRYSTAL-STRUCTURE; ORF VIRUS; EXTRACELLULAR DOMAIN; FLT-1; IDENTIFICATION; PERMEABILITY; NEUROPILIN-1; PROTEIN	The vascular endothelial growth factor (VEGF) family plays important roles in angiogenesis and vascular permeability. Novel members of the VEGF family encoded in the Orf virus genome, VEGF-E, function as potent angiogenic factors by specifically binding and activating VEGFR-2 (KDR). VEGF-E is about 45% homologous to VEGF-A at amino acid levels, however, the amino acid residues in VEGF-A crucial for the VEGFR-2-binding are not conserved in VEGF-E. To understand the molecular basis of the biological activity of VEGF-E, we have functionally mapped residues important for interaction of VEGF-E with VEGFR-2 by exchanging the domains between VEGF-ENZ-7 and PIGF, which binds only to VEGFR-1 (Flt-1). Exchange on the amino- and carboxyl-terminal regions had no suppressive effect on biological activity. However, exchange on either the loop-1 or -3 region of VEGF-ENZ-7 significantly reduced activities. On the other hand, introduction of the loop-1 and -3 of VEGF-ENZ-7 to placenta growth factor rescued the biological activities. The chimera between VEGF-A and VEGF-ENZ-7 gave essentially the same results. These findings strongly suggest that a common rule exists for VEGFR-2 ligands (VEGF-ENZ-7, and VEGF-A) that they build up the binding structure for VEGFR-2 through the appropriate interaction between loop-1 and -3 regions.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.							Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kreysing J, 1996, FEBS LETT, V385, P181, DOI 10.1016/0014-5793(96)00349-3; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wiesmann C, 1998, BIOCHEMISTRY-US, V37, P17765, DOI 10.1021/bi9819327; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	37	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13453	13461		10.1074/jbc.M210931200	http://dx.doi.org/10.1074/jbc.M210931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551914	hybrid			2022-12-27	WOS:000182189500108
J	Li, J; Gorospe, M; Barnes, J; Liu, Y				Li, J; Gorospe, M; Barnes, J; Liu, Y			Tumor promoter arsenite stimulates histone H3 phosphoacetylation of proto-oncogenes c-fos and c-jun chromatin in human diploid fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; MAP KINASE; DRINKING-WATER; CELL-PROLIFERATION; TERMINAL DOMAIN; AP-1 ACTIVITY; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; INDUCTION	Although epidemiological studies have long established that inorganic arsenic is a potent human carcinogen, the underlying mechanisms are still poorly understood. Recent studies suggest that inorganic arsenic may act as a tumor promoter by perturbing key signaling transduction pathways. We have shown previously that arsenite can potently activate the mitogen-activated protein kinase cascades and induce the expression of proliferation-associated genes, including protooncogenes c-jun and c-fos. In order to elucidate further the molecular mechanisms underlying its tumor-promoting properties, we investigated the signaling events involved in arsenite-mediated induction of c-fos and c-jun. We found that induction of both c-fos and c-jun by arsenite can be substantially inhibited by the MEK-selective inhibitor U0126, suggesting that the ERK pathway is critically involved in their up-regulation. Interestingly, arsenite dramatically induced the phosphorylation and acetylation of histone H3 preceding the induction of mRNAs encoding c-fos and c-jun. Finally, chromatin immunoprecipitation assays revealed that arsenite treatment markedly induced the phosphorylation/acetylation of histone H3 associated with the c-fos and c-jun genes through an ERK-dependent pathway. Our results strongly suggest that arsenic-triggered alterations in chromatin structure perturb specific gene transcription, including that of proto-oncogenes c-jun and c-fos, and may thereby contribute to the carcinogenic process.	NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Liu, Y (corresponding author), Ohio State Univ, Columbus Childrens Hosp, Ctr Dev Pharmacol & Toxicol, Columbus Childrens Res Inst,Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	liuy@pediatrics.ohio-state.edu	Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109	NATIONAL INSTITUTE ON AGING [ZIAAG000511, Z01AG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Calderon RL, 1999, ENVIRON HEALTH PERSP, V107, P663, DOI 10.2307/3434459; CANO E, 1995, J CELL SCI, V108, P3599; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Germolec DR, 1996, TOXICOL APPL PHARM, V141, P308, DOI 10.1016/S0041-008X(96)80037-8; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hartwig A, 1997, CARCINOGENESIS, V18, P399, DOI 10.1093/carcin/18.2.399; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Huang CS, 2001, ANTICANCER RES, V21, P261; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDOLPH JR, 1989, BIOL TRACE ELEM RES, V21, P459, DOI 10.1007/BF02917289; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; LI JH, 1989, BIOL TRACE ELEM RES, V21, P373, DOI 10.1007/BF02917278; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; *NAT RES COUNC, 2001, ARS DRINK WAT 2001 U, P217; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheth K, 2001, SURGERY, V130, P242, DOI 10.1067/msy.2001.115902; Simeonova PP, 2000, CANCER RES, V60, P3445; SMITH AH, 1992, ENVIRON HEALTH PERSP, V97, P259, DOI 10.2307/3431362; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tian DF, 2001, J TOXICOL ENV HEAL A, V64, P473, DOI 10.1080/152873901753215939; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wiencke JK, 1997, MUTAT RES-REV MUTAT, V386, P335, DOI 10.1016/S1383-5742(97)00016-1	48	71	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13183	13191		10.1074/jbc.M300269200	http://dx.doi.org/10.1074/jbc.M300269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547826	hybrid			2022-12-27	WOS:000182189500076
J	Taylor, WA; Hatch, GM				Taylor, WA; Hatch, GM			Purification and characterization of monolysocardiolipin acyltransferase from pig liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; HEART MITOCHONDRIA; ACYL-COA; CARDIOLIPIN; ACID; PHOSPHATIDYLGLYCEROL; BIOSYNTHESIS; LIPIDS; QUANTITATION; REQUIREMENT	In mammalian tissues cardiolipin is rapidly remodeled by monolysocardiolipin acyltransferase subsequent to its de novo biosynthesis (Ma, B. J., Taylor, W. A, Dolinsky, V. W., and Hatch, G. M. (1999) J. Lipid Res. 40, 1837-1845). We report here the purification and characterization of a monolysocardiolipin acyltransferase activity from pig liver mitochondria. Monolysocardiolipin acyltransferase activity was purified over 1000-fold by butanol extraction, hydroxyapatite chromatography, and preparative SDS-PAGE. The purified 74-kDa protein catalyzed acylation of monolysocardiolipin to cardiolipin with [C-14]linoleoyl coenzyme A. Photoaffinity labeling of the protein with 12-[(4-[I-125]azidosalicyl)amino]dodecanoyl coenzyme A indicated coenzyme A was bound at its active site and photoaffinity cross-linking of 12-[(4-azidosalicyl)amino]dodecanoyl coenzyme A to the enzyme inhibited enzyme activity. Enzyme activity was optimum at pH 7.0, and the enzyme did not utilize other lysophospholipids as substrate. The purified enzyme was heat-labile and exhibited an isoelectric point of pH 5.4. To determine the enzymes kinetic mechanism the effect of varying concentrations of linoleoyl coenzyme A and monolysocardiolipin on initial velocity were determined. Double-reciprocal plots revealed parallel lines consistent with a ping pong kinetic mechanism. When the enzyme was incubated in the absence of monolysocardiolipin, coenzyme A was produced from linoleoyl coenzyme A at a rate consistent with the formation of an enzyme-linoleate intermediate. The true K-m value for linoleoyl coenzyme A and true K-m value for monolysocardiolipin were 100 and 44 muM, respectively. The calculated V-max was 6802 pmol/min.mg of protein. A polyclonal antibody, raised in rabbits to the purified protein, cross-reacted with the protein in crude pig liver mitochondrial fractions. In liver mitochondria prepared from thyroxine-treated rats, the level of the protein was elevated compared with euthyroid controls indicating that expression of monolysocardiolipin acyltransferase is regulated by thyroid hormone. The study represents the first purification and characterization of a monolysocardiolipin acyltransferase activity from any organism.	Univ Manitoba, Ctr Res & Treatment Atherosclerosis, Ctr Aging, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada; Univ Manitoba, Ctr Res & Treatment Atherosclerosis, Ctr Aging, Dept Internal Med Biochem & Med Genet, Winnipeg, MB R3E 0T6, Canada	University of Manitoba; University of Manitoba	Hatch, GM (corresponding author), Univ Manitoba, Ctr Res & Treatment Atherosclerosis, Ctr Aging, Dept Pharmacol & Therapeut, A307 Chown Bldg,753 McDermot Ave, Winnipeg, MB R3E 0T6, Canada.	hatchgm@ms.umanitoba.ca						ADDANKI S, 1968, J BIOL CHEM, V243, P2337; BELEZNAI Z, 1989, BIOCHEM BIOPH RES CO, V159, P132, DOI 10.1016/0006-291X(89)92414-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EBLE KS, 1990, J BIOL CHEM, V265, P19434; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Esposti MD, 2002, CELL DEATH DIFFER, V9, P234, DOI 10.1038/sj.cdd.4400997; FIOL CJ, 1984, J BIOL CHEM, V259, P3084; HATCH GM, 1994, BIOCHEM J, V297, P201, DOI 10.1042/bj2970201; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; HUTSON SM, 1990, P NATL ACAD SCI USA, V87, P1028, DOI 10.1073/pnas.87.3.1028; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Ma BJ, 1999, J LIPID RES, V40, P1837; MULLER M, 1985, J BIOL CHEM, V260, P3839; Mutter T, 2000, BIOCHEM J, V346, P403, DOI 10.1042/0264-6021:3460403; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Pangborn MC, 1942, J BIOL CHEM, V143, P247; POORTHUIS BJHM, 1976, J LIPID RES, V17, P433; RAJASEKHARAN R, 1993, BIOCHEMISTRY-US, V32, P12386, DOI 10.1021/bi00097a016; RUSTOW B, 1989, BIOCHIM BIOPHYS ACTA, V1002, P261, DOI 10.1016/0005-2760(89)90296-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; TARDI PG, 1992, LIPIDS, V27, P65, DOI 10.1007/BF02537062; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; YAMAOKA S, 1990, J NUTR, V120, P415, DOI 10.1093/jn/120.5.415; YAMAOKAKOSEKI S, 1991, J NUTR, V121, P956, DOI 10.1093/jn/121.7.956	39	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12716	12721		10.1074/jbc.M210329200	http://dx.doi.org/10.1074/jbc.M210329200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569106	hybrid			2022-12-27	WOS:000182189500018
J	Turner, J; Nicholas, H; Bishop, D; Matthews, JM; Crossley, M				Turner, J; Nicholas, H; Bishop, D; Matthews, JM; Crossley, M			The LIM protein FHL3 binds basic Kruppel-like factor/Kruppel-like factor 3 and its co-repressor C-terminal-binding protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; FACTOR EKLF; DOMAIN PROTEIN; LEUKEMIA-CELLS; FAMILY; CTBP; ASSOCIATION; FINGER; COACTIVATOR; COREPRESSOR	The ability of DNA-binding transcription factors to recruit specific cofactors is central to the mechanism by which they regulate gene expression. BKLF/KLF3, a member of the Kruppel-like factor family of zinc finger proteins, is a potent transcriptional repressor that recruits a CtBP co-repressor. We show here that BKLF also recruits the four and a half LIM domain protein FHL3. Different but closely linked regions of BKLF mediate contact with CtBP2 and FHL3. We present evidence that CtBP2 also interacts with FHL3 and demonstrate that the three proteins co-elute in gel filtration experiments. CtBP and FHL proteins have been implicated in both nuclear and cytoplasmic functions, but expression of BKLF promotes the nuclear accumulation of both FHL3 and CtBP2. FHL proteins have been shown to act predominantly as co-activators of transcription. However, we find FHL3 can repress transcription. We suggest that LIM proteins like FHL3 are important in assembling specific repression or activation complexes, depending on conditions such as cofactor availability and promoter context.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Sydney	Crossley, M (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, G08, Sydney, NSW 2006, Australia.		Crossley, Merlin/D-7888-2011; Matthews, Jacqueline/A-7322-2013	Crossley, Merlin/0000-0003-2057-3642; Matthews, Jacqueline/0000-0001-8518-3472; Bishop, David/0000-0001-6415-1455; Nicholas, Hannah/0000-0002-2239-9249				Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P251, DOI 10.1006/bbrc.1999.0180; MORGAN MJ, 1995, BIOCHEM BIOPH RES CO, V212, P840, DOI 10.1006/bbrc.1995.2045; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Ng EKO, 2002, J CELL BIOCHEM, V84, P556, DOI 10.1002/jcb.10041.abs; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; PERKINS AC, 1997, BLOOD S, V90, P575; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Schuierer M, 2001, J BIOL CHEM, V276, P27944, DOI 10.1074/jbc.M100070200; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Turner J, 1999, INT J BIOCHEM CELL B, V31, P1169, DOI 10.1016/S1357-2725(99)00067-9; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	49	52	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12786	12795		10.1074/jbc.M300587200	http://dx.doi.org/10.1074/jbc.M300587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556451	hybrid			2022-12-27	WOS:000182189500027
J	Chreneik, JE; Burgin, AB; Pommier, Y; Stewart, L; Redinbo, MR				Chreneik, JE; Burgin, AB; Pommier, Y; Stewart, L; Redinbo, MR			Structural impact of the leukemia drug 1-beta-D-arabinofuranosyleytosine (Ara-C) on the covalent human topoisomerase I-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; CLEAVAGE COMPLEXES; ACTIVE-SITE; CAMPTOTHECIN; INDUCTION; ARABINOSYLCYTOSINE; RECOMBINATION; MOLSCRIPT	1-beta-D-Arabinofuranosylcytosine (Ara-C) is a potent antineoplastic drug used in the treatment of acute leukemia. Previous biochemical studies indicated the incorporation of Ara-C into DNA reduced the catalytic activity of human topoisomerase I by decreasing the rate of single DNA strand religation by the enzyme by 2-3-fold. We present the 3.1 Angstrom crystal structure of human topoisomerase I in covalent complex with an oligonucleotide containing Ara-C at the + 1 position of the non-scissile DNA strand. The structure reveals that a hydrogen bond formed between the 2'-hydroxyl of Ara-C and the O4' of the adjacent -1 base 5' to the damage site stabilizes a C3'-endo pucker in the Ara-C arabinose ring. The structural distortions at the site of damage are translated across the DNA double helix to the active site of human topoisomerase I. The free sulfhydryl at the 5'-end of the nicked DNA strand in this trapped covalent complex is shifted out of alignment with the 3'-phosphotyrosine linkage at the catalytic tyrosine 723 residue, producing a geometry not optimal for religation. The subtle structural changes caused by the presence of Ara-C in the DNA duplex may contribute to the cytotoxicity of this leukemia drug by prolonging the lifetime of the covalent human topoisomerase I-DNA complex.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; DeCODE Genet Inc, Biostruct Grp, Bainbridge Isl, WA 98110 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Redinbo, MR (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.	redinbo@unc.edu			NATIONAL CANCER INSTITUTE [Z01BC006161, ZIABC006161] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Burgin AB, 2000, METH MOL B, V95, P119; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; COLLINS ARS, 1977, BIOCHIM BIOPHYS ACTA, V478, P461, DOI 10.1016/0005-2787(77)90101-0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; Grant S, 1998, ADV CANCER RES, V72, P197; GRANT S, 1997, FRONT BIOSCIENCE, V2, P242; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Holden Joseph A., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P1, DOI 10.2174/1568011013354859; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Hwang Y, 1999, VIROLOGY, V262, P479, DOI 10.1006/viro.1999.9920; Kazmierczak RA, 2002, NUCLEIC ACIDS RES, V30, P5193, DOI 10.1093/nar/gkf652; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 1999, VIROLOGY, V264, P441, DOI 10.1006/viro.1999.0022; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; MASTRIANNI DM, 1992, AM J MED, V92, P286, DOI 10.1016/0002-9343(92)90079-Q; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SCHWEITZER BI, 1994, BIOCHEMISTRY-US, V33, P11460, DOI 10.1021/bi00204a008; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; THIBAUDEAU C, 1994, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39940000537; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEATES TO, 1988, ACTA CRYSTALLOGR A, V44, P142, DOI 10.1107/S0108767387009632	41	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12461	12466		10.1074/jbc.M212930200	http://dx.doi.org/10.1074/jbc.M212930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12533542	hybrid			2022-12-27	WOS:000182015700096
J	Wu, ZP; Yang, YW; Shaw, N; Bhattacharya, S; Yan, L; West, K; Roth, K; Noy, N; Qin, J; Crabb, JW				Wu, ZP; Yang, YW; Shaw, N; Bhattacharya, S; Yan, L; West, K; Roth, K; Noy, N; Qin, J; Crabb, JW			Mapping the ligand binding pocket in the cellular retinaldehyde binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE; MUTATIONS	Retinoid interactions determine the function of the cellular retinaldehyde binding protein (CRALBP) in the rod visual cycle where it serves as an 11-cis-retinol acceptor for the enzymatic isomerization of all-trans- to 11-cis-retinol and as a substrate carrier for 11-cis-retinol dehydrogenase (RDH5). Based on preliminary NMR studies suggesting retinoid interactions with Met and Trp residues, human recombinant CRALBP (rCRALBP) with altered Met or Trp were produced and analyzed for ligand interactions. The primary structures of the purified proteins were verified for mutants M20SA, M222A, M225A, W165F, and W244F, then retinoid binding properties and substrate carrier functions were evaluated. All the mutant proteins bound 11-cis- and 9-cis-retinal and therefore were not grossly misfolded. Altered UV-visible spectra and lower retinoid binding affinities were observed for the mutants, supporting modified ligand interactions. Altered kinetic parameters were observed for RDH5 oxidation of 11-cis-retinol bound to rCRALBP mutants M222A. M225A, and W244F, supporting impaired substrate carrier function. Heteronuclear single quantum correlation NMR analyses confirmed localized structural changes upon photoisomerization of rCRALBP-bound 11-cis-retinal and demonstrated ligand-dependent conformational changes for residues Met-208, Met-222, Trp-165, and Trp-244. Furthermore, residues Met-208, Met-222, Met-225, and Trp-244 are within a region exhibiting high homology to the ligand binding cavity of phosphatidylinositol transfer protein. Overall the data implicate Trp-165, Met-208, Met-222, Met-225, and Trp-244 as components of the CRALBP ligand binding cavity.	Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Cornell University	Crabb, JW (corresponding author), Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,I31, Cleveland, OH 44195 USA.	crabbj@ccf.org		Qin, Jun/0000-0002-2647-9270	NCI NIH HHS [CA68150] Funding Source: Medline; NEI NIH HHS [EY6603, EY14239] Funding Source: Medline; NHLBI NIH HHS [HL58758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhattacharya SK, 2002, FASEB J, V16, pA14; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507; CHEN Y, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P371; Crabb JW, 1998, METH MOL B, V89, P91; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; CRABB JW, 1997, CURRENT PROTOCOLS S, V7; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Golovleva I, 2003, J BIOL CHEM, V278, P12397, DOI 10.1074/jbc.M207300200; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Jang GF, 2000, J BIOL CHEM, V275, P28128; Luck LA, 1997, TECH PROT CHEM, V8, P439, DOI 10.1016/S1080-8914(97)80044-0; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; Qin J, 2001, METHOD ENZYMOL, V339, P377, DOI 10.1016/S0076-6879(01)39323-0; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; Saari John C., 1994, P351; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058; Wu Z, 2001, INVEST OPHTH VIS SCI, V42, pS358	28	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12390	12396		10.1074/jbc.M212775200	http://dx.doi.org/10.1074/jbc.M212775200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12536149	hybrid			2022-12-27	WOS:000182015700087
J	Hambrock, HO; Nitsche, DP; Hansen, U; Bruckner, P; Paulsson, M; Maurer, P; Hartmann, U				Hambrock, HO; Nitsche, DP; Hansen, U; Bruckner, P; Paulsson, M; Maurer, P; Hartmann, U			SC1/hevin - An extracellular calcium-modulated protein that binds collagen I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLYCOPROTEIN SC1/ECM2; CRYSTAL-STRUCTURE; SPARC; SC1; BRAIN; HEVIN; BM-40; LYMPHOPOIESIS; FOLLISTATIN; ASTROCYTES	SC1, a member of the BM-40 family of extracellular matrix proteins, was recombinantly expressed in a eukaryotic expression system. The full-length protein as well as truncated versions were purified to homogeneity under non-denaturing conditions. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry of full-length SC1 revealed a mass of 87.8 kDa of which 16.8 kDa is contributed by posttranslational modifications. In electron microscopy, after negative staining, SC1 was revealed as a globule attached to a thread-like structure. A calcium dependence of the SC1 conformation could be demonstrated by fluorescence spectroscopy. In the extracellular matrix of cultured osteosarcoma cells SC1 was found associated with collagen I-containing fibrils, and binding of SC1 to reconstituted collagen I fibrils could be demonstrated by immunogold labeling and electron microscopy. SC1 showed a broad expression in a variety of tissues.	Univ Cologne, Ctr Biochem, Fac Med, D-50931 Cologne, Germany; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Cologne; University of Munster	Hartmann, U (corresponding author), Univ Cologne, Ctr Biochem, Fac Med, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.		Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				Bendik I, 1998, CANCER RES, V58, P626; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Claeskens A, 2000, BRIT J CANCER, V82, P1123, DOI 10.1054/bjoc.1999.1051; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Girard JP, 1996, J BIOL CHEM, V271, P4511; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; IruelaArispe ML, 1996, DEV DYNAM, V207, P171, DOI 10.1002/(SICI)1097-0177(199610)207:2<171::AID-AJA5>3.0.CO;2-E; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; McKinnon PJ, 1996, BRAIN RES, V709, P27, DOI 10.1016/0006-8993(95)01224-9; McKinnon PJ, 2000, MOL CELL BIOL, V20, P656, DOI 10.1128/MCB.20.2.656-660.2000; MENDIS DB, 1994, BRAIN RES, V633, P197, DOI 10.1016/0006-8993(94)91540-7; Mendis DB, 1996, BRAIN RES, V713, P53, DOI 10.1016/0006-8993(95)01472-1; Mendis DB, 1996, BRAIN RES, V730, P95; Nelson PS, 1998, CANCER RES, V58, P232; Oritani K, 1997, BLOOD, V90, P3404, DOI 10.1182/blood.V90.9.3404; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Oritani K, 1998, LEUKEMIA LYMPHOMA, V32, P1; Ringuette M, 1998, DEV GENES EVOL, V208, P403, DOI 10.1007/s004270050196; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Vannahme C, 2002, J BIOL CHEM, V277, P37977, DOI 10.1074/jbc.M203830200; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200	30	71	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11351	11358		10.1074/jbc.M212291200	http://dx.doi.org/10.1074/jbc.M212291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538579	hybrid			2022-12-27	WOS:000181855400063
J	Tateno, H; Winter, HC; Petryniak, J; Goldstein, IJ				Tateno, H; Winter, HC; Petryniak, J; Goldstein, IJ			Purification, characterization, molecular cloning, and expression of novel members of jacalin-related lectins from rhizomes of the true fern Phlebodium aureum (L) J. Smith (Polypodiaceae)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CARBOHYDRATE-BINDING PROPERTIES; MUSA-ACUMINATA LECTIN; ARTOCARPUS-INTEGRIFOLIA; HELIANTHUS-TUBEROSUS; OLIGOSACCHARIDES; RECOGNITION; AGGLUTININ; PROTEINS; REVEALS	A lectin was purified from rhizomes of the fern Phlebodium aureum by affinity chromatography on mannose-Sepharose. The lectin, designated P. aureum lectin (PAL), is composed of two identical subunits of similar to15 kDa associated by noncovalent bonds. From a cDNA library and synthetic oligonucleotide probes based on a partial amino acid sequence, 5'- and 3'-rapid amplification of cDNA ends allowed the generation of two similar full-length cDNAs, termed PALa and PALb, each of which had an open reading frame of 438 by encoding 146 amino acid residues. The two proteins share 88% sequence identity and showed structural similarity to jacalin-related lectins. PALa contained peptide sequences exactly matching those found in the isolated lectin. PALa and PALb were expressed in Escherichia coli using pET-22b(+) vector and purified by one-step affinity chromatography. Native and recombinant forms of PAL agglutinated rabbit erythrocytes and precipitated with yeast mannan, dextran, and the high mannose-containing glycoprotein invertase. The detailed carbohydrate-binding properties of the native and recombinant lectins were elucidated by agglutination inhibition assay, and native lectin was also studied by isothermal titration calorimetry. Based on the results of these assays, we conclude that this primitive vascular plant, like many higher plants, contains significant quantities of a mannose/glucose-binding protein in its storage tissue, whose binding specificity differs in detail from either legume mannose/glucose-binding lectins or monocot mannose-specific lectins. The identification of a jacalin-related lectin in a true fern reveals for the first time the widespread distribution and molecular evolution of this lectin family in the plant kingdom.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Goldstein, IJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	igoldste@umich.edu	Tateno, Hiroaki/M-2706-2018	Tateno, Hiroaki/0000-0003-3006-1659	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bourne Y, 1999, STRUCTURE, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; FU DT, 1995, ANAL BIOCHEM, V227, P377, DOI 10.1006/abio.1995.1294; Goldstein I.J., 1997, GLYCOPROTEINS, P403; Goldstein IJ, 2001, EUR J BIOCHEM, V268, P2616, DOI 10.1046/j.1432-1327.2001.02149.x; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; Hirano K, 2000, PLANT CELL PHYSIOL, V41, P258, DOI 10.1093/pcp/41.3.258; HUI Y, 1993, J BIOL CHEM, V268, P5905; JEANES A, 1954, J AM CHEM SOC, V76, P5041, DOI 10.1021/ja01649a011; KAKU H, 1992, CARBOHYD RES, V229, P337, DOI 10.1016/S0008-6215(00)90579-2; KIMURA M, 1969, P NATL ACAD SCI USA, V63, P1181, DOI 10.1073/pnas.63.4.1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENER IE, 1986, LECTINS, P3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mann K, 2001, EUR J BIOCHEM, V268, P4414, DOI 10.1046/j.1432-1327.2001.02368.x; MELLOR RB, 1981, BIOCHEM BIOPH RES CO, V99, P1348, DOI 10.1016/0006-291X(81)90767-1; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; Mo HQ, 2001, EUR J BIOCHEM, V268, P2609, DOI 10.1046/j.1432-1327.2001.02148.x; Nomura K, 2000, BIOCHEM BIOPH RES CO, V276, P23, DOI 10.1006/bbrc.2000.3420; Novak T.P., 1975, BIOCHIM BIOPHYS ACTA, V393, P115; Peumans WJ, 1997, GLYCOCONJUGATE J, V14, P259, DOI 10.1023/A:1018502107707; Peumans WJ, 2000, PLANTA, V211, P546, DOI 10.1007/s004250000307; PLUMMER TH, 1964, J BIOL CHEM, V239, P2530; Rosa JC, 1999, PROTEIN SCI, V8, P13; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; Van Damme EJM, 1999, EUR J BIOCHEM, V259, P135, DOI 10.1046/j.1432-1327.1999.00013.x; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; Van Damme EJM, 2002, PLANT PHYSIOL, V130, P757, DOI 10.1104/pp.005892; Vasheka O. V., 1999, Ukrainskii Biokhimicheskii Zhurnal, V71, P93; Winter HC, 2002, J BIOL CHEM, V277, P14996, DOI 10.1074/jbc.M200161200; Yagi F, 2002, EUR J BIOCHEM, V269, P4335, DOI 10.1046/j.1432-1033.2002.03127.x; YOUNG NM, 1991, FEBS LETT, V282, P382, DOI 10.1016/0014-5793(91)80518-8; Zhang WL, 2000, PLANTA, V210, P970, DOI 10.1007/s004250050705	37	35	35	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10891	10899		10.1074/jbc.M211840200	http://dx.doi.org/10.1074/jbc.M211840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538584	hybrid			2022-12-27	WOS:000181855400004
J	Toustrup-Jensen, M; Vilsen, B				Toustrup-Jensen, M; Vilsen, B			Importance of conserved Thr(214) in domain A of the Na+,K+-ATPase for stabilization of the phosphoryl transition state complex in E2P dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; 4TH TRANSMEMBRANE SEGMENT; E1-E2 CONFORMATIONAL TRANSITIONS; RAT-KIDNEY NA+,K+-ATPASE; FUNCTIONAL CONSEQUENCES; ENERGY TRANSDUCTION; ALPHA-SUBUNIT; CALCIUM-PUMP; NA,K-ATPASE; MUTATIONS	Thr(214) of the highly conserved (214)TGES sequence in domain A of the Na+,K+-ATPase was replaced with alanine, and the mutant was compared functionally with the previously characterized domain A mutant Gly(263) --> Ala. Thr(214) --> Ala displayed a conspicuous 150-fold reduction of the apparent vanadate affinity for inhibition of ATPase activity, which could not simply be explained by the observed shifts of the conformational equilibria in favor of E-1 and E1P. The intrinsic vanadate affinity of the E-2 form and the effect on the apparent vanadate affinity of displacement of the E-1-E-2 equilibrium were determined in a phosphorylation assay that allows the enzyme-vanadate complex to be formed under equilibrium conditions. When the E-2 form prevailed, Thr(214) Ala retained a reduced vanadate affinity relative to wild type, whereas the affinity of Gly(263) --> Ala became wild type-like. Thus, mutation of Thr(214) affected the intrinsic affinity of E-2 for vanadate. Furthermore, Thr(214) --> Ala showed at least a 5-fold reduced E2P dephosphorylation rate relative to wild type in the presence of saturating concentrations of K+ and Mg2+. Because vanadate is a phosphoryl transition state analog, it is proposed that defective binding of the phosphoryl transition state complex (transition state destabilization) causes the inability to catalyze E2P dephosphorylation properly. By contrast, the phosphorylation site in the E-1 form was unaffected in Thr(214) --> Ala. Replacement of the glutamate, Glu(216), of (214)TGES with alanine was incompatible with cell viability, indicating a very low transport activity or expression level. Our results support the hypothesis that domain A is isolated in the E-1 form, but contributes to make up the catalytic site in the E-2 and E2P conformations.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Toustrup-Jensen, Mads Schak/0000-0003-2064-5861; Vilsen, Bente/0000-0002-4727-9382				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P1; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; Goldshleger R, 2001, J BIOENERG BIOMEMBR, V33, P387, DOI 10.1023/A:1010615422932; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KUNKEL TA, 1985, P NATL ACAD SCI USA, V85, P3314; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; SMITH RL, 1980, J BIOL CHEM, V255, P9852; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toustrup-Jensen M, 2002, J BIOL CHEM, V277, P38607, DOI 10.1074/jbc.M203665200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Vilsen B, 1997, ANN NY ACAD SCI, V834, P297, DOI 10.1111/j.1749-6632.1997.tb52260.x; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11402	11410		10.1074/jbc.M212136200	http://dx.doi.org/10.1074/jbc.M212136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531906	hybrid			2022-12-27	WOS:000181855400069
J	Zhang, WG; Wang, YM; Long, J; Girton, J; Johansen, J; Johansen, KM				Zhang, WG; Wang, YM; Long, J; Girton, J; Johansen, J; Johansen, KM			A developmentally regulated splice variant from the complex lola locus encoding multiple different zinc finger domain proteins interacts with the chromosomal kinase JIL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BTB DOMAIN; HISTONE DEACETYLASE; CHROMATIN STRUCTURE; POZ DOMAIN; N-COR; DOSAGE COMPENSATION; INTERACTION MOTIF; BTB/POZ DOMAIN; DNA-BINDING	Using a yeast two-hybrid screen we have identified a novel isoform. of the lola locus, Lola zf5, that interacts with the chromosomal kinase JIL-1. We characterized the lola locus and provide evidence that it is a complex locus from which at least 17 different splice variants are likely to be generated. Fifteen of these each have a different zinc finger domain, whereas two are without. This potential for expression of multiple gene products suggests that they serve diverse functional roles in different developmental contexts. By Northern and Western blot analyses we demonstrate that the expression of Lola zf5 is developmentally regulated and that it is restricted to early embryogenesis. Immunocytochemical labeling with a Lola zf5-specific antibody of Drosophila embryos indicates that Lola zf5 is localized to nuclei. Furthermore, by creating double-mutant flies we show that a reduction of Lola protein levels resulting from mutations in the lola locus acts as a dominant modifier of a hypomorphic JIL-1 allele leading to an increase in embryonic viability. Thus, genetic interaction assays provide direct evidence that gene products from the lola locus function within the same pathway as the chromosomal kinase JIL-1.	Iowa State Univ, Dept Zool & Genet, Ames, IA 50011 USA	Iowa State University	Johansen, KM (corresponding author), Iowa State Univ, Dept Zool & Genet, 3154 Mol Biol Bldg, Ames, IA 50011 USA.			Wang, Yanming/0000-0002-0710-043X; Zhang, Weiguo/0000-0002-3045-0569	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Akhtar A, 2001, EMBO REP, V2, P113, DOI 10.1093/embo-reports/kve022; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Arrizabalaga G, 1999, GENETICS, V153, P1825; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Buchner K, 2000, GENETICS, V155, P141; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Cavarec L, 1997, MOL CELL BIOL, V17, P482, DOI 10.1128/MCB.17.1.482; CHEN W, 1995, MOL CELL BIOL, V15, P3424; Crowner D, 2002, DEVELOPMENT, V129, P1317; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Ghosh D, 2001, EMBO J, V20, P2518, DOI 10.1093/emboj/20.10.2518; GINIGER E, 1994, DEVELOPMENT, V120, P1385; GODT D, 1993, DEVELOPMENT, V119, P799; Gorelick RJ, 1999, J VIROL, V73, P8185, DOI 10.1128/JVI.73.10.8185-8195.1999; Harlow E., 1988, ANTIBODIES LAB MANUA; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Jin Y, 2000, J CELL BIOL, V149, P1005, DOI 10.1083/jcb.149.5.1005; Jin Y, 1999, MOL CELL, V4, P129, DOI 10.1016/S1097-2765(00)80195-1; Johansen KM, 1999, CRIT REV EUKAR GENE, V9, P267, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.110; Kanezaki R, 2001, J BIOL CHEM, V276, P7278, DOI 10.1074/jbc.M004227200; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LINDSLEY DL, 1992, GENOM E DROSOPHILA M; Madden K, 1999, DEV BIOL, V213, P301, DOI 10.1006/dbio.1999.9399; Meller VH, 2002, ADV GENET, V46, P1; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; Roberts D. B, 1986, DROSOPHILA PRACTICAL; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Ruhf ML, 2001, DEVELOPMENT, V128, P1429; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Spradling AC, 1999, GENETICS, V153, P135; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521; Usuka J, 2000, J MOL BIOL, V297, P1075, DOI 10.1006/jmbi.2000.3641; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Wang YM, 2001, CELL, V105, P433, DOI 10.1016/S0092-8674(01)00325-7; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WOLFFE AP, 1996, SCIENCE, V272, P408; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	52	22	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11696	11704		10.1074/jbc.M213269200	http://dx.doi.org/10.1074/jbc.M213269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538650	hybrid			2022-12-27	WOS:000181855400104
J	Berry, GT; Wu, S; Buccafusca, R; Ren, J; Gonzales, LW; Ballard, PL; Golden, JA; Stevens, MJ; Greer, JJ				Berry, GT; Wu, S; Buccafusca, R; Ren, J; Gonzales, LW; Ballard, PL; Golden, JA; Stevens, MJ; Greer, JJ			Loss of murine Na+/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL UPTAKE; PHOSPHOINOSITIDE METABOLISM; MAMMALIAN BRAIN; RABBIT LUNG; SLC5A3 GENE; RAT; HOMEOSTASIS; PROTEIN; CELLS; PHOSPHATIDYLGLYCEROL	myo-Inositol (Ins) and its polyphosphoinositide derivatives that are important in membrane signaling have long been held to play a special role in brain metabolism. As polyphosphoinositides turn over rapidly and are exceptionally abundant in nervous tissue, high Ins levels in the range of 2-15 mM that have been observed in brain may be necessary to maintain the rates of phosphoinositide synthesis in diverse membrane locations within neurons. Cellular concentration gradients of this magnitude indicate a dependence on active Ins transport, especially at the time of growth and differentiation. The Na+/myo-inositol cotransporter (SMIT1 or SLC5A3) gene is highly expressed prenatally in the central nervous system and placenta. To gain more insight into brain Ins metabolism, while ascertaining the importance of SMIT1 as a transporter, we generated mice with a homozygous targeted deletion of this gene. Newborn SMIT1(-/-) animals have no evidence of SMIT1 mRNA, a 92% reduction in the level of brain Ins, an 84% reduction in whole body Ins, and expire shortly after birth due to hypoventilation. Gross pathologic and light microscopic examinations of each organ, as well as the placenta, of embryonic day 18.5 fetuses at near term gestation were normal. Based on [H-3] acetate incorporation into phospholipids of lung tissue explants, immunostaining of lung tissue for surfactant protein A, B, and C, and electron microscopic examination of alveolar cells, there was no evidence of abnormal pulmonary surfactant production by type 2 pneumocytes in lung. Although no histologic lesions were detected in the nervous system, electrophysiological studies of the brainstem pre-Botzinger respiratory control center demonstrated an abnormal rhythm discharge with periods of central apnea. The cause of death can be explained by the regulatory defect in brainstem control of ventilation. This model demonstrates the critical importance of SMIT1 in the developing nervous system. The high affinity SMIT1 transporter is responsible for the Ins concentration gradient in the murine fetal-placental unit.	Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Childrens Hosp, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Childrens Hosp, Div Neonatol Res, Philadelphia, PA 19104 USA; Univ Alberta, Div Neurosci, Dept Physiol, Edmonton, AB T6G 2S2, Canada; Univ Michigan, Sch Med, Dept Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Alberta; University of Michigan System; University of Michigan	Berry, GT (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, 1025 Walnut St,Suite 102, Philadelphia, PA 19107 USA.			Berry, Gerard/0000-0001-5299-3313; Golden, Jeffrey/0000-0001-9933-5502				BATTAGLIA F, 1961, Q J EXP PHYSIOL CMS, V46, P188, DOI 10.1113/expphysiol.1961.sp001532; Beers MF, 1998, AM J PHYSIOL-LUNG C, V275, pL950, DOI 10.1152/ajplung.1998.275.5.L950; BENJAMINS JA, 1969, J NEUROCHEM, V16, P513, DOI 10.1111/j.1471-4159.1969.tb06850.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BERRY GT, 1995, GENOMICS, V25, P507, DOI 10.1016/0888-7543(95)80052-N; BERRY GT, 1993, BIOCHEM J, V295, P863, DOI 10.1042/bj2950863; BERSUDSKY Y, 1994, EUR NEUROPSYCHOPHARM, V4, P463, DOI 10.1016/0924-977X(94)90294-1; BLEASDALE JE, 1983, BIOCHEM J, V212, P811, DOI 10.1042/bj2120811; BLEASDALE JE, 1979, BIOCHIM BIOPHYS ACTA, V575, P135, DOI 10.1016/0005-2760(79)90139-5; BLEASDALE JE, 1982, BIOCHEM J, V206, P43, DOI 10.1042/bj2060043; CAMPLING JD, 1954, J PHYSIOL-LONDON, V126, P71, DOI 10.1113/jphysiol.1954.sp005192; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; CHEN CP, 1979, J PHARM SCI, V68, P1022, DOI 10.1002/jps.2600680827; Coady MJ, 2002, J BIOL CHEM, V277, P35219, DOI 10.1074/jbc.M204321200; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DAWSON RM, 1961, BIOCHEM J, V78, P606, DOI 10.1042/bj0780606; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; GODFREY DA, 1982, J NEUROCHEM, V38, P939, DOI 10.1111/j.1471-4159.1982.tb05333.x; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P678, DOI 10.1210/jcem-62-4-678; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; Guo W, 1997, MOL BRAIN RES, V51, P91, DOI 10.1016/S0169-328X(97)00220-9; HALLMAN M, 1986, PEDIATR RES, V20, P179, DOI 10.1203/00006450-198602000-00018; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOLUB BJ, 1986, ANNU REV NUTR, V6, P563, DOI 10.1146/annurev.nu.06.070186.003023; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEWIN LM, 1978, PEDIATR RES, V12, P3, DOI 10.1203/00006450-197801000-00002; LOW MG, 2000, BIOL PHOSPHOINOSITIE; Lykidis A, 1997, J BIOL CHEM, V272, P33402, DOI 10.1074/jbc.272.52.33402; Mallee JJ, 1997, GENOMICS, V46, P459, DOI 10.1006/geno.1997.5055; McVeigh KE, 2000, CYTOGENET CELL GENET, V88, P153, DOI 10.1159/000015509; MOLITORIS BA, 1980, J CLIN INVEST, V65, P783, DOI 10.1172/JCI109728; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Novak JE, 1999, J NEUROCHEM, V72, P1431, DOI 10.1046/j.1471-4159.1999.721431.x; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; PAULUS H, 1960, J BIOL CHEM, V235, P1303; Porcellati F, 1998, AM J PHYSIOL-CELL PH, V274, pC1215, DOI 10.1152/ajpcell.1998.274.5.C1215; PRPIC V, 1982, J BIOL CHEM, V257, P1315; QUIRK JG, 1983, OBSTET GYNECOL, V62, P41; SHERMAN WR, 1981, J NEUROCHEM, V36, P1947, DOI 10.1111/j.1471-4159.1981.tb10819.x; SIGAL SH, 1993, METABOLISM, V42, P395, DOI 10.1016/0026-0495(93)90093-4; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; STOKES CE, 1983, BIOCHIM BIOPHYS ACTA, V753, P136, DOI 10.1016/0005-2760(83)90108-X; THURSTON JH, 1989, PEDIATR RES, V26, P482, DOI 10.1203/00006450-198911000-00024; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; WOOTTON JA, 1977, INT J BIOCHEM, V8, P449, DOI 10.1016/0020-711X(77)90045-3; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	51	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18297	18302		10.1074/jbc.M213176200	http://dx.doi.org/10.1074/jbc.M213176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12582158	hybrid			2022-12-27	WOS:000182838300093
J	Huse, JT; Byant, D; Yang, YX; Pijak, DS; D'Souza, I; Lah, JJ; Lee, VMY; Doms, RW; Cook, DG				Huse, JT; Byant, D; Yang, YX; Pijak, DS; D'Souza, I; Lah, JJ; Lee, VMY; Doms, RW; Cook, DG			Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain - A potential mechanism for regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; TRANSMEMBRANE ASPARTATES; CLEAVAGE; PEPTIDE; FURIN; PHOSPHORYLATION; LOCALIZATION; DISINTEGRIN	Sequential proteolysis of the amyloid precursor protein (APP) by beta- and gamma-secretase activities yields the amyloid beta peptide that is widely deposited in the brains of individuals with Alzheimer's disease. The membrane-anchored aspartyl protease (beta) under bar- site (A) under bar PP- cleaving (e) under bar nzyme (BACE) exhibits all of the characteristics of a beta-secretase and has been shown to cleave APP at its beta-site in vitro and in vivo. We found that BACE undergoes cleavage on a surface-exposed alpha-helix between amino acid residues Leu-228 and Ala-229, generating stable N- and C-terminal fragments that remain covalently associated via a disulfide bond. The efficiency of BACE endoproteolysis was observed to depend heavily on cell and tissue type. In contrast to brain where holoprotein was predominant, BACE was found primarily as endoproteolyzed fragments in pancreas, liver, and muscle. In addition, we observed a marked up-regulation of BACE endoproteolysis in C2 myoblasts upon differentiation into multinucleated myotubes, a well established model system of muscle tissue specification. As in liver, BACE exists as endoproteolyzed fragments in the hepatic cell line, HepG2. We found that HepG2 cells are capable of generating amyloid beta peptide, suggesting that endoproteolyzed BACE retains measurable beta-secretase activity. We also found that BACE endoproteolysis occurs only after export from the endoplasmic reticulum, is enhanced in the trans-Golgi network, and is sensitive to inhibitors of vesicular acidification. The membrane-bound proteases tumor necrosis factor alpha-converting enzyme and furin were not found to be responsible for this cleavage nor was BACE observed to mediate its own endoproteolysis by an autocatalytic mechanism. Thus, we characterize a specific processing event that may serve to regulate the enzymatic activity of BACE on a post-translational level.	Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Emory University	Cook, DG (corresponding author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, 1660 S Columbian Way, Seattle, WA 98108 USA.	dgcook@u.washington.edu			NATIONAL INSTITUTE ON AGING [R01AG011762, P01AG011542] Funding Source: NIH RePORTER; NIA NIH HHS [NIA-R01 AG11762, AG05136, P01 AG11542] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bodendorf U, 2001, J BIOL CHEM, V276, P12019, DOI 10.1074/jbc.M008861200; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Drose S, 1997, J EXP BIOL, V200, P1; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; LIE SO, 1973, BIOCHEM PHARMACOL, V22, P3109, DOI 10.1016/0006-2952(73)90197-4; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; TAKAHASHI K, 1995, ADV EXP MED BIOL, V362, P53; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAMOTO K, 1995, ADV EXP MED BIOL, V362, P223; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	60	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17141	17149		10.1074/jbc.M213303200	http://dx.doi.org/10.1074/jbc.M213303200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12551920	hybrid			2022-12-27	WOS:000182818600093
J	Sarafianos, SG; Clark, AD; Tuske, S; Squire, CJ; Das, K; Sheng, DQ; Ilankumaran, P; Ramesha, AR; Kroth, H; Sayer, JM; Jerina, DM; Boyer, PL; Hughes, SH; Arnold, E				Sarafianos, SG; Clark, AD; Tuske, S; Squire, CJ; Das, K; Sheng, DQ; Ilankumaran, P; Ramesha, AR; Kroth, H; Sayer, JM; Jerina, DM; Boyer, PL; Hughes, SH; Arnold, E			Trapping HIV-1 reverse transcriptase before and after translocation on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIBODY FAB FRAGMENT; DOUBLE-STRANDED DNA; ANGSTROM RESOLUTION; SELECTIVE EXCISION; CRYSTAL-STRUCTURE; TEMPLATE-PRIMER; RESISTANCE; COMPLEX; DISULFIDES	A disulfide cross-linking strategy was used to co-valently trap as a stable complex (complex N) a short-lived, kinetic intermediate in DNA polymerization. This intermediate corresponds to the product of polymerization prior to translocation. We also prepared the trapped complex that corresponds to the product of polymerization after translocation (complex P). The cross-linking method that we used is a variation of a technique developed by the Verdine and Harrison laboratories. It involves disulfide interchange between an engineered sulfhydryl group of the protein (Q258C mutation) and a disulfide-containing tether attached at the N-2 amino group of a modified dG in either the template or the primer strand of the nucleic acid. We report here a highly efficient synthesis of the precursor, bis(3-aminopropyl)disulfide dihydrochloride, used to introduce this substituent into the oligonucleotide. Efficient cross-linking takes place when the base pair containing the substituent is positioned seven registers from the dNTP-binding site (N site) and the N site is occupied. Complex N, but not complex P, is a substrate for the ATP-based excision reaction that unblocks nucleoside reverse transcriptase inhibitor (NRTI)-terminated primers and causes resistance to several NRTIs, confirming predictions that the excision reaction takes place only when the X-end of the primer is bound at the N site. These techniques can be used for biochemical and structural studies of the mechanism of DNA polymerization, translocation, and excision-based resistance of RT to NRTIs. They may also be useful in studying other DNA or RNA polymerases or other enzymes.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Arnold, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.	arnold@cabm.rutgers.edu	Das, Kalyan/O-9224-2019; Das, Kalyan/B-2967-2018	Das, Kalyan/0000-0002-8897-324X; Das, Kalyan/0000-0002-8897-324X; Sarafianos, Stefan G/0000-0002-5840-154X; Squire, Christopher/0000-0001-9212-0461; Kroth, Heiko/0000-0002-6936-3921	NATIONAL CANCER INSTITUTE [Z01BC010481, ZIABC010481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027690, R37AI027690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056609] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27690] Funding Source: Medline; NIGMS NIH HHS [GM 56609] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; Boyer PL, 2002, J VIROL, V76, P9143, DOI 10.1128/JVI.76.18.9143-9151.2002; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Clark AD, 1995, METHOD ENZYMOL, V262, P171, DOI 10.1016/0076-6879(95)62017-6; DeCorte BL, 1996, CHEM RES TOXICOL, V9, P630, DOI 10.1021/tx9501795; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; DIRSCHERL W, 1951, LIEBIGS ANN CHEM, V574, P131; DOI JT, 1985, J ORG CHEM, V50, P1, DOI 10.1021/jo00201a001; ERLANSON DA, 1993, J AM CHEM SOC, V115, P12583, DOI 10.1021/ja00079a047; EVANS BJ, 1990, J ORG CHEM, V55, P2580, DOI 10.1021/jo00296a009; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; MATTINGLY PG, 1990, SYNTHESIS-STUTTGART, P366; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Peletskaya EN, 2001, J VIROL, V75, P9435, DOI 10.1128/JVI.75.19.9435-9445.2001; RAMESHA AR, 1992, SYNTHETIC COMMUN, V22, P3277, DOI 10.1080/00397919208021143; RAMESHA AR, 1994, J ORG CHEM, V59, P1354, DOI 10.1021/jo00085a025; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449	27	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16280	16288		10.1074/jbc.M212911200	http://dx.doi.org/10.1074/jbc.M212911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12554739	Green Published, hybrid			2022-12-27	WOS:000182680000104
J	Bidasee, KR; Xu, L; Meissner, G; Besch, HR				Bidasee, KR; Xu, L; Meissner, G; Besch, HR			Diketopyridylryanodine has three concentration-dependent effects on the cardiac calcium-release channel/ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; CHANNEL; SKELETAL; DERIVATIVES; ACTIVATION; COMPLEX; PHARMACOLOGY; INHIBITION; SPARKS	By interacting with more than one site, ryanoids induce multiple effects on calcium-release channels. To date, the kinetics of interaction of only one of these sites has been characterized. Using C-4,C-12-diketopyridylryanodine in both [H-3]ryanodine binding and single channel experiments we characterized another site on the cardiac ryanodine receptor (RyR2) with which ryanoids interact. Competitive binding of this ryanoid to RyR2 implied a minimal two-site binding model. At the single channel level, C-4,C-12-diketopyridylryanodine induced three distinct effects. At nanomolar concentrations, it increased channel open probability several fold without inducing a subconductance. This effect was independent of membrane holding potential. As for other ryanoids, low micromolar concentrations of C-4,C-12-diketopyridylryanodine readily induced a subconductance state. The major subconductance had a current amplitude of 52% of fully open, it was reversible, and its time to induction and duration were voltage- and concentration-dependent, affording Hill slopes of >2. At higher micromolar concentrations C-4,C-12-diketopyridylryanodine induced long lasting, yet reversible shut states. Using a pharmacological strategy we have discerned an additional ryanoid-binding site on RyR2 that triggers an increase in channel activity. This site likely resides outside the strict confines of the transmembrane conducting pathway.	Univ Nebraska, Med Ctr, Dept Pharmacol, Nebraska Med Ctr 986260, Omaha, NE 68198 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Indiana Univ, Sch Med, Dept Pharmacol, Indiana Ctr Vasc Biol & Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indiana Ctr Vasc Biol & Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Krannert Inst Cardiol, Indiana Ctr Vasc Biol & Med, Indianapolis, IN 46202 USA	University of Nebraska System; University of Nebraska Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Bidasee, KR (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmacol, Nebraska Med Ctr 986260, Omaha, NE 68198 USA.	kbidasee@unmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430, R01HL066898] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66898, HL27430] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Bidasee KR, 1998, J BIOL CHEM, V273, P12176, DOI 10.1074/jbc.273.20.12176; BIDASEE KR, 1994, J LABELLED COMPD RAD, V34, P33, DOI 10.1002/jlcr.2580340106; Bidasee KR, 2000, J PHARMACOL EXP THER, V293, P1074; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Hui CS, 2001, J PHYSIOL-LONDON, V534, P327, DOI 10.1111/j.1469-7793.2001.00327.x; HUMERICKHOUSE RA, 1994, J BIOL CHEM, V269, P30243; HUMERICKHOUSE RA, 1993, MOL PHARMACOL, V44, P412; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; JEFFERIES PR, 1993, J MED CHEM, V36, P1128, DOI 10.1021/jm00061a003; KELLY RB, 1951, CAN J CHEM, V29, P905, DOI 10.1139/v51-105; LAI FA, 1989, J BIOL CHEM, V264, P16776; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LEE HB, 1994, J BIOL CHEM, V269, P13305; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; MEISSNER G, 1991, ADV EXP MED BIOL, V304, P241; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Motulsky H., 1999, ANAL DATA GRAPHPAD P; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Ozawa T, 2001, INT J MOL MED, V7, P21; Schleifer KJ, 2000, J COMPUT AID MOL DES, V14, P467, DOI 10.1023/A:1008141819487; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; SORRENTINO V, 1996, RYANODINE RECEPTOR; Sutko JL, 1997, PHARMACOL REV, V49, P53; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; Tanna B, 2000, J GEN PHYSIOL, V116, P1, DOI 10.1085/jgp.116.1.1; Tinker A, 1996, BIOPHYS J, V70, P2110, DOI 10.1016/S0006-3495(96)79777-1; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; Xu L, 1998, ANN NY ACAD SCI, V853, P130; Xu XH, 2000, BIOPHYS J, V78, P1270, DOI 10.1016/S0006-3495(00)76683-5; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971	41	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14237	14248		10.1074/jbc.M208372200	http://dx.doi.org/10.1074/jbc.M208372200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566457	hybrid			2022-12-27	WOS:000182405000086
J	Neumar, RW; Xu, YA; Gada, H; Guttmann, RP; Siman, R				Neumar, RW; Xu, YA; Gada, H; Guttmann, RP; Siman, R			Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR PROTEIN CALPASTATIN; TRANSIENT FOREBRAIN ISCHEMIA; DRUG-INDUCED APOPTOSIS; CELL-DEATH; DNA FRAGMENTATION; HYPOXIA-ISCHEMIA; NEUROBLASTOMA-CELLS; TRIGGERS APOPTOSIS; T-CELLS; ACTIVATION	Cross-talk between calpain and caspase proteolytic systems has complicated efforts to determine their distinct roles in apoptotic cell death. This study examined the effect of overexpressing calpastatin, the specific endogenous calpain inhibitor, on the activity of the two proteolytic systems following an apoptotic stimulus. Human SH-SY5Y neuroblastoma cells were stably transfected with full-length human calpastatin eDNA resulting in 20-fold overexpression based on Western blot and 5-fold greater calpain inhibitory activity in cell extracts. Wild type and calpastatin overexpressing (CST1) cells were neuronally differentiated and apoptosis-induced with staurosporine (0.1-1.0 muM). Calpastatin overexpression decreased calpain activation, increased caspase-3-like activity, and accelerated the appearance of apoptotic nuclear morphology. Following 0.1-0.2 muM staurosporine, plasma membrane integrity based on calcein-acetoxymethyl fluorescence was significantly greater at 24 h in differentiated CST1 compared with differentiated wild type cells. However, this protective effect was lost at higher staurosporine doses (0.5-1.0 muM), which resulted in pronounced caspase-mediated degradation of the overexpressed calpastatin. These results suggest a dual role for calpains during neuronal apoptosis. In the early execution phase, calpain down-regulates caspase-3-like activity and slows progression of apoptotic nuclear morphology. Subsequent calpain activity, facilitated by caspase-mediated degradation of calpastatin, contributes to plasma membrane disruption and secondary necrosis.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Kentucky, Ctr Aging, Lexington, KY 40536 USA	University of Pennsylvania; University of Kentucky	Neumar, RW (corresponding author), Hosp Univ Penn, Dept Emergency Med, Ground Floor,Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	rneumar@mail.med.upenn.edu	guttmann, rodney/AAN-8880-2021	guttmann, rodney/0000-0001-5553-3099				Atencio IA, 2000, CELL GROWTH DIFFER, V11, P247; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Blomgren K, 1999, ANN NY ACAD SCI, V890, P270, DOI 10.1111/j.1749-6632.1999.tb08002.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Chen SJ, 1998, MOL CELL BIOCHEM, V178, P141, DOI 10.1023/A:1006893528428; Cheng AG, 1999, BRAIN RES, V850, P234, DOI 10.1016/S0006-8993(99)01983-6; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Colbourne F, 1999, J NEUROSCI, V19, P4200; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gill R, 2002, J CEREBR BLOOD F MET, V22, P420, DOI 10.1097/00004647-200204000-00006; Gobbel GT, 2001, J NEUROCHEM, V76, P520, DOI 10.1046/j.1471-4159.2001.00070.x; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu Q, 1996, ARCH BIOCHEM BIOPHYS, V334, P175, DOI 10.1006/abbi.1996.0443; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakatsuka H, 2000, NEUROSCI LETT, V285, P127, DOI 10.1016/S0304-3940(00)01044-2; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; Shi YX, 2000, AM J PHYSIOL-RENAL, V279, pF509, DOI 10.1152/ajprenal.2000.279.3.F509; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Witkowski JM, 2002, BLOOD, V100, P1802, DOI 10.1182/blood-2001-11-0073; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhu DM, 2000, CLIN CANCER RES, V6, P2456; ZHU W, 1995, BIOCHEM BIOPH RES CO, V214, P1130, DOI 10.1006/bbrc.1995.2403	57	214	224	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14162	14167		10.1074/jbc.M212255200	http://dx.doi.org/10.1074/jbc.M212255200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576481	hybrid			2022-12-27	WOS:000182405000077
J	Sawaoka, H; Dixon, DA; Oates, JA; Boutaud, O				Sawaoka, H; Dixon, DA; Oates, JA; Boutaud, O			Tristetraprolin binds to the 3 '-untranslated region of cyclooxygenase-2 mRNA - A polyadenylation variant in a cancer cell line lacks the binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; INTESTINAL EPITHELIAL-CELLS; GROWTH-FACTOR-ALPHA; COLON-CANCER; POSTTRANSCRIPTIONAL REGULATION; TNF-ALPHA; PROSTAGLANDIN H-2; GENE-EXPRESSION; CARCINOMA CELLS	In human colorectal adenocarcinoma cell lines, we found two major transcripts of cyclooxygenase-2, the full-length mRNA and a short polyadenylation variant (2577 kb) lacking the distal segment of the 3'-untranslated region. Tristetraprolin, an mRNA-binding protein that promotes message instability, was shown to bind the cyclooxygenase-2 mRNA in the region of the W-untranslated region between nucleotides 3125 and 3432 and to reduce levels of the full-length mRNA. During cell growth and confluence, the expression of tristetraprolin mRNA was inversely correlated with that of the full-length cyclooxygenase-2 transcript, and transfection of tristetraprolin into HCA-7 cells reduced the level of full-length cyclooxygenase-2 mRNA. However, the truncated transcript escaped tristetraprolin binding and downregulation.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Boutaud, O (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 514 RRB,23rd Ave S Pierce, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P01CA077839, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839, CA68485] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGHIB DF, 1990, ONCOGENE, V5, P707; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUBOIS RN, 1994, AM J PHYSIOL, V266, P822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KIRKLAND SC, 1985, CANCER RES, V45, P3790; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Martinez J, 1997, AM J PHYSIOL-CELL PH, V273, pC1466, DOI 10.1152/ajpcell.1997.273.5.C1466; Masferrer JL, 2000, CANCER RES, V60, P1306; Molina MA, 1999, CANCER RES, V59, P4356; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; RAYMOND V, 1989, ONCOGENE RES, V5, P1; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Ristimaki A, 1997, CANCER RES, V57, P1276; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sawaoka H, 1999, PROSTAG LEUKOTR ESS, V61, P315, DOI 10.1054/plef.1999.0106; Sawaoka H, 1997, J CLIN GASTROENTEROL, V25, pS105, DOI 10.1097/00004836-199700001-00018; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VARNUM BC, 1989, ONCOGENE, V4, P119; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Wolff H, 1998, CANCER RES, V58, P4997; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117; Zimmermann KC, 1999, CANCER RES, V59, P198	62	118	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13928	13935		10.1074/jbc.M300016200	http://dx.doi.org/10.1074/jbc.M300016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578839	hybrid			2022-12-27	WOS:000182405000048
J	Lyu, J; Costantini, F; Jho, EH; Joo, CK				Lyu, J; Costantini, F; Jho, EH; Joo, CK			Ectopic expression of axin blocks neuronal differentiation of embryonic carcinoma P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; F-BOX PROTEIN; TRANSCRIPTION FACTOR LEF-1; MOUSE FUSED LOCUS; BETA-CATENIN; NEGATIVE REGULATOR; NEURAL CREST; COMPLEX; DOMAINS; PHOSPHORYLATION	Axin regulates Wnt signaling through down-regulation of beta-catenin. To test the role of Wnt signaling in neuronal differentiation, embryonal carcinoma P19 cells (P19 EC, which can be stimulated to differentiate into a neuron-like phenotype in response to retinoic acid (RA), were used. Reverse transcription-PCR and Western blot analysis showed that Axin is expressed in undifferentiated cells, whereas the level is clearly reduced during RA-induced neuronal differentiation. Interestingly, Axin levels were not reduced during endodermal differentiation of P19 EC cells and F9 EC cells by RA, suggesting that the reduction of the Axin level is a specific property of neuronal differentiation. Western analysis showed that the cytoplasmic level of beta-catenin increased during neuronal differentiation of P19 EC cells. Indirect immunofluorescence with beta-catenin antibody showed that the localization of beta-catenin was changed from membrane in undifferentiated cells to nuclei in neuronal P19 EC cells. Induced expression of Axin during endodermal and early neuronal differentiation, using the Tet-On system, did not block normal differentiation. However, maintenance of the Axin level blocked neuronal differentiation and inhibited expression of a neuron-specific marker protein, betaIII-tubulin. Also, ectopic induction of a beta-catenin signaling inhibitor, ICAT, inhibited expression of betaIII-tubulin. In contrast, addition of Wnt-3A-conditioned medium during the neuronal differentiation period enhanced the expression of betaIII-tubulin. Overall, our data show that Wnt-3a/canonical beta-catenin signaling through the down-regulation of Axin may play an important role in neuronal differentiation.	Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Catholic Univ Korea, Dept Ophthalmol, Seoul 137040, South Korea	University of Seoul; Columbia University; Catholic University of Korea	Jho, EH (corresponding author), Univ Seoul, Dept Life Sci, Seoul 130743, South Korea.			Jho, Eek-hoon/0000-0003-2414-6234				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gao X, 2001, BIOCHEM BIOPH RES CO, V284, P1098, DOI 10.1006/bbrc.2001.5089; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Julius MA, 2000, BIOCHEM BIOPH RES CO, V276, P1162, DOI 10.1006/bbrc.2000.3607; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kusek JC, 2001, BRAIN RES BULL, V54, P187, DOI 10.1016/S0361-9230(00)00447-0; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muroyama Y, 2002, GENE DEV, V16, P548, DOI 10.1101/gad.937102; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1993, DEVELOPMENT, V119, P247; PERRY WL, 1995, GENETICS, V141, P321; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Polakis P, 2000, GENE DEV, V14, P1837; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; Tago K, 2000, GENE DEV, V14, P1741; Tang K, 2002, BIOCHEM BIOPH RES CO, V293, P167, DOI 10.1016/S0006-291X(02)00215-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Willert K, 1999, DEVELOPMENT, V126, P4165; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	63	44	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13487	13495		10.1074/jbc.M300591200	http://dx.doi.org/10.1074/jbc.M300591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569091	hybrid			2022-12-27	WOS:000182189500112
J	Susan-Resiga, D; Nowak, T				Susan-Resiga, D; Nowak, T			The proton transfer step catalyzed by yeast pyruvate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED-FUNCTION-ANALYSIS; STEREOCHEMISTRY; HYDROXYLAMINE; ENOLPYRUVATE; INTERMEDIATE; MECHANISM; SUBSTRATE; ROLES; WATER	The nature of the proton donor to the C-3 of the enolate of pyruvate, the intermediate in the reaction catalyzed by yeast pyruvate kinase, was investigated by site-directed mutagenesis and physical and kinetic analyses. Thr-298 is correctly located to function as the proton donor. T298S and T298A were constructed and purified. Both mutants are catalytically active with a decrease in k(cat) and k(cat)/K-m,K-PEP. Mn2+-activated T298S and T298A do not exhibit homotropic kinetic cooperativity with phosphoenolpyruvate (PEP) in the absence of fructose 1,6-bisphosphate, although PEP binding to enzyme-Mn2+ is cooperative. The pH dependence of k(cat) for T298A indicates the loss of pK(alpha,2) = 6.4-6.9. Thr-298 affects the ionization (pK(alpha) approximate to6.5) responsible for modulation of k(cat). Fluorescence studies show altered dissociation constants of ligands to each enzyme complex upon Thr-298 mutations. The rates of the phosphoryl transfer and proton transfer steps in the pyruvate kinase-catalyzed reaction are altered; pyruvate enolization is affected to a greater extent. Proton inventory studies demonstrate solvent isotope effects on k(cat) and k(cat)/K-m,K-PEP. Fractionation factors are metal-dependent and significantly <1. The data suggest that a water molecule in a water channel is the direct proton donor to enolpyruvate and that Thr-298 affects a late step in catalysis.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Nowak, T (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.		Susan-Resiga@ircm.qc.ca, Delia/O-2548-2017	Susan-Resiga@ircm.qc.ca, Delia/0000-0002-4856-090X	NIDDK NIH HHS [DK 17049] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017049] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; Bollenbach TJ, 1999, BIOCHEMISTRY-US, V38, P9137, DOI 10.1021/bi990690n; Bollenbach TJ, 2001, BIOCHEMISTRY-US, V40, P13088, DOI 10.1021/bi010125w; BOLLENBACH TJ, 1999, THESIS U NOTRE DAME; BURKE RL, 1983, J BIOL CHEM, V258, P2193; CHABEREK S, 1952, J AM CHEM SOC, V74, P5057, DOI 10.1021/ja01140a019; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DOUGHERTY TM, 1985, BIOCHEMISTRY-US, V24, P5870, DOI 10.1021/bi00342a027; FORD SR, 1976, BIOCHIM BIOPHYS ACTA, V438, P119, DOI 10.1016/0005-2744(76)90228-X; GUPTA RK, 1976, BIOCHEMISTRY-US, V15, P2881, DOI 10.1021/bi00658a028; Hishiki T, 2000, J BIOCHEM, V128, P965, DOI 10.1093/oxfordjournals.jbchem.a022848; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KIICK DM, 1991, J AM CHEM SOC, V113, P8499, DOI 10.1021/ja00022a043; KIRSHENBAUM I, 1951, PHYSICAL PROPERTIES; KREAGE AJ, 1964, PURE APPL CHEM, V8, P243; KUO D J, 1979, Journal of the American Chemical Society, V101, P5025, DOI 10.1021/ja00511a037; KUO DJ, 1978, J AM CHEM SOC, V100, P6288, DOI 10.1021/ja00487a084; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LEBLOND DJ, 1976, BIOCHIM BIOPHYS ACTA, V438, P108, DOI 10.1016/0005-2744(76)90227-8; LORIA JP, 1997, THESIS U NOTRE DAME; LUMRY R, 1951, J AM CHEM SOC, V73, P4330, DOI 10.1021/ja01153a090; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6803, DOI 10.1021/bi962870s; MESECAR AM, 1995, THESIS U NOTRE DAME; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; Oprea TI, 1997, P NATL ACAD SCI USA, V94, P2133, DOI 10.1073/pnas.94.6.2133; Rigden DJ, 1999, J MOL BIOL, V291, P615, DOI 10.1006/jmbi.1999.2918; ROBINSON JL, 1972, J BIOL CHEM, V247, P1096; ROSE IA, 1989, BIOCHEMISTRY-US, V28, P9579, DOI 10.1021/bi00451a005; ROSE IA, 1991, BIOCHEMISTRY-US, V30, P722, DOI 10.1021/bi00217a021; ROSE IA, 1960, J BIOL CHEM, V235, P1170; ROSE IA, 1970, J BIOL CHEM, V245, P6052; SEEHOLZER SH, 1991, BIOCHEMISTRY-US, V30, P727, DOI 10.1021/bi00217a022; SHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SWINDELLS JF, 1958, C440 NAT BUR STAND, P5; TEITZ A, 1958, ARCH BIOCHEM BIOPHYS, V78, P477; WEISS PM, 1984, BIOCHEMISTRY-US, V23, P4346, DOI 10.1021/bi00314a015	39	21	22	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12660	12671		10.1074/jbc.M300257200	http://dx.doi.org/10.1074/jbc.M300257200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562754	hybrid			2022-12-27	WOS:000182189500011
J	De Sarno, P; Shestopal, SA; King, TD; Zmijewska, A; Song, L; Jope, RS				De Sarno, P; Shestopal, SA; King, TD; Zmijewska, A; Song, L; Jope, RS			Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; CYCLIN-DEPENDENT KINASES; NEURODEGENERATIVE DISEASES; BAX; DEATH; P53; NEURONS; BRAIN; NEUROTRANSMITTERS; NEUROTOXICITY	The impact of muscarinic receptor stimulation was examined on apoptotic signaling induced by DNA damage, oxidative stress, and mitochondrial impairment. Exposure of human neuroblastoma SH-SY5Y cells to the DNA-damaging agent camptothecin increased p53 levels, activated caspase-3, and caused cell death. Pretreatment with oxotremorine-M, a selective agonist of muscarinic receptors that are expressed endogenously in these cells, did not affect the accumulation of p53 but greatly attenuated caspase-3 activation and protected from cell death to nearly the same extent as treatment with a general caspase inhibitor. Treatment with 50-200 muM H2O2 caused the activation of caspase-3 beginning after 2-3 h, followed by eventual cell death. Oxotremorine-M pretreatment protected cells from H2O2-induced caspase-3 activation and death, and this was equivalent to protection afforded by a caspase inhibitor. Muscarinic receptor stimulation also protected cells from caspase-3 activation induced by exposure to rotenone, a mitochondrial complex 1 inhibitor, but no protection was evident from staurosporine-induced caspase-3 activation. The mechanism of protection afforded by muscarinic receptor activation from camptothecin-induced apoptotic signaling involved blockade of mitochondrial cytochrome c release associated with a bolstering of mitochondrial bcl-2 levels and blockade of the translocation of Bax to mitochondria. Likely the most proximal of these events to muscarinic receptor activation, mitochondrial Bax accumulation, also was attenuated by oxotremorine-M treatment after treatment with H2O2 or rotenone. These results demonstrate that stimulation of muscarinic receptors provides substantial protection from DNA damage, oxidative stress, and mitochondrial impairment, insults that may be encountered by neurons in development, aging, or neurodegenerative diseases. These findings suggest that neurotransmitter-induced signaling bolsters survival mechanisms, and inadequate neurotransmission may exacerbate neuronal loss.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama Birmingham, Dept Psychiat, 1720 7th Ave S,Sparks Ctr 1057, Birmingham, AL 35294 USA.	jope@uab.edu		Shestopal, Svetlana/0000-0003-0725-5885	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021045] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021045] Funding Source: Medline; NIMH NIH HHS [R01 MH038752] Funding Source: Medline; NINDS NIH HHS [R01 NS037768] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; Behl C, 1999, PROG NEUROBIOL, V57, P301, DOI 10.1016/S0301-0082(98)00055-0; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castagne V, 1999, PROG NEUROBIOL, V59, P397, DOI 10.1016/S0301-0082(99)00012-X; Costa LG, 1999, BIOCHEM PHARMACOL, V57, P721, DOI 10.1016/S0006-2952(98)00278-0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Gibson GE, 2002, FRONT BIOSCI, V7, pD1007, DOI 10.2741/gibson; Gottlieb RA, 2000, METHOD ENZYMOL, V322, P213; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Hohmann CF, 1998, PERSPECT DEV NEUROBI, V5, P401; Ikonomidou C, 2001, BIOCHEM PHARMACOL, V62, P401, DOI 10.1016/S0006-2952(01)00696-7; JACKSON GR, 1994, DEV NEUROSCI-BASEL, V16, P285, DOI 10.1159/000112121; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; JOPE RS, 1999, J ALZHEIMERS DIS, V1, P287; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamata H, 1996, NEUROSCI LETT, V212, P179, DOI 10.1016/0304-3940(96)12806-8; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; Krishnamurthy PK, 2000, J NEUROSCI RES, V61, P515, DOI 10.1002/1097-4547(20000901)61:5<515::AID-JNR6>3.0.CO;2-#; LAMBERT DG, 1989, EUR J PHARMACOL, V165, P71, DOI 10.1016/0014-2999(89)90771-1; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Manfredi G, 2000, BRAIN PATHOL, V10, P462; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MATTSON MP, 1997, ALZHEIMERS DIS REV, V2, P1; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nguyen L, 2001, CELL TISSUE RES, V305, P187, DOI 10.1007/s004410000343; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Nomura M, 1999, CANCER RES, V59, P5542; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Xiang H, 1998, J NEUROSCI, V18, P1363; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	60	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11086	11093		10.1074/jbc.M212157200	http://dx.doi.org/10.1074/jbc.M212157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538580	Green Accepted, hybrid			2022-12-27	WOS:000181855400030
J	Menendez, S; Khan, Z; Coomber, DW; Lane, DP; Higgins, M; Koufali, MM; Lain, S				Menendez, S; Khan, Z; Coomber, DW; Lane, DP; Higgins, M; Koufali, MM; Lain, S			Oligomerization of the human ARF tumor suppressor and its response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR-LOCALIZATION; UBIQUITIN LIGASE; NUCLEAR EXPORT; STABILIZES P53; IN-VIVO; MDM2; P19(ARF); P14(ARF); PROTEIN; INHIBITION	The tumor suppressor ARF plays an important role as an inhibitor of the Mdm2-mediated degradation of p53. Here we demonstrate that human ARF (p14ARF) can form homo-oligomers. The stability of the oligomers is favored by oxidizing agents in a reversible fashion and involves all three cysteine residues in p14ARF. Furthermore, the effect of p14ARF in clonogenic assays is moderately but reproducibly increased by the mutation of its cysteine residues. We also observed that altering the amino terminus of p14ARF resulted in the appearance of remarkably stable oligomers. This indicates that the amino terminus of p14ARF interferes with the ability of the protein to form multimeric complexes. These observations suggest that p14ARF activity may be linked to its oligomerization status and sensitive to the redox status of the cell.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Lain, S (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	s.lain@dundee.ac.uk	Lain, Sonia/B-6980-2014; Lane, David P/C-4920-2008	Lain, Sonia/0000-0001-9693-5246; Menendez, Sergio/0000-0002-7929-8641; Lane, David/0000-0003-0551-3545				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; DiGiammarino EL, 2001, BIOCHEMISTRY-US, V40, P2379, DOI 10.1021/bi0024005; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Nasir L, 2000, CANCER LETT, V152, P9, DOI 10.1016/S0304-3835(99)00427-9; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	35	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18720	18729		10.1074/jbc.M211007200	http://dx.doi.org/10.1074/jbc.M211007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12582152	hybrid			2022-12-27	WOS:000182932200004
J	Chen, MC; Hwang, MJ; Chou, YC; Chen, WH; Cheng, GH; Nakano, H; Luh, TY; Mai, SC; Hsieh, SL				Chen, MC; Hwang, MJ; Chou, YC; Chen, WH; Cheng, GH; Nakano, H; Luh, TY; Mai, SC; Hsieh, SL			The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CYTOPLASMIC DOMAIN; ACTIVATION; ASK1; LIGHT; INHIBITOR; PATHWAYS; BINDING; DISSOCIATION	LIGHT (homologous to lymphotoxins, shows inducible expression, and competes with herpes simplex virus glycoprotein D for herpesvirus entry mediator, a receptor expressed by T lymphocytes) is a member of the tumor necrosis factor superfamily that can interact with lym-photoxin-beta receptor (LTbetaR), herpes virus entry mediator, and decoy receptor (DcR3). In our previous study, we showed that LIGHT is able to induce cell death via the non-death domain containing receptor LTbetaR to activate both caspase-dependent and caspase-independent pathway. In this study, a LIGHT mutein, LIGHT-R228E, was shown to exhibit similar binding specificity as wild type LIGHT to LTbetaR, but lose the ability to interact with herpes virus entry mediator. By using both LIGHT-R228E and agonistic anti-LTbetaR monoclonal antibody, we found that signaling triggered by LTbetaR alone is sufficient to activate both caspase-dependent and caspase-independent pathways. Cross-linking of LTbetaR is able to recruit TRAF3 and TRAF5 to activate ASK1, whereas its activity is inhibited by free radical scavenger carboxyfullerenes. The activation of ASK1 is independent of caspase-3 activation, and kinase-inactive ASK1-KE mutant can inhibit LTbetaR-mediated cell death. This suggests that ASK1 is one of the factors involved in the caspase-independent pathway of LTbetaR-induced cell death.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan; Natl Yang Ming Univ, Dept Microbiol & Immunol, Taipei 11221, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Yang Ming Univ, Immunol Res Ctr, Taipei 11221, Taiwan; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Taiwan University; Juntendo University	Hsieh, SL (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan.		Hwang, Ming-jing/E-9210-2012; Hsieh, Shie-Liang Edmond/ABA-9184-2021	Hwang, Ming-jing/0000-0002-9657-5663; Luh, Tien-Yau/0000-0002-0415-6454; Nakano, Hiroyasu/0000-0003-4843-1427				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chang YH, 2002, EXP CELL RES, V278, P166, DOI 10.1006/excr.2002.5573; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen MC, 2000, J BIOL CHEM, V275, P38794, DOI 10.1074/jbc.M003292200; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; FORCE WR, 1995, J IMMUNOL, V155, P5280; Force WR, 2000, J BIOL CHEM, V275, P11121, DOI 10.1074/jbc.275.15.11121; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Koni PA, 1998, J EXP MED, V187, P1977, DOI 10.1084/jem.187.12.1977; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Puglielli MT, 1999, NAT MED, V5, P1370; Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627; Rooney IA, 2000, J BIOL CHEM, V275, P14307, DOI 10.1074/jbc.275.19.14307; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Wu MY, 1997, J BIOL CHEM, V272, P17154, DOI 10.1074/jbc.272.27.17154; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	47	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16073	16081		10.1074/jbc.M208661200	http://dx.doi.org/10.1074/jbc.M208661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12566458	hybrid			2022-12-27	WOS:000182680000079
J	Winklhofer, KF; Heske, J; Heller, U; Reintjes, A; Muranyi, W; Moarefi, I; Tatzelt, J				Winklhofer, KF; Heske, J; Heller, U; Reintjes, A; Muranyi, W; Moarefi, I; Tatzelt, J			Determinants of the in vivo folding of the prion protein - A bipartite function of helix 1 in folding and aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOSYLATION; CEREVISIAE GAS1 PROTEIN; PRP KNOCKOUT MICE; ENDOPLASMIC-RETICULUM; MOLECULAR ANALYSIS; SCRAPIE ISOFORM; ALKALINE-PHOSPHATASE; NEUROBLASTOMA-CELLS; STRAIN VARIATION; CULTURED-CELLS	Misfolding of the mammalian prion protein (PrP) is implicated in the pathogenesis of prion diseases. We analyzed wild type PrP in comparison with different PrP mutants and identified determinants of the in vivo folding pathway of PrP. The complete N terminus of PrP including the putative transmembrane domain and the first beta-strand could be deleted without interfering with PrP maturation. Helix 1, however, turned out to be a major determinant of PrP folding. Disruption of helix 1 prevented attachment of the glycosylphosphatidylinositol (GPI) anchor and the formation of complex N-linked glycans; instead, a high mannose PrP glycoform was secreted into the cell culture supernatant. In the absence of a C-terminal membrane anchor, however, helix 1 induced the formation of unglycosylated and partially protease-resistant PrP aggregates. Moreover, we could show that the C-terminal GPI anchor signal sequence, independent of its role in GPI anchor attachment, mediates core glycosylation of nascent PrP. Interestingly, conversion of high mannose glycans to complex type glycans only occurred when PrP was membrane-anchored. Our study indicates a bipartite function of helix 1 in the maturation and aggregation of PrP and emphasizes a critical role of a membrane anchor in the formation of complex glycosylated PrP.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Univ Munich, Max Von Pettenkofer Inst Virol, Genectr Munich, D-81377 Munich, Germany	Max Planck Society; University of Munich	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de		Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Blochberger TC, 1997, PROTEIN ENG, V10, P1465, DOI 10.1093/protein/10.12.1465; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; Korth C, 2000, J GEN VIROL, V81, P2555, DOI 10.1099/0022-1317-81-10-2555; Kretzschmar HA, 2000, ARCH VIROL, P239; Kuczius T, 1998, J INFECT DIS, V178, P693, DOI 10.1086/515337; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; LOW MG, 1980, BIOCHEMISTRY-US, V19, P3913, DOI 10.1021/bi00558a004; LOWE ME, 1992, J CELL BIOL, V116, P799, DOI 10.1083/jcb.116.3.799; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; MORAN P, 1991, J BIOL CHEM, V266, P1250; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Priola SA, 2001, EMBO J, V20, P6692, DOI 10.1093/emboj/20.23.6692; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zuegg J, 2000, GLYCOBIOLOGY, V10, P959, DOI 10.1093/glycob/10.10.959	66	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14961	14970		10.1074/jbc.M209942200	http://dx.doi.org/10.1074/jbc.M209942200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12556465	hybrid			2022-12-27	WOS:000182516100051
J	Janssen, E; de Groof, A; Wijers, M; Fransen, J; Dzeja, PP; Terzic, A; Wieringa, B				Janssen, E; de Groof, A; Wijers, M; Fransen, J; Dzeja, PP; Terzic, A; Wieringa, B			Adenylate kinase 1 deficiency induces molecular and structural adaptations to support muscle energy metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; CREATINE-KINASE; SKELETAL-MUSCLE; C-MYC; MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; KNOCKOUT HEART; RAT SKELETAL; FIBERS; MICE	Genetic ablation of adenylate kinase 1 (AK1), a member of the AK family of phosphotransfer enzymes, disturbs muscle energetic economy and decreases tolerance to metabolic stress, despite rearrangements in alternative high energy phosphoryl transfer pathways. To define the mechanisms of this adaptive response, soleus and gastrocnemius muscles from AK1(-/-) mice were characterized by cDNA array profiling, Western blot and ultrastructural analysis. We demonstrate that AK1 deficiency induces fiber-type specific variation in groups of transcripts involved in glycolysis and mitochondrial metabolism and in gene products defining structural and myogenic events. This was associated with increased phosphotransfer capacities of the glycolytic enzymes pyruvate kinase and 3-phosphoglycerate kinase. Moreover, in AK1(-/-) mice, fast-twitch gastrocnemius, but not slow-twitch soleus, had an increase in adenine nucleotide translocator (ANT) and mitochondrial creatine kinase protein, along with a doubling of the intermyofibrillar mitochondrial volume. These results provide molecular evidence for wide-scale remodeling in AK1-deficient muscles aimed at preservation of efficient energetic communication between ATP producing and utilizing cellular sites.	Univ Nijmegen, Univ Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Expt Therapeut, Rochester, MN 55905 USA	Radboud University Nijmegen; Mayo Clinic; Mayo Clinic; Mayo Clinic	Wieringa, B (corresponding author), Univ Nijmegen, Univ Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands.		Wijers-Rouw, Mietske/G-4456-2016; Fransen, Jack/E-8924-2010; Wieringa, Berend/A-5346-2011	Fransen, Jack/0000-0002-0571-7639; Wieringa, Berend/0000-0001-9192-8020				Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4; de Groof AJC, 2001, MUSCLE NERVE, V24, P1188, DOI 10.1002/mus.1131; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; GERLACH G, 1986, BIOCHIM BIOPHYS ACTA, V881, P398, DOI 10.1016/0304-4165(86)90032-2; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; KORGE P, 1995, SPORTS MED, V20, P215, DOI 10.2165/00007256-199520040-00002; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Liedtke AJ, 1999, AM J PHYSIOL-HEART C, V277, pH1435, DOI 10.1152/ajpheart.1999.277.4.H1435; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; MATSUURA S, 1989, J BIOL CHEM, V264, P10148; Mazurek S, 1998, ANTICANCER RES, V18, P3275; Merkulova T, 1999, J MUSCLE RES CELL M, V20, P55, DOI 10.1023/A:1005428328913; Merkulova T, 2000, AM J PHYSIOL-ENDOC M, V278, pE330, DOI 10.1152/ajpendo.2000.278.2.E330; MOERLAND TS, 1989, AM J PHYSIOL, V257, pC810, DOI 10.1152/ajpcell.1989.257.4.C810; Murdock DG, 1999, J BIOL CHEM, V274, P14429, DOI 10.1074/jbc.274.20.14429; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pette D, 1999, MUSCLE NERVE, V22, P666, DOI 10.1002/(SICI)1097-4598(199906)22:6<666::AID-MUS3>3.0.CO;2-Z; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; SAVABI F, 1994, MOL CELL BIOCHEM, V133, P145, DOI 10.1007/BF01267953; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Scholz TD, 1998, AM J PHYSIOL-CELL PH, V274, pC780, DOI 10.1152/ajpcell.1998.274.3.C780; Schuster S, 2002, BIOPHYS CHEM, V99, P63, DOI 10.1016/S0301-4622(02)00122-9; Sears PR, 1999, BIOCHEMISTRY-US, V38, P14881, DOI 10.1021/bi991076e; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; St-Amand J, 2001, FASEB J, V15, P684, DOI 10.1096/fj.00-0150com; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; THORSTENSSON A, 1977, ACTA PHYSIOL SCAND, V99, P225, DOI 10.1111/j.1748-1716.1977.tb10373.x; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	52	37	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12937	12945		10.1074/jbc.M211465200	http://dx.doi.org/10.1074/jbc.M211465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562761	Green Published, hybrid			2022-12-27	WOS:000182189500045
J	Lin, AP; McAlister-Henn, L				Lin, AP; McAlister-Henn, L			Homologous binding sites in yeast isocitrate dehydrogenase for cofactor (NAD(+)) and allosteric activator (AMP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; KINETIC-ANALYSIS; COENZYME SITE; PHOSPHORYLATION; SPECIFICITY; SUBUNITS; PROTEIN; ENZYME	Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an allosterically regulated octameric enzyme composed of two types of homologous subunits designated IDH1and IDH2. Based on sequence comparisons and structural models, both subunits are predicted to have adenine nucleotide binding sites. This was tested by alanine replacement of residues in putative sites in each subunit. Targets included adjacent aspartate/isoleucine residues implicated as important for determining cofactor specificity in related dehydrogenases and a residue in each IDH subunit in a position occupied by histidine in other cofactor binding sites. The primary kinetic effects of D286A/I287A and of H281A replacements in IDH2 were found to be a dramatic reduction in apparent affinity of the holoenzyme for NAD(+) and a concomitant reduction in V-max. Ligand binding assays also showed that the H281A mutant enzyme fails to bind NAD(+) under conditions that are saturating for the wild-type enzyme. In contrast, the primary effect of corresponding D279A/ D280A and of R274A replacements in IDH1 is a reduction in holoenzyme binding of AMP, with concomitant alterations in kinetic and isocitrate binding properties normally associated with activation by this allosteric effector. These results suggest that the nucleotide cofactor binding site is primarily contributed by the ID112 subunit, whereas the homologous nucleotide binding site in 1131111 has evolved for regulatory binding of AMP. These results are consistent with previous studies demonstrating that the catalytic isocitrate binding sites are comprised of residues primarily contributed by IDH2, whereas sites for regulatory binding of isocitrate are contributed by analogous residues of IDH1. In this study, we also demonstrate that a prerequisite for holoenzyme binding of NAD(+) is binding of isocitrate/Mg2+ at the IDH2 catalytic site. This is comparable to the dependence of AMP binding upon binding of isocitrate at the IDH1 regulatory site.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NIGMS NIH HHS [GM51265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEAN AM, 1989, J BIOL CHEM, V264, P20482; Doyle SA, 2000, BIOCHEMISTRY-US, V39, P14348, DOI 10.1021/bi001458g; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; Huang YC, 2002, BIOCHEMISTRY-US, V41, P5637, DOI 10.1021/bi0200716; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KORNBERG A, 1951, J BIOL CHEM, V189, P123; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; Lee P, 2002, ARCH BIOCHEM BIOPHYS, V401, P81, DOI 10.1016/S0003-9861(02)00041-3; Lin AP, 2002, J BIOL CHEM, V277, P22475, DOI 10.1074/jbc.M202534200; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; NICHOLS BJ, 1995, BIOCHEM J, V310, P917, DOI 10.1042/bj3100917; NICHOLS BJ, 1993, BIOCHEM J, V295, P347, DOI 10.1042/bj2950347; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; PANISKO EA, 2000, THESIS U TEXAS HLTH; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811	33	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12864	12872		10.1074/jbc.M300154200	http://dx.doi.org/10.1074/jbc.M300154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562755	hybrid			2022-12-27	WOS:000182189500036
J	Sato, Y; Sakaguchi, M; Goshima, S; Nakamura, T; Uozumi, N				Sato, Y; Sakaguchi, M; Goshima, S; Nakamura, T; Uozumi, N			Molecular dissection of the contribution of negatively and positively charged residues in S2, S3, and S4 to the final membrane topology of the voltage sensor in the K+ channel, KAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; ARABIDOPSIS-THALIANA; FUNCTIONAL EXPRESSION; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ION CHANNELS; GUARD-CELLS; SEQUENCE	Voltage-dependent ion channels control changes in ion permeability in response to membrane potential changes. The voltage sensor in channel proteins consists of the highly positively charged segment, S4, and the negatively charged segments, S2 and S3. The process involved in the integration of the protein into the membrane remains to be elucidated. In this study, we used in vitro translation and translocation experiments to evaluate interactions between residues in the voltage sensor of a hyperpolarization-activated potassium channel, KAT1, and their effect on the final topology in the endoplasmic reticulum (ER) membrane. A D95V mutation in S2 showed less S3-S4 integration into the membrane, whereas a D105V mutation allowed S4 to be released into the ER lumen. These results indicate that Asp(95) assists in the membrane insertion of S3-S4 and that Asp(105) helps in preventing S4 from being releasing into the ER lumen. The charge reversal mutation, R171D, in S4 rescued the D105R mutation and prevented S4 release into the ER lumen. A series of constructs containing different C-terminal truncations of S4 showed that Arg 174 was required for correct integration of S3 and S4 into the membrane. Interactions between Asp(105) and Arg 171 and between negative residues in S2 or S3 and Arg 174 may be formed transiently during membrane integration. These data clarify the role of charged residues in S2, S3, and S4 and identify posttranslational electrostatic interactions between charged residues that are required to achieve the correct voltage sensor topology in the ER membrane.	Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; Niigata Univ Pharm & Appl Life Sci, Fac Pharm, Niigata 9502081, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Nagoya University; Nagoya University; Niigata University; Kyushu University	Uozumi, N (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.		Uozumi, Nobuyuki/AAG-3252-2019	Uozumi, Nobuyuki/0000-0003-4268-1126				Ache P, 2000, FEBS LETT, V486, P93, DOI 10.1016/S0014-5793(00)02248-1; Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Basset M, 1995, PLANT MOL BIOL, V29, P947, DOI 10.1007/BF00014968; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; Chin CN, 2002, TRENDS BIOCHEM SCI, V27, P231, DOI 10.1016/S0968-0004(02)02082-0; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; OGATA S, 1989, J BIOL CHEM, V264, P3596; Ota K, 2000, J BIOL CHEM, V275, P29743, DOI 10.1074/jbc.M002468200; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Papazian D M, 1999, Adv Neurol, V79, P481; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; RADRIGUEZNAVARR.A, 2000, BIOCHIM BIOPHYS ACTA, V1469, P1; RIBERA AB, 1993, J NEUROSCI, V13, P4988; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; Schachtman DP, 2000, BBA-BIOMEMBRANES, V1465, P127, DOI 10.1016/S0005-2736(00)00134-6; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; UOZUMI N, 1995, J BIOL CHEM, V270, P24276, DOI 10.1074/jbc.270.41.24276; Uozumi N, 1998, P NATL ACAD SCI USA, V95, P9773, DOI 10.1073/pnas.95.17.9773; Uozumi N, 2001, AM J PHYSIOL-CELL PH, V281, pC733, DOI 10.1152/ajpcell.2001.281.3.C733; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zimmermann S, 1998, PLANT PHYSIOL, V116, P879, DOI 10.1104/pp.116.3.879	44	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13227	13234		10.1074/jbc.M300431200	http://dx.doi.org/10.1074/jbc.M300431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556517	hybrid			2022-12-27	WOS:000182189500081
J	Bache, KG; Raiborg, C; Mehlum, A; Stenmark, H				Bache, KG; Raiborg, C; Mehlum, A; Stenmark, H			STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TRANSDUCING ADAPTER MOLECULE; SRC HOMOLOGY 3; PLASMA-MEMBRANE; MOUSE SKD1; PROTEIN; YEAST; DEGRADATION; CLATHRIN; MUTANTS	STAM1 and STAM2, which have been identified as regulators of receptor signaling and trafficking, interact directly with Hrs, which mediates the endocytic sorting of ubiquitinated membrane proteins. The STAM proteins interact with the same coiled-coil domain that is involved in the targeting of Hrs to endosomes. In this work, we show that STAM1 and STAM2, as well as an endocytic regulator protein, Eps15, can be co-immunoprecipitated with Hrs both from membrane and cytosolic fractions and that recombinant Hrs, STAM1/STAM2, and Eps15 form a ternary complex. We find that overexpression of Hrs causes a strong recruitment of STAM2 to endosome membranes. Moreover, STAM2, like Hrs and Eps15, binds ubiquitin, and Hrs, STAM2, and Eps15 colocalize with ubiquitinated proteins in clathrin-containing endosomal microdomains. The localization of Hrs, STAM2, Eps15, and clathrin to endosome membranes is controlled by the AAA ATPase mVps4, which has been implicated in multivesicular body formation. Depletion of cellular Hrs by small interfering RNA results in a strongly reduced recruitment of STAM2 to endosome membranes and an impaired degradation of endocytosed epidermal growth factor receptors. We propose that Hrs, Eps15, and STAM proteins function in a multivalent complex that sorts ubiquitinated proteins into the multivesicular body pathway.	Norwegian Radium Hosp, Dept Biochem, Inst Canc Res, N-0310 Oslo, Norway	University of Oslo	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, Inst Canc Res, N-0310 Oslo, Norway.	stenmark@ulrik.uio.no	Bache, Kristi G./AAD-9335-2020; Stenmark, Harald/B-8868-2008					Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2002, EUR J BIOCHEM, V269, P3881, DOI 10.1046/j.1432-1033.2002.03046.x; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; BENMERSH A, 2003, J BIOL CHEM, V275, P3288; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Lohi O, 2001, FEBS LETT, V508, P287, DOI 10.1016/S0014-5793(01)03079-4; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, J CELL SCI, V114, P2255; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Scheuring S, 1999, GENE, V234, P149, DOI 10.1016/S0378-1119(99)00163-8; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yamada M, 2002, MOL CELL BIOL, V22, P8648, DOI 10.1128/MCB.22.24.8648-8658.2002; Yamada M, 2001, MOL CELL BIOL, V21, P3807, DOI 10.1128/MCB.21.11.3807-3819.2001; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	64	238	252	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12513	12521		10.1074/jbc.M210843200	http://dx.doi.org/10.1074/jbc.M210843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551915	hybrid			2022-12-27	WOS:000182015700103
J	Ninio, S; Schuldiner, S				Ninio, S; Schuldiner, S			Characterization of an archaeal multidrug transporter with a unique amino acid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BINDING-SITE; ESCHERICHIA-COLI; TRANSMEMBRANE HELICES; EMRE; PROTEINS; OLIGOMER; ENZYMES; EFFLUX; H+	The Smr family of multidrug transporters consists of small membrane proteins that extrude various drugs in exchange with protons rendering cells resistant to these drugs. Smr proteins identified to date have been found only in Eubacteria. In this work we present the cloning and characterization of an Smr protein from the archaeon Halobacterium salinarum, the first Smr in the archaeal kingdom. The protein, named Hsmr, was identified through sequence similarity to the Smr family, and the DNA sequence was cloned into an Escherichia coli expression system. Hsmr is heterologously expressed in a functional form despite the difference in lipid composition of the membrane and the lower salt in the cell and its environment. Cells harboring the Hsmr plasmid transport ethidium bromide in an uncoupler-sensitive process and gain resistance to ethidium bromide and acriflavine. Hsmr binds tetraphenylphosphonium (TPP+) with a relatively low affinity (K-D similar to200 nm) at low salt concentration that increases (K-D similar to40 nm) upon the addition of 2 m of either NaCl or KCl. The Hsmr protein contains many of the signature sequence elements of the Smr family and also a high content of negative residues in the loops, characteristic of extreme halophiles. Strikingly, Hsmr is composed of over 40% valine and alanine residues. These residues are clustered at certain regions of the protein in domains that are not important for activity, as judged from lack of conservation and from previous studies with other Smr proteins. We suggest that this high content of alanine and valine residues is a reflection of a "natural" alanine and valine scanning necessitated by the high GC content of the gene. This phenomenon reveals significant sequence elements in small multidrug transporters.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers SV, 2001, EXTREMOPHILES, V5, P285, DOI 10.1007/s007920100214; Elcock AH, 1998, J MOL BIOL, V280, P731, DOI 10.1006/jmbi.1998.1904; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GUTMAN N, 2003, J BIOL CHEM; Jiang SL, 2000, PROTEINS, V40, P429, DOI 10.1002/1097-0134(20000815)40:3<429::AID-PROT80>3.0.CO;2-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBERT B, 1984, BIOCHEMISTRY-US, V23, P166, DOI 10.1021/bi00296a027; Madern D, 2000, EXTREMOPHILES, V4, P91, DOI 10.1007/s007920050142; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Mevarech M, 2000, BIOPHYS CHEM, V86, P155, DOI 10.1016/S0301-4622(00)00126-5; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Stevens TJ, 2000, PROTEIN SCI, V9, P505; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; van de Vossenberg JLCM, 1998, EXTREMOPHILES, V2, P163, DOI 10.1007/s007920050056; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WATANABE Y, 1991, J BIOCHEM, V110, P40, DOI 10.1093/oxfordjournals.jbchem.a123540; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	30	40	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12000	12005		10.1074/jbc.M213119200	http://dx.doi.org/10.1074/jbc.M213119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551892	hybrid			2022-12-27	WOS:000182015700038
J	Stortelers, C; van der Woning, SP; Jacobs-Oomen, S; Wingens, M; van Zoelen, EJJ				Stortelers, C; van der Woning, SP; Jacobs-Oomen, S; Wingens, M; van Zoelen, EJJ			Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; RECEPTOR; DOMAIN; IDENTIFICATION; REVEALS; SPECIFICITY; RESIDUES; COMPLEX	EGF-like growth factors activate their ErbB receptors by promoting receptor-mediated homodimerization or, alternatively, by the formation of heterodimers with the orphan ErbB-2 through an as yet unknown mechanism. To investigate the selectivity in dimer formation by ligands, we have applied the phage display approach to obtain ligands with modified C-terminal residues that discriminate between ErbB-2 and ErbB-3 as dimerization partners. We used the epidermal growth factor/ transforming growth factor a chimera T1E as the template molecule because it binds to ErbB-3 homodimers with low affinity and to ErbB-2/ErbB-3 heterodimers with high affinity. Many phage variants were selected with enhanced binding affinity for ErbB-3 homodimers, indicating that C-terminal residues contribute to the interaction with ErbB-3. These variants were also potent ligands for ErbB-2/ErbB-3 heterodimers despite negative selection for such heterodimers. In contrast, phage variants positively selected for binding to ErbB-2/ErbB-3 heterodimers but negatively selected for binding to ErbB-3 homodimers can be considered as "second best" ErbB-3 binders, which require ErbB-2 heterodimerization for stable complex formation. Our findings imply that epidermal growth factor-like ligands bind ErbB-3 through a multi-domain interaction involving at least both linear endings of the ligand. Apparently the ErbB-3 affinity of a ligand determines whether it can form only ErbB-2/ErbB-3 complexes or also ErbB-3 homodimers. Because no separate binding domain for ErbB-2 could be identified, our data support a model in which ErbB heterodimerization occurs through a receptor-mediated mechanism and not through bivalent ligands.	Catholic Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	van Zoelen, EJJ (corresponding author), Catholic Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	vzoelen@sci.kun.nl	van Zoelen, Everardus J./D-9192-2012					ALIMANDI M, 1995, ONCOGENE, V10, P1813; Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harris A, 1998, BIOCHEM BIOPH RES CO, V251, P220, DOI 10.1006/bbrc.1998.9436; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kim JH, 2002, EUR J BIOCHEM, V269, P2323, DOI 10.1046/j.1432-1033.2002.02877.x; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Singer E, 2001, J BIOL CHEM, V276, P44266, DOI 10.1074/jbc.M105428200; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Souriau C, 1997, NUCLEIC ACIDS RES, V25, P1585, DOI 10.1093/nar/25.8.1585; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P8732, DOI 10.1021/bi025878c; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P4292, DOI 10.1021/bi012016n; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Whoriskey JS, 1998, GROWTH FACTORS, V15, P307, DOI 10.3109/08977199809017485; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	41	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12055	12063		10.1074/jbc.M211948200	http://dx.doi.org/10.1074/jbc.M211948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556529	Green Published, hybrid			2022-12-27	WOS:000182015700045
J	Ungefroren, H; Lenschow, W; Chen, WB; Faendrich, F; Kalthoff, H				Ungefroren, H; Lenschow, W; Chen, WB; Faendrich, F; Kalthoff, H			Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein kinase signaling downstream of smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; TGF-BETA; MESENCHYMAL TRANSDIFFERENTIATION; PANCREATIC-CANCER; INDUCED APOPTOSIS; PATHWAY; CELLS; PROTEOGLYCANS; TRANSDUCTION; FAMILY	Several signaling pathways have been implicated in mediating TGF-beta1-induced extracellular matrix production and fibrosis. We have shown recently that induction of biglycan (BGN) expression by TGF-beta1 depended on a functional Smad pathway (Chen, W.-B., Lenschow, W., Tiede, K., Fischer, J. W., Kalthoff, H., and Ungefroren, H. (2002) J. Biol. Chem. 277,36118-36128). Here, we present evidence that the ability of TGF-beta1 to induce BGN mRNA, in addition to Smads, requires p38 MAPK signaling, because 1) pharmacological inhibitors of p38 dose-dependently inhibited the TGF-beta effect without significantly affecting the transcriptional activity of a constitutively active mutant of the TGF-beta type I receptor or Smad2 phosphorylation at concentrations up to 10 pas, 2) the up-regulation of BGN mRNA was preceded by a delayed increase in the phosphorylation of p38 and its upstream activator MKK6 in TGF-beta1-treated PANC-1 cells, 3) inhibition of the p38 pathway by stable retroviral transduction with a dominant negative mutant of either p38 or MKK6 reduced TGF-beta1-induced BGN mRNA expression, and 4) overexpression of wild-type p38 or MKK6, but not MKK3, augmented the TGF-beta1 effect on BGN mRNA. We further demonstrate that the (delayed) p38 activation by TGF-beta1 is downstream of Smads and requires a functional Smad pathway, because blocking TGF-beta-induced p38 activity with SB202190 had no effect on Smad2 phosphorylation, but blocking Smad signaling by forced expression of Smad7 abolished TGF-beta1 induction of p38 activation and, as shown earlier, BGN mRNA expression; finally, re-expression of Smad4 in Smad4-null CFPAC-1 cells restored TGF-beta-induced p38 phosphorylation and, as demonstrated previously, BGN mRNA accumulation. These results clearly show that TGF-beta1 induction of BGN expression in pancreatic cells requires activation of MKK6-p38 MAPK signaling downstream of Smad signaling and provide a mechanistic clue to the up-regulation of BGN seen in inflammatory response-related fibrosis and desmoplasia.	Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, D-24105 Kiel, Germany	University of Kiel	Ungefroren, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, Arnold-Heller Str 7, D-24105 Kiel, Germany.	hungefroren@email.uni-kiel.de	Faendrich, Fred/B-1705-2010; Kalthoff, Holger/B-1618-2010					Behr TM, 2001, CIRCULATION, V104, P1292, DOI 10.1161/hc3601.094275; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Ellenrieder V, 2001, CANCER RES, V61, P4222; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocking AM, 1998, MATRIX BIOL, V17, P1; Howard BD, 2000, CANCER GENE THER, V7, P927, DOI 10.1038/sj.cgt.7700180; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Johansson N, 2000, J CELL SCI, V113, P227; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, J CELL SCI, V112, P4557; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Simeone DM, 2001, AM J PHYSIOL-CELL PH, V281, pC311, DOI 10.1152/ajpcell.2001.281.1.C311; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	62	54	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11041	11049		10.1074/jbc.M300035200	http://dx.doi.org/10.1074/jbc.M300035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538652	hybrid			2022-12-27	WOS:000181855400024
J	Wang, ZQ; Zhang, BC; Wang, MF; Carr, BI				Wang, ZQ; Zhang, BC; Wang, MF; Carr, BI			Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90(RSK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR; PC12 CELLS; TYROSINE PHOSPHORYLATION; KINASE ACTIVATION; COMPLEX-FORMATION; K-VITAMIN; INHIBITION; PATHWAY; CBP	Compound 5 (Cpd 5) or 2-(2-mercaptoethanol)-3-methyl-1,4-naphthoquinone, is an inhibitor of protein phosphatase Cdc25A and causes persistent activation of extracellular signal-regulated kinase (ERK) and cell growth inhibition. To study the mechanism(s) by which persistent ERK phosphorylation might induce cell growth inhibition, we used Cpd 5 as a tool to examine its effects on the activity of CREB (CAMP response element-binding protein) transcription factor in Hep3B human hepatoma cells. We found that CREB activity, including its DNA binding ability and phosphorylation on residue Ser-133, was strongly inhibited by Cpd 5, followed by suppression of CRE-mediated transcription of cyclin D1 and Bcl-2 genes. Cpd 5-mediated suppression of CREB phosphorylation and transcriptional activity was antagonized by mitogen-activated protein kinase kinase inhibitors PD 98059 and U-0126, implying that this inhibition of CREB activity was regulated at least in part by the ERK pathway. The phosphorylation of ribosomal S6 kinase (pp90(RSK)), a CREB kinase in response to mitogen stimulation, was also found to be inhibited by Cpd 5 action. This inhibition of pp90RSK phosphorylation is likely the result of its increased association with CREB-binding protein (CBP), which subsequently caused inhibition of CREB phosphorylation and activity. To support the hypothesis that Cpd 5 effects on Cdc25A inhibition with subsequent ERK activation could cause CREB inhibition, we examined the effects of Cdc25A inhibition without the use of Cpd 5. Hep3B cells were transfected with C430S Cdc25A mutant, and ERK was found to be phosphorylated in a constitutively activated manner, which was accompanied by decreased CREB phosphorylation and increased recruitment of CBP to pp90RSK. These data provide evidence that CBP-RSK complex formation in response to persistent ERK phosphorylation by Cpd 5 down-regulates CREB activity, leading to inhibition of both cAMP response element-mediated gene expression and cell growth.	Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg,Liver Canc Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Carr, BI (corresponding author), Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg,Liver Canc Ctr, E 1552 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.			Carr, Brian/0000-0002-6111-5077				Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Carr BI, 2003, J MOL BIOL, V326, P721, DOI 10.1016/S0022-2836(02)01445-6; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAVIS RJ, 1993, J BIOL CHEM, V268, P14533; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ni RZ, 1998, J BIOL CHEM, V273, P9906, DOI 10.1074/jbc.273.16.9906; Osada S, 2001, J MOL BIOL, V314, P765, DOI 10.1006/jmbi.2001.5171; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Parker D, 1996, MOL CELL BIOL, V16, P694; PAWSON AJ, 1997, ADV ONCOL, V13, P3; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Vogt A, 2001, J BIOL CHEM, V276, P20544, DOI 10.1074/jbc.M100078200; Wang ZQ, 2000, J CELL PHYSIOL, V183, P338, DOI 10.1002/(SICI)1097-4652(200006)183:3<338::AID-JCP6>3.0.CO;2-X; Wang ZQ, 2002, J HEPATOL, V36, P85, DOI 10.1016/S0168-8278(01)00230-6; Xia K, 1999, MOL CELL BIOL, V19, P4819; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7	44	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11138	11144		10.1074/jbc.M209108200	http://dx.doi.org/10.1074/jbc.M209108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540838	hybrid			2022-12-27	WOS:000181855400037
J	Richards, MR; Listenberger, LL; Kelly, AA; Lewis, SE; Ory, DS; Schaffer, JE				Richards, MR; Listenberger, LL; Kelly, AA; Lewis, SE; Ory, DS; Schaffer, JE			Oligomerization of the murine fatty acid transport protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; EXPRESSION CLONING; SACCHAROMYCES-CEREVISIAE; BINDING; CDNA	The 63-kDa murine fatty acid transport protein 1 (FATP1) was cloned on the basis of its ability to augment fatty acid import when overexpressed in mammalian cells. The membrane topology of this integral plasma membrane protein does not resemble that of polytopic membrane transporters for other substrates. Western blot analysis of 3T3-L1 adipocytes that natively express FATP1 demonstrate a prominent 130-kDa species as well as the expected 63-kDa FATP1, suggesting that this protein may participate in a cell surface transport protein complex. To test whether FATP1 is capable of oligomerization, we expressed functional FATP1 molecules with different amino- or carboxyl-terminal epitope tags in fibroblasts. These epitope-tagged proteins also form apparent higher molecular weight species. We show that, when expressed in the same cells, differentially tagged FATP1 proteins co-immunoprecipitate. The region between amino acid residues 191 and 475 is sufficient for association of differentially tagged truncated FATP1 constructs. When wild type FATP1 and the non-functional s250a FATP1 mutant are co-expressed in COS7 cells, mutant FATP1 has dominant inhibitory function in fatty acid uptake assays. Taken together, these results are consistent with a model in which FATP1 homodimeric complexes play an important role in cellular fatty acid import.	Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Schaffer, JE (corresponding author), Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Internal Med, 660 S Euclid Ave,Box 8086, St Louis, MO 63110 USA.	jschaff@im.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07275] Funding Source: Medline; NIDDK NIH HHS [DK54268] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; Gargiulo CE, 1999, J LIPID RES, V40, P881; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Schaffer JE, 2002, AM J PHYSIOL-ENDOC M, V282, pE239, DOI 10.1152/ajpendo.00462.2001; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Stump DD, 2001, J LIPID RES, V42, P509; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	25	33	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10477	10483		10.1074/jbc.M212469200	http://dx.doi.org/10.1074/jbc.M212469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533547	hybrid			2022-12-27	WOS:000181777500065
J	MacDiarmid, CW; Milanick, MA; Eide, DJ				MacDiarmid, CW; Milanick, MA; Eide, DJ			Induction of the ZRC1 metal tolerance gene in zinc-limited yeast confers resistance to zinc shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZAP1 TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; TRANSPORT-SYSTEM; EXPRESSION; HOMEOSTASIS; IRON; ACCUMULATION; ARABIDOPSIS; ENDOCYTOSIS; SENSITIVITY	Zinc is an essential nutrient but toxic to cells with overaccumulation. For this reason, intracellular zinc levels are tightly controlled. In the yeast Saccharomyces cerevisiae, the Zrc1 and Cot1 proteins have been implicated in the storage and detoxification of excess zinc in the vacuole. Surprisingly, transcription of ZRC1 is induced in zinc-limited cells by the zinc-responsive transcription factor Zap1. We show here that this increase in ZRC1 expression is a novel mechanism of zinc homeostasis and stress tolerance. Zinc-limited cells also express high levels of the plasma membrane zinc uptake transporters. As a consequence, when zinc-limited cells are resupplied with small amounts of zinc, large quantities quickly accumulate in the cell, a condition we refer to as "zinc shock." We show here that ZRC1 and its induction in zinc-limited cells are required for resistance to this zinc shock. Experiments using the zinc-responsive fluorophore FuraZin-1 as an indicator of vacuolar zinc levels indicated that Zrc1 is required for the rapid transport of zinc into the vacuole during zinc shock. We also present evidence that cytosolic zinc rises to higher levels in cells unable to sequester this excess zinc. Thus, the increase in ZRC1 expression occurs prior to the zinc shock stress for which this induction is important. We propose that this "proactive" strategy of homeostatic regulation, such as we document here for ZRC1, may represent a common but largely unrecognized phenomenon.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Physiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.		MacDiarmid, Colin/AAV-5920-2021	MacDiarmid, Colin/0000-0001-8578-5756	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37512] Funding Source: Medline; NIGMS NIH HHS [GM56285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Cheng CL, 1998, J NEUROCHEM, V71, P2401; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MacDiarmid CW, 2002, J BIOL CHEM, V277, P39187, DOI 10.1074/jbc.M205052200; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Ragozzino D, 2000, J PHYSIOL-LONDON, V529, P83, DOI 10.1111/j.1469-7793.2000.00083.x; Sherman F., 1986, METHODS YEAST GENETI; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; STEIN WD, 1990, CHANNELS CARRIERS PU, P199; Vagabov VM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P349; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Wunderli-Ye H, 1999, ADV EXP MED BIOL, V448, P255; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	37	134	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15065	15072		10.1074/jbc.M300568200	http://dx.doi.org/10.1074/jbc.M300568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12556516	hybrid			2022-12-27	WOS:000182516100064
J	Morales, JC; Xia, ZF; Lu, T; Aldrich, MB; Wang, B; Rosales, C; Kellems, RE; Hittelman, WN; Elledge, SJ; Carpenter, PB				Morales, JC; Xia, ZF; Lu, T; Aldrich, MB; Wang, B; Rosales, C; Kellems, RE; Hittelman, WN; Elledge, SJ; Carpenter, PB			Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; PHOSPHORYLATION; REPAIR; CHECKPOINTS; INSTABILITY; COMPONENT; COMPLEX; GENES; ATM	p53-binding protein-1 (53BP1) is phosphorylated in response to DNA damage and rapidly relocalizes to presumptive sites of DNA damage along with Mrell and the phosphorylated histone 2A variant, gamma-H2AX. 53BP1 associates with the BRCA1 tumor suppressor, and knockdown experiments with small interfering RNA have revealed a role for the protein in the checkpoint response to DNA damage. By generating mice defective in m53BP1 (m53BP1(tr/tr)), we have created an animal model to further explore its biochemical and genetic roles in vivo. We find that m53BP1(tr/tr) animals are growth-retarded and show various immune deficiencies including a specific reduction in thymus size and T cell count. Consistent with a role in responding to DNA damage, we find that m53BP1(tr/tr) mice are sensitive to ionizing radiation (gamma-IR), and cells from these animals exhibit chromosomal abnormalities consistent with defects in DNA repair. Thus, 53BP1 is a critical element in the DNA damage response and plays an integral role in maintaining genomic stability.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Mars Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Carpenter, PB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	Phillip.B.Carpenter@uth.tmc.edu		Morales, Julio/0000-0002-0854-7866	NCI NIH HHS [5P30 CA16672] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM65812-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM065812, R01GM065812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Jullien D, 2002, J CELL SCI, V115, P71; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang Y, 2000, GENE DEV, V14, P927; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	30	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14971	14977		10.1074/jbc.M212484200	http://dx.doi.org/10.1074/jbc.M212484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578828	hybrid			2022-12-27	WOS:000182516100052
J	Chilkova, O; Jonsson, BH; Johansson, E				Chilkova, O; Jonsson, BH; Johansson, E			The quaternary structure of DNA polymerase epsilon from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK; CHROMOSOMAL DNA; POL-EPSILON; S-PHASE; DELTA; YEAST; SUBUNIT; PURIFICATION; REPLISOME; STRANDS	DNA polymerase epsilon (Pol epsilon) from Saccharomyces cerevisiae consists of four subunits (Pol2, Dpb2, Dpb3, and Dpb4) and is essential for chromosomal DNA replication. Biochemical characterizations of Pol E have been cumbersome due to protease sensitivity and the limited amounts of Pol E in cells. We have developed a protocol for overexpression and purification of Pol E from S. cerevisiae. The native four-subunit complex was purified to homogeneity by conventional chromatography. Pol E was characterized biochemically by sedimentation velocity experiments and gel filtration experiments. The stoichiometry of the four subunits was estimated to be 1:1:1:1 from colloidal Coomassie-stained gels. Based on the sedimentation coefficient (11.9 S) and the Stokes radius (74.5 Angstrom), a molecular mass for Pol epsilon of 371 kDa was calculated, in good agreement with the calculated molecular mass of 379 kDa for a heterotetramer. Furthermore, analytical equilibrium ultracentrifugation experiments support the proposed heterotetrameric structure of Pol epsilon. Thus, both DNA polymerase 5 and Pol E are purified as monomeric complexes, in agreement with accumulating evidence that Pol delta and Pol epsilon are located on opposite strands of the eukaryotic replication fork.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden; Linkoping Univ, Dept Phys & Measurement Technol Mol Biotechnol, SE-58183 Linkoping, Sweden	Umea University; Linkoping University	Johansson, E (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	erik.johansson@medchem.umu.se		Johansson, Erik/0000-0002-8526-6224; Shilkova, Olga/0000-0001-8607-4008				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Bermudez VP, 2002, J BIOL CHEM, V277, P36853, DOI 10.1074/jbc.M202897200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; Burgers PMJ, 1995, METHOD ENZYMOL, V262, P49; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CHANCE B, 1950, BIOCHEM J, V46, P402, DOI 10.1042/bj0460402; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Dua R, 2002, J BIOL CHEM, V277, P7889, DOI 10.1074/jbc.M108546200; Falaschi A, 2000, TRENDS GENET, V16, P88, DOI 10.1016/S0168-9525(99)01917-4; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Johansson E, 2001, J BIOL CHEM, V276, P43824, DOI 10.1074/jbc.M108842200; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kawasaki Y, 2001, MOL CELLS, V12, P277; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Liu W, 2000, NUCLEIC ACIDS RES, V28, P4180, DOI 10.1093/nar/28.21.4180; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; Shcherbakova PV, 1996, GENETICS, V142, P717; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	31	53	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14082	14086		10.1074/jbc.M211818200	http://dx.doi.org/10.1074/jbc.M211818200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571237	hybrid			2022-12-27	WOS:000182405000068
J	Tincu, JA; Menzel, LP; Azimov, R; Sands, J; Hong, T; Waring, AJ; Taylor, SW; Lehrer, RI				Tincu, JA; Menzel, LP; Azimov, R; Sands, J; Hong, T; Waring, AJ; Taylor, SW; Lehrer, RI			Plicatamide, an antimicrobial octapeptide from Styela plicata Hemocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL 3,4-DIHYDROXYPHENYLALANINE; ERYTHROCYTE-MEMBRANES; AEROMONAS-HYDROPHILA; TYROSINE KINASE; BACTERIA; PHOSPHORYLATION; PHENOLOXIDASE; POLYPEPTIDES; DERIVATIVES; NEUTROPHILS	Plicatamide (Phe-Phe-His-Leu-His-Phe-His-dcDeltaDOPA), where dcDeltaDOPA represents decarboxy-(E)-alpha,beta-dehydro-3,4-dihydroxyphenylalanine, is a potently antimicrobial octapeptide from the blood cells of the solitary tunicate, Styela plicata. Wild type and methicillin-resistant Staphylococcus aureus (MRSA) responded to plicatamide exposure with a massive potassium efflux that began within seconds. Soon thereafter, treated bacteria largely ceased consuming oxygen, and most became nonviable. Native plicatamide also formed cation-selective channels in model lipid bilayers composed of bacterial lipids. Methicillin-resistant S. aureus treated with plicatamide for 5 min contained prominent mesosomes as well as multiple, small dome-shaped surface protrusions that suggested the involvement of osmotic forces in its antimicrobial effects. To ascertain the contribution of the C-terminal dcDeltaDOPA residue to antimicrobial activity, we synthesized several analogues of plicatamide that lacked it. One of these peptides, PL-101 (Phe-Phe-His-Leu-His-Phe-His-Tyr-amide), closely resembled native plicatamide in its antimicrobial activity and its ability to induce potassium efflux. Plicatamide was potently hemolytic for human red blood cells but did not lyse ovine erythrocytes. The small size, rapid action, and potent anti-staphylococcal activity of plicatamide and PL-101 make them intriguing subjects for future antimicrobial peptide design.	Univ Calif Los Angeles, Ctr Hlth Sci, Dept Med, Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pediat, Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego; Scripps Institution of Oceanography	Lehrer, RI (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Dept Med, Mol Biol Inst, 10833 LeConte Ave, Los Angeles, CA 90095 USA.		Menzel, Lorenzo/C-4179-2013	Menzel, Lorenzo/0000-0001-6974-5375				AZUMI K, 1990, EXPERIENTIA, V46, P1066, DOI 10.1007/BF01940675; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BAGELLA L, 1995, FEBS LETT, V376, P225, DOI 10.1016/0014-5793(95)01285-3; Ballarin L, 1998, DEV COMP IMMUNOL, V22, P479, DOI 10.1016/S0145-305X(98)00035-4; Bellm L, 2000, EXPERT OPIN INV DRUG, V9, P1731, DOI 10.1517/13543784.9.8.1731; BETTICHER DC, 1989, COMP BIOCHEM PHYS A, V93, P429, DOI 10.1016/0300-9629(89)90061-3; Craig AG, 2001, J AM SOC MASS SPECTR, V12, P470, DOI 10.1016/S1044-0305(01)00229-X; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Ganz T, 1997, Curr Opin Hematol, V4, P53; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hata S, 1998, COMP BIOCHEM PHYS B, V119, P769, DOI 10.1016/S0305-0491(98)00054-6; Hijikata M, 1999, FEBS LETT, V457, P405, DOI 10.1016/S0014-5793(99)01077-7; Karupiah G, 2000, Rev Immunogenet, V2, P387; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Leem JY, 1996, J BIOL CHEM, V271, P13573, DOI 10.1074/jbc.271.23.13573; Leem JY, 1998, BIOL PHARM BULL, V21, P784, DOI 10.1248/bpb.21.784; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Malabarba A, 2001, CURR MED CHEM, V8, P1759, DOI 10.2174/0929867013371716; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; Mirzabekov T A, 1999, Methods Enzymol, V294, P661; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; National Committee for Clinical Laboratory Standards, 1993, METH DIL ANT SUSC TE; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; NouriSorkhabi MH, 1996, LIPIDS, V31, P765, DOI 10.1007/BF02522893; NouriSorkhabi MH, 1996, COMP BIOCHEM PHYS B, V113, P221, DOI 10.1016/0305-0491(95)02011-X; Orlov D., 2001, Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, V41, P99; Orlov DS, 2002, J MICROBIOL METH, V49, P325, DOI 10.1016/S0167-7012(01)00383-9; ROMEO D, 1988, J BIOL CHEM, V263, P9573; RZEPECKI LM, 1991, ARCH BIOCHEM BIOPHYS, V285, P17, DOI 10.1016/0003-9861(91)90323-B; Sai KP, 2001, J BIOL CHEM, V276, P2701, DOI 10.1074/jbc.M006615200; Saiman L, 2001, ANTIMICROB AGENTS CH, V45, P2838, DOI 10.1128/AAC.45.10.2838-2844.2001; SALVIOLI G, 1993, LIPIDS, V28, P999, DOI 10.1007/BF02537121; Schibli DJ, 1999, BIOCHEMISTRY-US, V38, P16749, DOI 10.1021/bi990701c; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Taylor SW, 2002, ANAL BIOCHEM, V302, P70, DOI 10.1006/abio.2001.5522; TAYLOR SW, 1991, J NAT PROD, V54, P918, DOI 10.1021/np50075a034; Tincu JA, 2000, BIOCHEM BIOPH RES CO, V270, P421, DOI 10.1006/bbrc.2000.2449; Tossi A, 2000, BIOPOLYMERS, V55, P4; VALET G, 1978, J CELL PHYSIOL, V94, P215, DOI 10.1002/jcp.1040940211; Waite JH, 1999, ANN NY ACAD SCI, V875, P301, DOI 10.1111/j.1749-6632.1999.tb08513.x; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1991, MOL MICROBIOL, V5, P2745, DOI 10.1111/j.1365-2958.1991.tb01983.x; Zheng ZB, 1999, CHEM PHARM BULL, V47, P136	48	62	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13546	13553		10.1074/jbc.M211332200	http://dx.doi.org/10.1074/jbc.M211332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569105	hybrid			2022-12-27	WOS:000182189500119
J	Dehaye, JP; Nagy, A; Premkumar, A; Turner, RJ				Dehaye, JP; Nagy, A; Premkumar, A; Turner, RJ			Identification of a functionally important conformation-sensitive region of the secretory Na+-K+-2Cl(-) cotransporter (NKCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; CHLORIDE COTRANSPORT; BUMETANIDE BINDING; ION-TRANSPORT; CHANNEL; PHOSPHORYLATION; ACCESSIBILITY; TOPOLOGY; DOMAINS	The secretory Na+-K+-2Cl(-) cotransporter (NKCC1) is a member of a small gene family of electroneutral salt transporters that play essential roles in salt and water homeostasis in many mammalian tissues. We have identified a highly conserved residue (Ala-483) in the sixth membrane-spanning segment of rat NKCC1 that when mutated to cysteine renders the transporter sensitive to inhibition by the sulfhydryl reagents 2-aminoethyl methanethiosulfonate (MTSEA) and 2-(trimethylammonium)ethyl methanethiosulfonate (MTSET). The mutation of Ala-483 to cysteine (A483C) results in little or no change in the affinities of NKCC1 for substrate ions but produces a 6-fold increase in sensitivity to the inhibitor bumetanide, suggesting a specific modification of the bumetanide binding site. When residues surrounding Ala-483 were mutated to cysteine, only 1484C was sensitive to inhibition by MTSEA and MTSET. Surprisingly 1484C showed increased transport activity in the presence of low concentrations of mercury (1-10 mum), whereas A483C showed inhibition. The inhibition of A483C by MTSEA was unaffected by the presence or absence of sodium and potassium but required the presence of extracellular chloride. Taken together, our results indicate that Ala-483 lies at or near an important functional site of NKCC1 and that the exposure of this site to the extracellular medium is dependent on the conformation of the transporter. Specifically, our results indicate that the cysteine introduced at residue 483 is only available for interaction with MTSEA when chloride is bound to NKCC1 at the extracellular surface.	NIDCR, Gene Therapy & Therapeut Branch, Membrane Biol Sect, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA; Free Univ Brussels, Inst Pharm, Lab Biochim & Biol Cellulaire, B-1050 Brussels, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Turner, RJ (corresponding author), NIDCR, Gene Therapy & Therapeut Branch, Membrane Biol Sect, Dept Hlth & Human Serv,NIH, Bldg 10,Rm 1A01,10 Ctr Dr,MSC 1190, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; LYTLE C, 2002, AM J PHYSIOL, V43, pC299; Moore-Hoon ML, 1998, EUR J MORPHOL, V36, P137; Moore-Hoon ML, 2000, BIOCHEMISTRY-US, V39, P3718, DOI 10.1021/bi992301v; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252	19	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11811	11817		10.1074/jbc.M213148200	http://dx.doi.org/10.1074/jbc.M213148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556450	hybrid			2022-12-27	WOS:000182015700013
J	Dirac, AMG; Bernards, R				Dirac, AMG; Bernards, R			Reversal of senescence in mouse fibroblasts through lentiviral in suppression of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR SENESCENCE; TELOMERASE ACTIVITY; G(1) CONTROL; CELLS; IMMORTALIZATION; P16(INK4A); P19(ARF); CULTURE; MICE; RB	Senescence is generally defined as an irreversible state of G(1) cell cycle arrest in which cells are refractory to growth factor stimulation. In mouse embryo fibroblasts (MEFs), induction of senescence requires the presence of P19(ARF) and p53, as genetic ablation of either of these genes allows escape from senescence and leads to immortalization. We have developed a lentiviral vector that directs the synthesis of a p53-specific short hairpin transcript, which mediates stable suppression of p53 expression through RNA interference. We show that suppression of p53 expression in senescent MEFs leads to rapid cell cycle re-entry, is associated with loss of expression of senescence-associated genes, and leads to immortalization. These data indicate that senescence in MEFs is reversible and demonstrate that both initiation and maintenance of senescence is p53-dependent.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				Bacchetti S, 1996, SEMIN CELL DEV BIOL, V7, P31, DOI 10.1006/scdb.1996.0006; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SAITO H, 1995, EXP CELL RES, V217, P272, DOI 10.1006/excr.1995.1087; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	34	171	183	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11731	11734		10.1074/jbc.C300023200	http://dx.doi.org/10.1074/jbc.C300023200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551891	hybrid, Green Published			2022-12-27	WOS:000182015700002
J	Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M				Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M			Mutations of Arg(440) and Gly(455)/Gly(456) oppositely change pH sensing of Na+/H+ exchanger 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN HOMOLOGOUS PROTEIN; NA-H EXCHANGE; ESCHERICHIA-COLI; GROWTH-FACTOR; TRANSMEMBRANE HELIX; RANDOM MUTAGENESIS; ANTIPORTER NHAA; POINT MUTATION; NHE1; MEMBRANE	To identify important amino acid residues involved in intracellular pH (pH(i)) sensing of Na+/H+ exchanger 1, we produced single-residue substitution mutants in the region of the exchanger encompassing the putative 11 th transmembrane segment (TM11) and its adjacent intracellular (intracellular loop (IL) 5) and extracellular loops (extracellular loop 6). Substitution of Arg(440) in IL5 with other residues except positively charged Lys caused a large shift in pHi dependence of Na-22(+) uptake to an acidic side, whereas substitution of Gly(455) or Gly(456) within the highly conserved glycine-rich sequence of TM11 shifted pHi dependence to an alkaline side. The observed alkaline shift was larger with substitution of Gly(455) with residues with increasing sizes, suggesting the involvement of the steric effect. Interestingly, mutation of Arg440 (114401)) abolished the ATP depletion-induced acidic shift in pHi dependence of Na-22(+) uptake as well as the cytoplasmic alkalinization induced by various extracellular stimuli, whereas with that of Gly455 (G455Q) these functions were preserved. These mutant exchangers did not alter apparent affinities for extracellular transport substrates Na+ and H+ and the inhibitor 5-(N-ethyl-N-isopropyl)amiloride. These results suggest that positive charge at Arg440 is required for normal pHi sensing, whereas mutation-induced perturbation of the TM11 structure may be involved in the effects of Gly mutations. Thus, both Arg(440) in IL5 and Gly residues in the conserved segment of TM11 appear to constitute important elements for proper functioning of the putative "pH(i) sensor" of Na+/H+ exchanger 1.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishirodai 5-7-1, Suita, Osaka 5658565, Japan.	wak@ri.ncvc.go.jp						Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; CASSEL D, 1986, J BIOL CHEM, V261, P5460; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Khadilkar A, 2001, J BIOL CHEM, V276, P43792, DOI 10.1074/jbc.M106659200; Kobayashi Y, 2000, PFLUG ARCH EUR J PHY, V439, P455, DOI 10.1007/s004240050963; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Miyazaki E, 2001, J BIOL CHEM, V276, P49221, DOI 10.1074/jbc.M106267200; NAKAMURA T, 1995, BBA-BIOENERGETICS, V1230, P170, DOI 10.1016/0005-2728(95)00053-L; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 2000, FEBS LETT, V487, P257, DOI 10.1016/S0014-5793(00)02348-6; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; Yan WH, 2001, J BIOL CHEM, V276, P31349, DOI 10.1074/jbc.M102679200; YUN CHC, 1995, P NATL ACAD SCI USA, V92, P10723, DOI 10.1073/pnas.92.23.10723; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	44	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11828	11835		10.1074/jbc.M213243200	http://dx.doi.org/10.1074/jbc.M213243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12562776	hybrid			2022-12-27	WOS:000182015700015
J	Alvestad, RM; Grosshans, DR; Coultrap, SJ; Nakazawa, T; Yamamoto, T; Browning, MD				Alvestad, RM; Grosshans, DR; Coultrap, SJ; Nakazawa, T; Yamamoto, T; Browning, MD			Tyrosine dephosphorylation and ethanol inhibition of N-methyl-D-aspartate receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; NMDA-RECEPTOR; AMPA RECEPTORS; GLUTAMATE-RECEPTORS; HIPPOCAMPAL-NEURONS; SUBUNIT COMPOSITION; CORTICAL-NEURONS; HEK-293 CELLS; MESSENGER-RNA	The inhibitory effect of ethanol on N-methyl-D-aspartate receptors (NMDARs) is well documented in several brain regions. However, the molecular mechanisms by which ethanol affects NMDARs are not well understood. In contrast to the inhibitory effect of ethanol, phosphorylation of the NMDAR potentiates channel currents (Lu, W. Y., Xiong, Z. G., Lei, S., Orser, B. A., Dudek, E., Browning, M. D., and MacDonald, J. F. (1999) Nat. Neurosci. 2, 331-338). We have previously shown that protein kinase C activators induce tyrosine phosphorylation and potentiation of the NMDAR (Grosshans, D. R., Clayton, D. R., Coultrap, S. J., and Browning, M. D. (2002) Nat. Neurosci. 5, 27-33). We therefore hypothesized that the ethanol inhibition of NMDARs might be due to changes in tyrosine phosphorylation of NMDAR subunits. In support of this hypothesis, we found that tyrosine phosphorylation of both NR2A and NR2B subunits was significantly reduced following in situ exposure of hippocampal slices to 100 nM ethanol. Specifically, phosphorylation of tyrosine 1472 on NR2B was reduced 23.5%. These data suggest a possible mechanism by which ethanol may inhibit the NMDAR via activation of a tyrosine phosphatase. Electrophysiological studies demonstrated that ethanol inhibited NMDAR field excitatory postsynaptic potential slope and amplitude to a similar degree as previously reported by our laboratory and others (Schummers, J., Bentz, S., and Browning, M. D. (1997) Alcohol Clin. Exp. Res. 21, 404-408). Inclusion of bpV(phen), a potent phosphotyrosine phosphatase inhibitor, in the recording chamber prior to and during ethanol exposure significantly reduced the inhibitory effect of ethanol on NMDAR field excitatory postsynaptic potentials. Taken together, these data suggest that phosphatase-mediated dephosphorylation of NMDAR subunits may play an important role in mediating the inhibitory effects of ethanol on the N-methyl-D-aspartate receptor.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Tokyo	Browning, MD (corresponding author), 4200 E 9th Ave,Box C236, Denver, CO 80262 USA.		Nakazawa, Takanobu/E-1012-2014	Nakazawa, Takanobu/0000-0002-5049-9140; NAKAZAWA, Takanobu/0000-0003-4863-1277	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009675] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA09675] Funding Source: Medline; NIGMS NIH HHS [GM07635] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders DL, 1999, J NEUROCHEM, V72, P1389, DOI 10.1046/j.1471-4159.1999.721389.x; BARBAS H, 1993, J COMP NEUROL, V334, P1, DOI 10.1002/cne.903340102; Blevins T, 1997, J NEUROCHEM, V69, P2345; BLITZER RD, 1990, BRAIN RES, V537, P203, DOI 10.1016/0006-8993(90)90359-J; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; CHU B, 1995, J NEUROCHEM, V65, P140; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gordey M, 2001, NEUROSCIENCE, V105, P987, DOI 10.1016/S0306-4522(01)00234-2; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; Grosshans DR, 2001, J NEUROCHEM, V76, P737, DOI 10.1046/j.1471-4159.2001.00034.x; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; GROSSHANS DR, 2002, SCI STKE; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; Kalluri HSG, 1999, MOL BRAIN RES, V68, P159, DOI 10.1016/S0169-328X(99)00057-1; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kumari M, 2001, J BIOL CHEM, V276, P29764, DOI 10.1074/jbc.M100317200; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Maldve RE, 2002, NAT NEUROSCI, V5, P641, DOI 10.1038/nn877; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MORRISETT RA, 1993, J NEUROSCI, V13, P2264; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Peoples RW, 2000, NEUROPHARMACOLOGY, V39, P1681, DOI 10.1016/S0028-3908(00)00067-8; PEREZ RG, 1992, J COMP NEUROL, V318, P304, DOI 10.1002/cne.903180307; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; Pickard L, 2000, J NEUROSCI, V20, P7922; Popp RL, 1998, NEUROPHARMACOLOGY, V37, P45, DOI 10.1016/S0028-3908(97)00186-X; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Ronald KM, 2001, J BIOL CHEM, V276, P44729, DOI 10.1074/jbc.M102800200; Schummers J, 1997, ALCOHOL CLIN EXP RES, V21, P404; Seiler AEM, 2000, ALCOHOL CLIN EXP RES, V24, P1869, DOI 10.1111/j.1530-0277.2000.tb01992.x; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; SINCLAIR JG, 1986, GEN PHARMACOL, V17, P231, DOI 10.1016/0306-3623(86)90144-8; Snell LD, 1996, MOL BRAIN RES, V40, P71; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhao Y, 1996, BIOCHEMISTRY-US, V35, P11797, DOI 10.1021/bi960471r	60	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11020	11025		10.1074/jbc.M210167200	http://dx.doi.org/10.1074/jbc.M210167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536146	hybrid			2022-12-27	WOS:000181855400021
J	Cartron, PF; Priault, M; Oliver, L; Meflah, K; Manon, S; Vallette, FM				Cartron, PF; Priault, M; Oliver, L; Meflah, K; Manon, S; Vallette, FM			The N-terminal end of Bax contains a mitochondrial-targeting signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINUS; OUTER-MEMBRANE; BCL-2; DOMAIN; LOCALIZATION; YEAST; APOPTOSIS; FAMILY	The translocation of Bax alpha, a pro-apoptotic member of the BCL-2 family from the cytosol to mitochondria, is a central event of the apoptotic program. We report here that the N-terminal (NT) end of Bax alpha, which contains its first alpha helix (Halpha1), is a functional mitochondrial-addressing signal both in mammals and in yeast. Similar results were obtained with a newly described variant of Bax called Bax psi, which lacks the first 20 amino acids of Bax a and is constitutively associated with mitochondria. Deletion of Halpha1 impairs the binding of Bax psi to mitochondria, whereas a fusion of the N terminus of Bax alpha, which contains Halpha1 with a cytosolic protein, results in the binding of the chimeric proteins to mitochondria both in a cell-free assay and in vitro. More importantly, the mitochondria-bound chimeric proteins inhibit the interaction of Bax psi with mitochondria as well as Bax-apoptogenic properties. The mutations of the Halpha1, which inhibit Bax alpha and Bax psi translocation to mitochondria, also block the subsequent activation of the execution phase of apoptosis. Conversely, a deletion of the C terminus does not appear to influence Bax a and Bax psi mitochondrial addressing. Taken together, our results suggest that Bax is targeted to mitochondria by its NT and thus through a pathway that is unique for a member of the BCL-2 family.	INSERM, UMR 419, F-44035 Nantes 01, France; CNRS, UMR 5095, F-33007 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Vallette, FM (corresponding author), INSERM, UMR 419, 9 Quai Moncousu, F-44035 Nantes 01, France.	fval@nantes.inserm.fr	Cartron, Pierre Francois/K-9802-2015; Manon, Stéphen/C-7088-2017; Priault, Muriel/HHT-0658-2022; Oliver, Lisa J/L-3070-2015; Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018	Priault, Muriel/0000-0001-8193-0389; Oliver, Lisa J/0000-0002-5588-7564; Vallette, Francois M/0000-0002-3296-8572; Vallette, Francois/0000-0003-0802-0519; Cartron, Pierre-Francois/0000-0002-3393-784X; Manon, Stephen/0000-0002-5792-1084				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Lazebnik Y, 2001, CURR BIOL, V11, pR767, DOI 10.1016/S0960-9822(01)00465-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wattenberg B, 2001, TRAFFIC, V2, P66, DOI 10.1034/j.1600-0854.2001.20108.x; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zha HB, 1996, MOL CELL BIOL, V16, P6494	30	95	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11633	11641		10.1074/jbc.M208955200	http://dx.doi.org/10.1074/jbc.M208955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529375	hybrid			2022-12-27	WOS:000181855400096
J	Gal, I; Lesley, J; Ko, W; Gonda, A; Stoop, R; Hyman, R; Mikecz, K				Gal, I; Lesley, J; Ko, W; Gonda, A; Stoop, R; Hyman, R; Mikecz, K			Role of the extracellular and cytoplasmic domains of CD44 in the rolling interaction of lymphoid cells with hyaluronan under physiologic flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION; TRANSMEMBRANE DOMAIN; PROTEIN FAMILY; BINDING-SITE; ACID BINDING; IN-VIVO; RECEPTOR; IDENTIFICATION; EXTRAVASATION; ACTIVATION	CD44 can function as an adhesion receptor that mediates leukocyte rolling on hyaluronan (HA). To study the contributions of different domains of the standard isoform of CD44 to cell rolling, a CD44-negative mouse T lymphoma AKR1 was transfected with wild type (WT) or mutated cDNA constructs. A parallel flow chamber was used to study the rolling behavior of CD44 transfectants on immobilized HA. For CD44WT transfectants, the fraction of cells that rolled and the rolling velocity was inversely proportional to the amount of cell surface CD44. When the cytoplasmic domain distal to Gly(305) or sequences that serve as binding sites for cytoskeletal linker proteins, were deleted or replaced with foreign sequences, no significant changes in the rolling behavior of mutant cells, compared with the transfectant expressing CD44WT, were observed. Transfectants lacking 64 amino acids of the cytoplasmic tail distal to Cys(295) adhered to HA but showed enhanced rolling at low shear forces. When 83 amino acids from the "non-conserved" membrane-proximal region of the CD44 extracellular domain were deleted, cells adhered firmly to the HA substrate and did not roll at any fluid shear force tested. Unlike wild type cells that exhibited a nearly homogenous distribution of CD44 on a smooth cell surface, cells expressing the non-conserved region deletion mutant accumulated CD44 in membrane protrusions. Disruption of the actin cytoskeleton with cytochalasin B precluded the formation of membrane protrusions, however, treated cells still adhered firmly to HA and did not roll. We conclude that interaction between the cytoplasmic domain of CD44 and the cytoskeleton is not required for cell rolling on immobilized ligand. The strong effect of deletion of the non-conserved region of the extracellular domain argues for a critical role of this region in CD44-dependent rolling and adhesion interactions with HA under flow.	Rush Univ, St Lukes Med Ctr, Dept Orthoped Surg, Sect Biochem & Mol Biol, Chicago, IL 60612 USA; Salk Inst, Mol & Cell Biol Lab, San Diego, CA 92186 USA	Rush University; Salk Institute	Mikecz, K (corresponding author), Rush Univ, St Lukes Med Ctr, Dept Orthoped Surg, Sect Biochem & Mol Biol, 1735 W Harrison St,Cohn Bldg, Chicago, IL 60612 USA.	Katalin_Mikecz@rsh.net		, Reinout/0000-0002-8773-8248; Mikecz, Katalin/0000-0003-1506-4296	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045652] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31613] Funding Source: Medline; NIAMS NIH HHS [AR-45652] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Drillenburg P, 2000, BLOOD, V95, P1900, DOI 10.1182/blood.V95.6.1900; Esford LE, 1998, J CELL SCI, V111, P1021; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; Goebeler M, 1996, J CELL SCI, V109, P1957; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; Kogerman P, 1997, P NATL ACAD SCI USA, V94, P13233, DOI 10.1073/pnas.94.24.13233; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; Lesley J, 2000, EUR J IMMUNOL, V30, P245, DOI 10.1002/1521-4141(200001)30:1<245::AID-IMMU245>3.3.CO;2-O; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Li X, 1998, J EXP MED, V188, P1385, DOI 10.1084/jem.188.7.1385; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; Liu DC, 1997, J IMMUNOL, V159, P2702; Liu DC, 1998, CELL IMMUNOL, V190, P132, DOI 10.1006/cimm.1998.1397; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Peck D, 1998, J CELL SCI, V111, P1595; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; Ponta H, 1998, INT J BIOCHEM CELL B, V30, P299, DOI 10.1016/S1357-2725(97)00152-0; Siegelman M, 2001, J CLIN INVEST, V107, P159, DOI 10.1172/JCI11919; Siegelman MH, 2000, J CLIN INVEST, V105, P683, DOI 10.1172/JCI8692; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Sy MS, 1996, CURR TOP MICROBIOL, V213, P129; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Weber GF, 2002, CANCER RES, V62, P2281; Weiss L, 2000, P NATL ACAD SCI USA, V97, P285, DOI 10.1073/pnas.97.1.285; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	65	38	40	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11150	11158		10.1074/jbc.M210661200	http://dx.doi.org/10.1074/jbc.M210661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540844	hybrid			2022-12-27	WOS:000181855400039
J	Madore, E; Harvey, N; Parent, J; Chapdelaine, P; Arosh, JA; Fortier, MA				Madore, E; Harvey, N; Parent, J; Chapdelaine, P; Arosh, JA; Fortier, MA			An aldose reductase with 20 alpha-hydroxysteroid dehydrogenase activity is most likely the enzyme responsible for the production of prostaglandin F2 alpha in the bovine endometrium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F SYNTHASE; INTERFERON-TAU; MOLECULAR-CLONING; ESTROUS-CYCLE; STROMAL CELLS; CDNA CLONING; OXYTOCIN; EXPRESSION; CYCLOOXYGENASE-2; IDENTIFICATION	Prostaglandins are important regulators of reproductive function. In particular, prostaglandin F2alpha (PGF(2alpha)) is involved in labor and is the functional mediator of luteolysis to initiate a new estrous cycle in many species. These actions have been extensively studied in, ruminants, but the enzymes involved are not clearly identified. Our objective was to identify which prostaglandin F synthase is involved and to study its regulation in the endometrium and in endometrial primary cell cultures. The expression of all previously known prostaglandin F synthases (PGFSs), two newly discovered PGFS-like genes, and a 20alpha-hydroxysteroid dehydrogenase was studied by Northern blot and reverse transcription PCR. These analyses revealed that none of the known PGFS or the PGFS-like genes were significantly expressed in the endometrium. On the other hand, the 20alpha-hydroxysteroid dehydrogenase gene was strongly expressed in the endometrium at the time of luteolysis. The corresponding recombinant enzyme has a K-m of 7 muM for PGH(2) and a PGFS activity higher than the lung PGFS. This enzyme has two different activities with the ability to terminate the estrous cycle; it metabolizes progesterone and synthesizes PGF2alpha. Taken together, these data point to this newly identified enzyme as the functional endometrial PGFS.	Univ Laval, CHU Quebec, Unite Rech Ontogenie & Reprod, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, CHU Quebec, Dept Obstet & Gynecol, Ste Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Fortier, MA (corresponding author), Univ Laval, CHU Quebec, Unite Rech Ontogenie & Reprod, 2705 Boul Laurier, Ste Foy, PQ G1V 4G2, Canada.	mafortier@crchul.ulaval.ca						Arosh JA, 2002, BIOL REPROD, V67, P161, DOI 10.1095/biolreprod67.1.161; Asselin E, 1997, ENDOCRINOLOGY, V138, P4798, DOI 10.1210/en.138.11.4798; Asselin E, 1996, BIOL REPROD, V54, P371, DOI 10.1095/biolreprod54.2.371; Asselin E, 2000, BIOL REPROD, V62, P125, DOI 10.1095/biolreprod62.1.125; BEAVER CJ, 1992, PROSTAG OTH LIPID M, V44, P37, DOI 10.1016/0090-6980(92)90105-3; Bogacki M, 2002, BIOL REPROD, V67, P184, DOI 10.1095/biolreprod67.1.184; Chapdelaine P, 2001, BIOTECHNIQUES, V31, P478, DOI 10.2144/01313bm04; CHEN LY, 1992, ARCH BIOCHEM BIOPHYS, V296, P17, DOI 10.1016/0003-9861(92)90539-9; Cracowski JL, 2001, J VASC RES, V38, P93, DOI 10.1159/000051036; CRAWFORD K, 1987, ARCH OPHTHALMOL-CHIC, V105, P1112, DOI 10.1001/archopht.1987.01060080114039; FORTIER MA, 1988, J REPROD FERTIL, V83, P239, DOI 10.1530/jrf.0.0830239; Green K, 1978, Adv Prostaglandin Thromboxane Res, V5, P15; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; Kankofer M, 1999, PROSTAG LEUKOTR ESS, V61, P29, DOI 10.1054/plef.1999.0069; Kubata BK, 2000, J EXP MED, V192, P1327, DOI 10.1084/jem.192.9.1327; KUCHINKE W, 1992, BIOCHEM BIOPH RES CO, V183, P1238, DOI 10.1016/S0006-291X(05)80323-7; LACY WR, 1993, MOL ENDOCRINOL, V7, P58, DOI 10.1210/me.7.1.58; LEAVITT WW, 1985, J STEROID BIOCHEM, V22, P687, DOI 10.1016/0022-4731(85)90272-9; LEE JS, 1994, J ENDOCRINOL, V141, P491, DOI 10.1677/joe.0.1410491; Ma YF, 1995, BONE, V17, P549, DOI 10.1016/8756-3282(95)00387-8; Madore E, 2001, BIOL REPROD, V64, P319; McCracken JA, 1999, PHYSIOL REV, V79, P263, DOI 10.1152/physrev.1999.79.2.263; Mezzetti A, 2000, CARDIOVASC RES, V47, P475, DOI 10.1016/S0008-6363(00)00118-8; POYSER NL, 1995, PROSTAG LEUKOTR ESS, V53, P147, DOI 10.1016/0952-3278(95)90115-9; Robinson RS, 2001, REPRODUCTION, V122, P965, DOI 10.1530/rep.0.1220965; SILVIA WJ, 1994, J ENDOCRINOL, V141, P481, DOI 10.1677/joe.0.1410481; Soper DL, 2001, J MED CHEM, V44, P4157, DOI 10.1021/jm010264b; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Suzuki T, 1999, J BIOL CHEM, V274, P241, DOI 10.1074/jbc.274.1.241; Suzuki-Yamamoto T, 1999, FEBS LETT, V462, P335, DOI 10.1016/S0014-5793(99)01551-3; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; URADE Y, 1990, J BIOL CHEM, V265, P12029; WARREN JC, 1993, BIOCHEMISTRY-US, V32, P1401, DOI 10.1021/bi00057a003; WATANABE K, 1986, P NATL ACAD SCI USA, V83, P1583, DOI 10.1073/pnas.83.6.1583; WATANABE K, 1985, J BIOL CHEM, V260, P7035; Weber P C, 1980, Contrib Nephrol, V23, P83; WINTERGALEN N, 1995, EUR J BIOCHEM, V234, P264, DOI 10.1111/j.1432-1033.1995.264_c.x; Wu WX, 2001, J SOC GYNECOL INVEST, V8, P69, DOI 10.1016/S1071-5576(01)00094-6; Xiao CW, 1998, ENDOCRINOLOGY, V139, P2293, DOI 10.1210/en.139.5.2293; Xiao CW, 1999, BIOL REPROD, V60, P656, DOI 10.1095/biolreprod60.3.656	41	142	148	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11205	11212		10.1074/jbc.M208318200	http://dx.doi.org/10.1074/jbc.M208318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551929	hybrid			2022-12-27	WOS:000181855400046
J	Soon, LL; Yie, TA; Shvarts, A; Levine, AJ; Su, F; Tchou-Wong, KM				Soon, LL; Yie, TA; Shvarts, A; Levine, AJ; Su, F; Tchou-Wong, KM			Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; NOV PROTOONCOGENE; TUMOR-GROWTH; CCN FAMILY; CYR61; EXPRESSION; MEMBER; MIGRATION; PRODUCT	Wnt-induced-secreted-protein-1 (WISP-1) is a cysteine-rich, secreted factor belonging to the CCN family. These proteins have been implicated in the inhibition of metastasis; however, the mechanisms involved have not been described. We demonstrated that overexpression of WISP-1 in H460 lung cancer cells inhibited lung metastasis and in vitro cell invasion and motility. We investigated the possibility that WISP-1 may regulate activation of Rac, a small GTPase important for cytoskeletal reorganizations during motility. In an indirect assay, WISP-1-expressing cells exhibited marked reduction in Rac activation compared with control cells. Blocking antibodies to alpha(v)beta(5) and alpha(1) integrins restored Rac activation in WISP-1 cells, suggesting that the inhibitory effect of WISP-1 on Rac lies downstream of integrins. Constitutively activated Rac mutant (RacG12V) was transfected into WISP-1 cells to restore Rac activation and these WISP-1/RacG12V transfectants were used for further studies. We performed microarray and real-time PCR analyses to identify genes involved in invasion that may be differentially regulated by WISP-1. Here, we showed decreased expression of metalloproteinase-1 (MMP-1) in WISP-1 cells compared with controls but increased expression in WISP-1/RacG12V cells. In an invasion assay across collagen 1, an MMP-1 target matrix, WISP-1 cells were significantly less invasive compared with controls, whereas WISP-1/RacG12V cells showed elevated invasion levels. This work illustrates a negatively regulated pathway by WISP-1 involving integrins and Rac in the down-regulation of invasion.	NYU, Div Pulm & Crit Care Med, Dept Med, New York, NY 10016 USA; NYU, Dept Environm Med, New York, NY 10016 USA; NYU, Dept Microbiol, New York, NY 10016 USA; Princeton Univ, Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	New York University; New York University; New York University; Institute for Advanced Study - USA; Princeton University; Roche Holding	Tchou-Wong, KM (corresponding author), NYU, Div Pulm & Crit Care Med, Dept Med, 550 1St Ave,MSB141, New York, NY 10016 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00096] Funding Source: Medline; NIEHS NIH HHS [R01-ES0916] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Bredin CG, 1999, INT J CANCER, V82, P338, DOI 10.1002/(SICI)1097-0215(19990730)82:3<338::AID-IJC6>3.0.CO;2-Y; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; FEI S, 2002, GENE DEV, V16, P46; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; MARTINERIE C, 1992, ONCOGENE, V7, P2529; Noel A, 1997, INVAS METAST, V17, P221; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; Scholz G, 1996, MOL CELL BIOL, V16, P481; Suzuki-Inoue K, 2001, BLOOD, V98, P3708, DOI 10.1182/blood.V98.13.3708; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xu LF, 2000, GENE DEV, V14, P585; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	33	91	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11465	11470		10.1074/jbc.M210945200	http://dx.doi.org/10.1074/jbc.M210945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529380	hybrid			2022-12-27	WOS:000181855400077
J	Zarini, S; Murphy, RC				Zarini, S; Murphy, RC			Biosynthesis of 5-oxo-6,8,11,14-eicosatetraenoic acid from 5-hydroperoxyeicosatetraenoic acid in the murine macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE C-4 SYNTHASE; HUMAN NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; ACTIN POLYMERIZATION; POTENT STIMULATOR; ARACHIDONIC-ACID; HUMAN MONOCYTES; NADPH OXIDASE; IDENTIFICATION; EXPRESSION	5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a metabolite of arachidonic acid shown to possess important biological activities within different cell types. In the neutrophil, a specific NADP+-dependent dehydrogenase utilizes 5-lipoxygenase-derived 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5(S)-HETE) as the required substrate. In the present study, 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HpETE), rather than 5-HETE, was found to be the biosynthetic precursor of 5-oxo-ETE in the murine macrophage. The macrophage was not able to convert 5-HETE into 5-oxo-ETE even when preincubated with phorbol ester or with other lipid hydroperoxides. The factor responsible for the conversion of 5-HpETE into 5-oxo-ETE was found predominantly in the cytosolic fraction of the macrophage, with an approximate molecular weight of 50,000-60,000, as assessed by size exclusion chromatography. Formation of 5-oxo-ETE was rapid and the catalytic protein was found to have an apparent K-m of 5.3 muM for the eicosanoid. Furthermore, the protein could efficiently utilize 5(R,S)-HpETE as substrate and was heat and protease labile. This novel pathway of 5-oxo-ETE biosynthesis in the murine macrophage was consistent with reduction of a 5-hydroperoxy group to an intermediate alkoxy radical that could be subsequently oxidized to the 5-oxo product. Such a mechanism would enable racemic 5-HpETE, derived from free radical oxidation of arachidonic acid, to be efficiently converted into this potent chemotactic eicosanoid.	Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, Denver, CO 80206 USA.			Zarini, Simona/0000-0002-7460-3299	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN J, 1986, AGENTS ACTIONS, V17, P392, DOI 10.1007/BF01982660; BERTON G, 1985, IMMUNOLOGY, V54, P371; Bowers RC, 2000, J BIOL CHEM, V275, P29931, DOI 10.1074/jbc.C000502200; Brown K M, 2001, Public Health Nutr, V4, P593; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DELACLOS BF, 1988, BIOCHIM BIOPHYS ACTA, V958, P424, DOI 10.1016/0005-2760(88)90228-7; DELACLOS BF, 1987, PROSTAGLANDINS, V33, P315, DOI 10.1016/0090-6980(87)90016-5; DIX TA, 1985, J BIOL CHEM, V260, P5351; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GARDNER HW, 1981, BIOCHIM BIOPHYS ACTA, V665, P100, DOI 10.1016/0005-2760(81)90238-1; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; HAMBERG M, 1975, LIPIDS, V10, P87, DOI 10.1007/BF02532161; HASLETT C, 1985, AM J PATHOL, V119, P101; Hevko JM, 2002, J BIOL CHEM, V277, P7037, DOI 10.1074/jbc.M108942200; Hevko JM, 2001, J PHARMACOL EXP THER, V296, P293; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; LABEQUE R, 1988, BIOCHEMISTRY-US, V27, P7060, DOI 10.1021/bi00418a059; Lam BK, 2000, AM J RESP CRIT CARE, V161, pS16, DOI 10.1164/ajrccm.161.supplement_1.ltta-4; MacLeod RJ, 1999, J PHARMACOL EXP THER, V291, P511; Murphy RC, 2001, CHEM RES TOXICOL, V14, P463, DOI 10.1021/tx000250t; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; POWELL WS, 1994, J BIOL CHEM, V269, P25373; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; POWELL WS, 1993, J LIPID MEDIATOR, V6, P361; Powell WS, 2001, J ALLERGY CLIN IMMUN, V107, P272, DOI 10.1067/mai.2001.112847; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; Powell WS, 1997, J IMMUNOL, V159, P2952; POWELL WS, 1995, J IMMUNOL, V154, P4123; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; Sozzani S, 1996, J IMMUNOL, V157, P4664; WILBORN J, 1995, AM J PHYSIOL-LUNG C, V268, pL294, DOI 10.1152/ajplung.1995.268.2.L294; Zhang Y, 1996, J LEUKOCYTE BIOL, V59, P847, DOI 10.1002/jlb.59.6.847	38	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11190	11196		10.1074/jbc.M208496200	http://dx.doi.org/10.1074/jbc.M208496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547823	hybrid			2022-12-27	WOS:000181855400044
J	Dauphin, Y				Dauphin, Y			Soluble organic matrices of the calcitic prismatic shell layers of two pteriomorphid bivalves - Pinna nobilis and Pinctada margaritifera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLLUSK SHELLS; PROTEINS; GLYCOPROTEINS; LOCALIZATION; PURIFICATION; ORGANIZATION; CARBONATE; SULFUR; GROWTH	The calcitic prisms of the shells of two bivalves, Pinna and Pinctada, are considered simple prisms according to some morphological and mineralogical characteristics. Scanning electron microscopic and atomic force microscopic studies show that the microstructures and nanostructures of these two shells are different. Pinna prisms are monocrystalline, whereas Pinctada prisms are not. Moreover, intraprismatic membranes are present only in the Pinctada prisms. The soluble organic matrices extracted from these prisms are acidic, but their bulk compositions differ. Ultraviolet and infrared spectrometries, fluorescence, high pressure liquid chromatography, and electrophoresis show that the sugar-protein ratios and the molecular weights are different. Sulfur is mainly associated with acidic sulfated sugars, not with amino acids, and the role of acidic sulfated sugars is still underestimated. Thus, the simple prism concept is not a relevant model for the biomineralization processes in the calcitic prismatic layer of mollusk shells.	Univ Paris 11, Lab Paleontol, FRE 2566, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay	Dauphin, Y (corresponding author), Univ Paris 11, Lab Paleontol, FRE 2566, Bat 504, F-91405 Orsay, France.	dauphin@geol.u-psud.fr						Addadi L., 1991, P29; Aizenberg J, 2002, J AM CHEM SOC, V124, P32, DOI 10.1021/ja016990l; Albeck S, 1996, CHEM-EUR J, V2, P278, DOI 10.1002/chem.19960020308; Boggild O. B., 1930, Kongelige Danske Videnskabernes Selskabs Skrifter, Vix 2, P231; CAEL JJ, 1978, J MOL BIOL, V125, P21, DOI 10.1016/0022-2836(78)90252-8; Crenshaw MA., 1976, MECHANISMS MINERALIZ, P355; Cuif J.P., 1983, Haliotis, V13, P131; CUIF JP, 1988, CR ACAD SCI II, V307, P1943; CUIF JP, 1986, CR ACAD SCI II, V303, P251; CUIF JP, 1987, CR ACAD SCI II, V304, P475; CUIF JP, 1989, B SOC GEOL FR, V5, P569; Dauphin Y, 1999, ANN SCI NAT ZOOL, V20, P73, DOI 10.1016/S0003-4339(99)80010-0; Dauphin Y, 2002, COMP BIOCHEM PHYS A, V132, P577, DOI 10.1016/S1095-6433(02)00099-5; Dauphin Y, 2001, INT J BIOL MACROMOL, V28, P293, DOI 10.1016/S0141-8130(01)00124-6; Dauphin Y, 1997, ELECTROPHORESIS, V18, P1180, DOI 10.1002/elps.1150180726; delaPorte PL, 1996, J HEPATOL, V25, P339, DOI 10.1016/S0168-8278(96)80121-8; DEVILLEPOIX RM, 1877, J PHYSIOL-PARIS, P461; Fernandez MS, 2001, MATRIX BIOL, V19, P793, DOI 10.1016/S0945-053X(00)00128-1; FREMY E, 1855, ANN CHIM PARIS, V43, P47; Gregoire C., 1961, Bull Inst sci nat Belg, V37, P1; Hattan SJ, 2001, J BIOL CHEM, V276, P4461, DOI 10.1074/jbc.M006803200; Killian CE, 1996, J BIOL CHEM, V271, P9150, DOI 10.1074/jbc.271.15.9150; Krampitz G., 1976, MECHANISMS MINERALIZ, P155; Lowenstam HA, 1989, BIOMINERALIZATION; MARIN F, 1994, CR ACAD SCI II, V318, P1653; Marxen JC, 1997, COMP BIOCHEM PHYS B, V118, P23, DOI 10.1016/S0305-0491(97)00010-2; Masuda F., 1980, Science Reports of the Institute of Geoscience University of Tsukuba Section B Geological Sciences, V1, P163; Nakahara H., 1980, JPN J MALACOL, V39, P167; NATHUSIUSKONIGS.W, 1877, RES NONCELLULAR ORGA, P144; Prange A, 1999, BBA-GEN SUBJECTS, V1428, P446, DOI 10.1016/S0304-4165(99)00095-1; PREAZANT RS, 1990, HONOUR CM YONGE, P83; Rose K, 1998, J AM CHEM SOC, V120, P10743, DOI 10.1021/ja981350c; Samata T, 1999, FEBS LETT, V462, P225, DOI 10.1016/S0014-5793(99)01387-3; SAMATA T, 1990, VELIGER, V33, P190; Samata T., 1980, P37; SUZUKI S, 1981, J FAC SCI HOKKAIDO U, V1, P7; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; TAYLOR JD, 1969, B BRIT MUSEUM NATU S, V3, P1; TERMINE JD, 1981, J BIOL CHEM, V256, P403; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; Wada K., 1980, P79; Wada K., 1964, Bulletin of the Japanese Society of Scientific Fisheries, V30, P993; Wada K., 1956, B NATL PEARL RES LAB, V1, P1; Wada K., 1961, B NATN PEARL RES LAB, V7, P703; WATABE N, 1956, J FAC FISH PREFECT U, P227; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WEINER S, 1975, SCIENCE, V190, P987, DOI 10.1126/science.1188379; Weiss IM, 2000, BIOCHEM BIOPH RES CO, V267, P17, DOI 10.1006/bbrc.1999.1907; WISE SW, 1969, SCANNING ELECTRON MI, P205; WORMS D, 1986, J EXP ZOOL, V237, P11, DOI 10.1002/jez.1402370104	50	110	113	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15168	15177		10.1074/jbc.M204375200	http://dx.doi.org/10.1074/jbc.M204375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576478	hybrid			2022-12-27	WOS:000182516100076
J	Starke, DW; Chock, PB; Mieyal, JJ				Starke, DW; Chock, PB; Mieyal, JJ			Glutathione-thiyl radical scavenging and transferase properties of human glutaredoxin (thioltransferase) - Potential role in redox signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; S-THIOLATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ANTIOXIDANT FUNCTION; RESPIRATORY BURST; DISULFIDES; REDUCTION; OXIDATION; PEROXYNITRITE; THIOREDOXIN	Glutaredoxin (GRx, thioltransferase) is implicated in cellular redox regulation, and it is known for specific and efficient catalysis of reduction of protein-S-S-glutathione-mixed disulfides (protein-SSG) because of its remarkably low thiol pK(a) (approximate to3.5) and its ability to stabilize a catalytic S-glutathionyl intermediate (GRx-SSG). These unique properties suggested that GRx might also react with glutathione-thiyl radicals (GS(.)) and stabilize a disulfide anion radical intermediate (GRx-SSG(.)), thereby facilitating the conversion of GS(.) to GSSG or transfer of GS(.) to form protein-SSG. We found that GRx catalyzes GSSG formation in the presence of GS-thiyl radical generating systems (Fe2+/ADP/H2O2 + GSH or horseradish peroxidase/H2O2 + GSH). Catalysis is dependent on 02 and results in concomitant superoxide formation, and it is distinguished from glutathione peroxidase-like activity. With the horseradish peroxidase system and [S-35]GSH, GRx enhanced the rate of GS-radiolabel incorporation into GAPDH. GRx also enhanced the rate of S-glutathionylation of glyceraldehyde-3-phosphate dehydrogenase with GSSG or S-nitrosoglutathione, but these glutathionyl donors were much less efficient. Both actin and protein-tyrosine phosphatase-1B were superior substrates for GRx-facilitated S-glutathionylation with GS-radical. These studies characterize GRx as a versatile catalyst, facilitating GS-radical scavenging and S-glutathionylation of redox signal mediators, consistent with a critical role in cellular regulation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; NHLBI, Biochem Sect, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Mieyal, JJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.	jjm5@po.cwru.edu			NIA NIH HHS [AG15885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000202, Z01HL000202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; de Menezes SL, 2001, J BIOL CHEM, V276, P39879, DOI 10.1074/jbc.M104012200; FLOYD RA, 1983, ARCH BIOCHEM BIOPHYS, V225, P263, DOI 10.1016/0003-9861(83)90029-2; FLOYD RA, 1983, BIOCHEMISTRY-US, V22, P2645, DOI 10.1021/bi00280a008; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GOLDMAN R, 1995, BIOCHEMISTRY-US, V34, P4765, DOI 10.1021/bi00014a034; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRAVINA SA, 1993, THESIS CASE W RESERV; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KWAK HS, 1995, P NATL ACAD SCI USA, V92, P4582, DOI 10.1073/pnas.92.10.4582; Lind C, 1998, BIOCHEM BIOPH RES CO, V247, P481, DOI 10.1006/bbrc.1998.8695; Lobysheva II, 1999, BIOCHEMISTRY-MOSCOW+, V64, P153; MASON RP, 1990, METHOD ENZYMOL, V186, P318; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; MIEYAL JJ, 2003, IN PRESS CURRENT TOP; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SCHONEICH C, 1995, ANTIOX HEALTH DIS, V2, P21; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SIES H, 1987, ADV ENZYME REGUL, V26, P175, DOI 10.1016/0065-2571(87)90013-6; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Ward Paul, 1995, P1; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WINTERBOURN CC, 1995, METHOD ENZYMOL, V251, P81, DOI 10.1016/0076-6879(95)51112-1; Winterbourn CC, 1995, BIOTHIOLS HLTH DIS, P117; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; YIM MB, 1994, J BIOL CHEM, V269, P1621; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	41	140	143	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14607	14613		10.1074/jbc.M210434200	http://dx.doi.org/10.1074/jbc.M210434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12556467	hybrid			2022-12-27	WOS:000182516100006
J	Rybin, VO; Sabri, A; Short, J; Braz, JC; Molkentin, JD; Steinberg, SF				Rybin, VO; Sabri, A; Short, J; Braz, JC; Molkentin, JD; Steinberg, SF			Cross-regulation of novel protein kinase C (PKC) isoform function in cardiomyocytes - Role of PKC epsilon in activation loop phosphorylations and PKC delta in hydrophobic motif phosphorylations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE-1; PDK-1; AUTOPHOSPHORYLATION; EXPRESSION; ISOZYMES; APOPTOSIS; ISOTYPES; MYOCYTES; 3-KINASE; PATHWAY	Recent studies identify conventional protein kinase C (PKC) isoform phosphorylations at conserved residues in the activation loop and C terminus as maturational events that influence enzyme activity and targeting but are not dynamically regulated by second messengers. In contrast, this, study identifies phorbol 12-myristoyl 13-acetate (PMA)- and norepinephrine-induced phosphorylations of PKCepsilon (at the C-terminal hydrophobic motif) and PKCdelta (at the activation loop) as events that accompany endogenous novel PKC (nPKC) isoform activation in neonatal rat cardiomyocytes. Agonist-induced nPKC phosphorylations are prevented (and the kinetics of PMA-dependent PKC down-regulation are slowed) by pharmacologic inhibitors of nPKC kinase activity. PKCdelta is recovered from PMA-treated cultures with increased in vitro lipid-independent kinase activity (and altered substrate specificity); the PMA-dependent increase in PKCdelta kinase activity is attenuated when PKCdelta activation loop phosphorylation is prevented. To distinguish roles of individual nPKC isoforms in nPKC phosphorylations, wild-type (WT) and dominant negative (DN) PKCdelta and PKCepsilon mutants were introduced into cardiomyocyte cultures using adenovirus-mediated gene transfer. WT-PKCdelta and WT-PKCepsilon are highly phosphorylated at activation loop and hydrophobic motif sites, even in the absence of allosteric activators. DN-PKCdelta is phosphorylated at the activation loop but not the hydrophobic motif, DN-PKCepsilon is phosphorylated at the hydrophobic motif but not the activation loop. Collectively, these results identify a role for PKCepsilon in nPKC activation loop phosphorylations and PKCdelta in nPKC hydrophobic motif phosphorylations. Agonist-induced nPKC isoform phosphorylations that accompany activation/translocation of the enzyme contribute to the regulation of PKCdelta kinase activity, may influence nPKC isoform trafficking/down-regulation, and introduce functionally important cross-talk for nPKC signaling pathways in cardiomyocytes.	Columbia Univ, Dept Pharmacol, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; Univ Cincinnati, Childrens Hosp, Dept Pediat, Cincinnati, OH 45229 USA	Columbia University; Columbia University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Steinberg, SF (corresponding author), Columbia Univ, Dept Pharmacol, Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.			Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [HL-64639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; NEWTON AC, 1995, J BIOL CHEM, V270, P28496; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 1999, PHARMACOL THERAPEUT, V82, P263, DOI 10.1016/S0163-7258(98)00047-3; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Rybin V, 1996, CIRC RES, V79, P388, DOI 10.1161/01.RES.79.3.388; Rybin VO, 1997, AM J PHYSIOL-HEART C, V272, pH1636, DOI 10.1152/ajpheart.1997.272.4.H1636; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0	31	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14555	14564		10.1074/jbc.M212644200	http://dx.doi.org/10.1074/jbc.M212644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566450	hybrid			2022-12-27	WOS:000182405000124
J	Usui, I; Imamura, T; Huang, J; Satoh, H; Olefsky, JM				Usui, I; Imamura, T; Huang, J; Satoh, H; Olefsky, JM			Cdc42 is a rho GTPase family member that can mediate insulin signaling to glucose transport in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; ACTIVATION; PATHWAY; PROTEIN; RESISTANCE; KINASE; OVEREXPRESSION; INHIBITION	We investigated the role of cdc42, a Rho GTPase family member, in insulin-induced glucose transport in 3T3-L1 adipocytes. Microinjection of anti-cdc42 antibody or cdc42 siRNA led to decreased insulin-induced and constitutively active G. (CA-G(q); Q209L)-induced GLUT4 translocation. Adenovirus-mediated expression of constitutively active cdc42 (CA-cdc42; V12) stimulated 2-deoxyglucose uptake to 56% of the maximal insulin response, and this was blocked by treatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin, or LY294002. Both insulin and CA-G(q) expression caused an increase in cdc42 activity, showing that cdc42 is activated by insulin and is downstream of Galpha(q/11) in this activation pathway. Immunoprecipitation experiments showed that insulin enhanced a direct association of cdc42 and p85, and both insulin treatment and CA-cdc42 expression stimulated PI3-kinase activity in immunoprecipitates with anti-cdc42 antibody. Furthermore, the effects of insulin, CA-G(q), and CA-cdc42 on GLUT4 translocation or 2-deoxyglucose uptake were inhibited by microinjection of anti-protein kinase CA (PKClambda) antibody or overexpression of a kinase-deficient PKClambda construct. In summary, activated cdc42 can mediate 1) insulin-stimulated GLUT4 translocation and 2) glucose transport in a PI3-kinase-dependent manner. 3) Insulin treatment and constitutively active G(q) expression can enhance the cdc42 activity state as well as the association of cdc42 with activated PI3-kinase. 4) PKClambda inhibition blocks CA-cdc42, CA-G(q), and insulin-stimulated GLUT4 translocation. Taken together, these data indicate that cdc42 can mediate insulin signaling to GLUT4 translocation and lies downstream of Galpha(q/11) and upstream of PI3-kinase and PKClambda in this stimulatory pathway.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA; San Diego Vet Adm Med Res Serv, La Jolla, CA 92037 USA; Whittier Inst Diabet & Endocrinol, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Satoh, Hiroaki/E-9096-2017	Satoh, Hiroaki/0000-0002-0353-5807	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Imamura T, 1999, MOL CELL BIOL, V19, P6765; JAMES DE, 1993, J CELL SCI, V104, P607; Janez A, 2000, J BIOL CHEM, V275, P26870; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Kanoh Y, 2001, ENDOCRINOLOGY, V142, P1595, DOI 10.1210/en.142.4.1595; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Sakoda H, 2000, DIABETES, V49, P1700, DOI 10.2337/diabetes.49.10.1700; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	36	69	77	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13765	13774		10.1074/jbc.M208904200	http://dx.doi.org/10.1074/jbc.M208904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566459	hybrid			2022-12-27	WOS:000182405000027
J	Wang, B; Nguyen, M; Breckenridge, DG; Stojanovic, M; Clemons, PA; Kuppig, S; Shore, GC				Wang, B; Nguyen, M; Breckenridge, DG; Stojanovic, M; Clemons, PA; Kuppig, S; Shore, GC			Uncleaved BAP31 in association with A4 protein at the endoplasmic reticulum is an inhibitor of Fas-initiated release of cytochrome c from mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CONFORMATIONAL CHANGE; CASPASE ACTIVATION; INDUCED APOPTOSIS; IMPORT RECEPTOR; EARLY EVENTS; II CELLS; IN-VIVO; BAX; MEMBRANE	BAP31 is a polytopic integral protein of the endoplasmic reticulum. membrane and; like BID, is a preferred substrate of caspase-8. Upon Fas/CD95 stimulation, BAP31 is cleaved within. its cytosolic domain, generating proapoptotic p20 BAP31. In human KB epithelial cells expressing the caspase-resistant mutant crBAP31, Fas stimulation resulted in cleavage of BID and insertion of BAX into mitochondrial membrane, but subsequent oligomerization of BAX and BAK, egress of cytochrome c to the cytosol, and apoptosis were impaired. Bap31-null mouse cells expressing crBAP31 cannot generate the endogenous p20 BAP31 cleavage product, yet crBAP31 conferred resistance to cellular condensation and cytochrome c release in response to activation of ectopic FKBPcasp8 by FK1012z. Full-length BAP31, therefore, is a direct inhibitor of these caspase-8-initiated events, acting independently of its ability to sequester p20, with which it interacts. Employing a novel split ubiquitin yeast two-hybrid screen for BAP31-interacting membrane proteins, the putative ion channel protein of the endoplasmic reticulum, A4, was detected and identified as a constitutive binding partner of BAP31 in human cells. Ectopic A4 that was introduced into A4-deficient cells cooperated with crBAP31 to resist Fas-induced egress of cytochrome c from mitochondria and cytoplasmic apoptosis.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Univ Freiburg, Dept Mol Immunol Biol 3, D-71908 Freiburg, Germany; Max Planck Inst Immunbiol, D-71908 Freiburg, Germany	McGill University; Harvard University; Harvard Medical School; University of Freiburg; Max Planck Society	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.			wang, bing/0000-0002-6549-8837				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bouillet P, 2002, J CELL SCI, V115, P1567; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; BRECKENRIDGE DG, 2003, GENETICS APOPTOSIS, P93; BREITWIESER GE, 1997, AM J PHYSIOL, V272, P957; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chien MM, 1999, J BIOL CHEM, V274, P7059, DOI 10.1074/jbc.274.11.7059; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Csordas G, 2001, TRENDS CARDIOVAS MED, V11, P269, DOI 10.1016/S1050-1738(01)00123-2; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diver ST, 1997, J AM CHEM SOC, V119, P5106, DOI 10.1021/ja963891c; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GOPING IS, 1995, FEBS LETT, V373, P45; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McBride HM, 1996, J CELL BIOL, V134, P307, DOI 10.1083/jcb.134.2.307; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pinton P, 2002, BIOCHIMIE, V84, P195, DOI 10.1016/S0300-9084(02)01373-1; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060	50	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14461	14468		10.1074/jbc.M209684200	http://dx.doi.org/10.1074/jbc.M209684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12529377	hybrid			2022-12-27	WOS:000182405000113
J	Agarwal-Mawal, A; Qureshi, HY; Cafferty, PW; Yuan, ZF; Han, D; Lin, RT; Paudet, HK				Agarwal-Mawal, A; Qureshi, HY; Cafferty, PW; Yuan, ZF; Han, D; Lin, RT; Paudet, HK			14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2-LIKE PROTEIN-KINASE; BETA-CATENIN; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; BINDING; 14-3-3-PROTEINS; ACTIVATION; 3-BETA; FORMS; GSK3	In a recent study, we reported that in bovine brain extract, glycogen synthase kinase-3beta and tau are parts of an similar to400-500 kDa microtubule-associated tau phosphorylation complex (Sun, W., Qureshi, H. Y., Cafferty, P. W., Sobue, K., Agarwal-Mawal, A., Neufield, K. D., and Paudel, H. K. (2002) J. Biol. Chem. 277,11933-11940). In this study, we find that when purified brain microtubules are subjected to Superose 12 gel filtration column chromatography, the dimeric scaffold protein 14-3-3xi coelutes with the tau phosphorylation complex components tau and GSK3beta. From gel filtration fractions containing the tau phosphorylation complex, 14-3-3xi, GSK3beta, and tau co-immunoprecipitate with each other. From extracts of bovine brain, COS-7 cells, and HEK-293 cells transfected with GSK3beta, 14-3-3xi co-precipitates with GSK3beta, indicating that GSK3beta binds to 14-3-3xi. From HEK-293 cells transfected with tau, GSK3beta, and 14-3-3xi in different combinations, tau co-immunoprecipitates with GSK3beta only in the presence of 14-3-3xi. In vitro, similar to10-fold more tau binds to GSK3beta in the presence of than in the absence of 14-3-3xi. In transfected HEK-293 cells, 14-3-3xi stimulates GSK3beta-catalyzed tau phosphorylation in a dose-dependent manner. These data indicate that in brain, the 14-3-3xi dimer simultaneously binds and bridges tau and GSK3beta and stimulates GSK3beta-catalyzed tau phosphorylation.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Paudet, HK (corresponding author), Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca		Cafferty, Patrick/0000-0001-5563-1158				BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lovestone S, 1996, NEUROSCIENCE, V73, P1145, DOI 10.1016/0306-4522(96)00126-1; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PEI JJ, 1999, J NEUROPATHOL EXP NE, V56, P70; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Planel E, 2002, DRUG DEVELOP RES, V56, P491, DOI 10.1002/ddr.10100; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; SHIRUBA RA, 1998, BRAIN RES, V737, P119; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Sun W, 2002, J BIOL CHEM, V277, P11933, DOI 10.1074/jbc.M107182200; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wagner U, 1996, J CELL SCI, V109, P1537; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	45	194	201	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12722	12728		10.1074/jbc.M211491200	http://dx.doi.org/10.1074/jbc.M211491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551948	hybrid			2022-12-27	WOS:000182189500019
J	Olswang, Y; Blum, B; Cassuto, H; Cohen, H; Biberman, Y; Hanson, RW; Reshef, L				Olswang, Y; Blum, B; Cassuto, H; Cohen, H; Biberman, Y; Hanson, RW; Reshef, L			Glucocorticoids repress transcription of phosphoenolpyruvate carboxykinase (GTP) gene in adipocytes by inhibiting its C/EBP-mediated activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; RECEPTOR-GAMMA; FUNCTIONAL DOMAINS; GLYCERIDE-GLYCEROL; ADIPOSE EXPRESSION; MESSENGER-RNA; RESPONSE UNIT; PROMOTER; BETA; IDENTIFICATION	ddThe cytosolic form of the phosphoenolpyruvate carboxykinase (PEPCK-C) gene is selectively expressed in several tissues, primarily in the liver, kidney, and adipose tissue. The transcription of the gene is reciprocally regulated by glucocorticoids in these tissues. It is induced in the liver and kidney but repressed in the white adipose tissue. To elucidate which adipocyte-specific transcription factors participate in the repression of the gene, DNase I footprinting analyses of nuclear proteins from 3T3-F442A adipocytes and transient transfection experiments in NIH3T3 cells were utilized. Glucocorticoid treatment slightly reduced the nuclear C/EBPalpha concentration but prominently diminished the binding of adipocyte-derived nuclear proteins to CCAAT/enhancer-binding protein (C/EBP) recognition sites, without affecting the binding to nuclear receptor sites in the PEPCK-C gene promoter. Of members of the C/EBP family of transcription factors, C/EBPa was the strongest trans-activator of the PEPCK-C gene promoter in the NIH3T3 cell line. The glucocorticoid receptor (GR), in the presence of its hormone ligand, inhibited the activation of the PEPCK-C gene promoter by C/EBPa or C/EBPbeta but not by the adipocyte-specific peroxisome proliferator-activated receptor gamma2. This inhibition effect was similar using the wild type or mutant GR and did not depend on GR binding to the DNA. The glucocorticoid response unit (GRU) in the PEPCK-C gene promoter (-2000 to +73) restrained C/EBPalpha-mediated transactivation, because mutation of each single GRU element increased this activation by 3-4-fold. This series of GRU mutations were repressed by wild type GR to the same percent as was the nonmutated PEPCK-C gene promoter. In contrast, the repression by mutant GR depended on the intact AF1 site in the gene promoter, whereby mutation of the AF1 element abolished the repression.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biochem, IL-91120 Jerusalem, Israel; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Hebrew University of Jerusalem; Case Western Reserve University	Reshef, L (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biochem, IL-91120 Jerusalem, Israel.	reshef@cc.huji.ac.il		Blum, Barak/0000-0002-5308-4194	NIDDK NIH HHS [DK22541] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Allen-Jennings AE, 2002, J BIOL CHEM, V277, P20020, DOI 10.1074/jbc.M200727200; BALLARD FJ, 1967, J BIOL CHEM, V242, P2746; BAXTER JD, 1979, GLUCOCORTICOID HORMO, P10; BEALE EG, 1985, J BIOL CHEM, V260, P748; BENVENISTY N, 1987, P NATL ACAD SCI USA, V84, P1132, DOI 10.1073/pnas.84.5.1132; BENVENISTY N, 1989, P NATL ACAD SCI USA, V86, P1118, DOI 10.1073/pnas.86.4.1118; BERNE RM, 1998, PHYSIOLOGY, P942; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Botion LM, 1998, METABOLISM, V47, P1217, DOI 10.1016/S0026-0495(98)90326-2; Cassuto H, 1997, FEBS LETT, V412, P597, DOI 10.1016/S0014-5793(97)00867-3; Cassuto H, 1999, FEBS LETT, V457, P441, DOI 10.1016/S0014-5793(99)01080-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Eubank DW, 2001, J BIOL CHEM, V276, P30561, DOI 10.1074/jbc.M103019200; FABER S, 1993, J BIOL CHEM, V268, P24976; FEIFE LE, 2002, AM J PHYSIOL, V283, pF678; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; Lechner PS, 2001, J BIOL CHEM, V276, P22675, DOI 10.1074/jbc.M102422200; Lethimonier C, 2002, ENDOCRINOLOGY, V143, P2961, DOI 10.1210/en.143.8.2961; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTINSANZ P, 1990, BIOCHEM J, V271, P575, DOI 10.1042/bj2710575; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Raitskin O, 2001, P NATL ACAD SCI USA, V98, P6571, DOI 10.1073/pnas.111153798; RESHEF L, 1967, J LIPID RES, V8, P688; RESHEF L, 1969, J BIOL CHEM, V244, P5577; RESHEF L, 1970, HORM METAB RES S2, V2, P1136; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Williams CP, 1999, MOL CELL ENDOCRINOL, V148, P67, DOI 10.1016/S0303-7207(98)00234-2; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124	61	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12929	12936		10.1074/jbc.M300263200	http://dx.doi.org/10.1074/jbc.M300263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560325	hybrid			2022-12-27	WOS:000182189500044
J	Quadri, SK; Bhattacharjee, M; Parthasarathi, K; Tanita, T; Bhattacharya, J				Quadri, SK; Bhattacharjee, M; Parthasarathi, K; Tanita, T; Bhattacharya, J			Endothelial barrier strengthening by activation of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; E-CADHERIN; ACTIN; RAC; CATENIN; CDC42; RHO; PERMEABILITY	Endothelial cell barrier (EC) properties regulate blood tissue fluid flux. To determine the role of endothelial-matrix interactions in barrier regulation, we induced cell shrinkage by exposing confluent endothelial monolayers to hyperosmolarity. The dominant effect of a 15-min hyperosmolar exposure was an increase in the trans-endothelial electrical resistance, indicating the induction of barrier strengthening. Hyperosmolar exposure also increased activity of focal adhesion kinase and E-cadherin accumulation at the cell periphery. Concomitantly, the density of actin filaments increased markedly. In EC monolayers stably expressing constitutively active or dominant negative isoforms of Rac1, the actin response to hyperosmolar exposure was enhanced or blocked, respectively; although the response in transendothelial resistance was unaffected, indicating that the endothelial barrier enhancement occurred independently of actin. However, in monolayers expressing a kinase-deficient mutant of focal adhesion kinase, the hyperosmolarity-induced increases in activity of focal adhesion and peripheral E-cadherin enhancement were blocked and the induced increase of electrical resistance was markedly blunted. These findings indicate that in EC exposed to hyperosmolar challenge, the involvement of focal adhesion kinase was critical in establishing barrier strengthening.	Columbia Univ, St Lukes Roosevelt Hosp Ctr, Lung Biol Lab, Coll Phys & Surg, New York, NY 10019 USA; Iwate Med Univ, Sch Med, Dept Thorac Surg, Iwate 0208505, Japan	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Iwate Medical University	Bhattacharya, J (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, Lung Biol Lab, Coll Phys & Surg, 1000 10th Ave, New York, NY 10019 USA.				NHLBI NIH HHS [HL36024, HL57556, HL64896] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057556, R37HL036024, R01HL064896, R01HL036024] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Ehringer WD, 1999, MICROCIRCULATION, V6, P291; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J INVEST MED, V43, P117; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Glogauer M, 1997, J CELL SCI, V110, P11; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289; Moy AB, 2000, AM J PHYSIOL-LUNG C, V278, pL888, DOI 10.1152/ajplung.2000.278.5.L888; Ory S, 2000, J CELL SCI, V113, P1177; Paemeleire K, 1999, EXP BRAIN RES, V126, P473, DOI 10.1007/s002210050755; PHILLIPS PG, 1994, SEMIN THROMB HEMOST, V20, P417, DOI 10.1055/s-2007-1001930; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Ragette R, 1997, J CLIN INVEST, V100, P685, DOI 10.1172/JCI119581; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	39	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13342	13349		10.1074/jbc.M209922200	http://dx.doi.org/10.1074/jbc.M209922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556538	hybrid			2022-12-27	WOS:000182189500095
J	Santos, M; Perez, P; Segrelles, C; Ruiz, S; Jorcano, JL; Paramio, JM				Santos, M; Perez, P; Segrelles, C; Ruiz, S; Jorcano, JL; Paramio, JM			Impaired NF-kappa B activation and increased production of tumor necrosis factor alpha in Transgenic mice expressing keratin K10 in the basal layer of the epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; GENE-EXPRESSION; INTERMEDIATE-FILAMENTS; RELA/P65 SUBUNIT; IKK ACTIVATION; SKIN; PROTEIN; KINASE; AKT; GROWTH	Both the diversity and the precisely regulated tissue-and differentiation-specific expression patterns of keratins suggest that these proteins have specific functions in epithelia besides their well known maintenance of cell integrity. In the search for these specific functions, our previous results have demonstrated that the expression of K10, a keratin expressed in postmitotic suprabasal cells of the epidermis, prevents cell proliferation through the inhibition of Akt kinase activity. Given the roles of Alit in NF-kappaB signaling and the importance of these processes in the epidermis, a study was made into the possible alterations of the NF-kappaB pathway in transgenic mice expressing K10 in the proliferative basal layer. It was found that the inhibition of Akt, mediated by K10 expression, leads to impaired NF-kappaB activity. This appears to occur through the decreased expression of IKKbeta and IKKgamma. Remarkably, increased production of tumor necrosis factor a and concomitant JNK activation was observed in the epidermis of these transgenic mice. These results confirm that keratin K10 functions in vivo include the control of many aspects of epithelial physiology, which affect the cells not only in a cell autonomous manner but also influence tissue homeostasis.	CIEMAT, Dept Cell & Mol Biol, E-28040 Madrid, Spain; Inst Biomed Valencia, Valencia 46010, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Paramio, JM (corresponding author), CIEMAT, Dept Cell & Mol Biol, Ave Complutense 22, E-28040 Madrid, Spain.	jesusm.paramio@ciemat.es	Santos, Mirentxu/AAA-1727-2020; Segrelles, Carmen/E-3655-2016; Paramio, Jesus M/M-8482-2014; Perez, Paloma/K-8841-2017; Ruiz, Sergio/G-1561-2016	Segrelles, Carmen/0000-0001-9340-2102; Paramio, Jesus M/0000-0001-7520-3177; Perez, Paloma/0000-0002-7166-2824; Ruiz, Sergio/0000-0002-0177-6965				Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS EV, 1997, MOL BIOL CELL, V69, P899; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Relchelt J, 2002, J CELL SCI, V115, P2639; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; ROOP DR, 1988, CANCER RES, V48, P3245; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; TOFTGARD R, 1985, CANCER RES, V45, P5845; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	64	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13422	13430		10.1074/jbc.M208170200	http://dx.doi.org/10.1074/jbc.M208170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566451	hybrid			2022-12-27	WOS:000182189500105
J	Tebo, J; Der, S; Frevel, M; Khabar, KSA; Williams, BRG; Hamilton, TA				Tebo, J; Der, S; Frevel, M; Khabar, KSA; Williams, BRG; Hamilton, TA			Heterogeneity in control of mRNA stability by AU-rich elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STABILIZATION; CYTOKINE; REGION; TRANSCRIPTION; BIOSYNTHESIS; DEGRADATION; INHIBITION; SEQUENCE; ALPHA	AU-rich elements (AREs), located in the 3'-untranslated region of unstable cytokine and chemokine mRNAs, promote rapid decay of otherwise stable mRNAs and may mediate selective mRNA stabilization in response to stimulation with interleukin-1 (IL-1). AREs vary considerably, however, in both size and sequence context. To assess the heterogeneity involved in control of mRNA stability by ARE motifs, human mRNA sequences from IL-1alpha-stimulated HEK293 cells and T98G cells were screened for either instability or stability using both cDNA (950 ARE containing sequences) and Affymetrix oligonucleotide (U95Av2 GeneChip) array analysis. Although ARE-containing mRNAs exhibited a broad range of stability, IL-1alpha promoted stability in a subset of mRNAs that were unstable when transcriptionally induced by tumor necrosis factor alpha. Stabilization of granulocyte/macrophage-colony stimulating factor and IL-8 mRNAs by IL-1alpha was achieved only after 2 h of stimulation, required ongoing protein synthesis, and depended on the activation of p38 MAPK. In contrast, stabilization of Gro3 mRNA in response to IL-1alpha was achieved immediately and was insensitive to inhibitors of protein synthesis and p38 MAPK activation. In concert, these findings demonstrate that ARE sequences are functionally heterogeneous; only a subset of unstable mRNAs is sensitive to stabilization by IL-1alpha. Moreover, IL-1alpha promotes stabilization of unstable mRNAs through distinct mechanistic pathways that distinguish between specific mRNA sequences.	Cleveland Clin Fdn, Dept Immunol NB30, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Toronto; King Faisal Specialist Hospital & Research Center	Hamilton, TA (corresponding author), Cleveland Clin Fdn, Dept Immunol NB30, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hamiltt@ccf.org	Hamilton, Thomas Edward/GQB-4837-2022; Hamilton, Thomas A/A-7756-2009; Williams, Bryan R. G./A-5021-2009; Khabar, Khalid/AAG-3487-2019; Khabar, Khalid/A-4772-2011	Williams, Bryan R. G./0000-0002-4969-1151; Khabar, Khalid/0000-0003-1003-9788; Khabar, Khalid/0000-0003-1003-9788; Hamilton, Thomas/0000-0002-9817-242X	NCI NIH HHS [CA62220, CA39621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220, R01CA039621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HAMILTON TA, 2002, NATURAL IMMUNE SYSTE, V2, P73; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; NATHAN CF, 1995, TXB RHEUMATOLOGY, P144; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; Stoecklin G, 2001, RNA, V7, P1578; Tebo JM, 1998, BLOOD, V92, P4742, DOI 10.1182/blood.V92.12.4742.424k26_4742_4749; Tebo JM, 2000, J BIOL CHEM, V275, P12987, DOI 10.1074/jbc.275.17.12987; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001	27	100	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12085	12093		10.1074/jbc.M212992200	http://dx.doi.org/10.1074/jbc.M212992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556523	hybrid			2022-12-27	WOS:000182015700049
J	King, KE; Iyemere, VP; Weissberg, PL; Shanahan, CM				King, KE; Iyemere, VP; Weissberg, PL; Shanahan, CM			Kruppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor beta 1 in the regulation of vascular smooth muscle cell phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; IN-VIVO; OSTEOGENIC PROTEIN-1; NEGATIVE REGULATION; GENE-EXPRESSION; ARTERIAL INJURY; RAT; RECEPTORS; ELEMENT; ACTIVIN	Vascular smooth muscle cell (VSMC) differentiation and phenotypic modulation is characterized by changes in mRNA expression for smooth muscle (SM) marker contractile proteins such as alpha-SM actin and SM22alpha. Transforming growth factor beta1 (TGF-beta1) is a potent VSMC differentiation factor; however, it is not known if other TGF-beta-superfamily members, in particular the bone morphogenetic proteins (BMPs), modulate VSMC phenotype. Here we demonstrate that a large subset of TGF-beta-superfamily members and their type I receptors are differentially co-expressed as VSMC phenotype changes during fetal/neonatal development and that BMP2, -4, and -6 reciprocally regulate SM-marker mRNA and protein expression in vitro. BMP2 and BMP6 decrease expression of the SM markers alpha-SM actin, SM22alpha, and calponin in rat VSMCs, whereas BMP4 increases their expression. The effects of BMP-2, -4, and -6 on SM marker gene transcription are mediated through a consensus TGF-beta-controlling element, the TCE, which is common to regulatory regions of SM-marker genes. Moreover, co-treatment experiments revealed that BMP-2, -4, and -6 each inhibit TGF-beta1-modulated increases in SM22a reporter gene activity. Regardless of whether they positively or negatively regulate SM marker expression, TGF-beta1 and BMP-2, -4, and -6 all induced binding of the Kruppel-like transcription factor, GKLF/KLF4, to the TGF-beta control element. Induction of KLF4 was confirmed by immunocytochemistry and Western blotting, which revealed that a lower molecular weight KLF4 protein is induced after treatment with TGF-beta-superfamily members. Taken together, our results demonstrate that multiple members of the TGF-beta superfamily act in concert to modulate VSMC phenotype.	Univ Cambridge, Addenbrookes Ctr Clin Invest Level 6, Dept Med, Cambridge CB2 2QQ, England	University of Cambridge	Shanahan, CM (corresponding author), Univ Cambridge, Addenbrookes Ctr Clin Invest Level 6, Dept Med, Box 110 Addenbrookes Hosp,Hills Rd, Cambridge CB2 2QQ, England.			Shanahan, Catherine/0000-0002-8352-8171				Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Agrotis A, 1996, BIOCHEM BIOPH RES CO, V219, P613, DOI 10.1006/bbrc.1996.0282; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Chang H, 1999, DEVELOPMENT, V126, P1631; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; Engelse MA, 1999, CIRC RES, V85, P931; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JONES CM, 1991, DEVELOPMENT, V111, P531; Jung F, 1999, ARTERIOSCL THROM VAS, V19, P2591, DOI 10.1161/01.ATV.19.11.2591; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; LYONS KM, 1990, DEVELOPMENT, V109, P833; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MCCAFFERY RE, 1994, J GEN VIROL, V75, P3047, DOI 10.1099/0022-1317-75-11-3047; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; Miyazono K, 2000, J CELL SCI, V113, P1101; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakaoka T, 1997, J CLIN INVEST, V100, P2824, DOI 10.1172/JCI119830; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALTIS J, 1992, AM J PHYSIOL, V263, pC420, DOI 10.1152/ajpcell.1992.263.2.C420; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SCHLUESENER HJ, 1995, ATHEROSCLEROSIS, V113, P153, DOI 10.1016/0021-9150(94)05438-O; SHAH M, 1995, J CELL SCI, V108, P985; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Shanahan CM, 1998, ARTERIOSCL THROM VAS, V18, P333, DOI 10.1161/01.ATV.18.3.333; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; Ward MR, 1997, ARTERIOSCL THROM VAS, V17, P2461, DOI 10.1161/01.ATV.17.11.2461; Yang X, 1999, DEVELOPMENT, V126, P1571	43	94	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11661	11669		10.1074/jbc.M211337200	http://dx.doi.org/10.1074/jbc.M211337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538588	hybrid			2022-12-27	WOS:000181855400100
J	Matsui, Y; Chansky, HA; Barahmand-Pour, F; Zielinska-Kwiatkowska, A; Tsumaki, N; Myoui, A; Yoshikawa, H; Yang, L; Eyre, DR				Matsui, Y; Chansky, HA; Barahmand-Pour, F; Zielinska-Kwiatkowska, A; Tsumaki, N; Myoui, A; Yoshikawa, H; Yang, L; Eyre, DR			COL11A2 collagen gene transcription is differentially regulated by EWS/ERG sarcoma fusion protein and wild-type ERG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR GENE; HISTONE DEACETYLASE; EWINGS-SARCOMA; CELL-LINE; MOLECULAR-CLONING; PROMOTER ACTIVITY; BINDING PROTEIN; DNA-BINDING; EWS GENE; NF-Y	A specific t(21;22) chromosomal translocation creates the chimeric EWS/ERG gene in some cases of Ewing's sarcoma. In the resultant EWS/ERG fusion protein, the N-terminal part of the ETS family protein ERG is replaced by the N terminus of the RNA-binding protein EWS. We found that both the EWS/ERG and COL11A2 genes are expressed in the Ewing's sarcoma cell line, CADO-ES1. To investigate a potential role for EWS/ERG in COL11A2 gene expression, we characterized the COL11A2 promoter and tested the ability of wild-type ERG and EWS/ERG sarcoma fusion protein to transactivate COL11A2 promoter using a luciferase assay. We found that expression of EWS/ERG, but not wild-type ERG, transactivated the COL11A2 promoter and that this transactivation required not only the N-terminal region of EWS but also an intact DNA-binding domain from ERG. Electrophoretic mobility shift assay using COL11A2 promoter sequence showed involvement of EWS/ERG in the formation of DNA-protein complexes, and chromatin immunoprecipitation assay revealed direct interaction between COL11A2 promoter and EWS/ERG fusion protein in vivo. EWS/ERG, but not wild-type ERG, bound to RNA polymerase II. Treatment of cells with the histone deacetylase inhibitor trichostatin A enabled ERG to transactivate the COL11A2 promoter, therefore abolishing the differential effects of EWS/ERG and ERG. Taken together, these findings indicate that the COL11A2 gene is regulated both by potential ERG association with a histone deacetylase complex and by direct EWS/ERG recruitment of RNA polymerase II.	Osaka Univ, Sch Med, Dept Orthoped Surg, Suita, Osaka 5650871, Japan; Univ Washington, Dept Orthoped & Sports Med, Sch Med, Seattle, WA 98195 USA	Osaka University; University of Washington; University of Washington Seattle	Yang, L (corresponding author), Univ Washington, Dept Orthoped & Sports Med, Sch Med, Box 358280, Seattle, WA 98108 USA.		Myoui, Akira/E-8296-2010	Tsumaki, Noriyuki/0000-0002-0520-3654	NCI NIH HHS [1R01CA90941] Funding Source: Medline; NIAMS NIH HHS [R37 AR037318, 5R37AR36794, 5R01AR37318, R01 AR036794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR037318, R37AR036794, R01AR037318, R01AR036794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annunen S, 1999, AM J HUM GENET, V65, P974, DOI 10.1086/302585; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Chansky HA, 2001, CANCER RES, V61, P3586; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; Ginsberg JP, 1999, J CLIN ONCOL, V17, P1809, DOI 10.1200/JCO.1999.17.6.1809; GOJI J, 1992, CANCER RES, V52, P4214; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Im YH, 2000, CANCER RES, V60, P1536; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KODAMA K, 1991, CANCER GENET CYTOGEN, V57, P19, DOI 10.1016/0165-4608(91)90185-W; KODAMA K, 1994, JPN J CANCER RES, V85, P335, DOI 10.1111/j.1349-7006.1994.tb02363.x; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; Lui VCH, 1996, GENOMICS, V32, P401, DOI 10.1006/geno.1996.0135; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Matsui Y, 1998, CANCER LETT, V124, P143, DOI 10.1016/S0304-3835(97)00468-0; MORSE RH, 1991, J MOL BIOL, V222, P133, DOI 10.1016/0022-2836(91)90198-F; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; OHNO T, 1994, ONCOGENE, V9, P3087; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; REDDY ESP, 1991, ONCOGENE, V6, P2285; Reymond A, 2002, NATURE, V420, P582, DOI 10.1038/nature01178; Rudge TL, 2002, EXP CELL RES, V274, P45, DOI 10.1006/excr.2001.5451; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Soldatenkov VA, 2002, ONCOGENE, V21, P2890, DOI 10.1038/sj.onc.1205393; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Tanaka K, 2002, MOL CELL BIOL, V22, P4256, DOI 10.1128/MCB.22.12.4256-4267.2002; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Verger A, 2001, J BIOL CHEM, V276, P17181, DOI 10.1074/jbc.M010208200; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; YANG L, 1994, J BIOL CHEM, V269, P32732; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000	49	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11369	11375		10.1074/jbc.M300164200	http://dx.doi.org/10.1074/jbc.M300164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12554743	hybrid			2022-12-27	WOS:000181855400065
J	Lu, YB; Pan, ZZ; Devaux, Y; Ray, P				Lu, YB; Pan, ZZ; Devaux, Y; Ray, P			p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte growth factor receptor and participates in keratinocyte growth factor-mediated inhibition of oxidant-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; BRANCHING MORPHOGENESIS; TYROSINE KINASES; HEPARAN-SULFATE; ACTIVATION; LUNG; NCK; COMPLEX; GRB2; DIFFERENTIATION	Keratinocyte growth factor (KGF), a member of the fibroblast growth factor (FGF) family (also known as FGF-7), is an important protective factor for epithelial cells. The receptor for KGF (also called FGFR2-IIIb), which has intrinsic tyrosine kinase activity, is expressed specifically on epithelial cells and in the lung epithelium. Administration of KGF has been shown to protect the lung from various insults, but the mechanism of protection is not well understood. To understand the mechanism by which KGF exerts protective functions on epithelial cells, we used the yeast two-hybrid assay to identify proteins that interact with the KGF receptor (KGFR). Here we show that the cytoplasmic domain of KGFR interacts with p21-activated protein kinase (PAK) 4, which is a new member of the PAK family. The PAKs are regulated by the Rho-family GTPases Rac and Cdc42. PAK4 is the most divergent member of the PAK family of proteins and may have distinct functions. However, stimuli that regulate PAK4 activity are not known. Our data show that PAK4 can associate with the KGFR, which is dependent on KGFR tyrosine kinase activity. We show that a dominant negative mutant of PAK4 blocks KGF-mediated inhibition of caspase-3 activation in epithelial cells subjected to oxidant stress. Our data demonstrate that PAK4 is an important mediator of the anti-apoptotic effects of KGF on epithelial cells.	Univ Pittsburgh, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, Pittsburgh, PA 15213 USA; Yale Univ, Sch Med, New Haven, CT 06510 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Fox Chase Cancer Center	Ray, P (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, 3459 5th Ave,MUH 628 NW, Pittsburgh, PA 15213 USA.	rayp@pitt.edu	Pan, Zhong-Zong/B-6964-2012; DEVAUX, Yvan/AAK-3463-2020		NHLBI NIH HHS [HL 60207, R01 HL069810, HL 69810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069810, R01HL060207] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cardoso WV, 1997, DEV DYNAM, V208, P398, DOI 10.1002/(SICI)1097-0177(199703)208:3<398::AID-AJA10>3.0.CO;2-X; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guo J, 1998, AM J PHYSIOL-LUNG C, V275, pL800, DOI 10.1152/ajplung.1998.275.4.L800; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yano T, 1996, AM J RESP CELL MOL, V15, P433, DOI 10.1165/ajrcmb.15.4.8879176; Yi ES, 1996, AM J PATHOL, V149, P1963; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	41	39	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10374	10380		10.1074/jbc.M205875200	http://dx.doi.org/10.1074/jbc.M205875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529371	hybrid			2022-12-27	WOS:000181777500052
J	Mzhavia, N; Pan, H; Che, FY; Fricker, LD; Devi, LA				Mzhavia, N; Pan, H; Che, FY; Fricker, LD; Devi, LA			Characterization of endothelin-converting enzyme-2 - Implication for a role in the nonclassical processing of regulatory peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; PROENKEPHALIN-A; PROPROTEIN CONVERTASES; FAMILY; GENE; PURIFICATION; EXPRESSION; PROSAAS; BRAIN; METALLOPROTEASE	Most neuroendocrine peptides are generated by proteolysis of the precursors at basic residue cleavage sites. Prohormone convertases belonging to the subtilisin family of serine proteases are primarily responsible, for processing at these "classical sites." In addition to the classical cleavages, a subset of bioactive peptides is generated by processing at "nonclassical" sites. The proteases responsible for these cleavages have not been well explored. Members of several metalloprotease families have been proposed to be involved in nonclassical processing. Among them, endothelin-converting enzyme-2 (ECE-2) is a good candidate because it exhibits a neuroendocrine distribution and an acidic pH optimum. To examine the involvement of this protease in neuropeptide processing, we purified the recombinant enzyme and characterized its catalytic activity. Purified ECE-2 efficiently processes big endothelin-1 to endothelin-1 by cleavage between Trp(21) and Val(22) at acidic pH. To characterize the substrate specificity of ECE-2, we used mass spectrometry with a panel of 42 peptides as substrates to identify the products. Only 10 of these 42 peptides were processed by ECE-2. A comparison of residues around the cleavage site revealed that ECE-2 exhibits a unique cleavage site selectivity that is related to but distinct from that of ECE-1. ECE-2 tolerates a wide range of amino acids in the P1-position and prefers aliphatic/aromatic residues in the P1'-position. However, only a small fraction of the aliphatic/aromatic amino acid-containing sites were cleaved, indicating that there are additional constraints beyond the P1- and P1'-positions. The enzyme is able to generate a number of biologically active peptides from peptide intermediates, suggesting an important role for this enzyme in the biosynthesis of regulatory peptides. Also, ECE-2 processes proenkephalin-derived bovine adrenal medulla peptides, and this processing leads to peptide products known to have differential receptor selectivity. Finally, ECE-2 processes PEN-LEN, an endogenous inhibitor of prohormone convertase 1, into products that do not inhibit the enzyme. Taken together, these results are consistent with an important role for ECE-2 in the processing of regulatory peptides at nonclassical sites.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	Lakshmi.Devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Mzhavia, Nino/0000-0001-8602-9987	NIDA NIH HHS [DA00458, DA 04494, K02 DA000458, R01 DA004494] Funding Source: Medline; NINDS NIH HHS [R01 NS026880, NS 26880] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026880, R01NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000458] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; Che FY, 2001, P NATL ACAD SCI USA, V98, P9971, DOI 10.1073/pnas.161542198; Davenport AP, 2000, J CARDIOVASC PHARM, V36, pS12, DOI 10.1097/00005344-200036051-00006; DAVIS TP, 1990, EUR J PHARMACOL, V191, P253, DOI 10.1016/0014-2999(90)94157-S; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DRAY A, 1985, J PHARMACOL EXP THER, V235, P670; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Fahnoe DC, 2000, ARCH BIOCHEM BIOPHYS, V373, P385, DOI 10.1006/abbi.1999.1586; Fahnoe DC, 2000, J CARDIOVASC PHARM, V36, pS22, DOI 10.1097/00005344-200036051-00009; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; Ikeda S, 2002, BIOCHEM BIOPH RES CO, V293, P421, DOI 10.1016/S0006-291X(02)00252-8; Johnson GD, 2000, ANAL BIOCHEM, V286, P112, DOI 10.1006/abio.2000.4772; Johnson GD, 2002, ARCH BIOCHEM BIOPHYS, V398, P240, DOI 10.1006/abbi.2001.2708; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Lembo PMC, 2002, NAT NEUROSCI, V5, P201, DOI 10.1038/nn815; Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V97, P1283, DOI 10.1016/S0006-291X(80)80005-2; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V95, P1482, DOI 10.1016/S0006-291X(80)80064-7; Molineaux C, 1991, PEPTIDE BIOSYNTHESIS, P251; Mzhavia N, 1999, DNA CELL BIOL, V18, P369, DOI 10.1089/104454999315268; Mzhavia N, 2002, BIOCHEM J, V361, P67, DOI 10.1042/0264-6021:3610067; Mzhavia N, 2001, J BIOL CHEM, V276, P6207, DOI 10.1074/jbc.M009067200; Nakagomi S, 2000, NEUROSCIENCE, V101, P441, DOI 10.1016/S0306-4522(00)00345-6; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PITTIUS CW, 1984, BRAIN RES, V304, P127, DOI 10.1016/0006-8993(84)90868-0; PITTIUS CW, 1983, LIFE SCI, V33, P41, DOI 10.1016/0024-3205(83)90439-3; Qian YM, 2000, J BIOL CHEM, V275, P23596, DOI 10.1074/jbc.M001583200; Russell FD, 1999, CIRC RES, V84, P891; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; Seidah NG, 1999, ANN NY ACAD SCI, V885, P57; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; SIGAFOOS J, 1993, J ANAT, V183, P253; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; Vilim FS, 1999, MOL PHARMACOL, V55, P804; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	43	40	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14704	14711		10.1074/jbc.M211242200	http://dx.doi.org/10.1074/jbc.M211242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12560336	Green Accepted, hybrid			2022-12-27	WOS:000182516100017
J	Ghosh, P; Kornfeld, S				Ghosh, P; Kornfeld, S			Phosphorylation-induced conformational changes regulate GGAs 1 and 3, function at the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; KINASE-II PHOSPHORYLATION; EAR HOMOLOGY DOMAIN; GAMMA-ADAPTIN; VHS DOMAINS; CYTOPLASMIC DOMAINS; PROTEINS INTERACT; STRUCTURAL BASIS; BINDING; AP-1	The GGAs ((G) under bar olgi-localizing, (&gamma;) under bar -adaptin ear homology domain, (A) under bar RF-binding) are a family of multidomain proteins implicated in protein trafficking between the Golgi and the endosomes. All three GGAs (1, 2, and 3). bind to the mannose. 6-phosphate receptor tail via their VHS domains, as well as to the adaptor protein complex-1 via their hinge domains. The latter interaction has been proposed to be important for cooperative packaging of cargo into forming clathrin-coated carriers at the trans-Golgi network. Here we present evidence that GGA1 function is highly regulated by cycles of phosphorylation and dephosphorylation. Cell fractionation showed that the phosphorylated pool of GGA1 resided predominantly in the cytosol and that recruitment onto membranes was associated with dephosphorylation. Okadaic acid inhibition studies and in vitro dephosphorylation assays indicated that dephosphorylation is mediated by a protein phosphatase 2A-like phosphatase. Dephosphorylation of GGA1 induced a change in the conformation to an "open" form as measured by gel filtration and sucrose gradient analyses. This was associated with enhanced binding to ligands because of release of autoinhibition and increased binding to the adaptor protein complex-1 gamma-appendage. A model is proposed for the regulation of GGA1 function at the trans-Golgi network.	Washington Univ, Sch Med, Div Hematol, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.				NCI NIH HHS [CA08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTRAND F, 1997, J BIOL CHEM, V272, P13856; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Doray B, 2002, P NATL ACAD SCI USA, V99, P8072, DOI 10.1073/pnas.082235699; Doray B, 2002, J BIOL CHEM, V277, P18477, DOI 10.1074/jbc.M201879200; Ghosh P, 2003, J CELL BIOL, V160, P699, DOI 10.1083/jcb.200211080; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Kato Y, 2002, NAT STRUCT BIOL, V9, P532, DOI 10.1038/nsb807; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; PUERTOLLANO R, 2003, IN PRESS MOL BIOL CE; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Varlamov O, 2001, J CELL SCI, V114, P311; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	29	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14543	14549		10.1074/jbc.M212543200	http://dx.doi.org/10.1074/jbc.M212543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578827	hybrid			2022-12-27	WOS:000182405000122
J	Lauer-Fields, JL; Malkar, NB; Richet, G; Drauz, K; Fields, GB				Lauer-Fields, JL; Malkar, NB; Richet, G; Drauz, K; Fields, GB			Melanoma cell CD44 interaction with the alpha 1(IV)1263-1277 region from basement membrane collagen is modulated by ligand glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; AMINO-ACID-SEQUENCE; IV COLLAGEN; TRIPLE-HELIX; MOLECULAR ARCHITECTURE; ALPHA(3)BETA(1) INTEGRIN; SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; DISACCHARIDE UNIT	Invasion of the basement membrane is believed to be a critical step in the metastatic process. Melanoma cells have been shown previously to bind distinct triple-helical regions within basement membrane (type IV) collagen. Additionally, tumor cell binding sites within type IV collagen contain glycosylated hydroxylysine residues. In the present study, we have utilized triple-helical models of the type IV collagen alpha1(IV)1263-1277 sequence to (a) determine the melanoma cell receptor for this ligand and (b) analyze the results of single-site glycosylation on melanoma cell recognition. Receptor identification was achieved by a combination of methods, including (a) cell adhesion and spreading assays using triple-helical alpha1(IV)1263-1277 and an Asp(1266)Abu variant, W inhibition of cell adhesion and spreading assays, and (c) triple-helical al(IV)1263-1277 affinity chromatography with whole cell lysates and glycosaminoglycans. Triple-helical alpha1(IV)1263-1277 was bound by melanoma cell CD44/chondroitin sulfate proteoglycan receptors and not by the collagen-binding integrins or melanoma-associated proteoglycan. Melanoma cell adhesion to and spreading on the triple-helical al. (M 12631277 sequence was then compared for glycosylated (replacement of Lys(1265) with Hyl(O-beta-(D)-galactopyranosyl)) versus non-glycosylated ligand. Glycosylation was found to strongly modulate both activities, as adhesion and spreading were dramatically decreased due to the presence of galactose. CD44/chondroitin sulfate proteoglycan did not bind to glycosylated alpha1(IV)1263-1277. Overall, this study (a) is the first demonstration of the prophylactic effects of glycosylation on tumor cell interaction with the basement membrane, (b) provides a rare example of an apparent unfavorable interaction between carbohydrates, and (c) suggests that sugars may mask "cryptic sites" accessible to tumor cells with cell surface or secreted glycosidase activities.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Degussa Rexim SA, F-80400 Ham, France; Degussa AG, D-63457 Hanau, Germany	State University System of Florida; Florida Atlantic University; Evonik Industries; Evonik Industries	Lauer-Fields, JL (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	fieldsg@fau.edu			NCI NIH HHS [CA 77402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BABIARZ B, 1992, EXP CELL RES, V203, P276, DOI 10.1016/0014-4827(92)90065-G; Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; Bella J, 2000, STRUCTURE, V8, pR121, DOI 10.1016/S0969-2126(00)00153-2; BERMAN A, 1993, BIOCHEM BIOPH RES CO, V194, P351, DOI 10.1006/bbrc.1993.1827; Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820; BORGIA JA, 2001, J BIOMOLECULAR TECHN, V12, P4; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Broddefalk J, 1998, J AM CHEM SOC, V120, P7676, DOI 10.1021/ja980489k; BUTLER WT, 1966, J BIOL CHEM, V241, P3882; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CHRUMS SC, 1982, CRC HDB CHROMATOGRAP, V1, P190; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Dome B, 2001, VIRCHOWS ARCH, V439, P628; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FIELDS CG, 1993, PEPTIDE RES, V6, P39; Fields CG, 1996, LETT PEPT SCI, V3, P3, DOI 10.1007/BF00131080; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, TETRAHEDRON LETT, V34, P6661, DOI 10.1016/S0040-4039(00)61669-6; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; Fields GB, 1998, BIOPOLYMERS, V47, P143, DOI 10.1002/(SICI)1097-0282(1998)47:2<143::AID-BIP3>3.0.CO;2-U; FIELDS GB, 2001, SYNTHETIC PEPTIDES U, P93; Forns P, 2000, BIOPOLYMERS, V54, P531, DOI 10.1002/1097-0282(200012)54:7<531::AID-BIP60>3.0.CO;2-X; Fujisaki T, 1999, CANCER RES, V59, P4427; Golbik R, 2000, J MOL BIOL, V297, P501, DOI 10.1006/jmbi.2000.3575; Goldbrunner RH, 1999, ACTA NEUROCHIR, V141, P295, DOI 10.1007/s007010050301; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAMAZAKI H, 1980, EUR J BIOCHEM, V111, P587, DOI 10.1111/j.1432-1033.1980.tb04975.x; HAMILTON PB, 1955, J BIOL CHEM, V213, P249; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Henkel W, 1999, BIOCHEMISTRY-US, V38, P13610, DOI 10.1021/bi9905157; Herbold KW, 1996, J INVEST DERMATOL, V106, P1230, DOI 10.1111/1523-1747.ep12348871; ISHII I, 1987, COMP BIOCHEM PHYS B, V88, P313, DOI 10.1016/0305-0491(87)90121-0; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; KNUTZ T, 1995, SEA TECHNOL, V36, P68; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Leigh CJ, 1996, HUM PATHOL, V27, P1288, DOI 10.1016/S0046-8177(96)90339-1; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; Li CF, 1997, BIOCHEMISTRY-US, V36, P15404, DOI 10.1021/bi971817g; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Malkar NB, 2002, BIOCHEMISTRY-US, V41, P6054, DOI 10.1021/bi012071w; Malkar NB, 2000, TETRAHEDRON LETT, V41, P1137, DOI 10.1016/S0040-4039(99)02281-9; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; McCarthy JB, 1996, BIOPOLYMERS, V40, P371, DOI 10.1002/(SICI)1097-0282(1996)40:4<371::AID-BIP3>3.3.CO;2-2; MCCARTHY JB, 1993, PEPTIDES 1992, P109; MICKELSON D J, 1991, Journal of Cell Biology, V115, p287A; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; Naor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; NAYAK BR, 1991, J BIOL CHEM, V266, P13978; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; PAULSEN H, 1985, LIEBIGS ANN CHEM, P2028; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PILI R, 1995, CANCER RES, V55, P2920; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; Sacca B, 2002, CHEMBIOCHEM, V3, P904, DOI 10.1002/1439-7633(20020902)3:9<904::AID-CBIC904>3.0.CO;2-I; Spillmann D, 1996, J CELL BIOCHEM, V61, P562, DOI 10.1002/(SICI)1097-4644(19960616)61:4<562::AID-JCB9>3.0.CO;2-M; SPIRO MJ, 1971, J BIOL CHEM, V246, P4910; SPIRO RG, 1969, J BIOL CHEM, V244, P602; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.3.CO;2-K; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; YAMAMOTO M, 1995, EXP CELL RES, V219, P249, DOI 10.1006/excr.1995.1225; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1999, BIOCHEMISTRY-US, V38, P1659, DOI 10.1021/bi982315l; Yu YC, 1997, METHOD ENZYMOL, V289, P571; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656	88	54	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14321	14330		10.1074/jbc.M212246200	http://dx.doi.org/10.1074/jbc.M212246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574156	hybrid			2022-12-27	WOS:000182405000096
J	Brahmbhatt, AA; Klemke, RL				Brahmbhatt, AA; Klemke, RL			ERK and RhoA differentially regulate pseudopodia growth and retraction during chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; ACTIVATED PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; BREAST-CANCER CELLS; LYSOPHOSPHATIDIC ACID; MAP KINASE; MYOSIN-II; FOCAL ADHESIONS; P21-ACTIVATED KINASE; MLC PHOSPHORYLATION	Nonmotile cells extend and retract pseudopodia-like structures in a random manner, whereas motile cells establish a single dominant pseudopodium in the direction of movement. This is a critical step necessary for cell migration and occurs prior to cell body translocation, yet little is known about how this process is regulated. Here we show that myosin II light chain (MLC) phosphorylation at its regulatory serine 19 is elevated in growing and retracting pseudopodia. MLC phosphorylation in the extending pseudopodium was associated with strong and persistent amplification of extracellular-regulated signal kinase (ERK) and MLC kinase activity, which specifically localized to the leading pseudopodium. Interestingly, inhibition of ERK or MLC kinase activity prevented MLC phosphorylation and pseudopodia extension but not retraction. In contrast, inhibition of RhoA activity specifically decreased pseudopodia retraction but not extension. Importantly, inhibition of RhoA activity specifically blocked MLC phosphorylation associated with retracting pseudopodia. Inhibition of either ERK or RhoA signals prevents chemotaxis, indicating that both pathways contribute to the establishment of cell polarity and migration. Together, these findings demonstrate that ERK and RhoA are distinct pathways that control pseudopodia extension and retraction, respectively, through differential modulation of MLC phosphorylation and contractile processes.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Klemke, RL (corresponding author), Scripps Res Inst, Dept Immunol, SP-231,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R29CA078493, T32CA075924] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA75924, 5 R29 CA78493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; BENNETT H, 1986, J CELL SCI, V83, P61; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Buist A, 1998, BIOCHEM BIOPH RES CO, V251, P6, DOI 10.1006/bbrc.1998.9405; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; CHRZANOWSKAWODNICKA M, 1992, BIOESSAYS, V14, P777, DOI 10.1002/bies.950141110; CONTI MA, 1981, J BIOL CHEM, V256, P3178; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Filardo EJ, 1996, J CELL SCI, V109, P1615; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Goetzl EJ, 1999, CANCER RES, V59, P4732; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; Gustafson T, 1999, EXP CELL RES, V253, P288, DOI 10.1006/excr.1999.4744; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HONER B, 1988, EUR J CELL BIOL, V47, P14; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HU YL, 2001, J NATL CANCER I, V93, P734; Imamura F, 1999, CLIN EXP METASTAS, V17, P141, DOI 10.1023/A:1006598531238; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JAY PY, 1995, J CELL SCI, V108, P387; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Jin Z, 1997, J NEUROSCI, V17, P6256; Joshi SA, 1998, FEBS LETT, V441, P67, DOI 10.1016/S0014-5793(98)01527-0; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Machesky LM, 1997, CURR BIOL, V7, pR164, DOI 10.1016/S0960-9822(97)70079-4; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; MILLER JR, 1983, MOL PHARMACOL, V24, P235; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Raj GV, 2002, J UROLOGY, V167, P1458, DOI 10.1016/S0022-5347(05)65345-1; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sliva D, 2000, BIOCHEM BIOPH RES CO, V268, P471, DOI 10.1006/bbrc.2000.2111; Smith JL, 1996, P NATL ACAD SCI USA, V93, P12321, DOI 10.1073/pnas.93.22.12321; STULL JT, 1990, J BIOL CHEM, V265, P16683; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takenawa T, 2001, J CELL SCI, V114, P1801; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; UEDA M, 1994, J CELL SCI, V107, P2071; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; Wittmann T, 2001, J CELL SCI, V114, P3795; Word R. A., 1997, CELLULAR ASPECTS SMO, P209; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yamamura S, 1997, BIOCHEMISTRY-US, V36, P10751, DOI 10.1021/bi970926s; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200	81	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13016	13025		10.1074/jbc.M211873200	http://dx.doi.org/10.1074/jbc.M211873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571246	hybrid			2022-12-27	WOS:000182189500055
J	Ibata-Ombetta, S; Idziorek, T; Trinel, PA; Poulain, D; Jouault, T				Ibata-Ombetta, S; Idziorek, T; Trinel, PA; Poulain, D; Jouault, T			Candida albicans phospholipomannan promotes survival of phagocytosed yeasts through modulation of bad phosphorylation and macrophage apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-DEATH; BETA-1,2-LINKED OLIGOMANNOSIDES; CERAMIDE; ACTIVATION; INFECTION; INHIBITION; PATHWAY; SUPPRESSION; FAMILY	The surface of the pathogenic yeast Candida albicans is coated with phospholipomannan (PLM), a phylogenetically unique glycolipid composed of beta-1,2-oligomannosides and phytoceramide. This study compared the specific contribution of PLM to the modulation of signaling pathways linked to the survival of C. albicans in macrophages in contrast to Saccharomyces cerevisiae. C. albicans endocytosis by J774 and disregulation of the ERK1/2 signal transduction pathway was associated downstream with a reduction in Bad Ser-112 phosphorylation and disappearance of free Bcl-2. This suggested an apoptotic effect, which was confirmed by staining of phosphatidylserine in the macrophage outer membrane. The addition of PLM to macrophages incubated with S. cerevisiae mimicked each of the disregulation steps observed with C. albicans and promoted the survival of S. cerevisiae. Externalization of membranous phosphatidylserine, loss of mitochondrial integrity, and DNA fragmentation induced by PLM showed that this molecule promoted yeast survival by inducing host cell death. These findings suggest strongly that PLM is a virulence attribute of C. albicans and that elucidation of the relationship between structure and apoptotic activity is an innovative field of research.	Fac Med H Warembourg, INSERM U459, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Jouault, T (corresponding author), Univ Lille 2, Lab Mycol Fondamentale & Appl, Fac Med H Warembourg, INSERM EMI0360, Pole Rech,Pl Verdun, F-59037 Lille, France.	tjouault@univ-lille2.fr	Jouault, Thierry/I-1071-2018; Jouault, Thierry/J-7437-2012; Poulain, Daniel/I-6095-2018	Jouault, Thierry/0000-0003-1988-8647; Poulain, Daniel/0000-0002-0729-5468				Aga E, 2002, J IMMUNOL, V169, P898, DOI 10.4049/jimmunol.169.2.898; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Bourbon NA, 2001, AM J PHYSIOL-CELL PH, V280, pC1403, DOI 10.1152/ajpcell.2001.280.6.C1403; Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7; Calderone RA., 2002, CANDIDA CANDIDIASIS; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Fradin C, 1996, J LEUKOCYTE BIOL, V60, P81, DOI 10.1002/jlb.60.1.81; Freire-de-Lima CG, 1998, J IMMUNOL, V161, P4909; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; Gilmore K, 1999, CYTOMETRY, V36, P355, DOI 10.1002/(SICI)1097-0320(19990801)36:4<355::AID-CYTO11>3.0.CO;2-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hacker H, 2002, J IMMUNOL, V169, P3172, DOI 10.4049/jimmunol.169.6.3172; Heidenreich S, 1996, J LEUKOCYTE BIOL, V60, P737, DOI 10.1002/jlb.60.6.737; Heussler VT, 2001, INT J PARASITOL, V31, P1166, DOI 10.1016/S0020-7519(01)00271-5; Ibata-Ombetta S, 2001, J LEUKOCYTE BIOL, V70, P149; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Jouault T, 1998, J INFECT DIS, V178, P792, DOI 10.1086/515361; JOUAULT T, 1994, IMMUNOLOGY, V83, P268; JOUAULT T, 1995, INFECT IMMUN, V63, P2378, DOI 10.1128/IAI.63.6.2378-2381.1995; Jouault T, 2000, INFECT IMMUN, V68, P965, DOI 10.1128/IAI.68.2.965-968.2000; Kanto T, 2001, J IMMUNOL, V167, P3773, DOI 10.4049/jimmunol.167.7.3773; Kim DS, 2001, PIGM CELL RES, V14, P110, DOI 10.1034/j.1600-0749.2001.140206.x; Kitatani K, 2001, ARCH BIOCHEM BIOPHYS, V395, P208, DOI 10.1006/abbi.2001.2573; Kornfeld H, 1999, CELL DEATH DIFFER, V6, P71, DOI 10.1038/sj.cdd.4400454; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Lee JS, 2001, FEBS LETT, V499, P82, DOI 10.1016/S0014-5793(01)02527-3; Liu GL, 1999, CRIT REV CL LAB SCI, V36, P511, DOI 10.1080/10408369991239240; Luberto C, 2001, GENE DEV, V15, P201, DOI 10.1101/gad.856001; Luder CGK, 2001, TRENDS PARASITOL, V17, P480, DOI 10.1016/S1471-4922(01)02093-1; Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Monack D, 2000, INT J MED MICROBIOL, V290, P7; MOORE KJ, 1994, J IMMUNOL, V152, P2930; Navarre WW, 2000, CELL MICROBIOL, V2, P265, DOI 10.1046/j.1462-5822.2000.00056.x; Orth K, 2002, CURR OPIN MICROBIOL, V5, P38, DOI 10.1016/S1369-5274(02)00283-7; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V30, P121, DOI 10.1016/S0732-8893(97)00192-2; Poulain D, 2002, INFECT IMMUN, V70, P4323, DOI 10.1128/IAI.70.8.4323-4328.2002; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; Ropert C, 2000, CURR OPIN MICROBIOL, V3, P395, DOI 10.1016/S1369-5274(00)00111-9; Rotstein D, 2000, SHOCK, V14, P278, DOI 10.1097/00024382-200014030-00006; Ruvolo PP, 2001, LEUKEMIA, V15, P1153, DOI 10.1038/sj.leu.2402197; Santos RL, 2001, INFECT IMMUN, V69, P2293, DOI 10.1128/IAI.69.4.2293-2301.2001; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schroppel K, 2001, INT J MED MICROBIOL, V290, P659, DOI 10.1016/S1438-4221(01)80003-5; Shibayama K, 2001, INFECT IMMUN, V69, P3181, DOI 10.1128/IAI.69.5.3181-3189.2001; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; TamiyaKoizumi K, 1997, BIOCHEM MOL BIOL INT, V41, P1179; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200; TRINEL PA, 1993, INFECT IMMUN, V61, P4398, DOI 10.1128/IAI.61.10.4398-4405.1993; Trinel PA, 1999, J BIOL CHEM, V274, P30520, DOI 10.1074/jbc.274.43.30520; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497	56	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13086	13093		10.1074/jbc.M210680200	http://dx.doi.org/10.1074/jbc.M210680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551950	hybrid			2022-12-27	WOS:000182189500064
J	Leask, A; Holmes, A; Black, CM; Abraham, DJ				Leask, A; Holmes, A; Black, CM; Abraham, DJ			Connective tissue growth factor gene regulation - Requirements for its induction by transforming growth factor-beta 2 in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; FACTOR-BETA; TGF-BETA; TRANSCRIPTION FACTORS; MAP KINASE; SELECTIVE INHIBITOR; MESANGIAL CELLS; EXPRESSION; ACTIVATION; BINDING	In skin, the profibrotic protein connective tissue growth factor (CTGF) is not normally expressed. However, when skin cells are exposed to transforming growth factor-beta (TGF-beta), CTGF is induced in fibroblasts but not in epithelial cells. We have begun to investigate the requirements for the fibroblast-selective induction of CTGF by TGF-beta. Previously we found that this response was Smad-dependent. Now we show that protein kinase C and Ras/MIEK/ERK are necessary for the TGF-beta induction of the CTGF promoter but not of a generic Smad-responsive promoter (SBE-lux). Induction of the CTGF promoter is antagonized by c-Jun or by MEKK1, suggesting that a proper balance between the Ras/MEK/ ERK and JNK MAPK cascades is necessary for TGF-beta induction of CTGF. We identify the minimal CTGF promoter element necessary and sufficient to confer TGF-beta responsiveness to a heterologous promoter and show that a tandem repeat of a consensus transcription enhancer factor binding element, 5'-GAGGAATGG-3', is necessary for this induction. This element has not been previously shown to play a role in TGF-beta induction of gene expression in fibroblasts. Get shift analysis shows that this sequence binds nuclear factors that are greatly enriched in fibroblasts relative to epithelial cells. Thus Smads, Ras/MEK/ERK, protein kinase C, and fibroblast-enriched factors that bind GAGGAATGG act together to drive the TGF-beta-mediated induction of CTGF in fibroblasts.	Fibrogen Inc, San Francisco, CA 94080 USA; UCL Royal Free & Univ Coll, Sch Med, Ctr Rheumatol, London NW3 2PF, England	FibroGen; University of London; University College London; UCL Medical School	Leask, A (corresponding author), Fibrogen Inc, 225 Gateway Blvd, San Francisco, CA 94080 USA.		Leask, Andrew/G-5217-2015; Leask, Andy/ABH-9433-2020		NIAMS NIH HHS [AR45879] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045879] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Border WA, 1998, KIDNEY INT, V54, P1390, DOI 10.1046/j.1523-1755.1998.00127.x; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chen YJ, 2001, EXP CELL RES, V271, P109, DOI 10.1006/excr.2001.5364; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Goldberg HJ, 2002, CELL BIOL INT, V26, P165, DOI 10.1006/cbir.2001.0832; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hsu DKW, 1996, J BIOL CHEM, V271, P13786, DOI 10.1074/jbc.271.23.13786; IVKOVIC S, 2001, MOL PATHOL, V53, P118; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jiang SW, 2000, DNA CELL BIOL, V19, P507, DOI 10.1089/10445490050128430; Jiang SW, 2000, BIOCHEMISTRY-US, V39, P3505, DOI 10.1021/bi991048w; Kaneko KJ, 1998, DEV GENET, V22, P43, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;43::AID-DVG5&gt;3.0.CO;2-7; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kutz SM, 2001, J CELL SCI, V114, P3905; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; Rousse S, 2001, J BIOL CHEM, V276, P46961, DOI 10.1074/jbc.M104440200; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Shklyaev SS, 2001, THYROID, V11, P629, DOI 10.1089/105072501750362691; Simmonds AJ, 1998, GENE DEV, V12, P3815, DOI 10.1101/gad.12.24.3815; SMITH EA, 1990, J INVEST DERMATOL, V95, pS125, DOI 10.1111/1523-1747.ep12874998; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wong C, 1999, MOL CELL BIOL, V19, P1821; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yasunami M, 1996, BIOCHEM BIOPH RES CO, V228, P365, DOI 10.1006/bbrc.1996.1667; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zuzarte PC, 2000, BBA-GENE STRUCT EXPR, V1517, P82, DOI 10.1016/S0167-4781(00)00261-X	61	257	279	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13008	13015		10.1074/jbc.M210366200	http://dx.doi.org/10.1074/jbc.M210366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571253	hybrid			2022-12-27	WOS:000182189500054
J	Pias, EK; Ekshyyan, OY; Rhoads, CA; Fuseler, J; Harrison, L; Aw, TY				Pias, EK; Ekshyyan, OY; Rhoads, CA; Fuseler, J; Harrison, L; Aw, TY			Differential effects of superoxide dismutase isoform expression on hydroperoxide-induced apoptosis in PC-12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; OXIDATIVE STRESS; DOWNS-SYNDROME; CYTOCHROME-C; MITOCHONDRIAL GENERATION; ELEVATED LEVEL; OVEREXPRESSION; CUZNSOD; DAMAGE; MOUSE	The current study examines the contribution of mitochondria-derived reactive oxygen species (ROS) in tertbutyl-hydroperoxide (TBH)-induced apoptotic signaling using clones of undifferentiated pheochromocytoma (PC-12) cells that stably overexpress the human mitochondrial or cytoplasmic forms of superoxide dismutase (SOD) (viz. Mn-SOD or CuZn-SOD, respectively). Exposure of wild type cells to TBH caused an early generation of ROS (30 min) that resulted in cell apoptosis at 24 h. These responses were attenuated with N-acetylcysteine pretreatment; however, N-acetylcysteine as ineffective in cytoprotection when added after TBH-induced ROS formation. Stable overexpression of SOD isoforms caused a 2- and 3.5-fold elevation in CuZn-SOD and Mn-SOD activities in the cytoplasm and mitochondria, respectively, and 3-fold increases in cellular GSH content. Accordingly, the stable overexpression of M-nSOD attenuated TBH-induced mitochondrial ROS generation and cell apoptosis. Whereas transient Mn-SOD expression similarly prevented PC-12 apoptosis, this was associated with increases in SOD activity but not GSH, indicating that cytoprotection by Mn-SOD overexpression is related to mitochondrial ROS elimination and not due to increases in cellular GSH content per se. Stable or transient CuZn-SOD overexpression exacerbated cell apoptosis in conjunction with accelerated caspase-3 activation, regardless of cell GSH levels. Collectively, our results support a role for mitochondrial ROS in TBH-induced PC-12 apoptosis that is attenuated by Mn-SOD overexpression and is independent of cellular GSH levels per se.	Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	taw@lsuhsc.edu		Hines, Erin Pias/0000-0002-2458-6267	NIDDK NIH HHS [DK 44510, R01 DK044510-10, R01 DK044510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON BS, 1985, ANAL BIOCHEM, V146, P164, DOI 10.1016/0003-2697(85)90411-7; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen ZY, 2000, FREE RADICAL BIO MED, V29, P589, DOI 10.1016/S0891-5849(00)00363-4; Golenser J, 1998, FREE RADICAL BIO MED, V24, P1504, DOI 10.1016/S0891-5849(98)00026-4; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRISHAM MB, 1990, INFLAMMATION, V14, P669, DOI 10.1007/BF00916370; GRONER Y, 1994, BIOMED PHARMACOTHER, V48, P231, DOI 10.1016/0753-3322(94)90138-4; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Lam EWN, 1999, FREE RADICAL BIO MED, V27, P572, DOI 10.1016/S0891-5849(99)00109-4; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Midorikawa K, 2001, FEBS LETT, V495, P187, DOI 10.1016/S0014-5793(01)02383-3; Paz-Miguel JE, 1999, J IMMUNOL, V163, P5399; PeledKamar M, 1997, P NATL ACAD SCI USA, V94, P3883, DOI 10.1073/pnas.94.8.3883; PELEDKAMAR M, 1995, EMBO J, V14, P4985, DOI 10.1002/j.1460-2075.1995.tb00181.x; Pias EK, 2002, FASEB J, V16, DOI 10.1096/fj.01-0784com; Pias EK, 2002, CELL DEATH DIFFER, V9, P1007, DOI 10.1038/sj.cdd.4401064; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Stefanis L, 1998, J NEUROSCI, V18, P9204; Turrens JF, 2001, MED HYPOTHESES, V56, P617, DOI 10.1054/mehy.2001.1327; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022	33	100	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13294	13301		10.1074/jbc.M208670200	http://dx.doi.org/10.1074/jbc.M208670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551919	hybrid			2022-12-27	WOS:000182189500089
J	Li, MG; Katsura, K; Nomiyama, H; Komaki, K; Ninomiya-Tsuji, J; Matsumoto, K; Kobayashi, T; Tamura, S				Li, MG; Katsura, K; Nomiyama, H; Komaki, K; Ninomiya-Tsuji, J; Matsumoto, K; Kobayashi, T; Tamura, S			Regulation of the interleukin-1-induced signaling pathways by a novel member of the protein phosphatase 2C family (PP2C epsilon)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SERINE-THREONINE PHOSPHATASE; MOLECULAR-CLONING; TAK1 MAPKKK; KAPPA-B; 2C; P38; TRANSDUCTION; JNK; EXPRESSION	Although TAK1 signaling plays essential roles in eliciting cellular responses to interleukin-1 (IL-1), a proinflammatory cytokine, how the IL-1-TAK1 signaling pathway is positively and negatively regulated remains poorly understood. In this study, we investigated the possible role of a novel protein phosphatase 2C (PP2C) family member, PP2Cepsilon, in the regulation of the IL-1-TAK1 signaling pathway. PP2Cepsilon was composed of 303 amino acids, and the overall similarity of amino acid sequence between PP2Cepsilon and PP2Calpha was found to be 26%. Ectopic expression of PP2Cepsilon inhibited the IL-1- and TAK1-induced activation of mitogen-activated protein kinase kinase 4 (MKK4)-c-Jun N-terminal kinase or MKK3-p38 signaling pathway. PP2Cepsilon dephosphorylated TAK1 in vitro. Co-immunoprecipitation experiments indicated that PP2Cepsilon associates stably with TAK1 and attenuates the binding of TAK1 to MKK4 or MKK6. Ectopic expression of a phosphatase-negative mutant of PP2Cepsilon, PP2Cepsilon(D/A), which acted as a dominant negative form, enhanced both the association between TAK1 and MKK4 or MKK6 and the TAK1-induced activation of an AP-1 reporter gene. The association between PP2Cepsilon and TAK1 was transiently suppressed by IL-1 treatment of the cells. Taken together, these results suggest that, in the absence of IL-1-induced signal, PP2Cepsilon contributes to keeping the TAK1 signaling pathway in an inactive state by associating with and dephosphorylating TAK1.	Tohoku Univ, Dept Biochem, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan; Japan Int Res Ctr Agr Sci, Biol Resources Div, Tsukuba, Ibaraki 3050851, Japan; Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Mol, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Tohoku University; Japan International Research Center for Agricultural Sciences; Kumamoto University; University of North Carolina; North Carolina State University; Nagoya University	Kobayashi, T (corresponding author), Tohoku Univ, Dept Biochem, Inst Dev Aging & Canc, Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.	takayasu@idac.tohoku.ac.jp; tamura@idac.tohoku.ac.jp	Nomiyama, Hisayuki/F-2840-2013	Nomiyama, Hisayuki/0000-0002-2716-4043; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KATO S, 1995, ARCH BIOCHEM BIOPHYS, V318, P387, DOI 10.1006/abbi.1995.1244; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kusuda K, 1998, BIOCHEM J, V332, P243, DOI 10.1042/bj3320243; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; Merlot S, 2001, PLANT J, V25, P295, DOI 10.1046/j.1365-313x.2001.00965.x; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; PILGRIM D, 1995, MOL BIOL CELL, V6, P1159, DOI 10.1091/mbc.6.9.1159; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; TAMURA S, 1978, BIOCHIM BIOPHYS ACTA, V524, P349, DOI 10.1016/0005-2744(78)90171-7; Tamura S, 2002, EUR J BIOCHEM, V269, P1060, DOI 10.1046/j.0014-2956.2002.02754.x; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	39	74	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12013	12021		10.1074/jbc.M211474200	http://dx.doi.org/10.1074/jbc.M211474200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556533	hybrid			2022-12-27	WOS:000182015700040
J	Muller, JR; Siebenlist, U				Muller, JR; Siebenlist, U			Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALYMPHOPLASIA ALY MICE; DEFICIENT MICE; SPLENIC MICROARCHITECTURE; TRANSCRIPTIONAL ACTIVITY; INCONTINENTIA PIGMENTI; LYMPHOID-TISSUES; CELL ACTIVATION; KINASE-ALPHA; IKK-ALPHA; ORGANOGENESIS	Lymphotoxin beta receptor (LTbetaR)-induced activation of NF-kappaB in mouse embryo fibroblasts was mediated by the classical pathway and by an alternative or second pathway. The classical pathway involved the IkappaB kinase (IKK)beta- and IKKgamma-dependent degradation of IkappaBalpha and resulted in the rapid but transient activation of primarily RelA-containing NF-kappaB dimers. The alternative or second pathway proceeded via NF-kappaB-inducing kinase (NIK)-, IKKalpha-, and protein synthesis-dependent processing of the inhibitory NF-kappaB2 p100 precursor protein to the p52 form and resulted in a delayed but sustained activation of primarily RelB-containing NF-kappaB dimers. This second pathway was independent of the classical IKK complex, which is governed by its central IKKgamma regulatory subunit. The sequential engagement of two distinct pathways, coupled with the negative feedback inhibition of RelA complexes by NF-kappaB-induced resynthesis of IkappaBalpha, resulted in a pronounced temporal change in the nature of the NF-kappaB activity during the course of stimulation. Initially dominant ReIA complexes were replaced with time by RelB complexes. Therefore, the alternative activation path mediated by processing of p100 was necessary for sustained NF-kappaB activity in mouse embryo fibroblasts in response to LTbetaR stimulation. Based on the phenotype of mice deficient in various components of the LTbetaR-induced activation of p100 processing, we conclude that this pathway is critically involved in the function of stromal cells during the generation of secondary lymphoid organ microarchitectures.	NIAID, NIH, Immunoregulat Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Siebenlist, U (corresponding author), NIAID, NIH, Immunoregulat Lab, Bldg 10,Rm 11B16, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000722, ZIAAI000722, Z01AI000723] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 2002, TARGETED THERAPIES R, P381; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Matsumoto M, 1999, J IMMUNOL, V163, P1584; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Paxian S, 2002, GASTROENTEROLOGY, V122, P1853, DOI 10.1053/gast.2002.33651; Poljak L, 1999, J IMMUNOL, V163, P6581; Scheu S, 2002, J EXP MED, V195, P1613, DOI 10.1084/jem.20020215; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Tamada K, 2002, J IMMUNOL, V168, P4832, DOI 10.4049/jimmunol.168.10.4832; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	34	143	148	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12006	12012		10.1074/jbc.M210768200	http://dx.doi.org/10.1074/jbc.M210768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556537	hybrid			2022-12-27	WOS:000182015700039
J	Snyder, H; Mensah, K; Theisler, C; Lee, J; Matouschek, A; Wolozin, B				Snyder, H; Mensah, K; Theisler, C; Lee, J; Matouschek, A; Wolozin, B			Aggregated and monomeric alpha-synuclein bind to the S6 ' proteasomal protein and inhibit proteasomal function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; PARKINSONS-DISEASE; LEWY BODIES; NEURODEGENERATIVE DISEASES; DEGRADATION SIGNAL; FIBRIL FORMATION; BETA-SYNUCLEIN; 20S PROTEASOME; UBIQUITIN; PROTEOLYSIS	The accumulation of aggregated a-synuclein is thought to contribute to the pathophysiology of Parkinson's disease, but the mechanism of toxicity is poorly understood. Recent studies suggest that aggregated proteins cause toxicity by inhibiting the ubiquitin-dependent proteasomal system. In the present study, we explore how alpha-synuclein interacts with the proteasome. The proteasome exists as a 26 S and a 20 S species. The 26 S proteasome is composed of the 19 S cap and the 20 S core. Aggregated alpha-synuclein strongly inhibited the function of the 26 S proteasome. The IC50 of aggregated a-synuclein for ubiquitin-independent 26 S proteasomal activity was 1 nm. Aggregated a-synuclein also inhibited 26 S ubiquitin-dependent proteasomal activity at a dose of 500 nm. In contrast, the IC50 of aggregated a-synuclein for 20 S proteasomal activity was > 1 mum. This suggests that aggregated a-synuclein selectively interacts with the 19 S cap. Monomeric a-synuclein also inhibited proteasomal activity but with lower affinity and less potency. Recombinant monomeric alpha-synuclein inhibited the activity of the 20 S proteasomal core with an IC50 > 10 pm, exhibited no inhibition of 26 S ubiquitin-dependent proteasomal activity at doses up to 5 mum, and exhibited only partial inhibition (50%) of the 26 S ubiquitin-independent proteasomal activity at doses up to 10 mm. Binding studies demonstrate that both aggregated and monomeric alpha-synuclein selectively bind to the proteasomal protein SW, a subunit of the 19 S cap. These studies suggest that proteasomal inhibition by aggregated alpha-synuclein could be mediated by interaction with S6'.	Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Northwestern Univ, Dept Biochem & Mol Biol, Evanston, IL 60208 USA	Loyola University Chicago; Loyola University Chicago; Northwestern University	Wolozin, B (corresponding author), Loyola Univ, Med Ctr, Dept Pharmacol, Bldg 102,Rm 3634,2160 S 1st Ave, Maywood, IL 60153 USA.		Matouschek, Andreas/L-9379-2013	Matouschek, Andreas/0000-0001-6016-2341	NINDS NIH HHS [NS41786] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Golts N, 2002, J BIOL CHEM, V277, P16116, DOI 10.1074/jbc.M107866200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; LEE HJ, 2001, J BIOL CHEM, V25, P25; LEE MK, 2002, P NATL ACAD SCI US, V99; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; PRONIN AN, 2000, J BIOL CHEM; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O	57	313	323	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11753	11759		10.1074/jbc.M208641200	http://dx.doi.org/10.1074/jbc.M208641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551928	hybrid			2022-12-27	WOS:000182015700006
J	Dion, V; Coulombe, B				Dion, V; Coulombe, B			Interactions of a DNA-bound transcriptional activator with the TBP-TFIIA-TFIIB-promoter quaternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ORDERED RECRUITMENT; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING; YEAST; INITIATION; MECHANISM; DOMAIN; GENE	Site-specific protein-DNA photo-cross-linking was used to show that, when bound to its cognate site at various distances upstream of the TATA element, the chimeric transcriptional activator GAL4-VP16 can physically interact with a TATA box-binding protein (TBP)-transcription factor IIA (TFIIA)-TFIIB complex assembled on the TATA element. This result implies DNA bending and looping of promoter DNA as a result of the physical interaction between GAL4-VP16 and an interface of the TBP-TFIIA-TFIIB complex. This protein-protein interaction on promoter DNA minimally requires the presence of one GAL4 binding site and the formation of a quaternary complex containing TBP, TFIIB, and TFIIA on the TATA element. Notably, the topology of the TBP-TFIIA-TFIIB-promoter complex is not altered Significantly by the interaction with DNA-bound activators. We also show that the ability of GAL4-VP16 to activate transcription through a single GAL4 binding site varies according to its precise location and orientation relative to the TATA element and that it can approach the efficiency obtained with multiple binding sites. Taken together, our results indicate that the spatial positioning of the DNA-bound activation domain is important for efficient activation, possibly by maximizing its interactions with the transcriptional machinery including the TBP-TFIIA-TFIIB-promoter quaternary complex.	Inst Rech Clin Montreal, Lab Gene Transcript, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Coulombe, B (corresponding author), Inst Rech Clin Montreal, Lab Gene Transcript, 110 Ave Pins Quest, Montreal, PQ H2W 1R7, Canada.	coulomb@ircm.qc.ca			Canadian Institutes of Health Research [14309-2] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Blau J, 1996, MOL CELL BIOL, V16, P2044; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Coulombe Benoit, 1992, Gene Expression, V2, P99; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Ikeda K, 1999, MOL CELL BIOL, V19, P855; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; Langelier MF, 2001, J BIOL CHEM, V276, P38652, DOI 10.1074/jbc.M106422200; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Robert F, 2000, METH MOL B, V148, P383; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; Shaw SP, 1997, P NATL ACAD SCI USA, V94, P2427, DOI 10.1073/pnas.94.6.2427; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	62	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11495	11501		10.1074/jbc.M211938200	http://dx.doi.org/10.1074/jbc.M211938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538582	Green Accepted, hybrid			2022-12-27	WOS:000181855400081
J	Majumdar, A; Puri, N; Cuenoud, B; Natt, F; Martin, P; Khorlin, A; Dyatkina, N; George, AJ; Miller, PS; Seidman, MM				Majumdar, A; Puri, N; Cuenoud, B; Natt, F; Martin, P; Khorlin, A; Dyatkina, N; George, AJ; Miller, PS; Seidman, MM			Cell cycle modulation of gene targeting by a triple helix-forming oligonucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTRAND CROSS-LINKS; NUCLEOTIDE EXCISION-REPAIR; NUCLEOSOME CORE PARTICLES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; IN-VIVO; STRANDED DNA; 3RD STRAND; PSORALEN; CHROMATIN	Successful gene-targeting reagents must be functional under physiological conditions and must bind chromosomal target sequences embedded in chromatin. Triple helix-forming oligonucleotides (TFOs) recognize and bind specific sequences via the major groove of duplex DNA and may have potential for gene targeting in vivo. We have constructed chemically modified, psoralen-linked TFOs that mediate site-specific mutagenesis of a chromosomal gene in living cells. Here we show that targeting efficiency is sensitive to the biology of the cell, specifically, cell cycle status. Targeted mutagenesis was variable across the cycle with the greatest activity in S phase. This was the result of differential TFO binding as measured by cross-link formation. Targeted cross-linking was low in quiescent cells but substantially enhanced in S phase cells with adducts in similar to20-30% of target sequences. 75-80% of adducts were repaired faithfully, whereas the remaining adducts were converted into mutations (>5% mutation frequency). Clones with mutations could be recovered by direct screening of colonies chosen at random. These results demonstrate high frequency target binding and target mutagenesis by TFOs in living cells. Successful protocols for TFO-mediated manipulation of chromosomal sequences are likely to reflect a combination of appropriate oligonucleotide chemistry and manipulation of the cell biology.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Novartis, Horsham RH12 4AB, W Sussex, England; Novartis Pharma Ltd, CH-4002 Basel, Switzerland; Qiagen, Alameda, CA 94501 USA; Genelabs Inc, Redwood City, CA 94063 USA; ATCC, Manassas, VA 20108 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Novartis; Novartis; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Seidman, MM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.			George, Andrew/0000-0002-2866-0241	NATIONAL INSTITUTE ON AGING [Z01AG000738, ZIAAG000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asensio JL, 1999, J AM CHEM SOC, V121, P11063, DOI 10.1021/ja991949s; Barre FX, 1999, J MOL BIOL, V286, P1379, DOI 10.1006/jmbi.1999.2550; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; Barre FX, 1999, NUCLEIC ACIDS RES, V27, P743, DOI 10.1093/nar/27.3.743; Becker NA, 1999, ANTISENSE NUCLEIC A, V9, P313, DOI 10.1089/oli.1.1999.9.313; Belousov ES, 1998, NUCLEIC ACIDS RES, V26, P1324, DOI 10.1093/nar/26.5.1324; Blume SW, 1999, NUCLEIC ACIDS RES, V27, P695, DOI 10.1093/nar/27.2.695; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Brown PM, 1998, BIOCHEMISTRY-US, V37, P16139, DOI 10.1021/bi981768n; Brown PM, 1996, BIOCHEM J, V319, P607, DOI 10.1042/bj3190607; Brown PM, 1999, EUR J BIOCHEM, V261, P301, DOI 10.1046/j.1432-1327.1999.00279.x; CARIELLO NF, 1992, ENVIRON MOL MUTAGEN, V20, P81, DOI 10.1002/em.2850200202; Carlomagno T, 2001, J AM CHEM SOC, V123, P7364, DOI 10.1021/ja002592r; CHIOU CC, 1995, CARCINOGENESIS, V16, P1357, DOI 10.1093/carcin/16.6.1357; Cole R S, 1975, Basic Life Sci, V5B, P487; Cuenoud B, 1998, ANGEW CHEM INT EDIT, V37, P1288, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1288::AID-ANIE1288>3.0.CO;2-U; Dagneaux C, 1995, BIOCHEMISTRY-US, V34, P16618, DOI 10.1021/bi00051a009; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ESCUDE C, 1992, CR ACAD SCI III-VIE, V315, P521; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; Fox KR, 2000, CURR MED CHEM, V7, P17, DOI 10.2174/0929867003375506; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; Greenberg RB, 2001, J BIOL CHEM, V276, P31551, DOI 10.1074/jbc.M103588200; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; HARTLEY JA, 1993, J CHROMATOGR-BIOMED, V618, P277, DOI 10.1016/0378-4347(93)80038-6; HEARST JE, 1989, CHEM RES TOXICOL, V2, P69, DOI 10.1021/tx00008a001; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiralerspong S, 1996, P SOC EXP BIOL MED, V212, P116; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; LAQUERBE A, 1995, J MOL BIOL, V254, P38, DOI 10.1006/jmbi.1995.0597; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; Lin FLM, 2000, J BIOL CHEM, V275, P39117, DOI 10.1074/jbc.M005404200; Lorch Y, 2001, MOL CELL, V7, P89, DOI 10.1016/S1097-2765(01)00157-5; Maher LJ, 1996, CANCER INVEST, V14, P66, DOI 10.3109/07357909609018437; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; Puri N, 2002, BIOCHEMISTRY-US, V41, P7716, DOI 10.1021/bi025734y; Puri N, 2001, J BIOL CHEM, V276, P28991, DOI 10.1074/jbc.M103409200; Raha M, 1998, PHOTOCHEM PHOTOBIOL, V67, P289, DOI 10.1111/j.1751-1097.1998.tb05201.x; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; RIDDLE JC, 1978, MUTAT RES, V52, P409, DOI 10.1016/0027-5107(78)90179-3; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; Sedelnikova OA, 2002, ANTISENSE NUCLEIC A, V12, P43, DOI 10.1089/108729002753670256; SHIMIZU M, 1992, FEBS LETT, V302, P155, DOI 10.1016/0014-5793(92)80428-J; STEEN AM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P77, DOI 10.1016/0167-4781(91)90155-F; Subramanian PS, 1997, SOMAT CELL MOLEC GEN, V23, P97, DOI 10.1007/BF02679969; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Vasquez KM, 2001, J BIOL CHEM, V276, P38536, DOI 10.1074/jbc.M101797200; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; Vasquez KM, 2000, METH MOL B, V133, P183; VOS JMH, 1987, CELL, V50, P789, DOI 10.1016/0092-8674(87)90337-0; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; WESTIN L, 1995, NUCLEIC ACIDS RES, V23, P2184, DOI 10.1093/nar/23.12.2184; Zhang XW, 2001, CELL PROLIFERAT, V34, P321, DOI 10.1046/j.0960-7722.2001.00210.x	70	65	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11072	11077		10.1074/jbc.M211837200	http://dx.doi.org/10.1074/jbc.M211837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538585	hybrid			2022-12-27	WOS:000181855400028
J	Kalus, I; Schnegelsberg, B; Seidah, NG; Kleene, R; Schachner, M				Kalus, I; Schnegelsberg, B; Seidah, NG; Kleene, R; Schachner, M			The proprotein convertase PC5A and a metalloprotease are involved in the proteolytic processing of the neural adhesion molecule L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CELL-ADHESION; NEURITE OUTGROWTH; BIOCHEMICAL-CHARACTERIZATION; EXTRACELLULAR DOMAINS; MEDIATED RELEASE; SERINE PROTEASES; SCIATIC-NERVE; RAT-BRAIN; EXPRESSION	The transmembrane and multidomain neural adhesion molecule L1 plays important functional roles in the developing and adult nervous system. L1 is proteolytically processed at two distinct sites within the extracellular domain, leading to the generation of different fragments. In this report, we present evidence that the proprotein convertase PC5A is the protease that cleaves L1 in the third fibronectin type III domain, whereas the proprotein convertases furin, PC1, PC2, PACE4, and PC7 are not effective in cleaving L1. Analysis of mutations revealed Arg(845) to be the site of cleavage generating the N-terminal 140-kDa fragment. This fragment was present in the hippocampus, which expresses PC5A, but was not detectable in the cerebellum, which does not express PC5A. The 140-kDa L1 fragment was found to be tightly associated with the full-length 200-kDa L1 molecule. The complex dissociated from the membrane upon cleavage by a protease acting at a more membrane-proximal site of full-length L1. This proteolytic cleavage was inhibited by the metalloprotease inhibitor GM 6001 and enhanced by a calmodulin inhibitor. L1-dependent neurite outgrowth of cerebellar neurons was inhibited by GM 6001, suggesting that proteolytic processing of L1 by a metalloprotease is involved in neurite outgrowth.	Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany; Clin Res Inst Montreal, Lab Biochem Neuroendocrinol, Montreal, PQ H2W 1R7, Canada	University of Hamburg; University Medical Center Hamburg-Eppendorf; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Schachner, M (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	melitta.schachner@zmnh.uni-hamburg.de	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				APPEL F, 1993, J NEUROSCI, V13, P4764; Beer S, 1999, J CELL SCI, V112, P2667; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bix GJ, 1998, J NEUROSCI, V18, P307; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dityatev A, 2000, NEURON, V26, P207, DOI 10.1016/S0896-6273(00)81151-4; DONG W, 1995, J NEUROSCI, V15, P1778, DOI 10.1523/JNEUROSCI.15-03-01778.1995; FAISSNER A, 1984, DEV BRAIN RES, V15, P69, DOI 10.1016/0165-3806(84)90141-X; FISCHER G, 1986, J NEUROSCI, V6, P605; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; HOLM J, 1995, J NEUROSCI RES, V42, P9, DOI 10.1002/jnr.490420103; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hunter I, 1996, BIOCHEM J, V320, P847, DOI 10.1042/bj3200847; Jie CF, 2000, BBA-PROTEIN STRUCT M, V1479, P1, DOI 10.1016/S0167-4838(00)00030-3; Jun CD, 2001, J BIOL CHEM, V276, P29019, DOI 10.1074/jbc.M103394200; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kleene R, 2001, J BIOL CHEM, V276, P21656, DOI 10.1074/jbc.M101790200; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Lu XY, 2001, J NEUROCHEM, V77, P1553, DOI 10.1046/j.1471-4159.2001.00359.x; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Luthi A, 1996, J NEUROSCI RES, V46, P1; Lynch GW, 1999, EUR J IMMUNOL, V29, P2590, DOI 10.1002/(SICI)1521-4141(199908)29:08<2590::AID-IMMU2590>3.0.CO;2-R; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Marcinkiewicz M, 1998, MOL BRAIN RES, V59, P229, DOI 10.1016/S0169-328X(98)00141-7; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Nakagami Y, 2000, J NEUROSCI, V20, P2003; Nayeem N, 1999, J CELL SCI, V112, P4739; Newton JP, 1999, BIOCHEM BIOPH RES CO, V261, P283, DOI 10.1006/bbrc.1999.1018; Oka T, 2002, NEUROSCI LETT, V321, P141, DOI 10.1016/S0304-3940(01)02470-3; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; RATHJEN FG, 1984, EMBO J, V3, P1; REILLY PL, 1995, J IMMUNOL, V155, P529; SADOUL K, 1988, J NEUROCHEM, V50, P510, DOI 10.1111/j.1471-4159.1988.tb02941.x; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shiosaka S, 2000, NEUROSCI RES, V37, P85, DOI 10.1016/S0168-0102(00)00115-2; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Spira ME, 2001, CELL MOL NEUROBIOL, V21, P591, DOI 10.1023/A:1015135617557; Stallcup WB, 2000, J NEUROSCI RES, V61, P33, DOI 10.1002/1097-4547(20000701)61:1<33::AID-JNR4>3.0.CO;2-Y; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Thompson AJ, 2002, J NEUROSCI RES, V67, P766, DOI 10.1002/jnr.10167; Turner AJ, 1999, BIOCHEM SOC T, V27, P255, DOI 10.1042/bst0270255; Ulloa L, 2001, J BIOL CHEM, V276, P21387, DOI 10.1074/jbc.M006933200; Villeneuve P, 1999, NEUROSCIENCE, V92, P641, DOI 10.1016/S0306-4522(98)00763-5; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yoshida S, 1999, INT J MOL MED, V3, P405; Zhang Y, 2000, MOL CELL NEUROSCI, V16, P71, DOI 10.1006/mcne.2000.0852; Zheng M, 1997, DEV BIOL, V181, P268, DOI 10.1006/dbio.1996.8402	68	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10381	10388		10.1074/jbc.M208351200	http://dx.doi.org/10.1074/jbc.M208351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529374	hybrid			2022-12-27	WOS:000181777500053
J	Mikolajczyk, J; Boatright, KM; Stennicke, HR; Nazif, T; Potempa, J; Bogyo, M; Salvesen, GS				Mikolajczyk, J; Boatright, KM; Stennicke, HR; Nazif, T; Potempa, J; Bogyo, M; Salvesen, GS			Sequential autolytic processing activates the zymogen of Arg-gingipain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHYROMONAS-GINGIVALIS; CYSTEINE PROTEINASES; CRYSTAL-STRUCTURE; PROTEASE; GENES; MECHANISM; CHAPERONE; CASPASES; CLEAVAGE; SEPARASE	Most proteases are synthesized as inactive precursors to protect the synthetic machinery of the cell and allow timing of activation. The mechanisms used to render latency are varied but tend to be conserved within protease families. Proteases belonging to the caspase family have a unique mechanism mediated by transitions of two surface loops, and on the basis of conservation of mechanism one would expect this to be preserved by caspase relatives. We have been able to express the full-length precursor of the Arg-specific caspase relative from the bacterium Porphyromonas gingivalis, Arg-gingipain-B, and we show that it contains N- and C-terminal extensions that render a low amount of latency, meaning that the zymogen is substantially active. Three sequential autolytic processing steps at the N and C terminus are required for full activity, and the N-propeptide may serve as an intramolecular chaperone rather than an inhibitory peptide. Each step in activation requires the previous step, and an affinity probe reveals that incremental activity enhancements are achieved in a stepwise manner.	Burnham Inst, La Jolla, CA 92037 USA; Novo Nordisk AS, Dept Prot Design, DK-2880 Bagsvaerd, Denmark; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94043 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Fac Biotechnol, Dept Microbiol, PL-30060 Krakow, Poland	Sanford Burnham Prebys Medical Discovery Institute; Novo Nordisk; University of California System; University of California San Francisco; University System of Georgia; University of Georgia; Jagiellonian University	Salvesen, GS (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gsalvesen@burnham.org		Bogyo, Matthew/0000-0003-3753-4412; Nazif, Tamim/0000-0003-1239-2489	NCI NIH HHS [CA69381] Funding Source: Medline; NIDCR NIH HHS [DE009761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADUSEOPOKU J, 1995, INFECT IMMUN, V63, P4744, DOI 10.1128/IAI.63.12.4744-4754.1995; Aravind L, 2002, PROTEINS, V46, P355, DOI 10.1002/prot.10060; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; Curtis MA, 2001, CRIT REV ORAL BIOL M, V12, P192, DOI 10.1177/10454411010120030101; Eichinger A, 1999, EMBO J, V18, P5453, DOI 10.1093/emboj/18.20.5453; Genco CA, 1999, CLIN INFECT DIS, V28, P456, DOI 10.1086/515156; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JOHNSTON JR, 1994, MOL GENETICS YEAST P, V141, P123; Kadowaki T, 1998, J BIOL CHEM, V273, P29072, DOI 10.1074/jbc.273.44.29072; Lee A, 1999, J AM CHEM SOC, V121, P9907, DOI 10.1021/ja992009a; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; Margetts MB, 2000, PROTEIN EXPRES PURIF, V18, P262, DOI 10.1006/prep.2000.1193; Mikolajczyk-Pawlinska J, 1998, BIOL CHEM, V379, P205, DOI 10.1515/bchm.1998.379.2.205; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NIELSEN TL, 1990, APPL MICROBIOL BIOT, V33, P307, DOI 10.1007/BF00164527; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; Potempa J, 1998, J BIOL CHEM, V273, P21648, DOI 10.1074/jbc.273.34.21648; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; ROBINSON VJ, 1992, BIOORG CHEM, V20, P42, DOI 10.1016/0045-2068(92)90024-W; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SALVESEN GS, 1999, J BIOL CHEM, V274, P8359; SIKORSKI RS, 1989, GENETICS, V122, P19; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Veith PD, 2002, BIOCHEM J, V363, P105, DOI 10.1042/0264-6021:3630105; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	43	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10458	10464		10.1074/jbc.M210564200	http://dx.doi.org/10.1074/jbc.M210564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533545	hybrid			2022-12-27	WOS:000181777500063
J	Waltner-Law, M; Duong, DT; Daniels, MC; Herzog, B; Wang, XHL; Prasad, R; Granner, DK				Waltner-Law, M; Duong, DT; Daniels, MC; Herzog, B; Wang, XHL; Prasad, R; Granner, DK			Elements of the glucocorticoid and retinoic acid response units are involved in cAMP-mediated expression of the PEPCK gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; FACTOR-BINDING PROTEIN-1; COUP-TF; ACCESSORY FACTOR; AMINOTRANSFERASE GENE; NUCLEAR FACTOR-3; GTP GENE; FACTOR-I; TRANSCRIPTION; INSULIN	Although many genes are regulated by the concerted action of several hormones, hormonal signaling to gene promoters has generally been studied one hormone at a time. The phosphoenolpyruvate carboxykinase (PEPCK) gene is a case in point. Transcription of this gene is induced by glucagon (acting by the second messenger, cAMP), glucocorticoids, and retinoic acid, and it is dominantly repressed by insulin. These hormonal responses require the presence of different hormone response units (HRUs), which consist of constellations of DNA elements and associated transcription factors. These include the glucocorticoid response unit (GRU), cAMP response unit (CRU), retinoic acid response unit (RARU), and the insulin response unit. HRUs are known to have functional overlap. In particular, the cAMP response element of the CRU is also a component of the GRU. The purpose of this study was to determine whether known GRU or RARU elements or transcription factors function as components of the CRU. We show here that the glucocorticoid accessory factor binding site 1 and glucocorticoid accessory factor binding site 3 elements, which are components of both the GRU and RARU, are an important part of the CRU. Furthermore, we find that the transcription factor, chicken ovalbumin upstream promoter-transcription factor, and two coactivators, cAMP response element-binding protein-binding protein and steroid receptor coactivator-1, participate in both the cAMP and glucocorticoid responses. This provides a further illustration of how the PEPCK gene promoter integrates different hormone responses through overlapping HRUs that utilize some of the same transcription factors and coactivators.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, 707 Light Hall, Nashville, TN 37232 USA.	daryl.granner@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R37DK035107, K01DK002887, R01DK035107, T32DK007061] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35107, DK02887, DK07061, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRANNER DK, 1986, ANN NY ACAD SCI, V478, P175, DOI 10.1111/j.1749-6632.1986.tb15530.x; GRANNER DK, 1986, RECENT PROG HORM RES, V42, P111; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lin BC, 1998, DNA CELL BIOL, V17, P967, DOI 10.1089/dna.1998.17.967; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OFIR R, 1991, GENE EXPRESSION, V1, P55; ONATE SA, 1995, SCIENCE, V270, P1354; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PARK EA, 1993, J BIOL CHEM, V268, P613; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Streeper RS, 2000, J BIOL CHEM, V275, P12108, DOI 10.1074/jbc.275.16.12108; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Streeper RS, 2001, J BIOL CHEM, V276, P19111, DOI 10.1074/jbc.M101442200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wilson HL, 2002, J BIOL CHEM, V277, P43895, DOI 10.1074/jbc.M203169200; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	55	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10427	10435		10.1074/jbc.M211846200	http://dx.doi.org/10.1074/jbc.M211846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531892	hybrid			2022-12-27	WOS:000181777500059
J	Beaumont, NJ; Skinner, VO; Tan, TMM; Ramesh, BS; Byrne, DJ; MacColl, GS; Keen, JN; Bouloux, PM; Mikhailidis, DP; Bruckdorfer, KR; Vanderpump, MP; Srai, KS				Beaumont, NJ; Skinner, VO; Tan, TMM; Ramesh, BS; Byrne, DJ; MacColl, GS; Keen, JN; Bouloux, PM; Mikhailidis, DP; Bruckdorfer, KR; Vanderpump, MP; Srai, KS			Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE DEFICIENCY; ACROMEGALIC PATIENTS; HUMANS; PLASMA; PEPTIDE; TISSUE	Ghrelin is a 28-residue peptide hormone that is principally released from the stomach during fasting and prior to eating. Two forms are present in human plasma: the unmodified peptide and a less abundant acylated version, in which octanoic acid is attached to the third residue, a serine, via an ester linkage. The acylated form of ghrelin acts as a ligand for the growth hormone secretagogue receptor and can stimulate the release of growth hormone from the pituitary gland. It also initiates behavioral and metabolic adaptations to fasting. Here we show that an immobilized form of ghrelin specifically binds a species of high density lipoprotein associated with the plasma esterase, paraoxonase, and clusterin. Both free ghrelin and paraoxon, a substrate for paraoxonase, can inhibit this interaction. An endogenous species of ghrelin is found to co-purify with high density lipoprotein during density gradient centrifugation and subsequent gel filtration. This interaction links the orexigenic peptide hormone ghrelin to lipid transport and metabolism. Furthermore, the interaction of the esterified hormone ghrelin with a species of HDL containing an esterase suggests a possible mechanism for the conversion of ghrelin to des-acyl ghrelin.	UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England; UCL Royal Free Hosp NHS Trust, Dept Endocrinol, London NW3 2QG, England; UCL Royal Free Hosp NHS Trust, Dept Clin Biochem, London NW3 2QG, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; University of London; University College London; University of Leeds	Beaumont, NJ (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, Rowland Hill St, London NW3 2PF, England.	n.beaumont@rfc.ucl.ac.uk	Srai, Surjit K/C-5575-2009; Srai, Kaila/AAE-7039-2021; Tan, Tricia M.M./C-7140-2011; Mikhailidis, Dimitri P/A-1869-2013; Tan, Tricia/ABD-5502-2020	Tan, Tricia M.M./0000-0001-5873-3432; Mikhailidis, Dimitri P/0000-0002-9566-2263; MacColl, Gavin/0000-0001-5032-7018				Arosio M, 2000, ATHEROSCLEROSIS, V151, P551, DOI 10.1016/S0021-9150(99)00426-8; Caminos JE, 2002, EUR J ENDOCRINOL, V147, P159, DOI 10.1530/eje.0.1470159; Cappiello V, 2002, EUR J ENDOCRINOL, V147, P189, DOI 10.1530/eje.0.1470189; CHUNG BH, 1980, J LIPID RES, V21, P284; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; DEBOER H, 1994, METABOLISM, V43, P199, DOI 10.1016/0026-0495(94)90245-3; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Ozbey N, 2000, INT J OBESITY, V24, P619, DOI 10.1038/sj.ijo.0801206; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992	14	119	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8877	8880		10.1074/jbc.C200575200	http://dx.doi.org/10.1074/jbc.C200575200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12531885	hybrid			2022-12-27	WOS:000181524000003
J	Jairajpuri, MA; Lu, AQ; Desai, U; Olson, ST; Bjork, I; Bock, SC				Jairajpuri, MA; Lu, AQ; Desai, U; Olson, ST; Bjork, I; Bock, SC			Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITE; PENTASACCHARIDE BINDING; BETA-ANTITHROMBIN; ALPHA-THROMBIN; IDENTIFICATION; MECHANISM; INHIBITION; RESIDUES; GLYCOSYLATION; ACCELERATION	The dissociation equilibrium constant for heparin binding to antithrombin III (ATIII) is a measure of the cofactor's binding to and activation of the proteinase inhibitor, and its salt dependence indicates that ionic and non-ionic interactions contribute similar to40 and similar to60% of the binding free energy, respectively. We now report that phenylalanines 121 and 122 (Phe-121 and Phe-122) together contribute 43% of the total binding free energy and 77% of the energy of non-ionic binding interactions. The large contribution of these hydrophobic residues to the binding energy is mediated not by direct interactions with heparin, but indirectly, through contacts between their phenyl rings and the non-polar stems of positively charged heparin binding residues, whose terminal amino and guanidinium groups are thereby organized to form extensive and specific ionic and non-ionic contacts with the pentasaccharide. Investigation of the kinetics of heparin binding demonstrated that Phe-122 is critical for promoting a normal rate of conformational change and stabilizing AT*H, the high affinity-activated binary complex. Kinetic and structural considerations suggest that Phe-122 and Lys-114 act cooperatively through non-ionic interactions to promote P-helix formation and ATIII binding to the pentasaccharide. In summary, although hydrophobic residues Phe-122 and Phe-121 make minimal contact with the pentasaccharide, they play a critical role in heparin binding and activation of antithrombin by coordinating the P-helix-mediated conformational change and organizing an extensive network of ionic and non-ionic interactions between positively charged heparin binding site residues and the cofactor.	Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84132 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Swedish Univ Agr Sci, Dept Vet Med Chem, SE-75123 Uppsala, Sweden	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Virginia Commonwealth University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Swedish University of Agricultural Sciences	Bock, SC (corresponding author), Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, 50 N Med Dr, Salt Lake City, UT 84132 USA.	susan.bock@m.cc.utah.edu	Jairajpuri, Mohamad/AAS-2556-2020; Desai, Umesh/D-3741-2013	Desai, Umesh/0000-0002-1976-6597	NHLBI NIH HHS [HL 30712, HL 39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039888, R01HL030712, R37HL039888, R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; Arocas V, 2001, J BIOL CHEM, V276, P43809, DOI 10.1074/jbc.M105294200; Arocas V, 2000, BIOCHEMISTRY-US, V39, P8512, DOI 10.1021/bi9928243; Backovic M, 2002, J PROTEOME RES, V1, P367, DOI 10.1021/pr025515z; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; CHOWDHURY V, 1995, BRIT J HAEMATOL, V89, P602, DOI 10.1111/j.1365-2141.1995.tb08369.x; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; Hileman RE, 1998, BIOCHEMISTRY-US, V37, P15231, DOI 10.1021/bi980212x; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jairajpuri MA, 2002, J BIOL CHEM, V277, P24460, DOI 10.1074/jbc.M203127200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JORDAN RE, 1983, ARCH BIOCHEM BIOPHYS, V227, P587, DOI 10.1016/0003-9861(83)90488-5; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; Kridel SJ, 1997, J BIOL CHEM, V272, P7656, DOI 10.1074/jbc.272.12.7656; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OKAJIMA K, 1993, BLOOD, V81, P1300; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P198, DOI 10.1016/S1050-1738(02)00160-3; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; PICARD V, 1996, METHODS MOL BIOL PCR, P183; Schedin-Weiss S, 2002, BIOCHEMISTRY-US, V41, P4779, DOI 10.1021/bi012163l; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; VANBOECKEL C, 1996, NAT STRUCT BIOL, V1, P423	36	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15941	15950		10.1074/jbc.M212319200	http://dx.doi.org/10.1074/jbc.M212319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12556442	Green Submitted, hybrid			2022-12-27	WOS:000182680000063
J	Michele, DE; Campbell, KP				Michele, DE; Campbell, KP			Dystrophin-glycoprotein complex: Post-translational processing and dystroglycan function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CONGENITAL MUSCULAR-DYSTROPHY; MUSCLE ALPHA-DYSTROGLYCAN; NITRIC-OXIDE SYNTHASE; EXTRACELLULAR-MATRIX; BETA-DYSTROGLYCAN; BASEMENT-MEMBRANE; PERIPHERAL-NERVE; AGRIN RECEPTOR; GENE POMT1; LAMININ		Univ Iowa, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Howard Hughes Med Inst, Dept Physiol & Biophys, 400 EMRB, Iowa City, IA 52242 USA.			Campbell, Kevin/0000-0003-2066-5889				Aravind L, 1999, CURR BIOL, V9, pR836, DOI 10.1016/S0960-9822(00)80039-1; Bardoni A, 2000, NEUROMUSCULAR DISORD, V10, P194, DOI 10.1016/S0960-8966(99)00108-X; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; Brockington M, 2001, HUM MOL GENET, V10, P2851, DOI 10.1093/hmg/10.25.2851; Brockington M, 2001, AM J HUM GENET, V69, P1198, DOI 10.1086/324412; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Cote PD, 2002, J BIOL CHEM, V277, P4672, DOI 10.1074/jbc.M106879200; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Crosbie RH, 1998, HUM MOL GENET, V7, P823, DOI 10.1093/hmg/7.5.823; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Endo T, 1999, BBA-GEN SUBJECTS, V1473, P237, DOI 10.1016/S0304-4165(99)00182-8; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Hayashi YK, 2001, NEUROLOGY, V57, P115, DOI 10.1212/WNL.57.1.115; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, J CELL SCI, V114, P1137; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Kano H, 2002, BIOCHEM BIOPH RES CO, V291, P1283, DOI 10.1006/bbrc.2002.6608; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; LANE PW, 1976, J HERED, V67, P135, DOI 10.1093/oxfordjournals.jhered.a108687; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; Sciandra F, 2001, EUR J BIOCHEM, V268, P4590, DOI 10.1046/j.1432-1327.2001.02386.x; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; Smalheiser NR, 1998, J BIOL CHEM, V273, P23698, DOI 10.1074/jbc.273.37.23698; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Voit T, 1998, BRAIN DEV-JPN, V20, P65, DOI 10.1016/S0387-7604(97)00094-6; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Yamada H, 1996, J NEUROCHEM, V66, P1518; Yang BX, 2000, AM J PHYSIOL-CELL PH, V278, pC1108, DOI 10.1152/ajpcell.2000.278.6.C1108; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yoshida M, 2000, HUM MOL GENET, V9, P1033, DOI 10.1093/hmg/9.7.1033	65	322	329	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15457	15460		10.1074/jbc.R200031200	http://dx.doi.org/10.1074/jbc.R200031200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12556455	hybrid			2022-12-27	WOS:000182680000001
J	Fitzsimmons, TJ; Zhao, XL; Wank, SA				Fitzsimmons, TJ; Zhao, XL; Wank, SA			The extracellular domain of receptor activity-modifying protein 1 is sufficient for calcitonin receptor-like receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; PARATHYROID-HORMONE; BINDING; ADRENOMEDULLIN; SELECTIVITY; EXPRESSION	A functional calcitonin gene-related peptide (CGRP) receptor requires dimerization of calcitonin receptor-like receptor (CRLR) with receptor activity-modifying protein 1 (RAMP 1). To determine the function of the three domains (extracellular, ECD; transmembrane, TM; and tail domains) of human RAMP 1, three mutants were constructed: RAMP 1 without the cytoplasmic tail, a chimera consisting of the ECD of PUMP I and the TM and tail of the platelet-derived growth factor receptor, and the ECD of RAMP 1 alone. These RAMP I mutants were examined for their ability to associate with CRLR to effect CGRP-stimulated cAMP accumulation, CGRP binding, CRLR trafficking, and cell surface expression. All RAMP 1 mutants were able to associate with CRLR with full efficacy for CGRP-stimulated cAMP accumulation. However, the RAMP 1/platelet-derived growth factor receptor chimera demonstrated a 10-fold decrease in potency for CGRP signaling and binding, and the RAMP 1-ECD mutant had a 4000-fold decrease in potency. In conclusion, the ECD of RAMP 1 is sufficient for normal CRLR association and efficacy. The presence of a TM domain and the specific sequence of the RAMP 1 TM domain contribute to CGRP affinity and potency. The C-terminal tail of RAMP 1 is unnecessary for CRLR function.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wank, SA (corresponding author), NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK069083, Z01DK053209] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; Carter PH, 1999, J BIOL CHEM, V274, P31955, DOI 10.1074/jbc.274.45.31955; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Flahaut M, 2002, J BIOL CHEM, V277, P14731, DOI 10.1074/jbc.M112084200; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40	14	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14313	14320		10.1074/jbc.M211946200	http://dx.doi.org/10.1074/jbc.M211946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574158	hybrid			2022-12-27	WOS:000182405000095
J	Iwatani, Y; Rosen, AE; Guo, JH; Musier-Forsyth, K; Levin, JG				Iwatani, Y; Rosen, AE; Guo, JH; Musier-Forsyth, K; Levin, JG			Efficient initiation of HIV-1 reverse transcription in vitro - Requirement for RNA sequences downstream of the primer binding site abrogated by nucleocapsid protein-dependent primer-template interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACID-CHAPERONE ACTIVITY; ZINC-FINGER STRUCTURES; MURINE LEUKEMIA-VIRUS; STRAND DNA-SYNTHESIS; STRONG-STOP DNA; PSI-C LOOP; SECONDARY STRUCTURE; VIRAL-RNA; ANNEALING ACTIVITIES	Synthesis of HIV-1 (-) strong-stop DNA is initiated following annealing of the 3' IS nucleotides (nt) of tRNA(3)(Lys) to the primer binding site (PBS) near the 5' terminus of viral RNA. Here, we have investigated whether sequences downstream of the PBS play a role in promoting efficient (-) strong-stop DNA synthesis. Our findings demonstrate a template requirement for at least 24 bases downstream of the PBS when tRNA(3)(Lys) or an 18-nt RNA complementary to the PBS (1118), but not an 18-nt DNA primer, are used. Additional assays using 18-nt DNA-RNA chimeric primers, as well as melting studies and circular dichroism spectra of 18-nt primer: PBS duplexes, suggest that priming efficiency is correlated with duplex conformation and stability. Interestingly, in the presence of nucleocapsid protein (NC), the 24 downstream bases are dispensable for synthesis primed by tRNA(3)(Lys) but not by R18. We present data supporting the conclusion that NC promotes extended interactions between the anticodon stem and variable loop of tRNA(3)(Lys) and a sequence upstream of the A-rich loop in the template. Taken together, this study leads to new insights into the initiation of HIV-1 reverse transcription and the functional role of NC-facilitated tRNA-template interactions in this process.	NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Minnesota System; University of Minnesota Twin Cities	Levin, JG (corresponding author), NICHD, Mol Genet Lab, NIH, Bldg 6B,Rm 216, Bethesda, MD 20892 USA.	jlevin@mail.nih.gov	Iwatani, Yasumasa/A-8675-2016	Iwatani, Yasumasa/0000-0001-9269-4828	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008700] Funding Source: NIH RePORTER; NIAID NIH HHS [AI65056] Funding Source: Medline; NIGMS NIH HHS [T32-GM08700] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ARNOTT S, 1986, J MOL BIOL, V188, P631, DOI 10.1016/S0022-2836(86)80011-0; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Brule F, 2002, RNA, V8, P8, DOI 10.1017/S1355838202010981; Cen S, 1999, J VIROL, V73, P4485, DOI 10.1128/JVI.73.5.4485-4488.1999; Chan BD, 1999, P NATL ACAD SCI USA, V96, P459, DOI 10.1073/pnas.96.2.459; Coffin J, 1997, RETROVIRUSES; CRISTOFARI G, 2000, PROG NUCL ACIDS RES, V72, P223; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Goldschmidt V, 2002, J BIOL CHEM, V277, P43233, DOI 10.1074/jbc.M205295200; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Gyi JI, 1996, BIOCHEMISTRY-US, V35, P12538, DOI 10.1021/bi960948z; Hargittai MRS, 2001, J MOL BIOL, V312, P985, DOI 10.1006/jmbi.2001.5021; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Horton NC, 1996, J MOL BIOL, V264, P521, DOI 10.1006/jmbi.1996.0658; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; Kankia BI, 1999, J PHYS CHEM B, V103, P8759, DOI 10.1021/jp991614x; KHAN R, 1992, J BIOL CHEM, V267, P6689; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 2000, J BIOL CHEM, V275, P12306, DOI 10.1074/jbc.275.16.12306; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; Li XG, 1997, J VIROL, V71, P6003, DOI 10.1128/JVI.71.8.6003-6010.1997; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Liang C, 1998, J BIOL CHEM, V273, P21309, DOI 10.1074/jbc.273.33.21309; Liang C, 2000, J VIROL, V74, P6251, DOI 10.1128/JVI.74.14.6251-6261.2000; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Miller JT, 2001, J BIOL CHEM, V276, P27721, DOI 10.1074/jbc.M100513200; Morris S, 2002, J VIROL, V76, P7571, DOI 10.1128/JVI.76.15.7571-7577.2002; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Puglisi EV, 1998, NAT STRUCT BIOL, V5, P1033, DOI 10.1038/4141; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Rong LW, 2001, J BIOL CHEM, V276, P47725, DOI 10.1074/jbc.M105124200; Roy B, 1999, ANAL BIOCHEM, V269, P403, DOI 10.1006/abio.1999.4051; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; SPROAT B, 1995, NUCLEOS NUCLEOT, V14, P255, DOI 10.1080/15257779508014668; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Szyperski T, 1999, J BIOMOL NMR, V13, P343, DOI 10.1023/A:1008350604637; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wahl MC, 2000, NUCLEIC ACIDS RES, V28, P4356, DOI 10.1093/nar/28.21.4356; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; Yang J T, 1969, Prog Nucleic Acid Res Mol Biol, V9, P223, DOI 10.1016/S0079-6603(08)60770-9; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	79	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14185	14195		10.1074/jbc.M211618200	http://dx.doi.org/10.1074/jbc.M211618200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12560327	Green Submitted, hybrid			2022-12-27	WOS:000182405000080
J	Putilina, T; Skouri-Panet, F; Prat, K; Lubsen, NH; Tardieu, A				Putilina, T; Skouri-Panet, F; Prat, K; Lubsen, NH; Tardieu, A			Subunit exchange demonstrates a differential chaperone activity of calf alpha-crystallin toward beta(LOW)- and individual gamma-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; RESONANCE ENERGY-TRANSFER; A-CRYSTALLIN; B-CRYSTALLIN; MOLECULAR CHAPERONE; PHASE-SEPARATION; EYE LENS; BETA-CRYSTALLIN; METHANOCOCCUS-JANNASCHII; OSMOTIC-PRESSURE	The chaperone activity of native alpha-crystallins toward beta(LOW)- and various gamma-crystallins at the onset of their denaturation, 60 and 66 degreesC, respectively, was studied at high and low crystallin concentrations using small angle x-ray scattering (SAXS) and fluorescence energy transfer (FRET). The crystallins were from calf lenses except for one recombinant human gammaS. SAXS data demonstrated an irreversible doubling in molecular weight and a corresponding increase in size of alpha-crystallins at temperatures above 60 degreesC. Further increase is observed at 66 degreesC. More subtle conformational changes accompanied the increase in size as shown by changes in environments around tryptophan and cysteine residues. These alpha-crystallin temperature-induced modifications were found necessary to allow for the association with beta(LOW)- and gamma-crystallins to occur. FRET experiments using IAEDANS (iodoacetylaminoethylaminonaphthalene sulfonic acid)- and IAF (iodoacetamidofluorescein)-labeled subunits showed that the heat-modified alpha-crystallins retained their ability to exchange subunits and that, at 37 degreesC, the rate of exchange was increased depending upon the temperature of incubation, 60 or 66 degreesC. Association with beta(LOW)- (60 degreesC) or various gamma-crystallins (66 degreesC) resulted at 37 degreesC in decreased subunit exchange in proportion to bound ligands. Therefore, beta(LOW)- and gamma-crystallins were compared for their capacity to associate with alpha-crystallins and inhibit subunit exchange. Quite unexpectedly for a highly conserved protein family, differences were observed between the individual gamma-crystallin family members. The strongest effect was observed for gammaS, followed by hgammaSrec, gammaE, gammaA-F, gammaD, gammaB. Moreover, fluorescence properties of alpha-crystallins in the presence of bound beta(LOW)-and gamma-crystallins indicated that the formation Of beta(LOW)/alpha- or gamma/alpha-crystallin complexes involved various binding sites. The changes in subunit exchange associated with the chaperone properties of alpha-crystallins toward the other lens crystallins demonstrate the dynamic character of the heat-activated alpha-crystallin structure.	CNRS, Lab Mineral Cristallog, F-75252 Paris 05, France; Univ Nijmegen, Dept Biochem 161, NL-6500 HB Nijmegen, Netherlands; Univ Paris 06, F-75252 Paris 05, France; Univ Paris 07, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Radboud University Nijmegen; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Tardieu, A (corresponding author), CNRS, Lab Mineral Cristallog, P6-P7 Univ,Case 115,4 Pl Jussieu, F-75252 Paris 05, France.		Lubsen, Nicolette H./B-8426-2011	Skouri-Panet, Feriel/0000-0002-2623-9058				Abgar S, 2000, BIOCHEM BIOPH RES CO, V276, P619, DOI 10.1006/bbrc.2000.3518; Abgar S, 2001, BIOPHYS J, V80, P1986, DOI 10.1016/S0006-3495(01)76168-1; Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Arai H, 1997, CELL STRUCT FUNCT, V22, P539, DOI 10.1247/csf.22.539; Augusteyn Robert C, 2002, Clin Exp Optom, V85, P83; Bera S, 2002, BIOCHEMISTRY-US, V41, P297, DOI 10.1021/bi011010v; Bhattacharyya J, 2002, J PROTEIN CHEM, V21, P65, DOI 10.1023/A:1014187300930; Blakytny R, 1997, EXP EYE RES, V64, P1051, DOI 10.1006/exer.1997.0299; Borkman RF, 1996, EXP EYE RES, V62, P141, DOI 10.1006/exer.1996.0018; Bours J, 1996, OPHTHALMIC RES, V28, P23, DOI 10.1159/000267939; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; BROIDE ML, 1991, P NATL ACAD SCI USA, V88, P5660, DOI 10.1073/pnas.88.13.5660; Burgio MR, 2000, BIOCHEM BIOPH RES CO, V268, P426, DOI 10.1006/bbrc.1999.2036; Burgio MR, 2001, MOL VIS, V7, P228; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; Datta SA, 2000, J BIOL CHEM, V275, P41004, DOI 10.1074/jbc.M007686200; Derham BK, 2001, EUR J BIOCHEM, V268, P713, DOI 10.1046/j.1432-1327.2001.01929.x; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; Guinier A., 1955, SMALL ANGLE SCATTERI; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Liang JJN, 2000, FEBS LETT, V484, P98, DOI 10.1016/S0014-5793(00)02136-0; Liang JJN, 2000, MOL VIS, V6, P10; Lindner RA, 1997, J BIOL CHEM, V272, P27722, DOI 10.1074/jbc.272.44.27722; Lindner RA, 2001, BIOCHEM J, V354, P79, DOI 10.1042/0264-6021:3540079; Liu CW, 1996, P NATL ACAD SCI USA, V93, P377, DOI 10.1073/pnas.93.1.377; Lomakin A, 1996, J CHEM PHYS, V104, P1646, DOI 10.1063/1.470751; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Malfois M, 1996, J CHEM PHYS, V105, P3290, DOI 10.1063/1.471843; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; Pasta SY, 2002, J BIOL CHEM, V277, P45821, DOI 10.1074/jbc.M206499200; Rajaraman K, 1998, BIOCHEM BIOPH RES CO, V249, P917, DOI 10.1006/bbrc.1998.9242; Rajaraman K, 2001, FEBS LETT, V497, P118, DOI 10.1016/S0014-5793(01)02451-6; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Reddy GB, 2002, FEBS LETT, V522, P59, DOI 10.1016/S0014-5793(02)02884-3; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Sinha D, 2001, J BIOL CHEM, V276, P9308, DOI 10.1074/jbc.M010583200; Skouri-Panet F, 2001, BIOPHYS CHEM, V89, P65, DOI 10.1016/S0301-4622(00)00216-7; Sreelakshmi Y, 2001, J PROTEIN CHEM, V20, P123, DOI 10.1023/A:1011077307262; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; VERETOUT F, 1989, EUR BIOPHYS J BIOPHY, V17, P61, DOI 10.1007/BF00257103; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; WANG KY, 1994, J BIOL CHEM, V269, P13601; Wang KY, 2000, EUR J BIOCHEM, V267, P4705, DOI 10.1046/j.1432-1327.2000.01521.x; Weinreb O, 2000, INVEST OPHTH VIS SCI, V41, P3893; Wenk M, 2000, BIOPHYS CHEM, V86, P95, DOI 10.1016/S0301-4622(00)00161-7; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	69	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13747	13756		10.1074/jbc.M208157200	http://dx.doi.org/10.1074/jbc.M208157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562766	hybrid			2022-12-27	WOS:000182405000025
J	Guo, XG; Stafford, LJ; Bryan, B; Xia, CZ; Ma, WB; Wu, XS; Liu, D; Zhou, SY; Liu, MY				Guo, XG; Stafford, LJ; Bryan, B; Xia, CZ; Ma, WB; Wu, XS; Liu, D; Zhou, SY; Liu, MY			A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; RHO-FAMILY GTPASES; PLECKSTRIN HOMOLOGY DOMAINS; ACTIN STRESS FIBERS; KAPPA-B ACTIVATION; RAS TRANSFORMATION; DBL FAMILY; TRANSCRIPTIONAL ACTIVITY; P21-ACTIVATED KINASES	The Rho family of small GTPases, including Rho, Rac, and Cdc42, play essential roles in diverse cellular functions. The ability of Rho family GTPases to participate in signaling events is determined by the ratio of inactive (GDP-bound) and active (GTP-bound) forms in the cell. The activation of Rho family proteins requires the exchange of bound GDP for GTP, a process catalyzed by the Dbl family of guanine nucleotide exchange factors (GEFs). The GEFs have high affinity for the guanine nucleotide-free state of the GTPases and are thought to promote GDP release by stabilizing an intermediate transition state. In this study, we have identified and characterized a new Rac/Cdc42-specific Dbl family guanine nucleotide exchange factor, named GEFT. GEFT is highly expressed in the excitable tissues, including brain, heart, and muscle. Low or very little expression was detected in other nonexcitable tissues. GEFT has specific exchange activity for Rac and Cdc42 in our in vitro GTPase exchange assays and glutathione S-transferase-PAK pull-down assays with GTP-bound Rac1 and Cdc42. Overexpression of GEFT leads to changes in cell morphology and actin cytoskeleton re-organization, including the formation of membrane microspikes, filopodia, and lamilliopodia. Furthermore, expression of GEFT in NIH3T3 cells promotes foci formation, cell proliferation, and cell migration, possibly through the activation of transcriptional factors involved in cell growth and proliferation. Together, our data suggest that GEFT is a Rac/Cdc42-specific GEF protein that regulates cell morphology, cell proliferation, and transformation.	Texas A&M Univ, Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China; Texas A&M Univ, Hlth Sci Ctr, Dept Biochem Med & Genet, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Hunan Normal University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc Biol & Nutr, 2121 Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamu.edu		Liu, Mingyao/0000-0001-7339-5048	NHLBI NIH HHS [5R01 HL64792] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu D, 2000, ONCOGENE, V19, P5964, DOI 10.1038/sj.onc.1203992; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Penzes P, 2001, J NEUROSCI, V21, P8426, DOI 10.1523/JNEUROSCI.21-21-08426.2001; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Stafford LJ, 2002, CANCER RES, V62, P5399; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takenawa T, 2001, J CELL SCI, V114, P1801; Thrasher AJ, 2000, IMMUNOL REV, V178, P118, DOI 10.1034/j.1600-065X.2000.17803.x; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Xia CZ, 2001, P NATL ACAD SCI USA, V98, P6174, DOI 10.1073/pnas.101137298; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	77	63	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13207	13215		10.1074/jbc.M208896200	http://dx.doi.org/10.1074/jbc.M208896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547822	hybrid			2022-12-27	WOS:000182189500079
J	Ortiz-Lombardia, M; Pompeo, F; Boitel, B; Alzari, PM				Ortiz-Lombardia, M; Pompeo, F; Boitel, B; Alzari, PM			Crystal structure of the catalytic domain of the PknB serine/threonine kinase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TYROSINE KINASE; ACTIVE-SITE; SUBUNIT; SEQUENCE; INSIGHTS; COMPLEX	With the advent of the sequencing programs of prokaryotic genomes, many examples of the presence of serine/threonine protein kinases in these organisms have been identified. Moreover, these kinases could be classified as homologues of those belonging to the well characterized superfamily of the eukaryotic serine/threonine and tyrosine kinases. Eleven such kinases were recognized in the genome of Mycobacterium tuberculosis. Here we report the crystal structure of an active form of PknB, one of the four M. tuberculosis kinases that are conserved in the downsized genome of Mycobacterium leprae and are therefore presumed to play an important role in the processes that regulate the complex life cycle of mycobacteria. Our structure confirms again the extraordinary conservation of the protein kinase fold and constitutes a landmark that extends this conservation across the evolutionary distance between high eukaryotes and eubacteria. The structure of PknB, in complex with a nucleotide triphosphate analog, reveals an enzyme in the active state with an unprecedented arrangement of the Gly-rich loop associated with a new conformation of the nucleotide gamma-phosphoryl group. It presents as well a partially disordered activation loop, suggesting an induced fit mode of binding for the so far unknown substrates of this kinase or for some modulating factor(s).	Inst Pasteur, Unite Biochim Struct, URA 2185 CNRS, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ortiz-Lombardia, M (corresponding author), Inst Pasteur, Unite Biochim Struct, URA 2185 CNRS, 25 Rue Dr Roux, F-75724 Paris 15, France.	mol@ysbl.york.ac.uk; alzari@pasteur.fr	Pompeo, Frederique/Q-5772-2017	Alzari, Pedro/0000-0002-4233-1903				Ablooglu AJ, 2001, J BIOL CHEM, V276, P46933, DOI 10.1074/jbc.M107236200; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Av-Gay Y, 1999, INFECT IMMUN, V67, P5676, DOI 10.1128/IAI.67.11.5676-5682.1999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bakal CJ, 2000, TRENDS CELL BIOL, V10, P32, DOI 10.1016/S0962-8924(99)01681-5; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; FISCHER EH, 1955, J BIOL CHEM, V216, P121; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Koul A, 2001, MICROBIOL-SGM, V147, P2307, DOI 10.1099/00221287-147-8-2307; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; Leslie A. G. W.., 1992, PROTEIN CRYSTALLOGR, V26; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ogawara H, 1999, MICROBIOL-UK, V145, P3343, DOI 10.1099/00221287-145-12-3343; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Peirs P, 1997, EUR J BIOCHEM, V244, P604, DOI 10.1111/j.1432-1033.1997.00604.x; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; WANG JYJ, 1978, J BIOL CHEM, V253, P7605; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	38	132	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13094	13100		10.1074/jbc.M300660200	http://dx.doi.org/10.1074/jbc.M300660200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551895	hybrid			2022-12-27	WOS:000182189500065
J	Zhang, XJ; Kurnasov, OV; Karthikeyan, S; Grishin, NV; Osterman, AL; Zhang, H				Zhang, XJ; Kurnasov, OV; Karthikeyan, S; Grishin, NV; Osterman, AL; Zhang, H			Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; NMN ADENYLYLTRANSFERASE; CRYSTAL-STRUCTURE; WALLERIAN DEGENERATION; ADENINE-DINUCLEOTIDE; NUCLEAR ENZYME; DNA-REPAIR; PROTEIN; CHROMATIN; IDENTIFICATION	Pyridine dinucleotides (NAD and NADP) are ubiquitous cofactors involved in hundreds of redox reactions essential for the energy transduction and metabolism in all living cells. In addition, NAD also serves as a substrate for ADP-ribosylation of a number of nuclear proteins, for silent information regulator 2 (Sir2)-like histone deacetylase that is involved in gene silencing regulation, and for cyclic ADP ribose (cADPR)-dependent Ca2+ signaling. Pyridine nucleotide adenylyltransferase (PNAT) is an indispensable central enzyme in the NAD biosynthesis pathways catalyzing the condensation of pyridine mononucleotide (NMN or NaMN) with the AMP moiety of ATP to form NAD (or NaAD). Here we report the identification and structural characterization of a novel human PNAT (hsPNAT-3) that is located in the cytoplasm and mitochondria. Its subcellular localization and tissue distribution are distinct from the previously identified human nuclear PNAT-1 and PNAT-2. Detailed structural analysis of PNAT-3 in its apo form and in complex with its substrate(s) or product revealed the catalytic mechanism of the enzyme. The characterization of the cytosolic human PNAT-3 provided compelling evidence that the final steps of NAD biosynthesis pathways may exist in mammalian cytoplasm and mitochondria, potentially contributing to their NAD/NADP` pool.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Integrated Genom Inc, Chicago, IL 60612 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zhang, H (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	zhang@chop.swmed.edu	Karthikeyan, Subramanian/F-8808-2010		NIGMS NIH HHS [GM65243] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065243] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALDUCCI E, 1995, ANAL BIOCHEM, V228, P64, DOI 10.1006/abio.1995.1315; BALDUCCI E, 1995, BIOCHEM J, V310, P395, DOI 10.1042/bj3100395; BALDUCCI E, 1992, BIOCHEM BIOPH RES CO, V189, P1275, DOI 10.1016/0006-291X(92)90211-3; Barile M, 1996, BIOCHEM MOL BIOL INT, V38, P297; Begley TP, 2001, VITAM HORM, V61, P103; BERGER SJ, 1982, J NEUROCHEM, V38, P821, DOI 10.1111/j.1471-4159.1982.tb08704.x; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; BRANSTER MV, 1956, BIOCHEM J, V63, P640, DOI 10.1042/bj0630640; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkle A, 2001, CANCER LETT, V163, P1, DOI 10.1016/S0304-3835(00)00694-7; CANTAROW W, 1977, ARCH BIOCHEM BIOPHYS, V180, P26, DOI 10.1016/0003-9861(77)90004-2; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; COONEY DA, 1983, ADV ENZYME REGUL, V21, P271, DOI 10.1016/0065-2571(83)90019-5; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Guarente L, 2000, GENE DEV, V14, P1021; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Izard T, 2002, J MOL BIOL, V315, P487, DOI 10.1006/jmbi.2001.5272; JAYARAM HN, 1986, BIOCHEM PHARMACOL, V35, P587, DOI 10.1016/0006-2952(86)90352-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurnasov OV, 2002, J BACTERIOL, V184, P6906, DOI 10.1128/JB.184.24.6906-6917.2002; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; LOWE G, 1983, EUR J BIOCHEM, V132, P117, DOI 10.1111/j.1432-1033.1983.tb07334.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; MOAT AG, 1987, PYRIDINE NUCL COEN B, V2, P1; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; MORTON RK, 1958, NATURE, V181, P540, DOI 10.1038/181540a0; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENFOUND T, 1996, ESCHERICHIA COLI SAL, V1, P721; Raffaelli N, 2002, BIOCHEM BIOPH RES CO, V297, P835, DOI 10.1016/S0006-291X(02)02285-4; RUGGIERI S, 1990, BIOCHEMISTRY-US, V29, P2501, DOI 10.1021/bi00462a010; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Sestini S, 2000, ARCH BIOCHEM BIOPHYS, V379, P277, DOI 10.1006/abbi.2000.1888; Singh SK, 2002, J BIOL CHEM, V277, P33291, DOI 10.1074/jbc.M204368200; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; UHR ML, 1982, EUR J BIOCHEM, V128, P435; Werner E, 2002, FEBS LETT, V516, P239, DOI 10.1016/S0014-5793(02)02556-5; Zhang QH, 2000, CHEMOECOLOGY, V10, P69, DOI 10.1007/s000490050010; Zhou TJ, 2002, J BIOL CHEM, V277, P13148, DOI 10.1074/jbc.M111469200; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	54	105	113	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13503	13511		10.1074/jbc.M300073200	http://dx.doi.org/10.1074/jbc.M300073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574164	hybrid			2022-12-27	WOS:000182189500114
J	Katafuchi, T; Kikumoto, K; Hamano, K; Kangawa, K; Matsuo, H; Minamino, N				Katafuchi, T; Kikumoto, K; Hamano, K; Kangawa, K; Matsuo, H; Minamino, N			Calcitonin receptor-stimulating peptide, a new member of the calcitonin gene-related peptide family - Its isolation from porcine brain, structure, tissue distribution, and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; RAT-BRAIN; VASOPRESSIN RECEPTOR; NATRIURETIC PEPTIDE; ADENYLATE-CYCLASE; SALMON-CALCITONIN; EXPRESSION; ADRENOMEDULLIN; POLYPEPTIDE; AMYLIN	We isolated a novel biologically active peptide, designated calcitonin receptor-stimulating peptide (CRSP), from the acid extract of the porcine brain by monitoring cAMP production in the porcine kidney cell line LLC-PK1. Determination of the amino acid sequence and cDNA analysis encoding a CRSP precursor showed that this peptide has similar to60% identity in the amino acid sequence with human calcitonin gene-related peptide type-alpha (alphaCGRP), type-beta (betaCGRP), and porcine CGRP. Northern blot analysis and radioimmunoassay demonstrated that CRSP is expressed mainly in the thyroid gland and the central nervous system, in which the calcitonin receptor was abundantly expressed. Synthetic CRSP elicited a potent stimulatory effect on the cAMP production in LLC-PK1 cells. Although it shows significant sequence similarity with CGRPs, this peptide did not elicit cAMP elevation in cells that endogenously expressed a CGRP receptor or an adrenomedullin receptor or were transfected with either of these recombinant receptors. Administration of CRSP into anesthetized rats did not alter the blood pressure but induced a transient decrease in the plasma calcium concentration. In fact, this peptide potently increased the intracellular cAMP concentration in COS-7 cells that expressed the recombinant calcitonin receptor. These unique properties indicate that CRSP is not a porcine counterpart of betaCGRP and probably elicits its biological effects via the calcitonin receptor.	Natl Cardiovasc Ctr, Inst Res, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Minamino, N (corresponding author), Natl Cardiovasc Ctr, Inst Res, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	minamino@ri.ncvc.go.jp						ALIAPOUL.MA, 1966, SCIENCE, V151, P330, DOI 10.1126/science.151.3708.330; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; FISCHER JA, 1983, J CLIN ENDOCR METAB, V57, P1314, DOI 10.1210/jcem-57-6-1314; FREED WJ, 1979, SCIENCE, V206, P850, DOI 10.1126/science.493987; FRIEDMAN J, 1965, SCIENCE, V150, P1465, DOI 10.1126/science.150.3702.1465; FRIEDMAN PA, 1993, AM J PHYSIOL, V284, pF181; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; Hilton JM, 1998, ENDOCRINOLOGY, V139, P982, DOI 10.1210/en.139.3.982; HILTON JM, 1995, NEUROSCIENCE, V69, P1223, DOI 10.1016/0306-4522(95)00322-A; HOPPENER JWM, 1986, MOL CELL ENDOCRINOL, V47, P125, DOI 10.1016/0303-7207(86)90023-7; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; IKEGAME M, 1995, J BONE MINER RES, V10, P59; Isumi Y, 1998, ENDOCRINOLOGY, V139, P2552, DOI 10.1210/en.139.5.2552; KANGAWA K, 1984, BIOCHEM BIOPH RES CO, V118, P131, DOI 10.1016/0006-291X(84)91077-5; KIKUMOTO K, IN PRESS HYPERTENS R; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MONTEMURRO L, 1991, CALCIFIED TISSUE INT, V49, P71, DOI 10.1007/BF02565124; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORLEY JE, 1981, SCIENCE, V214, P671, DOI 10.1126/science.7292006; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SEXTON PM, 1992, BRAIN RES, V596, P279, DOI 10.1016/0006-8993(92)91558-V; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; WOHLWEND A, 1986, J CELL PHYSIOL, V128, P71, DOI 10.1002/jcp.1041280112	39	80	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12046	12054		10.1074/jbc.M207970200	http://dx.doi.org/10.1074/jbc.M207970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556539	hybrid			2022-12-27	WOS:000182015700044
J	Lebreton, S; Graciet, E; Gontero, B				Lebreton, S; Graciet, E; Gontero, B			Modulation, via protein-protein interactions, of glyceraldehyde-3-phosphate dehydrogenase activity through redox phosphoribulokinase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII CHLOROPLASTS; SITE-DIRECTED MUTAGENESIS; CALVIN CYCLE ACTIVITY; C-TERMINAL EXTENSION; MULTIENZYME COMPLEXES; INFORMATION-TRANSFER; HIGHER-PLANT; ESCHERICHIA-COLI; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; SPINACH-CHLOROPLASTS	The activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) embedded in the phosphoribulokinase (PRK)-GAPDH-CP12 complex was increased 2-3-fold by reducing agents. This occurred by interaction with PRK as the cysteinyl sulfhydryls (4 SH/subunit) of GAPDH within the complex were unchanged whatever the redox state of the complex. But isolated GAPDH was not activated. Alkylation plus mass spectrometry also showed that PRK had one disulfide bridge and three SH groups per monomer in the active oxidized complex. Reduction disrupted this disulfide bridge to give 2 more SH groups and a much more active enzyme. We assessed the kinetics and dynamics of the interactions between PRK and GAPDH/CP12 using biosensors to measure complex formation in real time. The apparent equilibrium binding constant for GAPDH/CP12 and PRK was 14 +/- 1.6 nm for oxidized PRK and 62 +/- 10 nm for reduced PRK. These interactions were neither pH- nor temperature-dependent. Thus, the dynamics of PRK-GAPDH-CP12 complex formation and GAPDH activity are modulated by the redox state of PRK.	Univ Paris 06, Inst Jacques Monod, UMR 7592, CNRS, F-75251 Paris 05, France; Univ Paris 07, Inst Jacques Monod, UMR 7592, CNRS, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Gontero, B (corresponding author), Univ Paris 06, Inst Jacques Monod, UMR 7592, CNRS, 2 Pl Jussieu, F-75251 Paris 05, France.			lebreton, Sandrine/0000-0003-4772-9467; Graciet, Emmanuelle/0000-0003-3548-8213				Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; Avilan L, 1997, EUR J BIOCHEM, V250, P296, DOI 10.1111/j.1432-1033.1997.0296a.x; Avilan L, 2000, J BIOL CHEM, V275, P9447, DOI 10.1074/jbc.275.13.9447; Baalmann E, 1996, PLANT MOL BIOL, V32, P505, DOI 10.1007/BF00019102; Balmer Y, 2002, TRENDS PLANT SCI, V7, P191, DOI 10.1016/S1360-1385(02)02263-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandes HK, 1996, J BIOL CHEM, V271, P6490, DOI 10.1074/jbc.271.11.6490; Brandes HK, 1996, J BIOL CHEM, V271, P3333; CERFF R, 1979, EUR J BIOCHEM, V94, P243, DOI 10.1111/j.1432-1033.1979.tb12891.x; CLASPER S, 1994, BBA-PROTEIN STRUCT M, V1209, P101, DOI 10.1016/0167-4838(94)90143-0; CLASPER S, 1991, EUR J BIOCHEM, V202, P1239, DOI 10.1111/j.1432-1033.1991.tb16496.x; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P489, DOI 10.1016/S0968-0004(02)02191-6; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Finerty PJ, 2002, J MOL BIOL, V322, P605, DOI 10.1016/S0022-2836(02)00803-3; Geck MK, 2000, J BIOL CHEM, V275, P18034, DOI 10.1074/jbc.M001936200; Geck RK, 1996, J BIOL CHEM, V271, P24736, DOI 10.1074/jbc.271.40.24736; GIUDICIORTICONI MT, 1992, CR ACAD SCI III-VIE, V314, P477; GONTERO B, 1993, EUR J BIOCHEM, V217, P1075, DOI 10.1111/j.1432-1033.1993.tb18339.x; GONTERO B, 1988, EUR J BIOCHEM, V173, P437, DOI 10.1111/j.1432-1033.1988.tb14018.x; GONTERO B, 1994, EUR J BIOCHEM, V226, P999, DOI 10.1111/j.1432-1033.1994.00999.x; Graciet E, 2003, EUR J BIOCHEM, V270, P129, DOI 10.1046/j.1432-1033.2003.03372.x; Graciet E, 2002, J BIOL CHEM, V277, P12697, DOI 10.1074/jbc.M111121200; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; HARRIS JI, 1976, ENZYMES, V13, P1; Harrison DHT, 1998, BIOCHEMISTRY-US, V37, P5074, DOI 10.1021/bi972805y; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Lebreton S, 1997, EUR J BIOCHEM, V246, P85, DOI 10.1111/j.1432-1033.1997.t01-2-00085.x; Lebreton S, 1997, EUR J BIOCHEM, V250, P286, DOI 10.1111/j.1432-1033.1997.0286a.x; Lebreton S, 1999, J BIOL CHEM, V274, P20879, DOI 10.1074/jbc.274.30.20879; Li AD, 1997, PHOTOSYNTH RES, V51, P167; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; Miziorko HM, 2000, ADV ENZYMOL RAMB, V74, P95; Mouche F, 2002, J BIOL CHEM, V277, P6743, DOI 10.1074/jbc.M106401200; MULLER B, 1972, Z NATURFORSCH PT B, VB 27, P925, DOI 10.1515/znb-1972-0814; NICHOLSON S, 1987, EUR J BIOCHEM, V162, P423, DOI 10.1111/j.1432-1033.1987.tb10619.x; Pohlmeyer K, 1996, PLANT MOL BIOL, V32, P969, DOI 10.1007/BF00020493; Qi JF, 2001, J BIOL CHEM, V276, P35247, DOI 10.1074/jbc.M103855200; REED LJ, 1975, P NATL ACAD SCI USA, V72, P3068, DOI 10.1073/pnas.72.8.3068; Runquist JA, 2001, BIOCHEMISTRY-US, V40, P14530, DOI 10.1021/bi010778c; SAINIS JK, 1986, BIOCHEM BIOPH RES CO, V139, P947, DOI 10.1016/S0006-291X(86)80269-8; SAINIS JK, 1994, INDIAN J BIOCHEM BIO, V31, P215; Sambrook J., 2002, MOL CLONING LAB MANU; Scheibe R, 1996, BBA-PROTEIN STRUCT M, V1296, P228, DOI 10.1016/0167-4838(96)00074-X; Sparla F, 2002, J BIOL CHEM, V277, P44946, DOI 10.1074/jbc.M206873200; SUSS KH, 1995, PLANT PHYSIOL, V107, P1387, DOI 10.1104/pp.107.4.1387; SUSS KH, 1993, P NATL ACAD SCI USA, V90, P5514, DOI 10.1073/pnas.90.12.5514; Wedel N, 1997, P NATL ACAD SCI USA, V94, P10479, DOI 10.1073/pnas.94.19.10479; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; Yu LP, 1996, BIOCHEMISTRY-US, V35, P9661, DOI 10.1021/bi960507f	49	38	41	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12078	12084		10.1074/jbc.M213096200	http://dx.doi.org/10.1074/jbc.M213096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556449	hybrid, Green Accepted			2022-12-27	WOS:000182015700048
J	Basi, DL; Ross, KF; Hodges, JS; Herzberg, MC				Basi, DL; Ross, KF; Hodges, JS; Herzberg, MC			The modulation of tissue factor by endothelial cells during heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GENE-EXPRESSION; SEPSIS; ACTIVATION; INHIBITION; ATHEROSCLEROSIS; PATHOGENESIS; COAGULATION; ASSOCIATION; HERPESVIRUS	Tissue factor (TF) initiates the extrinsic coagulation cascade on the surface of macrophages and endothelial cells. In septic patients, the extrinsic coagulation cascade is activated. When septic patients are febrile, mortality is decreased. The purpose of this study was to investigate the role of elevated temperatures on TF expression by endothelial cells during a sepsis-like challenge. Human endothelial vein cells (HUVECs) were incubated with lipopolysaccharide (LPS) or interleukin-1beta (IL-1beta) for 0, 2, 4, 6, or 8 h. At the 0-h time point, some HUVECs were heat shocked at 43 C for 2 h and then recovered at 37 C for 0, 2, 4, or 6 h. Heat-shocked and non-heat-shocked LPS-stimulated HUVECs were analyzed for TF-specific mRNA expression by ribonuclease protection assay (RPA), surface TF expression by flow cytometry, and TF activity by a two-stage clotting assay. Heat shocked LPS-stimulated HUVECs expressed significantly reduced TF-specific mRNA, TF surface protein levels, and TF surface activity when compared with non-heat-shocked, LPS-stimulated HUVECs (p < 0.0125, p < 0.0125, and p < 0.0001, respectively; repeated measures analysis of variance, ANOVA). If heat shock models elevated core temperature, these results suggest that fever may protect the host during sepsis by reducing TF activity on the surface of endothelial cells.	Univ Minnesota, Sch Dent, Dept Oral Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Herzberg, MC (corresponding author), Univ Minnesota, Sch Dent, Dept Oral Sci, 17-164 Moos Tower,515 Delaware St, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011831, K16DE000270] Funding Source: NIH RePORTER; NIDCR NIH HHS [K16 DE00270, R01 DE11831] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADERKA D, 1991, ISRAEL J MED SCI, V27, P52; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BALLA G, 1990, T ASSOC AM PHYSICIAN, V103, P174; BAUER KA, 1989, THROMB RES, V56, P425, DOI 10.1016/0049-3848(89)90255-7; BRYANT RE, 1971, ARCH INTERN MED, V127, P120, DOI 10.1001/archinte.127.1.120; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu EK, 1997, CRIT CARE MED, V25, P1727, DOI 10.1097/00003246-199710000-00025; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; DRAKE TA, 1993, AM J PATHOL, V142, P1458; Esmon CT, 1999, HAEMATOLOGICA, V84, P254; Gabrielli M, 2002, CIRCULATION, V106, pE32, DOI 10.1161/01.CIR.0000025824.66358.79; Gando S, 1998, THROMB HAEMOSTASIS, V79, P1111; Gando S, 1998, CRIT CARE MED, V26, P2005, DOI 10.1097/00003246-199812000-00030; Levi M, 1997, EUR J CLIN INVEST, V27, P3, DOI 10.1046/j.1365-2362.1997.570614.x; Mackowiak PA, 1998, ARCH INTERN MED, V158, P1870, DOI 10.1001/archinte.158.17.1870; MACKOWIAK PA, 1980, AM J MED SCI, V280, P73, DOI 10.1097/00000441-198009000-00002; MAYNARD JR, 1975, J CLIN INVEST, V55, P814, DOI 10.1172/JCI107992; MINICK CR, 1979, AM J PATHOL, V96, P673; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Nieto FJ, 1996, CIRCULATION, V94, P922, DOI 10.1161/01.CIR.94.5.922; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; Pritts TA, 2000, ARCH SURG-CHICAGO, V135, P860, DOI 10.1001/archsurg.135.7.860; REGOECZI E, 1969, BRIT J HAEMATOL, V17, P73, DOI 10.1111/j.1365-2141.1969.tb05665.x; Rugonfalvi-Kiss S, 2002, CIRCULATION, V106, P1071, DOI 10.1161/01.CIR.0000027137.96791.6A; Shi Y, 2002, PATHOL INT, V52, P31, DOI 10.1046/j.1440-1827.2002.01312.x; SNYDER YM, 1992, J LEUKOCYTE BIOL, V51, P181, DOI 10.1002/jlb.51.2.181; Weiss DJ, 1998, J VET INTERN MED, V12, P317, DOI 10.1111/j.1939-1676.1998.tb02129.x; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; Yang Rei-Cheng, 1998, Kaohsiung Journal of Medical Sciences, V14, P664; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11065	11071		10.1074/jbc.M211540200	http://dx.doi.org/10.1074/jbc.M211540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538587	hybrid			2022-12-27	WOS:000181855400027
J	Escher, G; Krozowski, Z; Croft, KD; Sviridov, D				Escher, G; Krozowski, Z; Croft, KD; Sviridov, D			Expression of sterol 27-hydroxylase (CYP27A1) enhances cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; INTRACELLULAR CHOLESTEROL; CELLULAR CHOLESTEROL; TISSUE DISTRIBUTION; MACROPHAGES; CELLS; ABCA1; ELIMINATION; HOMEOSTASIS; OXYSTEROLS	Cholesterol efflux from CHOP cells transfected with sterol 27-hydroxylase (CYP27A1) was compared with non-transfected and mock-transfected cells. Transfection caused expression of CYP27A1, formation of 27-hydroxycholesterol, and inhibition of cholesterol biosynthesis. Transfection enhanced cholesterol efflux to apolipoprotein A-I or human plasma by 2-3-fold but did not affect the efflux in the absence of acceptor. The analysis of released sterols revealed that 27-hydroxycholesterol represented only a small proportion of sterols, most of which was non-oxidized cholesterol. Time course and dose dependence studies showed that expression of CYP27A1 in CHOP cells mostly affected the efflux of the "fast" cholesterol pool, and relatively more cholesterol was released with low concentrations of an acceptor. Preincubation of non-transfected cells with exogenous 27-hydroxycholesterol (10(-9) and 10(-7) M) led to the stimulation of cholesterol efflux by 24-60%. Expression of CYP27A1 in CHOP cells did not affect ABCA1 expression and abundance of ABCA1 protein. Thus, introduction of CYP27A1 into cells stimulates cholesterol efflux and therefore may increase protection against atherosclerosis.	Baker Med Res Inst, Melbourne, Vic 8008, Australia; Univ Western Australia, Dept Med, Perth, WA 6001, Australia	Baker Heart and Diabetes Institute; University of Western Australia	Sviridov, D (corresponding author), Baker Med Res Inst, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		Sviridov, Dmitri/E-7943-2010; Croft, Kevin D/C-4675-2013	Escher, Genevieve/0000-0002-5125-2262; Croft, Kevin/0000-0003-1596-4913				ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Babiker A, 1998, BBA-LIPID LIPID MET, V1392, P333, DOI 10.1016/S0005-2760(98)00047-2; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; Edwards PA, 2002, J LIPID RES, V43, P2; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Gaus K, 2001, BIOCHEMISTRY-US, V40, P9363, DOI 10.1021/bi010323n; Gaus K, 2001, BIOCHEMISTRY-US, V40, P13002, DOI 10.1021/bi010833h; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; Meir K, 2002, J BIOL CHEM, V277, P34036, DOI 10.1074/jbc.M201122200; Mori TA, 1996, REDOX REP, V2, P25, DOI 10.1080/13510002.1996.11747023; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; von Bahr S, 2002, ARTERIOSCL THROM VAS, V22, P1129, DOI 10.1161/01.ATV.0000022600.61391.A5; Westman J, 1998, ARTERIOSCL THROM VAS, V18, P554, DOI 10.1161/01.ATV.18.4.554	29	55	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11015	11019		10.1074/jbc.M212780200	http://dx.doi.org/10.1074/jbc.M212780200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531903	hybrid			2022-12-27	WOS:000181855400020
J	Vespa, A; Darmon, AJ; Turner, CE; D'Souza, SJA; Dagnino, L				Vespa, A; Darmon, AJ; Turner, CE; D'Souza, SJA; Dagnino, L			Ca2+-dependent localization of integrin-linked kinase to cell junctions in differentiating keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDUCED CHANGES; EPIDERMAL-KERATINOCYTES; MEMBRANE RAFTS; BETA-CATENIN; ADHESION; PROTEIN; EXPRESSION; BETA-1-INTEGRINS; CYTOSKELETON; MATRIX	Integrin complexes are necessary for proper proliferation and differentiation of epidermal keratinocytes. Differentiation of these cells is accompanied by down-regulation of integrins and focal adhesions as well as formation of intercellular adherens junctions through E-cadherin homodimerization. A central component of integrin adhesion complexes is integrin-linked kinase (ILK), which can induce loss of E-cadherin expression and epithelial-mesenchymal transformation when ectopically expressed in intestinal and mammary epithelia. In cultured primary mouse keratinocytes, we find that ILK protein levels are independent of integrin expression and signaling, since they remain constant during Ca2+-induced differentiation. In contrast, keratinocyte differentiation is accompanied by marked reduction in kinase activity in ILK immunoprecipitates and altered ILK subcellular distribution. Specifically, ILK distributes in close apposition to actin fibers along intercellular junctions in differentiated but not in undifferentiated keratinocytes. ILK localization to cell-cell borders occurs independently of integrin signaling and requires Ca2+ as well as an intact actin cytoskeleton. Further, and in contrast to what is observed in other epithelial cells, ILK overexpression in differentiated keratinocytes does not promote E-cadherin down-regulation and epithelial-mesenchymal transition. Thus, novel tissue-specific mechanisms control the formation of ILK complexes associated with cell-cell junctions in differentiating murine epidermal keratinocytes.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Pediat, London, ON N6A 5C1, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada; SUNY Syracuse, Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	D'Souza, SJA (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	sjdsouza@uwo.ca; ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159	NHLBI NIH HHS [HL70244] Funding Source: Medline; NIGMS NIH HHS [R01 GM047607] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070244] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Boesze-Battaglia K, 2002, J BIOL CHEM, V277, P41843, DOI 10.1074/jbc.M207111200; BRAGA VMM, 1995, CELL ADHES COMMUN, V3, P201, DOI 10.3109/15419069509081287; Braga VMM, 1998, CELL ADHES COMMUN, V5, P137, DOI 10.3109/15419069809040287; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERTLE MD, 1991, DEVELOPMENT, V112, P193; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; JENSEN PJ, 1995, EXP CELL RES, V219, P322, DOI 10.1006/excr.1995.1235; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Li FG, 1999, J CELL SCI, V112, P4589; Li LW, 1996, J INVEST DERMATOL, V106, P254, DOI 10.1111/1523-1747.ep12340654; Lozano E, 1998, CELL ADHES COMMUN, V6, P51, DOI 10.3109/15419069809069760; MAGEE AI, 1987, EXP CELL RES, V172, P43, DOI 10.1016/0014-4827(87)90091-7; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rikimaru K, 1997, EXP DERMATOL, V6, P214, DOI 10.1111/j.1600-0625.1997.tb00165.x; Somasiri A, 2001, J CELL SCI, V114, P1125; Travis AJ, 2001, DEV BIOL, V240, P599, DOI 10.1006/dbio.2001.0475; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728; ZINKEL S, 1994, SEMIN CANCER BIOL, V5, P77	43	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11528	11535		10.1074/jbc.M208337200	http://dx.doi.org/10.1074/jbc.M208337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547824	hybrid			2022-12-27	WOS:000181855400085
J	Xiao, H; Chung, J; Kao, HY; Yang, YC				Xiao, H; Chung, J; Kao, HY; Yang, YC			Tip60 is a co-repressor for STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; RECEPTOR-ALPHA-CHAIN; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; COMPLEX CONTAINS; GENE-EXPRESSION; CLASS-I; PROTEIN; ACETYLATION; COREPRESSOR	Tip60 (Tat-interactive protein, 60 kDa), a cellular protein with intrinsic histone acetyltransferase activity, is involved in DNA damage repair and apoptosis. Recent studies have suggested that Tip60 acts either as a coactivator or a co-repressor to modulate transcription. In this study, we demonstrate that Tip60 represses reporter gene expression when it is fused to the Ga14 DNA binding domain. We also show that Tip60 associates with histone deacetylase 7 (HDAC7) through its N-terminal zinc finger-containing region and that HDAC7 activity is required for the repressive effect of Tip60. Because endogenous Tip60 interacts with STAT3, we hypothesized that Tip60 might complex with STAT3 and HDAC7 and modulate STAT3-mediated trans-activation. Consistent with this hypothesis, the overexpression of Tip60 represses STAT3-driven reporter gene expression, which can be further potentiated by the co-transfection of HDAC7. Furthermore, interleukin-9-induced c-myc expression, which depends on STAT3 activity, is abrogated by exogenous expression of Tip60. This is the first demonstration of which Tip60 represses STAT3 activity in part through the recruitment of HDAC7.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER; NCI NIH HHS [CA78433] Funding Source: Medline; NHLBI NIH HHS [HL48819] Funding Source: Medline; NIDDK NIH HHS [DK50570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DERUIJTER AJ, 2003, IN PRESS BIOCH J; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Grienenberger A, 2002, CURR BIOL, V12, P762, DOI 10.1016/S0960-9822(02)00814-X; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hlubek F, 2001, J BIOCHEM-TOKYO, V129, P635, DOI 10.1093/oxfordjournals.jbchem.a002901; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Huynh KD, 2000, GENE DEV, V14, P1810; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lejeune D, 2001, BIOCHEM J, V353, P109, DOI 10.1042/bj3530109; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lough JW, 2002, DEV DYNAM, V223, P419, DOI 10.1002/dvdy.10058; McAllister D, 2002, GENE, V289, P169, DOI 10.1016/S0378-1119(02)00546-2; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; RAN Q, 2002, GENE, V258, P169; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xiao H, 2002, J BIOL CHEM, V277, P8091, DOI 10.1074/jbc.M106650200; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	60	89	94	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11197	11204		10.1074/jbc.M210816200	http://dx.doi.org/10.1074/jbc.M210816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551922	hybrid			2022-12-27	WOS:000181855400045
J	Zhang, Y; Yu, CJ; Liu, J; Spencer, TA; Chang, CCY; Chang, TY				Zhang, Y; Yu, CJ; Liu, J; Spencer, TA; Chang, CCY; Chang, TY			Cholesterol is superior to 7-ketocholesterol or 7 alpha-hydroxycholesterol as an allosteric activator for acyl-coenzyme A : cholesterol acyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; OXYSTEROLS; CELLS; VESICLES; OXIDATION; MICELLES; LIVER; RECONSTITUTION; LOCALIZATION; QUANTITATION	We compared the abilities of cholesterol versus various oxysterols as substrate and/or as activator for the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT), by monitoring the activity of purified human ACAT1 in response to sterols solubilized in mixed micelles or in reconstituted vesicles. The results showed that 5alpha,6alpha-epoxycholesterol and 7alpha-hydroxycholesterol are comparable with cholesterol as the favored substrates, whereas 7-ketocholesterol, 7beta-hydroxycholesterol, 5beta,6beta-epoxycholesterol, and 24(S),25-epoxycholesterol are very poor substrates for the enzyme. We then tested the ability of 7-ketocholesterol as an activator when cholesterol was measured as the substrate, and vice versa. When cholesterol was measured as the substrate, the addition of 7-ketocholesterol could not activate the enzyme. In contrast, when 7-ketocholesterol was measured as the substrate, the addition of cholesterol significantly activated the enzyme and changed the shape of the substrate saturation curve from sigmoidal to essentially hyperbolic. Additional results show that, as an activator, cholesterol is much better than all the oxysterols tested. These results suggest that ACAT1 contains two types of sterol binding sites; the structural requirement for the ACAT activator site is more stringent than it is for the ACAT substrate site. Upon activation by cholesterol, ACAT1 becomes promiscuous toward various sterols as its substrate.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Chang, TY (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	Ta.Yuan.Chang@Dartmouth.edu	Yu, Chunjiang/E-9419-2012	Liu, Jay/0000-0002-4230-1843; Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjorkhem I, 2002, J CLIN INVEST, V110, P725, DOI 10.1172/JCI200216388; Brown AJ, 2000, J LIPID RES, V41, P226; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BROWN MS, 1975, J BIOL CHEM, V250, P4925; CADIGAN KM, 1988, J LIPID RES, V29, P1683; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6; ERICKSON SK, 1980, J LIPID RES, V21, P930; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; Kauffman JM, 2000, J LIPID RES, V41, P991; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LI QT, 1994, ARCH BIOCHEM BIOPHYS, V315, P473, DOI 10.1006/abbi.1994.1527; LICHTENSTEIN AH, 1980, J BIOL CHEM, V255, P9098; Lu XH, 2002, J BIOL CHEM, V277, P711, DOI 10.1074/jbc.M109427200; Moschetta A, 2001, BBA-MOL CELL BIOL L, V1532, P15, DOI 10.1016/S1388-1981(01)00110-X; Patel RP, 1996, J LIPID RES, V37, P2361; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SHI SP, 1989, BIOCHIM BIOPHYS ACTA, V982, P187, DOI 10.1016/0005-2736(89)90054-0; Spencer TA, 2000, J ORG CHEM, V65, P1919, DOI 10.1021/jo991370c; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; THEUNISSEN JJH, 1986, BIOCHIM BIOPHYS ACTA, V860, P66, DOI 10.1016/0005-2736(86)90499-2; Tomkinson NCO, 1998, J ORG CHEM, V63, P9919, DOI 10.1021/jo981753v; VENTIMIGLIA JB, 1986, ANAL BIOCHEM, V157, P323, DOI 10.1016/0003-2697(86)90633-0; Verhagen JCD, 1996, J LIPID RES, V37, P1488; White T, 1998, ANAL BIOCHEM, V258, P109, DOI 10.1006/abio.1997.2545; Yu CJ, 2002, BIOCHEMISTRY-US, V41, P3762, DOI 10.1021/bi0120188; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139	39	57	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11642	11647		10.1074/jbc.M211559200	http://dx.doi.org/10.1074/jbc.M211559200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12533546	hybrid			2022-12-27	WOS:000181855400097
J	Zha, XH; Gauthier, A; Genest, J; McPherson, R				Zha, XH; Gauthier, A; Genest, J; McPherson, R			Secretory vesicular transport from the golgi is altered during ATP-binding cassette protein A1 (ABCA1)-mediated cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CHOLESTEROL; CELLS; RAFTS; ABC1	Apolipoprotein AI (apoAI)-mediated cholesterol efflux is a process by which cells export excess cellular cholesterol to apoAI to form high density lipoprotein. ATP-binding cassette protein A1 (ABCA1) has recently been identified as the key regulator of this process. The pathways of intracellular cholesterol transport during efflux are largely unknown nor is the molecular mechanism by which ABCA1 governs cholesterol efflux well, understood. Here, we report that, in both macrophages and fibroblasts, the secretory vesicular transport changes in response to apoAI-mediated cholesterol efflux. Vesicular transport from the Golgi to the plasma membrane increased 2-fold during efflux. This increase in vesicular transport during efflux was observed in both raft-poor and raft-rich vesicle populations originated from the Golgi. Importantly, enhanced vesicular transport in response to apoAI is absent in Tangier fibroblasts, a cell type with deficient cholesterol efflux due to functional ABCA1 mutations. These findings are consistent with an efflux model whereby cholesterol is transported from the storage site to the plasma membrane via the Golgi. ABCA1 may influence cholesterol efflux in part by enhancing vesicular trafficking from the Golgi to the plasma membrane.	Univ Ottawa, Ottawa Hlth Res Inst, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W9, Canada; McGill Univ, Ctr Hlth, Div Cardiol, Montreal, PQ H3A 1A1, Canada	University of Ottawa; Ottawa Hospital Research Institute; McGill University	Zha, XH (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Lipoprot & Atherosclerosis Grp, 725 Parkdale Ave, Ottawa, ON K1Y 4W9, Canada.	xzha@ohri.ca; rmcpherson@ottawaheart.ca						Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Ito J, 2002, J BIOL CHEM, V277, P7929, DOI 10.1074/jbc.M103878200; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Mendez AJ, 1996, J LIPID RES, V37, P2510; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Oram JF, 1996, J LIPID RES, V37, P2473; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200	16	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10002	10005		10.1074/jbc.C300024200	http://dx.doi.org/10.1074/jbc.C300024200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12551894	hybrid			2022-12-27	WOS:000181777500002
J	Gu, BH; Johnston, VK; Gutshall, LL; Nguyen, TT; Gontarek, RR; Darcy, MG; Tedesco, R; Dhanak, D; Duffy, KJ; Kao, CC; Sarisky, RT				Gu, BH; Johnston, VK; Gutshall, LL; Nguyen, TT; Gontarek, RR; Darcy, MG; Tedesco, R; Dhanak, D; Duffy, KJ; Kao, CC; Sarisky, RT			Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; E2-NS2 REGION; IN-VITRO; NON-A; POLYMERASE; IDENTIFICATION; NS5B; REQUIREMENTS; TEMPLATE; REPLICATION	The hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRp), the primary catalytic enzyme of the HCV replicase complex. Recently, two benzo-1,2,4-thiadiazine compounds were shown to be potent, highly specific inhibitors of the genotype 1b HCV RdRp containing a carboxyl-terminal 21 residue truncation (Delta21 HCV RdRp) (Dhanak, D., Duffy, K., Johnston, V. K., Lin-Goerke, J., Darcy, M., Shaw, A. N. G. B., Silverman, C., Gates, A. T., Earnshaw, D. L., Casper, D. J., Kaura, A., Baker, A., Greenwood, C., Gutshall, L. L., Maley, D., DelVecchio, A., Macarron, R., Hofmann, G. A., Alnoah, Z., Cheng, H.-Y., Chan, G., Khandekar, S., Keenan, R. M., and Sarisky, R. T. (2002) J. Biol. Chem. 277, 38322-38327). Compound 4 (C21H21N3O4S) reduces viral replication by virtue of its direct interaction with the viral polymerase rather than by nonspecific titration of nucleic acid template. In this study, we present several lines of evidence to demonstrate that this inhibitor interferes with the initiation step of RNA synthesis rather than acting as an elongation inhibitor. Inhibition of initial phosphodiester bond formation occurred regardless of whether replication was initiated by primer-dependent or de novo mechanisms. Filter binding studies using increasing concentrations of compound 4 did not interfere with the ability of Delta21 HCV RdRp to interact with nucleic acid. Furthermore, varying the order of reagent addition in the primer extension assay showed no distinct differences in inhibition profile. Finally, surface plasmon resonance analyses provided evidence that a ternary complex is capable of forming between the RNA template, RdRp, and compound 4. Together, these data suggest that this heterocyclic agent interacts with the apoenzyme, as well as with the RNA-bound form of Delta21 HCV RdRp, and therefore does not directly interfere with the RdRp-RNA interaction to mediate inhibition.	GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Virol, Bloomington, IN 47405 USA; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Biochem, Bloomington, IN 47405 USA; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Med Chem, Bloomington, IN 47405 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Indiana University System; Indiana University Bloomington	Sarisky, RT (corresponding author), Centocor Inc, Dept Infect Dis, R-4-1,200 Great Valley Pkwy, Malvern, PA 19355 USA.	rsarisky@cntus.jnj.com		Duffy, Kevin/0000-0002-7184-2059; Tedesco, Rosanna/0000-0001-8489-2381				BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Irie M, 1999, PHARMACOL THERAPEUT, V81, P77, DOI 10.1016/S0163-7258(98)00035-7; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kim MJ, 2001, P NATL ACAD SCI USA, V98, P4972, DOI 10.1073/pnas.081077198; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; Shim JH, 2002, J VIROL, V76, P7030, DOI 10.1128/JVI.76.14.7030-7039.2002; Sun JH, 1997, VIROLOGY, V236, P348, DOI 10.1006/viro.1997.8742; Sun JH, 1997, VIROLOGY, V233, P63, DOI 10.1006/viro.1997.8583; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	35	76	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16602	16607		10.1074/jbc.M210891200	http://dx.doi.org/10.1074/jbc.M210891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12554734	hybrid			2022-12-27	WOS:000182818600022
J	Lu, BS; Bishop, CE				Lu, BS; Bishop, CE			Mouse GGN1 and GGN3, two germ cell-specific proteins from the single gene Ggn, interact with mouse POG and play a role in spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; PROTO-ONCOGENE; W-LOCUS; MICE; PROLIFERATION; GENERATION; MIGRATION; MUTATION; ENCODES; EMBRYO	The germ cell-deficient (gcd) mutation is a recessive transgenic insertional mutation leading to a deficiency of primordial germ cells (PGCs). We have recently shown that the gene underlying this mutation is Pog, which is necessary for normal proliferation of PGCs. Here we show that Pog is also involved in spermatogenesis in that meiosis is impaired in Pog-deficient mice. Yeast two-hybrid screening revealed that POG interacted with GGN1 and GGN3, two proteins formed by alternate splicing of the same gene, gametogenetin (Ggn). Ggn had more than 10 different splice variants giving rise to three proteins, GGN1, GGN2, and GGN3. The three proteins had different subcellular localizations, with GGN1, GGN2, and GGN3 localized along the nuclear membrane, in the cytoplasm, and in the nucleus/nucleoli respectively. The expression of Ggn was confined to late pachytene spermatocytes and round spermatids, a time window concomitant with the occurrence of meiosis. Mouse Ggn and Pog were both expressed in primary spermatocytes. Co-expression of POG with GGN1 or GGN3 in HeLa cells changed the localization of POG to the perinuclear localization or the nucleoli, respectively. Our data showed that in addition to functioning in proliferation of primordial germ cells, POG also functioned in spermatogenesis. Two spatial and temporal regulated proteins, GGN1 and GGN3, interacted with POG, regulated the localization of POG, and played a role in spermatogenesis.	Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Bishop, CE (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, 6550 Fannin St 880, Houston, TX 77030 USA.		Lu, Baisong/B-5837-2013	Lu, Baisong/0000-0001-9240-558X	NICHD NIH HHS [HD 36289] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD036289] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Agoulnik AI, 2002, HUM MOL GENET, V11, P3047, DOI 10.1093/hmg/11.24.3047; ANDERSEN B, 1993, P NATL ACAD SCI USA, V90, P11084, DOI 10.1073/pnas.90.23.11084; Anderson R, 1999, DEVELOPMENT, V126, P1655; Beck ARP, 1998, P NATL ACAD SCI USA, V95, P2331, DOI 10.1073/pnas.95.5.2331; Bendel-Stenzel MR, 2000, MECH DEVELOP, V91, P143, DOI 10.1016/S0925-4773(99)00287-7; BRADY G, 1993, METHOD ENZYMOL, V225, P611; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; BYSKOV AG, 1986, PHYSIOL REV, V66, P71, DOI 10.1152/physrev.1986.66.1.71; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Cobb J, 1998, SEMIN CELL DEV BIOL, V9, P445, DOI 10.1006/scdb.1998.0202; DUNCAN MK, 1995, MAMM GENOME, V6, P697, DOI 10.1007/BF00354290; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GINSBURG M, 1990, DEVELOPMENT, V110, P521; HATANAKA M, 1990, BIOESSAYS, V12, P143, DOI 10.1002/bies.950120310; HEYTING C, 1988, CHROMOSOMA, V96, P325, DOI 10.1007/BF00286921; KREMER EJ, 1991, EXP CELL RES, V197, P330, DOI 10.1016/0014-4827(91)90442-W; Krishnamurthy H, 1998, J ANDROL, V19, P710; LAWSON KA, 1994, CIBA F SYMP, V182, P68; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; LU B, 2003, IN PRESS BIOL REPROD; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; MOSS SB, 1993, MOL REPROD DEV, V34, P164, DOI 10.1002/mrd.1080340208; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; PELLAS TC, 1991, P NATL ACAD SCI USA, V88, P8787, DOI 10.1073/pnas.88.19.8787; Russell L. D., 1990, HISTOLOGICAL HISTOPA; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; Venables JP, 2002, CURR OPIN GENET DEV, V12, P615, DOI 10.1016/S0959-437X(02)00347-7; Ying Y, 2000, MOL ENDOCRINOL, V14, P1053, DOI 10.1210/me.14.7.1053; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	30	32	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16289	16296		10.1074/jbc.M211023200	http://dx.doi.org/10.1074/jbc.M211023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12574169	hybrid			2022-12-27	WOS:000182680000105
J	Morita, T; El-Kazzaz, W; Tanaka, Y; Inada, T; Aiba, H				Morita, T; El-Kazzaz, W; Tanaka, Y; Inada, T; Aiba, H			Accumulation of glucose 6-phosphate or fructose 6-phosphate is responsible for destabilization of glucose transporter mRNA in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; MAJOR GLUCOSE; GENE-EXPRESSION; LACTOSE DIAUXIE; HFQ; DEGRADATION; PTSG; DECAY; INACTIVATION; REPRESSION	Previously we found that a mutation in either pgi or pfkA, encoding phosphoglucose isomerase or phosphofructokinase X respectively, facilitates degradation of the ptsG mRNA in an RNase E-dependent manner in Escherichia coli (1). In this study, we examined the effects of a series of glycolytic genes on the degradation of ptsG mRNA and how the mutations destabilize the ptsG mRNA. The conditional lethal mutation ts8 in fda, encoding fructose-1,6-P-2 aldolase just downstream of pthA in the glycolytic pathway, caused the destabilization of ptsG mRNA at the nonpermissive temperature. Mutations in any other gene did not destabilize the ptsG mRNA, rather, they reduced the ptsG transcription mainly by affecting the cAMP level. The rapid degradation of ptsG mRNA in mutant strains was completely dependent upon the presence of glucose or any one of its compounds, which enter the Embden-Meyerhof glycolytic pathway before the block points. A significant increase in the intracellular glucose-6-P level was observed in the presence of glucose in the pgi strain. An overexpression of glucose-6-phosphate dehydrogenase eliminated both the accumulation and the degradation of ptsG mRNA in the pgi strain. In addition, accumulation of fructose-6-P led to the rapid degradation of ptsG mRNA in a pgi,pfkA mutant strain lacking glucose-6-P. We conclude that the RNase E-dependent destabilization of ptsG mRNA occurs in response to accumulation of glucose-6-P or fructose-6-P.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan	Nagoya University	Aiba, H (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan.	i45346a@nucc.cc.nagoya-u.ac.jp	kazzaz, waleed el/ABE-2805-2020; Inada, Toshifumi/AAE-1517-2019					AIBA H, 1981, J BIOL CHEM, V256, P1905; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; [Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; BRAND IA, 1986, J BIOL CHEM, V261, P5892; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; Hogema BM, 1999, MOL MICROBIOL, V31, P1825, DOI 10.1046/j.1365-2958.1999.01319.x; Inada T, 1996, GENES CELLS, V1, P293, DOI 10.1046/j.1365-2443.1996.24025.x; Inada T, 1996, MOL GEN GENET, V253, P198, DOI 10.1007/s004380050313; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; JOSEPH E, 1982, MOL GEN GENET, V185, P262, DOI 10.1007/BF00330796; Kimata K, 1997, P NATL ACAD SCI USA, V94, P12914, DOI 10.1073/pnas.94.24.12914; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; Kimata K, 2001, EMBO J, V20, P3587, DOI 10.1093/emboj/20.13.3587; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; LEE AT, 1987, P NATL ACAD SCI USA, V84, P8311, DOI 10.1073/pnas.84.23.8311; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; Levi B, 2001, J NUTR BIOCHEM, V12, P235, DOI 10.1016/S0955-2863(00)00158-3; LIN ECC, 1996, ESCHERICHIA COLI SAL, P307; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; Miller J. H., 1972, EXPT MOL GENETICS, P433; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Ow MC, 2000, MOL MICROBIOL, V38, P854, DOI 10.1046/j.1365-2958.2000.02186.x; PERLMAN RL, 1969, NATURE, V223, P810, DOI 10.1038/223810a0; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Regnier P, 2000, BIOESSAYS, V22, P235; Sambrook J, 1989, MOL CLONING LAB MANU, P202; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; SINGER M, 1991, J BACTERIOL, V173, P6249, DOI 10.1128/jb.173.19.6249-6257.1991; SINGER M, 1991, J BACTERIOL, V173, P6242, DOI 10.1128/jb.173.19.6242-6248.1991; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tsui HCT, 1997, J BACTERIOL, V179, P7476, DOI 10.1128/jb.179.23.7476-7487.1997; Vytvytska O, 2000, GENE DEV, V14, P1109; Vytvytska O, 1998, P NATL ACAD SCI USA, V95, P14118, DOI 10.1073/pnas.95.24.14118; Wachi M, 1997, MOL GEN GENET, V253, P515, DOI 10.1007/s004380050352; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	48	108	112	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15608	15614		10.1074/jbc.M300177200	http://dx.doi.org/10.1074/jbc.M300177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12578824	hybrid			2022-12-27	WOS:000182680000021
J	Goel, A; Mathupala, SP; Pedersen, PL				Goel, A; Mathupala, SP; Pedersen, PL			Glucose metabolism in cancer - Evidence that demethylation events play a role in activating type II hexokinase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BOUND HEXOKINASE; DNA METHYLATION PATTERNS; TUMOR-CELLS; OVARIAN CANCERS; CPG-ISLANDS; CATABOLISM; PROMOTER; PROTEIN; HYPOMETHYLATION; BINDING	One of the "signature" phenotypes of highly malignant, poorly differentiated tumors, including hepatomas, is their remarkable propensity to utilize glucose at a much higher rate than normal cells, a property frequently dependent on the marked overexpression of type II hexokinase (HKII). As the expression of the gene for this enzyme is nearly silent in liver tissue, we tested the possibility that DNA methylation/demethylation events may be involved in its regulation. Initial studies employing methylation restriction endonuclease analysis provided evidence for differential methylation patterns for the HKII gene in normal hepatocytes and hepatoma cells, the latter represented by a highly glycolytic model cell line (AS-30D). Subsequently, sequencing following sodium bisulfite treatment revealed 18 methylated CpG sites within a CpG island (- 350 to + 781 bp) in the hepatocyte gene but none in that of the hepatoma. In addition, treatment of a hepatocyte cell line with the DNA methyltransferase inhibitors, 5'-azacytidine and 5'-aza-2'-deoxycytidine, activated basal expression levels of HKII mRNA and protein. Finally, stably transfecting the hepatocyte cell line with DNA demethylase also resulted in activating the basal expression levels of HKII mRNA and protein. These novel observations indicate that one of the initial events in activating the HKII gene during either transformation or tumor progression may reside at the epigenetic level.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	ppederse@jhmi.edu			NCI NIH HHS [T32 CA 67751, CA 80118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067751, R01CA080118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aisenberg AC, 1961, GLYCOLYSIS RESP TUMO; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; CAMPAIN JA, 1993, MOL ENDOCRINOL, V7, P1331, DOI 10.1210/me.7.10.1331; CHANG JP, 1967, CANCER RES, V27, P2065; Freshney RI., 1987, CULTURE ANIMAL CELLS; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Geschickter C.F., 1930, J CHEM EDUC, DOI [10.1021/ed007p179, DOI 10.1021/ED007P179]; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; HANADA M, 1993, BLOOD, V82, P1820; Hattori M, 2001, J INT MED RES, V29, P204, DOI 10.1177/147323000102900308; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Leonhardt H, 2000, J CELL BIOCHEM, P78; Lichtenstein AV, 2001, BIOCHEMISTRY-MOSCOW+, V66, P235, DOI 10.1023/A:1010249510906; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Nabi Hani A, 2002, J Nucl Med Technol, V30, P3; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; NAKASHIMA RA, 1988, CANCER RES, V48, P913; PAGGI MG, 1991, BIOCHEM BIOPH RES CO, V178, P648, DOI 10.1016/0006-291X(91)90157-3; PARRY DM, 1983, J BIOL CHEM, V258, P904; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Rempel A, 1996, CANCER RES, V56, P2468; Rempel A, 1996, FEBS LETT, V385, P233, DOI 10.1016/0014-5793(96)00399-7; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Riddle SR, 2000, AM J PHYSIOL-LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407; ROSE IA, 1982, ARCH BIOCHEM BIOPHYS, V213, P625, DOI 10.1016/0003-9861(82)90592-6; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SHARRARD RM, 1992, BRIT J CANCER, V65, P667, DOI 10.1038/bjc.1992.142; SMITH DF, 1970, CANCER RES, V30, P2306; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; WEINSTEIN IB, 1975, CANCER RES, V35, P253; ZRIHANLICHT S, 1995, INT J CANCER, V62, P245, DOI 10.1002/ijc.2910620303	41	111	121	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15333	15340		10.1074/jbc.M300608200	http://dx.doi.org/10.1074/jbc.M300608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12566445	hybrid			2022-12-27	WOS:000182516100098
J	Priest, JW; Hajduk, SL				Priest, JW; Hajduk, SL			Trypanosoma brucei cytochrome c(1) is imported into mitochondria along an unusual pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C HEME LYASE; ADP ATP CARRIER; INTERMEMBRANE SPACE; PROTEIN IMPORT; APOCYTOCHROME-C; INNER MEMBRANE; BLOOD-STREAM; CRITHIDIA-FASCICULATA; PRECURSOR PROTEINS; ADP/ATP CARRIER	In most eukaryotic organisms, cytochrome c(1) is encoded in the nucleus, translated on cytosolic ribosomes, and directed to its final destination in the mitochondrial inner membrane by a bipartite, cleaved, amino-terminal presequence. However, in the kinetoplastids and euglenoids, the cytochrome c(1) protein has been shown to lack a cleaved presequence; a single methionine is removed from the amino terminus upon maturation, and the sequence upstream of the heme-binding site is generally shorter than that of the other eukaryotic homologs. We have used a newly developed mitochondrial protein import assay system from Trypanosoma brucei to demonstrate that the T. brucei cytochrome c(1) protein is imported along a non-conservative pathway similar to that described for the inner membrane carrier proteins of other organisms. This pathway requires external ATP and an external protein receptor but is not absolutely dependent on a membrane potential or on ATP hydrolysis in the mitochondrial matrix. We propose the cytochrome c(1) import in T. brucei is a two-step process first involving a membrane potential independent translocation across the outer mitochondrial membrane followed by heme attachment and a membrane potential-dependent insertion into the inner membrane.	Univ Alabama, Sch Med, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Dept Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hajduk, SL (corresponding author), Univ Alabama, Sch Med, Dept Biochem, Birmingham, AL 35294 USA.				NIAID NIH HHS [AI08259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allemann N, 2000, MOL BIOCHEM PARASIT, V111, P87, DOI 10.1016/S0166-6851(00)00303-0; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; Bertrand KI, 2000, MOL BIOCHEM PARASIT, V106, P249, DOI 10.1016/S0166-6851(99)00218-2; CUNARRO J, 1975, BIOCHIM BIOPHYS ACTA, V387, P234, DOI 10.1016/0005-2728(75)90106-1; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HARTL FU, 1987, CYTOCHROME SYSTEMS M, P189; Hausler T, 1997, EUR J CELL BIOL, V73, P240; JENSEN RE, 1992, MOL CELL BIOL, V12, P4677, DOI 10.1128/MCB.12.10.4677; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MUKAI K, 1989, J BIOCHEM-TOKYO, V106, P479, DOI 10.1093/oxfordjournals.jbchem.a122877; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P29, DOI 10.1111/j.1432-1033.1977.tb11567.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; PRIEST JW, 1994, MOL BIOCHEM PARASIT, V65, P291, DOI 10.1016/0166-6851(94)90080-9; Priest JW, 1996, J BIOL CHEM, V271, P20060, DOI 10.1074/jbc.271.33.20060; PRIEST JW, 1995, BBA-MOL CELL RES, V1269, P201, DOI 10.1016/0167-4889(95)00154-6; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; STUART RA, 1990, J BIOL CHEM, V265, P20210; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WILLIAMS N, 1990, MOL BIOCHEM PARASIT, V43, P125, DOI 10.1016/0166-6851(90)90137-B; Zara V, 2001, J MOL BIOL, V310, P965, DOI 10.1006/jmbi.2001.4833; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	55	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15084	15094		10.1074/jbc.M212956200	http://dx.doi.org/10.1074/jbc.M212956200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578826	hybrid			2022-12-27	WOS:000182516100066
J	Suzuki, M; Kobayashi, H; Tanaka, Y; Hirashima, Y; Kanayama, N; Takei, Y; Saga, Y; Suzuki, M; Itoh, H; Terao, T				Suzuki, M; Kobayashi, H; Tanaka, Y; Hirashima, Y; Kanayama, N; Takei, Y; Saga, Y; Suzuki, M; Itoh, H; Terao, T			Bikunin target genes in ovarian cancer cells identified by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY TRYPSIN-INHIBITOR; MEMBRANE SERINE-PROTEASE; HEPATOCYTE GROWTH-FACTOR; TRANSCRIPTION FACTOR; BINDING PROTEINS; CDNA CLONING; EXPRESSION; LOCALIZATION; FAMILY; MATRIPTASE	Bikunin, a Kunitz-type protease inhibitor, could potentially suppress tumor cell invasion and metastasis. Our previous study revealed that overexpression of bikunin in a human ovarian cancer cell line, HRA, resulted in a down-regulation in uPA and uPAR gene expression. For identifying the full repertoire of bikunin-regulated genes, a cDNA microarray hybridization screening was conducted using mRNA from bikunin-treated or bikunin-transfected HRA cells. A number of bikunin-regulated genes were identified, and their regulation was confirmed by Northern blot analysis. Our screen identified 11 bikunin-stimulated genes and 29 bikunin-repressed genes. The identified genes can indeed be classified into distinct subsets. These include transcriptional regulators, oncogenes/tumor suppressor genes, signaling molecules, growth/cell cycle, invasion/metastasis, cytokines, apoptosis, ion channels, extracellular matrix proteins, as well as some proteases. This screen identified suppression of several genes such as CDC-like kinase, LIM domain binding, Ets domain transcription factor, Rho GTPase-activating protein, tyrosine phosphorylation-regulated kinase, hyaluronan-binding protein, matriptase, and pregnancy-associated plasma protein-A (PAPP-A), which have previously been implicated in enhancing tumor promotion. Northern blot analysis confirmed that several genes including matriptase and PAPP-A were down-regulated by bikunin by similar to9-fold. Further, genetic inhibition of matriptase or PAPP-A could lead to diminished invasion. These results show that bikunin alters the pattern of gene expression in HRA cells leading to a block in cell invasion.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan; Jichi Med Sch, Dept Obstet & Gynecol, Tochigi 3290498, Japan; Miyazaki Univ, Sch Med, Dept Pathol 2, Miyazaki 8891692, Japan	Hamamatsu University School of Medicine; Jichi Medical University; University of Miyazaki	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Hamamatsu, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp	Takei, Yuji/ABD-2485-2020	Takei, Yuji/0000-0002-1744-5570				Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Cho EG, 2001, J BIOL CHEM, V276, P44581, DOI 10.1074/jbc.M107059200; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DRIVAS GT, 1991, ONCOGENE, V6, P3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fowlkes JL, 1999, ANN NY ACAD SCI, V878, P696, DOI 10.1111/j.1749-6632.1999.tb07765.x; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; Futamura Y, 1999, OBSTET GYNECOL, V93, P100, DOI 10.1016/S0029-7844(98)00396-2; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; KANAYAMA N, 1995, AM J OBSTET GYNECOL, V173, P192, DOI 10.1016/0002-9378(95)90189-2; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; KOBAYASHI H, 2002, J BIOL CHEM; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lee SMY, 1998, SOMAT CELL MOLEC GEN, V24, P197, DOI 10.1023/B:SCAM.0000007122.03392.4b; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Nakamura H, 1997, INT ARCH ALLERGY IMM, V112, P157, DOI 10.1159/000237448; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; Okumura K, 1997, NUCLEIC ACIDS RES, V25, P5025, DOI 10.1093/nar/25.24.5025; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Retaux S, 1999, J NEUROSCI, V19, P783; Soukas A, 2000, GENE DEV, V14, P963; SPENER F, 1990, MOL CELL BIOCHEM, V98, P57; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Suzuki M, 2001, BBA-PROTEIN STRUCT M, V1547, P26, DOI 10.1016/S0167-4838(01)00167-4; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Urabe M, 1997, GENE, V200, P157, DOI 10.1016/S0378-1119(97)00412-5; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wiksten JP, 2000, ANTICANCER RES, V20, P4905	46	42	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14640	14646		10.1074/jbc.M300239200	http://dx.doi.org/10.1074/jbc.M300239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12571229	hybrid			2022-12-27	WOS:000182516100010
J	Ervasti, JM				Ervasti, JM			Costameres: The Achilles' heel of herculean muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NITRIC-OXIDE SYNTHASE; INTERMEDIATE FILAMENT PROTEINS; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; ALPHA-DYSTROBREVIN; MDX MICE; DEFICIENT; ACTIN; INTERACTS; DESMIN		Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	ervasti@physiology.wisc.edu	Ervasti, James/AAZ-4786-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042423] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42423] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALENGHAT FJ, 2002, SCI STKE SCI STKE; Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Bezakova G, 2001, J CELL BIOL, V153, P1453, DOI 10.1083/jcb.153.7.1453; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Chaubourt E, 2002, J PHYSIOLOGY-PARIS, V96, P43, DOI 10.1016/S0928-4257(01)00079-1; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Frey N, 2002, J BIOL CHEM, V277, P13998, DOI 10.1074/jbc.M200712200; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Kemp TJ, 2001, GENOMICS, V72, P260, DOI 10.1006/geno.2000.6461; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Palmer S, 2001, J CELL BIOL, V153, P985, DOI 10.1083/jcb.153.5.985; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; Patel T J, 1997, Exerc Sport Sci Rev, V25, P321; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Poon E, 2002, J BIOL CHEM, V277, P3433, DOI 10.1074/jbc.M105273200; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 2002, MOL BIOL CELL, V13, P1512, DOI 10.1091/mbc.01-09-0446; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; Sam M, 2000, AM J PHYSIOL-CELL PH, V279, pC1116, DOI 10.1152/ajpcell.2000.279.4.C1116; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Sharp WW, 1997, AM J PHYSIOL-HEART C, V273, pH546, DOI 10.1152/ajpheart.1997.273.2.H546; STRAUB V, 1992, J CELL BIOL, V119, P1183, DOI 10.1083/jcb.119.5.1183; STREET SF, 1983, J CELL PHYSIOL, V114, P346, DOI 10.1002/jcp.1041140314; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Tidball JG, 1999, J BIOL CHEM, V274, P33155, DOI 10.1074/jbc.274.46.33155; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Warner LE, 2002, HUM MOL GENET, V11, P1095, DOI 10.1093/hmg/11.9.1095; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; Wieneke S, 2000, BIOCHEM BIOPH RES CO, V278, P419, DOI 10.1006/bbrc.2000.3810	54	314	320	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13591	13594		10.1074/jbc.R200021200	http://dx.doi.org/10.1074/jbc.R200021200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556452	hybrid			2022-12-27	WOS:000182405000001
J	Hu, G; Zhang, ZX; Wensel, TG				Hu, G; Zhang, ZX; Wensel, TG			Activation of RGS9-1GTPase acceleration by its membrane anchor, R9AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENT MEMBRANES; CRYO-ELECTRON MICROSCOPY; INHIBITORY GAMMA-SUBUNIT; CGMP-BINDING SITES; G-PROTEIN; GTPASE ACCELERATION; ROD PHOTORESPONSE; RETINAL RODS; PHOSPHODIESTERASE; PHOTOTRANSDUCTION	The GTPase-accelerating protein (GAP) complex RGS9-1(.)Gbeta(5) plays an important role in the kinetics of light responses by accelerating the GTP hydrolysis of Gat in vertebrate photoreceptors. Much, but not all, of this complex is tethered to disk membranes by the transmembrane protein R9AP. To determine the effect of the R9AP membrane complex on GAP activity, we purified recombinant R9AP and reconstituted it into lipid vesicles along with the photon receptor rhodopsin. Full-length RGS9-1(.)Gbeta(5) bound to R9AP-containing vesicles with high affinity (K-d < 10 nm), but constructs lacking the DEP (dishevelled/EGL-10/pleckstrin) domain bound with much lower affinity, and binding of those lacking the entire N-terminal domain (i.e. the dishevelled/EGL-10/pleekstrin domain plus intervening domain) was not detectable. Formation of the membrane-bound complex with R9AP increased RGS9-1 GAP activity by a factor of 4. Vesicle titrations revealed that on the time scale of phototransduction, the entire reaction sequence from GTP uptake to GAP-catalyzed hydrolysis is a membrane-delimited process, and exchange of Gat between membrane surfaces is much slower than hydrolysis. Because in rod cells different pools exist of RGS9-1(.)Gbeta(5) that are either associated with R9AP or not, regulation of the association between R9AP and RGS9-1(.)Gbeta(5) represents a potential mechanism for the regulation of recovery kinetics.	Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	twensel@bcm.tmc.edu	Hu, Guang/E-7474-2016	Hu, Guang/0000-0003-0437-4723; Wensel, Theodore/0000-0003-3518-9352				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; Calvert PD, 2002, J GEN PHYSIOL, V119, P129, DOI 10.1085/jgp.119.2.129; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HENSELMAN RA, 1974, BIOCHEMISTRY-US, V13, P5199, DOI 10.1021/bi00722a023; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Lyubarsky A, 2001, MOL VIS, V7, P71; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2002, J BIOL CHEM, V277, P32843, DOI 10.1074/jbc.M205170200; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Parmar MM, 1999, BBA-BIOMEMBRANES, V1421, P77, DOI 10.1016/S0005-2736(99)00118-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Quick M, 2002, P NATL ACAD SCI USA, V99, P8597, DOI 10.1073/pnas.132266599; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sokal I, 2003, J BIOL CHEM, V278, P8316, DOI 10.1074/jbc.M211782200; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zhang X, 2003, J NEUROSCI, V23, P1287, DOI 10.1523/JNEUROSCI.23-04-01287.2003	40	60	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14550	14554		10.1074/jbc.M212046200	http://dx.doi.org/10.1074/jbc.M212046200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12560335	hybrid			2022-12-27	WOS:000182405000123
J	Pedersen, LC; Dong, J; Taniguchi, F; Kitagawa, H; Krahn, JM; Pedersen, LG; Sugahara, K; Negishi, M				Pedersen, LC; Dong, J; Taniguchi, F; Kitagawa, H; Krahn, JM; Pedersen, LG; Sugahara, K; Negishi, M			Crystal structure of an alpha 1,4-N-acetylhexosaminyltransferase (EXTL2), a member of the exostosin gene family involved in heparan sulfate biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSORS; DONOR; ALPHA-1,3-GALACTOSYLTRANSFERASE; GLYCOSYLTRANSFERASES; ALIGNMENT; SEQUENCE; COMPLEX	EXTL2, an alpha1,4-N-acetylhexosaminyltransferase, catalyzes the transfer reaction of N-acetylglucosamine and N-acetylgalactosamine from the respective UDP-sugars to the non-reducing end of [glucuronic acid]beta1-3[galactose]/beta1-O-naphthalenemethanol, an acceptor substrate analog of the natural common linker of various glycosylaminoglycans. We have solved the x-ray crystal structure of the catalytic domain of mouse EXTL2 in the apo-form and with donor substrates UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine. In addition, a structure of the ternary complex with UDP and the acceptor substrate analog [glucuronic acid]beta1-3[galactose]beta1-O-naphthalenemethanol has been determined. These structures reveal three highly conserve residues, Asn-243, Asp-246, and Arg-293, located at the active site. Mutation of these residues greatly decreases the activity. In the ternary complex, an interaction exists between the P-phosphate of the UDP leaving group and the acceptor hydroxyl of the substrate that may play a functional role in catalysis. These structures represent the first structures from the exostosin gene family and provide important insight into the mechanisms of alpha1,4N-acetylhexosaminyl transfer in heparan biosynthesis.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6858858, Japan; NIH, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA; NIH, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA	Kobe Pharmaceutical University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6858858, Japan.		Pedersen, Lee G/E-3405-2013; Kitagawa, Hiroshi/AAJ-1344-2020; Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Pedersen, Lee G/0000-0003-1262-9861; Kitagawa, Hiroshi/0000-0002-9307-7079; Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, ZIAES080040, Z01ES080040] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Toth G, 2001, PROTEIN ENG, V14, P543, DOI 10.1093/protein/14.8.543; Wuyts W, 2000, HUM MUTAT, V15, P220, DOI 10.1002/(SICI)1098-1004(200003)15:3<220::AID-HUMU2>3.0.CO;2-K	27	86	89	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14420	14428		10.1074/jbc.M210532200	http://dx.doi.org/10.1074/jbc.M210532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562774	hybrid			2022-12-27	WOS:000182405000109
J	Pendleton, A; Pope, B; Weeds, A; Koffer, A				Pendleton, A; Pope, B; Weeds, A; Koffer, A			Latrunculin B or ATP depletion induces cofilin-dependent translocation of actin into nuclei of mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL F-ACTIN; DEPOLYMERIZING FACTOR; CYTOPLASMIC ACTIN; FILAMENT TURNOVER; BINDING PROTEIN; LOCALIZATION; SECRETION; DYNAMICS; REQUIREMENTS; CYTOSKELETON	Increasing cellular G-actin, using latrunculin B, in either intact or permeabilized rat peritoneal mast cells, caused translocation of both actin and an actin regulatory protein, cofilin, into the nuclei. The effect was not associated with an increase in the proportion of apoptotic cells. The major part of the nuclear actin was not stained by rhodamine-phalloidin but could be visualized with an actin antibody, indicating its monomeric or a conformationally distinct state, e.g. cofilin-decorated filaments. Introduction of anti-cofilin into permeabilized cells inhibited nuclear actin accumulation, implying that an active, cofilin-dependent, import exists in this system. Nuclear actin was localized outside the ethidium bromide-stained region, in the extrachromosomal nuclear domain. In permeabilized cells, the appearance of nuclear actin and cofilin was not significantly affected by increasing [Ca2+] and/or adding guanosine 5'-O-(3-thiotriphosphate), but was greatly promoted when ATP was withdrawn. Similarly, ATP depletion in intact cells also induced nuclear actin accumulation. In contrast to the effects of latrunculin B, ATP depletion was associated with an increase in cortical F-actin. Our results suggest that the presence of actin in the nucleus may be required for certain stress-induced responses and that cofilin is essential for the nuclear import of actin.	UCL, Dept Physiol, London WC1E 6JJ, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of London; University College London; MRC Laboratory Molecular Biology	Koffer, A (corresponding author), UCL, Dept Physiol, Univ St, London WC1E 6JJ, England.	a.koffer@ucl.ac.uk						ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Baluska F, 2001, DEV BIOL, V231, P113, DOI 10.1006/dbio.2000.0115; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; Belmont LD, 1999, J CELL SCI, V112, P1325; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; CAO LG, 1993, J CELL BIOL, V123, P173, DOI 10.1083/jcb.123.1.173; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Gonsior SM, 1999, J CELL SCI, V112, P797; Holt MR, 2000, METHOD ENZYMOL, V325, P356; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; Kellerman PS, 1996, AM J KIDNEY DIS, V27, P709, DOI 10.1016/S0272-6386(96)90107-9; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P222, DOI 10.1016/0167-4889(93)90048-T; Koffer A, 2002, CELL BIOL INT, V26, P885, DOI 10.1006/cbir.2002.0940; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Meijerman I, 1999, TOXICOL APPL PHARM, V156, P46, DOI 10.1006/taap.1998.8616; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; Minamide LS, 1997, J BIOL CHEM, V272, P8303, DOI 10.1074/jbc.272.13.8303; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Nosworthy NJ, 2001, PROTEOMICS, V1, P1513, DOI 10.1002/1615-9861(200111)1:12<1513::AID-PROT1513>3.0.CO;2-K; Pendleton A, 2001, CELL MOTIL CYTOSKEL, V48, P37; Pope BJ, 2000, J MOL BIOL, V298, P649, DOI 10.1006/jmbi.2000.3688; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; REUNER KH, 1995, EUR J BIOCHEM, V230, P32, DOI 10.1111/j.1432-1033.1995.0032i.x; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stanyon CA, 1999, INT J BIOCHEM CELL B, V31, P389, DOI 10.1016/S1357-2725(98)00116-2; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; Sullivan R, 2000, CELL CALCIUM, V28, P33, DOI 10.1054/ceca.2000.0127; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Wasser M, 2000, NAT CELL BIOL, V2, P268, DOI 10.1038/35010535; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; White P, 2000, AM J PHYSIOL-RENAL, V278, pF886, DOI 10.1152/ajprenal.2000.278.6.F886; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; Yeoh S, 2002, J MOL BIOL, V315, P911, DOI 10.1006/jmbi.2001.5280	50	125	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14394	14400		10.1074/jbc.M206393200	http://dx.doi.org/10.1074/jbc.M206393200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566455	hybrid			2022-12-27	WOS:000182405000105
J	Zhang, J; Liu, Z; Masumiya, H; Wang, RW; Jiang, DW; Li, F; Wagenknecht, T; Chen, SRW				Zhang, J; Liu, Z; Masumiya, H; Wang, RW; Jiang, DW; Li, F; Wagenknecht, T; Chen, SRW			Three-dimensional localization of divergent region 3 of the ryanodine receptor to the clamp-shaped structures adjacent to the FKBP binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNELS; SKELETAL-MUSCLE; CRYOELECTRON MICROSCOPY; FK506-BINDING PROTEIN; RECONSTRUCTION; IDENTIFICATION; INACTIVATION; RESOLUTION; ISOFORMS; RIBOSOME	Of the three divergent regions of ryanodine receptors (RyRs), divergent region 3 (DR3) is the best studied and is believed to be involved in excitation-contraction coupling as well as in channel regulation by Ca2+ and Mg2+. To gain insight into the structural basis of DR3 function, we have determined the location of DR3 in the three-dimensional structure of RyR2. We inserted green fluorescent protein (GFP) into the middle of the DR3 region after Thr-1874 in the sequence. HEK293 cells expressing this GFP-RyR2 fusion protein, RyR2(T1874-GFP), were readily detected by their green fluorescence, indicating proper folding of the inserted GFP. RyR2(T1874-GFP) was further characterized functionally by assays of Ca2+ release and [H-3]ryanodine binding. These analyses revealed that RyR2(T1874-GFP) functions as a caffeine- and ryanodine-sensitive Ca2+ release channel and displays Ca2+ dependence and [H-3]ryanodine binding properties similar to those of the wild type RyR2. RyR2T1874-GFP was purified from cell lysates in a single step by affinity chromatography using GST-FKBP12.6 as the affinity ligand. The three-dimensional structure of the purified RYR2(T1874-GFP) was then reconstructed using cryoelectron microscopy and single particle image analysis. Comparison of the three-dimensional reconstructions of wild type RyR2 and RyR2T(1874-GFP) revealed the location of the inserted GFP, and hence the DR3 region, in one of the characteristic domains of RyR, domain 9, in the clamp-shaped structure adjacent to the FKBP12 and FKBP12.6 binding sites. COOH-terminal truncation analysis demonstrated that a region between 1815 and 1855 near DR3 is essential for GST-FKBP12.6 binding. These results provide a structural basis for the role of the DR3 region in excitation-contraction coupling and in channel regulation.	Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	University of Calgary; University of Calgary; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Chen, SRW (corresponding author), Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada.	swchen@ucalgary.ca		Liu, Zheng/0000-0001-6952-3406	NIAMS NIH HHS [AR40615] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bhat MB, 1997, BIOPHYS J, V73, P1320, DOI 10.1016/S0006-3495(97)78165-7; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Doi Nobuhide, 2002, Methods Mol Biol, V183, P49; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Frank J., 1996, 3 DIMENSIONAL ELECT, P54; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Hayek SM, 2000, BIOCHEM J, V351, P57, DOI 10.1042/0264-6021:3510057; Hayek SM, 1999, FEBS LETT, V461, P157, DOI 10.1016/S0014-5793(99)01464-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; Lamb GD, 2002, FRONT BIOSCI-LANDMRK, V7, pD834, DOI 10.2741/lamb; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Liu Z, 2002, J BIOL CHEM, V277, P46712, DOI 10.1074/jbc.M208124200; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Lohn M, 2001, CIRC RES, V89, P1051, DOI 10.1161/hh2301.100250; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sambrook J, 1989, J SAMBROOK MOL CLONI; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; Serysheva II, 2002, P NATL ACAD SCI USA, V99, P10370, DOI 10.1073/pnas.162363499; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wagenknecht T, 2002, FRONT BIOSCI, V7, pD1464, DOI 10.2741/wagen; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Yang DM, 2001, J BIOL CHEM, V276, P40210, DOI 10.1074/jbc.M106944200; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	54	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14211	14218		10.1074/jbc.M213164200	http://dx.doi.org/10.1074/jbc.M213164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576471	hybrid			2022-12-27	WOS:000182405000083
J	Martin, NI; Hu, HJ; Moake, MM; Churey, JJ; Whittal, R; Worobo, RW; Vederas, JC				Martin, NI; Hu, HJ; Moake, MM; Churey, JJ; Whittal, R; Worobo, RW; Vederas, JC			Isolation, structural characterization, and properties of mattacin (Polymyxin M), a cyclic peptide antibiotic produced by Paenibacillus kobensis M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; LISTERIA-MONOCYTOGENES; H-1-NMR ANALYSIS; BIOSYNTHESIS; IDENTIFICATION; PROTEIN; CLONING; GENES; LANTIBIOTICS; CONFORMATION	antibiotic produced by Paenibacillus kobensis M. The producing strain was isolated from a soil/manure sample and identified using 16 S rRNA sequence homology along with chemical and morphological characterization. An efficient production and isolation procedure was developed to afford pure mattacin. Structure elucidation using a combination of chemical degradation, multidimensional NMR studies (COSY, HMBC, HMQC, ROESY), and mass spectrometric (MALDI MS/MS) analyses showed that mattacin is identical to polymyxin M, an uncommon antibiotic reported previously in certain Bacillus species by Russian investigators. Mattacin (polymyxin M) is cyclic and possesses an amide linkage between the C-terminal threonine and the side chain amino group of the diaminobutyric acid residue at position 4. It contains an (S)-6-methyloctanoic acid moiety attached as an amide at the N-terminal amino group, one D-leucine, Six L-alpha,gamma-diaminobutyric acid, and three L-threonine residues. Transfer NOE experiments on the conformational preferences of mattacin when bound to lipid A and microcalorimetry studies on binding to lipopolysaccharide showed that its behavior was very similar to that observed in previous studies of polymyxin B (a commercial antibiotic), suggesting an identical mechanism of action. It was capable of inhibiting the growth of a wide variety of Gram-positive and Gram-negative bacteria, including several human and plant pathogens with activity comparable with purified polymyxin B. The biosynthesis of mattacin was also examined briefly using transpositional mutagenesis by which 10 production mutants were obtained, revealing a set of genes involved in production.	Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Cornell Univ, New York State Agr Expt Stn, Dept Food Sci & Technol, Geneva, NY 14456 USA	University of Alberta; Cornell University	Vederas, JC (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.	john.vederas@ualberta.ca	Worobo, Randy/D-8779-2014	Worobo, Randy/0000-0002-5211-3125; Vederas, John/0000-0002-2996-0326; Whittal, Randy/0000-0003-1174-8172				AHN C, 1990, J APPL BACTERIOL, V69, P302, DOI 10.1111/j.1365-2672.1990.tb01520.x; AINSWORTH GC, 1947, NATURE, V160, P263, DOI 10.1038/160263a0; Baldwin MA, 2001, ANAL CHEM, V73, P1707, DOI 10.1021/ac0011080; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CAMILLI A, 1990, J BACTERIOL, V172, P3738, DOI 10.1128/jb.172.7.3738-3744.1990; CHEN CL, 1995, MOL GEN GENET, V248, P121, DOI 10.1007/BF02190792; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; Doekel S, 2001, METAB ENG, V3, P64, DOI 10.1006/mben.2000.0170; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Du LC, 1999, CHEM BIOL, V6, P507, DOI 10.1016/S1074-5521(99)80083-0; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; Garneau S, 2002, BIOCHIMIE, V84, P577, DOI 10.1016/S0300-9084(02)01414-1; GRONENBORN AM, 1982, J MOL BIOL, V157, P155, DOI 10.1016/0022-2836(82)90518-6; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLAENHAMMER TR, 1988, BIOCHIMIE, V70, P337, DOI 10.1016/0300-9084(88)90206-4; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KLEINKAUF H, 1988, CRIT REV BIOTECHNOL, V8, P1, DOI 10.3109/07388558809150536; Koch PJ, 1999, J COLLOID INTERF SCI, V213, P557, DOI 10.1006/jcis.1999.6137; KOMURA S, 1985, J BIOCHEM-TOKYO, V97, P1409, DOI 10.1093/oxfordjournals.jbchem.a135195; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; OKHANOV VV, 1991, BIOORG KHIM+, V17, P1689; OKHANOV VV, 1987, ANTIBIOT MED BIOTEK, V32, P738; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Reva ON, 2001, INT J SYST EVOL MICR, V51, P1361, DOI 10.1099/00207713-51-4-1361; RIETSCHEL ET, 1990, INT CONGR SER, V923, P15; Riley MA, 2002, ANNU REV MICROBIOL, V56, P117, DOI 10.1146/annurev.micro.56.012302.161024; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shida O, 1997, INT J SYST BACTERIOL, V47, P289, DOI 10.1099/00207713-47-2-289; SILAEV AB, 1975, ZH OBSHCH KHIM+, V45, P2331; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; TAGG JR, 1976, BACTERIOL REV, V40, P722, DOI 10.1128/MMBR.40.3.722-756.1976; TRAKHANOVA MN, 1989, ANTIBIOT KHIMIOTERAP, V34, P20; Tsubery H, 2000, J MED CHEM, V43, P3085, DOI 10.1021/jm0000057; Tsuge K, 2001, J BACTERIOL, V183, P6265, DOI 10.1128/JB.183.21.6265-6273.2001; Twomey D, 2002, ANTON LEEUW INT J G, V82, P165, DOI 10.1023/A:1020660321724; van Belkum MJ, 2000, NAT PROD REP, V17, P323, DOI 10.1039/a801347k; vanBelkum MJ, 1997, MOL MICROBIOL, V23, P1293, DOI 10.1046/j.1365-2958.1997.3111677.x; Wang YJ, 1999, BIOCHEMISTRY-US, V38, P15438, DOI 10.1021/bi991351x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zheng GL, 1999, J BACTERIOL, V181, P7346, DOI 10.1128/JB.181.23.7346-7355.1999	45	83	95	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13124	13132		10.1074/jbc.M212364200	http://dx.doi.org/10.1074/jbc.M212364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569104	hybrid			2022-12-27	WOS:000182189500069
J	Munoz-Pinedo, C; Ruiz-Ruiz, C; de Almodovar, CR; Palacios, C; Lopez-Rivas, A				Munoz-Pinedo, C; Ruiz-Ruiz, C; de Almodovar, CR; Palacios, C; Lopez-Rivas, A			Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRAIL-INDUCED APOPTOSIS; NECROSIS-FACTOR; CASPASE-8 ACTIVATION; MOLECULAR-CLONING; SURFACE ANTIGEN; C-FLIP; CD95; FAS; LIGAND	Tumors display a high rate of glucose uptake and glycolysis. We investigated how inhibition of glucose metabolism could affect death receptor-mediated apoptosis in human tumor cells of diverse origin. We show that both substitution of glucose for pyruvate and treatment with 2-deoxyglucose enhanced apoptosis induced by tumor necrosis factor (TNF)-alpha, CD95 agonistic antibody, and TNF-related apoptosis-inducing ligand (TRAIL). Inhibition of glucose metabolism enhanced killing of myeloid leukemia U937, cervical carcinoma HeLa, and breast carcinoma MCF-7 cells upon death receptor ligation. Caspase activation, mitochondrial depolarization, and cytochrome c release were increased under these conditions. Glucose deprivation-mediated sensitization to apoptosis was prevented in MCF-7 cells overexpressing BCL-2. Interestingly, the human B-lymphoblastoid cell line SKW6.4, a prototype for mitochondria-independent death receptor-induced apoptosis, was also sensitized to anti-CD95 and TRAIL-induced apoptosis under glucose-free conditions. Changes in c-FLIPL and cFLIPs levels were observed in some but not all the cell lines studied following glucose deprivation. Glucose deprivation enhanced death receptor-triggered formation of death-inducing signaling complex and early processing of procaspase-8. Altogether, these results suggest that the glycolytic pathway may be an important target for therapeutic intervention to sensitize tumor cells to selectively toxic soluble death ligands or death ligand-expressing cells of the immune system by facilitating the activation of initiator caspase-8.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.	alrivas@ipb.csic.es	Ruiz-Ruiz, Carmen/I-8792-2017; Palacios, Carmen/G-7422-2015; Munoz-Pinedo, Cristina/B-6118-2008; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Palacios, Carmen/0000-0002-1267-2619; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Ruiz de Almodovar, Carmen/0000-0001-5975-7815; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Berridge MV, 1996, J IMMUNOL, V156, P4092; Binder C, 1997, EXP CELL RES, V236, P223, DOI 10.1006/excr.1997.3718; BRAHMA CA, 1998, MOL CELL BIOL, V18, P6353; Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Dirks W, 1997, BRIT J HAEMATOL, V96, P584, DOI 10.1046/j.1365-2141.1997.d01-2048.x; Eguchi Y, 1997, CANCER RES, V57, P1835; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fulda S, 2000, CANCER RES, V60, P3947; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; HALICKA HD, 1995, CANCER RES, V55, P444; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; Ko YG, 1999, J IMMUNOL, V162, P7217; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Latta M, 2000, J EXP MED, V191, P1975, DOI 10.1084/jem.191.11.1975; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Linsinger G, 1999, MOL CELL BIOL, V19, P3299; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mohanti BK, 1996, INT J RADIAT ONCOL, V35, P103, DOI 10.1016/S0360-3016(96)85017-6; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; Obrador E., 2001, Current Pharmaceutical Biotechnology, V2, P119; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RACKER E, 1972, AM SCI, V60, P56; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THAKKAR NS, 1993, CANCER RES, V53, P2057; THAMS P, 1988, BIOCHEM J, V253, P229, DOI 10.1042/bj2530229; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLLAND S, 1992, INT J CANCER, V52, P384, DOI 10.1002/ijc.2910520310; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x	70	86	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12759	12768		10.1074/jbc.M212392200	http://dx.doi.org/10.1074/jbc.M212392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556444	hybrid			2022-12-27	WOS:000182189500024
J	Worthylake, RA; Burridge, K				Worthylake, RA; Burridge, K			RhoA and ROCK promote migration by limiting membrane protrusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; TRANSENDOTHELIAL MIGRATION; TYROSINE PHOSPHORYLATION; ACTIN CYTOSKELETON; INTEGRIN LFA-1; FAMILY GTPASES; SMOOTH-MUSCLE; ALPHA-ACTININ; MYOSIN-II; KINASE	Previously, we and others have shown that RhoA and ROCK signaling are required for negatively regulating integrin-mediated adhesion and for tail retraction of migrating leukocytes. This study continues our investigation into the molecular mechanisms underlying RhoA/ROCK-regulated integrin adhesion. We show that inhibition of ROCK up-regulates integrin-mediated adhesion, which is accompanied by both increased phosphotyrosine signaling through Pyk-2 and paxillin and inappropriate membrane protrusions. We provide evidence that inhibition of ROCK induces integrin adhesion by promoting remodeling of the actin cytoskeleton. Furthermore, we find that ROCK regulates membrane activity through a pathway involving cofilin. Inhibition of RhoA signaling allows the formation of multiple competing lamellipodia that disrupt productive migration of monocytes. Together, our results show that RhoA/ROCK signaling promotes migration by restricting integrin activity and membrane protrusions to the leading edge.	Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Worthylake, RA (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.				NIDCR NIH HHS [DE13079] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Allen WE, 1997, J CELL SCI, V110, P707; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brown EJ, 1997, TRENDS CELL BIOL, V7, P289, DOI 10.1016/S0962-8924(97)01076-3; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Dharmawardhane S, 1997, Curr Opin Hematol, V4, P12; Dunty JM, 2002, J BIOL CHEM, V277, P45644, DOI 10.1074/jbc.M201779200; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Eddy RJ, 2000, J CELL SCI, V113, P1287; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Johnson-Leger C, 2000, J CELL SCI, V113, P921; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Liu L, 2002, J IMMUNOL, V169, P2330, DOI 10.4049/jimmunol.169.5.2330; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Palecek SP, 1998, J CELL SCI, V111, P929; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rodriguez-Fernandez JL, 2001, J BIOL CHEM, V276, P40518, DOI 10.1074/jbc.M102896200; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; VAN AL, 1997, GENE DEV, V11, P2295; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; Watson JM, 2001, J BIOL CHEM, V276, P3536, DOI 10.1074/jbc.M006916200; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	57	234	250	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13578	13584		10.1074/jbc.M211584200	http://dx.doi.org/10.1074/jbc.M211584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574166	Green Published, hybrid			2022-12-27	WOS:000182189500123
J	Dai, CS; Yang, JW; Liu, YH				Dai, CS; Yang, JW; Liu, YH			Transforming growth factor-beta 1 potentiates renal tubular epithelial cell death by a mechanism independent of smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; ANGIOTENSIN-II; MYOFIBROBLAST TRANSITION; INTERSTITIAL FIBROSIS; URETERAL OBSTRUCTION; MAP KINASES; APOPTOSIS; GENE; EXPRESSION	Tubular atrophy resulting from epithelial cell loss is one of the characteristic features in the development of chronic renal interstitial fibrosis. Although the trigger(s) and mechanism for tubular cell loss remain undefined, the hyperactive transforming growth factor (TGF)-beta1 signaling has long been suspected to play an active role. Here we demonstrate that although TGF-beta1 did not induce cell death per se, it dramatically potentiated renal tubular cell apoptosis initiated by other death cues in vitro. Pre-incubation of human kidney epithelial cells (HKC) with TGF-beta1 markedly promoted staurosporine-induced cell death in a time- and dose-dependent manner. TGF-beta1 dramatically accelerated the cleavage and activation of pro-caspase-9, but not pro-caspase-8, in HKC cells. This event was followed by an accelerated activation of pro-caspase-3. To elucidate the mechanism underlying TGF-beta1 promotion of tubular cell death, we investigated the signaling pathways activated by TGF-beta1. Both Smad-2 and p38 mitogen-activated protein (MAP) kinase were rapidly activated by TGF-beta1, as demonstrated by the early induction of phosphorylated Smad-2 and p38 MAP kinase, respectively. We found that overexpression of inhibitory Smad-7 completely abolished Smad-2 phosphorylation and activation induced by TGF-beta1 but did not inhibit TGF-beta1-induced apoptosis. However, suppression of p38 MAP kinase with chemical inhibitor SC68376 not only abolished p38 MAP kinase phosphorylation but also obliterated apoptosis induced by TGF-beta1. These results suggest that hyperactive TGF-beta1 signaling potentiates renal tubular epithelial cell apoptosis by a Smad-independent, p38 MAP kinase-dependent mechanism.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, YH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, S-405 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	liuy@msx.upmc.edu		Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002611, R01DK061408, R01DK054922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-61408, DK-02611, DK-54922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Border WA, 1998, HYPERTENSION, V31, P181, DOI 10.1161/01.HYP.31.1.181; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chevalier RL, 1999, PEDIATR NEPHROL, V13, P612, DOI 10.1007/s004670050756; Chevalier RL, 2000, EXP NEPHROL, V8, P115; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Dai CS, 2002, J AM SOC NEPHROL, V13, P411, DOI 10.1681/ASN.V132411; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; Horster MF, 1999, PHYSIOL REV, V79, P1157, DOI 10.1152/physrev.1999.79.4.1157; Isaka Y, 2000, KIDNEY INT, V58, P1885, DOI 10.1046/j.1523-1755.2000.00360.x; Isaka Y, 1999, KIDNEY INT, V55, P465, DOI 10.1046/j.1523-1755.1999.00275.x; Jones EA, 2000, UROLOGY, V56, P346, DOI 10.1016/S0090-4295(00)00608-7; Klahr S, 2000, KIDNEY INT, V57, pS7, DOI 10.1046/j.1523-1755.2000.07509.x; Klahr S, 2002, AM J PHYSIOL-RENAL, V283, pF861, DOI 10.1152/ajprenal.00362.2001; Kopp JB, 1996, LAB INVEST, V74, P991; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; Liu YH, 1999, AM J PHYSIOL-RENAL, V277, pF624, DOI 10.1152/ajprenal.1999.277.4.F624; Liu YH, 1998, BIOCHEM BIOPH RES CO, V246, P821, DOI 10.1006/bbrc.1998.8676; Lorz C, 2000, J AM SOC NEPHROL, V11, P1266, DOI 10.1681/ASN.V1171266; Malik RK, 2001, AM J PHYSIOL-RENAL, V281, pF56, DOI 10.1152/ajprenal.2001.281.1.F56; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyajima A, 2000, KIDNEY INT, V58, P2301, DOI 10.1046/j.1523-1755.2000.00414.x; Mozes MM, 1999, J AM SOC NEPHROL, V10, P271; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ortiz A, 1999, NEPHROL DIAL TRANSPL, V14, P1831, DOI 10.1093/ndt/14.8.1831; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Patel P, 2000, J INVEST MED, V48, P403; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schlapbach R, 2000, EUR J IMMUNOL, V30, P3680, DOI 10.1002/1521-4141(200012)30:12<3680::AID-IMMU3680>3.0.CO;2-L; Schramek H, 2002, NEWS PHYSIOL SCI, V17, P62, DOI 10.1152/nips.01365.2001; Stahl PJ, 2001, AM J PATHOL, V159, P1187, DOI 10.1016/S0002-9440(10)62503-5; Sutaria PM, 1998, LIFE SCI, V62, P1965, DOI 10.1016/S0024-3205(98)00166-0; Wolf G, 1999, J MOL MED-JMM, V77, P556, DOI 10.1007/s001099900028; Yang J, 2001, GENE THER, V8, P1470, DOI 10.1038/sj.gt.3301545; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang G, 2001, EXP NEPHROL, V9, P71; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	58	125	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12537	12545		10.1074/jbc.M300777200	http://dx.doi.org/10.1074/jbc.M300777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560323	hybrid			2022-12-27	WOS:000182015700106
J	Hasegawa, Y; Erickson, JR; Goddard, GJ; Yu, SX; Liu, SY; Cheng, KW; Eder, A; Bandoh, K; Aoki, J; Jarosz, R; Schrier, AD; Lynch, KR; Mills, GB; Fang, XJ				Hasegawa, Y; Erickson, JR; Goddard, GJ; Yu, SX; Liu, SY; Cheng, KW; Eder, A; Bandoh, K; Aoki, J; Jarosz, R; Schrier, AD; Lynch, KR; Mills, GB; Fang, XJ			Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA(3) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; PLATELET-AGGREGATION; CELLULAR-RESPONSES; ACTIVATING-FACTOR; PHOSPHORIC-ACIDS; LIPID MEDIATOR; EDG FAMILY; PATHWAY	Lysophosphatidic acid (LPA) is a bioactive lysophospholipid mediator that acts through G protein-coupled receptors. Most cell lines in culture express one or more LPA receptors, making it difficult to assign a response to specific LPA receptors. Dissection of the signaling properties of LPA has been hampered by lack of LPA receptor subtype-specific agonists and antagonists. The present study characterizes an ester-linked thiophosphate derivative (1-oleoyl-2-O-methyl-rac-glycerophosphothionate, OMPT) of LPA. OMPT is a functional LPA analogue with potent mitogenic activity in fibroblasts. In contrast to LPA, OMPT does not couple to the pheromone response through the LPA(1) receptor in yeast cells. OMPT induces intracellular calcium increases efficiently in LPA(3) receptor-expressing Sf9 cells but poorly in LPA(2) receptor-expressing cells. Guanosine 5'-O-(3-[S-35]thio)triphosphate binding assays in mammalian cells showed that LPA exhibits agonistic activity on all three LPA receptor subtypes, whereas OMPT has a potent agonistic effect only on the LPA(3) receptor. In transiently transfected HEK293 cells, OMPT stimulates mitogen-activated protein kinases through the LPA(3) but not the LPA(1) or LPA(2) receptors. Furthermore, OMPT-induced intracellular calcium mobilization in mammalian cells is efficiently inhibited by the LPA(1)/LPA(3) receptor-selective antagonist VPC12249. These results establish that OMPT is an LPA(3)-selective agonist. OMPT binding to the LPA(3) receptor in mammalian cells is sufficient to elicit multiple responses, including activation of G proteins, calcium mobilization, and activation of mitogen-activated protein kinases. Thus OMPT offers a powerful probe for the dissection of LPA signaling events in complex mammalian systems.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; LXR Biotechnol, Richmond, CA 94804 USA; Univ Tokyo, Tokyo 1130033, Japan; Univ Virginia, Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Texas System; UTMD Anderson Cancer Center; University of Tokyo; University of Virginia	Fang, XJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 1515 Holcombe Blvd,Box 317, Houston, TX 77030 USA.			Aoki, Junken/0000-0001-9435-1896	NATIONAL CANCER INSTITUTE [R01CA088994, P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA88994, CA64602] Funding Source: Medline; NIGMS NIH HHS [GM052722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Aoki J, 2000, ANN NY ACAD SCI, V905, P263; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Erickson JR, 2000, ANN NY ACAD SCI, V905, P279; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GERRARD JM, 1979, AM J PATHOL, V96, P423; Gibbs TC, 2000, ANN NY ACAD SCI, V905, P290; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; GOETZL EJ, 2000, ANN NY ACAD SCI, V905, P11; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; Hopper DW, 1999, J MED CHEM, V42, P963, DOI 10.1021/jm970809v; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Imai A, 2000, J CLIN ENDOCR METAB, V85, P3370, DOI 10.1210/jc.85.9.3370; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Liliom K, 1996, MOL PHARMACOL, V50, P616; Lynch KR, 1997, MOL PHARMACOL, V52, P75, DOI 10.1124/mol.52.1.75; McAllister G, 2000, MOL PHARMACOL, V58, P407, DOI 10.1124/mol.58.2.407; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Mukai M, 2000, FEBS LETT, V484, P69, DOI 10.1016/S0014-5793(00)02129-3; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; Olson KA, 2002, INT J CANCER, V98, P923, DOI 10.1002/ijc.10282; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Scalia R, 2000, J LEUKOCYTE BIOL, V67, P26, DOI 10.1002/jlb.67.1.26; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Toews ML, 1997, J APPL PHYSIOL, V83, P1216, DOI 10.1152/jappl.1997.83.4.1216; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Xu J, 2000, J BIOL CHEM, V275, P27520; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223	53	101	108	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11962	11969		10.1074/jbc.M209168200	http://dx.doi.org/10.1074/jbc.M209168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12554733	hybrid			2022-12-27	WOS:000182015700033
J	Stahelin, RV; Rafter, JD; Das, S; Cho, W				Stahelin, RV; Rafter, JD; Das, S; Cho, W			The molecular basis of differential subcellular localization of C2 domains of protein kinase C-alpha and group IVa cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; MEMBRANE-BINDING RESIDUES; SURFACE-PLASMON RESONANCE; CRYSTAL-STRUCTURE; LIVING CELLS; C-2 DOMAINS; CALCIUM; TRANSLOCATION; ACTIVATION; ROLES	The C2 domain is a Ca2+-dependent membrane-targeting module found in many cellular proteins involved in signal transduction or membrane trafficking. C2 domains are unique among membrane targeting domains in that they show a wide range of lipid selectivity for the major components of cell membranes, including phosphatidylserine and phosphatidyleholine. To understand how C2 domains show diverse lipid selectivity and how this functional diversity affects their subcellular targeting behaviors, we measured the binding of the C2 domains of group IVa cytosolic phospholipase A(2) (cPLA(2)) and protein kinase C-alpha (PKC-alpha) to vesicles that model cell membranes they are targeted to, and we monitored their subcellular targeting in living cells. The surface plasmon resonance analysis indicates that the PKC-alpha C2 domain strongly prefers the cytoplasmic plasma membrane mimic to the nuclear membrane mimic due to high phosphatidylserine content in the former and that Asn(189) plays a key role in this specificity. In contrast, the cPLA(2) C2 domain has specificity for the nuclear membrane mimic over the cytoplasmic plasma membrane mimic due to high phosphatidylcholine content in the former and aromatic and hydrophobic residues in the calcium binding loops of the cPLA(2) C2 domain are important for its lipid specificity. The subcellular localization of enhanced green fluorescent protein-tagged C2 domains and mutants transfected into HEK293 cells showed that the subcellular localization of the C2 domains is consistent with their lipid specificity and could be tailored by altering their in vitro lipid specificity. The relative cell membrane translocation rate of selected C2 domains was also consistent with their relative affinity for model membranes. Together, these results suggest that biophysical principles that govern the in vitro membrane binding of C2 domains can account for most of their subcellular targeting properties.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.		Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987, GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Conesa-Zamora P, 2001, BIOCHEMISTRY-US, V40, P13898, DOI 10.1021/bi011303o; Corbalan-Garcia S, 1999, BIOCHEM J, V337, P513, DOI 10.1042/0264-6021:3370513; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Gerber SH, 2001, J BIOL CHEM, V276, P32288, DOI 10.1074/jbc.C100108200; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Haugland R., 1996, HDB FLUORESCENT PROB; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; KATES M, 1986, TECHNIQUES LIPIDOLOG, P113; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; MCMURRAY, 1973, FORM FUNCTION PHOSPH, P205; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Mochly-Rosen D, 1998, FASEB J, V12, P35; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Williams SD, 2000, J LIPID RES, V41, P1585; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	55	111	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12452	12460		10.1074/jbc.M212864200	http://dx.doi.org/10.1074/jbc.M212864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531893	hybrid			2022-12-27	WOS:000182015700095
J	Virolle, T; Krones-Herzig, A; Baron, V; De Gregorio, G; Adamson, ED; Mercola, D				Virolle, T; Krones-Herzig, A; Baron, V; De Gregorio, G; Adamson, ED; Mercola, D			Egr1 promotes growth and survival of prostate cancer cells - Identification of novel Egr1 target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; IN-VIVO; INCREASED EXPRESSION; PROTEIN INHIBITOR; CARCINOMA-CELLS; UP-REGULATION; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNALING PATHWAY; ACTIVATED STAT1	In the majority of aggressive tumorigenic prostate cancer cells, the transcription factor Egr1 is overexpressed. We provide new insights of Egr1 involvement in proliferation and survival of TRAMP C2 prostate cancer cells by the identification of several new target genes controlling growth, cell cycle progression, and apoptosis such as cyclin D2, P19ink4d, and Fas. Egr1 regulation of these genes, identified by Affymetrix microarray, was confirmed by real-time PCR, immunoblot, and chromatin immunoprecipitation assays. Furthermore we also showed that Egr1 is responsible for cyclin D2 overexpression in tumorigenic DU145 human prostate cells. The regulation of these genes by Egr1 was demonstrated using Egr1 antisense oligonucleotides that further implicated Egr1 in resistance to apoptotic signals. One mechanism was illustrated by the ability of Egr1 to inhibit CD95 (Fas/Apo) expression, leading to insensitivity to FasL. The results provide a mechanistic basis for the oncogenic role of Egr1 in TRAMP C2 prostate cancer cells.	La Jolla Canc Res Fdn, Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Neuromed, Ist Ricovero & Cura Carattere Sci, I-86077 Pozzilli, Italy	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; IRCCS Neuromed	Virolle, T (corresponding author), Fac Med Nice, INSERM, Biol & Physiopathol Peau, F-06107 Av Valombrose, France.	virolle@unice.fr; eadamson@burnham.org	calogero, antonella/U-5418-2019; Virolle, Thierry/E-5838-2016; mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NATIONAL CANCER INSTITUTE [R01CA067888, R01CA084107, U01CA084998, R01CA076173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76173, CA84107, CA 84998, CA 67888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Bartkova J, 2000, ONCOGENE, V19, P4146, DOI 10.1038/sj.onc.1203769; Bowen C, 1999, CELL DEATH DIFFER, V6, P394, DOI 10.1038/sj.cdd.4400502; Calogero A, 2001, CLIN CANCER RES, V7, P2788; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; Chatterjee D, 2001, CANCER RES, V61, P7148; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Chin MT, 1999, J MOL CELL CARDIOL, V31, P2199, DOI 10.1006/jmcc.1999.1054; Costa-Pereira AP, 1999, BRIT J CANCER, V80, P371, DOI 10.1038/sj.bjc.6690365; de Belle I, 2000, BIOTECHNIQUES, V29, P162; de la Taille A, 1999, PROSTATE, V40, P89, DOI 10.1002/(SICI)1097-0045(19990701)40:2<89::AID-PROS4>3.0.CO;2-E; Dinkel A, 1997, J IMMUNOL, V159, P2678; Drivdahl RH, 2001, ENDOCRINOLOGY, V142, P1990, DOI 10.1210/en.142.5.1990; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; Eid MA, 1998, CANCER RES, V58, P2461; Fahmy RG, 2002, J CELL BIOCHEM, V84, P575, DOI 10.1002/jcb.10057.abs; Foster BA, 1997, CANCER RES, V57, P3325; Frugis G, 1999, PLANT MOL BIOL, V40, P397, DOI 10.1023/A:1006215231492; Glynne R, 2000, IMMUNOL REV, V176, P216; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Guthridge MA, 1996, ONCOGENE, V12, P1267; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Howell SB, 2000, MOL UROL, V4, P225; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Lamharzi N, 1998, REGUL PEPTIDES, V77, P185, DOI 10.1016/S0167-0115(98)00119-0; Landesberg LJ, 2001, AM J PHYSIOL-LUNG C, V281, pL1138, DOI 10.1152/ajplung.2001.281.5.L1138; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Liu YG, 2000, ONCOGENE, V19, P1579, DOI 10.1038/sj.onc.1203442; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Marcelli M, 1999, CANCER RES, V59, P382; Marcelli M, 2000, J UROLOGY, V164, P518, DOI 10.1016/S0022-5347(05)67416-2; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; NAGLE RB, 1992, J CELL BIOCHEM, P26; Nakamoto K, 2001, AM J PATHOL, V159, P1363, DOI 10.1016/S0002-9440(10)62523-0; Paggi MG, 2001, CANCER RES, V61, P4651; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Qian JQ, 2002, MODERN PATHOL, V15, P35, DOI 10.1038/modpathol.3880487; Scharnhorst V, 2000, ONCOGENE, V19, P791, DOI 10.1038/sj.onc.1203390; Scher HI, 2000, UROLOGY, V55, P323, DOI 10.1016/S0090-4295(99)00471-9; Schmidt BA, 2001, CANCER RES, V61, P4214; Schwarz DA, 1998, IMMUNITY, V9, P657, DOI 10.1016/S1074-7613(00)80663-9; Shainkin-Kestenbaum R, 1996, Biomed Pept Proteins Nucleic Acids, V2, P79; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; Speirs V, 1999, BRIT J CANCER, V81, P690, DOI 10.1038/sj.bjc.6690749; Stewart JE, 2001, CELL BIOL INT, V25, P607, DOI 10.1006/cbir.2000.0693; Stravodimos K, 2000, ANTICANCER RES, V20, P3823; SUGIMOTO K, 1994, J STEROID BIOCHEM, V51, P167, DOI 10.1016/0960-0760(94)90090-6; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Vallabhapurapu S, 2001, EUR J IMMUNOL, V31, P2612, DOI 10.1002/1521-4141(200109)31:9<2612::AID-IMMU2612>3.0.CO;2-C; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wikstrom P, 2001, MICROSC RES TECHNIQ, V52, P411, DOI 10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124	73	129	132	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11802	11810		10.1074/jbc.M210279200	http://dx.doi.org/10.1074/jbc.M210279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556466	hybrid			2022-12-27	WOS:000182015700012
J	Yang, RC; Yutzy, WH; Viscidi, RP; Roden, RBS				Yang, RC; Yutzy, WH; Viscidi, RP; Roden, RBS			Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR CAPSID PROTEIN; VIRUS-LIKE PARTICLES; COMMON NEUTRALIZATION EPITOPE; BOVINE PAPILLOMAVIRUS; VIRAL TRANSPORT; CELL-SURFACE; L1; TYPE-16; POLYMERIZATION; IDENTIFICATION	Viruses that replicate in the nucleus, including the primary causative agent of cervical cancer, human papillomavirus type 16 (HPV16), must first cross the cytoplasm. We compared the uptake of HPV16 virus-like particles (VLPs) either with or without the minor capsid protein L2. Whereas VLPs containing only the major capsid protein L1 were diffusely distributed within the cytoplasm even 6 h post-infection, VLPs comprising both L1 and L2 exhibited a radial distribution in the cytoplasm and accumulated in the perinuclear region of BPHE-1 cells within 2 h. L2 of HPV16 or bovine papillomavirus was shown to bind to a 43-kDa cellular protein that was subsequently identified as beta-actin by matrix-assisted laser desorption ionization time-of-flight analysis. A conserved domain comprising residues 25-45 of HPV16 L2 was sufficient for interaction with beta-actin. HPV16 L2 residues 25-45 fused to green fluorescent protein, but not green fluorescent protein alone, colocalized with actin and caused cell retraction and disruption of the microfilament network. Finally, wild-type L2, but not L2 with residues 25-45 deleted, facilitated HPV16 pseudovirion infection. Thus, binding of beta-actin by L2 residues 25-45 facilitates transport of HPV16 across the cytoplasm during infection, and blockade of this novel interaction may be useful for prophylaxis.	Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Roden, RBS (corresponding author), Johns Hopkins Sch Med, Dept Pathol, Ross 512B,720 Rutland Ave, Baltimore, MD 21205 USA.	roden@jhmi.edu		Viscidi, Raphael/0000-0002-7906-8002	NATIONAL CANCER INSTITUTE [R01CA083706] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI048203] Funding Source: NIH RePORTER; NCI NIH HHS [CA83706] Funding Source: Medline; NCRR NIH HHS [1S10-RR14702] Funding Source: Medline; NIAID NIH HHS [AI48203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; CHARLTON CA, 1993, VIROLOGY, V197, P245, DOI 10.1006/viro.1993.1585; Christensen ND, 1996, VIROLOGY, V223, P174, DOI 10.1006/viro.1996.0466; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; Cudmore S, 1997, TRENDS MICROBIOL, V5, P142, DOI 10.1016/S0966-842X(97)01011-1; Da Silva DM, 2001, INT IMMUNOL, V13, P633, DOI 10.1093/intimm/13.5.633; DOORBAR J, 1987, J VIROL, V61, P2793, DOI 10.1128/JVI.61.9.2793-2799.1987; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Evander M, 1997, J VIROL, V71, P2449, DOI 10.1128/JVI.71.3.2449-2456.1997; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; HAGENSEE ME, 1994, J VIROL, V68, P4503, DOI 10.1128/JVI.68.7.4503-4505.1994; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; Kawana K, 1998, J VIROL, V72, P10298, DOI 10.1128/JVI.72.12.10298-10300.1998; Kawana K, 1999, J VIROL, V73, P6188, DOI 10.1128/JVI.73.7.6188-6190.1999; Kawana Y, 2001, J VIROL, V75, P2331, DOI 10.1128/JVI.75.5.2331-2336.2001; KIRNBAUER R, 1993, J VIROL, V67, P6929, DOI 10.1128/JVI.67.12.6929-6936.1993; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; Lanier LM, 1998, VIROLOGY, V243, P167, DOI 10.1006/viro.1998.9065; Liu WJ, 2001, VIROLOGY, V282, P237, DOI 10.1006/viro.2000.0728; Luby-Phelps K, 2000, INT REV CYTOL, V192, P189; Merle E, 1999, J CELL BIOCHEM, V74, P628, DOI 10.1002/(SICI)1097-4644(19990915)74:4<628::AID-JCB12>3.0.CO;2-I; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Moss B, 2001, NAT CELL BIOL, V3, pE245, DOI 10.1038/ncb1101-e245; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Ploubidou A, 2001, CURR OPIN CELL BIOL, V13, P97, DOI 10.1016/S0955-0674(00)00180-0; Ravkov EV, 1998, J VIROL, V72, P2865, DOI 10.1128/JVI.72.4.2865-2870.1998; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Roden RBS, 2000, VIROLOGY, V270, P254, DOI 10.1006/viro.2000.0272; RODEN RBS, 1994, J VIROL, V68, P7260, DOI 10.1128/JVI.68.11.7260-7266.1994; Roden RBS, 1997, J VIROL, V71, P6247, DOI 10.1128/JVI.71.8.6247-6252.1997; RODEN RBS, 1994, J VIROL, V68, P7570, DOI 10.1128/JVI.68.11.7570-7574.1994; Roden RBS, 2001, J VIROL, V75, P10493, DOI 10.1128/JVI.75.21.10493-10497.2001; Roden RBS, 1996, J VIROL, V70, P5875, DOI 10.1128/JVI.70.9.5875-5883.1996; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sodeik B, 2000, TRENDS MICROBIOL, V8, P465, DOI 10.1016/S0966-842X(00)01824-2; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Touze A, 1998, NUCLEIC ACIDS RES, V26, P1317, DOI 10.1093/nar/26.5.1317; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; Unckell F, 1997, J VIROL, V71, P2934, DOI 10.1128/JVI.71.4.2934-2939.1997; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; ZHANG YL, 1987, J VIROL, V61, P2924, DOI 10.1128/JVI.61.9.2924-2928.1987; ZHOU J, 1993, J GEN VIROL, V74, P763, DOI 10.1099/0022-1317-74-4-763; ZHOU J, 1995, VIROLOGY, V214, P167, DOI 10.1006/viro.1995.9943; ZHOU J, 1994, J VIROL, V68, P619, DOI 10.1128/JVI.68.2.619-625.1994; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	50	48	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12546	12553		10.1074/jbc.M208691200	http://dx.doi.org/10.1074/jbc.M208691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560332	hybrid			2022-12-27	WOS:000182015700107
J	Lopez-Camarillo, C; Luna-Arias, JP; Marchat, LA; Orozco, E				Lopez-Camarillo, C; Luna-Arias, JP; Marchat, LA; Orozco, E			EhPgp5 mRNA stability is a regulatory event in the Entamoeba histolytica multidrug resistance phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE-RICH SEQUENCE; 3' UNTRANSLATED REGION; P-GLYCOPROTEIN; TRANSCRIPTIONAL ANALYSIS; 3-UNTRANSLATED REGION; PROTEIN-SYNTHESIS; GENE; PROMOTER; BINDING; INHIBITION	The multidrug resistance (MDR) phenotype in Entamoeba histolytica is characterized by the overexpression of the EhPgp5 gene in trophozoites grown in high drug concentrations. Here we evaluated the role of EhPgp5 mRNA stability on MDR using actinomycin D. EhPgp5 mRNA from trophozoites growing without emetine had a half-life of 2.1 h, which augmented to 3.1 h in cells cultured with 90 mum and to 7.8 h with 225 mum emetine. Polyadenylation sites were detected at 118-, 156-, and 189-nucleotide (nt) positions of the EhPgp5 mRNA 3'-untranslated region. Interestingly, trophozoites grown with 225 pm emetine exhibited an extra polyadenylation site at 19 nt. The 3'-untranslated region sequence is AU-rich and has putative consensus sequences for RNA-binding proteins. We detected a RNA-protein complex in a region that contains a polypyrimidine tract (142-159 nt) and a cytoplasmic polyadenylation element (146-154 nt). A longer poly(A) tail in the EhPgp5 mRNA was seen in trophozoites grown with 225 mum emetine. Emetine stress may affect factors involved in mRNA turnover, including polyadenylation/deadenylation proteins, which could induce changes in the EhPgp5 mRNA half-life and poly(A) tail length. Novel evidence on mechanisms participating in E. histolytica MDR phenotype is provided.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Expt Pathol, Mexico City 07738, DF, Mexico; Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City 07738, DF, Mexico; Inst Politecn Nacl, Program Biomed Mol, Escuela Nacl Med & Homeopatia, Mexico City 07738, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico	Orozco, E (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Expt Pathol, Mexico City 07738, DF, Mexico.	esther@mail.cinvestav.mx	Luna-Arias, Juan Pedro/D-4395-2019; Lopez-Camarillo, Cesar/I-1946-2019; Marchat, Laurence A./S-8418-2018	Luna-Arias, Juan Pedro/0000-0002-3602-8000; Lopez-Camarillo, Cesar/0000-0002-9417-2609; Marchat, Laurence A./0000-0003-1615-8614				Belasco J. G., 1993, CONTROL MESSENGER RN, P475; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Delgadillo DM, 2002, MICROB DRUG RESIST, V8, P15, DOI 10.1089/10766290252913719; DESCOTEAUX S, 1992, MOL BIOCHEM PARASIT, V54, P201, DOI 10.1016/0166-6851(92)90112-W; DESCOTEAUX S, 1995, GENE, V164, P179, DOI 10.1016/0378-1119(95)00533-C; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; EDMAN U, 1987, P NATL ACAD SCI USA, V84, P3024, DOI 10.1073/pnas.84.9.3024; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENTNER N, 1973, J PROTOZOOL, V20, P160, DOI 10.1111/j.1550-7408.1973.tb06025.x; Gomez C, 1998, J BIOL CHEM, V273, P7277, DOI 10.1074/jbc.273.13.7277; Hake LE, 1998, MOL CELL BIOL, V18, P685, DOI 10.1128/MCB.18.2.685; Higgins C.F., 1993, CONTROL MESSENGER RN, P13; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LEE CH, 1995, CELL GROWTH DIFFER, V6, P347; Lee CH, 1998, J CELL PHYSIOL, V177, P1; Lee CH, 2001, MOL CELL BIOCHEM, V216, P103, DOI 10.1023/A:1011086716568; Lopez C, 1997, Arch Med Res, V28 Spec No, P66; Marchat LA, 2002, CELL MICROBIOL, V4, P725, DOI 10.1046/j.1462-5822.2002.00220.x; MCCLEAN S, 1993, EUR J CANCER, V29A, P2243, DOI 10.1016/0959-8049(93)90215-2; MULLER C, 1995, J CELL PHYSIOL, V163, P538, DOI 10.1002/jcp.1041630314; Orozco E, 2002, PARASITOL INT, V51, P353, DOI 10.1016/S1383-5769(02)00041-7; OROZCO E, 1985, MOL BIOCHEM PARASIT, V15, P49, DOI 10.1016/0166-6851(85)90028-3; OROZCO E, 1995, PARASITOL TODAY, V11, P473, DOI 10.1016/0169-4758(95)80067-0; Perez DG, 1998, J BIOL CHEM, V273, P7285, DOI 10.1074/jbc.273.13.7285; Prokipcak RD, 1999, BIOCHEM BIOPH RES CO, V261, P627, DOI 10.1006/bbrc.1999.1101; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SALLES FJ, 1995, PCR METH APPL, V4, P317; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; ULLMAN B, 1995, J BIOENERG BIOMEMBR, V27, P77, DOI 10.1007/BF02110334; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Zhang WD, 2000, J CELL PHYSIOL, V184, P17, DOI 10.1002/(SICI)1097-4652(200007)184:1<17::AID-JCP2>3.0.CO;2-U; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	49	34	35	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11273	11280		10.1074/jbc.M211757200	http://dx.doi.org/10.1074/jbc.M211757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12556531	hybrid			2022-12-27	WOS:000181855400054
J	Petrenko, O; Fingerle-Rowson, G; Peng, T; Mitchell, RA; Metz, CN				Petrenko, O; Fingerle-Rowson, G; Peng, T; Mitchell, RA; Metz, CN			Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; S-PHASE; RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL REPRESSION; TARGETED DISRUPTION; SELECTIVE INDUCTION; TUMOR SUPPRESSION; ONCOGENIC STRESS; MRE11 COMPLEX; MOUSE EMBRYOS	Macrophage migration inhibitory factor (MIF) has been shown to functionally inactivate the p53 tumor suppressor and to inhibit p53-responsive gene expression and apoptosis. To better understand the role of MIF in cell growth and tumor biology, we evaluated MIF-null embryonic fibroblasts with respect to their immortalization and transformation properties. Although minor deviations in the growth characteristics of MIF-/- fibroblasts were observed under normal culture conditions, MIF-deficient cells were growth-impaired following the introduction of immortalizing oncogenes. The growth retardation by the immortalized MIF-/- cultures correlated with their reduced susceptibility to Ras-mediated transformation. Our results identify E2F as part of the restraining mechanism that is activated in response to oncogenic signaling and show that the biological consequences of E2F induction in MIF-/- fibroblasts vary depending on the p53 status, inducing predominantly G(1) arrest or apoptosis in p53-positive cells. This E2F activity is independent of Rb binding, but contingent on binding DNA. Resistance to oncogenic transformation by MIF-/- cells could be overcome by concomitant interference with p53- and E2F-responsive transcriptional control. Our results demonstrate that MIF plays a role in an E2F/p53 pathway that operates downstream of Rb regulation and implicate MIF as a mediator of normal and malignant cell growth.	Picower Inst Med Res, Manhasset, NY 11030 USA	Northwell Health	Metz, CN (corresponding author), N Shore Long Isl Jewish Res Inst, 350 Community Dr, Manhasset, NY 11030 USA.			Christine, Metz/0000-0002-1013-1691				Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Bacher M, 1997, AM J PATHOL, V150, P235; Bazarov AV, 2001, CANCER RES, V61, P1178; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Huang YY, 1997, CANCER RES, V57, P3640; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Humbert PO, 2000, GENE DEV, V14, P690; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kobayashi S, 1999, MECH DEVELOP, V84, P153, DOI 10.1016/S0925-4773(99)00057-X; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin WC, 2001, GENE DEV, V15, P1833; MAESTRO R, 1995, BLOOD, V85, P3239, DOI 10.1182/blood.V85.11.3239.bloodjournal85113239; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Metz CN, 1997, ADV IMMUNOL, V66, P197, DOI 10.1016/S0065-2776(08)60598-2; METZ CN, 2000, CYTOKINE REFERENCE, V1, P703; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Suzuki H, 1996, IMMUNOL LETT, V51, P141, DOI 10.1016/0165-2478(96)02543-6; Suzuki T, 1999, BRAIN RES, V816, P457, DOI 10.1016/S0006-8993(98)01179-2; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	80	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11078	11085		10.1074/jbc.M211985200	http://dx.doi.org/10.1074/jbc.M211985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538581	hybrid			2022-12-27	WOS:000181855400029
J	Tran, NH; Frost, JA				Tran, NH; Frost, JA			Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-CASCADE ACTIVATION; B-RAF; PLASMA-MEMBRANE; PAK ACTIVATION; SERINE-338; ERK; PHOSPHATIDYLSERINE; PROTEINS; PATHWAYS; DOMAINS	Exposure of cells to mitogens or growth factors stimulates Raf-1 activity through a complex mechanism that involves binding to active Ras, phosphorylation on multiple residues, and protein-protein interactions. Recently it was shown that the amino terminus of Raf-1 contains an sutoregulatory domain that can inhibit its activity in Xenopus oocytes. In the present work we show that expression of the Raf-1 autoinhibitory domain blocks extracellular signal-regulated kinase 2 activation by the Raf-1 catalytic domain in mammalian cells. We also show that phosphorylation of Raf-1 on serine 338 by PAK1 and tyrosines 340 and 341 by Src relieves autoinhibition and that this occurs through a specific decrease in the binding of the Raf-1 regulatory domain to its catalytic domain. In addition, we demonstrate that phosphorylation of threonine 491 and serine 494, two phosphorylation sites in the catalytic domain that are required for Raf-1 activation, is unlikely to regulate autoinhibition. These results demonstrate that the autoinhibitory domain of Raf-1 is functional in mammalian cells and that its interaction with the Raf-1 catalytic domain is regulated by phosphorylation of serine 338 and tyrosines 340 and 341.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Frost, JA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.			Frost, Jeffrey/0000-0001-9722-1536				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	34	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11221	11226		10.1074/jbc.M210318200	http://dx.doi.org/10.1074/jbc.M210318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551923	hybrid			2022-12-27	WOS:000181855400048
J	Xu, HS; Zhao, HY; Tian, W; Yoshida, K; Roullet, JB; Cohen, DM				Xu, HS; Zhao, HY; Tian, W; Yoshida, K; Roullet, JB; Cohen, DM			Regulation of a transient receptor potential (TRP) channel by tyrosine phosphorylation - Src family kinase-dependent tyrosine phosphorylation of TRPV4 on Tyr-253 mediates its response to hypotonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASES TRANSCRIPTION; PROTEIN; ACTIVATION; EXPRESSION; SEQUENCE; SITES; CELLS; EGR-1	The recently identified transient receptor potential (TRP) channel family member, TRPV4 (formerly known as OTRPC4, VR-OAC, TRP12, and VRL-2) is activated by hypotonicity. It is highly expressed in the kidney as well as blood-brain barrier-deficient hypothalamic nuclei responsible for systemic osmosensing. Apart from its gating by hypotonicity, little is known about TRPV4 regulation. We observed that hypotonic stress resulted in rapid tyrosine phosphorylation of TRPV4 in a heterologous expression model and in native murine distal convoluted tubule cells in culture. This tyrosine phosphorylation was sensitive to the inhibitor of Src family tyrosine kinases, PP1, in a dose-dependent fashion. TRPV4 associated with Src family kinases by co-immunoprecipitation studies and confocal immunofluorescence microscopy, and this interaction required an intact Src family kinase SH2 domain. One of these kinases, Lyn, was activated by hypotonic stress and phosphorylated TRPV4 in an immune complex kinase assay and an in vitro kinase assay using recombinant Lyn and TRPV4. Transfection of wild-type Lyn dramatically potentiated hypotonicity-dependent TRPV4 tyrosine phosphorylation whereas dominant negative-acting Lyn modestly inhibited it. Through mutagenesis studies, the site of tonicity-dependent tyrosine phosphorylation was mapped to Tyr-253, which is conserved across all species from which TRPV4 has been cloned. Importantly, point mutation of Tyr-253 abolished hypotonicity-dependent channel activity. In aggregate, these data indicate that hypotonic stress results in Src family tyrosine kinase-dependent tyrosine phosphorylation of the tonicity sensor TRPV4 at residue Tyr-253 and that this residue is essential for channel function in this context. This is the first example of direct regulation of TRP channel function through tyrosine phosphorylation.	Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Cohen, DM (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, Mailcode PP262,3314SW US Vet Hosp Rd, Portland, OR 97201 USA.	cohend@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052494] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52494] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BUCHER P, 1994, ISMB, V2, P53; Chin H, 1998, BLOOD, V91, P3734; COHEN DM, 1994, J BIOL CHEM, V269, P25865; Colbert HA, 1997, J NEUROSCI, V17, P8259; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Crepel V, 1998, J NEUROSCI, V18, P1196; Deleuze C, 2000, J PHYSIOL-LONDON, V523, P291, DOI 10.1111/j.1469-7793.2000.t01-2-00291.x; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Harlow E, 1999, USING ANTIBODIES LAB, P321; HUNTER T, 1982, J BIOL CHEM, V257, P4843; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Musch MW, 1999, J BIOL CHEM, V274, P7923, DOI 10.1074/jbc.274.12.7923; Nilius B, 1998, J PHYSIOL-LONDON, V506, P353, DOI 10.1111/j.1469-7793.1998.353bw.x; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Roullet JB, 1997, J BIOL CHEM, V272, P32240, DOI 10.1074/jbc.272.51.32240; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shuba YM, 2000, AM J PHYSIOL-CELL PH, V279, pC1144, DOI 10.1152/ajpcell.2000.279.4.C1144; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Sorota S, 1995, PFLUG ARCH EUR J PHY, V431, P178, DOI 10.1007/BF00410189; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Voets T, 1998, J PHYSIOL-LONDON, V506, P341, DOI 10.1111/j.1469-7793.1998.341bw.x; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663; Zhang Z, 1998, AM J PHYSIOL-CELL PH, V275, pC1104, DOI 10.1152/ajpcell.1998.275.4.C1104; Zhang Z, 1997, AM J PHYSIOL-RENAL, V273, pF837, DOI 10.1152/ajprenal.1997.273.5.F837	41	144	158	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11520	11527		10.1074/jbc.M211061200	http://dx.doi.org/10.1074/jbc.M211061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538589	hybrid			2022-12-27	WOS:000181855400084
J	Kornberg, HL				Kornberg, HL			Memoirs of a biochemical hod carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Biographical-Item									Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Kornberg, HL (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.								0	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					9993	10001		10.1074/jbc.X200008200	http://dx.doi.org/10.1074/jbc.X200008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12556462	hybrid			2022-12-27	WOS:000181777500001
J	Schaufele, F; Wang, X; Liu, XW; Day, RN				Schaufele, F; Wang, X; Liu, XW; Day, RN			Conformation of CCAAT/enhancer-binding protein alpha dimers varies with intranuclear location in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; GENE-EXPRESSION; TRANSCRIPTION; ACTIVATION; HETEROCHROMATIN; PHOSPHORYLATION; DIFFERENTIATION; ARCHITECTURE; INHIBITION; INCLUSIONS	The structure of a protein defines its biochemical properties, but the impact of intracellular location and environment on protein structure remains poorly defined. CCAAT/enhancer-binding protein alpha (C/EBPalpha) is a master regulator of transcription and cellular proliferation that concentrates and is kept inactive at transcriptionally quiescent, pericentromeric regions in mouse cell nuclei. C/EBPalpha dimer structure was measured in living cells from the amounts of fluorescence energy transferred between derivatives of the green fluorescent protein attached to different CAEBPalpha domains. Comparing the levels of fluorescence resonance energy transfer at pericentromeric and nonpericentromeric regions of the nucleus indicated that the DNA binding domains of C/EBPalpha dimers were further apart and interacted more poorly at pericentromeric heterochromatin than in the more euchromatic regions of the nucleus. In contrast, the position and interactions of the transcriptional activation domains were similar throughout the nucleus. Phorbol ester treatment caused a shift in the position of the transcriptional activation domain relative to the DNA binding domain. Thus, C/EBPalpha conformation varies with intranuclear location and with cellular environment. These "fluorescence resonance energy transfer nanoscopy" techniques will be broadly applicable for associating conformational and kinetic variations to subcompartment-specific actions of C/EBPalpha or any protein in the dynamic intracellular environment.	Univ Calif San Francisco, Ctr Diabet, Metabol Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, Dept Med, San Francisco, CA 94143 USA; Univ Virginia, Hlth Sci Ctr, Natl Sci Fdn, Ctr Biol Timing,Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Natl Sci Fdn, Ctr Biol Timing,Dept Cell Biol, Charlottesville, VA 22908 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia	Schaufele, F (corresponding author), Univ Calif San Francisco, Ctr Diabet, Metabol Res Unit, San Francisco, CA 94143 USA.	freds@diabetes.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054345] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK054345-04A1, DK 54345] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Brown K, 1999, CRIT REV EUKAR GENE, V9, P203, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.50; CAO Z, 1992, GENE DEV, V5, P1538; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Day RN, 2003, MOL ENDOCRINOL, V17, P333, DOI 10.1210/me.2002-0136; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Enwright JF, 2003, MOL ENDOCRINOL, V17, P209, DOI 10.1210/me.2001-0222; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Forster T., 1948, ANN PHYS, V6, P54; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; Hager GL, 2002, CURR OPIN GENET DEV, V12, P137, DOI 10.1016/S0959-437X(02)00278-2; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE KAW, 1992, J CELL SCI, V103, P9; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Liu WQ, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-6; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; PARKS JS, 1993, HORM RES, V40, P54, DOI 10.1159/000183768; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radovick S, 1998, HORM RES, V49, P30, DOI 10.1159/000053065; Rubinsztein DC, 1999, J MED GENET, V36, P265; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; STEPHANOVA E, 1988, EXP CELL RES, V179, P545, DOI 10.1016/0014-4827(88)90292-3; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Weatherman RV, 2002, MOL ENDOCRINOL, V16, P487, DOI 10.1210/me.16.3.487; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1; Zhang WH, 2001, J BIOL CHEM, V276, P40373, DOI 10.1074/jbc.C100505200	53	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10578	10587		10.1074/jbc.M207466200	http://dx.doi.org/10.1074/jbc.M207466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531886	hybrid			2022-12-27	WOS:000181777500078
J	Ohdate, H; Lim, CR; Kokubo, T; Matsubara, K; Kimata, Y; Kohno, K				Ohdate, H; Lim, CR; Kokubo, T; Matsubara, K; Kimata, Y; Kohno, K			Impairment of the DNA binding activity of the TATA-binding protein renders the transcriptional function of Rvb2p/Tih2p, the yeast RuvB-like protein, essential for cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO; C-MYC; ONCOGENIC TRANSFORMATION; BETA-CATENIN; BOX C/D; NUCLEOSOME; MUTANTS; IDENTIFICATION	In Saccharomyces cerevisiae, two highly conserved proteins, Rvb1p/Tih1p and Rvb2p/Tih2p, have been demonstrated to be major components of the chromatin-remodeling INO80 complex. The mammalian orthologues of these two proteins have been shown to physically associate with the TATA-binding protein (TBP) in vitro but not clearly in vivo. Here we show that yeast proteins interact with TBP under both conditions. To assess the functional importance of these interactions, we examined the effect of mutating both TIH2/RVB2 and SPT15, which encodes TBP, on yeast cell growth. Intriguingly, only those spt15 mutations that affected the ability of TBP to bind to the TATA box caused synthetic growth defects in a tih2-ts160 background. This suggests that Tih2p might be important in recruiting TBP to the promoter. A DNA microarray technique was used to identify genes differentially expressed in the tih2-ts160 strain grown at the restrictive temperature. Only 34 genes were significantly and reproducibly affected; some up-regulated and others down-regulated. We compared the transcription of several of these Tih2p target genes in both wild type and various mutant backgrounds. We found that the transcription of some genes depends on functions possessed by both Tih2p and TBP and that these functions are substantially impaired in the spt15/tih2-ts160 double mutants that confer synthetic growth defects.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; DNA Chip Res Inc, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Div Mol & Cellular Biol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Nara Institute of Science & Technology; DNA Chip Research Inc.; Yokohama City University	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Nara 6300101, Japan.							ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Chao DM, 1996, NATURE, V383, P119, DOI 10.1038/383119a0; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Holzmann K, 1998, BIOCHEM BIOPH RES CO, V252, P39, DOI 10.1006/bbrc.1998.9604; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; John S, 2000, GENE DEV, V14, P1196; Jonsson ZO, 2001, J BIOL CHEM, V276, P16279, DOI 10.1074/jbc.M011523200; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; Kikuchi N, 1999, J BIOCHEM, V125, P487, DOI 10.1093/oxfordjournals.jbchem.a022312; KIMATA Y, 1994, J BIOL CHEM, V269, P13497; King TH, 2001, MOL CELL BIOL, V21, P7731, DOI 10.1128/MCB.21.22.7731-7746.2001; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kobayashi A, 2001, J BIOL CHEM, V276, P395, DOI 10.1074/jbc.M008208200; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; LEE M, 1995, MOL CELL BIOL, V15, P5461; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lim CR, 2000, J BIOL CHEM, V275, P22409, DOI 10.1074/jbc.M001031200; Morales V, 2001, BIOCHIMIE, V83, P1029, DOI 10.1016/S0300-9084(01)01347-5; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neuwald AF, 1999, GENOME RES, V9, P27; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Salzer U, 1999, BBA-GENE STRUCT EXPR, V1446, P365, DOI 10.1016/S0167-4781(99)00104-9; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SIKORSKI RS, 1989, GENETICS, V122, P19; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	59	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14647	14656		10.1074/jbc.M213220200	http://dx.doi.org/10.1074/jbc.M213220200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576485	hybrid			2022-12-27	WOS:000182516100011
J	Zhou, AW; Stein, PE; Huntington, JA; Carrell, RW				Zhou, AW; Stein, PE; Huntington, JA; Carrell, RW			Serpin polymerization is prevented by a hydrogen bond network that is centered on His-334 and stabilized by glycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ELECTRON-DENSITY MAPS; BETA-SHEET-A; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL DISEASES; CRYSTAL-STRUCTURE; IN-VIVO; ANTITHROMBIN; MECHANISM	Polymerization of serpins commonly results from mutations in the shutter region underlying the bifurcation of strands 3 and 5 of the A-sheet, with entry beyond this point being barred by a H-bond network centered on His-334. Exposure of this histidine in antithrombin, which has a partially opened sheet, allows polymerization and peptide insertion to occur at pH 6 or less when His-334 will be predictably protonated with disruption of the H-bond network. Similarly, thermal stability of antithrombin is pH-dependent with a single unfolding transition at pH 6, but there is no such transition when His-334 is buried by a fully closed A-sheet in heparin-complexed antithrombin or in alpha(1)-antitrypsin. Replacement of His-334 in alpha(1)-antitrypsin by a serine or alanine at pH 7.4 results in the same polymerization and loop-peptide acceptance observed with antithrombin at low pH. The critical role of His-334 and the re-formation of its H-bond network by the conserved P8 threonine, on the full insertion of strand 4, are relevant for the design of therapeutic blocking agents. This is highlighted here by the crystallographic demonstration that glycerol, which at high concentrations blocks polymerization, can replace the P8 threonine and re-form the disrupted H-bond network with His-334.	Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England	University of Cambridge	Zhou, AW (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 2XY, England.	awz20@cus.cam.ac.uk		ZHOU, Aiwu/0000-0002-2555-5091				Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Carrell RW, 2001, THROMB HAEMOSTASIS, V86, P14; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; EVANS PR, 1993, P CCP4 STUD WEEK DAT, V114; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Hansen M, 2001, EUR J BIOCHEM, V268, P6274, DOI 10.1046/j.0014-2956.2001.02582.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 2002, J BIOL CHEM, V277, P46347, DOI 10.1074/jbc.M207682200; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane DA, 1997, THROMB HAEMOSTASIS, V77, P197; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Petitou M, 1992, Fortschr Chem Org Naturst, V60, P143; POLLER W, 1993, GENOMICS, V17, P740, DOI 10.1006/geno.1993.1396; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	50	62	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15116	15122		10.1074/jbc.M211663200	http://dx.doi.org/10.1074/jbc.M211663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578831	hybrid			2022-12-27	WOS:000182516100069
J	Kim, YM; Watanabe, T; Allen, PB; Kim, YM; Lee, SJ; Greengard, P; Nairn, AC; Kwon, YG				Kim, YM; Watanabe, T; Allen, PB; Kim, YM; Lee, SJ; Greengard, P; Nairn, AC; Kwon, YG			PNUTS, a protein phosphatase 1 (PP1) nuclear targeting subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SPLICING FACTORS; MESSENGER-RNA; RETINOBLASTOMA PROTEIN; CATALYTIC SUBUNIT; BINDING-PROTEINS; MAMMALIAN-CELLS; PHOSPHORYLATION; TYPE-1; GENE; KINASE	PNUTS, Phosphatase 1 NUclear Targeting Subunit, is a recently described protein that targets protein phosphatase 1 (PP1) to the nucleus. In the present study, we characterized the biochemical properties of PNUTS. A variety of truncation and site-directed mutants of PNUTS was prepared and expressed either as glutathione S-transferase fusion proteins in Escherichia coli or as FLAG-tagged proteins in 293T cells. A 50-amino acid domain in the center of PNUTS mediated both high affinity PP1 binding and inhibition of PP1 activity. The PP1-binding domain is related to a motif found in several other PP1-binding proteins but is distinct in that Trp replaces Phe. Mutation of the Trp residue essentially abolished the ability of PNUTS to bind to and inhibit PP1. The central PP1-binding domain of PNUTS was an effective substrate for protein kinase A in vitro, and phosphorylation substantially reduced the ability of PNUTS to bind to PP1 in vitro and following stimulation of protein kinase A in intact cells. In vitro RNA binding experiments showed that a C-terminal region including several RGG motifs and a novel repeat domain rich in His and Gly interacted with mRNA and single-stranded DNA. PNUTS exhibited selective binding for poly(A) and poly(G) compared with poly(U) or poly(C) ribonucleotide homopolymers, with specificity being mediated by distinct regions within the domain rich in His and Gly and the domain containing the RGG motifs. Finally, a PNUTS-PP1 complex was isolated from mammalian cell lysates using RNA-conjugated beads. Together, these studies support a role for PNUTS in protein kinase A-regulated targeting of PP1 to specific RNA-associated complexes in the nucleus.	Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Kangwon National University; Kangwon National University; Rockefeller University	Kwon, YG (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea.	ygkwon@kangwon.ac.kr		Nairn, Angus/0000-0002-7075-0195	NIDA NIH HHS [P01 DA010044] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Das A, 1996, J BIOL CHEM, V271, P15675, DOI 10.1074/jbc.271.26.15675; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KILEDJIAN M, 1992, EMBO J, V11, P2644; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014-5793(88)81331-0; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 2000, J CELL SCI, V113, P1841; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Peggie MW, 2002, J CELL SCI, V115, P195; Rubin Ethel, 1998, Frontiers in Bioscience, V3, pD1209; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	63	58	61	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13819	13828		10.1074/jbc.M209621200	http://dx.doi.org/10.1074/jbc.M209621200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574161	hybrid			2022-12-27	WOS:000182405000034
J	Wuebbens, MM; Rajagopalan, KV				Wuebbens, MM; Rajagopalan, KV			Mechanistic and mutational studies of Escherichia coli molybdopterin synthase clarify the final step of molybdopterin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; STRUCTURAL CHARACTERIZATION; THIAMIN BIOSYNTHESIS; UBIQUITIN ACTIVATION; CONVERTING FACTOR; PRECURSOR-Z; IDENTIFICATION; SULFUR; THIOCARBOXYLATE; INVOLVEMENT	Biosynthesis of the molybdenum cofactor, a chelate of molybdenum or tungsten with a novel pterin, occurs in virtually all organisms including humans. In the cofactor, the metal is complexed to the unique cis-dithiolene moiety located on the pyran ring of molybdopterin. Escherichia coli molybdopterin synthase, the protein responsible for adding the, dithiolene to a desulfo precursor termed precursor Z, is a dimer of dimers containing the MoaD and MoaE proteins. The sulfur used for dithiolene formation is carried in the form of a thiocarboxylate at the MoaD C terminus. Using an intein expression system for preparation of thiocarboxylated MoaD, the mechanism of the molybdopterin synthase reaction was examined. A stoichiometry of 2 molecules of thiocarboxylated MoaD per conversion of a single precursor Z molecule to molybdopterin was observed. Examination of several synthase variants bearing mutations in the MoaE subunit identified Lys-119 as a residue essential for activity and Arg-39 and Lys-126 as other residues critical for the reaction. An intermediate of the synthase reaction was identified and characterized. This intermediate remains tightly associated with the protein and is the predominant product formed by synthase containing the K126A variant of MoaE. Mass spectral data obtained from protein-bound intermediate are consistent with a monosulfurated structure that contains a terminal phosphate group similar to that present in molybdopterin.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Hanzelmann P, 2002, J BIOL CHEM, V277, P18303, DOI 10.1074/jbc.M200947200; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; Johnson JL., 2001, METABOLIC MOL BASES, P3163; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; Kinsland C, 1998, PROTEIN SCI, V7, P1839, DOI 10.1002/pro.5560070821; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Reiss J, 1999, AM J HUM GENET, V64, P706, DOI 10.1086/302296; Remko M, 1997, J MOL STRUC-THEOCHEM, V418, P179, DOI 10.1016/S0166-1280(96)05025-7; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; Rudolph MJ, 2003, J BIOL CHEM, V278, P14514, DOI 10.1074/jbc.M300449200; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698	35	83	89	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14523	14532		10.1074/jbc.M300453200	http://dx.doi.org/10.1074/jbc.M300453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571226	hybrid			2022-12-27	WOS:000182405000120
J	Fan, CX; Chen, XK; Zhang, C; Wang, LX; Duan, KL; He, LL; Cao, Y; Liu, SY; Zhong, MN; Ulens, C; Tytgat, J; Chen, JS; Chi, CW; Zhou, Z				Fan, CX; Chen, XK; Zhang, C; Wang, LX; Duan, KL; He, LL; Cao, Y; Liu, SY; Zhong, MN; Ulens, C; Tytgat, J; Chen, JS; Chi, CW; Zhou, Z			A novel conotoxin from Conus betulinus, kappa-BtX, unique in cysteine pattern and in function as a specific BK channel modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CA2+-ACTIVATED K+ CHANNELS; POTASSIUM CHANNELS; MOLECULAR-BASIS; VENOM PEPTIDES; VOLTAGE; CHARYBDOTOXIN; INACTIVATION; CONDUCTANCE; DIVERSITY	A novel conotoxin, kappa-conotoxin (kappa-BtX), has been purified and characterized from the venom of a worm-hunting cone snail, Conus betulinus. The toxin, with four disulfide bonds, shares no sequence homology with any other conotoxins. Based on a partial amino acid sequence, its cDNA was cloned and sequenced. The deduced sequence consists of a 26-residue putative signal peptide, a 31-residue mature toxin, and a 13-residue extra peptide at the C terminus. The extra peptide is cleaved off by proteinase post-processing. All three Glu residues are gamma-carboxylated, one of the two Pro residues is hydroxylated at position 27, and its C-terminal residue is Pro-amidated. The monoisotopic mass of the toxin is 3569.0 Da. Electrophysiological experiments show that: 1) among voltage-gated channels;, K-BtX is a specific modulator of K+ channels; 2) among the K channels, kappa-BtX specifically up-modulates the Ca2+- and voltage-sensitive BK channels (252 47%); 3) its EC50 is 0.7 nm with a single binding site (Hill = 0.88); 4) the time constant of wash-out is 8.3 s; and 5) kappa-BtX has no effect on single channel conductance, but increases the open probability of BK channels. It is concluded that kappa-BtX is a novel specific biotoxin against BK channels.	Res Inst Pharmaceut Chem, Beijing 102205, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Katholieke Univ Leuven, Toxicol Lab, Louvain, Belgium	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; KU Leuven	Zhou, Z (corresponding author), Res Inst Pharmaceut Chem, Beijing 102205, Peoples R China.		chen, xiaoke/E-5385-2011; zhou, zhuan/A-8285-2011; Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; Chen JS, 1999, J NAT TOXINS, V8, P341; Colquhoun David, 1995, P397; Elhamdani A, 1998, J NEUROSCI, V18, P6230; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GARCIA ML, 1995, AM J PHYSIOL-CELL PH, V269, pC1, DOI 10.1152/ajpcell.1995.269.1.C1; Hille B., 1992, IONIC CHANNELS EXCIT; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOSHI T, 1988, J GEN PHYSIOL, V91, P73, DOI 10.1085/jgp.91.1.73; JOHNS MB, 1989, ANAL BIOCHEM, V180, P276, DOI 10.1016/0003-2697(89)90430-2; Latorre R, 2000, HANDB EXP PHARM, V147, P197; Lawson K, 1996, CLIN SCI, V91, P651, DOI 10.1042/cs0910651; Le Gall F, 1999, BELG J ZOOL, V129, P17; McIntosh J M, 1999, Methods Enzymol, V294, P605; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NEELY A, 1992, J PHYSIOL-LONDON, V453, P133, DOI 10.1113/jphysiol.1992.sp019221; Olivera BM, 1999, J COMP PHYSIOL A, V185, P353, DOI 10.1007/s003590050394; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; SOLARO CR, 1995, J NEUROSCI, V15, P6110; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wu JJ, 2002, BIOCHEMISTRY-US, V41, P2844, DOI 10.1021/bi011367z; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	32	68	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12624	12633		10.1074/jbc.M210200200	http://dx.doi.org/10.1074/jbc.M210200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547831	hybrid			2022-12-27	WOS:000182189500007
J	Mohamed, MR; Niles, EG				Mohamed, MR; Niles, EG			UUUUUNU oligonucleotide stimulation of vaccinia virus early gene transcription termination, in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA POLYMERASE; TRIPHOSPHATE PHOSPHOHYDROLASE I; TEMPERATURE-SENSITIVE MUTANTS; MESSENGER-RNA; CAPPING ENZYME; H4L SUBUNIT; EUKARYOTIC TRANSCRIPTION; ESCHERICHIA-COLI; PURIFICATION; EXPRESSION	Vaccinia virus early gene transcription termination requires the vaccinia termination factor (VTF), NPH1, a single stranded DNA-dependent ATPase, the virion form of RNA polymerase containing the Rap 94 subunit, and the signal UUUUUNU, which resides in the nascent mRNA, located 30 to 50 bases upstream from the poly(A) addition site. Evidence indicates that a required termination factor acts through binding to the UUUUUNU signal. To further investigate the function of UUUUUNU, the ability of UUUUUNU containing oligonucleotides to inhibit transcription termination was tested. A 22-mer RNA oligonucleotide containing a central U9 sequence exhibited sequence and concentration-dependent stimulation of premature transcription termination and transcript release, in trans. Activation of premature termination required VTF, NPH 1, Rap 94, and ATP, demonstrating that the normal termination machinery was employed. Premature termination was not stimulated by RNA harboring a mutant UUUUUNU, demonstrating specificity. These data are consistent with a model in which a required termination factor is converted from an inactive to an active form by binding to a UUUUUNU containing oligonucleotide. The active termination factor then interacts with the ternary complex stimulating transcription termination through the normal mechanism, independent of the nascent mRNA sequence.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Niles, EG (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, 138 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	eniles@buffalo.edu	Mohamed, Mohamed Ragaa/V-9143-2019	Mohamed, Mohamed Ragaa/0000-0002-9269-3128	NIAID NIH HHS [R01-AI 43933] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; Christen LA, 1999, BIOCHEMISTRY-US, V38, P8072, DOI 10.1021/bi9903749; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Condit RC, 1996, VIROLOGY, V220, P10, DOI 10.1006/viro.1996.0280; Condit RC, 2002, BBA-GENE STRUCT EXPR, V1577, P325, DOI 10.1016/S0167-4781(02)00461-X; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; ENSINGER MJ, 1975, P NATL ACAD SCI USA, V72, P2525, DOI 10.1073/pnas.72.7.2525; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; LUO Y, 1993, J BIOL CHEM, V268, P21253; Mohamed MR, 2000, J BIOL CHEM, V275, P25798, DOI 10.1074/jbc.M002250200; Mohamed MR, 2002, VIROLOGY, V299, P142, DOI 10.1006/viro.2002.1498; Mohamed MR, 2001, J BIOL CHEM, V276, P20758, DOI 10.1074/jbc.M101641200; MORGAN JR, 1984, J VIROL, V51, P283, DOI 10.1128/JVI.51.2.283-297.1984; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 2001, POXVIRIDAE VIRUSES T, V2, P2849; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; PAOLETTI E, 1974, J BIOL CHEM, V249, P3281; PIACENTE SC, 2002, IN PRESS VIROLOGY; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; WEI CM, 1974, P NATL ACAD SCI USA, V71, P3014, DOI 10.1073/pnas.71.8.3014; Wright CF, 2001, J BIOL CHEM, V276, P40680, DOI 10.1074/jbc.M102399200; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	41	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11794	11801		10.1074/jbc.M213263200	http://dx.doi.org/10.1074/jbc.M213263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556520	hybrid			2022-12-27	WOS:000182015700011
J	Nur-E-Kamal, A; Li, TK; Zhang, AL; Qi, HY; Hars, ES; Liu, LF				Nur-E-Kamal, A; Li, TK; Zhang, AL; Qi, HY; Hars, ES; Liu, LF			Single-stranded DNA induces ataxia telangiectasia mutant (ATM)/p53-dependent DNA damage and apoptotic signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DEPENDENT APOPTOSIS; IONIZING-RADIATION; TOPOISOMERASE-I; NERVOUS-SYSTEM; S-PHASE; ATM; P53; PROTEIN; PHOSPHORYLATION	Single-stranded DNA has been speculated to be the initial signal in the DNA damage signaling pathway. We showed that introduction of single-stranded DNA with diverse sequences into mammalian cells induced DNA damage as well as apoptosis signals. Like DNA damaging agents, single-stranded DNA up-regulated p53 and activated the nuclear kinase ataxia telangiectasia mutant (ATM) as evidenced by phosphorylation of histone 2AX, an endogenous ATM substrate. Single-stranded DNA also triggered apoptosis as evidenced by the formation of caspase-dependent chromosomal DNA strand breaks, cytochrome c release, and increase in reactive oxygen species production. Moreover, single-stranded DNA-induced apoptosis was reduced significantly in p53 null cells and in cells treated with ATM small interfering RNA. These results suggest that single-stranded DNA may act upstream of ATM/p53 in DNA damage signaling.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Nur-E-Kamal, A (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.			LI, TSAI-KUN/0000-0003-0393-2340; Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA39662] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Delia D, 2000, BRIT J CANCER, V82, P1938; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Flaherty KT, 2001, CURR OPIN ONCOL, V13, P499, DOI 10.1097/00001622-200111000-00013; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Guo CY, 2002, J BIOL CHEM, V277, P4839, DOI 10.1074/jbc.M110092200; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert G, 2000, BIOCHEM BIOPH RES CO, V279, P401, DOI 10.1006/bbrc.2000.3963; Lee SH, 2002, MOL CELLS, V13, P159; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Milyavsky M, 2001, NUCLEIC ACIDS RES, V29, P5207, DOI 10.1093/nar/29.24.5207; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Schiavone N, 2000, BIOCHEM BIOPH RES CO, V270, P406, DOI 10.1006/bbrc.2000.2433; Shen WY, 2002, ANTISENSE NUCLEIC A, V12, P155, DOI 10.1089/108729002760220752; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sureda FX, 1998, GEN PHARMACOL, V30, P507, DOI 10.1016/S0306-3623(97)00294-2; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tidd DM, 2000, NUCLEIC ACIDS RES, V28, P2242, DOI 10.1093/nar/28.11.2242; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang H, 2001, CURR CANCER DRUG TAR, V1, P177, DOI 10.2174/1568009013334133; Wei ZP, 1996, NUCLEIC ACIDS RES, V24, P655, DOI 10.1093/nar/24.4.655; Xu H, 2001, Biotechnol Annu Rev, V7, P131, DOI 10.1016/S1387-2656(01)07035-1; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	50	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12475	12481		10.1074/jbc.M212915200	http://dx.doi.org/10.1074/jbc.M212915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540848	hybrid			2022-12-27	WOS:000182015700098
J	Pluquet, O; North, S; Bhoumik, A; Dimas, K; Ronai, Z; Hainaut, P				Pluquet, O; North, S; Bhoumik, A; Dimas, K; Ronai, Z; Hainaut, P			The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; DNA-DAMAGE; PROTEIN-KINASE; P53-DEPENDENT PATHWAY; TRANSCRIPTION FACTORS; TOPOISOMERASE-II; PHOSPHORYLATION; AMIFOSTINE; WR-1065; CANCER	WR1065 is an aminothiol with selective cytoprotective effects in normal cells compared with cancer cells. In a previous study (North, S., El-Ghissassi, F., Pluquet, O., Verhaegh, G., and Hainaut, P. (2000) Oncogene 19, 1206-1214), we have shown that WR1065 activates wildtype p53 in cultured cells. Here we show that WR1065 induces p53 to accumulate through escape from proteasome-dependent degradation. This accumulation is not prevented by inhibitors of phosphatidylinositol 3-kinases and is not accompanied by phosphorylation of Ser-15, -20, or -37, which are common targets of the kinases activated in response to DNA damage. Furthermore, WR1065 activates the JNK (c-Jun N-terminal kinase), decreases complex formation between p53 and inactive JNK, and phosphorylates p53 at Thr-81, a known site of phosphorylation by JNK. A dominant negative form of JNK (JNK-APF) reduces by 50% the activation of p53 by WR1065. Thus, WR1065 activates p53 through a JNK-dependent signaling pathway. This pathway may prove useful for pharmacological modulation of p53 activity through non-genotoxic mechanisms.	Int Agcy Res Canc, Unit Mol Carcinogenesis, F-69372 Lyon 08, France; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	World Health Organization; International Agency for Research on Cancer (IARC); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012; Dimas, Konstantinos/AAU-5461-2020	Hainaut, Pierre/0000-0002-1303-1610; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER; NCI NIH HHS [CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bacus SS, 1996, ONCOGENE, V12, P2535; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; CALABROJONES PM, 1988, CANCER RES, V48, P3634; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capizzi RL, 1996, EUR J CANCER, V32A, pS5, DOI 10.1016/S0959-8049(96)00333-4; Chehab NH, 2000, GENE DEV, V14, P278; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOUAY L, 1995, EUR J CANCER, V31A, pS14, DOI 10.1016/0959-8049(95)00146-A; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOMEZ DA, 1996, J BIOL CHEM, V271, P26335; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRDINA DJ, 1995, CARCINOGENESIS, V16, P767, DOI 10.1093/carcin/16.4.767; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kataoka Y, 2000, INT J RADIAT BIOL, V76, P633; Kemp G, 1996, J CLIN ONCOL, V14, P2101, DOI 10.1200/JCO.1996.14.7.2101; Kramer DL, 1999, CANCER RES, V59, P1278; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; List AF, 1996, SEMIN ONCOL, V23, P58; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu SC, 1997, CARCINOGENESIS, V18, P2457, DOI 10.1093/carcin/18.12.2457; Lu WG, 2002, CANCER RES, V62, P1305; Maurici D, 2001, ONCOGENE, V20, P3533, DOI 10.1038/sj.onc.1204428; MEIER T, 1995, BIOCHEM PHARMACOL, V50, P489, DOI 10.1016/0006-2952(95)00164-U; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Murley JS, 1997, CELL PROLIFERAT, V30, P283, DOI 10.1046/j.1365-2184.1997.00092.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Paasinen-Sohns A, 2000, J CELL BIOL, V151, P801, DOI 10.1083/jcb.151.4.801; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; PLUQUET O, 2003, IN PRESS BIOCH PHARM; POPLIN EA, 1994, CANCER CHEMOTH PHARM, V33, P415, DOI 10.1007/s002800050074; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiller JH, 1996, J CLIN ONCOL, V14, P1913, DOI 10.1200/JCO.1996.14.6.1913; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067; Shieh SY, 2000, GENE DEV, V14, P289; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Snyder RD, 2000, CANCER RES, V60, P1186; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TRAVIS EL, 1988, INT J RADIAT ONCOL, V15, P377, DOI 10.1016/S0360-3016(98)90019-0; TRESKES M, 1992, BIOCHEM PHARMACOL, V43, P1013, DOI 10.1016/0006-2952(92)90607-K; TRESKES M, 1994, EUR J CANCER, V30A, P183, DOI 10.1016/0959-8049(94)90084-1; TRESKES M, 1992, CANCER RES, V52, P2257; Vasilevskaya IA, 1999, CANCER RES, V59, P3935; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WOLOSCHAK GE, 1995, CANCER RES, V55, P4788; YUHAS JM, 1980, CANCER RES, V40, P1519	76	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11879	11887		10.1074/jbc.M207396200	http://dx.doi.org/10.1074/jbc.M207396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531896	hybrid			2022-12-27	WOS:000182015700022
J	Rojkova, AM; Woodard, GE; Huang, TC; Combs, CA; Zhang, JH; Simonds, WF				Rojkova, AM; Woodard, GE; Huang, TC; Combs, CA; Zhang, JH; Simonds, WF			G gamma subunit-selective G protein beta(5) mutant defines regulators of G protein signaling protein binding requirement for nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RGS PROTEINS; SUBCELLULAR-LOCALIZATION; CRYSTAL-STRUCTURE; EXPRESSION; INTERACTS; G-BETA-5; BRAIN; TRANSLOCATION; COEXPRESSION; MUTAGENESIS	The signal transducing function of Gbeta(5) in brain is unknown. When studied in vitro Gbeta(5) is the only heterotrimeric Gbeta subunit known to interact with both Ggamma subunits and regulators of G protein signaling (RGS) proteins. When tested with Ggamma, Gbeta(5) interacts with other classical components of heterotrimeric G protein signaling pathways such as Galpha and phospholipase C-beta. We recently demonstrated nuclear expression of Gbeta(5) in neurons and brain (Zhang, J. H., Barr, V. A., Mo, Y., Rojkova, A M., Liu, S., and Simonds, W. F. (2001) J. Biol. Chem. 276, 10284-10289). To gain further insight into the mechanism of Gbeta(5) nuclear localization, we generated a Gbeta(5) mutant deficient in its ability to interact with RGS7 while retaining its ability to bind Ggamma, and we compared its properties to the wild-type Gbeta(5). In HEK-293 cells co-transfection of RGS7 but not Ggamma(2) supported expression in the nuclear fraction of transfected wild-type Gbeta(5). In contrast the Ggamma-preferring Gbeta(5), mutant was not expressed in the HEK-293 cell nuclear fraction with either co-transfectant. The Ggamma-selective Gbeta(5) mutant was also excluded from the cell nucleus of transfected PC12 cells analyzed by laser confocal microscopy. These results define a requirement for RGS protein binding for Gbeta(5) nuclear expression.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Confocal Microscopy Core Facil, Div Intramural Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Simonds, WF (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C-101,10 Ctr Dr,MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov	Rozhkova, Alexandra/E-5607-2014; Woodard, Geoffrey/A-8608-2009	Rozhkova, Alexandra/0000-0003-4901-4705; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043304, Z01DK043304] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1995, J NEUROCHEM, V64, P1267; Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Benzing T, 2000, J BIOL CHEM, V275, P28167; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Crouch MF, 1997, FASEB J, V11, P189, DOI 10.1096/fasebj.11.2.9039962; Dessauer CW, 1996, CLIN SCI, V91, P527, DOI 10.1042/cs0910527; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jones MB, 1999, ANAL BIOCHEM, V268, P126, DOI 10.1006/abio.1998.3064; Jones PG, 1998, BBA-MOL CELL RES, V1402, P288, DOI 10.1016/S0167-4889(98)00017-2; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Patikoglou GA, 2002, J BIOL CHEM, V277, P47004, DOI 10.1074/jbc.M208186200; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Robatzek M, 2001, CURR BIOL, V11, P288, DOI 10.1016/S0960-9822(01)00074-4; Ryan JC, 2001, MOL VIS, V7, P222; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Song L, 2001, BIOCHEM BIOPH RES CO, V283, P102, DOI 10.1006/bbrc.2001.4742; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van der Linden AM, 2001, GENETICS, V158, P221; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Yoshikawa DM, 2000, BIOCHEMISTRY-US, V39, P11340, DOI 10.1021/bi0005557; Zhang JH, 2000, J NEUROCHEM, V75, P393, DOI 10.1046/j.1471-4159.2000.0750393.x; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	48	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12507	12512		10.1074/jbc.M207302200	http://dx.doi.org/10.1074/jbc.M207302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551930	hybrid			2022-12-27	WOS:000182015700102
J	Smani, T; Zakharov, SI; Leno, E; Csutora, P; Trepakova, ES; Bolotina, VM				Smani, T; Zakharov, SI; Leno, E; Csutora, P; Trepakova, ES; Bolotina, VM			Ca2+-independent phospholipase A(2) is a novel determinant of store-operated Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; NONSELECTIVE CATION CHANNEL; ARACHIDONIC-ACID; PHOSPHATIDATE PHOSPHOHYDROLASE; INTRACELLULAR CA2+; BROMOENOL LACTONE; HUMAN PLATELETS; CALCIUM INFLUX; T-LYMPHOCYTES; DEPLETION	Store-operated cation (SOC) channels and capacitative Ca2+ entry (CCE) play very important role in cellular function, but the mechanism of their activation remains one of the most intriguing and long lasting mysteries in the field of Ca2+ signaling. Here, we present the first evidence that Ca2+-independent phospholipase A(2) (iPLA(2)) is a crucial molecular determinant in activation of SOC channels and store-operated Ca2+ entry pathway. Using molecular, imaging, and electrophysiological techniques, we show that directed molecular or pharmacological impairment of the functional activity of iPLA(2) leads to irreversible inhibition of CCE mediated by nonselective SOC channels and by Ca2+-release-activated Ca2+ (CRAC) channels. Transfection of vascular smooth muscle cells (SMC) with antisense, but not sense, oligonucleotides for iPLA(2) impaired thapsigargin (TG)-induced activation of iPLA(2) and TG-induced Ca2+ and Mn2+ influx. Identical inhibition of TG-induced Ca2+ and Mn2+ influx (but not Ca2+ release) was observed in SMC, human platelets, and Jurkat T-lymphocytes when functional activity of iPLA(2) was inhibited by its mechanism-based suicidal substrate, bromoenol lactone (BEL). Moreover, irreversible inhibition of iPLA(2) impaired TG-induced activation of single nonselective SOC channels in SMC and BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)-induced activation of whole-cell CRAC current in rat basophilic leukemia cells. Thus, functional iPLA(2) is required for activation of store-operated channels and capacitative Ca2+ influx in wide variety of cell types.	Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Pecs, H-7624 Pecs, Hungary	Boston University; University of Pecs	Bolotina, VM (corresponding author), EBRC, Vasc Biol Unit, X-704,650 Albany St, Boston, MA 02118 USA.	vbolotina@medicine.bu.edu	Hajami, Tarik Smani/D-5372-2016; IBIS, CARDIOVASCULAR/P-3910-2015	Hajami, Tarik Smani/0000-0002-1877-7438; Bolotina, Victoria/0000-0001-5862-181X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054150] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Albert AP, 2002, J PHYSIOL-LONDON, V538, P717, DOI 10.1113/jphysiol.2001.013101; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Creer MH, 1998, AM J PHYSIOL-CELL PH, V275, pC1498, DOI 10.1152/ajpcell.1998.275.6.C1498; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Glitsch MD, 2002, J PHYSIOL-LONDON, V539, P93, DOI 10.1113/jphysiol.2001.012826; Golovina VA, 2001, AM J PHYSIOL-HEART C, V280, pH746, DOI 10.1152/ajpheart.2001.280.2.H746; Hirakawa Y, 1999, AM J PHYSIOL-HEART C, V277, pH1732, DOI 10.1152/ajpheart.1999.277.5.H1732; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Iwamuro Y, 1998, BRIT J PHARMACOL, V124, P1541, DOI 10.1038/sj.bjp.0701984; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; McFadzean I, 2002, BRIT J PHARMACOL, V135, P1, DOI 10.1038/sj.bjp.0704468; Mignen O, 2001, J BIOL CHEM, V276, P21365, DOI 10.1074/jbc.M102311200; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Ng LC, 2001, CIRC RES, V89, P923, DOI 10.1161/hh2201.100315; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Parekh AB, 1995, J PHYSIOL-LONDON, V489, P377, DOI 10.1113/jphysiol.1995.sp021058; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 2001, J CELL SCI, V114, P2223; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; Trepakova ES, 2002, BIOL MEMBRANY, V19, P49; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wayman CP, 1996, BRIT J PHARMACOL, V117, P566, DOI 10.1111/j.1476-5381.1996.tb15228.x; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	114	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11909	11915		10.1074/jbc.M210878200	http://dx.doi.org/10.1074/jbc.M210878200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547829	hybrid			2022-12-27	WOS:000182015700026
J	Sun, JP; Fedorov, AA; Lee, SY; Guo, XL; Shen, K; Lawrence, DS; Almo, SC; Zhang, ZY				Sun, JP; Fedorov, AA; Lee, SY; Guo, XL; Shen, K; Lawrence, DS; Almo, SC; Zhang, ZY			Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SUBSTRATE-TRAPPING MUTANTS; STRUCTURE-BASED DESIGN; HUMAN BREAST-CANCER; MOLECULAR-BASIS; INSULIN SENSITIVITY; SIGNAL-TRANSDUCTION; IN-VIVO; 1B; SPECIFICITY	Protein-tyrosine phosphatase 1B (PTP1B) has been implicated as an important regulator in several signaling pathways including those initiated by insulin and leptin. Potent and specific PTP1B inhibitors could serve as useful tools in elucidating the physiological functions of PTP1B and may constitute valuable therapeutics in the treatment of several human diseases. We have determined the crystal structure of PTP1B in complex with compound 2, the most potent and selective PTP1B inhibitor reported to date. The structure at 2.15-Angstrom resolution reveals that compound 2 simultaneously binds to the active site and a unique proximal noncatalytic site formed by Lys-41, Arg-47, and Asp-48. The structural data are further corroborated by results from kinetic analyses of the interactions of PTP1B and its site-directed mutants with compound 2 and several of its variants. Although many of the residues important for interactions between PTP1B and compound 2 are not unique to PTP1B, the combinations of all contact residues differ between PTP isozymes, which provide a structural basis for potent and selective PTP1B inhibition. Our data further suggest that potent, yet highly selective, PTP1B inhibitory agents can be acquired by targeting the area defined by residues Lys-41, Arg-47, and Asp-48, in addition to the previously identified second aryl phosphate-binding pocket.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		sun, Jinpeng/AAR-9196-2020; SUN, JINPENG/F-9551-2013		NIGMS NIH HHS [GM55242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asante-Appiah E, 2002, BIOCHEMISTRY-US, V41, P9043, DOI 10.1021/bi0259554; Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Groves MR, 1998, BIOCHEMISTRY-US, V37, P17773, DOI 10.1021/bi9816958; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; Iversen LF, 2001, BIOCHEMISTRY-US, V40, P14812, DOI 10.1021/bi011389l; Jia ZC, 2001, J MED CHEM, V44, P4584, DOI 10.1021/jm010266w; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu Gang, 2002, Curr Opin Investig Drugs, V3, P1608; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Taylor SD, 1998, BIOORGAN MED CHEM, V6, P1457, DOI 10.1016/S0968-0896(98)00075-3; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	44	128	135	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12406	12414		10.1074/jbc.M212491200	http://dx.doi.org/10.1074/jbc.M212491200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547827	hybrid			2022-12-27	WOS:000182015700090
J	Liu, CH; Gaca, MDA; Swenson, ES; Vellucci, VF; Reiss, M; Wells, RG				Liu, CH; Gaca, MDA; Swenson, ES; Vellucci, VF; Reiss, M; Wells, RG			Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells - Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; RAT-LIVER; GENE-EXPRESSION; II RECEPTOR; SIGNALING PATHWAYS; IN-VIVO; FIBRONECTIN SYNTHESIS; CELLULAR SOURCES; CARCINOMA-CELLS; TRANSGENIC MICE	Hepatic stellate cells are the primary cell type. responsible for matrix deposition in liver fibrosis, undergoing a process of transdifferentiation into fibrogenic myofibroblasts. These cells, which undergo a similar transdifferentiation process when cultured in vitro, are a major target of the profibrogenic agent transforming growth factor-beta (TGF-beta). We have studied activation of the TGF-beta downstream signaling molecules Smads 2, 3, and 4 in hepatic stellate cells (HSC) cultured in vitro for 1, 4, and 7 days, with quiescent, intermediate, and fully transdifferentiated phenotypes, respectively. Total levels of Smad4, common to multiple TGF-beta superfamily signaling pathways, do not change as HSC transdifferentiate, and the protein is found in both nucleus and cytoplasm, independent of treatment with TGF-beta or the nuclear export inhibitor leptomycin B. TGF-beta mediates activation of Smad2 primarily in early cultured cells and that of Smad3 primarily in transdifferentiated cells. The linker protein SARA, which is required for Smad2 signaling, disappears with transdifferentiation. Additionally, day 7 cells demonstrate constitutive phosphorylation and nuclear localization of Smad 2, which is not affected by pretreatment with TGF-beta-neutralizing antibodies, a type I TGF-beta receptor kinase inhibitor, or activin-neutralizing antibodies. These results demonstrate essential differences between TGF-beta-mediated signaling pathways in quiescent and in vitro transdifferentiated hepatic stellate cells.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Wells, RG (corresponding author), Univ Penn, Sch Med, Dept Med Gastroenterol, 415 Curie Blvd,670 CRB 6140, Philadelphia, PA 19104 USA.	rgwells@mail.med.upenn.edu	Reiss, Michael/A-8314-2009	Reiss, Michael/0000-0001-8543-8092	NCI NIH HHS [CA41556] Funding Source: Medline; NIDDK NIH HHS [DK58123, DK34989] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R01DK058123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BACHEM MG, 1993, VIRCHOWS ARCH B, V63, P123, DOI 10.1007/BF02899251; BACHEM MG, 1989, FEBS LETT, V257, P134, DOI 10.1016/0014-5793(89)81804-6; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Bauer M, 2001, FEBS LETT, V502, P1, DOI 10.1016/S0014-5793(01)02655-2; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; DeBleser PJ, 1997, HEPATOLOGY, V26, P905; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; DIGIOVANNA MP, 1996, CURRENT PROTOCOLS MO, P1; Dooley S, 2001, BIOCHEM BIOPH RES CO, V283, P554, DOI 10.1006/bbrc.2001.4811; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Feldmann K, 2002, EUR J IMMUNOL, V32, P1393, DOI 10.1002/1521-4141(200205)32:5<1393::AID-IMMU1393>3.0.CO;2-M; Flanders KC, 2001, DEV DYNAM, V220, P141, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1096>3.0.CO;2-4; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; GRESSNER AM, 1994, PATHOL RES PRACT, V190, P864; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Kanzler S, 1999, AM J PHYSIOL-GASTR L, V276, pG1059, DOI 10.1152/ajpgi.1999.276.4.G1059; KNAGAKI Y, 2001, J CELL PHYSL, V187, P117; Knittel T, 1996, GASTROENTEROLOGY, V111, P745, DOI 10.1053/gast.1996.v111.pm8780581; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knittel T, 1996, HEPATOLOGY, V24, P352; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Lu SL, 1999, BIOCHEM BIOPH RES CO, V259, P385, DOI 10.1006/bbrc.1999.0788; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; MILANI S, 1995, J HEPATOL, V22, P71; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; RAMADORI G, 1992, GASTROENTEROLOGY, V103, P1313, DOI 10.1016/0016-5085(92)91522-6; Roberts AB, 2001, CHEST, V120, p43S, DOI 10.1378/chest.120.1_suppl.S43-a; Roulot D, 1999, HEPATOLOGY, V29, P1730, DOI 10.1002/hep.510290622; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; Sakou T, 1999, J BONE MINER RES, V14, P1145, DOI 10.1359/jbmr.1999.14.7.1145; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stopa M, 2000, MAMM GENOME, V11, P169, DOI 10.1007/s003350010032; Tahashi Y, 2002, HEPATOLOGY, V35, P49, DOI 10.1053/jhep.2002.30083; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ueno H, 2000, HUM GENE THER, V11, P33, DOI 10.1089/10430340050016139; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Wells RG, 2000, AM J PHYSIOL-GASTR L, V279, pG845, DOI 10.1152/ajpgi.2000.279.5.G845; WILLIAMS EJ, 2001, CELLS HEPATIC SINUSO, V8, P191; Wrana JL, 1999, HEPATOLOGY, V29, P1909, DOI 10.1002/hep.510290641; Wu DN, 2001, MOL CELL ENDOCRINOL, V175, P111, DOI 10.1016/S0303-7207(01)00397-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yan W, 2000, ONCOL RES, V12, P157; Yata Y, 2002, HEPATOLOGY, V35, P1022, DOI 10.1053/jhep.2002.32673; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	73	145	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11721	11728		10.1074/jbc.M207728200	http://dx.doi.org/10.1074/jbc.M207728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547835	hybrid			2022-12-27	WOS:000181855400107
J	Cordes, FS; Komoriya, K; Larquet, E; Yang, SX; Egelman, EH; Blocker, A; Lea, SM				Cordes, FS; Komoriya, K; Larquet, E; Yang, SX; Egelman, EH; Blocker, A; Lea, SM			Helical structure of the needle of the type III secretion system of Shigella flexneri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL FLAGELLAR FILAMENTS; PROTEIN SECONDARY STRUCTURE; RAY FIBER DIFFRACTION; SUPRAMOLECULAR STRUCTURE; ELECTRON CRYOMICROSCOPY; NEURAL NETWORKS; SALMONELLA; RECONSTRUCTION; PREDICTION; COMPLEX	Gram-negative bacteria commonly interact with animal and plant hosts using type III secretion systems (TTSSs) for translocation of proteins into eukaryotic cells during infection. 10 of the 25 TTSS-encoding genes are homologous to components of the bacterial flagellar basal body, which the TTSS needle complex morphologically resembles. This indicates a common ancestry, although no TTSS sequence homologues for the genes encoding the flagellum are found. We here present an similar to16-Angstrom structure of the central component, the needle, of the TTSS. Although the needle subunit is significantly smaller and shares no sequence homology with the flagellar hook and filament, it shares a common helical architecture (similar to5.6 subunits/turn, 24-Angstrom helical pitch). This common architecture implies that there will be further mechanistic analogies in the functioning of these two bacterial systems.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Inst Pasteur, F-75724 Paris, France; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Oxford; University of Oxford; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Virginia	Lea, SM (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.		larquet, eric/ABB-3063-2021; Lea, Susan M/B-7678-2009; Egelman, Edward H/A-2488-2009; yang, shixin/B-4015-2010; Blocker, Ariel/Q-6617-2016	larquet, eric/0000-0002-9994-6845; Lea, Susan M/0000-0001-9287-8053; yang, shixin/0000-0002-3639-7818; Egelman, Edward/0000-0003-4844-5212	NIGMS NIH HHS [GM66771] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; BLOCKER A, 2003, IN PRESS P NATL ACAD; CALLADINE CR, 1975, NATURE, V255, P121, DOI 10.1038/255121a0; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DEROSIER DJ, 1968, NATURE, V217, P130, DOI 10.1038/217130a0; DIXON MF, 2000, GEN SYSTEMATIC PATHO, P383; Donnenberg MS, 2000, NATURE, V406, P768, DOI 10.1038/35021212; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; MORGAN DG, 1993, J MOL BIOL, V229, P79, DOI 10.1006/jmbi.1993.1009; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; Szewzyk U, 2000, ANNU REV MICROBIOL, V54, P81, DOI 10.1146/annurev.micro.54.1.81; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Thomas D, 2001, J BACTERIOL, V183, P6404, DOI 10.1128/JB.183.21.6404-6412.2001; YAMASHITA I, 1991, J MOL BIOL, V217, P293, DOI 10.1016/0022-2836(91)90543-F; Yamashita I, 1998, J MOL BIOL, V278, P609, DOI 10.1006/jmbi.1998.1710; Yamashita I, 1998, NAT STRUCT BIOL, V5, P125; Yonekura K, 2001, J STRUCT BIOL, V133, P246, DOI 10.1006/jsbi.2000.4345; 2000, MERCK MANUAL DIAGNOS, P1164	28	154	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17103	17107		10.1074/jbc.M300091200	http://dx.doi.org/10.1074/jbc.M300091200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12571230	hybrid			2022-12-27	WOS:000182818600088
J	Anderson, LM; Choe, SE; Yukhananov, RY; Hopfner, RL; Church, GM; Pratt, RE; Dzau, VJ				Anderson, LM; Choe, SE; Yukhananov, RY; Hopfner, RL; Church, GM; Pratt, RE; Dzau, VJ			Identification of a novel set of genes regulated by a unique liver X receptor-alpha-mediated transcription mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENIN GENE; NUCLEAR RECEPTORS; IN-VIVO; MOLECULAR MECHANISM; TRANSGENIC MICE; HUMAN GENOME; FACTOR DECOY; LXR-ALPHA; EXPRESSION; PROTEIN	We have reported previously that liver X receptor-alpha (LXRalpha) can mediate a novel cAMP-dependent increase in renin and c-myc gene transcription by binding as a monomer to a unique regulatory element termed the cAMP-negative response element (CNRE). To determine whether this novel action of LXRalpha has global implications on gene regulation, we employed expression profiling to identify other genes regulated by this unique mechanism. Here we report the existence of a set of known and unknown transcripts regulated in parallel with renin. Querying the Celera Mouse Genome Assembly revealed that a majority of these genes contained the consensus CNRE. We have confirmed the functionality of these CNREs by competition for LXRalpha binding via electrophoretic mobility shift assays (EMSA) and by the use of CNRE decoy molecules documenting the abolishment of the cAMP-mediated gene induction. Taken together, these results demonstrate that the interaction between cAMP-activated LXRalpha and the CNRE enhancer element is responsible for widespread changes in gene expression and identify a set of LXRalpha/cAMP-regulated genes that may have important biological implications.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc Res, Lab Genet Physiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Anesthesiol, Neurogenomic Lab, Pain Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Pratt, RE (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Res, Lab Genet Physiol, 75 Francis St, Boston, MA 02115 USA.	rpratt@ries.bwh.harvard.edu; VDZAU@Partners.org		church, george/0000-0001-6232-9969; Choe, Sung/0000-0001-9140-4198	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL058516, R01HL035610, R01HL061661] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61661, HL58516, HL35610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BAXTER JD, 1991, RECENT PROG HORM RES, V47, P211; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; BURT DW, 1989, J BIOL CHEM, V264, P7357; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hamilton BA, 2001, CELL, V107, P13, DOI 10.1016/S0092-8674(01)00514-1; Harrington CA, 2000, CURR OPIN MICROBIOL, V3, P285, DOI 10.1016/S1369-5274(00)00091-6; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Murray GI, 2001, ANNU REV PHARMACOL, V41, P297, DOI 10.1146/annurev.pharmtox.41.1.297; Niesor EJ, 2001, CURR PHARM DESIGN, V7, P231, DOI 10.2174/1381612013398185; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pertea M, 2001, NUCLEIC ACIDS RES, V29, P1185, DOI 10.1093/nar/29.5.1185; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Stulnig TM, 2002, MOL PHARMACOL, V62, P1299, DOI 10.1124/mol.62.6.1299; Subramanian G, 2001, JAMA-J AM MED ASSOC, V286, P2296, DOI 10.1001/jama.286.18.2296; Takasaki N, 2001, MOL CELL BIOL, V21, P8197, DOI 10.1128/MCB.21.23.8197-8202.2001; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; TAMURA K, 2000, CIRCULATION S2, V18, P415; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tomita S, 1999, CIRC RES, V84, P1059, DOI 10.1161/01.RES.84.9.1059; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Xu GR, 1998, GENOMICS, V47, P171, DOI 10.1006/geno.1997.5072; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	36	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15252	15260		10.1074/jbc.M208644200	http://dx.doi.org/10.1074/jbc.M208644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12551904	hybrid			2022-12-27	WOS:000182516100087
J	Adessi, C; Frossard, MJ; Boissard, C; Fraga, S; Bieler, S; Ruckle, T; Vilbois, F; Robinson, SM; Mutter, M; Banks, WA; Soto, C				Adessi, C; Frossard, MJ; Boissard, C; Fraga, S; Bieler, S; Ruckle, T; Vilbois, F; Robinson, SM; Mutter, M; Banks, WA; Soto, C			Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PEPTIDES; IN-VIVO; FIBRIL FORMATION; PSEUDO-PROLINES; AMINO-ACIDS; RAT-BRAIN; METABOLISM; AMYLOIDOGENICITY; FIBRILLOGENESIS; CONFORMATION	Amyloid plaques in brain, composed of aggregates of amyloid-beta peptide, play a central role in the pathogenesis of Alzheimer's disease and represent a good target for treatment. We have shown previously that a 5-amino acid beta-sheet breaker peptide (iAbeta5p), end-protected, has the ability to induce a dramatic reduction in amyloid deposition in two different transgenic Alzheimer's models (Permanne, B., Adessi, C., Saborio, G. P., Fraga, S., Frossard, M.-J., Dewachter, I., Van Dorpe, J., Banks, W. A., Van Leuven, F., and Soto, C. (2002) FASEB J. 16, 860 - 862). The aim of this study was to evaluate the effect of chemical modifications of the peptide bonds at the metabolite cleavage sites on the pharmacological properties of iAbeta5p derivatives. Using a rational approach, peptide analogs were designed and tested for in vitro activity and enzymatic stability. One peptide analog containing a methyl group introduced at the nitrogen atom of one amide bond showed increased stability in vitro, a 10-fold higher in vivo half-life, and good brain uptake compared with iAbeta5p while maintaining a similar activity in vitro. Our results suggest that the pharmacological profile of beta-sheet breaker peptides can be improved to produce compounds with drug-like properties that might offer a new promise in the treatment of Alzheimer's disease.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland; St Louis Univ, Sch Med, Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, St Louis, MO 63106 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Geriatric Research Education & Clinical Center; Saint Louis University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Soto, C (corresponding author), Serono Pharmaceut Res Inst, Chemin Aulx,14 Plan Ouates, CH-1228 Geneva, Switzerland.	Claudio.Soto@serono.com	Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619				Adessi C, 2002, CURR MED CHEM, V9, P963, DOI 10.2174/0929867024606731; Al-Obeidi E, 1998, MOL BIOTECHNOL, V9, P205, DOI 10.1007/BF02915794; Banks W A, 1993, Rev Neurosci, V4, P365; Banks WA, 1996, LIFE SCI, V59, P1923, DOI 10.1016/S0024-3205(96)00380-3; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; FAUCHERE JL, 1986, ADV DRUG RES, V15, P29; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; KHOSLA MC, 1981, P NATL ACAD SCI-BIOL, V78, P757, DOI 10.1073/pnas.78.2.757; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MATSAS R, 1989, NEUROSCIENCE, V31, P237, DOI 10.1016/0306-4522(89)90046-8; Murphey LJ, 2000, CIRCULATION, V102, P829; Murphey LJ, 2000, J PHARMACOL EXP THER, V294, P263; Mutter M, 1999, BIOPOLYMERS, V51, P121, DOI 10.1002/(SICI)1097-0282(1999)51:2<121::AID-BIP2>3.0.CO;2-O; MUTTER M, 1995, PEPTIDE RES, V8, P145; NAGARAJ R, 1978, FEBS LETT, V96, P273, DOI 10.1016/0014-5793(78)80416-5; Permanne B, 2002, FASEB J, V16, P860, DOI 10.1096/fj.01-0841fje; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POWELL MF, 1993, ANNU REP MED CHEM, V28, P285; Schaller A, 1998, PHYTOCHEMISTRY, V47, P605, DOI 10.1016/S0031-9422(97)00523-2; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Sigurdsson EM, 2000, J NEUROPATH EXP NEUR, V59, P11, DOI 10.1093/jnen/59.1.11; Sommer B, 2002, CURR OPIN PHARMACOL, V2, P87, DOI 10.1016/S1471-4892(01)00126-6; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Sugawara M, 2001, SPECTROCHIM ACTA A, V57, P1305, DOI 10.1016/S1386-1425(00)00493-5; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; WALTER R, 1980, MOL CELL BIOCHEM, V30, P111; Wen JJ, 1997, J PEPT RES, V49, P3; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205	38	168	183	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13905	13911		10.1074/jbc.M211976200	http://dx.doi.org/10.1074/jbc.M211976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578830	hybrid			2022-12-27	WOS:000182405000045
J	Caplan, MR; Erickson, HP				Caplan, MR; Erickson, HP			Apparent cooperative assembly of the bacterial cell division protein FtsZ demonstrated by isothermal titration calorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GLUTAMATE-DEHYDROGENASE; INDUCED SELF-ASSOCIATION; CALF BRAIN TUBULIN; ESCHERICHIA-COLI; LIGHT-SCATTERING; POLYMERIZATION; SEDIMENTATION; EQUILIBRIUM; GTP	The assembly dynamics of FtsZ, a prokaryotic homolog of tubulin, are important for their role in bacterial cytokinesis. Here we used isothermal titration calorimetry (ITC) to measure the heat of FtsZ self-association under various conditions. The measurements were designed to test whether FtsZ protofilaments are assembled by an isodesmic (linear aggregates in which each bond has an identical equilibrium constant) or a cooperative (aggregates only become stable after forming a oligomeric nucleus) assembly process. The isodesmic model can fit the assembly in GDP closely but cannot fit the assembly in GTP. FtsZ-GTP without Mg2+ exhibits an apparent critical concentration, which is indicative of cooperative assembly, near 2.9 muM. With 2.5 mm Mg2+ (which allows FtsZ to hydrolyze GTP) the critical concentration is reduced 10-fold to similar to0.31 muM. Both with and without Mg2+ there is no evidence for assembly below the critical concentration, but there is an abrupt transition to full assembly above. The ITC data are highly suggestive of a cooperative assembly, although this is difficult to reconcile with the 1-subunit-thick protofilaments observed by electron microscopy.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Res Dr,POB 3709, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu			NIGMS NIH HHS [GM066014] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ET, 1968, BIOCHEMISTRY-US, V7, P1044, DOI 10.1021/bi00843a025; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; Erickson HP, 2000, J CELL BIOL, V148, P1103, DOI 10.1083/jcb.148.6.1103; ERICKSON HP, 1981, BIOPHYS J, V34, P293, DOI 10.1016/S0006-3495(81)84850-3; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4567, DOI 10.1021/bi00692a002; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4559, DOI 10.1021/bi00692a001; Levin PA, 1996, GENE DEV, V10, P478, DOI 10.1101/gad.10.4.478; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 1998, J STRUCT BIOL, V124, P235, DOI 10.1006/jsbi.1998.4041; Lu CL, 1997, PROTEIN EXPRES PURIF, V11, P179, DOI 10.1006/prep.1997.0775; Lutkenhaus J, 1998, CURR BIOL, V8, pR619, DOI 10.1016/S0960-9822(98)70391-4; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 2000, FEMS MICROBIOL REV, V24, P531, DOI 10.1016/S0168-6445(00)00038-3; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; REISLER E, 1970, BIOCHEMISTRY-US, V9, P3095, DOI 10.1021/bi00817a600; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; THUSIUS D, 1975, J MOL BIOL, V92, P413, DOI 10.1016/0022-2836(75)90289-2; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; WANG XD, 1993, MOL MICROBIOL, V9, P435, DOI 10.1111/j.1365-2958.1993.tb01705.x; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000	28	51	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13784	13788		10.1074/jbc.M300860200	http://dx.doi.org/10.1074/jbc.M300860200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566454	hybrid			2022-12-27	WOS:000182405000029
J	Detarsio, E; Wheeler, MCG; Bermudez, VAC; Andreo, CS; Drincovich, MF				Detarsio, E; Wheeler, MCG; Bermudez, VAC; Andreo, CS; Drincovich, MF			Maize C(4)NADP-malic enzyme - Expression in Escherichia coli and characterization of site-directed mutants at the putative nucleotide-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADP-MALIC ENZYME; CRYSTAL-STRUCTURE; DINUCLEOTIDE; PURIFICATION; PROTEINS; ISOFORMS; DISTINCT; TISSUES; C-3; C4	Malic enzymes catalyze the oxidative decarboxylation Of L-malate to yield pyruvate, CO2, and NAD(P)H in the presence of a bivalent metal ion. In plants, different isoforms of the NADP-malic enzyme (NADP-ME) are involved in a wide range of metabolic pathways. The C-4-specific NADP-ME has evolved from C-3-type malic enzymes to represent a unique and specialized form of NADP-ME as indicated by its particular kinetic and regulatory properties. In the present study, the mature C-4- specific NADP-ME of maize was expressed in Escherichia coli. The recombinant enzyme has essentially the same physicochemical properties and K-m for the substrates as those of the naturally occurring NADP-ME previously characterized. However, the k(cat) was almost 7-fold higher, which may suggest that the previously purified enzyme from maize leaves was partially inactive. The recombinant NADP-ME also has a very low intrinsic NAD-dependent activity. Five mutants of NADP-ME at the postulated putative NADP-binding site(s) (Gsite5V, Gsite2V, A392G, A387G, and R237L) were constructed by site-directed mutagenesis and purified to homogeneity. The participation of these residues in substrate binding and/or the catalytic reaction was inferred by kinetic measurements and circular dichroism and intrinsic fluorescence spectra. The results obtained were compared with a predicted three-dimensional model of maize C-4 NADP-ME based on crystallographic studies of related animal NAD(P)-MEs. The data presented here represent the first prokaryotic expression of a plant NADP-ME and reveals valuable insight regarding the participation of the mutated amino acids in the binding of substrates and/or catalysis.	Univ Nacl Rosario, CEFOBI, CONICET, RA-2000 Rosario, Argentina	National University of Rosario	Andreo, CS (corresponding author), Univ Nacl Rosario, CEFOBI, CONICET, Fund M Lillo,Suipacha 531, RA-2000 Rosario, Argentina.	candreo@fbioyf.unr.edu.ar	Drincovich, Maria F/Q-4195-2019; Drincovich, Maria F/F-3902-2017	Drincovich, Maria F/0000-0003-4897-3285; Drincovich, Maria F/0000-0003-4897-3285; Campos Bermudez, Valeria/0000-0003-0135-6482				Ashton AR, 1997, ARCH BIOCHEM BIOPHYS, V345, P251, DOI 10.1006/abbi.1997.0260; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Coleman DE, 2002, BIOCHEMISTRY-US, V41, P6928, DOI 10.1021/bi0255120; Drincovich MF, 1995, BIOCHEM MOL BIOL INT, V36, P1287; DRINCOVICH MF, 1991, PHYSIOL PLANTARUM, V81, P462; Drincovich MF, 2001, FEBS LETT, V490, P1, DOI 10.1016/S0014-5793(00)02331-0; Edwards G., 1983, C3 C4 MECH CELLULAR; EDWARDS GE, 1992, PHYTOCHEMISTRY, V31, P1845, DOI 10.1016/0031-9422(92)80322-6; GROVER SD, 1981, ARCH BIOCHEM BIOPHYS, V209, P396, DOI 10.1016/0003-9861(81)90297-6; HANSEN EJ, 1975, BIOCHEM BIOPH RES CO, V65, P559, DOI 10.1016/S0006-291X(75)80183-5; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HATCH MD, 1977, ARCH BIOCHEM BIOPHYS, V179, P361, DOI 10.1016/0003-9861(77)90123-0; Kuo CC, 2000, BIOCHEM BIOPH RES CO, V270, P821, DOI 10.1006/bbrc.2000.2502; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai LB, 2002, PLANT PHYSIOL, V128, P125, DOI 10.1104/pp.010448; Maurino VG, 1997, J EXP BOT, V48, P799, DOI 10.1093/jxb/48.3.799; Maurino VG, 1996, BIOCHEM MOL BIOL INT, V38, P239; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO SR, 1991, PHYTOCHEMISTRY, V30, P431, DOI 10.1016/0031-9422(91)83699-L; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROTHERMEL BA, 1989, J BIOL CHEM, V264, P19587; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Sheen J, 1999, ANNU REV PLANT PHYS, V50, P187, DOI 10.1146/annurev.arplant.50.1.187; Spampinato CP, 1998, BBA-PROTEIN STRUCT M, V1383, P245, DOI 10.1016/S0167-4838(97)00214-8; SPINA J, 1970, BIOCHEMISTRY-US, V9, P3794, DOI 10.1021/bi00821a019; Takeuchi K, 2000, PLANTA, V211, P265, DOI 10.1007/s004250000282; Tausta SL, 2002, PLANT MOL BIOL, V50, P635, DOI 10.1023/A:1019998905615; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2000, NAT STRUCT BIOL, V7, P251; Yang ZR, 2002, PROTEIN SCI, V11, P332, DOI 10.1110/ps.38002	35	48	52	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13757	13764		10.1074/jbc.M212530200	http://dx.doi.org/10.1074/jbc.M212530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562758	hybrid			2022-12-27	WOS:000182405000026
J	Salinas, M; Diaz, R; Abraham, NG; de Galarreta, CMR; Cuadrado, A				Salinas, M; Diaz, R; Abraham, NG; de Galarreta, CMR; Cuadrado, A			Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISMUTASE GENE-EXPRESSION; MEDIATED CELL-DEATH; PC12 CELLS; SUPEROXIDE-PRODUCTION; PARKINSONS-DISEASE; MESSENGER-RNA; RAT-BRAIN; KINASE-B; NEURONS; OVEREXPRESSION	The survival signal elicited by the phosphatidylinositol 3-kinase (PI3K)/Akt1 pathway has been correlated with inactivation of pro-apoptotic proteins and attenuation of the general stress-induced increase in reactive oxygen species (ROS). However, the mechanisms by which this pathway regulates intracellular ROS levels remain largely unexplored. In this study, we demonstrate that nerve growth factor (NGF) prevents the accumulation of ROS in dopaminergic PC12 cells challenged with the Parkinson's disease-related neurotoxin 6-hydroxydopamine (6-OHDA) by a mechanism that involves PI3K/Akt-dependent induction of the stress response protein heme oxygenase-1 (HO-1). The effect of NGF was mimicked by induction of HO-1 expression with CoCl2,; by treatment with bilirubin, an end product of heme catabolism; and by infection with a retroviral expression vector for human HO-1. The relevance of HO-1 in NGF-induced ROS reduction was further demonstrated by the evidence that cells treated with the HO-1 inhibitor tin-protoporphyrin or infected with a retroviral expression vector for antisense HO-1 exhibited enhanced ROS release in response to 6-OHDA, despite the presence of the neurotrophin. Inhibition of PI3K prevented NGF induction of HO-1 mRNA and protein and partially reversed its protective effect against 6-OHDA-induced ROS release. By contrast, cells transfected with a membrane-targeted active version of Akt1 exhibited increased HO-1 expression, even in the absence of NGF, and displayed a greatly attenuated production of ROS and apoptosis in response to 6-OHDA. These observations indicate that the PI3K/Akt pathway controls the intracellular levels of ROS by regulating the expression of the antioxidant enzyme HO-1.	Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Palmas Gran Canaria, Fac Med, Dept Bioquim, Gran Canaria 35016, Spain; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	Autonomous University of Madrid; Autonomous University of Madrid; Universidad de Las Palmas de Gran Canaria; New York Medical College	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Bioquim, Arzobispo Morcillo 4, E-28029 Madrid, Spain.	antonio.cuadrado@uam.es		Cuadrado, Antonio/0000-0002-4039-7140; Cuadrado, Antonio/0000-0002-3444-9012				Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Dennery PA, 2000, CURR TOP CELL REGUL, V36, P181; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Goldshmit Y, 2001, J BIOL CHEM, V276, P46379, DOI 10.1074/jbc.M105637200; Gourley G R, 1997, Adv Pediatr, V44, P173; Hegyi T, 1994, J Perinatol, V14, P296; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Kirschner PB, 1996, BRAIN RES, V713, P178, DOI 10.1016/0006-8993(95)01513-2; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Lotharius J, 1999, J NEUROSCI, V19, P1284; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Ohashi T, 2002, FEBS LETT, V511, P21, DOI 10.1016/S0014-5793(01)03262-8; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Panahian N, 1999, J NEUROCHEM, V72, P1187; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Quan SO, 2001, P NATL ACAD SCI USA, V98, P12203, DOI 10.1073/pnas.211399398; Rubboli G, 1997, NEUROPEDIATRICS, V28, P281, DOI 10.1055/s-2007-973715; Ryter SW, 2000, METH MOL B, V99, P369; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Sampath D, 1997, NEUROCHEM RES, V22, P351, DOI 10.1023/A:1027387105882; Satoh T, 1999, J BIOCHEM-TOKYO, V125, P952, DOI 10.1093/oxfordjournals.jbchem.a022374; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; TABU J, 1999, NATURE, V399, P162; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; Takeda A, 2000, J BIOL CHEM, V275, P5395, DOI 10.1074/jbc.275.8.5395; Volti GL, 2002, BIOCHEM BIOPH RES CO, V296, P1077, DOI 10.1016/S0006-291X(02)02054-5; Wang W, 1999, NEUROSCI LETT, V259, P115, DOI 10.1016/S0304-3940(98)00929-X; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200	50	213	222	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13898	13904		10.1074/jbc.M209164200	http://dx.doi.org/10.1074/jbc.M209164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578834	Green Published, hybrid			2022-12-27	WOS:000182405000044
J	Vukmirica, J; Tran, K; Liang, XQ; Shan, J; Yuan, J; Miskie, BA; Hegele, RA; Resh, MD; Yao, ZM				Vukmirica, J; Tran, K; Liang, XQ; Shan, J; Yuan, J; Miskie, BA; Hegele, RA; Resh, MD; Yao, ZM			Assembly and secretion of very low density lipoproteins containing apolipoprotein B48 in transfected McA-RH7777 cells - Lack of evidence that palmitoylation of apolipoprotein B48 is required for lipoprotein secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; NITRIC-OXIDE SYNTHASE; ACYLATION; PHOSPHORYLATION; IDENTIFICATION; CAVEOLAE; B100	We examined the role of S-linked palmitoylation of human apolipoprotein (apo) B in the assembly and secretion of very low density lipoproteins using recombinant human apoB48. There are four free cysteine residues (Cys(1085), Cys(1396), Cys(1478), and Cys(1635)) within apoB48 that potentially can be palmitoylated. All four cysteine residues were substituted with serine by site-specific mutagenesis. The mutant protein was expressed in transfected rat hepatoma McA-RH7777 cells. Metabolic labeling of the stably transfected cells with iodo-palmitic acid analog showed that the mutant apoB48 lacked palmitoylation. The lack of palmitoylation had little impact on the ability of apoB48 to assemble and secrete,very low density lipoproteins or high density lipoproteins. Immunocytochemistry experiments using confocal microscopy failed to reveal any major alterations in the intracellular distribution of the mutant apoB48 at steady state. Pulse-chase analysis combined with subcellular fractionation showed no apparent deficiency in the movement of the mutant apoB48 protein from the endoplasmic reticulum to cis/medial Golgi. However, the mutant apoB48 lacking palmitoylation showed retarded movement toward the distal Golgi and increased association (>2-fold) with the membranes of the secretory compartments. A marginal decrease (by 15-20%) in secretion efficiency as compared with that of wild type apoB48 was also observed. These results suggest that lack of palmitoylation may influence the partitioning of apoB48 between microsomal membranes and microsomal lumen, but it does not compromise the ability of apoB48 to assemble lipoproteins.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1H 8M5, Canada; Cornell Univ, Weill Grad Sch Med Sci, Cell Biol Program, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Biochem & Struct Biol, New York, NY 10021 USA; Robarts Res Inst, London, ON N6A 5K8, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Western University (University of Western Ontario)	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.		Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020	Hegele, Robert/0000-0003-2861-5325; Resh, Marilyn/0000-0001-6118-9466	NIGMS NIH HHS [GM 57966] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; GABEL B, 1994, FEBS LETT, V350, P77, DOI 10.1016/0014-5793(94)00737-3; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; HOEG JM, 1988, J LIPID RES, V29, P1215; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Tran K, 2000, J BIOL CHEM, V275, P25023, DOI 10.1074/jbc.M908971199; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhao Y, 2000, MOL BIOL CELL, V11, P721, DOI 10.1091/mbc.11.2.721	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14153	14161		10.1074/jbc.M211995200	http://dx.doi.org/10.1074/jbc.M211995200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582154	hybrid			2022-12-27	WOS:000182405000076
J	Campbell, KP; Stull, JT				Campbell, KP; Stull, JT			Skeletal muscle basement membrane-sarcolemma-cytoskeleton interaction minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MUSCULAR-DYSTROPHIES; FORM		Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol, Iowa City, IA 52242 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 400 EMRB, Iowa City, IA 52242 USA.			Campbell, Kevin/0000-0003-2066-5889				Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Brown SC, 2001, BRAIN PATHOL, V11, P193; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DURBEEJ M, 2002, CURR OPIN GENE DEV, V95, P2019; Engel A., 1994, MYOLOGY; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; MICHELE DE, 2003, J BIOL CHEM     0129; Sanes JR, 2003, J BIOL CHEM, V278, P12601, DOI 10.1074/jbc.R200027200; Spence HJ, 2002, BIOESSAYS, V24, P542, DOI 10.1002/bies.10098	12	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12599	12600		10.1074/jbc.R300005200	http://dx.doi.org/10.1074/jbc.R300005200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556456	hybrid			2022-12-27	WOS:000182189500001
J	Hilton, TL; Wang, EH				Hilton, TL; Wang, EH			Transcription factor IID recruitment and sp1 activation - Dual function of Taf1 in cyclin D1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEIN; RNA-POLYMERASE-II; PROMOTER SELECTIVITY; GENE; CELLS; EXPRESSION; UPSTREAM; REGION; TAF(II)250; ELEMENTS	Cyclin D1 is an oncogene that regulates progression through the G(1) phase of the cell cycle. A temperature-sensitive missense mutation in the transcription factor TAF1/TAF(II)250 induces the mutant ts13 cells to arrest in late G(1) by decreasing transcription of cell cycle regulators, including cyclin D1. Here we provide evidence that TAF1 serves two independent functions, one at the core promoter and one at the upstream activating Sp1 sites of the cyclin D1 gene. Using in vivo genomic footprinting, we have identified protein-DNA interactions within the cyclin D1 core promoter that are disrupted upon inactivation of TAF1 in ts13 cells. This 33-bp segment, which we termed the TAF1-dependent element 1 (TDE1), contains an initiation site that displays homology to the consensus motif and is sufficient to confer a requirement for TAF1 function. Electrophoretic mobility shift assays reveal that binding of ts13-TAF1-containing TFIID complexes to the cyclin D1 TDE1 occurs at 25 degreesC but not at 37 degreesC in vitro and involves the initiator element. Temperature-dependent DNA binding activity is also observed for TAF1-TAF2 heterodimers assembled with the ts13 mutant but not the wild-type TAF1 protein. These data suggest that a function of TAF is required for the interaction of TFIID with the cyclin D1 initiator. Our finding that recruitment of TFIID, by insertion of a TBP binding site upstream of the TDE1, restores basal but not activated transcription supports the model that TAF1 carries out two independent functions at the cyclin D1 promoter.	Univ Washington, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wang, EH (corresponding author), Univ Washington, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	ehwang@u.washington.edu			NIGMS NIH HHS [GM7750] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen JL, 1996, METHOD ENZYMOL, V273, P208; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Eto I, 2000, CELL PROLIFERAT, V33, P167, DOI 10.1046/j.1365-2184.2000.00176.x; HAYASHIDA T, 1994, GENE, V141, P267; HERBER B, 1994, ONCOGENE, V9, P1295; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; LIU HT, 1985, J BIOL CHEM, V260, P3269; MANTOVANI R, 1993, NUCLEIC ACIDS RES, V21, P4873, DOI 10.1093/nar/21.21.4873; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Mencia M, 2001, MOL CELL BIOL, V21, P1145, DOI 10.1128/MCB.21.4.1145-1154.2001; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MUELLER PR, 1992, CURRENT PROTOCOLS MO; MURRAY A, 1993, CELL CYCLE; Musgrove EA, 1996, J MAMMARY GLAND BIOL, V1, P153, DOI 10.1007/BF02013639; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nakamura S, 1997, PATHOL INT, V47, P421, DOI 10.1111/j.1440-1827.1997.tb04519.x; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Perry JE, 1998, PROSTATE, V35, P117; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Strauss EC, 1997, METHODS, V11, P164, DOI 10.1006/meth.1996.0402; Sutherland RL, 2002, BREAST CANCER RES, V4, P14, DOI 10.1186/bcr411; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; Tsukihashi Y, 2001, J BIOL CHEM, V276, P25715, DOI 10.1074/jbc.M102416200; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zerby D, 1997, METHODS, V12, P217, DOI 10.1006/meth.1997.0474	49	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12992	13002		10.1074/jbc.M300412200	http://dx.doi.org/10.1074/jbc.M300412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569092	hybrid			2022-12-27	WOS:000182189500052
J	Sugimoto, H; Hamano, Y; Charytan, D; Cosgrove, D; Kieran, M; Sudhakar, A; Kalluri, R				Sugimoto, H; Hamano, Y; Charytan, D; Cosgrove, D; Kieran, M; Sudhakar, A; Kalluri, R			Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REMNANT KIDNEY MODEL; GLOMERULAR-PERMEABILITY; SLIT DIAPHRAGM; IMPAIRED ANGIOGENESIS; AMNIOTIC-FLUID; FACTOR FAMILY; MOUSE KIDNEY; NEPHRIN; EXPRESSION; GENE	There are about 2.5 million glomeruli in the kidneys each consisting of a barrel of glomerular basement membrane surrounded by glomerular endothelial cells on the inside and glomerular epithelial cells with established foot processes (podocytes) on the outside. Defects in this filtration apparatus lead to glomerular vascular leak or proteinuria. The role of vascular endothelial growth factor (VEGF) in the regulation of glomerular vascular permeability is still unclear. Recent studies indicate that patients receiving anti-VEGF antibody therapy may have an increased incidence of proteinuria. In a different setting, pregnancies complicated by preeclampsia are associated with elevated soluble VEGF receptor 1 protein (sFIt-1), endothelial cell dysfunction and proteinuria. These studies suggest that neutralization of physiologic levels of VEGF, a key endothelial survival factor, may lead to proteinuria. In the present study, we evaluated the potential of anti-VEGF neutralizing antibodies and sFlt-1 in the induction of proteinuria. Our studies demonstrate that anti-VEGF antibodies and sFIt-1 cause rapid glomerular endothelial cell detachment and hypertrophy, in association with down-regulation of nephrin, a key epithelial protein in the glomerular filtration apparatus. These studies suggest that down-regulation or neutralization of circulating VEGF may play an important role in the induction of proteinuria in various kidney diseases, some forms of cancer therapy and also in women with preeclampsia.	Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Gastroenterol, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Nephrol, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Nephrol, Ctr Canc, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Gastroenterol, Ctr Canc, Boston, MA 02215 USA; Boys Town Natl Res Hosp, Gene Express Lab, Omaha, NE 68131 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boys Town National Research Hospital; Harvard University; Dana-Farber Cancer Institute	Kalluri, R (corresponding author), Harvard Univ, Sch Med, DANA 514,330 Brookline Ave, Boston, MA 02215 USA.	rkalluri@bidme.harvard.edu	; Kalluri, Raghu/E-2677-2015	charytan, david/0000-0002-7695-3583; Kieran, Mark/0000-0003-2184-7692; Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [T32DK07199-25, DK 55001, DK-51711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007199, R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680; Benigni A, 2001, J AM SOC NEPHROL, V12, P941, DOI 10.1681/ASN.V125941; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; BROWN LF, 1997, EXS, V79, P233; BULGER RE, 1983, J CLIN INVEST, V72, P128, DOI 10.1172/JCI110950; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CAULFIEL.JP, 1974, J CELL BIOL, V63, P883, DOI 10.1083/jcb.63.3.883; CAULFIELD JP, 1975, J EXP MED, V142, P61, DOI 10.1084/jem.142.1.61; Cosgrove D, 2000, AM J PATHOL, V157, P1649, DOI 10.1016/S0002-9440(10)64802-X; Deen WM, 2001, AM J PHYSIOL-RENAL, V281, pF579; Fan LY, 2002, NEPHRON, V90, P95, DOI 10.1159/000046320; Farquhar MG, 1999, J AM SOC NEPHROL, V10, P2645; Feng D, 2000, J HISTOCHEM CYTOCHEM, V48, P545, DOI 10.1177/002215540004800412; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; GRAHAM RC, 1966, J EXP MED, V124, P1123, DOI 10.1084/jem.124.6.1123; Hamano Y, 2002, J BIOL CHEM, V277, P31154, DOI 10.1074/jbc.M204806200; Hasumi Y, 2002, CANCER RES, V62, P2019; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Honkanen EO, 2000, KIDNEY INT, V57, P2343, DOI 10.1046/j.1523-1755.2000.00094.x; JONES DB, 1985, LAB INVEST, V52, P453; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kang DH, 2001, J AM SOC NEPHROL, V12, P1434, DOI 10.1681/ASN.V1271434; Kang DH, 2001, J AM SOC NEPHROL, V12, P1448, DOI 10.1681/ASN.V1271448; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; KRISTAL B, 1988, AM J NEPHROL, V8, P198, DOI 10.1159/000167583; Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959; Langham RG, 2002, DIABETOLOGIA, V45, P1572, DOI 10.1007/s00125-002-0946-y; OLIVER C, 1972, J EXP MED, V136, P291, DOI 10.1084/jem.136.2.291; Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740; Pridjian G, 2002, OBSTET GYNECOL SURV, V57, P598, DOI 10.1097/00006254-200209000-00023; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Rantanen M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016142.29721.22; RENNKE HG, 1977, FED PROC, V36, P2619; RENNKE HG, 1977, KIDNEY INT, V11, P44, DOI 10.1038/ki.1977.6; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SCHNEEBERGER EE, 1975, KIDNEY INT, V8, P48, DOI 10.1038/ki.1975.75; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simon M, 1998, J AM SOC NEPHROL, V9, P1032; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VENKATACHALAM MA, 1970, J EXP MED, V132, P1153, DOI 10.1084/jem.132.6.1153; Vuorela P, 2000, OBSTET GYNECOL, V95, P353, DOI 10.1016/S0029-7844(99)00565-7; Vuorela-Vepsalainen P, 1999, HUM REPROD, V14, P1346, DOI 10.1093/humrep/14.5.1346; Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583; Wong AK, 2001, P NATL ACAD SCI USA, V98, P7481, DOI 10.1073/pnas.121192298; Yang WG, 2001, CANCER RES, V61, P7840; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9	56	433	470	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12605	12608		10.1074/jbc.C300012200	http://dx.doi.org/10.1074/jbc.C300012200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12538598	hybrid			2022-12-27	WOS:000182189500003
J	Ferreira-Pereira, A; Marco, S; Decottignies, A; Nader, J; Goffeau, A; Rigaud, JL				Ferreira-Pereira, A; Marco, S; Decottignies, A; Nader, J; Goffeau, A; Rigaud, JL			Three-dimensional reconstruction of the Saccharomyces cerevisiae multidrug resistance protein Pdr5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAINS; YEAST ABC PROTEINS; P-GLYCOPROTEIN; ELECTRON-MICROSCOPY; CYSTIC-FIBROSIS; BIOLOGICAL MACROMOLECULES; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE	Pdr5p, the major multidrug exporter in Saccharomyces cerevisiae, is a member of the ATP-binding cassette (ABC) superfamily. Pdr5p shares similar mechanisms of substrate recognition and transport with the human MDR1-Pgp, despite an inverted topology of transmembrane and ATP-binding domains. The hexahistidine-tagged Pdr5p multidrug transporter was highly overexpressed in yeast strains where other ABC genes have been deleted. After solubilization and purification, the 160-kDa recombinant Pdr5p has been reconstituted into a lipid bilayer. Controlled detergent removal from Pdr5p-lipid-detergent micelles allowed the production of peculiar square-shaped particles coexisting with liposomes and proteoliposomes. These particles having 11 nm in side were well suited for single particle analysis by electron microscopy. From such analysis, a computed volume has been determined at 25-Angstrom resolution, giving insight into the structural organization of Pdr5p. Comparison with the reported structures of different bacterial ABC transporters was consistent with a dimeric organization of Pdr5p in the square particles. Each monomer was composed of three subregions corresponding to a membrane region of about 50 Angstrom in height that joins two well separated protruding stalks of about 40 Angstrom in height, ending each one with a cytoplasmic nucleotide-binding domain (NBD) lobe of about 50-60 Angstrom in diameter. The three-dimensional reconstruction of Pdr5p revealed a close arrangement and a structural asymmetric organization of the two NBDs that appeared oriented perpendicularly within a monomer. The existence of different angular positions of the NBDs, with respect to the stalks, suggest rotational movements during the catalytic cycle.	Inst Curie, CNRS, Sect Rech, Unite Mixte Rech 168, F-75231 Paris 05, France; Commissariat Energie, Lab Rech Correspondant, F-75231 Paris 05, France; Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Microbiol, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Fac Farm, Dept Anal Clin & Toxicol, BR-21949900 Rio De Janeiro, Brazil; Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universite Catholique Louvain	Marco, S (corresponding author), Inst Curie, CNRS, Sect Rech, Unite Mixte Rech 168, 11 Rue Pierre & Marie Curie, F-75231 Paris 05, France.	sergio.marco@curie.fr	Ferreira-Pereira, Antonio/A-2910-2011; marco, SERGIO/E-4875-2017; marco garrido, sergio/F-5876-2013	Ferreira-Pereira, Antonio/0000-0002-0474-8388; 				Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Conseil G, 2001, BIOCHEMISTRY-US, V40, P2564, DOI 10.1021/bi002453m; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kolaczkowski M, 1997, PHARMACOL THERAPEUT, V76, P219, DOI 10.1016/S0163-7258(97)00094-6; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; LEPPERT G, 1990, GENETICS, V125, P13; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Manciu L, 2003, J BIOL CHEM, V278, P3347, DOI 10.1074/jbc.M207963200; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; Mullick R, 1998, ANN M SOC COMP APPL; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Proff C, 2001, MOL GEN GENET, V264, P883, DOI 10.1007/s004380000378; Rao G. Subba, 2002, Functional and Integrative Genomics, V1, P357; Rogers B, 2001, J MOL MICROB BIOTECH, V3, P207; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Soszynski M, 1998, ARCH BIOCHEM BIOPHYS, V354, P311, DOI 10.1006/abbi.1998.0687; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; van Veen HW, 2001, J MOL MICROB BIOTECH, V3, P185; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; Velarde G, 2001, J BIOL CHEM, V276, P46054, DOI 10.1074/jbc.M108435200; Wang EJ, 2000, BIOCHEM BIOPH RES CO, V276, P909, DOI 10.1006/bbrc.2000.3554	61	49	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11995	11999		10.1074/jbc.M212198200	http://dx.doi.org/10.1074/jbc.M212198200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551908	hybrid			2022-12-27	WOS:000182015700037
J	Herron, SR; Scavetta, RD; Garrett, M; Legner, M; Jurnak, F				Herron, SR; Scavetta, RD; Garrett, M; Legner, M; Jurnak, F			Characterization and implications of Ca2+ binding to pectate lyase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERWINIA-CHRYSANTHEMI EC16; PLANT VIRULENCE FACTOR; ELECTRON-DENSITY MAPS; 3-DIMENSIONAL STRUCTURE; TISSUE MACERATION; CELL-WALLS; CALCIUM; PROTEINS; PATHOGENICITY; ENZYMES	Ca2+ is essential for in vitro activity of Erwinia chrysanthemi pectate lyase C (PeIC). Crystallographic analyses of 11 PelC-Ca2+ complexes, formed at pH 4.5, 9.5, and 11.2 under varying Ca2+ concentrations, have been solved and refined at a resolution of 2.2 Angstrom. The Ca2+ site represents a new motif for Ca2+, consisting primarily of beta-turns and beta-strands. The principal differences between PelC and the PelC-Ca2+ structures at all pH values are the side-chain conformations of Asp-129 and Glu-166 as well as the occupancies of four water molecules. According to calculations of pK(a) values, the presence of Ca2+ and associated structural changes lower the pK(a) of Arg-218, the amino acid responsible for proton abstraction during catalysis. The Ca2+ affinity for PelC is weak, as the K-d was estimated to be 0.132 (+/- 0.004) m(M) at pH 9.5, 1.09 (+/- 0.29) m(M) at pH 11.2, and 5.84 (+/- 0.41) m(M) at pH 4.5 from x-ray diffraction studies and 0.133 (+/- 0.045) m(M) at pH 9.5 from intrinsic tryptophan fluorescence measurements. Given the pH dependence of Ca2+ affinity, PelC activity at pH 4.5 has been reexamined. At saturating Ca2+ concentrations, PelC activity increases 10-fold at pH 4.5 but is less than 1% of maximal activity at pH 9.5. Taken together, the studies suggest that the primary Ca2+ ion in PelC has multiple functions.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92612 USA	University of California System; University of California Irvine	Jurnak, F (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, D-350 Med Sci Bldg 1, Irvine, CA 92612 USA.							Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; BOCCARA M, 1988, PHYSIOL MOL PLANT P, V33, P95, DOI 10.1016/0885-5765(88)90046-X; BOCCARA M, 1989, J BACTERIOL, V171, P4085, DOI 10.1128/jb.171.7.4085-4087.1989; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BRUNGER AT, 1996, X PLOR VERSION 3 8; CARRELL CJ, 1988, J AM CHEM SOC, V110, P8651, DOI 10.1021/ja00234a011; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; CRAWFORD MS, 1987, ARCH BIOCHEM BIOPHYS, V258, P196, DOI 10.1016/0003-9861(87)90336-5; DELORENZO G, 1991, PHYSIOL MOL PLANT P, V39, P335, DOI 10.1016/0885-5765(91)90015-A; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVENS SV, 1993, J MOL GRAPHICS, V11, P134; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; HEFFRON S, 1995, MOL PLANT MICROBE IN, V8, P331, DOI 10.1094/MPMI-8-0331; HENRISSAT B, 1995, PLANT PHYSIOL, V107, P963, DOI 10.1104/pp.107.3.963; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; HERRON SR, 2002, IN PRESS PECTINS PEC; HOTCHKISS AT, 1993, CARBOHYD RES, V247, P1, DOI 10.1016/0008-6215(93)84236-Y; Hotchkiss AT, 1996, PHYSIOL MOL PLANT P, V48, P1, DOI 10.1006/pmpp.1996.0001; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kita N, 1996, J BIOL CHEM, V271, P26529, DOI 10.1074/jbc.271.43.26529; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIETZKE SE, 1994, PLANT PHYSIOL, V106, P849, DOI 10.1104/pp.106.3.849; LIM C, 1991, J PHYS CHEM-US, V95, P5610, DOI 10.1021/j100167a045; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pidcock E, 2001, J BIOL INORG CHEM, V6, P479, DOI 10.1007/s007750100214; Ried J. L., 1988, Molecular Plant-Microbe Interactions, V1, P32, DOI 10.1094/MPMI-1-032; RIHOUEY C, 1995, PLANT PHYSIOL BIOCH, V33, P497; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; TAMAKI SJ, 1988, J BACTERIOL, V170, P3468, DOI 10.1128/jb.170.8.3468-3478.1988; Tardy F, 1997, J BACTERIOL, V179, P2503, DOI 10.1128/jb.179.8.2503-2511.1997; THURN KK, 1985, APPL ENVIRON MICROB, V50, P894, DOI 10.1128/AEM.50.4.894-898.1985; VIRK SS, 1988, PLANTA, V176, P60, DOI 10.1007/BF00392480; WILSON AJC, 1942, NATURE, V150, P90; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; YODER MD, 1995, PLANT PHYSIOL, V107, P349, DOI 10.1104/pp.107.2.349; YODER MD, 1990, J BIOL CHEM, V265, P11429; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; ZUKER M, 1970, J BACTERIOL, V104, P13; [No title captured]	48	44	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12271	12277		10.1074/jbc.M209306200	http://dx.doi.org/10.1074/jbc.M209306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540845	hybrid			2022-12-27	WOS:000182015700072
J	Kirsch, M; Fuchs, A; de Groot, H				Kirsch, M; Fuchs, A; de Groot, H			Regiospecific nitrosation of N-terminal-blocked tryptophan derivatives by N2O3 at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; S-NITROSYLATION; CREATINE-KINASE; PEROXYNITRITE; NITROSOTHIOLS; MECHANISM; OXIDATION; KINETICS; CALCIUM; AMINES	N2O3 formed from nitric oxide in the presence of oxygen attacks thiols in proteins to yield S-nitrosothiols, which are believed to play a central role in NO signaling. In the present study we examined the N-nitrosation of N-terminal-blocked (N-blocked) tryptophan derivatives in the presence of N2O3 generating systems, such as preformed nitric oxide and nitric oxide donor compounds in the presence of oxygen at pH 7.4. Under these conditions N-nitrosation of N-acetyltryptophan and lysine-tryptophan-lysine, respectively, was proven unequivocally by UV-visible spectroscopy as well as N-15 NMR spectrometry. Competition experiments performed with the known N2O3 scavenger morpholine demonstrated that the selected tryptophan derivatives were nitrosated by N2O3 with similar rate constants. It is further shown that the addition of ascorbate (vitamin C) induced the release of nitric oxide from N-acetyl-N-nitrosotryptophan as monitored polarographically with a NO electrode. Theoretical considerations strongly suggested that the reactivity of protein-bound tryptophan would be high enough to compete effectively with protein-bound cysteine for N2O3. Our data demonstrate conclusively that N2O3 nitrosates the secondary amine function (N-indole) at the indole ring of N-blocked tryptophan with high reactivity at physiological pH values.	Univ Klinikum, Inst Physiol Chem, D-45122 Essen, Germany	University of Duisburg Essen	Kirsch, M (corresponding author), Univ Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.	michael.kirsch@uni-essen.de						ARENDT J, 1979, ANN CLIN BIOCHEM, V16, P307, DOI 10.1177/000456327901600182; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P979, DOI 10.1006/jmcc.1998.0662; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blanchard B, 2000, J PINEAL RES, V29, P184, DOI 10.1034/j.1600-079X.2000.290308.x; Blanchard-Fillion B, 2001, FREE RADICAL RES, V35, P857, DOI 10.1080/10715760100301351; BONNETT R, 1979, J CHEM SOC PERK T 1, P1969, DOI 10.1039/p19790001969; BONNETT R, 1974, J CHEM SOC P1, V1, P962; Borgs M, 1996, HEPATOLOGY, V23, P1564, DOI 10.1053/jhep.1996.v23.pm0008675178; CHALLIS BC, 1972, J CHEM SOC P1, V2, P918; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; DORIE J, 1986, J MOL STRUCT, V144, P185, DOI 10.1016/0022-2860(86)80178-8; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Garcia-Santos MD, 2002, J AM CHEM SOC, V124, P2177, DOI 10.1021/ja0119503; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P488; Harohalli K, 2002, J BIOMED SCI, V9, P47, DOI 10.1007/BF02256578; HETZER HB, 1966, J PHYS CHEM-US, V70, P2869, DOI 10.1021/j100881a024; Holmes AJ, 2000, J CHEM SOC PERK T 2, P1639, DOI 10.1039/b004028m; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; Kirsch M, 2000, CHEM RES TOXICOL, V13, P451, DOI 10.1021/tx990138z; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kirsch M, 2002, J BIOL CHEM, V277, P13379, DOI 10.1074/jbc.M108079200; Konorev EA, 2000, FREE RADICAL BIO MED, V28, P1671, DOI 10.1016/S0891-5849(00)00281-1; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LEWIS RS, 1995, J AM CHEM SOC, V117, P3933, DOI 10.1021/ja00119a006; LIJINSKY W, 1970, NATURE, V225, P21, DOI 10.1038/225021a0; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lomonosova EE, 1998, FREE RADICAL BIO MED, V24, P522, DOI 10.1016/S0891-5849(97)00295-5; MEYER T, 1982, J CHEM SOC P1, V2, P1383; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Noble DR, 2001, J CHEM SOC PERK T 2, P13, DOI 10.1039/b008112o; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Redfearn J, 1997, PHYS WORLD, V10, P14; Schmidt K, 1998, FREE RADICAL BIO MED, V24, P859, DOI 10.1016/S0891-5849(97)00366-3; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; Turjanski AG, 2000, J AM CHEM SOC, V122, P10468, DOI 10.1021/ja002006u; VENITT S, 1980, CARCINOGENESIS, V1, P523, DOI 10.1093/carcin/1.6.523; WILLIAMS DLH, 1986, NITROSATION; Witanowski M., 1993, ANN REPORTS NMR SPEC, V25; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271	55	48	48	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11931	11936		10.1074/jbc.M300237200	http://dx.doi.org/10.1074/jbc.M300237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551937	hybrid			2022-12-27	WOS:000182015700029
J	Whiteman, SC; Bianco, A; Knight, RA; Spiteri, MA				Whiteman, SC; Bianco, A; Knight, RA; Spiteri, MA			Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAINS; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; IFN-GAMMA; IN-VITRO; EXPRESSION; INHIBITION; SECRETION; CYTOKINES; SUGGESTS	Human rhinoviruses are responsible for many upper respiratory tract infections. 90% of rhinoviruses utilize intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor, which also plays a critical role in recruitment of immune effector cells. Two forms of this receptor exist; membrane-bound (mICAM-1) and soluble ICAM-1 (sICAM-1). The soluble receptor may be produced independently from the membrane-bound form or it may be the product of proteolytic cleavage of mICAM-1. The ratio of airway epithelial cell expression of mlCAM-1 to the sICAM-1 form may influence cell infectivity and outcome of rhinovirus infection. We therefore investigated the effect of rhinovirus on expression of both ICAM-1 receptors in normal human bronchial epithelial cells. We observed separate distinct messenger RNA transcripts coding for mlCAM-1 and sICAM-1 in these cells, which were modulated by virus. Rhinovirus induced mICAM-1 expression on epithelial cells while simultaneously down-regulating sICAM-1 release, with consequent increase in target cell infectivity. The role of protein tyrosine kinases was investigated as a potential mechanistic pathway. Rhinovirus infection induced rapid phosphorylation of intracellular tyrosine kinase, which may be critical in up-regulation of mICAM-1. Elucidation of the underlying molecular mechanisms involved in differential modulation of both ICAM-1 receptors may lead to novel therapeutic strategies.	N Staffordshire Hosp, Lung Injury & Inflammat Res Grp, Directorate Resp Med, Stoke On Trent ST4 6QG, Staffs, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Cyst Fibrosis, London SW3 64R, England	Keele University; University Hospital of North Staffordshire NHS Trust; Imperial College London	Whiteman, SC (corresponding author), N Staffordshire Hosp, Lung Injury & Inflammat Res Grp, Directorate Resp Med, Newcastle Rd, Stoke On Trent ST4 6QG, Staffs, England.	med16_2000@yahoo.com						ARRUDA E, 1992, ANTIMICROB AGENTS CH, V36, P1186, DOI 10.1128/AAC.36.6.1186; BECKER JC, 1991, J IMMUNOL, V147, P4398; Bella J, 1999, VIRUS RES, V62, P107, DOI 10.1016/S0168-1702(99)00038-6; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Bianco A, 1998, EUR RESPIR J, V12, P619, DOI 10.1183/09031936.98.12030619; Budnik A, 1992, Exp Dermatol, V1, P27, DOI 10.1111/j.1600-0625.1992.tb00068.x; Budnik A, 1996, EXP HEMATOL, V24, P352; BurkeGaffney A, 1996, BRIT J PHARMACOL, V119, P1149, DOI 10.1111/j.1476-5381.1996.tb16017.x; Carnes J, 2000, RNA, V6, P1468, DOI 10.1017/S1355838200001242; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Gustin KE, 2002, J VIROL, V76, P8787, DOI 10.1128/JVI.76.17.8787-8796.2002; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; HIS ED, 1995, J INTERFERON CYTOKIN, V15, P89; Huber M, 1997, J VIROL, V71, P595, DOI 10.1128/JVI.71.1.595-600.1997; Huguenel ED, 1997, AM J RESP CRIT CARE, V155, P1206, DOI 10.1164/ajrccm.155.4.9105055; JACKSON AM, 1993, INT J CANCER, V55, P921, DOI 10.1002/ijc.2910550608; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; Leung KH, 1999, BIOCHEM BIOPH RES CO, V260, P734, DOI 10.1006/bbrc.1999.0965; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; Papadopoulos NG, 1999, J VIROL METHODS, V80, P179, DOI 10.1016/S0166-0934(99)00045-2; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Schofield L, 1996, J IMMUNOL, V156, P1886; SETH R, 1991, LANCET, P338; Sethi SK, 1997, CLIN EXP IMMUNOL, V110, P362, DOI 10.1046/j.1365-2249.1997.4221440.x; Stanciu LA, 1998, EUR RESPIR J, V11, P949, DOI 10.1183/09031936.98.11040949; STRATOWA C, 1995, IMMUNOBIOLOGY, V193, P293, DOI 10.1016/S0171-2985(11)80558-9; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; Turner RB, 1999, JAMA-J AM MED ASSOC, V281, P1797, DOI 10.1001/jama.281.19.1797; van Kempen M., 1999, Rhinology (Utrecht), V37, P97; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wakatsuki T, 1995, CELL ADHES COMMUN, V3, P283, DOI 10.3109/15419069509081014; WHITEMAN SC, 1999, EUR RESPIR J, V14, pS250; Winther B, 2002, ARCH OTOLARYNGOL, V128, P131, DOI 10.1001/archotol.128.2.131; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	41	63	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11954	11961		10.1074/jbc.M205329200	http://dx.doi.org/10.1074/jbc.M205329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551926	hybrid			2022-12-27	WOS:000182015700032
J	Bahadoran, P; Busca, R; Chiaverini, C; Westbroek, W; Lambert, J; Bille, K; Valony, G; Fukuda, M; Naeyaert, JM; Ortonne, JP; Ballotti, R				Bahadoran, P; Busca, R; Chiaverini, C; Westbroek, W; Lambert, J; Bille, K; Valony, G; Fukuda, M; Naeyaert, JM; Ortonne, JP; Ballotti, R			Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN-VA; MELANOSOME TRANSPORT; C2 DOMAINS; EFFECTOR; PROTEIN; MELANOCYTES; SLAC2-A/MELANOPHILIN; DETERMINANT; DYNAMICS; CLONING	Rab27a plays a pivotal role in the transport of melanosomes to dendrite tips of melanocytes and mutations in RAB27A, which impair melanosome transport cause the pigmentary dilution and the immune deficiency found in several patients with Griscelli syndrome (GS). Interestingly, three GS patients present single homozygous missense mutations in RAB27A, leading to W73G, L130P, and A152P transitions that affect highly conserved residues among Rab proteins. However, the functional consequences of these mutations have not been studied. In the present report, we evaluated the effect of overexpression of these mutants on melanosome, melanophilin, and myosin-Va localization in B16 melanoma cells. Then we studied several key parameters for Rab27a function, including GTP binding and interaction with melanophilin/myosin-Va complex, which links melanosomes to the actin network. Our results showed that Rab27a-L130P cannot bind GTP, does not interact with melanophilin, and consequently cannot allow melanosome transport on the actin filaments. Interestingly, Rab27a-W73G binds GTP but does not interact with melanophilin. Thus, Rab27a-W73G cannot support the actin-dependent melanosome transport. Finally, Rab27a-A152P binds both GTP and melanophilin. However, Rab27a-A152P does not allow melanosome transport and acts as a dominant negative mutant, because its overexpression, in B16 melanoma cells, mimics a GS phenotype. Hence, the interaction of Rab27a with melanophilin/myosin-Va is not sufficient to ensure a correct melanosome transport. Our results pointed to an unexpected complexity of Rab27a function and open the way to the search for new Rab27a effectors or regulators that control the transport of Rab27a-dependent vesicles.	INSERM, U385, Biol & Physiopathol Peau, Fac Med, F-06107 Nice 2, France; Ghent Univ Hosp, Dept Dermatol, B-9000 Ghent, Belgium; RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Ghent University; Ghent University Hospital; RIKEN	Ballotti, R (corresponding author), INSERM, U385, Biol & Physiopathol Peau, Fac Med, Ave Valombrose, F-06107 Nice 2, France.		Jo, Lambert LW/AAG-4880-2021; BALLOTTI, Robert/F-8825-2013; Fukuda, MItsunori/I-1511-2015; Jo, Lambert LW/ABD-3264-2021	Fukuda, MItsunori/0000-0002-8620-5853; BALLOTTI, Robert/0000-0002-7322-4908; Bahadoran, Philippe/0000-0002-2481-0556; Lambert, Jo/0000-0001-5303-9310				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pastural E, 2000, GENOMICS, V63, P299, DOI 10.1006/geno.1999.6081; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; WESTBROEK W, 2002, IN PRESS J INVEST DE; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	28	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11386	11392		10.1074/jbc.M211996200	http://dx.doi.org/10.1074/jbc.M211996200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531900	hybrid			2022-12-27	WOS:000181855400067
J	Gaziova, I; Lukes, J				Gaziova, I; Lukes, J			Mitochondrial and nuclear localization of topoisomerase II in the flagellate Bodo saltans (Kinetoplastida), a species with non-catenated kinetoplast DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; SITES; EXPRESSION; MECHANISM; EVOLUTION; PROTEINS; GENES; ALPHA; BETA	We have studied topoisomerase II (topo II) in the cells of Bodo saltans, a free-living bodonid (Kinetoplastida). Phylogenetic analysis based on the sequence of the entire topo II gene, which is a single-copy gene, confirmed that B. saltans is a predecessor of parasitic trypanosomatids. Antibodies generated against either an overexpressed unique C-terminal region of topo II or a synthetic oligopeptide derived from the same region did not cross-react with cell lysates of related trypanosomatids, while they recognized a single specific band in the B. saltans lysate. Immunolocalization experiments using both antibodies showed that topo II is evenly dispersed throughout the kinetoplast. This is in striking difference from the localization of topo II in other flagellates, where it occurs in two antipodal centers flanking the kinetoplast disk. Moreover, the same topo II has a distinct localization in multiple loci at the periphery of the nucleus of B. saltans. With a minicircle probe derived from the conserved region we have shown that all relaxed non-catenated minicircles are confined to the globular kinetoplast DNA bundle. Therefore, in the mitochondrion of this primitive eukaryote topo II does not catenate relaxed DNA circles into a network in vivo, while a decatenating activity is present in partially purified cell lysates.	Acad Sci Czech Republ, Inst Parasitol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol, CR-37005 Ceske Budejovice, Czech Republic	Czech Academy of Sciences; University of South Bohemia Ceske Budejovice	Lukes, J (corresponding author), Acad Sci Czech Republ, Inst Parasitol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	jula@paru.cas.cz	Lukes, Julius/H-6760-2012	Lukes, Julius/0000-0002-0578-6618				Blom D, 1998, NUCLEIC ACIDS RES, V26, P1205, DOI 10.1093/nar/26.5.1205; Blom D, 2000, RNA, V6, P121, DOI 10.1017/S1355838200992021; Burri C, 1996, PARASITOL TODAY, V12, P226, DOI 10.1016/0169-4758(96)10017-X; Das A, 2001, NUCLEIC ACIDS RES, V29, P1844, DOI 10.1093/nar/29.9.1844; Dolezel D, 2000, INT J SYST EVOL MICR, V50, P1943, DOI 10.1099/00207713-50-5-1943; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; Fragoso SP, 1998, MOL BIOCHEM PARASIT, V94, P197, DOI 10.1016/S0166-6851(98)00066-8; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; Guilbride DL, 1998, J CELL SCI, V111, P675; Johnson CE, 1998, J CELL BIOL, V143, P911, DOI 10.1083/jcb.143.4.911; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; Komori K, 1997, J PLANT RES, V110, P65, DOI 10.1007/BF02506844; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Lukes J, 1998, EMBO J, V17, P838, DOI 10.1093/emboj/17.3.838; LUKES J, 1994, EMBO J, V13, P5086, DOI 10.1002/j.1460-2075.1994.tb06838.x; Lukes J, 2002, EUKARYOT CELL, V1, P495, DOI 10.1128/EC.1.4.495-502.2002; Lukes J, 2001, MOL BIOCHEM PARASIT, V117, P179, DOI 10.1016/S0166-6851(01)00348-6; Mahmood R, 1999, MOL CELL BIOL, V19, P6174; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Morris JC, 2001, INT J PARASITOL, V31, P453, DOI 10.1016/S0020-7519(01)00156-4; Niimi A, 2001, CHROMOSOMA, V110, P102, DOI 10.1007/s004120100140; PASION SG, 1992, MOL BIOCHEM PARASIT, V50, P57, DOI 10.1016/0166-6851(92)90244-E; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; Sakaguchi A, 2001, BIOCHEM BIOPH RES CO, V283, P876, DOI 10.1006/bbrc.2001.4856; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SHAPIRO TA, 1993, ACTA TROP, V54, P251, DOI 10.1016/0001-706X(93)90097-U; SHLOMAI J, 1994, PARASITOL TODAY, V10, P341, DOI 10.1016/0169-4758(94)90244-5; SHLOMAI J, 1983, NUCLEIC ACIDS RES, V11, P4019, DOI 10.1093/nar/11.12.4019; Simpson AGB, 2002, MOL BIOL EVOL, V19, P2071, DOI 10.1093/oxfordjournals.molbev.a004032; Stolba P, 2001, MOL BIOCHEM PARASIT, V113, P323, DOI 10.1016/S0166-6851(01)00218-3; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; SWOFFORD DL, 1998, PAUPASTERISK VERSION; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Xu CW, 1996, MOL CELL BIOL, V16, P564; Yasuhira S, 1996, RNA, V2, P1153	42	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10900	10907		10.1074/jbc.M202347200	http://dx.doi.org/10.1074/jbc.M202347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12533517	hybrid			2022-12-27	WOS:000181855400005
J	Maynard, MA; Qi, H; Chung, J; Lee, EHL; Kondo, Y; Hara, S; Conaway, RC; Conaway, JW; Ohh, M				Maynard, MA; Qi, H; Chung, J; Lee, EHL; Kondo, Y; Hara, S; Conaway, RC; Conaway, JW; Ohh, M			Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 uhiquitin ligase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTOR; PAS DOMAIN PROTEIN; PROLYL HYDROXYLATION; GROWTH-FACTOR; FACTOR-ALPHA; GENE-EXPRESSION; MESSENGER-RNAS; REGULATE HIF; ELONGIN-B	Functional inactivation of the von Hippel-Lindau (VHL) tumor suppressor protein is the cause of familial VHL disease and sporadic kidney cancer. The VHL gene product (pVHL) is a component of an E3 ubiquitin ligase complex that targets the hypoxia-inducible factor (HIF) 1 and 2 alpha subunits for polyubiquitylation. This process is dependent on the hydroxylation of conserved proline residues on the a subunits of HIF-1/2 in the presence of oxygen. In our effort to identify orphan HIF-like proteins in the data base that are potential targets of the pVHL complex, we report multiple splice variants of the human HIF-3alpha locus as follows: hHIF-3alpha1, hHIF-3alpha2 (also referred to as hIPAS; human inhibitory PAS domain protein), hHIF-3alpha3, hHIF-3alpha4, hHIF-3alpha5, and hHIF-3alpha6. We demonstrate that the common oxygen-dependent degradation domain of hHIF-3alpha1-3 splice variants is targeted for ubiquitylation by the pVHL complex an vitro and an vivo. This activity is enhanced in the presence of prolyl hydroxylase and is dependent on a proline residue at position 490. Furthermore, the ubiquitin conjugation occurs on lysine residues at position 465 and 568 within the oxygen-dependent degradation domain. These results demonstrate additional targets of the pVHL complex and suggest a growing complexity in the regulation of hypoxia-inducible genes by the HIF family of transcription factors.	Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Nippon Med Coll, Dept Urol, Bunkyo Ku, Tokyo 1138603, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Publ Hlth, Minato Ku, Tokyo 1088641, Japan; Stowers Inst Med Res, Kansas City, MO 64110 USA	University of Toronto; Nippon Medical School; Kitasato University; Stowers Institute for Medical Research	Maynard, MA (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.			Conaway, Joan/0000-0002-2786-0663				Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Siemeister G, 1996, CANCER RES, V56, P2299; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199	42	224	236	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11032	11040		10.1074/jbc.M208681200	http://dx.doi.org/10.1074/jbc.M208681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538644	hybrid			2022-12-27	WOS:000181855400023
J	Slater, EC				Slater, EC			Keilin, cytochrome, and the respiratory chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Biographical-Item									Univ Amsterdam, Biochem Lab, Amsterdam, Netherlands	University of Amsterdam	Slater, EC (corresponding author), Univ Amsterdam, Biochem Lab, Amsterdam, Netherlands.								0	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16455	16461		10.1074/jbc.X200011200	http://dx.doi.org/10.1074/jbc.X200011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12560322	hybrid			2022-12-27	WOS:000182818600001
J	Nakatani, F; Tanaka, K; Sakimura, R; Matsumoto, Y; Matsunobu, T; Li, X; Hanada, M; Okada, T; Iwamoto, Y				Nakatani, F; Tanaka, K; Sakimura, R; Matsumoto, Y; Matsunobu, T; Li, X; Hanada, M; Okada, T; Iwamoto, Y			Identification of p21(WAF1/CIP1) as a direct target of EWS-Fli1 oncogenic fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EWINGS-SARCOMA; SODIUM-BUTYRATE; CELL-GROWTH; TRANSCRIPTION FACTOR; BINDING-PROTEIN; GENE PROMOTER; SOFT-TISSUE; EXPRESSION; P300; P53	Translocation t(11;22) is a karyotypic abnormality detected in over 90% of Ewing's family tumors. This translocation results in the EWS-Fli1 fusion gene, which has been shown to be a potent, single-step transforming gene. We reported previously that suppression of the EWS-Fli1 fusion protein altered the expression of G(1) regulatory cyclins and cyclin-dependent kinase inhibitors both at mRNA and protein levels, resulting in G(1) growth arrest in Ewing's family tumor cell lines. These data suggest that the G(1) regulatory molecules may be targets of the EWS-Fli1 fusion protein, which functions as an aberrant transcription factor. By using electrophoretic mobility shift assays, we show here the direct association of EWS-Fli1 fusion protein with ETS consensus sequences, which are in the promoter of the p21(WAF1/CIP1) gene. Reporter gene assays revealed that the activity of the p21(WAF1/CIP1) promoter is negatively regulated by EWS-Fli1 fusion protein through at least two ETS-binding sites in the promoter. EWS-Fli1 interacted with p300 cotransactivator and suppressed its histone acetyltransferase activity, which may explain the down-regulation of p21(WAF1/CIP1) by EWS-Fli1. In the presence of a histone deacetylase inhibitor, the histone acetyltransferase activity of the Ewing's family tumor cell was recovered resulting in the induction of p21, and the cell growth was dramatically inhibited. These results demonstrated that p21(WAF1/CIP1) might be one of the direct targets of EWS-Fli1, and that p21(WAF1/CIP1) could serve as a target for a molecularly based therapy for Ewing's family tumors.	Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Tanaka, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tanaka@ortho.med.kyushu-u.ac.jp	Tanaka, Kazuhiro/Q-7387-2019	Tanaka, Kazuhiro/0000-0002-5138-8952				Ahrens S, 1999, MED PEDIATR ONCOL, V32, P186, DOI 10.1002/(SICI)1096-911X(199903)32:3<186::AID-MPO5>3.0.CO;2-D; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG QG, 1993, ANTI-CANCER DRUG, V4, P617, DOI 10.1097/00001813-199312000-00003; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Fujimura Y, 2001, ONCOGENE, V20, P6653, DOI 10.1038/sj.onc.1204684; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Goodman RH, 2000, GENE DEV, V14, P1553; GRAHAM KA, 1988, J CELL PHYSIOL, V136, P63, DOI 10.1002/jcp.1041360108; Hahm KB, 1999, NAT GENET, V23, P481, DOI 10.1038/70611; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOVAR H, 1993, ONCOGENE, V8, P2683; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Rossow KL, 2001, CANCER RES, V61, P2690; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; TANAKA K, 1995, CANCER RES, V55, P2927; TANAKA K, 1995, LAB INVEST, V72, P237; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka Kazuhiro, 2002, J Orthop Sci, V7, P477, DOI 10.1007/s007760200083; Thompson AD, 1996, ONCOGENE, V13, P2649; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	108	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15105	15115		10.1074/jbc.M211470200	http://dx.doi.org/10.1074/jbc.M211470200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12560328	hybrid			2022-12-27	WOS:000182516100068
J	Becker, L; Webb, BA; Chitayat, S; Nesheim, ME; Koschinsky, ML				Becker, L; Webb, BA; Chitayat, S; Nesheim, ME; Koschinsky, ML			A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE-BINDING-SITE; KRINGLE-IV REPEATS; RECOMBINANT APOLIPOPROTEIN(A); HUMAN PLASMINOGEN; LIPOPROTEIN(A); FORM; IDENTIFICATION; ASSOCIATION; EXPRESSION; CLEAVAGE	Lipoprotein(a) (Lp(a)) assembly proceeds via a twostep mechanism in which initial non-covalent interactions between apolipoprotein(a) (apo(a)) and low density lipoprotein precede disulfide bond formation. In this study, we used analytical ultracentrifugation, differential scanning calorimetry, and intrinsic fluorescence to demonstrate that in the presence of the lysine analog E-aminocaproic acid, apo(a) undergoes a substantial conformational change from a "closed" to an "open" structure that is characterized by an increase in the hydrodynamic radius (similar to10%), an alteration in domain stability, as well as a decrease in tryptophan fluorescence. Although E-aminocaproic acid is a well characterized inhibitor of the non-covalent interaction between apo(a) and low density lipoprotein, we report the novel observation that this ligand at low concentrations (100 pm-l mm) significantly enhances covalent Lp(a) assembly by altering the conformation of apo(a). We developed a model for the kinetics of Lp(a) assembly that incorporates the conformational change as a determinant of the efficiency of the process; this model quantitatively explains our experimental observations. Interestingly, an analogous conformational change has been previously described for plasminogen resulting in an increase in the hydrodynamic radius, an increase in tryptophan fluorescence, and an acceleration of the rate of plasminogen activation. Although the functions of apio(a) and plasminogen have diverged considerably, elements of structural and conformational homology have been retained leading to similar regulation of two unrelated biological processes.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	mk11@post.queensu.ca	Webb, Bradley/F-6946-2013; Webb, Bradley/HDO-7820-2022	Webb, Bradley/0000-0002-5299-2852; Koschinsky, Marlys/0000-0002-2643-2288				Becker L, 2001, J BIOL CHEM, V276, P36155, DOI 10.1074/jbc.M104789200; Brunner C, 1996, J BIOL CHEM, V271, P32403, DOI 10.1074/jbc.271.50.32403; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CASTELLINO F J, 1988, Haemostasis, V18, P15; Cockell CS, 1998, BIOCHEM J, V333, P99, DOI 10.1042/bj3330099; Fless GM, 1996, BIOCHEMISTRY-US, V35, P2289, DOI 10.1021/bi951792q; GABEL BR, 1995, BIOCHEMISTRY-US, V34, P15777, DOI 10.1021/bi00048a023; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; Gabel BR, 1998, BIOCHEMISTRY-US, V37, P7892, DOI 10.1021/bi973186w; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Hervio L, 1999, BBA-PROTEIN STRUCT M, V1434, P124, DOI 10.1016/S0167-4838(99)00179-X; Hrzenjak A, 2000, PROTEIN ENG, V13, P661, DOI 10.1093/protein/13.9.661; KEELSER GA, 1996, J BIOL CHEM, V271, P32096; Kornblatt JA, 2000, BBA-PROTEIN STRUCT M, V1481, P1, DOI 10.1016/S0167-4838(00)00119-9; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; MALCOLM L, 2002, J BIOL CHEM, V277, P1040; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; Marcovina S M, 1999, Curr Cardiol Rep, V1, P105, DOI 10.1007/s11886-999-0067-z; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; OSTERBERG R, 1980, BIOCHEMISTRY-US, V19, P2283; Ozhogina OA, 2001, PROTEIN SCI, V10, P2114, DOI 10.1110/ps.15801; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Privalov P L, 1986, Methods Enzymol, V131, P4; Rahman MN, 2002, BIOCHEMISTRY-US, V41, P1149, DOI 10.1021/bi010964i; Sangrar W, 2000, BIOCHEM CELL BIOL, V78, P519, DOI 10.1139/bcb-78-4-519; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Watanabe K, 2002, J MOL BIOL, V319, P283, DOI 10.1016/S0022-2836(02)00199-7; Weisel JW, 2001, BIOCHEMISTRY-US, V40, P10424, DOI 10.1021/bi010556e; WHITE AL, 1994, J BIOL CHEM, V269, P28716	36	19	21	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14074	14081		10.1074/jbc.M212855200	http://dx.doi.org/10.1074/jbc.M212855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566443	hybrid			2022-12-27	WOS:000182405000067
J	Bes, C; Briant-Longuet, L; Cerutti, M; Heitz, F; Troadec, S; Pugniere, M; Roquet, F; Molina, F; Casset, F; Bresson, D; Peraldi-Roux, S; Devauchelle, G; Devaux, C; Granier, C; Chardes, T				Bes, C; Briant-Longuet, L; Cerutti, M; Heitz, F; Troadec, S; Pugniere, M; Roquet, F; Molina, F; Casset, F; Bresson, D; Peraldi-Roux, S; Devauchelle, G; Devaux, C; Granier, C; Chardes, T			Mapping the paratope of anti-CD4 recombinant fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; VARIABLE REGIONS; CDR3-LIKE REGION; ANTIGEN-BINDING; SPOT-SYNTHESIS; CD4 MOLECULE; T-CELLS; IDENTIFICATION; RECOGNITION; VACCINATION	We analyzed antigen-binding residues from the variable domains of anti-CD4 antibody 13B8.2 using the Spot method of parallel peptide synthesis. Sixteen amino acids, defined as Spot critical residues (SCR), were identified on the basis of a 50% decrease in CD4 binding to alanine analogs of reactive peptides. Recombinant Fab 13B8.2 mutants were constructed with alanine residues in place of each of the 16 SCR, expressed in the baculovirus cell system, and purified. CD measurements indicated that the mutated proteins were conformationally intact, with a beta-sheet secondary structure similar to that of wild-type Fab. Compared with the CD4-binding capacity of wildtype Fab 13B8.2, 11 light (Y32-L, W35-L, Y36-L, H91-L, and Y92-L) and heavy chain (H35-H, R38-H, W52-H, R53-H, F100K-H, and W103-H) Fab single mutants showed a decrease in CD4 recognition as demonstrated by enzymelinked immunosorbent assay, BIAcore, and flow cytometry analyses. The five remaining Fab mutants showed antigen-binding properties similar to those of wild-type Fab. Recombinant Fab mutants that showed decreased CD4 binding also lost their capacity to inhibit human immunodeficiency virus promoter activation and the antigen-presenting ability that wild-type Fab displays. Molecular modeling of the 13B8.2 antibody paratope indicated that most of these critical residues are appropriately positioned inside the putative CD4-binding pocket, whereas the five SCR that were not confirmed by mutagenesis show an unfavorable positioning. Taken together, these results indicate that most of the residues defined by the Spot method as critical matched with important residues defined by mutagenesis in the whole protein context. The identification of critical residues for CD4 binding in the paratope of anti-CD4 recombinant Fab 13B8.2 provides the opportunity for the generation of improved anti-CD4 molecules with more efficient pharmacological properties.	CNRS, UMR 5094, Inst Biotechnol & Pharmacol, Fac Pharm, Montpellier 5, France; CNRS, UMR 5121, Lab Infect Retrovirales & Signalisat Cellulaire, Inst Biol, F-34060 Montpellier 2, France; INRA, CNRS, UMR 5087, Lab Pathol Comparee, F-30380 St Christol Les Ales, France; CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France; Syntem, F-30035 Nimes 1, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Chardes, T (corresponding author), CNRS, UMR 5094, Inst Biotechnol & Pharmacol, Fac Pharm, 15 Ave Charles Flahault, Montpellier 5, France.		Pugniere, Martine/T-1355-2017; Briant, Laurence/AAB-9281-2021; Chardès, Thierry/B-5420-2019; Molina, Franck/E-8419-2011; PUGNIERE, Martine/AAD-4315-2020	Pugniere, Martine/0000-0002-2049-2909; Chardès, Thierry/0000-0002-1836-7439; PUGNIERE, Martine/0000-0002-2049-2909				Anderson D, 1997, CLIN IMMUNOL IMMUNOP, V84, P73, DOI 10.1006/clin.1997.4363; BENKIRANE M, 1993, EMBO J, V12, P4909, DOI 10.1002/j.1460-2075.1993.tb06185.x; Bes C, 2001, FEBS LETT, V508, P67, DOI 10.1016/S0014-5793(01)03036-8; Bes Cedric, 2001, Human Antibodies, V10, P67; Bosshard HR, 2001, NEWS PHYSIOL SCI, V16, P171; Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998; Briant L, 2000, Adv Pharmacol, V48, P373; Chardes T, 1999, FEBS LETT, V452, P386, DOI 10.1016/S0014-5793(99)00649-3; Cohen GH, 1996, ACTA CRYSTALLOGR D, V52, P315, DOI 10.1107/S0907444995014855; CORBEAU P, 1993, J IMMUNOL, V150, P290; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Deckert PM, 1996, J IMMUNOL, V156, P826; DHIVER C, 1989, AIDS, V3, P835, DOI 10.1097/00002030-198912000-00009; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GORMAN SD, 1991, P NATL ACAD SCI USA, V88, P4181, DOI 10.1073/pnas.88.10.4181; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honegger A, 2001, J MOL BIOL, V309, P657, DOI 10.1006/jmbi.2001.4662; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; Laune D, 2002, J IMMUNOL METHODS, V267, P53, DOI 10.1016/S0022-1759(02)00140-0; Leder L, 1995, BIOCHEMISTRY-US, V34, P16509, DOI 10.1021/bi00050a035; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; Manca F, 1996, EUR J IMMUNOL, V26, P2461, DOI 10.1002/eji.1830261029; Monnet C, 1999, J BIOL CHEM, V274, P3789, DOI 10.1074/jbc.274.6.3789; Pearlman R S, 1991, NIDA Res Monogr, V112, P62; Poul MA, 1995, IMMUNOTECHNOLOGY, V1, P189, DOI 10.1016/1380-2933(95)00019-4; POULIN L, 1991, J VIROL, V65, P4893, DOI 10.1128/JVI.65.9.4893-4901.1991; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; Pulito VL, 1996, J IMMUNOL, V156, P2840; REES AR, 1992, ABM COMPUTER PROGRAM; Reimann KA, 1997, AIDS RES HUM RETROV, V13, P933, DOI 10.1089/aid.1997.13.933; Reineke U, 1999, NAT BIOTECHNOL, V17, P271, DOI 10.1038/7018; Reineke U, 2002, J IMMUNOL METHODS, V267, P37, DOI 10.1016/S0022-1759(02)00139-4; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; Schedel I, 1999, VACCINE, V17, P1837, DOI 10.1016/S0264-410X(98)00483-6; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; TANIYAMA Y, 1990, J BIOL CHEM, V265, P16767; VRANA M, 1976, J IMMUNOL, V116, P1662; Welfle K, 2001, J MOL RECOGNIT, V14, P89, DOI 10.1002/jmr.523	46	21	43	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14265	14273		10.1074/jbc.M210694200	http://dx.doi.org/10.1074/jbc.M210694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566463	Green Published, hybrid			2022-12-27	WOS:000182405000089
J	Chu, CJ; Huang, SM; De Petrocellis, L; Bisogno, T; Ewing, SA; Miller, JD; Zipkin, RE; Daddario, N; Appendino, G; Di Marzo, V; Walker, JM				Chu, CJ; Huang, SM; De Petrocellis, L; Bisogno, T; Ewing, SA; Miller, JD; Zipkin, RE; Daddario, N; Appendino, G; Di Marzo, V; Walker, JM			N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLOID VR1 RECEPTORS; ACID AMIDE HYDROLASE; CANNABINOID-RECEPTOR; CB1 RECEPTOR; IN-VITRO; ANANDAMIDE; PALMITOYLETHANOLAMIDE; ACTIVATION; BRAIN; RATS	N-Arachidonoyldopamine (NADA) was recently identified as an endogenous ligand for the vanilloid type 1 receptor (VR1). Further analysis of the bovine striatal extract from which NADA was isolated indicated the existence of substances corresponding in molecular mass to N-oleoyldopamine (OLDA), N-palmitoyldopamine (PALDA), and N-stearoyldopamine (STEARDA). Quadrupole time-of-flight mass spectrometric analysis of bovine striatal extracts revealed the existence of OLDA, PALDA, and STEARDA as endogenous compounds in the mammalian brain. PALDA and STEARDA failed to affect calcium influx in VR1-transfected human embryonic kidney (HEK) 293 cells or paw withdrawal latencies from a radiant heat source, and there was no evidence of spontaneous pain behavior. By contrast, OLDA induced calcium influx (EC50 = 36 nM), reduced the latency of paw withdrawal from a radiant heat source in a dose-dependent manner (EC50 = 0.72 mug), and produced nocifensive behavior. These effects were blocked by co-administration of the VR1. antagonist iodo-resiniferatoxin (10 nm for HEK cells and 1 mug/50 mul for pain behavior). These findings demonstrate the existence of an endogenous compound in the brain that is similar to capsaicin and NADA in its chemical structure and activity on VR1. Unlike NADA, OLDA was only a weak ligand for rat CB1 receptors; but like NADA, it was recognized by the anandamide membrane transporter while being a poor substrate for fatty-acid amide hydrolase. Analysis of the activity of six additional synthetic and potentially endogenous N-acyldopamine indicated the requirement of a long unsaturated fatty acid chain for an optimal functional interaction with VR1 receptors.	Brown Univ, Dept Psychol, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA; CNR, Inst Biomol Chem & Cybernet, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy; Appl Biosyst Inc, Framingham, MA 01701 USA; BIOMOL Res Labs Inc, Plymouth Meeting, PA 19462 USA; Dipartimento Sci Chim, I-28100 Novara, Italy	Brown University; Brown University; Consiglio Nazionale delle Ricerche (CNR); Thermo Fisher Scientific; Applied Biosystems	Walker, JM (corresponding author), Brown Univ, Dept Psychol, 89 Waterman St,POB 1853, Providence, RI 02912 USA.		Bisogno, Tiziana/B-7891-2015; Appendino, Giovanni/O-4832-2015; Di Marzo, Vincenzo/AAD-7742-2019; Latyshev, Nikolay/D-1464-2014	Appendino, Giovanni/0000-0002-4170-9919; Di Marzo, Vincenzo/0000-0002-1490-3070; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000375, R01DA013012] Funding Source: NIH RePORTER; NIDA NIH HHS [DA13012, K02DA00375] Funding Source: Medline; NINDS NIH HHS [NS33247] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Appendino G, 2002, J MED CHEM, V45, P3739, DOI 10.1021/jm020844o; Bezuglov V, 2001, BIOORG MED CHEM LETT, V11, P447, DOI 10.1016/S0960-894X(00)00689-2; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655; DAWBARN D, 1981, NEUROPHARMACOLOGY, V20, P341, DOI 10.1016/0028-3908(81)90006-X; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; De Petrocellis L, 2001, FEBS LETT, V506, P253, DOI 10.1016/S0014-5793(01)02934-9; De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200; De Petrocellis L, 2002, FUND CLIN PHARMACOL, V16, P297, DOI 10.1046/j.1472-8206.2002.00094.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Di Marzo V, 2001, BIOCHEM J, V358, P249, DOI 10.1042/0264-6021:3580249; Di Marzo V, 2001, EUR J PHARMACOL, V420, P123, DOI 10.1016/S0014-2999(01)01012-3; Fowler CJ, 2002, PROSTAG LEUKOTR ESS, V66, P193, DOI 10.1054/plef.2001.0357; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; HAJOS M, 1988, J NEURAL TRANSM, V74, P129, DOI 10.1007/BF01244779; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Hayes P, 2000, PAIN, V88, P205, DOI 10.1016/S0304-3959(00)00353-5; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; JANCSOGABOR A, 1970, J PHYSIOL-LONDON, V208, P449, DOI 10.1113/jphysiol.1970.sp009130; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 1999, J NEUROSCI, V19, P529; Marinelli S, 2002, J PHYSIOL-LONDON, V543, P531, DOI 10.1113/jphysiol.2002.022863; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Melzack R, 2001, ANN NY ACAD SCI, V933, P157; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Palazzo E, 2002, EUR J PHARMACOL, V439, P69, DOI 10.1016/S0014-2999(02)01367-5; Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smart D, 2002, BRIT J PHARMACOL, V136, P452, DOI 10.1038/sj.bjp.0704732; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Szabo T, 2002, MOL BRAIN RES, V98, P51, DOI 10.1016/S0169-328X(01)00313-8; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Szallasi A, 1999, PHARMACOL REV, V51, P159; TSENG CF, 1992, CHEM PHARM BULL, V40, P396, DOI 10.1248/cpb.40.396; Wahl P, 2001, MOL PHARMACOL, V59, P9, DOI 10.1124/mol.59.1.9; WALPOLE CSJ, 1993, STRUCTURAL REQUIREME, P63	40	274	287	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13633	13639		10.1074/jbc.M211231200	http://dx.doi.org/10.1074/jbc.M211231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12569099	hybrid			2022-12-27	WOS:000182405000011
J	Coleman, KM; Dutertre, M; El-Gharbawy, A; Rowan, BG; Weigel, NL; Smith, CL				Coleman, KM; Dutertre, M; El-Gharbawy, A; Rowan, BG; Weigel, NL; Smith, CL			Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; CHICKEN PROGESTERONE-RECEPTOR; PROTEIN-KINASE-A; BREAST-CANCER CELLS; P68 RNA HELICASE; GROWTH FACTOR-I; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTOR; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; GLUCOCORTICOID RECEPTOR	Although increases in intracellular cAMP can stimulate estrogen receptor-alpha (ERalpha) activity in the absence of exogenous hormone, no studies have addressed whether ERbeta can be similarly regulated. In transient transfections, forskolin plus 3-isobutyl-1-methylxanthine (IBMX), which increases intracellular cAMP, stimulated the transcriptional activities of both ERalpha and ERbeta. This effect was blocked by the protein kinase A inhibitor H89 (N-(2-(p-bromocinnamylamino)-ethyl)-5-isoquinolinesulfonamide) and was dependent on an estrogen response element. A 12-O-tetradecanoylphorbol-13-acetate response element (TRE) located 5' to the estrogen response element was necessary for cAMP-dependent activation of gene expression by ERbeta but not ERalpha, indicating that the former subtype requires a functional interaction with TRE-interacting factor(s) to stimulate transcription. Both p160 and CREB-binding protein coactivators stimulated cAMP-induced ERalpha and ERbeta transcriptional activity. However, mutation of the two cAMP-inducible SRC-1 phosphorylation sites important for cAMP activation of chicken progesterone receptor or all seven known SRC-1 phosphorylation sites did not specifically impair cAMP activation of ERalpha. The E/F domains of ERa are sufficient for activation by forskolin/IBMX, and this is accompanied by an increase in receptor phosphorylation. In contrast, cAMP signaling reduces the phosphorylation of the corresponding region of ERbeta, and this correlates with the lack of forskolin/IBMX stimulated transcriptional activity. Our data suggest that cAMP activation of ERalpha transcriptional activity is associated with receptor instead of SRC-1 phosphorylation. Moreover, differences in the cofactor requirements, domains of ERalpha and ERbeta sufficient for forskolin/IBMX activation, and the effect of cAMP on receptor phosphorylation indicate that this signaling pathway utilizes distinct mechanisms to stimulate ERalpha and ERbeta transcriptional activity.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA	Baylor College of Medicine	Smith, CL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Dutertre, Martin/N-7060-2017; DUTERTRE, Martin/Q-1815-2019	Dutertre, Martin/0000-0003-0278-4120; DUTERTRE, Martin/0000-0003-0278-4120	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053002] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07165] Funding Source: Medline; NIDDK NIH HHS [DK53002] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Bai WL, 1997, J BIOL CHEM, V272, P10457; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; BUELT MK, 1994, J BIOL CHEM, V269, P29367; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHO HS, 1994, ENDOCRINOLOGY, V134, P658, DOI 10.1210/en.134.2.658; Coleman KM, 2001, FRONT BIOSCI, V6, pD1379, DOI 10.2741/Coleman; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Dowhan DH, 1996, NUCLEIC ACIDS RES, V24, P264, DOI 10.1093/nar/24.2.264; Driggers PH, 2001, J BIOL CHEM, V276, P46792, DOI 10.1074/jbc.M106927200; ElTanani MKK, 1996, MOL CELL ENDOCRINOL, V124, P71, DOI 10.1016/S0303-7207(96)03930-5; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; Glass CK, 2000, GENE DEV, V14, P121; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; INCE BA, 1994, MOL ENDOCRINOL, V8, P1397, DOI 10.1210/me.8.10.1397; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Walters MR, 2002, J BIOL CHEM, V277, P1669, DOI 10.1074/jbc.M109320200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	78	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12834	12845		10.1074/jbc.M212312200	http://dx.doi.org/10.1074/jbc.M212312200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566449	hybrid			2022-12-27	WOS:000182189500033
J	Heiss, A; DuChesne, A; Denecke, B; Grotzinger, J; Yamamoto, K; Renne, T; Jahnen-Dechent, W				Heiss, A; DuChesne, A; Denecke, B; Grotzinger, J; Yamamoto, K; Renne, T; Jahnen-Dechent, W			Structural basis of calcification inhibition by alpha(2)-HS glycoprotein/fetuin-A - Formation of colloidal calciprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; SECONDARY STRUCTURE; APATITE FORMATION; FETUIN FAMILY; IN-VITRO; BONE; CALCIUM; SERUM; GROWTH; HYDROXYAPATITE	Genetic evidence from mutant mice suggests that alpha(2)-HS glycoprotein/fetuin-A (Ahsg) is a systemic inhibitor of precipitation of basic calcium phosphate preventing unwanted calcification. Using electron microscopy and dynamic light scattering, we demonstrate that precipitation inhibition by Ahsg is caused by the transient formation of soluble, colloidal spheres, containing Ahsg, calcium, and phosphate. These "calciprotein particles" of 30-150 nm in diameter are initially amorphous and soluble but turn progressively more crystalline and insoluble in a time- and temperature-dependent fashion. Solubilization in Ahsg-containing calciprotein particles provides a novel conceptual framework to explain how insoluble calcium precipitates may be transported and removed in the bodies of mammals. Mutational analysis showed that the basic calcium phosphate precipitation inhibition activity resides in the amino-terminal cystatin-like domain D1 of Ahsg. A structure-function analysis of wild type and mutant forms of cystatin-like domains from Ahsg, full-length fetuin-B, histidine-rich glycoprotein, and kininogen demonstrated that Ahsg domain D1 is most efficient in inhibiting basic calcium phosphate precipitation. The computer-modeled domain structures suggest that a dense array of acidic residues on an extended beta-sheet of the cystatin-like domain Ahsg-D1 mediates efficient inhibition.	Univ Clin, IZKF BIOMAT, RWTH Aachen, D-52074 Aachen, Germany; Max Planck Inst Polymer Res, D-55128 Mainz, Germany; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Kinki Univ, Sch Med, Dept Biochem, Osaka 5898511, Japan; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	Max Planck Society; University of Kiel; Kindai University (Kinki University); University of Wurzburg	Jahnen-Dechent, W (corresponding author), Univ Clin, IZKF BIOMAT, RWTH Aachen, Pauwelsstr 30, D-52074 Aachen, Germany.	willi.jahnen@rwth-aachen.de	Heiss, Alexander/C-9698-2009; Heiss, Alexander/AAK-4928-2020; Jahnen-Dechent, Willi/A-7608-2011	Heiss, Alexander/0000-0002-6033-6636; Jahnen-Dechent, Willi/0000-0003-1315-4407; Renne, Thomas/0000-0003-4594-5975				ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BLUMENTHAL NC, 1989, CLIN ORTHOP RELAT R, P279; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BROWN WM, 1992, EUR J BIOCHEM, V205, P321, DOI 10.1111/j.1432-1033.1992.tb16783.x; Busch E, 2000, J BIOL CHEM, V275, P25508, DOI 10.1074/jbc.M001770200; Busch S, 1999, EUR J INORG CHEM, P1643; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; Du Chesne A, 1999, MACROMOL CHEM PHYSIC, V200, P1813, DOI 10.1002/(SICI)1521-3935(19990801)200:8<1813::AID-MACP1813>3.0.CO;2-N; GILMAN H, 1994, J INORG BIOCHEM, V55, P21, DOI 10.1016/0162-0134(94)85129-8; GLIMCHER MJ, 1990, BIOMATERIALS, V11, P7; Haglund AC, 2001, BIOCHEM J, V357, P437, DOI 10.1042/0264-6021:3570437; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HAUSCHKA PV, 1982, BIOCHEMISTRY-US, V21, P2538, DOI 10.1021/bi00539a038; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; JAHNENDECHENT W, 1994, EUR J BIOCHEM, V226, P59, DOI 10.1111/j.1432-1033.1994.tb20026.x; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KETTELER M, 2003, IN PRESS LANCET; Kirschvink JL, 2001, CURR OPIN NEUROBIOL, V11, P462, DOI 10.1016/S0959-4388(00)00235-X; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Nakamura I, 1999, HUM GENET, V104, P492, DOI 10.1007/s004390050993; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Neuman W. F., 1980, FUNDAMENTAL CLIN BON, P83; Olivier E, 2000, BIOCHEM J, V350, P589, DOI 10.1042/0264-6021:3500589; Price PA, 2002, J BONE MINER RES, V17, P1171, DOI 10.1359/jbmr.2002.17.7.1171; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; RAJ PA, 1992, J BIOL CHEM, V267, P5968; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Schinke T, 1997, FEBS LETT, V412, P559, DOI 10.1016/S0014-5793(97)00827-2; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; Schinke T, 1999, NAT GENET, V21, P150, DOI 10.1038/5928; Shen XY, 1997, J BIOL CHEM, V272, P32472, DOI 10.1074/jbc.272.51.32472; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Suvorova EI, 1999, J MICROSC-OXFORD, V196, P46, DOI 10.1046/j.1365-2818.1999.00608.x; SUZUKI M, 1994, J EXP ZOOL, V270, P501, DOI 10.1002/jez.1402700603; Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; TERMINE JD, 1988, CIBA FDN S, V136, P178; Triffit J. T., 1980, FUNDAMENTAL CLIN BON, P45; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; WALSH D, 1994, SCIENCE, V264, P1576, DOI 10.1126/science.264.5165.1576; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200	51	375	395	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13333	13341		10.1074/jbc.M210868200	http://dx.doi.org/10.1074/jbc.M210868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556469	Green Submitted, hybrid			2022-12-27	WOS:000182189500094
J	Laneve, P; Altieri, F; Fiori, ME; Scaloni, A; Bozzoni, I; Caffarelli, E				Laneve, P; Altieri, F; Fiori, ME; Scaloni, A; Bozzoni, I; Caffarelli, E			Purification, cloning, and characterization of XendoU, a novel endoribonuclease involved in processing of intron-encoded small nucleolar RNAs in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING ENDONUCLEASE; RIBOSOMAL-RNA; ACTIVE-SITE; IN-VITRO; RIBONUCLEASE; YEAST; SNORNA; CLEAVAGE; GENE; ENZYME	Here we report the purification, from Xenopus laevis oocyte nuclear extracts, of a new endoribonuclease, XendoU, that is involved in the processing of the intron-encoded box C/D U16 small nucleolar RNA (snoRNA) from its host pre-mRNA. Such an activity has never been reported before and has several uncommon features that make it quite a novel enzyme: it is poly(U)-specific, it requires Mn2+ ions, and it produces molecules with 2'-3'-cyclic phosphate termini. Even if XendoU cleaves U-stretches, it displays some preferential cleavage on snoRNA precursor molecules. XendoU also participates in the biosynthesis of another intron-encoded snoRNA, U86, which is contained in the NOP56 gene of Xenopus laevis. A common feature of these snoRNAs is that their production is alternative to that of the mRNA, suggesting an important regulatory role for all the factors involved in the processing reaction.	Univ Roma La Sapienza, Dept Genet & Mol Biol, Inst Mol Biol & Pathol, Inst Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem, I-00185 Rome, Italy; CNR, Inst Anim Prod Syst Mediterranean Environm, Proteom & Mass Spectrometry Lab, I-80147 Naples, Italy; CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Caffarelli, E (corresponding author), Univ Roma La Sapienza, Dept Genet & Mol Biol, Inst Mol Biol & Pathol, Inst Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	elisa.caffarelli@uniroma1.it	Altieri, Fabio/D-2790-2009; Fiori, Micol Eleonora/J-7295-2016; Fiori, Micol E/J-4043-2014; laneve, pietro/ABD-1633-2020; laneve, pietro/M-3386-2014	Altieri, Fabio/0000-0002-6546-2738; Fiori, Micol Eleonora/0000-0002-1813-7035; Fiori, Micol E/0000-0002-1813-7035; Scaloni, Andrea/0000-0001-9362-8515; bozzoni, irene/0000-0002-3485-8537; laneve, pietro/0000-0002-8865-4038				AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Ambros V, 2001, SCIENCE, V293, P811, DOI 10.1126/science.1064400; Bachellerie JP, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P191; BACHMANN M, 1984, BIOCHIM BIOPHYS ACTA, V783, P89, DOI 10.1016/0167-4781(84)90082-4; Bujnicki JM, 2000, FEBS LETT, V486, P328, DOI 10.1016/S0014-5793(00)02322-X; Caffarelli E, 1998, MOL CELL BIOL, V18, P1023, DOI 10.1128/MCB.18.2.1023; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; Caffarelli E, 1997, BIOCHEM BIOPH RES CO, V233, P514, DOI 10.1006/bbrc.1997.6487; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DEUTSCHER MP, 1985, CELL, V40, P731, DOI 10.1016/0092-8674(85)90330-7; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; EDER PS, 1991, J BIOL CHEM, V266, P6472; Filippini D, 2001, BIOCHEM BIOPH RES CO, V288, P16, DOI 10.1006/bbrc.2001.5720; FORSTER AC, 1990, METHOD ENZYMOL, V181, P583; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; Giorgi C, 2001, EMBO J, V20, P6856, DOI 10.1093/emboj/20.23.6856; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P243, DOI 10.1089/dna.1990.9.243; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; NASHIMOTO M, 1995, NUCLEIC ACIDS RES, V23, P3642, DOI 10.1093/nar/23.18.3642; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; Pan  T., 1993, RNA WORLD, P271; PRISLEI S, 1992, NUCLEIC ACIDS RES, V20, P4473, DOI 10.1093/nar/20.17.4473; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; SANTORO B, 1994, MOL CELL BIOL, V14, P6975, DOI 10.1128/MCB.14.10.6975; SCHOENBERG DR, 1997, MRNA METABOLISM POST, P217; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Zamore PD, 2001, MOL CELL, V8, P1158, DOI 10.1016/S1097-2765(01)00418-X	41	73	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13026	13032		10.1074/jbc.M211937200	http://dx.doi.org/10.1074/jbc.M211937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571235	hybrid			2022-12-27	WOS:000182189500056
J	Schmidt, P; Youhnovski, N; Daiber, A; Balan, A; Arsic, M; Bachschmid, M; Przybylski, M; Ullrich, V				Schmidt, P; Youhnovski, N; Daiber, A; Balan, A; Arsic, M; Bachschmid, M; Przybylski, M; Ullrich, V			Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE POLYACRYLAMIDE-GELS; NITRIC-OXIDE; SELECTIVE NITRATION; PEROXYNITRITE; PROTEINS; IDENTIFICATION; NITROTYROSINE; INACTIVATION; MACROPHAGES; SUPEROXIDE	Treatment of bovine aortic microsomes containing active prostacyclin synthase (PGI(2) synthase) with increasing concentrations of peroxynitrite (PN) up to 250 muM of PN yielded specific staining of this enzyme on Western blots with antibodies against 3-nitrotyrosine (3-NT), whereas above 500 muM PN staining of additional proteins was also observed. Following treatment of aortic microsomes with 25 muM PN, PGI(2) synthase was about half-maximally nitrated and about half-inhibited. It was then isolated by gel electrophoresis and subjected to proteolytic digestion with several proteases. Digestion with thermolysin for. 24 h provided a single specific peptide that was isolated by high performance liquid chromatography and identified as a tetrapeptide Leu-Lys-Asn-Tyr(3-nitro)-COOH corresponding to positions 427-430 of PGI(2) synthase. Its structure was established by precise mass determination using Fourier transform-ion cyclotron resonance-nanoelectrospray mass spectrometry and Edman microsequencing and ascertained by synthesis and mass spectrometric characterization of the authentic Tyr-nitrated peptide. Complete digestion by Pronase to 3-nitrotyrosine was obtained only after 72 h, suggesting that the nitrated Tyr-430 residue may be embedded in a tight fold around the heme binding site. These results provide evidence for the specific inhibition of PGI(2) synthase by nitration at Tyr-430 that may occur already at low levels of PN as a consequence of endothelial co-generation of nitric oxide and superoxide.	Univ Konstanz, Fak Biol, Dept Biol, Biol Chem Lab, D-78457 Constance, Germany; Univ Konstanz, Dept Chem, Analyt Chem Lab, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fak Biol, Dept Biol, Biol Chem Lab, Fach X910,Sonnenbuhl, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de	Petre, Brindusa/S-8307-2016; Petre, Brindusa-Alina/C-2793-2011	Bachschmid, Markus Michael/0000-0002-0748-5528				BACHSCHMID M, 2003, IN PRESS FASEB J; Bauer SHJ, 2001, ANAL BIOCHEM, V298, P25, DOI 10.1006/abio.2001.5330; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bian K, 2001, FREE RADICAL BIO MED, V31, P421, DOI 10.1016/S0891-5849(01)00600-1; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; Crow J P, 1995, Adv Pharmacol, V34, P17; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Daiber A, 2000, J INORG BIOCHEM, V81, P213, DOI 10.1016/S0162-0134(00)00110-0; FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; Fligge TA, 2000, BIOCHEMISTRY-US, V39, P8491, DOI 10.1021/bi9922751; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; Hatae T, 1996, FEBS LETT, V389, P268, DOI 10.1016/0014-5793(96)00600-X; Heinz Kathrin, 2002, Nitric Oxide, V6, P400; HORIKAWA S, 1979, ANAL BIOCHEM, V97, P116, DOI 10.1016/0003-2697(79)90334-8; JACOBS E, 1986, ANAL BIOCHEM, V154, P583, DOI 10.1016/0003-2697(86)90033-3; Jiao KS, 2001, ANAL BIOCHEM, V293, P43, DOI 10.1006/abio.2001.5118; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Kroncke KD, 2002, J BIOL CHEM, V277, P13294, DOI 10.1074/jbc.M111216200; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; Michels J, 2002, PROTEIN SCI, V11, P1565, DOI 10.1110/ps.2760102; MONCADA S, 1978, PHARMACOL REV, V30, P293; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Rossier JS, 2003, ANGEW CHEM INT EDIT, V42, P54; Sarver A, 2001, J AM SOC MASS SPECTR, V12, P439, DOI 10.1016/S1044-0305(01)00213-6; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shyue SK, 1997, J BIOL CHEM, V272, P3657, DOI 10.1074/jbc.272.6.3657; SIEGLE I, 1994, FEBS LETT, V347, P221, DOI 10.1016/0014-5793(94)00504-4; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Ullrich V, 2001, BBA-MOL CELL BIOL L, V1532, P1, DOI 10.1016/S1388-1981(01)00126-3; ULLRICH V, 1981, BIOCHEM PHARMACOL, V30, P2033, DOI 10.1016/0006-2952(81)90218-5; ULLRICH V, 1994, ANGEW CHEM INT EDIT, V33, P1911, DOI 10.1002/anie.199419111; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1999, DRUG METAB REV, V31, P343, DOI 10.1081/DMR-100101922; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	45	114	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12813	12819		10.1074/jbc.M208080200	http://dx.doi.org/10.1074/jbc.M208080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562775	hybrid			2022-12-27	WOS:000182189500030
J	van Weelden, SWH; Fast, B; Vogt, A; van der Meer, P; Saas, J; van Hellemond, JJ; Tielens, AGM; Boshart, M				van Weelden, SWH; Fast, B; Vogt, A; van der Meer, P; Saas, J; van Hellemond, JJ; Tielens, AGM; Boshart, M			Procyclic Trypanosoma brucei do not use Krebs cycle activity for energy generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; ENZYME-ACTIVITIES; CIS-ACONITATE; DIFFERENTIATION; METABOLISM; TRANSFORMATION; COMPARTMENTATION; STRAINS; CULTURE; GLUCOSE	The importance of a functional Krebs cycle for energy generation in the procyclic stage of Trypanosoma brucei was investigated under physiological conditions during logarithmic phase growth of a pleomorphic parasite strain. Wild type procyclic cells and mutants with targeted deletion of the gene coding for aconitase were derived by synchronous in vitro differentiation from wild type and mutant (Deltaaco::NEO/Deltaaco::HYG) bloodstream stage parasites, respectively, where aconitase is not expressed and is dispensable. No differences in intracellular levels of glycolytic and Krebs cycle intermediates were found in procyclic wild type and mutant cells, except for citrate that accumulated up to 90-fold in the mutants, confirming the absence of aconitase activity. Surprisingly, deletion of aconitase did not change differentiation nor the growth rate or the intracellular ATP/ADP ratio in those cells. Metabolic studies using radioactively labeled substrates and NMR analysis demonstrated that glucose and proline were not degraded via the Krebs cycle to CO2. Instead, glucose was degraded to acetate, succinate, and alanine, whereas proline was degraded to succinate. Importantly, there was absolutely no difference in the metabolic products released by wild type and aconitase knockout parasites, and both were for survival strictly dependent on respiration via the mitochondrial electron transport chain. Hence, although the Krebs cycle enzymes are present, procyclic T. brucei do not use Krebs cycle activity for energy generation, but the mitochondrial respiratory chain is essential for survival and growth. We therefore propose a revised model of the energy metabolism of procyclic T. brucei.	Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Free Univ Berlin, Inst Mol Biol & Biochem, Mol Cell Biol Unit, D-12203 Berlin, Germany; Heidelberg Univ, Dept Internal Med 3, D-69115 Heidelberg, Germany; DLO, ATO, Agrotechnol Res Inst, NL-6700 AA Wageningen, Netherlands	Utrecht University; Free University of Berlin; Ruprecht Karls University Heidelberg	Boshart, M (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	boshart@lmu.de	van Hellemond, Jaap/T-7555-2019; Boshart, Michael/A-2700-2011	van Hellemond, Jaap/0000-0003-4862-7796; Boshart, Michael/0000-0002-5070-2663; Tielens, Aloysius/0000-0002-5485-1105				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Bergmeyer H. U., 1970, METHODEN ENZYMATISCH, P1163; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN R, 1981, Z PARASITENKD, V66, P17, DOI 10.1007/BF00941941; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; CRONIN CN, 1989, FEBS LETT, V244, P26, DOI 10.1016/0014-5793(89)81154-8; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; DURIEUX PO, 1991, MOL BIOCHEM PARASIT, V45, P19, DOI 10.1016/0166-6851(91)90023-Y; EVANS DA, 1972, J PROTOZOOL, V19, P686, DOI 10.1111/j.1550-7408.1972.tb03561.x; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; Fast B, 1999, BIOCHEM J, V342, P691, DOI 10.1042/0264-6021:3420691; HENSON CP, 1967, J BIOL CHEM, V242, P3833; HOREMANS AMC, 1991, PARASITOLOGY, V102, P259, DOI 10.1017/S0031182000062570; MATTHEWS KR, 1994, J CELL BIOL, V125, P1147, DOI 10.1083/jcb.125.5.1147; MRACEK J, 1991, J PROTOZOOL, V38, P554, DOI 10.1111/j.1550-7408.1991.tb06079.x; Mutomba MC, 1998, MOL BIOCHEM PARASIT, V93, P11, DOI 10.1016/S0166-6851(98)00012-7; MUTURINJOGU R, 1980, MOL BIOCHEM PARASIT, V1, P13, DOI 10.1016/0166-6851(80)90038-9; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; PANDE SV, 1976, ANAL BIOCHEM, V74, P25, DOI 10.1016/0003-2697(76)90306-7; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; ROLIN S, 1993, MOL BIOCHEM PARASIT, V61, P115, DOI 10.1016/0166-6851(93)90164-S; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; TIELENS AGM, 1992, MOL BIOCHEM PARASIT, V56, P49, DOI 10.1016/0166-6851(92)90153-B; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; TIELENS AGM, 1981, MOL BIOCHEM PARASIT, V3, P205, DOI 10.1016/0166-6851(81)90052-9; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P91, DOI 10.1016/0166-6851(96)02727-2; Vassella E, 2001, MOL MICROBIOL, V41, P33, DOI 10.1046/j.1365-2958.2001.02471.x; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; Vogt AM, 1998, BIOCHEM BIOPH RES CO, V248, P527, DOI 10.1006/bbrc.1998.9005; ZIEGELBAUER K, 1990, EUR J BIOCHEM, V192, P373, DOI 10.1111/j.1432-1033.1990.tb19237.x	39	87	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12854	12863		10.1074/jbc.M213190200	http://dx.doi.org/10.1074/jbc.M213190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562769	hybrid			2022-12-27	WOS:000182189500035
J	Katagiri, Y; Brew, SA; Ingham, KC				Katagiri, Y; Brew, SA; Ingham, KC			All six modules of the gelatin-binding domain of fibronectin are required for full affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR	The gelatin-binding sites of fibronectin are confined to a 42-kDa region having four type I and two type II modules in the following order: I-6-II1-II2-I-7-I-8-I-9. To determine the relative importance of each module for recognition of gelatin, recombinant green fluorescent fusion proteins were prepared in which individual modules or groups of modules were deleted, and the resulting proteins were tested for binding to gelatin by analytical affinity chromatography. Deletion of both type II modules did not eliminate binding, confirming that at least some of the type I modules in this region are able to bind gelatin. It was found that deletion of type I module 6 tends to increase the affinity, whereas deletion of any other module decreases it. Deletion of module I-9 had a large effect but only if module II2 was also present, suggesting an interaction between these two noncontiguous modules. Analysis of more than 20 recombinant fusion products led to the conclusion that all modules contribute to the interaction either directly by contacting the ligand or indirectly through module-module interactions.	Amer Red Cross Holland Lab, Dept Biochem, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA	American Red Cross	Ingham, KC (corresponding author), Amer Red Cross Holland Lab, Dept Biochem, Jerome H Holland Lab Biomed Sci, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	ingham@usa.redcross.org						BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; Bocquier AA, 1999, STRUCT FOLD DES, V7, P1451, DOI 10.1016/S0969-2126(00)88336-7; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; Ingham KC, 2002, ARCH BIOCHEM BIOPHYS, V407, P217, DOI 10.1016/S0003-9861(02)00454-X; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; ISAACS BS, 1989, BIOCHEMISTRY-US, V28, P842, DOI 10.1021/bi00428a065; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Katagiri Y, 2002, BIOTECHNIQUES, V33, P24, DOI 10.2144/02331bm01; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083	12	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11897	11902		10.1074/jbc.M212512200	http://dx.doi.org/10.1074/jbc.M212512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538576	hybrid			2022-12-27	WOS:000182015700024
J	Lundin, A; Nilsson, C; Gerhard, M; Andersson, DI; Krabbe, M; Engstrand, L				Lundin, A; Nilsson, C; Gerhard, M; Andersson, DI; Krabbe, M; Engstrand, L			The NudA protein in the gastric pathogen Helicobacter pylori is an ubiquitous and constitutively expressed dinucleoside polyphosphate hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; BARTONELLA-BACILLIFORMIS; INVASION GENE; HEAT-SHOCK; APPPPA; PYROPHOSPHATASE; IDENTIFICATION; COLONIZATION; SEQUENCE; REVEALS	The gastric pathogen Helicobacter pylori harbors one Nudix hydrolase, NudA, that belongs to the nucleoside polyphosphate hydrolase subgroup. In this work, the enzymatic activity of purified recombinant NudA protein was analyzed on a number of nucleoside polyphosphates. This predicted 18.6-kDa protein preferably hydrolyzes diadenosine tetraphosphate, AP(4)A at a k(cat) of 0.15 s(-1) and a K-m of 80 mum, resulting in an asymmetrical cleavage of the molecule into ATP and AMP. To study the biological role of this enzyme in H. pylori, an insertion mutant was constructed. There was a 2-7-fold decrease in survival of the mutant as compared with the wild type after hydrogen peroxide exposure but no difference in survival after heat shock or in spontaneous mutation frequency. Western blot analyses revealed that NudA is constitutively expressed in H. pylori at different growth stages and during stress, which would indicate that this protein has a housekeeping function. Given that H. pylori is a diverse species and that all the H. pylori strains tested in this study harbor the nudA gene and show protein expression, we consider NudA to be an important enzyme in this bacterium.	Swedish Inst Infect Dis Control, Dept Bacteriol, S-17182 Solna, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Tech Univ Munich, Dept Med 2, D-81675 Munich, Germany; Pyrosequencing AB, S-75228 Uppsala, Sweden	Swedish Institute for Infectious Disease Control; Karolinska Institutet; Technical University of Munich	Engstrand, L (corresponding author), Swedish Inst Infect Dis Control, Dept Bacteriol, S-17182 Solna, Sweden.	lars.engstrand@smi.ki.se	Gerhard, Markus/P-8996-2019; Gerhard, Markus/N-3387-2014	Gerhard, Markus/0000-0001-9110-3950; Gerhard, Markus/0000-0001-9110-3950; Andersson, Dan/0000-0001-6640-2174				Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; AMES BN, 1960, J BIOL CHEM, V235, P769; Amieva MR, 2002, CELL MICROBIOL, V4, P677, DOI 10.1046/j.1462-5822.2002.00222.x; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; Bjorkholm B, 2001, INFECT IMMUN, V69, P7832, DOI 10.1128/IAI.69.12.7832-7838.2001; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Bjorkholm BM, 2002, J BIOL CHEM, V277, P34191, DOI 10.1074/jbc.M203613200; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Conyers GB, 2000, BIOCHEMISTRY-US, V39, P2347, DOI 10.1021/bi992458n; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; FERRERO RL, 1992, J BACTERIOL, V174, P4212, DOI 10.1128/JB.174.13.4212-4217.1992; GARRISON PN, 1986, MOL CELL BIOL, V6, P1179, DOI 10.1128/MCB.6.4.1179; Gaywee J, 2002, MOL CELL PROTEOMICS, V1, P179, DOI 10.1074/mcp.M100030-MCP200; Gaywee J, 2002, INFECT IMMUN, V70, P6346, DOI 10.1128/IAI.70.11.6346-6354.2002; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; Guo BP, 2002, P NATL ACAD SCI USA, V99, P8354, DOI 10.1073/pnas.122244899; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; JOHNSTONE DB, 1991, EMBO J, V10, P3897, DOI 10.1002/j.1460-2075.1991.tb04959.x; Kwok T, 2002, INFECT IMMUN, V70, P2108, DOI 10.1128/IAI.70.4.2108-2120.2002; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; Lock RA, 2001, PATHOLOGY, V33, P365; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MITCHELL SJ, 1995, INFECT IMMUN, V63, P1552, DOI 10.1128/IAI.63.4.1552-1562.1995; Nakamura A, 2000, FREE RADICAL BIO MED, V28, P1611, DOI 10.1016/S0891-5849(00)00284-7; Nishimura A, 1997, GENES CELLS, V2, P401, DOI 10.1046/j.1365-2443.1997.1300328.x; NOACH LA, 1994, J CLIN PATHOL, V47, P699, DOI 10.1136/jcp.47.8.699; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Salama N, 2000, P NATL ACAD SCI USA, V97, P14668, DOI 10.1073/pnas.97.26.14668; Tassotto ML, 2002, J BIOL CHEM, V277, P15807, DOI 10.1074/jbc.M200965200; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Vartanian A, 1999, FEBS LETT, V456, P175, DOI 10.1016/S0014-5793(99)00956-4; Xu WL, 2002, J BIOL CHEM, V277, P23181, DOI 10.1074/jbc.M203325200	39	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12574	12578		10.1074/jbc.M212542200	http://dx.doi.org/10.1074/jbc.M212542200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551907	hybrid			2022-12-27	WOS:000182015700110
J	Biswas, K; Bandyopadhyay, U; Chattopadhyay, I; Varadaraj, A; Ali, E; Banerjee, RK				Biswas, K; Bandyopadhyay, U; Chattopadhyay, I; Varadaraj, A; Ali, E; Banerjee, RK			A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROESOPHAGEAL-REFLUX DISEASE; FIBROBLAST-GROWTH-FACTOR; PROTON-PUMP INHIBITORS; HELICOBACTER-PYLORI; ACID-SECRETION; MUCOSAL INJURY; LIPID-PEROXIDATION; NITRIC-OXIDE; C-FOS	The mechanism of the antiulcer effect of omeprazole was studied placing emphasis on its role to block oxidative damage and apoptosis during ulceration. Dose-response studies on gastroprotection in stress and indomethacin-induced ulcer and inhibition of pylorus ligation-induced acid secretion indicate that omeprazole significantly blocks gastric lesions at lower dose (2.5 mg/kg) without inhibiting acid secretion, suggesting an independent mechanism for its antiulcer effect. Time course studies on gastroprotection and acid reduction also indicate that omeprazole almost completely blocks lesions at 1 h when acid inhibition is partial. The severity of lesions correlates well with the increased level of endogenous hydroxyl radical ((OH)-O-.), which when scavenged by dimethyl sulfoxide causes around 90% reduction of the lesions, indicating that (OH)-O-. plays a major role in gastric damage. Omeprazole blocks stress-induced increased generation of (OH)-O-. and associated lipid peroxidation and protein oxidation, indicating that its antioxidant role plays a major part in preventing oxidative damage. Omeprazole also prevents stress-induced DNA fragmentation, suggesting its antiapoptotic role to block cell death during ulceration. The oxidative damage of DNA by (OH)-O-. generated in vitro is also protected by omeprazole or its analogue, lansoprazole. Lansoprazole when incubated in a (OH)-O-.-generating system scavenges (OH)-O-. to produce four oxidation products of which the major one in mass spectroscopy shows a molecular ion peak at m/z 385, which is 16 mass units higher than that of lansoprazole (m/z 369). The product shows no additional aromatic proton signal for aromatic hydroxylation in H-1 NMR. The product absorbing at 278 nm shows no alkaline shift for phenols, thereby excluding the formation of hydroxylansoprazole. The product is assigned to lansoprazole sulfone formed by the addition of one oxygen atom at the sulfur center following attack by the (OH)-O-.. Thus, omeprazole plays a significant role in gastroprotection by acting as a potent antioxidant and antiapoptotic molecule.	Indian Inst Chem Biol, Dept Physiol, Kolkata 700032, W Bengal, India; Indian Inst Chem Biol, Dept Immunol, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Banerjee, RK (corresponding author), Indian Inst Chem Biol, Dept Physiol, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	ranajitb@yahoo.com	Biswas, Kaushik/AAR-1446-2020	Biswas, Kaushik/0000-0003-2502-9515; Varadaraj, Archana/0000-0002-1868-1268				Akimoto M, 2000, J CARDIOVASC PHARM, V36, pS282, DOI 10.1097/00005344-200036051-00083; ARAI I, 1987, RES COMMUN CHEM PATH, V57, P313; BABBS CF, 1990, METHOD ENZYMOL, V186, P137; Bandyopadhyay D, 2000, J PINEAL RES, V29, P143, DOI 10.1034/j.1600-079X.2000.290303.x; Bandyopadhyay Debashis, 2001, Current Molecular Medicine (Hilversum), V1, P501, DOI 10.2174/1566524013363483; Bandyopadhyay U, 2002, LIFE SCI, V71, P2845, DOI 10.1016/S0024-3205(02)02143-4; Bhattacharjee M, 2002, FREE RADICAL BIO MED, V32, P731, DOI 10.1016/S0891-5849(02)00757-8; Buege J A, 1978, Methods Enzymol, V52, P302; BURGET DW, 1990, GASTROENTEROLOGY, V99, P345, DOI 10.1016/0016-5085(90)91015-X; CHO CH, 1979, EUR J PHARMACOL, V55, P23, DOI 10.1016/0014-2999(79)90144-4; Cho JY, 2002, BRIT J CLIN PHARMACO, V53, P393, DOI 10.1046/j.1365-2125.2002.01366.x; CURIPEDROSA R, 1993, BR J CLIN PHARM, V36, P156; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; DAS D, 1993, MOL CELL BIOCHEM, V125, P115, DOI 10.1007/BF00936440; Das D, 1998, FREE RADICAL BIO MED, V24, P460, DOI 10.1016/S0891-5849(97)00281-5; DAVIES GR, 1994, GUT, V35, P179, DOI 10.1136/gut.35.2.179; DAVIES GR, 1994, EUR J GASTROEN HEPAT, V6, P1; Esplugues JV, 1996, P NATL ACAD SCI USA, V93, P14839, DOI 10.1073/pnas.93.25.14839; Evbuomwan M I, 1993, Afr J Med Med Sci, V22, P29; FELDMAN M, 1986, GASTROENTEROLOGY, V90, P540, DOI 10.1016/0016-5085(86)91106-6; FELLENIUS E, 1981, NATURE, V290, P159, DOI 10.1038/290159a0; Fujii Y, 2000, P SOC EXP BIOL MED, V224, P102, DOI 10.1046/j.1525-1373.2000.22407.x; Garnett WR, 1996, ANN PHARMACOTHER, V30, P1425, DOI 10.1177/106002809603001212; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Guslandi M, 1999, AM J GASTROENTEROL, V94, P2797, DOI 10.1111/j.1572-0241.1999.02797.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAYASE M, 1986, DIGEST DIS SCI, V31, P166, DOI 10.1007/BF01300703; Horn J, 2000, CLIN THER, V22, P266, DOI 10.1016/S0149-2918(00)80032-6; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; ITO T, 1990, GASTROENTEROLOGY, V98, P1525, DOI 10.1016/0016-5085(90)91085-K; ITOH M, 1985, GASTROENTEROLOGY, V88, P1162, DOI 10.1016/S0016-5085(85)80075-5; Jones MK, 1999, AM J PHYSIOL-GASTR L, V276, pG1345, DOI 10.1152/ajpgi.1999.276.6.G1345; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Kanazawa H, 2002, J CHROMATOGR A, V949, P1, DOI 10.1016/S0021-9673(01)01508-4; Kobayashi T, 2002, PHARMACOL RES, V46, P75, DOI 10.1016/S1043-6618(02)00034-8; Kohda K, 1999, GUT, V44, P456, DOI 10.1136/gut.44.4.456; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P695; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P211; Kusuhara H, 1998, EUR J PHARMACOL, V360, P273, DOI 10.1016/S0014-2999(98)00679-7; Kwiecien S, 2002, J PHYSIOL PHARMACOL, V53, P39; LANGMAN MJS, 1991, J GASTROEN HEPATOL, V6, P442, DOI 10.1111/j.1440-1746.1991.tb00885.x; Langtry HD, 1998, DRUGS, V56, P447, DOI 10.2165/00003495-199856030-00012; LARSSON H, 1985, SCAND J GASTROENTERO, V20, P23, DOI 10.3109/00365528509095817; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MATTSSON H, 1983, EUR J PHARMACOL, V91, P111, DOI 10.1016/0014-2999(83)90370-9; Miller T A, 1987, Am J Med, V83, P8, DOI 10.1016/0002-9343(87)90805-9; MILNE L, 1993, ARCH BIOCHEM BIOPHYS, V304, P102, DOI 10.1006/abbi.1993.1327; MIZUI T, 1986, LIFE SCI, V38, P2163, DOI 10.1016/0024-3205(86)90216-X; MOORE D, 1998, CURRENT PROTOCOLS MO, V1; Morise Z, 1998, AM J PHYSIOL-GASTR L, V274, pG246, DOI 10.1152/ajpgi.1998.274.2.G246; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Obst B, 2000, CARCINOGENESIS, V21, P1111, DOI 10.1093/carcin/21.6.1111; PERRY MA, 1986, GASTROENTEROLOGY, V90, P362, DOI 10.1016/0016-5085(86)90933-9; PHULL PS, 1995, EUR J GASTROEN HEPAT, V7, P265; PIHAN G, 1987, DIGEST DIS SCI, V32, P1395, DOI 10.1007/BF01296666; Piotrowski J, 1997, BIOCHEM MOL BIOL INT, V42, P247; Piotrowski J, 1997, SCAND J GASTROENTERO, V32, P203, DOI 10.3109/00365529709000195; Piotrowski J, 1996, BIOCHEM MOL BIOL INT, V40, P597; Piotrowski J, 1999, SCAND J GASTROENTERO, V34, P129; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; Sachs G, 1997, PHARMACOTHERAPY, V17, P22; SACHS G, 1993, ALIMENT PHARM THER, V7, P4; SALIM AS, 1991, INTENS CARE MED, V17, P455, DOI 10.1007/BF01690766; SHAY H, 1954, GASTROENTEROLOGY, V26, P906, DOI 10.1016/s0016-5085(54)80008-4; SHIMATSU K, 1997, HEPATOLOGY, V145, P1323; Slomiany BL, 1998, J PHYSIOL PHARMACOL, V49, P489; Slomiany BL, 1997, SCAND J GASTROENTERO, V32, P638, DOI 10.3109/00365529708996511; Szabo I, 2000, J PHYSIOL PHARMACOL, V51, P3; SZABO S, 1995, SCAND J GASTROENTERO, V30, P3, DOI 10.3109/00365529509107754; SZABO S, 1994, GASTROENTEROLOGY, V106, P1106, DOI 10.1016/0016-5085(94)90773-0; Tarnawski A, 1995, J CLIN GASTROENTEROL, V21, pS93; TARNAWSKI A, 2001, AM J GASTROENTEROL, V96, pS74; Tarnawski AS, 1998, J PHYSIOL PHARMACOL, V49, P479; VAANANEN PM, 1991, AM J PHYSIOL, V261, pG470, DOI 10.1152/ajpgi.1991.261.3.G470; Wallace JL, 1996, FASEB J, V10, P731, DOI 10.1096/fasebj.10.7.8635690; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; WANG JY, 1994, AM J PHYSIOL, V266, pG878, DOI 10.1152/ajpgi.1994.266.5.G878; Watanabe S, 2000, J GASTROEN HEPATOL, V15, P168, DOI 10.1046/j.1440-1746.2000.02062.x; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; Wolfe MM, 2000, GASTROENTEROLOGY, V118, pS9, DOI 10.1016/S0016-5085(00)70004-7; YOSHIKAWA T, 1993, GUT, V34, P732, DOI 10.1136/gut.34.6.732; YOSHIKAWA T, 1986, J CLIN BIOCHEM NUTR, V1, P271; Zimmermann AE, 1997, PHARMACOTHERAPY, V17, P308	84	220	226	4	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10993	11001		10.1074/jbc.M210328200	http://dx.doi.org/10.1074/jbc.M210328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529378	hybrid			2022-12-27	WOS:000181855400017
J	Frank, S; Boudko, S; Mizuno, K; Schulthess, T; Engel, J; Bachinger, HP				Frank, S; Boudko, S; Mizuno, K; Schulthess, T; Engel, J; Bachinger, HP			Collagen triple helix formation can be nucleated at either end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE; PROTEINS; ISOMERIZATION; STABILITY; SEQUENCE; COIL	The directional dependence of folding rates for rodlike macromolecules such as parallel a-helical coiled-coils, DNA double-helices, and collagen triple helices is largely unexplored. This is mainly due to technical difficulties in measuring rates in different directions. Folding of collagens is nucleated by trimeric non-collagenous domains. These are usually located at the COOH terminus, suggesting that triple helix folding proceeds from the COOH to the NH2 terminus. Evidence is presented here that effective nucleation is possible at both ends of the collagen-like peptide (Gly-Pro-Pro)(10), using designed proteins in which this peptide is fused either NH2- or COOH-terminal to a nucleation domain, either T4-phage foldon or the disulfide knot of type III collagen. The location of the nucleation domain influences triple-helical stability, which might be explained by differences in the linker sequences and the presence or absence of repulsive charges at the carboxyl-terminal end of the triple helix. Triple helical folding rates are found to be independent of the site of nucleation and consistent with cis-trans isomerization being the rate-limiting step.	Oregon Hlth Sci Univ, Shriners Hosp Children, Dept Res, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland	Oregon Health & Science University; Oregon Health & Science University; University of Basel	Bachinger, HP (corresponding author), Oregon Hlth Sci Univ, Shriners Hosp Children, Dept Res, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.		Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264; Boudko, Sergei/0000-0003-3856-4859				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Areida SK, 2001, J BIOL CHEM, V276, P1594, DOI 10.1074/jbc.M008709200; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; Boudko S, 2002, J MOL BIOL, V317, P459, DOI 10.1006/jmbi.2002.5439; Buevich AV, 2002, J AM CHEM SOC, V124, P7156, DOI 10.1021/ja012699u; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; DAVIS MT, 1995, ANAL CHEM, V67, P4549, DOI 10.1021/ac00120a019; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; Krantz BA, 2001, NAT STRUCT BIOL, V8, P1042, DOI 10.1038/nsb723; Ottl J, 1999, J PEPT SCI, V5, P103, DOI 10.1002/(SICI)1099-1387(199902)5:2<103::AID-PSC188>3.0.CO;2-N; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4134, DOI 10.1021/bi00823a016; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; VANHOLDE KE, 1985, PHYSICAL BIOCHEMISTR; Xu YJ, 2002, BIOCHEMISTRY-US, V41, P8143, DOI 10.1021/bi015952b	20	45	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7747	7750		10.1074/jbc.C200698200	http://dx.doi.org/10.1074/jbc.C200698200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12540847	hybrid			2022-12-27	WOS:000181466800002
J	Campanella, GSV; Lee, EMJ; Sun, J; Luster, AD				Campanella, GSV; Lee, EMJ; Sun, J; Luster, AD			CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ALPHA-CHEMOATTRACTANT; INTERFERON-INDUCIBLE PROTEIN-10; MONOCYTE CHEMOTACTIC PROTEIN-1; ACUTE ALLOGRAFT-REJECTION; X-C CHEMOKINE; T-CELLS; DIFFERENTIAL EXPRESSION; RECEPTOR-BINDING; SULFATE PROTEOGLYCANS; MULTIPLE-SCLEROSIS	The chemokine IP-10 (interferon-inducible protein of 10 kDa, CXCL10) binds the G protein-coupled receptor CXCR3, which is found mainly on activated T cells and NK cells, and plays an important role in Th1-type inflammatory diseases. IP-10 also binds to glycosaminoglycans (GAGs), an interaction thought to be important for its sequestration on endothelial and other cells. In this study, we performed an extensive mutational analysis to identify the CXCR3 and heparin binding sites of murine IP-10. The mutants were characterized for heparin binding, CXCR3 binding, and the ability to induce chemotaxis, Ca2+ flux, and CXCR3 internalization. Double mutations neutralizing adjacent basic residues at the C terminus did not lead to a significant reduction in heparin binding, indicating that the main heparin binding site of IP-10 is not along the C-terminal alpha helix. Alanine exchange of Arg-22 had the largest effect on heparin binding, with residues Arg-20, Ile-24, Lys-26, Lys-46, and Lys-47 further contributing to heparin binding. A charge change mutation of Arg-22 resulted in further reduction in heparin binding. The N-terminal residue Arg-8, preceding the first cysteine, was critical for CXCR3 signaling. Mutations of charged and uncharged residues in the loop regions of residues 20-24 and 46-47, which caused reduced heparin binding, also resulted in reduced CXCR3 binding and signaling. CXCR3 expressing GAG-deficient Chinese hamster ovary cells revealed that GAG binding was not required for IP-10 binding and signaling through CXCR3, which suggests that the CXCR3 and heparin binding sites of IP-10 are partially overlapping.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, Bldg 149,13th St, Charlestown, MA 02129 USA.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NATIONAL CANCER INSTITUTE [R01CA069212] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA69212] Funding Source: Medline; NIDDK NIH HHS [R01-DK50305] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Booth V, 2002, BIOCHEMISTRY-US, V41, P10418, DOI 10.1021/bi026020q; Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Fleischer J, 2002, J IMMUNOL, V169, P770, DOI 10.4049/jimmunol.169.2.770; Flier J, 1999, J INVEST DERMATOL, V113, P574, DOI 10.1046/j.1523-1747.1999.00730.x; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; Melter M, 2001, CIRCULATION, V104, P2558, DOI 10.1161/hc4601.098010; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oravecz T, 1997, J IMMUNOL, V159, P4587; Ottersbach K, 2001, BIOCHEM J, V354, P447, DOI 10.1042/0264-6021:3540447; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Sauty A, 2001, J IMMUNOL, V167, P7084, DOI 10.4049/jimmunol.167.12.7084; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205; Zhao DXM, 2002, J IMMUNOL, V169, P1556, DOI 10.4049/jimmunol.169.3.1556	50	84	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17066	17074		10.1074/jbc.M212077200	http://dx.doi.org/10.1074/jbc.M212077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12571234	hybrid			2022-12-27	WOS:000182818600084
J	de Belle, I; Wu, JX; Sperandio, S; Mercola, D; Adamson, ED				de Belle, I; Wu, JX; Sperandio, S; Mercola, D; Adamson, ED			In vivo cloning and characterization of a new growth suppressor protein TOE1 as a direct target gene of EGR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IN-VIVO; CELLS; BINDING; TRANSFORMATION; CHROMATIN; APOPTOSIS; INDUCTION; LOCALIZATION; FORMALDEHYDE	Egr1, an immediate early transcription factor, responds to diverse stimuli and affects gene transcription to accomplish its biological effects. One important effect of Egr1 expression is to decrease the growth and tumorigenic potential of several tumor cell types. To identify important Egr1 target genes, we have adapted a methodology involving formaldehyde-induced protein-DNA cross-linking, chromatin immunoprecipitation, and multiplex PCR. Using this approach, we report the cloning of a new Egr1 target gene that is able to account, at least in part, for the growth inhibitory activity of Egr1. We have named this new protein TOE1 for target of Egr1.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA; Buck Inst Age Res, Novato, CA 94945 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Buck Institute for Research on Aging; University of California System; University of California San Diego	de Belle, I (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NATIONAL CANCER INSTITUTE [R01CA067888] Funding Source: NIH RePORTER; NCI NIH HHS [CA67888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Cheung TH, 1999, CANCER-AM CANCER SOC, V86, P1294, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1294::AID-CNCR26>3.3.CO;2-F; de Belle I, 2000, BIOTECHNIQUES, V29, P162; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Evdokiou A, 1999, MOL ENDOCRINOL, V13, P1738, DOI 10.1210/me.13.10.1738; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Leary T, 1999, LAB INVEST, V79, P1461; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Smedley D, 2000, GENE CHROMOSOME CANC, V28, P121, DOI 10.1002/(SICI)1098-2264(200005)28:1<121::AID-GCC14>3.0.CO;2-O; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102	29	26	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14306	14312		10.1074/jbc.M210502200	http://dx.doi.org/10.1074/jbc.M210502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562764	hybrid			2022-12-27	WOS:000182405000094
J	Liu, Y; Bambara, RA				Liu, Y; Bambara, RA			Analysis of human flap endonuclease 1 mutants reveals a mechanism to prevent triplet repeat expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; MICROSATELLITE INSTABILITY; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEATS; SECONDARY STRUCTURE; GENETIC INSTABILITY; MUTATION AVOIDANCE; OKAZAKI FRAGMENTS; EXCISION-REPAIR	Flap endonuclease 1 (FEN1), involved in the joining of Okazaki fragments, has been proposed to restrain DNA repeat sequence expansion, a process associated with aging and disease. Here we analyze properties of human FEN1 having mutations at two conserved glycines (G66S and G242D) causing defects in nuclease activity. Introduction of these mutants into yeast led to sequence expansions. Reconstituting triplet repeat expansion in vitro, we previously found that DNA ligase I promotes expansion, but FEN1 prevents the ligation that forms expanded products. Here we show that among the intermediates that could generate sequence expansion, a bubble is necessary for ligation to produce the expansion product. Severe exonuclease defects in the mutant FEN1 suggested that the inability to degrade bubbles exonucleolytically leads to expansion. However, even wild type FEN1 exonuclease cannot compete with DNA ligase I to degrade a bubble structure before it can be ligated. Instead, we propose that FEN1 suppresses sequence expansion by degrading flaps that equilibrate with bubbles, thereby reducing bubble concentration. In this way FEN1 employs endonuclease rather than exonuclease to prevent expansions. A model is presented describing the roles of DNA structure, DNA Iigase 1, and FEN1 in sequence expansion.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NIGMS NIH HHS [GM24441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; BUDD ME, 2000, MUTAT RES, V459, P137; Debrauwere H, 1997, BIOCHIMIE, V79, P577, DOI 10.1016/S0300-9084(97)82006-8; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Greene AL, 1999, HUM MOL GENET, V8, P2263, DOI 10.1093/hmg/8.12.2263; Harfe BD, 1999, MOL CELL BIOL, V19, P4766; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HENDERSON ST, 1993, GENETICS, V134, P57; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lopes J, 2002, EMBO J, V21, P3201, DOI 10.1093/emboj/cdf310; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; MERLO A, 1994, CANCER RES, V54, P2098; Mirkin SM, 2002, NAT GENET, V31, P5, DOI 10.1038/ng0502-5; MIRONOV NM, 1994, CANCER RES, V54, P41; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Morel P, 1998, P NATL ACAD SCI USA, V95, P10003, DOI 10.1073/pnas.95.17.10003; Nagata Y, 2002, GENETICS, V160, P13; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; PFAFFENBERGER RC, 1981, STAT METHODS BUSINES, P665; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROSE MD, 2000, METHODS YEAST GENETI, P171; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; White PJ, 1999, MOL CELL BIOL, V19, P5675; Wierdl M, 1997, GENETICS, V146, P769; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001	64	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13728	13739		10.1074/jbc.M212061200	http://dx.doi.org/10.1074/jbc.M212061200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12554738	hybrid			2022-12-27	WOS:000182405000023
J	Ortega, AL; Carretero, J; Obrador, E; Gambini, J; Asensi, M; Rodilla, V; Estrela, JM				Ortega, AL; Carretero, J; Obrador, E; Gambini, J; Asensi, M; Rodilla, V; Estrela, JM			Tumor cytotoxicity by endothelial cells - Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; INTRACELLULAR-DISTRIBUTION; METASTATIC ACTIVITY; OXIDATIVE INJURY; REDOX REGULATION; COMPLEX-I; INHIBITION; DAMAGE	High GSH content associates with high metastatic activity in B16-F10 melanoma cells cultured to low density (LD B16M). GSH homeostasis was investigated in LD B16M cells that survive after adhesion to the hepatic sinusoidal endothelium (HSE). Invasive B16M (iB16M) cells were isolated using anti-Met-72 monoclonal antibodies and flow cytometry-coupled cell sorting. HSE-derived NO and H2O2 caused GSH depletion and a decrease in gamma-glutamyleysteine synthetase activity in iB16M cells. Overexpression of y-glutamyleysteine synthetase heavy and light subunits led to a rapid recovery of cytosolic GSH, whereas mitochondrial GSH (mtGSH) further decreased during the first 18 h of culture. NO and H2O2 damaged the mitochondrial system for GSH uptake (rates in iB16M were approximately 75% lower than in LD B16M cells). iB16M cells also showed a decreased activity of mitochondrial complexes II,III, and IV, less O-2 consumption, lower ATP levels, higher O-2(.-) and H2O2 production, and lower mitochondrial Membrane potential. In vitro growing iB16M cells maintained high viability (>98%) and repaired HSE-induced mitochondrial damages within 48 h. However, iB16M cells with low mtGSH levels were highly susceptible to TNF-alpha-induced oxidative stress and death. Therefore depletion of mtGSH levels may represent a critical target to challenge survival of invasive cancer cells.	Univ Valencia, Fac Med & Odontol, Dept Fisiol, E-46010 Valencia, Spain; Univ Cardenal Herrera CEU, Dept Fisiol Farmacol & Toxicol, E-46113 Moncada, Spain	University of Valencia; Universidad CEU Cardenal Herrera	Estrela, JM (corresponding author), Univ Valencia, Fac Med & Odontol, Dept Fisiol, Av Blasco Ibanez 17, E-46010 Valencia, Spain.	jose.m.estrela@uv.es	OBRADOR, ELENA/H-4069-2015; Ortega, Angel L./A-4113-2014; Carretero, Julian/N-5214-2014; Rodilla, Vicent/L-6977-2014; Miralles, Miguel A Asensi/I-2756-2015; Estrela, Jose/H-4449-2015	OBRADOR, ELENA/0000-0002-5934-5543; Ortega, Angel L./0000-0002-9901-3383; Carretero, Julian/0000-0001-7269-8506; Miralles, Miguel A Asensi/0000-0003-1922-7777; Estrela, Jose/0000-0002-2540-9190; Rodilla, Vicent/0000-0001-9460-7505; Ortega Granados, Ana Laura/0000-0002-5727-3371; Gambini, Juan/0000-0001-8979-2865				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Akerboom T P, 1981, Methods Enzymol, V77, P373; Anasagasti MJ, 1997, HEPATOLOGY, V25, P840, DOI 10.1002/hep.510250410; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; ANDERSON ME, 1985, ARCH BIOCHEM BIOPHYS, V239, P538, DOI 10.1016/0003-9861(85)90723-4; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; Bergmeyer H.U., 1985, METHODS ENZYMATIC AN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; ESTRELA JM, 1992, BIOCHEM J, V286, P257, DOI 10.1042/bj2860257; FIDLER IJ, 1990, CANCER RES, V50, P6130; Fukumura D, 1996, HEPATOLOGY, V24, P141, DOI 10.1053/jhep.1996.v24.pm0008707254; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; HAN J, 1995, BIOL NITRIC OXIDE, P84; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang ZZ, 2001, FASEB J, V15, P19, DOI 10.1096/fj.00-0445fje; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; KIMURA AK, 1986, JNCI-J NATL CANCER I, V76, P1247; KOVACS AL, 1981, EXP CELL RES, V133, P431, DOI 10.1016/0014-4827(81)90336-0; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAFRENIE R, 1992, CANCER METAST REV, V11, P377, DOI 10.1007/BF01307188; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LASH LH, 1995, METHOD ENZYMOL, V252, P14; LI L, 1991, CANCER RES, V51, P245; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Pearce LL, 2001, NITRIC OXIDE-BIOL CH, V5, P128, DOI 10.1006/niox.2001.0338; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; Raha S, 2002, FREE RADICAL BIO MED, V32, P421, DOI 10.1016/S0891-5849(01)00816-4; REED DJ, 1980, BIOCHEM BIOPH RES CO, V94, P1273, DOI 10.1016/0006-291X(80)90557-4; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; SELLAK H, 1994, BLOOD, V83, P2669; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; Sies H, 1982, METABOLIC COMPARTMEN; Stevenson D, 2002, TOXICOL IN VITRO, V16, P609, DOI 10.1016/S0887-2333(02)00042-5; Stewart VC, 2000, J NEUROCHEM, V75, P694, DOI 10.1046/j.1471-4159.2000.0750694.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang HM, 2000, CANCER RES, V60, P5862; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	75	44	46	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13888	13897		10.1074/jbc.M207140200	http://dx.doi.org/10.1074/jbc.M207140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578841	hybrid			2022-12-27	WOS:000182405000043
J	Rajagopal, L; Clancy, A; Rubens, CE				Rajagopal, L; Clancy, A; Rubens, CE			A eukaryotic type serine/threonine kinase and phosphatase in Streptococcus agalactiae reversibly phosphorylate an inorganic pyrophosphatase and affect growth, cell segregation, and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SER/THR PROTEIN-KINASE; GROUP-B STREPTOCOCCUS; BACILLUS-SUBTILIS; SUBSTRATE-SPECIFICITY; ALKALINE-PHOSPHATASE; SECONDARY METABOLISM; SIGNAL-TRANSDUCTION; GENES; THREONINE; SERINE	Protein phosphorylation is essential for the regulation of cell growth, division, and differentiation in both prokaryotes and eukaryotes. Signal transduction in prokaryotes was previously thought to occur primarily by histidine kinases, involved in two-component signaling pathways. Lately, bacterial homologues of eukaryotictype serine/threonine kinases and phosphatases have been found to be necessary for cellular functions such as growth, differentiation, pathogenicity, and secondary metabolism. The Gram-positive bacteria Streptococcus agalactiae (group B streptococci, GBS) is an important human pathogen. We have identified and characterized a eukaryotic-type serine/threonine protein kinase (Stk1) and its cognate phosphatase (Stp1) in GBS. Biochemical assays revealed that Stk1 has kinase activity and localizes to the membrane and that Stp1 is a soluble protein with manganese-dependent phosphatase activity on Stk1. Mutations in these genes exhibited pleiotropic effects on growth, virulence, and cell segregation of GBS. Complementation of these mutations restored the wild type phenotype linking these genes to the regulation of various cellular processes in GBS. In vitro phosphorylation of cell extracts from wild type and mutant strains revealed that Stk1 is essential for phosphorylation of six GBS proteins. We have identified the predominant endogenous substrate of both Stk1 and Stp1 as a manganese-dependent inorganic pyrophosphatase (PpaC) by liquid chromatography/tandem mass spectrometry. These results suggest that these eukaryotictype enzymes regulate pyrophosphatase activity and other cellular functions of S. agalactiae.	Childrens Hosp & Reg Med Ctr, Dept Pediat, Div Infect Dis, Seattle, WA 98105 USA	Seattle Children's Hospital	Rubens, CE (corresponding author), Childrens Hosp & Reg Med Ctr, Dept Pediat, Div Infect Dis, Mail Stop 8G-1,4800 Sandpoint Way NE, Seattle, WA 98105 USA.	craig.rubens@seattlechildrens.org			NIAID NIH HHS [811501/N01-AI-75326] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075326] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu Kwaik Y, 1998, INFECT IMMUN, V66, P203; Adler E, 1997, MOL MICROBIOL, V23, P57, DOI 10.1046/j.1365-2958.1997.1801552.x; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Av-Gay Y., 1997, MICROB COMP GENOMICS, V2, P63, DOI DOI 10.1089/OMI.1.1997.2.63; Bakal CJ, 2000, TRENDS CELL BIOL, V10, P32, DOI 10.1016/S0962-8924(99)01681-5; Bork P, 1996, PROTEIN SCI, V5, P1421, DOI 10.1002/pro.5560050720; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Chaffin DO, 1998, GENE, V219, P91, DOI 10.1016/S0378-1119(98)00396-5; Chaffin DO, 2000, J BACTERIOL, V182, P4466, DOI 10.1128/JB.182.16.4466-4477.2000; Cieslewicz MJ, 2001, J BIOL CHEM, V276, P139, DOI 10.1074/jbc.M005702200; CLARK JM, 1977, EXPT BIOCH, P105; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanlon WA, 1997, MOL MICROBIOL, V23, P459, DOI 10.1046/j.1365-2958.1997.d01-1871.x; HENRICHSEN J, 1985, NEONATAL GROUP B STR, V35, P53; Hooper GR, 1986, PROCEDURES TRANSMISS; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; Inouye Sumiko, 2000, Microbial and Comparative Genomics, V5, P103, DOI 10.1089/10906590050179783; Jones AL, 2000, MOL MICROBIOL, V37, P1444, DOI 10.1046/j.1365-2958.2000.02099.x; Juris SJ, 2000, P NATL ACAD SCI USA, V97, P9431, DOI 10.1073/pnas.170281997; Kamei A, 2001, J BACTERIOL, V183, P1505, DOI 10.1128/JB.183.5.1505-1510.2001; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; LAHTI R, 1983, MICROBIOL REV, V47, P169, DOI 10.1128/MMBR.47.2.169-178.1983; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; Lee MH, 1999, J BACTERIOL, V181, P5790, DOI 10.1128/JB.181.18.5790-5799.1999; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; Lower BH, 2000, J BACTERIOL, V182, P3452, DOI 10.1128/JB.182.12.3452-3459.2000; Ma PS, 1997, MICROBIOL-SGM, V143, P3451, DOI 10.1099/00221287-143-11-3451; MACKINTOSH C, 1993, PROTEIN PHOSPHORYLAT, P197; Madec E, 2002, MOL MICROBIOL, V46, P571, DOI 10.1046/j.1365-2958.2002.03178.x; MADOFF LC, 1991, INFECT IMMUN, V59, P204, DOI 10.1128/IAI.59.1.204-210.1991; MATSUMOTO A, 1994, GENE, V146, P47; Mijakovic I, 2002, P NATL ACAD SCI USA, V99, P13442, DOI 10.1073/pnas.212410399; Muench, 1938, AM J HYG, V27, P493, DOI [10.1093/oxfordjournals.aje.a118408, DOI 10.1093/OXFORDJOURNALS.AJE.A118408]; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; Nizet V, 1999, STREPTOCOCCAL INFECTIONS, P180; NotleyMcRobb L, 1997, MICROBIOL-SGM, V143, P1909, DOI 10.1099/00221287-143-6-1909; O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x; Ogawara H, 1999, MICROBIOL-UK, V145, P3343, DOI 10.1099/00221287-145-12-3343; OKADA N, 1993, MOL MICROBIOL, V7, P893, DOI 10.1111/j.1365-2958.1993.tb01180.x; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; PINCUS SH, 1992, J BACTERIOL, V174, P3739, DOI 10.1128/JB.174.11.3739-3749.1992; RANDERATH K, 1964, THIN LAYER CHROMATOG, P93; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; Rudd JJ, 2003, J EXP BOT, V54, P141, DOI 10.1093/jxb/54.380.141; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; Schuchat A, 1998, CLIN MICROBIOL REV, V11, P497, DOI 10.1128/CMR.11.3.497; SHAKHOV YA, 1981, BIOCHEM INT, V3, P139; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi L, 1998, FEMS MICROBIOL REV, V22, P229, DOI 10.1016/S0168-6445(98)00015-1; Shintani T, 1998, FEBS LETT, V439, P263, DOI 10.1016/S0014-5793(98)01381-7; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Treuner-Lange A, 2001, MOL MICROBIOL, V40, P126, DOI 10.1046/j.1365-2958.2001.02362.x; Umeyama T, 2002, APPL MICROBIOL BIOT, V59, P419, DOI 10.1007/s00253-002-1045-1; Umeyama T, 2000, GENE, V258, P55, DOI 10.1016/S0378-1119(00)00450-9; Villafranca JE, 1996, CURR OPIN BIOTECH, V7, P397; Wang JY, 1998, J BACTERIOL, V180, P6764, DOI 10.1128/JB.180.24.6764-6768.1998; Whittaker CJ, 1996, INFECT IMMUN, V64, P4137, DOI 10.1128/IAI.64.10.4137-4142.1996; WILLETT NP, 1966, J BACTERIOL, V91, P2245, DOI 10.1128/JB.91.6.2245-2250.1966; Wu JG, 1999, P NATL ACAD SCI USA, V96, P13068, DOI 10.1073/pnas.96.23.13068; Yang XF, 1996, GENE DEV, V10, P2265, DOI 10.1101/gad.10.18.2265; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; ZHANG CC, 1993, P NATL ACAD SCI USA, V90, P11840, DOI 10.1073/pnas.90.24.11840; Zhang CC, 1998, NUCLEIC ACIDS RES, V26, P3619, DOI 10.1093/nar/26.16.3619; Zhang CC, 1998, J BACTERIOL, V180, P2616, DOI 10.1128/JB.180.10.2616-2622.1998; Zhang CC, 1996, MOL MICROBIOL, V20, P9, DOI 10.1111/j.1365-2958.1996.tb02483.x	75	132	144	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14429	14441		10.1074/jbc.M212747200	http://dx.doi.org/10.1074/jbc.M212747200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562757	hybrid			2022-12-27	WOS:000182405000110
J	Ruiz-Palacios, GM; Cervantes, LE; Ramos, P; Chavez-Munguia, B; Newburg, DS				Ruiz-Palacios, GM; Cervantes, LE; Ramos, P; Chavez-Munguia, B; Newburg, DS			Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; EPITHELIAL-CELLS; ESCHERICHIA-COLI; HELICOBACTER-PYLORI; TOXIN PRODUCTION; SUCKLING MICE; ENTERO-TOXIN; OLIGOSACCHARIDES; EXPRESSION; RECOGNITION	The most common cause of infant mortality is diarrhea; the most common cause of bacterial diarrhea is Campylobacter jejuni, which is also the primary cause of motor neuron paralysis. The first step in campylobacter pathogenesis is adherence to intestinal mucosa. We found that such binding was inhibited in vitro by human milk and, with high avidity, by alpha1,2-fucosylated carbohydrate moieties containing the H(O) blood group epitope (Fucalpha1,2Galbeta1,4GlcNAc...). In studies on the mechanism of adherence, campylobacter, which normally does not bind to Chinese hamster ovary cells, bound avidly when the cells were transfected with a human alpha1,2-fucosyltransferase gene that caused overexpression of H-2 antigen; binding was specifically inhibited by H-2 ligands (lectins Ulex europaeus and Lotus tetragonolobus and H-2 monoclonal antibody), H-2 mimetics, and human milk oligosaccharides. Human milk oligosaccharides inhibited campylobacter colonization of mice in vivo and human intestinal mucosa ex vivo. Campylobacter colonization of nursing mouse pups was inhibited if their dams had been transfected with a human alpha1,2-fucosyltransferase gene that caused expression of H(O) antigen in milk. We conclude that campylobacter binding to intestinal H-2 antigen is essential for infection. Milk fucosyloligosaccharides and specific fucosyl alpha1,2-linked molecules inhibit this binding and may represent a novel class of antimicrobial agents.	Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City 14000, DF, Mexico; IPN, Ctr Invest & Estudios Avanzados, Dept Expt Pathol, Mexico City 07360, DF, Mexico; Univ Massachusetts, Sch Med, Shriver Ctr, Program Glyobiol, Waltham, MA 02452 USA	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; University of Massachusetts System	Ruiz-Palacios, GM (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Vasco Quiroga 15, Mexico City 14000, DF, Mexico.	gmrps@servidor.unam.mx	Ghorayeb, Imad/B-3473-2012; Duarte, Graziela Biude Silva/Q-7728-2016; Newburg, david/ABE-8139-2020; Ghorayeb, Imad/D-5073-2017; Ruiz-Palacios, Guillermo/GYQ-5462-2022	Ghorayeb, Imad/0000-0003-1996-8049; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD013021] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLACKWELL CC, 1986, PROTEIN CARBOHYDRATE, P229; BLASER MJ, 1983, INFECT IMMUN, V39, P908, DOI 10.1128/IAI.39.2.908-916.1983; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; Carvalho ACT, 2001, J CLIN MICROBIOL, V39, P1353, DOI 10.1128/JCM.39.4.1353-1359.2001; CINCO M, 1984, FEMS MICROBIOL LETT, V21, P347, DOI 10.1111/j.1574-6968.1984.tb00334.x; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; CLEARY TG, 1983, J INFECT DIS, V148, P1114, DOI 10.1093/infdis/148.6.1114; COPPA GV, 1990, LANCET, V335, P569, DOI 10.1016/0140-6736(90)90350-E; CRANE JK, 1994, J NUTR, V124, P2358, DOI 10.1093/jn/124.12.2358; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; DU MH, 1994, GLYCOCONJUGATE J, V11, P443, DOI 10.1007/BF00731281; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; FAUCHERE JL, 1986, INFECT IMMUN, V54, P283, DOI 10.1128/IAI.54.2.283-287.1986; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; GLASS RI, 1985, AM J EPIDEMIOL, V121, P791, DOI 10.1093/oxfordjournals.aje.a114050; HAKOMORI S, 1985, CANCER RES, V45, P2405; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; Hutson AM, 2002, J INFECT DIS, V185, P1335, DOI 10.1086/339883; Ikehara Y, 2001, CANCER EPIDEM BIOMAR, V10, P971; JENNESS R, 1979, SEMIN PERINATOL, V3, P225; Jin SM, 2001, MOL MICROBIOL, V39, P1225, DOI 10.1046/j.1365-2958.2001.02294.x; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; Kelle K, 1998, RES MICROBIOL, V149, P723, DOI 10.1016/S0923-2508(99)80019-9; Konkel ME, 1999, MOL MICROBIOL, V32, P691, DOI 10.1046/j.1365-2958.1999.01376.x; KUNZ C, 1993, ACTA PAEDIATR, V82, P903, DOI 10.1111/j.1651-2227.1993.tb12597.x; LOMBERG H, 1986, PROTEIN CARBOHYDRATE, P235; Marchant J, 2002, TRENDS MICROBIOL, V10, P155, DOI 10.1016/S0966-842X(02)02323-5; Marionneau S, 2002, GASTROENTEROLOGY, V122, P1967, DOI 10.1053/gast.2002.33661; Mitchell E, 2002, NAT STRUCT BIOL, V9, P918, DOI 10.1038/nsb865; Mollicone R, 1996, GLYCOCONJUGATE J, V13, P263, DOI 10.1007/BF00731501; Newburg DS, 1996, J MAMMARY GLAND BIOL, V1, P271, DOI 10.1007/BF02018080; NEWBURG DS, 1993, J INFECT DIS, V168, P476, DOI 10.1093/infdis/168.2.476; NEWBURG DS, 1990, J INFECT DIS, V162, P1075, DOI 10.1093/infdis/162.5.1075; Pei ZH, 1998, INFECT IMMUN, V66, P938, DOI 10.1128/IAI.66.3.938-943.1998; PEI ZH, 1991, J BIOL CHEM, V266, P16363; Pickett CL, 1996, INFECT IMMUN, V64, P2070, DOI 10.1128/IAI.64.6.2070-2078.1996; PRIETO PA, 1995, J BIOL CHEM, V270, P29515, DOI 10.1074/jbc.270.49.29515; Prieto PA, 1997, J BIOL CHEM, V272, P2089; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; RUIZPALACIOS GM, 1983, LANCET, V2, P250; RUIZPALACIOS GM, 1992, CAMPLYLOBACTER JEJUNI, P176; RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6; RUIZPALACIOS GM, 1997, PRINCIPLES PRACTICE, P987; RUSSELL RG, 1994, INFECT IMMUN, V62, P3773, DOI 10.1128/IAI.62.9.3773-3779.1994; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; van Vliet AHM, 2001, J APPL MICROBIOL, V90, p45S, DOI 10.1046/j.1365-2672.2001.01353.x; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WALKER RI, 1986, MICROBIOL REV, V50, P81, DOI 10.1128/MMBR.50.1.81-94.1986; Wassenaar TM, 1997, CLIN MICROBIOL REV, V10, P466, DOI 10.1128/CMR.10.3.466; Wassenaar TM, 1999, MICROBES INFECT, V1, P1023, DOI 10.1016/S1286-4579(99)80520-6	51	443	492	9	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14112	14120		10.1074/jbc.M207744200	http://dx.doi.org/10.1074/jbc.M207744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562767	hybrid			2022-12-27	WOS:000182405000072
J	Satchell, DP; Sheynis, T; Shirafuji, Y; Kolusheva, S; Ouellette, AJ; Jelinek, R				Satchell, DP; Sheynis, T; Shirafuji, Y; Kolusheva, S; Ouellette, AJ; Jelinek, R			Interactions of mouse paneth cell alpha-defensins and alpha-defensin precursors with membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT NEUTROPHIL DEFENSINS; NATURAL PEPTIDE ANTIBIOTICS; INTESTINAL HOST-DEFENSE; ANTIMICROBIAL PEPTIDES; PHOSPHOLIPID-VESICLES; COLORIMETRIC ASSAY; LUNG MACROPHAGES; LIPID VESICLES; MELITTIN; BILAYERS	The bactericidal activity of mouse alpha-defensins (cryptdins) requires proteolytic activation of inactive precursors by matrix metalloproteinase-7 (matrilysin, EC 3.4.24.23, NEAP-7(a)). To investigate mechanisms of cryptdin-4 (Crp4) peptide interactions with membrane bilayers and to determine whether NMP-7-mediated proteolysis activates the membrane disruptive activity of Crp4, associations of Crp4 and melittin with biomimetic lipid/polydiacetylene chromatic vesicles were characterized. The peptides differ in their sensitivity to vesicle lipid composition and their depth of bilayer penetration. Crp4 undergoes strong interfacial binding onto lipid bilayers with disruption of the bilayer head group region, unlike melittin, which inserts more deeply into the hydrophobic core of the bilayer. Colorimetric and tryptophan fluorescence studies showed that Crp4 insertion is favored by negatively charged phospholipids and that zwitterionic and Escherichia coli phospholipids promote stronger interfacial binding; melittin-membrane interactions were independent of either variable. In contrast to the membrane disruptive activity of Crp4, pro-Crp4 did not perturb vesicular membranes, consistent with the lack of bactericidal activity of the precursor, and incubation of Crp4 with prosegment in trans blocked Crp4 and G1W-Crp4 membrane interactions at concentrations that inhibit Crp4 bactericidal activity. CD measurements showed that Crp4 has an expected beta-sheet structure that is not evident in the pro-Crp4 CD trace or when Crp4 is incubated with prosegment, indicating that the beta-sheet signal is attenuated by proregion interactions or possibly disrupted by the prosegment. Collectively, the results suggest that the prosegment inhibits Crp4 bactericidal activity by blocking peptide-mediated perturbation of target cell membranes, a constraint that is relieved when NMP-7 cleaves the prosegment.	Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Ben Gurion University; University of California System; University of California Irvine; University of California System; University of California Irvine	Jelinek, R (corresponding author), Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel.		JELINEK, RAZ/F-2023-2012	jelinek, raz/0000-0002-0336-1384; Kolusheva, Sofiya/0000-0002-4406-2241	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044632, R55DK044632, F32DK010184] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44632, DK10184] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; BATENBURG AM, 1987, BIOCHIM BIOPHYS ACTA, V903, P155, DOI 10.1016/0005-2736(87)90165-9; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BRAUNER JW, 1987, BIOCHEMISTRY-US, V26, P8151, DOI 10.1021/bi00399a020; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; Evrard D, 2001, PHARMACEUT RES, V18, P943, DOI 10.1023/A:1010980009823; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Hristova K, 2001, BIOPHYS J, V80, P801, DOI 10.1016/S0006-3495(01)76059-6; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; Kolusheva S, 2000, NAT BIOTECHNOL, V18, P225, DOI 10.1038/72697; Kolusheva S, 2000, BIOCHEMISTRY-US, V39, P15851, DOI 10.1021/bi000570b; Kolusheva S, 2001, J AM CHEM SOC, V123, P417, DOI 10.1021/ja0034139; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; Ladokhin AS, 2001, BBA-BIOMEMBRANES, V1514, P253, DOI 10.1016/S0005-2736(01)00382-0; LEHRER RI, 1983, INFECT IMMUN, V42, P10, DOI 10.1128/IAI.42.1.10-14.1983; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Ouellette AJ, 2001, INFLAMM BOWEL DIS, V7, P43, DOI 10.1097/00054725-200102000-00007; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SMITH R, 1994, J MOL BIOL, V241, P456, DOI 10.1006/jmbi.1994.1520; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; White SH, 1998, METHOD ENZYMOL, V295, P62; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	41	95	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13838	13846		10.1074/jbc.M212115200	http://dx.doi.org/10.1074/jbc.M212115200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574157	hybrid			2022-12-27	WOS:000182405000036
J	Cheskis, BJ; McKenna, NJ; Wong, CW; Wong, JM; Komm, B; Lyttle, CR; O'Malley, BW				Cheskis, BJ; McKenna, NJ; Wong, CW; Wong, JM; Komm, B; Lyttle, CR; O'Malley, BW			Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; CONFORMATIONAL-CHANGES; TRAP220 COMPONENT; LIGAND-BINDING; DRIP COMPLEX; ER-ALPHA; ACTIVATION; TRANSCRIPTION; COREGULATORS; BETA	Nuclear receptor (NR)-mediated transcription is driven by dynamic multiprotein coactivator complexes, the composition of which is thought to determine the biological activity of NRs at specific promoters. The extent to which NRs discriminate between a spectrum of potential binding partners is intuitively a function of the inherent affinities of these individual interactions. Using real time interaction analysis with BIAcore, we evaluated the affinities and kinetics of the interactions of full-length members of the SRC/p160 coactivator family with estrogen receptor a (ERalpha) and ERbeta bound to a variety of ligands. We substantiate that 17beta-estradiol enhances the affinity of ER-SRC/p160 interactions, whereas 4(OH)-tamoxifen, raloxifene, and ICI-182,780 inhibit these interactions. We show that a well defined, ER isoform-specific hierarchy governs the association of liganded ERs with full length SRC/p160 family members. Moreover, our data indicate that the interaction affinities of the full-length SRC/p160s with ERs are significantly higher then those of the NR interaction domains of the same coactivators, indicating that portions of coactivator molecules distinct from NR interaction domains might participate in receptor-coactivator complex formation. Finally, the interaction kinetics of SRC/p160s with ERs are consistent with a bipartite model, involving initial rapid formation of an unstable intermediate complex, and a subsequent slower reaction leading to its stabilization. We interpret our results as evidence that hierarchical coactivator interaction affinities are an important source of diversity in NR-mediated signaling and that the complexity of receptor-coactivator cross-talk might be best understood in the context of full-length molecules.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Wyeth Ayerst Res, Womens Hlth Res Inst, Collegeville, PA 19426 USA	Baylor College of Medicine; Pfizer	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Wong, Jiemin/0000-0002-5311-842X; McKenna, Neil/0000-0001-6689-0104	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19 DK62434-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHESKIS BJ, 1999, STEROID NUCL HORMONE, P95; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Graham JD, 2000, STEROIDS, V65, P579, DOI 10.1016/S0039-128X(00)00116-1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939	36	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13271	13277		10.1074/jbc.M211031200	http://dx.doi.org/10.1074/jbc.M211031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12540843	hybrid			2022-12-27	WOS:000182189500086
J	Ober, D; Harms, R; Witte, L; Hartmann, T				Ober, D; Harms, R; Witte, L; Hartmann, T			Molecular evolution by change of function - Alkaloid-specific homospermidine synthase retained all properties of deoxyhypusine synthase except binding the eIF5A precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; YEAST SACCHAROMYCES-CEREVISIAE; BEAN CANAVALIA-GLADIATA; PYRROLIZIDINE ALKALOIDS; CELL VIABILITY; CHROMATOGRAPHIC DETERMINATION; RHODOPSEUDOMONAS-VIRIDIS; SUBSTRATE-SPECIFICITY; HYPUSINE MODIFICATION; ESCHERICHIA-COLI	Deoxyhypusine synthase participates in the post-translational activation of the eukaryotic initiation factor 5A (eIF5A). The enzyme transfers the aminobutyl moiety of spermidine to a specific lysine residue in the eIF5A precursor protein, i.e. eIF5A(lys). Homospermidine synthase catalyzes an analogous reaction but uses putrescine instead of eIF5A(lys) as substrate yielding the rare polyamine homospermidine as product. Homospermidine is an essential precursor in the biosynthesis of pyrrolizidine alkaloids, an important class of plant defense compounds against herbivores. Sequence comparisons of the two enzymes indicate an evolutionary origin of homospermidine synthase from ubiquitous deoxyhypusine synthase. The two recombinant enzymes from Senecio vernalis were purified, and their properties were compared. Protein-protein binding and kinetic substrate competition studies confirmed that homospermidine synthase, in comparison to deoxyhypusine synthase, lost the ability to bind the eIF5A(lys) to its surface. The two enzymes show the same unique substrate specificities, catalyze the aminobutylation of putrescine with the same specific activities, and exhibit almost identical Michaelis kinetics. In conclusion, homospermidine synthase behaves like a deoxyhypusine synthase that lost its major function (aminobutylation of eIF5A precursor protein) but retained unaltered its side activity (aminobutylation of putrescine). It is suggested as having evolved from deoxyhypusine synthase by gene duplication and being recruited for a new function.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Pharmazeut Biol, D-38106 Braunschweig, Germany	Braunschweig University of Technology	Hartmann, T (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Pharmazeut Biol, Mendelssohnstr 1, D-38106 Braunschweig, Germany.							Boettcher F., 1994, CAN J CHEM, V72, P80; Boettcher Frank, 1993, Phytochemistry (Oxford), V32, P679; Chen KY, 1997, BIOL SIGNAL, V6, P105; Frey M, 2000, P NATL ACAD SCI USA, V97, P14801, DOI 10.1073/pnas.260499897; FUJIHARA S, 1986, PLANT PHYSIOL, V82, P795, DOI 10.1104/pp.82.3.795; FUJIHARA S, 1982, BIOCHEM BIOPH RES CO, V107, P403, DOI 10.1016/0006-291X(82)91718-1; FUJIHARA S, 1995, J BIOL CHEM, V270, P9932, DOI 10.1074/jbc.270.17.9932; Gierl A, 2001, PLANTA, V213, P493, DOI 10.1007/s004250100594; Graser G, 1998, PHYTOCHEMISTRY, V47, P1017, DOI 10.1016/S0031-9422(97)00600-6; HAMANA K, 1985, J BIOCHEM-TOKYO, V97, P1311, DOI 10.1093/oxfordjournals.jbchem.a135182; HAMANA K, 1995, COMP BIOCHEM PHYS B, V111, P91, DOI 10.1016/0305-0491(94)00222-G; HAMANA K, 1985, J BIOCHEM-TOKYO, V97, P1595, DOI 10.1093/oxfordjournals.jbchem.a135216; Hamana K, 2000, CAN J BOT, V78, P266, DOI 10.1139/cjb-78-2-266; HAMANA K, 1991, COMP BIOCHEM PHYS B, V100, P399, DOI 10.1016/0305-0491(91)90393-R; HAMANA K, 1991, COMP BIOCHEM PHYS B, V100, P59, DOI 10.1016/0305-0491(91)90084-Q; HAMANA K, 1989, COMP BIOCHEM PHYS B, V92, P691, DOI 10.1016/0305-0491(89)90251-4; Hartmann T, 2000, TOP CURR CHEM, V209, P207; Hartmann T, 1999, PLANTA, V207, P483, DOI 10.1007/s004250050508; Hartmann T., 1995, CHEM BIOL PERSPECT, V9, P155; Hashimoto T, 1998, PLANT CELL PHYSIOL, V39, P73, DOI 10.1093/oxfordjournals.pcp.a029291; Hennion F, 1999, PHYTOCHEMISTRY, V52, P247, DOI 10.1016/S0031-9422(99)00191-0; HUSEK P, 1992, ANAL CHIM ACTA, V259, P185, DOI 10.1016/0003-2670(92)85367-F; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; KANG KR, 1995, J BIOL CHEM, V270, P18408, DOI 10.1074/jbc.270.31.18408; Kang KR, 1999, EXP MOL MED, V31, P210, DOI 10.1038/emm.1999.34; KRISHNA RG, 1993, ADV ENZYMOL RAMB, V67, P265; Lee CH, 2000, BIOCHEM J, V352, P851, DOI 10.1042/0264-6021:3520851; Lee YB, 1999, BIOCHEM J, V340, P273, DOI 10.1042/0264-6021:3400273; Lee YB, 1998, BIOORGAN MED CHEM, V6, P253, DOI 10.1016/S0968-0896(97)10030-X; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; Liu YP, 1997, BIOL SIGNAL, V6, P166; MATSUZAKI S, 1987, BIOCHEM INT, V15, P817; Matsuzaki Shigeru, 1993, Dokkyo Journal of Medical Sciences, V20, P43; Mayr E, 1997, THIS IS BIOL; Moll S, 2002, PLANT PHYSIOL, V130, P47, DOI 10.1104/pp.004259; Ober D, 2000, PLANT MOL BIOL, V44, P445, DOI 10.1023/A:1026597621646; Ober D, 2003, PHYTOCHEMISTRY, V62, P339, DOI 10.1016/S0031-9422(02)00553-8; Ober D, 1996, J GEN APPL MICROBIOL, V42, P411, DOI 10.2323/jgam.42.411; Ober D, 1999, J BIOL CHEM, V274, P32040, DOI 10.1074/jbc.274.45.32040; Ober D, 1999, P NATL ACAD SCI USA, V96, P14777, DOI 10.1073/pnas.96.26.14777; Ober D, 2000, PHYTOCHEMISTRY, V55, P305, DOI 10.1016/S0031-9422(00)00267-3; Park M H, 1988, Adv Exp Med Biol, V250, P435; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; REDMOND JW, 1979, J CHROMATOGR, V170, P479, DOI 10.1016/S0021-9673(00)95481-5; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; TAO Y, 1994, BIOCHEM J, V302, P517, DOI 10.1042/bj3020517; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; TAO Y, 1995, J BIOL CHEM, V270, P23984, DOI 10.1074/jbc.270.41.23984; Tholl D, 1996, EUR J BIOCHEM, V240, P373, DOI 10.1111/j.1432-1033.1996.0373h.x; Valentini SR, 2002, GENETICS, V160, P393; Wang TW, 2001, J BIOL CHEM, V276, P17541, DOI 10.1074/jbc.M008544200; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; Wolff EC, 2000, J BIOL CHEM, V275, P9170, DOI 10.1074/jbc.275.13.9170; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1	65	49	51	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12805	12812		10.1074/jbc.M207112200	http://dx.doi.org/10.1074/jbc.M207112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562768	hybrid			2022-12-27	WOS:000182189500029
J	Mcclain, MS; Iwamoto, H; Cao, P; Vinion-Dubiel, AD; Li, Y; Szabo, G; Shao, ZF; Cover, TL				Mcclain, MS; Iwamoto, H; Cao, P; Vinion-Dubiel, AD; Li, Y; Szabo, G; Shao, ZF; Cover, TL			Essential role of a GXXXG motif for membrane channel formation by Helicobacter pylori vacuolating toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; ANION-SELECTIVE CHANNELS; STAPHYLOCOCCUS-AUREUS; CELLULAR VACUOLATION; DIMERIZATION MOTIF; GASTRIC EPITHELIUM; ACID ACTIVATION; LIPID BILAYERS; VACA TOXIN; LOW PH	Helicobacter pylori secretes a toxin, VacA, that can form anion-selective membrane channels. Within a unique amino-terminal hydrophobic region of VacA, there are three tandem GXXXG motifs (defined by glycines at positions 14, 18, 22, and 26), which are characteristic of transmembrane dimerization sequences. The goals of the current study were to investigate whether these GXXXG motifs are required for membrane channel formation and cytotoxicity and to clarify the role of membrane channel formation in the biological activity of VacA. Six different alanine substitution mutations (P9A, G13A, G14A, G18A, G22A, and G26A) were introduced into the unique hydrophobic region located near the amino terminus of VacA. The effects of these mutations were first analyzed using the TOXCAT system, which permits the study of transmembrane oligomerization of proteins in a natural membrane environment. None of the mutations altered the capacity of ToxR-VacA-maltose-binding protein fusion proteins to insert into a membrane, but G14A and G18A mutations markedly diminished the capacity of the fusion proteins to oligomerize. We then introduced the six alanine substitution mutations into the vacA chromosomal gene of H. pylori and analyzed the properties of purified mutant VacA proteins. VacA-G13A, VacA-G22A, and VacA-G26A induced vacuolation of HeLa cells, whereas VacA-P9A, VacA-G14A, and VacA-G18A did not. Subsequent experiments examined the capacity of each mutant toxin to form membrane channels. In a planar lipid bilayer assay, VacA proteins containing G13A, G22A, and G26A mutations formed anion-selective membrane channels, whereas VacA proteins containing P9A, G14A, and G18A mutations did not. Similarly, VacA-G13A, VacA-G22A, and VacA-G26A induced depolarization of HeLa cells, whereas VacA-P9A, VacA-G14A, and VacA-G18A did not. These data indicate that an intact proline residue and an intact G(14)XXXG(18) motif within the amino-terminal hydrophobic region of VacA are essential for membrane channel formation, and they also provide strong evidence that membrane channel formation is essential for VacA cytotoxicity.	Vanderbilt Univ, Div Infect Dis, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Biophys Program, Charlottesville, VA 22908 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Virginia; University of Virginia	Cover, TL (corresponding author), Vanderbilt Univ, Div Infect Dis, Sch Med, Dept Med, A3310 Med Ctr N, Nashville, TN 37232 USA.	timothy.L.cover@vanderbilt.edu	Shao, Zhifeng/B-6075-2013; Cover, Timothy/I-3814-2015; McClain, Mark S/A-6942-2009	Cover, Timothy/0000-0001-8503-002X; McClain, Mark S/0000-0002-9857-4883	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39657] Funding Source: Medline; NIDDK NIH HHS [DK53623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; ATHERTON JC, 2001, HELICOBACTER PYLORI, P97; Breed J, 1996, BIOPHYS J, V70, P1643, DOI 10.1016/S0006-3495(96)79727-8; Brosig B, 1998, PROTEIN SCI, V7, P1052; Copass M, 1997, INFECT IMMUN, V65, P1949, DOI 10.1128/IAI.65.5.1949-1952.1997; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; COVER TL, 2001, PRINCIPLES BACTERIAL, P510; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Fiocca R, 1999, J PATHOL, V188, P220, DOI 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C; Forsyth MH, 1998, INFECT IMMUN, V66, P3088, DOI 10.1128/IAI.66.7.3088-3094.1998; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; HAWRYLIK SJ, 1994, J CLIN MICROBIOL, V32, P790, DOI 10.1128/JCM.32.3.790-792.1994; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MARSHALL BJ, 1991, J GASTROEN HEPATOL, V6, P121, DOI 10.1111/j.1440-1746.1991.tb01450.x; McClain MS, 2000, MOL MICROBIOL, V37, P433, DOI 10.1046/j.1365-2958.2000.02013.x; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; Montecucco C, 2001, NAT REV MOL CELL BIO, V2, P457, DOI 10.1038/35073084; MONTECUCCO C, 1992, FEMS MICROBIOL IMMUN, V105, P101; Montecucco C, 1999, COMPREHENSIVE SOURCE, P264; Nguyen VQ, 2001, INFECT IMMUN, V69, P543, DOI 10.1128/IAI.69.1.543-546.2001; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OLSNES S, 1990, MICROB PATHOGENESIS, V8, P163, DOI 10.1016/0882-4010(90)90043-P; Papini E, 1998, J CLIN INVEST, V102, P813, DOI 10.1172/JCI2764; Papini E, 1998, FOLIA MICROBIOL, V43, P279, DOI 10.1007/BF02818613; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; Peek RM, 1999, CANCER RES, V59, P6124; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Valeva A, 1997, P NATL ACAD SCI USA, V94, P11607, DOI 10.1073/pnas.94.21.11607; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wang XM, 2000, FEBS LETT, V481, P96, DOI 10.1016/S0014-5793(00)01978-5; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WARREN JR, 1983, LANCET, V1, P1273; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; WILLIAMS KA, 1995, J MOL BIOL, V252, P6, DOI 10.1006/jmbi.1995.0469; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 2002, MOL MICROBIOL, V43, P1243, DOI 10.1046/j.1365-2958.2002.02818.x; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	80	120	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12101	12108		10.1074/jbc.M212595200	http://dx.doi.org/10.1074/jbc.M212595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12562777	hybrid			2022-12-27	WOS:000182015700051
J	Mine, M; Brivet, M; Touati, G; Grabowski, P; Abitbol, M; Marsac, C				Mine, M; Brivet, M; Touati, G; Grabowski, P; Abitbol, M; Marsac, C			Splicing error in E1 alpha pyruvate dehydrogenase mRNA caused by novel intronic mutation responsible for lactic acidosis and mental retardation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR PROTEINS; COMPLEX DEFICIENCY; EXONIC MUTATIONS; GENE; ENHANCER; SITE; RECOGNITION; INCLUSION; SC35	An intronic point mutation was identified in the E1alpha PDH gene from a boy with delayed development and lactic acidosis, an X-linked disorder associated with a partial defect in pyruvate dehydrogenase (PDH) activity. Protein analysis demonstrated a corresponding decrease in immunoreactivity of the alpha and beta subunits of the PDH complex. In addition to the normal spliced mRNA product of the E1alpha PDH gene, patient samples contained significant levels of an aberrantly spliced mRNA with the first 45 nucleotides of intron 7 inserted in-frame between exons 7 and 8. The genomic DNA analysis found no mutation in the coding regions but revealed a hemizygous intronic G to A substitution 26 nucleotides downstream from the normal exon 7 5'-splice site. Splicing experiments in COS-7 cells demon. strated that this point mutation at intron 7 position 26 is responsible for the aberrant splicing phenotype, which involves a switch from the use of the normal 5'-splice site (intron 7 position 1) to the cryptic 5'-splice site downstream of the mutation (intron 7 position 45). The intronic mutation is unusual in that it generates a consensus binding motif for the splicing factor, SC35, which normally binds to exonic enhancer elements resulting in increased exon inclusion. Thus, the aberrant splicing phenotype is most likely explained by the generation of a de novo splicing enhancer motif, which activates the downstream cryptic 5'-splice site. The mutation documented here is a novel case of intron retention responsible for a human genetic disease.	Fac Med Necker Enfants Malad, Lab Ctr Rech Therapeut Ophtalmol, F-75015 Paris, France; Hop Bicetre, Hop Kremlin Bicetre, AP HP, Biochim Lab, Le Kremlin Bicetre, France; Hop Necker Enfants Malad, Serv Neuropediat, F-75015 Paris, France; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Marsac, C (corresponding author), Fac Med Necker Enfants Malad, Lab Ctr Rech Therapeut Ophtalmol, 156 Rue Vaugirard, F-75015 Paris, France.	marsac@necker.fr		Mine, Manuele/0000-0001-8682-6660				Abed AA, 2001, HUM MUTAT, V18, P397, DOI 10.1002/humu.1211; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BONNE G, 1993, PEDIATR RES, V33, P284, DOI 10.1203/00006450-199303000-00016; BROWN GK, 1994, J MED GENET, V31, P875, DOI 10.1136/jmg.31.11.875; Cardozo AK, 2000, PEDIATR RES, V48, P748; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Dey R, 2002, MOL GENET METAB, V76, P344, DOI 10.1016/S1096-7192(02)00104-X; Ding WQ, 2002, CANCER RES, V62, P947; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Hanamura A, 1998, RNA, V4, P430; Ishii S, 2002, AM J HUM GENET, V70, P994, DOI 10.1086/339431; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KRAWCZAK M, 1992, HUM GENET, V90, P41; Labourier E, 1999, GENE DEV, V13, P740, DOI 10.1101/gad.13.6.740; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Lissens W, 1996, HUM MUTAT, V7, P46, DOI 10.1002/(SICI)1098-1004(1996)7:1<46::AID-HUMU6>3.3.CO;2-2; Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.0.CO;2-K; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Marsac C, 1997, HUM GENET, V99, P785, DOI 10.1007/s004390050449; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Sakamoto O, 2001, HUM GENET, V109, P559, DOI 10.1007/s00439-001-0612-3; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0	27	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11768	11772		10.1074/jbc.M211106200	http://dx.doi.org/10.1074/jbc.M211106200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology	663QF	12551913	hybrid			2022-12-27	WOS:000182015700008
J	Grinberg, AV; Kerppola, T				Grinberg, AV; Kerppola, T			Both Max and TFE3 cooperate with Smad proteins to bind the plasminogen activator inhibitor-1 promoter, but they have opposite effects on transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR SMAD4; TGF-BETA; DNA-BINDING; C-MYC; FUNCTIONAL-CHARACTERIZATION; HETERO-OLIGOMERIZATION; SIGNALING PATHWAYS; GENE; REPRESSION	Transforming growth factor (TGF)-beta regulates gene expression in large part through combinatorial interactions between members of the Smad family and other transcription factors. The basic helix-loop-helix leucine zipper (bHLHZIP) protein TFE3 and Smad3 synergistically activate transcription of the plasminogen activator inhibitor-1 (PAI-1) as well as other genes. We investigated interactions among different bHLHZIP and Smad family proteins. TFE3, TFEB, and Max associated with Smad3 and Smad4 in the absence of DNA and at the PE2.1 element of the PAI-1 promoter. These interactions were mediated by the leucine zipper and MH1 regions of the respective proteins. No interactions were observed with the E47 bHLH family protein. Chimeric proteins, in which leucine zippers from bHLHZIP or bZIP proteins were fused to heterologous bHLH domains, associated with Smad proteins both in the absence of DNA and at the PE2.1 element. The kinetics of bHLHZIP and Smad protein binding at the PE2.1 element were examined using surface plasmon resonance analysis. TFE3 exhibited cooperative DNA binding with Smad proteins, whereas no cooperativity was observed between E47 and Smads. Max inhibited transcription activation by Smad3 and TGF-beta at the PAI-1 promoter, whereas TFE3 and TFEB stimulated transcription activation. These results suggest that Smad family proteins can interact with several bHLHZIP proteins, resulting in different transcriptional outcomes.	Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kerppola, T (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Kerppola, Tom/AFK-6155-2022; Kerppola, Tom/AAG-4457-2022	Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Correia JJ, 2001, BIOCHEMISTRY-US, V40, P1473, DOI 10.1021/bi0019343; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McDonnell JM, 2001, CURR OPIN CHEM BIOL, V5, P572, DOI 10.1016/S1367-5931(00)00251-9; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	63	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11227	11236		10.1074/jbc.M211734200	http://dx.doi.org/10.1074/jbc.M211734200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551947	hybrid			2022-12-27	WOS:000181855400049
J	Leskov, KS; Klokov, DY; Li, J; Kinsella, TJ; Boothman, DA				Leskov, KS; Klokov, DY; Li, J; Kinsella, TJ; Boothman, DA			Synthesis and functional analyses of nuclear clusterin, a cell death protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSED PROSTATE MESSAGE-2; RAT VENTRAL PROSTATE; STRAND BREAK REPAIR; AMINO-ACID-SEQUENCE; SULFATED GLYCOPROTEIN-2; MESSENGER-RNA; HEAT-SHOCK; GENE-EXPRESSION; APOPTOSIS; STRESS	Nuclear clusterin (nCLU) is an ionizing radiation (IR)-inducible protein that binds Ku70, and triggers apoptosis when overexpressed in MCF-7 cells. We demonstrate that endogenous nCLU synthesis is a product of alternative splicing. Reverse transcriptase-PCR analyses revealed that exon II, containing the first AUG and encoding the endoplasmic reticulum-targeting peptide, was omitted. Exons I and III are spliced together placing a downstream AUG in exon III as the first available translation start site. This shorter mRNA produces the 49-kDa precursor nCLU protein. Ku70 binding activity was localized to the C-terminal coiled-coil domain of nCLU. Leucine residues 357, 358, and 361 of nCLU were necessary for Ku70-nCLU interaction. The N- and C-terminal coiled-coil domains of nCLU interacted with each other, suggesting that the protein could dimerize or fold. Mutation analyses indicate that the C-terminal NLS was functional in nCLU with the same contribution from N-terminal NLS. The C-terminal coiled-coil domain of nCLU was the minimal region required for Ku binding and apoptosis. MCF-7 cells show nuclear as well as cytoplasmic expression of GFP-nCLU in apoptotic cells. Cytosolic aggregation of GFP-nCLU was found in viable cells. These results indicate that an inactive precursor of nCLU exists in the cytoplasm of non-irradiated MCF-7 cells, translocates into the nucleus following IR, and induces apoptosis.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr,Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr,Sch Med, BRB-326 E,10900 Euclid Ave, Cleveland, OH 44106 USA.		Boothman, David/Q-7776-2019; Klokov, Dmitry/AAM-7316-2020; Leskov, Konstantin S/J-2339-2017	Klokov, Dmitry/0000-0003-1629-1431; Leskov, Konstantin S/0000-0001-6201-5660	NCI NIH HHS [P30 CA43703, CA84578, R01 CA078530, CA78530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA084578, R01CA078530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; BURSCH W, 1995, ARCH TOXICOL, V69, P253, DOI 10.1007/s002040050167; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Clark AM, 1997, J ANDROL, V18, P257; DANIK M, 1991, P NATL ACAD SCI USA, V88, P8577, DOI 10.1073/pnas.88.19.8577; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; HARMONY JAK, 1995, CLUSTERIN ROLE VERTE, P75; HARPER JW, 1993, CELL, V75, P805; HIRAI S-I, 1989, New Biologist, V1, P181; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; Kim SH, 1999, CANCER RES, V59, P4012; Kimura K, 1997, CELL BIOCHEM FUNCT, V15, P251, DOI 10.1002/(SICI)1099-0844(199712)15:4<251::AID-CBF748>3.0.CO;2-3; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; KOUZARIDES T, 1991, ONCOGENE, V6, P195; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; Leskov KS, 2001, SEMIN RADIAT ONCOL, V11, P352, DOI 10.1053/srao.2001.26912; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAY PC, 1993, ANN NY ACAD SCI, V679, P235, DOI 10.1111/j.1749-6632.1993.tb18303.x; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Miyake H, 2000, CANCER RES, V60, P2547; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SENSIBAR JA, 1995, CANCER RES, V55, P2431; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; TSURUTA JK, 1990, BIOCHEM J, V268, P571, DOI 10.1042/bj2680571; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066; WONG P, 1993, J BIOL CHEM, V268, P5021; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907	45	326	353	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11590	11600		10.1074/jbc.M209233200	http://dx.doi.org/10.1074/jbc.M209233200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551933	hybrid			2022-12-27	WOS:000181855400092
J	Shouldice, SR; Dougan, DR; Skene, RJ; Tari, LW; McRee, DE; Yu, RH; Schryvers, AB				Shouldice, SR; Dougan, DR; Skene, RJ; Tari, LW; McRee, DE; Yu, RH; Schryvers, AB			High resolution structure of an alternate form of the ferric ion binding protein from Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING; ACTIVE-TRANSPORT; TRANSFERRIN; NEISSERIA; COORDINATION; ACQUISITION; EXPRESSION; LIMITATION; RECEPTORS; SYSTEMS	The periplasmic iron binding protein of pathogenic Gram-negative bacteria performs an essential role in iron acquisition from transferrin and other iron sources. Structural analysis of this protein from Haemophilus influenzae identified four amino acids that ligand the bound iron: His(9), Glu(57), Tyr(195), and Tyr(196). A phosphate provides an additional ligand, and the presence of a water molecule is required to complete the octahedral geometry for stable iron binding. We report the 1.14-Angstrom resolution crystal structure of the iron-loaded form of the H. influenzae periplasmic ferric ion binding protein (FbpA) mutant H9Q. This protein was produced in the periplasm of Escherichia coli and, after purification and conversion to the apo form, was iron-loaded. H9Q is able to bind ferric iron in an open conformation. A surprising finding in the present high resolution structure is the presence of EDTA located at the previously determined anion ternary binding site, where phosphate is located in the wild type holo and apo structures. EDTA contributes four of the six coordinating ligands for iron, with two Tyr residues, 195 and 196, completing the coordination. This is the first example of a metal binding protein with a bound metal.EDTA complex. The results suggest that FbpA may have the ability to bind and transport iron bound to biological chelators, in addition to bare ferric iron.	Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Syrrx Inc, San Diego, CA 92121 USA	University of Calgary; University of Calgary	Schryvers, AB (corresponding author), Univ Calgary, Dept Microbiol & Infect Dis, Rm 274,Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	schryver@ucalgary.ca	Schryvers, Anthony B./AAF-3417-2020	Skene, Robert/0000-0002-1482-6546				Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker HM, 2001, BIOCHEMISTRY-US, V40, P11670, DOI 10.1021/bi010907p; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Griffiths E, 1988, VIRULENCE MECHANISMS, P121; Guo ML, 2003, J BIOL CHEM, V278, P2490, DOI 10.1074/jbc.M208776200; He QY, 2000, BIOCHEMISTRY-US, V39, P1205, DOI 10.1021/bi9915216; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizutani K, 1999, J BIOL CHEM, V274, P10190, DOI 10.1074/jbc.274.15.10190; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; OGUNNARIWO JA, 1990, MICROB PATHOGENESIS, V9, P397, DOI 10.1016/0882-4010(90)90058-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Sebastian S, 1999, INFECT IMMUN, V67, P3141, DOI 10.1128/IAI.67.6.3141-3145.1999; SOLANS X, 1984, ACTA CRYSTALLOGR C, V40, P635, DOI 10.1107/S0108270184005151; Stojiljkovic I, 1997, J BACTERIOL, V179, P805, DOI 10.1128/jb.179.3.805-812.1997; Taboy CH, 2001, J BIOL CHEM, V276, P2719, DOI 10.1074/jbc.M004763200; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; WEINBERG ED, 1995, CURR OPIN INFECT DIS, V8, P164, DOI 10.1097/00001432-199506000-00004; WEST SEH, 1985, INFECT IMMUN, V47, P388, DOI 10.1128/IAI.47.2.388-394.1985; WILLIAMS P, 1990, J GEN MICROBIOL, V136, P2343, DOI 10.1099/00221287-136-12-2343; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W	35	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11513	11519		10.1074/jbc.M211780200	http://dx.doi.org/10.1074/jbc.M211780200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12533539	hybrid			2022-12-27	WOS:000181855400083
J	Buchsbaum, RJ; Connolly, BA; Feig, LA				Buchsbaum, RJ; Connolly, BA; Feig, LA			Regulation of p70 S6 kinase by complex formation between the rac guanine nucleotide exchange factor (Rac-GEF) Tiam1 and the scaffold spinophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; FILAMENT-BINDING PROTEIN; N-TERMINAL PLECKSTRIN; CELL-ADHESION; NEURABIN; INVASION; RHO; FAMILY; CDC42; RAS-GRF1/CDC25(MM)	Tiam1 is a ubiquitous guanine nucleotide exchange factor (GEF) that activates the Rac GTPase. We have shown previously that the N terminus of Tiam1 contributes to the signaling specificity of its downstream target Rac via association with IB2, a scaffold that promotes Rac activation of a p38 kinase cascade. Here we show that the N terminus of Tiam1 can influence Rac signaling specificity in a different way by interaction with spinophilin, a scaffold that binds to p70 S6 kinase, another protein regulated by Rac. In particular, spinophilin binding promotes the plasma membrane localization of Tiam1 and enhances the ability of Tiam1 to activate p70 S6 kinase. In contrast, spinophilin binding suppresses the ability of Tiam to activate Pak1, a different Rac effector. Finally, a mutant spinophilin that cannot bind to Tiam1 suppresses serum-induced p70 S6 kinase activation in cells, suggesting that a Tiam1/spinophilin complex contributes to p70 S6 kinase regulation by extracellular signals. These findings add to a growing body of evidence supporting the concept that some Rac-GEFs not only activate Rac GTPases but also participate in the selection of Rac effector by binding to particular scaffolds that complex with components of specific Rac effector pathways.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA	Tufts University; Tufts Medical Center; Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK34928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kawazoe N, 1999, ONCOGENE, V18, P2413, DOI 10.1038/sj.onc.1202555; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stephens DJ, 1999, J BIOL CHEM, V274, P30080, DOI 10.1074/jbc.274.42.30080; Stephens DJ, 2000, BIOCHEM J, V345, P185, DOI 10.1042/0264-6021:3450185; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	38	95	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18833	18841		10.1074/jbc.M207876200	http://dx.doi.org/10.1074/jbc.M207876200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12531897	hybrid			2022-12-27	WOS:000182932200018
J	Yatsuda, AP; Krijgsveld, J; Cornelissen, AWCA; Heck, AJR; de Vries, E				Yatsuda, AP; Krijgsveld, J; Cornelissen, AWCA; Heck, AJR; de Vries, E			Comprehensive analysis of the secreted proteins of the parasite Haemonchus contortus reveals extensive sequence variation and differential immune recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; C-TYPE LECTIN; PROTECTIVE ANTIGEN; CYSTEINE PROTEASES; MOLECULAR-CLONING; IMMUNOLOGICAL CHARACTERIZATION; ONCHOCERCA-VOLVULUS; NEMATODE PARASITES; INFECTIVE LARVAE; TOXOCARA-CANIS	Haemonchus contortus is a nematode that infects small ruminants. It releases a variety of molecules, designated excretory/secretory products (ESP), into the host. Although the composition of ESP is largely unknown, it is a source of potential vaccine components because ESP are able to induce up to 90% protection in sheep. We used proteomic tools to analyze ESP proteins and determined the recognition of these individual proteins by hyperimmune sera. Following two-dimensional electrophoresis of ESP, matrix-assisted laser desorption ionization time-of-flight and liquid chromatography-tandem mass spectrometry were used for protein identification. Few sequences of H. contortus have been determined. Therefore, the data base of expressed sequence tags (dbEST) and a data base consisting of contigs from Haemonchus ESTs were also consulted for identification. Approximately 200 individual spots were observed in the two-dimensional gel. Comprehensive proteomics analysis, combined with bioinformatic search tools, identified 107 proteins in 102 spots. The data include known as well as novel proteins such as serine, metallo- and aspartyl proteases, in addition to H. contortus ESP components like Hc24, Hc40, Hc15, and apical gut GA1 proteins. Novel proteins were identified from matches with H. contortus ESTs displaying high similarity with proteins like cyclophilins, nucleoside diphosphate kinase, OV39 antigen, and undescribed homologues of Caenorhabditis elegans. Of special note is the finding of microsomal peptidase H11, a vaccine candidate previously regarded as a "hidden antigen" because it was not found in ESP. Extensive sequence variation is present in the abundant Hc15 proteins. The Hc15 isoforms are differentially recognized by hyperimmune sera, pointing to a possible specific role of Hc15 in the infectious process and/or in immune evasion. This concept and the identification of multiple novel immune-recognized components in ESP should assist future vaccine development strategies.	Univ Utrecht, Dept Immunol & Infect Dis, Div Parasitol & Trop Vet Med, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	de Vries, E (corresponding author), Univ Utrecht, Dept Immunol & Infect Dis, Div Parasitol & Trop Vet Med, POB 80165, NL-3508 TD Utrecht, Netherlands.	e.vries@vet.uu.nl	Heck, Albert/D-7098-2011; Krijgsveld, Jeroen/F-5974-2011; AP, Yatsuda/D-2565-2012	Heck, Albert/0000-0002-2405-4404; AP, Yatsuda/0000-0001-7957-2279; Krijgsveld, Jeroen/0000-0001-7549-9326				Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bird AF, 1991, STRUCTURE NEMATODES, P167; BLAXTER ML, 1994, MOL BIOCHEM PARASIT, V68, P1, DOI 10.1016/0166-6851(94)00127-8; BRAUN G, 1995, J EXP MED, V182, P1121, DOI 10.1084/jem.182.4.1121; BRAUN G, 1991, J EXP MED, V174, P169, DOI 10.1084/jem.174.1.169; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; CHANDARSHEKAR R, 1995, PARASITOLOGY, V73, P231; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P271, DOI 10.1098/rspb.1949.0025; De Graaf DC, 1996, PARASITOLOGY, V113, P63, DOI 10.1017/S0031182000066282; Dornan J, 1999, J BIOL CHEM, V274, P34877, DOI 10.1074/jbc.274.49.34877; Fetterer RH, 1999, J PARASITOL, V85, P295, DOI 10.2307/3285637; Fluckiger S, 2002, EUR J IMMUNOL, V32, P10, DOI 10.1002/1521-4141(200201)32:1<10::AID-IMMU10>3.0.CO;2-I; FRENKEL MJ, 1992, MOL BIOCHEM PARASIT, V50, P27, DOI 10.1016/0166-6851(92)90241-B; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; Gill JH, 1998, INT J PARASITOL, V28, P863, DOI 10.1016/S0020-7519(98)00068-X; Godovac-Zimmermann J, 2001, MASS SPECTROM REV, V20, P1, DOI 10.1002/1098-2787(2001)20:1<1::AID-MAS1001>3.0.CO;2-J; Gounaris K, 2001, INFECT IMMUN, V69, P3658, DOI 10.1128/IAI.69.6.3658-3662.2001; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Hawdon JM, 1996, J BIOL CHEM, V271, P6672, DOI 10.1074/jbc.271.12.6672; Hawdon JM, 1999, MOL BIOCHEM PARASIT, V99, P149, DOI 10.1016/S0166-6851(99)00011-0; HEALER J, 1991, PARASITOLOGY, V103, P305, DOI 10.1017/S0031182000059588; Henkle-Duhrsen K, 2001, MOL BIOCHEM PARASIT, V114, P129, DOI 10.1016/S0166-6851(01)00252-3; Holland MJ, 2000, EUR J IMMUNOL, V30, P1977, DOI 10.1002/1521-4141(200007)30:7&lt;1977::AID-IMMU1977&gt;3.0.CO;2-3; Hong HY, 2000, ELECTROPHORESIS, V21, P841, DOI 10.1002/(SICI)1522-2683(20000301)21:5<841::AID-ELPS841>3.3.CO;2-W; HONG XQ, 1993, EXP PARASITOL, V76, P127, DOI 10.1006/expr.1993.1015; Hotez PJ, 1999, IMMUNOL REV, V171, P163, DOI 10.1111/j.1600-065X.1999.tb01347.x; Jackson F, 2000, PARASITOLOGY, V120, pS95, DOI 10.1017/S0031182099005740; JASMER DP, 1993, J IMMUNOL, V151, P5450; Jasmer DP, 2001, MOL BIOCHEM PARASIT, V116, P159, DOI 10.1016/S0166-6851(01)00312-7; Jasmer DP, 1996, P NATL ACAD SCI USA, V93, P8642, DOI 10.1073/pnas.93.16.8642; Jefferies JR, 2001, PROTEOMICS, V1, P1128, DOI 10.1002/1615-9861(200109)1:9<1128::AID-PROT1128>3.0.CO;2-0; Jones BF, 2002, MOL BIOCHEM PARASIT, V119, P107, DOI 10.1016/S0166-6851(01)00409-1; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; Lazzaroni JC, 1999, FEMS MICROBIOL LETT, V177, P191, DOI 10.1016/S0378-1097(99)00293-1; Liddell S, 1998, PARASITOLOGY, V116, P383, DOI 10.1017/S0031182098002418; Longbottom D, 1997, MOL BIOCHEM PARASIT, V88, P63, DOI 10.1016/S0166-6851(97)00074-1; Loukas A, 1999, CURR BIOL, V9, P825, DOI 10.1016/S0960-9822(99)80366-2; Loukas A, 2000, PARASITOLOGY, V121, P545, DOI 10.1017/S0031182099006721; McKechnie NM, 2002, INVEST OPHTH VIS SCI, V43, P411; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; Munn EA, 1997, PARASITE IMMUNOL, V19, P243, DOI 10.1046/j.1365-3024.1997.d01-205.x; Murray J, 2001, MOL BIOCHEM PARASIT, V118, P89, DOI 10.1016/S0166-6851(01)00374-7; Newton SE, 1999, PARASITOL TODAY, V15, P116, DOI 10.1016/S0169-4758(99)01399-X; ONDEK B, 1992, J BIOL CHEM, V267, P16460; Ortona E, 2002, CLIN EXP IMMUNOL, V128, P124, DOI 10.1046/j.1365-2249.2002.01807.x; Page Antony P., 2001, P167, DOI 10.1079/9780851994239.0167; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Prichard RK, 2001, TRENDS PARASITOL, V17, P445, DOI 10.1016/S1471-4922(01)01983-3; Punj V, 2000, INFECT IMMUN, V68, P4930, DOI 10.1128/IAI.68.9.4930-4937.2000; Redmond DL, 1997, MOL BIOCHEM PARASIT, V85, P77, DOI 10.1016/S0166-6851(96)02812-5; Rehman A, 1998, MOL BIOCHEM PARASIT, V97, P55, DOI 10.1016/S0166-6851(98)00132-7; RHOADS ML, 1995, J PARASITOL, V81, P505, DOI 10.2307/3283844; SCHALLIG HDFH, 1994, PARASITOLOGY, V108, P351, DOI 10.1017/S0031182000076198; Schallig HDFH, 1997, MOL BIOCHEM PARASIT, V88, P203, DOI 10.1016/S0166-6851(97)00093-5; Schallig HDFH, 1997, PARASITE IMMUNOL, V19, P447, DOI 10.1046/j.1365-3024.1997.d01-148.x; Selkirk ME, 1998, INT J PARASITOL, V28, P1315, DOI 10.1016/S0020-7519(98)00107-6; Shompole S, 2001, J BIOL CHEM, V276, P2928, DOI 10.1074/jbc.M007321200; SMITH MD, 1963, BIOCHIM BIOPHYS ACTA, V111, P503; SMITH TS, 1993, INT J PARASITOL, V23, P271, DOI 10.1016/0020-7519(93)90150-W; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TODOROVA VK, 1995, PARASITOLOGY, V111, P201, DOI 10.1017/S0031182000064957; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; Vervelde L, 2002, PARASITE IMMUNOL, V24, P189, DOI 10.1046/j.1365-3024.2002.00454.x; Yatsuda AP, 2002, RES VET SCI, V73, P297, DOI 10.1016/S0034-5288(02)00125-X; YATSUDA AP, 2001, PARASITOLOGY, V105, P131; Zaborina O, 2000, MICROBIOL-UK, V146, P2521, DOI 10.1099/00221287-146-10-2521; Zaborina O, 1999, MOL MICROBIOL, V31, P1333, DOI 10.1046/j.1365-2958.1999.01240.x; Zaborina O, 1999, INFECT IMMUN, V67, P5231, DOI 10.1128/IAI.67.10.5231-5242.1999	71	175	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16941	16951		10.1074/jbc.M212453200	http://dx.doi.org/10.1074/jbc.M212453200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12576473	hybrid			2022-12-27	WOS:000182818600068
J	Saito, K; Sarai, A; Oda, M; Azuma, T; Kozono, H				Saito, K; Sarai, A; Oda, M; Azuma, T; Kozono, H			Thermodynamic analysis of the increased stability of major histocompatibility complex class II molecule I-E-k complexed with an antigenic peptide at an acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND SINGLE PEPTIDES; MHC MOLECULES; PROTEINS; BINDING; CALORIMETRY; KINETICS; EXCHANGE; EMPTY	The differential scanning calorimetry analysis of the murine major histocompatibility complex class II molecule, I-E-k, in complex with an antigenic peptide derived from mouse hemoglobin, showed that the thermal stability at the mildly acidic pH is higher than that at the neutral pH. Although the thermal unfolding of I-E-k-hemoglobin was irreversible, we extracted the equilibrium thermodynamic parameters from the kinetically controlled heat capacity curves. Both the denaturation temperatures and the enthalpy changes were almost independent of the heating rate over 1degreesC per min. The linear relation between the denaturation temperature and the calorimetric enthalpy change provided the heat capacity changes, which are classified into one for the mildly acidic pH region and another for the neutral pH region. The equilibrium thermodynamic parameters showed that the increased stability at the mildly acidic pH is because of the entropic effect. These thermodynamic data provided new insight into the current structural model of a transition to an open conformation at the mildly acidic pH, which is critical for the peptide exchange function of major histocompatibility complex class II in the endosome.	Sci Univ Tokyo, RIBS, Noda, Chiba 2780022, Japan; Tsukuba Inst, Inst Phys & Chem Res, RIKEN, Tsukuba, Ibaraki 3050077, Japan	Tokyo University of Science; RIKEN	Kozono, H (corresponding author), Sci Univ Tokyo, RIBS, 2669 Yamazaki, Noda, Chiba 2780022, Japan.			, Haruo/0000-0003-3352-0638; Oda, Masayuki/0000-0002-8568-4223				Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1; Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.0.CO;2-E; Kasson PM, 2000, BIOCHEMISTRY-US, V39, P1048, DOI 10.1021/bi9921337; Kersh GJ, 2001, J IMMUNOL, V166, P3345, DOI 10.4049/jimmunol.166.5.3345; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; LEE JM, 1992, INT IMMUNOL, V4, P889, DOI 10.1093/intimm/4.8.889; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; McFarland BJ, 2001, P NATL ACAD SCI USA, V98, P9231, DOI 10.1073/pnas.151131498; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; Petrosian SA, 2000, PROTEIN SCI, V9, P387; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; Rotzschke O, 2002, P NATL ACAD SCI USA, V99, P16946, DOI 10.1073/pnas.212643999; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SETTE A, 1992, J IMMUNOL, V148, P844; Simon A, 2000, BIOPHYS J, V79, P2305, DOI 10.1016/S0006-3495(00)76476-9; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Tobita T, 2003, IMMUNOL LETT, V85, P47, DOI 10.1016/S0165-2478(02)00206-7; Villadangos JA, 2000, IMMUNITY, V12, P233, DOI 10.1016/S1074-7613(00)80176-4; Vogl T, 1997, BIOCHEMISTRY-US, V36, P1657, DOI 10.1021/bi962163z; Wilson N, 2001, IMMUNITY, V14, P513, DOI 10.1016/S1074-7613(01)00140-6	32	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14732	14738		10.1074/jbc.M301086200	http://dx.doi.org/10.1074/jbc.M301086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578842	hybrid			2022-12-27	WOS:000182516100020
J	Steenbergen, SM; Vimr, ER				Steenbergen, SM; Vimr, ER			Functional relationships of the sialyltransferases involved in expression if the polysialic acid capsules of Escherichia coli K1 and K92 and Neisseria meningitidis groups B or C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; OVERLAP EXTENSION; COLOMINIC ACID; SEROGROUP-B; ENDO-N; BIOSYNTHESIS; POLYSACCHARIDE; MECHANISM; POLYSIALYLTRANSFERASE; GLYCOSYLTRANSFERASE	Polysialic acid (PSA) capsules are cell-associated homopolymers of alpha2,8-, alpha2,9-, or alternating alpha2,8/2,9-linked sialic acid residues that function as essential virulence factors in neuroinvasive diseases caused by certain strains of Escherichia coli and Neisseria meningitidis. SA chains structurally identical to the bacterial alpha2,8-linked capsular polysaccharides are also synthesized by the mammalian central nervous system, where they regulate neuronal function in association with the neural cell adhesion molecule (NCAM). Despite the structural identity between bacterial and NCAM PSAs, the respective polysialyltransferases (polySTs) responsible for polymerizing sialyl residues from donor CMP-sialic acid are not homologous glycosyltransferases. To better define the mechanism of capsule biosynthesis, we established the functional interchangeability of bacterial polySTs by complementation of a polymerase-deficient E. coli K1 mutant with the polyST genes from groups B or C N. meningitidis and the control E. coli K92 polymerase gene. The biochemical and immunochemical results demonstrated that linkage specificity is dictated solely by the source of the polymerase structural gene. To determine the molecular basis for linkage specificity, we created chimeras of the K1 and K92 polySTs by overlap extension PCR. Exchanging the first 52 N-terminal amino acids of the K1 NeuS with the C terminus of the K92 homologue did not alter specificity of the resulting chimera, whereas exchanging the first 85 or reciprocally exchanging the first 100 residues did. These results demonstrated that linkage specificity is dependent on residues located between positions 53 and 85 from the N terminus. Site-directed mutagenesis of the K92 polyST N terminus indicated that no single residue alteration was sufficient to affect specificity, consistent with the proposed function of this domain in orienting the acceptor. The combined results provide the first evidence for residues critical to acceptor binding and elongation in polysialyltransferase.	Univ Illinois, Lab Sialobiol, Div Microbiol & Immunol, Dept Pathobiol, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Vimr, ER (corresponding author), Univ Illinois, Lab Sialobiol, Div Microbiol & Immunol, Dept Pathobiol, 2001 S Lincoln Ave, Urbana, IL 61802 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042015] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI42015] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Arrecubieta C, 2001, J BIOL CHEM, V276, P4245, DOI 10.1074/jbc.M008183200; BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; Chao CF, 1999, J BIOL CHEM, V274, P18206, DOI 10.1074/jbc.274.26.18206; Charnock SJ, 2001, PLANT PHYSIOL, V125, P527, DOI 10.1104/pp.125.2.527; CHO JW, 1994, P NATL ACAD SCI USA, V91, P11427, DOI 10.1073/pnas.91.24.11427; Cieslewicz M, 1997, MOL MICROBIOL, V26, P237, DOI 10.1046/j.1365-2958.1997.5651942.x; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 2001, J BIOL CHEM, V276, P15200, DOI 10.1074/jbc.M010542200; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; EDWARDS U, 1994, MOL MICROBIOL, V14, P141, DOI 10.1111/j.1365-2958.1994.tb01274.x; EGAN W, 1977, BIOCHEMISTRY-US, V16, P3687, DOI 10.1021/bi00635a028; FERRERO MA, 1991, BIOCHEM J, V280, P575, DOI 10.1042/bj2800575; Gonzalez MD, 2002, J BACTERIOL, V184, P6050, DOI 10.1128/JB.184.21.6050-6055.2002; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodson N, 2000, J BIOL CHEM, V275, P27311; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Johnson JR, 2001, J INFECT DIS, V183, P1508, DOI 10.1086/320198; KWIATKOWSKI B, 1982, J VIROL, V43, P697, DOI 10.1128/JVI.43.2.697-704.1982; McGowen MM, 2001, GLYCOBIOLOGY, V11, P613, DOI 10.1093/glycob/11.8.613; ORTIZ AI, 1989, EUR J BIOCHEM, V178, P741, DOI 10.1111/j.1432-1033.1989.tb14505.x; PETTER JG, 1993, J BACTERIOL, V175, P4354, DOI 10.1128/JB.175.14.4354-4363.1993; PETTER JG, 1991, THESIS U ILLINOIS UR; Pogulis RJ, 2000, NUCLEIC ACID PROTOCOLS HANDBOOK, P857; Rappuoli R, 2001, VACCINE, V19, P2319, DOI 10.1016/S0264-410X(00)00552-1; Ringenberg M, 2001, GLYCOBIOLOGY, V11, P533, DOI 10.1093/glycob/11.7.533; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; Shen GJ, 1999, J BIOL CHEM, V274, P35139, DOI 10.1074/jbc.274.49.35139; Silver RP, 1990, BACTERIA, V11, P39; STEENBERGEN SM, 1990, MOL MICROBIOL, V4, P603, DOI 10.1111/j.1365-2958.1990.tb00629.x; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VIMR E, 1995, J IND MICROBIOL, V15, P352, DOI 10.1007/BF01569991; VIMR ER, 1992, J BACTERIOL, V174, P6191, DOI 10.1128/JB.174.19.6191-6197.1992; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; VIMR ER, 1993, POLYSIALIC ACID MICR, P73; VIMR ER, 1985, ANNU M AM SOC MICROB, V152, P154	45	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15349	15359		10.1074/jbc.M208837200	http://dx.doi.org/10.1074/jbc.M208837200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578835	hybrid			2022-12-27	WOS:000182516100100
J	Beaudoin, J; Mercier, A; Langlois, R; Labbe, S				Beaudoin, J; Mercier, A; Langlois, R; Labbe, S			The Schizosaccharomyces pombe Cuf1 is composed of functional modules from two distinct classes of copper metalloregulatory transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER GENE-EXPRESSION; TRANSITION-METAL TRANSPORT; SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; YEAST COPPER; DNA-BINDING; FISSION YEAST; FACTOR MAC1; MOLECULAR CHARACTERIZATION; SUPEROXIDE-DISMUTASE	In fission yeast, the genes encoding proteins that are components of the copper transporter family are controlled at the transcriptional level by the Cuf1 transcription factor. Under low copper availability, Cuf1 induces expression of the copper transporter genes. In contrast, sufficient levels of copper inactivate Cuf1 and expression of its target genes. Our study reveals that Cuf1 harbors a putative copper-binding motif, Cys-X-Cys-X-3-Cys-X-Cys-X-2-Cys-X-2-His, within its carboxyl-terminal region to sense changing environmental copper levels. Binding studies reveal that the amino-terminal 174-residue segment of Cuf1 expressed as a fusion protein in Escherichia coli specifically interacts with the cis-acting copper transporter promoter element CuSE (copper-signaling element). Within this region, the first 61 amino acids of Cuf1 exhibit more overall homology to the Saccharomyces cerevisiae Ace1 copper-detoxifying factor (from residues 1 to 63) than to Mac1, its functional ortholog. Consistently, we demonstrate that a chimeric Cuf1 protein bearing the amino-terminal 63-residue segment of Ace1 complements cuf1Delta null phenotypes. Furthermore, we show that Schizosaccharomyces pombe cuf1Delta mutant cells expressing the full-length S. cerevisiae Ace1 protein are hypersensitive to copper ions, with a concomitant up-regulation of CuSE-mediated gene expression in fission yeast. Taken together, these studies reveal that S. cerevisiae Ace1 1-63 is functionally exchangeable with S. pombe Cuf1 1-61, and the nature of the amino acids located downstream of, this amino-terminal conserved region may be crucial in dictating the type of regulatory response required to establish and maintain copper homeostasis.	Univ Sherbrooke, Fac Med, Dept Biochem, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Med Nucl & Radiobiol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Sherbrooke Poistron Emiss Tomog Ctr, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke	Labbe, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochem, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.			Labbe, Simon/0000-0002-4947-523X				ALFA C, 1993, EXPT FISSION YEASTS; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Bellemare DR, 2002, J BIOL CHEM, V277, P46676, DOI 10.1074/jbc.M206444200; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Brown KR, 2002, BIOCHEMISTRY-US, V41, P6469, DOI 10.1021/bi0160664; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Heredia J, 2001, J BIOL CHEM, V276, P8793, DOI 10.1074/jbc.M008179200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU S, 1990, New Biologist, V2, P544; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Keller G, 2000, J BIOL CHEM, V275, P29193, DOI 10.1074/jbc.M001552200; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Koch KA, 1996, MOL CELL BIOL, V16, P724; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Labbe Simon, 2002, P571; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McDaniels CPJ, 1999, J BIOL CHEM, V274, P26962, DOI 10.1074/jbc.274.38.26962; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1993, J BIOL CHEM, V268, P12512; Turner RB, 1998, NAT STRUCT BIOL, V5, P551, DOI 10.1038/805; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200; ZHOU PB, 1993, BIOFACTORS, V4, P105; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	61	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14565	14577		10.1074/jbc.M300861200	http://dx.doi.org/10.1074/jbc.M300861200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578838	hybrid			2022-12-27	WOS:000182405000125
J	Booth, JW; Telio, D; Liao, EH; McCaw, SE; Matsuo, T; Grinstein, S; Gray-Owen, SD				Booth, JW; Telio, D; Liao, EH; McCaw, SE; Matsuo, T; Grinstein, S; Gray-Owen, SD			Phosphatidylinositol 3-kinases in carcinoembryonic antigen-related cellular adhesion molecule-mediated internalization of Neisseria gonorrhoeae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; PHAGOSOME MATURATION; IGA1 PROTEASE; HOST-CELLS; INVASION; SALMONELLA; PROTEINS; PHAGOCYTOSIS; BIOGENESIS	Neisseria gonorrhoeae can be internalized by mammalian cells through interactions between bacterial opacity-associated (Opa) adhesins and members of the human carcinoembryonic antigen-related cellular adhesion molecule (CEACAM) family. We examined the role of phosphatidylinositol 3-kinases (PI3Ks) in gonococcal invasion of epithelial cell lines expressing either CEACAM1 or CEACAM3. CEACAM3-mediated internalization, but not that mediated by CEACAM1, was accompanied by localized and transient accumulation of the class I PI3K product phosphatidylinositol 3,4,5-trisphosphate at sites of bacterial engulfment. Inhibition of phosphatidylinositol 3-kinases reduced CEACAM3-mediated uptake but, paradoxically, led to an increase in intracellular survival of bacteria internalized via either CEACAM1 or CEACAM3, suggesting-additional roles for PI3K products. Consistent with this finding, the class III PI3K product phosphatidylinositol 3-phosphate accumulated and persisted in the membrane of gonococcal phagosomes after internalization. Inhibition of PI3K blocked phagosomal acquisition of the late endosomal marker lysosome-associated membrane protein 2 and reduced phagosomal acidification. Inhibiting phagosomal acidification with concanamycin A also increased survival of intracellular gonococci. These results suggest two modes of action of phosphatidylinositol 3-kinases during internalization of gonococci: synthesis of phosphatidylinositol 3,4,5-trisphosphate is important for CEACAM3-mediated uptake, while phosphatidylinositol 3-phosphate is needed for phagosomal maturation and acidification, which are required for optimal bacterial killing.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Takeda Chem Ind Ltd, Osaka 5408645, Japan	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Takeda Chemical Industries	Gray-Owen, SD (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 4381 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Gray-Owen, Scott/AAG-7337-2022; Gray-Owen, Scott/AFL-7380-2022	Liao, Edward/0000-0002-4955-6881; Gray-Owen, Scott D./0000-0002-1477-3616				Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Balla T., 2002, SCI STKE, V2002, p3pl; Billker O, 2002, EMBO J, V21, P560, DOI 10.1093/emboj/21.4.560; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen T, 2001, J BIOL CHEM, V276, P17413, DOI 10.1074/jbc.M010609200; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Dehio C, 1998, TRENDS MICROBIOL, V6, P489, DOI 10.1016/S0966-842X(98)01365-1; Demaurex N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P380; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Gray-Owen SD, 1997, MOL MICROBIOL, V26, P971, DOI 10.1046/j.1365-2958.1997.6342006.x; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; Hauck CR, 1997, FEBS LETT, V405, P86, DOI 10.1016/S0014-5793(97)00163-4; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; Kwok T, 2002, INFECT IMMUN, V70, P2108, DOI 10.1128/IAI.70.4.2108-2120.2002; Lin L, 1997, MOL MICROBIOL, V24, P1083, DOI 10.1046/j.1365-2958.1997.4191776.x; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; MCGEE ZA, 1983, REV INFECT DIS, V5, P708; Mecsas J, 1998, MOL MICROBIOL, V28, P1269, DOI 10.1046/j.1365-2958.1998.00891.x; Mosleh IM, 1998, J BIOL CHEM, V273, P35332, DOI 10.1074/jbc.273.52.35332; Muenzner P, 2000, INFECT IMMUN, V68, P3601, DOI 10.1128/IAI.68.6.3601-3607.2000; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Scott CC, 2002, J BIOL CHEM, V277, P12770, DOI 10.1074/jbc.M110399200; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Wang J, 1998, MOL MICROBIOL, V30, P657, DOI 10.1046/j.1365-2958.1998.01102.x	33	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14037	14045		10.1074/jbc.M211879200	http://dx.doi.org/10.1074/jbc.M211879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571236	hybrid			2022-12-27	WOS:000182405000062
J	Yabe, U; Sato, C; Matsuda, T; Kitajima, K				Yabe, U; Sato, C; Matsuda, T; Kitajima, K			Polysialic acid in human milk - CD36 is a new member of mammalian polysialic acid-containing glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; N-ACETYLNEURAMINIC ACID; DIFFERENTIATION-DEPENDENT EXPRESSION; B SCAVENGER RECEPTOR; CARBOHYDRATE UNITS; OLIGOSIALIC ACIDS; ESCHERICHIA-COLI; POSSIBLE ROLES; SIALIC ACIDS; FAT GLOBULE	The neural cell adhesion molecule and the voltage-sensitive sodium channel a-subunit are the only two molecules in mammals known to be modified by alpha-2,8-linked polysialic acid (polySia). We found a new polySia-containing glycoprotein in human milk and identified it as CD36, a member of the B class of the scavenger receptor superfamily. The polySia-containing glycan chain(s) were removed by alkaline treatment but not by peptide: N-glycanase F digestion, indicating that milk CD36 contained polySia on O-linked glycan chain(s). Polysialylation of CD36 occurs not only in human milk but also in mouse milk. However, CD36 in human platelets is not polysialylated. PolySia CD36 is secreted in milk at any lactation stage and reaches peak level at 1 month after parturition. Thus, it is suggested that polySia of milk CD36 is significant for neonatal development in terms of protection and nutrition.	Nagoya Univ, Biosci Ctr, Div Organogenesis, Dept Anim Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University; Nagoya University	Kitajima, K (corresponding author), Nagoya Univ, Biosci Ctr, Div Organogenesis, Dept Anim Sci, Nagoya, Aichi 4648601, Japan.		SATO, Chihiro/B-7396-2014					AIKEN ML, 1990, BLOOD, V76, P2501; Angata K, 2002, J BIOL CHEM, V277, P36808, DOI 10.1074/jbc.M204632200; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; ASAHINA S, 2001, GLYCOCONJUGATE J, V18, P148; BRUES JL, 2001, BIOCHIMIE PARIS, V83, P635; CARLSON SE, 1985, AM J CLIN NUTR, V41, P720, DOI 10.1093/ajcn/41.4.720; CARLSON SE, 1986, J NUTR, V116, P881, DOI 10.1093/jn/116.5.881; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FINNE J, 1982, J BIOL CHEM, V257, P1966; Fukuda M, 1996, CANCER RES, V56, P2237; GLASS JD, 1994, NEUROENDOCRINOLOGY, V60, P87; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HOWARD LM, 2002, LEUKOCYTE TYPING, V7, P781; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; LI WX, 1993, J BIOL CHEM, V268, P16179; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mather IH, 2000, J DAIRY SCI, V83, P203, DOI 10.3168/jds.S0022-0302(00)74870-3; MICHALIDES R, 1994, INT J CANCER, P34; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; MORGAN BLG, 1980, J NUTR, V110, P416, DOI 10.1093/jn/110.3.416; Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Peterson JA, 1998, BIOL NEONATE, V74, P143, DOI 10.1159/000014020; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROHR TE, 1980, J BIOL CHEM, V255, P2332; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Sato C, 2002, J BIOL CHEM, V277, P45299, DOI 10.1074/jbc.M206046200; Sato C, 1999, TRENDS GLYCOSCI GLYC, V11, P371, DOI 10.4052/tigg.11.371; SATO C, 1993, J BIOL CHEM, V268, P23675; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SATO C, 1999, GLYCOCONJUGATE J S, V16, P117; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Seki T, 1999, J COMP NEUROL, V410, P115, DOI 10.1002/(SICI)1096-9861(19990719)410:1<115::AID-CNE10>3.0.CO;2-C; Tanaka F, 2001, CANCER RES, V61, P1666; TANDON NN, 1989, J BIOL CHEM, V264, P7576; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; TROY FA, 1996, BIOL SIALIC ACIDS, P95; Tsuji S., 1999, SIALOBIOLOGY OTHER N, P145; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; ZUBER C, 1992, J BIOL CHEM, V267, P9965	55	113	115	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13875	13880		10.1074/jbc.M300458200	http://dx.doi.org/10.1074/jbc.M300458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576469	hybrid			2022-12-27	WOS:000182405000041
J	Chiu, PCN; Koistinen, R; Koistinen, H; Seppala, M; Lee, KF; Yeung, WSB				Chiu, PCN; Koistinen, R; Koistinen, H; Seppala, M; Lee, KF; Yeung, WSB			Binding of zona binding inhibitory factor-1 (ZIF-1) from human follicular fluid on spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG BINDING; PLACENTAL PROTEIN-14; IN-VITRO; PELLUCIDA BINDING; MAMMALIAN FERTILIZATION; ENDOMETRIAL PROTEIN; LIPOCALIN PROTEIN; GLYCODELIN; RECOGNITION; CAPACITY	Previous studies showed that zona binding inhibitory factor-1 (ZIF-1) was the glycoprotein mainly responsible for the spermatozoa zona binding inhibitory activity of human follicular fluid. ZIF-1 has a number of properties similar to glycodelin-A. A binding kinetics experiment in the present study demonstrated the presence of two binding sites of ZIF-1 on human spermatozoa. These binding sites were saturable, reversible, and bound to I-125-ZIF-1 in a time-, concentration-, and temperature-dependent manner. Glycodelin-A shared one common binding site with ZIF-1 on spermatozoa, and it could displace only 70% of the I-125-ZIF-1 bound on human spermatozoa. ZIF-1 and glycodelin-A formed complexes with the soluble extract of human spermatozoa. Coincubation of solubilized zona pellucida proteins reduced the binding of ZIF-1 to two complexes of the extract, suggesting that the ZIF-1 binding sites and zona pellucida protein receptors on human spermatozoa were closely related. ZIF-1, but not glycodelin-A, significantly suppressed progesterone-induced acrosome reaction of human spermatozoa. The carbohydrate moieties derived from ZIF-1 reduced the binding of native ZIF-1 on human spermatozoa as well as the zona binding inhibitory activity of the glycoprotein, although the intensity of the effects are lower when compared with the native protein. These effects are not due to the action of the molecules on the motility, viability, and acrosomal status of the treated spermatozoa. Deglycosylated ZIF-1 had no inhibitory effect on both ZIF-1 binding and zona binding capacity of spermatozoa. We concluded that the carbohydrate part of ZIF-1 was critical for the functioning of the glycoprotein.	Univ Hong Kong, Dept Obstet & Gynaecol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; Univ Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland	University of Hong Kong	Yeung, WSB (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, Queen Mary Hosp, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		/C-7476-2009; Seppala, Markku/AAT-6618-2021; Chiu, Chi Ngong/C-4245-2009; Koistinen, Hannu/AGU-1279-2022; Lee, Calvin Kai Fai/C-4328-2009	Chiu, Chi Ngong/0000-0001-6217-1970; Koistinen, Hannu/0000-0003-0926-3109; Lee, Calvin Kai Fai/0000-0001-5957-439X				Benoff S, 1997, MOL HUM REPROD, V3, P599, DOI 10.1093/molehr/3.7.599; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; Chapman NR, 1996, MOL HUM REPROD, V2, P767, DOI 10.1093/molehr/2.10.767; Chiu PCN, 2002, MOL REPROD DEV, V61, P205, DOI 10.1002/mrd.1149; Chryssikopoulos A, 1996, FERTIL STERIL, V66, P599, DOI 10.1016/S0015-0282(16)58574-4; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DUNBAR BS, 1980, BIOCHEMISTRY-US, V19, P356, DOI 10.1021/bi00543a017; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; FRANKEN DR, 1994, ANDROLOGIA, V26, P277; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; KADAM AL, 1995, J REPROD IMMUNOL, V29, P19, DOI 10.1016/0165-0378(95)00928-E; Koistinen H, 1999, FEBS LETT, V450, P158, DOI 10.1016/S0014-5793(99)00490-1; Koistinen H, 1997, LAB INVEST, V76, P683; Koistinen H, 1996, MOL HUM REPROD, V2, P759, DOI 10.1093/molehr/2.10.759; LIU DY, 1990, J REPROD FERTIL, V89, P127; MACEK MB, 1988, GAMETE RES, V20, P93, DOI 10.1002/mrd.1120200109; Mansouri A, 1998, BIOFACTORS, V7, P287, DOI 10.1002/biof.5520070401; MEIZEL S, 1990, SERONO S, V16, P205; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Miller RE, 1998, FEBS LETT, V436, P455, DOI 10.1016/S0014-5793(98)01184-3; Miranda PV, 2000, MOL HUM REPROD, V6, P699, DOI 10.1093/molehr/6.8.699; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; Oehninger S, 2001, CELLS TISSUES ORGANS, V168, P58, DOI 10.1159/000016806; Oehninger S, 1998, ANDROLOGIA, V30, P269; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; ORAND MG, 1988, GAMETE RES, V19, P315, DOI 10.1002/mrd.1120190402; Ozgur K, 1998, MOL HUM REPROD, V4, P318, DOI 10.1093/molehr/4.4.318; Qiao J, 1998, HUM REPROD, V13, P128, DOI 10.1093/humrep/13.1.128; RAM PA, 1989, GAMETE RES, V22, P321, DOI 10.1002/mrd.1120220309; RIITTINEN L, 1991, J IMMUNOL METHODS, V136, P85, DOI 10.1016/0022-1759(91)90253-C; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Seppala M, 2002, ENDOCR REV, V23, P401, DOI 10.1210/er.2001-0026; Shi YL, 1998, MOL REPROD DEV, V50, P354, DOI 10.1002/(SICI)1098-2795(199807)50:3<354::AID-MRD12>3.0.CO;2-4; Sinowatz F, 1998, ACTA ANAT, V161, P196; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; TOPFERPETERSEN E, 1985, HISTOCHEMISTRY, V83, P139; Tse JYM, 2002, MOL HUM REPROD, V8, P142, DOI 10.1093/molehr/8.2.142; TULSIANI DRP, 1990, BIOL REPROD, V42, P843, DOI 10.1095/biolreprod42.5.843; Tulsiani DRP, 1997, BIOL REPROD, V57, P487, DOI 10.1095/biolreprod57.3.487; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Verostek MF, 2000, ANAL BIOCHEM, V278, P111, DOI 10.1006/abio.1999.4433; Vigne JL, 2001, J BIOL CHEM, V276, P17101, DOI 10.1074/jbc.M010451200; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; *WHO, 1998, LAB MAN EX HUM SEM S; Yao YQ, 1996, HUM REPROD, V11, P1516; Yao YQ, 1998, HUM REPROD, V13, P2541, DOI 10.1093/humrep/13.9.2541; Yao YQ, 1996, HUM REPROD, V11, P2674; YEUNG WSB, 1994, HUM REPROD, V9, P656, DOI 10.1093/oxfordjournals.humrep.a138566; YOGEV L, 1995, HUM REPROD, V10, P851, DOI 10.1093/oxfordjournals.humrep.a136049	50	28	33	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13570	13577		10.1074/jbc.M212086200	http://dx.doi.org/10.1074/jbc.M212086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571233	hybrid			2022-12-27	WOS:000182189500122
J	Hoshino, T; Tsutsumi, S; Tomisato, W; Hwang, HJ; Tsuchiya, T; Mizushima, T				Hoshino, T; Tsutsumi, S; Tomisato, W; Hwang, HJ; Tsuchiya, T; Mizushima, T			Prostaglandin E-2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-INDUCED APOPTOSIS; BICARBONATE SECRETION; SELECTIVE INHIBITOR; CASPASE ACTIVATION; EP(3) RECEPTORS; INTEGRAL-PART; RAT; KINASE; PHOSPHORYLATION; EXPRESSION	Prostaglandin E-2 (PGE(2)) has a strong protective effect on the gastric mucosa in vivo; however, the molecular mechanism of a direct cytoprotective effect of PGE(2) on gastric mucosal cells has yet to be elucidated. Although we reported previously that PGE(2) inhibited gastric irritant-induced apoptotic DNA fragmentation in primary cultures of guinea pig gastric mucosal cells, we show here that PGE(2) inhibits the ethanol-dependent release of cytochrome c from mitochondria. Of the four main subtypes of PGE(2) receptors, we also demonstrated, using subtype-specific agonists, that EP2 and EP4 receptors are involved in the PGE(2)-mediated protection of gastric mucosal cells from ethanol-induced apoptosits. Activation of EP2 and EP4 receptors is coupled with an increase in cAMP, for which a cAMP analogue was found here to inhibit the ethanol-induced apoptosis. The increase in cAMP is known to activate both protein kinase A (PKA) and phosphatidylinositol 3-kinase pathways. An inhibitor of PKA but not of phosphatidylinositol 3-kinase blocked the PGE(2)-mediated protection of cells from ethanol-induced apoptosis, suggesting that a PKA pathway is mainly responsible for the PGE(2)-mediated inhibition of apoptosis. Based on these results, we considered that PGE(2) inhibited gastric irritant-induced apoptosis in gastric mucosal cells via induction of an increase in cAMP and activation of PKA, and that this effect was involved in the PGE(2)-mediated protection of the gastric mucosa from gastric irritants in vivo.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan; Japan Sci & Technol Corp, PRESTO, Okayama 7008530, Japan	Okayama University; Japan Science & Technology Agency (JST)	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	mizushima@pharm.okayama-u.ac.jp						Araki H, 2000, ALIMENT PHARM THERAP, V14, P116, DOI 10.1046/j.1365-2036.2000.014s1116.x; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chen WS, 2001, MOL CELL BIOL, V21, P4636, DOI 10.1128/MCB.21.14.4636-4646.2001; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; GRYGLEWSKI RJ, 1987, BIOCHEM PHARMACOL, V36, P4209, DOI 10.1016/0006-2952(87)90660-5; Hassan S, 1996, DIGESTION, V57, P196, DOI 10.1159/000201339; Hoshino T, 2002, DIGEST DIS SCI, V47, P2370, DOI 10.1023/A:1020164000898; Houchen CW, 2003, AM J PHYSIOL-GASTR L, V284, pG490, DOI 10.1152/ajpgi.00240.2002; Ikari A, 1999, JPN J PHYSIOL, V49, P365, DOI 10.2170/jjphysiol.49.365; Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689; Iordanov MS, 2000, CANCER RES, V60, P1983; KAUFFMAN GL, 1980, AM J PHYSIOL, V239, pG44, DOI 10.1152/ajpgi.1980.239.1.G44; Keogh JP, 1997, CLIN EXP PHARMACOL P, V24, P844, DOI 10.1111/j.1440-1681.1997.tb02701.x; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P211; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Mizushima T, 1999, DIGEST DIS SCI, V44, P510, DOI 10.1023/A:1026692920848; Morimoto K, 1997, AM J PHYSIOL-GASTR L, V272, pG681, DOI 10.1152/ajpgi.1997.272.3.G681; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Morris GP, 1998, J CLIN GASTROENTEROL, V27, pS53, DOI 10.1097/00004836-199800001-00010; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; NARIBAYASHIINOMOTO Y, 1995, GASTROENTEROLOGY, V109, P341, DOI 10.1016/0016-5085(95)90319-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; PIHAN G, 1986, GASTROENTEROLOGY, V91, P1415, DOI 10.1016/0016-5085(86)90195-2; POWIS G, 1994, CANCER RES, V54, P2419; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Rokutan K, 1998, AM J PHYSIOL-GASTR L, V275, pG526, DOI 10.1152/ajpgi.1998.275.3.G526; Srinivasan B D, 1989, Prog Clin Biol Res, V312, P229; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Suzuki K, 2001, DIGESTION, V63, P92, DOI 10.1159/000051876; Takano T, 2002, DIGEST DIS SCI, V47, P1546, DOI 10.1023/A:1015819203084; Takeuchi K, 1997, GASTROENTEROLOGY, V113, P1553, DOI 10.1053/gast.1997.v113.pm9352857; Takeuchi K, 2001, J PHARMACOL EXP THER, V297, P1160; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomisato W, 2002, DIGEST DIS SCI, V47, P2125, DOI 10.1023/A:1019653719397; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; WATABE A, 1993, J BIOL CHEM, V268, P20175; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Webster CRL, 2002, AM J PHYSIOL-GASTR L, V283, pG727, DOI 10.1152/ajpgi.00410.2001; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yokotani K, 1996, BRIT J PHARMACOL, V117, P653, DOI 10.1111/j.1476-5381.1996.tb15240.x; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	51	117	121	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12752	12758		10.1074/jbc.M212097200	http://dx.doi.org/10.1074/jbc.M212097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556459	hybrid			2022-12-27	WOS:000182189500023
J	Irihimovitch, V; Eichler, J				Irihimovitch, V; Eichler, J			Post-translational secretion of fusion proteins in the halophilic archaea Haloferax volcanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ARGININE TRANSLOCATION PATHWAY; CELLULOSE-BINDING DOMAIN; MEMBRANE INSERTION; ER MEMBRANE; HALOBACTERIUM-VOLCANII; ENDOPLASMIC-RETICULUM; INNER MEMBRANE; ALPHA-FACTOR; IN-VIVO	Although protein secretion occurs post-translationally in bacteria and is mainly a cotranslational event in Eukarya, the relationship between the translation and translocation of secreted proteins in Archaea is not known. To address this question, the signal peptide-encoding region of the surface layer glycoprotein gene from the Haloarchaea Haloferax volcanii was fused either to the cellulose-binding domain of the Clostridium thermocellum cellulosome or to the cytoplasmic enzyme dihydrofolate reductase from H. volcanii. Signal peptide-cleaved mature versions of both the cellulose-binding domain and dihydrofolate reductase could be detected in the growth medium of transformed H. volcanii cells. Immunoblot analysis revealed, however, the presence of full-length signal peptide-bearing forms of both proteins inside the cytoplasm of the transformed cells. Proteinase accessibility assays confirmed that the presence of cell-associated signal peptide-bearing proteins was not due to medium contamination. Moreover, the pulse-radiolabeled signal peptide cellulose-binding domain chimera could be chased from the cytoplasm into the growth medium even following treatment with anisomycin, an antibiotic inhibitor of haloarchaeal protein translation. Thus, these results provide evidence that, in Archaea, at least some secreted proteins are first synthesized inside the cell and only then translocated across the plasma membrane into the medium.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Eichler, J (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.		EICHLER, JERRY/F-2351-2012	EICHLER, JERRY/0000-0001-9409-8026				Berdichevsky Y, 1999, PROTEIN EXPRES PURIF, V17, P249, DOI 10.1006/prep.1999.1125; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bolhuis A, 2002, MICROBIOL-SGM, V148, P3335, DOI 10.1099/00221287-148-11-3335; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CLINE SW, 1989, J BACTERIOL, V171, P4987, DOI 10.1128/jb.171.9.4987-4991.1989; Dale H, 2000, P NATL ACAD SCI USA, V97, P7847, DOI 10.1073/pnas.140216497; Dale H, 1999, J BIOL CHEM, V274, P22693, DOI 10.1074/jbc.274.32.22693; Danner S, 1996, MOL MICROBIOL, V19, P1265, DOI 10.1111/j.1365-2958.1996.tb02471.x; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Eichler J, 2001, TRENDS MICROBIOL, V9, P130, DOI 10.1016/S0966-842X(01)01954-0; Eichler J, 2000, EUR J BIOCHEM, V267, P3402, DOI 10.1046/j.1432-1327.2000.01396.x; Eichler J, 2000, ARCH MICROBIOL, V173, P445, DOI 10.1007/s002030000152; GROPP R, 1992, P NATL ACAD SCI USA, V89, P1204, DOI 10.1073/pnas.89.4.1204; Irihimovitch V, 2003, EXTREMOPHILES, V7, P71, DOI 10.1007/s00792-002-0297-0; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kinch LN, 2002, TRENDS BIOCHEM SCI, V27, P170, DOI 10.1016/S0968-0004(01)02055-2; KOSHLAND D, 1982, CELL, V30, P893, DOI 10.1016/0092-8674(82)90294-X; Macario AJL, 1999, MICROBIOL MOL BIOL R, V63, P923, DOI 10.1128/MMBR.63.4.923-967.1999; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MEVARECH M, 1985, J BACTERIOL, V162, P461, DOI 10.1128/JB.162.1.461-462.1985; MORAG E, 1995, APPL ENVIRON MICROB, V61, P1980, DOI 10.1128/AEM.61.5.1980-1986.1995; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Ortenberg R, 2000, J BIOL CHEM, V275, P22839, DOI 10.1074/jbc.M908916199; Ortenberg R, 2000, MOL MICROBIOL, V35, P1493, DOI 10.1046/j.1365-2958.2000.01815.x; ORTENBERG R, 2001, THESIS TEL AVIV U; Patenge N, 1999, FEMS MICROBIOL LETT, V171, P27, DOI 10.1016/S0378-1097(98)00583-7; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; Rapoport TA, 1996, CURR OPIN CELL BIOL, V8, P499, DOI 10.1016/S0955-0674(96)80027-5; Ring G, 2001, J MEMBRANE BIOL, V183, P195, DOI 10.1007/s00232-001-0067-4; Rose RW, 2002, MOL MICROBIOL, V45, P943, DOI 10.1046/j.1365-2958.2002.03090.x; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; Tozik I, 2002, NUCLEIC ACIDS RES, V30, P4166, DOI 10.1093/nar/gkf548; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629	45	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12881	12887		10.1074/jbc.M210762200	http://dx.doi.org/10.1074/jbc.M210762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566448	hybrid			2022-12-27	WOS:000182189500038
J	Mauro, SA; Pawlowski, D; Koudelka, GB				Mauro, SA; Pawlowski, D; Koudelka, GB			The role of the minor groove substituents in indirect readout of DNA sequence by 434 repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-434 REPRESSOR; HIGH-RESOLUTION; OPERATOR; RECOGNITION; DIAMINOPURINE; AFFINITY; INOSINE; SPECIFICITY; CURVATURE; DODECAMER	The sequence of non-contacted bases at the center of the 434 repressor binding site affects the strength of the repressor-DNA complex by influencing the structure and flexibility of DNA (Koudelka, G. B., and Carlson, P. (1992) Nature 355, 89-91). We synthesized 434 repressor binding sites that differ in their central sequence base composition to test the importance of minor groove substituents and/or the number of base pair hydrogen bonds between these base pairs on DNA structure and strength of the repressor-DNA complex. We show here that the number of base pair H-bonds between the central bases apparently has no role in determining the relative affinity of a DNA site for repressor. Instead we find that the affinity of DNA for repressor depends on the absence or presence the N2-NH2 group on the purine bases at the binding site center. The N2-NH2 group on bases at the center of the 434 binding site appears to destabilize 434 repressor-DNA complexes by decreasing the intimacy of the specific repressor-DNA contacts, while increasing the reliance on protein contacts to the DNA phosphate backbone. Thus, the presence of an N2-NH2 group on the purines at the center of a binding site globally alters the precise conformation of the protein-DNA interface.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Koudelka, GB (corresponding author), SUNY Buffalo, Dept Biol Sci, Cooke Hall,N Campus, Buffalo, NY 14260 USA.		Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; Bailly C, 1998, NUCLEIC ACIDS RES, V26, P4309, DOI 10.1093/nar/26.19.4309; BAILLY C, 1995, EMBO J, V14, P2121, DOI 10.1002/j.1460-2075.1995.tb07204.x; BELL AC, 1993, J MOL BIOL, V234, P542, DOI 10.1006/jmbi.1993.1610; Duong TH, 1998, J MOL BIOL, V280, P31, DOI 10.1006/jmbi.1998.1846; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; JOACHIMIAK A, 1994, EMBO J, V13, P367, DOI 10.1002/j.1460-2075.1994.tb06270.x; JOHNSON BB, 1981, BIOCHEMISTRY-US, V20, P73, DOI 10.1021/bi00504a013; KILKUSKIE R, 1988, BIOCHEMISTRY-US, V27, P4377, DOI 10.1021/bi00412a026; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; Koudelka GB, 1998, NUCLEIC ACIDS RES, V26, P669, DOI 10.1093/nar/26.2.669; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; Lankas F, 2002, BIOPHYS J, V82, P2592, DOI 10.1016/S0006-3495(02)75601-4; MAIBENCO D, 1989, BIOPOLYMERS, V28, P549, DOI 10.1002/bip.360280203; Mollegaard NE, 1997, NUCLEIC ACIDS RES, V25, P3497, DOI 10.1093/nar/25.17.3497; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ShatzkySchwartz M, 1997, J MOL BIOL, V267, P595, DOI 10.1006/jmbi.1996.0878; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; Shui XQ, 1998, BIOCHEMISTRY-US, V37, P8341, DOI 10.1021/bi973073c; XUAN JC, 1992, NUCLEIC ACIDS RES, V20, P5457, DOI 10.1093/nar/20.20.5457	24	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12955	12960		10.1074/jbc.M212667200	http://dx.doi.org/10.1074/jbc.M212667200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569094	hybrid			2022-12-27	WOS:000182189500047
J	Pallavi, B; Nagaraj, R				Pallavi, B; Nagaraj, R			Palmitoylated peptides from the cysteine-rich domain of SNAP-23 cause membrane fusion depending on peptide length, position of cysteines, and extent of palmitoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNARE COMPLEX; PROTEIN; BINDING; STIMULATION; EXOCYTOSIS; MECHANISM; VESICLES; SYNDET	Synaptosome-associated proteins SNAP-23/25, members of a family of proteins essential for exocytosis, have a highly conserved central cysteine-rich domain that plays an important role in membrane targeting. More than one cysteine in this domain is modified by palmitic acid through a thioester linkage. In an effort to address the biological significance of acylation of this domain, we have generated synthetic peptides corresponding to the cysteine-rich region of SNAP-23 and covalently modified the cysteines with palmitic acid. The interaction of acylated and nonacylated peptides with lipid vesicles and natural membranes has been investigated. Our results indicate that palmitoylation is essential for membrane association. The palmitoylated peptides were able to fuse both model and natural membranes. The extent of fusion depended on the length of the peptides and the number and positions of covalently linked palmitic acids. Peptide-mediated fusion was suppressed by lysolipid and involved both outer and inner leaflets of the lipid bilayer, which is characteristic of natural membrane fusion. Our results suggest an important role for the cysteine-rich palmitoylated domain of SNAP-23 in promoting membrane fusion in cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Nagaraj, R (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	nraj@ccmb.res.in						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burger KNJ, 2000, TRAFFIC, V1, P605, DOI 10.1034/j.1600-0854.2000.010804.x; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1995, CURR OPIN STRUC BIOL, V5, P541, DOI 10.1016/0959-440X(95)80041-7; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Edwardson JM, 1998, METHODS, V16, P209, DOI 10.1006/meth.1998.0669; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gonelle-Gispert C, 2000, J CELL SCI, V113, P3197; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k; Harishchandran A, 2002, PROTEIN PEPTIDE LETT, V9, P411, DOI 10.2174/0929866023408571; HEBN CA, 1993, METHOD ENZYMOL, V220, P130; HENNANDEZ LD, 1996, ANN REV CELL BIOL, V12, P627; HOEKSTRA D, 1993, METHOD ENZYMOL, V220, P15, DOI 10.1016/0076-6879(93)20070-J; Hughson FM, 1999, CURR BIOL, V9, pR49, DOI 10.1016/S0960-9822(99)80008-6; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Koticha DK, 2002, J CELL SCI, V115, P3341; Koticha DK, 1999, J BIOL CHEM, V274, P9053, DOI 10.1074/jbc.274.13.9053; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lane SR, 1997, J NEUROCHEM, V69, P1864; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Langosch D, 2001, J BIOL CHEM, V276, P32016, DOI 10.1074/jbc.M102579200; Lentz BR, 2000, CURR OPIN STRUC BIOL, V10, P607, DOI 10.1016/S0959-440X(00)00138-X; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACLEAN CM, 1993, BIOCHEM J, V294, P325, DOI 10.1042/bj2940325; MAUKIN VS, 1984, GEN PHYSL BIOPHYS, V5, P361; MELDOLESI J, 1971, J CELL BIOL, V49, P109, DOI 10.1083/jcb.49.1.109; Misura KMS, 2000, CURR OPIN STRUC BIOL, V10, P662, DOI 10.1016/S0959-440X(00)00151-2; MOBLEY PW, 1995, BBA-MOL BASIS DIS, V1271, P304, DOI 10.1016/0925-4439(95)00048-9; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Peisajovich SG, 2000, J MOL BIOL, V296, P1353, DOI 10.1006/jmbi.2000.3543; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; STRUCK KD, 1981, BIOCHEMISTRY-US, V20, P4039; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamm LK, 2000, BIOSCIENCE REP, V20, P501, DOI 10.1023/A:1010406920417; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	53	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12737	12744		10.1074/jbc.M208598200	http://dx.doi.org/10.1074/jbc.M208598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551899	hybrid			2022-12-27	WOS:000182189500021
J	Zeigler, MM; Doseff, AI; Galloway, MF; Opalek, JM; Nowicki, PT; Zweier, JL; Sen, CK; Marsh, CB				Zeigler, MM; Doseff, AI; Galloway, MF; Opalek, JM; Nowicki, PT; Zweier, JL; Sen, CK; Marsh, CB			Presentation of nitric oxide regulates monocyte survival through effects on caspase-9 and caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE NITRATION; CELL-DEATH; APOPTOSIS; KINASE; INHIBITION; GENE; PEROXYNITRITE; MICE	In the absence of survival factors, blood monocytes undergo spontaneous apoptosis, which involves the activation of caspase-3. Although nitric oxide can block caspase-3 activation and promote cell survival, it can also induce apoptosis. We hypothesized that nitrosothiols that promote protein S-nitrosylation would reduce caspase-3 activation and cell survival, whereas nitric oxide donors (such as I-propamine 3-(2-hydroxy-2-nitroso-1-propylhydrazine (PAPA) NONOate and diethylamine (DEA) NONOate) that do not target thiol residues would not. Using human monocytes as a model, we observed that nitrosothiol donors S-nitrosoglutathione and S-nitroso-N-acetylpenicillamine suppressed caspase-9 and caspase-3 activity and DNA fragmentation. In contrast, PAPA or DEA NONOate did not promote monocyte survival events and appeared to inhibit monocyte survival induced by macrophage colony-stimulating factor. The caspase-3-selective inhibitor DEVD-fluoromethyl ketone reversed DNA fragmentation events, and the caspase-9 inhibitor LEHD-fluoromethyl ketone reversed caspase-3 activity in monocytes treated with PAPA or DEA NONOate in the presence of macrophage colony-stimulating factor. These results were not caused by differences in glutathione levels or the kinetics of nitric oxide release. Moreover, S-nitrosoglutathione and S-nitroso-N-acetylpenicillamine directly blocked the activity of recombinant caspase-3, which was reversed by the reducing agent dithiothreitol, whereas PAPA or DEA NONOate did not block the enzymatic activity of caspase-3. These data support the hypothesis that nitrosylation of protein thiol residues by nitric oxide is critical for promoting the survival of human monocytes.	Ohio State Univ, Dorothy M Davis Heart & Lung Res Int, Div Pulm & Crit Care Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; Ohio State Univ, Childrens Hosp, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Marsh, CB (corresponding author), Ohio State Univ, Dorothy M Davis Heart & Lung Res Int, Div Pulm & Crit Care Med, Rm 110 D HLRI,473 W 12th Ave, Columbus, OH 43210 USA.		Doseff, Andrea/E-2991-2011; Sen, Chandan K/A-8762-2013; Opalek, Judy/G-7755-2018	Opalek, Judy/0000-0001-5046-3562	NHLBI NIH HHS [HL67176, HL66108, HL63800] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063800, R01HL067176, R01HL066108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427; Bosca L, 1999, CELL SIGNAL, V11, P239, DOI 10.1016/S0898-6568(98)00064-3; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Brune B, 1998, BIOCHEMISTRY-MOSCOW+, V63, P817; Deiana M, 1999, FREE RADICAL BIO MED, V26, P762, DOI 10.1016/S0891-5849(98)00231-7; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Estevez AG, 1999, METHOD ENZYMOL, V301, P393; Fahy RJ, 1999, J IMMUNOL, V163, P1755; FEELISCH M, 1995, METHODS NITRIC OXIDE; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; LUKIC ML, 1991, BIOCHEM BIOPH RES CO, V178, P913, DOI 10.1016/0006-291X(91)90978-G; MANGAN DF, 1991, J IMMUNOL, V147, P3408; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MULLERQUERNHEIM J, 1986, J IMMUNOL, V137, P3475; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Sen CK, 1999, METHOD ENZYMOL, V299, P239; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Thornberry NA, 1997, BRIT MED BULL, V53, P478; TOCCI MJ, 1987, J IMMUNOL, V138, P1109; Xi L, 2000, TOXICOLOGY, V155, P37, DOI 10.1016/S0300-483X(00)00275-4; Zhao TC, 2000, CIRCULATION, V102, P902	29	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12894	12902		10.1074/jbc.M213125200	http://dx.doi.org/10.1074/jbc.M213125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566444	hybrid			2022-12-27	WOS:000182189500040
J	Zhang, N; Hodge, D; Rogers, TJ; Oppenheim, JJ				Zhang, N; Hodge, D; Rogers, TJ; Oppenheim, JJ			Ca2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHEMOATTRACTANTS; CROSS-DESENSITIZATION; CALCIUM MOBILIZATION; MORPHINE; ACTIVATION; LOCALIZATION; CELLS; PHOSPHORYLATION; CORTICOSTERONE; DEGRADATION	Heterologous desensitization of chemokine receptors by opioids has been considered to contribute to their immunosuppressive effects. Previous studies show that Met-enkephalin, an endogenous opioid, down-regulates chemotaxis of selected chemokine receptors via phosphorylation. In the present study, we further investigated the molecular mechanism of such cross-regulation. Our data showed that preincubation with Metenkephalin inhibited both MIP-1alpha-mediated chemotaxis and Ca2+ flux of monocytes in a dose-dependent manner. The inhibitory effects were maximal using nanomolar concentrations of activating chemokines, a concentration found in physiological conditions. A decrease both in chemokine receptor affinity and in coupling efficiency between receptors and G protein were observed, which directly contributed to the desensitization effects. However, comparing with chemokines such as MIP-1alpha and MCP-1, opioids did not elicit a calcium flux, failed to induce MIP-1alpha receptors internalization, and mediated a less potent heterologous desensitization. We hypothesized that these differences might originate from the involvement of different protein kinase C (PKC) isotypes. In our studies, opioid-mediated down-regulation of MIP-1alpha receptors could be blocked by the general PKC inhibitor calphostin C, but not by the calcium-dependent classic PKC inhibitor Go6976. Western blotting analysis and immunofluorescent staining further showed that only calcium-independent PKCs were activated upon opioid stimulation. Thus, opioids achieve desensitization of chemokine receptors via a unique pathway, involving only calcium-independent PKC isotypes.	Intramural Res Support Program, Mol Immunoregulat Lab, Frederick, MD 21702 USA; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Oppenheim, JJ (corresponding author), Intramural Res Support Program, Mol Immunoregulat Lab, Bldg 560,Rm 21-89A, Frederick, MD 21702 USA.				NIDA NIH HHS [DA-06550, DA-14230, DA-11130, DA-13429] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009369, ZIABC009369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014230, R01DA011130, R03DA006550, P30DA013429] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; BADOLATO R, 1995, J IMMUNOL, V155, P4004; BRYANT HU, 1991, ENDOCRINOLOGY, V128, P3253, DOI 10.1210/endo-128-6-3253; CATERINA MJ, 1995, J BIOL CHEM, V270, P4418, DOI 10.1074/jbc.270.9.4418; Ceder G, 2001, CLIN CHEM, V47, P1980; DONAHOE RM, 1988, ADV BIOCHEM PSYCHOPH, V44, P145; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Flores LR, 1996, EUR J PHARMACOL, V318, P437, DOI 10.1016/S0014-2999(96)00788-1; FREIER DO, 1994, J PHARMACOL EXP THER, V270, P1127; Fuertes G, 2000, EUR J PHARMACOL, V388, P49, DOI 10.1016/S0014-2999(99)00829-8; Grimm MC, 1998, ANN NY ACAD SCI, V840, P9, DOI 10.1111/j.1749-6632.1998.tb09544.x; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; Heemskerk MHM, 1999, CELL IMMUNOL, V195, P10, DOI 10.1006/cimm.1999.1520; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; McCarthy L, 2001, J NEUROIMMUNOL, V114, P173, DOI 10.1016/S0165-5728(01)00248-X; Meller N, 1999, CELL IMMUNOL, V193, P185, DOI 10.1006/cimm.1999.1478; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; MUELLER SG, 1995, J BIOL CHEM, V270, P10439, DOI 10.1074/jbc.270.18.10439; NOVICK DM, 1989, J PHARMACOL EXP THER, V250, P606; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; Richmond A, 1997, METHOD ENZYMOL, V288, P3; TAUB DD, 1991, P NATL ACAD SCI USA, V88, P360, DOI 10.1073/pnas.88.2.360; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; Yang D, 2001, J IMMUNOL, V166, P4092, DOI 10.4049/jimmunol.166.6.4092; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Yang W, 1997, BIOCHEMISTRY-US, V36, P15193, DOI 10.1021/bi971594u	37	50	51	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12729	12736		10.1074/jbc.M300430200	http://dx.doi.org/10.1074/jbc.M300430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551901	hybrid			2022-12-27	WOS:000182189500020
J	Kitagawa, A; Shimohama, S; Oeda, T; Uemura, K; Kohno, R; Kuzuya, A; Shibasaki, H; Ishii, N				Kitagawa, A; Shimohama, S; Oeda, T; Uemura, K; Kohno, R; Kuzuya, A; Shibasaki, H; Ishii, N			The role of the presenilin-1 homologue gene sel-12 of Caenorhabditis elegans in apoptotic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PROGRAMMED CELL-DEATH; AMYLOID BETA-PEPTIDE; C-ELEGANS; OXIDATIVE STRESS; IN-VIVO; PROTEIN; MUTATION; CALCIUM; MUTANT	Many cases of autosomal dominant early onset familial Alzheimer's disease result from mutations in presenilin-l (PSI). In this study, we examined the role of the PS1 homologue gene sel-12 of Caenorhabditis elegans under oxidative stress and clarified the sel-12-induced apoptosis. A genetic null allele mutant, sel-12(ar171), showed resistance to oxidative stress and prevented mitochondrial dysfunction-induced apoptosis. On the other hand, another allele mutant, sel-12(ar131), that carries a missense mutation showed a proapoptotic activity, which may be the result of a gain of function property. Also, sel-12 (ar131)-induced apoptosis was ced-3- and ced-4-dependent. Dantrolene, which specifically inhibits Ca2+ release from endoplasmic reticulum stores, prevents sel-12(ar131)-induced apoptosis. SEL-12, which is localized in the endoplasmic reticulum, may induce apoptosis through abnormal calcium release from the endoplasmic reticulum. Together, with the previous finding that human PSI could substitute for SEL-12, these results suggest the similar involvement of PS1-inducing apoptosis under oxidative stress and mitochondrial dysfunction in the Alzheimer's Disease brain.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Kyoto University; Tokai University	Shimohama, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogin Kawaharacho, Kyoto 6068507, Japan.							BAGLEY AC, 1986, P NATL ACAD SCI USA, V83, P3189, DOI 10.1073/pnas.83.10.3189; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRENNER S, 1974, GENETICS, V77, P71; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DRISCOLL M, 1995, METHOD CELL BIOL, V46, P323; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; HOSONO R, 1978, EXP GERONTOL, V13, P369, DOI 10.1016/0531-5565(78)90047-5; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Leissring MA, 1999, J BIOL CHEM, V274, P32535, DOI 10.1074/jbc.274.46.32535; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Lewis PA, 2000, BIOCHEM BIOPH RES CO, V277, P261, DOI 10.1006/bbrc.2000.3646; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SOHAL RS, 1988, EXP GERONTOL, V23, P211, DOI 10.1016/0531-5565(88)90008-3; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; SULSTON JE, 1974, GENETICS, V77, P95; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	35	11	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12130	12134		10.1074/jbc.M212058200	http://dx.doi.org/10.1074/jbc.M212058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556527	hybrid			2022-12-27	WOS:000182015700054
J	Lee, JM; Calkins, MJ; Chan, KM; Kan, YW; Johnson, JA				Lee, JM; Calkins, MJ; Chan, KM; Kan, YW; Johnson, JA			Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; NRF2 TRANSCRIPTION FACTOR; HUMAN NEUROBLASTOMA-CELLS; HEME OXYGENASE-1 GENE; GLUTATHIONE S-TRANSFERASES; DETOXIFYING ENZYME GENES; CREB-BINDING-PROTEIN; MEDIATED EXPRESSION; SUBUNIT GENE; QUINONE REDUCTASE	The antioxidant responsive element (ARE) mediates transcriptional regulation of phase II detoxification enzymes and antioxidant proteins such as NAD(P)H:quinone oxidoreductase (NQO1), glutathione S-transferases, and glutamate-cysteine ligase. In this study, we demonstrate that NF-E2-related factor-2 (Nrf2) plays a major role in transcriptional activation of ARE-driven genes and identify Nrf2-dependent genes by oligonucleotide microarray analysis using primary cortical astrocytes from Nrf2(+/+) and Nrf2(-/-) mice. Nrf2(-/-) astrocytes had decreased basal NQO1 activity and no induction by tert-butylhydroquinone compared with Nrf2(+/+) astrocytes. Similarly, both basal and induced levels of human NQO1-ARE-luciferase expression in Nrf2(-/-) astrocytes were significantly lower than in Nrf2(+/+) astrocytes. Furthermore, human NQO1-ARE-luciferase expression in Nrf2(-/-) astrocytes was restored by overexpression of Nrf2, whereas ARE activation in Nrf2(+/+) astrocytes was completely blocked by dominant-negative Nrf2. In addition, we observed that Nrf2-dependent genes protected primary astrocytes from H2O2-or platelet-activating factor-induced apoptosis. In support of these observations, we identified Nrf2-dependent genes encoding detoxification enzymes, glutathione-related proteins, antioxidant proteins, NADPH-producing enzymes, and anti-inflammatory genes using oligonucleotide microarrays. Proteins within these functional categories are vital to the maintenance and responsiveness of a cell defense system, suggesting that an orchestrated change in gene expression via Nrf2 and the ARE gives a synergistic protective effect against oxidative stress.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Univ Wisconsin, Ctr Neurosci, Madison, WI 53705 USA; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Hong Kong; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Johnson, JA (corresponding author), Univ Wisconsin, Sch Pharm, 6125 Rennebohm Hall,777 Highland Ave, Madison, WI 53705 USA.		Chan, Kaimin/C-4207-2009		NIDDK NIH HHS [DK16666] Funding Source: Medline; NIEHS NIH HHS [ES09090, ES10042, ES08089] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016666, R37DK016666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008089, P30ES009090, R01ES008089, R01ES010042] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Aschner M, 2000, NEUROTOXICOLOGY, V21, P1101; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Chen YH, 2000, J BIOL CHEM, V275, P27366; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; Drukarch B, 1998, FREE RADICAL BIO MED, V25, P217, DOI 10.1016/S0891-5849(98)00050-1; Duffy S, 1998, J NEUROCHEM, V71, P69; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hostettler ME, 2002, GLIA, V38, P228, DOI 10.1002/glia.10065; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Kang KW, 2001, MOL PHARMACOL, V59, P1147, DOI 10.1124/mol.59.5.1147; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; Li J, 2002, PHYSIOL GENOMICS, V9, P137, DOI 10.1152/physiolgenomics.00003.2002; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Sonnewald U, 2002, J PHARMACOL EXP THER, V301, P1, DOI 10.1124/jpet.301.1.1; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545	60	607	641	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12029	12038		10.1074/jbc.M211558200	http://dx.doi.org/10.1074/jbc.M211558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556532	hybrid			2022-12-27	WOS:000182015700042
J	Gales, L; Cardoso, I; Fayard, B; Quintanilha, A; Saraiva, MJ; Damas, AM				Gales, L; Cardoso, I; Fayard, B; Quintanilha, A; Saraiva, MJ; Damas, AM			X-ray absorption spectroscopy reveals a substantial increase of sulfur oxidation in transthyretin (TTR) upon fibrillization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRILS; IN-VITRO; SULFONATED TRANSTHYRETIN; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; K-EDGE; BETA(2)-MICROGLOBULIN; AMYLOIDOGENICITY; PROTEINS; MONOMERS	Transthyretin (TTR) amyloid fibrils are the main component of the amyloid deposits occurring in Familial Amyloidotic Polyneuropathy patients. This is 1 of 20 human proteins leading to protein aggregation disorders such as Alzheimer's and Creutzfeldt-Jakob diseases. The structural details concerning the association of the protein molecules are essential for a better understanding of the disease and consequently the design of new strategies for diagnosis and therapeutics. Disulfide bonds are frequently considered essential for the stability of protein aggregates and since in the TTR monomers there is one cysteine residue, it is important to determine unambiguously the redox state of sulfur present in the fibrils. In this work we used x-ray spectroscopy to further characterize TTR amyloid fibrils. The sulfur K-edge absorption spectra for the wild type and some amyloidogenic TTR variants in the soluble and fibrillar forms were analyzed. Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH3) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Further interpretation of the data reveals that there are no disulfide bridges in the fibrillar samples and suggest conformational changes in the TTR molecule, namely in strand A and/or in its vicinity, upon fibril formation.	Univ Porto, ICBAS, P-4099003 Oporto, Portugal; Univ Porto, Inst Mol & Cell Biol, P-4150 Oporto, Portugal; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Universidade do Porto; Universidade do Porto; European Synchrotron Radiation Facility (ESRF)	Damas, AM (corresponding author), Univ Porto, ICBAS, Largo Prof Abel Salazar N2, P-4099003 Oporto, Portugal.		Saraiva, Maria João/K-3907-2013; Gales, Luis/J-8716-2013; Quintanilha, Alexandre/L-5371-2013; Cardoso, Isabel/K-3903-2013	Saraiva, Maria João/0000-0002-3360-6899; Gales, Luis/0000-0002-8352-6539; Quintanilha, Alexandre/0000-0001-8544-0061; Cardoso, Isabel/0000-0003-2472-7055				ATLAND K, 1999, NEUROGENETICS, V2, P183; Bellacchio E, 2001, J SYNCHROTRON RADIAT, V8, P1056, DOI 10.1107/S0909049500017210; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; CAMBILLAU C, 1997, TURBO FRODO VERSION; Cardoso I, 2002, J MOL BIOL, V317, P683, DOI 10.1006/jmbi.2002.5441; DAMAS A, 1995, AMYLOID, V2, P173, DOI 10.3109/13506129509036922; Eneqvist T, 2000, MOL CELL, V6, P1207, DOI 10.1016/S1097-2765(00)00117-9; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Hammersley A. P., 1998, ESRF98HA01T; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Inouye H, 1998, AMYLOID, V5, P163, DOI 10.3109/13506129809003842; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kishikawa M, 2000, PEDIATR RES, V47, P492, DOI 10.1203/00006450-200004000-00013; Kishikawa M, 1999, AMYLOID, V6, P183, DOI 10.3109/13506129909007324; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCCUTCHEN SL, 1993, BIOCHEM BIOPH RES CO, V197, P415, DOI 10.1006/bbrc.1993.2495; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Redondo C, 2000, BIOCHEM J, V348, P167, DOI 10.1042/0264-6021:3480167; Rompel A, 1998, P NATL ACAD SCI USA, V95, P6122, DOI 10.1073/pnas.95.11.6122; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; Sarret G, 1999, J SYNCHROTRON RADIAT, V6, P670, DOI 10.1107/S0909049598014253; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; Serag AA, 2002, NAT STRUCT BIOL, V9, P734, DOI 10.1038/nsb838; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; Theberge R, 1999, ANAL CHEM, V71, P452, DOI 10.1021/ac980531u; THYLEN C, 1993, EMBO J, V12, P743, DOI 10.1002/j.1460-2075.1993.tb05708.x; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399	33	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11654	11660		10.1074/jbc.M210798200	http://dx.doi.org/10.1074/jbc.M210798200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538647	hybrid			2022-12-27	WOS:000181855400099
J	McHugh, D; Flemming, R; Xu, SZ; Perraud, AL; Beech, DJ				McHugh, D; Flemming, R; Xu, SZ; Perraud, AL; Beech, DJ			Critical intracellular Ca2+ dependence of transient receptor potential melastatin 2 (TRPM2) cation channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE; FAMILY; LTRPC2	TRPM2 is a member of the melastatin-related TRP (transient receptor potential) subfamily. It is expressed in brain and lymphocytes and forms a cation channel that is activated by intracellular ADP-ribose and associated with cell death. In this study we investigated the calcium dependence of human TRPM2 expressed under a tetracycline-dependent promoter in HEK-293 cells. TRPM2 expression was associated with enhanced hydrogen peroxide-evoked intracellular calcium signals. In whole-cell patch clamp recordings, switching from barium- to calcium-containing extracellular solution markedly activated TRPM2 as long as ADP-ribose was in the patch pipette and exogenous intracellular calcium buffering was minimal. We suggest this effect reveals a critical dependence of TRPM2 channel activity on intracellular calcium. In the absence of extracellular calcium we observed concentration-dependent activation of TRPM2 channels by calcium delivered from the patch pipette (EC50 340 nM, slope 4.9); the maximum effect was at least as large as that evoked by extracellular calcium. Intracellular dialysis of cells with high concentrations of EGTA or 1,2-bis(o-Aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) strongly reduced the amplitude of the extracellular calcium response, and the residual response was abolished by a mixture of high and low affinity calcium buffers. TRPM2 channel currents in inside-out patches showed a strong requirement for Ca2+ at the intracellular face of the membrane. We suggest that calcium entering via TRPM2 proteins acts at an intracellular calcium sensor closely associated with the channel, providing essential positive feedback for channel activation.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Leeds; National Jewish Health	Beech, DJ (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.		Xu, Shang-Zhong/P-2807-2015	Xu, Shang-Zhong/0000-0002-7295-9347; McHugh, Damian/0000-0001-9677-2934; Beech, David/0000-0002-7683-9422				BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; SMITH GA, 1983, P NATL ACAD SCI-BIOL, V80, P7178, DOI 10.1073/pnas.80.23.7178; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84	17	215	220	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11002	11006		10.1074/jbc.M210810200	http://dx.doi.org/10.1074/jbc.M210810200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529379	hybrid			2022-12-27	WOS:000181855400018
J	Jourdain, S; Acker, J; Ducrot, C; Sentenac, A; Lefebvre, O				Jourdain, S; Acker, J; Ducrot, C; Sentenac, A; Lefebvre, O			The tau 95 subunit of yeast TFIIIC influences upstream and downstream functions of TFIIIC-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; SACCHAROMYCES-CEREVISIAE; BINDING DOMAINS; GENE; PROTEIN; MUTATION; CLONING; RECRUITMENT; COMPONENTS	The yeast transcription factor IIIC (TFIIIC) is organized in two distinct multisubunit domains, tauA and tauB, that are respectively responsible for TFIIIB assembly and stable anchoring of TFIIIC on the B block of tRNA genes. Surprisingly, we found that the removal of tauA by mild proteolysis stabilizes the residual tauB(.)DNA complexes at high temperatures. Focusing on the well conserved tau95 subunit that belongs to the tauA domain, we found that the tau95-E447K mutation has long distance effects on the stability of TFIIIC-DNA complexes and start site selection. Mutant TFIIIC(.)DNA complexes presented a shift in their 5' border, generated slow-migrating TFIIIB(.)DNA complexes upon stripping TFIIIC by heparin or heat treatment, and allowed initiation at downstream sites. In addition, mutant TFIIIC(.)DNA complexes were highly unstable at high temperatures. Co-immunoprecipitation experiments indicated that tau95 participates in the interconnection of tauA with tauB via its contacts with tau138 and tau91 polypeptides. The results suggest that tau95 serves as a scaffold critical for tauA-DNA spatial configuration and tauB-DNA stability.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lefebvre, O (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 144, F-91191 Gif Sur Yvette, France.	Olivier.Lefebvre@Cea.Fr	LEFEBVRE, Olivier/C-3847-2014; Acker, Joël/F-5138-2010	LEFEBVRE, Olivier/0000-0002-3903-9450; Acker, Joël/0000-0002-0855-875X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arrebola R, 1998, MOL CELL BIOL, V18, P1; Aye M, 2001, MOL CELL BIOL, V21, P7839, DOI 10.1128/MCB.21.22.7839-7851.2001; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BRAUN BR, 1992, J BIOL CHEM, V267, P22562; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; CONESA C, 1993, J BIOL CHEM, V268, P18047; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; FABRIZIO P, 1987, P NATL ACAD SCI USA, V84, P8763, DOI 10.1073/pnas.84.24.8763; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Huang Y, 2000, J BIOL CHEM, V275, P31480, DOI 10.1074/jbc.M004635200; Huet J, 1996, METHOD ENZYMOL, V273, P249; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; Manaud N, 1998, MOL CELL BIOL, V18, P3191, DOI 10.1128/MCB.18.6.3191; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Maxam A M, 1980, Methods Enzymol, V65, P499; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2000, J BIOL CHEM, V275, P26591, DOI 10.1074/jbc.M003991200; Moir RD, 2002, MOL CELL BIOL, V22, P6131, DOI 10.1128/MCB.22.17.6131-6141.2002; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STILLMAN DJ, 1984, EMBO J, V3, P847, DOI 10.1002/j.1460-2075.1984.tb01895.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102	49	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10450	10457		10.1074/jbc.M213310200	http://dx.doi.org/10.1074/jbc.M213310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533520	hybrid			2022-12-27	WOS:000181777500062
J	Raja, A; DeStefano, JJ				Raja, A; DeStefano, JJ			Interaction of HIV reverse transcriptase with structures mimicking recombination intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STRAND TRANSFER-REACTIONS; NUCLEOCAPSID PROTEIN; CLEAVAGE SPECIFICITY; INTERNAL REGIONS; MECHANISM; BINDING; MODEL; ENDONUCLEASE; POLYMERASE	Interactions between human immunodeficiency virus (HIV) reverse transcriptase (RT) and structures mimicking intermediates proposed to occur during recombination (strand transfer) were investigated. One mechanism proposed for strand transfer is strand exchange in which a homologous RNA (acceptor) "invades" a donor RNA-DNA duplex (replication intermediate) on which DNA synthesis is occurring. The acceptor displaces the donor of the duplex and binds to the DNA. During exchange a transient trimeric structure forms. A model structure was designed with a replication intermediate to which an acceptor RNA was bound. The acceptor was bound to the 5'-end of the DNA over a 54-base region, whereas the donor associated with the DNA 3'-end over a 28-base region. The dimeric constituents of the trimer (acceptor RNA-DNA and donor RNA-DNA) were also constructed. The acceptor RNA-DNA formed a branched structure in this case. Results showed that RT could cleave the RNA portion of all the structures examined. Association with junction substrates was less stable as determined by off-rates. On the trimer, RT cleaved both RNAs but showed a clear preference for cleaving the donor RNA region. This preference was accentuated by HIV nucleocapsid protein (NC). Results suggest that during recombination RT generally associates with the donor-RNA portion of the trimer and the acceptor RNA is protected but not immune from cleavage. The partial protection likely allows the acceptor RNA to more easily complete strand exchange and shield this RNA to provide a means to salvage replication if the DNA were to dissociate from the cleaved donor RNA.	Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	DeStefano, JJ (corresponding author), Univ Maryland, Dept Mol Genet & Cell Biol, Bldg 231, College Pk, MD 20742 USA.	jd146@umail.umd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051140, R29GM051140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51140, R01 GM051140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cristofaro JV, 2002, BIOCHEMISTRY-US, V41, P10968, DOI 10.1021/bi025871v; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Delviks KA, 1999, J VIROL, V73, P7923, DOI 10.1128/JVI.73.10.7923-7932.1999; DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1994, J MOL BIOL, V243, P558, DOI 10.1016/0022-2836(94)90030-2; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gorshkova II, 2001, ANAL BIOCHEM, V291, P198, DOI 10.1006/abio.2001.5053; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kensch O, 2000, J MOL BIOL, V301, P1029, DOI 10.1006/jmbi.2000.3998; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Sambrook J., 2001, MOL CLONING LAB MANU; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	27	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10102	10111		10.1074/jbc.M210201200	http://dx.doi.org/10.1074/jbc.M210201200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533519	hybrid			2022-12-27	WOS:000181777500017
J	Ikeuchi, T; Sisodia, SS				Ikeuchi, T; Sisodia, SS			The notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent "gamma-secretase" cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; NUCLEAR ACCESS; APP; MUTATIONS; RECEPTOR; TRAFFICKING; DEFICIENCY; MEMBRANE	The evolutionary conserved Notch signaling pathway is involved in cell fate specification and mediated by molecular interactions between the Notch receptors and the Notch ligands, Delta, Serrate, and Jagged. In this report, we demonstrate that like Notch, Delta1 and Jagged2 are subject to presenilin (PS)-dependent, intramembranous "gamma-secretase" processing, resulting in the production of soluble intracellular derivatives. Moreover, and paralleling the observation that expression of familial Alzheimer's disease-linked mutant PSI compromises production of Notch S3/NICD, we show that the PS-dependent production of Delta1 cytoplasmic derivatives are also reduced in cells expressing mutant PS1. These studies led us to conclude that a similar molecular apparatus is responsible for intramembranous processing of Notch and it's ligands. To assess the potential role of the cytoplasmic derivative on nuclear transcriptional events, we expressed a Delta1-Gal4VP16 chimera and demonstrated marked transcriptional stimulation of a luciferase-based reporter. Our findings offer the proposal that Delta1 and Jagged2 play dual roles as activators of Notch receptor signaling and as receptors that mediate nuclear signaling events via gamma-secretase-generated cytoplasmic domains.	Univ Chicago, Ctr Mol Neurobiol, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Sisodia, SS (corresponding author), Univ Chicago, Ctr Mol Neurobiol, Dept Neurobiol Pharmacol & Physiol, Abbott 210,947 E 58th St, Chicago, IL 60637 USA.				NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER; NIA NIH HHS [AG021494] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GRACE GE, 1999, AM J PATHOL, V165, P785; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171	29	184	196	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7751	7754		10.1074/jbc.C200711200	http://dx.doi.org/10.1074/jbc.C200711200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12551931	hybrid			2022-12-27	WOS:000181466800003
J	Cham, CM; Xu, H; O'Keefe, JP; Rivas, FV; Zagouras, P; Gajewski, TF				Cham, CM; Xu, H; O'Keefe, JP; Rivas, FV; Zagouras, P; Gajewski, TF			Gene array and protein expression profiles suggest post-transcriptional regulation during CD8(+) T cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-STIMULATED CLONE-22; GROWTH-FACTOR-BETA; MAP KINASE PHOSPHATASE-1; BLOOD MONONUCLEAR-CELLS; IMMUNOLOGICAL SYNAPSE; CATALYTIC ACTIVATION; NEGATIVE REGULATION; IN-VIVO; RECEPTOR; PROLIFERATION	Peripheral CD8(+) T cells circulate in a quiescent naive state until they are primed by specific antigen and differentiate into effector cells. In the effector state, CD8(+) T cells acquire cytolytic activity and produce increased levels of cytokines such as interferon-gamma. They also exhibit increased T cell receptor sensitivity, decreased CD28 dependence, and become inhibitable by CTLA-4 and other negative regulatory pathways. We hypothesized that one mechanism by which these two states are regulated is via differential expression of specific genes. To this end, basal gene expression profiles of naive and effector 2C TCR transgenic x RAG2(-/-) CD8(+) T cells were analyzed using Affymetrix arrays representing 11,000 genes. Of the 177 differentially expressed known genes, 68 were expressed at higher levels in effector cells, but 109 were more abundant in naive cells, supporting the notion that the naive state is not passive. Expression of genes related to metabolism, actin cytoskeletal dynamics, and effector function increased with priming, whereas expression of putative anti-proliferative genes decreased. Semiquantitative reverse transcription-PCR was utilized as a secondary validation for selected transcripts, and Western blot analysis was used to examine protein expression for molecules of interest. Surprisingly, for 24 genes examined, 12 showed discordant protein versus mRNA expression. In summary, our study indicates that: 1) not only does the expression of some genes in naive CD8(+) T cells become up-regulated upon priming, but the expression of other genes is down-regulated as well and 2) the complexities of T cell differentiation include regulation at the post-transcriptional level.	Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Pfizer	Gajewski, TF (corresponding author), Univ Chicago, Comm Canc Biol, 5841 S Maryland Ave,MC2115, Chicago, IL 60637 USA.	tgajewsk@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047919] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI47919] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Aulwurm UR, 2000, EUR J BIOCHEM, V267, P5693, DOI 10.1046/j.1432-1327.2000.01576.x; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BRAND K, 1985, BIOCHEM J, V228, P353, DOI 10.1042/bj2280353; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Carroll RG, 1998, SEMIN IMMUNOL, V10, P195, DOI 10.1006/smim.1998.0131; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; CRONIN DC, 1994, IMMUNOL RES, V13, P215, DOI 10.1007/BF02935614; DAndrea A, 1996, J EXP MED, V184, P789, DOI 10.1084/jem.184.2.789; Davis SJ, 2001, CURR BIOL, V11, pR289, DOI 10.1016/S0960-9822(01)00165-8; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Fallarino F, 1998, J EXP MED, V188, P205, DOI 10.1084/jem.188.1.205; Fields PE, 1998, J IMMUNOL, V161, P5268; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gajewski TF, 2001, J IMMUNOL, V166, P3900, DOI 10.4049/jimmunol.166.6.3900; Glynne R, 2000, IMMUNOL REV, V176, P216; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; Grayson JM, 2001, J IMMUNOL, V166, P795, DOI 10.4049/jimmunol.166.2.795; GREINER EF, 1994, J BIOL CHEM, V269, P31484; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Hayashi RJ, 1998, J IMMUNOL, V160, P33; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Huard B, 2000, NATURE, V403, P325, DOI 10.1038/35002105; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Kester HA, 1999, J BIOL CHEM, V274, P27439, DOI 10.1074/jbc.274.39.27439; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nakashiro K, 1998, CANCER RES, V58, P549; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Ohta S, 1997, BIOCHEM J, V324, P777, DOI 10.1042/bj3240777; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sprent J, 2000, PHILOS T R SOC B, V355, P317, DOI 10.1098/rstb.2000.0568; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Uchida D, 2000, LAB INVEST, V80, P955, DOI 10.1038/labinvest.3780098; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139	52	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17044	17052		10.1074/jbc.M212741200	http://dx.doi.org/10.1074/jbc.M212741200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12582156	hybrid			2022-12-27	WOS:000182818600081
J	Braunwarth, A; Fromont-Racine, M; Legrain, P; Bischoff, FR; Gerstberger, T; Hurt, E; Kunzler, M				Braunwarth, A; Fromont-Racine, M; Legrain, P; Bischoff, FR; Gerstberger, T; Hurt, E; Kunzler, M			Identification and characterization of a novel RanGTP-binding protein in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT RECEPTOR; MESSENGER-RNA EXPORT; IMPORTIN-ALPHA; TRANSPORT FACTOR; EGG EXTRACTS; GTPASE RAN; IN-VIVO; BETA; XENOPUS; EXPRESSION	The small Ras-like GTPase Ran plays an essential role in the transport of macromolecules in and out of the nucleus and has been implicated in spindle (1, 2) and nuclear envelope formation (3, 4) during mitosis in higher eukaryotes. We identified Saccharomyces cerevisiae open reading frame YGL164c encoding a novel RanGTP-binding protein, termed Yrb30p. The protein competes with yeast RanBP1 (Yrb1p) for binding to the GTP-bound form of yeast Ran (Gsp1p) and is, like Yrb1p, able to form trimeric complexes with RanGTP and some of the karyopherins. In contrast to Yrb1p, Yrb30p does not coactivate but inhibits RanGAP1(Rna1p)-mediated GTP hydrolysis on Ran, like the karyopherins. At steady state, Yrb30p localizes exclusively to the cytoplasm, but the presence of a functional nuclear export signal and the localization of truncated forms of Yrb30p suggest that the protein shuttles between nucleus and cytoplasm and is exported via two alternative pathways, dependent on the nuclear export receptor Xpo1p/Crm1p and on RanGTP binding. Whereas overproduction of the full-length protein and complete deletion of the open reading frame reveal no obvious phenotype, overproduction of C-terminally truncated forms of the protein inhibits yeast vegetative growth. Based on these results and the exclusive conservation of the protein in the fungal kingdom, we hypothesize that Yrb30p represents a novel modulator of the Ran GTPase switch related to fungal lifestyle.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; Inst Pasteur, Dept Biotechnol, F-75724 Paris 15, France; Hybrigen SA, F-75014 Paris, France; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Helmholtz Association; German Cancer Research Center (DKFZ)	Kunzler, M (corresponding author), ETH Zentrum, Inst Mikrobiol, LFV E23,Schelzbergstr 7, CH-8092 Zurich, Switzerland.		Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255; Kunzler, Markus/0000-0003-1275-0629; Fromont-Racine, Micheline/0000-0001-9906-0334				Bamba C, 2002, CURR BIOL, V12, P503, DOI 10.1016/S0960-9822(02)00741-8; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Kaiser C., 1994, METHODS YEAST GENETI; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kunzler M, 2001, J CELL SCI, V114, P3233; Lau D, 2000, J BIOL CHEM, V275, P467, DOI 10.1074/jbc.275.1.467; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; Nicolas FJ, 2001, J CELL SCI, V114, P3013; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Sazer S, 2000, J CELL SCI, V113, P1111; Schroeder AJ, 1999, MOL GEN GENET, V261, P788, DOI 10.1007/s004380050022; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Steggerda SM, 2000, J BIOL CHEM, V275, P23175, DOI 10.1074/jbc.C000252200; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 2002, CURR BIOL, V12, P498, DOI 10.1016/S0960-9822(02)00714-5	39	8	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15397	15405		10.1074/jbc.M210630200	http://dx.doi.org/10.1074/jbc.M210630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578832	hybrid, Green Published			2022-12-27	WOS:000182516100105
J	Fujita, T; Maggio, A; Garcia-Rios, M; Stauffacher, C; Bressan, RA; Csonka, LN				Fujita, T; Maggio, A; Garcia-Rios, M; Stauffacher, C; Bressan, RA; Csonka, LN			Identification of regions of the tomato gamma-glutamyl kinase that are involved in allosteric regulation by proline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA(1)-PYRROLINE-5-CARBOXYLATE SYNTHETASE; ESCHERICHIA-COLI; OSMOTIC-STRESS; SALMONELLA-TYPHIMURIUM; ARABIDOPSIS-THALIANA; FEEDBACK INHIBITION; TRANSFERASE KINASE; PROB GENE; ENHANCED OSMOTOLERANCE; CARBAMOYL-PHOSPHATE	The first step of proline biosynthesis is catalyzed by gamma-glutamyl kinase (GK). To better understand the feedback inhibition properties of GK, we randomly mutagenized a plasmid carrying tomato tomPRO1 cDNA, which encodes proline-sensitive GK. A pool of mutagenized plasmids was transformed into an Escherichia coli GK mutant, and proline-overproducing derivatives were selected on minimal medium containing the toxic proline analog 3,4-dehydro-DL-proline. Thirty-two mutations that conferred 3,4-dehydro-DL-proline resistance were obtained. Thirteen different single amino acid substitutions were identified at nine different residues. The residues were distributed throughout the N-terminal two-thirds of the polypeptide, but 9 mutations affecting 6 residues were in a cluster of 16 residues. GK assays revealed that these amino acid substitutions caused varying degrees of diminished sensitivity to proline feedback inhibition and also resulted in a range of increased proline accumulation in vivo. GK belongs to a family of amino acid kinases, and a predicted three-dimensional model of this enzyme was constructed on the basis of the crystal structures of three related kinases. In the model, residues that were identified as important for allosteric control were located close to each other, suggesting that they may contribute to the structure of a proline binding site. The putative allosteric binding site partially overlaps the dimerization and substrate binding domains, suggesting that the allosteric regulation of GK may involve a direct structural interaction between the proline binding site and the dimerization and catalytic domains.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47906 USA; Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47906 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Csonka, LN (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47906 USA.	lcsonka@bilbo.bio.purdue.edu		Bressan, Ray/0000-0002-8754-606X				Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1988, GENE, V64, P199, DOI 10.1016/0378-1119(88)90335-6; CSONKA LN, 1988, J BACTERIOL, V170, P2374, DOI 10.1128/jb.170.5.2374-2378.1988; CSONKA LN, 1981, MOL GEN GENET, V182, P82, DOI 10.1007/BF00422771; CSONKA LN, 1983, AMINO ACIDS BIOSYNTH, P35; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; DANDEKAR AM, 1988, J BACTERIOL, V170, P5943, DOI 10.1128/jb.170.12.5943-5945.1988; Davis R., 1980, ADV BACTERIAL GENETI; DELAUNEY AJ, 1993, PLANT J, V4, P215, DOI 10.1046/j.1365-313X.1993.04020215.x; Fujita T, 1998, PLANT PHYSIOL, V118, P661, DOI 10.1104/pp.118.2.661; GarciaRios M, 1997, P NATL ACAD SCI USA, V94, P8249, DOI 10.1073/pnas.94.15.8249; Hong ZL, 2000, PLANT PHYSIOL, V122, P1129, DOI 10.1104/pp.122.4.1129; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; Igarashi Y, 1997, PLANT MOL BIOL, V33, P857, DOI 10.1023/A:1005702408601; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; Kosuge T, 1998, APPL ENVIRON MICROB, V64, P4328; KRISHNA RV, 1979, BIOCHEM J, V181, P215, DOI 10.1042/bj1810215; MAHAN MJ, 1983, J BACTERIOL, V156, P1249, DOI 10.1128/JB.156.3.1249-1262.1983; Marina A, 1999, PROTEIN SCI, V8, P934; Massarelli I, 2000, FEMS MICROBIOL LETT, V182, P143, DOI 10.1016/S0378-1097(99)00573-X; Nanjo T, 1999, PLANT J, V18, P185, DOI 10.1046/j.1365-313X.1999.00438.x; OMORI K, 1992, J GEN MICROBIOL, V138, P693, DOI 10.1099/00221287-138-4-693; OMORI K, 1991, J GEN MICROBIOL, V137, P507; Paleg L. G., 1981, PHYSL BIOCH DROUGHT; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Ramon-Maiques S, 2002, STRUCTURE, V10, P329, DOI 10.1016/S0969-2126(02)00721-9; RHODES D, 1986, PLANT PHYSIOL, V82, P890, DOI 10.1104/pp.82.4.890; Roosens NH, 1999, PLANT PHYSIOL, V121, P1281, DOI 10.1104/pp.121.4.1281; RUSHLOW KE, 1985, GENE, V39, P109, DOI 10.1016/0378-1119(85)90115-5; SAMARAS Y, 1995, ENV PLANT B, P161; Sambrook J., 2002, MOL CLONING LAB MANU; SAVOURE A, 1995, FEBS LETT, V372, P13, DOI 10.1016/0014-5793(95)00935-3; Sleator RD, 2001, APPL ENVIRON MICROB, V67, P4560, DOI 10.1128/AEM.67.10.4560-4565.2001; SMITH CJ, 1984, J BACTERIOL, V157, P545, DOI 10.1128/JB.157.2.545-551.1984; SMITH LT, 1985, J BACTERIOL, V164, P1088, DOI 10.1128/JB.164.3.1088-1093.1985; STEWART CR, 1981, BIOCH DROUG RESISTAN, P243; Stines AP, 1999, PLANT PHYSIOL, V120, P923, DOI 10.1104/pp.120.3.923; SZOKE A, 1992, PLANT PHYSIOL, V99, P1642, DOI 10.1104/pp.99.4.1642; TRISTRAM H, 1966, NATURE, V212, P74, DOI 10.1038/212074a0; YOSHIBA Y, 1995, PLANT J, V7, P751, DOI 10.1046/j.1365-313X.1995.07050751.x; ZHANG CS, 1995, J BIOL CHEM, V270, P20491, DOI 10.1074/jbc.270.35.20491; Zhou ZM, 2000, GENE, V243, P105, DOI 10.1016/S0378-1119(99)00552-1	45	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14203	14210		10.1074/jbc.M212177200	http://dx.doi.org/10.1074/jbc.M212177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566437	hybrid			2022-12-27	WOS:000182405000082
J	Shenoy, SK; Lefkowitz, RJ				Shenoy, SK; Lefkowitz, RJ			Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; UBIQUITIN; ENDOCYTOSIS; ACTIVATION; IDENTIFICATION; COMPLEXES; BINDING; PATHWAY; KINASES; SYSTEM	Agonist-dependent internalization of G protein-coupled receptors via clathrin-coated pits is dependent on the adaptor protein beta-arrestin, which interacts with elements of the endocytic machinery such as AP2 and clathrin. For the beta(2)-adrenergic receptor (beta(2)AR) this requires ubiquitination of beta-arrestin by E3 ubiquitin ligase, Mdm2. Based on trafficking patterns and affinity of beta-arrestin, G protein-coupled receptors are categorized into two classes. For class A receptors (e.g. beta(2)AR), which recycle rapidly, beta-arrestin directs the receptors to clathrin-coated pits but does not internalize with them. For class B receptors (e.g. V2 vasopressin receptors), which recycle slowly, beta-arrestin internalizes with the receptor into endosomes. In COS-7 and human embryonic kidney (HEK)-293 cells, stimulation of the beta(2)AR or V2 vasopressin receptor leads, respectively, to transient or stable beta-arrestin ubiquitination. The time course of ubiquitination and deubiquitination of beta-arrestin correlates with its association with and dissociation from each type of receptor. Chimeric receptors, constructed by switching the cytoplasmic tails of the two classes of receptors (beta(2)AR and V2 vasopressin receptors), demonstrate reversal of the patterns of both beta-arrestin trafficking and beta-arrestin ubiquitination. To explore the functional consequences of beta-arrestin ubiquitination we constructed a yellow fluorescent protein-tagged beta-arrestin2-ubiquitin chimera that cannot be deubiquitinated by cellular deubiquitinases. This "permanently ubiquitinated" beta-arrestin did not dissociate from the beta(2)AR but rather internalized with it into endosomes, thus transforming this class A receptor into a class B receptor with respect to its trafficking pattern. Overexpression of this beta-arrestin ubiquitin chimera in HEK-293 cells also results in enhancement of beta(2)AR internalization and degradation. In the presence of N-ethylmaleimide (an inhibitor of deubiquitinating enzymes), coimmunoprecipitation of the receptor and beta-arrestin was increased dramatically, suggesting that deubiquitination of beta-arrestin triggers its dissociation from the receptor. Thus the ubiquitination status of beta-arrestin determines the stability of the receptor-beta-arrestin complex as well as the trafficking pattern of beta-arrestin.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821,Rm 467,CARL Bldg, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mori S, 1997, EUR J BIOCHEM, V247, P1190, DOI 10.1111/j.1432-1033.1997.01190.x; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	26	194	198	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14498	14506		10.1074/jbc.M209626200	http://dx.doi.org/10.1074/jbc.M209626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574160	hybrid			2022-12-27	WOS:000182405000117
J	Takagi, T; Walker, AK; Sawa, C; Diehn, F; Takase, Y; Blackwell, TK; Buratowski, S				Takagi, T; Walker, AK; Sawa, C; Diehn, F; Takase, Y; Blackwell, TK; Buratowski, S			The Caenorhabditis elegans mRNA 5 '-capping enzyme - In vitro and in vivo characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CAPPING ENZYME; CARBOXYL-TERMINAL DOMAIN; POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSITION-STATE; P-TEFB; PROTEIN; GUANYLYLTRANSFERASE; TRANSCRIPTION; PHOSPHATASE	Eukaryotic mRNA capping enzymes are bifunctional, carrying both RNA triphosphatase (RTPase) and guanylyltransferase (GTase) activities. The Caenorhabditis elegans CEL-1 capping enzyme consists of an N-terminal region with RTPase activity and a C-terminal region that resembles known GTases, However, CEL-1 has not previously been shown to have GTase activity. Cloning of the cel-1 cDNA shows that the full-length protein has 623 amino acids, including an additional 38 residues at the C termini and 12 residues at the N termini not originally predicted from the genomic sequence. Full-length CEL-1 has RTPase and GTase activities, and the cDNA can functionally replace the capping enzyme genes in Saccharomyces cerevisiae. The CEL-1 RTPase domain is related by sequence to protein-tyrosine phosphatases; therefore, mutagenesis of residues predicted to be important for RTPase activity was carried out. CEL-1 uses a mechanism similar to protein-tyrosine phosphatases, except that there was not an absolute requirement for a conserved acidic residue that acts as a proton donor. CEL-1 shows a strong preference for RNA substrates of at least three nucleotides in length. RNA-mediated interference in C. elegans embryos shows that lack of CEL-1 causes development to arrest with a phenotype similar to that seen when RNA polymerase 11 elongation activity is disrupted. Therefore, capping is essential for gene expression in metazoans.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Buratowski, S (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	steveb@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056663, R01GM062891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56663, GM62891, R01 GM062891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1991, Methods Enzymol, V194, P1; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bellier S, 1997, EMBO J, V16, P6250, DOI 10.1093/emboj/16.20.6250; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Hausmann S, 2001, J BIOL CHEM, V276, P36116, DOI 10.1074/jbc.M105856200; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ichetovkin IE, 1997, J BIOL CHEM, V272, P33009, DOI 10.1074/jbc.272.52.33009; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3930; JOVE R, 1984, J BIOL CHEM, V259, P8513; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Martins A, 2000, J BIOL CHEM, V275, P35070, DOI 10.1074/jbc.M005748200; Matsuo H, 2000, J AM CHEM SOC, V122, P2417, DOI 10.1021/ja9926820; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P1693, DOI 10.1073/pnas.79.6.1693; Mukhopadhyay R, 2001, J BIOL CHEM, V276, P34738, DOI 10.1074/jbc.M103354200; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Seydoux G, 1997, DEVELOPMENT, V124, P2191; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shim EY, 2002, J BIOL CHEM, V277, P30413, DOI 10.1074/jbc.C200305200; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 2002, EUKARYOT CELL, V1, P448, DOI 10.1128/EC.1.3.448-457.2002; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Takase Y, 2000, MOL CELL BIOL, V20, P9307, DOI 10.1128/MCB.20.24.9307-9316.2000; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; VENKATESAN S, 1980, J BIOL CHEM, V255, P2835; Victor M, 2002, EMBO REP, V3, P50, DOI 10.1093/embo-reports/kvf006; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; WANG D, 1982, MOL CELL BIOL, V2, P993, DOI 10.1128/MCB.2.8.993; WANG DH, 1984, NUCLEIC ACIDS RES, V12, P2303, DOI 10.1093/nar/12.5.2303; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yokoska J, 2000, BIOCHEM BIOPH RES CO, V268, P617, DOI 10.1006/bbrc.2000.2188; Yuan Y, 1998, J BIOL CHEM, V273, P20347, DOI 10.1074/jbc.273.32.20347; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	84	19	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14174	14184		10.1074/jbc.M212101200	http://dx.doi.org/10.1074/jbc.M212101200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576476	hybrid			2022-12-27	WOS:000182405000079
J	Yi, XW; Conesa, A; Punt, PJ; Hager, LP				Yi, XW; Conesa, A; Punt, PJ; Hager, LP			Examining the role of glutamic acid 183 in chloroperoxidase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALDARIOMYCES-FUMAGO CHLOROPEROXIDASE; ENANTIOSELECTIVE EPOXIDATION; BIOLOGICAL CHLORINATION; COMPOUND-I; OXIDATIONS; MECHANISM; BIOSYNTHESIS; PEROXIDASES; RESONANCE; ALKENES	Site-directed mutagenesis has been used to investigate the role of glutamic acid 183 in chloroperoxidase catalysis. Based on the x-ray crystallographic structure of chloroperoxidase, Glu-183 is postulated to function on distal side of the heme prosthetic group as an acid-base catalyst in facilitating the reaction between the peroxidase and hydrogen peroxide with the formation of Compound I. In contrast, the other members of the heme peroxidase family use a histidine residue in this role. Plasmids have now been constructed in which the codon for Glu-183 is replaced with a histidine codon. The mutant recombinant gene has been expressed in Aspergillus niger. An analysis of the produced mutant gene shows that the substitution of Glu-183 with a His residue is detrimental to the chlorination and dismutation activity of chloroperoxidase. The activity is reduced by 85 and 50% of wild type activity, respectively. However, quite unexpectedly, the epoxidation activity of the mutant enzyme is significantly enhanced similar to2.5-fold. These results show that Glu-183 is important but not essential for the chlorination activity of chloroperoxidase. It is possible that the increased epoxidation of the mutant enzyme is based on an increase in the hydrophobicity of the active site.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; TNO, Nutr & Food Res Inst, NL-3704 HE Zeist, Netherlands	University of Illinois System; University of Illinois Urbana-Champaign; Netherlands Organization Applied Science Research	Hager, LP (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	l-hager@uiuc.edu	punt, peter/AAI-8180-2020; Cegarra, Ana V Conesa/A-9559-2014; moreno manzano, Victoria/B-4175-2014	punt, peter/0000-0002-5689-9938; Cegarra, Ana V Conesa/0000-0001-9597-311X; moreno manzano, Victoria/0000-0002-6035-9491; , Xianwen/0000-0001-9320-2020	NIGMS NIH HHS [GM 07768] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES IZ, 1987, ARCH BIOCHEM BIOPHYS, V253, P297, DOI 10.1016/0003-9861(87)90182-2; ALLAIN EJ, 1993, J AM CHEM SOC, V115, P4415, DOI 10.1021/ja00063a091; ALVAREZ JC, 1992, BIOCHEMISTRY-US, V31, P8315, DOI 10.1021/bi00150a027; ARAISO T, 1981, CAN J BIOCHEM CELL B, V59, P233, DOI 10.1139/o81-031; BECKWITH JR, 1963, J BIOL CHEM, V238, P3091; BECKWITH JR, 1963, J BIOL CHEM, V238, P3086; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; Clutterbuck PW, 1940, BIOCHEM J, V34, P664, DOI 10.1042/bj0340664; COLONNA S, 1990, BIOCHEMISTRY-US, V29, P10465, DOI 10.1021/bi00498a006; Conesa A, 2000, APPL ENVIRON MICROB, V66, P3016, DOI 10.1128/AEM.66.7.3016-3023.2000; Conesa A, 2001, J BIOL CHEM, V276, P17635, DOI 10.1074/jbc.M010571200; Conesa A, 2001, FEBS LETT, V503, P117, DOI 10.1016/S0014-5793(01)02698-9; CORBETT MD, 1970, BIOCHEM J, V183, P269; Debrunner PG, 1996, P NATL ACAD SCI USA, V93, P12791, DOI 10.1073/pnas.93.23.12791; DEEB SS, 1964, J BIOL CHEM, V239, P1024; DEXTER AF, 1995, J AM CHEM SOC, V117, P817, DOI 10.1021/ja00107a026; DOERGE DR, 1986, ARCH BIOCHEM BIOPHYS, V244, P678, DOI 10.1016/0003-9861(86)90636-3; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HAGER LP, 1973, OXIDASES RELATED RED, V1, P311; Herbaud ML, 2000, BBA-PROTEIN STRUCT M, V1481, P18, DOI 10.1016/S0167-4838(00)00117-5; HEWSON WD, 1980, J PHYCOL, V16, P340; HOLLENBERG PF, 1992, FASEB J, V6, P686, DOI 10.1096/fasebj.6.2.1537457; Hu SH, 1998, BIOCHEM BIOPH RES CO, V253, P544, DOI 10.1006/bbrc.1998.9721; Hu SH, 1999, J AM CHEM SOC, V121, P872, DOI 10.1021/ja983612g; HUTNER S. H., 1950, PROC AMER PHIL SOC, V94, P152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakner FJ, 1996, J ORG CHEM, V61, P3923, DOI 10.1021/jo960074m; Lakner FJ, 1997, J AM CHEM SOC, V119, P443, DOI 10.1021/ja962998x; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLER VP, 1995, ARCH BIOCHEM BIOPHYS, V319, P333, DOI 10.1006/abbi.1995.1302; MORRIS DR, 1966, J BIOL CHEM, V241, P1763; POULOS TL, 1980, J BIOL CHEM, V255, P322; Rai GP, 2001, ADV SYNTH CATAL, V343, P638, DOI 10.1002/1615-4169(200108)343:6/7<638::AID-ADSC638>3.0.CO;2-6; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER RJ, 1999, J BIOL CHEM, V257, P7958; SHAW PD, 1961, J BIOL CHEM, V236, P1626; SUNDARAMOORTHY M, 1995, ACTA CRYSTALLOGR D, V51, P842, DOI 10.1107/S0907444995001144; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; THOMAS JA, 1970, J BIOL CHEM, V245, P3135; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; THOMAS JA, 1969, BIOCHEM BIOPH RES CO, V35, P444, DOI 10.1016/0006-291X(69)90365-9; vanDeurzen MPJ, 1996, J MOL CATAL B-ENZYM, V2, P33, DOI 10.1016/1381-1177(96)00008-2; Yi XW, 1999, P NATL ACAD SCI USA, V96, P12412, DOI 10.1073/pnas.96.22.12412; ZAKS A, 1995, J AM CHEM SOC, V117, P10419, DOI 10.1021/ja00147a001; ZONG Q, 1995, BIOCHEMISTRY-US, V34, P12420, DOI 10.1021/bi00038a040; ZONG Q, 1997, THESIS U ILLINOIS	48	41	43	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13855	13859		10.1074/jbc.M210906200	http://dx.doi.org/10.1074/jbc.M210906200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576477	hybrid, Green Published			2022-12-27	WOS:000182405000038
J	Bao, XM; Thelen, JJ; Bonaventure, G; Ohlrogge, JB				Bao, XM; Thelen, JJ; Bonaventure, G; Ohlrogge, JB			Characterization of cyclopropane fatty-acid synthase from Sterculia foetida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-CHARACTERIZATION; MICROSOMAL PREPARATIONS; BIOSYNTHESIS; DESATURASE; PLANTS; DEHYDROGENASE; PURIFICATION; INHIBITION; LIPIDS; TISSUE	Cyclopropane synthase from Sterculia foetida developing seeds catalyzes the addition of a methylene group from S-adenosylmethionine to the cis double bond of oleic acid (Bao, X., Katz, S., Pollard, M., and Ohlrogge, J. (2002) Proc. NatL Aca& Sci. U. S. A. 99, 7172-7177). To understand this enzyme better, differential expression in leaf and seed tissues, protein properties, and substrate preferences of plant cyclopropane synthase were investigated. Immunoblot analysis with antibodies raised to recombinant S. foetida cyclopropane synthase (SfCPA-FAS) revealed that SfCPA-FAS is expressed in S. foetida seeds, but not in leaves, and is a membrane protein localized to microsomal fractions. Transformed tobacco cells expressing SfCPA-FAS were labeled in vivo with L-[methyl-C-14]methionine and assayed in vitro with S-adenosyl-L-[methyl-C-14]methionine. These kinetic experiments demonstrated that dihydrosterculate was synthesized from oleic acid esterified at the sn-1 position of phosphatidylcholine (PC). Furthermore, analysis of acyl chains at sn-1 and sn-2 positions that accumulated in PC from S. foetida developing seeds and from tobacco cells expressing SfCPA-FAS also demonstrated that greater than 90% of dihydrosterculate was esterified to the sn-1 position. Thus, we conclude that SfCPA-FAS is a microsomal localized membrane protein that catalyzes the addition of methylene groups derived from S-adenosyl-L-methionine across the double bond of oleic acid esterified to the sn-1 position of PC. A survey of plant and bacterial genomes for sequences related to SfCPA-FAS indicated that a peptide domain with a putative flavin-binding site is either fused to the methyltransferase domain of the plant protein or is often found encoded by a gene adjacent to a bacterial cyclopropane synthase gene.	Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University	Ohlrogge, JB (corresponding author), Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA.			Bonaventure, Gustavo/0000-0001-6120-3897; Thelen, Jay/0000-0001-5995-1562				BAFOR M, 1991, BIOCHEM J, V280, P507, DOI 10.1042/bj2800507; Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAO JM, 1993, BIOCHIM BIOPHYS ACTA, V1210, P27, DOI 10.1016/0005-2760(93)90045-B; Chapman KD, 2001, J AM OIL CHEM SOC, V78, P941, DOI 10.1007/s11746-001-0368-y; CHRISTIE W. W., 1970, Topics in Lipid Chemistry, V1, P1; Christie WW, 1982, LIPID ANAL, P155; CHUNG AE, 1964, BIOCHEMISTRY-US, V3, P967, DOI 10.1021/bi00895a021; CRAVEN B, 1960, J AM CHEM SOC, V82, P3858, DOI 10.1021/ja01500a017; ELHUSSEIN SA, 1988, BIOCHEM J, V252, P39, DOI 10.1042/bj2520039; FOGERTY AC, 1972, LIPIDS, V7, P335, DOI 10.1007/BF02532651; GAYDOU EM, 1993, J AGR FOOD CHEM, V41, P886, DOI 10.1021/jf00030a009; Grogan DW, 1997, MICROBIOL MOL BIOL R, V61, P429, DOI 10.1128/.61.4.429-441.1997; HAYES MK, 1991, PLANT PHYSIOL, V97, P1381, DOI 10.1104/pp.97.4.1381; HILDEBRAND JG, 1964, BIOCHEMISTRY-US, V3, P1304, DOI 10.1021/bi00897a020; Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200; JIE MSF, 1977, J CHEM SOC CHEM COMM, V1264, P78; KLEIMAN R, 1969, LIPIDS, V4, P317, DOI 10.1007/BF02530999; LAW JH, 1963, BIOCHIM BIOPHYS ACTA, V70, P143, DOI 10.1016/0926-6542(63)90023-4; LI RX, 1993, TETRAHEDRON LETT, V34, P1279, DOI 10.1016/S0040-4039(00)91774-X; MARINARI LA, 1978, BIOCHEMISTRY-US, V13, P1978; MEYER H, 1966, J BIOL CHEM, V241, P5000; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; OHLROGGE JB, 1976, BIOCHIM BIOPHYS ACTA, V431, P257, DOI 10.1016/0005-2760(76)90146-6; Page AM, 1997, COMP BIOCHEM PHYS B, V118, P79, DOI 10.1016/S0305-0491(97)00027-8; PASHA MK, 1992, J AGR FOOD CHEM, V40, P626, DOI 10.1021/jf00016a020; PHELPS RA, 1965, POULTRY SCI, V44, P358, DOI 10.3382/ps.0440358; RALAIMANARIVO A, 1982, LIPIDS, V17, P1, DOI 10.1007/BF02535115; ROTHFIELD L, 1966, J BIOL CHEM, V241, P1386; SCHMID KM, 1988, PHYTOCHEMISTRY, V27, P2831, DOI 10.1016/0031-9422(88)80672-1; SCHMID KM, 1988, LIPIDS, V23, P248, DOI 10.1007/BF02535466; SERGHINICAID H, 1988, PLANT SCI, V54, P93, DOI 10.1016/0168-9452(88)90086-6; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; STYMNE S, 1986, BIOCHEM J, V240, P385, DOI 10.1042/bj2400385; TAYLOR FR, 1979, BIOCHEMISTRY-US, V18, P3292, DOI 10.1021/bi00582a015; Thelen JJ, 2001, PLANT PHYSIOL, V125, P2016, DOI 10.1104/pp.125.4.2016; Thelen JJ, 1999, PLANT PHYSIOL, V119, P635, DOI 10.1104/pp.119.2.635; THOMAS PJ, 1966, J BIOL CHEM, V241, P5013; WANG AY, 1992, BIOCHEMISTRY-US, V31, P11020, DOI 10.1021/bi00160a011; YANO I, 1972, LIPIDS, V7, P30, DOI 10.1007/BF02531266; ZALKIN H, 1963, J BIOL CHEM, V238, P1242	42	42	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12846	12853		10.1074/jbc.M212464200	http://dx.doi.org/10.1074/jbc.M212464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562759	hybrid			2022-12-27	WOS:000182189500034
J	Banbury, AN; Oakley, JD; Sessions, RB; Banting, G				Banbury, AN; Oakley, JD; Sessions, RB; Banting, G			Tyrphostin A23 inhibits internalization of the transferrin receptor by perturbing the interaction between tyrosine motifs and the medium chain subunit of the AP-2 adaptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CYTOPLASMIC DOMAIN; CELL-PROLIFERATION; KINASE INHIBITORS; CYTOSOLIC DOMAIN; SORTING SIGNALS; MU-2 SUBUNIT; CLATHRIN; TGN38; ENDOCYTOSIS	Several intracellular membrane trafficking events are mediated by tyrosine-containing motifs within the cytosolic domains of integral membrane proteins. Many such motifs conform to the consensus YXXPhi, where Phi represents a bulky hydrophobic residue. This motif interacts with the medium chain (mu) subunits of adaptor complexes that link the cytosolic domains of integral membrane proteins to the clathrin coat involved in vesicle formation. The YXXPhi motif is similar to motifs in which the tyrosine residue is phosphorylated by tyrosine kinases. Tyrphostins (structural analogs of tyrosine) are inhibitors of tyrosine kinases and function by binding to the active sites of the enzymes. We previously showed that, in vitro and in yeast two-hybrid interaction assays, some tyrphostins can inhibit the interaction between YXXPhi motifs and the mu2 subunit of the AP-2 adaptor complex (Crump, C., Williams, J. L., Stephens, D. J., and Banting, G. (1998) J. Biol. Chem. 273, 2807328077). A23 is such a tyrphostin. We now show that molecular modeling of tyrphostin A23 into the tyrosine-binding pocket in mu2 provides a structural explanation for A23 being able to inhibit the interaction between YXXPhi motifs and mu2. Furthermore, we show that A23 inhibited the internalization of I-125-transferrin in Heb7a cells without having any discernible effect on the morphology of compartments of the endocytic pathway. Control tyrphostins, active as inhibitors of tyrosine kinase activity, but incapable of inhibiting the YXXPhi motif/mu2 interaction, did not inhibit endocytosis. These data are consistent with A23 inhibition of the YXXPhi motif/mu2 interaction in intact cells and with the possibility that different tyrphostins may be used to inhibit specific membrane trafficking events in eukaryotic cells.	Univ Bristol, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England	University of Bristol	Banting, G (corresponding author), Univ Bristol, Dept Biochem, Sch Med Sci, Univ Walk, Bristol BS8 1TD, Avon, England.			Sessions, Richard/0000-0003-0320-0895; Banting, George/0000-0001-8249-1621				Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chuang E, 1997, J IMMUNOL, V159, P144; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Crump CM, 1998, J BIOL CHEM, V273, P28073, DOI 10.1074/jbc.273.43.28073; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; LYALL RM, 1989, J BIOL CHEM, V264, P14503; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; McGraw T. E., 1999, CURRENT PROTOCOLS CE; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Stephens DJ, 1997, FEBS LETT, V416, P27, DOI 10.1016/S0014-5793(97)01165-4; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WALKER J, 1995, J CELL SCI, V108, P2433; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L; WILDE A, 1994, J BIOL CHEM, V269, P7131; WONG SH, 1993, J BIOL CHEM, V268, P22853; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	103	106	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12022	12028		10.1074/jbc.M211966200	http://dx.doi.org/10.1074/jbc.M211966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556528	hybrid			2022-12-27	WOS:000182015700041
J	Dearth, LR; DeWille, J				Dearth, LR; DeWille, J			Posttranscriptional and posttranslational regulation of C/EBP delta in G(0) growth-arrested mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; DEPENDENT KINASE INHIBITOR; BINDING-PROTEIN-EPSILON; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; MAMMALIAN-CELLS; MEDIATED DEGRADATION; GROWING CELLS; EXPRESSION; BETA	Previous work from our laboratory demonstrated that CCAAT/enhancer-binding protein delta (C/EBPdelta) functions in the initiation and maintenance of G(0) growth arrest in mouse mammary epithelial cells (MECs). In this report, we investigated the posttranscriptional and posttranslational regulation of C/EBPdelta in G(0) growth-arrested mouse MECs. The results of transcriptional inhibitor studies demonstrated that the C/EBPdelta mRNA exhibits a relatively short half-life in G(0) growth-arrested mouse MECs (t(1/2) similar to35 min). In contrast, C/EBPdelta mRNA has a longer half-life in G(0) growth-arrested mouse fibroblast cells (t(1/2) > 100 min). Oligo/RNase H cleavage analysis and rapid amplification of cDNA ends-poly(A) test both confirmed the short C/EBPdelta mRNA half-life observed in MECs and demonstrated that the C/EBPdelta mRNA poly(A) tail is relatively short (similar to100 nucleotides). In addition, the poly(A) tail length was not shortened during C/EBPdelta mRNA degradation, which suggested a deadenylation-independent pathway. The C/EBPdelta protein also exhibited a relatively short half-life in Go growth-arrested mouse MECs (t(1/2) similar to120 min). The C/EBPbeta protein was degraded in a ubiquitin-dependent manner, primarily in the nucleus, during G(0) growth arrest. In conclusion, these studies indicated that the C/EBPdelta mRNA and protein content are under tight regulation in G(0) growth-arrested mouse MECs, despite the general concept that G(0) growth arrest is associated with a decrease in cellular activity.	Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Ohio State University; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	DeWille, J (corresponding author), Ohio State Univ, Dept Vet Biosci, 1900 Coffey Rd, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [P30CA016058, R43CA057067, R44CA057067] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058, CA57067] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BAER MR, 1992, BLOOD, V79, P1319; Bosse F, 1999, J NEUROSCI RES, V55, P164, DOI 10.1002/(SICI)1097-4547(19990115)55:2<164::AID-JNR4>3.0.CO;2-9; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chuang LC, 2001, J BIOL CHEM, V276, P1610, DOI 10.1074/jbc.M008896200; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Dearth LR, 2001, J CELL BIOCHEM, V82, P357, DOI 10.1002/jcb.1167; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Dennis AP, 2001, FRONT BIOSCI, V6, pD954, DOI 10.2741/Dennis; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; Evdokiou A, 1998, EXP CELL RES, V240, P359, DOI 10.1006/excr.1998.4011; FERRERO M, 1994, J CELL PHYSIOL, V158, P263, DOI 10.1002/jcp.1041580208; Ferrini JB, 2001, J HEPATOL, V35, P170, DOI 10.1016/S0168-8278(01)00112-X; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Gigliotti AP, 1999, BREAST CANCER RES TR, V58, P57, DOI 10.1023/A:1006381906288; Gonos ES, 1998, ANN NY ACAD SCI, V851, P466, DOI 10.1111/j.1749-6632.1998.tb09024.x; Gu HD, 1999, P NATL ACAD SCI USA, V96, P8943, DOI 10.1073/pnas.96.16.8943; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; JACKMAN J, 1994, CANCER RES, V54, P5656; JOHNSON LF, 1975, CELL, V4, P69, DOI 10.1016/0092-8674(75)90135-X; JOHNSON LF, 1976, J CELL BIOL, V71, P933, DOI 10.1083/jcb.71.3.933; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; O'Rourke JP, 1999, BIOCHEM BIOPH RES CO, V262, P696, DOI 10.1006/bbrc.1999.1256; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; Touriol C, 1999, J BIOL CHEM, V274, P21402, DOI 10.1074/jbc.274.30.21402; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	76	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11246	11255		10.1074/jbc.M207930200	http://dx.doi.org/10.1074/jbc.M207930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12554732	hybrid			2022-12-27	WOS:000181855400051
J	Huo, HR; Guo, XM; Hong, SY; Jiang, MR; Liu, XY; Liao, K				Huo, HR; Guo, XM; Hong, SY; Jiang, MR; Liu, XY; Liao, K			Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-I RECEPTOR; TYROSINE PHOSPHORYLATION; CAVEOLAE MEMBRANE; ADIPOCYTE DIFFERENTIATION; CHOLESTEROL DEPLETION; GLUT4 TRANSLOCATION; PLASMA-MEMBRANE; MDCK CELLS; C-CRK	Lipid rafts/caveolae are found to be essential for insulin-like growth factor (IGF)-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. In 3T3-L1 cells, IGF-1 receptor is located in lipid rafts/caveolae of the plasma membrane and can directly interact with caveolin-1, the major protein component in caveolae. Disruption of lipid rafts/caveolae by depleting cellular cholesterol with cholesterol-binding reagent, beta-methylcyclodextrin or filipin, blocks the IGF-1 receptor signaling in 3T3-L1 preadipocyte. Both hormonal induced adipocyte differentiation and mitotic clonal expansion are inhibited by lipid rafts/caveolae disruption. However, a nonspecific lipid binding reagent, xylazine, does not affect adipocyte differentiation or mitotic clonal expansion. Further studies indicate that lipid rafts/caveolae are required only for IGF-1 receptor downstream signaling and not the activation of receptor itself by ligand. Thus, our results suggest that localization in lipid rafts/caveolae and association with caveolin enable IGF-1 receptor to have a close contact with downstream signal molecules recruited into lipid rafts/caveolae and transmit the signal through these signal molecule complexes.	Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Chinese Acad Sci, State Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Liao, K (corresponding author), Shanghai Inst Biochem & Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	kliao@sibs.ac.cn	Jiang, Manrong/E-6991-2011; Huo, Hairong/B-7700-2011					Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Czech MP, 2000, NATURE, V407, P147, DOI 10.1038/35025183; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hailstones D, 1998, J LIPID RES, V39, P369; Jin SH, 2000, J BIOL CHEM, V275, P34344, DOI 10.1074/jbc.M004927200; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Koval AP, 1998, BIOCHEM J, V330, P923; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LIAO K, 1995, J BIOL CHEM, V270, P12123, DOI 10.1074/jbc.270.20.12123; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Maggi D, 2002, BIOCHEM BIOPH RES CO, V295, P1085, DOI 10.1016/S0006-291X(02)00809-4; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Modan-Moses D, 1998, BIOCHEM J, V333, P825, DOI 10.1042/bj3330825; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tibayan FA, 2002, FASEB J, V16, pA1127; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	56	109	109	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11561	11569		10.1074/jbc.M211785200	http://dx.doi.org/10.1074/jbc.M211785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538586	hybrid			2022-12-27	WOS:000181855400089
J	Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Kobayashi, R				Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Kobayashi, R			A single amino acid difference between alpha and beta Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; REGULATORY MECHANISM; CATALYTIC SUBUNIT; CALMODULIN; CASCADE; IV; ACTIVATION; EXPRESSION; CALCIUM; CREB	We recently developed STO-609, a selective inhibitor of Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), and we demonstrated that CaM-KKbeta is more sensitive to STO-609 than the CaM-KKalpha isoform (Tokumitsu H., Inuzuka H., Ishikawa Y., Ikeda M., Saji I., and Kobayashi R. (2002) J. Biol. Chem. 277,15813-15818). By using catalytic chimera and point mutants of both isoforms, we demonstrated that Val(269) in CaM-KKbeta/Leu(233) in CaM-KKalpha confers a distinct sensitivity (similar to10fold) to STO-609 on CaM-KK isoforms. Various mutations of Val(269) in CaM-KKbeta indicate that substitution by hydrophobic residues with bulky side chains significantly decreases drug sensitivity and that the V269F mutant is the most effective drug-resistant enzyme (similar to80-fold higher IC50 value). These findings are consistent with a result obtained with a full-length mutant expressed in COS-7 cells. Furthermore, suppression of CaM-KK-mediated CaM-KIV activation in transfected HeLa cells by STO-609 treatment was completely abolished by the co-expression of the CaM-KKbeta V269F mutant. Based on the results that the distinct sensitivity of CaM-KK isoforms to STO-609 is because of a single amino acid substitution (Val/Leu) in the ATP-binding pocket, we have generated an STO-609-resistant CaM-KK mutant, which might be useful for validating the pharmacological effects and specificity of STO-609 in vivo.	Kagawa Med Univ, Dept Signal Transduct Sci, Kagawa 7610793, Japan	Kagawa University	Tokumitsu, H (corresponding author), Kagawa Med Univ, Dept Signal Transduct Sci, 1750-1 Miki Cho, Kagawa 7610793, Japan.	tokumit@kms.ac.jp	Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kostich M, 2002, GENOME BIOL, V3; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Wu JY, 2000, ENDOCRINOLOGY, V141, P4777, DOI 10.1210/en.141.12.4777; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153	35	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10908	10913		10.1074/jbc.M213183200	http://dx.doi.org/10.1074/jbc.M213183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540834	hybrid			2022-12-27	WOS:000181855400006
J	Castrillo, A; Joseph, SB; Marathe, C; Mangelsdorf, DJ; Tontonoz, P				Castrillo, A; Joseph, SB; Marathe, C; Mangelsdorf, DJ; Tontonoz, P			Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE INHIBITION; MUSCLE-CELL-MIGRATION; FACTOR-KAPPA-B; GENE-EXPRESSION; GELATINASE-B; CHOLESTEROL EFFLUX; LIPID-METABOLISM; DEFICIENT MICE; FOAM CELLS; GAMMA	Matrix metalloproteinases (MMPs) are zinc endopeptidases that degrade extracellular matrix (ECM) components during normal and pathogenic tissue remodeling. Inappropriate expression of these enzymes contributes to the development of vascular pathology, including atherosclerosis. MMP-9 is expressed in its active form in atherosclerotic lesions and is believed to play an important role in vascular remodeling, smooth muscle cell migration, and plaque instability. We demonstrate here that the liver X receptors (LXRs) LXRalpha and LXRbeta inhibit basal and cytokine-inducible expression of MMP-9. Treatment of murine peritoneal macrophages with the synthetic LXR agonists GW3965 or T1317 reduces MMP-9 mRNA expression and blunts its induction by pro-inflammatory stimuli including lipopolysaccharide, interleukin-1beta, and tumor necrosis factor a. In contrast, macrophage expression of MMP-12 and MMP-13 is not altered by LXR ligands. We further show that the ability of LXR ligands to regulate MMP-9 expression is strictly receptor-dependent and is not observed in macrophages obtained from LXRalphabeta null mice. Analysis of the 5'-flanking region of the MMP-9 gene indicates that LXR/RXR heterodimers do not bind directly to the MMP-9 promoter. Rather, activation of LXRs represses MMP-9 expression, at least in part through antagonism of the NFkappaB signaling pathway. These observations identify the regulation of macrophage MMP-9 expression as a mechanism whereby activation of LXRs may impact macrophage inflammatory responses.	Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Box 951662, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu		Joseph, Sean/0000-0002-2602-8517; Mangelsdorf, David/0000-0002-4355-0796				Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Dubois B, 2002, EUR J IMMUNOL, V32, P2163, DOI 10.1002/1521-4141(200208)32:8<2163::AID-IMMU2163>3.0.CO;2-Q; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Jeng AY, 1999, ANN NY ACAD SCI, V878, P555, DOI 10.1111/j.1749-6632.1999.tb07725.x; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; LAFFITTE BA, 2003, IN PRESS MOL CELL BI; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LIBBY P, 1995, ANN NY ACAD SCI, V748, P158; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mason DP, 1999, CIRC RES, V85, P1179; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Prescott MF, 1999, ANN NY ACAD SCI, V878, P179, DOI 10.1111/j.1749-6632.1999.tb07683.x; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; SATO H, 1993, J BIOL CHEM, V268, P23460; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schuster GU, 2002, CIRCULATION, V106, P1147, DOI 10.1161/01.CIR.0000026802.79202.96; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Woessner JF, 1999, ANN NY ACAD SCI, V878, P388, DOI 10.1111/j.1749-6632.1999.tb07697.x	47	258	275	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10443	10449		10.1074/jbc.M213071200	http://dx.doi.org/10.1074/jbc.M213071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531895	hybrid			2022-12-27	WOS:000181777500061
J	Hooks, SB; Waldo, GL; Corbitt, J; Bodor, ET; Krumins, AM; Harden, TK				Hooks, SB; Waldo, GL; Corbitt, J; Bodor, ET; Krumins, AM; Harden, TK			RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of G(i) family G-proteins with differential selectivity and maximal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; COUPLED RECEPTORS; BINDING PROTEIN; NERVOUS-SYSTEM; SIGNALING RGS; REGULATORS; SUBUNIT; DOMAIN; SPECIFICITY; INHIBITION	Regulator of G-protein signaling (RGS) proteins are GTPase activating proteins (GAPs) of heterotrimeric G-proteins that alter the amplitude and kinetics of receptor-promoted signaling. In this study we defined the G-protein alpha-subunit selectivity of purified Sf9 cell-derived R7 proteins, a subfamily of RGS proteins (RGS6,-7, -9, and -11) containing a Ggamma-like (GGL) domain that mediates dimeric interaction with Gbeta(5). Gbeta(5)/R7 dimers stimulated steady state GTPase activity of Galpha-subunits of the G(i) family, but not of Galpha(q) or Galpha(11), when added to proteoliposomes containing M2 or M1 muscarinic receptor-coupled G-protein heterotrimers. Concentration effect curves of the Gbeta(5)/R7 proteins revealed differences in potencies and efficacies toward Galpha-subunits of the G(i) family. Although all four Gbeta(5)/R7 proteins exhibited similar potencies toward Galpha(o), Gbeta(5)/RGS9 and Gbeta(5)/RGS11 were more potent GAPs of Galpha(i1), Galpha(i2), and Galpha(i3), than were Gbeta(5)/RGS6 and Gbeta(5)/RGS7. The maximal GAP activity exhibited by Gbeta(5)/RGS11 was 2- to 4-fold higher than that of Gbeta(5)/RGS7 and Gbeta(5)/RGS9, with Gbeta(5)/RGS6 exhibiting an intermediate maximal GAP activity. Moreover, the less efficacious Gbeta(5)/RGS7 and Gbeta(5)/RGS9 inhibited Gbeta(5)/RGS11-stimulated GTPase activity of Galpha(o). Therefore, R7 family RGS proteins are G(i) family-selective GAPs with potentially important differences in activities.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hooks, SB (corresponding author), Univ N Carolina, Dept Pharmacol, Campus Box 7365, Chapel Hill, NC 27599 USA.	shelleyb@med.unc.edu		Hooks, Shelley/0000-0003-4702-0490	NIGMS NIH HHS [GM66561, GM65533, GM34497, GM29536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R37GM034497, F32GM066561, P01GM065533, R01GM029536, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Capuano B, 2002, CURR MED CHEM, V9, P521, DOI 10.2174/0929867024606939; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Chidiac P, 1999, BIOCHEM PHARMACOL, V58, P39, DOI 10.1016/S0006-2952(99)00080-5; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gold SJ, 1997, J NEUROSCI, V17, P8024; Gurrath M, 2001, CURR MED CHEM, V8, P1605, DOI 10.2174/0929867013371798; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Ingi T, 1998, J NEUROSCI, V18, P7178; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LIU YF, 1994, J BIOL CHEM, V269, P13880; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2002, J BIOL CHEM, V277, P32843, DOI 10.1074/jbc.M205170200; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; OHara CM, 1996, J PHARMACOL EXP THER, V278, P354; PARKER EM, 1991, J BIOL CHEM, V266, P519; Patikoglou GA, 2002, J BIOL CHEM, V277, P47004, DOI 10.1074/jbc.M208186200; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SADEE W, 2002, AAPS PHARMSCI, V3, pE22; Sautel M, 2000, CURR MED CHEM, V7, P889, DOI 10.2174/0929867003374570; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Sierra DA, 2000, TRENDS CARDIOVAS MED, V10, P263, DOI 10.1016/S1050-1738(00)00072-4; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watts VJ, 1998, J NEUROSCI, V18, P8692; Weiner DM, 2001, J PHARMACOL EXP THER, V299, P268; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	50	121	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10087	10093		10.1074/jbc.M211382200	http://dx.doi.org/10.1074/jbc.M211382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531899	hybrid, Green Published			2022-12-27	WOS:000181777500015
J	Okabe, T; Nakamura, T; Nishimura, YN; Kohu, K; Ohwada, S; Morishita, Y; Akiyama, T				Okabe, T; Nakamura, T; Nishimura, YN; Kohu, K; Ohwada, S; Morishita, Y; Akiyama, T			RICS, a novel GTPase-activating protein for Cdc42 and Rac1, is involved in the beta-catenin-N-cadherin and N-methyl-D-aspartate receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CALMODULIN KINASE-II; POSTSYNAPTIC DENSITY PROTEIN; DENDRITIC SPINE MORPHOLOGY; CELL-ADHESION MOLECULES; NMDA RECEPTOR; SYNAPTIC PLASTICITY; EXCITATORY SYNAPSES; MUTANT MICE; IN-VIVO	Cadherin adhesion molecules are believed to be important for synaptic plasticity. beta-Catenin, which links cadherins and the actin cytoskeleton, is a modulator of cadherin adhesion and regulates synaptic structure and function. Here we show that)beta-catenin interacts with a novel GTPase-activating protein, named RICS, that acts on Cdc42 and Rac1. The RICS-betacatenin complex was found to be associated with N-cadherin, N-methyl-D-aspartate receptors, and postsynaptic density-95, and localized to the postsynaptic density. Furthermore, the GTPase-activating protein activity of RICS was inhibited by phosphorylation by Ca2+ /calmodulin-dependent protein kinase H. These results suggest that RICS is involved in the synaptic adhesion- and N-methyl-D-aspartate-mediated organization of cytoskeletal networks and signal transduction. Thus, RICS may regulate dendritic spine morphology and strength by modulating Rho GTPases.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Gunma Univ, Sch Med, Dept Surg 2, Maebashi, Gumma 371, Japan	University of Tokyo; Gunma University	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp						AEL DE, 2002, CELL, V108, P849; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Benson DL, 1998, J NEUROSCI, V18, P6892; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; El-Hussein AE, 2000, SCIENCE, V290, P1364; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2001, J NEUROSCI, V21, P1501, DOI 10.1523/JNEUROSCI.21-05-01501.2001; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Hinds HL, 1998, LEARN MEMORY, V5, P344; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Margo, 1998, Cancer Control, V5, P310; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Murase S, 1999, CURR OPIN CELL BIOL, V11, P549, DOI 10.1016/S0955-0674(99)00019-8; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ouyang Y, 1997, J NEUROSCI, V17, P5416; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Roy BC, 2002, GENES CELLS, V7, P607; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Sheng M, 2001, J CELL SCI, V114, P1251; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Takeichi M., 1986, P373; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Toni N, 2001, J NEUROSCI, V21, P6245, DOI 10.1523/JNEUROSCI.21-16-06245.2001; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	80	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9920	9927		10.1074/jbc.M208872200	http://dx.doi.org/10.1074/jbc.M208872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12531901	hybrid			2022-12-27	WOS:000181524000139
J	Gimeno, RE; Ortegon, AM; Patel, S; Punreddy, S; Ge, P; Sun, Y; Lodish, HF; Stahl, A				Gimeno, RE; Ortegon, AM; Patel, S; Punreddy, S; Ge, P; Sun, Y; Lodish, HF; Stahl, A			Characterization of a heart-specific fatty acid transport protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CARDIAC MYOCYTES; BINDING-PROTEIN; ADIPOSE-TISSUE; MUSCLE; FAMILY; RAT; TRANSLOCATION	Fatty acids are a major source of energy for cardiac myocytes. Changes in fatty acid metabolism have been implicated as causal in diabetes and cardiac disease. The mechanism by which long chain fatty acids (LCFAs) enter cardiac myocytes is not well understood but appears to occur predominantly by protein-mediated transport. Here we report the cloning, expression pattern, and subcellular localization of a novel member of the fatty acid transport protein (FATP) family termed FATP6. FATP6 is principally expressed in the heart where it is the predominant FATP family member. Similar to other FATPs, transient and stable transfection of FATP6 into 293 cells enhanced uptake of LCFAs. FATP6 mRNA was localized to cardiac myocytes by in situ hybridization. Immunofluorescence microscopy of FATP6 in monkey and murine hearts revealed that the protein is exclusively located on the sarcolemma. FATP6 was restricted in its distribution to areas of the plasma membrane juxtaposed with small blood vessels. In these membrane domains FATP6 also colocalizes with another molecule involved in LCFA uptake, CD36. These findings suggest that FATP6 is involved in heart LCFA uptake, in which it may play a role in the pathogenesis of lipid-related cardiac disorders.	Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Stanford Univ, Sch Med, Palo Alto, CA 94301 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Palo Alto Medical Foundation Research Institute; Stanford University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Stahl, A (corresponding author), Palo Alto Med Fdn, Palo Alto, CA 94301 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618, R01DK047618] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41484] Funding Source: Medline; NIDDK NIH HHS [DK 47618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLARD FB, 1960, J CLIN INVEST, V39, P717, DOI 10.1172/JCI104088; Barger PM, 1999, AM J MED SCI, V318, P36, DOI 10.1097/00000441-199907000-00006; BASSINGTHWAIGHTE JB, 1989, MOL CELL BIOCHEM, V88, P51, DOI 10.1007/BF00223423; BECKER W, 1985, PROG LIPID RES, V24, P325, DOI 10.1016/0163-7827(85)90010-4; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; BING RJ, 1955, CIRCULATION, V12, P635, DOI 10.1161/01.CIR.12.4.635; Binnert C, 2000, AM J PHYSIOL-ENDOC M, V279, pE1072, DOI 10.1152/ajpendo.2000.279.5.E1072; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DEGRELLA RF, 1985, BASIC RES CARDIOL, V80, P107; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; HENSON LC, 1977, BIOCHIM BIOPHYS ACTA, V487, P212, DOI 10.1016/0005-2760(77)90057-1; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; Pohl J, 2000, Eur J Med Res, V5, P438; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; STRAUSS AW, 1995, P NATL ACAD SCI USA, V92, P10496, DOI 10.1073/pnas.92.23.10496; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; van der Vusse GJ, 2000, CARDIOVASC RES, V45, P279, DOI 10.1016/S0008-6363(99)00263-1; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	31	147	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16039	16044		10.1074/jbc.M211412200	http://dx.doi.org/10.1074/jbc.M211412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12556534	hybrid			2022-12-27	WOS:000182680000075
J	Cao, JS; Lockwood, J; Burn, P; Shi, YG				Cao, JS; Lockwood, J; Burn, P; Shi, YG			Cloning and functional characterization of a mouse intestinal Acyl-CoA : monoacylglycerol acyltransferase, MGAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; TRIGLYCERIDE SYNTHESIS; ENZYMES; OBESITY; BIOSYNTHESIS; MUCOSA; RATS; IDENTIFICATION; ABSORPTION	Acyl-CoA:monoacylglycerol transferase (MGAT) plays a predominant role in dietary fat absorption in the small intestine, where it catalyzes the first step of triacylglycerol resynthesis in enterocytes for chylomicron formation and secretion. Although the mouse small intestine exhibits the highest MGAT enzyme activity among all of the tissues studied, the gene encoding the enzyme has not been identified so far. In the present studies, we report the identification and characterization of a mouse intestinal MGAT, MGAT2. Transient expression of MGAT2 in AV-12, COS-7, and Caco-2 cells led to a more than 70-, 30-, and 35-fold increase in the synthesis of diacylglycerol, respectively. MGAT2 expressed in mammalian cells can catalyze the acylation of rac-1-, sn-2-, and sn-3-monoacylglycerols, and the enzyme prefers monoacylglycerols containing unsaturated fatty acyls as substrates. MGAT2 also demonstrates weak DGAT activity, which can be distinguished from its MGAT activity by detergent treatment that abolishes DGAT but not MGAT activity. We also analyzed the biochemical features of MGAT2 and demonstrated homogenate protein-, time-, and substrate concentration-dependent MGAT enzyme activity in transiently transfected COS-7 cells. Northern blot analysis indicates that the mouse MGAT2 is most abundantly expressed in the small intestine, suggesting that MGAT2 may play an important role in dietary fat absorption.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, DK 0545, Indianapolis, IN 46285 USA.							BARACNIETO M, 1971, NEPHRON, V8, P488, DOI 10.1159/000179952; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRECKENRIDGE WC, 1975, CAN J BIOCHEM CELL B, V53, P1184, DOI 10.1139/o75-163; BRECKENRIDGE WC, 1975, CAN J BIOCHEM CELL B, V53, P1170, DOI 10.1139/o75-162; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2000, TRENDS CARDIOVAS MED, V10, P188, DOI 10.1016/S1050-1738(00)00066-9; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Farese RV, 2000, CURR OPIN LIPIDOL, V11, P229, DOI 10.1097/00041433-200006000-00002; JAMDAR SC, 1995, BBA-LIPID LIPID MET, V1255, P237, DOI 10.1016/0005-2760(94)00217-M; JOHNSTON JM, 1970, BIOCHIM BIOPHYS ACTA, V218, P124, DOI 10.1016/0005-2760(70)90099-8; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; Luan Y, 2002, DIABETES RES CLIN PR, V57, P75, DOI 10.1016/S0168-8227(02)00026-8; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; Mansbach CM, 1998, J LIPID RES, V39, P963; PALTAUF F, 1971, BIOCHIM BIOPHYS ACTA, V239, P47, DOI 10.1016/0005-2760(71)90191-3; Phan CT, 2001, FRONT BIOSCI-LANDMRK, V6, pD299, DOI 10.2741/Phan; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; RAO GA, 1966, BIOCHEM BIOPH RES CO, V22, P696; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Swanton EMS, 1997, BBA-LIPID LIPID MET, V1346, P93, DOI 10.1016/S0005-2760(97)00024-6; Trimble M E, 1977, Curr Probl Clin Biochem, V8, P362; TRIMBLE ME, 1978, LIFE SCI, V22, P883; TSO P, 2000, BIOCH PHYSL ASPECTS, P125; Tsujita T, 1996, J BIOL CHEM, V271, P2156, DOI 10.1074/jbc.271.4.2156; WESTERGAARD H, 1976, J CLIN INVEST, V58, P97, DOI 10.1172/JCI108465; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	33	103	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13860	13866		10.1074/jbc.M300139200	http://dx.doi.org/10.1074/jbc.M300139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576479	hybrid			2022-12-27	WOS:000182405000039
J	Colombi, M; Zoppi, N; De Petro, G; Marchina, E; Gardella, R; Tavian, D; Ferraboli, S; Barlati, S				Colombi, M; Zoppi, N; De Petro, G; Marchina, E; Gardella, R; Tavian, D; Ferraboli, S; Barlati, S			Matrix assembly induction and cell migration and invasion inhibition by a 13-amino acid fibronectin peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATIN-BINDING FRAGMENTS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; TUMOR INVASION; MESSENGER-RNAS; IV COLLAGENASE; DOMAIN; TRANSFORMATION; FIBROBLASTS; EXPRESSION	Fibronectin (FN) is an extracellular matrix (ECM) protein involved in tumor growth and metastasis. Five human FN cDNA segments encoding for FN fragments, all starting with the Ill repeat and ending with different C-terminal extensions, have been stably expressed in chick embryo fibroblasts (CEF). These FN cDNAs induce the formation of an organized ECM in CEF as long as they retain a sequence coding for a 13-amino acid stretch (FN13), with collagen binding activity, localized between type 112 and 17 repeats. An FN13 synthetic peptide induces in control CEF the assembly of an FN-ECM comparable with that observed in CEF-expressing FN fragments. The activity of FN13 is specific for its amino acid sequence, although the cysteine present in the 6th position can be substituted with a polar serine without affecting the induction of a fibrillar FN-ECM. A less fibrillar matrix is induced by FN13-modified peptides in which the cysteine is methylated or substituted by a non-polar alanine. FN13 induces the assembly of an FN-ECM also in Rous sarcoma virus-transformed CEF lacking the ECM and in hepatoma (SK-Hepl) and fibrosarcoma (HT-1080) human cell lines. FN13 also promotes the adhesion of CEF and Rous sarcoma virus-CEF at levels comparable with those obtained with purified intact FN. Finally, FN13 inhibits the migratory and invasive properties of tumorigenic cells, whereas intact FN favors their migration. All FN13-modified peptides show similar effects, although with reduced efficiency. None of these activities is supported by a scrambled peptide. These data suggest a possible role of FN13 in tumor growth and metastasis inhibition and its possible use as anti-tumorigenic agent.	Univ Brescia, Div Biol & Genet, Dept Biomed Sci & Biotechnol, Fac Med, I-25123 Brescia, Italy	University of Brescia	Barlati, S (corresponding author), Univ Brescia, Div Biol & Genet, Dept Biomed Sci & Biotechnol, Fac Med, Viale Europa 11, I-25123 Brescia, Italy.	barlati@med.unibs.it	tavian, daniela/AAE-4584-2020; De Petro, Giuseppina/C-2719-2011; Barlati, Sergio/A-2666-2010	De Petro, Giuseppina/0000-0001-9306-0851; MARCHINA, Eleonora/0000-0002-1672-1908; ZOPPI, Nicoletta/0000-0003-0197-8927; Colombi, Marina/0000-0002-3105-5990				BARLATI S, 1994, B I PASTEUR, V92, P269; BARLATI S, 1988, CANCER J, V2, P95; BARLATI S, 1995, TUMOR MATRIX BIOL, P81; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; COLOMBI M, 1993, DNA CELL BIOL, V12, P629, DOI 10.1089/dna.1993.12.629; DARRIBERE T, 1992, DEV DYNAM, V194, P63, DOI 10.1002/aja.1001940108; De Petro G, 1998, CANCER RES, V58, P2234; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEPETRO G, 1981, P NATL ACAD SCI-BIOL, V78, P4965; Givol I, 1995, ONCOGENE, V11, P2609; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN LHE, 1979, P NATL ACAD SCI USA, V76, P1160, DOI 10.1073/pnas.76.3.1160; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1979, J SUPRAMOL STR CELL, V11, P95, DOI 10.1002/jss.400110110; INGHAM KC, 1992, PROTEINS, V12, P180, DOI 10.1002/prot.340120211; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRYCEVEMARTINERIE C, 1981, VIROLOGY, V112, P436, DOI 10.1016/0042-6822(81)90291-9; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; LESOT H, 1992, DIFFERENTIATION, V49, P109, DOI 10.1111/j.1432-0436.1992.tb00775.x; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; RUOSLAHTI E, 1979, J BIOL CHEM, V254, P6054; RUOSLAHTI E, 1994, B I PASTEUR, V92, P242; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SALONEN EM, 1984, J IMMUNOL METHODS, V72, P145, DOI 10.1016/0022-1759(84)90442-3; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; Schnepel J, 2000, J PROTEIN CHEM, V19, P685, DOI 10.1023/A:1007104420017; Schor SL, 1996, J CELL SCI, V109, P2581; SCHWARZBAUER JE, 1987, P NATL ACAD SCI USA, V84, P754, DOI 10.1073/pnas.84.3.754; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SKORSTENGAARD K, 1994, FEBS LETT, V343, P47, DOI 10.1016/0014-5793(94)80604-7; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TAKEUCHI J, 1995, TUMOR MATRIX BIOL, P1; Tremble P M, 1992, Matrix Suppl, V1, P212; VAHERI A, 1974, INT J CANCER, V13, P579, DOI 10.1002/ijc.2910130502; VAHERI A, 1989, FIBRONECTIN, P255; VARTIO T, 1983, INVAS METAST, V3, P125; VARTIO T, 1983, EUR J BIOCHEM, V135, P203, DOI 10.1111/j.1432-1033.1983.tb07638.x; VIDMAR SL, 1991, EUR J BIOCHEM, V201, P79, DOI 10.1111/j.1432-1033.1991.tb16258.x; VIDMAR SL, 1991, EUR J BIOCHEM, V201, P71, DOI 10.1111/j.1432-1033.1991.tb16257.x; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; Yamada KM, 1989, FIBRONECTIN, P47; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620	58	22	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14346	14355		10.1074/jbc.M211997200	http://dx.doi.org/10.1074/jbc.M211997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582155	hybrid			2022-12-27	WOS:000182405000099
J	McCloskey, DE; Pegg, AE				McCloskey, DE; Pegg, AE			Properties of the spermidine/spermine N-1-acetyltransferase mutant L156F that decreases cellular sensitivity to the polyamine analogue N-1, N-11-bis(ethyl)norspermine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMINE N1-ACETYLTRANSFERASE; BIS(ETHYL)POLYAMINE ANALOGS; CANCER-CELLS; LUNG-CANCER; GROWTH; METABOLISM; CHEMOTHERAPY; DEGRADATION; RESIDUES; SEQUENCE	Properties of a mutant form of spermidine/spermine N-1-acetyltransferase, L156F (L156F-SSAT), that is present in Chinese hamster ovary cells selected for resistance to the polyamine analogue N-1, N-11-bis(ethyl)norspermine (BE 3-3-3) were investigated. Increased K. values, decreased V-max. values, and decreased k(cat) values with both polyamine substrates, spermidine and spermine, indicated that L156F-SSAT is an inferior and less efficient acetyltransferase than wild-type SSAT. Transfection of L156F-SSAT into C55.7Res cells indicated that cellular SSAT activity per nanogram of SSAT protein correlated well with the in vitro data and was also similar to20fold less for the mutant protein than for wild-type SSAT. Increased expression of L156F-SSAT was unable to restore cellular sensitivity to BE 3-3-3 despite providing measurable basal SSAT activity. Only a 4-fold induction of L156F-SSAT activity resulted from the exposure of cells to the polyamine analogue, whereas wild-type SSAT was induced similar to300-fold. Degradation studies indicated that BE 3-3-3 cannot prevent ubiquitination of L156F-SSAT and is therefore unable to protect the mutant protein from degradation. These studies indicate that the decreased cellular sensitivity to BE 3-3-3 is caused by the lack of SSAT activity induction in the presence of the analogue due to its inability to prevent the rapid degradation of the L156F-SSAT protein.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol H166, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	McCloskey, DE (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol H166, Rm C4731B,500 Univ Dr, Hershey, PA 17033 USA.				NIGMS NIH HHS [GM-26290] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Casero RA, 2001, J MED CHEM, V44, P1, DOI 10.1021/jm000084m; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; Coleman CS, 2001, BIOCHEM J, V358, P137, DOI 10.1042/0264-6021:3580137; Fersht A., 1999, STRUCTURE MECH PROTE, P103; Frydman B, 1999, EXPERT OPIN THER PAT, V9, P1055, DOI 10.1517/13543776.9.8.1055; Hahm HA, 2002, CLIN CANCER RES, V8, P684; Kanugula S, 2001, ENVIRON MOL MUTAGEN, V38, P235, DOI 10.1002/em.1077; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUI I, 1981, J BIOL CHEM, V256, P2454; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Niiranen K, 2002, J BIOL CHEM, V277, P25323, DOI 10.1074/jbc.M203599200; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1988, ISI ATLAS-BIOCHEM, V1, P11; PILZ RB, 1990, J BIOL CHEM, V265, P8880; PORTER CW, 1991, CANCER RES, V51, P3715; Reddy VK, 2001, J MED CHEM, V44, P404, DOI 10.1021/jm000310s; SARHAN S, 1989, ANTICANCER RES, V9, P215; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Valasinas A, 2001, J MED CHEM, V44, P390, DOI 10.1021/jm000309t	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13881	13887		10.1074/jbc.M205689200	http://dx.doi.org/10.1074/jbc.M205689200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578836	hybrid			2022-12-27	WOS:000182405000042
J	Tamm, I; Trepel, M; Cardo-Vila, M; Sun, Y; Welsh, K; Cabezas, E; Swatterthwait, A; Arap, W; Reed, JC; Pasqualini, R				Tamm, I; Trepel, M; Cardo-Vila, M; Sun, Y; Welsh, K; Cabezas, E; Swatterthwait, A; Arap, W; Reed, JC; Pasqualini, R			Peptides targeting caspase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; BINDING CONSTANTS; IAP; XIAP; SPECIFICITIES; PROTEINS; DOMAIN	Here we report on the identification of peptides targeting the X-inhibitor of apoptosis protein (XIAP). XIAP functions as a caspase inhibitor and is a member of the inhibitors of apoptosis (IAP) family of proteins. IAPs are often overexpressed in cancers and leukemias and are associated with an unfavorable clinical prognosis. We have selected peptides from a phage library by using recombinant full-length human XIAP or a fragment containing only the baculovirus. IAP repeat 2 (BIR2) domain. A consensus motif, C(D/E/P)(W/F/Y)-acid/basic-XC, was recovered from two independent screenings by using different libraries. Phage-displaying variations of the consensus sequence bound specifically to the BIR2 domain of XIAP but not to other IAPs The interaction was specific as it could be blocked by the cognate synthetic peptides in a dose-dependent manner. Phage displaying the XIAP-binding motif CEFESC bound to the BIR2 domain of XIAP with an estimated dissociation constant of 1.8 nm as determined by surface plasmon resonance. Protein-protein interaction assays revealed that caspase-3 and caspase-7 (but not caspase-8) blocked the binding of the CEFESC phage to XIAP, indicating that this peptide targets a domain within XIAP that is related to the caspase-binding site. In fact, the sequence EFES is homologous to a loop unique to the executioner caspase-3 and caspase-7 that are targeted by XIAP. Finally, we demonstrated that an internalizing version of the XIAP-binding peptide identified in our screenings (PFKQ) can induce programmed cell death in leukemia cells. Peptides interacting with XIAP could serve as prototypes for the design of low molecular weight modulators of apoptosis.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Burnham Inst, La Jolla, CA USA; Virchow Clin, Dept Hematol & Oncol, Charite, Berlin, Germany	University of Texas System; UTMD Anderson Cancer Center; Sanford Burnham Prebys Medical Discovery Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Pasqualini, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.	jreed@burnham-inst.org; rpasqual@notes.mdace.tmc.edu			NCI NIH HHS [CA90270, CA8297601, CA9081001, CA55164] Funding Source: Medline; NIA NIH HHS [AG15402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, P50CA090270, U54CA090810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; KOINSTINEN P, 1991, LEUKEMIA, V5, P704; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i	28	60	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14401	14405		10.1074/jbc.M210133200	http://dx.doi.org/10.1074/jbc.M210133200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12538646	Green Published, hybrid			2022-12-27	WOS:000182405000106
J	Hsu, STD; Breukink, E; Bierbaum, G; Sahl, HG; de Kruijff, B; Kaptein, R; van Nuland, NAJ; Bonvin, AMJJ				Hsu, STD; Breukink, E; Bierbaum, G; Sahl, HG; de Kruijff, B; Kaptein, R; van Nuland, NAJ; Bonvin, AMJJ			NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles - Conformational changes are a key to antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MOLECULAR-DYNAMICS SIMULATION; LANTIBIOTIC MERSACIDIN; STEREOSPECIFIC ASSIGNMENTS; COUPLING-CONSTANTS; PORE FORMATION; PROTEINS; BIOSYNTHESIS; MECHANISM; NISIN	Mersacidin belongs to the type B lantibiotics (lanthionine-containing antibiotics) that contain post-translationally modified amino acids and cyclic ring structures. It targets the cell wall precursor lipid 11 and thereby inhibits cell wall synthesis. In light of the emerging antibiotics resistance problem, the understanding of the antibacterial activity on a structural basis provides a key to circumvent this issue. Here we present solution NMR studies of mersacidin-lipid II interaction in dodecylphosphocholine (DPC) micelles. Distinct solution structures of mersacidin were determined in three different states: in water/methanol solution and in DPC micelles with and without lipid II. The structures in various sample conditions reveal remarkable conformational changes in which the junction between Ala-12 and Abu-13 (where Abu is aminobutyric acid) effectively serves as the hinge for the opening and closure of the ring structures. The DPC micelle-bound form resembles the previously determined NMR and x-ray crystal structures of mersacidin in pure methanol but substantially deviates from the other two states in our current report. The structural changes delineate the large chemical shift perturbations observed during the course of a two-step N-15-H-1 heteronuclear single quantum coherence titration. They also modulate the surface charge distribution of mersacidin suggesting that electrostatics play a central role in the mersacidin-lipid II interaction. The observed conformational adaptability of mersacidin might be a general feature of lipid II-interacting antibiotics/peptides.	Univ Utrecht, Ctr Biomembrane & Lipid Enzymol, NMR Dept, Bijovet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Univ Bonn, Inst Med Microbiol & Immunol, D-53015 Bonn, Germany	Utrecht University; University of Bonn	Bonvin, AMJJ (corresponding author), Univ Utrecht, Ctr Biomembrane & Lipid Enzymol, NMR Dept, Bijovet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands.	abonvin@nmr.chem.uu.nl	Breukink, Eefjan/I-3039-2016; Bonvin, Alexandre M.J.J./A-5420-2009; Hsu, Shang-Te Danny/B-2324-2009; Hsu, Shang-Te Danny/L-2826-2014	Breukink, Eefjan/0000-0002-7311-0660; Bonvin, Alexandre M.J.J./0000-0001-7369-1322; Hsu, Shang-Te Danny/0000-0002-7231-0185; 				ANGLISTER J, 1993, J BIOMOL NMR, V3, P121; Bader R, 2001, J MOL BIOL, V305, P307, DOI 10.1006/jmbi.2000.4264; BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BIERBAUM G, 1995, FEMS MICROBIOL LETT, V127, P121, DOI 10.1016/0378-1097(95)00048-A; Bonvin AMJJ, 2001, J BIOMOL NMR, V21, P221, DOI 10.1023/A:1012935005256; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Brotz H, 2000, J ANTIMICROB CHEMOTH, V46, P1, DOI 10.1093/jac/46.1.1; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; Brotz H, 1998, ANTIMICROB AGENTS CH, V42, P154, DOI 10.1128/AAC.42.1.154; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cudic P, 2002, P NATL ACAD SCI USA, V99, P7384, DOI 10.1073/pnas.102192099; Dayie KT, 1996, ANNU REV PHYS CHEM, V47, P243, DOI 10.1146/annurev.physchem.47.1.243; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Feenstra KA, 1999, J COMPUT CHEM, V20, P786, DOI 10.1002/(SICI)1096-987X(199906)20:8<786::AID-JCC5>3.0.CO;2-B; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; Jack RW, 2000, CURR OPIN CHEM BIOL, V4, P310, DOI 10.1016/S1367-5931(00)00094-6; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KESSLER H, 1993, HELV CHIM ACTA, V76, P117, DOI 10.1002/hlca.19930760106; KESSLER H, 1992, BIOPOLYMERS, V32, P427, DOI 10.1002/bip.360320420; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LUDVIGSEN S, 1991, J MOL BIOL, V217, P731, DOI 10.1016/0022-2836(91)90529-F; Marrink SJ, 2000, J PHYS CHEM B, V104, P12165, DOI 10.1021/jp001898h; Mattos C, 2001, CURR OPIN STRUC BIOL, V11, P761, DOI 10.1016/S0959-440X(01)00278-0; NAGARJAN R, 1993, J ANTIBIOT, V46, P1181, DOI 10.7164/antibiotics.46.1181; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Opella SJ, 2001, METHOD ENZYMOL, V339, P285, DOI 10.1016/S0076-6879(01)39319-9; Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; Prasch T, 1997, EUR J BIOCHEM, V244, P501, DOI 10.1111/j.1432-1033.1997.00501.x; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P705, DOI 10.1107/S0907444900003711; Vertesy L, 1999, J ANTIBIOT, V52, P730; Wand AJ, 1998, P NATL ACAD SCI USA, V95, P15299, DOI 10.1073/pnas.95.26.15299; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Williams KA, 1996, BIOCHEMISTRY-US, V35, P5145, DOI 10.1021/bi952897w; Wymore T, 1999, J MOL STRUCT, V485, P195, DOI 10.1016/S0022-2860(99)00090-3; XU RX, 1992, FEBS LETT, V305, P137, DOI 10.1016/0014-5793(92)80881-G; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zimmermann N, 1997, EUR J BIOCHEM, V246, P809, DOI 10.1111/j.1432-1033.1997.00809.x; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	50	110	114	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13110	13117		10.1074/jbc.M211144200	http://dx.doi.org/10.1074/jbc.M211144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562773	hybrid, Green Published			2022-12-27	WOS:000182189500067
J	Maccarrone, M; Di Rienzo, M; Finazzi-Agro, A; Rossi, A				Maccarrone, M; Di Rienzo, M; Finazzi-Agro, A; Rossi, A			Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID AMIDE HYDROLASE; TRANSCRIPTIONAL REGULATION; ENDOCANNABINOIDS; CELLS; EXPRESSION; CYTOKINES; RECEPTOR; BINDING; SYSTEM; ROLES	Physiological concentrations of leptin stimulate the activity of the endocannabinoid-degrading enzyme anandamide hydrolase (fatty acid amide hydrolase, FAAH) in human T lymphocytes up to similar to300% over the untreated controls. Stimulation of FAAH occurred through up-regulation of gene expression at transcriptional and translational levels and involved binding of leptin to its receptor with an apparent dissociation constant K-d of 1.95 +/- 0.14 nM and maximum binding (B-max) of 392 8 fmol(.)mg protein(-1). Leptin binding to the receptor triggered activation of STAT3 but not STAT1 or STAT5 or the mitogen-activated protein kinases p38, p42, and p44. Peripheral lymphocytes of leptin knockout (ob/ob) mice showed decreased FAAH activity and expression (similar to25% of the wild-type littermates), which were reversed to control levels by exogenous leptin. Analysis of the FAAH promoter showed a cAMP-response element-like site, which is a transcriptional target of STAT3. Consistently, mutation of this site prevented FAAH activation by leptin in transient expression assays. Electrophoretic mobility shift and supershift assays further corroborated the promoter activity data. Taken together, these results suggest that leptin, by up-regulating the FAAH promoter through STAT3, enhances FAAH expression, thus tuning the immunomodulatory effects of anandamide. These findings might also have critical implications for human fertility.	Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	University of Teramo; University of Rome Tor Vergata	Maccarrone, M (corresponding author), Univ Teramo, Dept Biomed Sci, Piazza A Moro 45, I-64100 Teramo, Italy.	Maccarrone@vet.unite.it						Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bouaboula M, 1999, FEBS LETT, V449, P61, DOI 10.1016/S0014-5793(99)00395-6; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cunningham MJ, 1999, BIOL REPROD, V60, P216, DOI 10.1095/biolreprod60.2.216; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Deutsch DG, 2002, PROSTAG LEUKOTR ESS, V66, P201, DOI 10.1054/plef.2001.0358; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Fowler CJ, 2002, PROSTAG LEUKOTR ESS, V66, P193, DOI 10.1054/plef.2001.0357; Fride E, 2002, PROSTAG LEUKOTR ESS, V66, P221, DOI 10.1054/plef.2001.0360; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Kirkham TC, 2002, BRIT J PHARMACOL, V136, P550, DOI 10.1038/sj.bjp.0704767; Lee JH, 1996, J BIOL CHEM, V271, P4561; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Maccarrone M, 2002, MOL HUM REPROD, V8, P188, DOI 10.1093/molehr/8.2.188; Maccarrone M, 2001, J IMMUNOL, V166, P7183, DOI 10.4049/jimmunol.166.12.7183; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2000, EUR J BIOCHEM, V267, P2991; Maccarrone M, 2000, LANCET, V355, P1326, DOI 10.1016/S0140-6736(00)02115-2; Maccarrone M, 2002, PROSTAG LEUKOTR ESS, V66, P309, DOI 10.1054/plef.2001.0354; Maccarrone M, 2002, BLOOD, V100, P4040, DOI 10.1182/blood-2002-05-1444; Matarese G, 2002, TRENDS IMMUNOL, V23, P182, DOI 10.1016/S1471-4906(02)02188-9; Mechoulam R, 2002, PROSTAG LEUKOTR ESS, V66, P93, DOI 10.1054/plef.2001.0340; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Paria BC, 2001, J BIOL CHEM, V276, P20523, DOI 10.1074/jbc.M100679200; Parolaro D, 2002, PROSTAG LEUKOTR ESS, V66, P319, DOI 10.1054/plef.2001.0355; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Puffenbarger RA, 2001, NEUROSCI LETT, V314, P21, DOI 10.1016/S0304-3940(01)02274-1; Schrager JA, 2002, J BIOL CHEM, V277, P6137, DOI 10.1074/jbc.M107322200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Waleh NS, 2002, GENE, V291, P203, DOI 10.1016/S0378-1119(02)00598-X; Wan MH, 1998, GENOMICS, V54, P408, DOI 10.1006/geno.1998.5597; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200	40	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13318	13324		10.1074/jbc.M211248200	http://dx.doi.org/10.1074/jbc.M211248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556536	hybrid			2022-12-27	WOS:000182189500092
J	McKenna, S; Moraes, T; Pastushok, L; Ptak, C; Xiao, W; Spyracopoulos, L; Ellison, MJ				McKenna, S; Moraes, T; Pastushok, L; Ptak, C; Xiao, W; Spyracopoulos, L; Ellison, MJ			An NMR-based model of the ubiquitin-bound human ubiquitin conjugation complex Mms2 center dot Ubc13 - The structural basis for lysine 63 chain catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; KAPPA-B-ALPHA; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN CHAIN; DNA-REPAIR; PROTEOLYTIC PATHWAY; ENZYME COMPLEX	A heterodimer composed of the catalytically active ubiquitin-conjugating enzyme hUbc13 and its catalytically inactive paralogue, hMms2, forms the catalytic core for the synthesis of an alternative type of multiubiquitin chain where ubiquitin molecules are tandemly linked to one another through a Lys-63 isopeptide bond. This type of linkage, as opposed to the more typical Lys-48-linked chains, serves as a non-proteolytic marker of protein targets involved in error-free post-replicative DNA repair and NF-kappaB signal transduction. Using a two-dimensional H-1-N-15 NMR approach, we have mapped: 1) the interaction between the subunits of the human Uhc13(.)Mms2 heterodimer and 2) the interactions between each of the subunits or heterodimer with a non-covalently bound acceptor ubiquitin or a thiolester-linked donor ubiquitin. Using these NMR-derived constraints and an unbiased docking approach, we have assembled the four components of this catalytic complex into a three-dimensional model that agrees well with its catalytic function.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Inst Biomol Design, Edmonton, AB T6G 2H7, Canada; Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada	University of Alberta; University of Alberta; University of Saskatchewan	Spyracopoulos, L (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	leo.spyracopoulos@ualberta.ca; mike.ellison@ualberta.ca		Xiao, Wei/0000-0001-7568-0782; McKenna, Sean/0000-0002-9407-7257				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jiang F, 1999, BIOCHEMISTRY-US, V38, P6471, DOI 10.1021/bi9901329; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Morelli XJ, 2001, PROTEIN SCI, V10, P2131, DOI 10.1110/ps.07501; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1999, J CELL SCI, V112, P1375; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; [No title captured]	49	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13151	13158		10.1074/jbc.M212353200	http://dx.doi.org/10.1074/jbc.M212353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569095	hybrid			2022-12-27	WOS:000182189500072
J	Metzger, JM; Michele, DE; Rust, EM; Borton, AR; Westfall, MV				Metzger, JM; Michele, DE; Rust, EM; Borton, AR; Westfall, MV			Sarcomere thin filament regulatory isoforms - Evidence of a dominant effect of slow skeletal troponin I on cardiac contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEFT-VENTRICLE; HYPERTROPHIC CARDIOMYOPATHY; BETA-TROPOMYOSIN; STRIATED-MUSCLE; GENE-TRANSFER; COOPERATIVE ACTIVATION; DEVELOPMENTAL-CHANGES; MYOFILAMENT TENSION; MOLECULAR-CLONING; ALPHA-TROPOMYOSIN	Thin filament proteins tropomyosin (Tm), troponin T (TnT), and troponin I (TnI) form an allosteric regulatory complex that is required for normal cardiac contraction. Multiple isoforms of TnT, Tm, and TnI are differentially expressed in both cardiac development and disease, but concurrent TnI, Tin, and TnT isoform switching has hindered assignment of cellular function to these transitions. We systematically incorporated into the adult sarcomere the embryonic/fetal isoforms of Tin, TnT, and TnI by using gene transfer. In separate experiments, greater than 90% of native TnI and 40-50% of native Tin or TnT were specifically replaced. The Ca2+ sensitivity of tension development was markedly enhanced by TnI replacement but not by TnT or Tin isoform replacement. Titration of TnI replacement from >90% to <30% revealed a dominant functional effect of slow skeletal TnI to modulate regulation. Over this range of isoform replacement, TnI, but not Tin or TnT embryonic isoforms, influenced calcium regulation of contraction, and this identifies TnI as a potential target to modify contractile performance in normal and diseased myocardium.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Metzger, JM (corresponding author), Univ Michigan, Dept Physiol, 7730 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.			Westfall, Margaret/0000-0001-9491-0125				ANDERSON PAW, 1988, CIRC RES, V63, P742, DOI 10.1161/01.RES.63.4.742; ANDERSON PAW, 1992, BASIC RES CARDIOL, V87, P117; ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BRANDT PW, 1990, J MOL BIOL, V212, P473, DOI 10.1016/0022-2836(90)90326-H; Fabiato A, 1978, Ann N Y Acad Sci, V307, P491, DOI 10.1111/j.1749-6632.1978.tb41979.x; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; GREIG A, 1994, CIRC RES, V74, P41, DOI 10.1161/01.RES.74.1.41; James J, 1997, AM J PHYSIOL-HEART C, V273, pH2105, DOI 10.1152/ajpheart.1997.273.5.H2105; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; LEE JA, 1991, J CLIN INVEST, V88, P361, DOI 10.1172/JCI115311; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; MacGowan GA, 2001, AM J PHYSIOL-HEART C, V281, pH2539, DOI 10.1152/ajpheart.2001.281.6.H2539; MARTIN AF, 1981, J BIOL CHEM, V256, P964; MCAULIFFE JJ, 1991, PEDIATR RES, V29, P580, DOI 10.1203/00006450-199106010-00012; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; MesnardRouiller L, 1997, J MOL CELL CARDIOL, V29, P3043, DOI 10.1006/jmcc.1997.0519; METZGER JM, 1995, BIOPHYS J, V68, P1430, DOI 10.1016/S0006-3495(95)80316-4; METZGER JM, 1994, J CELL BIOL, V126, P701, DOI 10.1083/jcb.126.3.701; Michele DE, 1999, NAT MED, V5, P1413; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Michele DE, 2000, TRENDS CARDIOVAS MED, V10, P177, DOI 10.1016/S1050-1738(00)00067-0; Michele DE, 2000, J MOL MED, V78, P543, DOI 10.1007/s001090000161; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Muthuchamy M, 1998, J MOL CELL CARDIOL, V30, P1545, DOI 10.1006/jmcc.1998.0720; Muthuchamy M, 1999, CIRC RES, V85, P47; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; Rust EM, 1998, MOL CELL BIOCHEM, V181, P143, DOI 10.1023/A:1006802719136; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SMILLIE L, 1996, BIOCH SMOOTH MUSCLE; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 1999, J BIOL CHEM, V274, P22508, DOI 10.1074/jbc.274.32.22508; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2001, NEWS PHYSIOL SCI, V16, P278; Westfall MV, 2001, AM J PHYSIOL-CELL PH, V280, pC324, DOI 10.1152/ajpcell.2001.280.2.C324; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13118	13123		10.1074/jbc.M212601200	http://dx.doi.org/10.1074/jbc.M212601200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551900	hybrid			2022-12-27	WOS:000182189500068
J	Ramos, CRR; Figueredo, RCR; Pertinhez, TA; Vilar, MM; do Nascimento, ALTO; Tendler, M; Raw, I; Spisni, A; Ho, PL				Ramos, CRR; Figueredo, RCR; Pertinhez, TA; Vilar, MM; do Nascimento, ALTO; Tendler, M; Raw, I; Spisni, A; Ho, PL			Gene structure and M20T polymorphism of the Schistosoma mansoni Sm14 fatty acid-binding protein - Molecular, functional, and immunoprotection analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD FLUKE	The Schistosoma mansoni Sm14 antigen belongs to the fatty acid-binding protein family and is considered a vaccine candidate against at least two parasite worms, Fasciola hepatica and S. mansoni. Here the genomic sequence and the polymorphism of Sm14 have been characterized for the first time. We found that the conserved methionine at position 20 is polymorphic, being exchangeable with threonine (M20T). To evaluate the function of the amino acid residue at this position, we have also constructed the mutant Sm14-A20 besides the two native isoforms (Sm14-M20 and Sm14-T20). The three purified recombinant His(6)-tagged Sm14 proteins (rSm14-M20, rSm14-T20, and rSm14-A20) present a predominant beta-barrel structure as shown by CD spectroscopy. Thermal and urea unfolding studies evidenced a higher structural stability of rSm14-M20 over the other forms (rSm14-M20>rSm14-T20>rSm14-A20). All of the Sm14 proteins were able to bind 11-(dansylamino)undecanoic acid (DAUDA) without substantial difference in the binding affinity. However, rSm14-M20 exhibited a higher affinity for natural fatty acids than the rSm14-T20 and rSm14-A20 proteins as judged by competitive experiments against DAUDA (rSm14-M20>rSm14-T20> rSm14-A20). The rSm14-M20 or rSm14-T20 isoforms but not the rSm14-A20 mutant was able to induce significant protection against S. mansoni cercariae challenge in immunized mice. The level of protection efficacy correlates with the extent of structure stability of the recombinant Sm14 isoforms and mutant.	Ctr Biotecnol, Inst Butantan, BR-05503900 Sao Paulo, SP, Brazil; Univ Sao Paulo, Inst Quim, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Biociencias, BR-05508900 Sao Paulo, Brazil; Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Fiocruz MS, Inst Oswaldo Cruz, Dept Helmintol, BR-21045900 Rio De Janeiro, Brazil; Univ Parma, Dept Expt Med, I-43100 Parma, Italy	Instituto Butantan; Universidade de Sao Paulo; Universidade de Sao Paulo; Laboratorio Nacional de Luz Sincrotron (LNLS); Fundacao Oswaldo Cruz; University of Parma	Ho, PL (corresponding author), Ctr Biotecnol, Inst Butantan, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.	hoplee@butantan.gov.br	Ramos, Celso R. R./H-6349-2015; Spisni, Alberto/AAY-7778-2020; Nascimento, Ana L. T. O./E-8488-2012; Ho, Paulo/P-8267-2015	Ramos, Celso R. R./0000-0002-5760-8661; Nascimento, Ana L. T. O./0000-0003-4851-0870; Ho, Paulo/0000-0003-3652-241X; Magno Vilar, Monica/0000-0001-9015-8247				Balendiran GK, 2000, J BIOL CHEM, V275, P27045; BECKER MM, 1994, GENE, V148, P321, DOI 10.1016/0378-1119(94)90706-4; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brito CFA, 2000, SCAND J IMMUNOL, V51, P595; Dalessio PM, 2000, BIOCHEMISTRY-US, V39, P860, DOI 10.1021/bi991937j; DESPRES L, 1993, MOL BIOCHEM PARASIT, V60, P221, DOI 10.1016/0166-6851(93)90133-I; Esteves A, 1997, INT J PARASITOL, V27, P1013, DOI 10.1016/S0020-7519(97)00071-4; Junqueira de Azevedo ILM, 2001, J BIOL CHEM, V276, P39836; Kennedy MW, 2000, BIOCHEM J, V349, P377, DOI 10.1042/0264-6021:3490377; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; Krajewski JL, 2001, MOL PHARMACOL, V60, P725; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; MOSER D, 1991, J BIOL CHEM, V266, P8447; Plenefisch J, 2000, MOL BIOCHEM PARASIT, V105, P223, DOI 10.1016/S0166-6851(99)00179-6; Richieri GV, 1998, J BIOL CHEM, V273, P7397, DOI 10.1074/jbc.273.13.7397; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scott JC, 2000, BBA-GENE STRUCT EXPR, V1517, P53, DOI 10.1016/S0167-4781(00)00254-2; Tendler M, 1996, P NATL ACAD SCI USA, V93, P269, DOI 10.1073/pnas.93.1.269; TENDLER M, 1986, INT J PARASITOL, V16, P347, DOI 10.1016/0020-7519(86)90113-X; Wu QW, 2001, INSECT BIOCHEM MOLEC, V31, P553, DOI 10.1016/S0965-1748(00)00158-2; Zimmerman AW, 2001, INT J BIOCHEM CELL B, V33, P865, DOI 10.1016/S1357-2725(01)00070-X	25	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12745	12751		10.1074/jbc.M211268200	http://dx.doi.org/10.1074/jbc.M211268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551912	hybrid, Green Submitted			2022-12-27	WOS:000182189500022
J	Sadek, CM; Jimenez, A; Damdimopoulos, AE; Kieselbach, T; Nord, M; Gustafsson, JA; Spyrou, I; Davis, EC; Oko, R; van der Hoorn, FA; Miranda-Vizuete, A				Sadek, CM; Jimenez, A; Damdimopoulos, AE; Kieselbach, T; Nord, M; Gustafsson, JA; Spyrou, I; Davis, EC; Oko, R; van der Hoorn, FA; Miranda-Vizuete, A			Characterization of human thioredoxin-like 2 - A novel microtubule-binding thioredoxin expressed predominantly in the cilia of lung airway epithelium and spermatid manchette and axoneme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; OUTER ARM DYNEIN; CELL-DIFFERENTIATION; MOLECULAR-CLONING; IN-VITRO; PROTEIN; TESTIS; CENTROSOME; TRANSPORT; FAMILY	We describe here the cloning and characterization of a novel member of the thioredoxin family, thioredoxin-like protein 2 (Txl-2). The Txl-2 open reading frame codes for a protein of 330 amino acids consisting of two distinct domains: an N-terminal domain typical of thioredoxins and a C-terminal domain belonging to the nucleoside-diphosphate kinase family, separated by a small interface domain. The Txl-2 gene spans similar to28 kb, is organized into 11 exons, and maps at locus 3q22.3-q23. A splicing variant lacking exon 5 (Delta5Txl-2) has also been isolated. By quantitative real time PCR we demonstrate that Txl-2 mRNA is ubiquitously expressed, with testis and lung having the highest levels of expression. Unexpectedly, light and electron microscopy analyses show that the protein is associated with microtubular structures such as lung airway epithelium cilia and the manchette and axoneme of spermatids. Using in vitro translated proteins, we demonstrate that full-length Txl-2 weakly associates with microtubules. In contrast, Delta5Txl-2 specifically binds with very high affinity brain microtubule preparations containing microtubule-binding proteins. Importantly, Delta5Txl-2 also binds to pure microtubules, proving that it possesses intrinsic microtubule binding capability. Taken together, Delta5Txl-2 is the first thioredoxin reported to bind microtubules and might therefore be a novel regulator of microtubule physiology.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, Prot Anal Unit,Ctr Struct Biol, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Med Nutr, S-14157 Huddinge, Sweden; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; McGill University; University of Calgary; Queens University - Canada	Miranda-Vizuete, A (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, Halsovagen 7, S-14157 Huddinge, Sweden.		Davis, Elaine/F-3449-2012; IBIS, REDOX/J-7473-2017; Sadek, Christine/A-7356-2010; Kieselbach, Thomas/O-6023-2015; Jiménez, Alberto/A-6234-2009; Miranda-Vizuete, Antonio/D-6927-2012	Kieselbach, Thomas/0000-0001-5577-2938; Jiménez, Alberto/0000-0003-3685-6479; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189	Canadian Institutes of Health Research [11361] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9; Blouin JL, 2000, EUR J HUM GENET, V8, P109, DOI 10.1038/sj.ejhg.5200429; Chaudhuri AR, 2001, BIOCHEMISTRY-US, V40, P8834, DOI 10.1021/bi0101603; COUTAVAS EE, 1994, MAMM GENOME, V5, P623, DOI 10.1007/BF00411457; Cowan MJ, 2001, AM J MED SCI, V321, P3, DOI 10.1097/00000441-200101000-00002; DUTCHER SK, 1995, TRENDS GENET, V11, P398, DOI 10.1016/S0168-9525(00)89123-4; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GAN ZR, 1991, J BIOL CHEM, V266, P1692; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harrison A, 2002, CELL MOTIL CYTOSKEL, V52, P131, DOI 10.1002/cm.10044; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Junco A, 2001, BIOL REPROD, V64, P1320, DOI 10.1095/biolreprod64.5.1320; Kierszenbaum AL, 2002, MOL REPROD DEV, V63, P131, DOI 10.1002/mrd.10164; Kierszenbaum AL, 2002, MOL REPROD DEV, V63, P1, DOI 10.1002/mrd.10179; Kierszenbaum AL, 2001, MOL REPROD DEV, V59, P347, DOI 10.1002/mrd.1040; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; LECROISEY A, 1995, BIOCHEMISTRY-US, V34, P12445, DOI 10.1021/bi00038a043; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; LOMBARDI D, 1995, EXP CELL RES, V217, P267, DOI 10.1006/excr.1995.1086; Mehus JG, 1999, HUM GENET, V104, P454, DOI 10.1007/s004390050987; Milon L, 2000, J BIOL CHEM, V275, P14264, DOI 10.1074/jbc.275.19.14264; Miranda-Vizuete A, 1998, BIOCHEM BIOPH RES CO, V243, P284, DOI 10.1006/bbrc.1997.8003; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; Mochida K, 1998, DEV BIOL, V200, P46, DOI 10.1006/dbio.1998.8942; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; Oko R, 1998, ANDROLOGIA, V30, P193; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Padma P, 2001, GENE, V275, P177, DOI 10.1016/S0378-1119(01)00661-8; Patel-King RS, 2002, J BIOL CHEM, V277, P34271, DOI 10.1074/jbc.M204137200; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; Roymans D, 2001, EXP CELL RES, V262, P145, DOI 10.1006/excr.2000.5087; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; Sapiro R, 2002, MOL CELL BIOL, V22, P6298, DOI 10.1128/MCB.22.17.6298-6305.2002; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; Valiron O, 2001, CELL MOL LIFE SCI, V58, P2069, DOI 10.1007/PL00000837; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; Zou Y, 2002, BIOL REPROD, V66, P843, DOI 10.1095/biolreprod66.3.843	56	70	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13133	13142		10.1074/jbc.M300369200	http://dx.doi.org/10.1074/jbc.M300369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569107	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000182189500070
J	Tsivkovskii, R; Efremov, RG; Lutsenko, S				Tsivkovskii, R; Efremov, RG; Lutsenko, S			The role of the invariant His-1069 in folding and function of the Wilson's disease protein, the human copper-transporting ATPase ATP7B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; CALCIUM-PUMP; SACCHAROMYCES-CEREVISIAE; REGULATED TRAFFICKING; MUTATION; CA2+-ATPASE; EXPRESSION; RETICULUM; MEMBRANE; BINDING	The copper-transporting ATPase ATP7B is essential for normal distribution of copper in human cells. Mutations in ATP7B lead to Wilson's disease, a severe disorder with neurological and hepatic manifestations. One of the most common disease mutations, a H1069Q substitution, causes intracellular mislocalization of ATP7B (the Wilson's disease protein, WNDP). His-1069 is located in the nucleotide-binding domain of WNDP and is conserved in all copper-transporting ATPases from bacteria to mammals; however, the specific role of this His in the structure and function of WNDP remains unclear. We demonstrate that substitution of His-1069 for Gln, Ala, or Cys does not significantly alter the folding of the WNDP nucleotide-binding domain or the proteolytic resistance of the full-length WNDP. In contrast, the function of WNDP is markedly affected by the mutations. The ability to form an acylphosphate intermediate in the presence of ATP is entirely lost in all three mutants, suggesting that His-1069 is important for ATP-dependent phosphorylation. Other steps of the WNDP enzymatic cycle are less dependent on His-1069. The H1069C mutant shows normal phosphorylation in the presence of inorganic phosphate; it binds an ATP analogue, beta,gamma-imidoadenosine 5'-triphosphate (AMP-PNP), and copper and undergoes nucleotide-dependent conformational transitions similar to those of the wild-type WNDP. Although binding of AMP-PNP is not disrupted by the mutation, the apparent affinity for the nucleotide is decreased by 4-fold. We conclude that His-1069 is responsible for proper orientation of ATP in the catalytic site of WNDP prior to ATP hydrolysis.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	Oregon Health & Science University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	lutsenko@ohsu.edu	Roman, Efremov/A-7460-2014	Roman, Efremov/0000-0002-5474-4721	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55719] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, GASTROENTEROLOGY, V124, P335, DOI 10.1053/gast.2003.50066; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Okkeri J, 2002, EUR J BIOCHEM, V269, P1579, DOI 10.1046/j.1432-1033.2002.02810.x; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; THOMAS GR, 1995, AM J HUM GENET, V56, P1315; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	23	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13302	13308		10.1074/jbc.M300034200	http://dx.doi.org/10.1074/jbc.M300034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551905	hybrid			2022-12-27	WOS:000182189500090
J	Valkova, N; Lepine, F; Labrie, L; Dupont, M; Beaudet, R				Valkova, N; Lepine, F; Labrie, L; Dupont, M; Beaudet, R			Purification and characterization of PrbA, a new esterase from Enterobacter cloacae hydrolyzing the esters of 4-hydroxybenzoic acid (parabens)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLPARABEN	The esterase PrbA from Enterobacter cloacae strain EM has previously been shown to confer additional resistance to the esters of 4-hydroxybenzoic acid (parabens) to two species of Enterobacter. The PrbA protein has been purified from E. cloacae strain EM using a three-step protocol resulting in a 60-fold increase in specific activity. The molecular mass of the mature enzyme was determined to be 54,619 +/- 1 Da by mass spectrometry. It is highly active against a series of parabens with alkyl groups ranging from methyl to butyl, with K-m and V-max values ranging from 0.45 to 0.88 mm and 0.031 to 0.15 mM/min, respectively. The K-m and V-max values for p-nitrophenyl acetate were 3.7 mm and 0.051 mM/min. PrbA hydrolyzed a variety of structurally analogous compounds, with activities larger than 20% relative to propyl paraben for methyl 3-hydroxybenzoate, methyl 4-aminobenzoate, or methyl vanillate. The enzyme showed optimum activity at 31 degreesC and at pH 7.0. PrbA was able to transesterify parabens with alcohols of increasing chain length from methanol to n-butanol, achieving 64% transesterification of 0.5 mm propyl paraben with 5% methanol within 2 h. PrbA was inhibited by 1-chloro-3-tosyl-amido-4-phenyl-2-butanone and 1-chloro-3-tosylamido-7-amino-2-heptanone (TLCK), with k(i) values of 0.29 and 0.20 mM, respectively, and was irreversibly inhibited by Diisopropyl fluorophosphate (DFP) or diethyl pyrocarbonate. The stoichiometry of addition of DFP to the enzyme was 1:1 and only 1 TLCK molecule was found in TLCK-modified enzyme, as measured by mass spectrometry. Analysis of the tryptic digest of the DFP-modified PrbA demonstrated that the addition of a DFP molecule occurred at Ser-189, indicating the location of the active serine.	Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada	University of Quebec; Institut national de la recherche scientifique (INRS)	Lepine, F (corresponding author), Univ Quebec, Inst Armand Frappier, INRS, 531 Blvd Prairies, Laval, PQ H7V 1B7, Canada.							CHILD JJ, 1971, CAN J MICROBIOL, V17, P1455, DOI 10.1139/m71-231; CLOSE J, 1976, APPL ENVIRON MICROB, V31, P718, DOI 10.1128/AEM.31.5.718-722.1976; GOTTFRIED NS, 1962, AM J HOSP PHARM, V19, P310; HAAG T, 1984, COSMET SCI TECHNOL S, V1, P63; HORIUCHI K, 1994, J FERMENT BIOENG, V77, P324, DOI 10.1016/0922-338X(94)90243-7; HUGO WB, 1964, J PHARM PHARMACOL, V16, P209, DOI 10.1111/j.2042-7158.1964.tb07445.x; Lobemeier C, 1996, BIOL CHEM, V377, P647, DOI 10.1515/bchm3.1996.377.10.647; RASTOGI SC, 1995, CONTACT DERMATITIS, V32, P28, DOI 10.1111/j.1600-0536.1995.tb00836.x; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; Valkova N, 2002, J BACTERIOL, V184, P5011, DOI 10.1128/JB.184.18.5011-5017.2002; Valkova N, 2001, APPL ENVIRON MICROB, V67, P2404, DOI 10.1128/AEM.67.6.2404-2409.2001; W. T. SOKOLSKI, 1962, Developments in industrial microbiology. Vol. 3., P179; WALLS AF, 1992, BIOCHEM PHARMACOL, V43, P1243, DOI 10.1016/0006-2952(92)90498-8; WILSON BW, 1974, P NATL ACAD SCI USA, V71, P3194, DOI 10.1073/pnas.71.8.3194; ZEDAN H H, 1984, Egyptian Journal of Microbiology, V19, P41	15	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12779	12785		10.1074/jbc.M213281200	http://dx.doi.org/10.1074/jbc.M213281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556461	hybrid			2022-12-27	WOS:000182189500026
J	Zsembery, A; Boyce, AT; Liang, LH; Peti-Peterdi, J; Bell, PD; Schwiebert, EM				Zsembery, A; Boyce, AT; Liang, LH; Peti-Peterdi, J; Bell, PD; Schwiebert, EM			Sustained calcium entry through P2X nucleotide receptor channels in human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EXTRACELLULAR ATP; NA+ ABSORPTION; ION-TRANSPORT; PHARMACOLOGICAL MODULATION; PURINERGIC REGULATION; CL-SECRETION; RELEASE; EXPRESSION; MEMBRANE	Purinergic receptor stimulation has potential therapeutic effects for cystic fibrosis (CF). Thus, we explored roles for P2Y and P2X receptors in stably increasing [Ca2+](i) in human CF (IB3-1) and non-CF (16HBE14o(-)) airway epithelial cells. Cytosolic Ca2+ was measured by fluorospectrometry using the fluorescent dye Fura-2/AM. Expression of P2X receptor (P2XR) subtypes was assessed by immunoblotting and biotinylation. In IB3-1 cells, ATP and other P2Y agonists caused only a transient increase in [Ca2+](i) derived from intracellular stores in a Na+-rich environment. In contrast, ATP induced an increase in [Ca2+](i) that had transient and sustained components in a Na+-free medium; the sustained plateau was potentiated by zinc or increasing extracellular pH. Benzoyl-benzoyl-ATP, a P2XR-selective agonist, increased [Ca2+](i) only in Na+-free medium, suggesting competition between Na+ and Ca2+ through P2XRs. Biochemical evidence showed that the P2X(4) receptor is the major subtype shared by these airway epithelial cells. A role for store-operated Ca2+ channels, voltage-dependent Ca2+ channels, or Na+/Ca2+ exchanger in the ATP-induced sustained Ca2+ signal was ruled out. In conclusion, these data show that epithelial P2X(4) receptors serve as ATP-gated calcium entry channels that induce a sustained increase in [Ca2+](i) . In airway epithelia, a P2XR-mediated Ca2+ signal may have therapeutic benefit for CF.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming Jones Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Semmelweis Univ, Dept Pathophysiol, H-1085 Budapest, Hungary	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Semmelweis University	Zsembery, A (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, MCLM 740,1918 Univ Blvd, Birmingham, AL 35294 USA.	zsembery@physiology.uab.edu; eschwiebert@physiology.uab.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL63934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNON A, 2002, AM J PHYSIOL, V278, pC163; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Bennett BD, 2001, ENDOCRINOLOGY, V142, P1968, DOI 10.1210/en.142.5.1968; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Collo G, 1996, J NEUROSCI, V16, P2495; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Dhulipala PDK, 1998, GENE, V207, P259, DOI 10.1016/S0378-1119(97)00647-1; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; Furukawa M, 1997, AM J PHYSIOL-CELL PH, V272, pC827, DOI 10.1152/ajpcell.1997.272.3.C827; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRUENERT DC, 1990, IN VITRO CELL DEV B, V26, P411; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; Inglis SK, 1999, PFLUG ARCH EUR J PHY, V438, P621, DOI 10.1007/s004240051085; Iwase N, 1997, RESP PHYSIOL, V107, P173, DOI 10.1016/S0034-5687(96)02516-9; Jung S, 2000, J PHYSIOL-LONDON, V527, P549, DOI 10.1111/j.1469-7793.2000.00549.x; KNOWLES MR, 1995, AM J RESP CRIT CARE, V151, pS65, DOI 10.1164/ajrccm/151.3_Pt_2.S65; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 2001, CLIN EXP PHARMACOL P, V28, P857, DOI 10.1046/j.1440-1681.2001.03541.x; Laubinger W, 1998, BIOCHEM PHARMACOL, V55, P687, DOI 10.1016/S0006-2952(97)00532-7; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406, DOI 10.1152/ajpcell.1994.266.2.C406; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Le KT, 1998, J NEUROSCI, V18, P7152; Lomri N, 1996, SEMIN LIVER DIS, V16, P201, DOI 10.1055/s-2007-1007232; Ma WY, 1999, NATURE, V400, P894, DOI 10.1038/23743; Mall M, 2000, AM J RESP CELL MOL, V23, P755, DOI 10.1165/ajrcmb.23.6.4207; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; Ralevic V, 1998, PHARMACOL REV, V50, P413; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; Sak K, 2002, ARCH BIOCHEM BIOPHYS, V397, P131, DOI 10.1006/abbi.2001.2616; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; STUTTS MJ, 1995, AM J PHYSIOL-CELL PH, V268, pC425, DOI 10.1152/ajpcell.1995.268.2.C425; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; VANSCOTT MR, 1995, AM J PHYSIOL-LUNG C, V269, pL30, DOI 10.1152/ajplung.1995.269.1.L30; Vennekens R, 2001, PFLUG ARCH EUR J PHY, V442, P237, DOI 10.1007/s004240100517; Wang X, 2000, CELL CALCIUM, V27, P205, DOI 10.1054/ceca.2000.0110; WARTH R, 1993, CELL PHYSIOL BIOCHEM, V3, P2, DOI 10.1159/000154663; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Wildman SS, 1999, BRIT J PHARMACOL, V126, P762, DOI 10.1038/sj.bjp.0702325; WILEY JS, 1989, BLOOD, V73, P1316; ZEITLIN PL, 1991, AM J PHYSIOL, V4, pL313; Zsembery A, 1998, HEPATOLOGY, V28, P914, DOI 10.1002/hep.510280403; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423	68	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13398	13408		10.1074/jbc.M212277200	http://dx.doi.org/10.1074/jbc.M212277200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566439	hybrid			2022-12-27	WOS:000182189500102
J	Fujino, H; Xu, W; Regan, JW				Fujino, H; Xu, W; Regan, JW			Prostaglandin E-2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; EGR-1 MESSENGER-RNA; PROTEIN-KINASE; COLON CARCINOGENESIS; CARCINOMA CELLS; EP(2) SUBTYPE; CYCLIN D1; C-FOS; ACTIVATION; PHOSPHORYLATION	Prostaglandin E-2 (PGE(2)) mediates its physiological effects by interactions with a subfamily of G-protein-coupled receptors known as EP receptors. These receptors consist of four primary subtypes named EP, EP2, EP3, and EP4. The EP2 and EP4 subtypes are known to couple to Galpha(s) and stimulate intracellular cyclic 3,5-adenosine monophosphate formation, whereas the EP1 and EP3 receptors are known to couple to Galpha(q) and Galpha(i), respectively. Recently we found that EP2 and EP4 receptors can activate T-cell factor signaling; however, EP2 receptors did this primarily through a cAMP-dependent protein kinase-dependent pathway, whereas EP4 receptors primarily utilized a phosphatidylinositol 3-kinase (PI3K)-dependent pathway (Fujino, H., West, K. A., and Regan, J. W. (2002) J. Biol. Chem. 277, 2614-2619). We now report that PGE(2) stimulation of EP4 receptors, but not EP2 receptors, leads to phosphorylation of the extracellular signal-regulated kinases (ERKs) through a PI3K-dependent mechanism. Furthermore, this activation of PI3K/ERK signaling by the EP4 receptors induces the functional expression of early growth response factor-1 (EGR-1). Under the same conditions induction of EGR-1 protein expression was not observed following PGE(2) stimulation of EP2 receptors. These findings point to important differences in the signaling potential of the EP2 and EP4 receptors, which could be significant with respect to the potential involvement of EP4 receptors in inflammation and cancer.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NEI NIH HHS [EY11291] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aeberli D, 2002, SWISS MED WKLY, V132, P414; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Chulada PC, 2000, CANCER RES, V60, P4705; DANESCH U, 1994, J BIOL CHEM, V269, P27258; Desai S, 2000, MOL PHARMACOL, V58, P1279, DOI 10.1124/mol.58.6.1279; Desai S, 2001, FEBS LETT, V501, P156, DOI 10.1016/S0014-5793(01)02640-0; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Fang MA, 1996, PROSTAG LEUKOTR ESS, V54, P109, DOI 10.1016/S0952-3278(96)90067-8; Fujino H, 2002, J BIOL CHEM, V277, P48786, DOI 10.1074/jbc.M209393200; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Mutoh M, 2002, CANCER RES, V62, P28; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; NISHIGAKI N, 1995, FEBS LETT, V364, P339, DOI 10.1016/0014-5793(95)00421-5; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Pierce KL, 1998, LIFE SCI, V62, P1479, DOI 10.1016/S0024-3205(98)00093-9; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; REGAN JW, 1994, MOL PHARMACOL, V46, P213; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shin SY, 2001, J BIOL CHEM, V276, P7797, DOI 10.1074/jbc.M009465200; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Watanabe K, 1999, CANCER RES, V59, P5093; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	30	250	262	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12151	12156		10.1074/jbc.M212665200	http://dx.doi.org/10.1074/jbc.M212665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12566441	hybrid			2022-12-27	WOS:000182015700057
J	Gauthier, A; Vassiliou, G; Benoist, F; McPherson, R				Gauthier, A; Vassiliou, G; Benoist, F; McPherson, R			Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; HUMAN ADIPOSE-TISSUE; CELL-SURFACE PROTEOGLYCANS; CETP MESSENGER-RNA; LDL-RECEPTOR; PPAR-GAMMA; ALPHA-2-MACROGLOBULIN RECEPTOR; ALZHEIMERS-DISEASE; DEPENDENT ACTIVATION; MOLECULAR CHAPERONE	The alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) is a large multifunctional receptor that interacts with a variety of molecules. It is implicated in biologically important processes such as lipoprotein metabolism, neurological function, tissue remodeling, protease complex clearance, and cell signal transduction. However, the regulation of LRP gene expression remains largely unknown. In this study, we have analyzed 2 kb of the 5'-flanking region of the LRP gene and identified a predicted peroxisome proliferator response element (PPRE) from -1185 to -1173. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation. These agents were found to increase LRP transcription. Gel shift analysis of the putative PPRE demonstrated direct binding of PPARgamma/retinoid X receptor alpha heterodimers to the PPRE in the LRP gene. Furthermore, these heterodimers could no longer interact with a mutated PPRE probe. The isolated promoter was functional in SW872 cells, and its activity was increased by 1.5-fold with the addition of rosiglitazone. Furthermore, the isolated response element was similarly responsive to rosiglitazone when placed upstream of an ideal promoter. Mutagenesis of the predicted PPRE abolished the ability of this construct to respond to rosiglitazone. These data demonstrate that fatty acids and rosiglitazone directly stimulate transcription of the LRP gene through activation of PPARgamma and increase functional LRP expression.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute	McPherson, R (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Rm H441,40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.							ADOLPH S, 1993, J CELL SCI, V105, P113; Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; Baumann CA, 2000, J BIOL CHEM, V275, P9131, DOI 10.1074/jbc.275.13.9131; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; BENOIST F, 1997, CIRCULATION, V96, P485; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Businaro R, 1997, J NEUROIMMUNOL, V72, P75, DOI 10.1016/S0165-5728(96)00157-9; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dodd F, 2000, J CELL BIOCHEM, V77, P624, DOI 10.1002/(SICI)1097-4644(20000615)77:4<624::AID-JCB10>3.0.CO;2-M; DUGAIL I, 2001, ADIPOSE TISSUE PROTO, P141; Edvardsson U, 1999, J LIPID RES, V40, P1177; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAETA BA, 1994, BBA-GENE STRUCT EXPR, V1219, P307, DOI 10.1016/0167-4781(94)90053-1; GAFVELS ME, 1992, J BIOL CHEM, V267, P21230; Gauthier B, 1999, J LIPID RES, V40, P1284; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1999, LIPOPROTEINS HLTH DI; Hill MR, 1997, ENDOCRINOLOGY, V138, P3073, DOI 10.1210/en.138.7.3073; Izem L, 2001, J BIOL CHEM, V276, P26534, DOI 10.1074/jbc.M103624200; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Krapp A, 1996, J LIPID RES, V37, P926; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Kuchenhoff A, 1997, AM J PHYSIOL-CELL PH, V272, pC369, DOI 10.1152/ajpcell.1997.272.2.C369; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Martin G, 2000, J BIOL CHEM, V275, P12612, DOI 10.1074/jbc.275.17.12612; Medh JD, 1996, J BIOL CHEM, V271, P17073, DOI 10.1074/jbc.271.29.17073; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Radeau T, 1998, BBA-LIPID LIPID MET, V1392, P245, DOI 10.1016/S0005-2760(98)00039-3; Radeau T, 1998, ATHEROSCLEROSIS, V139, P369, DOI 10.1016/S0021-9150(98)00051-3; Radeau T, 1995, J LIPID RES, V36, P2552; Reblin T, 1997, J LIPID RES, V38, P2103; Richardson MA, 1996, J LIPID RES, V37, P1162; Sambrook J., 2002, MOL CLONING LAB MANU; Savonen R, 1999, J BIOL CHEM, V274, P25877, DOI 10.1074/jbc.274.36.25877; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1996, J LIPID RES, V37, P907; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Slomiany BA, 2000, BIOTECHNIQUES, V28, P938, DOI 10.2144/00285st08; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; Ulery PG, 2000, J CLIN INVEST, V106, P1077, DOI 10.1172/JCI11455; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; VANLEUVEN F, 1994, GENOMICS, V24, P78, DOI 10.1006/geno.1994.1584; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vassiliou G, 2001, J BIOL CHEM, V276, P48823, DOI 10.1074/jbc.M103954200; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350	76	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11945	11953		10.1074/jbc.M212989200	http://dx.doi.org/10.1074/jbc.M212989200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551936	hybrid			2022-12-27	WOS:000182015700031
J	Koglin, M; Behrends, S				Koglin, M; Behrends, S			A functional domain of the alpha(1) subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BOVINE LUNG; 2 SUBUNITS; RAT LUNG; EXPRESSION; SITE	Soluble guanylyl cyclase is a heterodimeric enzyme consisting of an alpha(1) and a beta(1) subunit and is an important target for endogenous nitric oxide and the guanylyl cyclase modulator YC-1. The activation of the enzyme by both substances is dependent on the presence of a prosthetic heme group. It has been unclear whether this prosthetic heme group is sandwiched between the alpha(1) and beta(1) subunits or whether it exclusively binds to the beta(1) subunit. Here we analyze progressive amino-terminal deletion mutants of the human alpha(1) subunit after co-expression with the human beta(1) subunit in the baculovirus/Sf9 system. Spectral, biochemical, and pharmacological analysis shows that the first 259 amino acids of the alpha(1) subunit can be deleted without loss of sensitivity to nitric oxide (NO) or YC-1 or loss of heme binding of the respective enzyme complex with the beta(1) subunit. This is in contrast to previous data indicating that NO sensitivity and a functional heme binding site requires full-length amino termini of bovine alpha(1) and beta(1) subunits. Further deletion of the first 364 amino acids of the alpha(1) subunit leads to an enzyme complex with preserved heme binding but loss of sensitivity to NO or YC-1 despite induction of the typical spectral shift by NO binding to the prosthetic heme group. We conclude that 1) the amino-terminal part of the alpha(1) subunit is not involved in heme binding and 2) amino acids 259-364 of the alpha(1) subunit represent an important functional domain for the transduction of the NO activation signal and likely represent the target for NO-sensitizing substances like YC-1.	Univ Hamburg, Inst Expt & Klin Pharmakol, D-20246 Hamburg, Germany	University of Hamburg	Behrends, S (corresponding author), Univ Clin Eppendorf, Pharmakol Inst, Martinistr 52, D-20246 Hamburg, Germany.		Behrends, Sönke/A-2551-2010	Behrends, Sönke/0000-0002-9068-0729				Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Friebe A, 1999, BIOCHEMISTRY-US, V38, P15253, DOI 10.1021/bi9908944; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; Koglin M, 2000, BBA-GENE STRUCT EXPR, V1494, P286, DOI 10.1016/S0167-4781(00)00211-6; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Lucas KA, 2000, PHARMACOL REV, V52, P375; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; NAKANE M, 1990, J BIOL CHEM, V265, P16841; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	21	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12590	12597		10.1074/jbc.M212740200	http://dx.doi.org/10.1074/jbc.M212740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560334	hybrid			2022-12-27	WOS:000182015700112
J	Angermayr, M; Bandlow, W				Angermayr, M; Bandlow, W			Permanent nucleosome exclusion from the Ga14p-inducible yeast GCY1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; POSITIONED NUCLEOSOMES; ACTIVATE TRANSCRIPTION; ADENYLATE KINASE; GENE-REGULATION; PHO5 PROMOTER; PROTEIN; DNA; POLY(DA-DT)	The promoter of the galactose-inducible yeast GCY1 gene allows high rates of basal transcription and is kept free of nucleosomes regardless of growth conditions. The general regulatory factor, Reb1p, as well as the nucleotide sequence of a single Gal4p-binding site, structurally cooperate to exclude nucleosomes from about 480 by of DNA that spans the UAS(GAL), the Reb1p-binding site, the TATA-box, and the transcriptional initiation sites. Gal4p, which induces transcription of GCY1 about 25-fold in the presence of galactose, is not required for the alteration in chromatin configuration in the promoter upstream region since the hypersensitive site is unchanged when Gal4p is inactive or absent. As soon as either the Reb1p-binding site or the UASGAL or both are mutated, nucleosomes slip into the promoter of GCY1 paralleled by a reduction of basal transcription activity to about 30% in either single mutant and to <10% in the double mutant. In the mutant of the Reb1p-binding site, induction by galactose/Gal4p restores a nucleosome-free state to an extent resembling the GCY1 wild-type promoter, showing that, in principle, activated Gal4p can exclude nucleosomes on its own. Northern blots of GCY1 transcripts confirm that Reb1p modulates basal transcription and has little influence on the galactose-induced state.	Univ Munich, Dept Biol 1, Bereich Genet, D-80638 Munich, Germany	University of Munich	Angermayr, M (corresponding author), Univ Munich, Dept Biol 1, Bereich Genet, Maria Ward Str 1A, D-80638 Munich, Germany.							ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Angermayr M, 1997, MOL GEN GENET, V256, P682, DOI 10.1007/s004380050616; Angermayr M, 2002, NUCLEIC ACIDS RES, V30, P4199, DOI 10.1093/nar/gkf551; Angermayr M, 1997, J BIOL CHEM, V272, P31630, DOI 10.1074/jbc.272.50.31630; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; Costenoble R, 2000, YEAST, V16, P1483, DOI 10.1002/1097-0061(200012)16:16<1483::AID-YEA642>3.0.CO;2-K; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; McLean M, 1995, MOL MICROBIOL, V18, P605, DOI 10.1111/j.1365-2958.1995.mmi_18040605.x; Moreira JMA, 2002, J BIOL CHEM, V277, P3202, DOI 10.1074/jbc.M108962200; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; OECHSNER U, 1988, FEBS LETT, V242, P187, DOI 10.1016/0014-5793(88)81013-5; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; Thoma F, 1996, METHOD ENZYMOL, V274, P197; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	40	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11026	11031		10.1074/jbc.M210932200	http://dx.doi.org/10.1074/jbc.M210932200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536147	hybrid			2022-12-27	WOS:000181855400022
J	Renato, J; Cussiol, R; Alves, SV; de Oliveira, MA; Netto, LES				Renato, J; Cussiol, R; Alves, SV; de Oliveira, MA; Netto, LES			Organic hydroperoxide resistance gene encodes a thiol-dependent peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPESTRIS PV. PHASEOLI; SALMONELLA-TYPHIMURIUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; PSEUDOMONAS-AERUGINOSA; BACILLUS-SUBTILIS; GENOME SEQUENCE; OHR GENE; REDUCTASE; ANTIOXIDANT	ohr (organic hydroperoxide resistance gene) is present in several species of bacteria, and its deletion renders cells specifically sensitive to organic peroxides. The goal of this work was to determine the biochemical function of Ohr from Xylella fastidiosa. All of the Ohr homologues possess two cysteine residues, one of them located in a VCP motif, which is also present in all of the proteins from the peroxiredoxin family. Therefore, we have investigated whether Ohr possesses thiol-dependent peroxidase activity. The ohr gene from X. fastidiosa was expressed in Escherichia coli, and the recombinant Ohr decomposed hydroperoxides in a dithiothreitol-dependent manner. Ohr was about twenty times more efficient to remove. organic hydroperoxides than to remove H2O2. This result is consistent with the organic hydroperoxide sensitivity of Deltaohr strains. The dependence of Ohr on thiol compounds was ascertained by glutamine synthetase protection assays. Approximately two thiol equivalents were consumed per peroxide removed indicating that Ohr catalyzes the following reaction: 2RSH + ROOH --> RSSR + ROH + H2O. Pretreatment of Ohr with N-ethyl maleimide and substitution of cysteine residues by serines inhibited this peroxidase activity indicating that both of the Ohr cysteines are important to the decomposition of peroxides. C125S still had a residual enzymatic activity indicating that Cys-61 is directly involved in peroxide removal. Monothiol compounds do not support the peroxidase activity of Ohr as well as thioredoxin from Saccharomyces cerevisaae and from Spirulina. Interestingly, dithiothreitol and dyhydrolipoic acid, which possess two sulfhydryl groups, do support the peroxidase activity of Ohr. Taken together our results unequivocally demonstrated that Ohr is a thiol-dependent peroxidase.	Univ Sao Paulo, Inst Biociencias, Dept Biol, BR-05508900 Sao Paulo, SP, Brazil	Universidade de Sao Paulo	Netto, LES (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Biol, Rua Matao 277, BR-05508900 Sao Paulo, SP, Brazil.		Cussiol, José Renato/E-5142-2015; Netto, Luis/A-3783-2008; de Oliveira, Marcos A/K-5746-2015	Cussiol, José Renato/0000-0001-5909-8215; Netto, Luis/0000-0002-4250-9177; de Oliveira, Marcos A/0000-0002-1192-7296				AKAIKE T, 1992, ARCH BIOCHEM BIOPHYS, V294, P55, DOI 10.1016/0003-9861(92)90136-K; Atichartpongkul S, 2001, MICROBIOL-SGM, V147, P1775, DOI 10.1099/00221287-147-7-1775; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Bsat N, 1996, J BACTERIOL, V178, P6579, DOI 10.1128/jb.178.22.6579-6586.1996; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Fuangthong M, 2001, J BACTERIOL, V183, P4134, DOI 10.1128/JB.183.14.4134-4141.2001; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; KIM KW, 1988, J BIOL CHEM, V263, P4704; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; Maeng JH, 1996, J BACTERIOL, V178, P3695, DOI 10.1128/jb.178.13.3695-3700.1996; Mongkolsuk S, 1998, J BACTERIOL, V180, P2636, DOI 10.1128/JB.180.10.2636-2643.1998; MONGKOLSUK S, 2000, J BACTERIOL, V182, P2636; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Ochsner UA, 2001, J BACTERIOL, V183, P773, DOI 10.1128/JB.183.2.773-778.2001; Ochsner UA, 2000, J BACTERIOL, V182, P4533, DOI 10.1128/JB.182.16.4533-4544.2000; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; RADI R, 1991, J BIOL CHEM, V266, P4244; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rince A, 2001, J BACTERIOL, V183, P1482, DOI 10.1128/JB.183.4.1482-1488.2001; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Shea RJ, 2002, INFECT IMMUN, V70, P794, DOI 10.1128/IAI.70.2.794-802.2002; Simpson AJG, 2000, NATURE, V406, P151, DOI 10.1038/35018003; Sriprang R, 2000, APPL ENVIRON MICROB, V66, P4017, DOI 10.1128/AEM.66.9.4017-4021.2000; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Sukchawalit R, 2001, J BACTERIOL, V183, P4405, DOI 10.1128/JB.183.15.4405-4412.2001; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Vattanaviboon P, 2000, GENE, V241, P259, DOI 10.1016/S0378-1119(99)00483-7; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	43	72	76	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11570	11578		10.1074/jbc.M300252200	http://dx.doi.org/10.1074/jbc.M300252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540833	hybrid			2022-12-27	WOS:000181855400090
J	Treber, M; Dai, J; Woldegiorgis, G				Treber, M; Dai, J; Woldegiorgis, G			Identification by mutagenesis of conserved arginine and glutamate residues in the C-terminal domain of rat liver carnitine palmitoyltransferase I that are important for catalytic activity and malonyl-CoA sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PICHIA-PASTORIS; FUNCTIONAL-CHARACTERIZATION; HEART; ENZYME; ISOFORM; BINDING; TISSUE	Carnitine palmitoyltransferase I (CPTI) catalyzes the conversion of long chain fatty acyl-CoAs to acylcarnitines in the presence of L-carnitine. To determine the role of the conserved glutamate residue, Glu-603, on catalysis and malonyl-CoA sensitivity, we separately changed the residue to alanine, histidine, glutamine, and aspartate. Substitution of Glu-603 with alanine or histidine resulted in complete loss of L-CPTI activity. A change of Glu-603 to glutamine caused a significant decrease in catalytic activity and malonyl-CoA sensitivity. Substitution of Glu-603 with aspartate, a negatively charged amino acid with only one methyl group less than the glutamate residue in the wild type enzyme, resulted in partial loss in CPTI activity and a 15-fold decrease in malonyl-CoA sensitivity. The mutant L-CPTI with a replacement of the conserved Arg-601 or Arg-606 with alanine also showed over 40-fold decrease in malonyl-CoA sensitivity, suggesting that these two conserved residues may be important for substrate and inhibitor binding. Since a conservative substitution of Glu-603 to aspartate or glutamine resulted in partial loss of activity and malonyl-CoA sensitivity, it further suggests that the negative charge and the longer side chain of glutamate are essential for catalysis and malonyl-CoA sensitivity. We predict that this region of L-CPTI spanning these conserved C-terminal residues may be the region of the protein involved in binding the CoA moiety of palmitoyl-CoA and malonyl-CoA and/or the putative low affinity acyl-CoA/malonyl-CoA binding site.	Oregon Hlth & Sci Univ, Oregon Grad Inst, Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA	Oregon Health & Science University	Woldegiorgis, G (corresponding author), Oregon Hlth & Sci Univ, Oregon Grad Inst, Sch Sci & Engn, Dept Environm & Biomol Syst, 20000 NW Walker Rd, Beaverton, OR 97006 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barycki JJ, 2001, J BIOL CHEM, V276, P36718, DOI 10.1074/jbc.M104839200; BENNEFONT JP, 1996, AM J HUM GENET, V58, P971; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CORR PB, 1995, HERZ, V20, P156; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Tao Bernard Y., 1994, P69; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; Woldegiorgis G, 2000, J NUTR, V130, p310S, DOI 10.1093/jn/130.2.310S; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zheng GL, 2002, J BIOL CHEM, V277, P42219, DOI 10.1074/jbc.M202914200; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	24	11	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11145	11149		10.1074/jbc.M210566200	http://dx.doi.org/10.1074/jbc.M210566200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540837	hybrid			2022-12-27	WOS:000181855400038
J	Wang, P; Wu, YL; Ge, X; Ma, L; Pei, G				Wang, P; Wu, YL; Ge, X; Ma, L; Pei, G			Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PROSTAGLANDIN E-2 RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CLATHRIN ADAPTER; VISUAL ARRESTIN; BINDING; BETA-ARRESTIN2	beta-Arrestinl and beta-arrestin2 play a key role in the regulation of G protein-coupled receptor-mediated signaling, whereas the subcellular distribution of beta-arrestin1 and beta-arrestin2 has been shown to be quite different. In this study, we found that although both beta-arrestin1 and beta-arrestin2 are able to interact with ubiquitin-protein isopeptide ligase (E3) Mdm2, only expression of beta-arrestin2 leads to the relocalization of Mdm2 from the nucleus to the cytoplasm. Further study reveals that beta-arrestin2 but not beta-arrestin1 shuttles between the cytoplasm and nucleus in a leptomycin B-sensitive manner. A hydrophobic amino acid-rich region (VXXX-LXL) at the C terminus of beta-arrestin2 was further demonstrated to serve as a nuclear export signal responsible for the extranuclear localization of beta-arrestin2. In the corresponding region of beta-arrestin1, there is a single amino acid difference (Glu instead of Leu. in beta-arrestin2), and mutation of Glu to Leu conferred to beta-arrestin1 similar subcellular distribution to that of beta-arrestin2. Moreover, data from a series of deletion mutations demonstrated that the N domain (residues 1-185) was indispensable for the nuclear localization of both beta-arrestins, and the results from a Val to Asp point mutation in the N domain also supported this notion. In addition, our data showed that nucleocytoplasmic shuttling of beta-arrestin2 was required, via protein/protein interaction, for the cytoplasmic relocalization of Mdm2 and JNK3, another well known beta-arrestin2-binding protein. Our study thus suggests that both the nuclear export signal motif and the N domain of beta-arrestins are critical for the regulation of their subeellular localization and that beta-arrestin2 may modulate the function of its binding partners such as Mdm2 and JNK3 by alteration of their subcellular distribution.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Fudan Univ, Med Ctr, Natl Lab Med Neurobiol, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472				Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; NISHI K, 1994, J BIOL CHEM, V269, P6320; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; WANG P, 2002, J BIOL CHEM     1217; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yu QM, 1999, ACTA BIOCH BIOPH SIN, V31, P344; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	40	119	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11648	11653		10.1074/jbc.M208109200	http://dx.doi.org/10.1074/jbc.M208109200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538596	hybrid			2022-12-27	WOS:000181855400098
J	Malli, R; Frieden, M; Osibow, K; Graier, WF				Malli, R; Frieden, M; Osibow, K; Graier, WF			Mitochondria efficiently buffer subplasmalemmal Ca2+ elevation during agonist stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE CONTRIBUTES; ENTRY; STORE; ACTIVATION; CHANNELS; CELLS; INHIBITION; FREQUENCY; DYNAMICS; SIGNALS	In endothelial cells, local Ca2+ release from superficial endoplasmic reticulum (ER) activates BKCa channels. The resulting hyperpolarization promotes capacitative Ca2+ entry (CCE), which, unlike BKCa channels, is inhibited by high Ca2+. To understand how the coordinated activation of plasma membrane ion channels with opposite Ca2+ sensitivity is orchestrated, the individual contribution of mitochondria and ER in regulation of subplasmalemmal Ca2+ concentration ([Ca2+](pm)) was investigated. For organelle visualization, cells were transfected with DsRed and yellow cameleon targeted to mitochondria and ER. The patch pipette was placed far from any organelle (L1), close to ER (L3), or mitochondria (L2) and activity of BKCa. channels was used to estimate local [Ca2+](pm). Under standard patch conditions (130 mm K+ in the bath), histamine increased [Ca2+](pm) at L1 and L3 to similar to1.6 mum, whereas close to mitochondria [Ca2+](pm) remained unchanged. If mitochondria moved apart from the pipette or in the presence of carbonyl cyanide-4-trifluoromethoxyphenylhyrazone, [Ca2+](pm) at L2 increased in response to histamine. Under standard patch conditions Ca2+ entry was negligible due to cell depolarization. Using a physiological patch approach (5.6 mm K+ in the bath), changes in [Ca2+](pm) to histamine could be monitored without cell depolarization and, thus, in conditions where Ca2+ entry occurred. Here, histamine induced an initial transient Ca2+ elevation to greater than or equal to3.5 muM followed by a long lasting plateau at similar to1.2 muM in L1 and L3, whereas mitochondria kept neighboring [Ca2+](pm) low during stimulation. Thus, superficial mitochondria and ER generate local domains of low and high Ca2+ allowing simultaneous activation of BKCa. and CCE, despite their opposite Ca2+ sensitivity.	Graz Univ, Dept Med Biochem & Med Mol Biol, A-8010 Graz, Austria; Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva 4, Switzerland	University of Graz; University of Geneva	Graier, WF (corresponding author), Graz Univ, Dept Med Biochem & Med Mol Biol, Harrachgassee 21-III, A-8010 Graz, Austria.	wolfgang.graier@uni-graz.at	Graier, Wolfgang F./B-7052-2008; Malli, Roland/B-7369-2008	Graier, Wolfgang F./0000-0003-1871-3298; Malli, Roland/0000-0001-6327-8729; Frieden, Maud/0000-0001-7135-0874; Osibow, Karin/0000-0002-9703-595X				BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Frieden M, 2000, J PHYSIOL-LONDON, V524, P715, DOI 10.1111/j.1469-7793.2000.00715.x; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; GRAIER WF, 1994, ENDOTHELIUM, V1, P223; GROSCHNER K, 1992, BIOCHIM BIOPHYS ACTA, V1137, P162, DOI 10.1016/0167-4889(92)90198-K; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Kamouchi M, 1999, GEN PHYSIOL BIOPHYS, V18, P199; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; Krendel M, 1998, CELL MOTIL CYTOSKEL, V40, P368, DOI 10.1002/(SICI)1097-0169(1998)40:4<368::AID-CM5>3.3.CO;2-R; Krutetskaia Z I, 1998, Tsitologiia, V40, P93; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lipp P, 2002, J PHYSIOL-LONDON, V542, P383, DOI 10.1113/jphysiol.2001.013382; Madge L, 1997, J PHYSIOL-LONDON, V498, P351, DOI 10.1113/jphysiol.1997.sp021863; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Orlati S, 1996, CELL CALCIUM, V20, P399, DOI 10.1016/S0143-4160(96)90002-0; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; PALTAUFDOBURZYN.J, 2000, J PHYSL, V524, P501; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Park KS, 2002, PFLUG ARCH EUR J PHY, V443, P344, DOI 10.1007/s004240100703; Perez GJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1769, DOI 10.1152/ajpcell.2001.281.6.C1769; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Sedova M, 2000, J BIOL CHEM, V275, P35402, DOI 10.1074/jbc.M006058200; Thyagarajan B, 2002, BRIT J PHARMACOL, V137, P821, DOI 10.1038/sj.bjp.0704949; Yaffe MP, 1999, NAT CELL BIOL, V1, pE149, DOI 10.1038/14101; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	41	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10807	10815		10.1074/jbc.M212971200	http://dx.doi.org/10.1074/jbc.M212971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529366	hybrid			2022-12-27	WOS:000181777500106
J	Bisaglia, M; Laalami, S; Uzan, M; Bontems, F				Bisaglia, M; Laalami, S; Uzan, M; Bontems, F			Activation of the RegB endoribonuclease by the S1 ribosomal protein is due to cooperation between the S1 four C-terminal modules in a substrate-dependant manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BINDING PROPERTIES; ESCHERICHIA-COLI; MESSENGER-RNAS; IN-VITRO; BACTERIOPHAGE-T4; SITE; RIBONUCLEASE; SPECIFICITY	The RegB protein, encoded by the T4 bacteriophage genome, is a ribonuclease involved in the inactivation of the phage early messenger RNAs. Its in vitro activity is very low but can be enhanced up to 100-fold in the presence of the ribosomal protein S1. The latter is made of six repeats of a conserved module found in many other proteins of RNA metabolism. Considering the difference between its size (556 amino acids) and that of several RegB substrates (10 nucleotides), we wondered whether all six modules are necessary for RegB activation. We studied the influence of twelve S1 fragments on the cleavage efficiency of three short substrates. RegB activation requires the cooperation of different sets of modules depending on the substrates. Two RNAs are quite well cleaved in the presence of the fragment formed by the fourth and fifth modules, whereas the third requires the presence of the four C-terminal domains. However, NNR interaction experiments showed that, despite these differences, the interactions of the substrates with either the bi- or tetra-modules are similar, suggesting a common interaction surface. In the case of the tetra-module the interactions involve all four domains, raising the question of the spatial organization of this region.	Ecole Polytech, Grp ICSN RMN, F-91128 Palaiseau, France; Inst Jacques Monod, F-75005 Paris, France	Institut Polytechnique de Paris; UDICE-French Research Universities; Universite Paris Cite	Bontems, F (corresponding author), Ecole Polytech, Grp ICSN RMN, F-91128 Palaiseau, France.	Francois.Bontems@polytechnique.fr						BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Boni IV, 2000, J BACTERIOL, V182, P5872, DOI 10.1128/JB.182.20.5872-5879.2000; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DELSUC MA, 1989, FUND THEOR, V36, P285; DRAPER DE, 1977, P NATL ACAD SCI USA, V74, P4786, DOI 10.1073/pnas.74.11.4786; DRAPER DE, 1978, J MOL BIOL, V122, P321, DOI 10.1016/0022-2836(78)90193-6; DRAPER DE, 1978, J MOL BIOL, V122, P339; FARWELL MA, 1992, MOL MICROBIOL, V6, P3375, DOI 10.1111/j.1365-2958.1992.tb02205.x; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200; Jayasena VK, 1996, BIOCHEMISTRY-US, V35, P2349, DOI 10.1021/bi951879b; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Lebars I, 2001, J BIOL CHEM, V276, P13264, DOI 10.1074/jbc.M010680200; LEBARS I, 2001, THESIS U VERSAILLES; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUNIYAPPA K, 1993, BIOCHEM MOL BIOL INT, V31, P1; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; ROBERTS MW, 1989, J BIOL CHEM, V264, P2228; RUCKMAN J, 1989, New Biologist, V1, P54; RUCKMAN J, 1994, J BIOL CHEM, V269, P26655; Sanson B, 2000, J MOL BIOL, V297, P1063, DOI 10.1006/jmbi.2000.3626; SANSON B, 1993, J MOL BIOL, V233, P429, DOI 10.1006/jmbi.1993.1522; SEETHARA.A, 1973, J MOL BIOL, V76, P207, DOI 10.1016/0022-2836(73)90385-9; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; Snoussi K, 2001, J MOL BIOL, V309, P139, DOI 10.1006/jmbi.2001.4618; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; TZAREVA NV, 1994, FEBS LETT, V337, P189, DOI 10.1016/0014-5793(94)80271-8; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895; Uzan M, 2001, METHOD ENZYMOL, V342, P467, DOI 10.1016/S0076-6879(01)42567-5; VANDUIN J, 1988, VIRUSES, P116; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	35	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15261	15271		10.1074/jbc.M212731200	http://dx.doi.org/10.1074/jbc.M212731200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576472	hybrid			2022-12-27	WOS:000182516100088
J	Kroesen, BJ; Jacobs, S; Pettus, BJ; Sietsma, H; Kok, JW; Hannun, YA; de Leij, LFMH				Kroesen, BJ; Jacobs, S; Pettus, BJ; Sietsma, H; Kok, JW; Hannun, YA; de Leij, LFMH			BcR-induced apoptosis involves differential regulation of C-16 and C-24-ceramide formation and sphingolipid-dependent activation of the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE ACTIVITY; IGM-INDUCED APOPTOSIS; CERAMIDE GENERATION; ANTIGEN RECEPTOR; INHIBITION; UBIQUITIN; MITOCHONDRIA; SPHINGOMYELIN; DEGRADATION; MEMBRANE	In this study, we describe an ordered formation of long- and very long-chain ceramide species in relation to the progression of B-cell receptor (BcR) triggering induced apoptosis. An early and caspase-independent increase in long-chain ceramide species, in which C-24-ceramide predominated, was observed 6 h after Belt triggering. In contrast, very long-chain ceramide species were generated later, 12-24 h after BeR triggering. The formation of these very long-chain ceramide species, in which C-24-ceramide predominated, required the activation of effector caspases. BcR-induced formation of long-chain ceramide species resulted in proteasomal activation and degradation of XIAP and subsequent activation of effector caspases, demonstrating an important cell-biological mechanism through which longchain ceramides may be involved in the progression of BcR triggering induced apoptosis and subsequent formation of very long-chain ceramide species. BcR-induced activation of the proteasome was blocked with ISP-1/myriocin, a potent and selective inhibitor of serine palmitoyl transferase that catalyzes the first and rate-limiting step in the de novo formation of ceramide. Both ISP-1 and clasto-lactacystin beta-lactone, an irreversible inhibitor of the proteasome, prevented BcR cross-linking-induced XIAP degradation. Also, a mutant XIAP lacking the ubiquitin-ligating ring finger motif was completely resistant to proteasome-mediated degradation, and Ramos cells overexpressing XIAP became highly resistant to BcR cross-linking-induced activation of caspases. The formation of C-16-ceramide in response to BcR cross-linking was found unaltered in XIAP overexpressing Ramos cells, whereas C-24-ceramide formation was completely abolished. These results demonstrate how de novo generated long-chain ceramide species may be involved in the activation of downstream effector caspases and subsequent formation of very long-chain ceramide species. As such, these results provide novel and important insights into the significance of specific ceramide species in defined stages of apoptosis.	Univ Groningen Hosp, Dept Pathol & Lab Med, Med Biol Branch, NL-9713 GZ Groningen, Netherlands; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Groningen Hosp, Dept Pathol, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Dept Cell Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; Medical University of South Carolina; University of Groningen; University of Groningen	Kroesen, BJ (corresponding author), Univ Groningen Hosp, Dept Pathol & Lab Med, Med Biol Branch, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	b.j.kroesen@thorax.azg.nl						Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Andjelic S, 1998, EUR J IMMUNOL, V28, P570, DOI 10.1002/(SICI)1521-4141(199802)28:02<570::AID-IMMU570>3.0.CO;2-M; ARIZTI P, 1993, ENZYME PROTEIN, V47, P285, DOI 10.1159/000468686; Berard R, 1999, J IMMUNOL, V163, P4655; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dawson G, 1998, ACTA BIOCHIM POL, V45, P287, DOI 10.18388/abp.1998_4225; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; Dick LR, 1997, J BIOL CHEM, V272, P182; Donjerkovic D, 2000, CELL RES, V10, P179, DOI 10.1038/sj.cr.7290047; Doyle BT, 2002, J LEUKOCYTE BIOL, V71, P247; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gold MR, 2002, TRENDS PHARMACOL SCI, V23, P316, DOI 10.1016/S0165-6147(02)02045-X; Goldberg AL, 2000, NAT BIOTECHNOL, V18, P494, DOI 10.1038/75349; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hideshima T, 2001, CANCER RES, V61, P3071; Hirsch T, 1998, J IMMUNOL, V161, P35; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kong JY, 2002, AM J PHYSIOL-HEART C, V282, pH717, DOI 10.1152/ajpheart.00257.2001; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; PREISS J, 1986, J BIOL CHEM, V261, P8597; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Riley RT, 1999, ENVIRON TOXICOL PHAR, V7, P109, DOI 10.1016/S1382-6689(98)00047-7; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sauerwald TM, 2002, BIOTECHNOL BIOENG, V77, P704, DOI 10.1002/bit.10154; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Shounan Y, 1998, J IMMUNOL METHODS, V217, P61, DOI 10.1016/S0022-1759(98)00090-8; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zollner TM, 2002, J CLIN INVEST, V109, P671, DOI 10.1172/JCI200212736	51	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14723	14731		10.1074/jbc.M210756200	http://dx.doi.org/10.1074/jbc.M210756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578840	hybrid			2022-12-27	WOS:000182516100019
J	Liang, FQ; Webb, P; Marimuthu, A; Zhang, SM; Gardner, DG				Liang, FQ; Webb, P; Marimuthu, A; Zhang, SM; Gardner, DG			Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; MYOSIN HEAVY-CHAIN; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONGESTIVE-HEART-FAILURE; CARDIAC-HYPERTROPHY; RESPONSE ELEMENTS; MESSENGER-RNA; NUCLEAR RECEPTORS; COACTIVATOR COMPLEXES; TRAP220 COMPONENT	Brain natriuretic peptide (BNP) gene expression is a well documented marker of hypertrophy in the cardiac myocyte. Triiodothyronine (T-3), the bioactive form of thyroid hormone, triggers a unique form of hypertrophy in cardiac myocytes that accompanies the selective activation or suppression of specific gene targets. In this study, we show that the BNP gene is a target of T-3 action. BNP secretion was increased 6-fold, BNP mRNA levels 3-fold, and BNP promoter activity 3-5-fold following T-3 treatment. This was accompanied by an increase in myocyte size, sarcomeric organization, and protein synthesis. Of note, several of the responses to T-3 synergized with those to the conventional hypertrophic agonist endothelin. The response to the liganded thyroid hormone receptor (TR) was mediated by an unusual thyroid hormone response element located between -1000 and -987 relative to the transcription start site. Both TR homodimers and TR-retinoid X receptor heterodimers associated with this element in an electrophoretic mobility shift assay. Protein fragments harboring the LXXLL motifs of the coactivators GRIP1 and SRC1 or TRAP220 interacted predominantly with the TR-retinoid X receptor heterodimeric pair in a ligand-dependent fashion. Both TR homodimers and heterodimers in the unliganded state selectively associated with glutathione S-transferase-nuclear receptor corepressor fragments harboring one of three receptor interaction domains containing the sequence (I/L)XX-(I/V)I. These interactions were dissociated following the addition of T-3. Collectively, these findings identify the BNP gene as a potential model for the investigation of TR-dependent gene regulation in the heart.	Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, 1109 HSW,3rd & Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1991, CIRC RES, V69, P266, DOI 10.1161/01.RES.69.2.266; Basset A, 2001, J CARDIOVASC PHARM, V37, P163, DOI 10.1097/00005344-200102000-00004; BOERTH SR, 1996, CARDIOVASC RES, V31, P145; Chang KC, 1997, J CLIN INVEST, V100, P1742, DOI 10.1172/JCI119699; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; GARDNER DG, 1987, MOL ENDOCRINOL, V1, P260, DOI 10.1210/mend-1-3-260; GICK GG, 1990, J MEMBRANE BIOL, V115, P273, DOI 10.1007/BF01868642; HARTONG R, 1994, J BIOL CHEM, V269, P13021; Hoit BD, 1997, CIRCULATION, V96, P592, DOI 10.1161/01.cir.96.2.592; Hojo Y, 1997, J CARDIOVASC PHARM, V29, P75, DOI 10.1097/00005344-199701000-00012; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hystad ME, 2001, ACTA PHYSIOL SCAND, V171, P395, DOI 10.1046/j.1365-201X.2001.00805.x; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Kinugawa K, 2001, CIRC RES, V89, P591, DOI 10.1161/hh1901.096706; Kinugawa K, 2001, CIRCULATION, V103, P1089, DOI 10.1161/01.CIR.103.8.1089; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; KISS E, 1994, CIRC RES, V75, P245, DOI 10.1161/01.RES.75.2.245; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Kobori H, 1999, J ENDOCRINOL, V160, P43, DOI 10.1677/joe.0.1600043; KOHNO M, 1993, METABOLISM, V42, P1059, DOI 10.1016/0026-0495(93)90023-H; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Ojamaa K, 2000, METABOLISM, V49, P275, DOI 10.1016/S0026-0495(00)92262-5; Ojamaa K, 1999, ENDOCRINOLOGY, V140, P3170, DOI 10.1210/en.140.7.3170; Ojamaa K, 1996, ENDOCRINOLOGY, V137, P802, DOI 10.1210/en.137.3.802; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; RUPP H, 1990, J APPL PHYSIOL, V68, P973, DOI 10.1152/jappl.1990.68.3.973; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; WU JP, 1989, J BIOL CHEM, V264, P6472; YAO JL, 1992, CIRC RES, V71, P831, DOI 10.1161/01.RES.71.4.831; YEN PM, 1994, J BIOL CHEM, V269, P12704; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; YOSHIMURA M, 1991, CIRCULATION, V84, P1581, DOI 10.1161/01.CIR.84.4.1581; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	62	65	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15073	15083		10.1074/jbc.M207593200	http://dx.doi.org/10.1074/jbc.M207593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12562779	hybrid			2022-12-27	WOS:000182516100065
J	Yang, J; Jones, SP; Suhara, T; Greer, JJM; Ware, PD; Nguyen, NP; Perlman, H; Nelson, DP; Lefer, DJ; Walsh, K				Yang, J; Jones, SP; Suhara, T; Greer, JJM; Ware, PD; Nguyen, NP; Perlman, H; Nelson, DP; Lefer, DJ; Walsh, K			Endothelial cell overexpression of Fas ligand attenuates ischemia-reperfusion injury in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULAR IMMUNE PRIVILEGE; CD95 LIGAND; NEUTROPHIL DEPLETION; MEDIATED APOPTOSIS; GENE-TRANSFER; EXPRESSION; DEATH; SENSITIVITY; FLIP; AUTOIMMUNITY	Fas ligand (FasL) is a member of tumor necrosis factor family that induces apoptosis in target cells that express Fas. The function of FasL during inflammation remains controversial. In this study, we examined the role of vascular endothelial FasL during acute myocardial ischemia-reperfusion that is closely associated with inflammation. Transgenic mouse lines were established that overexpress human FasL on endothelium under the control of the vascular endothelial cadherin promoter. Expression of FasL transgene was detected at both mRNA and protein levels, and functional transgene-encoded FasL protein was specifically expressed on the surface of vascular endothelial cells. Transgenic mice developed normally and had normal hearts. When subjected to 30 min of myocardial ischemia and 72 h of reperfusion, myocardial infarct size was reduced by 42% in the transgenic mice compared with nontransgenic littermates (p < 0.05). Moreover, hemodynamic data demonstrated that transgenic hearts performed better following ischemia and reperfusion compared with nontransgenic hearts. Myocardial neutrophil infiltration was reduced by 54% after 6 h of reperfusion in transgenic hearts (p < 0.01). Neutrophil depletion prior to ischemia-reperfusion injury led to smaller infarcts that were not different between transgenic and nontransgenic mice, suggesting that endothelial FasL may attenuate ischemia-reperfusion injury by abating the inflammatory response. These results indicate that vascular endothelial FasL may exert potent anti-inflammatory actions in the setting of myocardial ischemia-reperfusion injury.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Tufts Univ, Sch Med, Program Cellular Mol & Dev Biol, Boston, MA 02111 USA; Louisiana State Univ, Ctr Hlth Sci, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Johns Hopkins Med Inst, Div Cardiol, Baltimore, MD 21205 USA; Osaka Univ, Sch Med, Dept Geriatr Med, Osaka 553, Japan; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Childrens Hosp, Med Ctr, Div Cardiol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Boston University; Tufts University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Johns Hopkins University; Johns Hopkins Medicine; Osaka University; Saint Louis University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.		Lefer, David/A-6372-2012; Jones, Steven P./D-5092-2009	Jones, Steven P./0000-0001-5376-8089; Lefer, David/0000-0003-2293-7278	NHLBI NIH HHS [HL-66957, HL60849] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG-17241, AG-15052] Funding Source: Medline; NICHD NIH HHS [HD-23681] Funding Source: Medline; NIDDK NIH HHS [DK43785] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957, R01HL060849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R37AG015052, R01AG017241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bao JL, 2001, AM J PHYSIOL-HEART C, V281, pH2612, DOI 10.1152/ajpheart.2001.281.6.H2612; Behrens CK, 2001, J IMMUNOL, V166, P3240, DOI 10.4049/jimmunol.166.5.3240; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bouchet D, 2002, MOL MED, V8, P612, DOI 10.1007/BF03402172; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DREYER WJ, 1991, CIRCULATION, V84, P400, DOI 10.1161/01.CIR.84.1.400; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Gregory MS, 2002, J IMMUNOL, V169, P2727, DOI 10.4049/jimmunol.169.5.2727; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hohlbaum AM, 2001, J IMMUNOL, V167, P6217, DOI 10.4049/jimmunol.167.11.6217; Jeremias I, 2000, CIRCULATION, V102, P915; Jones SP, 2001, AM J PHYSIOL-HEART C, V281, pH48, DOI 10.1152/ajpheart.2001.281.1.H48; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Luo ZY, 1999, CIRCULATION, V99, P1776, DOI 10.1161/01.CIR.99.14.1776; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; Muruve DA, 1997, HUM GENE THER, V8, P955, DOI 10.1089/hum.1997.8.8-955; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nelson DP, 2000, J CLIN INVEST, V105, P1199, DOI 10.1172/JCI8212; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Perlman H, 2000, CARDIOVASC RES, V45, P570, DOI 10.1016/S0008-6363(99)00346-6; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Sano Y, 2002, EXP EYE RES, V75, P475, DOI 10.1006/exer.2002.2044; Sata M, 2001, FASEB J, V15, P2530, DOI 10.1096/fj.01-0415fje; Sata M, 2001, J IMMUNOL, V166, P6964, DOI 10.4049/jimmunol.166.11.6964; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, NAT MED, V4, P415, DOI 10.1038/nm0498-415; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Shiraishi H, 2002, LAB INVEST, V82, P1121, DOI 10.1097/01.LAB.0000029148.88524.CE; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; Stassi G, 2000, NAT IMMUNOL, V1, P483, DOI 10.1038/82725; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Takeuchi T, 1999, J IMMUNOL, V162, P518; Tourneur U, 2001, J IMMUNOL, V167, P1338, DOI 10.4049/jimmunol.167.3.1338; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9	48	35	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15185	15191		10.1074/jbc.M211707200	http://dx.doi.org/10.1074/jbc.M211707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576484	hybrid			2022-12-27	WOS:000182516100078
J	Jambrina, E; Alonso, R; Alcalde, M; Rodriguez, MD; Serrano, A; Martinez-A, C; Garcia-Sancho, J; Izquierdo, M				Jambrina, E; Alonso, R; Alcalde, M; Rodriguez, MD; Serrano, A; Martinez-A, C; Garcia-Sancho, J; Izquierdo, M			Calcium influx through receptor-operated channel induces mitochondria-triggered paraptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR; APOPTOSIS; STIMULATION; ACTIVATION; EVENT; DNA	We address the specific role of cytoplasmic Ca2+ overload as a cell death trigger by expressing a receptor-operated specific Ca2+ channel, vanilloid receptor subtype 1 (VR1), in Jurkat cells. Ca2+ uptake through the VR1 channel, but not capacitative Ca2+ influx stimulated by the muscarinic type 1 receptor, induced sustained intracellular [Ca2+] rises, exposure of phosphatidylserine, and cell death. Ca2+ influx was necessary and sufficient to induce mitochondrial damage, as assessed by opening of the permeability transition pore and collapse of the mitochondrial membrane potential. Ca2+- induced cell death was inhibited by ruthenium red, protonophore carbonyl cyanide m-chlorophenylhydrazone, or cyclosporin A treatment, as well as by Bcl-2 expression, indicating that this process requires mitochondrial calcium uptake and permeability transition pore opening. Cell death occurred without caspase activation, oligonucleosomal/50-kilobase pair DNA cleavage, or release of cytochrome c or apoptosis inducer factor from mitochondria, but it required oxidative/nitrative stress. Thus, Ca2+ influx triggers a distinct program of mitochondrial dysfunction leading to paraptotic cell death, which does not fulfill the criteria for either apoptosis or necrosis.	Univ Valladolid, CSIC, Inst Biol & Genet Mol, Fac Med, E-47005 Valladolid, Spain; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Izquierdo, M (corresponding author), Univ Valladolid, CSIC, Inst Biol & Genet Mol, Fac Med, Ramon & Cajal 7, E-47005 Valladolid, Spain.	mizdo@ibgm.uva.es	Izquierdo, Manuel/D-2971-2017; Izquierdo, Manuel/I-4812-2013; Garcia-Sancho, Javier/K-2975-2014; Izquierdo, Manuel/I-4812-2013	Izquierdo, Manuel/0000-0002-7701-1002; Izquierdo, Manuel/0000-0002-7701-1002; Serrano, Antonio/0000-0003-1993-640X; Garcia-Sancho, Javier/0000-0003-4573-7930; Izquierdo, Manuel/0000-0002-7261-404X				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; Alvarez J, 1999, NEWS PHYSIOL SCI, V14, P161; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Golstein P, 1998, SCIENCE, V281, P1283, DOI 10.1126/science.281.5381.1283; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Izquierdo M, 1996, J IMMUNOL, V157, P21; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2001, ARCH BIOCHEM BIOPHYS, V393, P321, DOI 10.1006/abbi.2001.2500; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; Montero M, 2001, MOL BIOL CELL, V12, P63, DOI 10.1091/mbc.12.1.63; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; PREMACK BA, 1994, J IMMUNOL, V152, P5226; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, FEBS LETT, V501, P79, DOI 10.1016/S0014-5793(01)02629-1; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Slagsvold HH, 2000, EXP BRAIN RES, V135, P173, DOI 10.1007/s002210000521; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Villalobos C, 1996, FASEB J, V10, P654, DOI 10.1096/fasebj.10.5.8621065	47	89	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14134	14145		10.1074/jbc.M211388200	http://dx.doi.org/10.1074/jbc.M211388200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571238	Green Published, hybrid			2022-12-27	WOS:000182405000074
J	Joglekar, AP; Xu, DL; Rigotti, DJ; Fairman, R; Hay, JC				Joglekar, AP; Xu, DL; Rigotti, DJ; Fairman, R; Hay, JC			The SNARE motif contributes to rbet1 intracellular targeting and dynamics independently of SNARE interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; GOLGI NETWORK; BREFELDIN-A; COMPLEX; LOCALIZATION; ER; TRANSPORT; PROTEINS; FUSION	The endoplasmic reticulum/Golgi SNARE rbet1 cycles between the endoplasmic reticulum and Golgi and is essential for cargo transport in the secretory pathway. Although the quaternary SNARE complex containing rbet1 is known to function in membrane fusion, the structural role of rbet1 is unclear. Furthermore, the structural determinants for rbet1 targeting and its cyclical itinerary have not been investigated. We utilized protein interaction assays to demonstrate that the rbet1 SNARE motif plays a structural role similar to the carboxyl-terminal helix of SNAP-25 in the synaptic SNARE complex and demonstrated the importance to SNARE complex assembly of a conserved salt bridge between rbet1 and sec22b. We also examined the potential role of the rbet1 SNARE motif and SNARE interactions in rbet1 localization and dynamics. We found that, in contrast to what has been observed for syntaxin 5'. the rbet1 SNARE motif was essential for proper targeting. To test whether SNARE interaction's were important for the targeting function of the SNARE motif, we used charge repulsion mutations at the conserved salt bridge position that rendered rbet1 defective for binary, ternary, and quaternary SNARE interactions. We found that heteromeric SNARE interactions are not required at any step in rbet1 targeting-or dynamics. Furthermore, the heteromeric state of the SNARE motif does not influence its interaction with the COPI coat or efficient recruitment onto transport vesicles. We conclude that protein targeting is a completely independent function of the rbet1 SNARE motif, which is capable of distinct classes of protein interactions.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Haverford Coll, Dept Biol, Haverford, PA 19041 USA	University of Michigan System; University of Michigan; Haverford College	Hay, JC (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	jessehay@umich.edu			NIGMS NIH HHS [GM59378] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059378] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; Hao JC, 1997, J NEUROSCI, V17, P1596; Hasegawa H, 2003, MOL BIOL CELL, V14, P698, DOI 10.1091/mbc.E02-09-0556; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; Kasai K, 2001, J CELL SCI, V114, P3115; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Rein U, 2002, J CELL BIOL, V157, P395, DOI 10.1083/jcb.200112092; SARASTE J, 1991, J CELL SCI, V100, P415; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200	41	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14121	14133		10.1074/jbc.M300659200	http://dx.doi.org/10.1074/jbc.M300659200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566453	hybrid			2022-12-27	WOS:000182405000073
J	Meima, ME; Weening, KE; Schaap, P				Meima, ME; Weening, KE; Schaap, P			Characterization of a cAMP-stimulated cAMP phosphodiesterase in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP PHOSPHODIESTERASE; METALLO-BETA-LACTAMASE; CRYSTAL-STRUCTURE; BACILLUS-CEREUS; CGMP PHOSPHODIESTERASE; ADENYLYL-CYCLASE; GENE-EXPRESSION; GLYOXALASE-II; BINDING	A cyclic nucleotide phosphodiesterase, PdeE, that harbors two cyclic nucleotide binding motifs and a binuclear Zn2+-binding domain was characterized in Dictyostelium. In other eukaryotes, the Dictyostelium domain shows greatest homology to the 73-kDa subunit of the pre-mRNA cleavage and polyadenylation specificity factor. The Dictyostelium PdeE gene is expressed at its highest levels during aggregation, and its disruption causes the loss of a cAMP-phosphodiesterase activity. The pdeE null mutants show a normal cAMP-induced cGMP response and a 1.5-fold increase of cAMP-induced cAMP relay. Overexpression of a PdeE-yellow fluorescent protein (YFP) fusion construct causes inhibition of aggregation and loss of the cAMP relay response, but the cells can aggregate in synergy with wild-type cells. The PdeE-YFP fusion protein was partially purified by immunoprecipitation and biochemically characterized. PdeE and its Dictyostelium ortholog, PdeD, are both maximally active at pH 7.0. Both enzymes require bivalent cations for activity. The common cofactors Zn2+ and Mg2+ activated PdeE and PdeD maximally at 10 mm, whereas Mn2+ activated the enzymes to 4-fold higher levels, with half-maximal activation between 10 and 100 gm. PdeE is an allosteric enzyme, which is similar to4-fold activated by cAMP, with half-maximal activation occurring at about 10 muM and an apparent K-m of similar to1 mm. cGMP is degraded at a 6-fold lower rate than cAMP. Neither cGMP nor 8-Br-cAMP are efficient activators of PdeE activity.	Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Schaap, P (corresponding author), Univ Dundee, Sch Life Sci, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.		Schaap, Pauline/A-3682-2009; Schaap, Pauline/M-5355-2019	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555				Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; Bosgraaf L, 2002, MOL BIOL CELL, V13, P3878, DOI 10.1091/mbc.E02-05-0302; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DELOZANNE A, 1987, METHOD CELL BIOL, V28, P489; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; Dunn O. J., 1987, APPL STAT ANAL VARIA; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; GILMAN AG, 1972, ADV CYCL NUCL RES<D>, V2, P9; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Goldberg JM, 2002, P NATL ACAD SCI USA, V99, P6749, DOI 10.1073/pnas.102167299; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KALPAXIS D, 1990, DEV GENET, V11, P396, DOI 10.1002/dvg.1020110512; KESBEKE F, 1985, EUR J BIOCHEM, V151, P179, DOI 10.1111/j.1432-1033.1985.tb09083.x; KESSIN RH, 1979, P NATL ACAD SCI USA, V76, P5450, DOI 10.1073/pnas.76.11.5450; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; Kuwayama H, 2001, BIOCHEM J, V353, P635, DOI 10.1042/0264-6021:3530635; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; Laub MT, 1998, MOL BIOL CELL, V9, P3521, DOI 10.1091/mbc.9.12.3521; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MARTIEL JL, 1987, BIOPHYS J, V52, P807, DOI 10.1016/S0006-3495(87)83275-7; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Meima ME, 2002, MOL BIOL CELL, V13, P3870, DOI 10.1091/mbc.E02-05-0285; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; PANNBACKER RG, 1972, SCIENCE, V175, P1014, DOI 10.1126/science.175.4025.1014; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; ROSS FM, 1981, J GEN MICROBIOL, V127, P339; SCHULKES C, 1995, FEBS LETT, V368, P381, DOI 10.1016/0014-5793(95)00676-Z; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHABB JB, 1991, J BIOL CHEM, V266, P24320; Shaulsky G, 1998, DEVELOPMENT, V125, P691; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TANG YH, 1994, MATH BIOSCI, V120, P25, DOI 10.1016/0025-5564(94)90037-X; THEIBERT A, 1983, J CELL BIOL, V97, P173, DOI 10.1083/jcb.97.1.173; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X	54	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14356	14362		10.1074/jbc.M209648200	http://dx.doi.org/10.1074/jbc.M209648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574165	hybrid			2022-12-27	WOS:000182405000100
J	Mukhopadhyay, A; Heard, TS; Wen, XH; Hammen, PK; Weiner, H				Mukhopadhyay, A; Heard, TS; Wen, XH; Hammen, PK; Weiner, H			Location of the actual signal in the negatively charged leader sequence involved in the import into the mitochondrial matrix space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ISOPROPYLMALATE SYNTHASE; LIVER ALDEHYDE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; PROCESSING PEPTIDASE; PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; RAT CHAPERONIN-10; PRECURSOR PROTEIN; INNER MEMBRANE; IDENTIFICATION	Proteins destined for the mitochondrial matrix space have leader sequences that are typically present at the most N-terminal end of the nuclear-encoded precursor protein. The leaders are rich in positive charges and usually deficient of negative charges. This observation led to the acid-chain hypothesis to explain how the leader sequences interact with negatively charged receptor proteins. Here we show using both chimeric leaders and one from isopropyl malate synthase that possesses a negative charge that the leader need not be at the very N terminus of the precursor. Experiments were performed with modified non-functioning leader sequences fused to either the native or a non-functioning leader of aldehyde dehydrogenase so that an internal leader sequence could exist. The internal leader is sufficient for the import of the modified precursor protein. It appears that this leader still needs to form an amphipathic helix just like the normal N-terminal leaders do. This internal leader could function even if the most N-terminal portion contained negative charges in the first 7-11 residues. If the first 11 residues were deleted from isopropyl malate synthase, the resulting protein was imported more successfully than the native protein. It appears that precursors that carry negatively charged leaders use an internal signal sequence to compensate for the non-functional segment at the most N-terminal portion of the protein.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weiner, H (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ St, W Lafayette, IN 47907 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010795] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10795] Funding Source: Medline; NIGMS NIH HHS [GM 53269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BELTZER JP, 1988, J BIOL CHEM, V263, P368; Bomer U, 1997, J BIOL CHEM, V272, P30439, DOI 10.1074/jbc.272.48.30439; Casalone E, 2000, YEAST, V16, P539, DOI 10.1002/(SICI)1097-0061(200004)16:6<539::AID-YEA547>3.0.CO;2-K; CHU TW, 1987, J BIOL CHEM, V262, P12806; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HAMPSEY DM, 1983, P NATL ACAD SCI-BIOL, V80, P1270, DOI 10.1073/pnas.80.5.1270; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; Heard TS, 1998, J BIOL CHEM, V273, P29389, DOI 10.1074/jbc.273.45.29389; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; Mukhopadhyay A, 2002, PROTEIN SCI, V11, P1026, DOI 10.1110/ps.3760102; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RYAN MT, 1994, FEBS LETT, V337, P152, DOI 10.1016/0014-5793(94)80263-7; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schleiff E, 1999, FEBS LETT, V461, P9, DOI 10.1016/S0014-5793(99)01415-5; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VANHEIJNE G, 1986, EMBO J, V5, P1335; Voss H, 1997, YEAST, V13, P655, DOI 10.1002/(SICI)1097-0061(19970615)13:7<655::AID-YEA120>3.0.CO;2-I; Waltner M, 1996, J BIOL CHEM, V271, P21226, DOI 10.1074/jbc.271.35.21226; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; WANG Y, 1993, J BIOL CHEM, V268, P4759; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Zhou JZ, 2001, PROTEIN SCI, V10, P1490, DOI 10.1110/ps.5301	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13712	13718		10.1074/jbc.M212743200	http://dx.doi.org/10.1074/jbc.M212743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12551941	hybrid			2022-12-27	WOS:000182405000021
J	Senn, JJ; Klover, PJ; Nowak, IA; Zimmers, TA; Koniaris, LG; Furlanetto, RW; Mooney, RA				Senn, JJ; Klover, PJ; Nowak, IA; Zimmers, TA; Koniaris, LG; Furlanetto, RW; Mooney, RA			Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; ADIPOSE-TISSUE; GROWTH-HORMONE; FACTOR-ALPHA; MICE LACKING; TNF-ALPHA; GLUCOSE-PRODUCTION; BOX MOTIF	Interleukin-6 (IL-6) is one of several pro-inflammatory cytokines implicated in insulin resistance during infection, cachexia, and obesity. We recently demonstrated that IL-6 inhibits insulin signaling in hepatocytes (Senn, J. J., Klover, P. J., Nowak, I. A., and Mooney, R. A. (2002) Diabetes 51, 3391-3399). Members of the suppressors of cytokine signaling (SOCS) family associate with the insulin receptor (IR), and their ectopic expression inhibits IR signaling. Since several SOCS proteins are induced by IL-6, a working hypothesis is that IL-6-dependent insulin resistance is mediated, at least in part, by induction of SOCS protein(s) in insulin target cells. To examine the involvement of SOCS protein(s) in IL-6-dependent inhibition of insulin receptor signaling, HepG2 cells were treated with IL-6 (20 ng/ml) for periods from 1 min to 8 h. IL-6 induced SOCS-3 transcript at 30 min with a maximum effect at 1 h. SOCS-3 protein levels were also markedly elevated at 1 h. Transcript and protein levels returned to near basal levels by 2 h. SOCS-3 induction by IL-6 paralleled IL-6-dependent inhibition of IR signal transduction. Ectopically expressed SOCS-3 associated with the IR and suppressed insulin-dependent receptor autophosphorylation, insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, association of IRS-1 with the p85 subunit of phosphatidylinositol 3-kinase, and activation of Akt. SOCS-3 was also a direct inhibitor of insulin receptor autophosphorylation in vitro. In mice exposed to IL-6 for 60-90 min, hepatic SOCS-3 expression was increased. This was associated with inhibition of hepatic insulin-dependent receptor autophosphorylation and IRS-1 tyrosine phosphorylation. These data suggest that induction of SOCS-3 in liver may be an important mechanism of IL-6-mediated insulin resistance.	Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Surg, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Mooney, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, 601 Elmwood Ave, Rochester, NY 14642 USA.		Zimmers, Teresa/AAD-5461-2019	Zimmers, Teresa/0000-0001-7872-0540	PHS HHS [R01-38138] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Boisclair YR, 2000, J BIOL CHEM, V275, P3841, DOI 10.1074/jbc.275.6.3841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Cheung AT, 1998, ENDOCRINOLOGY, V139, P4928, DOI 10.1210/en.139.12.4928; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hong F, 2001, FASEB J, V15, P1595, DOI 10.1096/fj.00-0908fje; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING PR, 1994, METABOLISM, V43, P279, DOI 10.1016/0026-0495(94)90093-0; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; RIZZA RA, 1982, DIABETES, V31, P663, DOI 10.2337/diabetes.31.8.663; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang Y, 2000, AM J PHYSIOL-ENDOC M, V279, pE196, DOI 10.1152/ajpendo.2000.279.1.E196	54	461	490	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13740	13746		10.1074/jbc.M210689200	http://dx.doi.org/10.1074/jbc.M210689200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12560330	hybrid			2022-12-27	WOS:000182405000024
J	Grimm, HS; Beher, D; Lichtenthaler, SF; Shearman, MS; Beyreuther, K; Hartmann, T				Grimm, HS; Beher, D; Lichtenthaler, SF; Shearman, MS; Beyreuther, K; Hartmann, T			gamma-secretase cleavage site specificity differs for intracellular and secretory amyloid beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PRECURSOR PROTEIN APP; ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; LATE COMPARTMENTS; NEURONAL CELLS; BREFELDIN-A; PRESENILIN-1; PEPTIDE	The final step in Abeta generation is the cleavage of the C-terminal 99 amino acid residues of the amyloid precursor protein by gamma-secretase. gamma-Secretase activity is closely linked to the multi-transmembrane-spanning proteins presenilin 1 and presenilin 2. To elucidate whether the cleavage site specificities of gamma-secretase leading to the formation of secreted and intracellular A,6 are identical, we made use of point mutations close to the gamma-cleavage site, known to have a dramatic effect on the 42/40 ratio of secreted Abeta. We found that the selected point mutations only marginally influenced the 42/40 ratio of intracellular Abeta, suggesting differences in the gamma-secretase cleavage site specificity for the generation of secreted and intracellular Abeta. The analysis of the subcellular compartments involved in the generation of intracellular Abeta revealed that Abeta is not generated in the early secretory pathway in the human SH-SY5Y neuroblastoma cell line. In this study we identified late Golgi compartments to be involved in the generation of intracellular Abeta. Moreover, we demonstrate that the presence of processed PS1 is not sufficient to obtain gamma-secretase processing of the truncated amyloid precursor protein construct C99, proposing the existence of an additional factor downstream of the endoplasmic reticulum and early Golgi required for the formation of an active gamma-secretase complex.	Heidelberg Univ, ZMBH, Ctr Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Biochem, Harlow CM20 2QR, Essex, England; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Mol Biol, Harlow CM20 2QR, Essex, England	Ruprecht Karls University Heidelberg; University of Munich; Merck & Company; Merck & Company	Grimm, HS (corresponding author), Heidelberg Univ, ZMBH, Ctr Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	h.grimm@mail.zmbh.uni-heidelberg.de; tobias.hartmann@zmbh.uni-heidelberg	Hartmann, Tobias/AAB-8297-2022; Lichtenthaler, Stefan F/B-6587-2016	Lichtenthaler, Stefan F/0000-0003-2211-2575; Beher, Dirk/0000-0001-8005-5359; Hartmann, Tobias/0000-0001-7481-6430				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Culvenor JG, 2000, EXP CELL RES, V255, P192, DOI 10.1006/excr.1999.4791; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; D'Andrea MR, 2002, NEUROSCI LETT, V333, P163, DOI 10.1016/S0304-3940(02)00875-3; De Strooper B, 2000, J CELL SCI, V113, P1857; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Grziwa B, 2003, J BIOL CHEM, V278, P6803, DOI 10.1074/jbc.M210047200; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LE AQ, 1994, J BIOL CHEM, V269, P7514; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Lichtenthaler SF, 2002, P NATL ACAD SCI USA, V99, P1365, DOI 10.1073/pnas.032395699; Lichtenthaler SF, 1999, FEBS LETT, V453, P288, DOI 10.1016/S0014-5793(99)00730-9; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Mochizuki A, 2000, LANCET, V355, P42, DOI 10.1016/S0140-6736(99)04937-5; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Peraus GC, 1997, J NEUROSCI, V17, P7714; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Petanceska SS, 2000, J NEUROCHEM, V74, P1878, DOI 10.1046/j.1471-4159.2000.0741878.x; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	86	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13077	13085		10.1074/jbc.M210380200	http://dx.doi.org/10.1074/jbc.M210380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556458	hybrid			2022-12-27	WOS:000182189500063
J	Henderson, CJ; Otto, DME; Carrie, D; Magnuson, MA; McLaren, AW; Rosewell, I; Wolf, CR				Henderson, CJ; Otto, DME; Carrie, D; Magnuson, MA; McLaren, AW; Rosewell, I; Wolf, CR			Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7 ALPHA-HYDROXYLASE; BILE-ACID; CHOLESTEROL ABSORPTION; GENE; MICE; EXPRESSION; LIVER; HEPATOTOXICITY; GLUTATHIONE; DISRUPTION	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of a large number of endogenous compounds and the majority of ingested environmental chemicals, leading to their elimination and often to their metabolic activation to toxic products. This enzyme system therefore provides our primary defense against xenobiotics and is a major determinant in the therapeutic efficacy of pharmacological agents. To evaluate the importance of hepatic P450s in normal homeostasis, drug pharmacology, and chemical toxicity, we have conditionally deleted the essential electron transfer protein, NADH:ferrihemoprotein reductase (EC 1.6.2.4, cytochrome P450 reductase, CPR) in the liver, resulting in essentially complete ablation of hepatic microsomal P450 activity. Hepatic CPR-null mice could no longer break down cholesterol because of their inability to produce bile acids, and whereas hepatic lipid levels were significantly increased, circulating levels of cholesterol and triglycerides were severely reduced. Loss of hepatic P450 activity resulted in a 5-fold increase in P450 protein, indicating the existence of a negative feedback pathway regulating P450 expression. Profound changes in the in vivo metabolism of pentobarbital and acetaminophen indicated that extrahepatic metabolism does not play a major role in the disposition of these compounds. Hepatic CPR-null mice developed normally and were able to breed, indicating that hepatic microsomal P450-mediated steroid hormone metabolism is not essential for fertility, demonstrating that a major evolutionary role for hepatic P450s is to protect mammals from their environment.	Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland	University of Dundee	Wolf, CR (corresponding author), Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Level 5, Dundee DD1 9SY, Scotland.	mark.magnuson@vanderbilt.edu; roland.wolf@cancer.org.uk	Magnuson, Mark A/B-1335-2009; Henderson, Colin J/A-6347-2009; Henderson, Colin/AAE-7141-2019; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Henderson, Colin/0000-0002-4764-639X; Magnuson, Mark/0000-0002-8824-6499; Wolf, Charles Roland/0000-0002-6969-0113; CARRIE, didier/0000-0003-2479-8144				Bosner MS, 1999, J LIPID RES, V40, P302; Brochet D, 1999, GEN PHARMACOL-VASC S, V33, P249, DOI 10.1016/S0306-3623(99)00018-X; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cairns W, 1996, J BIOL CHEM, V271, P25269, DOI 10.1074/jbc.271.41.25269; Carter CP, 1997, J NUTR, V127, P1344, DOI 10.1093/jn/127.7.1344; COLES B, 1988, ARCH BIOCHEM BIOPHYS, V264, P253, DOI 10.1016/0003-9861(88)90592-9; CONNEY AH, 1982, CANCER RES, V42, P4875; DIETSCHY JM, 1983, BIOCHEM SOC T, V11, P639, DOI 10.1042/bst0110639; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; GOEPTAR AR, 1995, CRIT REV TOXICOL, V25, P25, DOI 10.3109/10408449509089886; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Henderson CJ, 2000, P NATL ACAD SCI USA, V97, P12741, DOI 10.1073/pnas.220176997; HENDERSON CJ, 1990, BIOCHEM J, V266, P675, DOI 10.1042/bj2660675; HENDERSON CJ, 1992, IMMUNOCHEMICAL PROTO, V10, P221; Hines RN, 2001, DRUG METAB DISPOS, V29, P623; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; Kang S, 2000, BBA-MOL CELL BIOL L, V1529, P223, DOI 10.1016/S1388-1981(00)00151-7; Kelly SL, 2001, BIOCHEM SOC T, V29, P122, DOI 10.1042/0300-5127:0290122; Lamb DC, 1999, FEBS LETT, V462, P283, DOI 10.1016/S0014-5793(99)01548-3; Le YZ, 2001, MOL BIOTECHNOL, V17, P269, DOI 10.1385/MB:17:3:269; Lee SST, 1996, J BIOL CHEM, V271, P12063, DOI 10.1074/jbc.271.20.12063; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEEHAN RR, 1988, BIOCHEM J, V254, P789, DOI 10.1042/bj2540789; MODI S, 1995, BIOCHEM SOC T, V23, pS476, DOI 10.1042/bst023476s; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Oinonen T, 1998, BIOCHEM J, V329, P17, DOI 10.1042/bj3290017; Omura T, 1999, BIOCHEM BIOPH RES CO, V266, P690, DOI 10.1006/bbrc.1999.1887; Pikuleva I, 1999, Mol Aspects Med, V20, P33; PIKULEVA L, 1999, MOL ASPECTS MED, V20, P43; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Raucy J. L., 2001, Pharmacogenomics Journal, V1, P178; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SEN CK, 1992, J APPL PHYSIOL, V73, P1265, DOI 10.1152/jappl.1992.73.4.1265; SHAPIRO BH, 1989, ENDOCRINOLOGY, V125, P2935, DOI 10.1210/endo-125-6-2935; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; SMITH G, 1993, BIOCHEM J, V289, P807, DOI 10.1042/bj2890807; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; SPADY DK, 1983, J LIPID RES, V24, P303; Stromstedt M, 1996, ARCH BIOCHEM BIOPHYS, V329, P73, DOI 10.1006/abbi.1996.0193; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; Tonge RP, 1998, TOXICOL APPL PHARM, V153, P102, DOI 10.1006/taap.1998.8543; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Voice MW, 1999, ARCH BIOCHEM BIOPHYS, V366, P116, DOI 10.1006/abbi.1999.1192; WOLF CR, 1984, CARCINOGENESIS, V5, P993, DOI 10.1093/carcin/5.8.993; WOLF CR, 1986, TRENDS GENET, V2, P209, DOI 10.1016/0168-9525(86)90232-5; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	53	213	219	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13480	13486		10.1074/jbc.M212087200	http://dx.doi.org/10.1074/jbc.M212087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566435	hybrid			2022-12-27	WOS:000182189500111
J	Koldamova, RP; Lefterov, LM; Ikonomovic, MD; Skoko, J; Lefterov, PI; Isanskis, BA; DeKosky, ST; Lazo, JS				Koldamova, RP; Lefterov, LM; Ikonomovic, MD; Skoko, J; Lefterov, PI; Isanskis, BA; DeKosky, ST; Lazo, JS			22R-Hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; LIVER-X RECEPTORS; PRECURSOR PROTEIN; MESSENGER-RNA; HIPPOCAMPAL-NEURONS; BLEOMYCIN HYDROLASE; CEREBROSPINAL-FLUID; ABCA1 TRANSPORTER; IN-VITRO; APOA-I	The ATP-binding cassette transporter A1 (ABCA1) is a major regulator of peripheral cholesterol efflux and plasma high density lipoprotein metabolism. In adult rat brain we found high expression of ABCA1 in neurons in the hypothalamus, thalamus, amygdala, cholinergic basal forebrain, and hippocampus. Large neurons of the cholinergic nucleus basalis together with CA1 and CA3 pyramidal neurons were among the most abundantly immunolabeled neurons. Glia cells were largely negative. Because cholesterol homeostasis may have an essential role in central nervous system function and neurodegeneration, we examined ABCA1 expression and function in different brain cell types using cultures of primary neurons, astrocytes, and microglia isolated from embryonic rat brain. The basal ABCA1 mRNA and protein levels detected in these cell types were increased markedly after exposure to oxysterols and 9-cis-retinoic acid, which are ligands for the nuclear hormone liver X receptors and retinoic X receptors, respectively. Functionally, the increased ABCA1 expression caused by these ligands was followed by elevated apoA-I- and apoE-specific cholesterol efflux in neurons and glia. In non-neuronal and neuronal cells overexpressing a human Swedish variant of amyloid precursor protein, 22R-hydroxycholesterol and 9-cis-retinoic acid induced ABCA1 expression and increased apoA-I-mediated cholesterol efflux consequently decreasing cellular cholesterol content. More importantly, we demonstrated that these ligands alone or in combination with apoA-I caused a substantial reduction in the stability of amyloid precursor protein C-terminal fragments and decreased amyloid beta production. These effects of 22R-hydroxycholesterol may provide a novel strategy to decrease amyloid beta secretion and consequently reduce the amyloid burden in the brain.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E-1358 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		Skoko, John/AAL-1885-2021	Koldamova, Radosveta/0000-0002-6761-0984; Skoko, John/0000-0002-1885-6929; DeKosky, Steven/0000-0003-3743-2758; Lefterov, Iliya/0000-0002-0249-0280	NIA NIH HHS [AG 18558] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Attie AD, 2001, J LIPID RES, V42, P1717; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; CACERES A, 1986, J NEUROSCI, V6, P714; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Clee SM, 2001, CIRCULATION, V103, P1198; Costet P, 2000, J BIOL CHEM, V275, P28240; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; De Strooper B, 2000, J CELL SCI, V113, P1857; Dean M, 2001, J LIPID RES, V42, P1007; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; GAYEN AK, 1995, ARCH BIOCHEM BIOPHYS, V322, P475, DOI 10.1006/abbi.1995.1491; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Hobbs HH, 1999, J CLIN INVEST, V104, P1015, DOI 10.1172/JCI8509; IKONOMOVIC MD, 1995, J COMP NEUROL, V359, P239, DOI 10.1002/cne.903590205; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lefterov IM, 2001, BIOCHEM BIOPH RES CO, V283, P994, DOI 10.1006/bbrc.2001.4860; Lefterov IM, 2000, FASEB J, V14, P1837, DOI 10.1096/fj.99-0938com; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Panzenboeck U, 2002, J BIOL CHEM, V277, P42781, DOI 10.1074/jbc.M207601200; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Steiner RD, 2000, J LIPID RES, V41, P1437; van Dam MJ, 2002, LANCET, V359, P37, DOI 10.1016/S0140-6736(02)07277-X; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; WOLLMER MA, 2002, NEUROBIOL AGING, V23, pS216; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992	63	211	220	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13244	13256		10.1074/jbc.M300044200	http://dx.doi.org/10.1074/jbc.M300044200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547833	hybrid			2022-12-27	WOS:000182189500083
J	Medley, QG; Buchbinder, EG; Tachibana, K; Ngo, H; Serra-Pages, C; Streuli, M				Medley, QG; Buchbinder, EG; Tachibana, K; Ngo, H; Serra-Pages, C; Streuli, M			Signaling between focal adhesion kinase and trio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HIGH-AFFINITY BINDING; SRC FAMILY KINASES; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; PROTEIN-KINASE; SERINE/THREONINE KINASE; SERINE PHOSPHORYLATION; SUBSTRATE P130(CAS); NEURITE OUTGROWTH	The Trio guanine nucleotide exchange factor functions in neural development in Caenorhabditis elegans and Drosophila and in the development of neural tissues and skeletal muscle in mouse. The association of Trio with the Lar tyrosine phosphatase led us to study the role of tyrosine phosphorylation in Trio function using focal adhesion kinase (FAK). The Lar-interacting domain of Trio is constitutively tyrosine-phosphorylated when expressed in COS-7 cells and was highly phosphorylated when it was co-transfected with FAK. Co-precipitation. studies indicated that Trio binds to the FAK amino-terminal domain and to the FAK kinase domain via its SH3 and kinase domains, respectively. Tyrosine-phosphorylated FAK and Trio were present mainly in the detergent-insoluble fraction of cell lysates, and co-expression of Trio and FAK resulted in increased amounts of Trio present in the detergent-insoluble fraction. Immunofluorescence of cells co-transfected with FAK and Trio revealed significant co-localization. of the proteins at the cell periphery, indicating that they form a stable complex in vivo. A FAK phosphorylation site, tyrosine residue 2737, was identified in subdomain I of the Trio kinase domain. Additionally, in vitro phosphorylation assays and in vivo co-expression studies indicated that Trio enhances FAK kinase activity. These results suggest Trio may be involved in the regulation of focal adhesion dynamics in addition to effecting changes in the actin cytoskeleton. through the activation of Rho family GTPases.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Medley, QG (corresponding author), UCB Res, 840 Mem Dr, Cambridge, MA 02139 USA.				NATIONAL CANCER INSTITUTE [R01CA075091, R01CA055547] Funding Source: NIH RePORTER; NCI NIH HHS [CA75091, CA55547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blangy A, 2000, J CELL SCI, V113, P729; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chernoff J, 1999, NAT CELL BIOL, V1, pE115, DOI 10.1038/12942; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Ma A, 2001, MOL BIOL CELL, V12, P1; Medley QG, 2000, J BIOL CHEM, V275, P36116, DOI 10.1074/jbc.M003775200; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Seipel K, 2001, J CELL SCI, V114, P389; Seipel K, 1999, J CELL SCI, V112, P1825; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sieg DJ, 1999, J CELL SCI, V112, P2677; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Turner CE, 2000, J CELL SCI, V113, P4139; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	51	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13265	13270		10.1074/jbc.M300277200	http://dx.doi.org/10.1074/jbc.M300277200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551902	hybrid			2022-12-27	WOS:000182189500085
J	Pan, Y; Zvaritch, E; Tupling, AR; Rice, WJ; de Leon, S; Rudnick, M; McKerlie, C; Banwell, BL; MacLennan, DH				Pan, Y; Zvaritch, E; Tupling, AR; Rice, WJ; de Leon, S; Rudnick, M; McKerlie, C; Banwell, BL; MacLennan, DH			Targeted disruption of the ATP2A1 gene encoding the sarco(endo)plasmic reticulum Ca2+ ATPase isoform 1 (SERCA1) impairs diaphragm function and is lethal in neonatal mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; BRODY-DISEASE; CARDIAC CONTRACTILITY; MESSENGER-RNA; CA-2+ ATPASE; CA2+-ATPASE; EXPRESSION; HEART; RAT	Mutations in the ATP2A1 gene, encoding isoform I of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA1), are one cause of Brody disease, characterized in humans by exercise-induced contraction of fast twitch (type 11) skeletal muscle fibers. In an attempt to create a model for Brody disease, the mouse ATP2A1 gene was targeted to generate a SERCA1-null mutant mouse line. In contrast to humans, term SERCA1-null mice had progressive cyanosis and gasping respiration and succumbed from respiratory failure shortly after birth. The percentage of affected homozygote SERCA1(-/-) mice was consistent with predicted Mendelian inheritance. A survey of multiple organs from 10-, 15-, and 18-day embryos reirealed no morphological abnormalities, but analysis of the lungs in term mice revealed diffuse congestion and epithelial hypercellularity and studies of the diaphragm muscle revealed prominent hypercontracted regions in scattered fibers and increased fiber size variability. The V-max of Ca2+ transport activity in mutant diaphragm and skeletal muscle was reduced by 80% compared with wild-type muscle, and the contractile response to electrical stimulation under physiological conditions was reduced dramatically in mutant diaphragm muscle. No compensatory responses were detected in analysis of mRNAs encoding other Ca2+ handling proteins or of protein levels. Expression of ATP2A1 is largely restricted to type 11 fibers, which predominate in normal mouse diaphragm. The absence of SERCA1 in type II fibers, and the absence of compensatory increases in other Ca2+ handling proteins, coupled with the marked increase in contractile function required of the diaphragm muscle to support postnatal respiration, can account for respiratory failure in term SERCA1-null mice.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Banting Inst, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Hosp Sick Children, Dept Pediat Neurol, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.			Rudnicki, Michael/0000-0002-3866-5249; McKerlie, Colin/0000-0002-2232-0967; Rice, William/0000-0002-5187-255X; Tupling, A. Russell/0000-0002-3895-6767				ARAI M, 1992, AM J PHYSIOL, V262, P614; ARMSTRONG RB, 1991, SPORTS MED, V12, P184, DOI 10.2165/00007256-199112030-00004; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BENDERS AAGM, 1994, J CLIN INVEST, V94, P741, DOI 10.1172/JCI117393; Bernhard W, 2001, AM J RESP CELL MOL, V25, P725, DOI 10.1165/ajrcmb.25.6.4616; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRODY IA, 1969, NEW ENGL J MED, V281, P187, DOI 10.1056/NEJM196907242810403; BURK SE, 1989, J BIOL CHEM, V264, P18561; DANON MJ, 1988, NEUROLOGY, V38, P812, DOI 10.1212/WNL.38.5.812; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fournier M, 2000, AM J PHYSIOL-ENDOC M, V278, pE707, DOI 10.1152/ajpendo.2000.278.4.E707; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; HOU PCL, 1989, RESP PHYSIOL, V78, P265, DOI 10.1016/0034-5687(89)90103-5; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KARPATI G, 1986, ANN NEUROL, V20, P38, DOI 10.1002/ana.410200108; KARPATI G, 1999, EXERCISE INTOLERANCE, P45; KOLBECK RC, 1994, J APPL PHYSIOL, V77, P1991, DOI 10.1152/jappl.1994.77.4.1991; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Mortola J. P., 2001, RESP PHYSL NEWBORN M; Neville C, 1997, METHOD CELL BIOL, V52, P85, DOI 10.1016/S0091-679X(08)60375-1; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Odermatt A, 2000, HUM GENET, V106, P482, DOI 10.1007/s004390000297; Ortenblad N, 2000, J APPL PHYSIOL, V89, P210; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7; Pette D, 2001, HISTOCHEM CELL BIOL, V115, P359, DOI 10.1007/s004180100268; SCHWARTZ WN, 1977, BIOCHEM J, V167, P811, DOI 10.1042/bj1670811; Takekura H, 2001, DEV BIOL, V239, P204, DOI 10.1006/dbio.2001.0437; TAYLOR DJ, 1988, J NEUROL NEUROSUR PS, V51, P1425, DOI 10.1136/jnnp.51.11.1425; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WEVERS RA, 1992, J INHERIT METAB DIS, V15, P423, DOI 10.1007/BF02435994; Williams JH, 1997, J APPL PHYSIOL, V83, P444, DOI 10.1152/jappl.1997.83.2.444; WU KD, 1993, AM J PHYSIOL, V264, P333; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	46	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13367	13375		10.1074/jbc.M213228200	http://dx.doi.org/10.1074/jbc.M213228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556521	hybrid			2022-12-27	WOS:000182189500098
J	Weber, J; Wilke-Mounts, S; Senior, AE				Weber, J; Wilke-Mounts, S; Senior, AE			Identification of the F-1-binding surface on the delta-Subunit of ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVITY CONFERRING PROTEIN; B-SUBUNIT; F1F0-ATP SYNTHASE; ALPHA-SUBUNIT; CROSS-LINKING; H+-ATPASE; BINDING; F1; DOMAIN; STATOR	The stator function in ATP synthase was studied by a combined mutagenesis and fluorescence approach. Specifically, binding of delta-subunit to delta-depleted F-1 was studied. A plausible binding surface on delta-subunit was identified from conservation of amino acid sequence and the high resolution NMR structure. Specific mutations aimed at modulating binding were introduced onto this surface. Affinity of binding of wild-type and mutant delta-subunits to delta-depleted F-1 was determined quantitatively using the fluorescence signals of natural delta-Trp-28, inserted delta-Trp-11, or inserted delta-Trp-79. The results demonstrate that helices 1 and 5 in the N-terminal domain of the delta-subunit provide the F-1-binding surface of delta. Unexpectedly, mutations that impaired binding between F-1 and delta were found to not necessarily mpair ATP synthase activity. Further investigation revealed that inclusion of the soluble cytoplasmic domain of the b subunit substantially enhanced affinity of binding of delta-subunit to F-1. The new data show that the stator is "overengineered" to resist rotor torque during catalysis.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Covell DG, 1997, J MOL BIOL, V269, P281, DOI 10.1006/jmbi.1997.1028; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; DeLano W.L, PYMOL MOL GRAPHICS S; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; Golden TR, 1998, BIOCHEMISTRY-US, V37, P13871, DOI 10.1021/bi981120a; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; HAZARD AL, 1994, J BIOL CHEM, V269, P418; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rubinstein JL, 2002, J MOL BIOL, V321, P613, DOI 10.1016/S0022-2836(02)00671-X; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	31	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13409	13416		10.1074/jbc.M212037200	http://dx.doi.org/10.1074/jbc.M212037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556473	hybrid			2022-12-27	WOS:000182189500103
J	Wu, DH; Govindasamy, L; Lian, W; Gu, YR; Kukar, T; Agbandje-McKenna, M; McKenna, R				Wu, DH; Govindasamy, L; Lian, W; Gu, YR; Kukar, T; Agbandje-McKenna, M; McKenna, R			Structure of human carnitine acetyltransferase - Molecular basis for fatty acyl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MALONYL-COA SENSITIVITY; ELECTRON-DENSITY MAPS; PALMITOYLTRANSFERASE-I; CHLORAMPHENICOL ACETYLTRANSFERASE; CATALYTIC-ACTIVITY; HISTIDINE RESIDUE; ATOMIC-STRUCTURE; CDNA CLONING; PROTEIN	Carnitine acyltransferases are a family of ubiquitous enzymes that play a pivotal role in cellular energy metabolism. We report here the x-ray structure of human carnitine acetyltransferase to a 1.6-Angstrom resolution. This structure reveals a monomeric protein of two equally sized alpha/beta domains. Each domain is shown to have a partially similar fold to other known but oligomeric enzymes that are also involved in group-transfer reactions. The unique monomeric arrangement of the two domains constitutes a central narrow active site tunnel, indicating a likely universal feature for all members of the carnitine acyltransferase family. Superimposition of the substrate complex of a related protein, dihydrolipoyl trans-acetylase, reveals that both substrates localize to the active site tunnel of human carnitine acetyltransferase, suggesting the location of the ligand binding sites for carnitine and coenzyme A. Most significantly, this structure provides critical insights into the molecular basis for fatty acyl chain transfer and a possible common mechanism among a wide range of acyltransferases utilizing a catalytic dyad.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	McKenna, R (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.	rmckenna@ufl.edu	Kukar, Thomas/AAW-2612-2021	Kukar, Thomas/0000-0002-3750-6262	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058197] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM58197] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BROWN NF, 1994, J BIOL CHEM, V269, P19157; BROWN NF, 1994, J BIOL CHEM, V269, P26438; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHASE JFA, 1970, BIOCHEM J, V116, P713, DOI 10.1042/bj1160713; CHASE JFA, 1966, BIOCHEM J, V99, P32, DOI 10.1042/bj0990032; CORTI O, 1994, GENOMICS, V23, P94, DOI 10.1006/geno.1994.1463; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V238, P784, DOI 10.1006/bbrc.1997.7390; Cronin CN, 1997, EUR J BIOCHEM, V247, P1029, DOI 10.1111/j.1432-1033.1997.01029.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Lian W, 2002, ACTA CRYSTALLOGR D, V58, P1193, DOI 10.1107/S0907444902005498; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; MOMANY C, 1995, J MOL BIOL, V252, P643, DOI 10.1006/jmbi.1995.0526; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; Ramsay RR, 2000, BIOCHEM SOC T, V28, P182, DOI 10.1042/bst0280182; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; RAMSAY RR, 1993, ARCH BIOCHEM BIOPHYS, V302, P307, DOI 10.1006/abbi.1993.1216; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P131; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wagman AS, 2001, CURR PHARM DESIGN, V7, P417, DOI 10.2174/1381612013397915; WU DH, 1993, J NEUROCHEM, V61, P1416, DOI 10.1111/j.1471-4159.1993.tb13635.x; Zarain-Herzberg A, 2002, EXPERT OPIN INV DRUG, V11, P345	39	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13159	13165		10.1074/jbc.M212356200	http://dx.doi.org/10.1074/jbc.M212356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562770	hybrid			2022-12-27	WOS:000182189500073
J	DeVries, ME; Cao, HN; Wang, J; Xu, LL; Kelvin, AA; Ran, LS; Chau, LA; Madrenas, J; Hegele, RA; Kelvin, DJ				DeVries, ME; Cao, HN; Wang, J; Xu, LL; Kelvin, AA; Ran, LS; Chau, LA; Madrenas, J; Hegele, RA; Kelvin, DJ			Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; HUMAN MONOCYTE; CUTTING EDGE; VMIP-I; CC; I-309; IDENTIFICATION; PROMOTER; GENE; POLYMORPHISM	The chemokine receptors CCR8 and CX3CR1 are key players in adaptive immunity and are co-receptors for human immunodeficiency virus. We describe here the genomic organization and evolutionary history of both of these genes. CX3CR1 has three promoters that transcribe three separate exons that are spliced with a fourth exon containing the coding region. CCR8 has two promoters. One promoter produces a transcript of two spliced exons, and the other promoter transcribes an exon containing the coding region and lacks introns. We analyzed these promoters in the context of a luciferase reporter and identified several positive and negative regulatory elements. Identification of the genomic organization of these genes in mouse demonstrates a similar organization for CCR8, but mouse CX3CR1 lacks two of the human promoters and has an additional mouse-specific promoter that transcribes only the exon containing the coding region and therefore resembles the organization of the human and mouse CCR8 genes. We also identify two nontranscribed regions that are highly conserved between human and mouse CX3CR1 containing possible regulatory elements. Examination of the CX3CR1 and CCR8 genes and surrounding genomic regions indicates that these genes are the result of the duplication of an ancestral gene prior to the divergence of teleost fish. We characterize single nucleotide polymorphisms in the promoters of human CCR8 and CX3CR1 and establish linkage relationships between CX3CR1 promoter polymorphisms and two previously described CX3CR1 coding polymorphisms associated with human immunodeficiency virus disease progression and arteriosclerosis susceptibility.	Univ Toronto, Div Expt Therapeut, Toronto Gen Hosp, Toronto Gen Res Inst,Hlth Network, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Immunol, Toronto Gen Hosp, Toronto Gen Res Inst,Hlth Network, Toronto, ON M5G 2C4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Robarts Res Inst, London, ON N6G 2V4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Kelvin, DJ (corresponding author), Univ Toronto, Div Expt Therapeut, 200 Elizabeth St,MBRC5R425, Toronto, ON M5G 2C4, Canada.		Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020; Madrenas, Quim/P-5008-2019	Hegele, Robert/0000-0003-2861-5325; 				AHUJA SK, 1994, J BIOL CHEM, V269, P26381; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Foussat A, 2001, BLOOD, V98, P1678, DOI 10.1182/blood.V98.6.1678; GARIN A, 2002, BIOCHEM J, V15, P753; Goya I, 1998, J IMMUNOL, V160, P1975; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; HEGELE RA, 1990, GENET EPIDEMIOL, V7, P69, DOI 10.1002/gepi.1370070114; Hendel H, 2001, J ACQ IMMUN DEF SYND, V26, P507, DOI 10.1097/00126334-200104150-00019; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; Jinno A, 1998, BIOCHEM BIOPH RES CO, V243, P497, DOI 10.1006/bbrc.1998.8130; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; McDermott D H, 2000, Science, V290, P2031; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Moriuchi M, 1997, J IMMUNOL, V159, P4322; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Randolph DA, 1999, SCIENCE, V286, P2159, DOI 10.1126/science.286.5447.2159; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Yamamoto K, 1999, J BIOL CHEM, V274, P4646, DOI 10.1074/jbc.274.8.4646; Zimmermann N, 2000, BLOOD, V96, P2346; Zingoni A, 1998, J IMMUNOL, V161, P547	41	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11985	11994		10.1074/jbc.M211422200	http://dx.doi.org/10.1074/jbc.M211422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551893	hybrid			2022-12-27	WOS:000182015700036
J	Kahler, RA; Westendorf, JJ				Kahler, RA; Westendorf, JJ			Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; RECEPTOR-RELATED PROTEIN-5; LEUKEMIA-VIRUS ENHANCERS; CLEIDOCRANIAL DYSPLASIA; SIGNAL-TRANSDUCTION; BONE-FORMATION; DNA-BINDING; OSTEOBLAST DIFFERENTIATION; EMBRYONIC-DEVELOPMENT; COLON-CANCER	Functional control of the transcription factor Runx2 is crucial for normal bone formation. Runx2 is detectable throughout osteoblast development and maturation and temporally regulates several bone-specific genes. In this study, we identified a novel post-translational mechanism regulating Runx2-dependent activation of the osteocalcin promoter. A functional binding site for the high mobility group protein lymphoid enhancer-binding factor 1 (LEF1) was found adjacent to the proximal Runx2-binding site in the osteocalcin promoter. In transcription assays, LEF1 repressed Runx2-induced activation of the mouse osteocalcin 2 promoter in several osteoblast lineage cell lines. Mutations in the LEF1-binding site increased the basal activity of the osteocalcin promoter; however, the LEF1 recognition site in the osteocalcin promoter was surprisingly not required for LEF1 repression. A novel interaction between the DNA-binding domains of Runx2 and LEF1 was identified and found crucial for LEF1-mediated repression of Runx2. LEF1 is a nuclear effector of the Wnt/LRP5/beta-catenin signaling pathway, which is also essential for osteoblast proliferation and normal skeletal development. A constitutively active beta-catenin enhanced LEF1-dependent repression of Runx2. These data identify a novel mechanism of regulating Runx2 activity in osteoblasts and link Runx2 transcriptional activity to beta-catenin signaling.	Univ Minnesota, Ctr Canc, Dept Orthopaed Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Grad Program Microbiol Immunol & Canc Biol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Westendorf, JJ (corresponding author), Univ Minnesota, Ctr Canc, Dept Orthopaed Surg, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	weste047@umn.edu						Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Bejsovec A, 1999, CURR BIOL, V9, pR684, DOI 10.1016/S0960-9822(99)80439-4; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Cadigan KM, 2002, DEVELOPMENT, V129, P3393; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Ezashi T, 2001, MOL CELL BIOL, V21, P7883, DOI 10.1128/MCB.21.23.7883-7891.2001; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hetman M, 2000, J NEUROSCI, V20, P2567; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Latchman DS, 1996, INT J BIOCHEM CELL B, V28, P965, DOI 10.1016/1357-2725(96)00039-8; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Peifer M, 1999, NATURE, V400, P213, DOI 10.1038/22214; Piepenburg O, 2000, MOL CELL, V6, P203, DOI 10.1016/S1097-2765(00)00022-8; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Van Hul E, 2002, J BONE MINER RES, V17, P1111, DOI 10.1359/jbmr.2002.17.6.1111; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Yang X, 2000, DEVELOPMENT, V127, P3695; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang J, 1998, DEVELOPMENT, V125, P3075; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	68	161	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11937	11944		10.1074/jbc.M211443200	http://dx.doi.org/10.1074/jbc.M211443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551949	hybrid			2022-12-27	WOS:000182015700030
J	O'Brien, KB; Argetsinger, LS; Diakonova, M; Carter-Su, C				O'Brien, KB; Argetsinger, LS; Diakonova, M; Carter-Su, C			YXXL motifs in SH2-B beta are phosphorylated by JAK2, JAK1, and platelet-derived growth factor receptor and are required for membrane ruffling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; STAT5 ACTIVATION; ADAPTER PROTEIN; SH2 DOMAIN; FACTOR-I; HORMONE; BINDING; IDENTIFICATION	SH2-Bbeta binds to the activated form of JAK2 and various receptor tyrosine kinases. It is a potent stimulator of JAK2, is required for growth hormone (GH)-induced membrane ruffling, and increases mitogenesis stimulated by platelet-derived growth factor (PDGF) and insulin-like growth factor I. Its domain structure suggests that SH2-Bbeta may act as an adapter protein to recruit downstream signaling proteins to kinase-SH2-Bbeta complexes. SH2-Bbeta is tyrosyl-phosphorylated in response to GH and interferon-gamma, stimulators of JAK2, as well as in response to PDGF and nerve growth factor. To begin to elucidate the role of tyrosyl phosphorylation in the function of SH2-Bbeta, we used phosphopeptide mapping, mutagenesis, and a phosphotyrosine-specific antibody to identify Tyr-439 and Tyr-494 in SH2-Bbeta as targets of JAK2 both in vitro and in intact cells. SH2-Bbeta lacking Tyr-439 and Tyr-494 inhibits GH-induced membrane ruffling but still activates JAK2. We provide evidence that JAK1, like JAK2, phosphorylates Tyr-439 and Tyr-494 in SH2-Bbeta and that PDGF receptor phosphorylates SH2-Bbeta on Tyr-439. Therefore, phosphorylated Tyr-439 and/or Tyr-494 in SH2-Bbeta may provide a binding site for one or more proteins linking cytokine receptor JAK2 complexes and/or receptor tyrosine kinases to the actin cytoskeleton.	Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 49109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 48109 USA.	cartersu@umich.edu		Diakonova, Maria/0000-0002-4554-2730	NCI NIH HHS [P30-CA46592] Funding Source: Medline; NIDDK NIH HHS [P60-DK20572, R01-DK54222, R37 DK034171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, R01DK054222, R37DK034171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Diakonova M, 2002, J BIOL CHEM, V277, P10669, DOI 10.1074/jbc.M111138200; Gergely J, 1999, IMMUNOL LETT, V68, P3, DOI 10.1016/S0165-2478(99)00024-3; Goh ELK, 2000, J BIOL CHEM, V275, P17683, DOI 10.1074/jbc.M001972200; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Herrington J, 2000, J BIOL CHEM, V275, P13126, DOI 10.1074/jbc.275.17.13126; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Brien KB, 2002, J BIOL CHEM, V277, P8673, DOI 10.1074/jbc.M109165200; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Pandey A, 2002, ONCOGENE, V21, P8029, DOI 10.1038/sj.onc.1205988; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Riedel H, 2000, ONCOGENE, V19, P39, DOI 10.1038/sj.onc.1203253; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1999, J BIOL CHEM, V274, P26485, DOI 10.1074/jbc.274.37.26485; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Yousaf N, 2001, J BIOL CHEM, V276, P40940, DOI 10.1074/jbc.M104191200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	38	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11970	11978		10.1074/jbc.M210765200	http://dx.doi.org/10.1074/jbc.M210765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551917	hybrid			2022-12-27	WOS:000182015700034
J	Vander Kooi, BT; Streeper, RS; Svitek, CA; Oeser, JK; Powell, DR; O'Brien, RM				Vander Kooi, BT; Streeper, RS; Svitek, CA; Oeser, JK; Powell, DR; O'Brien, RM			The three insulin response sequences in the glucose-6-phosphatase catalytic subunit gene promoter are functionally distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; TRANSCRIPTION FACTOR FKHR; NUCLEAR FACTOR-I; PHOSPHOENOLPYRUVATE CARBOXYKINASE; FORKHEAD TRANSCRIPTION; KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE; PEPCK GENE; PROXIMAL PROMOTER; MAMMALIAN TARGET	Glucose-6-phosphatase catalyzes the terminal step in the gluconeogenic and glycogenolytic pathways. In HepG2 cells, the maximum repression of basal glucose-6-phosphatase catalytic subunit (G6Pase) gene transcription by insulin requires two distinct promoter regions, designated A (located between -231 and -199) and B (located between -198 and -159), that together form an insulin response unit. Region A binds hepatocyte nuclear factor-1, which acts as an accessory factor to enhance the effect of insulin, mediated through region B, on G6Pase gene transcription. We have previously shown that region B binds the transcriptional activator FKHR (FOXO1a) in vitro. Chromatin immunoprecipitation assays demonstrate that FKHR also binds the G6Pase promoter in situ and that insulin inhibits this binding. Region B contains three insulin response sequences (IRSs), designated IRS 1, 2, and 3, that share the core sequence T(G/A)TTTT. However, detailed analyses reveal that these three G6Pase IRSs are functionally distinct. Thus, FKHR binds IRS 1 with high affinity and IRS 2 with low affinity but it does not bind IRS 3. Moreover, in the context of the G6Pase promoter, IRS I and 2, but not IRS 3, are required for the insulin response. Surprisingly, IRS 3, as well as IRS 1 and IRS 2, can each confer an inhibitory effect of insulin on the expression of a heterologous fusion gene, indicating that, in this context, a transcription factor other than FKHR, or its orthologs, can also mediate an insulin response through the T(G/A)TTTT motif.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Vanderbilt University; Baylor College of Medicine	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 761 PRB,MRB 2Hall, Nashville, TN 37232 USA.				NIDDK NIH HHS [P60 DK20593, DK56374, 5 T 32 DK07563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, T32DK007563, R01DK056374] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Band CJ, 1997, J BIOL CHEM, V272, P138; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; CONSOLI A, 1992, DIABETES CARE, V15, P430, DOI 10.2337/diacare.15.3.430; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Kaestner KH, 2000, GENE DEV, V14, P142; Khan A, 1998, METABOLISM, V47, P627, DOI 10.1016/S0026-0495(98)90021-X; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; MARTIN CC, 2003, IN PRESS BIOCH J; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBrien RM, 1995, BBA-GENE STRUCT EXPR, V1264, P284, DOI 10.1016/0167-4781(95)00194-8; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Patel S, 2002, BIOCHEM J, V365, P537, DOI 10.1042/BJ20020266; Patel S, 2002, J BIOL CHEM, V277, P9889, DOI 10.1074/jbc.M109870200; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 2000, J BIOL CHEM, V275, P12108, DOI 10.1074/jbc.275.16.12108; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200	86	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11782	11793		10.1074/jbc.M212570200	http://dx.doi.org/10.1074/jbc.M212570200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556524	hybrid			2022-12-27	WOS:000182015700010
J	Wu, GS; Olivecrona, G; Olivecrona, T				Wu, GS; Olivecrona, G; Olivecrona, T			The distribution of lipoprotein lipase in rat adipose tissue - Changes with nutritional state engage the extracellular enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG TISSUES; ADIPOCYTES; METABOLISM; STARVATION; MECHANISMS; EXPRESSION; INSULIN; MUSCLE; CELLS; HEART	Lipoprotein lipase (LPL) acts at the vascular endothelium. Earlier studies have shown that down-regulation of adipose tissue LPL during fasting is post-translational and involves a shift from active to inactive forms of the lipase. Studies in cell systems had indicated that during fasting LPL might be retained in the endoplasmic reticulum. We have now explored the relation between active/inactive and intra/extracellular forms of the lipase. Within adipocytes, neither LPL mass nor the distribution of LPL between active and inactive forms changed on fasting. Extracellular LPL mass also did not change significantly, but shifted from predominantly active to predominantly inactive. To explore if changes in secretion were compensated by changes in turnover, synthesis of new protein was blocked by cycloheximide. The rates at which intra- and extracellular LPL mass and activity decreased did not change on fasting. To further explore how LPL is distributed in the tissue, heparin (which detaches the enzyme from the endothelial surface) was injected. Tissue LPL activity decreased by about 10% in 2 min and by 50% in 1 h. Heparin released mainly the active form of the lipase. There was no change of LPL activity or mass within adipocytes. The fraction of extracellular LPL that heparin released and the time course were the same in fed and fasted rats, indicating that active, extracellular LPL was distributed in a similar way in the two nutritional states. This study suggests that the nutritional regulation of LPL in adipose tissue determines the activity state of extracellular LPL.	Umea Univ, Dept Med Biosci, SE-90185 Umea, Sweden	Umea University	Olivecrona, T (corresponding author), Umea Univ, Dept Med Biosci, Bldg 6M,3rd Floor, SE-90185 Umea, Sweden.	Thomas.Olivecrona@medbio.umu.se						Ben-Zeev O, 2002, J BIOL CHEM, V277, P10727, DOI 10.1074/jbc.M108128200; Bergo M, 2002, J BIOL CHEM, V277, P11927, DOI 10.1074/jbc.M200325200; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BORENSZTAJN J, 1987, LIPOPROTEIN LIPASE, P133; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; CRYER A, 1975, BIOCHEM J, V146, P481, DOI 10.1042/bj1460481; CRYER A, 1973, BIOCHEM J, V132, P833, DOI 10.1042/bj1320833; CRYER A, 1976, CLIN SCI MOL MED, V50, P213, DOI 10.1042/cs0500213; CUNNINGHAM VJ, 1969, BIOCHEM J, V112, P203, DOI 10.1042/bj1120203; CUPP M, 1987, J BIOL CHEM, V262, P6383; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; ENERBACK S, 1988, GENE, V64, P97, DOI 10.1016/0378-1119(88)90484-2; ERSKINE JM, 1994, J NUTR, V124, P500, DOI 10.1093/jn/124.4.500; FRIEDMAN G, 1982, BIOCHIM BIOPHYS ACTA, V711, P114, DOI 10.1016/0005-2760(82)90016-9; GARFINKEL AS, 1976, BIOCHIM BIOPHYS ACTA, V424, P264, DOI 10.1016/0005-2760(76)90194-6; Goldberg IJ, 1996, J LIPID RES, V37, P693; HOLLENBERG CH, 1959, AM J PHYSIOL, V197, P667, DOI 10.1152/ajplegacy.1959.197.3.667; KUWAJIMA M, 1988, METABOLISM, V37, P597, DOI 10.1016/0026-0495(88)90178-3; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LASUNCION MA, 1983, BIOCHEM J, V210, P639, DOI 10.1042/bj2100639; Lee JJ, 1998, J NUTR, V128, P940, DOI 10.1093/jn/128.6.940; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; Olivecrona G, 1997, METHOD ENZYMOL, V286, P102; OLIVECRONA G, 1995, ATHEROSCLEROSIS, V10; Olivecrona T, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P223; Ong JM, 1995, METABOLISM, V44, P1596, DOI 10.1016/0026-0495(95)90081-0; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Roh C, 2001, J BIOL CHEM, V276, P35990, DOI 10.1074/jbc.M102791200; SCHOTZ MC, 1965, BIOCHIM BIOPHYS ACTA, V106, P202, DOI 10.1016/0005-2760(65)90109-8; SEMB H, 1986, BIOCHIM BIOPHYS ACTA, V878, P330, DOI 10.1016/0005-2760(86)90240-7; SEMB H, 1986, BIOCHIM BIOPHYS ACTA, V876, P249, DOI 10.1016/0005-2760(86)90281-X; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SPEAKE BK, 1985, BIOCHIM BIOPHYS ACTA, V840, P419, DOI 10.1016/0304-4165(85)90223-5; SPENCER IM, 1978, BIOCHIM BIOPHYS ACTA, V530, P375, DOI 10.1016/0005-2760(78)90157-1; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; TERRETTAZ J, 1994, INT J OBESITY, V18, P9	39	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11925	11930		10.1074/jbc.M212736200	http://dx.doi.org/10.1074/jbc.M212736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551943	hybrid			2022-12-27	WOS:000182015700028
J	Maniscalco, SJ; Tally, JF; Harris, SW; Fisher, HF				Maniscalco, SJ; Tally, JF; Harris, SW; Fisher, HF			The direct measurement of thermodynamic parameters of reactive transient intermediates of the L-glutamate dehydrogenase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; LOCATION; PATHWAY	In a previous report (Fisher, H. F., Maniscalco, S. J., and Tally, J. (2002) Biochem. Biophys. Res. Commun. 287, 343347) we demonstrated the capability of the "Le Chatelier forcing method" of producing stable solutions containing substantial amounts of transitory enzyme intermediate complexes that can otherwise be observed only fleetingly in the millisecond time range. The method requires nothing more than running an enzyme reaction using forcing concentrations of reactants against an equally forcing concentration of products until equilibrium is attained. Here we have applied this approach to the measurement of the thermodynamics of several such reactive (and normally transient) intermediate complexes of the bovine liver L-glutamate dehydrogenase-catalyzed reaction. At pH 9.5 and 20 degreesC, we observe both the enzyme-NADPH-alpha-iminoglutarate and enzyme-NADPH-a-carbinolamine complexes at concentrations whose sum accounts for 70% of the total enzyme. The pH dependence of these two complexes under equilibrium conditions provides thermodynamic parameters for both the protonated and the unprotonated forms of each of these two entities as well as those of the enzyme-NADP-L-glutamate complex. The equilibrium concentrations of each of these reactive complexes are compared with their corresponding transient steady-state values.	Vet Affairs Med Ctr, Res Serv, Lab Mol Biochem, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Biochem, Kansas City, MO 64128 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas	Fisher, HF (corresponding author), Vet Affairs Med Ctr, Res Serv, Lab Mol Biochem, 4801 Linwood Blvd, Kansas City, MO 64128 USA.							ANDERSON KS, 1990, BIOCHEMISTRY-US, V29, P1460, DOI 10.1021/bi00458a017; BRUNHUBER NMW, 1994, CRIT REV BIOCHEM MOL, V29, P415, DOI 10.3109/10409239409083486; Fisher HF, 2002, BIOORG CHEM, V30, P199, DOI 10.1006/bioo.2002.1243; Fisher HF, 2001, BIOCHEM BIOPH RES CO, V287, P343, DOI 10.1006/bbrc.2001.5592; Maniscalco SJ, 1998, BIOCHEMISTRY-US, V37, P14585, DOI 10.1021/bi980923v; Maniscalco SJ, 1996, BIOCHEMISTRY-US, V35, P89, DOI 10.1021/bi9509098; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; PISZKIEW.D, 1970, J BIOL CHEM, V245, P2622; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; SAHA SK, 1994, J BIOL CHEM, V269, P29592; Saha SK, 1999, BBA-PROTEIN STRUCT M, V1431, P261, DOI 10.1016/S0167-4838(99)00040-0; SUBRAMANIAN S, 1978, BIOPHYS CHEM, V7, P375, DOI 10.1016/0301-4622(78)85013-3; Tally JF, 2002, BIOCHEMISTRY-US, V41, P11284, DOI 10.1021/bi0202068	13	3	3	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16129	16134		10.1074/jbc.M300692200	http://dx.doi.org/10.1074/jbc.M300692200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12578821	hybrid			2022-12-27	WOS:000182680000085
J	Gilberger, TW; Thompson, JK; Triglia, T; Good, RT; Duraisingh, MT; Cowman, AF				Gilberger, TW; Thompson, JK; Triglia, T; Good, RT; Duraisingh, MT; Cowman, AF			A novel erythrocyte binding antigen-175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; GLYCOPHORIN-B; INVASION; RECOMBINATION; PROTEIN; MEROZOITES; EBA-175; GENOME; SEQUENCES; FAMILY	The recognition and invasion of human erythrocytes by the most lethal malaria parasite Plasmodium falciparum is dependent on multiple ligand-receptor interactions. Members of the erythrocyte binding-like (ebl) family, including the erythrocyte binding antigen-175 (EBA-175), are responsible for high affinity binding to glycoproteins on the surface of the erythrocyte. Here we describe a paralogue of EBA-175 and show that this protein (EBA-181/JESEBL) binds in a sialic acid-dependent manner to erythrocytes. EBA-181 is expressed at the same time as EBA-175 and co-localizes with this protein in the microneme organelles of asexual stage parasites. The receptor binding specificity of EBA-181 to erythrocytes differs from other members of the ebl family and is trypsin-resistant and chymotrypsin-sensitive. Furthermore, using glycophorin B-deficient erythrocytes we show that binding of EBA-181 is not dependent on this sialoglycoprotein. The level of expression of EBA-181 differs among parasite lines, and the importance of this ligand for invasion appears to be strain-dependent as the EBA-181 gene can be disrupted in W2mef parasites, without affecting the invasion phenotype, but cannot be targeted in 3D7 parasites.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.		Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004; Gilberger, Tim-Wolf/0000-0002-7965-8272				Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1; ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; Barnwell John W., 1998, P93; BIANCO AE, 1986, P NATL ACAD SCI USA, V83, P8713, DOI 10.1073/pnas.83.22.8713; Butler D, 2002, NATURE, V419, P426, DOI 10.1038/419426a; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; Chitnis CE, 2000, PARASITOL TODAY, V16, P411, DOI 10.1016/S0169-4758(00)01756-7; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; Cowman AF, 2002, SCIENCE, V298, P126, DOI 10.1126/science.1078169; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Duraisingh MT, 2002, INT J PARASITOL, V32, P81, DOI 10.1016/S0020-7519(01)00345-9; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; KAIN KC, 1993, J EXP MED, V178, P1497, DOI 10.1084/jem.178.5.1497; Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; Michon P, 2002, MOL BIOL EVOL, V19, P1128, DOI 10.1093/oxfordjournals.molbev.a004171; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Narum DL, 2002, MOL BIOCHEM PARASIT, V119, P159, DOI 10.1016/S0166-6851(01)00428-5; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SIM BKL, 1990, MOL BIOCHEM PARASIT, V41, P293, DOI 10.1016/0166-6851(90)90193-P; SIM BKL, 1994, EXP PARASITOL, V78, P259, DOI 10.1006/expr.1994.1027; SIM BKL, 1992, MOL BIOCHEM PARASIT, V51, P157, DOI 10.1016/0166-6851(92)90211-2; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Triglia T, 2001, MOL BIOCHEM PARASIT, V116, P55, DOI 10.1016/S0166-6851(01)00303-6; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	35	149	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14480	14486		10.1074/jbc.M211446200	http://dx.doi.org/10.1074/jbc.M211446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556470	hybrid			2022-12-27	WOS:000182405000115
J	Galvan, V; Logvinova, A; Sperandio, S; Ichijo, H; Bredesen, DE				Galvan, V; Logvinova, A; Sperandio, S; Ichijo, H; Bredesen, DE			Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASES; INDUCED ACTIVATION; DEATH; CELL; PATHWAY; AKT; TRANSDUCTION; REQUIREMENT; THIOREDOXIN; LIGAND	The type 1 insulin-like growth factor receptor (IGF-IR) is a receptor-tyrosine kinase that plays a critical role in signaling cell survival and proliferation. IGF-IR binding to its ligand, insulin-like growth factor (IGF-1) activates phosphoinositide 3-kinase (PI3K), promotes cell proliferation by activating the mitogen-activated protein kinase (MAPK) cascade, and blocks apoptosis by inducing the phosphorylation and inhibition of proapoptotic proteins such as BAD. Apoptosis signal-regulating kinase 1 (ASK1) is a MAP kinase kinase kinase (MAPKKK) that is required for c-Jun N-terminal kinase (JNK) and p38 activation in response to Fas and tumor necrosis factor (TNF) receptor stimulation, and for oxidative stress- and TNFalpha-induced apoptosis. The results presented here indicate that ASK1 forms a complex with the IGF-IR and becomes phosphorylated on tyrosine residue(s) in a manner dependent on IGF-IR activity. IGF-IR signaling inhibited ASK1 irrespective of TNFalpha-induced ASK1 activation and resulted in decreasedASKIdependent JNK1 stimulation. Signaling through IGF-IR rescued cells from ASK1-induced apoptotic cell death in a manner independent of PI3K activity. These results indicate that IGF-IR signaling suppresses the ASK-1-mediated stimulation of JNK/p38 and the induction of programmed cell death. The simultaneous activation of MAP kinases and the inhibition of the stress-activated arm of the cascade by IGF-IR may constitute a potent proliferative signaling system and is possibly a mechanism by which IGF-I can stimulate growth and inhibit cell death in a wide variety of cell types and biological settings.	Buck Inst Age Res, Novato, CA 94945 USA; Tokyo Med & Dent Univ, Lab Cell Signaling, Grad Sch, Tokyo 1138549, Japan	Buck Institute for Research on Aging; Tokyo Medical & Dental University (TMDU)	Bredesen, DE (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.			Ichijo, Hidenori/0000-0002-5005-6438				Abe K, 2000, ANN NY ACAD SCI, V926, P52; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Gatzka M, 2000, CANCER RES, V60, P4222; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Holzenberger M, 2001, ENDOCRINOLOGY, V142, P4469, DOI 10.1210/en.142.10.4469; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Nicholas RS, 2002, J NEUROIMMUNOL, V124, P36, DOI 10.1016/S0165-5728(02)00011-5; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Parrizas M, 1997, J BIOL CHEM, V272, P154; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200	32	68	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13325	13332		10.1074/jbc.M211398200	http://dx.doi.org/10.1074/jbc.M211398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556535	hybrid			2022-12-27	WOS:000182189500093
J	Gonzalez, T; Seoane, M; Caamano, P; Vinuela, J; Dominguez, F; Zalvide, J				Gonzalez, T; Seoane, M; Caamano, P; Vinuela, J; Dominguez, F; Zalvide, J			Inhibition of Cdk4 activity enhances translation of p27(kip1) in quiescent Rb-negative cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; P27 MESSENGER-RNA; RETINOBLASTOMA PROTEIN; GENE FAMILY; GROWTH; P16(INK4A); CANCER; MICE; D1; TRANSFORMATION	We show in this work that the inhibition of Cdk4 (6) in Rb-l- 3T3 cells enhances the accumulation of the P27(kip1) cyclin-dependent kinase inhibitor when these cells are induced into quiescence. Two different forms of inhibition of Cdk4 (6), namely overexpression of the Cdk4 (6) inhibitor p16 and overexpression of a dominant negative mutant of Cdk4 (Cdk4(N158)), result in this effect. This suggests that the relevant activity of Cdk4 (6) that has to be inactivated in this setting is its kinase activity. The accumulation of p27(kip1) is due to enhanced translation of the protein, mediated by the 3'-untranslated region of the p27 mRNA. Moreover, the cells that overexpress p16(ink4alpha) or Cdk4(N158) show a delay in G(1) when made quiescent and restimulated to proliferate. This delay is overcome by transfection of a plasmid expressing antisense p27(kip1), which shows that the accumulation of P27(kip1) in these cells is related to their G(1) delay. In summary, we report a new functional link between two important cell cycle regulators, Cdk4 and p27(kip1), and provide a mechanistic explanation to the previously reported epistatic relations between these two proteins.	Univ Santiago de Compostela, Fac Med, Dept Fisiol, Santiago De Compostela 15705, A Coruna, Spain; Complejo Hosp Univ Santiago, Unidad Inmunol, Santiago De Compostela 15705, A Coruna, Spain; Complejo Hosp Univ Santiago, Unidad Biol Mol, Santiago De Compostela 15705, A Coruna, Spain	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Zalvide, J (corresponding author), Univ Santiago de Compostela, Fac Med, Dept Fisiol, Santiago De Compostela 15705, A Coruna, Spain.		Souto, Marcos Seoane/I-3380-2018; Zalvide, Juan/ABG-4050-2020	Vinuela, Juan Evaristo/0000-0001-7778-901X; Caamano Vara, Maria del Pilar/0000-0002-0853-3421; Zalvide, Juan/0000-0001-7645-156X				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Savatier P, 1996, ONCOGENE, V12, P309; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	42	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12688	12695		10.1074/jbc.M207530200	http://dx.doi.org/10.1074/jbc.M207530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566456	hybrid			2022-12-27	WOS:000182189500014
J	Huber, TB; Schmidts, M; Gerke, P; Schermer, B; Zahn, A; Hartleben, B; Sellin, L; Walz, G; Benzing, T				Huber, TB; Schmidts, M; Gerke, P; Schermer, B; Zahn, A; Hartleben, B; Sellin, L; Walz, G; Benzing, T			The carboxyl terminus of Neph family members binds to the PDZ domain protein zonula occludens-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLIT DIAPHRAGM; TRANSMEMBRANE PROTEINS; NEPHROTIC SYNDROME; LOCALIZES; PODOCIN; COMPONENT; ZO-1; PHOSPHORYLATION; INTERACTS; MOTIFS	The PSD95/Dlg/(ZO-1 (PDZ) domain-containing protein zonula occludens-1 (ZO-1) selectively localizes to the cytoplasmic basis of the slit diaphragm, a specialized cell-cell contact in between glomerular podocytes necessary to prevent the loss of protein in the urine. However, the function of ZO-1 at the slit diaphragm has remained elusive. Deletion of Neph1, a slit diaphragm protein of the immunoglobulin superfamily with a cytoplasmic PDZ binding site, causes proteinuria in mice. We demonstrate now that Neph1 binds ZO-1. This interaction was mediated by the first PDZ domain of ZO-1 and involved the conserved PDZ domain binding motif present in the carboxyl terminus of the three known Neph family members. Furthermore, Neph1 co-immunoprecipitates with ZO-1 from lysates of mouse kidneys, demonstrating that this interaction occurs in vivo. Both deletion of the PDZ binding motif of Neph1 as well as threonine-to-glutamate mutation of the threonine within the binding motif abrogated binding of ZO-1, suggesting that phosphorylation may regulate this interaction. ZO-1 binding was associated with a strong increase in tyrosine phosphorylation of the cytoplasmic tail of Neph1 and dramatically accelerated the ability of Neph1 to induce signal transduction. Thus, our data suggest that ZO-1 may organize Neph proteins and recruit signal transduction.	Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany; Univ Hosp, D-44625 Herne, Germany	University of Freiburg; Ruhr University Bochum	Walz, G (corresponding author), Univ Hosp Freiburg, Div Renal, Hugstetter Str 55, D-79106 Freiburg, Germany.	walz@med1.ukl.uni-freiburg.de	Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014; Schmidts, Miriam/A-3777-2012	Schermer, Bernhard/0000-0002-5194-9000; Schmidts, Miriam/0000-0002-1714-6749; Huber, Tobias B./0000-0001-7175-5062				Antignac C, 2002, J CLIN INVEST, V109, P447, DOI 10.1172/JC1200215094; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Benzing T, 2000, J BIOL CHEM, V275, P28167; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; Harris BZ, 2001, J CELL SCI, V114, P3219; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Inoue T, 2001, KIDNEY INT, V59, P1003, DOI 10.1046/j.1523-1755.2001.00583.x; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kawachi H, 1997, AM J PHYSIOL-RENAL, V273, pF984, DOI 10.1152/ajprenal.1997.273.6.F984; Kerjaschki D, 2001, J CLIN INVEST, V108, P1583, DOI 10.1172/JCI200114629; KURIHARA H, 1992, AM J PATHOL, V141, P805; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Roselli S, 2002, AM J PATHOL, V160, P131, DOI 10.1016/S0002-9440(10)64357-X; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SCHNABEL E, 1990, J CELL BIOL, V111, P1255, DOI 10.1083/jcb.111.3.1255; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	37	91	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13417	13421		10.1074/jbc.C200678200	http://dx.doi.org/10.1074/jbc.C200678200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12578837	hybrid			2022-12-27	WOS:000182189500104
J	Koehl, C; Knight, CG; Bieth, JG				Koehl, C; Knight, CG; Bieth, JG			Compared action of neutrophil proteinase 3 and elastase on model substrates - Favorable effect of S '-P ' interactions on proteinase 3 catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; PORCINE PANCREATIC ELASTASE; SERINE PROTEINASE; REACTIVE SITE; BINDING-SITE; CATHEPSIN-G; INHIBITOR; PEPTIDE	Neutrophil proteinase 3 (Pr3) and elastase (NE) may cause lung tissue destruction in emphysema and cystic fibrosis. These serine proteinases have similar P-1 specificities. We have compared their catalytic activity using acyl-tetrapeptide-p-nitroanilides, which occupy the S-5-S'(1) subsites of their substrate binding site, and intramolecularly quenched fluorogenic heptapeptides, which bind at S-5-S'(4). Most p-nitroanilide substrates are turned over slowly by Pr3 as compared with NE. These differences disappear with the fluorogenic heptapeptides, some of which are hydrolyzed even faster by Pr3 than by NE. Elongation of substrates strongly increases the catalytic efficiency of Pr3, whereas it has little effect on NE catalysis. These different sensitivities to S'-P' interactions show that Pr3 and NE are not interchangeable enzymes despite their similar P-1 specificity.	Univ Strasbourg 1, INSERM, Enzymol Lab, U392,Fac Pharm, F-67400 Illkirch Graffenstaden, France; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Cambridge	Bieth, JG (corresponding author), Univ Strasbourg 1, INSERM, Enzymol Lab, U392,Fac Pharm, 74 Route Rhin, F-67400 Illkirch Graffenstaden, France.							BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; Boudier C, 2001, BIOCHEMISTRY-US, V40, P9962, DOI 10.1021/bi010701o; BRUBAKER MJ, 1992, BIOCHEM BIOPH RES CO, V188, P1318, DOI 10.1016/0006-291X(92)91375-Z; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; Fruh H, 1996, BIOL CHEM, V377, P579, DOI 10.1515/bchm3.1996.377.9.579; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; HOIDAL JR, 1998, HDB PROTEOLYTIC ENZY, P62; KAM CM, 1992, FEBS LETT, V297, P119, DOI 10.1016/0014-5793(92)80340-M; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LESTIENNE P, 1980, J BIOL CHEM, V255, P9289; MCRAE B, 1980, BIOCHEMISTRY-US, V19, P3973, DOI 10.1021/bi00558a013; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RAO NV, 1991, J BIOL CHEM, V266, P9540; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P2238, DOI 10.1021/bi00382a025; YASUTAKE A, 1981, BIOCHEMISTRY-US, V20, P3675, DOI 10.1021/bi00516a002	19	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12609	12612		10.1074/jbc.M210074200	http://dx.doi.org/10.1074/jbc.M210074200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12538645	hybrid			2022-12-27	WOS:000182189500004
J	Lee, K; Neigeborn, L; Kaufman, RJ				Lee, K; Neigeborn, L; Kaufman, RJ			The unfolded protein response is required for haploid tolerance in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; GLUCOSE-REGULATED PROTEINS; KAR2 BIP GENE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; DNA-REPLICATION; CELL-CYCLE; TRANSCRIPTION FACTOR; CENTROSOME DUPLICATION; TRANSMEMBRANE PROTEIN	HAC1 encodes a transcription factor that mediates the unfolded protein response (UPR) in Saccharomyces cerevisiae. We characterized hac1Delta mutants in the sporulation-proficient SK1 genetic background and found a novel function for HAC1 in haploid tolerance. hac1Delta spore clones contain a diploid DNA content as determined by fluorescence-activated cell sorting and genetic analyses. Autodiploidization of hac1 spore clones occurred after germination; hac1 spores were born haploid, but efficiently generated diploid progeny during the subsequent mitotic division. Once the hac1 mutant acquired a diploid DNA content, no further ploidy increase was observed. Interestingly, the increase in genome content following meiosis was not a general property associated with hac1 spore clones; instead, it was restricted to an inability to tolerate the haploid state. Genetic analyses involving the UPR target gene KAR2 and the UPR regulator IRE1 revealed that autodiploidization associated with hac1 mutants is a consequence of its role in the UPR pathway. Inhibition of the UPR pathway induces autodiploidization, and constitutive activation of UPR target genes suppresses this response.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA; Rutgers Coll, New Brunswick, NJ 08901 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Rutgers State University New Brunswick	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, MSRB 2,Rm 4570,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Longo, Kenneth A/A-5631-2010					Archambault J, 1996, GENETICS, V142, P737; Bloom K, 2001, CURR BIOL, V11, pR326, DOI 10.1016/S0960-9822(01)00176-2; BRIZA P, 1986, J BIOL CHEM, V261, P4288; CHAN CSM, 1993, GENETICS, V135, P677; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Chevalier S, 1996, CURR OPIN CELL BIOL, V8, P815, DOI 10.1016/S0955-0674(96)80082-2; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; Detweiler CS, 1997, J CELL SCI, V110, P753; DeZwaan TM, 1997, J CELL BIOL, V138, P1023, DOI 10.1083/jcb.138.5.1023; Dricu A, 1997, CANCER RES, V57, P543; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Guthrie C, 1991, METHODS ENZYMOL, V194; Hamilton TG, 1996, J BIOL CHEM, V271, P30610, DOI 10.1074/jbc.271.48.30610; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Higashio H, 2002, BIOCHEM BIOPH RES CO, V296, P568, DOI 10.1016/S0006-291X(02)00923-3; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HOSAKA K, 1994, J BIOCHEM-TOKYO, V116, P1317, DOI 10.1093/oxfordjournals.jbchem.a124681; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kagiwada S, 1996, GENETICS, V143, P685; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1998, J BIOL CHEM, V273, P1802, DOI 10.1074/jbc.273.3.1802; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LARSSON O, 1993, J CELL SCI, V106, P299; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOIDL J, 1995, GENETICS, V139, P1511; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nikawa J, 1997, GENE, V201, P5, DOI 10.1016/S0378-1119(97)00418-6; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NOJIMA H, 1994, NUCLEIC ACIDS RES, V22, P5279, DOI 10.1093/nar/22.24.5279; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; POLAINA J, 1993, CURR GENET, V24, P369, DOI 10.1007/BF00351842; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Sato M, 2002, BIOCHEM BIOPH RES CO, V296, P560, DOI 10.1016/S0006-291X(02)00922-1; Schroder M, 2000, GENE DEV, V14, P2962, DOI 10.1101/gad.852300; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sherman F, 1986, LAB COURSE MANUAL ME; Shirra MK, 2001, MOL CELL BIOL, V21, P5710, DOI 10.1128/MCB.21.17.5710-5722.2001; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearns T, 2001, CELL, V105, P417, DOI 10.1016/S0092-8674(01)00366-X; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sugiyama M, 2001, J BACTERIOL, V183, P4985, DOI 10.1128/JB.183.17.4985-4993.2001; VALLEN EA, 1994, GENETICS, V137, P407; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; WEISS RL, 1975, P NATL ACAD SCI USA, V72, P794, DOI 10.1073/pnas.72.3.794; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	83	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11818	11827		10.1074/jbc.M210475200	http://dx.doi.org/10.1074/jbc.M210475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560331	hybrid			2022-12-27	WOS:000182015700014
J	Mueller, SO; Hall, JM; Swope, DL; Pedersen, LC; Korach, KS				Mueller, SO; Hall, JM; Swope, DL; Pedersen, LC; Korach, KS			Molecular determinants of the stereoselectivity of agonist activity of estrogen receptors (ER) alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; DIETHYLSTILBESTROL METABOLITES; CONFORMATIONAL-CHANGES; TISSUE DISTRIBUTION; CELL-LINES; WILD-TYPE; TRANSACTIVATION; ANTIESTROGENS; ANALOGS; IDENTIFICATION	The two known estrogen receptors, ERalpha and ERbeta, are hormone-inducible transcription factors that have distinct roles in regulating cell proliferation and differentiation. Previously, our laboratory demonstrated that ERalpha exhibits stereoselective ligand binding and transactivation for several structural derivatives and metabolites of the synthetic estrogen diethylstilbestrol. We have previously described the properties of indenestrol A (IA) enantiomers on ERalpha. In the study presented here, the estrogenic properties of the S and R enantiomers of IA, IA-S and IA-R, respectively, were expanded to exam. ine the activity in different cell and promoter contexts using ERalpha and ERbeta. Using human cell lines stably expressing either ERalpha or ERbeta, we found that IA-S was a more potent activator of transcription than IA-R through ERalpha in human endometrial Ishikawa and breast MDA-MB 231 (MDA) cells. Interestingly, IA-R was more potent on ERbeta when compared with ERalpha in MDA, but not in Ishikawa cells, and IA-R exhibited equally low binding affinities to ERalpha and ERbeta in vitro in contrast to its cell line-dependent preferential activation of ERG. Alignment of the protein structures of the ligand-binding domains of ERalpha and ERbeta revealed one mismatched residue, Leu-384 in ERalpha and Met-283 in ERbeta, which may be responsible for making contact with the methyl substituent at the chiral carbon of IA-S and IA-R. Mutagenesis and exchange of this one residue showed that the binding of IA-R and IA-S was not affected by this mutation in ERalpha and ERbeta. However, in transactivation studies, IA-R showed higher potency in activating L384M-mutated ERalpha and wild-type ERbeta compared with wild-type ERalpha and M283L-mutated ERbeta in all cell and promoter contexts examined. Furthermore, IA-R-bound ERalpha L384M and wild-type ERbeta displayed enhanced interactions with the nuclear receptor interaction domains of the coactivators SRC-1 and GRIP1. These data demonstrate that a single residue in the ligand-binding domain determines the stereoselectivity of ERalpha and ERbeta for indenestrol ligands and that IA-R shows cell type selectivity through ERbeta.	NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Korach, KS (corresponding author), Merck KGaA, Inst Toxicol, POB 64271, Darmstadt, Germany.		Pedersen, Lars/C-6173-2019	Pedersen, Lars/0000-0002-4488-4077; Korach, Kenneth/0000-0002-7765-418X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES070065, Z01ES070065] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; BUCCHINFUSO WP, 1997, MOL ENDOCRINOL, V11, P587; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chaidarun SS, 1998, MOL ENDOCRINOL, V12, P1355, DOI 10.1210/me.12.9.1355; Chang WY, 1999, PROSTATE, V40, P115; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kohno H, 1996, J MOL ENDOCRINOL, V16, P277, DOI 10.1677/jme.0.0160277; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; KORACH KS, 1989, J BIOL CHEM, V264, P5642; KORACH KS, 1979, J BIOL CHEM, V254, P8963; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Mueller SO, 2001, J ANDROL, V22, P652; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; SCHROEDER J, 1989, SIGNAL PROCESS, V17, P19, DOI 10.1016/0165-1684(89)90069-8; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SOULE HD, 1990, CANCER RES, V50, P6075; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; Tyulmenkov VV, 2000, ARCH BIOCHEM BIOPHYS, V381, P135, DOI 10.1006/abbi.2000.1974; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200	36	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12255	12262		10.1074/jbc.M203578200	http://dx.doi.org/10.1074/jbc.M203578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547836	hybrid			2022-12-27	WOS:000182015700070
J	Que-Gewirth, NLS; Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH				Que-Gewirth, NLS; Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH			Origin of the 2-amino-2-deoxy-gluconate unit in Rhizobium leguminosarum lipid A - Expression cloning of the outer membrane oxidase LpxQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACYL CHAINS; BIOSYNTHESIS; PROTEIN; LIPOPOLYSACCHARIDE; SALMONELLA; ENZYME; GENE; PRECURSORS	An unusual feature of the lipid A from the plant endosymbionts Rhizobium etli and Rhizobium leguminosarum is the presence of a proximal sugar unit consisting of a 2-amino-2-deoxy-gluconate moiety in place of glucosamine. An outer membrane oxidase that generates the 2-amino-2-deoxy-gluconate unit from a glucosamine-containing precursor is present in membranes of R. leguminosarum and R. etli but not in S. meliloti or Escherichia coli. We now report the identification of a hybrid cosmid that directs the overexpression of this activity by screening 1800 lysates of individual colonies of a R. leguminosarum 3841 genomic DNA library in the host strain R. etli CE3. Two cosmids (p1S11D and p1U12G) were identified in this manner and transferred into S. meliloti, in which they also directed the expression of oxidase activity in the absence of any chromosomal background. Subcloning and sequencing of the oxidase gene on a 6.5-kb fragment derived from the similar to20-kb insert in p1S11D revealed that the enzyme is encoded by a gene (lpxQ) that specifies a protein of 224 amino acid residues with a putative signal sequence cleavage site at position 28. Heterologous expression of lpxQ using the T7lac promoter system in E. coli resulted in the production of catalytically active oxidase that was localized in the outer membrane. A new outer membrane protein of the size expected for LpxQ was present in this construct and was subjected to microsequencing to confirm its identity and the site of signal peptide cleavage. LpxQ expressed in E. coli generates the same products as seen in R. leguminosarum membranes. LpxQ is dependent on O-2 for activity, as demonstrated by inhibition of the reaction under strictly anaerobic conditions. An ortholog of LpxQ is present in the genome of Agrobacterium tumefaciens, as shown by heterologous expression of oxidase activity in E. coli.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R37GM051796, T32GM008558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fernandez C, 2001, FEBS LETT, V504, P173, DOI 10.1016/S0014-5793(01)02742-9; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GLAZEBROOK J, 1991, METHOD ENZYMOL, V204, P398; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Miller J. H, 1972, EXPT MOL GENETICS; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; RUSSA R, 1985, ARCH MICROBIOL, V141, P284, DOI 10.1007/BF00428838; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14186, DOI 10.1074/jbc.M200408200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	60	28	31	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12120	12129		10.1074/jbc.M300379200	http://dx.doi.org/10.1074/jbc.M300379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531908	hybrid, Green Accepted			2022-12-27	WOS:000182015700053
J	Zhou, Y; Ching, YP; Chun, ACS; Jin, DY				Zhou, Y; Ching, YP; Chun, ACS; Jin, DY			Nuclear localization of the cell cycle regulator CDH1 and its regulation by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CHECKPOINT PROTEIN MAD2; MITOTIC CHECKPOINT; SPINDLE CHECKPOINT; KEN BOX; INHIBITOR PDS1; DIRECT BINDING; AURORA-A; CDC20; YEAST	The anaphase-promoting complex activated by CDC20 and CDH1 is a major ubiquitination system that controls the destruction of cell cycle regulators. Exactly how ubiquitination is regulated in time and space is incompletely understood. Here we report on the cell cycle-dependent localization of CDH1 and its regulation by phosphorylation. CDH1 localizes dynamically to the nucleus during interphase and to the centrosome during metaphase and anaphase. The nuclear accumulation of CDH1 correlates with a reduction in the steady-state amount of cyclin A, but not of cyclin E. A nuclear localization signal conserved in various species was identified in CDH1, and it sufficiently targets green fluorescent protein to the nucleus. Interestingly, a CDH1-4D mutant mimicking the hyperphosphorylated form was constitutively found in the cytoplasm. In further support of the notion that phosphorylation inhibits nuclear import, the nuclear localization signal of CDH1 with two phospho-accepting serine/threonine residues changed into aspartates was unable to drive heterologous protein into the nucleus. On the other hand, abolition of the cyclin-binding ability of CDH1 has no influence on its nuclear localization. Taken together, our findings document the phosphorylation-dependent localization of CDH1 in vertebrate cells.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Dept Biochem, 3rd Floor,Lab Block,Fac Med Bldg 21,Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	dyjin@hkucc.hku.hk	Ching, Yick Pang/C-4244-2009	CHING, Yick Pang/0000-0002-6461-8358	FIC NIH HHS [D43 TW06186] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006186] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Ching YP, 2002, GENOMICS, V79, P2, DOI 10.1006/geno.2001.6670; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hendrickson C, 2001, CURR BIOL, V11, P1781, DOI 10.1016/S0960-9822(01)00564-4; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Huang JY, 2002, J CELL SCI, V115, P2847; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Inbal N, 1999, FEBS LETT, V463, P350, DOI 10.1016/S0014-5793(99)01640-3; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; Jorgensen PM, 1998, MOL CELL BIOL, V18, P468; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V268, P530, DOI 10.1006/bbrc.2000.2167; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	79	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12530	12536		10.1074/jbc.M212853200	http://dx.doi.org/10.1074/jbc.M212853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560341	hybrid			2022-12-27	WOS:000182015700105
J	Hojlund, K; Wrzesinski, K; Larsen, PM; Fey, SJ; Roepstorff, P; Handberg, A; Dela, F; Vinten, J; McCormack, JG; Reynet, C; Beck-Nielsen, H				Hojlund, K; Wrzesinski, K; Larsen, PM; Fey, SJ; Roepstorff, P; Handberg, A; Dela, F; Vinten, J; McCormack, JG; Reynet, C; Beck-Nielsen, H			Proteome analysis reveals phosphorylation of ATP synthase beta-subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BINDING-PROTEIN; INSULIN-RESISTANCE; CREATINE-KINASE; GENE-EXPRESSION; GLYCOGEN-SYNTHASE; STRESS-PROTEINS; OKADAIC ACID; VI COLLAGEN; MITOCHONDRIAL; ACTIVATION	Insulin resistance in skeletal muscle is a hallmark feature of type 2 diabetes. An increasing number of enzymes and metabolic pathways have been implicated in the development of insulin resistance. However, the primary cellular cause of insulin resistance remains uncertain. Proteome analysis can quantitate a large number of proteins and their post-translational modifications simultaneously and is a powerful tool to study polygenic diseases like type 2 diabetes. Using this approach on human skeletal muscle biopsies, we have identified eight potential protein markers for type 2 diabetes in the fasting state. The observed changes in protein expression indicate increased cellular stress, e.g. up-regulation of two heat shock proteins, and perturbations in ATP (re)synthesis and mitochondrial metabolism, e.g. down-regulation of ATP synthase 6-subunit and creatine kinase B, in skeletal muscle of patients with type 2 diabetes. Phosphorylation appears to play a key, potentially coordinating role for most of the proteins identified in this study. In particular, we demonstrated that the catalytic beta-subunit of ATP synthase is phosphorylated in vivo and that the levels of a down-regulated ATP synthase beta-subunit phosphoisoform in diabetic muscle correlated inversely with fasting plasma glucose levels. These data suggest a role for phosphorylation of ATP synthase beta-subunit in the regulation of ATP synthesis and that alterations in the regulation of ATP synthesis and cellular stress proteins may contribute to the pathogenesis of type 2 diabetes.	Odense Univ Hosp, Diabet Res Ctr, Dept Endocrinol, DK-5000 Odense C, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Univ Copenhagen, Panum Inst, Dept Med Physiol, Copenhagen Muscle Res Ctr, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Physiol, DK-2200 Copenhagen N, Denmark; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Copenhagen; University of Copenhagen; Novo Nordisk	Beck-Nielsen, H (corresponding author), Odense Univ Hosp, Diabet Res Ctr, Dept Endocrinol, Kloevervaenget 6, DK-5000 Odense C, Denmark.	henning.beck-nielsen@ouh.fyns-amt.dk	Wrzesinski, Krzysztof/B-1464-2013; Dela, Flemming/AAU-1691-2021; Dela, Flemming/B-3239-2008; Fey, Stephen/G-3677-2012; Fey, Stephen/B-5253-2015; Handberg, Aase/G-6744-2011	Wrzesinski, Krzysztof/0000-0002-0381-4523; Dela, Flemming/0000-0001-9970-9535; Dela, Flemming/0000-0001-9970-9535; Fey, Stephen/0000-0001-6463-9477; Fey, Stephen/0000-0001-6463-9477; Handberg, Aase/0000-0001-5719-203X				Anderson CM, 1999, DRUG DEVELOP RES, V46, P67, DOI 10.1002/(SICI)1098-2299(199901)46:1<67::AID-DDR10>3.0.CO;2-V; ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790; APPLE FS, 1989, J APPL PHYSIOL, V66, P2717, DOI 10.1152/jappl.1989.66.6.2717; BASHAN N, 1993, AM J PHYSIOL, V264, pC430, DOI 10.1152/ajpcell.1993.264.2.C430; Beck-Nielsen Henning, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P255; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; Chen KD, 2000, J CELL BIOCHEM, V76, P585, DOI 10.1002/(SICI)1097-4644(20000315)76:4<585::AID-JCB7>3.0.CO;2-U; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; Fey SJ, 1997, ELECTROPHORESIS, V18, P1361, DOI 10.1002/elps.1150180811; Fey SJ, 2001, CURR OPIN CHEM BIOL, V5, P26, DOI 10.1016/S1367-5931(00)00167-8; Fredericks S, 2001, CLIN CHIM ACTA, V304, P65, DOI 10.1016/S0009-8981(00)00409-5; Gaster M, 2001, DIABETES, V50, P1324, DOI 10.2337/diabetes.50.6.1324; Gebhart SSP, 1996, METABOLISM, V45, P526, DOI 10.1016/S0026-0495(96)90231-0; Gonzalez B, 2000, PFLUG ARCH EUR J PHY, V440, P42, DOI 10.1007/s004240051020; He J, 2001, DIABETES, V50, P817, DOI 10.2337/diabetes.50.4.817; HEMMER W, 1993, FEBS LETT, V327, P35, DOI 10.1016/0014-5793(93)81034-W; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HICKSON RC, 1976, J APPL PHYSIOL, V40, P868, DOI 10.1152/jappl.1976.40.6.868; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Jensen ON, 1998, PROTEINS, P74; JOSHI JG, 1988, TOXICOLOGY, V48, P21, DOI 10.1016/0300-483X(88)90055-8; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KATZ A, 1995, BBA-GEN SUBJECTS, V1244, P229, DOI 10.1016/0304-4165(95)00050-L; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; LENNY N, 1991, J BIOL CHEM, V266, P20532; MANNING DR, 1982, AM J PHYSIOL, V242, pC234, DOI 10.1152/ajpcell.1982.242.3.C234; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Mote PL, 1998, MECH AGEING DEV, V104, P149, DOI 10.1016/S0047-6374(98)00064-5; MUONA P, 1993, AM J PATHOL, V142, P1586; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nishizawa J, 1999, CIRCULATION, V99, P934, DOI 10.1161/01.CIR.99.7.934; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sawa T, 1996, BIOCHEM BIOPH RES CO, V218, P449, DOI 10.1006/bbrc.1996.0080; SPIRO MJ, 1993, DIABETOLOGIA, V36, P93, DOI 10.1007/BF00400687; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; THOMAS F, 1994, DIABETES, V43, P63, DOI 10.2337/diabetes.43.1.63; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200	49	176	189	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10436	10442		10.1074/jbc.M212881200	http://dx.doi.org/10.1074/jbc.M212881200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531894	hybrid			2022-12-27	WOS:000181777500060
J	Kiss, RS; McManus, DC; Franklin, V; Tan, WL; McKenzie, A; Chimini, G; Marcel, YL				Kiss, RS; McManus, DC; Franklin, V; Tan, WL; McKenzie, A; Chimini, G; Marcel, YL			The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; APOA-I; TANGIER-DISEASE; CELL-LINE; ABCA1 TRANSPORTER; APOPTOTIC CELLS; GENE-EXPRESSION; CHICKEN LIVER; STEROL EFFLUX	The pathways of hepatic intra- and peri-cellular lipidation of apolipoprotein A-I (apoA-I) were studied by infecting primary mouse hepatocytes from either apoAI-deficient or ABCA1-deficient mice with a recombinant adenovirus expressing the human apoA-I (hapoA-I) cDNA (endo apoA-I) or incubating the hepatocytes with exogenously added hapoA-I (exo apoA-I) and examining the hapoA-1-containing lipoproteins formed. The cells, maintained in serum-free medium, were labeled with [H-3]choline, and the cell medium was separated by fast protein liquid chromatography or immunoprecipitated to quantify labeled choline phospholipids specifically associated with hapoA-I. With the apoA-I-deficient hepatocytes, the high density lipoprotein fraction formed with endo apoA-I contained proportionally more phospholipids than that formed with exo apoA-I. However, the lipoprotein size and electrophoretic mobility and phospholipid profiles were similar for exo apoA-I and endo apoA-I. Taken together, these data demonstrate that a significant proportion of hapoA-I is secreted from hepatocytes in a phospholipidated state but that hapoA-I is also phospholipidated peri-cellularly. With primary hepatocytes from ABCA1-deficient mice, the expression and net secretion of adenoviral-generated endogenous apoA-I was unchanged compared with control mice, but H-3-phospholipids associated with endo apoA-I and exo apoA-I decreased by 63 and 25%, respectively. The lipoprotein size and electrophoretic migration and their phospholipid profiles remained unchanged. In conclusion, we demonstrated that intracellular and peri-cellular lipidation of apoA-I represent distinct and additive pathways that may be regulated independently. Hepatocyte expression of ABCA1 is central to the lipidation of newly synthesized apoA-I but also contributes to the lipidation of exogenous apoA-I. However, a significant basal level of phospholipidation occurs in the absence of ABCA1.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Microbiol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Immunol, Ottawa, ON K1Y 4W7, Canada; CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille, France	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Pathol & Lab Med, Rm H460,40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ymarcel@ottawaheart.ca						Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; BANERJEE D, 1984, J CELL BIOL, V99, P1917, DOI 10.1083/jcb.99.6.1917; BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; CASTLE CK, 1991, J LIPID RES, V32, P439; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Chisholm JW, 2002, J LIPID RES, V43, P36; Costet P, 2000, J BIOL CHEM, V275, P28240; EISENBERG S, 1984, J LIPID RES, V25, P1017; EMMERICH J, 1993, ARTERIOSCLER THROMB, V13, P1299, DOI 10.1161/01.ATV.13.9.1299; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FORTE TM, 1987, BIOCHIM BIOPHYS ACTA, V920, P185, DOI 10.1016/0005-2760(87)90094-4; Fungwe TV, 1998, J NUTR, V128, P1270, DOI 10.1093/jn/128.8.1270; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; HAMILTON RL, 1991, J LIPID RES, V32, P529; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hayden MR, 2000, CURR OPIN LIPIDOL, V11, P117, DOI 10.1097/00041433-200004000-00003; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; Huang ZH, 2002, J LIPID RES, V43, P375; Huang ZH, 2001, ARTERIOSCL THROM VAS, V21, P2019, DOI 10.1161/hq1201.100242; HUSSAIN MM, 1991, ELECTROPHORESIS, V12, P273, DOI 10.1002/elps.1150120408; LAMONFAVA S, 1987, J BIOL CHEM, V262, P8944; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MCCALL MR, 1988, J LIPID RES, V29, P1127; McManus DC, 2001, J BIOL CHEM, V276, P21292, DOI 10.1074/jbc.M100463200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; Neufeld EB, 2002, BIOCHEM BIOPH RES CO, V297, P974, DOI 10.1016/S0006-291X(02)02274-X; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Nobusawa A, 2000, J CARDIOVASC PHARM, V36, P101, DOI 10.1097/00005344-200007000-00014; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PATSCH JR, 1978, P NATL ACAD SCI USA, V75, P4519, DOI 10.1073/pnas.75.9.4519; REMALEY AT, 1995, J LIPID RES, V36, P407; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1981, J LIPID RES, V22, P217; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; SCHREYER SA, 1994, ARTERIOSCLER THROMB, V14, P2053, DOI 10.1161/01.ATV.14.12.2053; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SIMON J B, 1970, Biochimica et Biophysica Acta, V218, P549, DOI 10.1016/0005-2760(70)90020-2; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SUBRAHMANYAN L, 1988, SCAND J IMMUNOL, V27, P251, DOI 10.1111/j.1365-3083.1988.tb02345.x; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TALL AR, 1978, NEW ENGL J MED, V299, P1232, DOI 10.1056/NEJM197811302992207; TAM SP, 1983, J LIPID RES, V24, P1343; THOMAS SS, 1995, BBA-MOL BASIS DIS, V1272, P37, DOI 10.1016/0925-4439(95)00065-C; THRIFT RN, 1986, J LIPID RES, V27, P236; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; ZANNIS VI, 1992, CURR OPIN LIPIDOL, V3, P96	67	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10119	10127		10.1074/jbc.M300137200	http://dx.doi.org/10.1074/jbc.M300137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12547832	hybrid			2022-12-27	WOS:000181777500019
J	Yellaturu, CR; Rao, GN				Yellaturu, CR; Rao, GN			Cytosolic phospholipase A(2) is an effector of Jak/STAT signaling and is involved in platelet-derived growth factor BB-induced growth in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RAT MESANGIAL CELLS; SRC TYROSINE KINASE; ARACHIDONIC-ACID; P388D(1) MACROPHAGES; ENDOTHELIAL-CELLS; FACTOR EXPRESSION; ACTIVATION; APOPTOSIS; PHOSPHORYLATION	Platelet-derived growth factor-BB (PDGF-BB) is a potent mitogen and chemoattractant for vascular smooth muscle cells (VSMC). To understand its mitogenic and chemotactic signaling events, we studied the role of cytosolic phospholipase A(2) (cPLA(2)) and the Jak/STAT pathway. PDGF-BB induced the expression and activity of cPLA(2) in a time-dependent manner in VSMC. Arachidonyl trifluoromethyl ketone, a potent and specific inhibitor of cPLA2, significantly reduced PDGF-BB-induced arachidonic acid release and DNA synthesis. PDGF-BB stimulated tyrosine phosphorylation of Jak-2 in a time-dependent manner. In addition, PDGF-BB activated STAT-3 as determined by its tyrosine phosphorylation, DNA-binding activity, and reporter gene expression, and these responses were suppressed by AG490, a selective inhibitor of Jak-2. AG490 and a dominant-negative mutant of STAT-3 also attenuated PDGF-BB-induced expression of cPLA2, arachidonic acid release, and DNA synthesis in VSMC. Together, these results suggest that induction of expression of cPLA2 and arachidonic acid release are involved in VSMC growth in response to PDGF-BB and that these events are mediated by Jak-2-dependent STAT-3 activation.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu			NHLBI NIH HHS [R01 HL65165] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; BACHHUBER BG, 1995, AM J PHYSIOL-CELL PH, V268, pC1141, DOI 10.1152/ajpcell.1995.268.5.C1141; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Denson DD, 1999, AM J PHYSIOL-CELL PH, V276, pC201, DOI 10.1152/ajpcell.1999.276.1.C201; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mallat Z, 1999, J CLIN INVEST, V103, P421, DOI 10.1172/JCI3985; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mezentsev A, 2002, J BIOL CHEM, V277, P18670, DOI 10.1074/jbc.M201143200; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Panini SR, 2001, J LIPID RES, V42, P1678; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1994, J BIOL CHEM, V269, P32586; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	53	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9986	9992		10.1074/jbc.M211276200	http://dx.doi.org/10.1074/jbc.M211276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12529382	hybrid			2022-12-27	WOS:000181524000147
J	Butt, E; Gambaryan, S; Gottfert, N; Galler, A; Marcus, K; Meyer, HE				Butt, E; Gambaryan, S; Gottfert, N; Galler, A; Marcus, K; Meyer, HE			Actin binding of human LIM and SH3 protein is regulated by cGMP- and cAMP-dependent protein kinase phosphorylation on serine 146	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; INTACT HUMAN PLATELETS; VASP IN-VITRO; NITRIC-OXIDE; THROMBOXANE RECEPTOR; SUBSTRATE; ADHESION; MEMBRANE; LASP-1; PATHWAY	Various drugs that elevate cGMP levels and activate cGMP-dependent protein kinase (cGK) inhibit agonist-induced platelet activation. In the present study we identified the LIM and SH3 domain protein (LASP) that was recently cloned from human breast cancer cells (Tomasetto, C., Regnier, C., Moog-Lutz, C., Mattei, M. G., Chenard, M. P., Liderau, R., Basset, P., and Rio, M. C. (1995) Genomics 28, 367-376) as a novel substrate of cGK in human platelets. Recombinant human LASP was phosphorylated by cGMP- and cAMP-dependent protein kinase (cAK) in vitro. Cotransfection of PtK-2 cells with LASP and cGK confirmed phosphorylation of LASP in vivo. Studies with human LASP mutants identified serine 146 as a specific phosphorylation site for cGK and cAK in vivo. LASP is an actin-binding protein, and the phospho-LASP-mimicking mutant S146D showed reduced binding affinity for F-actin in cosedimentation experiments. Immunofluorescence of transfected PtK2 cells demonstrated the localization of LASP in the tips of cell membrane extensions and at cell-cell contacts. Expression of the human LASP mutant S146D resulted in nearly complete relocalization to the cytosol and reduced migration of the cells. Taken together, these data suggest that phosphorylation of LASP by cGK and cAK may be involved in cytoskeletal organization and cell motility.	Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Ruhr Univ Bochum, Med Proteome Ctr, D-44780 Bochum, Germany	University of Wurzburg; Ruhr University Bochum	Butt, E (corresponding author), Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	butt@klin-biochem.uni-wuerzburg.de	Gambaryan, Stepan/I-3940-2016	Gambaryan, Stepan/0000-0002-1470-0791				ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Bieche I, 1996, CANCER RES, V56, P3886; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; BUTT E, 1994, J BIOL CHEM, V269, P14509; BUTT E, 1997, ADV MOL CEL, V18, P311; Chew CS, 2000, J CELL SCI, V113, P2035; Chew CS, 2002, J CELL SCI, V115, P4787, DOI 10.1242/jcs.00174; CHEW CS, 1998, J PHYSL, V275, pC56; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; El-Daher SS, 2000, BLOOD, V95, P3412, DOI 10.1182/blood.V95.11.3412.011k03_3412_3422; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; Okamoto CT, 2002, J CONTROL RELEASE, V78, P35, DOI 10.1016/S0168-3659(01)00479-5; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Reep BR, 1996, BIOCHEM BIOPH RES CO, V219, P1, DOI 10.1006/bbrc.1996.0171; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; TORTI M, 1994, THROMB HAEMOSTASIS, V71, P533; VONBRUCHHAUSEN F, 1997, HDB EXPT PHARM, V126; WALTER U, 1980, J BIOL CHEM, V255, P3757; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Yamamoto S, 2001, ARCH BIOCHEM BIOPHYS, V393, P97, DOI 10.1006/abbi.2001.2505; YOSHINORI S, 1999, BLOOD, V93, P3408	38	86	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15601	15607		10.1074/jbc.M209009200	http://dx.doi.org/10.1074/jbc.M209009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12571245				2022-12-27	WOS:000182680000020
J	Rachmilewitz, J; Borovsky, Z; Riely, GJ; Miller, R; Tykocinski, ML				Rachmilewitz, J; Borovsky, Z; Riely, GJ; Miller, R; Tykocinski, ML			Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; THYMIC EPITHELIAL-CELLS; IMMUNOSUPPRESSIVE FACTOR; MEMBRANE MICRODOMAINS; SIGNAL-TRANSDUCTION; ENDOGENOUS LECTIN; HUMAN THYMOCYTES; RAT MACROPHAGES; PHOSPHORYLATION; GALECTIN-1	CD45 is the major protein tyrosine phosphatase receptor on T cell surfaces that functions as both a positive and a negative regulator of T cell receptor (TCR) signaling. Although CD45 is required for the activation of TCR-associated Src family kinases, it also dephosphorylates phosphoproteins involved in the TCR-signaling cascade. This study links CD45 to the inhibitory activity of placental protein 14 (PP14), a major soluble protein of pregnancy that is now known to be a direct modulator of T cells and to function by desensitizing TCR signaling. PP14 and CD45 co-capped with each other, pointing to a physical linkage between the two. Interestingly, however, the binding of PP,14 to T cell surfaces was not restricted to CD45 alone, with evidence showing that PP14 binds to other surface molecules in a carbohydrate-dependent fashion. Notwithstanding the broader molecular binding potential of PP14, its interaction with CD45 appeared to have special functional significance. Using transfected derivatives of the HPB.ALL mutant T cell line that differ in CD45 expression, we established that the inhibitory effects of PP14 are dependent upon the expression of intact CD45 on T cell surfaces. Based upon these findings, we propose a new immunoregulatory model for PP14, wherein. one of its surface molecular targets, CD45, mediates its T cell inhibitory activity, accounting for the intriguing capacity of PP14 to elevate TCR activation thresholds and thereby down-regulate T cell activation.	Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Hebrew University of Jerusalem; Case Western Reserve University; University of Pennsylvania	Rachmilewitz, J (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, POB 12000, IL-91120 Jerusalem, Israel.				NIAID NIH HHS [R01 AI-38960] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038960] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Blank N, 2001, J IMMUNOL, V166, P6034, DOI 10.4049/jimmunol.166.10.6034; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; BOLTON AE, 1987, LANCET, V1, P593; BRUNSCHWIG EB, 1995, J IMMUNOL, V155, P5498; Clark GF, 2001, CELLS TISSUES ORGANS, V168, P113, DOI 10.1159/000016812; D'Oro U, 1999, J IMMUNOL, V162, P1879; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Flower DR, 1996, BIOCHEM J, V318, P1; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; HALL LR, 1988, J IMMUNOL, V141, P2781; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Johnson KG, 2000, P NATL ACAD SCI USA, V97, P10138, DOI 10.1073/pnas.97.18.10138; JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; MORROW DM, 1994, AM J PATHOL, V145, P1485; Motoya S, 1999, J BIOL CHEM, V274, P1407, DOI 10.1074/jbc.274.3.1407; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Pace KE, 1999, J IMMUNOL, V163, P3801; Paz FL, 2001, EUR J IMMUNOL, V31, P777; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; POCKLEY AG, 1989, CLIN EXP IMMUNOL, V77, P252; POCKLEY AG, 1990, IMMUNOLOGY, V69, P277; Rabinovich G, 1996, J LEUKOCYTE BIOL, V59, P363, DOI 10.1002/jlb.59.3.363; Rabinovich GA, 1998, J IMMUNOL, V160, P4831; Rachmilewitz J, 1999, CELL IMMUNOL, V191, P26, DOI 10.1006/cimm.1998.1408; Rachmilewitz J, 2002, J IMMUNOL, V168, P2745, DOI 10.4049/jimmunol.168.6.2745; Rachmilewitz J, 2001, BLOOD, V98, P3727, DOI 10.1182/blood.V98.13.3727; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; Riely GJ, 2000, BIOCHEM J, V351, P503, DOI 10.1042/0264-6021:3510503; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEPPALA M, 1985, ANN NY ACAD SCI, V442, P212, DOI 10.1111/j.1749-6632.1985.tb37522.x; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Shivnan E, 1996, J IMMUNOL, V157, P101; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Thomas ML, 1999, CURR OPIN IMMUNOL, V11, P270, DOI 10.1016/S0952-7915(99)80044-2; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TURKA LA, 1992, EUR J IMMUNOL, V22, P551, DOI 10.1002/eji.1830220238; Veillette A, 1999, J BIOL CHEM, V274, P14392, DOI 10.1074/jbc.274.20.14392; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Walzel H, 1999, IMMUNOL LETT, V67, P193, DOI 10.1016/S0165-2478(99)00012-7; YAKURA H, 1994, CRIT REV IMMUNOL, V14, P311, DOI 10.1615/CritRevImmunol.v14.i3-4.50	59	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14059	14065		10.1074/jbc.M211716200	http://dx.doi.org/10.1074/jbc.M211716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556471	hybrid			2022-12-27	WOS:000182405000065
J	Fraunberg, MV; Nyronen, T; Kauppinen, R				Fraunberg, MV; Nyronen, T; Kauppinen, R			Mitochondrial targeting of normal and mutant protoporphyrinogen oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT RECEPTORS TOM20; VARIEGATE PORPHYRIA; STRUCTURAL BASIS; PRESEQUENCE; MUTATIONS; YEAST; GENE; IDENTIFICATION; MEMBRANE; FAMILIES	We have investigated the signal sequence for mitochondrial transport of mutants (I12T, 78insC, IVS2-2a-->c, 338G-->C, R152C, 470A-->C, and L401F) and the wild type protoporphyrinogen oxidase (PPOX), which is the penultimate enzyme in the heme biosynthesis. We constructed the corresponding green fluorescent protein fusion proteins and studied their intracellular localization in COS-1 cells. We showed that 28 amino acids in the amino terminus of PPOX contain an independently functioning signal for mitochondrial targeting. The experiments with amino-terminally truncated green fluorescent protein fusion proteins revealed that amino acids 25-477 of PPOX contained an additional mitochondrial targeting signal(s). We constructed a structural model for the interaction between the amino-terminal end of PPOX and the putative mitochondrial receptor protein Tom20. The model suggests that leucine and isoleucine residues Leu-8, Ile-12, and Leu-15 forming an a-helical hydrophobic motif, LXXXIXXL, were crucial for the recognition of the targeting signal. The validity of the model was tested using mutants L8Q, I12T, and L15Q disrupting the hydrophobic surface of the LXXXIXXL helix. The results from in vitro expression studies and molecular modeling were in accordance supporting the hypothesis that the recognition of the mitochondrial targeting signal is dependent on hydrophobic interactions between the targeting signal and the mitochondrial receptor.	Univ Helsinki, Biomedicum Helsinki, Dept Med, Div Endocrinol, Helsinki 00029, Finland; CSC Sci Comp Ltd, Espoo 02101, Finland	University of Helsinki; Finnish IT center for science	Fraunberg, MV (corresponding author), Univ Helsinki, Cent Hosp, Dept Med, Porphyria Res Ctr,Biomedicum Helsinki, POB 700, Helsinki 00029, Finland.		Nyrönen, Tommi H./A-3612-2010	von und zu Fraunberg, Mikael/0000-0002-8457-4639; Kauppinen, Raili/0000-0002-8799-3425; Nyronen, Tommi/0000-0002-5569-5183				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Arnould S, 1999, P NATL ACAD SCI USA, V96, P14825, DOI 10.1073/pnas.96.26.14825; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAY RS, 1986, SEMIN DERMATOL, V5, P138; DeLabre ML, 1999, FEBS LETT, V449, P201, DOI 10.1016/S0014-5793(99)00415-9; DEYBACH JC, 1985, EUR J BIOCHEM, V149, P431, DOI 10.1111/j.1432-1033.1985.tb08943.x; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; Folsch H, 1998, EMBO J, V17, P6508, DOI 10.1093/emboj/17.22.6508; Frank J, 2001, J INVEST DERMATOL, V116, P821, DOI 10.1046/j.1523-1747.2001.01308.x; Fraunberg MVZ, 2001, MOL MED, V7, P320, DOI 10.1007/BF03402215; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAPPAS A, 1905, METABOLIC MOL BASES, P2116; Kauppinen R, 2001, J INVEST DERMATOL, V116, P610, DOI 10.1046/j.1523-1747.2001.01293.x; Krause-Buchholz U, 2000, YEAST, V16, P353, DOI 10.1002/1097-0061(20000315)16:4<353::AID-YEA539>3.0.CO;2-#; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MUSTAJOKI P, 1980, Q J MED, V49, P191; NISHIMURA K, 1995, J BIOL CHEM, V270, P8076, DOI 10.1074/jbc.270.14.8076; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Tzschoppe K, 2000, BIOL CHEM, V381, P1175, DOI 10.1515/BC.2000.145; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Warnich L, 1996, HUM MOL GENET, V5, P981, DOI 10.1093/hmg/5.7.981; Whatley SD, 1999, AM J HUM GENET, V65, P984, DOI 10.1086/302586; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZARA V, 1992, J BIOL CHEM, V267, P12077; [No title captured]	36	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13376	13381		10.1074/jbc.M300151200	http://dx.doi.org/10.1074/jbc.M300151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556518	hybrid			2022-12-27	WOS:000182189500099
J	Newell, JG; Czajkowski, C				Newell, JG; Czajkowski, C			The GABA(A) receptor alpha(1) subunit Pro(174)-Asp(191) segment is involved in GABA binding and channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CYSTEINE SCANNING MUTAGENESIS; AGONIST-BINDING; BENZODIAZEPINE BINDING; SUBSTITUTED CYSTEINES; SECONDARY STRUCTURE; DELTA-SUBUNIT; ACH-BINDING; SITE; RESIDUES	The GABA-binding site undergoes structural rearrangements during the transition from agonist binding to channel opening. To define possible roles of the GABA(A) receptor a, subunit Pro(174)-Asp(191) segment in these processes, we used the substituted cysteine accessibility method to characterize this region. Each residue was individually mutated to cysteine, expressed with wild-type beta(2) subunits in Xenopus laevis oocytes, and examined using two-electrode voltage clamp. Most mutations did not alter GABA EC50 values. The D183C mutation produced a 7-fold reduction in GABA sensitivity. There were no significant changes in the K, values for the competitive antagonist, SR-95531. N-Biotinylaminoethyl methanethiosulfonate modified P174C-, R176C-, S177C-, V178C-, V180C-, A181C-, D183C-, R186C- and N188C-containing receptors. The pattern of accessibility suggests that this protein segment is aqueous-exposed and adopts a random coil conformation. Both GABA and SR-95531 slowed covalent modification of V178C, V180C, and D183C, indicating that these residues may line the GABA-binding site. Further, pentobarbital-induced channel activation accelerated modification of V180C and A181C and slowed the modification of R186C, suggesting that this region of the a, subunit may act as a dynamic element during channel-gating transitions.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Czajkowski, C (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave,Rm 197 MSC, Madison, WI 53706 USA.	czajkowski@physiology.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034727] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34727] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akk G, 2000, BRIT J PHARMACOL, V130, P249, DOI 10.1038/sj.bjp.0703335; Akk G, 1999, BIOPHYS J, V76, P207, DOI 10.1016/S0006-3495(99)77190-0; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Fisher JL, 2002, NEUROPHARMACOLOGY, V42, P922, DOI 10.1016/S0028-3908(02)00050-3; GALZI JL, 1990, J BIOL CHEM, V265, P10430; Holden JH, 2002, J BIOL CHEM, V277, P18785, DOI 10.1074/jbc.M111778200; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kucken AM, 2000, MOL PHARMACOL, V57, P932; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; MCLAUGHLIN JT, 1995, BIOCHEMISTRY-US, V757, P222; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; PRESS WH, 1988, NUMERICAL RECIPES, P301; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; Sine SM, 2002, J GEN PHYSIOL, V120, P483, DOI 10.1085/jgp.20028568; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Spura A, 1999, BIOCHEMISTRY-US, V38, P4912, DOI 10.1021/bi982656z; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; Sullivan D, 2002, MOL PHARMACOL, V61, P463, DOI 10.1124/mol.61.2.463; Sullivan DA, 2000, J BIOL CHEM, V275, P12651, DOI 10.1074/jbc.275.17.12651; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Torres VI, 2002, J BIOL CHEM, V277, P43741, DOI 10.1074/jbc.M202007200; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129; Williams DB, 2002, J NEUROSCI, V22, P7417	46	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13166	13172		10.1074/jbc.M211905200	http://dx.doi.org/10.1074/jbc.M211905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556472	hybrid			2022-12-27	WOS:000182189500074
J	Yang, HB; Cooley, D; Legakis, JE; Ge, QY; Andrade, R; Mattingly, RR				Yang, HB; Cooley, D; Legakis, JE; Ge, QY; Andrade, R; Mattingly, RR			Phosphorylation of the Ras-GRF1 exchange factor at Ser(916/898) reveals activation of ras signaling in the cerebral cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; PROTEIN-MEDIATED SIGNALS; MAP KINASE; MUSCARINIC RECEPTORS; TYROSINE KINASE; NEUROFIBROMATOSIS TYPE-1; DEPENDENT ACTIVATION; FACTOR CDC25(MM); PC12 CELLS; HA-RAS	The Ras-GRF1 exchange factor, which is regulated by increases in intracellular calcium and the release of Gbetagamma subunits from heterotrimeric G proteins, plays a critical role in the activation of neuronal Ras. Activation of G protein-coupled receptors stimulates an increase in the phosphorylation of Ras-GRF1 at certain serine residues. The first of these sites to be identified, Ser(916) in the mouse sequence (equivalent to Ser(898) in the rat sequence), is required for full activation of the Ras exchange factor activity of Ras-GRF1 by muscarinic receptors. We demonstrate here that Ras-GRF1 is highly expressed in rat brain compared with the Sos exchange factor and that there is an increase in incorporation of P-32 into Ser(898) of brain Ras-GRF1 following activation of protein kinase A. Phosphorylation of Ras-GRF1 at Ser(916) is also required for maximal induction of Ras-dependent neurite outgrowth in PC12 cells. A novel antibody (termed 2152) that selectively recognizes Ras-GRF1 when it is phosphorylated at Ser(916/898) confirmed the regulated phosphorylation of Ras-GRF1 by Western blotting in both model systems of transfected COS-7 and PC12 cells and also of the endogenous protein in rat forebrain slices. Indirect confocal immunofluorescence of transfected PC12 cells using antibody 2152 demonstrated reactivity only under conditions in which Ras-GRF1 was phosphorylated at Ser(916/898). Confocal immunofluorescence of cortical slices of rat brain revealed widespread and selective phosphorylation of Ras-GRF1 at Ser(898). In the prefrontal cortex, there was striking phosphorylation of Ras-GRF1 in the dendritic tree, supporting a role for Ras activation and signal transduction in neurotransmission in this area.	Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Barbara Ann Karmanos Canc Inst, Program Mol Biol & Genet, Detroit, MI 48201 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Mattingly, RR (corresponding author), Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Pharmacol, 640 E Canfield Ave, Detroit, MI 48201 USA.	r.mattingly@wayne.edu			NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043985] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA22453, R01 CA381150] Funding Source: Medline; NIEHS NIH HHS [P30 ES06639] Funding Source: Medline; NIMH NIH HHS [R01 MH43985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Arozarena I, 2001, J BIOL CHEM, V276, P21878, DOI 10.1074/jbc.M011383200; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Baouz S, 2001, J BIOL CHEM, V276, P1742, DOI 10.1074/jbc.M005770200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Coccetti P, 1998, BBA-PROTEIN STRUCT M, V1383, P292, DOI 10.1016/S0167-4838(97)00212-4; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fernandez-Medarde A, 2002, MOL CELL BIOL, V22, P2498, DOI 10.1128/MCB.22.8.2498-2504.2002; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; Finkbeiner S, 1998, BIOESSAYS, V20, P691, DOI 10.1002/(SICI)1521-1878(199809)20:9<691::AID-BIES1>3.3.CO;2-H; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Giese KP, 2001, NEUROPHARMACOLOGY, V41, P791, DOI 10.1016/S0028-3908(01)00096-X; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Innocenti M, 1999, FEBS LETT, V460, P357, DOI 10.1016/S0014-5793(99)01374-5; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; Mattingly RR, 2001, CELL SIGNAL, V13, P499, DOI 10.1016/S0898-6568(01)00173-5; Mattingly RR, 2001, TOXICOL APPL PHARM, V176, P162, DOI 10.1006/taap.2001.9272; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Mattingly RR, 1999, CELL SIGNAL, V11, P603, DOI 10.1016/S0898-6568(99)00034-0; Mattingly RR, 1998, IN VITRO MOL TOXICOL, V11, P57; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Mattingly RR, 1999, J BIOL CHEM, V274, P37379, DOI 10.1074/jbc.274.52.37379; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; Messer William S. Jr., 2002, Current Topics in Medicinal Chemistry, V2, P353, DOI 10.2174/1568026024607553; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Pak Y, 2002, MOL CELL BIOL, V22, P7942, DOI 10.1128/MCB.22.22.7942-7952.2002; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tonini R, 2001, MOL CELL NEUROSCI, V18, P691, DOI 10.1006/mcne.2001.1050; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Weeber EJ, 2002, NEURON, V33, P845, DOI 10.1016/S0896-6273(02)00634-7; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; Yang HB, 1999, J NEUROSCI RES, V55, P687, DOI 10.1002/(SICI)1097-4547(19990315)55:6<687::AID-JNR4>3.0.CO;2-6; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zippel R, 1997, MOL BRAIN RES, V48, P140; Zippel R, 1996, ONCOGENE, V12, P2697	69	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13278	13285		10.1074/jbc.M209805200	http://dx.doi.org/10.1074/jbc.M209805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12538592	hybrid			2022-12-27	WOS:000182189500087
J	Bianchi, L; Kwok, SM; Driscoll, M; Sesti, F				Bianchi, L; Kwok, SM; Driscoll, M; Sesti, F			A potassium channel-MiRP complex controls neurosensory function in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINK-RELATED PEPTIDE-1; I-KS; BETA-SUBUNIT; K+ CHANNEL; GENE; KCNQ1; HERG; EXPRESSION; NEURONS; IDENTIFICATION	MinK-related peptides (MiRPs) are single transmembrane proteins that associate with mammalian voltage-gated K+ subunits. Here we report the cloning and functional characterization of a MiRP beta-subunit, MPS-1, and of a voltage-gated pore-forming potassium subunit, KVS-1, from the nematode Caenorhabditis elegans. mps-1 is expressed in chemosensory and mechanosensory neurons and co-localizes with kvs-1 in a subset of these. Inactivation of either mps-1 or kvs-1 by RNA interference (RNAi) causes partially overlapping neuronal defects and results in broad-spectrum neuronal dysfunction, including defective chemotaxis, disrupted mechanotransduction, and impaired locomotion. Inactivation of one subunit by RNAi dramatically suppresses the expression of the partner subunit only in cells where the two proteins co-localize. Co-expression of MPS-1 and KVS-1 in mammalian cells gives rise to a potassium current distinct from the KVS-1 current. Taken together these data indicate that potassium currents constitute a basic determinant for C. elegans neuronal function and unravel a unifying principle of evolutionary significance: that potassium channels in various organisms use MiRPs to generate uniqueness of function with rich variation in the details.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln, Piscataway, NJ 08854 USA.	sestife@umdnj.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037955] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 37955] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; Cowley EA, 2002, J PHYSIOL-LONDON, V538, P747, DOI 10.1113/jphysiol.2001.013300; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Finley MR, 2002, AM J PHYSIOL-HEART C, V283, pH126, DOI 10.1152/ajpheart.00622.2001; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Hart AC, 1999, J NEUROSCI, V19, P1952; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Piccini M, 1999, GENOMICS, V60, P251, DOI 10.1006/geno.1999.5904; Pierce-Shimomura JT, 2001, NATURE, V410, P694, DOI 10.1038/35070575; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Song WJ, 2002, NEUROSCI RES, V42, P7, DOI 10.1016/S0168-0102(01)00305-4; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Thomas JH, 1999, PRACT APPROACH SER, V213, P143; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tseng GN, 1996, J PHARMACOL EXP THER, V279, P865; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	35	54	56	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12415	12424		10.1074/jbc.M212788200	http://dx.doi.org/10.1074/jbc.M212788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12533541	hybrid			2022-12-27	WOS:000182015700091
J	Takatsuna, H; Kato, H; Gohda, J; Akiyama, T; Moriya, A; Okamoto, Y; Yamagata, Y; Otsuka, M; Umezawa, K; Semba, K; Inoue, J				Takatsuna, H; Kato, H; Gohda, J; Akiyama, T; Moriya, A; Okamoto, Y; Yamagata, Y; Otsuka, M; Umezawa, K; Semba, K; Inoue, J			Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; FHA DOMAIN; DEFECTIVE INTERLEUKIN-1; TRAF6-DEFICIENT MICE; MOLECULAR-BASIS; ACTIVATION; CD40; PATHWAY; FAMILY; OLIGOMERIZATION	Tumor necrosis factor receptor-associated factor 6 (TRAF6) transduces signals from members of the Toll/interleukin-1 (IL-1) receptor family by interacting with IL-1 receptor-associated kinase-1 (IRAK-1) after IRAK-1 is released from the receptor-MyD88 complex upon IL-1 stimulation. However, the molecular mechanisms underlying regulation of the IRAK-1/TRAF6 interaction are largely unknown. We have identified TIFA, a TRAF-interacting protein with a forkhead-associated (FHA) domain. The FHA domain is a motif known to bind directly to phosphothreonine and phosphoserine. In transient transfection assays, TIFA activates NFkappaB and c-Jun amino-terminal kinase. However, TIFA carrying a mutation that abolishes TRAF6 binding or mutations in the FHA domain that are known to abolish FHA domain binding to phosphopeptide fails to activate NFkappaB and c-Jun amino-terminal kinase. TIFA, when overexpressed, binds both TRAF6 and IRAK-1 and significantly enhances the IRAK-1/TRAF6 interaction. Furthermore, analysis of endogenous proteins indicates that TIFA associates with TRAF6 constitutively, whereas it associates with IRAK-1 in an IL-1 stimulation-dependent manner in vivo. Thus, TIFA is likely to mediate IRAK-1/TRAF6 interaction upon IL-1 stimulation.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan; Keio Univ, Grad Sch Sci & Technol, Yokohama, Kanagawa 2238522, Japan; Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan	University of Tokyo; Keio University; Kumamoto University	Inoue, J (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan.		Yamagata, Yoshiki/T-6489-2019					Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fitzgerald KA, 2000, MICROBES INFECT, V2, P933, DOI 10.1016/S1286-4579(00)00396-8; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Kanamori M, 2002, BIOCHEM BIOPH RES CO, V290, P1108, DOI 10.1006/bbrc.2001.6315; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Li J, 2000, J CELL SCI, V113, P4143; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; NINOMIYA TJ, 1999, NATURE, V398, P252; O'Neill LAJ, 2002, MOL CELL, V10, P969, DOI 10.1016/S1097-2765(02)00754-2; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yaffe MB, 1999, NATURE, V402, P30; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	39	68	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12144	12150		10.1074/jbc.M300720200	http://dx.doi.org/10.1074/jbc.M300720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12566447	hybrid			2022-12-27	WOS:000182015700056
J	Gurung, R; Tan, A; Ooms, LM; McGrath, MJ; Huysmans, RD; Munday, AD; Prescott, M; Whisstock, JC; Mitchell, CA				Gurung, R; Tan, A; Ooms, LM; McGrath, MJ; Huysmans, RD; Munday, AD; Prescott, M; Whisstock, JC; Mitchell, CA			Identification of a novel domain in two mammalian inositol-polyphosphate 5-phosphatases that mediates membrane ruffle localization - The inositol 5-phosphatase skip localizes to the endoplasmic reticulum and translocates to membrane ruffles following epidermal growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; LIPID PHOSPHATASE; PROTEIN; INSULIN; 3-KINASE; ACTIVATION; MOVEMENT; GAMMA; SHIP	SKIP (skeletal muscle and kidney enriched inositol phosphatase) is a recently identified phosphatidylinositol 3,4,5-trisphosphate- and phosphatidylinositol 4,5-bisphosphate-specific 5-phosphatase. In this study, we investigated the intracellular localization of SKIP. Indirect immunofluorescence and subcellular fractionation showed that, in serum-starved cells, both endogenous and recombinant SKIP colocalized with markers of the endoplasmic reticulum (ER). Following epidermal growth factor (EGF) stimulation, SKIP transiently translocated to plasma membrane ruffles and colocalized with submembranous actin. Data base searching demonstrated a novel 128-amino acid domain in the C terminus of SKIP, designated SKICH for SKIP carboxyl homology, which is also found in the 107-kDa 5-phosphatase PIPP and in members of the TRAF6-binding protein family. Recombinant SKIP lacking the SKICH domain localized to the ER, but did not translocate to membrane ruffles following EGF stimulation. The SKIP SKICH domain showed perinuclear localization and mediated EGF-stimulated plasma membrane ruffle localization. The SKICH domain of the 5-phosphatase PIPP also mediated plasma membrane ruffle localization. Mutational analysis identified the core sequence within the SKICH domain that mediated constitutive membrane association and C-terminal sequences unique to SKIP that contributed to ER localization. Collectively, these studies demonstrate a novel membrane-targeting domain that serves to recruit SKIP and PIPP to membrane ruffles.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	christina.mitchell@med.monash.edu.au	Ooms, Lisa/AGZ-7420-2022	McGrath, Meagan/0000-0002-9414-6558; Whisstock, James/0000-0003-4200-5611; Mitchell, Christina A/0000-0001-9372-3192; Ooms, Lisa Michelle/0000-0002-8918-9932				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hellsten E, 2001, DEV BIOL, V240, P641, DOI 10.1006/dbio.2001.0476; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Ikonomov OC, 2002, J BIOL CHEM, V277, P9206, DOI 10.1074/jbc.M108750200; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; Janne PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Kong AM, 2000, J BIOL CHEM, V275, P24052, DOI 10.1074/jbc.M000874200; Konrad G, 2002, J BIOL CHEM, V277, P10547, DOI 10.1074/jbc.M200090200; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sternsdorf T, 1997, J CELL BIOL, V138, P435, DOI 10.1083/jcb.138.2.435; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Uyeda A, 2000, NEUROSCI LETT, V284, P61, DOI 10.1016/S0304-3940(00)00959-9; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Whisstock JC, 2000, J BIOL CHEM, V275, P37055, DOI 10.1074/jbc.M006244200; Wiradjaja F, 2001, J BIOL CHEM, V276, P7643, DOI 10.1074/jbc.M010471200; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	47	73	81	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11376	11385		10.1074/jbc.M209991200	http://dx.doi.org/10.1074/jbc.M209991200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536145	hybrid			2022-12-27	WOS:000181855400066
J	Mitchell, KJ; Lai, FA; Rutter, GA				Mitchell, KJ; Lai, FA; Rutter, GA			Ryanodine receptor type I and nicotinic acid adenine dinucleotide phosphate receptors mediate Ca2+ release from insulin-containing vesicles in living pancreatic beta-cells (MIN6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRANSMEMBRANE GLYCOPROTEIN CD38; CALCIUM-RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; SECRETORY GRANULES; SARCOPLASMIC-RETICULUM; DANTROLENE INHIBITION; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; CYTOSOLIC CA2+	We have demonstrated recently (Mitchell, K. J., Pinton, P., Varadi, A., Tacchetti, C., Ainscow, E. K., Pozzan, T., Rizzuto, R., and Rutter, G. A. (2001) J. Cell Biol. 155, 41-51) that ryanodine receptors (RyR) are present on insulin-containing secretory vesicles. Here we show that pancreatic islets and derived beta-cell lines express type I and II, but not type III, RyRs. Purified by subcellular fractionation and membrane immuno-isolation, dense core secretory vesicles were found to possess a similar level of type I RyR immunoreactivity as Golgi/endoplasmic reticulum (ER) membranes but substantially less RyR II than the latter. Monitored in cells expressing appropriately targeted aequorins, dantrolene, an inhibitor of RyR I channels, elevated free Ca2+ concentrations in the secretory vesicle compartment from 40.1 +/- 6.7 to 90.4 +/- 14.8 muM (n = 4, p < 0.01), while having no effect on ER Ca2+ concentrations. Furthermore, nicotinic acid adenine dinucleotide phosphate (NAADP), a novel Ca2+-mobilizing agent, decreased dense core secretory vesicle but not ER free Ca2+ concentrations in permeabilized MIN6 beta-cells, and flash photolysis of caged NAADP released Ca2+ from a thapsigargin-insensitive Ca2+ store in single MIN6 cells. Because dantrolene strongly inhibited glucose-stimulated insulin secretion (from 3.07 +/- 0.51-fold stimulation to no significant glucose effect; n = 3, p < 0.01), we conclude that RyR I-mediated Ca2+-induced Ca2+ release from secretory vesicles, possibly potentiated by NAADP, is essential for the activation of insulin secretion.	Univ Bristol, Sch Med Sci, Henry Wellcome Labs Integrated Cell Signalling, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Cardiff Univ, Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, S Glam, Wales	University of Bristol; University of Bristol; Cardiff University	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Henry Wellcome Labs Integrated Cell Signalling, Univ Walk, Bristol BS8 1TD, Avon, England.	g.a.rutter@bris.ac.uk		Rutter, Guy/0000-0001-6360-0343; Lai, Tony/0000-0003-2852-8547				Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Ainscow EK, 2001, BIOCHEM J, V353, P175, DOI 10.1042/0264-6021:3530175; AIREY JA, 1990, J BIOL CHEM, V265, P14187; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Brailoiu E, 2001, MOL PHARMACOL, V60, P718; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; DEAN PM, 1975, J THEOR BIOL, V54, P309, DOI 10.1016/S0022-5193(75)80133-0; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Fitzsimmons TJ, 2000, BIOCHEM J, V351, P265, DOI 10.1042/0264-6021:3510265; Franco L, 1998, FASEB J, V12, P1507; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; Gamberucci A, 1999, FEBS LETT, V446, P309, DOI 10.1016/S0014-5793(99)00220-3; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JANJIC D, 1982, AM J PHYSIOL, V243, pE59, DOI 10.1152/ajpendo.1982.243.1.E59; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; Mears D, 1999, DIABETES, V48, pA443; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mojzisova A, 2001, PFLUG ARCH EUR J PHY, V441, P674, DOI 10.1007/s004240000465; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Paul-Pletzer K, 2001, BIOCHEMISTRY-US, V40, P531, DOI 10.1021/bi001502s; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; Rutter GA, 1998, CHEM BIOL, V5, pR285, DOI 10.1016/S1074-5521(98)90287-3; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; SHIMOMURA O, 1993, BIOCHEM J, V296, P549, DOI 10.1042/bj2960549; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TANIGUCHI T, 1996, ENDOCRINOL METAB, V3, P135; Tengholm A, 2000, CELL CALCIUM, V27, P43, DOI 10.1054/ceca.1999.0087; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; Varadi A, 2002, DIABETES, V51, pS190, DOI 10.2337/diabetes.51.2007.S190; Varadi A, 2002, J CELL SCI, V115, P4177, DOI 10.1242/jcs.00083; WOLLHEIM CB, 1975, J BIOL CHEM, V250, P1354; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; Yusufi ANK, 2002, EXP BIOL MED, V227, P36, DOI 10.1177/153537020222700107; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8	77	151	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11057	11064		10.1074/jbc.M210257200	http://dx.doi.org/10.1074/jbc.M210257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538591	hybrid			2022-12-27	WOS:000181855400026
J	Ouyang, YS; Tu, YP; Barker, SA; Yang, FY				Ouyang, YS; Tu, YP; Barker, SA; Yang, FY			Regulators of G-protein signaling (RGS) 4, insertion into model membranes and inhibition of activity by phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D; RGS PROTEINS; DIACYLGLYCEROL KINASES; APOCYTOCHROME-C; RECEPTOR; BINDING; DOMAIN; TRANSLOCATION; LOCALIZATION; ASSOCIATION	Regulators of G-protein signaling (RGS) proteins are critical for attenuating G protein-coupled signaling pathways. The membrane association of RGS4 has been reported to be crucial for its regulatory activity in reconstituted vesicles and physiological roles in vivo. In this study, we report that RGS4 initially binds onto the surface of anionic phospholipid vesicles and subsequently inserts into, but not through, the membrane bilayer. Phosphatidic acid, one of anionic phospholipids, could dramatically inhibit the ability of RGS4 to accelerate GTPase activity in vitro. Phosphatidic acid is an effective and potent inhibitor of RGS4 in a Ga-i1-[gamma-P-32]GTP single turnover assay with an IC50 similar to 4 pm and maximum inhibition of over 90%. Furthermore, phosphatidic acid was the only phospholipid tested that inhibited RGS4 activity in a receptor-mediated, steady-state GTP hydrolysis assay. When phosphatidic acid (10 mol %) was incorporated into m1 acetylcholine receptor-Galpha(q). vesicles, RGS4 GAP activity was markedly inhibited by more than 70% and the EC50 of RGS4 was increased from 1.5 to 7 nM. Phosphatidic acid also induced a conformational change in the RGS domain of RGS4 measured by acrylamide-quenching experiments. Truncation of the N terminus of RGS4 (residues 1-57) resulted in the loss of both phosphatidic acid binding and lipid-mediated functional inhibition. A single point mutation in RGS4 (Lys(20) to Glu) permitted its binding to phosphatidic acid-containing vesicles but prevented lipid-induced conformational changes in the RGS domain and abolished the inhibition of its GAP activity. We speculate that the activation of phospholipase D or diacylglycerol kinase via G protein-mediated signaling cascades will increase the local concentration of phosphatidic acid, which in turn block RGS4 GAP activity in vivo. Thus, RGS4 may represent a novel effector of phosphatidic acid, and this phospholipid may function as a feedback regulator in G protein-mediated signaling pathways.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yang, FY (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	yangfy@sun5.ibp.ac.cn						ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Cui Y, 1997, CELL SIGNAL, V9, P257, DOI 10.1016/S0898-6568(96)00177-5; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Fahimi-Vahid M, 2002, J MOL CELL CARDIOL, V34, P441, DOI 10.1006/jmcc.2002.1525; GENNIS RB, 1988, BIOMEMBRANES MOL STR, P21; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Han XH, 1996, THIN SOLID FILMS, V284, P789, DOI 10.1016/S0040-6090(95)08447-9; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; MacDonald R., 1996, VESICLES, P3; Miao Q, 2001, BIOCHEM J, V354, P681, DOI 10.1042/0264-6021:3540681; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; PARKER EM, 1991, J BIOL CHEM, V266, P519; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RIETVELD A, 1986, J BIOL CHEM, V261, P3846; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	51	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11115	11122		10.1074/jbc.M212606200	http://dx.doi.org/10.1074/jbc.M212606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538649	hybrid			2022-12-27	WOS:000181855400034
J	Artigiani, S; Barberis, D; Fazzari, P; Longati, P; Angelini, P; van de Loo, JW; Comoglio, PM; Tamagnone, L				Artigiani, S; Barberis, D; Fazzari, P; Longati, P; Angelini, P; van de Loo, JW; Comoglio, PM; Tamagnone, L			Functional regulation of semaphorin receptors by proprotein convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE RAC; FURIN; PLEXIN; GROWTH; GUIDANCE; LIGAND; TRANSMEMBRANE; INHIBITION; ACTIVATION; INTERACTS	PLEXIN genes encode receptors for secreted and membrane-bound semaphorins. It was proposed that the extracellular domain of plexins acts as an inhibitory moiety, preventing receptor activation. Here we show that plexin-B1 and plexin-B2 undergo proteolytic processing in their extracellular portion, thereby converting single-chain precursors into non-disulfide-linked, heterodimeric receptors. We demonstrate that plexin processing is mediated by subtilisin-like proprotein convertases, by inhibition with alpha1-antitrypsin Portland, and by mutagenesis of the substrate-cleavage sites. We provide evidence indicating that proprotein convertases cleave plexins in a post-Golgi compartment and, likely, at the cell surface. In addition, we find that both cell surface targeting and proteolytic processing of plexin-B1 depend on protein-protein interaction motifs in the cytoplasmic domain of the receptor. We then show that proteolytic conversion of plexin-B1 into a heterodimeric receptor greatly increases the binding and the functional response to its specific ligand semaphorin 4D/CD100. Thus, we conclude that cleavage by proprotein convertases is a novel regulatory step for semaphorin receptors localized at the cell surface.	Univ Turin, Inst Canc Res & Treatment, Sch Med, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Tamagnone, L (corresponding author), Univ Turin, Inst Canc Res & Treatment, Sch Med, SP 142, I-10060 Candiolo, Italy.	luca.tamagnone@ircc.it	Fazzari, Pietro/ABE-9368-2020; Tamagnone, Luca/J-8948-2018	Fazzari, Pietro/0000-0003-3457-9201; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328	Telethon [E.1129] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Artigiani S, 1999, IUBMB LIFE, V48, P477, DOI 10.1080/713803563; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Constam DB, 2000, DEVELOPMENT, V127, P245; DIRENZO MF, 1995, CANCER RES, V55, P1129; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GIORDANO S, 1989, ONCOGENE, V4, P1383; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; RHOM B, 2000, FEBS LETT, V486, P68; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	39	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10094	10101		10.1074/jbc.M210156200	http://dx.doi.org/10.1074/jbc.M210156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533544	hybrid			2022-12-27	WOS:000181777500016
J	Okamura-Ikeda, K; Kameoka, N; Fujiwara, K; Motokawa, Y				Okamura-Ikeda, K; Kameoka, N; Fujiwara, K; Motokawa, Y			Probing the H-protein-induced conformational change and the function of the N-terminal region of Escherichia coli T-protein of the glycine cleavage system by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; DECARBOXYLASE COMPLEX; MOLECULAR-CLONING; MECHANISM; GENE; IDENTIFICATION; EXPRESSION	T-protein, a component of the glycine cleavage system, catalyzes a tetrahydrofolate-dependent reaction. Previously, we reported a conformational change of Escherichia coli T-protein upon interacting with E. coli H-protein (EH), showing an important role for the N-terminal region of the T-protein in the interaction. To further investigate the T-protein catalysis, the wild type (ET) and mutants were subjected to limited proteolysis. ET was favorably cleaved at Lys(81), Lys(154), Lys(288), and Lys(360) by lysylendopeptidase and the cleavages at Lys(81) and Lys(288) were strongly prevented by EH. Although ET was highly resistant to trypsinolysis, the mutant with an N-terminal 7-residue deletion (ETDelta7) was quite susceptible and instantly cleaved at Arg(16) accompanied by the rapid degradation of the resulting C-terminal fragment, indicating that the cleavage at Arg(16) is the trigger for the C-terminal fragmentation. EH showed no protection from the N-terminal cleavage, although substantial protection from the C-terminal fragmentation was observed. The replacement of Leu(6) of ET with alanine resulted in a similar sensitivity to trypsin as ETDelta7. These results suggest that the N-terminal region of ET functions as a molecular "hasp" to hold ET in the compact form required for the proper association with EH. Leu(6) seems to play a central role in the hasp function. Interestingly, Lys(360) of ET was susceptible to proteolysis even after the stabilization of the entire molecule of ET by EH, indicating its location at the surface of the ET-EH complex. Together with the buried position of Lys(81) in the complex and previous results on folate binding sites, these results suggest the formation of a folate-binding cavity via the interaction of ET with EH. The polyglutamyl tail of the folate substrate may be inserted into the bosom of the cavity leaving the pteridine ring near the entrance of the cavity in the context of the catalytic reaction.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	Tokushima University	Okamura-Ikeda, K (corresponding author), Univ Tokushima, Inst Enzyme Res, Kuramotocho 3 Chome, Tokushima 7708503, Japan.	ikeda@ier.tokushima-u.ac.jp						BOURGUIGNON J, 1993, EUR J BIOCHEM, V217, P377, DOI 10.1111/j.1432-1033.1993.tb18256.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHENADDAD C, 1995, NAT STRUCT BIOL, V2, P63, DOI 10.1038/nsb0195-63; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; Guilhaudis L, 2000, BIOCHEMISTRY-US, V39, P4259, DOI 10.1021/bi992674w; HAYASAKA K, 1993, BIOCHEM BIOPH RES CO, V192, P766, DOI 10.1006/bbrc.1993.1480; KISLIUK RL, 1957, J BIOL CHEM, V227, P805; KOPRIVA S, 1995, PLANT MOL BIOL, V27, P1215, DOI 10.1007/BF00020895; Kure S, 1998, HUM GENET, V102, P430, DOI 10.1007/s004390050716; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; MOTOKAWA Y, 1995, BIOTHIOLS HLTH DIS, P389; NANAO K, 1994, HUM GENET, V93, P655; Okamura-Ikeda K, 1999, EUR J BIOCHEM, V264, P446, DOI 10.1046/j.1432-1327.1999.00637.x; Okamura-Ikeda K, 1999, J BIOL CHEM, V274, P17471, DOI 10.1074/jbc.274.25.17471; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; OKAMURAIKEDA K, 1992, J BIOL CHEM, V267, P18284; OKAMURAIKEDA K, 1991, J BIOL CHEM, V266, P4917; OSBORN MJ, 1960, J AM CHEM SOC, V82, P4921, DOI 10.1021/ja01503a043; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	22	9	9	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10067	10072		10.1074/jbc.M210853200	http://dx.doi.org/10.1074/jbc.M210853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531904	hybrid			2022-12-27	WOS:000181777500012
J	Xu, JG; He, JQ; Castleberry, AM; Balasubramanian, S; Lau, AG; Hall, RA				Xu, JG; He, JQ; Castleberry, AM; Balasubramanian, S; Lau, AG; Hall, RA			Heterodimerization of alpha(2A)- and beta(1)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL CORTICAL MEMBRANES; RESONANCE ENERGY-TRANSFER; OPIOID RECEPTORS; ALPHA-2-ADRENERGIC RECEPTORS; ADRENERGIC-RECEPTORS; PROTEIN; INTERNALIZATION; GLYCOSYLATION; SOMATOSTATIN; AGONIST	beta- and alpha(2)-adrenergic receptors are known to exhibit substantial cross-talk and mutual regulation in tissues where they are expressed together. We have found that the beta(1)-adrenergic receptor (beta(1)AR) and alpha(2A)-adrenergic receptor (alpha(2A)AR) heterodimerize when coexpressed in cells. Immunoprecipitation studies with differentially tagged beta(1)AR and alpha(2A)AR expressed in HEK-293 cells revealed robust co-immunoprecipitation of the two receptors. Moreover, agonist stimulation Of alpha(2A)AR was found to induce substantial internalization of coexpressed beta(1)AR, providing further evidence for a physica association between the two receptors in a cellular environment. Ligand binding assays examining displacement of [H-3]dihydroalprenolol binding to the beta(1)AR by various ligands revealed that beta(1)AR pharmacological properties were significantly altered when the receptor was coexpressed with alpha(2A)AR. Finally, beta(1)AR/alpha(2A)AR heterodimerization was found to be markedly enhanced by a beta(1)AR point mutation (N15A) that blocks N-linked glycosylation of the beta(1)AR as well as by point mutations (N10A/N14A) that block N-linked glycosylation of the alpha(2A)AR. These data reveal an interaction between beta(1)AR and alpha(2A)AR that is regulated by glycosylation and that may play a key role in cross-talk and mutual regulation between these receptors.	Emory Univ, Sch Med, Rollins Res Ctr 5113, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hall, RA (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr 5113, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060982] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL64713] Funding Source: Medline; NIGMS NIH HHS [R01-GM60982] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Anderson Joe R., 2001, Cardiology Clinics, V19, P215, DOI 10.1016/S0733-8651(05)70209-5; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; ATKINSON BN, 1992, MOL PHARMACOL, V41, P688; BIRNBAUM AK, 1995, MOL BRAIN RES, V28, P72, DOI 10.1016/0169-328X(94)00185-H; BYLUND DB, 1994, PHARMACOL REV, V46, P121; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; He JQ, 2002, BIOCHEM BIOPH RES CO, V297, P565, DOI 10.1016/S0006-291X(02)02259-3; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; HEIDENREICH KA, 1986, ENDOCRINOLOGY, V118, P1835, DOI 10.1210/endo-118-5-1835; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; LI X, 2002, P NATL ACAD SCI USA, V96, P9992; LILJA M, 1980, ACTA MED SCAND, V207, P173; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MAGGI A, 1980, SCIENCE, V207, P645, DOI 10.1126/science.6101510; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Muller D, 2002, ENDOCRINOLOGY, V143, P23, DOI 10.1210/en.143.1.23; NAKAMURA T, 1991, BRAIN RES, V542, P181, DOI 10.1016/0006-8993(91)91564-H; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; NOMURA Y, 1984, BRAIN RES, V302, P101, DOI 10.1016/0006-8993(84)91289-7; NOTHAM WJ, 1985, EUR J PHARMACOL, V113, P153; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; Rathz DA, 2002, J CARDIOVASC PHARM, V39, P155, DOI 10.1097/00005344-200202000-00001; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Saunders C, 1999, PHARMACOL THERAPEUT, V84, P193, DOI 10.1016/S0163-7258(99)00032-7; Wheatley M, 1999, HUM REPROD UPDATE, V5, P356, DOI 10.1093/humupd/5.4.356; WOODCOCK EA, 1980, NATURE, V286, P159, DOI 10.1038/286159a0; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200	49	84	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10770	10777		10.1074/jbc.M207968200	http://dx.doi.org/10.1074/jbc.M207968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529373	hybrid			2022-12-27	WOS:000181777500101
